ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ࡢ⌧≧࡜ㄢ㢟
⮬ᕫⅬ᳨࣭ホ౯ሗ࿌᭩
ᖹᡂ㸰㸱ᖺ㸰᭶
ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊
ࡣࡌࡵ࡟
⸆Ꮫࡣࠊேయ࡟ാࡁࡑࡢᶵ⬟ࡢㄪ⠇➼ࢆ௓ࡋ࡚⑌⑓ࡢ἞⒵ࠊ೺ᗣࡢቑ㐍ࢆࡶࡓࡽࡍࠊ་⸆ရࡢ๰〇ࠊ
⏕⏘ࠊ㐺ṇ࡞౑⏝ࢆ┠ᶆ࡜ࡋࡓ⥲ྜ⛉Ꮫ࡛࠶ࡿࠋࡲࡓࠊ⸆Ꮫࢆಟࡵࡓ⪅࡟ࡣ⸆๣ᖌᅜᐙヨ㦂ࡢཷ㦂㈨
᱁ࡀ୚࠼ࡽࢀࠊ⸆Ꮫࡣ་⒪࡟࠾࠸࡚㔜せ࡞ᙺ๭ࢆᢸ࠺⸆๣ᖌࡢ⫱ᡂࢆ♫఍࠿ࡽ௜クࡉࢀ࡚࠸ࡿࠋ
ࡇࡢࡼ࠺࡟ࠊ⸆≀἞⒪࣭་⸆ရ㛤Ⓨࡢᇶ┙࡜࡞ࡿᏛၥయ⣔ࡢᵓ⠏࣭ᛂ⏝࡜ࡇࢀࢆᢸ࠺◊✲࣭ᢏ⾡⪅
ࡢ⫱ᡂࠊ࠾ࡼࡧ㧗ᗘ࡞ᑓ㛛ⓗ▱㆑࣭ᢏ⬟࡟ᇶ࡙ࡃ⸆๣ᖌ⫋⬟ࡢᨭ᥼࡜࠸࠺ࠊᩍ⫱࣭◊✲ࡢ┠ᶆ࡜ࡋ࡚
஧ࡘࡢഃ㠃ࢆᣢࡘࡇ࡜ࡀ⸆Ꮫࡢ≉ᚩ࡜࡞ࡗ࡚࠾ࡾࠊࡑࢀࡒࢀࡢⓎᒎ࡟ᑐࡍࡿㄪ࿴ࡢ࡜ࢀࡓ㈉⊩ࡀ⸆Ꮫ
඲య࡟ồࡵࡽࢀ࡚࠸ࡿࠋ࡜ࡾࢃࡅࠊࢃࡀᅜ࡟࠾࠸࡚ࡣࠊ⸆Ꮫࡢ⤌⧊ࡢࡶ࡜࡟㛵㐃ࡍࡿᇶ♏⛉Ꮫࡀ⥲ྜ
ࡉࢀࠕ๰⸆⛉Ꮫࠖ࡜ࡋ࡚య⣔໬ࡉࢀ࡚࠸ࡿⅬࡀୡ⏺ⓗ࡟ࡶ㝿❧ࡗࡓ≉ᚩ࡜࡞ࡗ࡚࠾ࡾࠊ་⒪⸆Ꮫ࡜๰
⸆⛉Ꮫࡢ┦஌ⓗⓎᒎࡀ᪥ᮏࡢ⸆Ꮫ࡟୚࠼ࡽࢀࡓ౑࿨࡜఩⨨௜ࡅࡽࢀࡿࠋ኱Ꮫࡣࠊࡇ࠺ࡋࡓ⫼ᬒࡢࡶ࡜
⊂⮬ࡢ⌮ᛕ࡟ᇶ࡙࠸࡚ᩍ⫱࣭◊✲ࡢ┠ᶆࢆᐃࡵࠊࡑࡢᐇ⌧࡟ྥࡅ࡚άືࡋ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ
ி㒔኱Ꮫ⸆Ꮫ㒊࡟࠾࠸࡚ࡣࠊᖹᡂ㸱ᖺࡢ኱Ꮫタ⨨ᇶ‽ᨵṇ࡟క࠸㸲ᖺ୍㈏ᩍ⫱ࡢ⌮ᛕࡢࡶ࡜࡟᪂ࡋ
࠸ᩍ⫱ㄢ⛬࣭࣒࢝ࣜ࢟ࣗࣛࢆᐇ᪋ࡋࠊࡉࡽ࡟ᖹᡂ㸳ᖺ࡟ࡣ኱Ꮫ㝔⊂❧ᑓᨷࢆ᪂ࡓ࡟タ⨨ࡋ࡚ඛ➃◊✲
ࡢ᥎㐍࡟ྲྀࡾ⤌ࡳࠊᖹᡂ㸵ᖺ࡟ࡑࡢᡂᯝࢆሗ࿌᭩࡜ࡋ࡚ห⾜ࡋࡓࠋࡑࡢᚋࠊᖹᡂ㸷ᖺᗘ࡟⸆Ꮫ◊✲࣭
ᩍ⫱ࡢ୍ᒙࡢ㧗ᗘ໬ࢆ┠ᣦࡋ࡚኱Ꮫ㝔㔜Ⅼ໬ࢆ⾜࠸ࠊ⸆Ꮫ㒊ࡣ㸱ᑓᨷ㸶኱ㅮᗙ࠿ࡽ࡞ࡿ኱Ꮫ㝔⸆Ꮫ◊
✲⛉࡟෌⦅ᡂࡉࢀࠊ᪂ࡋ࠸Ꮫၥయ⣔ࡢ๰ฟ࡜㧗ᗘ࡞ᑓ㛛ⓗ▱㆑ࢆ᭷ࡍࡿ◊✲⪅ࠊ⸆๣ᖌࡢ⫱ᡂ࡟ྲྀࡾ
⤌ࡴࡇ࡜࡟࡞ࡗࡓࠋ኱Ꮫ㝔㔜Ⅼ໬ᚋ㸳ᖺࢆ⤒㐣ࡋࡓᖹᡂ㸯㸲ᖺ࡟ࡣࠊࡇ࠺ࡋࡓ⤒㐣ࢆⅬ᳨ࡋ⥲ྜⓗ࡞
ホ౯ࢆ⾜ࡗ࡚ࠊ⮬ᕫⅬ᳨࣭ホ౯ሗ࿌᭩ࢆห⾜ࡋࡓࠋࡲࡓࠊᖹᡂ㸯㸴ᖺᗘࡢᅜ❧኱Ꮫἲே໬ࢆ⤒࡚᪂ࡋ
࠸⟶⌮㐠Ⴀయไࡀᐃ╔ࡋࡓᖹᡂ㸯㸶ᖺ㸯᭶࡟ࡶ⮬ᕫⅬ᳨࣭ホ౯ሗ࿌᭩ࢆห⾜ࡋࡓࠋᖹᡂ㸯㸶ᖺ㸲᭶ࡼ
ࡾࠊ⸆Ꮫᩍ⫱㸴ᖺไࡀᑟධࡉࢀࠊ๰⸆◊✲⪅ࢆึࡵ࡜ࡍࡿከᵝ࡞ேᮦࡢ㣴ᡂࢆ┠ⓗ࡜ࡍࡿ㸲ᖺไࡢ⸆
⛉Ꮫ⛉࡜ࠊ་⒪ே࡜ࡋ࡚ࡢ⸆๣ᖌ㈨᱁ࢆᇶ┙࡜ࡍࡿࠊ་⒪ࠊ◊✲ࠊᩍ⫱ᚑ஦⪅ࡢ㣴ᡂࢆ┠ⓗ࡜ࡍࡿ㸴
ᖺไࡢ⸆Ꮫ⛉ࢆే⨨ࡍࡿ᪂ࡋ࠸ᩍ⫱ไᗘ࡟⛣⾜ࡋࡓࠋࡉࡽ࡟ࠊᖹᡂ㸯㸷ᖺᗘ࡟ࡣࠊ᝟ሗ⛉Ꮫ࡜๰⸆⛉
Ꮫ࡜⼥ྜࡉࡏࠊ㹇㹒๰⸆◊✲⪅ࠊᢏ⾡⪅ࡢ⫱ᡂࢆ┠ᣦࡋ࡚᪂ࡓ࡟་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࡀタ⨨ࡉࢀࠊ
ࡉࡽ࡟ᖹᡂ㸰㸰ᖺᗘ࡟ࡣࠊ㸱ᑓᨷࡀ⸆⛉Ꮫᑓᨷࡢ㸯ᑓᨷ࡟ᨵ⤌ࡉࢀࠊ㸰ᑓᨷ㸷኱ㅮᗙ࡜㸱༠ຊㅮᗙࡢ
ᩍ⫱◊✲యไ࡜࡞ࡗࡓࠋ௨ᚋࠊ⸆Ꮫ◊✲⛉࡟࠾࠸࡚ࡣࠊ◊✲࣭ᩍ⫱ࡢ୧㠃࡛ከࡃࡢࣉࣟࢪ࢙ࢡࢺࡀ᥎
㐍ࡉࢀࡿ࡜ඹ࡟ࠊ◊✲࣭ᩍ⫱యไࡢࡉࡽ࡞ࡿ඘ᐇࡶႚ⥭ࡢㄢ㢟࡜࡞ࡗ࡚࠸ࡿࠋᮏ᭩ࡣࠊࡇ࠺ࡋࡓ≧ἣ
ࢆ⫼ᬒ࡟ࠊ◊✲⛉ࡢάືࡢ⌧≧ศᯒ࡜ㄢ㢟ᩚ⌮ࢆ㏻ࡌ࡚ࠊ⤌⧊ࡢᑗ᮶ീࢆᵓ⠏ࡍࡿࡓࡵ࡟⦅⧩ࡉࢀࡓࠋ
㏆ᖺࠊ⸆Ꮫࡣ๰⸆⛉Ꮫࡸ⮫ᗋ⸆ᏛࡢⓎᒎࢆ㏻ࡌ࡚♫఍࡟┦ᛂࡢ㈉⊩ࢆᯝࡓࡋ࡚࠸ࡿࡀࠊ㧗㱋⪅ேཱྀ
ࡢቑຍ࡟క࠸㢧ᅾ໬ࡋࡓከࡃࡢ㞴἞ᛶ⑌ᝈࡢ἞⒪ࡸ་⒪㐣ㄗࡢ㜵Ṇ࡞࡝ࠊ⸆Ꮫ࡟ồࡵࡽࢀࡿ♫఍ࡢᮇ
ᚅࡣࡲࡍࡲࡍቑ኱ࡋ࡚࠸ࡿࠋᮏ᭩ࡢసᡂࢆ㏻ࡌ࡚ࠊ◊✲⛉ࡢᩍ⫱࣭◊✲άືࡢ⌧≧ࢆ⥲ᣓࡋၥ㢟Ⅼࢆ
᫂ࡽ࠿࡟ࡋࡓࡇ࡜࠿ࡽࠊ௒ᚋࡣእ㒊࠿ࡽࡢホ౯࠾ࡼࡧ◊✲⛉ᵓᡂဨ࡟ࡼࡿ⮬ࡽࡢάືࡢⅬ᳨࣭ホ౯ࢆ
⾜࠸ࠊ◊✲⛉ࡢᑗ᮶ࡢⓎᒎ࡟㈨ࡍࡿࡼ࠺࡟ດࡵࡓ࠸ࠋ
ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉㛗
⮬ᕫⅬ᳨࣭ホ౯ጤဨ఍ጤဨ㛗
బ἞ⱥ㑻
┠ ḟ
ࡣࡌࡵ࡟
, ⌮ᛕ࣭┠ᶆ࣭ᑗ᮶ᵓ᝿
㸦㸯㸧⌮ᛕ࡜┠ᶆ
㸦㸰㸧ἢ㠉࡜⌧≧
㸦㸱㸧ᑗ᮶ᵓ᝿
,,ᩍ⫱
㸦㸯㸧⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ࡢᩍ⫱࣭ᣦᑟ┠ᶆ
㸯㸧Ꮫ㒊ᩍ⫱
㸰㸧኱Ꮫ㝔ᩍ⫱
㸱㸧ᩍ⫱ᣦᑟἲࡢ㛤Ⓨ
㸲㸧ᩍ⫱ᣦᑟయไࡢᩚഛ
㸳㸧ᩍ⫱㛵㐃ࣉࣟࢪ࢙ࢡࢺࡢ᥎㐍
㸦㸰㸧Ꮫ㒊Ꮫ⏕࣭኱Ꮫ㝔⏕➼ࡢཷࡅධࢀ
㸯㸧⸆Ꮫ㒊ࡢධᏛ⪅㑅ᢤ
㸰㸧኱Ꮫ㝔ࡢධᏛ⪅㑅ᢤ
㸱㸧♫఍ே࣭ᖐᅜᏊዪࡢཷࡅධࢀ≧ἣ
㸦㸱㸧Ꮫ㒊࣭኱Ꮫ㝔ࡢ࣒࢝ࣜ࢟ࣗࣛ⦅ᡂ᪉㔪࡜ᣦᑟ
㸯㸧Ꮫ㒊࣒࢝ࣜ࢟ࣗࣛ
㸰㸧Ꮫ㒊Ꮫ⏕࡟ᑐࡍࡿᒚಟᣦᑟ
㸱㸧⸆Ꮫ㒊Ꮫ㒊⛉┠࠾ࡼࡧ⸆Ꮫ㒊ᥦ౪඲Ꮫඹ㏻⛉┠
㸲㸧௚Ꮫ㒊⫈ㅮ➼ࡢ≧ἣ
㸳㸧኱Ꮫ㝔࣒࢝ࣜ࢟ࣗࣛ
㸦㸲㸧Ꮫᴗࡢ㐩ᡂ≧ἣ
㸯㸧Ꮫ㒊Ꮫ⏕ࡢᡂ⦼ホ౯࡜༞ᴗ࡟ᚲせ࡞༢఩
㸰㸧⸆๣ᖌᅜᐙヨ㦂
㸱㸧ಟኈㄢ⛬࣭༤ኈᚋᮇㄢ⛬ಟ஢ࡢせ௳
㸲㸧༤ኈㄽᩥᑂᰝࡢ⌧≧࡜ᑂᰝ᪉ἲ࣭యไ
,,,◊✲άື
㸦㸯㸧◊✲άືࡢ┠ᶆ
㸦㸰㸧◊✲⤌⧊ࡢ⌧≧࡜ᑗ᮶ᵓ᝿
㸦㸱㸧ᑓᨷศ㔝࣭◊✲㡿ᇦࡢ◊✲ෆᐜ
㸦㸲㸧ᵓᡂဨ࡟ࡼࡿ◊✲ᡂᯝࡢⓎ⾲
㸦㸳㸧Ꮫ఍άື࡬ࡢཧຍ≧ἣ
㸦㸴㸧ᅜෆ࣭ᅜ㝿ඹྠ◊✲ࠊࣉࣟࢪ࢙ࢡࢺ࡬ࡢཧຍ
㸦㸵㸧ᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲㈝⿵ຓ㔠࠾ࡼࡧእ㒊㈨㔠ࡢཷࡅධࢀ≧ἣ
㸦㸶㸧ෆእࡢᏛ⾡㈹ࡢཷ㈹≧ἣ
㸦㸷㸧ᩍဨࡢ♫఍ⓗάື
㸦㸯㸮㸧◊✲ᨭ᥼యไࡢ≧ἣ
㸦㸯㸯㸧
ୡ⣖ &2(ࠕࢤࣀ࣒⛉Ꮫࡢ▱ⓗ᝟ሗᇶ┙࣭◊✲ᣐⅬᙧᡂࠖ
㸦㸯㸰㸧㠉᪂ⓗࢼࣀࣂ࢖࢜◊✲ᣐⅬ
㸦㸯㸱㸧᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮
,9⫋ဨ⤌⧊
㸦㸯㸧ᩍᐁࡢ㓄⨨ࠊ඘㊊࣭௵⏝≧ἣ
㸦㸰㸧ᩍ⫱࣭◊✲ᨭ᥼⫋ဨᩘ
㸦㸱㸧ࢸ࢖࣮ࢳࣥࢢ࢔ࢩࢫࢱࣥࢺࠊࣜࢧ࣮ࢳ࢔ࢩࢫࢱࣥࢺࠊ
࠾ࡼࡧ᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ᥇⏝≧ἣ
9⟶⌮࣭㐠Ⴀ
㸦㸯㸧⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ࡢ⤌⧊
㸦㸰㸧஦ົ㒊⤌⧊࣭ᢏ⾡㒊⤌⧊
㸦㸱㸧ᩍဨೃ⿵⪅ࡢ㑅⪃᪉ἲ
9,㈈ᨻ
㸦㸯㸧ண⟬ᴫἣ࡜᭱㏆ࡢືྥ
㸦㸰㸧ᴫ⟬せồ஦㡯ࡢỴᐃ
㸦㸱㸧ண⟬㓄ศ᪉㔪
9,,᪋タ࣭タഛ
㸦㸯㸧᪋タࡢ⌧≧
㸦㸰㸧ᑗ᮶ィ⏬
㸦㸱㸧Ᏻ඲࣭㜵⅏ᑐ⟇
㸦㸲㸧タഛࡢ඘㊊≧ἣ࡜ᑗ᮶ィ⏬
9,,,Ꮫ⾡᝟ሗ
㸦㸯㸧ᅗ᭩ᐊ
㸦㸰㸧ᶆᮏ
㸦㸱㸧᝟ሗࢩࢫࢸ࣒
,;ᅜ㝿஺ὶ
㸦㸯㸧␃Ꮫ⏕ࡢཷࡅධࢀ≧ἣ࣭␃Ꮫ⏕ᩍ⫱࣭◊✲ᣦᑟ
㸦㸰㸧ᅜ㝿஺ὶጤဨ఍ࡢάື
㸦㸱㸧ᾏእࡢ኱Ꮫ࣭ᩍ⫱ᶵ㛵࡜ࡢᩍ⫱࣭◊✲ࡢ஺ὶ
㸦㸲㸧ᩍᐁࡢᅾእ◊✲ࡢ≧ἣ࣭ᾏእฟᙇࡢ≧ἣ
㸦㸳㸧ᣍ࡬࠸እᅜேᏛ⪅࠾ࡼࡧ◊✲⪅ࡢཷࡅධࢀ≧ἣ
;♫఍࡜ࡢ㐃ᦠ
㸦㸯㸧◊✲ဨࡢཷࡅධࢀ
㸦㸰㸧◊✲஺ὶ
㸦㸱㸧⏕ᾭᩍ⫱ㅮ₇఍
㸦㸲㸧㸵㸮࿘ᖺグᛕ஦ᴗ
㸦㸳㸧ඹྠ◊✲
◊✲ᴗ⦼┠㘓
኱Ꮫ㝔⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ᩍဨ୍ぴ
⸆ရ᭷ᶵ〇㐀Ꮫศ㔝
⸆ရྜᡂ໬Ꮫศ㔝
⸆ရศᏊ໬Ꮫศ㔝 ⸆ရ㈨※Ꮫศ㔝
⸆ရᶵ⬟ゎᯒᏛศ㔝
ᵓ㐀⏕≀⸆Ꮫศ㔝
ࢤࣀ࣒๰⸆⛉Ꮫศ㔝
〇๣ᶵ⬟ゎᯒᏛศ㔝
⢭ᐦ᭷ᶵྜᡂศ㔝
⏕యศᏊㄆ㆑Ꮫศ㔝
ศᏊᚤ⏕≀Ꮫศ㔝
⏕యᶵ⬟ゎᯒᏛศ㔝
㑇ఏᏊ⸆Ꮫศ㔝
⏕⌮άᛶไᚚᏛศ㔝
⏕య᝟ሗไᚚᏛศ㔝
⚄⤒ᶵ⬟ไᚚᏛศ㔝
⏕యᶵ⬟໬Ꮫศ㔝
⸆ရືែไᚚᏛศ㔝
⸆ရస⏝ゎᯒᏛศ㔝
⮫ᗋ⸆Ꮫᩍ⫱ศ㔝
⑓ែᶵ⬟ศᯒᏛศ㔝
⑓ែ᝟ሗ⸆Ꮫศ㔝
་⒪⸆๣Ꮫศ㔝
ࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮ศ㔝
ࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮㸦ไᚚศᏊᏛ㸧ศ㔝
ࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮㸦๰⸆ィ⟬໬Ꮫ㸧ศ㔝
⤫ྜࢤࣀ࣑ࢡࢫศ㔝
ศᏊタィ᝟ሗᏛศ㔝
ࢼࣀࣂ࢖࢜་⸆๰ᡂ⛉Ꮫㅮᗙ
ࢩࢫࢸ࣒๰⸆⛉Ꮫㅮᗙ
๰⸆⚄⤒⛉Ꮫᐤ㝃ㅮᗙ
་⸆ရ⌮ㄽタィᏛᐤ㝃ㅮᗙ
⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮
Ϩ ⌮ᛕ࣭┠ᶆ࣭ᑗ᮶ᵓ᝿
㹙Ϩ㹛⌮ᛕ࣭┠ᶆ࣭ᑗ᮶ᵓ᝿
㸦㸯㸧⌮ᛕ࡜┠ᶆ
⸆Ꮫࡣࠊேయ࡟ാࡁࡑࡢᶵ⬟ࡢㄪ⠇➼ࢆ௓ࡋ࡚⑌⑓ࡢ἞⒵ࠊ೺ᗣࡢቑ㐍ࢆࡶࡓࡽࡍࠕ་⸆ရࠖࡢ๰
〇ࠊ⏕⏘ࠊ㐺ṇ࡞౑⏝ࢆ┠ᶆ࡜ࡍࡿ⥲ྜ⛉Ꮫ࡛࠶ࡾࠊㅖᇶ♏⛉Ꮫࡢ⥲ྜࢆᇶ┙࡜ࡍࡿᛂ⏝Ꮫ㝿Ꮫၥ㡿
ᇦ࡜఩⨨࡙ࡅࡽࢀࡿࠋ⸆Ꮫ࡜་Ꮫࡣᐦ᥋୙㞳ࡢ㛵ಀ࡟࠶ࡿࡀࠊ་Ꮫࡀேࡢ⏕࿨ࡸ⑌⑓ࢆ┤᥋ࡢᑐ㇟࡜
ࡍࡿࡢ࡟ᑐࡋࠊ⸆Ꮫࡣ⏕࿨࡜≀㉁㸦་⸆ရ㸧ࡢ࢖ࣥࢱ࣮ࣇ࢙࢖ࢫᵓ⠏ࢆ௓ࡋ࡚๰⸆࡜⸆≀౑⏝㐺ṇ໬
ࢆᇶ┙࡜ࡋࡓ᭱㐺໬⸆≀἞⒪ࢆᐇ㊶ࡋࠊே㢮♫఍࡟㈉⊩ࡍࡿࠋ୍᪉ࠊ⸆Ꮫࢆಟࡵࡓ⪅࡟ࡣ⸆๣ᖌᅜᐙ
ヨ㦂ࡢཷ㦂㈨᱁ࡀ୚࠼ࡽࢀࠊ⸆Ꮫࡣ་⒪࡟࠾࠸࡚㔜せ࡞ᙺ๭ࢆᢸ࠺⸆๣ᖌࡢ⫱ᡂࢆ♫఍࠿ࡽ௜クࡉࢀ
࡚࠸ࡿࠋ
ᮏ⸆Ꮫ◊✲⛉ࡣࠊㅖᏛၥ㡿ᇦࡢ⤫ྜ࡜₇⧢ࢆ㏻ࡌ࡚ୡ⏺࡟౛ࢆぢ࡞࠸๰㐀ⓗ࡞⸆Ꮫࡢ͆๰͇࡜͆⒪͇
ࡢᣐⅬࢆᵓ⠏ࡋࠊඛ➃ⓗ๰⸆⛉Ꮫ࣭་⒪⸆Ꮫ◊✲ࢆ㐙⾜ࡋ࡚♫఍ࡢⓎᒎ࡟኱ࡁࡃ㈉⊩ࡍࡿࡇ࡜ࢆ┠ᶆ
࡜ࡍࡿࠋᩍ⫱࡟࠾࠸࡚ࡣࠊ⏕࿨೔⌮ࢆᇶ┙࡟⊂๰ⓗ࡞๰⸆◊✲ࢆ㐙⾜ࡋ࠺ࡿ㈨㉁ࠊ⬟ຊࢆ᭷ࡍࡿ◊✲
⪅࡜ࠊ㧗ᗘ࡞ᑓ㛛ⓗ▱㆑࣭ᢏ⬟ࢆ᭷ࡋ⫋⬟ࡢᣦᑟ⪅࡜࡞ࡿ⸆๣ᖌࡢ⫱ᡂࢆ┠ᣦࡍࠋࡲࡓࠊ⸆Ꮫ㒊࡟࠾
࠸࡚ࡣࠊ⸆Ꮫࡢᇶ♏࡜࡞ࡿ⮬↛⛉ᏛࡢㅖᏛၥ㸦᭷ᶵ໬Ꮫࠊ≀⌮໬Ꮫࠊ⏕≀໬Ꮫ➼㸧࡜⸆Ꮫᅛ᭷ࡢᏛၥ
㸦⸆⌮Ꮫࠊ⸆๣Ꮫࠊ⾨⏕໬Ꮫ➼㸧࡟㛵ࡍࡿᇶ♏▱㆑࡜ᢏ⾡ࢆᩍ⫱ࡋࠊ⸆Ꮫ◊✲࡟ᑐࡍࡿ▱ⓗዲወᚰ࠾
ࡼࡧ⸆๣ᖌ⫋⬟ࡢᇶ♏࡜࡞ࡿ⮫ᗋ⸆Ꮫ▱㆑ࠊ⫋ᴗ೔⌮ࡢᾰ㣴ࢆ㏻ࡌ࡚ࠊ◊✲⪅ࠊ་⒪ே࡜ࡋ࡚ồࡵࡽ
ࢀࡿᏛ⏕ࡢᇶᮏⓗ⣲㣴ࡢྥୖࢆᅗࡿࠋ
ᖹᡂ㸯㸶ᖺᗘࡼࡾࠊ⸆ᏛࡢᏛ㒊ᩍ⫱ࡣࠊ๰⸆◊✲⪅ࢆึࡵ࡜ࡍࡿከᵝ࡞ேᮦࡢ㣴ᡂࢆ┠ⓗ࡜ࡍࡿ㸲
ᖺไࡢ⸆⛉Ꮫ⛉࡜ࠊ་⒪ே࡜ࡋ࡚ࡢ⸆๣ᖌ㈨᱁ࢆᇶ┙࡜ࡍࡿࠊ་⒪ࠊ◊✲ࠊᩍ⫱ᚑ஦⪅ࡢ㣴ᡂࢆ┠ⓗ
࡜ࡍࡿ㸴ᖺไࡢ⸆Ꮫ⛉ࢆే⨨ࡍࡿ᪂ࡋ࠸ᩍ⫱ไᗘ࡟⛣⾜ࡋࡓࠋࡇࢀࡣࠊࡇࢀࡲ࡛⸆Ꮫ㒊ࡀᥖࡆ࡚ࡁࡓ
Ꮫ㒊ᩍ⫱ࡢ⌮ᛕࠊ┠ᶆࢆࡼࡾ୍ᒙ᫂☜໬ࡋࡓࡶࡢ࡛ࠊᮏᏛࡣࠊᨵ㠉ࡢ⌮ᛕ࡜┠ᶆࢆᑛ㔜ࡋࠊࡇࢀࢆ୺
ᑟࡋ࡚ࠊ᪂ࡋ࠸⸆Ꮫ◊✲ࠊᩍ⫱ീࡢ☜❧࡟ᣮᡓࡍࡿࠋࡲࡓࠊ⌮ᛕ࡜┠ᶆࡢᐇ⌧࡟ྥࡅࠊ◊✲ᩍ⫱ࢩࢫ
ࢸ࣒ࡢᰂᵓ㐀໬ࠊࢢ࣮ࣟࣂࣝ໬ࠊ♫఍ⓗ㐃ᦠࡢᙉ໬࡞࡝ࢆ┠ᣦࡋࡓไᗘᨵ㠉࡟⥅⥆ⓗ࡟ྲྀࡾ⤌ࡴࠋ
㸦㸰㸧ἢ㠉࡜⌧≧
⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ࡢἢ㠉ࢆ㈨ᩱ,㸫㸯࡟♧ࡋࡓࠋ
ி㒔኱Ꮫ⸆Ꮫ㒊ࡣࠊ᫛࿴㸯㸲ᖺ࡟་Ꮫ㒊⸆Ꮫ⛉࡜ࡋ࡚᪂タࡉࢀࠊ᫛࿴㸰㸶ᖺ࡟኱Ꮫ㝔ࡀタ⨨ࡉࢀࡓᚋ
᫛࿴㸱㸳ᖺ࡟⸆Ꮫ㒊࡟⛣⾜ࡋࠊ௨ᚋ᫛࿴㸱㸷ᖺ࠿ࡽᖹᡂ㸲ᖺࡲ࡛ࡣ㸯㸱ㅮᗙయไ࡛㐠Ⴀࡉࢀࡓࠋᖹᡂ
㸳ᖺ࡟኱Ꮫ㝔⊂❧ᑓᨷ࡜ࡋ࡚ࠊ㸰ㅮᗙࡢ᪂タࢆྵࡴࠕ⸆ရస⏝ไᚚࢩࢫࢸ࣒ᑓᨷࠖࢆタ⨨ࡋඛ➃◊✲
ࡢ᥎㐍࡟ྲྀࡾ⤌ࡴయไࢆᩚ࠼ࡓᚋࠊ⸆Ꮫ◊✲࣭ᩍ⫱ࡢ୍ᒙࡢ㧗ᗘ໬ࢆ┠ᣦࡋ࡚ࠊ⌮ᛕࠊ┠ᶆࠊ⤌⧊ࠊ
ᩍ⫱ࢩࢫࢸ࣒࡞࡝࡟㛵ࡍࡿ⥲ྜⓗ㆟ㄽࢆ㋃ࡲ࠼ࠊ᪂ࡋ࠸ᴫᛕࡢᩜ⾝࡟ྥࡅ࡚ᖹᡂ㸷ᖺᗘ࡟኱Ꮫ㝔㔜Ⅼ
໬ࢆ⾜ࡗࡓࠋᮏᨵ⤌࡟ࡼࡾࠊ⸆Ꮫ㒊ࡣ㸱ᑓᨷ㸶኱ㅮᗙ࡜㸱༠ຊㅮᗙ࠿ࡽ࡞ࡿ኱Ꮫ㝔⸆Ꮫ◊✲⛉࡟෌⦅
ᡂࡉࢀࠊඛ➃ⓗ࡞⸆Ꮫࡢ᪂Ꮫၥయ⣔ࡢᵓ⠏࡜㧗ᗘ࡞ᑓ㛛ⓗ▱㆑ࢆ᭷ࡍࡿ◊✲⪅ࠊ⸆๣ᖌࡢ⫱ᡂ࡟ྲྀࡾ
⤌ࡴࡇ࡜࡟࡞ࡗࡓࠋᖹᡂ㸯㸷ᖺᗘ࡟ࡣࠊࢥࣥࣆ࣮ࣗࢱ⛉Ꮫࡢ㐍Ṍ࡟ᨭ࠼ࡽࢀࡓࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕
−1−
ࢡࢫࢆ᰾࡜ࡍࡿ᝟ሗ⛉Ꮫࢆ๰⸆⛉Ꮫ࡜⼥ྜࡉࡏࠊ㹇㹒๰⸆◊✲⪅ࠊᢏ⾡⪅ࡢ⫱ᡂࢆ┠ᣦࡋ࡚᪂ࡓ࡟་
⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࡀタ⨨ࡉࢀࠊࡉࡽ࡟ᖹᡂ㸰㸰ᖺᗘ࡟ࡣࠊ๰⸆⛉Ꮫᑓᨷࠊ⏕࿨⸆⛉Ꮫᑓᨷࠊ་⒪⸆
⛉Ꮫᑓᨷࡢ㸱ᑓᨷࡀ⸆⛉Ꮫᑓᨷࡢ㸯ᑓᨷ࡟ᨵ⤌ࡉࢀࠊ㸰ᑓᨷ㸷኱ㅮᗙ࡜㸱༠ຊㅮᗙࡢᩍ⫱◊✲యไ࡜
࡞ࡾࠊ⌧ᅾ࡟⮳ࡗ࡚࠸ࡿࠋ
㸦㈨ᩱϨ㸫㸰㸧ࠋ
⌧ᅾᮏ◊✲⛉ࡢ◊✲ᩍ⫱యไࡣࠊ⸆⛉Ꮫᑓᨷ㸰㸱ศ㔝ࠊ་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷ㸵ศ㔝ࡼࡾ࡞ࡾࠊࡇ
ࡢ୰࡟ࡣ໬Ꮫ◊✲ᡤ㸲ศ㔝࡜་Ꮫ㒊௜ᒓ⑓㝔⸆๣㒊㸯ศ㔝ࡢィ㸳ศ㔝ࡢ༠ຊㅮᗙࠊ࠾ࡼࡧྠᵝ࡟༠ຊ
యไ࡟࠶ࡿ⏕࿨⛉Ꮫ◊✲⛉㸰ศ㔝ࡀྵࡲࢀࡿ㸦㈨ᩱ,㸫㸰㸧
ࠋࡉࡽ࡟ࠊ⤫ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥ
ࢱ࣮ࠊ⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮ࠊ᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮ࠊ㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬ࠾ࡼࡧ
ᐤ㝃ㅮᗙ㸰ࡀຍࢃࡾࠊ⌧ᅾࠊ඲య࡛◊✲యไࡣ㸱㸴◊✲ศ㔝ࡢᵓᡂ࡜࡞ࡗ࡚࠸ࡿࠋ◊✲⛉ࡢᇶᖿศ㔝
ࡣࠊ᪂タࠊ⤫ྜ࡞࡝ࡢᩚഛࢆ⤒࡚ᖹᡂ㸯㸷ᖺᗘ࡟ࡣ㸰㸱◊✲ศ㔝యไ࡜࡞ࡾࠊᑗ᮶ᵓ᝿࡟ᇶ࡙ࡃඛ➃
◊✲㡿ᇦࡢᑟධ࡞࡝ࡀ㐍ᒎࡋࡓࡇ࡜࠿ࡽࠊ➨Ϫ❶࠶ࡿ࠸ࡣᕳᮎࡢᴗ⦼୍ぴ࡟⧳ࡵࡽࢀ࡚࠸ࡿ࡜࠾ࡾࠊ
๰㐀ⓗ࡞๰⸆⛉Ꮫࠊ⏕࿨⛉Ꮫࠊ་⒪⸆Ꮫࠊ᝟ሗ⸆Ꮫ◊✲ࢆ⥲ྜⓗ࡟㐍ࡵࡿᇶ┙ࡀᵓ⠏ࡉࢀࡘࡘ࠶ࡿࠋ
⌧ᅾࠊᇶᖿㅮᗙࡢ◊✲⛉ᩍဨࡢ౑⏝ᐃဨࡣࠊ኱Ꮫ㝔㔜Ⅼ໬ᚋࠊᅜᐙබົဨࡢᐃဨ๐ῶࠊ⏕࿨⛉Ꮫ◊✲
⛉࡬ࡢ⛣⟶➼ࢆ⤒࡚ࠊ㸳㸮ே࡜࡞ࡗ࡚࠸ࡿ㸦㈨ᩱϨ㸫㸱㸧ࠋ
ᖹᡂ㸰㸰ᖺᗘࡢࠊ኱Ꮫ㝔ಟኈㄢ⛬࡜༤ኈᚋᮇㄢ⛬ࡢᏛ⏕ᐃဨࡣࡑࢀࡒࢀ㸯㸲㸱ྡ࡜㸯㸮㸶ྡ࡛࠶ࡿ
ࡀࠊ⌧ဨࡣࡑࢀࡒࢀ㸯㸳㸰ྡ࡜㸯㸮㸯ྡ࡛࠶ࡾࠊಟኈㄢ⛬ࡣᐃဨࢆୖᅇࡗ࡚࠸ࡿ㸦㈨ᩱ,㸫㸲㸧ࠋࡇࢀ
ࡣࠊᮏᏛᏛ㒊Ꮫ⏕ࡢ◊✲⪅ᣦྥࡀᙉ࠸ࡇ࡜࡟ຍ࠼ࠊ◊✲⛉ಟ஢⪅࡟ᑐࡍࡿ♫఍ࡢ㟂せࡶ኱ࡁ࠸ࡇ࡜ࢆ
཯ᫎࡋ࡚࠸ࡿࠋࡲࡓࠊᅜ㈝࣭⚾㈝␃Ꮫ⏕ࡶᩘከࡃᅾ⡠ࡋ࡚࠾ࡾࠊᅜ㝿஺ὶࡶάⓎ࡟⾜ࢃࢀ࡚࠸ࡿࠋᖹ
ᡂ㸰㸯ᖺᗘࡢ኱Ꮫ㝔◊✲⛉ಟ஢⪅ࡢ㐍㊰ࡣࠊಟኈㄢ⛬࡛ࡣࠊ⣙㸱㸰㸣ࡀ༤ኈᚋᮇㄢ⛬࡬ࡢ㐍Ꮫࠊ⣙㸴
㸴㸣ࡀ௻ᴗࡢ◊✲㛤Ⓨ⫋࡬ᑵ⫋ࡋࠊ༤ኈᚋᮇㄢ⛬ಟ஢⪅ࡣࠊᅜබ⚾❧ࡢᩍ⫱࣭◊✲⫋࡜௻ᴗࡢ◊✲㛤
Ⓨ⫋࡟ᑵ⫋ࡋ࡚࠾ࡾࠊ◊✲⪅ᚿྥࡀᴟࡵ࡚ᙉ࠸㸦㈨ᩱ,,㸫㸰ཧ↷㸧
ࠋ
ᖹᡂ㸯㸶ᖺᗘ࠿ࡽࠊ㸴ᖺไ⸆ᏛᏛ㒊ᩍ⫱ࡢᐇ᪋࡟ࡼࡾࠊ㸳㸮ேࡢධᏛᐃဨࢆᣢࡘ⸆⛉Ꮫ⛉㸦㸲ᖺไ㸧
࡜㸱㸮ேࡢධᏛᐃဨࢆᣢࡘ⸆Ꮫ⛉㸦㸴ᖺไ㸧ࡢ㸰Ꮫ⛉ไ࡜࡞ࡗࡓࠋ⸆Ꮫ㒊ࡢ㸯Ꮫᖺࡢᐃဨࡣࠊ⸆⛉Ꮫ
⛉㸳㸮ྡࠊ⸆Ꮫ⛉㸱㸮ྡ࡛ࠊᖹᡂ㸯㸶ᖺࡣࠊ๓ᮇヨ㦂㸵㸮ྡࠊᚋᮇヨ㦂㸯㸮ྡࡢເ㞟ᐃဨ࡛ධᏛ⪅ࡢ
㑅ᢤࢆ⾜ࡗࡓࡀࠊᖹᡂ㸯㸷ᖺ௨㝆ࡣ๓ᮇヨ㦂ࡢࡳ࡛㑅ᢤࢆ⾜ࡗ࡚࠸ࡿ㸦㈨ᩱϨ㸫㸳㸧ࠋᏛ㒊࢝ࣜ࢟ࣗࣛ
࣒ࡣධᏛ᫬࠿ࡽ༞ᴗ᫬ࡲ࡛ࡢ㸲ᖺ㛫࠶ࡿ࠸ࡣ㸴ᖺ㛫୍㈏ᩍ⫱ࡢ⌮ᛕࡢࡶ࡜࡟⦅ᡂࡉࢀ࡚࠸ࡿࡀࠊᇶᮏ
ⓗ࡟᭱ึࡢ㸰ᖺ㛫࡟඲Ꮫඹ㏻⛉┠ࢆ⥲ྜே㛫Ꮫ㒊࡛ᒚಟࡋࠊᖹ⾜ࡋ࡚㸯ᖺḟࡼࡾ⸆Ꮫ㒊࡛Ꮫ㒊⛉┠ࢆ
ᒚಟࡍࡿࠋࡲࡓࠊᐇ㦂⛉Ꮫࢆ㔜どࡍࡿ❧ሙ࠿ࡽࠊ㸱ᖺḟ࡟ᑓ㛛ᐇ⩦ࡀ㓄ᙜࡉࢀࠊ⸆⛉Ꮫ⛉࡛ࡣ㸲ᖺḟ
࡟ࠊ⸆Ꮫ⛉࡛ࡣ㸲ᖺ㹼㸴ᖺḟ࡟ศ㔝㓄ᒓ࡟ࡼࡿ≉ูᐇ⩦ࡀ㓄ᙜࡉࢀ࡚࠸ࡿࠋࡲࡓࠊ⸆Ꮫ⛉ࡢ㸲ᖺ㹼㸴
ᖺḟ࡟ࡣࠊ་⒪⸆Ꮫ࡟㛵ࡍࡿㅮ⩏ࡸ₇⩦ࡀ⾜ࢃࢀࠊ㸳ᖺḟ࡟ࡣ㛗ᮇᐇົᐇ⩦ࡀ⾜ࢃࢀࡿࠋᖹᡂ㸰㸯ᖺ
ᗘࡢᏛ㒊༞ᴗ⏕㸦ᪧไᗘ㸧ࡢ㐍㊰ඛࡣࠊ⣙㸷㸵㸣ࡀ኱Ꮫ㝔◊✲⛉ಟኈㄢ⛬࡬ࡢ㐍Ꮫࠊ⣙㸱㸣ࡀ〇⸆఍
♫ࠊ໬Ꮫ఍♫࡞࡝ࡢ◊✲㛤Ⓨ⫋࡬ࡢᑵ⫋࡛࠶ࡿࠋ኱Ꮫ㝔◊✲⛉࡬ࡢ㐍Ꮫࡣࠊ౛ᖺ㸶᭶ୗ᪪࡟ᐇ᪋ࡉࢀ
ࡿ㑅ᢤヨ㦂࡛Ỵᐃࡉࢀࡿࠋ඲Ꮫඹ㏻ᩍ⫱࡟࠾࠸࡚ࡣ࣏ࢣࢵࢺࢮ࣑࡞࡝ࡢᐇ㊶ࠊᏛ㒊ᩍ⫱࡟࠾࠸࡚ࡣᑓ
㛛ᐇ⩦ࡢయ⣔ⓗࢢ࣮ࣝࣉ໬ࠊ㸴ᖺไᩍ⫱࡟ᑐᛂࡍࡿࡓࡵࡢ᪂ࡋ࠸⛉┠ࡸ㸲ᖺไࠊ㸴ᖺไࢆಠ▔ⓗ࡟Ꮫ
⩦࡛ࡁࡿศ㔝ᶓ᩿ᆺࡢ⛉┠ࡢᑟධ࡞࡝ࡢᨵ㠉ࢆ㐍ࡵࡿ࡜ඹ࡟ࠊᏛ⏕࡜ࡢ஺ὶᙉ໬ࢆ┠ⓗ࡜ࡋࡓࢢ࣮ࣝ
ࣉᢸ௵ไᗘ࡟ᇶ࡙࠸ࡓᣦᑟࡢᐇ᪋࡞࡝ࠊᩍ⫱ᨵ㠉࡟ྥࡅࡓྲྀࡾ⤌ࡳࢆ⥅⥆ⓗ࡟㐍ࡵ࡚࠸ࡿࠋ
−2−
⌧᭷ࡍࡿᰯᆅࠊ᪋タᘓ≀ࡣ㈨ᩱϨ㸫㸴ࡢ࡜࠾ࡾ࡛ࠊ࠿ࡘ࡚ࡣ᪋タࡢ⊃㝼໬ࠊ⪁ᮙ໬ࡀ኱ࡁ࡞ၥ㢟࡜
࡞ࡗ࡚࠸ࡓࡀࠊ⣙㸳㸪㸳㸮㸮੍ࡢᗋ㠃✚ࢆᣢࡘ⥲ྜ◊✲Ჷࡀᖹᡂ㸯㸳ᖺ㸯᭶࡟ࠊࡲࡓᩍ⫱Ჷ⣙㸯㸪㸮
㸮㸮੍ࡀᖹᡂ㸯㸳ᖺ㸯㸰᭶࡟᪂Ⴀࡉࢀࡓࠋᘬࡁ⥆ࡁ᪤Ꮡᘓ≀ࡢᨵಟ࣭ᨵ⠏ࡀ㐍ࡵࡽࢀࠊᖹᡂ㸯㸴ᖺ㸱
᭶࡟ࡣ⸆Ꮫ㒊ᮏ㤋ᮾすᲷ⣙㸴㸪㸮㸮㸮੍ࡢᨵಟᕤ஦ࡀ❹ᕤࡋࠊᖹᡂ㸯㸵ᖺ㸯㸰᭶࡟ࡣ⸆Ꮫ㒊ู㤋⣙㸷
㸮㸮੍ࡢᨵಟࡶ⾜ࡗࡓࠋࡉࡽ࡟ࠊᖹᡂ㸯㸷ᖺ㸱᭶࡟ࡣࠊ⸆Ꮫ㒊ᮏ㤋༡໭Ჷࡢᨵಟᕤ஦ࡶ❹ᕤࡍࡿ࡜ඹ
࡟ᖹᡂ㸰㸰ᖺ㸱᭶࡟ࡣࠊ་⒪⸆Ꮫᩍ⫱Ჷࡀ᪂Ⴀࡉࢀࠊ᪋タ㠃࡛ࡢᩚഛࡣ඲࡚ࡢᘓ≀࡟ࡘ࠸࡚࡯ࡰ᏶ᡂ
ࡋࡓࠋ
㸦㸱㸧ᑗ᮶ᵓ᝿
ᖹᡂ㸷ᖺᗘ࡟ᐇ᪋ࡋࡓ኱Ꮫ㝔㔜Ⅼ໬ᚋ㸳ᖺࢆ⤒㐣ࡋࡓᖹᡂ㸯㸱ᖺᗘᮎࢆࡶࡗ࡚ࠊᮏࢩࢫࢸ࣒ࠊ࢝ࣜ
࣒࢟ࣗࣛ࡟ࡼࡿ኱Ꮫ㝔ཬࡧᏛ㒊ᩍ⫱ࡣᖺḟ㐍⾜࡟ࡼࡾ᏶ᡂࡋࡓࠋࡇࢀ࡟ࡼࡾࠊ㧗ᗘ࡞ᩍ⫱◊✲ᇶ┙ࡢ
☜❧ࠊ୍య໬ࡋࡓᏛ㒊࣭኱Ꮫ㝔ᩍ⫱ࠊ༤ኈㄢ⛬࡟࠾ࡅࡿຠ⋡ⓗ࡞Ꮫ఩ྲྀᚓࡢ᥎㐍࡞࡝ࠊ㔜Ⅼ໬ࡢ┠ⓗ
࡜ࡉࢀࡓ㡯┠ࡢከࡃࡣ㡰ḟᐇ⌧ࡉࢀࡓࡀࠊ௨ᚋࡉࡽ࡟ࠊ㧗➼ᩍ⫱ᶵ㛵ࡢ⤌⧊㐠Ⴀయไࡢᨵၿ࡜㈈ᨻᇶ
┙ࡢ☜ಖࢆ┠ᣦࡍᅜ❧኱Ꮫࡢἲே໬ࡀᖹᡂ㸯㸴ᖺ࡟ᐇ᪋ࡉࢀࠊᘬࡁ⥆ࡁୡ⏺Ỉ‽ࡢ◊✲ᇶ┙ࡸ➇தⓗ
◊✲⎔ቃࡢᩚഛ࡞࡝ࢆ┠ᣦࡋࡓ኱Ꮫᨵ㠉ࡀᛴົ࡜࡞ࡗ࡚࠸ࡿࠋࡉࡽ࡟ࠊᖹᡂ㸯㸶ᖺᗘ࠿ࡽ⸆Ꮫᩍ⫱㸴
ᖺไࡀᑟධࡉࢀࠊ㸲ᖺไᏛ⛉ࠊ㸴ᖺไᏛ⛉ࢆే⨨ࡍࡿᅜ❧኱Ꮫࡣࠊ᪂ᩍ⫱ไᗘࡢࡶ࡜ࠊᩍ⫱◊✲యไ
ࡸ⎔ቃࢆᩚഛࡍࡿࡇ࡜ࡶồࡵࡽࢀ࡚࠸ࡿࠋ
ᮏ◊✲⛉࡛ࡣࠊࡇ࠺ࡋࡓືࡁ࡟ᑐᛂࡋ࡚ࠊ㸦㸯㸧๰⸆⛉Ꮫࡢᛴ㏿࡞Ⓨᒎࠊ㸦㸰㸧་⒪࡟࠾ࡅࡿ⸆≀἞
⒪ࡢ㔜せᛶࡢቑ኱ࠊ
㸦㸱㸧⮫ᗋ⸆Ꮫࡢᇶ┙ᵓ⠏࡜㧗ᗘᑓ㛛⫋⬟ࢆ᭷ࡍࡿ⸆๣ᖌ⫱ᡂ࡬ࡢ♫఍ⓗせㄳࡢቑ
኱࡞࡝ࢆ⫼ᬒ࡜ࡋࡓ◊✲⛉ᑗ᮶ᵓ᝿ࢆ⟇ᐃࡋࠊࡑࡢ୍⎔࡜ࡋ࡚ࠊᖹᡂ㸯㸲ᖺᗘ࡟๰⸆࣭་⒪㐃ᦠ⸆Ꮫ
ࢥ࢔㒊㛛ࢆ◊✲⛉⤌⧊࡜ࡋ࡚タ⨨ࡋࡓࠋ㸰ᐤ㝃ㅮᗙࡢ᪂タ➼ࢆ㏻ࡌ࡚ࠊᮏࢥ࢔㒊㛛ࡣ๰⸆ࠊ་⒪ࡢ୧
㠃࡟ࢃࡓࡿ◊✲࣭ᩍ⫱ࡢᣐⅬ࡜ࡋ࡚᭷ຠ࡟ᶵ⬟ࡋࠊࡑࡢᡂᯝࢆཷࡅ࡚ᖹᡂ㸯㸶ᖺᗘ࡟ࡣࠊ⣧ቑᐃဨ㸲
ேࢆྵࡴ⥲ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥࢱ࣮ࡢタ⨨ࡀ≉ูᩍ⫱◊✲⤒㈝࡛ᥐ⨨ࡉࢀࡓࠋࡉࡽ࡟ࠊ᪂ᩍ
⫱ไᗘ㛤ጞ࠿ࡽ㸳ᖺ┠ࢆ㏄࠼ࡓᖹᡂ㸰㸰ᖺᗘ࡟ࡣࠊ᪂ࡓ࡟⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮ࢆ᪂タࡋࠊᮏᏛ
ࡢᩍ⫱యไࢆᩚഛࡋࡓࠋ
௒ᚋࡢᑗ᮶ᵓ᝿࡜ࡋ࡚ࠊ⌧ᅾࠊ⤌⧊㠃࡛ࡣ㸦㸯㸧๰⸆࡜་⒪ࢆ࣮࣮࢟࣡ࢻ࡜ࡋ♫఍ࠊ⏘ᴗ⏺࡜ࡢ㐃
ᦠࡢᇶ┙࡜࡞ࡿ◊✲ࢭࣥࢱ࣮ࡢタ⨨ࢆィ⏬ࡋࠊࡇࢀ࡜㐃ືࡋ࡚ࠊ
㸦㸰㸧ඛ➃ⓗ◊✲㡿ᇦࡢᑟධ࡜ᑐᛂࡍ
ࡿே஦㑅⪃ࠊ㸦㸱㸧እ㒊㈨㔠࡟ᇶ࡙ࡃ◊✲⤌⧊ࡢタ⨨ࠊ㸦㸲㸧♫఍㐃ᦠࡸᅜ㝿࣭Ꮫ⼥ඹྠ◊✲ࡢᐇ᪋ࢆ
ྍ⬟࡜ࡍࡿ◊✲᪋タࡢ☜ಖ➼ࢆ㐍ࡵ࡚࠸ࡿࠋ➇தⓗእ㒊㈨㔠࡟ࡼࡿࣉࣟࢪ࢙ࢡࢺ࡜ࡋ࡚ࡣࠊ◊✲⛉ࢆ
༢఩࡜ࡍࡿ㸰㸯ୡ⣖ &2( ࣉࣟࢢ࣒ࣛࠕࢤࣀ࣒⛉Ꮫࡢ▱ⓗ᝟ሗᇶ┙࣭◊✲ᣐⅬᙧᡂࠖ
㸦ᖹᡂ㸯㸳ᖺᗘ㹼㸯
㸷ᖺᗘ㸧ࡸ㨩ຊ࠶ࡿ኱Ꮫ㝔ᩍ⫱࢖ࢽࢩ࢔ࢸ࢕ࣈࠕ⏕࿨࣭⛉Ꮫ᝟ሗ࡟ᇶ࡙ࡃ⼥ྜ๰⸆◊✲⪅㣴ᡂࠖ
㸦ᖹᡂ
㸯㸵ᖺᗘ㹼㸯㸶ᖺᗘ㸧
ࠊᆅᇦ་⒪➼♫఍ⓗࢽ࣮ࢬ࡟ᑐᛂࡋࡓ㉁ࡢ㧗࠸་⒪ே㣴ᡂ᥎㐍ࣉࣟࢢ࣒ࣛ㸦་
⒪ே *3㸧ࠕඛ➃་⒪ࡢ⫱࣭๰⸆ࢆඛᑟࡍࡿ⸆๣ᖌ⫱ᡂࠖ㸦ᖹᡂ㸯㸶ᖺᗘ㹼㸰㸮ᖺᗘ㸧ࡀ᥇ᢥࡉࢀࠊ᪤࡟
ᐇ⦼ࢆᣲࡆ࡚࠸ࡿࠋࡲࡓࠊ኱Ꮫ㝔ᩍ⫱ᨵ㠉ᨭ᥼ࣉࣟࢢ࣒ࣛࠕᐇ㊶ⓗ๰⸆ᡓ␎ᐙ㣴ᡂࣉࣟࢢ࣒ࣛ㸦ᖹᡂ
㸰㸮ᖺᗘ㹼㸰㸰ᖺᗘ㸧ࠊ⏘Ꮫ㐃ᦠ࡟ࡼࡿᐇ㊶ᆺேᮦ⫱ᡂ஦ᴗ㸦ࢧ࣮ࣅࢫ࣭࢖ࣀ࣮࣋ࢩࣙࣥேᮦ⫱ᡂ㸧
ࠕࣘ
ࣅ࢟ࢱࢫ೺ᗣ♫఍ࡢ᭱᪂ࢽ࣮ࢬ࡟ᑐᛂࡋࡓᐇ㊶ᆺேᮦ⫱ᡂࠖ
㸦ᖹᡂ㸰㸮ᖺᗘ㹼㸰㸰ᖺᗘ㸧ࡀ⌧ᅾ㐍⾜୰
−3−
࡛࠶ࡿࠋࡉࡽ࡟ࠊᖹᡂ㸰㸯ᖺᗘ࡟ࡣࠊ㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬ࠾ࡼࡧ᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮
ࢆ᪂タࡋࠊࡉࡽ࡞ࡿ⸆Ꮫ◊✲⛉ࡢ◊✲᥎㐍ࢆᅗࡿ᪂ࡓ࡞◊✲యไࢆᩚ࠼ࡓࠋ⥲ྜ◊✲Ჷࡢ᪂Ⴀࡸ⸆Ꮫ
㒊ᮏ㤋ࡢᨵಟ➼ࠊ࡯ࡰ᏶ᡂࡋࡓ᪋タ㠃࡛ࡢᩚഛࡀࡇࢀࢆᨭ࠼࡚࠾ࡾࠊ௒ᚋࠊ◊✲࡜ᩍ⫱ࡢ୧㠃࡟࠾࠸
࡚ࠊᑗ᮶ᵓ᝿ࡢᐇ⌧࡟ྥࡅࠊ⥲ྜⓗయไᩚഛࢆ㐍ࡵࡿィ⏬࡛࠶ࡿࠋ
୍᪉ࠊ┤㏆ࡢ㔜せ࡞ㄢ㢟࡜ࡋ࡚ࠊ኱Ꮫ㝔ࡢᩚഛࡀᣲࡆࡽࢀࡿࠋᖹᡂ㸯㸶ᖺᗘࡢᏛ㒊ᨵ⤌ࠊ࠾ࡼࡧᖹ
ᡂ㸰㸰ᖺᗘࡢಟኈㄢ⛬ࡢᨵ⤌࡟కࡗ࡚ࠊᖹᡂ㸰㸲ᖺᗘ࠿ࡽࠊ⸆Ꮫ㒊㸲ᖺไ⸆⛉Ꮫ⛉࡜⸆Ꮫ◊✲⛉ಟኈ
ㄢ⛬⸆⛉Ꮫᑓᨷࢆᇶ♏࡟࠾ࡃ༤ኈᚋᮇㄢ⛬ࡢᩚഛࠊ࠾ࡼࡧ⸆Ꮫ㒊㸴ᖺไ⸆Ꮫ⛉ࢆᇶ♏࡟࠾ࡃ⸆Ꮫ◊✲
⛉༤ኈㄢ⛬ࡢタ⨨ࡀᚲせ࡟࡞ࡿࡓࡵ‽ഛࢆ㐍ࡵ࡚࠸ࡿ㸦ୗᅗ㸧ࠋ㏆ᖺࡢ་⸆ရ㛤Ⓨ᪉ἲࡢከᵝ໬ࢆ཯ᫎ
ࡋ࡚ࠊ⸆Ꮫ኱Ꮫ㝔ᩍ⫱࡟ᑐࡍࡿ♫఍ⓗ࡞せㄳࡣࠊ⊂๰ⓗ࡞๰⸆◊✲ࢆ㐙⾜࡛ࡁࡿேᮦ࠿ࡽ㧗ᗘ࡛ከᵝ
࡞ඛ➃་⒪ࢆᨭ࠼ࡿேᮦࡲ࡛ࠊࡇࢀࡲ࡛௨ୖ࡟ከᒱ࡟ࢃࡓࡾࠊ⤫ྜⓗ࡞⪃࠼᪉ࡢ࡛ࡁࡿேᮦࡢ㣴ᡂࡀ
ồࡵࡽࢀ࡚࠸ࡿࠋࡑࢀ࡟కࡗ࡚ࠊᚑ᮶࠿ࡽࡢ๰⸆⛉Ꮫࠊ⏕࿨⸆⛉Ꮫࠊ་⒪⸆⛉Ꮫࡢࡼ࠺࡞࠸ࢃࡺࡿࠕ⦪
๭ࡾᩍ⫱ࠖࡣࠊ㏆ᖺࡢ♫఍ⓗせㄳ࡟ࡣ࡞ࡌࡲ࡞ࡃ࡞ࡗ࡚ࡁࡓࠋࡇ࠺ࡋࡓ⫼ᬒࢆ㚷ࡳࠊᖹᡂ㸰㸰ᖺᗘ࡟
ࡣࠊከᵝ໬࡟ᑐᛂ࡛ࡁࡿࡼ࠺࡟⤫ྜⓗ࡟⸆Ꮫ኱Ꮫ㝔ᩍ⫱ࢆ⾜࠺ࡓࡵࠊ⸆Ꮫ㒊㸲ᖺไᏛ⛉ࡢ༞ᴗ⏕ࢆ୺
࡞ᑐ㇟࡜ࡍࡿಟኈㄢ⛬ࢆᚑ᮶ࡢ๰⸆⛉Ꮫࠊ⏕࿨⸆⛉Ꮫࠊ་⒪⸆⛉Ꮫࡢ㸱ᑓᨷ࠿ࡽ㸯ᑓᨷ㸦⸆⛉Ꮫᑓᨷࠊ
ᐃဨ㸳㸮ே㸧࡬࡜ᨵ⤌ࡋࡓࠋ༤ኈᚋᮇㄢ⛬ࡢᨵ⤌࡟㝿ࡋ࡚ࡶࠊಟኈㄢ⛬ࡢᨵ⤌࡜ྠࡌ㊃᪨࡛ࠊᚑ᮶ࡢ
㸱ᑓᨷࢆ⸆⛉Ꮫᑓᨷࡢ㸯ᑓᨷ࡜ࡍࡿィ⏬࡛࠶ࡿࠋ୍᪉ࠊ᪂ࡓ࡟タ⨨ࡍࡿ༤ኈㄢ⛬⸆Ꮫᑓᨷ࡟࠾࠸࡚ࡣࠊ
᪂ࡋ࠸⸆Ꮫᩍ⫱ไᗘࡢୗ࡛ࠊ㧗ᗘ࡞ඛ➃་⒪ࢆᨭ࠼ࡿ་⒪⸆Ꮫ◊✲⪅ࡸ⸆๣ᖌࡢ㣴ᡂࡔࡅ࡛࡞ࡃࠊ་
⸆ရࡢ◊✲࣭㛤Ⓨ࣭᝟ሗᥦ౪➼࡟ᚑ஦ࡍࡿ◊✲⪅ࡸᢏ⾡⪅ࠊ་⸆ရᢎㄆᑂᰝࡸබ⾗⾨⏕࡞࡝ࢆᢸᙜࡍ
ࡿ⾜ᨻᚑ஦⪅ࠊ⸆Ꮫᩍ⫱࡟ᦠࢃࡿᩍဨ࡞࡝ࡢ㣴ᡂࢆࡵࡊࡍࠋࡇ࠺ࡋࡓ኱Ꮫ㝔ࡢᩚഛࢆ㏻ࡌ࡚ྛᑓᨷࡢ
࣑ࢵࢩࣙࣥ㐩ᡂࡢࡓࡵࡢᇶ┙ࢆ☜❧ࡍࡿ࡜ඹ࡟ࠊᑗ᮶ᵓ᝿ᐇ⌧࡟ྥࡅࡓᩍ⫱◊✲άືࢆ᥎㐍ࡋ࡚࠸ࡃ
ィ⏬࡛࠶ࡿࠋ
ᖹᡂ㸰㸲ᖺᗘ௨㝆ࡢ⦅ᡂ࡜Ꮫᖺ㐍⾜
−4−
Ϩ㸫㸯 ⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ἢ㠉
᫛࿴ ᖺ ᭶
་Ꮫ㒊⸆ရศᯒ໬Ꮫㅮᗙࠊ⸆ရ〇㐀Ꮫㅮᗙ᪂タ
ᖺ ᭶
་Ꮫ㒊⸆Ꮫ⛉᪂タ
ᖺ ᭶
᭷ᶵ⸆໬Ꮫㅮᗙ᪂タ
ᖺ ᭶
↓ᶵ⸆໬Ꮫㅮᗙ᪂タ
ᖺ ᭶
⏕⸆Ꮫㅮᗙ᪂タ
ᖺ ᭶ Ꮫ఩ࡢ⛠ྕ࡟⸆Ꮫ༤ኈࡀຍࢃࡿ
ᖺ ᭶ ་Ꮫ㒊⸆Ꮫ⛉➨ ᅇ༞ᴗᘧᣲ⾜
ᖺ ᭶
᪂ไி㒔኱Ꮫタ⨨
ᖺ ᭶ ⸆๣Ꮫㅮᗙ᪂タ
ᖺ ᭶ ⏕≀⸆ရ໬Ꮫㅮᗙ᪂タ
ᖺ ᭶ ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉⸆Ꮫᑓᨷタ⨨
ᖺ ᭶ ་Ꮫ㒊᭷ᶵᚤ㔞ඖ⣲ศᯒ⥲ྜ◊✲᪋タタ⨨
ᖺ ᭶ ⸆Ꮫ㒊㸦⸆Ꮫ⛉㸧タ⨨ࠊ⸆ရศᯒᏛࠊ⸆ရ〇㐀Ꮫࠊ᭷ᶵ⸆໬Ꮫࠊ↓ᶵ⸆໬Ꮫࠊ⏕⸆
Ꮫࠊ⸆๣Ꮫࠊ⏕≀⸆ရ໬Ꮫㅮᗙ᪂タ㸦་Ꮫ㒊ྠㅮᗙࡢᗫṆ㸧
ᖺ ᭶
᭷ᶵᚤ㔞ඖ⣲ศᯒ⥲ྜ◊✲᪋タࢆ⸆Ꮫ㒊࡟㝃⨨
ᖺ ᭶ 〇⸆⛉Ꮫ⛉ࠊ⸆⏝᳜≀໬Ꮫㅮᗙ᪂タ
ᖺ ᭶ ⸆ရస⏝Ꮫㅮᗙࠊ⸆ရᕤᏛㅮᗙ᪂タ
ᖺ ᭶ ⸆ရ≀⌮໬Ꮫㅮᗙࠊ⾨⏕໬Ꮫㅮᗙ᪂タ
ᖺ ᭶ ᨺᑕᛶ⸆ရ໬Ꮫㅮᗙ᪂タ
ᖺ ᭶ ⸆Ꮫ◊✲⛉〇⸆໬Ꮫᑓᨷタ⨨
ᖺ ᭶
⸆ရస⏝Ꮫㅮᗙࢆ⸆⌮Ꮫㅮᗙ࡟ࠊ⏕≀⸆ရ໬Ꮫㅮᗙࢆ⏕≀໬Ꮫㅮᗙ࡟ᨵ⛠
ᖺ ᭶
⸆Ꮫ㒊㝃ᒓ⸆⏝᳜≀ᅬタ⨨
ᖺ ᭶
⸆ရᕤᏛㅮᗙࢆᚤ⏕≀⸆ရᏛㅮᗙ࡟ᨵ⛠
ᖹᡂ ᖺ ᭶
⸆Ꮫ◊✲⛉࡟᝟ሗ⸆Ꮫㅮᗙ㸦⸆Ꮫ⛉↓ᶵ⸆໬Ꮫㅮᗙ᣺᭰㸧
ࠊศᏊస⏝ไᚚᏛㅮᗙ㸦᪂
タ㸧ࠊ㑇ఏᏊ⸆ရᏛㅮᗙ㸦᪂タ㸧ࢆᇶᖿㅮᗙ࡜ࡋࠊ⑓ែᶵ⬟ศᯒᏛࠊືែไᚚࢩࢫ
ࢸ࣒⸆๣Ꮫࠊ⏕≀᭷ᶵ໬Ꮫ㸦໬Ꮫ◊✲ᡤ㸧ࠊ⏕యᶵ⬟໬Ꮫ㸦໬Ꮫ◊✲ᡤ㸧
ࠊ་⒪⸆๣
Ꮫ㸦་Ꮫ㒊㝃ᒓ⑓㝔㸧ࡢྛㅮᗙࢆ༠ຊㅮᗙ࡜ࡍࡿ⸆ရస⏝ไᚚࢩࢫࢸ࣒ᑓᨷ㸦⊂❧
ᑓᨷ㸧ಟኈㄢ⛬タ⨨
ᖺ ᭶
⸆Ꮫ◊✲⛉⸆ရస⏝ไᚚࢩࢫࢸ࣒ᑓᨷ㸦⊂❧ᑓᨷ㸧༤ኈᚋᮇㄢ⛬タ⨨
ᖺ ᭶
኱Ꮫ㝔㔜Ⅼ໬࡟ࡼࡾ⸆Ꮫᑓᨷࠊ〇⸆໬Ꮫᑓᨷࢆ๰⸆⛉Ꮫᑓᨷࠊ⏕࿨⸆⛉Ꮫᑓᨷࠊ་
⒪⸆⛉Ꮫᑓᨷࡢ ᑓᨷ ኱ㅮᗙ࡟ᨵ⤌
⸆Ꮫ㒊⸆Ꮫ⛉ࠊ〇⸆໬Ꮫ⛉ࢆ⥲ྜ⸆Ꮫ⛉ࡢ Ꮫ⛉࡟ᨵ⤌
ᖺ ᭶
⸆Ꮫ㒊㝃ᒓ⸆⏝᳜≀ᅬࢆ኱Ꮫ㝔⸆Ꮫ◊✲⛉ࡢ㝃ᒓ࡟⛣⾜
ᖺ ᭶
኱Ꮫ㝔⏕࿨⛉Ꮫ◊✲⛉Ⓨ㊊࡟క࠸ࠊ༠ຊㅮᗙ⏕⌮άᛶไᚚᏛศ㔝ࠊ⚄⤒ᶵ⬟ไᚚᏛ
−5−
ศ㔝タ⨨
ᖺ ᭶
⸆ရ〇๣タィᏛㅮᗙ⸆ရศᏊᵓ㐀Ꮫศ㔝ࢆྠㅮᗙࢤࣀ࣒๰⸆⛉Ꮫศ㔝࡟ᨵ⛠
⸆ရᶵ⬟⤫ᚚᏛㅮᗙ࡟ᵓ㐀⏕≀⸆Ꮫศ㔝ࢆ᪂タ
ᖺ ᭶ ⸆Ꮫ◊✲⛉⥲ྜ◊✲Ჷ❹ᕤ
ᖺ ᭶
ᐤ㝃ㅮᗙࠕ๰⸆⚄⤒⛉Ꮫㅮᗙࠖ᪂タ
⸆Ꮫ◊✲⛉㝃ᒓ๰⸆࣭་⒪㐃ᦠ⸆Ꮫࢥ࢔㒊㛛᪂タ
ᖺ ᭶
ᐤ㝃ㅮᗙࠕ་⸆ရ⌮ㄽタィᏛㅮᗙࠖ᪂タ
ᖺ ᭶
ୡ⣖㹁㹍㹃ࣉࣟࢢ࣒ࣛ᥇ᢥ࡟క࠸༠ຊㅮᗙ⏕࿨▱㆑ࢩࢫࢸᏛศ㔝タ⨨㸦タ⨨ᮇ
㛫㸸 ୡ⣖㹁㹍㹃ࣉࣟࢢ࣒ࣛᐇ᪋ᮇ㛫㸧
ᖺ ᭶
ᅜ❧኱Ꮫἲேி㒔኱Ꮫタ❧
ᖺ ᭶
⸆Ꮫ㒊ࡢ⥲ྜ⸆Ꮫ⛉ࢆ⸆⛉Ꮫ⛉ࠊ⸆Ꮫ⛉࡟ᨵ⤌
⸆Ꮫ◊✲⛉㝃ᒓ⤫ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥࢱ࣮᪂タ㸦㝃ᒓ๰⸆࣭་⒪㐃ᦠ⸆Ꮫ
ࢥ࢔㒊㛛ࡢᗫṆ㸧
ᖺ ᭶
⸆Ꮫ◊✲⛉ᮏ㤋ᨵಟᕤ஦❹ᕤ
ᖺ ᭶
⸆Ꮫ◊✲⛉་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷタ⨨
ᖺ ᭶
ᐤ㝃ㅮᗙࠕࢼࣀࣂ࢖࢜་⸆๰ᡂ⛉Ꮫㅮᗙࠖ᪂タ
ᖺ ᭶ ᐤ㝃ㅮᗙࠕࢩࢫࢸ࣒๰⸆⛉Ꮫㅮᗙࠖ᪂タ
ᖺ ᭶
㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬ᪂タ
ᖺ ᭶
᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮᪂タ
ᖺ ᭶
⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮᪂タ
−6−
Ϩ㸫㸰 ⸆Ꮫ◊✲⛉ࡢᑓᨷࠊㅮᗙ࠾ࡼࡧศ㔝
ᑓᨷ
ㅮᗙ
ศ㔝
⸆⛉Ꮫ
⸆ရ๰〇໬Ꮫ
⸆ရ᭷ᶵ〇㐀Ꮫ
⸆ရྜᡂ໬Ꮫ
⸆ရศᏊ໬Ꮫ
⸆ရ㈨※Ꮫ
⸆ရᶵ⬟⤫ᚚᏛ
⸆ရᶵ⬟ゎᯒᏛ
ᵓ㐀⏕≀⸆Ꮫ
⸆ရ〇๣タィᏛ
ࢤࣀ࣒๰⸆⛉Ꮫ
〇๣ᶵ⬟ゎᯒᏛ
⢭ᐦ᭷ᶵྜᡂ໬Ꮫ
⢭ᐦ᭷ᶵྜᡂ㸦໬Ꮫ◊✲ᡤ㸧
⏕యศᏊ⸆Ꮫ
⏕యศᏊㄆ㆑Ꮫ
ศᏊᚤ⏕≀Ꮫ
⏕యᶵ⬟⸆Ꮫ
⏕యᶵ⬟ゎᯒᏛ
㑇ఏᏊ⸆Ꮫ
⏕⌮άᛶไᚚᏛ㸦⏕࿨⛉Ꮫ◊✲⛉㸧
⏕య᝟ሗ⸆Ꮫ
⏕య᝟ሗไᚚᏛ
⚄⤒ᶵ⬟ไᚚᏛ㸦⏕࿨⛉Ꮫ◊✲⛉㸧
⏕యᶵ⬟໬Ꮫ
⏕యᶵ⬟໬Ꮫ㸦໬Ꮫ◊✲ᡤ㸧
⸆ရືែ་⒪⸆Ꮫ
⸆ရືែไᚚᏛ
⸆ရస⏝ゎᯒᏛ
⮫ᗋ⸆Ꮫᩍ⫱
⑓ែᶵ⬟ゎᯒᏛ
⑓ែᶵ⬟ศᯒᏛ
⑓ែ᝟ሗ⸆Ꮫ
⸆ရືែ་⒪⸆Ꮫ
⸆ရືែไᚚᏛ
⸆ရస⏝ゎᯒᏛ
⮫ᗋ⸆Ꮫᩍ⫱
⑓ែᶵ⬟ゎᯒᏛ
⑓ែᶵ⬟ศᯒᏛ
⑓ែ᝟ሗ⸆Ꮫ
་⒪⸆๣Ꮫ
་⒪⸆๣Ꮫ㸦་Ꮫ㒊㝃ᒓ⑓㝔㸧
−7−
་⸆๰ᡂ᝟ሗ
་⸆๰ᡂ᝟ሗ⛉Ꮫ
⸆⌮ࢤࣀ࣑ࢡࢫ
⛉Ꮫ
ࢣࣔࢤࣀ࣑ࢡࢫ
ࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮
ࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮
㸦ไᚚศᏊᏛ㸧
ࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮
㸦๰⸆ィ⟬໬Ꮫ㸧
⤫ྜࢤࣀ࣑ࢡࢫ㸦໬Ꮫ◊✲ᡤ㸧
ศᏊタィ᝟ሗ㸦໬Ꮫ◊✲ᡤ㸧
ᐤ㝃ㅮᗙ
⤫ྜ⸆Ꮫ
ࢼࣀࣂ࢖࢜་⸆๰ᡂ⛉Ꮫㅮᗙ
ࢩࢫࢸ࣒๰⸆⛉Ꮫㅮᗙ
⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨ
ࣇࣟࣥࢸ࢕࢔
ඛ➃⸆Ꮫᩍ⫱㛤ᣅ
ᩍ⫱ࢭࣥࢱ࣮
⮫ᗋ⸆Ꮫᩍ⫱㛤ᣅ
⤫ྜ⸆Ꮫᩍ⫱
㛤Ⓨࢭࣥࢱ࣮
་⸆ရ㛤Ⓨᩍ⫱
๰⸆⛉Ꮫᩍ⫱
ᐇ㊶⮫ᗋ⸆Ꮫ
᝟ሗ⛉Ꮫᩍ⫱
㠉᪂ⓗ
㐃ᦠᨭ᥼ࣘࢽࢵࢺ㸦6&8㸧
ࢼࣀࣂ࢖࢜
ඛ㐍ࢼࣀࣂ࢖࢜◊✲ࣘࢽࢵࢺ㸦1%8㸧
๰⸆◊✲ᣐⅬ
⸆≀㏦㐩◊✲⌜㸦'6*㸧
་⸆๰ฟ◊✲⌜㸦6+*㸧
᭱ඛ➃๰⸆◊✲
ࢭࣥࢱ࣮
ࡀࢇ◊✲ࢢ࣮ࣝࣉ
࢔ࣝࢶࣁ࢖࣐࣮◊✲ࢢ࣮ࣝࣉ
−8−
Ϩ㸫㸱 ᩍ⫋ဨ
㸦ᖹᡂ㸰㸱ᖺ㸯᭶㸯᪥⌧ᅾ㸧
ᩍ ⫱ ⫋ ဨ
஦ົ⣔⫋ဨ
ᩍ ᤵ ෸ᩍᤵ ㅮ ᖌ ຓ ᩍ
ே
㸯㸴
ே
㸯㸶
ே
㸱
ᑠ ィ
ே
ே
ே
㸯㸱
㸳㸮
㸯㸰
Ϩ㸫㸲 ኱Ꮫ㝔Ꮫ⏕ࡢᅾᏛ≧ἣ
஦ົ⫋ဨ
ࡑࡢ௚
ᢏ⾡⫋ဨ
ࡢ⫋ဨ
ே
㸱
ᅾᏛ⪅ᩘ
ே
ே
㸯㸳
཰ᐜᐃဨ
ᑠィ
ே
㸴㸳
㸦ྛᖺᗘ㸳᭶㸯᪥⌧ᅾ㸧
ಟኈㄢ⛬
ྜィ
༤ኈᚋᮇㄢ⛬
๭ྜ
཰ᐜᐃဨ
ᅾᏛ⪅ᩘ
๭ྜ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
Ϩ㸫㸳 Ꮫ㒊Ꮫ⏕ࡢධᏛᖺูᅾᏛ≧ἣ
Ꮫ㒊Ꮫ⏕ධᏛᖺูᅾᏛ⪅ᩘ
㸦ᖹᡂ㸰㸰ᖺ㸳᭶㸯᪥⌧ᅾ㸧
+ ᖺᗘ
+ ᖺᗘ
+ ᖺᗘ
+ ᖺᗘ
+ ᖺᗘ + ᖺᗘ
ධ Ꮫ
ධ Ꮫ ධ Ꮫ ධ Ꮫ ධ Ꮫ ධ Ꮫ ༊ ศ
⥲ྜ⸆Ꮫ⛉ ⸆⛉Ꮫ⛉
+ ᖺᗘ
௨๓
ධᏛ
ィ
⸆ Ꮫ ⛉
ᅾᏛ⪅ྜィ
−9−
Σ㧢 ⮎ቇㇱᧄ㙚࡮ᢎ⢒᫟‫ޔ‬೎㙚ߩᐔ㕙࿑
− 10 −
− 11 −
Ϩ㸴㸦㸰㸧 ⥲ྜ◊✲➼ࡢᖹ㠃ᅗ
− 12 −
− 13 −
ϩ ᩍ⫱
㹙ϩ㹛ᩍ⫱
㸦㸯㸧⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ࡢᩍ⫱࣭ᣦᑟ┠ᶆ
㸯㸧Ꮫ㒊ᩍ⫱
⸆Ꮫࡣࠊே㢮ࡢཿᬛࡢ⤖ᬗ࡛࠶ࡿࠕࡃࡍࡾࠖ࡜ࡑࢀ࡟㛵㐃ࡍࡿㅖ⛉Ꮫࢆໟᣓࡍࡿ⛉Ꮫ࡛࠶ࡿࠋᚑࡗ
࡚⸆Ꮫ㒊ࡣࠊ་⸆ရࡢ๰〇࡜⏕⏘ࢆ᥎㐍ࡍࡿ◊✲⪅࡜ᢏ⾡⪅ࡢ⫱ᡂࠊ⏕࿨⛉Ꮫࢆᢸ࠺◊✲⪅࡜ᢏ⾡⪅
ࡢ⫱ᡂࠊ୪ࡧ࡟་⸆ရࡢ㐺ṇ౑⏝࡜⟶⌮ࢆᢸ࠺⸆๣ᖌࡢ㣴ᡂࡀ౑࿨࡛࠶ࡿࠋࡑࡢṔྐࢆ⣣ゎࡅࡤࠊ⸆
Ꮫ㒊ࡢ๓㌟࡛࠶ࡿ་Ꮫ㒊⸆Ꮫ⛉᫬௦ࡢᩍ⫱ࡣ⸆ࡢ≀㉁ⓗഃ㠃ࡀᙉㄪࡉࢀࡓࠋࡑࡢᚋࠊ᫛࿴㸱㸳ᖺࡢ⸆
Ꮫ㒊ࡢ๰タࢆᶵ࡟⸆Ꮫ⛉࡜〇⸆໬Ꮫ⛉ࡢ㸰Ꮫ⛉ไࡀ࡜ࡽࢀࠊ⸆≀࡜⏕య࣭⏕యᵓᡂ≀㉁࡜ࡢ┦஫స⏝
࡞࡝⏕≀Ꮫⓗ࠾ࡼࡧ་⒪⸆Ꮫⓗᩍ⫱ࡶᮏ᱁ⓗ࡟ጞࡲࡗࡓࠋࡋ࠿ࡋࠊ㏆ᖺ⸆Ꮫ࡟ᑐࡍࡿ♫఍ⓗせㄳࡀከ
㠃໬ࡍࡿ࡟క࠸ࠊ⸆Ꮫᩍ⫱ࡣࡇࢀࡽࡢᯟ⤌ࡳ࡟࡜ࡽࢃࢀࡿࡇ࡜࡞ࡃࠊ⸆Ꮫ࡜࠸࠺ඹ㏻ࡢᇶ┙࡟❧ࡗࡓ
య⣔ⓗᏛ⩦࡜㧗ᗘᑓ㛛ᩍ⫱㸦኱Ꮫ㝔➼ᩍ⫱㸧࡟ࡴࡅࡓᇶ┙▱㆑Ꮫ⩦ࡢᚲせᛶࡀᣦ᦬ࡉࢀ࡚࠸ࡓࠋࡇࡢ
ࡼ࠺࡞せㄳ࠿ࡽࠊᖹᡂ㸷ᖺ࡟๓グ㸰Ꮫ⛉ࡣ⥲ྜ⸆Ꮫ⛉࡜ࡋ࡚⤫ྜᨵ⤌ࡉࢀࡓࠋࡉࡽ࡟ᖹᡂ㸯㸶ᖺᗘ࠿
ࡽࠊ⏕࿨⛉Ꮫ͌๰⸆⛉Ꮫ◊✲⪅ᩍ⫱ࡢ୍ᒙࡢ඘ᐇࢆ┠ⓗ࡜ࡋࡓ㸲ᖺไࡢ⸆⛉Ꮫ⛉࡟ຍ࠼࡚ࠊᐇᡓⓗ࡞⸆
๣ᖌࡢ㣴ᡂࢆ┠ᶆ࡜ࡋ࡚㸴ᖺไࡢ⸆Ꮫ⛉ࢆ᪂タࡋࡓࠋ
⸆Ꮫࡣࠊ་⸆ရࡢ๰〇࣭⏕⏘࣭⟶⌮࣭㐺⏝ࢆ┠ᶆ࡜ࡍࡿ⥲ྜ⼥ྜ⛉Ꮫ࡛࠶ࡿࠋࡑࡇ࡛ࡣᇶ♏࡜ᐇ㊶
ⓗᑐᛂࡀ୙ྍศࡢ㛵ಀ࡟࠶ࡾࠊ≀⌮Ꮫࠊ໬Ꮫࠊ⏕≀Ꮫ࡞࡝ࡢ῝໬ࢆᇶ♏࡜ࡋࠊࡑࢀࡽࢆ⥲ྜⓗ࡟⼥ྜ
ࡋࡓᏛၥ㡿ᇦࡢᣑࡀࡾࡀ࠶ࡿࠋࡲࡓࠊ་⸆ရ࡜࠸࠺⑌ᝈࡢ἞⒪࣭ண㜵࡞࡝ே㛫ࡢ⏕࿨ཬࡧ೺ᗣࡢಖ඲
࡟┤᥋ୟࡘ῝ࡃ㛵୚ࡋࡓ≀㉁ࢆᑐ㇟࡟ࡍࡿ࡜࠸࠺ࠊ♫఍ⓗ࡟㔜せ࡞ᙺ๭ࢆᢸࡗ࡚࠸ࡿࠋࡍ࡞ࢃࡕࠊ⸆
Ꮫ㒊ࡣ♫఍࡟ᑐࡋࠊ་⸆ရࡢ๰〇࣭⏕⏘ࢆᢸ࠺⸆Ꮫ◊✲⪅࣭ᢏ⾡⪅ࠊ⏕࿨⛉Ꮫࢆ᥎㐍ࡍࡿ⸆Ꮫ◊✲⪅͌
ᢏ⾡⪅ࠊ୪ࡧ࡟་⒪࡟࠾ࡅࡿ་⸆ရࡢ㐺⏝࣭⟶⌮ࢆᢸ࠺⸆๣ᖌࢆ㣴ᡂࡍࡿ౑࿨ࡀ࠶ࡿࠋ
ࡋࡓࡀࡗ࡚ࠊᏛ㒊ᩍ⫱࡛ࡣࠊ㇏࠿࡞▱ᛶ࡜᱁ㄪ㧗࠸ே㛫ᛶ࣭೔⌮ほ࡟⿬ᡴࡕࡉࢀࡓែᗘࢆ㣴࠺࡜࡜
ࡶ࡟ࠊ⮬↛⛉Ꮫ࡬ࡢ῝࠸⯆࿡ࢆ⫱ࡳࠊே㛫ࡢ⥲ྜⓗ೺ᗣࡢព⩏ࢆ⪃࠼ࡉࡏࡿࡇ࡜ࢆᇶᮏ࡟ࠊ⸆Ꮫ◊✲
⪅࣭ᢏ⾡⪅࠶ࡿ࠸ࡣ⸆๣ᖌ࡜ࡋ࡚ᑗ᮶ά㌍ࡍࡿࡓࡵ࡟ᚲせ࡞ᇶ♏ⓗ▱㆑ࢆಟᚓࡉࡏࠊࡑࢀࢆᛂ⏝ฟ᮶
ࡿᢏ⾡ࢆ㌟࡟௜ࡅࡉࡏࡿࡇ࡜ࢆ┠ᶆ࡜ࡍࡿࠋᖹᡂ㸯㸶ᖺᗘ࠿ࡽࠊ㸲ᖺไࡢ⸆⛉Ꮫ⛉࡜㸴ᖺไࡢ⸆Ꮫ⛉
࡜ࢆే⨨ࡋ࡚࠸ࡿࡀࠊࡇ࠺ࡋࡓᏛ㒊ᩍ⫱࡟࠾ࡅࡿᇶᮏⓗ࡞⌮ᛕࡣኚࢃࡗ࡚࠸࡞࠸ࠋ⮬↛⛉ᏛࡢᏛ⩦࡛
ࡣࠊ୍ᐃࡢẁ㝵࡟㐩ࡍࡿࡲ࡛ࡣ✚ࡳୖࡆⓗ࡞⣔⤫ⓗᏛ⩦ࡀᚲせ࡛࠶ࡾࠊᩍ㣴㒊ࡀᏑᅾࡋ࡚࠸ࡓ᫬௦ࡶࠊ
ࡑࡢ㸯ࠊ㸰ᖺḟ࡟ᒚಟࡍ࡭ࡁ⛉┠ࡢᣦᐃࡀ⾜ࢃࢀ࡚࠸ࡓࠋᖹᡂ㸱ᖺᗘࡢ኱Ꮫタ⨨ᇶ‽ࡢᨵゞ࡟కࡗ࡚
ᩍ㣴㒊ࡀᗫṆࡉࢀࠊ᪂ࡓ࡟ᑟධࡉࢀࡓ㸲ᖺ୍㈏ᩍ⫱ࡢ⌮ᛕ࡟ᑐᛂࡋ࡚ࠊᖺḟⓗ࡞✚ࡳୖࡆ᪉ᘧࡀ୍ᒙ
᫂☜໬ࡉࢀࠊᇶᮏⓗ࡞ㅮ⩏⛉┠ࡣᚲಟ⛉┠࡟ᣦᐃࡉࢀࡓࠋ㸴ᖺไࡀᑟධࡉࢀࡓ⌧ᅾࡶࡇࡢᏛ㒊୍㈏ᩍ
⫱ࡢ⌮ᛕࢆᇶ┙࡟ྛᏛ⛉࡟≉ᚩⓗ࡞࣒࢝ࣜ࢟ࣗࣛࡀ⤌ࡲࢀ࡚࠸ࡿࠋࡉࡽ࡟ࠊ⸆Ꮫࡣᐇ㦂⛉Ꮫ࡛࠶ࡿ࡜
ࡢㄆ㆑ࢆᏛ⏕࡟ᙉࡃ᳜࠼௜ࡅࡿࡓࡵ࡟ࠊࡇࢀࡲ࡛Ꮫ㒊ᩍ⫱࡟࠾࠸࡚ࡶᐇ⩦⛉┠ࡀ㔜せどࡉࢀ࡚࠾ࡾࠊ
඲ᐇ⩦⛉┠ࡀᚲಟ⛉┠࡟ᣦᐃࡉࢀ࡚࠸ࡿࠋࡲࡓࠊ⸆Ꮫ࡜ࡣఱ࠿ࠊఱࢆᏛࡪ࡭ࡁ࠿ࠊ⸆Ꮫ࡟㌟ࢆ⨨ࡃࡶ
ࡢ࡟ࡣ࡝ࡢࡼ࠺࡞೔⌮ほࡀᚲせ࠿ࠊ➼ࢆ᫂☜࡟⮬ぬࡉࡏࡿࡓࡵ࡟ࠕ⸆Ꮫ೔⌮࣭ᴫㄽࠖࡀࠊᑗ᮶ࡢᅜ㝿
ⓗ࡞ά㌍࡟ഛ࠼ࡿ㓄៖࠿ࡽࠕ⛉Ꮫⱥㄒ㸿ࠊ㹀ࠖࡀᚲಟ⛉┠࡜ࡋ࡚タࡅࡽࢀ࡚࠸ࡿࠋ
ᖹᡂ㸳ᖺᗘ࡟㸲ᖺ୍㈏ᩍ⫱ࡢ⌮ᛕࡢᇶ࡟࣒࢝ࣜ࢟ࣗࣛࡀᨵゞࡉࢀࠊࡑࢀࡲ࡛Ꮫ㒊⛉┠࡜㒊ศⓗ࡟㔜
− 15 −
」ࡋ࡚࠸ࡓᪧᩍ㣴㒊⛉┠ࡢ⮬↛⛉Ꮫ⣔⛉┠ࡀᩚ⌮ࡉࢀࠊࡼࡾ⣔⤫ⓗ࡞ᑓ㛛ᇶ♏ᩍ⫱ࡀྍ⬟࡜࡞ࡗࡓࠋ
ࡲࡓࠊྛ⛉┠ࡢᇶ♏ⓗ㒊ศࠊ඲ᐇ⩦⛉┠ࠊ⸆Ꮫᴫㄽࠊ⛉Ꮫⱥㄒࢆᚲಟ⛉┠࡟ᣦᐃࡍࡿࡇ࡜࡟ࡼࡾᩍ⫱
┠ⓗࢆ᫂☜໬ࡋࡓࠋࡉࡽ࡟ࠊࡇࡢࡼ࠺࡞ᇶᮏ⌮ᛕࢆ୍ᒙᙉ໬ࡍࡿࡓࡵࠊᖹᡂ㸷ᖺ࡟⸆Ꮫ⛉࡜〇⸆໬Ꮫ
⛉ࡣ⥲ྜ⸆Ꮫ⛉࡜ࡋ࡚⤫ྜᨵ⤌ࡉࢀࠊ࣒࢝ࣜ࢟ࣗࣛࡶ኱ᖜ࡟ᨵゞࡉࢀࡓࠋࡉࡽ࡟ࠊᖹᡂ㸯㸶ᖺᗘ࠿ࡽ
ࡣ᪂ᩍ⫱ไᗘࡀᑟධࡉࢀࠊ㸲ᖺไ⸆⛉Ꮫ⛉ཬࡧ㸴ᖺไ⸆Ꮫ⛉ࢆే⨨ࡋࡓࡀࠊྛᏛ⛉ࡢᩍ⫱┠ᶆࡢ㐩ᡂ
ࡍࡿࡓࡵ࣒࢝ࣜ࢟ࣗࣛࡣ඲㠃ⓗ࡟ᨵゞࡉࢀࡓࠋᖹᡂ㸰㸮ᖺᗘ௨㝆࡟⸆Ꮫ㒊࡛㛤ㅮࡉࢀ࡚࠸ࡿ⛉┠ࢆᏛ
⛉ู࡟㈨ᩱ ,,㸫㸯㸦㸧
ࠊ㸦㸧࡟♧ࡍࠋ
⸆Ꮫࣔࢹࣝࢥ࢔࣒࢝ࣜ࢟ࣗࣛ࡟ἢࡗ࡚య⣔໬ࡉࢀࡓ⛉┠ࠊ≉ูᐇ⩦ࡀ㓄ᙜࡉࢀ࡚࠸ࡿࠋᚑ᮶Ϩ㹼ϫ
⩌࡟ศ㢮ࡋ࡚࠸ࡓᏛ㒊ᑓ㛛⛉┠ࢆࠊ໬Ꮫ⣔ࠊ≀⌮⣔ࠊ⏕≀⣔ࠊ་⒪⣔࡜᫂☜໬ࡋࠊࡉࡽ࡟㐍ᒎࡍࡿ᝟
ሗ⛉Ꮫ࡟✚ᴟⓗ࡟ᑐᛂࡉࡏࡿࡓࡵ᝟ሗ⣔ࡶ᪂ࡓ࡟タᐃࡋࡓࠋᏛ⛉ࡢᩍ⫱┠ᶆ࡟ᇶ࡙ࡁᚲಟ⛉┠ࠊ㑅ᢥ
⛉┠ࢆ㑅ᐃࡋ࡚࠸ࡿࡀࠊ୺࡜ࡋ࡚๰⸆⛉Ꮫ◊✲⪅ࡢ㣴ᡂࢆ┠ⓗ࡜ࡋ࡚࠸ࡿ⸆⛉Ꮫ⛉࡟࠾࠸࡚ࡶ㸳ࡘࡢ
་⒪⣔⛉┠ࢆᣦᐃ⛉┠࡜ࡋ࡚࠸ࡿࠋ⸆Ꮫ⛉࡟࠾࠸࡚ࡣࠊ㸲㹼㸴ᖺḟ࡟⊂⮬ࡢ་⒪⣔ᚲಟ⛉┠࠶ࡿ࠸ࡣ
ᣦᐃ⛉┠ࡀ㓄ᙜࡉࢀ࡚࠾ࡾࠊ㸳ᖺḟ࡟ࡣ㛗ᮇࡢᐇົᐇ⩦ࡀ㓄ᙜࡉࢀ࡚࠸ࡿࠋ⸆Ꮫ⛉ࡢᏛ⏕ࡣࠊ་Ꮫ㒊
௜ᒓ⑓㝔⸆๣㒊࡟࡚ᐇ᪋ࡉࢀࡿ⑓㝔ᐇ⩦ཬࡧㄪ๣⸆ᒁ࡛ᐇ᪋ࡉࢀࡿ⸆ᒁᐇ⩦ࢆྛ㸯㸯㐌㛫࡟Ώࡾᒚಟ
ࡍࡿࠋࡉࡽ࡟ࠊᖹᡂ㸰㸰ᖺᗘ࡟ࡣࠊྛᏛ⛉ࡢᯟࢆ㉸࠼ࡓᶓ᩿ⓗ⤫ྜᆺᩍ⫱ࢆᐇ᪋ࡋࠊ๰⸆ࠊ་⒪ࡢศ
㔝ᶓ᩿ⓗ࡞Ꮫኈຊࢆ⫱ᡂࡍࡿࡓࡵ࡟᪂ࡓ࡟㸲ࡘࡢ₇⩦ࠊᐇ⩦⛉┠ࢆ୧Ꮫ⛉࡟᪂タࡋࠊ࣒࢝ࣜ࢟ࣗࣛࡢ
୍ᒙࡢ඘ᐇࢆᅗࡗ࡚࠸ࡿࠋ
ࡲࡓࠊி㒔኱Ꮫ⸆Ꮫ㒊࡛ࡣࡼࡾ㧗ᗘ࡞ᩍ⫱ࢆồࡵ࡚኱Ꮫ㝔࡬㐍ᏛࡍࡿᏛ⏕ࡀቑຍࡍࡿഴྥࡀ࠶ࡾࠊ
ᖹᡂ㸯㸮ᖺᗘ௨㝆ࡣ༞ᴗ⪅ࡢ㸶㸮㸣௨ୖࡀ኱Ꮫ㝔◊✲⛉࡟㐍Ꮫࡋ࡚࠸ࡿ㸦㈨ᩱ ,,㸫㸰㸧
ࠋࡇࡢࡓࡵࠊᏛ
㒊ᩍ⫱ࡣ኱Ꮫ㝔ᩍ⫱࡜ࡶ᭷ᶵⓗ࡞ᩚྜᛶࢆࡶࡗ࡚㐍ࡵࡽࢀࡿࡼ࠺ὀពࢆᡶࡗ࡚࠸ࡿ
㸰㸧኱Ꮫ㝔ᩍ⫱
኱Ꮫ㝔ࡣඃ⚽࡞ேᮦࡢ⫱ᡂ࡜ᇶ♏◊✲ࡢ୰᰾࡛࠶ࡾࠊࡑࡇ࡛ࡢᩍ⫱ࡣᏛ㒊ᩍ⫱࡜ࡢᐦ᥋࡞㐃ᦠ࡜༠
ຊࢆಖࡕࡘࡘ⾜ࢃࢀ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࡀࠊࡲࡓ⊂⮬ᛶࢆࡶᣢࡘ࡭ࡁࡶࡢ࡛࠶ࡿࠋ㏆ᖺࠊ⛉Ꮫᢏ⾡ࡢ㐍
Ṍࡀⴭࡋࡃࠊ㧗ᗘ࡞◊✲⬟ຊ࡜ᑓ㛛▱㆑ࢆᣢࡗࡓ኱Ꮫ㝔ಟ஢⪅࡟ᑐࡍࡿ♫఍ⓗせㄳࡀቑ኱ࡋࠊ኱Ꮫ㝔
ࡢ㔜せᛶࡀ♫఍࡟ᗈࡃㄆ㆑ࡉࢀࡿࡼ࠺࡟࡞ࡗࡓࠋ⸆Ꮫ◊✲⛉࡟࠾࠸࡚ࡶࠊࡼࡾᗈ࠸ど㔝࡜▱㆑ࠊࡼࡾ
ඃࢀࡓ⛉Ꮫ◊✲ᡓ␎ࢆᏛ⩦ࡍࡿࡓࡵࡢㅮ⩏⛉┠ࢆ㛤タࡋࠊྛㅮᗙ࡟࠾ࡅࡿ₇⩦࣭ᐇ⩦࣭ᐇ㦂ࢆ඘ᐇࡉ
ࡏ࡚ࡁࡓࡀࠊࡉࡽ࡟㧗ᗘ࡞ᑓ㛛ⓗ▱㆑࡜⬟ຊࠊᗈ࠸ど㔝ࢆᣢࡘேᮦࢆࡼࡾከࡃ㣴ᡂࡋࠊ♫఍ⓗせㄳ࡟
ᛂ࠼ࡿ࡭ࡃࠊᖹᡂ㸳ᖺᗘ࡟ࡣ⊂❧ᑓᨷ⛉ࠕ⸆ရస⏝ไᚚࢩࢫࢸ࣒ᑓᨷࠖࢆタ⨨ࡋࠊ኱Ꮫ㝔ᩍ⫱ࡢ඘ᐇ
ࢆ┠ᣦࡍែໃࢆᩚ࠼ࡓࠋᖹᡂ㸷ᖺ࡟ࡣඛ➃ⓗ࣭⊂๰ⓗ࡞ᅜ㝿ⓗỈ‽ࡢ◊✲ࢆᢸ࠺◊✲⪅⫱ᡂࡢࡓࡵࠊ
኱Ꮫ㝔㔜Ⅼ໬ࢆ⾜࠸⸆Ꮫࠊ〇⸆໬Ꮫࠊ⸆ရస⏝ไᚚࢩࢫࢸ࣒ࡢ㸱ᑓᨷࢆ๰⸆⛉Ꮫࠊ⏕࿨⸆⛉Ꮫ࠾ࡼࡧ
་⒪⸆⛉Ꮫᑓᨷ࡟኱ᖜᨵ⤌ࡋࡓࠋࡲࡓ㸯㸯኱ㅮᗙ㸰㸳ศ㔝ไࢆ᥇⏝ࡋ࡚◊✲ᣦᑟయไࢆ୍ẁ࡜ᙉ໬ࡋ
ࡓࠋࡲࡓࠊᖹᡂ㸯㸳ᖺᗘ࡟ࡣࠕ๰⸆⚄⤒⛉Ꮫㅮᗙࠖ࡜ࠕ་⸆ရ⌮ㄽタィᏛㅮᗙࠖࡢ㸰ᐤ௜ㅮᗙࢆタ⨨
ࡋ⸆Ꮫ㡿ᇦࡢᖜᗈࡉࡢ☜ಖ࡟ࡶດࡵ࡚ࡁࡓࠋࡉࡽ࡟ࠊᖹᡂ㸯㸷ᖺᗘ࡟ࡣࠊࢥࣥࣆ࣮ࣗࢱ⛉Ꮫࡢ㐍Ṍ࡟
ᨭ࠼ࡽࢀࡓࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢆ᰾࡜ࡍࡿ᝟ሗ⛉Ꮫࢆ๰⸆⛉Ꮫ࡜⼥ྜࡉࡏࠊ㹇㹒๰⸆◊✲⪅ࠊ
ᢏ⾡⪅ࡢ⫱ᡂࢆ┠ᣦࡋ࡚᪂ࡓ࡟་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࡀタ⨨ࡉࢀࡓࠋࡲࡓࠊᖹᡂ㸰㸮ᖺ࡟ࡣࠊ
ࠕࢼࣀࣂ
− 16 −
࢖࢜་⸆๰ᡂ⛉Ꮫㅮᗙࠖ࡜ࠕࢩࢫࢸ࣒๰⸆⛉Ꮫㅮᗙࠖࡢ㸰ᐤ௜ㅮᗙࢆ᪂タࡋࡓࠋࡉࡽ࡟ᖹᡂ㸰㸰ᖺᗘ
࡟ࡣࠊ๰⸆⛉Ꮫᑓᨷࠊ⏕࿨⸆⛉Ꮫᑓᨷࠊ་⒪⸆⛉Ꮫᑓᨷࡢ㸱ᑓᨷࡀ⸆⛉Ꮫᑓᨷࡢ㸯ᑓᨷ࡟ᨵ⤌ࡉࢀࠊ
㸰ᑓᨷ㸷኱ㅮᗙ㸱㸮ศ㔝࡜㸳༠ຊㅮᗙࡢᩍ⫱◊✲యไ࡜࡞ࡾࠊ⌧ᅾ࡟⮳ࡗ࡚࠸ࡿࠋ
㸱㸧ᩍ⫱ᣦᑟἲࡢ㛤Ⓨ
⸆Ꮫࡢᩍ⫱࣭◊✲ࡣࠊ୍ᒙࡢ㧗ᗘඛ➃໬ࠊᅜ㝿໬ࡲࡓከ㠃ⓗ࡞♫఍ⓗせㄳ࡟࿧ᛂࡍࡿᚲせࡀ࠶ࡿࡇ
࡜ࡣࡍ࡛࡟グࡋࡓࠋࡇࢀ࡟ࡣྛᑓ㛛ศ㔝ࡢ㧗ᗘ໬ࡢࡳ࡞ࡽࡎྛᩍဨࡢᏛ⏕࡟ᑐࡍࡿᩍ⫱࣭ᣦᑟἲࡢᨵ
Ⰻࠊ㛤Ⓨࡶ㔜せ࡛࠶ࡿࠋᮏᏛ㒊࣭◊✲⛉ᩍဨࡣி㒔኱Ꮫᩍ⫱ᨵၿ㐃⥆ࢩ࣏ࣥࢪ࣒࢘࡟⥅⥆ⓗ࡟ཧຍࡍ
ࡿ࡜࡜ࡶ࡟ࠊ)DFXOW\'HYHORSPHQW㸦)'㸧3URJUDP ࡟ࡶࠊ௨ୗࡢ㏻ࡾࠊி㒔኱Ꮫ㧗➼ᩍ⫱ᩍᤵࢩࢫࢸ࣒
㛤Ⓨࢭࣥࢱ࣮ࡢᤵᴗཧほࣉࣟࢪ࢙ࢡࢺ࡟ᖹᡂ㸯㸰ᖺࡢ㛤タ௨᮶㸯㸲ྡࡀཧຍࡋࡓࠋࡲࡓ⸆Ꮫᩍ⫱༠㆟
఍࣭᪥ᮏ⸆Ꮫ఍࣭᪥ᮏ⸆๣ᖌ◊ಟࢭࣥࢱ࣮ඹദࡢ⸆Ꮫᩍ⫱࣮࣡ࢡࢩࣙࢵࣉ࡟ࡣࠊᩍᤵࠊ෸ᩍᤵࠊຓᩍ
ࡀࢱࢫࢡࣇ࢛࣮ࢫᣦᑟဨ㸦ࢳ࣮ࣇࢱࢫࢡࣇ࢛࣮ࢫࢆྵࡴ㸧࡜ࡋ࡚࣮࣡ࢡࢩࣙࢵࣉ㐠Ⴀࢆ୺ᑟࡍࡿ࡜ඹ
࡟ࠊຓᩍ௨ୖࡢ࡯ࡰ඲࡚ࡢᩍဨࡀ◊ಟཷㅮ⏕࡜ࡋ࡚ཧຍࡍࡿ࡞࡝ࠊᩍ⫱ᣦᑟἲࡢᨵၿ࡟✚ᴟⓗ࡟ྲྀ⤌
ࢇ࡛࠸ࡿࠋ᭱㏆ࠊ㸳ᖺ㛫ࡢཧຍ≧ἣࢆϩ㸱㸦㸯㸧
㸧࡟♧ࡍࠋ
ᖹᡂ㸯㸳ᖺᗘ࠿ࡽ࢔ࣥࢣ࣮ࢺ᪉ᘧ࡟ࡼࡿᏛ⏕࠿ࡽࡢᤵᴗホ౯ࡶ⾜࠸ࠊᤵᴗࡢᨵၿ࡟ᙺ❧࡚࡚࠸ࡿࠋࡲࡓࠊ
ᖹᡂ㸯㸷ᖺᗘᚋᮇ࠿ࡽࡣࠊ඲࡚ࡢㅮ⩏⛉┠࡟ࡘ࠸࡚ᤵᴗ࢔ࣥࢣ࣮ࢺࢆᐇ᪋ࡋ࡚࠸ࡿ㸦㈨ᩱϩ㸱㸦㸰㸧㸧ࠋ
ࡲࡓࠊᖹᡂ㸯㸶ᖺ࡟Ⓨ㊊ࡋࡓி㒔኱Ꮫ )' ◊✲᳨ウጤဨ఍ࡢάື࡟✚ᴟⓗ࡟ཧຍࡋࠊᮏጤဨ఍୺ദࡢࠕᤵ
ᴗホ౯࣮࣡ࢡࢩࣙࢵࣉ࡛ࠖ࢔ࣥࢣ࣮ࢺࡢෆᐜ࡜ࡑࡢ⤖ᯝࡢ୰㛫ホ౯ࢆබ㛤ࠊᖹᡂ㸰㸰ᖺᗘࡣྠ఍୺ദࡢࠕຮ
ᙉ఍ࠖ࡟ཧຍࡍࡿ࡞࡝ࠊᩍ⫱᪉ἲࡢᨵၿ࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋࡉࡽ࡟ࠊᤵᴗホ౯ࡢ⤖ᯝࡣᤵᴗᢸᙜᩍဨ࡟㑏
ඖࡍࡿ࡜࡜ࡶ࡟ࠊᖹᡂ㸰㸯ᖺᗘ࠿ࡽࡣ᭱ࡶホ౯ࡢ㧗࠿ࡗࡓᩍဨࡢㅮ⩏ࢆ௚ࡢᩍဨࡀ⫈ㅮࡋࠊ⮬ࡽࡢㅮ⩏࡟
ࡘ࠸࡚ᨵၿࡍ࡭ࡁⅬ࡞࡝ࢆሗ࿌ࡍࡿࡼ࠺࡟ࡋ࡚࠸ࡿ㸦㈨ᩱϩ㸱㸦㸱㸧
㸧ࠋ
㸲㸧ᩍ⫱ᣦᑟయไࡢᩚഛ
Ꮫ㒊ᩍ⫱ࠊ኱Ꮫ㝔ᩍ⫱࡟࠾࠸࡚ࡣࠊ⊂⮬ࡢᩍ⫱⌮ᛕ࡟ᇶ࡙ࡁ≉ᚩ࠶ࡿ࣒࢝ࣜ࢟ࣗࣛࢆᵓ⠏ࡍࡿࡇ࡜
ࡀ㔜せ࡛࠶ࡿࡇ࡜ࡣゝ࠺ࡲ࡛ࡶ࡞࠸ࡀࠊྠ᫬࡟෇⁥࡞ᩍ⫱άືࢆ㐙⾜ࡍࡿࡓࡵࡢᩍ⫱ᣦᑟయไࡢᩚഛ
ࡶ㔜せ࡞ㄢ㢟࡛࠶ࡿࠋᮏ◊✲⛉࡛ࡣࠊ๰⸆⛉Ꮫࡸ་⒪⸆ᏛࡢⓎᒎࡸ♫఍ⓗせㄳࡢ≧ἣࢆ㋃ࡲ࠼࡚ᑗ᮶
ᵓ᝿ࢆ⟇ᐃࡋࠊࡇࢀࡲ࡛ᩍ⫱యไࢆᩚഛࡋ࡚ࡁࡓࠋࡲࡎᖹᡂ㸯㸲ᖺᗘ࡟ࡣࠊ๰⸆࣭་⒪㐃ᦠ⸆Ꮫࢥ࢔
㒊㛛ࢆ◊✲⛉⤌⧊࡜ࡋ࡚タ⨨ࡋࡓࠋࡲࡓࠊᮏࢥ࢔ࡢᡂᯝࢆཷࡅ࡚⸆Ꮫᩍ⫱㸴ᖺไࡀᑟධࡉࢀࡓᖹᡂ㸯
㸶ᖺᗘ࡟ࡣࠊ
ࠕ⥲ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥࢱ࣮ࠖࡢタ⨨ࡀ≉ูᩍ⫱◊✲⤒㈝࡛ᥐ⨨ࡉࢀࡓࠋࡉࡽ࡟ࠊ
᪂ᩍ⫱ไᗘ㛤ጞ࠿ࡽ㸳ᖺ┠ࢆ㏄࠼ࡓᖹᡂ㸰㸰ᖺᗘ࡟ࡣࠊ᪂ࡓ࡞≉ูᩍ⫱◊✲⤒㈝ࡀᥐ⨨ࡉࢀࠊ
ࠕ⤫ྜ⸆
Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮ࠖࢆ᪂タࡋࡓࠋ
ࠕ⥲ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥࢱ࣮ࠖ࡟ᑐࡍࡿண⟬ᥐ⨨ࡣᖹᡂ㸰
㸰ᖺᗘ࡛⤊஢ࡍࡿࡀࠊᖹᡂ㸰㸱ᖺᗘ࠿ࡽࡣࠊ
ࠕ⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮ࠖࢆ㸲ᖺไ࠾ࡼࡧ㸴ᖺไࡢᏛ
㒊ᩍ⫱ࢆಠ▔ⓗ࡟ぢΏࡋࡘࡘࠊ࠿ࡘᏛ㒊࣭኱Ꮫ㝔ࢆ୍㈏ࡋ࡚ຠᯝⓗ࡟ᩍ⫱ࡋ࡚࠸ࡃࡓࡵࡢ඲Ꮫ⤌⧊ࡢ
୰࡛ࡢ᪋タ࡜ࡋ࡚఩⨨௜ࡅࠊᩍ⫱άືࢆ㐍ࡵࡿணᐃ࡛࠶ࡿࠋྛࢭࣥࢱ࣮ࡢᴫせ࡜άື࡟ᑐࡍࡿ⮬ᕫⅬ
᳨࣭ホ౯ࡣ௨ୗࡢ࡜࠾ࡾ࡛࠶ࡿࠋ
− 17 −
‫⸆ྜ⤫ۑ‬Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥࢱ࣮
㸦ࢭࣥࢱ࣮ࡢᴫせ㸧
ᮏࢭࣥࢱ࣮ࡣࠊᖹᡂ㸯㸶ᖺ㸲᭶ࡼࡾࠊி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ࡢ㝃ᒓ᪋タ࡜ࡋ࡚ࠊ㧗ᗘ໬ࡋࡘ࡙
ࡅࡿ๰⸆ࡸ་⒪࡟༶ᛂ࡛ࡁࡿඛ➃ⓗ࡞⸆Ꮫᩍ⫱࣭◊✲యไࢆᙧᡂࡍࡿࡓࡵࡢ͆๰͇࡜͆⒪͇ࡢ⤫ྜⓗ
⸆ᏛᣐⅬ࡜ࡋ࡚᪂タࡉࢀࡓࠋ⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨศ㔝ࠊ⮫ᗋ⸆Ꮫᩍ⫱㛤ᣅศ㔝ࠊඛ➃⸆Ꮫᩍ⫱㛤ᣅศ㔝
ࡢ㸱ᑓ௵ศ㔝ࡀタ⨨ࡉࢀࠊᏛ㒊ෆවᢸศ㔝ࠊᐤ㝃ㅮᗙࠊ⮫ᗋ㒊㛛㸦ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔⸆๣㒊࡞
࡝㸧ࡸி㒔኱Ꮫ௚Ꮫ㒊࡜ࡢ༠ຊయไࠊࡲࡓ㐃ᦠᩍᤵࡢࡈᣦᑟࡢࡶ࡜ࠊ⤫ྜᆺ⸆Ꮫᩍ⫱ࢩࢫࢸ࣒ࡢ㛤Ⓨ
࡜᥎㐍ࢆ㏻ࡌ࡚㧗ᗘ࡞⬟ຊࢆ᭷ࡍࡿ⸆Ꮫேࢆ㣴ᡂࡋࠊ๰⸆࡜་⒪࡟࠾ࡅࡿ♫఍㈉⊩ࢆ┠ᣦࡋ࡚࠸ࡿࠋ
ేࡏ࡚ྛᩍဨࡣ㛵㐃௚ศ㔝࡜㐃ᦠࡋ࡚⊂⮬ࡢ◊✲ࡶ㐍ࡵ࡚࠸ࡿࠋྛศ㔝ࡢᩍ⫱࣭◊✲ෆᐜࢆ௨ୗ࡟♧
ࡍࠋ
⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨศ㔝!
͆๰͇࡜͆⒪͇ࡢ⤫ྜᆺ⸆Ꮫᩍ⫱ࢩࢫࢸ࣒ࡢ㛤Ⓨ࡜᥎㐍ࢆ⾜ࡗ࡚࠸ࡿࠋලయⓗ࡟ࡣࠊᖹᡂ㸯㸶ᖺᗘ
ࡼࡾጞࡲࡗࡓ㸴ᖺไ⸆Ꮫᩍ⫱࡜㸲ᖺไ⸆Ꮫᩍ⫱ࡢ⤫ྜᆺ⸆Ꮫᩍ⫱యไࢆᵓ⠏ࡍࡿ࡜࡜ࡶ࡟ࠊ୍᪉࡛ࠊ
⸆Ꮫᩍ⫱㐃ᦠࢿࢵࢺ࣮࣡ࢡࡢᵓ⠏ࢆ┠ⓗ࡜ࡋ࡚ࠊ⸆Ꮫ࡟㛵㐃ࡍࡿྛ✀ࢹ࣮ࢱ࣮࣋ࢫ࡜ H࣮ࣛࢽࣥࢢࢩ
ࢫࢸ࣒ࢆ≉ᚩ࡜ࡍࡿࠕ⤫ྜᆺᩍ⫱ᨭ᥼⸆Ꮫ᝟ሗࢼࣅࢤ࣮ࢩࣙࣥࢩࢫࢸ࣒ࠖࢆ㛤Ⓨࠊࢥࣥࢸࣥࢶࡢ඘ᐇ
࡟ດࡵ࡚࠸ࡿࠋ୍᪉ࠊ◊✲㠃࡟࠾࠸࡚ࡣࠊ་⒪ᶵ㛵ࡢ༠ຊࢆᚓ࡚ࠊ㑇ఏᏊ㛵㐃᝟ሗࠊ⸆≀⾑୰⃰ᗘࢹ
࣮ࢱ࡟ᇶ࡙ࡃಶู໬་⒪ࠊࡶࡋࡃࡣࢺࣛࣥࢫࢡࣜࣉࢺ࣮࣒ゎᯒࠊࣉࣟࢸ࣮࣒࢜ゎᯒ࡟ࡼࡿ᪂つࣂ࢖࢜
࣐࣮࣮࢝᥈⣴ࢆࢸ࣮࣐࡟ࢺࣛࣥࢫ࣮ࣞࢩࣙࢼࣝࣜࢧ࣮ࢳࢆᐇ᪋ࠊ᭱᪂ࡢ◊✲ᡂᯝࢆ⤫ྜᆺᩍ⫱࡟㑏ඖ
ࡋ࡚࠸ࡿࠋ
ඛ➃⸆Ꮫᩍ⫱㛤ᣅศ㔝!
ࢿࢥ࢚࢖ࢬࡢཎᅉ࢘࢖ࣝࢫ࡛࠶ࡿࢿࢥච␿୙඲࢘࢖ࣝࢫ㸦),9㸧ࡣࠊᐇ㦂ⓗ࡟ࡣࣄࢺᇵ㣴⣽⬊ࡸࢧࣝ
࡟ ),9 ឤᰁࢆᘬࡁ㉳ࡇࡍࡇ࡜ࡀ▱ࡽࢀ࡚࠾ࡾࠊ㟋㛗㢮࡟ぶ࿴ᛶࡀ࠶ࡿ࡜࠸࠺Ⅼ࠿ࡽ ),9 ࡣ⌮᝿ⓗ࡞ࣄ
ࢺࡢ㑇ఏᏊ἞⒪⏝࣋ࢡࢱ࣮࡜࡞ࡿྍ⬟ᛶࡀ⪃࠼ࡽࢀ࡚࠸ࡿࠋࡇࡢࡼ࠺࡞≧ἣࢆ㋃ࡲ࠼ࠊ⌧ᅾᙜศ㔝࡛
ࡣ ),9 ࡀࣄࢺ⣽⬊ᣦྥᛶࢆ⋓ᚓࡍࡿࡓࡵࡢᅉᏊࡢ᥈⣴◊✲࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ୍᪉ࠊᏛ㒊Ꮫ⏕࣭኱Ꮫ
㝔⏕ࢆᑐ㇟࡜ࡋࡓᩍ⫱㠃࡟࠾࠸࡚ࡣࠊ୍㐃ࡢ◊✲άືࢆ㏻ࡌ࡚ࠊᇶ♏࢘࢖ࣝࢫᏛࡢࡳ࡞ࡽࡎᛂ⏝࢘࢖
ࣝࢫᏛ࡟ࡶ㔜Ⅼࢆ⨨࠸࡚ࠊᣦᑟࢆ⾜ࡗ࡚࠸ࡿࠋ ⮫ᗋ⸆Ꮫᩍ⫱㛤ᣅศ㔝!
⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨศ㔝ࠊඛ➃⸆Ꮫᩍ⫱㛤ᣅศ㔝࡜༠ຊࡋ࡚ࠊ⤫ྜᆺ⸆Ꮫᩍ⫱ࢩࢫࢸ࣒ࡢ㛤Ⓨ࡜᥎㐍
ࢆ⾜ࡗ࡚࠸ࡿࡀࠊᮏศ㔝ࡣࠊ㸴ᖺไ⸆Ꮫᩍ⫱యไࡢᩚഛ࡟㔜Ⅼࢆ⨨࠸࡚࠾ࡾࠊ⮫ᗋ⸆Ꮫศ㔝ࢆ୰ᚰ࡟ࠊ
ࠕ⤫ྜᆺᩍ⫱ᨭ᥼⸆Ꮫ᝟ሗࢼࣅࢤ࣮ࢩࣙࣥࢩࢫࢸ࣒࡛ࠖ฼⏝ࡍࡿࢥࣥࢸࣥࢶࡢ཰㞟ࠊ඘ᐇ࡟ດࡵ࡚࠸
ࡿࠋ୍᪉ࠊ◊✲㠃࡟࠾࠸࡚ࡶࠊ⮫ᗋ⸆Ꮫࢆ୰ᚰ࡟ᒎ㛤ࡋ࡚࠾ࡾࠊ་⸆ရࡢ㐺ṇ౑⏝ࠊ࠶ࡿ࠸ࡣ⸆≀἞
⒪ࣔࢽࢱࣜࣥࢢ࡞࡝᪤࡟་⒪⌧ሙ࡛ᐇ⏝໬ࡉࢀ࡚࠸ࡿࢩࢫࢸ࣒ࡢ᭱㐺໬ࢆࢸ࣮࣐࡜ࡋ࡚࠸ࡿࠋ
㸦ࢭࣥࢱ࣮άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯㸧
ᮏࢭࣥࢱ࣮࡛ࡣࠊ᪂ᴫᛕ࡟ᇶ࡙ࡃ H࣮ࣛࢽࣥࢢࢆᐇ㊶ࡍࡿࠕ⤫ྜᆺᩍ⫱ᨭ᥼⸆Ꮫ᝟ሗࢼࣅࢤ࣮ࢩࣙ
ࣥࢩࢫࢸ࣒ࠖࢆ㛤ⓎࡋࠊᏛ⾡࠿ࡽᑓ㛛⫋⬟࡟ࢃࡓࡿ⸆Ꮫࡢ඲Ꮫၥ㡿ᇦࢆయ⣔ⓗ࡟⤫ྜࡋࡓ⸆Ꮫᩍ⫱ࢿ
ࢵࢺ࣮࣡ࢡࡢᵓ⠏ࢆ⾜ࡗࡓࠋᮏࢩࢫࢸ࣒ࡣࠊ◊✲࡜ᩍ⫱ࡢࢥࣥࢸࣥࢶࢆ㞟✚ࡋࡓࠕ⸆Ꮫ᝟ሗ⤫ྜࢹ࣮
− 18 −
ࢱ࣮࣋ࢫࠖ࡜ࠊᏛ⏕࣭ᩍဨࡢᩍ⫱ᐇ㊶࢖ࣥࢱ࣮ࣇ࢙࣮ࢫ࡛࠶ࡿࠕH࣮ࣛࢽࣥࢢࢩࢫࢸ࣒ࠖࡢ㸰ࡘࡢࢩ
ࢫࢸ࣒ࢆ㐃ᦠࡍࡿࡇ࡜࡟ࡼࡾࠊᅜෆእࡢ᭱᪂ࡢ་⸆࣭་⒪᝟ሗࡸㅮ⩏࢔࣮࢝࢖ࣈࢆᏛ⏕ࠊᩍဨࠊ◊✲
⪅ࠊ་⒪ᚑ஦⪅࡬ᥦ౪ࡍࡿ⊂⮬ࡢᩍ⫱ࢩࢫࢸ࣒࡛࠶ࡿࠋ
ࠕ⸆Ꮫ᝟ሗ⤫ྜࢹ࣮ࢱ࣮࣋ࢫࠖࡣࠊ」㞧࡛ከᒱ࡟Ώࡿᅜෆእࡢ⏕࿨⛉Ꮫ࣭་⸆ရ࣭་⒪࡟㛵ࡍࡿ◊
✲᝟ሗ࡟ຍ࠼ᮏ◊✲⛉ࡢᩍဨࡢㅮ⩏࢔࣮࢝࢖ࣈࡸᏛ⏕࣏࣮ࣞࢺࢆࢥࣥࢸࣥࢶ࡜ࡋ࡚ࢹ࣮ࢱ࣮࣋ࢫ໬ࡋࠊ
ࡑࢀࡽࡢ⤫ྜⓗ࡞᳨⣴ࢆྍ⬟࡟ࡋࡓࢩࢫࢸ࣒࡛࠶ࡿࠋලయⓗ࡟ࡣࠊ㸯㸧་⸆ရࡢຠ⬟ຠᯝࠊ⚗ᚷ᝟ሗࠊ
๪స⏝᝟ሗ࡞࡝ࡢ་⸆࣭་⒪᝟ሗࢆᥦ౪ࡍࡿ -$3,& ῧ௜ᩥ᭩グ㍕⑓ྡ㞟ࠊ$GYHUVH(YHQW5HSRUWLQJ
6\VWHP㸦$(56㸧ࠊ0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV㸦0HG'5$㸧ࠊ8QLILHG0HGLFDO/DQJXDJH
6\VWHP㸦80/6㸧ࠊ㸰㸧๰⸆ࡢ◊✲㛤Ⓨࡢ▱㆑࣮࣋ࢫ࡜ࡋ࡚⊂⮬㛤Ⓨࡋࡓ * ࢱࣥࣃࢡ㉁ඹᙺᆺཷᐜయ㸫ࣜ
࢞ࣥࢻ┦஫స⏝ࢹ࣮ࢱ࣮࣋ࢫ㸦*/,'$㸧ࠊ㸱㸧ࢤࣀ࣒᝟ሗࡢ▱㆑࣮࣋ࢫ࡜ࡋ࡚⊂⮬㛤Ⓨࡋࡓࢤࣀ࣒ࢿࢵ
ࢺ࣮࣡ࢡࢹ࣮ࢱ࣮࣋ࢫ㸦*(075(1'㸧ࠊ㸲㸧ᮏ◊✲⛉ᩍဨ࡟ࡼࡿᤵᴗ㈨ᩱࠊࡢᐇ⿦ࡀ᏶஢ࡋ࡚࠸ࡿࠋࡲ
ࡓࠊᑓ㛛⏝ㄒࡢⱥㄒ⾲⌧࡟୙័ࢀ࡞Ꮫ㒊Ꮫ⏕ࡢᏛ⩦ຠᯝࢆᮇᚅࡋࠊᮏᏛ࡛⊂⮬㛤Ⓨࡢࣛ࢖ࣇࢧ࢖࢚ࣥ
ࢫ㎡᭩࡟ࡼࡿ᪥ᮏㄒ࡜ⱥㄒࡢ⮬ື┦஫ኚ᥮ࢆᐇ⌧ࡋࠊ3XE0HG ࡸ *RRJOH ࡞࡝ࡢබඹ :HE ࢧ࣮ࣅࢫ࡬ࡢࣜ
ࣥࢡᣑᙇ࡟ࡶᡂຌࡋ࡚࠸ࡿࠋ
ࠕH࣮ࣛࢽࣥࢢࢩࢫࢸ࣒ࠖ࡟㛵ࡋ࡚ࡣࠊ᪤࡟ᖹᡂ㸯㸶ᖺᗘ࡟ࢩࢫࢸ࣒ࡢᑟධ࡜ᵓ⠏ࢆ᏶஢ࡋࠊᖹᡂ㸯
㸷ᖺᗘ௨㝆ࠊヨ㦂ⓗ㐠⏝ࢆ⤒࡚ࠊᩍ⫱࡛ࡢά⏝ࢆ㛤ጞࡋ࡚࠸ࡿࠋᮏࢩࢫࢸ࣒ࡢᇶᮏᵓᡂ࡜ࡋ࡚ࡣࠊㅮ
⩏ࢫࢣࢪ࣮ࣗࣝࡢ᪥⛬⟶⌮⾲ࢆ࣓࢖ࣥ࡜࡞ࡿ㜀ぴ࣮࣌ࢪ࡜ࡋࠊࡑࡇ࠿ࡽྛᤵᴗࡢㅮ⩏㈨ᩱࡸㅮ⩏㡢ኌࠊ
࠶ࡿ࠸ࡣ ([FHO ࣇ࢓࢖ࣝ➼ࡢ㟁Ꮚᩍᮦࢆ࢖ࣥࢱ࣮ࢿࢵࢺ㓄ಙࡍࡿࡇ࡜࡟ࡼࡾࠊᒚಟⓏ㘓Ꮫ⏕ࢆᑐ㇟࡜
ࡋࡓ⮬ᕫᏛ⩦ཬࡧᩍ⫱⟶⌮ࢆᐇ⌧ࡋ࡚࠸ࡿࠋࡲࡓࠊᏛ⏕࠿ࡽࡢ࣏࣮ࣞࢺᥦฟࠊᩍဨ࡟ࡼࡿ᥇Ⅼ࡜Ꮫ⩦
ᣦᑟࡶࢩࢫࢸ࣒ࢆ௓ࡋ࡚⾜ࢃࢀࠊⓏ㘓⛉┠࡟㛵ࡋࡓᡂ⦼⟶⌮࡜ࡋ࡚ࡶά⏝ࡋ࡚࠸ࡿࠋᖹᡂ㸰㸰ᖺ㸯㸰
᭶⌧ᅾࠊⓏ㘓ࡋ࡚࠸ࡿ⛉┠ᩘཬࡧᑐ㇟Ꮫ⏕ᩘࡣࡢ࡭㸰㸵⛉┠ࠊ㸯㸮㸳㸰ྡ࡛࠶ࡿࠋ
ᮏࢭࣥࢱ࣮࡛ࡣࠊᖹᡂ㸯㸶ᖺᗘ࡟᥇ᢥࡉࢀࡓᩥ㒊⛉Ꮫ┬ࠕ་⒪ே *3 ࣉࣟࢪ࢙ࢡࢺࠖࡢᑓ௵ᩍဨ㸰ྡ
࡜㐃ᦠࡋࠊ㸴ᖺไ⸆Ꮫᩍ⫱ࣉࣟࢢ࣒ࣛࢆ☜❧ࡋࡓࠋ㸴ᖺไ⸆Ꮫᩍ⫱࡟࠾࠸࡚㸳ᖺḟ࡟ᐇ᪋ࡉࢀࡿ㛗ᮇ
ᐇົᐇ⩦࡟ྥࡅࠊ⸆Ꮫඹ⏝ヨ㦂 26&(㸦2EMHFWLYH6WUXFWXUHG&OLQLFDO([DPLQDWLRQ㸹ᐈほⓗ⮫ᗋ⬟ຊ
ヨ㦂㸧ࡢࡓࡵࡢయไ࡙ࡃࡾࢆ⾜࠸ࠊᖹᡂ㸰㸰ᖺᗘࠊ᭱ึࡢ⸆Ꮫඹ⏝ヨ㦂 26&( ࢆ↓஦⤊஢ࡉࡏࡓࠋホ౯
⪅ࡸᶍᨃᝈ⪅ࠊ㐍⾜ࢫࢱࢵࣇ࡜࠸ࡗࡓேᮦ⫱ᡂࢆ⥅⥆ࡍࡿ࡜࡜ࡶ࡟ࠊ୍᪉࡛ࠊᐇົᐇ⩦㛵㐃ࡢᩍ⫱ࡸ
26&( ࡟ྥࡅࡓタഛ㠃ࡢᩚഛࢆ⾜࠸ࠊ་⒪⸆Ꮫᩍ⫱ࡢࡓࡵࡢ⎔ቃタഛࢆᩚ࠼ࡓࠋ
௨ୖࠊ
ࠕ⤫ྜᆺᩍ⫱ᨭ᥼⸆Ꮫ᝟ሗࢼࣅࢤ࣮ࢩࣙࣥࢩࢫࢸ࣒ࠖࡢ㛤Ⓨࢆ⾜࠺࡜࡜ࡶ࡟ࠊ㸴ᖺไ⸆Ꮫᩍ⫱
ࣉࣟࢢ࣒ࣛࡢᵓ⠏࡜ᐇ᪋ࢆ⾜࠸ࠊࡇࢀࡽࢆ௓ࡋ࡚ࠊ㧗ᗘ࡞⬟ຊࢆ᭷ࡍࡿ⸆Ꮫேࢆ㣴ᡂࡍࡿࡓࡵࡢయไ
ࢆ☜❧ࡋࡓࠋ
‫⸆ྜ⤫ۑ‬Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮
㸦ࢭࣥࢱ࣮ࡢᴫせ㸧
ᮏࢭࣥࢱ࣮ࡣࠊ㸲ᖺไᩍ⫱࡜㸴ᖺไᩍ⫱ࡢᯟࢆ㉸࠼࡚ࠊࡉࡽ࡟Ꮫ㒊࣭኱Ꮫ㝔ࢆ୍㈏ࡍࡿຠᯝⓗ࡞⥲
ྜⓗᩍ⫱ࡀྍ⬟࡞᪂ᩍ⫱࣒࢝ࣜ࢟ࣗࣛࠕ๰⸆࣭⫱⸆ຊ⫱ᡂࣉࣟࢢ࣒ࣛࠖࢆᵓ⠏ࡋࠊศ㔝ᶓ᩿ⓗ࡞๰⸆
ຊࠊ⫱⸆ຊࢆᣢࡗࡓඛᑟⓗ๰⸆࣭⫱⸆◊✲࣮ࣜࢲ࣮ࢆ⫱ᡂࡍࡿࡇ࡜ࢆ┠ⓗ࡟ࠊᖹᡂ㸰㸰ᖺ㸲᭶࡟ி㒔
− 19 −
኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ࡢ㝃ᒓ᪋タ࡜ࡋ࡚᪂タࡉࢀࡓࠋᖹᡂ㸰㸱ᖺᗘ࠿ࡽࡣࠊ඲Ꮫ⤌⧊࡜ࡋ࡚⸆Ꮫ㒊࣭
⸆Ꮫ◊✲⛉ࡢᩍ⫱ࡢ୰ᚰⓗᙺ๭ࢆᢸ࠺ணᐃ࡛࠶ࡿࠋ
་⸆ရ㛤Ⓨࡣࠊ๰⸆ࢱ࣮ࢤࢵࢺ᥈⣴ࠊ࣮ࣜࢻ໬ྜ≀ࡢ๰ᡂ㺃᭱㐺໬ࠊ᭷ຠᛶ࣭Ᏻ඲ᛶホ౯ࠊ⮫ᗋ◊✲
➼ࠊከᒱ࡟Ώࡿ୍㐃ࡢࣉࣟࢭࢫ࠿ࡽ࡞ࡿࠋ㏆ᖺࠊᚑ᮶ࡢὶࢀ࡟ἢࡗ࡚ྛࣉࣟࢭࢫࢆಶู࡟ 㐍ࡵࡿࡔ
ࡅ࡛ࡣ㛤Ⓨࡀᅔ㞴࡞ᑐ㇟໬ྜ≀ࡀከࡃࠊ᪂ࡓ࡟ࣉࣟࢭࢫ඲యࢆಠ▔ࡋࡓ㛤Ⓨࡀồࡵࡽࢀ࡚࠸ࡿࠋᚑࡗ
࡚ࡇࢀ࠿ࡽࡢ๰⸆⛉Ꮫ⪅࡟ࡣࠊಶูࡢᑓ㛛㡿ᇦࡢࢫ࣌ࢩࣕࣜࢫࢺࡢ㈨㉁ࡢࡳ࡞ࡽࡎࠊ ་⸆ရ㛤Ⓨࣉ
ࣟࢭࢫ඲యࢆど㔝࡟ศ㔝ᶓ᩿ⓗ࡞▱㆑ࠊᢏ⬟ࠊែᗘࢆවࡡഛ࠼࡚࠸ࡿࡇ࡜ࡀ୙ྍḞ࡜࡞ࡿࠋ
ி㒔኱Ꮫ⸆Ꮫ㒊࣭⸆Ꮫ◊✲⛉࡛ࡣࠊ⸆Ꮫ࡟࠾ࡅࡿ͆๰͇࡜͆⒪͇ࡢᣐⅬᙧᡂࢆᩍ⫱࣭◊✲ࡢᇶᮏⓗ
⌮ᛕ࡜ࡋ࡚ᥖࡆࠊ኱Ꮫタ⨨ᇶ‽࡟ᇶ࡙ࡁࠊᏛ㒊ᩍ⫱࡟࠾࠸࡚ࡣࠊᖹᡂ㸯㸶ᖺᗘ࡟ᑟධࡉࢀࡓ㧗ᗘ࡞⸆
๣ᖌᩍ⫱ࢆ┠ᣦࡍ㸴ᖺไᩍ⫱ไᗘ࡜ࠊ๰⸆◊✲⪅ࢆึࡵ࡜ࡍࡿከᵝ࡞ேᮦࡢ㣴ᡂࢆ┠ⓗ࡜ࡍࡿ㸲ᖺไ
ᩍ⫱ไᗘࢆ୪⨨ࡋࠊྛ㡿ᇦ࡛ࡢࢫ࣌ࢩࣕࣜࢫࢺ㣴ᡂࢆ┠ᣦࡋ࡚ᩍ⫱ࢆ㐍ࡵ࡚࠸ࡿࠋྛไᗘࡢᏛ⏕ࡀ௚
᪉ࡢไᗘࡢ࣒࢝ࣜ࢟ࣗࣛࢆᒚಟࡋ࡚┦஫࡟⛉┠ࢆྲྀࡾྜ࠺ࡇ࡜ࡀ࡛ࡁࡿࡼ࠺㓄៖ࡋࠊ࠾஫࠸࡟᩿∦ⓗ
࡟ࡣྛ㡿ᇦ࡟㛵ࡍࡿᏛ⩦ࡀྍ⬟࡞≧ἣ࡛࠶ࡿࠋ
ࡇࡢࡼ࠺࡞⫼ᬒࡢࡶ࡜ࠊᮏྲྀ⤌ࡳ࡛ࡣࠊࡇࢀ࠿ࡽࡢ๰⸆࡟ồࡵࡽࢀࡿ⬟ຊࢆ⫱ᡂࡍࡿࡓࡵࠊ⌧ᅾࡢ
ಶูࡢᑓ㛛㡿ᇦࡢࢫ࣌ࢩࣕࣜࢫࢺࡢ㈨㉁⫱ᡂᩍ⫱࡟ຍ࠼ࠊ་⸆ရ㛤Ⓨࢆಠ▔ⓗ࡟ᤊ࠼ᝈ⪅࡟Ⰻ㉁ࡢ⸆
≀἞⒪ࢆᥦ౪ࡍࡿ࡜࠸࠺⸆Ꮫࡢᮏ㉁࡟㛵ࢃࡾࠊ⤫୍ⓗ࡟ᚲせ࡜ࡉࢀࡿ⸆Ꮫ⥲ྜᇶ♏ᩍ⫱ࢆ᪂つ࡟ᒎ㛤
ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚ࠊ᪂⸆Ꮫᩍ⫱ไᗘୗ࡛ࡢྛᏛ⛉ࡢᯟࢆ㉸࠼࡚ࠊ་⸆ရ◊✲⌧ሙ࡬ࡢཧຍ࣭య㦂
ᆺᏛ⩦ཬࡧࣔࢹࣝ་⸆ရ㛤Ⓨ࣭་⒪ᛂ⏝஦ᴗ࡬ࡢཧຍࢆ᝿ᐃࡋࡓၥ㢟ゎỴᆺࡢ₇⩦࣭ᐇ⩦ࢆ୰ᚰ࡜ࡋ
ࡓ᪂ࡓ࡞ᩍ⫱࣒࢝ࣜ࢟ࣗࣛࠕ๰⸆࣭⫱⸆ຊ⫱ᡂࣉࣟࢢ࣒ࣛࠖࢆᵓ⠏ࡍࡿࠋࡉࡽ࡟ࠊࡑࡢᡂᯝࢆ㧗Ꮫᖺࠊ
኱Ꮫ㝔ᩍ⫱࡛㐍ᒎࡉࡏࡿࡇ࡜࡟ࡼࡗ࡚ศ㔝ᶓ᩿ⓗ࡞๰⸆࣭⫱⸆ຊࢆᣢࡗࡓඛᑟⓗ๰⸆◊✲࣮ࣜࢲ࣮ࢆ
⫱ᡂࡍࡿࡓࡵࡢᶓ᩿ⓗ⤫ྜᆺᩍ⫱ࡢࣉࣛࢵࢺࣇ࢛࣮࣒ࢆ⠏ࡁࠊᏛኈຊࢆ⥲ྜⓗ࡟㧗ࡵࡿᩍ⫱ࢩࢫࢸ࣒
ࢆᵓ⠏ࡍࡿࠋ
㸦⤌⧊㸧
࣭་⸆ရ㛤Ⓨᩍ⫱ศ㔝 㧗㡲 Ύㄔ෸ᩍᤵ㸦ව㸧ኳ㔝 ༤ኵ ≉ᐃຓᩍ
࣭๰⸆⛉Ꮫᩍ⫱ศ㔝 㧗಴ ႐ಙᩍᤵ㸦ව㸧
࣭ᐇ㊶⮫ᗋ⸆Ꮫศ㔝 ᰤ⏣ ᩄஅ≉ᐃᩍᤵ ஂ⡿ ฼᫂෸ᩍᤵ㸦ව㸧
࣭᝟ሗ⛉Ꮫᩍ⫱ศ㔝 ᥃㇂ ⚽᫛ᩍᤵ㸦ව㸧 ኱▼ ┿ஓㅮᖌ 㸦ව㸧
㐠Ⴀ⤌⧊㸺⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮㐠Ⴀ༠㆟఍ጤဨ㸼
ࢭࣥࢱ࣮㛗 బ἞ ⱥ㑻 㸦⑓ែᶵ⬟ศᯒᏛ࣭ᩍᤵ㸧
୰ᒣ ࿴ஂ 㸦⏕య᝟ሗไᚚᏛ࣭ᩍᤵ㸧
㧘಴ ႐ಙ 㸦⑓ែ᝟ሗ⸆Ꮫ࣭ᩍᤵ㸧
ᰤ⏣ ᩄஅ 㸦ᐇ㊶⮫ᗋ⸆Ꮫศ㔝࣭≉ᐃᩍᤵ㸧
㉥ụ ᫛⣖ 㸦⸆ရస⏝ゎᯒᏛศ㔝࣭ᩍᤵ㸧
ᶫ⏣ ඘ 㸦⸆ရືែไᚚᏛศ㔝࣭ᩍᤵ㸧
㸦ࢭࣥࢱ࣮άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯㸧
᪂ࡓ࡟ࠕ་⸆ရ㛤Ⓨࣉࣟࢪ࢙ࢡࢺ₇⩦Ϩࠖ
㸦㸱ᖺḟࠊ₇⩦⛉┠ࠊ㞟୰㸧
ࠊ
ࠕ་⸆ရ㛤Ⓨࣉࣟࢪ࢙ࢡࢺ₇
− 20 −
⩦ϩࠖ
㸦㸲ᖺḟࠊ₇⩦⛉┠ࠊ㞟୰㸧ࠊ
ࠕ⤫ྜᆺ⸆Ꮫ₇⩦ࠖ㸦㸯ࠊ㸱ᖺḟࠊ₇⩦⛉┠ࠊ㞟୰㸧ࠊ
ࠕ་⒪೔⌮ᐇ
⩦ࠖ㸦㸯ࠊ㸲ᖺḟࠊㅮ⩏₇⩦⛉┠ࠊ㞟୰㸧ࢆ㛤ㅮࡋࡓࠋᏛ⏕ࡢホุࡣ㠀ᖖ࡟ࡼࡃࠊศ㔝ᶓ᩿ⓗ࡞๰⸆࣭
⫱⸆ຊࢆᣢࡗࡓඛᑟⓗ๰⸆◊✲࣮ࣜࢲ࣮ࢆ⫱ᡂࡍࡿࡓࡵࡢᶓ᩿ⓗ⤫ྜᆺᩍ⫱ࡢᇶ┙ࡀᙧᡂ࡛ࡁࡓ࡜⪃
࠼࡚࠸ࡿࠋ
㸳㸧ᩍ⫱㛵㐃ࣉࣟࢪ࢙ࢡࢺࡢ᥎㐍
ᩍ⫱ᣦᑟయไࡢᩚഛ࡜୪⾜ࡋ࡚ࠊᏛ㒊ᩍ⫱ࠊ኱Ꮫ㝔ᩍ⫱ࡢᨵၿࢆ┠ⓗ࡟✀ࠎࡢᩍ⫱㛵㐃ࣉࣟࢪ࢙ࢡ
ࢺࢆ᥎㐍ࡋ࡚ࡁࡓࠋ≉ู⤒㈝ࡢᥐ⨨ࢆཷࡅࠊ᪤࡟㨩ຊ࠶ࡿ኱Ꮫᩍ⫱࢖ࢽࢩ࢔ࢸ࢕ࣈ㸦ᖹᡂ㸯㸵ᖺᗘ㹼
ᖹᡂ㸯㸶ᖺᗘ㸧࠾ࡼࡧ་⒪ே *3㸦ᖹᡂ㸯㸶ᖺᗘ㹼ᖹᡂ㸰㸮ᖺᗘ㸧ࢆᐇ᪋ࡋࠊ⌧ᅾ⏘Ꮫ㐃ᦠ࡟ࡼࡿᐇ㊶
ᆺேᮦ⫱ᡂ஦ᴗ㸦ᖹᡂ㸰㸮ᖺᗘ㹼ᖹᡂ㸰㸰ᖺᗘ㸧࠾ࡼࡧ⏘Ꮫ㐃ᦠ࡟ࡼࡿᐇ㊶ᆺேᮦ⫱ᡂ஦ᴗ㸦ᖹᡂ㸰
㸮ᖺᗘ㹼ᖹᡂ㸰㸰ᖺᗘ㸧ࢆᐇ᪋ࡋ࡚࠸ࡿࠋࡲࡓࠊ⛉Ꮫ᣺⯆ㄪᩚ㈝ࡢᨭ᥼ࢆཷࡅ࡚ࠊி㒔኱Ꮫඛ➃ᢏ⾡
ࢢ࣮ࣟࣂ࣮ࣝࣜࢲ࣮㣴ᡂࣉࣟࢢ࣒ࣛ㸭ࣘࢽࢵࢺ㸦ᖹᡂ㸰㸮ᖺᗘ㹼ᖹᡂ㸰㸲ᖺᗘ㸧ࡶᐇ᪋ࡋ࡚࠸ࡿࠋྛ
ࣉࣟࢪ࢙ࢡࢺࡢᴫせ࡜ᡂᯝࡣ௨ୗࡢ࡜࠾ࡾ࡛࠶ࡿࠋ
‫ۑ‬㨩ຊ࠶ࡿ኱Ꮫᩍ⫱࢖ࢽࢩ࢔ࢸ࢕ࣈ㸦ᖹᡂ㸯㸵ᖺᗘ㹼ᖹᡂ㸯㸶ᖺᗘ㸧
࣭ᮏ஦ᴗࡢ኱Ꮫ඲య࡜ࡋ࡚ࡢ఩⨨௜ࡅ
⸆Ꮫ࡟ᑐࡍࡿ♫఍ⓗᮇᚅ࣭せㄳࡣ๰⸆࠿ࡽ་⒪㡿ᇦࡲ࡛ከᒱ࡟ࢃࡓࡾࠊࢃࡀᅜࡢ⸆Ꮫᩍ⫱࣭◊✲ࢆ
௦⾲ࡍࡿᮏᏛ⸆Ꮫ◊✲⛉࡟ᑐࡋ࡚ࡣࠊඛ➃ⓗ⸆Ꮫᩍ⫱ࢆ᥎㐍ࡋ࡚๰⸆࣭⸆≀἞⒪ࡢⓎᒎࢆඛᑟࡍࡿே
ᮦࠊ◊✲⪅ࢆ㍮ฟࡍࡿࡇ࡜ࡀᙉࡃồࡵࡽࢀ࡚࠸ࡿࠋᮏᩍ⫱࣭◊✲⪅㣴ᡂࣉࣟࢢ࣒ࣛࡣࠊ㸰㸯ୡ⣖㹁㹍
㹃ࣉࣟࢢ࣒ࣛࠕࢤࣀ࣒⛉Ꮫࡢ▱ⓗ᝟ሗᇶ┙࣭◊✲ᣐⅬᙧᡂ࡛ࠖ᥎㐍ࡋ࡚ࡁࡓ⸆Ꮫ㡿ᇦ࡟࠾ࡅࡿ᝟ሗ⛉
Ꮫᇶ┙ᩍ⫱ࢆࡉࡽ࡟඘ᐇࡉࡏࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࡸࢣࣔ࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢆ⤫ྜࡍࡿࣇ࢓
࣮࣐ࢥ࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢆᇶ┙࡜ࡋࡓ๰⸆◊✲࣭ᩍ⫱ࢆ᥎㐍ࡍࡿࡶࡢ࡛࠶ࡿࠋ」ᩘࡢ◊✲ศ㔝ࡀ㐃
ᦠ࣭⼥ྜࡋࡓᮏ◊✲ࣉࣟࢪ࢙ࢡࢺࢆ኱Ꮫ㝔〇࡟❧᱌࣭ᐇ⾜ࡉࡏࡿࣉࣟࢢ࣒ࣛࢆ᥎㐍ࡍࡿࡇ࡜࡟ࡼࡾᑗ
᮶ࠊ◊✲⪅࡜ࡋ࡚⮬❧ࡍࡿࡓࡵࡢ࢖ࣥࢭࣥࢸ࢕ࣈࢆ୚࠼ࠊ♫఍ⓗࢽ࣮ࢬ࡟࣐ࢵࢳࡋࡓ᪂ୡ௦ࡢ๰⸆◊
✲ࢆ㣴ᡂࡍࡿᩍ⫱ᨵ㠉࡜ࡋ࡚఩⨨௜ࡅࡽࢀࡿࠋ
࣭ࡇࢀࡲ࡛ࡢᩍ⫱◊✲άືࡢ≧ἣ
ᮏ⸆Ꮫ◊✲⛉࡛ࡣࠊከᵝ࠿ࡘㄪ࿴ࡢ࡜ࢀࡓᩍ⫱య⣔ࡢࡶ࡜༟㉺ࡋࡓ▱ࡢ⥅ᢎ࡜๰㐀ⓗ⢭⚄ࡢᾰ㣴࡟
ດࡵࠊ♫఍ࡢㄪ࿴࠶ࡿⓎᒎ࡟㈉⊩࡛ࡁࡿඃࢀࡓ◊✲⬟ຊࡸ་⒪ே࡜ࡋ࡚ࡢ㧗ᗘࡢᑓ㛛▱㆑ࢆᣢࡘேᮦ
ࢆ⫱ᡂࡍࡿ࡜࠸࠺ᇶᮏ┠ᶆࢆ㐩ᡂࡍࡿࡓࡵࠊ๰⸆࣭་⒪㐃ᦠ⸆Ꮫࢥ࢔㒊㛛ࢆ᪂タࡋࠊ͆๰⸆͇ࠊ
͆་⒪͇
࡜࠸࠺ᚑ᮶ࡢ஧ศ໬ࡋࡓ⦪ᆺࡢ⸆Ꮫᩍ⫱࣭◊✲ࡢᯟ⤌ࡳࢆඞ᭹ࡋࠊ๰⸆⛉Ꮫ࡜་⒪⛉Ꮫࡢ㐃ᦠ࡟ࡼࡿ
ᇶ♏࡜་⒪࣭⮫ᗋࢆ࢖ࣥࢸࢢ࣮ࣞࢺࡋࡓ᪂ࡋ࠸⸆Ꮫᩍ⫱ࢩࢫࢸ࣒ࡢᵓ⠏ࢆᅗࡗ࡚ࡁࡓࠋࡲࡓࠊ᭱㏆ࡢ
⛉Ꮫᢏ⾡ࡢᛴ㏿࡞Ⓨᒎ࡟࿧ᛂࡋࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࠊࣇ࢓࣮࣐ࢥࢤࣀ࣑ࢡࢫࠊࢤࣀ࣒࣭ࣉࣟ
ࢸ࣮࣒࣭࣓࢜ࢱ࣮࣒࣎ࣟ๰⸆࡞࡝ࡢ᪂ࡋ࠸๰⸆◊✲ᡭἲࡸࠊศᏊᶆⓗ་⸆ࠊ㑇ఏᏊ἞⒪ࠊ⛣᳜་⒪ࠊ
ࢸ࣮࣮࣓࣮ࣛࢻ་⒪࡞࡝ࡢ㠉᪂ⓗ་⒪ࡢ◊✲࣭ᩍ⫱ࡢሙ࡬ࡢᑟධ࡟ィ⏬ⓗ࡟ྲྀࡾ⤌ࢇ࡛ࡁࡓࠋࡋ࠿ࡋࠊ
ࡇ࠺ࡋࡓ㠀ᖖ࡟ᖜᗈࡃࡲࡓ㧗ᗘ࡟ᑓ㛛໬ࡋࡓ⛉Ꮫᩍ⫱ࢆᐇ᪋ࡍࡿ࡟ࡣࠊ⌧≧ࡢ࣮࢜ࢯࢻࢵࢡࢫ࡞ᑓ㛛
ᩍ⫱ࢩࢫࢸ࣒ࡣ㡿ᇦࡢ᭷ᶵⓗ⤖ྜ࡟ᇶ࡙ࡃ◊✲ࡢ῝໬ࡸ᪋⟇ࡢᶵືᛶ࡟Ḟࡅࡁࢃࡵ࡚୙༑ศ࡛࠶ࡿࡓ
− 21 −
ࡵࠊḟୡ௦ࡢⓎᒎ࡬ࡢࢫࢸࢵࣉ࡜ࡋ࡚᪂ࡋ࠸Ⓨ᝿࡟ᇶ࡙ࡃࣉࣟࢪ࢙ࢡࢺᒎ㛤ࡀ୙ྍḞ࡛࠶ࡿࠋ
࣭㨩ຊ࠶ࡿ኱Ꮫ㝔ᩍ⫱࡬ࡢྲྀ⤌࣭ィ⏬
㏆ᖺࠊ⏕࿨⛉Ꮫ࡜໬Ꮫࡢᛴ㏿࡞㐍ᒎ࡟క࠸ࠊࡑࢀࡽࡢ⼥ྜ㡿ᇦ࡛࠶ࡿ๰⸆⛉Ꮫ࡟ࣃࣛࢲ࢖࣒ࢩࣇࢺ
ࡀ⏘ࡲࢀࡘࡘ࠶ࡿࠋࡍ࡞ࢃࡕࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࠊࢣࣔ࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ➼ࡢ᝟ሗ⛉Ꮫࢆ
ᇶ┙࡜ࡋ࡚ࠊ๰⸆ᶆⓗࡢ᥈⣴ࡸࢩ࣮ࢻ໬ྜ≀ࡢ᭱㐺໬࡟ά⏝ࡍࡿࢤࣀ࣒๰⸆࡟኱ࡁ࡞ᮇᚅࡀᐤࡏࡽࢀ
࡚࠸ࡿࠋࡋ࠿ࡋ࡞ࡀࡽࠊ⏕࿨⛉Ꮫࠊ໬Ꮫࠊ᝟ሗ⛉Ꮫ࡟⢭㏻ࡋࡓ๰⸆◊✲⪅ࡢ㣴ᡂ࡟ᚑ᮶ࡢ኱Ꮫ㝔࢝ࣜ
࣒࡛࢟ࣗࣛࡣ༑ศᑐᛂ࡛ࡁ࡚࠸࡞࠸⌧≧࡛࠶ࡿࠋࡲࡓࠊᐇ㝿ࡢ๰⸆ࡣᗈ⠊࡛㧗ᗘ࡟ᑓ㛛໬ࡋࡓ㡿ᇦ࠿
ࡽ࡞ࡿ⼥ྜᏛ㝿㡿ᇦ࡛࠶ࡿࡓࡵࠊᚑ᮶ࡢ࣮࢜ࢯࢻࢵࢡࢫ࡞๰⸆ࡢࡓࡵࡢ༢୍◊✲ᐊࡢࡳ࡛᏶⤖ࡍࡿᑓ
㛛ᩍ⫱యไ࡛ࡣࠊ♫఍ࢽ࣮ࢬ࡟࣐ࢵࢳࡍࡿ๰⸆◊✲⪅ࡢ㣴ᡂࡀᅔ㞴࡛ࠊᶓ᩿ⓗᩍ⫱ࢩࢫࢸ࣒ࡢᚲせᛶ
ࡀ③ឤࡉࢀ࡚࠸ࡿࠋ
ᙜᩍ⫱ࣉࣟࢢ࣒࡛ࣛࡣࠊࡇࢀࡲ࡛㸰㸯ୡ⣖㹁㹍㹃ࣉࣟࢢ࣒࡛ࣛ᥎㐍ࡋ࡚ࡁࡓᇶ♏ࣂ࢖࢜࢖ࣥࣇ࢛࣐
ࢸ࢕ࢡࢫᩍ⫱ࢆⓎᒎࡉࡏ࡚ࢤࣀ࣒๰⸆ࢆ㍈࡟㧗ᗘ໬ࡋࡓ኱Ꮫ㝔࣒࢝ࣜ࢟ࣗࣛࢆ๰ᡂࡍࡿ࡜࡜ࡶ࡟ࠊ๰
⸆◊✲ࣉࣟࢭࢫ࡟༶ࡋ࡚⤌⧊໬ࡋࡓ」ᩘࡢ◊✲ᐊ࠿ࡽ࡞ࡿࣉࣟࢪ࢙ࢡࢺࢳ࣮࣒ࢆ⦅ᡂࡋࠊ␗࡞ࡿᑓᨷ
ࡢᩍဨࡀඹྠ࡛኱Ꮫ㝔⏕ࡢ◊✲ࢸ࣮࣐ࢆᣦᑟࡍࡿᶓ᩿ⓗ◊✲ᩍ⫱యไࢆ☜❧ࠊᐇ㊶ࡍࡿࡓࡵࡢࠕࢤࣀ
࣒๰⸆ࢥ࣮ࢫࠖࠊࠕࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮ࢥ࣮ࢫࠖࠊࠕࣇ࢓࣮࣐ࢥࢤࣀ࣑ࢡࢫࢥ࣮ࢫࠖࡢ㸱ࡘࡢ⼥ྜࢥ࣮
ࢫࢆ๰タࡋࡓࠋࡇࢀ࡟ࡼࡾࠊ♫఍ࡢ༶ᡓຊ࡜࡞ࡿࢤࣀ࣒๰⸆ࡢᐇ㊶ⓗ◊✲⪅࣭ᢏ⾡⪅࣭ᩍ⫱ᣦᑟ⪅ࠊ
᝟ሗ⛉Ꮫ࡜ࡢ⼥ྜ࡟ࡼࡾ᪂ࡓ࡞◊✲㛤Ⓨ㡿ᇦࢆษࡾᣅࡃ๰⸆◊✲⪅ࠊࡉࡽ࡟ࡣࢸ࣮࣮࣓࣮ࣛࢻ⸆≀἞
⒪࡞࡝ࡢ㧗ᗘ་⒪ࡸ་⒪᝟ሗ໬࡟ᑐᛂ࡛ࡁࡿ་⒪࣭⾜ᨻᚑ஦⪅ࢆ⫱ᡂࡋࠊ኱Ꮫࠊྛ✀◊✲ᶵ㛵ࠊ๰⸆
㛵㐃⏘ᴗࠊ⾜ᨻᶵ㛵ࠊ་⒪ᶵ㛵࡟㍮ฟࡍࡿࠋᖹᡂ㸯㸵ᖺᗘ࠾ࡼࡧ㸯㸶ᖺᗘ࡟᥇ᢥࡉࢀࡓ⼥ྜࢥ࣮ࢫ
ࡢ◊✲ᥦ᱌ࡣ௨ୗࡢ࡜࠾ࡾ࡛࠶ࡿࠋ
㸦ᖹᡂ㸯㸵ᖺᗘ⼥ྜ◊✲ࢥ࣮ࢫ㸧
ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮
ࠗ ⬻ ෆ ฟ ⾑ ἞ ⒪ ⸆ 㛤 Ⓨ ࢆ ┠ ᣦ ࡋ ࡓ ࢺ ࣟ ࣥ ࣅ ࣥ ㄏ Ⓨ 㐜 ᘏ ᛶ ⚄ ⤒ ⣽ ⬊ Ṛ ཎ ᅉ ࢱ ࣥ ࣃ ࢡ ࡢ ᥈ ⣴ ࠘ ⸆ရస⏝ゎᯒᏛศ㔝 ⸨ᮏ ┿஧
ࠗග࡟ࡼࡿᶵ⬟ศᏊ࢖࣓࣮ࢪࣥࢢࡢࡓࡵࡢࣉ࣮ࣟࣈࡢ㛤Ⓨ◊✲࠘
⑓ែᶵ⬟ศᯒᏛศ㔝 ┦⏣ ୍ᶞ
ࠗᢠ⳦ᛶ࣌ࣉࢳࢻࡢస⏝ᶆⓗࡢไᚚ࡜⣽⬊ෆศᏊᑟධ࣋ࢡࢱ࣮࡬ࡢᛂ⏝࠘
⸆ရᶵ⬟ゎᯒᏛศ㔝 ஭ᮧ 㞝୍
ࠗ ࢔ ࢫ ࢺ ࣟ ࢧ ࢖ ࢺ ᙧ ែ ࢆ ᣦ ᶆ ࡜ ࡋ ࡓ ࢭ ࣜ ࣥ ࣉ ࣟ ࢸ ࢔ ࣮ ࢮ ཷ ᐜ య ࣜ ࢞ ࣥ ࢻ ᥈ ⣴ ἲ ࡢ ᭱ 㐺 ໬ ࠘ ⏕యᶵ⬟ゎᯒᏛศ㔝 ୰ᑿ ㈼἞
ࠗ ࣌ ࣝ ࢜ ࢟ ࢩ ࢯ ࣮ ࣒ ⭷ ࢱ ࣥ ࣃ ࢡ ㉁ ㍺ ㏦ ࡟ 㛵 ࡍ ࡿ 3H[S3H[S303 ࡢ ⤖ ྜ ᵝ ᘧ ࡢ ゎ ᯒ ࠘ ᵓ㐀⏕≀⸆Ꮫศ㔝 బ⸨ ᗣᙪ
ࠗࢱࣥࢹ࣒ᆺ 0DQQLFKR[LGDWLRQ ཯ᛂࢆ฼⏝ࡋࡓ 7D[RO ㄏᑟయྜᡂ࠘
⸆ရྜᡂ໬Ꮫศ㔝 ⏿ ㄔྖ
ࠗ.RSVLMDVPLQH ࡢຠ⋡ⓗ୙ᩧ඲ྜᡂ࠘ ⸆ရྜᡂ໬Ꮫศ㔝 ᆏ஭ ೺⏨
− 22 −
ࢤࣀ࣒๰⸆
ࠗࣉࣟࢸ࢔ࢯ࣮࣒㜼ᐖ≀㉁ࡢྜᡂ࡜ホ౯࠘
⸆ရศᏊ໬Ꮫศ㔝 ᑠᯘ ⿱㍜
ࠗ᪂つศἪᛶᅉᏊ 1HXGHVLQ ࡢ⚄⤒ᰤ㣴࣭ศ໬ᅉᏊ࡜ࡋ࡚ࡢᙺ๭ࡢゎ᫂࠘
㑇ఏᏊ⸆Ꮫศ㔝 ᮌᮧ 㑳ኵ
ࠗȘ㸵ࢽࢥࢳࣥཷᐜయ࡟ᑐࡍࡿ᳜≀࢔ࣝ࢝ࣟ࢖ࢻࡢ⸆⌮స⏝ࡢ᥈⣴ⓗ◊✲࠘
⏕యᶵ⬟ゎᯒᏛศ㔝 ᒣෆ 㝧௓
ࠗ⬡⫫㓟ཷᐜయ㹅㹎㹐㸯㸰㸮ࡢࢤࣀ࣒⸆⌮Ꮫⓗゎᯒ࠘
ࢤࣀ࣒๰⸆⛉Ꮫศ㔝 ▮㔝 Ṋ᫂
ࠗࢱࣥࣃࢡ㉁ࡢᶵ⬟Ⓨ⌧ࢆไᚚࡍࡿ࣌ࣉࢳࢻᛶࣜ࢞ࣥࢻࡢ㧗άᛶ㠀࣌ࣉࢳࢻ໬࡟ࡼࡿࢤࣀ࣒๰⸆◊
✲࠘
⸆ရ᭷ᶵ〇㐀Ꮫศ㔝 㬆ᾏ ဴኵ
ࠗࣄ࢔ࣝࣟࣥ㓟㹁㹂㸲㸲ࢩࢢࢼࣝ࡟ࡼࡿ࣐ࢫࢺ⣽⬊ࡢᡂ⇍ᢚไᶵᵓࡢゎ᫂࠘
⏕య᝟ሗไᚚᏛศ㔝 㧗㔝 ⿱Ⴙ
ࣇ࢓࣮࣐ࢥࢤࣀ࣑ࢡࢫ
ࠗᶵ⬟ᛶ࣌ࣉࢳࢻࡢ฼⏝࡟ࡼࡿ᪂つ⒴ච␿⒪ἲࡢ㛤Ⓨ࠘
⑓ែ᝟ሗ⸆Ꮫศ㔝 ➉ᮏ ㄔ஧
ࠗ㦵㌿⛣ᕢ࡬ࡢࢱࣥࣃࢡ㉁ࢱ࣮ࢤࢸ࢕ࣥࢢࢩࢫࢸ࣒ࡢ㛤Ⓨ࡟ࡼࡿ㦵㌿⛣ᢚไ࠘
⸆ရືែไᚚᏛศ㔝 ර㢌 ೺἞
୍ࠗ㓟໬❅⣲ࢹࣜࣂ࣮ࣜ࡟ࡼࡿάᛶ㓟⣲㞀ᐖࡢᢚไ࠘
⸆ရືែไᚚᏛศ㔝 ຾ぢ ⱥṇ
ࠗ⣽⬊ෆ㹋㹀㹎࡟ࡼࡿ⢾ࢱࣥࣃࢡ㉁ࡢ⩻ヂᚋಟ㣭࣭㍺㏦࡟㛵ࡍࡿ◊✲࠘
⏕యศᏊㄆ㆑Ꮫศ㔝 㔝୰ ඖ⿱
㸦ᖹᡂ㸯㸶ᖺᗘ⼥ྜ◊✲ࢥ࣮ࢫ㸧
⸆ရ᭷ᶵ〇㐀Ꮫ ᐩ⏣೺Ⴙ ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸦⸨஭ಙᏕ㸪㎷ᮏ㇦୕㸧͒࣌ࣉࢳࢻࢆᇶ┙࡜ࡋ
ࡓ᪂つ⒴㌿⛣ᢚไ๣ࡢ㛤Ⓨ◊✲
⸆ရྜᡂ໬Ꮫ +$2;,1<8 ࣇ࢓࣮࣐ࢥࢤࣀ࣑ࢡࢫ㸦ᐩᒸΎ㸪㉥ụ᫛⣖㸧͒%RF/9DOLQH 㐃⤖ᆺ࢟ࣛ
ࣝ࢔࣑ࢻࣔࣀ࣍ࢫࣇ࢓ࣥ㸫ࣟࢪ࣒࢘,ゐ፹ࢆ⏝࠸ࡓ࢔࣮ࣜࣝ࣎ࣟ࢟ࢩࣥࡢ 1࣍ࢫࣇ࢕ࣀ࢖ࣝ࢖࣑
ࣥ࡬ࡢ୙ᩧ௜ຍ཯ᛂ
⸆ရศᏊ໬Ꮫ ᒣᒸᗤ௓ ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸦➉ᮏెྖ㸪㔠Ꮚ࿘ྖ㸧͒᭷ᶵゐ፹ࢆ⏝࠸ࡓ୙ᩧ
3HWDVLV ཯ᛂࡢ◊✲࡜⏕⌮άᛶ≀㉁᥈⣴࡬ࡢᛂ⏝
⸆ရᶵ⬟ゎᯒᏛ ụ⏣ᜨ௓ ࢤࣀ࣒๰⸆㸦ᯇᓮ຾ᕭ㸪༙⏣ဴ㑻㸧͒࢔࣑ࣟ࢖ࢻșࢱࣥࣃࢡ㉁࡜⬡㉁
⭷࡜ࡢ⤖ྜ࡟࠾ࡅࡿศᏊ㛫┦஫స⏝ゎᯒ
ရᶵ⬟ゎᯒᏛ ஭ᮧ㞝୍ ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸦ᯇᓮ຾ᕭ㸪㧗಴႐ಙ㸧͒ᢠ⳦ᛶ࣌ࣉࢳࢻ࡜⣽⬊
ࡢ┦஫స⏝࡟㛵ࡍࡿ◊✲࡜⣽⬊ෆศᏊᑟධ࣋ࢡࢱ࣮࡬ࡢᛂ⏝
ᵓ㐀⏕≀⸆Ꮫ బ⸨཭⨾ ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸦ຍ⸨༤❶㸪୰ᒣ࿴ஂ㸧͒ࣄࢺ 3 ⢾ࢱࣥࣃࢡ㉁ࡢ
− 23 −
⤖ᬗ໬ࢆ┠ᣦࡋࡓ◊✲
ࢤࣀ࣒๰⸆⛉Ꮫ ཎ㈗ྐ ࢤࣀ࣒๰⸆㸦㎷ᮏ㇦୕㸪ዟ㔝ᜤྐ㸧͒LQVLOLFR ࣜ࢞ࣥࢻண ࣉࣟࢢ࣒ࣛ
࡟ࡼࡿ *3&5 ᪂つࣜ࢞ࣥࢻࡢ᥈⣴࡜ࡑࡢホ౯
⏕యศᏊㄆ㆑Ꮫ ᙇ ࣅࣙ࢘ ࢤࣀ࣒๰⸆㸦➉ᓥᾈ㸪㎷ᮏ㇦୕㸧͒ᑠ⬊య᪂つ࢝ࣝࢩ࣒࢘⤖ྜ⭷ࢱ
ࣥࣃࢡ &DOXPLQ ࡟㛵ࡍࡿ◊✲
⏕యᶵ⬟ゎᯒᏛ 㕥ᮌ♸୍ ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸦㔠Ꮚ࿘ྖ㸪ᮏከ⩏᫛㸧͒ࢭࣟࢺࢽࣥ⚄⤒ྵ᭷
୰⬻ෙ≧ษ∦ᇵ㣴⣔ࢆ⏝࠸ࡓ㐪ἲࢻࣛࢵࢢ࡟ࡼࡿࢭࣟࢺࢽࣥ⚄⤒ẘᛶࡢศᏊᶵᗎ࡟㛵ࡍࡿ◊✲
⏕యᶵ⬟ゎᯒᏛ ఀ⸨ᝋᏊ ࣇ࢓࣮࣐ࢥࢤࣀ࣑ࢡࢫ㸦㔠Ꮚ࿘ྖ㸪▮㔝⩏Ꮥ㸧͒๪స⏝᝟ሗࡢࢸ࢟ࢫ
ࢺ࣐࢖ࢽࣥࢢࢆ┠ᶆ࡜ࡋࡓ⸆⌮Ꮫస⏝Ⅼࢹ࣮ࢱ࣮࣋ࢫࡢ㛤Ⓨ
㑇ఏᏊ⸆Ꮫ ᒣෆ⫕ ࢤࣀ࣒๰⸆㸦ఀ⸨ಙ⾜㸪ᰣ಴໷ᩥ㸧͒)JI ࡢ㐀⾑ᅉᏊ࡜ࡋ࡚ࡢᙺ๭࡜ࡑࡢ
స⏝࣓࢝ࢽࢬ࣒ࡢゎ᫂
㑇ఏᏊ⸆Ꮫ ୰ᒣ႐᫂ ࢤࣀ࣒๰⸆㸦ఀ⸨ಙ⾜㸪Ώ㒊ዲᙪ㸧͒)*) ࡢ⬻ཬࡧ║⚄⤒⣽⬊࡟࠾ࡅࡿ
ᶵ⬟ゎᯒ
⏕య᝟ሗไᚚᏛ ▼ᓮ⋹ ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸦୰ᒣ࿴ஂ㸪ຍ⸨༤❶㸧͒⣽⬊ෆᑠ⬊㍺㏦࡟࠾ࡅ
ࡿపศᏊ㔞 * ⺮ⓑ㉁ $5) ࡢ *'3*73 ஺᥮ᅉᏊࡢᙺ๭
⸆ရືែไᚚᏛ ᱵᒣኤ㤶㔛 ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸦ᶫ⏣඘㸪బ἞ⱥ㑻㸧͒ච␿άᛶ໬ &S*'1$
ࡢ⣽⬊㑅ᢥⓗࢱ࣮ࢤࢸ࢕ࣥࢢ࡟ᇶ࡙ࡃ᪂つ⒴ච␿⒪ἲࡢ㛤Ⓨ
⸆ရస⏝ゎᯒᏛ ἨᏳᙪ ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸦㉥ụ᫛⣖㸪㔠Ꮚ࿘ྖ㸧͒ࣃ࣮࢟ࣥࢯࣥ⑓἞⒪⸆
ࣉ࣑ࣛ࣌࢟ࢯ࣮ࣝࡢ⚄⤒ಖㆤస⏝ᶵᗎࡢゎ᫂
⑓ែᶵ⬟ゎᯒᏛ ▼㔝ㄔᝅ ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸦బ἞ⱥ㑻㸪ᶫ⏣඘㸧͒ศᏊ࢖࣓࣮ࢪࣥࢢἲࢆ
⏝࠸ࡓື⬦◳໬ࣉ࣮ࣛࢡࡢ㉁ⓗデ᩿⏝ᨺᑕᛶ⸆๣ࡢ㛤Ⓨ
⑓ែ᝟ሗ⸆Ꮫ ྜྷ⏣ᐶᖾ ࣇ࢓࣮࣐ࢥࢤࣀ࣑ࢡࢫ㸦㧗಴႐ಙ㸪㎷ᮏ㇦୕㸧͒'1$ ࡟ࡼࡿච␿ᛂ⟅ㄏ
ᑟᶵᵓࡢゎ᫂
࣭ᩍ⫱ࣉࣟࢢ࣒ࣛࡢᴫせ
㨩ຊ࠶ࡿ኱Ꮫ㝔ᩍ⫱࢖ࢽࢩ࢔ࢸ࢕ࣈࠕ⏕࿨࣭໬Ꮫ᝟ሗ࡟ᇶ࡙ࡃ⼥ྜ๰⸆◊✲⪅㣴ᡂࠖࣉࣟࢢ࣒࡛ࣛ
ࡣࠊ᝟ሗ⛉Ꮫ࡟❧⬮ࡋࡓ๰⸆◊✲⪅ࡢ㣴ᡂࢆ᥎㐍ࡍࡿࡓࡵࠊ࠸ࡃࡘ࠿ࡢ᪂ࡋ࠸ᩍ⫱ᨵ㠉ࢆᐇ㊶ࡋࡓࠋ
ࡑࢀࡽࡢᡂᯝࡢᴫせࡣ௨ୗࡢ࡜࠾ࡾ࡛࠶ࡿࠋ
㸬:HE&7HOHDUQLQJࢩࢫࢸ࣒ࡢᵓ⠏࡜㐠⏝
኱Ꮫ㝔࡟࠾࠸࡚ㅮ⩏㸦≉ㄽ㸧ࡣࠊ࣒࢝ࣜ࢟ࣗࣛ࡟࠾࠸࡚ᐃ᫬ࡢཧຍࡀồࡵࡽࢀ࡚࠸ࡿࡀࠊ㐲㝸ᆅ࡟
࠾࠸࡚◊✲ࢆ⾜ࡗ࡚࠸ࡿ⪅ࡸࠊᐇ㦂ࡢ㒔ྜ࡟ࡼࡗ࡚ฟᖍࡀᅔ㞴࡞⪅ࡣࠊฟᖍ࡛ࡁ࡞࠸࡜࠸࠺୙㒔ྜ࡟
┤㠃ࡍࡿࠋࡲࡓࠊㅮ⩏ࡣᮏ᮶ࡑࡢሙ࡟ฟᖍࡋࡓ⪅࡟ᑐࡋ࡚ࡢࡳࣛ࢖ࣈ࡛⾜ࢃࢀࡿࡶࡢ࡛࠶ࡿࡀࠊࡇࢀ
ࢆㅮᖌࡢ஢ゎࡢඖ࡟࢔࣮࢝࢖ࣈ࡜ࡋ࡚ಖᏑࡋ࡚࠾ࡃࡇ࡜࡟ࡼࡗ࡚ࠊཷㅮ⏕ࡣ௵ពࡢᶵ఍࡟Ꮫ⩦ࢆ཯᚟
ࡍࡿࡇ࡜ࡀྍ⬟࡟࡞ࡿࠋࡉࡽ࡟ᑗ᮶ⓗ࡟ࡣ♫఍ே኱Ꮫ㝔⏕࡞࡝࡟ᑐࡍࡿᏛ⩦ᶵ
఍ࢆಖドࡍࡿព࿡࡛ࡶࠊㅮ⩏࢔࣮࢝࢖ࣈ࡜HOHDUQLQJࢩࢫࢸ࣒ࡢᩚഛࡣ᭷ຠ࡞ලయⓗゎỴ⟇࡛࠶ࢁ࠺ࠋ
ᮏࣉࣟࢢ࣒࡛ࣛࡣࠊ࢔࣓ࣜ࢝࡟࠾࠸࡚㛤ⓎࡉࢀࡓHOHDUQLQJࢩࢫࢸ࣒࡛࠶ࡿ:HE&7ࢩࢫࢸ࣒ࢆ⏝࠸࡚ࠊ
− 24 −
ㅮ⩏ࡢ㡢ኌ࡜ㅮ⩏࡟⏝࠸ࡓࢫࣛ࢖ࢻࢆཷㅮ⏕ࡀ⮬⏤࡟ࢲ࣮࢘ࣥࣟࢻࡋ࡚ཷㅮࡋࠊㅮᖌࡀᥦ♧ࡋࡓㄢ㢟
࡟ᑐࡍࡿ࣏࣮ࣞࢺᥦฟࡀ࡛ࡁࡿࡼ࠺࡟ࡋࡓࠋᮏࢩࢫࢸ࣒ࡢ≉ᚩࡣḟࡢ㏻ࡾ࡛࠶ࡿࠋ
࣭ㅮ⩏グ㘓ࡣ୍⯡ⓗ࡟ື⏬࡛⾜ࢃࢀࡿࡀࠊࢫࣛ࢖ࢻ౑⏝ࡢሙྜ࡟ࡣㅮᖌࡢᫎീ⮬యࡣព࿡ࢆᣢࡓ࡞࠸
ࡓࡵࠊㅮᖌ㡢ኌࡢࡳࢆグ㘓ࡋࡓࠋࡇࢀ࡟ࡼࡗ࡚ࠊࢧ࣮ࣂࡢ㈇Ⲵࡶ㍍ῶࡋࡓࠋ
࣭ࣃ࣮࣏࣡࢖ࣥࢺࢫࣛ࢖ࢻࢆ3')ᙧᘧ࡟ࡍࡿ࡟࠶ࡓࡾࠊ⏬ീࢹ࣮ࢱ➼ࡢ㒊ศᢳฟࡀ୙ྍ⬟࡛ࠊపゎീᗘ
࡛ࡢ༳ๅࡢࡳࢆチࡍไ㝈ࢆ࠿ࡅࠊㅮᖌࡢⴭసᶒࢆಖㆤࡋࡓࠋ
࣭ཷㅮ⏕ࡣ㡢ኌࢆ⪺ࡁ࡞ࡀࡽ⮬ࡽ3')࣮࣌ࢪࢆ⧞ࡗ࡚ㅮ⩏ࡢ㐍⾜ࢆᢕᥱࡍࡿࡼ࠺࡟ࡋࡓࠋࡇࢀࡣᩍ⛉᭩
ࢆぢ࡞ࡀࡽ⾜࠺㏻ᖖࡢᏛ⩦⎔ቃ࡟‽ᣐࡋ࡚࠾ࡾࠊື⏬ࡢど⫈࡟౫Ꮡࡍࡿཷືⓗ࡞Ꮫ⩦ࡼࡾ୺యᛶࡀồ
ࡵࡽࢀࡿ࡜⪃࠼ࡽࢀࡿࠋ
:HE&7࡟࠾࠸࡚ࢫࣛ࢖ࢻ࡜㡢ኌࢆᥖ㍕ࡋࡓ⛉┠ࡣḟࡢ㏻ࡾ࡛࠶ࡿࠋ
‫⸆ۑ‬Ꮫ◊✲⛉㸦༤ኈㄢ⛬㸧
㸨ࢤࣀ࣒᝟ሗゎᯒ≉ㄽ
㸨ࢿࢵࢺ࣮࣡ࢡ᝟ሗゎᯒ≉ㄽ
㸨ඛ➃ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ₇⩦
㸨ࢸࢡࢽ࢝ࣝࣛ࢖ࢸ࢕ࣥࢢ₇⩦
㸨ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᐇ⩦
‫⸆ۑ‬Ꮫ◊✲⛉㸦ಟኈㄢ⛬㸧
㸨ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᴫㄽ
㸨⏕࿨⸆⛉Ꮫᴫㄽ
‫⸆ۑ‬Ꮫ㒊
㸨ᇶ♏ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ
㸨ᛂ⏝ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ
㸬ᩍ⫱◊✲⎔ቃ࢖ࣥࣇࣛࡢᩚഛ
Ꮫ఍࡟࠾ࡅࡿཱྀ㢌Ⓨ⾲࡛ࡣ㟁Ꮚࢫࣛ࢖ࢻࢆ⏝࠸ࡿࡇ࡜ࡀᶆ‽ⓗ࡟࡞ࡾࠊ᭱㏆࡛ࡣ࣏ࢫࢱ࣮Ⓨ⾲࡟࠾
࠸࡚ࡶ%࠶ࡿ࠸ࡣ$ุ࡞࡝ࡢ኱ᆺ⏝⣬ࢆ⏝࠸࡚どぬⓗ࡟ඃࢀࡓࣇ࣮࣏ࣝ࢝ࣛࢫࢱ࣮ࢆᥖ♧ࡍࡿࡇ࡜ࡀ
୍⯡ⓗ࡟࡞ࡗ࡚ࡁࡓࠋࡲࡓࠊ་⸆ࢹ࣮ࢱ࣮࣋ࢫࡢᩚഛࡸᩍ⛉᭩ࡢ㟁Ꮚ໬࡟కࡗ࡚ࠊᅗ᭩㤋ࡢ㟁Ꮚ໬ࡀ
ᚲせ࡜࡞ࡗ࡚ࡁࡓࠋ
ᮏࣉࣟࢢ࣒࡛ࣛࡣࡇࢀࡽࡢせồ࡟ᛂ࠼ࡿࡓࡵࠊḟࡢᩍ⫱◊✲⎔ቃ࢖ࣥࣇࣛࡢᩚഛࢆ⾜ࡗࡓࠋࡇࢀࡽ
ࡣタ⨨ᚋ࠿ࡽ኱Ꮫ㝔⏕࠾ࡼࡧᩍᖌ࡟ࡼࡗ࡚㢖⦾࡟౑ࢃࢀ࡚࠸ࡿࠋ
Ꮫ⏕⏝ࣀ࣮ࢺࣃࢯࢥࣥ
ᮏࣉࣟࢢ࣒ࣛ࡟࡚㸯㸳ྎࡢࣀ࣮ࢺࣃࢯࢥࣥࢆᑟධࡋࠊ་⒪ே*3࡟࡚ᑟධࡋࡓ㸱㸮ྎࡢࣃࢯࢥࣥ࡜ే
ࡏ࡚ࠊᅗ᭩ᐊࡢඹ㏻23$&➃ᮎ㸦㸳ྎ㸧࠾ࡼࡧ୍᫬㈚ࡋฟࡋࣃࢯࢥࣥ㸦㸱㸮ྎ㸧࡜ࡋ࡚ᩚഛࡋࡓࠋ㈚ࡋ
ฟࡋࡣ㸷᫬࠿ࡽ㸳᫬ࡲ࡛ࠊ⫋ဨド࠶ࡿ࠸ࡣᏛ⏕ド࡜ᘬࡁ᭰࠼࡟ᅗ᭩࢝࢘ࣥࢱ࣮࡟࡚⾜ࡗ࡚࠸ࡿࠋࡲࡓࠊ
ᅗ᭩23$&➃ᮎ࡛ࡣࠊ&KHP'UDZ8OWUD࡛໬Ꮫᵓ㐀ᘧࢆᥥฟࡍࡿࡇ࡜ࡸࠊ௒᪥ࡢデ⒪ࢹ࣮ࢱ࣮࣋ࢫ࡞࡝་
⸆㈨※ࢹ࣮ࢱ࣮࣋ࢫࡀ⮬⏤࡟᳨⣴࡛ࡁࡿࠋ
− 25 −
'63㉸ⷧᆺࣉࣟࢪ࢙ࢡࢱ
㸱ྎࡢ࣏࣮ࢱࣈࣝ'63㉸ⷧᆺࣉࣟࢪ࢙ࢡࢱ࡜㸱ᮏࡢ࣮ࣞࢨ࣮࣏࢖ࣥࢱࢆᩍົ᥃࡟࡚㈚ࡋฟࡋ࡚࠸ࡿࠋ
ᅗ᭩ᐊࡢ㈚ࡋฟࡋࣃࢯࢥࣥ࡜⤌ࡳྜࢃࡏ࡚ᩍᐊࢭ࣑ࢼ࣮ࡸ◊✲఍ࠊຮᙉ఍ࠊᏛ఍Ⓨ⾲⦎⩦࡞࡝࡛ά⏝
ࡉࢀ࡚࠸ࡿࠋ
኱ᆺ࣏ࢫࢱ࣮ࣉࣜࣥࢱ
%ุࣇ࣮ࣝ࢝ࣛ༳ๅࡀ࡛ࡁࡿ࣏ࢫࢱ࣮ࣉࣜࣥࢱࢆᅗ᭩ᐊ࡟タ⨨ࡋࡓࠋྛ✀ࡢᏛ఍Ⓨ⾲࡟࠾࠸࡚኱Ꮫ
㝔Ꮫ⏕ࡀά⏝ࡋ࡚࠸ࡿࠋ࣏ࢫࢱ࣮ࡢ୍㒊ࡣᮏሗ࿌᭩ࡢ⼥ྜ◊✲ࢥ࣮ࢫሗ࿌࡟ᥖ㍕ࡋࡓࠋ
㘓㡢᧜ᙳ࢟ࢵࢺ
ㅮ⩏ࡸ≉ㄽࡢ㡢ኌグ㘓࡜Ꮫ⩦㢼ᬒ࠾ࡼࡧࣇ࢕࣮ࣝࢻ࣮࣡ࢡࡢグ㘓ࢆ┠ⓗ࡜ࡋ࡚ᩍᐊ㡢㡪タഛ࠿ࡽࡢ
ࣛ࢖ࣥ㘓㡢ࡀྍ⬟࡞,&ࣞࢥ࣮ࢲ࠾ࡼࡧࢹࢪࢱ࣓ࣝ࢝ࣛ࠿ࡽ࡞ࡿ㘓㡢᧜ᙳ࢟ࢵࢺࢆᩍົ᥃࡟࡚㈚ࡋฟࡋ
࡚࠸ࡿࠋ
↓⥺/$1タഛ
ᵓෆ㸲࢝ᡤ㸦ᅗ᭩ᐊࠊ࣐ࣝࢳ࣓ࢹ࢕࢔ㅮ⩏ᐊࠊ༡໭Ჷ㸯㝵ࠊ༡໭Ჷ㸰㝵㸧࡟↓⥺/$1ࢫࢸ࣮ࢩࣙࣥࢆ
タ⨨ࡋࡓࠋᣢཧࡋࡓࣀ࣮ࢺࣃࢯࢥࣥ࡜⤌ࡳྜࢃࡏ࡚◊✲ᡴྜࡏ࡞࡝࡛࢖ࣥࢱ࣮ࢿࢵࢺࡀ౑࠼ࡿࡼ࠺࡟
㏻ಙ⎔ቃࢆᩚഛࡋࡓࠋ
ᩍ⫱㈨※࢔࣮࢝࢖ࣈࢧ࣮ࣂ
ᩍ⫱㈨※ࢆᏛ㒊ෆ࡟ᥦ౪ࡍࡿ✀ࠎࡢࢧ࣮ࣂࢆᵓ⠏ࡋࡓࠋ
࣭:HE&7ㅮ⩏࢔࣮࢝࢖ࣈ 㡢ኌ࣭ື⏬㓄ಙࠊ࣏࣮ࣞࢺཷ௜ࠊᡂ⦼⟶⌮
࣭ᩍ⫱㈨※ࡸࣉࣟࢲࢡࢺࢆ࢔࣮࢝࢖ࣈࡍࡿ࢖ࣥࢺࣛࣇ࢓࢖ࣝࢧ࣮ࣂࠋ
࣭௒᪥ࡢデ⒪࢖ࣥࢺࣛࢿࢵࢺࢧ࣮ࣂ ྠ᫬࡟㸳ேࡲ࡛ࣟࢢ࢖ࣥྍ⬟ࠋ
㸬◊✲఍࠾ࡼࡧ◊✲ሗ࿌఍ࡢᐇ᪋
ᮏࣉࣟࢢ࣒࡛ࣛࡣࠊ኱Ꮫ⏕ࡢࢤࣀ࣒๰⸆࡟ᑐࡍࡿ⌮ゎࢆ᥎㐍ࡍࡿࡓࡵࠊ㸰㸯ୡ⣖&2(ࢤࣀ࣒⛉Ꮫ࡜ࡢ
ඹദ࡟ࡼࡾࠊࠕࢤࣀ࣒๰⸆ࣇ࢛࣮࣒ࣛࠖࢆᐇ᪋ࡋࡓࠋࡲࡓࠊᮏࣉࣟࢢ࣒࡛ࣛᐇ᪋ࡋࡓ⼥ྜ◊✲ࢥ࣮ࢫ
ࡢᡂᯝⓎ⾲ࢆ㸰㸯ୡ⣖&2(ࢤࣀ࣒⛉Ꮫ࡜ࡢඹദ࡛ᖺᗘᮎ࡟⾜ࡗࡓࠋᡂᯝሗ࿌఍࡟࠾࠸࡚ࡣࠊඃ⚽Ⓨ⾲࡟
ᑐࡋ࡚ዡບ㈹ࢆᤵ୚ࡋࡓࠋ
ࢤࣀ࣒๰⸆ࣇ࢛࣮࣒ࣛ ࣮࢟ࢸࢡࣀࣟࢪ࣮
ᖺ㸷᭶᪥㸦ⅆ㸧 ி㒔ࣜࢧ࣮ࢳࣃ࣮ࢡ
୺ദ㸸ࢤࣀ࣒๰⸆ࣇ࢛࣮࣒ࣛ
ඹദ㸸ୡ⣖&2(ࣉࣟࢢ࣒ࣛ
ࠕࢤࣀ࣒⛉Ꮫࡢ▱ⓗ᝟ሗᇶ┙࣭◊✲ᣐⅬᙧᡂࠖ
㨩ຊ࠶ࡿ኱Ꮫ㝔ᩍ⫱࢖ࢽࢩ࢔ࢸ࢕ࣈ
ࠕ⏕࿨࣭໬Ꮫ᝟ሗ࡟ᇶ࡙ࡃ⼥ྜ๰⸆◊✲⪅㣴ᡂࠖ
㸸2SHQLQJ5HPDUN
㔝ཱྀ ↷ஂ㸦ࢤࣀ࣒๰⸆ࣇ࢛࣮࣒ࣛ ௦⾲㸧
㸸 㛗㔝 ဴ㞝㸦ᮾி኱Ꮫ኱Ꮫ㝔⸆Ꮫ⣔◊✲⛉⸆ရ௦ㅰ໬Ꮫᩍᐊ ᩍᤵ㸧
ࠕࣂ࢖࢜࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢ㛤Ⓨ࡜⏕య࡬ࡢᛂ⏝࡟㛵ࡍࡿ◊✲ࠖ
− 26 −
㸸 'U$QWRQ6LPHRQRY㸦&KLHI1,+&KHPLFDO*HQRPLFV&HQWHU㸧
ࠕ1,+&KHPLFDO*HQRPLFV&HQWHU2SHQLQJD1HZ'RRUWR'LVFRYHU\ࠖ
㸸 ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮㸦'U9LFWRU6HPHQWFKHQNR࣭$II\PHWUL[㸧
ࠕ7LOLQJ$UUD\V$SSOLFDWLRQVDQG'DWD$QDO\VLVࠖ
㸸 ᭱᪂ᢏ⾡⤂௓
ओᓥὠ〇సᡤ ศᯒィ ஦ᴗ㒊 ࣛ࢖ࣇࢧ࢖࢚ࣥࢫ◊✲ᡤす᰿ ໅
㸸 ᒎ♧ࣈ࣮ࢫぢᏛ
㸸 ୖᮡ ᚿᡂ㸦ி㒔኱Ꮫ໬Ꮫ◊✲ᡤࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲ᐊ ᩍᤵ㸧
ࠕྜᡂᑠศᏊ໬ྜ≀࡟ࡼࡿࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮ࠖ
㸸 ኱ᕝ ඞஓ㸦ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ඛ➃㡿ᇦ⼥ྜ་Ꮫ◊✲ᶵᵓඛ➃ᢏ⾡ࢭࣥࢱ࣮
⏕యศᏊゎᯒࢢ࣮ࣝࣉຓᩍᤵ࣭ࢢ࣮ࣝࣉ࣮ࣜࢲ࣮㸧
ࠕࢱࣥࣃࢡ㉁ࡢᚤ㔞ศᯒᢏ⾡࡜ࡑࡢព⩏ࠖ
㸸 ᆏ⏣ ᜏ᫛㸦኱㜰኱Ꮫࢧ࢖ࣂ࣮࣓ࢹ࢕࢔ࢭࣥࢱ࣮ ᐈဨᩍᤵ㸧
ࠕࢤࣀ࣒࣭࣏ࢫࢺࢤࣀ࣒᫬௦ࡢ๰⸆◊✲ࠖ
㸸 &ORVLQJ5HPDUN
㎷ᮏ ㇦୕㸦ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ ᩍᤵ㸧
බ㛤ᅜ㝿ࢩ࣏ࣥࢪ࣒࢘
㸦㨩ຊ࠶ࡿ኱Ꮫ㝔ᩍ⫱࢖ࢽࢩ࢔ࢸ࢕ࣈ⼥ྜ◊✲ࢥ࣮ࢫᡂᯝሗ࿌఍㸧
᪥᫬㸸ᖺ㸯᭶᪥㸦᭶㸧㹼᪥㸦ⅆ㸧
఍ሙ㸸ி㒔኱Ꮫ་Ꮫ㒊 Ⱚ⹒఍㤋✄᳃࣮࣭࣍ࣝᒣෆ࣮࣍ࣝ
-DQXDU\ 㸸㹼㸸 3RVWHUVHVVLRQ6WXGHQW
㸸㹼㸸 2SHQLQJUHPDUN
㸸㹼㸸 +LURDNL0LWVX\D0'3K'.XPDPRWR8QLYHUVLW\
ࠕ'HYHORSPHQWRIWKHUDSHXWLFVIRU$,'66WUXFWXUHEDVHGPROHFXODU WDUJHWLQJࠖ
㸸㹼㸸 .D]X\D.LNXFKL3K'2VDND8QLYHUVLW\
ࠕ'HVLJQV\QWKHVLVDQGELRORJLFDODSSOLFDWLRQRIFKHPLFDOSUREHVZKLFK
FRQYHUWELRORJLFDOVLJQDOVWRFKHPLFDORXWSXW㺁
㸸㹼㸸 +R-HRQJ.ZRQ3K'<RQVHL8QLYHUVLW\
ࠕ&KHPLFDOJHQRPLFVWRZDUGDQJLRJHQHVLV㺁
㸸㹼㸸 6XQJKRRQ.LP3K'6HRXO1DWLRQDO8QLYHUVLW\
ࠕ&KHPLFDOPRGXODWLRQRIHVVHQWLDOHQ]\PHVLQWKHLULQWUDDQG
LQWHUPROHFXODUVSDFHࠖ
㸸㹼㸸 .LPLWR)XQDWVX3K'8QLYHUVLW\RI7RN\R
ࠕ&KHPRLQIRUPDWLFVIRUSUHGLFWLRQDQGGHVLJQࠖ
− 27 −
-DQXDU\
㸸㹼㸸 2UDOSUHVHQWDWLRQ3'
㸸㹼㸸 2UDOSUHVHQWDWLRQ6WXGHQW
㸸㹼㸸 &ORVLQJUHPDUN
㸬኱Ꮫ㝔⏕ࡢ◊✲⫋࢖ࣥࢱ࣮ࣥࢩࢵࣉࡢᐇ᪋
ᮏࣉࣟࢢ࣒ࣛ࡟࠾࠸࡚ࡣࠊ኱Ꮫ㝔Ꮫ⏕ࢆᑐ㇟࡟ࡋ࡚◊✲⫋ࡢᑵᴗయ㦂㸦࢖ࣥࢱ࣮ࣥࢩࢵࣉ㸧ࢆ௻⏬
ࡋࡓࠋ◊✲⛉ᩍဨ࡟ࡼࡿ࢔ࣞࣥࢪ࡜ࠊෆእࡢ〇⸆࠾ࡼࡧ໬Ꮫ⣔࣓࣮࣮࢝ࡸ኱Ꮫ◊
✲ᡤࡢ༠ຊࢆᚓ࡚ࠊྜィ㸴ྡࡢ኱Ꮫ㝔⏕ࡀᐇ㝿ࡢ๰⸆࣭⏕࿨⛉Ꮫ◊✲ࡢ⌧ሙࢆయ㦂ࡋࡓࠋࡑࢀࡒࢀ࡟
ཷࡅධࢀ⎔ቃࡸᮇ㛫࡞࡝ࡣ␗࡞ࡾࠊ኱Ꮫ㝔⏕ࡀᐇ♫఍ࢆయ㦂ࡋࡓ᫬㛫ࡣ᭱▷㸯᪥࠿ࡽ᭱㛗㸯ࣨ᭶࡟ࡲ
࡛ࢃࡓࡿࡀࠊࡑࢀࡒࢀ࡟ᙉ࠸༳㇟ࢆࡶࡗࡓⅬ࡛㈗㔜࡞య㦂ࡀ࡛ࡁࠊ◊✲࡟ᑐࡍࡿࣔࢳ࣮࣋ࢩࣙࣥࡢ㧗
ᥭ࡟ࡘ࡞ࡀࡗࡓ࡜ᛮࢃࢀࡿࠋ
‫ۑ‬་⒪ே *3㸦ᖹᡂ㸯㸶ᖺᗘ㹼ᖹᡂ㸰㸮ᖺᗘ㸧
ᮏྲྀ⤌ࡣࠊᩥ㒊⛉Ꮫ┬ࡀ㑅ᐃ࣭ᨭ᥼ࡍࡿᩍ⫱ᨭ᥼ࣉࣟࢢ࣒ࣛࠕᆅᇦ་⒪➼♫఍ⓗࢽ࣮ࢬ࡟ᑐᛂࡋࡓ
㉁ࡢ㧗࠸་⒪ே㣴ᡂ᥎㐍ࣉࣟࢢ࣒ࣛࠖࡢࢸ࣮࣐㸰ࠕ⮫ᗋ⬟ຊྥୖ࡟ྥࡅࡓ⸆๣ᖌࡢ㣴ᡂ࡛ࠖ᥇ᢥࡉࢀ
ࡓࣉࣟࢪ࢙ࢡࢺ࡛࠶ࡾࠊᮏᏛ⸆Ꮫ◊✲⛉ࡢ་⒪⣔ศ㔝ࢆ୰ᚰ࡜ࡋࡓ◊✲⛉඲యࡢඹྠయไࡢࡶ࡜ࠊࡲ
ࡓி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔ࠊ⤫ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥࢱ࣮ࠊ
ࠕ㨩ຊ࠶ࡿ኱Ꮫ㝔ᩍ⫱ࠊ࢖ࢽࢩ࢔ࢳ
ࣈࠖࣉࣟࢪ࢙ࢡࢺ㸦ᖹᡂ㸯㸵ᖺᗘ㹼ᖹᡂ㸯㸶ᖺᗘ㸧
ࠊ㸰㸯ୡ⣖ &2( ࣉࣟࢢ࣒ࣛ㸦ᖹᡂ㸯㸳ᖺᗘ㹼㸯㸷ᖺ
ᗘ㸧࡜ࡢ㐃ᦠ࡟ࡼࡾ㐙⾜ࡋࡓࠋ͒ ᮏྲྀ⤌࡛ࡣࠊ་⒪ࠊ⸆Ꮫᩍ⫱ࠊ་⸆ရ㛤Ⓨ࣭⏕⏘ࠊ⸆஦⾜ᨻࡢఱࢀ࡟࠸࡚ࡶࠊ㧗ᗘ࣭ඛ➃་⒪࡟ᑐ
ࡍࡿඛᑟⓗᙺ๭ࢆᢸ࠺ᐇ㊶ཬࡧᏛ⾡⬟ຊࢆ᭷ࡍࡿ⸆๣ᖌࡢ⫱ᡂࢆ┠ᶆ࡜ࡋ࡚࠾ࡾࠊࡇࢀࢆᐇ⌧ࡍࡿࡓ
ࡵࠊ⛉Ꮫࡸ་⒪ࡢᇶ┙࡜࡞ࡿ⬟ຊ㸦▱㆑ࠊᢏ⬟ࠊែᗘ㸧ࡢಟᚓࡢࡳ࡞ࡽࡎࠊ⤒Ⴀࡸ⾜ᨻ⬟ຊࡢᾰ㣴ࢆ
ࡶ┠ᶆ࡜ࡋࡓᏛ㒊㸴ᖺ୍㈏ࡢᩍ⫱ࣉࣟࢢ࣒ࣛࡢᵓ⠏ࢆ⾜ࡗࡓࠋࡲࡎࠊࡑࡢ๓ᮇ㐣⛬࡜ࡋ࡚ḟࡢ㸳ࡘࡢ
ㄢ㢟࠿ࡽ࡞ࡿ་⒪⸆Ꮫ⤫ྜᩍ⫱ࣉࣟࢢ࣒ࣛࡢᵓ⠏ࢆ㐍ࡵ࡚࠸ࡿࠋձ⸆Ꮫ᝟ሗࢼࣅࢤ࣮ࢩࣙࣥࢩࢫࢸ࣒
ࢆᇶ┙࡜ࡋࡓ་⒪᝟ሗᩍ⫱࡜ ,7 㛵㐃▱㆑࣭ᢏ⬟ࡢ⩦ᚓࠊղ⮬❧ᆺᏛ⩦ࢆᇶ┙࡜ࡋࡓࢳ࣮ࣗࢺࣜ࢔ࣝᩍ
⫱ࠊճᅜ㝿ᛶࡢᾰ㣴ࢆ┠ᣦࡋࡓㄒᏛᩍ⫱ࠊᾏእ࢖ࣥࢱ࣮ࣥࢩࢵࣉࠊմ⸆๣ᖌ⫋⬟ࡢ⥲ྜⓗ᪩ᮇయ㦂Ꮫ
⩦ࠊյ௚Ꮫ㒊࡜ࡢ㐃ᦠ࡟ࡼࡿ࢖ࣥࢸࢢ࣮ࣞࢩࣙࣥᩍ⫱ࠋࡇࢀࡽࢆᑡேᩘ࢖ࣥࢱࣛࢡࢸ࢕ࣈᩍ⫱ࢆ㏻ࡌ
࡚ᐇ㊶ࡋࠊከᵝ࡞⸆๣ᖌ⫋⬟ࡢ⌧ሙ࡛ඛᑟⓗ࡟㧗ᗘ་⒪ཬࡧඛ➃ⓗ⫱๰⸆ࢆᢸ࠺⸆๣ᖌࢆ⫱ᡂࡍࡿࠋ͒ ᮏᏛࡢᩍ⫱┠ᶆ࡜ࡍࡿ⸆๣ᖌീ࡜ࡋ࡚ࡣࠊ་⒪ே࡜ࡋ࡚㧗࠸೔⌮ほࠊ༑ศ࡞ၥ㢟ゎỴ⬟ຊࠊ᝟ሗ㛵
ಀࡢ▱㆑࣭ᢏ⬟ࠊᅜ㝿ᛶࢆేࡏᣢࡕࠊ་⒪⌧ሙ࡛㈐௵࠶ࡿᙺ๭ࢆᯝࡓࡍ࡜ඹ࡟ࠊࡑࢀࢆ㏻ࡌ࡚⛣᳜་
⒪ࠊ෌⏕་⒪ࠊ㑇ఏᏊ἞⒪ࠊࣃ࣮ࢯࢼࣛ࢖ࢬࢻ⸆≀἞⒪➼ࡢ㧗ᗘ་⒪ࢆ㛤ᣅࡍࡿ⸆๣ᖌࡀᣲࡆࡽࢀࡿࠋ
ࡉࡽ࡟ࠊ⸆๣ᖌࡢᐇ㊶⤒㦂ࢆ⏕࠿ࡋ኱Ꮫᩍ⫱ࡢ୰࡛ᚋ㐍ࡢᣦᑟ࡟ᙜࡓࡿ⸆๣ᖌࠊ〇⸆⏘ᴗ࡟࠾࠸࡚་
⒪⤒㦂ࢆ⏕࠿ࡋ࡚᪂⸆ࡢ㛤Ⓨࡸ◊✲࡟ᚑ஦ࡍࡿ⸆๣ᖌࠊ⥲ᣓ〇㐀㈍኎㈐௵⪅➼࡜ࡋ࡚་⸆ရࡢ⏕⏘ࠊ
ရ㉁⟶⌮࡟ᚑ஦ࡋࠊඃࢀࡓရ㉁ࢆ᭷ࡍࡿ་⸆ရࡢ౪⤥࡟㈐௵ࢆᣢࡘ⸆๣ᖌࠊ⸆๣ᖌ⫋⬟ࢆᇶ┙࡟⸆஦
⾜ᨻ➼࡟ᚑ஦ࡍࡿ⸆๣ᖌࠊ࡞࡝ࠊ㧗ᗘ࡞⸆๣ᖌ⫋⬟ࡀồࡵࡽࢀࡿ⫋ᇦࡀᩘከࡃ࠶ࡾࠊࡇࢀ➼ࡢ⫋⬟࡟
ໟᣓⓗ࠿ࡘᰂ㌾࡟ᑐᛂ࡛ࡁࡿ㧗ᗘ࡞ᑓ㛛⫋⬟ࢆᣢࡗࡓ⸆๣ᖌࡢ㣴ᡂࢆᅗࡿࠋ
− 28 −
㸦ᖹᡂ㸯㸶ᖺᗘࡢྲྀࡾ⤌ࡳෆᐜ㸧
㸯㸶ᖺᗘࡢ┠ⓗࡣࠊ㸴ᖺ୍⎔ࡢ་⒪⸆Ꮫ⤫ྜᩍ⫱ࣉࣟࢢ࣒ࣛࡢ➨୍ẁ㝵ࢆ㐩ᡂࡍࡿࡓࡵ࡟ࠊࡲࡎࢥ
ࣥࣆ࣮ࣗࢱࢆ⏝࠸ࡓ₇⩦ࢆ୺య࡜ࡋࡓᩍ⫱ࡢᐇ᪋࡟ࡼࡾࢹ࣮ࢱ࣮࣋ࢫ࡜࢖ࣥࢱ࣮ࢿࢵࢺࢆᢅ࠺ࡓࡵࡢ
,7 ᢏ⬟࡜᝟ሗ೔⌮ᩍ⫱ࢆᐇ᪋ࡋࡓࠋࡲࡓࠊ࢖ࣥࢸࢢ࣮ࣞࢩࣙࣥᩍ⫱࡜ࡋ࡚⸆Ꮫࢆྲྀࡾᅖࡴ✀ࠎࡢศ㔝
࡛ࡢᏛၥࢆᏛࡪࡇ࡜࡟ࡼࡾࠊ་⒪⤒῭ࠊ་⒪⾜ᨻࠊ♫఍⸆⌮Ꮫ➼࡟ࡘ࠸࡚ࡶᖜᗈ࠸▱㆑࡜⬟ຊࢆ⩦ᚓ
ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࠊᾏእ໅ົ⤒㦂ࡢ࠶ࡿ⸆๣ᖌ࡟ࡼࡿᾏእ࡛ࡢ⸆๣ᖌࡢά㌍࡟㛵ࡍࡿㅮ⩏ࠊ་⒪㐣
ㄗࢆᑓ㛛࡜ࡍࡿᘚㆤኈ࡟ࡼࡿ་⒪ッゴࡸ་⒪ே࡜ࡋ࡚ࡢ೔⌮࡟㛵ࡍࡿㅮ⩏ࠊ་Ꮫᩍ⫱࡟ᦠࢃࡿ኱Ꮫᩍ
ဨ࡟ࡼࡿ་⒪ே࡟ᚲせ࡞ࢥ࣑ࣗࢽࢣ࣮ࢩࣙࣥ࡟㛵ࡍࡿㅮ⩏ࠊࢆᐇ᪋ࡋࡓࠋࡉࡽ࡟ࠊ⮫ᗋ⸆Ꮫⱥㄒ࡟㛵
ࡍࡿㅮ⩏࡜ࡋ࡚ࠊ⮫ᗋ⸆Ꮫ⏝ㄒࡢゎㄝࠊ᭹⸆ᣦᑟᩍ⫱ࠊᾏእ་⸆ရ᝟ሗࢆධᡭࡍࡿࡓࡵࡢ ,7 ᩍ⫱ࢆ
ᐇ᪋ࡋࡓࠋ୍᪉ࠊ⮬❧ⓗᏛ⩦ែᗘࠊࢥ࣑ࣗࢽࢣ࣮ࢩࣙࣥ⬟ຊࠊࣜࢧ࣮ࢳ࣐࢖ࣥࢻࠊၥ㢟ゎỴ⬟ຊࡢ⫱
ᡂࢆ┠ⓗ࡜ࡋ࡚ࢢࣜࢵࢻࢳ࣮ࣗࢺࣜ࢔ࣝᩍ⫱ࢆᐇ᪋ࡋࠊ㑇ఏᏊ἞⒪ࠊࣃ࣮ࢯࢼࣛ࢖ࢬࢻ⸆≀⒪ἲࠊࣂ
࢖࢜࢖࣓࣮ࢪࣥࢢ࡜་⒪ࠊ⛣᳜་⒪ࠊ෌⏕་⒪ࠊࢆࢸ࣮࣐࡜ࡋ࡚ྲྀࡾୖࡆࠊඛ➃་⒪࡟㛵ࡍࡿᑟධᩍ
⫱ࢆᐇ᪋ࡋࡓࠋ
࣭⸆Ꮫ᝟ሗࢼࣅࢤ࣮ࢩࣙࣥࢩࢫࢸ࣒ᩍ⫱
ࢥࣥࣆ࣮ࣗࢱࢆ⏝࠸ࡓ₇⩦ࢆ୺య࡜ࡋࡓࠊࢹ࣮ࢱ࣮࣋ࢫ࠾ࡼࡧ࢖ࣥࢱ࣮ࢿࢵࢺࢆᢅ࠺ࡓࡵࡢ ,7 ᢏ⬟
ᩍ⫱࡜᝟ሗ೔⌮ᩍ⫱ࢆᐇ᪋ࡋࡓࠋ
࣭⮬❧ᆺᏛ⩦ࢆᇶ┙࡜ࡋࡓࢢࣜࢵࢻࢳ࣮ࣗࢺࣜ࢔ࣝᩍ⫱
㑇ఏᏊ἞⒪ࠊࣃ࣮ࢯࢼࣛ࢖ࢬࢻ⸆≀⒪ἲࠊࣂ࢖࢜࢖࣓࣮ࢪࣥࢢ࡜་⒪ࠊ⛣᳜་⒪ࠊ෌⏕་⒪ࢆࢸ࣮
࣐࡜ࡋ࡚ྲྀࡾୖࡆࠊඛ➃་⒪࡟㛵ࡍࡿᑟධᩍ⫱ࢆᐇ᪋ࡋࡓࠋ
࣭ㄒᏛᩍ⫱
⮫ᗋ⸆Ꮫⱥㄒ࡟㛵ࡍࡿㅮ⩏࡛ࡣࠊ௦⾲ⓗ࡞⑌ᝈࠊ⑕≧ࠊ⏝ἲ࡟㛵ࡿⱥ༢ㄒࠊ་⒪ࠊ᭹⸆࡟㛵ࡍࡿ఍
ヰ⾲⌧ࢆゎㄝࡋࠊ་⒪⸆Ꮫ⏝ㄒ࡬ࡢ㛵ᚰࢆ㧗ࡵࡓࠋࡲࡓࠊᾏእ࡛ࡢ᭹⸆ᣦᑟࣅࢹ࢜ࢆ⫈ㅮࡋࠊ2SHQ(QGHG
4XHVWLRQ ࡢᡭἲࡢ⌮ゎࠊ఍ヰෆᐜࡢ⪺ࡁྲྀࡾࢆ⾜࠸ࠊⱥ఍ヰ⬟ຊྥୖࡢᚲせᛶࢆㄝࡁࡲࡋࡓࠋࡉࡽ࡟
་⸆ရ᝟ሗࢆධᡭࡍࡿࡓࡵࡢ᪉ἲ࡜ࡋ࡚ࠊᾏእ࢖ࣥࢱ࣮ࢿࢵࢺ᳨⣴㸦⛉Ꮫㄽᩥࠊῧ௜ᩥ᭩ࠊ࢞࢖ࢻࣛ
࢖ࣥ㸧ࡢᐇ౛ࢆ⤂௓ࡋࠊ⮬❧ⓗᏛ⩦࡬ࡢືᶵ௜ࡅࢆ⾜ࡗࡓࠋ
࣭࢖ࣥࢸࢢ࣮ࣞࢩࣙࣥᩍ⫱
⸆Ꮫࢆྲྀࡾᅖࡴ✀ࠎࡢศ㔝࡛ࡢᏛၥࢆᏛࡪࡇ࡜࡟ࡼࡾࠊ་⒪⤒῭ࠊ་⒪⾜ᨻࠊ♫఍⸆Ꮫ➼࡟ࡘ࠸࡚
ࡶᖜᗈ࠸▱㆑࡜⬟ຊࢆ⩦ᚓࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࠊᑓ㛛ᐙ࡟ࡼࡿㅮ₇ཬࡧࡑࡢෆᐜ࡟㛵ࡍࡿᏛ⏕ࡢᑡே
ᩘ࡟ࡼࡿࢢ࣮ࣝࣉウ㆟㸦6*'㸧ࢆᐇ᪋ࠋ௒ᖺᗘࡣࠊᾏእ໅ົ⤒㦂ࡢ࠶ࡿ⸆๣ᖌ࡟ࡼࡿᾏእ࡛ࡢ⸆๣ᖌࡢ
ά㌍࡟㛵ࡍࡿㅮ⩏ࠊ₇⩦ࠊ་⒪㐣ㄗࢆᑓ㛛࡜ࡍࡿᘚㆤኈ࡟ࡼࡿㅮ⩏ࠊ₇⩦ࠊ་Ꮫᩍ⫱࡟ᦠࢃࡿ኱Ꮫᩍ
ဨ࡟ࡼࡿㅮ⩏ࠊ₇⩦ࢆᐇ᪋ࡋࡓࠋ
࣭⸆๣ᖌ⫋⬟ࡢ⥲ྜⓗ᪩ᮇయ㦂ᩍ⫱
ி㒔኱Ꮫ་Ꮫ㒊௜ᒓ⑓㝔⸆๣㒊ぢᏛࡢᐇ᪋㸸⑓㝔⸆๣ᖌ࡜ࡋ࡚ࡢㄪ๣ࠊὀᑕ⸆ㄪ〇ࠊ἞㦂ࠊ་⸆ရ
᝟ሗᥦ౪ࠊ᭹⸆ᣦᑟ࡜࠸ࡗࡓᴗົࢆ⌮ゎࡋࠊࡲࡓࠊฎ᪉࡟ᑐࡍࡿ␲⩏↷఍࡜࠸ࡗࡓ་⒪ࢳ࣮࣒ࡢ୍ဨ
࡜ࡋ࡚ࡢ⸆๣ᖌࡢ㈐ົ࡟ࡘ࠸࡚Ꮫࢇࡔࠋ
ಖ㝤ㄪ๣⸆ᒁぢᏛࡢᐇ᪋㸸኱Ꮫ㏆㑹ࡢㄪ๣⸆ᒁࢆࢢ࣮ࣝࣉ࡟ศ࠿ࢀ࡚ࡋࠊᆅᇦ࡟㈉⊩ࡍࡿㄪ๣⸆ᒁ
− 29 −
ࡢᙺ๭ࠊᝈ⪅࡜ࡢࢥ࣑ࣗࢽࢣ࣮ࢩࣙࣥࢫ࢟ࣝࠊࢭࣝࣇ࣓ࢹ࢕ࢣ࣮ࢩࣙࣥ࡟ࡘ࠸࡚⌧ሙ⸆๣ᖌ࠿ࡽࡢㄝ
᫂ࢆཷࡅࡓࠋぢᏛ⤊஢ᚋࡣᘬ⋡ᩍဨ࡜࡜ࡶ࡟⮬⏤ウㄽࢆ⾜࠺ࡇ࡜࡛ࠊᏛ㒊ᤵᴗ࡜⸆๣ᖌ⫋⬟࡜ࡢ㛵ಀ
➼࡟ࡘ࠸࡚ヰࡋྜࡗࡓࠋ
㐃ᦠㅮᗙ་⒪ᶵ㛵ࠊᐁබᗇぢᏛࡢᐇ᪋㸸᭱ඛ➃ࡢ་⒪ཬࡧ་⸆ရ⾜ᨻ⌧ሙ࡟࠾ࡅࡿ⸆๣ᖌࡢᙺ๭࡜
㔜せᛶࢆ⌮ゎࡋࠊ⸆๣ᖌ⫋⬟⩦ᚓ࡟ᑐࡍࡿࣔࢳ࣮࣋ࢩࣙࣥࢆႏ㉳ࡉࡏࠊ࠶ࢃࡏ࡚་⒪ே࡜ࡋ࡚ࡢ೔⌮
ほࡸ⮬ぬࢆ㧗ࡵࡿࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚ࠊ㸯Ἡ㸰᪥ࡢ᪥⛬࡛ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤࠊ་⸆ရ་⒪ᶵჾ
⥲ྜᶵᵓࠊᮾி་⛉ṑ⛉኱ᏛࢆぢᏛࡋࡓࠋ
་⒪࣎ࣛࣥࢸ࢕࢔άື࡬ࡢཧຍ㸸ኟఇࡳࢆ฼⏝ࡋࠊி㒔኱Ꮫ་Ꮫ㒊་Ꮫᩍ⫱᥎㐍ࢭࣥࢱ࣮ࡢ༠ຊࡢ
ࡶ࡜ࠊி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔እ᮶ཷ௜ᨭ᥼࣎ࣛࣥࢸ࢕࢔ࢆᐇ᪋ࡋࡓࠋࡑࡇ࡛ࡣࠊᝈ⪅ࡉࢇ࡜┤᥋࡟
᥋ࡍࡿࡇ࡜࡛་⒪ே࡜ࡋ࡚ࡢ⮬ぬࢆ㧗ࡵࡿ࡜ඹ࡟ࢥ࣑ࣗࢽࢣ࣮ࢩࣙࣥ⬟ຊࡢྥୖࢆᅗࡗࡓࠋࡲࡓࠊ་
Ꮫ㒊་Ꮫ⛉ࠊಖ೺Ꮫ⛉࡜ࡢඹྠ࡟ࡼࡾ௚Ꮫ㒊࡜ࡢ஺ὶࢆᅗࡗࡓࠋᏛ⏕ࡸᝈ⪅ࡉࢇ࠿ࡽࡢホุࡶࡼࡃࠊ
⌧ᅾࡶ⥅⥆ⓗ࡟ᐇ᪋ࡋ࡚࠸ࡿࠋ
㸦ᖹᡂ㸯㸷ᖺᗘࡢྲྀࡾ⤌ࡳෆᐜ㸧
࣭⸆Ꮫ᝟ሗࢼࣅࢤ࣮ࢩࣙࣥࢩࢫࢸ࣒ᩍ⫱
⮫ᗋ⸆≀ືែࢹ࣮ࢱゎᯒࢆ౛࡟ࠊࢥࣥࣆ࣮ࣗࢱࢆ⏝࠸ࡓ⮫ᗋ⤫ィゎᯒ₇⩦ࢆᐇ᪋ࡋࡓࠋ
࣭⮬❧ᆺᏛ⩦ࢆᇶ┙࡜ࡋࡓࢢࣜࢵࢻࢳ࣮ࣗࢺࣜ࢔ࣝᩍ⫱
᭱᪂་⒪ࡸ་⒪ࢆྲྀࡾᕳࡃヰ㢟ࢆࢸ࣮࣐࡟ࠊ⮬❧ᆺᏛ⩦ࢆᇶ┙࡜ࡋࡓࢳ࣮ࣗࢺࣜ࢔ࣝᩍ⫱ࢆ㹑㹂㹅
ᙧᘧࡢࡶ࡜࡟Ꮫ⩦ࡋࡓࠋᩍᮦ࡜ࡋ࡚ᥦ♧ࡉࢀࡓ඾ᆺⓗ࡞⑕౛ࡢᴫせ࡜ࡑࡢ⤒㐣ࡢㄝ᫂ࢆཷࡅ࡚ࠊ⸆
≀἞⒪࡟㛵ࡋ࡚␲ၥⅬࠊၥ㢟Ⅼࢆᢳฟࡋࠊ㛵㐃ࡍࡿ᝟ሗࢆᩚ⌮ࡋ⮬ศࡢពぢ࡜࡜ࡶ࡟௚ே࡟ㄝ᫂
࡛ࡁࡿࡇ࡜ࢆᏛ⩦┠ᶆ࡜ࡋࡓࠋ
࣭ㄒᏛᩍ⫱
་Ꮫ㒊ⱥㄒ఍ヰᣦᑟᩍဨ࡟ࡼࡿ⮫ᗋ་Ꮫ࣭⸆Ꮫⱥ఍ヰ₇⩦ࢆᐇ᪋ࡋࡓࠋ་⒪ࢥ࣑ࣗࢽࢣ࣮ࢩࣙࣥ㸦⸆
๣ᖌ᭹⸆ᣦᑟ㸧ࢆ㢟ᮦ࡟ࠊ⮫ᗋ་Ꮫ࣭⸆Ꮫⱥ఍ヰࡢㅮ⩏ࠊ₇⩦ࢆᐇ᪋ࡋࡓࠋࡲࡓ㹒㹍㹃㹇㹁ࠊ㹒㹍㹃
㹄㹊ᩍᮦࢆᑟධࡋࠊࢥ࣑ࣗࢽࢣ࣮ࢩࣙࣥࡢᚲせᛶࠊㄒᏛᏛ⩦ࡢᚲせᛶࢆㄝ࠸ࡓ㸦ᖹᡂ㸯㸷ᖺ㸳ࠊ㸴᭶㸧
ࠋ
࣭࢖ࣥࢸࢢ࣮ࣞࢩࣙࣥᩍ⫱
ึᅇᑟධㅮ⩏࡛ࡣࠊ་⒪ࢆྲྀࡾᕳࡃ⎔ቃࡢኚ໬ࢆᴫㄝࡋࠊ⸆๣ᖌࡢ♫఍㈉⊩ࡢᅾࡾ᪉࡟ࡘ࠸࡚ࠊゎ
ㄝࡋࡓࠋ⸆๣ᖌࡢᾏእ⅏ᐖᨭ᥼࡟㛵ࡍࡿㅮ₇఍ࢆᐇ᪋ࡋࠊᾏእ࡛ᆅ㟈ࡸὠἼ⅏ᐖࡢ⌧ሙ࡛ά㌍ࡋ
ࡓ⸆๣ᖌ࡟ࡼࡿ⸆๣ᖌࡢᾏእὴ㐵⤒㦂㛵ࡍࡿㅮ₇ࢆཷࡅࡓ㸦ᖹᡂ㸯㸷ᖺ㸳᭶㸧ࠋ་⸆ရᑂᰝ⾜ᨻ࡟
㛵ࡍࡿㅮ₇ࡲࡓ་⸆ရᶵᵓ࠿ࡽࡢㅮᖌࢆᣍࡁࠊ་⸆ရᑂᰝࡸᏳ඲ᛶホ౯࡟㛵ࢃࡿ⾜ᨻ඲⯡࡟㛵ࡍ
ࡿㅮ₇ࢆཷࡅࡓ㸦ᖹᡂ㸯㸷ᖺ㸴᭶㸧
ࠋࡉࡽ࡟㸿㹃㹂ࡢ౑⏝య㦂ࢆྵࡴࠊᩆᛴ⸽⏕ἲ࡟㛵ࡍࡿ₇⩦ࢆ
ᐇ᪋ࡋࡓ㸦ᖹᡂ㸯㸷ᖺ㸴᭶㸧ࠋ
࣭⸆๣ᖌ⫋⬟ࡢ⥲ྜⓗ᪩ᮇయ㦂ᩍ⫱
ᶍᨃ⸆ᒁࡢタႠ࠾ࡼࡧ 26&( ࢺࣛ࢖࢔ࣝࢆᐇ᪋ࡋࡓࠋ
− 30 −
㸦ᖹᡂ㸰㸮ᖺᗘࡢྲྀࡾ⤌ࡳෆᐜ㸧
࣭⸆Ꮫ᝟ሗࢼࣅࢤ࣮ࢩࣙࣥࢩࢫࢸ࣒ᩍ⫱
㸰ᖺḟ㓄ᙜࡢᇶ♏⤫ィ⛉┠࡟㛵㐃ࡋ࡚᝟ሗฎ⌮ᇶᮏᢏ⬟ࡢ⩦ᚓࢆ┠ⓗ࡜ࡋ࡚ࢥࣥࣆ࣮ࣗࢱ࣮ࢆ⏝࠸
ࡓᇶ♏⤫ィ₇⩦ࢆᐇ᪋ࡋࡓࠋ
࣭⮬❧ᆺᏛ⩦ࢆᇶ┙࡜ࡋࡓࢢࣜࢵࢻࢳ࣮ࣗࢺࣜ࢔ࣝᩍ⫱
⸆Ꮫᩍ⫱࡟㐺ࡋࡓ⸆Ꮫࢳ࣮ࣗࢺࣜ࢔ࣝᩍ⫱ࡢᩍᮦࠊᩍ⫱ࢩࢫࢸ࣒ࢆࡣࡌࡵ࡚ᵓ⠏ࡋࡓࠋ
࣭ㄒᏛᩍ⫱
་Ꮫ㒊ⱥㄒ఍ヰᣦᑟᩍဨ࡟ࡼࡿ⮫ᗋ་Ꮫ࣭⸆Ꮫⱥ఍ヰ₇⩦ࢆᐇ᪋ࡋࡓࠋ
࣭࢖ࣥࢸࢢ࣮ࣞࢩࣙࣥᩍ⫱
ᑓ㛛ᐙ࡟ࡼࡿㅮ₇࠾ࡼࡧࡑࡢෆᐜ࡟㛵ࡍࡿᏛ⏕࡜ࡢウ㆟ࢆᐇ᪋ࡋࡓࠋࡲࡓࠊ᪥ᮏ୰ẘ᝟ሗࢭࣥࢱ࣮
ࡢぢᏛ࣭ி㒔኱Ꮫ་Ꮫ㒊௜ᒓ⑓㝔ࡢྛ㒊⨫ぢᏛࢆᐇ᪋ࡋࡓࠋࡉࡽ࡟ࠊ་Ꮫ㒊་Ꮫ⛉ࠊ་Ꮫ㒊ಖ೺Ꮫ⛉
࡜ࡢඹྠᐇ⩦ࢆᐇ᪋ࡋࡓࠋ
ᖹ ᡂ 㸯 㸷 ᖺ 㸯 㸯 ᭶ 㸯 㸲 ᪥ ࡟ ࡣ ࠊ ி 㒔 ኱ Ꮫ ⸆ Ꮫ 㒊 ་ ⒪ ே *3 ᅜ 㝿 ᩍ ⫱ ࢩ ࣥ ࣏ ࢪ ࢘ ࣒
,QWHUQDWLRQDO6\PSRVLXPRQ(GXFDWLRQ3URJUDPIRU&OLQLFDO3KDUPDFLVWVࢆ㛤ദࡋࡓࠋ
ࣉࣟࢢ࣒ࣛ
㛤఍ࡢ㎡ బ἞ⱥ㑻㸦ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉㸧
➨୍㒊
ᗙ㛗 㧗಴႐ಙ㸦ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉㸧
ࠕඛ➃་⒪ࡢ⫱๰⸆ࢆඛᑟࡍࡿ⸆๣ᖌ⫱ᡂࣉࣟࢢ࣒ࣛࠖ
బ἞ⱥ㑻㸦ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉㸧
ࠕி㒔኱Ꮫ࡟࠾ࡅࡿ⮫ᗋ⸆๣ᖌᩍ⫱ࡢᴫせࠖ
㉥ụ᫛⣖㸦ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉㸧
➨஧㒊
ᗙ㛗 బ἞ⱥ㑻㸦ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉㸧
ࠕ⸆Ꮫᩍ⫱ ᖺไ࡟ᮃࡴࡶࡢࠖ
㇂ᕝཎ♸௓ඛ⏕㸦៞᠕⩏ሿ኱Ꮫ་Ꮫ㒊⸆๣㒊ᩍᤵ㸧
ࠕ(GXFDWLRQSURJUDPVIRUWKH3KDUP'FRXUVHLQ8&6)ࠖ
'RQDOG7.LVKL3KDUP'8&6)86$
㛢఍ࡢ㎡ బ἞ⱥ㑻㸦ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉㸧
ᮏ஦ᴗࠕࣘࣅ࢟ࢱࢫ೺ᗣ♫఍ࡢ᭱᪂ࢽ࣮ࢬ࡟ᑐᛂࡋࡓᐇ㊶ᆺேᮦ⫱ᡂࠖࡣࠊᩥ㒊⛉Ꮫ┬࡟ࡼࡿᩍ⫱
ᨭ᥼ࣉࣟࢢ࣒ࣛࠕ⏘Ꮫ㐃ᦠ࡟ࡼࡿᐇ㊶ᆺேᮦ⫱ᡂ஦ᴗ㸦ࢧ࣮ࣅࢫ࣭࢖ࣀ࣮࣋ࢩࣙࣥேᮦ⫱ᡂ᥎㐍ࣉࣟ
ࢢ࣒ࣛ㸧࡛ࠖ᥇ᢥࡉࢀࡓࣉࣟࢪ࢙ࢡࢺ࡛࠶ࡾࠊ㸱ᖺ㛫ࡢணᐃ࡛ࠊᖹᡂ㸰㸮ᖺᗘࡼࡾάືࢆ㛤ጞࡋࡓࠋ
ᮏ㑥ࡣࠊ๓౛ࡢ࡞࠸ࢫࣆ࣮ࢻ࡛ᑡᏊ㧗㱋໬ࡀ㐍ࢇ࡛࠾ࡾࠊ㞴἞ᛶ࡜ࡉࢀࡿ࠸ࡃࡘ࠿ࡢ⑌ᝈ࡜ࠊࡇࢀ
ࡽࡢ἞⒪࡟ᑐᛂࡍࡿ་ᖌࡢ㉁ⓗ㔞ⓗ࡞୙㊊ࡀ♫఍ၥ㢟࡜࡞ࡗ࡚࠸ࡿࠋ་⒪ಖ㝤ไᗘࡢ⥔ᣢࢆ┠ⓗ࡜ࡋ
࡚ࠊデ⒪ሗ㓘ᨵᐃࠊಖ㝤ᩱ㈇ᢸቑ኱࡞࡝ࡀᐇ᪋ࡉࢀࠊࡑࢀ┦ᙜࡢ་⒪⤒῭Ꮫⓗ࡞ຠᯝࡀ࠶ࡗࡓ࡜ࡉࢀ
− 31 −
࡚࠸ࡿࡶࡢࡢࠊᑡᏊ㧗㱋໬࡟ṑṆࡵࡀ࠿࠿ࡽ࡞࠸ᐇ᝟ࢆ຺᱌ࡍࡿ࡜ࠊࡉࡽ࡞ࡿᨵ㠉ࡀᚲせ࠿ࡶ▱ࢀ࡞
࠸ࠋࡋ࠿ࡋ࡞ࡀࡽࠊ᪤࡟ࠊ་ᖌ࡬ࡢ㐣㔜㈇ᢸ࡞࡝ࡀᣦ᦬ࡉࢀ࡚࠾ࡾࠊ୍㒊ࡢᆅᇦ࡛ࡣ་⒪ᔂቯ࡟㏆࠸
≧ែࢆᠱᛕࡍࡿኌࡶᑡ࡞ࡃ࡞ࡃࠊ௨ୖࡢࡇ࡜࠿ࡽࠊᮏ㑥࡛ࡣࠊ⑓㝔ࢆ୰ᚰ࡜ࡋࡓ་⒪࠿ࡽࠊᅾᏯ་⒪ࠊ
ࢭࣝࣇ࣓ࢹ࢕ࢣ࣮ࢩࣙࣥ࡬⛣⾜ࡍࡿࡇ࡜ࡀ☜ᐇ࡞≧ἣୗ࡟࠶ࡿ࡜⪃࠼ࡿࠋ
ᮏ㑥࡟࠾ࡅࡿᆅᇦ་⒪ࡢᐇ᝟ࢆ⪃࠼ࡿ࡜ࠊࡼࡾ᭷ຠ࡛Ᏻ඲࡞⏬ᮇⓗ᪂⸆ࢆ㛤Ⓨࡍࡿࡇ࡜࡜ࡶ࡟ࠊ୍
᪉࡛ࠊᅾᏯ་⒪ࠊࢭࣝࣇ࣓ࢹ࢕ࢣ࣮ࢩࣙࣥࢆ᥎㐍ࡍࡿࡓࡵ࡟ࠊ་⒪ࢧ࣮ࣅࢫ⏘ᴗࢆ඘ᐇࡉࡏࡿࡇ࡜ࡀ
㔜せ࡜ᛮࢃࢀࡿࠋࡍ࡭࡚ࡢᅜẸࡀࠊ࠸ࡘ࡛ࡶࠊᏳᚰ࡛ࠊᏳ඲࡞་⒪ࢆཷࡅࡿࡇ࡜ࡀ࡛ࡁࡿ♫఍ࢆసࡾ
ࡓ࠸࡜࠸࠺㢪࠸ࢆ㎸ࡵ࡚ࠊࡇࢀࢆࠕࣘࣅ࢟ࢱࢫ೺ᗣ♫఍ࠖ࡜ྡ௜ࡅࠊᮏேᮦ⫱ᡂࣉࣟࢢ࣒ࣛࢆィ⏬ࡋ
ࡓࠋ
㸦ᮏ஦ᴗࡢ┠ⓗࠊ᪉㔪ࠊ㣴ᡂࡍࡿேᮦീ➼㸧
ᮏ㑥࡟࠾ࡅࡿ་⸆ရ⏘ᴗ࡟ࡘ࠸࡚ࡣࠊᅜ㝿➇தຊࡢపࡉࠊලయⓗ࡟ࡣࠊ᪂⸆㛤Ⓨ࡟᫬㛫ࡀ࠿࠿ࡾ㐣
ࡂࡿࡇ࡜ࢆᣦ᦬ࡍࡿኌࡀᑡ࡞࠿ࡽࡎ࠶ࡾࠊ㎿㏿࡞᪂⸆㛤Ⓨࢆᨭ᥼࡛ࡁࡿ἞㦂ࢥ࣮ࢹ࢕ࢿ࣮ࢱ࣮ࡢ⫱ᡂ
ࡀⅆᛴࡢㄢ㢟࡜࡞ࡗ࡚࠸ࡿࠋ୍᪉ࠊ᪤Ꮡ་⸆ရ࡟ࡘ࠸࡚ࡣࠊ⭾኱໬ࡍࡿ་⒪㈝ࡢᢚไࡢⅭࡢᵝࠎ࡞᪋
⟇㸦་⸆ศᴗ᥎㐍➼㸧ࡀ㏻▱ࡉࢀ࡚࠾ࡾࠊࡇࢀࡽࢆⓗ☜࡟ᐇ⾜ࡋࠊ་⸆ရࡢ㐺ṇ࡛ຠ⋡ⓗ࡞฼⏝ࢆᐇ
㊶ࡋ࡚ᆅᇦ་⒪ࡸ⚟♴࡟㈉⊩࡛ࡁࡿᐇ㊶ᆺேᮦࡢ⫱ᡂࡀᚲせ࡛࠶ࡿࠋࡑࡇ࡛ࠊ
ձ᪂つ་⸆ရࡢ㎿㏿࡞㛤Ⓨࢆᨭ᥼࡛ࡁࡿ἞㦂ࢥ࣮ࢹ࢕ࢿ࣮ࢱ࣮
ղ᪤Ꮡ་⸆ရࡢ㐺ṇ౑⏝ࢆ௓ࡋ࡚ᆅᇦ་⒪ࡸ⚟♴࡟㈉⊩࡛ࡁࡿᐇ㊶ᆺேᮦ
ճ་⒪ࢧ࣮ࣅࢫ㛵㐃ศ㔝࡟࠾ࡅࡿ᪂つ⏘ᴗࡢ࢖ࣀ࣮࣋ࢩࣙࣥࢆ≌ᘬ࡛ࡁࡿேᮦ
ࡢ⫱ᡂࢆ┠ⓗ࡜ࡋ࡚ᮏ஦ᴗࢆィ⏬ࡋࡓࠋ
⏘ᐁࠊࡉࡽ࡟ࡣᆅᇦ་⒪㛵㐃ㅖᅋయ࡜ࡢ㐃ᦠ࡟ࡼࡾࠊ᝟ሗࢥࣥࢸࣥࢶࠊᩍ⫱ࢥࣥࢸࣥࢶࢆᩚഛࡍࡿ
࡜࡜ࡶ࡟ࠊ඲ࡃ᪂ࡓ࡞ᩍ⫱య⣔ࢆᵓ⠏ࡋࠊศ㔝ᶓ᩿ⓗ࡞᪂ࡋ࠸▱㆑࡜ࢫ࢟ࣝࢆᣢࡘ་⒪⣔ேᮦࢆ⫱ᡂ
ࡍࡿࠋලయⓗ࡟ࡣࠊ་⒪ࠊ≉࡟་⸆ရ࡟ᑐࡍࡿ་⒪ᚑ஦⪅ࠊᝈ⪅ࡉࢇࡢពぢࢆ཰㞟ࡋࠊ⌧ᅾࡢ་⒪ࡀ
࠿࠿࠼ࡿၥ㢟Ⅼࢆ་⒪⌧ሙࡢど⥺࡛ᩚ⌮ࠊࡇࢀࢆࠊ᝟ሗࢥࣥࢸࣥࢶࠊᩍ⫱ࢥࣥࢸࣥࢶ࡜ࡋ࡚ࠊᩍᮦ࡟
ά⏝ࡍࡿࠋ
㸦஦ᴗάື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯㸧
᪂ࡓ࡟ࠕ་⸆ရ㛤ⓎᏛࠖ㸦㸲ᖺḟࠊㅮ⩏⛉┠ࠊ๓ᮇ㸧ࠊࠕᆅᇦ་⒪⸆Ꮫࠖ㸦㸰ᖺḟࠊ₇⩦⛉┠ࠊ๓ᮇࠊ
⸆Ꮫ⛉㸧ࠊ
ࠕ་⸆ရ㛤Ⓨࣉࣟࢪ࢙ࢡࢺ₇⩦ϩࠖ㸦㸲ᖺḟࠊ₇⩦⛉┠ࠊኟᏘ㞟୰㸧ࡢ㸱⛉┠ࢆ㛤ㅮࡋࡓࠋ
་⸆ရ⏘ᴗ࡟࠾࠸࡚ࡣࠊࡇࢀࡲ࡛ࠊࠕ࢚ࣥࢻ࣮ࣘࢨ࣮࡟ᑐࡍࡿ࣐࣮ࢣࢸ࢕ࣥࢢࠖ࡜࠸࠺ᩥ໬ࡀ࡞ࡃࠊ
ࡇࡢࡓࡵࠊ་⒪ᚑ஦⪅ࠊᝈ⪅ࡉࢇ࠿ࡽ୙ホ࡞་⸆ရࡀᑡ࡞࠿ࡽࡎ࠶ࡾࠊ་⒪ࡢ㐺ṇ໬࡟ᑡ࡞࠿ࡽࡎᙳ
㡪ࢆ୚࠼࡚࠸ࡿ࡜ᛮࢃࢀࡓࠋᮏ஦ᴗ࡟࠾࠸࡚ࠊ་⒪ࠊ≉࡟་⸆ရ࡟ᑐࡍࡿ་⒪ᚑ஦⪅ࠊᝈ⪅ࡉࢇࡢព
ぢࢆ཰㞟ࡋࡓࡀࠊᏛ⏕ࡢホุࡣ㠀ᖖ࡟Ⰻ࠿ࡗࡓࠋࡑࡢୖࠊㄪᰝࡑࡢࡶࡢࠊࡶࡋࡃࡣㄪᰝ⤖ᯝ࡟ᇶ࡙࠸
࡚సᡂࡋࡓ᝟ሗࢥࣥࢸࣥࢶࠊᩍ⫱ࢥࣥࢸࣥࢶ࡟ᑐࡍࡿ཯㡪ࡀ᝿ീ௨ୖ࡟኱ࡁࡃࠊᆅᇦ་⒪㛵㐃ㅖᅋయ
ࡸ〇⸆௻ᴗࠊㅖᏛ఍࠿ࡽࠊㅮ₇఍ࡸ◊ಟ఍࡞࡝ࡢㅮ₇౫㢗ࢆཷࡅࡓࠋࡇࢀࡽࡣࠊ᝟ሗࢥࣥࢸࣥࢶࠊᩍ
⫱ࢥࣥࢸࣥࢶࡢࠊࡲࡓᮏ஦ᴗ඲యࡢ᭷⏝ᛶࢆ㇟ᚩࡋ࡚࠸ࡿࠋ
− 32 −
‫ۑ‬ி㒔኱Ꮫඛ➃ᢏ⾡ࢢ࣮ࣟࣂ࣮ࣝࣜࢲ࣮㣴ᡂࣘࢽࢵࢺ㸭ࣉࣟࢢ࣒ࣛ㸦ᖹᡂ㸰㸮ᖺᗘ㹼
ᖹᡂ㸰㸲ᖺᗘ㸧
⛉Ꮫ᣺⯆ㄪᩚ㈝ࠕ࢖ࣀ࣮࣋ࢩࣙࣥ๰ฟⱝᡭ◊✲ேᮦ㣴ᡂࠖࡢ᥇ᢥ㸦ᖹᡂ㸰㸮㸰㸲ᖺᗘ㸧ࢆᚓ࡚ࠊඛ
➃ᢏ⾡ศ㔝࡟࠾࠸࡚ᅜ㝿ⓗ࡟ά㌍ࡍࡿ࣮ࣜࢲ࣮㸦*OREDO/HDGHU㸧ࢆ㣴ᡂࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࠊ༤ኈᚋ
ᮇㄢ⛬኱Ꮫ㝔⏕ࢆྵࡴⱝᡭ◊✲⪅ࢆᑐ㇟࡟ࠕඛ➃ᢏ⾡ࢢ࣮ࣟࣂ࣮ࣝࣜࢲ࣮㸦*/㸧㣴ᡂࣉࣟࢢ࣒ࣛࠖࢆ
ᥦ౪ࡋ࡚࠸ࡿࠋᮏࣉࣟࢢ࣒ࣛࢆ᥎㐍ࡍࡿࡓࡵࡢ⤌⧊࡜ࡋ࡚ࠊி㒔኱Ꮫ࡟ࠕඛ➃ᢏ⾡ࢢ࣮ࣟࣂ࣮ࣝࣜࢲ
࣮㣴ᡂࣘࢽࢵࢺ㸦␎⛠㸸*/ 㣴ᡂࣘࢽࢵࢺ㸧ࠖࡀタ⨨ࡉࢀࠊ㐃ᦠ◊✲ᶵ㛵࣭௻ᴗ➼ࡢ༠ຊࢆᚓ࡚ࢢ࣮ࣟ
ࣂ࣮ࣝࣜࢲ࣮㣴ᡂࢥࣥࢯ࣮ࢩ࢔࣒ࢆᵓᡂࡍࡿ࡜ඹ࡟ࠊᕤᏛ◊✲⛉࡜⸆Ꮫ◊✲⛉ࡀ㐃ᦠࡋ࡚㐠Ⴀ࡟࠶ࡓ
ࡗ࡚࠸ࡿࠋ
㸦ࣉࣟࢢ࣒ࣛࡢෆᐜ㸧
༤ኈᚋᮇㄢ⛬࡛Ꮫ఩ྲྀᚓ┤๓ࡢᏛ⏕࡜Ꮫ఩ྲྀᚓ┤ᚋࡢ࣏ࢫࢻࢡࢆᑐ㇟࡜ࡋ࡚ࠊ῝࠸ᑓ㛛ᛶ࡟ຍ࠼࡚
ᖜᗈ࠸㆑ぢࢆഛ࠼ࠊᅜ㝿ⓗ࡟࣮ࣜࢲ࣮࡜ࡋ࡚ά㌍ࡍࡿேᮦࢆ㣴ᡂࡍࡿࡓࡵࠊୗグࡢ㣴ᡂࣉࣟࢢ࣒ࣛࢆ
ᥦ౪ࡋ࡚࠸ࡿࠋ
㸦㸧⏘ᐁᏛ஺ὶሿ㸸␗ศ㔝ࡢ◊✲⪅࡜⬟ືⓗ࡟◊✲஺ὶࡍࡿሙ࡜ࡋ࡚ࠊࠕ⏘ᐁᏛ஺ὶሿࠖࢆ㛤タࡋ࡚
࠸ࡿࠋሿ⏕㸦ᒚಟ⏕㸧ࡣ⮬ࡢ༤ኈㄽᩥ◊✲ࡢෆᐜࢆሗ࿌ࡋࠊ♫఍ⓗព⩏ࠊⓎᒎᛶ➼ࢆྵࡴᗈ࠸どⅬ࠿
ࡽࢹ࢕࣮࣋ࢺࢆ⾜࠺ࠋࢹ࢕࣮࣋ࢺ࡟ࡣࠊሿ⏕௨እ࡟࣓ࣥࢱ࣮ᩍဨࠊࢥࣥࢯ࣮ࢩ࢔࣒ཧຍ௻ᴗ➼࠿ࡽ㑅
ฟࡉࢀࡓጤဨࡀཧຍࡍࡿࠋࡇࢀ࡟ࡼࡾࠊᒚಟ⏕ࡣࠕྛ⮬ࡢ◊✲ࢆᗈ࠸ど㔝࠿ࡽᐈほⓗ࡟ᢕᥱࡍࡿ⬟ຊࠖ
ࢆ㌟࡟ࡘࡅࠊሿ࡛ࡢ㆟ㄽࢆࡶ࡜࡟ࠊࠕ཮᪉ྥᩍ⫱ᆺඹྠ◊✲ࠖࡢὴ㐵ඛࢆ㑅ᐃࡍࡿࠋ
㸦㸧཮᪉ྥᩍ⫱ᆺඹྠ◊✲㸸ᮏࣉࣟࢢ࣒ࣛࡢᒚಟ⏕ࡣࠊ◊✲⪅࡜ࡋ࡚ཷධᶵ㛵࣭௻ᴗ➼ࡢ◊✲⪅࡜࠾
஫࠸࡟่⃭ࢆཷࡅ࡞ࡀࡽ◊✲ࢆ㐍ࡵࡿࠊ཮᪉ྥᩍ⫱ᆺඹྠ◊✲㸦ᮇ㛫ࠊ㸱࢝᭶௨ୖ㸧࡟ཧຍࡍࡿࠋὴ
㐵ඛᶵ㛵࣭௻ᴗ➼ࡣࠊ⏘ᐁᏛ஺ὶሿ࡛ࡢࢹ࢕࣮࣋ࢺࢆ㏻ࡋ࡚ᒚಟ⏕ࡢ◊✲ศ㔝ࡸ㐺ᛶࢆ༑ศ࡟ᢕᥱࡋࠊ
ຠᯝࡀᮇᚅ࡛ࡁࡿᶵ㛵࣭௻ᴗ➼ࢆ㑅ᐃࡍࡿࠋᒚಟ⏕ࡣࠊ‽ഛẁ㝵࠿ࡽඹྠ◊✲࡟ཧຍࡋࠊ◊✲⬟ຊࡢ
ࡳ࡞ࡽࡎࠊࠕྛ⮬ࡢ◊✲ࢆ㛵㐃ࡍࡿศ㔝࡟ᒎ㛤ࡋࠊ᪂ࡋ࠸◊✲ィ⏬ࢆ❧᱌ࡍࡿ⬟ຊࠖ࡜ࠕ࣮ࣜࢲ࣮࡜
ࡋ࡚ࠊࢢ࣮ࣝࣉࢆ⤫⋡ࡍࡿ⬟ຊࠖࢆ㣴࠺ࠋ
㸦㸧ᐇ㊶ⱥㄒᩍ⫱㸸እᅜேᩍᖌ࡟ࡼࡿ࣐ࣥࢶ࣮࣐ࣥ࡟㏆࠸ᩍ⫱⎔ቃ࡛ࠊᅜ㝿఍㆟➼࡟࠾ࡅࡿⱥㄒ࡛ࡢ
ࣉࣞࢮࣥࢸ࣮ࢩࣙࣥࠊ㉁␲ᛂ⟅࣭ウ㆟ࠊ⛉Ꮫᢏ⾡ㄽᩥࡢసᡂἲ➼ࢆಟᚓࡍࡿࡓࡵࡢᐇ㊶ⱥㄒᩍ⫱ࢆཷ
ㅮࡍࡿࠋㄽᩥసᡂἲ࡟ࡘ࠸࡚ࡣࠊᐇ㝿࡟ᒚಟ⏕ࡀ᭩࠸ࡓ◊✲ㄽᩥࡢⲡ✏➼ࢆ㢟ᮦ࡟ࠊၥ㢟Ⅼ࣭ᨵၿⅬ
➼ࢆᣦ᦬ࡋྜ࠺ࡇ࡜࡛ㄽᩥసᡂ࠾ࡼࡧᩍ⫱ᢏ⾡ࡢྥୖࢆᅗࡗ࡚࠸ࡿࠋ
▱㈈ᩍ⫱㸸㏆ᖺ㔜せᛶࡀቑࡋ࡚࠸ࡿ▱ⓗ㈈⏘࡟ࡘ࠸࡚㞟୰ⓗ࡟ᏛࡪࠋㅖẶࡀ⏘ᐁᏛࡢఱฎ࡛άື
ࡍࡿࡇ࡜࡟࡞ࡗ࡚ࡶࠊᚲࡎ᭷⏝࡜࡞ࡿ▱㆑ࢆಟᚓࡍࡿࠋ◊ಟࡣ௨ୗࡢ㸱ࡘ࠿ࡽᵓᡂࡉࢀ࡚࠸ࡿࠋ
㸧▱㈈ᶒ඲⯡㸦≉チ࡟ຍ࠼ࠊၟᶆࠊ୙ṇ➇த㜵Ṇἲ➼ࡢ▱ⓗ㈈⏘඲⯡ࢆᏛࡪ㸧
㸧≉チᴫせ㸦⮬ࡽࡢᶒ฼ࢆ☜ಖࡍࡿࡇ࡜࡜ࠊ➨㸱⪅ࡢᶒ฼࡬ࡢᑐᛂࠊ࡜࠸࠺㸰ࡘࡢどⅬ࠿ࡽᏛࡪ㸧
㸧≉チㄪᰝ₇⩦㸦≉チᶒ฼≧ἣࡸᑓᨷᢏ⾡ㄪᰝࡢ᪉ἲࢆᐇ⩦ࡍࡿ㸧
㸦⤌⧊㸧
ࢢ࣮ࣟࣂ࣮ࣝࣜࢲ࣮㣴ᡂࣘࢽࢵࢺෆ࡟ྛ✀ጤဨ఍ࢆタ⨨ࡋࠊᕤᏛ◊✲⛉࡜⸆Ꮫ◊✲⛉ࡀ㐃ᦠࡋ࡚㐠Ⴀ
ࡋ࡚࠸ࡿࠋྛ✀ጤဨ఍ጤဨ࠾ࡼࡧࢫࢱࢵࣇࡣḟࡢ࡜࠾ࡾ࡛࠶ࡿ㸦ᖹᡂ㸰㸰ᖺᗘ㸧ࠋ
− 33 −
*/ 㣴ᡂࣘࢽࢵࢺ㛗 㛗㇂㒊ఙ἞㸦ᕤ㸧
ࠊ๪ࣘࢽࢵࢺ㛗 ໭ᾆ࿴ኵ㸦⸆㸧
㐠Ⴀ༠㆟఍㸸ጤဨ㛗 㛗㇂㒊ఙ἞㸦ᕤ㸧
ࠊ๪ጤဨ㛗 ໭ᾆ࿴ኵ㸦⸆㸧ࠊᑠ᳃ ᝅ㸦ᕤᏛ◊✲⛉㛗㸧
᳷ᮌဴኵ㸦ᕤ㸧ࠊ㛛ෆ㍤⾜㸦ᕤ㸧
ࠊ㧗ᒸ⩏ᐶ㸦ᕤ㸧ࠊ⸨஭ ⪽㸦ᕤ㸧ࠊబ἞ⱥ㑻㸦⸆Ꮫ◊✲⛉㛗㸧ࠊ
ᰤ⏣ᩄஅ㸦⸆㸧ࠊ➉ᓥ ᾈ㸦⸆㸧
ࠊዟ㔝ᜤྐ㸦⸆㸧
ೃ⿵⪅㑅ᐃጤဨ఍㸸ጤဨ㛗 ໭ᾆ࿴ኵ㸦⸆㸧ࠊ๪ጤဨ㛗 㛗㇂㒊ఙ἞㸦ᕤ㸧
⏘ᐁᏛ஺ὶሿᐇ᪋ጤဨ఍㸸ጤဨ㛗 ᳷ᮌဴኵ㸦ᕤ㸧ࠊ๪ጤဨ㛗 ໭ᾆ࿴ኵ㸦⸆㸧
཮᪉ྥᩍ⫱ᆺඹྠ◊✲ᨭ᥼ጤဨ఍㸸ጤဨ㛗 Ⲩᮌ㏻ၨ㸦⸆㸧
ࠊ๪ጤဨ㛗 㛛ෆ㍤⾜㸦ᕤ㸧
ᅜ㝿໬ᩍ⫱ጤဨ఍㸸ጤဨ㛗 㛗㇂㒊ఙ἞㸦ᕤ㸧
ࠊ๪ጤဨ㛗 ᰤ⏣ᩄஅ㸦⸆㸧
▱㈈ᩍ⫱ጤဨ఍㸸ጤဨ㛗 ➉ᓥ ᾈ㸦⸆㸧ࠊ๪ጤဨ㛗 ᯇᒃᏹ඾
ᗈሗጤဨ఍㸸ጤဨ㛗 㧗ᒸ⩏ᐶ㸦ᕤ㸧ࠊ๪ጤဨ㛗 ዟ㔝ᜤྐ㸦⸆㸧
ᑓ௵ࢫࢱࢵࣇ㸸≉ᐃ෸ᩍᤵ Ⲩᮌ㏻ၨ㸦⸆㸧ࠊ≉ᐃㅮᖌ Ἀ࿴ဢ㸦ᕤ㸧ࠊ≉ᐃຓᩍ ゅᒣ㤶⧊㸦⸆㸧
ࠊ
ࢥ࣮ࢹ࢕ࢿ࣮ࢱ࣮㸸ᯇᒃᏹ඾㸦ᕤ㸧
㸦άືᐇ⦼㸧
ᖹᡂ㸰㸰ᖺᗘࢆྵࡵ࡚ࠊࡇࢀࡲ࡛ࡢᒚಟ⏕ࡣ඲㒊࡛㸲㸮ྡ࡛࠶ࡿ㸦᥇⏝᫬Ⅼ࡛༤ኈㄢ⛬Ꮫ⏕ࡀ
㸰㸴ྡࠊ࣏ࢫࢻࢡࡀ㸯㸲ྡ㸧ࠋಟ஢⏕㸰㸲ྡ㸦୰㏵ᑵ⫋ࡋࡓ㸱ྡࢆྵࡴ㸧ࡢᑵ⫋ඛࡣࠊ኱Ꮫ㛵ಀ㸶
ྡࠊᅜ❧◊✲ᶵ㛵㸱ྡࠊ௻ᴗ㸷ྡࠊᾏእࡢ኱Ꮫ࣭௻ᴗ࣭ᅜ㝿ᶵ㛵࡬㸱ྡࠊ㉳ᴗᐙ㸯ྡ࡜ከᙬ࡛࠶
ࡾࠊᮏࣉࣟࢢ࣒࡛ࣛᥖࡆࡓ୰ᮇ┠ᶆࢆ࡯ࡰ㐩ᡂࡋ࡚࠸ࡿࠋ
㸦㸰㸧Ꮫ㒊Ꮫ⏕࣭኱Ꮫ㝔Ꮫ⏕➼ࡢཷධࢀ
㸯㸧⸆Ꮫ㒊ࡢධᏛ⪅㑅ᢤ
ᖹᡂ㸰㸰ᖺ⌧ᅾࡢ⸆Ꮫ㒊ࡢᐃဨࡣࠊ⸆⛉Ꮫ⛉㸳㸮ྡࠊ⸆Ꮫ⛉㸱㸮ྡࡢྜィ㸶㸮ྡ࡛࠶ࡿࠋ➨஧ḟᏛ
ຊ᳨ᰝ࡛ࡣࠊி㒔኱Ꮫࡢ௚ࡢᏛ㒊࡜ྠࡌࡃศ㞳ศ๭᪉ᘧ࡟ࡼࡿ๓ᮇ᪥⛬ヨ㦂ࢆ⾜࠸ࠊ඲ᐃဨࡢ㸶㸮ྡ
ࢆເ㞟ࡋ࡚࠸ࡿࠋ㑅ᢤヨ㦂ࡢฟ㢪㈨᱁࡞࡝࡟ࡘ࠸࡚≉グࡍ࡭ࡁ஦㡯ࡣ࡞࠸ࠋ
኱Ꮫධヨࢭࣥࢱ࣮ヨ㦂࡛ࡣࠊᅜㄒࡣᚲ㡲ࠊ♫఍㸦ᆅ⌮Ṕྐ࣭බẸ㸧ࡣ᪥ᮏྐ %ࠊୡ⏺ྐ %ࠊᆅ⌮ %ࠊ
⌧௦♫఍ࠊ೔⌮ࠊᨻ἞࣭⤒῭ࡢෆ㸯⛉┠ࢆ㑅ᢥࠊᩘᏛࡣᩘᏛ ,࣭ᩘᏛ $ࠊᩘᏛ,,࣭ᩘᏛ % ࢆᚲ㡲ࠊ⌮
⛉ࡣ≀⌮ ,ࠊ໬Ꮫ ,ࠊ⏕≀ ,ࠊᆅᏛ ,ࠊࡢෆ㸰⛉┠ࢆ㑅ᢥࠊእᅜㄒࡣⱥㄒࢻ࢖ࢶㄒࠊࣇࣛࣥࢫㄒࠊ୰ᅜ
ㄒࠊ㡑ᅜㄒࡢෆ㸯⛉┠ࢆ㑅ᢥ࡜ࡋࠊ㑅ᢤᐇ᪋ᩍ⛉࣭⛉┠࡜ࡋ࡚࠸ࡿࠋ➨஧ḟᏛຊ᳨ᰝ࡛ࡣࠊᚿ㢪⪅ࡀ
ྛᏛ⛉ࡢເ㞟ேဨࡢ⣙㸱㸳ಸࢆ኱ᖜ࡟ୖᅇࡗࡓሙྜ࡟ࡣࠊ኱Ꮫධヨࢭࣥࢱ࣮࡛ࡢᚓⅬࢆ୍ᐃ᪉ᘧ࡛᥮
⟬ࡋࡓ⤖ᯝࡢ⥲ᚓⅬ㡰࡟ࠊྛチᐜಸ⋡࡟㏆࠸ဨᩘ࡟ࡲ࡛➨㸯ḟẁ㝵㑅ᢤࢆ⾜࠺ࡇ࡜࡟ࡋ࡚࠸ࡿࠋ⸆Ꮫ
㒊࡟࠾࠸࡚ࡣࠊ➨㸯ḟẁ㝵㑅ᢤࡣᖹᡂ㸳ᖺᗘᚋᮇ➨஧ḟᏛຊ᳨ᰝ࡟࠾࠸୍࡚ᗘ⾜ࢃࢀࡓࡔࡅ࡛࠶ࡿࠋ
ࡇࢀࡣᮏᏛ㒊ࡀ͆ฟ᮶ࡿࡔࡅࡍ࡭࡚ࡢᚿ㢪⪅࡟ཷ㦂ᶵ఍ࢆ୚࠼ࡿ͇࡜ᇶᮏⓗ࡟⪃࠼࡚࠸ࡿࡓࡵ࡛࠶ࡿࠋ
➨஧ḟᏛຊ᳨ᰝ࡛ࡣࠊᅜㄒ⥲ྜ࣭⌧௦ᩥ࣭ྂ඾ࠊᩘᏛ㸦ᩘᏛ,ࠊᩘᏛ ,,ࠊᩘᏛ ,,,ࠊᩘᏛ$ࠊᩘᏛ %ࠊ
ᩘᏛ &㸧
ࠊ⌮⛉㸦≀⌮ࠊ໬Ꮫࠊ⏕≀࠿ࡽ㸰⛉┠㑅ᢥ㸧
ࠊእᅜㄒ㸦ⱥㄒࠊࢻ࢖ࢶㄒࠊࣇࣛࣥࢫㄒࠊ୰ᅜㄒ࠿
ࡽ㸯⛉┠㸧ࡢ㸲ᩍ⛉ࢆཷ㦂ࡉࡏࡿࠋ኱Ꮫධヨࢭࣥࢱ࣮ヨ㦂ࡢᚓⅬ㸦ᅜㄒࠊ♫఍ࠊᩘᏛࠊ⌮⛉ࠊእᅜㄒ
− 34 −
ධᏛ⪅ࢆ㑅ᢤࡋ࡚࠸ࡿࠋ
⸆Ꮫ㒊࡟ᑐࡍࡿධᏛᚿ㢪⪅ࡣࠊເ㞟ேဨࡢ㸱̾㸲ಸࡢ➇த⋡࡜࡞ࡗ࡚࠸ࡿ㸦㈨ᩱ ,,㸫㸲㸧ࠋࡲࡓࠊ㌿
Ꮫ㒊࡟ࡘ࠸࡚ࡣࠊᖹᡂ㸯㸶ᖺᗘ࡟㎰Ꮫ㒊࡜ࡢ㛫࡟ⱝᖸྡࡢ㌿ධࠊ㌿ฟࡀ࠶ࡗࡓࡀᖹᡂ㸯㸷ᖺᗘ௨㝆ࡣ
࡞࠸ࠋ㌿Ꮫ⛉࡟ࡘ࠸࡚ࡣࠊᖹᡂ㸰㸯ᖺᗘ࡟⸆Ꮫ⛉࠿ࡽ⸆⛉Ꮫ⛉࡬㸯ྡࡀ㌿Ꮫ⛉ࡋࡓࡢࡳ࡛࠶ࡿࠋ
㸰㸧኱Ꮫ㝔ࡢධᏛ⪅㑅ᢤ
኱Ꮫ㝔ಟኈㄢ⛬࡟ࡣࠊ⮫ᗋ⸆Ꮫ࡟㛵ࡍࡿ㧗ᗘ࡞ᑓ㛛ⓗ▱㆑࡜ᢏ⾡ࢆᣢࡗࡓ⸆๣ᖌࡢ⫱ᡂࢆࡵࡊࡋࡓ
⮫ᗋ⸆Ꮫࢥ࣮ࢫࢆᖹᡂ㸯㸱ᖺᗘ࡟㛤タࡋࠊ୍⯡ࢥ࣮ࢫ࡜ేタࡋ࡚࠸ࡓࡀࠊ⸆Ꮫᩍ⫱㸴ᖺไࡢᑟධ࡟క
࠸ᖹᡂ㸰㸰ᖺᗘධᏛ⪅௨㝆ࠊࢥ࣮ࢫไࡣ࡜ࡽࡎࠊ⌧ᅾࡣ⸆⛉Ꮫᑓᨷ࡜་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࢆ୍ᣓࡋ
࡚ເ㞟ࡋ࡚࠸ࡿࠋ
኱Ꮫ㝔ಟኈㄢ⛬࡬ࡢධᏛヨ㦂࡟ࡘ࠸࡚ࡣࠊ࠿ࡘ࡚ࡣእᅜㄒ㸰⛉┠㸦ⱥㄒ࡜ࢻ࢖ࢶㄒ࠶ࡿ࠸ࡣࣇࣛࣥ
ࢫㄒ㸧࠾ࡼࡧᑓ㛛⛉┠㸦㸯㸱⛉┠ࡢෆ㸴⛉┠㑅ᢥ㸧࡛ᵓᡂࡉࢀ࡚࠸ࡓࠋᖹᡂ㸳ᖺᗘ࠿ࡽእᅜㄒࡣⱥㄒ
ࡢࡳ࡜࡞ࡾࠊࡉࡽ࡟ᖹᡂ㸴ᖺᗘ࠿ࡽࡣࠊ኱Ꮫ㝔⏕࡜ࡋ࡚ࡢᇶ♏Ꮫຊࢆ㔜どࡋࠊⱥㄒࠊᇶ♏⸆Ꮫ㸦≀⌮ࠊ
໬Ꮫࠊ⏕≀㸧
ࠊᑓ㛛⛉┠ࡢ㸱ᮏ❧࡚࡜ࡋࠊᑓ㛛⛉┠ࡣྛᑓ㛛ศ㔝ࢆ⦅ᡂࡋ࡚సᡂࡋࡓ㸳⩌⛉┠୰ࠊᚿᮃ
ᑓ㛛⩌⛉┠ࢆᚲ㡲࡜ࡋ࡚ཷ㦂ࡍࡿෆᐜ࡟ᨵࡵࡓࠋᖹᡂ㸯㸵ᖺᗘ࡟ࡣࠊᑓ㛛⛉┠ࡣྛᑓ㛛ศ㔝ࢆ⦅ᡂࡋ
࡚సᡂࡋࡓ㸲⩌⛉┠୰㸰㒆⛉┠௨ୖ࠿ࡽࡢ⮬⏤㑅ᢥ࡟ኚ᭦ࡋࡓࠋࡇࡢࡼ࠺࡞⥲ྜホ౯᪉ᘧ࡜ࠊ≉ᐃࡢ
◊✲ศ㔝࡟≉࡟ඃࢀࡓᏛ⏕ࢆ㑅ᢤࡍࡿࡓࡵ➹グヨ㦂ࡣእᅜㄒ㸦ⱥㄒ㸧ࡢ௚࡟ᙜヱ◊✲ศ㔝ࡢ▱㆑ࢆၥ
࠺≉ูᑓ㛛ヨ㦂࡜㑅ᢤࡢ㔜Ⅼ㡯┠࡟఩⨨࡙ࡅ࡚࠸ࡿཱྀ㢌ヨၥࢆㄢࡍᑓ㛛㔜Ⅼホ౯᪉ᘧ࡜ࢆే⏝ࡋ࡚࠸
ࡓࡀࠊᚋ⪅ࡣᖹᡂ㸯㸶ᖺᗘ࡟ᗫṆࡋࡓࠋࡲࡓࠊᇶ♏⸆Ꮫ㸦≀⌮ࠊ໬Ꮫࠊ⏕≀㸧࡟ࡘ࠸࡚ࡶྠ᫬࡟ᗫṆ
ࡋࠊᖹᡂ㸯㸷ᖺᗘ࠿ࡽࡣࠊ⛉┠ࡢ㸳⩌ࢆ㸲ࡘࡢࠕ⣔ࠖ࡟෌⦅ࡋࠊ㸲ၥ㑅ᢥᙧᘧ࡜㸰ၥ㑅ᢥᙧᘧ㸦௚Ꮫ
㒊ฟ㌟⪅㸧࡟ኚ᭦ࡋࡓࠋࡑࡢ⤖ᯝࠊᮏᏛ௚Ꮫ㒊࠿ࡽࡶྜ᱁⪅ࢆཷࡅධࢀࡿࡇ࡜࡜࡞ࡾࠊ௚኱Ꮫ࠿ࡽࡢ
ྜ᱁⪅࡜ྜࢃࡏ࡚㧗࠸๭ྜࢆ⥔ᣢࡋ࡚࠸ࡿ㸦,,㸫㸯㸮㸧ࠋ
ᖹᡂ㸷ᖺᗘࡢ㔜Ⅼ໬࡟క࠸ಟኈㄢ⛬ᐃဨࡣ㸯㸲ಸࡢ㸴㸳ྡ࡟࡞ࡾࠊᖹᡂ㸯㸷ᖺᗘࡢ་⸆๰ᡂ᝟ሗ⛉
Ꮫᑓᨷࡢ᪂タ࡟ࡼࡾ㸯㸲ྡቑຍࡋࡓࡓࡵ㸵㸷ྡ࡜࡞ࡗࡓࠋྠㄢ⛬࡬ࡢᚿ㢪⪅ᩘࡣᐃဨࡢ⣙㸯㸵㸮㹼㸰
㸮㸮㸣࡜ከࡃࠊධᏛ⪅ࡢᐃဨ࡟ᑐࡍࡿ๭ྜࡣࠊ㸯㸮㸷㹼㸯㸱㸮㸣࡛࠶ࡗࡓࠋᖹᡂ㸰㸰ᖺᗘ࠿ࡽࡣࠊ㸴
ᖺไࡢᑟධ࡟ࡼࡾಟኈㄢ⛬ᐃဨࡣ㸴㸲ྡ࡜࡞ࡾࠊᚿ㢪⪅ᩘࡣᐃဨࡢ⣙㸯㸰㸶㸣ࠊධᏛ⪅ࡢᐃဨ࡟ᑐࡍ
ࡿ๭ྜࡣࠊ㸯㸮㸱㸣࡛࠶ࡗࡓࠋ
༤ኈᚋᮇㄢ⛬࡬ࡢධᏛ⪅࡟ࡘ࠸࡚ࡣ௚኱Ꮫฟ㌟⪅ࡢ๭ྜࡣᖺᗘ࡟ࡼࡾከᑡ๓ᚋࡍࡿࡀ㸰㸱㹼㸱㸵㸣
࡜኱ࡁ࡞๭ྜࢆ༨ࡵ࡚࠸ࡿࠋ᭱㏆㸳ᖺ㛫ࡢᐃဨ඘㊊⋡ࡣᖹᆒࡍࡿ࡜㸯㸮㸮㸣ࢆ㉸࠼࡚࠸ࡿࠋ௒ᚋ࡜ࡶࠊ
ᮏ኱Ꮫ㝔௨እࡢฟ㌟Ꮫ⏕ࢆ༤ኈᚋᮇㄢ⛬࠾ࡼࡧ༤ኈㄢ⛬࡛ቑࡸࡍດຊࢆ⥅⥆ࡍࡿᚲせࡀ࠶ࢁ࠺ࠋ᭱㏆
㸳ᖺ㛫ࡢධᏛ≧ἣࠊᅾᏛ≧ἣࠊฟ㌟኱Ꮫ㸦Ꮫ㒊㸧ᵓᡂࢆ㈨ᩱ ,,㸫㸶㹼,,㸫㸯㸮࡟♧ࡍࠋ
ୖグࡢಟኈㄢ⛬࡜༤ኈᚋᮇㄢ⛬ධᏛ⪅㑅ᢤࡢ௚࡟ࠊእᅜே␃Ꮫ⏕ࢆᑐ㇟࡟≉ู㑅⪃ເ㞟ࢆࡋ࡚ᩍ
⫱࣭◊✲ࡢᅜ㝿໬ࢆ᥎㐍ࡋ࡚࠸ࡿࠋᮏ㑅ᢤ࡛ධᏛࡍࡿ␃Ꮫ⏕ᩘࡣ୧ㄢ⛬ࢆྜィࡋ࡚ࠊẖᖺ㸯㸮ྡ๓ᚋ
࡜ከ࠸ࠋධᏛ᫬ᮇࡣࠊ㸲᭶࠿ࡽࡢ➨㸯ࢭ࣓ࢫࢱ࣮㸦᫓ᮇධᏛ㸧࡜㸯㸮᭶࠿ࡽࡢ➨㸰ࢭ࣓ࢫࢱ࣮㸦⛅ᮇ
ධᏛ㸧ࡢ୧᪉ࢆཷࡅධࢀ࡚࠸ࡿࠋ
ᖹᡂ㸰㸲ᖺᗘ࡟ࠊ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬㸦⸆⛉Ꮫᑓᨷ㸧ࡢᨵ⤌࠾ࡼࡧ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤
− 35 −
− 36 −
− 37 −
− 38 −
࡞ࡽ࡞࠸ࠋ
LL ⸆⛉Ꮫᑓᨷ࡜་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࢆタ⨨ࡋࠊྛᑓᨷ࡟≉ᚩⓗ࡞࣒࢝ࣜ࢟ࣗࣛ⦅ᡂࢆ⾜ࡗ࡚࠸ ࡿࠋ
LLL ಟኈㄢ⛬⸆⛉Ꮫᑓᨷ࡟࠾࠸࡚ࡣࠊᇶ♏₇⩦ࠊ₇⩦ࠊᐇ㦂ࠊᐇ⩦ࠊ≉ู₇⩦ཬࡧㅮ⩏ࢆᒚಟࡍࡿࠋ
๓㸲⛉┠ࡣᚲಟ⛉┠࡛ࠊ࡜ࡾࢃࡅᐇ㦂࡟㔜Ⅼࡀ⨨࠿ࢀ࡚࠸ࡿࠋㅮ⩏ࡣ㑅ᢥ⛉┠࡛࠶ࡿࡀࠊᖹᡂ㸷
ᖺࡢ኱Ꮫ㝔㔜Ⅼ໬௨㝆ࠊ◊✲⛉ࡢྛᑓᨷࢆᵓᡂࡍࡿㅮᗙ࣭ศ㔝ࡀ㐃ᦠࡋ࡚ᢸᙜࡋࠊ◊✲ᑟධㅮ⩏ࠊ ᐇ㦂ᢏ⾡ࠊ◊✲≉ㄽࡢ༊ศ࡛㓄ᙜࡋ࡚࠸ࡿࠋ◊✲≉ㄽ࡛ࡣࠊእ᮶㠀ᖖ໅ㅮᖌࢆ㐺ᐅຍ࠼࡚ࠊㅮᗙ࣭
ศ㔝ࡢᯟࢆ㉸࠼ࡓྛᑓᨷ㡿ᇦࡢ㔜せ࡞▱ぢࡸ㐍Ṍࡀㅮ⩏ࡉࢀ࡚࠸ࡿࠋ୍᪉ࠊಟኈㄢ⛬་⸆๰ᡂ᝟
ሗ⛉Ꮫᑓᨷ࡛ࡣࠊᑟධᩍ⫱ࠊㅮ⩏ࠊࢫ࢟ࣝಟᚓࢆᒚಟࡋࠊࡉࡽ࡟≉ᐃࡢ◊✲ㄢ㢟࡟ࡘ࠸࡚ᣦᑟᩍ
ဨࡢᣦᑟ࡟ࡼࡿ◊✲ࠊ,7 ࢥࣥࢸࣥࢶไసࢆ⾜࠺ࠋ
LY ⸆Ꮫ◊✲⛉Ꮫ⏕ࡢ௚◊✲⛉࡛ࡢ⫈ㅮࠊ࠾ࡼࡧ௚◊✲⛉Ꮫ⏕࡟ࡼࡿ⸆Ꮫ㒊◊✲⛉ㅮ⩏⛉┠ࡢ⫈ㅮ࡟
ࡣ≉ูࡢไ⣙ࡣ࡞࠸ࠋᖹᡂ㸯㸶ᖺᗘ௨㝆ࡢࡇࢀࡽࡢ≧ἣࢆ㈨ᩱ ,,㸫㸯㸱࠾ࡼࡧ,,㸫㸯㸲࡟♧ࡍࠋ
Y ༤ኈᚋᮇㄢ⛬࡛ࡣࠊ᪤ᏑࡢᏛၥ࡟ᑐࡍࡿᢈุ⢭⚄ࢆᣢࡕ᭱ඛ➃ࡢ⛉Ꮫ࡟ᣮᡓ࡛ࡁࡿࠊ๰㐀ᛶ㇏࠿
࡞㧗ᗘ◊✲⪅ࢆ㣴ᡂࡍࡿࠋ⛉Ꮫ◊✲ࡢඛ➃࣭Ꮫ㝿໬࡟㚷ࡳࠊ㔜Ⅼ໬௨㝆ࠊඛ➃ⓗ࡞≉ㄽࡢ⫈ㅮࢆ
ᮏㄢ⛬ࡢᏛ⏕࡟ࡶㄢࡋࡓࠋᖹᡂ㸰㸲ᖺᗘ࡟ࡣࠊ᪂ᩍ⫱ไᗘୗ࡟࠾࠸࡚ࠊ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋ
ᮇㄢ⛬㸦⸆⛉Ꮫᑓᨷ㸧ࡢᨵ⤌࠾ࡼࡧ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬㸦⸆Ꮫᑓᨷ㸧ࡢタ⨨ࡀᚲせ࡜࡞ࡾࠊ
⌧ᅾ࣒࢝ࣜ࢟ࣗࣛ⦅ᡂࢆ᳨ウࡋ࡚࠸ࡿࠋ
YL ᖹᡂ㸯㸲ᖺᗘ࠿ࡽࠊ㛤ㅮࡉࢀ࡚࠸ࡿ኱Ꮫ㝔⸆Ꮫ◊✲⛉⛉┠࡟ࡘ࠸࡚ࡣࢩࣛࣂࢫࡀసᡂࡉࢀ࡚࠸ࡿࠋ
⌧ᅾࠊࢩࣛࣂࢫࡣ⸆Ꮫ㒊࣭⸆Ꮫ◊✲⛉ࡢ࣮࣒࣮࣍࣌ࢪ࡛ࡶබ㛤ࡉࢀ࡚࠸ࡿࠋ
YLL ࡇ࠺ࡋࡓᕤኵ࡟ຍ࠼࡚ࠊ⏕࿨⛉Ꮫ◊✲⛉࡜ࡢ༠ຊࡢࡶ࡜࡟ᩥ㒊⛉Ꮫ┬኱Ꮫ㝔ᩍ⫱ᨵ㠉ᨭ᥼ࣉࣟ
ࢢ࣒ࣛࠕᐇ㊶ⓗ๰⸆ᡓ␎ᐙ㣴ᡂࣉࣟࢢ࣒ࣛࠖ
㸦ᖹᡂ㸰㸮㸫㸰㸰ᖺᗘ㸧ࠖࢆᐇ᪋ࡋࠊ㸰ࡘࡢ๪ᑓᨷࠕ๰
⸆ᡓ␎ಟᚓࢥ࣮ࢫࠖ࠾ࡼࡧࠕ๰⸆ࣉࣟࢪ࢙ࢡࢺ࣮ࣜࢲ࣮ࢥ࣮ࢫࠖࢆタ⨨ࡋࡓࠋ
㸦㸲㸧Ꮫᴗࡢ㐩ᡂ≧ἣ
㸯㸧Ꮫ㒊࡟࠾ࡅࡿᡂ⦼ホ౯࡜༞ᴗ࡟ᚲせ࡞༢఩
ᖹᡂ㸯㸵ᖺᗘ௨๓ࡣࠊヨ㦂ࡢᡂ⦼ࢆࠊ㸯㸮㸮Ⅼ㹼㸷㸮Ⅼ㸹⚽ࠊ㸶㸷Ⅼ㹼㸶㸮Ⅼ㸹ඃࠊ㸵㸷Ⅼ㹼㸵㸮
Ⅼ㸹Ⰻࠊ㸴㸷Ⅼ㹼㸴㸮Ⅼ㸹ྍࠊ࡛⾲ࢃࡋࠊ㸴㸮Ⅼ㹼㸯㸮㸮Ⅼࡀྜ᱁࡜ࡋ࡚࠸ࡓࠋᖹᡂ㸯㸶ᖺᗘ࠿ࡽࡣࠊ
ᵝࠎ࡞≧ἣ࡟࠾࠸࡚ᡂ⦼ホ౯ࢆཝᐦ࡟⾜࠺ᚲせࡀ⏕ࡌࡿྍ⬟ᛶࡀ⪃࠼ࡽࢀࡿࡇ࡜࠿ࡽࠊྜ᱁ࡢᇶ‽ࡣ
ྠᵝ࡛࠶ࡿࡀࠊ⣲Ⅼ࡛ᡂ⦼ホ౯ࢆ⾜ࡗ࡚࠸ࡿࠋ
༞ᴗ࡟ᚲせ࡞༢఩ࡣࠊ኱Ꮫタ⨨ᇶ‽ࡢ኱⥘໬ࠊᩍ㣴㒊ࡢᗫṆ࣭⥲ྜே㛫Ꮫ㒊ࡢ๰タ࡞࡝࡟కࡗ࡚᪤
࡟ኚ᭦ࡉࢀ࡚࠸ࡿࠋᖹᡂ㸰㸮ᖺᗘ௨㝆ධᏛ⪅ࡢ༞ᴗ࡟ᚲせ࡞⛉┠ᩘ࠾ࡼࡧ༢఩ᩘࢆ㈨ᩱ ,,㸫㸯㸳
࠾ࡼࡧ࡟♧ࡋࡓࠋ
㸰㸧⸆๣ᖌᅜᐙヨ㦂
⸆๣ᖌࡢ㣴ᡂࡣࠊ♫఍ⓗ࠿ࡽせㄳࡉࢀ࡚࠸ࡿ⸆Ꮫ㒊ࡢ᭱ࡶ㔜せ࡞࣑ࢵࢩࣙࣥࡢ୍ࡘ࡛࠶ࡿࠋᖹᡂ㸯
− 39 −
㸶ᖺᗘࡢ⸆Ꮫᩍ⫱ไᗘࡢኚ᭦௨㝆ࠊᖹᡂ㸰㸷ᖺᗘࡲ࡛ࡢ᪂㸲ᖺไㄢ⛬ධᏛ⪅࡬ࡢ⤒㐣ᥐ⨨ࡣㄆࡵࡽࢀ
࡚ࡣ࠸ࡿࡀࠊᇶᮏⓗ࡟ࡣ㸴ᖺไ⸆Ꮫ⛉ࡢṇつࡢㄢ⛬ࢆಟࡵ࡚༞ᴗࡋࡓ⪅ࡀཷ㦂㈨᱁ࢆࡶࡘࡼ࠺࡟࡞ࡗ
ࡓࠋᮏᏛ㒊࡛ࡶ⸆๣ᖌ࡜ࡋ࡚ࡢ⫋⬟ࡢᇶ♏࡟㛵ࡍࡿᏛ㒊ᩍ⫱࡟ࡣ௨๓࠿ࡽ༑඲ࡢ㓄៖ࢆ࡯࡝ࡇࡋ࡚ࡁ
ࡓࡀࠊ⌧ᅾࡢ⸆Ꮫ⛉ࡢ࣒࡛࢝ࣜ࢟ࣗࣛࡶ㸴ᖺḟ࡟ࠕ⮫ᗋ⸆Ꮫ⥲ㄽࠖࢆ㓄ᙜࡍࡿ➼ࠊᏛ⏕ࡀᅜᐙヨ㦂࡟
⮫ࡴ༑ศ࡞⎔ቃࢆᩚഛࡋ࡚࠸ࡿࠋ㈨ᩱ ,,㸫㸯㸴࡟ࠊᪧไᗘୗ࡛ᐇ᪋ࡉࢀࡓ㐣ཤ㸯㸰ᖺ㛫ࡢ⸆๣ᖌᅜᐙ
ヨ㦂᪂༞⪅ࡢྜ᱁⋡ࢆ♧ࡍࠋᖹᡂ㸯㸮㹼㸰㸮ᖺᗘࡣ㸴㸮㹼㸶㸳㸣࡛᥎⛣ࡋ࡚࠸ࡓࠋᖹᡂ㸰㸲ᖺᗘ࡟ࠊ
㸴ᖺไᏛ㒊༞ᴗ⏕ࢆᑐ㇟࡜ࡋࡓ➨㸯ᅇࡢ⸆๣ᖌᅜᐙヨ㦂ࡀᐇ᪋ࡉࢀࡿࠋ
㸱㸧ಟኈㄢ⛬࣭༤ኈᚋᮇㄢ⛬࡟࠾ࡅࡿᡂ⦼ホ౯࡜ಟ஢ࡢせ௳
኱Ꮫ㝔࡟࠾ࡅࡿᡂ⦼ホ౯࣭༢఩ㄆᐃࡢᇶ‽ࡣḟࡢ㏻ࡾ࡛࠶ࡿࠋヨ㦂ࡢᡂ⦼ࡣࠊ㸯㸮㸮Ⅼ㹼㸷㸮Ⅼ㸹
⚽ࠊ㸶㸷Ⅼ㹼㸶㸮Ⅼ㸹ඃࠊ㸵㸷Ⅼ㹼㸵㸮Ⅼ㸹Ⰻࠊ㸴㸷Ⅼ㹼㸴㸮Ⅼ㸹ྍࠊ࡛⾲ࡉࢀࠊ㸴㸮Ⅼ㹼㸯㸮㸮Ⅼ
ࡀྜ᱁࡛࠶ࡿࠋ⛉┠࡟ࡼࡗ࡚ࡇࡢࡼ࠺࡞Ⅼᩘ࡛ホ౯࡛ࡁ࡞࠸ࡶࡢࡶ࠶ࡿࡀࠊࡇࢀࢆᇶ‽࡜ࡋ࡚ࠊᩍᐁ
ྛ⮬ࡢุᐃ࡟ࡼࡗ࡚ホ౯ࡀ⾜ࢃࢀ࡚࠸ࡿࠋ
⸆⛉Ꮫᑓᨷࡢಟኈㄢ⛬ࢆಟ஢ࡍࡿせ௳࡜ࡋ࡚ࡣࠊྠㄢ⛬࡟㸰ᖺ௨ୖᅾᏛࡋ࡚◊✲ᣦᑟࢆཷࡅࠊᚲಟ
⛉┠㸯㸴༢఩ࠊ㑅ᢥ⛉┠㸯㸲༢఩௨ୖࠊィ㸱㸮༢఩௨ୖࢆᏛಟࡋࠊ࠿ࡘಟኈㄽᩥࢆᥦฟࡢ࠺࠼ࠊࡑࡢ
ᑂᰝ࠾ࡼࡧヨ㦂࡟ྜ᱁ࡍࡿࡇ࡜ࢆせࡍࡿࠋ་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࡢಟኈㄢ⛬ࡶྠᵝ࡛࠶ࡿࡀࠊᚲせ༢
఩ᩘࡣࠊᚲಟ⛉┠㸯㸶༢఩ࠊ㑅ᢥ⛉┠㸯㸰༢఩௨ୖࠊィ㸱㸮༢఩௨ୖ࡜࡞ࡗ࡚࠸ࡿࠋ᭱㏆ࡢಟኈࡢᏛ
఩ྲྀᚓ⪅㸦ಟ஢⪅㸧ᩘࢆ㈨ᩱ ,,㸫㸯㸵࡟♧ࡍࠋ
༤ኈᚋᮇㄢ⛬ࢆಟ஢ࡍࡿせ௳࡜ࡋ࡚ࡣࠊྠㄢ⛬࡟㸱ᖺ௨ୖᅾᏛࡋ࡚◊✲ᣦᑟࢆཷࡅࠊ࠿ࡘ⊂๰ⓗ◊
✲࡟ᇶ࡙ࡃ༤ኈㄽᩥࢆᥦฟࡋࠊࡑࡢᑂᰝ࠾ࡼࡧヨ㦂࡟ྜ᱁ࡍࡿࡇ࡜ࢆせࡍࡿࠋᖹᡂ㸰㸲ᖺᗘ௨㝆ࡢ኱
Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬㸦⸆⛉Ꮫᑓᨷ㸧࠾ࡼࡧ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬㸦⸆Ꮫᑓᨷ㸧࡟ࡘ࠸࡚
ࡣࠊ⌧ᅾ᳨ウ୰࡛࠶ࡿࠋ᪂ไࡢ༤ኈᏛ఩ྲྀᚓ⪅ᩘࢆ㈨ᩱ ,,㸫㸯㸶࡟ࠊࡲࡓᪧไࡢ༤ኈᏛ఩ྲྀᚓ⪅ᩘࢆ
㈨ᩱ ,,㸫㸯㸷࡟♧ࡍࠋ
㸲㸧༤ኈㄽᩥᑂᰝࡢ⌧≧࡜ᑂᰝ᪉ἲ࣭యไ
⸆Ꮫ◊✲⛉࡛ࡣࠊ౛ᖺ㸱㸮௳㹼㸲㸮௳ࡢ༤ኈᏛ఩⏦ㄳㄽᩥࢆᑂᰝࡋ࡚࠸ࡿࠋ㈨ᩱ ,,㸫㸯㸶࡟ぢࡽࢀ
ࡿࡼ࠺࡟ࠊᖹᡂ㸯㸴ᖺᗘࡲ࡛ࡢ⏦ㄳࡢ࠺ࡕㄢ⛬༤ኈࡣ⣙㸲㸳㸣࡛ࠊṧࡾ⣙㸳㸳㸣ࡣ࠸ࢃࡺࡿㄽᩥ༤ኈ
࡛࠶ࡗࡓࠋࡍ࡞ࢃࡕࠊ༤ኈᚋᮇㄢ⛬࡟㐍Ꮫࡋࡓࡶࡢࡣࡶ࡜ࡼࡾࠊಟኈㄢ⛬ࢆಟ஢࠶ࡿ࠸ࡣᏛ㒊ࢆ༞ᴗ
ࡋ࡚௻ᴗࡸ◊✲ᶵ㛵࡟ᑵ⫋ࡋࡓ⪅࠿ࡽ࠿࡞ࡾࡢᩘࡢ༤ኈᏛ఩ࡢ⏦ㄳࡀ࡞ࡉࢀ࡚ࡁࡓࠋࡋ࠿ࡋ࡞ࡀࡽࠊ
᭱㏆ࡣㄽᩥ༤ኈࡢᩘࡣῶᑡࡋ࡚࠾ࡾࠊ㐣ཤ㸳ᖺ㛫࡛ぢࡿ࡜ㄢ⛬༤ኈࡀ⣙㸶㸮㸣ࢆ༨ࡵ࡚࠾ࡾࠊࡇࡢഴ
ྥࡣ௒ᚋࡶ⥆ࡃࡶࡢ࡜⪃࠼ࡽࢀࡿࠋ
ᮏ◊✲⛉ࡢ┠ᶆࡢ୍ࡘࡣࠊ㧗ᗘ࡞◊✲࣭ᣦᑟ⬟ຊࢆᣢࡘ◊✲⪅ࡢ⫱ᡂ࡟࠶ࡿࠋࡲࡓࠊ⛉Ꮫࡢ㐍ṌⓎ
ᒎ࡟ᐤ୚ࡍࡿ◊✲ㄽᩥࡢసᡂࢆࡶࡗ࡚༤ኈᏛ఩ࡢᤵ୚ࢆ⾜࠺ࠋㄽᩥᑂᰝࡢ᪉ἲ࣭యไ࡟ࡘ࠸࡚ࡢᴫ␎
ࢆ௨ୗ࡟グࡍࠋ
L ணഛᑂᰝ㸸Ꮫ఩⏦ㄳㄽᩥࡣࠊඛࡎᢸᙜᩍᐁ㸦ᩍᤵࠊຓᩍᤵ㸧࡟ᥦฟࡉࢀࠊᙜヱᩍᐁࡢៅ㔜࡞ᰝㄞ
ࢆཷࡅࡿࠋࡑࡢᚋࠊᩥ᭩࡟ࡼࡿㄽᩥෆᐜࡢせ᪨ࡀ◊✲⛉఍㆟࡟ᥦฟࡉࢀࠊᙜヱㄽᩥࢆබ㛤ࡢㄽᩥ
− 40 −
Ⓨ⾲఍࡟࠾࠸ཱྀ࡚㢌Ⓨ⾲ࡉࡏࡿࡇ࡜ࡢጇᙜᛶࡀᑂᰝࡉࢀࠊጇᙜ࡜ㄆࡵࡽࢀࡓሙྜ࡟ࡣㄽᩥⓎ⾲఍
࡟࠾࠸࡚⏦ㄳ⪅⮬㌟࡟ཱྀ㢌Ⓨ⾲ࢆ⾜ࢃࡏࡓᚋࠊᑓᨷᏛ⾡࡟㛵ࡍࡿヨၥࢆ⾜࠺ࠋ
LL ◊✲⛉࡟࠾ࡅࡿᑂᰝ㸸ணഛᑂᰝ࡟ྜ᱁ࡋࡓㄽᩥࡣ◊✲⛉࡟ᥦฟࡉࢀࡿࠋᥦฟࡉࢀࡓㄽᩥࢆཷ௜ࡅ
ࡿࡇ࡜ࡀỴࡲࡿ࡜ࠊᢞ⚊࡟ࡼࡾ㸦ཎ๎࡜ࡋ࡚㸧㸱ྡࡢ◊✲⛉఍㆟ᵓᡂဨ࠿ࡽ࡞ࡿㄪᰝဨࢆ㑅ฟࡍ
ࡿࠋㄪᰝဨࡣㄪᰝࢆ⤊஢ࡍࡿ࡜ࠊᩥ᭩࡟ࡼࡗ࡚ᑂᰝ⤖ᯝࡢせ᪨ࢆ๓ࡶࡗ࡚◊✲⛉࡟ᥦฟࡋࠊࡇࢀ
ࢆ◊✲⛉఍㆟࡟࠾࠸࡚ሗ࿌ࡋࠊウ㆟ࢆ⾜ࡗࡓᚋ࡟ࠊྍྰ࡟㛵ࡍࡿᢞ⚊ࢆ⾜࠺ࠋࡑࡢ㝿ࡢ◊✲⛉఍
㆟ࡣᵓᡂဨࡢ㸱ศࡢ㸰ࡢฟᖍࢆࡶࡗ࡚ᡂ❧࡜ࡋࠊฟᖍ⪅ࡢ㸱ศࡢ㸰ࡢ㈶ᡂࢆࡶࡗ࡚ྜ᱁࡜Ỵᐃࡍ
ࡿࠋㄽᩥ༤ኈࡢሙྜ࡟ࡣࠊ㸱ྡࡢㄪᰝဨࡢ௚࡟㸰㹼㸱ྡࡢヨ㦂ጤဨࢆᢞ⚊࡟ࡼࡾ㑅ฟࡋࠊᏛ㆑☜
ㄆࡢࡓࡵࡢヨ㦂ࢆ⾜࠺ࠋヨ㦂ࡣእᅜㄒ࡜ᑓ㛛⛉┠࡟ࡘ࠸࡚⾜࠺ࡀࠊእᅜㄒࡣ኱Ꮫ㝔ಟኈㄢ⛬௨ୖ
ࡢಟ஢⪅࡟ࡘ࠸࡚ࡣච㝖ࡉࢀࡿሙྜࡀ࠶ࡿࠋ
− 41 −
− 42 −
− 43 −
ϩ㸦㸧ᖹᡂ㸯㸶ᖺᗘ௨㝆ධᏛ⪅ࡢ⸆Ꮫ㒊㛤ㅮ⛉┠㓄ᙜ⾲
− 44 −
− 45 −
ϩ㸦㸧ᖹᡂ㸯㸶ᖺᗘ௨㝆ධᏛ⪅ࡢ⸆Ꮫ㒊㛤ㅮ⛉┠㓄ᙜ⾲
− 46 −
− 47 −
− 48 −
ϩ㸦㸧
ϩ㸦㸧
− 49 −
ϩ㸦㸧
− 50 −
− 51 −
− 52 −
− 53 −
Ÿ KM˜Mv7KMD7M–.z|l[
œ5J}
iM‡M–
iM3M–
3KM
Š
V[¡¡WX
V[¡ WX
V[¡ŸWX
V[ §WX
V[ ¦WX
œCJYh}
iM‡Mz|
iM3z|
3KM
Š
V[¡¡WX
V[¡ WX
V[¡ŸWX
V[ §WX
V[ ¦WX
ž M–Mv3M–|yƒso
FmbS72bœB4b{
? 8
c
a
p
€
u
@ T
‘
2
Š
V[ WX;h.“W
Yh
V[ WX;h.“W
Yh
V[ WX;h.“W
Yh
V[ WX;h.“W
Yh
V[ WX;h.“W
Yh
− 54 −
− 55 −
− 56 −
− 57 −
ž ¤ ‡<UIO‹šdA‚Gjt
?8
Gjt
Eš‚b
Gj‚b
V[¡ WX
V[¡ŸWX
V[ §WX
V[ ¦WX
V[ ¥WX
WX
›
ž ¥ 5JM4]1b
? 8
W X
2bœ2
œ‡M ‡|M
G Šœ2
fH¡§WX¨V[§WX
V[ ¥WX
V[ ¦WX
V[ §WX
V[¡ŸWX
V[¡ WX
G Š
ž ¦ CJM4]1bœd:
? 8
W X
}CJœ2
ŽcCJœ2
œ‡M ‡|M œ‡M ‡|M
G Šœ2
fH¢¢WX¨V[ ¤WX
V[ ¥WX
V[ ¦WX
V[ §WX
V[¡ŸWX
V[¡ WX
G Š
− 58 −
ž § CJM4]1bœe:
… fH ¦W Ÿg
¢Ÿ¦2
† fH¢¥W ¡g
ž¡Ÿ =P`$/&ŒN‚
œ5J}
WX WX WX WX WX
>‡\x5Z$/&
Š
WX‰’
œCJYh}
WX WX WX WX WX
P—‡<U
)-#+*
)-%!"(_”
ˆG$/&
>‡)-%!"(
,/'/™[$/&
Š
WX‰’
ž¡ r9zMvb
WX WX WX WX WX
Š
E6b
q•b
− 59 −
ž¡¡ LMv^wso
œ M– Wn
?8
WX
0~
¡Wn
0~
¢Wn
0~
£Wn
0~
Q Š
0~
G Š
V[¡¡WX
V[¡ WX
V[¡ŸWX
V[ §WX
V[ ¦WX
œ¡KM˜
?8
5 J  }
Wn
¡Wn
CJYh}
G Š
Wn
¡Wn
¢Wn
G Š
0
0
0
0
0
0
0
~
~
~
~
~
~
~
V[¡¡WX V[¡ WX V[¡ŸWX V[ §WX V[ ¦WX WX
− 60 −
¡¢ AkvR„so
− 61 −
Ϫ ◊✲άື
>Ϫ@◊✲άື
㸦㸯㸧◊✲άືࡢ┠ᶆ
⸆Ꮫࡣࠊேయ࡟ാࡁࡑࡢᶵ⬟ࡢㄪ⠇࡞࡝ࢆ௓ࡋ࡚⑌⑓ࡢ἞⒵ࠊ೺ᗣࡢቑ㐍ࢆࡶࡓࡽࡍࠕ་⸆ရࠖࡢ
๰〇ࠊ⏕⏘ࠊ㐺ṇ࡞౑⏝ࢆ┠ᶆ࡜ࡍࡿ⥲ྜ⛉Ꮫ࡛࠶ࡾࠊㅖᇶ♏⛉Ꮫࡢ⤫ྜࢆᇶ♏࡜ࡍࡿᛂ⏝Ꮫ㝿Ꮫၥ
㡿ᇦ࡜఩⨨࡙ࡅࡽࢀࡿࠋ⸆Ꮫࡣࠊ⏕࿨࡜≀㉁㸦་⸆ရ㸧ࡢ࢖ࣥࢱ࣮ࣇ࢙࢖ࢫᵓ⠏ࢆ௓ࡋ࡚་⸆ရࡢⓎ
ぢ࡜㛤Ⓨ࡟㛵ࢃࡿ๰⸆◊✲࡜⸆≀౑⏝㐺ṇ໬ࢆᇶ┙࡜ࡋࡓ᭱㐺໬⸆≀἞⒪ࢆᐇ㊶ࡋே㢮♫఍࡟㈉⊩ࡍ
ࡿࡇ࡜ࢆᮇᚅࡉࢀ࡚࠸ࡿࠋࡉࡽ࡟ࠊ་⒪࡟࠾࠸࡚㔜せ࡞ᙺ๭ࢆᢸ࠺⸆๣ᖌࡢ⫱ᡂࡶ♫఍࠿ࡽ௜クࡉࢀ
࡚࠸ࡿࠋࡑࡇ࡛ࠊி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ࡣࠊㅖᏛၥ㡿ᇦࡢ⤫ྜ࡜₇⧢ࢆ㏻ࡌ࡚ୡ⏺࡟౛ࢆぢ࡞࠸
๰㐀ⓗ࡞⸆Ꮫࡢ͆๰͇࡜͆⒪͇ࡢᣐⅬࢆᵓ⠏ࡋࠊඛ➃ⓗ๰⸆⛉Ꮫ࣭་⒪⸆Ꮫ◊✲ࢆ㐙⾜ࡋ࡚ே㢮ࡢ೺
ᗣ࡜♫఍ࡢⓎᒎ࡟㈉⊩ࡍࡿࡇ࡜ࢆ♫఍ⓗ౑࿨࡜ࡋ࡚࠾ࡾࠊ◊✲࡟࠾࠸࡚ࡣࠊ⏕࿨೔⌮ࢆᇶ┙࡟ࠊ⊂๰
ⓗ࡛᭱ඛ➃ࡢ⸆Ꮫ◊✲ࢆ᥎㐍ࡍࡿࡇ࡜ࢆ┠ᶆ࡜ࡋ࡚࠸ࡿࠋ
ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ࡢ◊✲ࡢ≉ᚩࡣࠊ⸆Ꮫࢆᵓᡂࡍࡿᇶ┙⛉Ꮫ㡿ᇦࡢ᭱ඛ➃◊✲࡟ᣮᡓࡋ࡚
ୡ⏺ࡢ⸆Ꮫ◊✲ࢆ࣮ࣜࢻࡍࡿ࡜࡜ࡶ࡟ࠊ๰⸆⛉Ꮫ࡜་⒪⸆Ꮫࡢ⤫ྜࢆᅗࡿࡇ࡜࡟ࡼࡾࠊ⊂๰ⓗ࡞⸆Ꮫ
◊✲ࢆ⾜ࡗ࡚࠸ࡿࡇ࡜࡟࠶ࡿࠋᙜ◊✲⛉࡟࠾ࡅࡿ⸆Ꮫ◊✲ࡣࠊ㸲ࡘࡢ㡿ᇦᵓᡂ࡟ࡼࡾ⾜ࢃࢀ࡚ࡁࡓࠋ
ࡍ࡞ࢃࡕࠊ≀⌮໬Ꮫ࡜ศᯒ໬Ꮫ࡞࡝ࢆ୰ᚰ࡜ࡋࡓ≀⌮⣔⸆Ꮫࠊ᭷ᶵྜᡂ໬Ꮫࡸኳ↛≀໬Ꮫ࡞࡝ࢆ୰ᚰ
࡜ࡋࡓ໬Ꮫ⣔⸆Ꮫࠊ⏕໬ᏛࠊศᏊ⏕≀Ꮫࠊ⣽⬊⏕≀Ꮫ࡞࡝ࢆ୰ᚰ࡜ࡋࡓ⏕≀⣔⸆Ꮫࠊࡑࡋ࡚ࠊ⸆⌮Ꮫࠊ
⸆๣Ꮫࢆ୰ᚰ࡜ࡋࡓ་⒪⣔⸆Ꮫࡢ㸲㡿ᇦ࡛࠶ࡿࠋ≀⌮⣔⸆Ꮫ㡿ᇦ࡛ࡣࠊ⸆≀ࡸ⏕యศᏊࡢᵓ㐀࣭┦஫
స⏝ࢆཎᏊ࣭ศᏊ࡛ࣞ࣋ࣝゎᯒࡍࡿ◊✲ࡀ⾜ࢃࢀ࡚࠸ࡿࠋ໬Ꮫ⣔⸆Ꮫ㡿ᇦ࡛ࡣࠊ་⸆ရࡢ✀࡜࡞ࡿࢩ
࣮ࢻ໬ྜ≀ࡢࣛ࢖ࣈ࣮ࣛࣜ໬࡜᥈⣴ࠊࡉࡽ࡟ࡣࢩ࣮ࢻ໬ྜ≀࠿ࡽ࣮ࣜࢻ໬ྜ≀ࢆࢹࢨ࢖ࣥࡋࡑࢀࡽࢆ
ຠ⋡ⓗ࠿ࡘ⤒῭ᛶ࡟ඃࢀࡓ᪉ἲ࡛ྜᡂࡍࡿࡓࡵࡢ᪂ᡭἲࡢ㛤Ⓨࢆ┠ᣦࡋࡓ◊✲ࡀ⾜ࢃࢀ࡚࠸ࡿࠋ⏕≀
⣔⸆Ꮫ㡿ᇦ࡛ࡣࠊ๰⸆ᶆⓗࡢྠᐃࡸ⏕࿨άືࡢṇᖖ࡜␗ᖖࡢ㐪࠸ࢆ▱ࡿࡓࡵ࡟ࠊ⣽⬊ෆእࡢ᝟ሗఏ㐩
ࡸ⭷㍺㏦࡞࡝ศᏊࡸ⣽⬊࡛ࣞ࣋ࣝࡢ◊✲࠿ࡽ⣽⬊ศ໬ࡸ⤌⧊ᙧᡂ࡞࡝ಶయ࡛ࣞ࣋ࣝࡢ௙⤌ࡳࡢゎ᫂࡟
࠸ࡓࡿ⏕࿨⛉Ꮫ◊✲ࡀ⾜ࢃࢀ࡚࠸ࡿࠋ་⒪⣔⸆Ꮫ㡿ᇦ࡛ࡣࠊ᪂ࡓ࡞๰⸆ᶆⓗศᏊࡢ᥈⣴ࡸ⸆≀ࡢయෆ
ືែ࣭⸆⌮ຠᯝࡢᶵᵓゎᯒ࡜ࡑࢀ࡟ᇶ࡙࠸ࡓ⸆≀἞⒪ࡢ᭱㐺໬ࢆ┠ᣦࡋࡓ◊✲ࡀ⾜ࢃࢀ࡚࠸ࡿࠋ㏆ᖺࠊ
ࣄࢺࢤࣀ࣒ࡢゎㄞ㐩ᡂ࡟ࡼࡾࠊ་⸆ရ㛤Ⓨ࡟㛵ࡍࡿᢏ⾡࡜᪉ἲㄽࡣࠊ኱ࡁ࡞ኚ㠉ᮇࢆ㏄࠼࡚࠸ࡿࠋಶࠎ
ேࡢ㑇ఏᙧ㉁࡟ᇶ࡙࠸ࡓ⸆≀἞⒪ࢆ┠ⓗ࡜ࡍࡿ࠸ࢃࡺࡿࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪࡞࡝ࢆᐇ⌧ࡍࡿࡓࡵ࡟ࡣࠊ
⏕࿨࡜ࡑࢀࢆᵓᡂࡋไᚚࡍࡿศᏊ࡟ᑐࡍࡿ῝࠸⌮ゎ࡜◊✲ࡀᚲせ࡜࡞ࡿ࡞࡝ࠊ⸆Ꮫࢆᵓᡂࡍࡿྛᑓ㛛
㡿ᇦࡢᇶ♏◊✲ࢆ᥎㐍ࡍࡿ࡜࡜ࡶ࡟ࠊ͆๰͇࡜͆⒪͇ࡢ⤫ྜࢆᅗࡿࡇ࡜ࢆ┠ᣦࡋ࡚࠸ࡿࠋ
㸦㸰㸧◊✲⤌⧊ࡢ⌧≧࡜ᑗ᮶ᵓ᝿
◊✲άືࡢ୰ᚰ࡜࡞ࡿ⸆Ꮫ◊✲⛉ࡣࠊ㸰ᑓᨷ㸦㸰㸱ᇶᖿศ㔝ࠊ㸵༠ຊㅮᗙ㸧ࠊᐤ௜ㅮᗙ㸰㸪ࣉࣟࢪ࢙
ࢡࢺศ㔝㸦᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮ࠊ㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬࠊ
㸧㸰࠿ࡽᵓᡂࡉࢀ࡚࠸ࡿࠋ⸆⛉
Ꮫᑓᨷࡣࠊᖹᡂ㸰㸯ᖺᗘࡲ࡛ࡣࠊ๰⸆⛉Ꮫᑓᨷࠊ⏕࿨⸆⛉Ꮫᑓᨷࠊ་⒪⸆⛉Ꮫᑓᨷࡢ㸱ᑓᨷ࡛ᵓᡂࡉ
ࢀ࡚࠸ࡓࠋ๰⸆⛉Ꮫᑓᨷ࡛ࡣࠊศᏊࡢᵓ㐀ࠊ≀ᛶࠊྜᡂ࡟㛵ࢃࡿ≀⌮⣔⸆Ꮫ◊✲࡜໬Ꮫ⣔⸆Ꮫ◊✲ࠊ
⏕࿨⸆⛉Ꮫᑓᨷ࡛ࡣࠊศᏊ⏕≀Ꮫࡸ⣽⬊⏕≀Ꮫࢆ୰ᚰ࡜ࡍࡿ⏕≀⣔⸆Ꮫ◊✲ࠊ་⒪⸆⛉Ꮫᑓᨷ࡛ࡣࠊ
− 63 −
⸆Ꮫᅛ᭷ࡢᏛၥ࡛࠶ࡿࠊ⸆⌮Ꮫࠊ⸆๣Ꮫࢆ୰ᚰ࡜ࡋࡓ་⒪⣔⸆Ꮫ◊✲ࡀᐇ᪋ࡉࢀ࡚ࡁࡓࠋࡋ࠿ࡋࠊඛ
➃㡿ᇦࡢ◊✲࡬ᶵᩄ࡟ᑐᛂࡍࡿࡓࡵ࡟ࡣࠊ๰⸆⛉Ꮫࠊ⏕࿨⛉Ꮫࠊ་⒪⸆Ꮫࠊ᝟ሗ⸆Ꮫ◊✲ࢆ⥲ྜⓗ࡟
㐍ࡵࡿᇶ┙ࡢᵓ⠏ࡀ㔜せ࡜࡞ࡗ࡚ࡁࡓࡇ࡜࠿ࡽࠊᖹᡂ㸰㸰ᖺᗘ࡟ࠊ๰⸆⛉Ꮫᑓᨷࠊ⏕࿨⸆⛉Ꮫᑓᨷࠊ
་⒪⸆⛉Ꮫᑓᨷࡢ㸱ᑓᨷࢆ⸆⛉Ꮫᑓᨷࡢ㸯ᑓᨷ࡟ᨵ⤌ࡋ࡚ᑐᛂࡍࡿࡇ࡜࡜ࡋࡓࠋ୍᪉ࠊ་⸆๰ᡂ᝟ሗ
⛉Ꮫᑓᨷࡣࠊᖹᡂ㸯㸷ᖺᗘ࡟᪂ࡓ࡟タ⨨ࡉࢀࠊᡃࡀᅜึࡢ᝟ሗ⛉Ꮫ࡜⸆Ꮫ࡜ࡢ⼥ྜ࡟ࡼࡿ᪂ࡓ࡞ ,7 ⸆
Ꮫ◊✲ࡀ⾜ࢃࢀ࡚ࡁࡓࠋࡍ࡞ࢃࡕࠊ㸱ࡘࡢᑓᨷ࡟ࡼࡗ࡚ᢸࢃࢀ࡚ࡁࡓ㸲ࡘࡢᇶ┙⛉Ꮫ㡿ᇦ࡜᝟ሗ⛉Ꮫ
ࢆ⤫ྜࡍࡿࡇ࡜࡟ࡼࡾࠊᙜ◊✲⛉⊂⮬ࡢ⤫ྜⓗ࡞⸆Ꮫ◊✲ࡀ⾜ࢃࢀ࡚ࡁࡓࡢ࡛࠶ࡿࠋ
ࡉࡽ࡟ࠊ㸰ࡘࡢᐤ㝃ㅮᗙࡣ♫఍࡜ࡢ᥋Ⅼ࡜ࡋ࡚ࠊᙜ◊✲⛉࡛ࡢලయⓗ࡞◊✲ᡂᯝࢆ♫఍࡟㑏ඖࡍࡿ
ࡇ࡜ࡸࠊ♫఍ࡀせㄳࡍࡿㅖㄢ㢟࡟ᙜ◊✲⛉ࡀྲྀࡾ⤌ࡴࡓࡵ࡟᭷ຠ࡟ᶵ⬟ࡋ࡚࠸ࡿࠋࡲࡓࠊᖹᡂ㸰㸯ᖺ
ᗘ࡟ࠊ㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬ࠾ࡼࡧ᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮ࢆ᪂タࡋࠊࡉࡽ࡞ࡿ⸆Ꮫ◊✲⛉
ࡢ◊✲᥎㐍ࢆᅗࡿ᪂ࡓ࡞◊✲యไࢆᩚ࠼ࡓࠋ㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬࡣࠊ❧࿨㤋኱Ꮫ࠾ࡼࡧᮏ
Ꮫ࢘࢖ࣝࢫ◊✲ᡤ࡜ࡢ⸆ᕤ㐃ᦠ࡟ࡼࡿࣂ࢖࢜ࢸࢡࣀࣟࢪ࣮࡜ࢼࣀࢸࢡࣀࣟࢪ࣮ࡢ⼥ྜ࡞࡝ࢆᇶ┙࡜ࡋ
ࡓ㠉᪂ⓗ๰⸆◊✲ࡢ᥎㐍ࢆ┠ⓗ࡜ࡋ࡚タ⨨ࡉࢀࡓࡶࡢ࡛ࠊ⒴࡞࡝ࡢ㞴἞ᛶ⑌ᝈࡢඞ᭹ࢆྍ⬟࡜ࡍࡿ἞
⒪⸆ࠊ἞⒪ࢩࢫࢸ࣒ࡢ㛤Ⓨࢆ┠ᣦࡋ࡚ࠊᏛ㝿⼥ྜⓗ◊✲ࡢ᥎㐍࡜᭱ඛ➃๰⸆⛉Ꮫࡢ◊✲࣭ᩍ⫱యไࡢ
☜❧࡟ྲྀࡾ⤌ࡴ࡜ඹ࡟ࠊ㏆ᮍ᮶ࡢ⸆≀⒪ἲࢆᢸ࠺་⸆ရࡸ་⒪ᶵჾࡢ㛤Ⓨࡉࡽ࡟ḟୡ௦ࢼࣀࣂ࢖࢜◊
✲ࢆ≌ᘬࡍࡿඃࢀࡓேᮦࡢ㣴ᡂࢆ┠ᣦࡋ࡚࠸ࡿࠋ୍᪉ࠊ᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮ࡣࠊୡ⏺᭱㧗ᛶ⬟ࡢ
㉁㔞ศᯒࢩࢫࢸ࣒ࢆ㛤Ⓨࡋࠊᙜヱࢩࢫࢸ࣒ࢆ⏝࠸ࡓࡀࢇࡸ࢔ࣝࢶࣁ࢖࣐࣮⑓ࡢ᪂ࡓ࡞デ᩿࣭἞⒪ᡭἲ
ࡢ☜❧࡟ྥࡅ࡚ࠊࣂ࢖࣐࣮࣮࢜࢝ࡢⓎぢࡸࡀࢇ๰⸆ࡢࡓࡵࡢᶆⓗศᏊೃ⿵ࡢⓎぢ࡟ດࡵࡿ஦ࢆ┠ⓗ࡜
ࡋ࡚࠸ࡿࠋࡍ࡞ࢃࡕࠊࣉࣟࢪ࢙ࢡࢺศ㔝࡛ࡣࠊ๰⸆⛉Ꮫ࡜་⒪⸆Ꮫࡢ⤫ྜⓗ࡞⸆Ꮫ◊✲ࡀᐇ᪋ࡉࢀ࡚
࠸ࡿࠋ
௒ᚋࡣࠊ㒊ᒁࢆ㉺࠼ࡓ㐃ᦠࢆ῝ࡵࠊ᭱ඛ➃ィ ᢏ⾡ࡸ⑌ᝈࢤࣀ࣒⛉Ꮫࠊࡉࡽ࡟ࡣࠊ᪂ࡋ࠸ࣛ࢖
ࣇࢫࢱ࢖ࣝ࡟ᑐᛂࡍࡿᶵ⬟ᛶ㣗ရࡸ་⸆ရࢩ࣮ࢬ๰ฟࢆど㔝࡟ධࢀࡓඛ㥑ⓗ࡞⏕⌮Ꮫ࡜໬Ꮫࡢ⼥
ྜ◊✲ࠊ๰⸆◊✲ࠊ་⒪⸆Ꮫ◊✲࡬࡜Ⓨᒎࡉࡏ࡚ࠊඛ➃ⓗ࡞་⒪࠾ࡼࡧ೺ᗣ⏕άࡢᐇ⌧࡟㈉⊩ࡍ
ࡿࡇ࡜ࢆ┠ᣦࡍࠋ
㸦㸱㸧ᑓᨷศ㔝࣭◊✲㡿ᇦࡢ◊✲ෆᐜ
࠙⸆⛉Ꮫᑓᨷࠚ
⸆ရ๰〇໬Ꮫㅮᗙ
⸆ရ᭷ᶵ〇㐀Ꮫ㸦≉ูᩍᤵ ⸨஭ಙᏕࠊ෸ᩍᤵ኱㔝 ᾈ❶ࠊㅮᖌ ኱▼┿ஓ㸧
ࢤࣀ࣒㸭ࣉࣟࢸ࣮࣒࢜᝟ሗ཰ᩡᆺ๰⸆◊✲
᪂つ」⣲⎔㦵᱁ᵓ⠏ἲࡢ㛤Ⓨ࡜๰⸆ࢸࣥࣉ࣮ࣞࢺ࡬ࡢᛂ⏝
᪂つࣇࣛࢢ࣓ࣥࢺྜᡂἲࡢ㛤Ⓨ࡜㛗㙐࣌ࣉࢳࢻྜᡂ࡬ࡢᛂ⏝
࣌ࣉࢳࢻ࣭࣌ࣉࢳࢻ㢮⥳యࢆࣉ࣮ࣟࣈ࡜ࡍࡿࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲
ᢠ⒴๣࣭ᢠ࢘࢖ࣝࢫ๣ࡢศᏊタィ࣭ྜᡂ◊✲
⸆ရྜᡂ໬Ꮫ㸦෸ᩍᤵᒣ⏣ ೺୍㸧
୙ᩧྜᡂ཯ᛂࡢタィ࡜㛤ᣅ
− 64 −
ศᏊάᛶ໬ᡭἲࡢ㛤ᣅ
㐃⥆ኚ᥮཯ᛂࡢ㛤ᣅ
⏕⌮άᛶ᭷ᶵ໬ྜ≀ࡢྜᡂ◊✲
⸆ရศᏊ໬Ꮫ㸦ᩍᤵ➉ᮏ ెྖࠊ෸ᩍᤵ㧗㡲 Ύㄔࠊຓᩍሯ㔝 ༓ᑜ㸧
ࣉࣟࢭࢫྜᡂࢆᣦྥࡋࡓ⎔ቃㄪ࿴ᆺ᭷ᶵྜᡂ཯ᛂࡢ㛤Ⓨ
㔠ᒓࡢ≉ᛶࢆ฼⏝ࡋࡓ᪂つศᏊኚ᥮ἲࡢ㛤ᣅ
⏕≀άᛶኳ↛᭷ᶵ໬ྜ≀ཬࡧࡑࡢ㢮⦕యࡢ඲ྜᡂ◊✲
ᶵ⬟ᛶ」⣲⎔໬ྜ≀ࡢ๰〇࡜ࣂ࢖࢜ࣉ࣮ࣟࣈศᏊ࡬ࡢᒎ㛤
ከⅬศᏊ㛫┦஫స⏝ࡍࡿ࣍ࢫࢺศᏊࡢタィ࡜⏕యᶵ⬟ࡢᵓ⠏
⸆ရ㈨※Ꮫ㸦෸ᩍᤵఀ⸨⨾༓✑㸧
஧ḟ௦ㅰᶵ⬟Ⓨ⌧࡟㛵ࡍࡿ◊✲ࠊ≉࡟ࢸࣝ࣌ࣀ࢖ࢻࡢ⏕ྜᡂᶵᵓࡢゎ᫂
⏕⸆࡞ࡽࡧ࡟⸆⏝᳜≀࡟ྵࡲࢀࡿ⏕⌮άᛶᡂศࡢ◊✲
⸆⏝᳜≀ࡢᐇែ࡜ከᵝᛶ࡟㛵ࡍࡿㄪᰝ◊✲
ᾏእఏ⤫⸆≀ࡢㄪᰝ◊✲
⸆ရᶵ⬟⤫ไᏛㅮᗙ
⸆ရᶵ⬟ゎᯒᏛ㸦ᩍᤵᯇᓮ ຾ᕭࠊ෸ᩍᤵ ᫍ㔝 ኱ࠊຓᩍ ▮㔝 ⩏᫂㸧
ᢠ⳦ᛶ࣌ࣉࢳࢻࡢస⏝ᶵᵓࡢゎ᫂࡜๰⸆࡬ࡢᒎ㛤
࢔ࣝࢶࣁ࢖࣐࣮⑓Ⓨ⑕ᶵᵓࡢゎ᫂࡜ண㜵࣭἞⒪ἲࡢ㛤Ⓨ
⭷ࢱࣥࣃࢡ㉁ࡢᵓ㐀ᙧᡂཎ⌮ࡢゎ᫂
ཷᐜయࡢᶵ⬟ゎᯒ࡜๰⸆
105࡟ࡼࡿ⏕యศᏊࡢᵓ㐀ゎᯒ
ᵓ㐀⏕≀⸆Ꮫ㸦ᩍᤵຍ⸨ ༤❶ࠊ෸ᩍᤵ ୰ὠ ஽ࠊຓᩍ ᒣཱྀ▱ᏹ㸧
;⥺⤖ᬗᵓ㐀࡟ᇶ࡙࠸ࡓ$%&ࢺࣛࣥࢫ࣏࣮ࢱ࣮ࡢᵓ㐀⏕⌮Ꮫ
࣌ࣝ࢜࢟ࢩࢯ࣮࣒⭷ࢱࣥࣃࢡ㉁ࡢ⭷ᒁᅾ໬࣓࢝ࢽࢬ࣒ࡢᵓ㐀⏕≀Ꮫ
⢭ᐦ❧యᵓ㐀࡟ᇶ࡙ࡃ㓝⣲ࡢゐ፹స⏝ࡢᵓ㐀ⓗ㉳※ࡢゎ᫂
;⥺⤖ᬗᵓ㐀ゎᯒ࡟ࡼࡿ⏕≀᫬ィࡢᵓ㐀࡜ᶵ⬟ࡢゎ᫂
⸆ရ〇๣タィᏛㅮᗙ
ࢤࣀ࣒๰⸆⛉Ꮫ㸦ᩍᤵ ㎷ᮏ ㇦୕ࠊ෸ᩍᤵ ᖹ⃝ ᫂ࠊຓᩍ ᮌᮧ 㑳ኵ㸧
ࢤࣀ࣒ໟᣓⓗゎᯒ࡟ࡼࡿ᪂つ๰⸆ᶆⓗࡢⓎぢ࡜ࢱ࣮ࢤࢵࢺࣂࣜࢹ࣮ࢩࣙࣥ
ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢵࢡ࡟ࡼࡿLQVLOLFR๰⸆◊✲
⏕యෆ࣮࢜ࣇ࢓ࣥ㹅⺮ⓑ㉁ඹᙺᆺཷᐜయࡢࣜ࢞ࣥࢻ᥈⣴
㑇ఏᏊᨵኚື≀ࠊ⑓ែື≀ࢆ⏝࠸ࡓ㑇ఏᏊࡢಶయࣞ࣋ࣝࡢᶵ⬟ゎᯒ
ᝈ⪅ಶேࡢ㑇ఏᏊከᆺ᝟ሗ࡟ᇶ࡙࠸ࡓ⮳㐺⮫ᗋ⸆≀⒪ἲࡢᐇ⌧
− 65 −
〇๣ᶵ⬟ゎᯒᏛ㸦ᩍᤵ ▼℈ Ὀࠊ෸ᩍᤵ୰㔝ᐇ㸧
࣏ࣜ⺮ⓑ㉁⢏Ꮚ࡜࢔࣏࣏ࣜ⺮ⓑ㉁ࡢ┦஫స⏝࡟㛵ࡍࡿ⏕≀≀⌮໬Ꮫⓗ◊✲
ࢹ࢕ࢫࢡ≧+'/ࡢ᪂⏕࡟㛵ࡍࡿ⏕≀≀⌮໬Ꮫⓗ◊✲
⬡㉁㠀࣓ࣛࣛ┦ࡢᵓ㐀ホ౯࡜ࡑࡢᶵ⬟࡟㛵ࡍࡿ≀⌮໬Ꮫⓗ◊✲
࣒ࣞࢼࣥࢺ⢏Ꮚࡢ⣽⬊ẘᛶ࡟㛵ࡍࡿ◊✲
⬡㉁㍺㏦ࢱࣥࣃࢡ㉁ࡢάᛶ࡜⬡㉁⭷┦஫స⏝࡟㛵ࡍࡿ◊✲
⢭ᐦ᭷ᶵྜᡂ໬Ꮫ
⢭ᐦ᭷ᶵྜᡂ໬Ꮫ㸦ᩍᤵᕝ➃ ⊛ኵࠊ෸ᩍᤵ ྂ⏣ ᕦࠊຓᩍ ྜྷᮧ ᬛஅ㸧
ືⓗ୙ᩧไᚚࡢ᪉ἲㄽ࡜୙ᩧ཯ᛂ࡬ࡢ฼⏝
᭷ᶵゐ፹࡟ࡼࡿ⢭ᐦ཯ᛂไᚚ
ศᏊࡢ࢟ࣛࣜࢸ࢕࣮࡟ᇶ࡙ࡃ㧗ḟᵓ㐀ࡢᵓ⠏
ศᏊㄆ㆑࠾ࡼࡧ㉸ศᏊ໬Ꮫ࡟㛵ࡍࡿ◊✲
⏕≀άᛶ໬ྜ≀ࡢ๰ฟࢆᣦྥࡋࡓ᪂つྜᡂἲࡢ㛤Ⓨ
⏕యศᏊ⸆Ꮫㅮᗙ
⏕యศᏊㄆ㆑Ꮫ㸦ᩍᤵ➉ᓥ ᾈࠊ෸ᩍᤵ ᰠ⃝ ᫀࠊຓᩍ ᒣᮏ ఙ୍㑻ࠊ≉ᐃຓᩍᒣᓮ ኱ᶞ㸧
ᑠ⬊య&Dࢩࢢࢼࣜࣥࢢ࡟㛵ࡍࡿ◊✲
୰ᯡ⣔ࡢ᪂つ᝟ሗఏ㐩࡟㛵ࡍࡿ◊✲
➽⣽⬊ࡢ⭷ᵓ⠏࡜ᶵ⬟࡟㛵ࡍࡿ◊✲
ศᏊᚤ⏕≀Ꮫ෸ᩍᤵΏ㒊 ዲᙪ
࢖ࣥࢱ࣮ࣇ࢙ࣟࣥࡢ⏘⏕࡜స⏝ᶵᗎᢠ࢘࢖ࣝࢫᶵᵓࡢゎᯒ
࢖ࣥࢱ࣮ࣇ࢙ࣟࣥ࡟ᑐࡍࡿከ㠃ⓗ࡞⣽⬊ᛂ⟅ᶵᗎࡢゎᯒ
࢖ࣥࢱ࣮ࣇ࢙ࣟࣥ࡜ྛ✀⑌ᝈ࡜ࡢ┦㛵ࡢ᥈⣴
࢖ࣥࢱ࣮ࣇ࢙ࣟࣥ㑇ఏᏊ἞⒪ࡢᇶ♏ⓗ◊✲
⏕యᶵ⬟⸆Ꮫㅮᗙ
⏕యᶵ⬟ゎᯒᏛ㸦ᩍᤵ㔠Ꮚ ࿘ྖࠊ෸ᩍᤵ ୰ᕝ㈗அࠊຓᩍ ⓑᕝஂᚿ㸧
࢖࢜ࣥࢳࣕࢿࣝ࡞࡝ࡢ⭷㍺㏦ࢱࣥࣃࢡ㉁ࢆᑐ㇟࡜ࡍࡿ๰⸆㸪ᶵ⬟ゎᯒ㸪⸆ຠゎᯒ㸪Ᏻ඲ᛶホ౯㸪⑓
ᅉㄽ㸪ࢤࣀ࣒⛉Ꮫ࡟㛵ࡍࡿ◊✲
③ࡳࡢ≀㉁ⓗᇶ┙࠾ࡼࡧ㙠③⸆ࡢస⏝ᶵᗎ࡟㛵ࡍࡿ◊✲
⸆≀౫Ꮡࡸ⸆≀᭷ᐖ஦㇟ࡢศᏊᶵᵓ࡟㛵ࡍࡿ◊✲
⏕࿨⛉Ꮫ⏝ㄒ࢜ࣥࢺࣟࢪ࣮ࡢ◊✲
㑇ఏᏊ⸆Ꮫ㸦ᩍᤵఀ⸨ ಙ⾜ࠊㅮᖌ ୕Ꮿ Ṍࠊຓᡭ ᒣෆ ⫕㸧
㹄㹅㹄࡞࡝᪂つศἪᛶᅉᏊࡢ⬡⫫⤌⧊ࠊᚰ⮚ࠊ⬻ᙧᡂ࡞࡝࡟࠾ࡅࡿᙺ๭ࡢゎ᫂
㹄㹅㹄࡞࡝᪂つศἪᛶᅉᏊࡢ࢚ࢿࣝࢠ࣮௦ㅰㄪ⠇࡞࡝࡟࠾ࡅࡿᙺ๭ࡢゎ᫂
− 66 −
㹄㹅㹄࡞࡝᪂つศἪᛶᅉᏊ㑇ఏᏊࡢศᏊ㐍໬㐣⛬ࡢゎ᫂
㑇ఏᏊḞᦆ࣐࢘ࢫࡢసᡂ࡟ࡼࡿ᪂つศἪᛶ㑇ఏᏊࡢᶵ⬟ゎᯒ
㑇ఏᏊᶵ⬟ᢚไᑠᆺ㨶㢮ࡢసᡂ࡟ࡼࡿ᪂つศἪᛶ㑇ఏᏊࡢᶵ⬟ゎᯒ
⏕⌮άᛶไᚚᏛ㸦ᩍᤵᑠሐ ಖ๎ࠊ෸ᩍᤵ ➉ᯇ ᘯࠊຓᩍ ෆ⸨ ⿱Ꮚ㸧
ࢫࣇ࢕ࣥࢦ⬡㉁ࠊࢫࣇ࢕ࣥࢦ⢾⬡㉁ࡢ⣽⬊ෆࢩࢢࢼࣝఏ㐩࡟࠾ࡅࡿᶵ⬟ࡢゎ᫂
ࢩ࢔ࣝ㓟ศᏊ✀ࢆぢศࡅࡿ⢾㙐ㄆ㆑ᶵᵓ࡜ࡑࡢᶵ⬟࡟㛵ࡍࡿ◊✲
ࢺࣛࣥࢫࢡࣜࣉࢺ࣮࣒ゎᯒࢆ฼⏝ࡋࡓᐃ㔞ⓗ࡞⾲⌧ᆺ࣮㑇ఏᆺ┦㛵ゎᯒ
άᛶ໬ࣜࣥࣃ⌫࡟࠾ࡅࡿ⢾㙐ࡢච␿ไᚚᶵ⬟ࡢゎᯒ
⢾㙐⏕ྜᡂ⤒㊰ศᒱⅬ࡟࠾ࡅࡿไᚚᶵᵓࡢゎ᫂
⏕య᝟ሗ⸆Ꮫㅮᗙ
⏕య᝟ሗไᚚᏛ㸦ᩍᤵ୰ᒣ ࿴ஂࠊຓᩍ ຍ⸨ ὒᖹ㸧
పศᏊ㔞*73DVH࡟ࡼࡿ⣽⬊ෆࢱࣥࣃࢡ㉁㍺㏦ࡢㄪ⠇࡟㛵ࡍࡿ◊✲
ከᵝ࡞࢚ࣥࢻࢧ࢖ࢺ࣮ࢩࢫ⤒㊰ࡢㄪ⠇࡟㛵ࡍࡿ◊✲
࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡ࡟ࡼࡿ⣽⬊ศ⿣ࡢㄪ⠇࡟㛵ࡍࡿ◊✲
࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡ࡜ࢱࣥࣃࢡ㉁ศゎࡢඹᙺ࡟㛵ࡍࡿ◊✲
⚄⤒ᶵ⬟ไᚚᏛ㸦ᩍᤵ᰿ᓊ Ꮫࠊ෸ᩍᤵ ຍ⸨⿱ᩍࠊຓᩍ ⏕἟ Ἠ㸧
⚄⤒ᅇ㊰ᙧᡂ࡟࠾ࡅࡿ*⺮ⓑ㉁ࡢᶵ⬟ࡢ◊✲
⚄⤒㍈⣴࢞࢖ࢲࣥࢫศᏊࡢ᝟ሗఏ㐩ᶵᵓࡢ◊✲
ࢩࢼࣉࢫᙧᡂ࡟࠾ࡅࡿ*⺮ⓑ㉁ࡢᶵ⬟ࡢ◊✲
⏕యᶵ⬟໬Ꮫ
⏕యᶵ⬟໬Ꮫ㸦ᩍᤵ஧ᮌ ྐᮁࠊຓᩍ ௒すᮍ᮶ࠊຓᩍ ୰℩ ⏕ᙪ㸧
⣽⬊ᶵ⬟࣭㑇ఏᏊࢆไᚚࡍࡿ⏕⌮άᛶ⺮ⓑ㉁ࡢ๰〇
⣽⬊⭷㏱㐣࣌ࣉࢳࢻ࣋ࢡࢱ࣮ࡢ㛤Ⓨ࡜࣓࢝ࢽࢬ࣒
ள㖄ࣇ࢕࣮ࣥ࢞ᆺ㌿෗ᅉᏊࡢ㹂㹌㸿ㄆ㆑࡜ᶵ⬟ゎᯒ
⣽⬊ෆࢱ࣮ࢤࢸ࢕ࣥࢢ㸦᰾࣭࣑ࢺࢥࣥࢻࣜ࢔࡞࡝㸧ࡢ໬Ꮫ࡜ศᏊタィ
⎔ቃᛂ⟅ᆺᶵ⬟ᛶ࣌ࣉࢳࢻࡢࢹࢨ࢖ࣥ
⸆ရືែ་⒪⸆Ꮫㅮᗙ
⸆ရືែไᚚᏛ㸦ᩍᤵᶫ⏣ ඘ࠊ෸ᩍᤵ ᒣୗᐩ⩏ࠊㅮᖌ ᕝୖ ⱱ㸧
་⸆ရࡢయෆືែࡢศᏊᶵᵓࡢゎ᫂࡜ືែࣔࢹࣝ࡟ᇶ࡙ࡃᩘ⌮Ꮫⓗゎᯒ
἞⒪ࡢ᭱㐺໬ࢆ┠ⓗ࡜ࡍࡿ⸆≀ࡢయෆືែไᚚἲࠊ〇๣タィἲࡢ㛤Ⓨ
ࢱࣥࣃࢡ㉁་⸆ရࡢ⮚ჾࠊ⣽⬊≉␗ⓗࢱ࣮ࢤࢸ࢕ࣥࢢᢏ⾡ࡢ㛤Ⓨ
㑇ఏᏊ་⸆ရࢆᑐ㇟࡜ࡍࡿࢻࣛࢵࢢࢹࣜࣂ࣮ࣜࢩࢫࢸ࣒ࡢ㛤Ⓨ
⸆≀ࡢ⤒⢓⭷࣭⤒⓶྾཰ࡢᶵᵓゎᯒ࡜ࢥࣥࣆ࣮ࣗࢱ྾཰ண ἲࡢ㛤Ⓨ
− 67 −
⸆ရస⏝ゎᯒᏛ㸦ᩍᤵ㉥ụ ᫛⣖ࠊ෸ᩍᤵ ஂ⡿ ฼᫂ࠊຓᩍ Ἠ Ᏻᙪ㸧
୰ᯡ⚄⤒స⏝⸆ࡢ⸆⌮Ꮫࢆ୺せ◊✲ㄢ㢟࡜ࡍࡿ
࢔ࣝࢶࣁ࢖࣐࣮⑓ࠊࣃ࣮࢟ࣥࢯࣥ⑓ࠊ⬻⹫⾑ࡢ἞⒪⸆ࡢ⸆⌮స⏝ࡢゎᯒ
୰ᯡ⚄⤒⣔ࢽࢥࢳࣥᛶ࢔ࢭࢳࣝࢥࣜࣥ⣔ࡢᶵ⬟ࡢゎᯒ
⫾௘⾑Ύ࡟⏤᮶ࡍࡿ⚄⤒ಖㆤ໬ྜ≀ࢭࣟࣇ࢙ࣥࢻ㓟ࡢస⏝ᶵᗎࡢゎᯒ
ࢽ࣮ࣗࣟࣥ⏕Ꮡ࡜⚄⤒෌⏕ࢆไᚚࡍࡿపศᏊ㔞໬ྜ≀ࡢ᥈⣴
⮫ᗋ⸆Ꮫᩍ⫱㸦෸ᩍᤵ▮㔝 ⫱Ꮚ㸧
་⸆ရࡢ㐺ṇ౑⏝࡟㛵ࡍࡿᩍ⫱࣭◊✲
⸆≀ືែ࡜⸆ຠࡢ㏿ᗘㄽⓗゎᯒ࡟ᇶ࡙ࡃಶู໬ᢞ୚タィ࡟㛵ࡍࡿ◊✲
⑓యᶵ⬟ゎᯒᏛㅮᗙ
⑓ែᶵ⬟ศᯒᏛ㸦ᩍᤵబ἞ ⱥ㑻ࠊ෸ᩍᤵ ᑠ㔝 ṇ༤ࠊຓᩍ ኳ⁹ ᩗࠊ≉ᐃຓᩍ బ㔝⣫ᖹ㸧
⬻⑌ᝈࠊᚰ⑌ᝈࠊࡀࢇ࡛ࡢ⏕యᶵ⬟ኚ໬ࢆ࢖ࣥࣅ࣎ゎᯒࡍࡿศᏊ࢖࣓࣮ࢪࣥࢢἲࡢ㛤Ⓨ࡜ࡑࢀ࡟ᇶ ࡙ࡃ⑓ែࡢ௙⤌ࡳࡢゎ᫂ཬࡧ⸆≀స⏝ࡢゎ᫂࡟㛵ࡍࡿ◊✲
⑓ែࡢ≉ᛶ࡟ᇶ࡙ࡃᶆⓗ㒊఩㑅ᢥⓗ⛣⾜ࠊ㑅ᢥⓗάᛶ໬ࢆ࠾ࡇࡍᶵ⬟ᛶ⏬ീデ᩿࣭἞⒪⸆๣ࡢ๰⸆ ◊✲
⏕⌮άᛶ㔠ᒓ໬ྜ≀ࡢ⏕యస⏝ࡢゎ᫂࡜἞⒪࡬ࡢᛂ⏝࡟㛵ࡍࡿ◊✲
⑓ែ᝟ሗ⸆Ꮫ㸦ᩍᤵ㧗಴ ႐ಙࠊ෸ᩍᤵ すᕝඖஓࠊຓᩍ 㧗ᶫ ᭷ᕫ㸧
㑇ఏᏊ἞⒪࣭'1$࣡ࢡࢳࣥ⒪ἲࡢ᭱㐺໬ࢆ┠ᣦࡋࡓ᰾㓟་⸆ရ㛤Ⓨ
᰾㓟ࢼࣀࢹࣂ࢖ࢫ࣭ࣁ࢖ࢻࣟࢤࣝࡢ㛤Ⓨ
㹐㹌㸿ᖸ΅ࢆ฼⏝ࡋࡓ⑌ᝈ἞⒪ࢩࢫࢸ࣒ࡢ㛤Ⓨ
ከᶵ⬟⣽⬊἞⒪๣ࡢ㛤Ⓨ
་⒪⸆๣Ꮫ
་⒪⸆๣Ꮫ㸦෸ᩍᤵ᱇ ᩄஓࠊㅮᖌ ቑ⏣ᬛඛࠊຓᩍ ᮏᶫ⚽அࠊຓᩍ ⡿⃝ ῟ࠊຓᩍ ⚟ኈ
ᑗ⚽㸧
་⸆ရࡢయෆືែ࡜⸆ຠ࣭ẘᛶ࡟㛵ࡍࡿᇶ♏࡜⮫ᗋ
⸆≀ࢺࣛࣥࢫ࣏࣮ࢱࡢศᏊ࣭⣽⬊⏕≀Ꮫⓗゎᯒ࡜⮫ᗋᛂ⏝࡟㛵ࡍࡿ◊✲
⑓ែ᫬ࡢ⸆≀ືែ࣭⸆ຠࡢኚືせᅉゎᯒ࡜ᝈ⪅ಶูᢞ୚タィ࡟㛵ࡍࡿ◊✲
⸆≀┦஫స⏝ࡢLQYLWURண ࣭ホ౯⣔ࡢ㛤Ⓨ࡟㛵ࡍࡿ◊✲
⸆≀ࢺࣛࣥࢫ࣏࣮ࢱ࣭௦ㅰ㓝⣲ࡢ㑇ఏⓗከᆺ࡜ࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪
࠙་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࠚ
་⸆๰ᡂ᝟ሗ⛉Ꮫㅮᗙ
ࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮㸦ᩍᤵᒸᮧ ᆒࠊ෸ᩍᤵ ᅵᒃ 㞞ኵࠊຓᩍ ᒣཱྀ ㈡❶㸧
့ங㢮⏕యࣜࢬ࣒࡟࠾ࡅࡿ᫬㛫ࡢ⏕ᡂ࡜ㄪᚊࡢ௙⤌ࡳࢆࠊ⣽⬊ࠊ⤌⧊ࠊ⏕య࡜࠸࠺ከᒙ࡛ࣞ࣋ࣝゎ
− 68 −
᫂ࡍࡿࠋ
⏕యࣜࢬ࣒␗ᖖ࡟ࡼࡿ⑌⑓ࡢ◊✲
့ங㢮᫬ィ㑇ఏᏊࡢྠᐃ࡜ࣜࢬ࣒ࡢศᏊᶵᵓࡢ◊✲
ࣜ࢞ࣥࢻࠊཷᐜయࡢゎᯒ࡟ࡼࡿ᫬㛫ࢆㄪᚊࡍࡿ๰⸆◊✲
ࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮㸦
㸦ไᚚศᏊᏛ㸧㸦ᩍᤵ᥃㇂ ⚽᫛ࠊ෸ᩍᤵ ᭹㒊 ᫂ࠊຓᩍ すᮧ ៅ୍㸧
ከᅉᏊ⑌ᝈ㸦⒴ࠊᚰ⑌ᝈࠊឤᰁ⑕ࠊ⚄⤒ኚᛶ⑌ᝈࠊච␿⑌ᝈࠊ⢾ᒀ⑓➼㸧࡟ᑐࡍࡿḟୡ௦໬Ꮫ⒪ἲ
ࡢ㛤Ⓨࢆᣦྥࡋࡓඛ➃ⓗࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲
๰⸆࣮ࣜࢻ໬ྜ≀ࡢ㛤ᣅࢆᣦྥࡋࡓ᪂つ⏕⌮άᛶ≀㉁ࡢኳ↛≀໬Ꮫ࣭ኳ↛≀⸆Ꮫ
ࢣࣔ࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢆά⏝ࡋࡓ࣓ࢹ࢕ࢩࢼࣝࢣ࣑ࢫࢺ࣮ࣜ◊✲࠾
ࡼࡧࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮◊✲
᭷⏝≀㉁⏕⏘࣭๰〇ࡢࡓࡵࡢ㑇ఏᏊᕤᏛⓗ◊✲㸦ࢥࣥࣅࢼࢺࣜ࢔ࣝ⏕ྜᡂ◊✲➼㸧
ࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮㸦๰⸆ィ⟬໬Ꮫ㸧㸦ᩍᤵ໭ᾆ ࿴ኵ㸧
⏕య㧗ศᏊࡢࡓࡵࡢ㔞Ꮚ໬Ꮫィ⟬ἲࡢ㛤Ⓨ
⏕ែ㧗ศᏊࡢᵓ㐀࡜ᶵ⬟ࡢ⌮ㄽⓗ◊✲
⺮ⓑ㉁࡜పศᏊࡢศᏊ㛫┦஫స⏝ࡢ⌮ㄽゎᯒ
ィ⟬໬Ꮫᡭἲ࡟ࡼࡿࢻࣛࢵࢢࢹࢨ࢖ࣥ
⤫ྜࢤࣀ࣑ࢡࢫ㸦ᩍᤵ㔠ஂ ᐿࠊ෸ᩍᤵ ஬ᩯ 㐍ࠊຓᩍ ᫬ᯇ ᩄ᫂ࠊຓᩍ ᑠᑎ ṇ᫂㸧
ࣂ࢖࢜᝟ሗࢆ⤫ྜࡍࡿࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᢏ⾡ࡢ㛤Ⓨ◊✲
⸆≀࣭໬Ꮫ≀㉁࡜⏕యࢩࢫࢸ࣒࡜ࡢ┦஫స⏝ண ⸆≀࣭໬Ꮫ≀㉁ࡢ⏕ศゎ࣭⏕ྜᡂண ๰⸆࣭་⒪ࡢࡓࡵࡢ⤫ྜࢹ࣮ࢱ࣮࣋ࢫ㛤Ⓨ
ศᏊタィ᝟ሗ㸦ᩍᤵ㤿ぢሯ ᣅࠊຓᩍ ℧ᕝ ୍Ꮫࠊຓᩍ ᚿ㈡ ඖ⣖㸧
ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ㸸ࢤࣀ࣒࣡࢖ࢻ࡞ࢹ࣮ࢱ࠿ࡽࡢ᝟ሗฎ⌮ᢏ⾡࡟ࡼࡿ▱㆑Ⓨぢ
ඛ➃᝟ሗ⛉Ꮫᢏ⾡ࡢ๰ฟ࡟ࡼࡿ⏕࿨᝟ሗゎᯒ࣭๰⸆ᢏ⾡ࡢ㧗ᗘ໬
⸆≀ᢞ୚ࢹ࣮ࢱ࠿ࡽࡢ⏕యศᏊ㛫ࢿࢵࢺ࣮࣡ࢡ᥎ᐃ࡟ࡼࡿ๰⸆࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ
⏕యศᏊࡢ⏕࿨ᶵᵓࡢ⌮ゎ࡟ྥࡅࡓ᝟ሗᢳฟᢏ⾡ࡢ㧗⢭ᗘ໬
ࢩࢫࢸ࣒ࢬࣂ࢖࢜ࣟࢪ࣮㸸ィ⟬ᶵ࡟ࡼࡿᶍೌ࠿ࡽࡢ⏕࿨⌧㇟ࡢゎᯒ࣭⌮ゎ
㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬ
㸦ࢩࢽ࢔ࣜࢧ࣮ࢳࣇ࢙࣮ࣟ ᅵᒃ Ꮥ⾜ࠊ≉ᐃຓᩍ ᵽཱྀ ࡺࡾᏊࠊ≉ᐃຓᩍ ΎỈ ୍᠇㸧
⒴἞⒪࡟↔Ⅼࢆᙜ࡚ࡓ᪂つ໬ྜ≀ࡢྜᡂ࠾ࡼࡧホ౯
ᢠ⒴๣ೃ⿵໬ྜ≀ࡢLQYLYRホ౯ࢆᐇ᪋ࡍࡿࡓࡵࡢ⒴⑌ᝈࣔࢹࣝసᡂ
ศᏊ࢖࣓࣮ࢪࣥࢢἲࢆ฼⏝ࡋࡓ་⸆ရࡢయෆືែゎᯒ࠾ࡼࡧᚓࡽࢀࡓ⤖ᯝ࡟ᇶ࡙ࡃ⸆≀㏦㐩ࢩࢫ
ࢸ࣒ࡢ㛤Ⓨ
࣐࢖ࢡࣟయෆࣟ࣎ࢵࢺࠊࢼࣀ࣐ࢩࣥࢩࢫࢸ࣒➼࡜ࡢ⼥ྜ࡟ࡼࡿ⸆≀㏦㐩''6ࢩࢫࢸ࣒ࡢ㛤Ⓨ
⒴἞⒪ࢆ┠ⓗ࡜ࡋࡓᶆⓗศᏊࡢᵓ㐀Ꮫⓗゎᯒ࠾ࡼࡧᶵ⬟ホ౯
− 69 −
᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮
㸦ࢭࣥࢱ࣮㛗 ᩍᤵ㎷ᮏ ㇦୕ࠊᐈဨᩍᤵ⏣୰ ⪔୍ࠊᐈဨᩍᤵ ΎỈ ୍἞ࠊᐈဨᩍᤵ ᮡᮏඵ
㑻㸧
㸦ࡀࢇ◊✲ࢢ࣮ࣝࣉ≉ᐃᩍᤵෆᾏ ₶㸧
㸦࢔ࣝࢶࣁ࢖࣐࣮◊✲ࢢ࣮ࣝࣉ≉ᐃᩍᤵᯇᮏ ᫂㸧
᭱ඛ➃◊✲㛤Ⓨᨭ᥼ࣉࣟࢢ࣒ࣛ㸦),567㸧࡟࠾ࡅࡿࠊ㸦ᰴ㸧ᓥὠ〇సᡤࡢ⏣୰⪔୍ࣇ࢙࣮ࣟ
ࢆ୰ᚰ◊✲⪅࡜ࡍࡿࠕḟୡ௦㉁㔞ศᯒࢩࢫࢸ࣒㛤Ⓨ࡜๰⸆ࠊデ᩿࡬ࡢ㈉⊩ࠖࣉࣟࢪ࢙ࢡࢺࡢ᥎㐍
㸦ᰴ㸧ᓥὠ〇సᡤ࡟࠾࠸࡚ୡ⏺᭱㧗ᛶ⬟ࡢḟୡ௦㧗ឤᗘ㉁㔞ศᯒࢩࢫࢸ࣒㸦ᚑ᮶࡟㍑࡭࡚ឤᗘ
ಸ㸧ࢆ㛤Ⓨ
ி㒔኱Ꮫ࡟࠾࠸࡚ୖグḟୡ௦ศᯒࢩࢫࢸ࣒ࢆ⏝࠸ࡓࣉࣟࢸ࣮࣒࢜ゎᯒ࡟ࡼࡿ⮫ᗋࣂ࢖࣐࣮࣮࢜࢝ ࡢྲྀᚓ࡜ά⏝
᪂つ࣐࣮࣮࢝࡟ࡼࡿデ᩿ἲࡢ๰ฟ࡜᪂つࢱࣥࣃࢡ㉁ࢆᶆⓗ࡜ࡍࡿศᏊᶆⓗ⸆ࡢ๰⸆
᪂つ࣐࣮࣮࢝࡟ࡼࡿ㍍ᗘㄆ▱ᶵ⬟㞀ᐖ࠿ࡽ࢔ࣝࢶࣁ࢖࣐࣮⑓࡟ࡲࡓࡀࡿデ᩿᪉ἲࡢ㛤Ⓨ
ᐤ㝃ㅮᗙ
ࢼࣀࣂ࢖࢜་⸆๰ᡂ⛉Ꮫ㸦ᐈဨᩍᤵΎỈ ୍἞ࠊ≉ᐃ෸ᩍᤵ బ⸨ ྐ㢧ࠊ≉ᐃຓᩍ ᅵᒇ ๰
೺㸧
ࢼࣀࣞ࣋ࣝ᭱ඛ➃ᢏ⾡㸦㹂㹌㸿ࢳࢵࣉࠊḟୡ௦㉁㔞ศᯒჾ㸧࡜ࣂ࢖࢜ᢏ⾡ࢆ⼥ྜ
ࡀࢇࡢ⮫ᗋ᳨యศᯒ࡟ࡼࡿศᏊᶆⓗ⸆ࡢࢱ࣮ࢤࢵࢺ᥈⣴ࠊ⸆⌮ࢤࣀ࣑ࢡࢫ◊✲
᭱ඛ➃◊✲㛤Ⓨ㸦⏣୰ࣉࣟࢪ࢙ࢡࢺ㸧ࡢ୰࡛㉸㧗ឤᗘࢱࣥࣃࢡ㉁㉁㔞ศᯒ
⑓ែ㛵㐃㑇ఏᏊࡸࢱࣥࣃࢡ㉁᝟ሗࢆά⏝ࡋࡓࢸ࣮࣮࣓࣮ࣛࢻ་⒪
ࢩࢫࢸ࣒๰⸆⛉Ꮫ㸦≉ᐃᩍᤵዟ㔝 ᜤྐࠊ≉ᐃ෸ᩍᤵ℩ᮌ ᜨ㔛ࠊ≉ᐃຓᩍ ᪂ᓥ ⪽㸧
⑓ែⓎ⑕ࣉࣟࢭࢫࡸ⸆⌮స⏝ࣉࣟࢭࢫ࡟࠾ࡅࡿࢤࣀ࣒Ⓨ⌧ゎᯒ࡟ࡼࡿ⑓ែ࣓࢝ࢽࢬ࣒ࠊ⸆⌮࣓࢝ࢽ ࢬ࣒ࡢࢩࢫࢸ࣒ⓗゎᯒ
⑓ែⓎ⑕ࣉࣟࢭࢫࡸ⸆⌮స⏝ࣉࣟࢭࢫࡢࢩࢫࢸ࣒ࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡿ⑓ែཎᅉ㑇ఏᏊࠊ⸆≀ᶆ ⓗ㑇ఏᏊࡢྠᐃ
ࢣ࣑࢝ࣝࢤࣀ࣑ࢡࢫ᝟ሗࠊ㑇ఏᏊⓎ⌧ࢹ࣮ࢱࠊ๪స⏝᝟ሗ࡞࡝ࡢࢹ࣮ࢱ⤫ྜ࡟ࡼࡿከ㔜ᶆⓗ⸆⌮స
⏝ࡢࢩ࣑࣮ࣗࣞࢩࣙࣥࣔࢹࣝࡢ㛤Ⓨ
ከ㔜ᶆⓗ⸆⌮స⏝ࣔࢹࣝ࡟ᇶ࡙ࡃ⸆⌮ຠᯝಁ㐍࡜Ᏻ඲ᛶྥୖࢆᚿྥࡋࡓྜ⌮ⓗ⸆≀᥈⣴ᡭἲࡢ㛤
Ⓨ࡜ࢻࣛࢵࢢࢹࢨ࢖ࣥ⌮ㄽࡢᵓ⠏
㸦㸲㸧ᵓᡂဨ࡟ࡼࡿ◊✲ᡂᯝࡢⓎ⾲
ᮏ◊✲⛉ࡢᵓᡂဨࡢ◊✲ពḧࡣᴟࡵ࡚㧗࠸ࠋ኱㒊ศࡢศ㔝࡟࠾࠸࡚ᖺ㛫㸯㸮ሗ௨ୖࡢㄽᩥࢆୡ⏺ⓗ
࡟ホ౯ࡢ㧗࠸Ꮫ⾡㞧ㄅ࡟ሗ࿌ࡋ࡚࠸ࡿࠋᮏ෉Ꮚᮎᑿ࡟ᴗ⦼ࣜࢫࢺࢆᥖ㍕ࡋࡓࠋ
− 70 −
㸦㸳㸧Ꮫ఍άື࡬ࡢཧຍ≧ἣ Ꮫ఍➼࡟࠾ࡅࡿ኱Ꮫ㝔Ꮫ⏕ࡢ◊✲Ⓨ⾲ࡶᩘከࡃ⾜ࢃࢀ࡚࠾ࡾࠊಟኈㄢ⛬࠾ࡼࡧࠊ༤ኈㄢ⛬Ꮫ⏕ࡣࠊ
㸯ᖺ࡟ᅜෆ࠾ࡼࡧᅜ㝿Ꮫ఍࡛◊✲ᡂᯝࢆሗ࿌ࡋ࡚࠸ࡿࠋࡲࡓࠊᩍᐁࡶᅜෆእࢆၥࢃࡎࠊᏛ఍࡟࠾࠸࡚
ᩘከࡃࡢᣍᚅㅮ₇ࢆ⾜ࡗ࡚࠸ࡿࠋ
኱Ꮫ㝔Ꮫ⏕ࡢᅜෆᏛ఍࡛ࡢⓎ⾲ᩘ ᖹᡂ㸰㸰ᖺᗘ 㸯㸲㸳
ᖹᡂ㸰㸯ᖺᗘ 㸯㸷㸮
ᖹᡂ㸰㸮ᖺᗘ 㸰㸮㸳
ᖹᡂ㸯㸷ᖺᗘ 㸰㸶㸮
ᖹᡂ㸯㸶ᖺᗘ 㸯㸷㸱
኱Ꮫ㝔Ꮫ⏕ࡢᅜ㝿Ꮫ఍࡛ࡢⓎ⾲ᩘ ᖹᡂ㸰㸰ᖺᗘ 㸲㸰
ᖹᡂ㸰㸯ᖺᗘ 㸱㸵
ᖹᡂ㸰㸮ᖺᗘ 㸰㸶
ᖹᡂ㸯㸷ᖺᗘ 㸲㸵
ᖹᡂ㸯㸶ᖺᗘ 㸳㸲
ᅜෆᏛ఍࡛ࡢᣍᚅㅮ₇ᩘ
ᖹᡂ㸯㸶ᖺᗘ㹼㸰㸰ᖺᗘ 㸲㸶㸷
ᅜ㝿Ꮫ఍࡛ࡢᣍᚅㅮ₇ᩘ
ᖹᡂ㸯㸶ᖺᗘ㹼㸰㸰ᖺᗘ 㸰㸰㸳
㸦㸴㸧ᅜෆ࣭ᅜ㝿ඹྠ◊✲ࠊࣉࣟࢪ࢙ࢡࢺ࡬ࡢཧຍ
ᅜෆእࡢඹྠ◊✲ࡣᴟࡵ࡚άⓎ࡛࠶ࡿࠋ┦ᡭᶵ㛵࠾ࡼࡧ┦ᡭඛᅜࡶከᒱ࡟Ώࡗ࡚࠾ࡾࠊᖜᗈࡃࠊ
ࡲࡓ῝࠸ඹྠ◊✲ࡀᐇ᪋ࡉࢀ࡚࠸ࡿࠋ
㸦㸵㸧ᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲㈝⿵ຓ㔠࠾ࡼࡧእ㒊㈨㔠ࡢཷࡅධࢀ≧ἣ
ᮏ◊✲⛉࡟࠾ࡅࡿᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲㈝⿵ຓ㔠ࡢཷ㡿≧ἣࡣ㈨ᩱϪ㸫㸯ࡢ࡜࠾ࡾ࡛࠶ࡿࠋ㸰㸯
ୡ⣖㹁㹍㹃ࣉࣟࢢ࣒ࣛ࡟㛵ࢃࡿ◊✲ᣐⅬᙧᡂ㈝⿵ຓ㔠ࢆ㈨ᩱϪ̿㸱ࠊዡᏛᐤ௜㔠ࠊཷク◊✲ࠊඹ
ྠ◊✲࡟㛵ࢃࡿእ㒊㈨㔠ࡢཷࡅධࢀ≧ἣࢆ㈨ᩱϪ㸫㸯㸱ࠊࡲࡓᐤ௜ㅮᗙ࡟㛵ࢃࡿ㈨㔠ཷࡅධࢀ≧
ἣࢆ㈨ᩱϪ㸫㸯㸲࡟♧ࡋࡓࠋᮏࣜࢫࢺ࡟࠶ࡿࡶࡢ௨እ࡟ࠊ㸱༠ຊㅮᗙࡢ◊✲ศ㔝ࠊ࠾ࡼࡧ⏕࿨⛉
Ꮫ◊✲⛉࠾ࡼࡧ࢘࢖ࣝࢫ◊✲ᡤ࡟ᒓࡍࡿ㸱◊✲ศ㔝ࡣࡑࢀࡒࢀ࠿࡞ࡾࡢ㢠ࡢຓᡂ㔠ࢆཷ㡿ࡋ࡚࠸
ࡿࠋᮏ◊✲⛉ࡢࠊᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲㈝⿵ຓ㔠௨እࡢእ㒊㈨㔠ࡢཷࡅධࢀࡶᴟࡵ࡚άⓎ࡛ࠊ᪲┒
࡞◊✲≧ἣࢆⰋࡃ཯ᫎࡋ࡚࠸ࡿࠋ
− 71 −
㸦㸶㸧ෆእࡢᏛ⾡㈹ࡢᤵ㈹≧ἣ
◊✲ࣞ࣋ࣝࡢ㧗ࡉࢆ཯ᫎࡋ࡚ᮏ◊✲⛉ࡢᵓᡂဨࡢཷ㈹≧ἣࡣ༳㇟῝࠸࡯࡝άⓎ࡛࠶ࡿࠋ౛࠼ࡤࠊ
⸆Ꮫ◊✲࡛ࡢ᭱㧗ࡢ㈹࡛࠶ࡿ᪥ᮏ⸆Ꮫ఍㈹ࠊ࠶ࡿ࠸ࡣᅜ㝿Ꮫ఍ࡀไᐃࡍࡿᏛ⾡㈹ࠊࡲࡓⱝᡭࡢᣮ
ᡓ┠ᶆ࡛࠶ࡿ᪥ᮏ⸆Ꮫ఍ዡບ㈹ࢆࡣࡌࡵྛᏛ఍ࡢዡບ㈹ࢆᩘከࡃཷ㈹ࡋ࡚࠸ࡿࠋᩍဨࡤ࠿ࡾ࡛࡞
ࡃࠊ኱Ꮫ㝔⏕ࡸ≉ู◊✲ဨࡢ◊✲ࣞ࣋ࣝࡶ㧗ࡃࠊ᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ዡບ㈹࡞࡝ࢆᩘከࡃཷ㈹ࡋ
࡚࠸ࡿࠋ
ᖹᡂ㸰㸰ᖺᗘ㸦㸰㸮㸯㸮ᖺᗘ㸧
᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊 ዡບ㈹
᪥ᮏ⸆Ꮫ఍≀⌮໬Ꮫ㒊఍33) ⱝᡭ◊✲⪅ዡບ㈹
」⣲㑏໬Ꮫウㄽ఍ᐇ⾜ጤဨ఍ ࣏ࢫࢱ࣮㈹ ḟୡ௦ࢆᢸ࠺๰⸆࣭་⒪⸆⌮ࢩ࣏ࣥࢪ࣒࢘ ࣏ࢫࢱ࣮㈹
᪥ᮏ⸆⌮Ꮫ఍ ዡບ㈹
ࡑࡢ௚Ꮫ⾡㈹ 㸰
ᖹᡂ㸰㸯ᖺᗘ㸦㸰㸮㸮㸷ᖺᗘ㸧
᪥ᮏ⸆Ꮫ఍ ዡບ㈹ 㸱
᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊 ዡບ㈹㸰
᪥ᮏ໬Ꮫ఍ ≉ูㅮ₇㈹
᪥ᮏ㉁㔞ศᯒᏛ఍ ఍ㄅ㈹
᭷ᶵྜᡂ໬Ꮫ༠఍㛵すᨭ㒊 ⱝᡭࢭ࣑ࢼ࣮࣏ࢫࢱ࣮㈹
」⣲㑏໬Ꮫウㄽ఍ᐇ⾜ጤဨ఍ Ꮫ⏕ㅮ₇㈹
㉸ศᏊ໬Ꮫ◊✲఍ ࣏ࢫࢱ࣮㈹
᪥ᮏ࣌ࣉࢳࢻᏛ఍ ࣌ࣉࢳࢻウㄽ఍࣏ࢫࢱ࣮㈹
$$36)HOORZ
1XFOHLF$FLGV5HVHDUFK$6-3RVWHU$ZDUG
*,:ࠊ%HVW3DSHU$ZDUGࠊ1HOVRQ+D\HV
ࡑࡢ௚Ꮫ⾡㈹ 㸲
ᖹᡂ㸰㸮ᖺᗘ㸦㸰㸮㸮㸶ᖺᗘ㸧
᪥ᮏ⸆Ꮫ఍ Ꮫ⾡᣺⯆㈹
᪥ᮏ⸆Ꮫ఍≀⌮໬Ꮫ㒊఍ 33) ඃ⚽㈹
⮫ᗋ⸆⌮◊✲᣺⯆㈈ᅋ ➨㸯ᅇ◊✲኱㈹
ඛ➃་⒪ᢏ⾡◊✲ᡤ ➨㸯ᅇศᏊ࢖࣓࣮ࢪࣥࢢ㈹
᪥ᮏ᰾་Ꮫ఍ ◊✲ዡບ㈹᭱ඃ⚽Ⓨ⾲㈹
− 72 −
− 73 −
− 74 −
㸦㸯㸯㸧㸰㸯ୡ⣖ &2(ࠕࢤࣀ࣒⛉Ꮫࡢ▱ⓗ᝟ሗᇶ┙࣭◊✲ᣐⅬᙧᡂࠖ
㸦ᖹᡂ㸯㸳ᖺᗘ㹼
㸯㸷ᖺᗘ㸧
㸰㸮㸮㸱ᖺࡼࡾᩥ㒊⛉Ꮫ┬ࠕ◊✲ᣐⅬᙧᡂ㈝⿵ຓ㔠ࠖ࡟ࡼࡿ㸰㸯ୡ⣖ &2( ࣉࣟࢢ࣒࣭ࣛᏛ㝿ࠊ」ྜࠊ
᪂㡿ᇦศ㔝࡟᥇ᢥࡉࢀཧ⏬ࡋࡓࠋᣐⅬࡢࣉࣟࢢ࣒ࣛྡ⛠ࡣࠕࢤࣀ࣒⛉Ꮫࡢ▱ⓗ᝟ሗᇶ┙࣭◊✲ᣐⅬᙧ
ᡂ࡛ࠖ࠶ࡾࠊி㒔኱Ꮫ໬Ꮫ◊✲ᡤࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢭࣥࢱ࣮࡜⸆Ꮫ◊✲⛉ࡣ୍య࡜࡞ࡾ◊✲࣭
ᩍ⫱ᣐⅬᙧᡂࢆ⾜ࡗࡓࠋ⸆Ꮫ◊✲⛉࡟࠾࠸࡚ᮏࣉࣟࢢ࣒ࣛ࡟ࡼࡾ⸆Ꮫᩍ⫱࡟࠾࠸࡚ࡣึࡢ⏕≀᝟ሗᏛ
ࡢ⸆Ꮫᩍ⫱࡬ࡢᑟධࠊ࣒࢝ࣜ࢟ࣗࣛ⦅ᡂࢆ⾜࠸ࠊḟୡ௦๰⸆⛉Ꮫ࡟㔜せ࡞ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ
ࢆ๪ᑓᨷ⛉࡜ࡋ࡚ᙧᡂࡋࡓࠋ௨ୗࠊࡑࡢᴫせࠊ⤌⧊ࠊάື࡟ࡘ࠸࡚ࡲ࡜ࡵࡓࠋ
㸦ᣐⅬᙧᡂࡢᴫせ㸧
ࢤࣀ࣒⛉Ꮫࡣࠊࢤࣀ࣒ࡢ᝟ሗ࠿ࡽ⣽⬊࣭ಶయ࣭⏕ែ⣔࡛ࣞ࣋ࣝࡢ㧗ḟ⏕࿨⌧㇟ࡢ඲యീࢆ᫂ࡽ࠿࡟
ࡋ࡚࠸ࡃࠊ㸰㸯ୡ⣖ࡢ᪂ࡋ࠸⏕࿨⛉Ꮫ࡛ࡍࠋࡑࡢ୰᰾࡜࡞ࡿࡢࡀࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ࡛ࠊಶࠎ
ࡢ㒊ရ㸦㑇ఏᏊ࣭ศᏊ㸧ࡢ㞟ࡲࡾ࠿ࡽ⏕࿨ࡢ᝟ሗࢩࢫࢸ࣒ࢆ෌ᵓ⠏ࡍࡿᴫᛕ࡜᪉ἲㄽࡀ㛤Ⓨࡉࢀ࡚ࡁ
ࡲࡋࡓࠋࡇࢀ࠿ࡽࡢࢤࣀ࣒⛉Ꮫ࡟࠾࠸࡚ࡣࠊ࡜ࡃ࡟་⒪ࡸ⏘ᴗ࡬ࡢᛂ⏝ࢆ┠ᣦࡋࡓࢤࣀ࣒⛉Ꮫ࡟࠾࠸
࡚ࡣࠊಶయࡸ⏕ែ⣔ࢆ」㞧࡞᝟ሗࢩࢫࢸ࣒࡜ࡋ࡚࡜ࡽ࠼ࠊࢩࢫࢸ࣒࡜⎔ቃ࡜ࡢ┦஫స⏝ࡢほⅬ࠿ࡽࠊ
ࣄࢺࡢ೺ᗣࡸᆅ⌫⎔ቃࡢಖ඲ࢆ⪃࠼࡚࠸ࡃᚲせࡀ࠶ࡿࠋ
ᮏᣐⅬ࡛ࡣࡑࡢࡓࡵ࡟ࠊࢤࣀ࣒᝟ሗࡔࡅ࡛࡞ࡃࢣ࣑࢝ࣝ᝟ሗࡢ㔜せᛶࢆ⪃៖ࡋࠊᚑ᮶࠿ࡽࡢࢤࣀ࣒
᝟ሗࡢ⣔⤫ⓗゎᯒ㸦⸆⌮ࢤࣀ࣑ࢡࢫ㸧࡟ຍ࠼࡚ࠊࢣ࣑࢝ࣝ᝟ሗࡢ⣔⤫ⓗゎᯒ㸦ࢣࣔࢤࣀ࣑ࢡࢫ㸧ࠊ࠾ࡼ
ࡧࢤࣀ࣒᝟ሗ࡜ࢣ࣑࢝ࣝ᝟ሗࡢ㛵㐃ゎᯒ㸦⎔ቃࢤࣀ࣑ࢡࢫ㸧ࡢ᪉ἲㄽࢆ㛤ᣅࡋࠊࡇࢀࡽ㸱ࡘࡢඛ➃◊
✲㡿ᇦࢆᶓ᩿ⓗ࡟ࡘ࡞࠸ࡔ◊✲ᣐⅬసࡾࢆ⾜ࡗ࡚࠸ࡿࠋྠ᫬࡟ࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࡢ㧗ᗘᑓ
㛛ᩍ⫱࡜๪ᑓᨷᩍ⫱ࠊ.(**ࢆ୰ᚰ࡜ࡋࡓ▱㆑㞟⣙ᆺࢹ࣮ࢱ࣮࣋ࢫᵓ⠏࡟ࡼࡿᅜ㝿ⓗ࡞᝟ሗᇶ┙ᩚഛࢆ
⾜ࡗ࡚࠸ࡿࠋ
ᮏᣐⅬࡣࠊி㒔኱ᏛࡢᏱ἞࢟ࣕࣥࣃࢫ࡟࠶ࡿ໬Ꮫ◊✲ᡤࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢭࣥࢱ࣮࡜ࠊྜྷ
⏣࢟ࣕࣥࣃࢫ࡟࠶ࡿ⸆Ꮫ◊✲⛉ࠊ་Ꮫ㒊㝃ᒓ⑓㝔⸆๣㒊ࡀ㐃ᦠࡋࡓࣉࣟࢢ࣒࡛ࣛ࠶ࡿࠋ๰⸆ࢱ࣮ࢤࢵ
ࢺ࡜๰⸆࣮ࣜࢻࡢ᥈⣴࡟᪂ࡋ࠸᪉ἲㄽࢆᚲせ࡜ࡋ࡚࠸ࡿ๰⸆⛉Ꮫࡣࠊࢤࣀ࣒࡜ࢣ࣑ࢫࢺ࣮ࣜࢆ⼥ྜࡋ
ࡓࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࡀ᭱ࡶ᭷ຠ࡞ศ㔝࡛࠶ࡿࠋ୍᪉࡛ࡣࠊࡑࡢࡼ࠺࡞ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕
ࢡࢫࡣࠊ⏕࿨ࢩࢫࢸ࣒࡜ࢣ࣑࢝ࣝ⎔ቃ࡜ࡢ┦஫స⏝ࢆゎᯒࡍࡿ୍⯡ⓗ࡞᪉ἲㄽ࡛ࡶ࠶ࡿࠋᇶ┙࡜࡞ࡿ
๰⸆⛉Ꮫ࠿ࡽࡼࡾᏛ㝿ⓗ࡞᪉ྥ࡟Ⓨᒎࡍࡿࡇ࡜࡟ࡼࡗ࡚㺂ୡ⏺Ỉ‽ࡢ&2(࡜ࡋ࡚ࡢ㛗ᮇⓗ࡞⥔ᣢ࣭ᙉ໬
࡟ຍ࠼ࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ࡟࠾ࡅࡿᒙࡢཌ࠸ேᮦ㣴ᡂࡀྍ⬟࡟࡞ࡿ࡜⪃࠼࡚࠸ࡿࠋ
㸦㸯㸧Ꮫ⾡◊✲ࡢ᥎㐍㸸
‫ࡢ࣒ࣀࢤۑ‬᝟ሗ࠿ࡽ⏕࿨ࢩࢫࢸ࣒ࡢࡣࡓࡽࡁ࡜᭷⏝ᛶࢆぢ࠸ࡔࡍࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᢏ⾡ࡢᐇ
⏝໬
‫⏕ۑ‬࿨ࢩࢫࢸ࣒࡜⎔ቃ࡜ࡢ┦஫స⏝ࢆゎᯒࡍࡿ⏕࿨ࢩࢫࢸ࣒⛉Ꮫ◊✲ࡢ᥎㐍
㸦㸰㸧ⱝᡭேᮦࡢ⫱ᡂ㸸ி㒔኱Ꮫ࡟࠾ࡅࡿࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᩍ⫱◊✲ᣐⅬᙧᡂ͒㸦⸆Ꮫ◊✲⛉
་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷ 㸰㸮㸮㸵ᖺ㸲᭶タ⨨㸧
㸦㸱㸧᝟ሗᇶ┙ࡢᩚഛ㸸ࢤࣀ࣒࡜ࢣ࣑ࢫࢺ࣮ࣜࡢ⼥ྜ࡟ࡼࡿ᪂ࡓ࡞▱ⓗ᝟ሗᇶ┙ᙧᡂ
− 75 −
㸦⤌⧊㸧
ᣐⅬ࣮ࣜࢲ࣮
㔠ஂ ᐿ ໬Ꮫ◊✲ᡤࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢭࣥࢱ࣮࣭ࢭࣥࢱ࣮㛗࣭ᩍᤵ
஦ᴗ᥎㐍ᢸᙜ⪅
>⎔ቃࢤࣀ࣑ࢡࢫ@
㔠ஂ ᐿ ໬Ꮫ◊✲ᡤࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢭࣥࢱ࣮࣭ࢭࣥࢱ࣮㛗࣭ᩍᤵ
㜿ஂὠ㐩ஓ ໬Ꮫ◊✲ᡤࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢭࣥࢱ࣮࣭ᩍᤵ
㤿ぢሯ ᣅ ໬Ꮫ◊✲ᡤࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢭࣥࢱ࣮࣭ᩍᤵ
ຍ⸨ ༤❶ ⸆Ꮫ◊✲⛉๰⸆⛉Ꮫᑓᨷ࣭ᩍᤵ
ᱵ⏣ ┿㒓 ໬Ꮫ◊✲ᡤ」ྜᇶ┙໬Ꮫ◊✲⣔࣭ᩍᤵ
>ࢣࣔࢤࣀ࣑ࢡࢫ@
⸨஭ ಙᏕ ⸆Ꮫ◊✲⛉๰⸆⛉Ꮫᑓᨷ࣭ᩍᤵ
ᐩᒸ Ύ ⸆Ꮫ◊✲⛉๰⸆⛉Ꮫᑓᨷ࣭ᩍᤵ
➉ᮏ ెྖ ⸆Ꮫ◊✲⛉๰⸆⛉Ꮫᑓᨷ࣭ᩍᤵ
>⸆⌮ࢤࣀ࣑ࢡࢫ@
㎷ᮏ ㇦୕ ⸆Ꮫ◊✲⛉๰⸆⛉Ꮫᑓᨷ࣭ᩍᤵ
஝ ㈼୍ ་Ꮫ㒊㝃ᒓ⑓㝔⸆๣㒊࣭ᩍᤵ
㔠Ꮚ ࿘ྖ ⸆Ꮫ◊✲⛉⏕࿨⸆⛉Ꮫᑓᨷ࣭ᩍᤵ
஬ᩯ 㐍 ໬Ꮫ◊✲ᡤࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢭࣥࢱ࣮࣭෸ᩍᤵ
㸦ᩍ⫱࡬ࡢྲྀࡾ⤌ࡳ㸧
‫ࢫࢡ࢕ࢸ࣐࢛ࣇࣥ࢖࢜࢖ࣂۑ‬ᩍ⫱㸦㧗ᗘᑓ㛛ᩍ⫱࡜๪ᑓᨷᩍ⫱㹼㸧
ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫศ㔝࡛ᮇᚅࡉࢀࡿ◊✲ேᮦ࡟ࡣ኱ࡁࡃ㸰ࡘࡢࢱ࢖ࣉࡀ࠶ࡿࠋ㸯ࡘࡣ᪂ࡋ
࠸᝟ሗᢏ⾡ࡢ㛤Ⓨࡸ㧗ᗘ࡞᝟ሗゎᯒࢆ⾜࠺ࡇ࡜ࡢ࡛ࡁࡿேᮦࢆ㣴ᡂࡍࡿᑓ㛛ᐙᩍ⫱ࠊࡶ࠺㸯ࡘࡣᐇ㦂
⣔ࡢ⏕࿨⛉Ꮫ◊✲⪅࡟᝟ሗ⛉Ꮫࡢࢭࣥࢫࢆ୚࠼ࡿ㠀ᑓ㛛ᐙᩍ⫱࡛࠶ࡿࠋ▷ᮇⓗ࡟ࡣࠊ࠶ࡿ࠸ࡣ༶ᡓຊ
࡜ࡋ࡚ࡣࠊᚋ⪅ࡢࢱ࢖ࣉࡢࢺ࣮ࣞࢽࣥࢢ࡟♫఍ⓗࢽ࣮ࢬࡀ㧗࠸ࡼ࠺࡟ᛮࢃࢀࡿࡀࠊእᅜ〇ࡢࢶ࣮ࣝࡸ
ࢹ࣮ࢱ࣮࣋ࢫࢆ࠺ࡲࡃ౑࠸ࡇ࡞ࡍேᮦࡀ࠸ࡃࡽ⫱ࡗࡓ࡜ࡋ࡚ࡶࠊᖖ࡟እᅜࡢᚋ㏣࠸ࡢ≧ἣ࠿ࡽ㏨ࢀࡿ
ࡇ࡜ࡣ࡛ࡁ࡞࠸ࠋ㛗ᮇⓗ࡞ࠊ࠶ࡿ࠸ࡣᅜ㝿➇தຊࡢほⅬ࠿ࡽࡣࠊ๓⪅ࡢࢱ࢖ࣉࡢᩍ⫱ࡀ୙ྍḞ࡛࠶ࡾࠊ
ᚋ⪅࡟࠾࠸࡚ࡶ⏕࿨ࢩࢫࢸ࣒ࡢᴫᛕ࡟ᑐࡍࡿ⌮ゎࢆ῝ࡵࡿᚲせࡀ࠶ࡿࠋࡇࢀࡣᮏᣐⅬࡢᇶᮏⓗ࡞⪃࠼
᪉ࠊࡍ࡞ࢃࡕࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ࡜ࡣࠊ༢࡟⏕࿨⛉Ꮫࡢ኱㔞ࢹ࣮ࢱ࡜᝟ሗ⛉Ꮫࡢᐇ⏝ⓗࢶ࣮ࣝ
࡜ࡢ⼥ྜ࡛ࡣ࡞ࡃࠊ⏕࿨ࢆ」㞧࡞᝟ሗࢩࢫࢸ࣒࡜ࡋ࡚⌮ゎࡍࡿᏛၥศ㔝ࡢ⼥ྜ࡛࠶ࡿ࡜ࡢ⪃࠼᪉࡟ἢ
࠺ࡶࡢ࡛࠶ࡿࠋ
− 76 −
㧗ᗘ࡞ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᑓ㛛ᩍ⫱ࡢᅜ㝿໬㸦ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢭࣥࢱ࣮㸧
໬Ꮫ◊✲ᡤࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢭࣥࢱ࣮ࡣᮾி኱Ꮫ་⛉Ꮫ◊✲ᡤࣄࢺࢤࣀ࣒ゎᯒࢭࣥࢱ࣮࡜
ඹྠ࡛ࠊ⛉Ꮫᢏ⾡᣺⯆ㄪᩚ㈝ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫேᮦ㣴ᡂࣉࣟࢢ࣒ࣛࠕࢤࣀ࣒᝟ሗ⛉Ꮫ◊✲ᩍ
⫱ᶵᵓࠖࢆᐇ᪋ࡋ࡚࠸ࡿࠋ࡜ࡃ࡟᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍ࡀ⟇ᐃࡋࡓᩍ⫱࣒࢝ࣜ࢟ࣗࣛ࡟
ᇶࡃ኱Ꮫ㝔ㅮ⩏ࢆࠊி㒔࣭ᮾி㛫ࡢࢸࣞࣅ఍㆟ࢩࢫࢸ࣒ࢆ⏝࠸࡚⾜ࡗ࡚࠸ࡿࠋᮏᣐⅬᙧᡂࣉࣟࢢ࣒ࣛ
࡛ࡣࡇࡢேᮦ㣴ᡂࣉࣟࢢ࣒ࣛ࡜㐃ᦠࡋࠊࡲࡓ⡿ᅜ࣎ࢫࢺࣥ኱Ꮫ࠾ࡼࡧࢻ࢖ࢶࡢࣇࣥ࣎ࣝࢺ኱Ꮫ࡜㐃ᦠ
ࡋ࡚ࠊᅜ㝿ⓗ࡞ά㌍ࢆᮇᚅ࡛ࡁࡿ㧗ᗘ࡞ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᑓ㛛ᐙࡢ⫱ᡂࢆ⾜ࡗ࡚࠸ࡿࠋ
ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ๪ᑓᨷᩍ⫱㸦⸆Ꮫ◊✲⛉㸧
ࢤࣀ࣒◊✲ࡸ࣏ࢫࢺࢤࣀ࣒◊✲ࠊࡲࡓ㏆ᖺࡢࢣ࣑࢝ࣝࢤࣀ࣒◊✲ࡀ๰⸆⛉Ꮫ࡟୚࠼ࡓ࢖ࣥࣃࢡࢺࡣ
㠀ᖖ࡟኱ࡁ࠸ࠋṔྐⓗ࡟ᵝࠎ࡞ศ㔝ࢆ⼥ྜࡋ࡚ࡁࡓ⥲ྜ⛉Ꮫ࡜ࡋ࡚ࡢ⸆Ꮫ࡟࠾࠸࡚ࠊ᝟ሗ⛉Ꮫࢆྲྀࡾ
ධࢀࡓ⸆Ꮫᩍ⫱ࢆ⾜࠸ࠊୡ⣖ࡢ᪂ࡓ࡞ᒎ㛤ࢆࡣ࠿ࡿᚲせࡀ࠶ࡿࡇ࡜ࡣ⮬᫂ࡢࡇ࡜࡛࠶ࢁ࠺ࠋᮏᣐⅬ
ᙧᡂࣉࣟࢢ࣒ࣛ࡟ࡼࡿ⸆Ꮫᩍ⫱ࡢᨵ㠉ࡢ㸯ࡘࡣࠊ⸆Ꮫ◊✲⛉༤ኈㄢ⛬࡟ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ๪
ᑓᨷࢥ࣮ࢫࢆタ⨨ࡋࡓࡇ࡜࡛࠶ࡿࠋୖグேᮦ㣴ᡂࣉࣟࢢ࣒ࣛࡢㅮ⩏ࡣࢸࣞࣅ఍㆟ࢩࢫࢸ࣒࡛⸆Ꮫ◊✲
⛉࡬ࡶ㓄ಙࡉࢀ࡚࠾ࡾࠊࡑࡢ୍㒊ࢆཷㅮࡍࡿࡇ࡜࡛༢఩ㄆᐃࢆ⾜ࡗ࡚࠸ࡿࠋ
ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᇶ♏ᩍ⫱㸦⸆Ꮫ㒊㸧
⸆Ꮫᩍ⫱ࡢᨵ㠉ࡢࡶ࠺㸯ࡘࡣᏛ㒊ᩍ⫱࣒࡛࢝ࣜ࢟ࣗࣛ࠶ࡿࠋ
ࠕᇶ♏ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࠖ࡜ࠕᛂ
⏝ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࠖࡢ㸰⛉┠ࢆ᪂タࡋࠊ᪤Ꮡ⛉┠ࡢࠕᇶ♏᝟ሗฎ⌮ࠖ
ࠊ
ࠕᇶ♏᝟ሗฎ⌮₇⩦ࠖࠊ
ࠕࣂ࢖࢜ࢧ࢖࢚ࣥࢫ⤫ィᇶ♏ࠖࡸᏛ⏕ᐇ⩦ࡢぢ┤ࡋࢆ⾜࠸ࠊ㸰ᅇ⏕࠿ࡽ㸲ᅇ⏕ࡲ࡛ᇶ♏ⓗ࡞ࣂ࢖࢜࢖
ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢆẁ㝵ⓗ࡟㌟࡟ࡘࡅࡿࡇ࡜ࡀ࡛ࡁࡿࡼ࠺࡟ࡋࡓࠋࡇࢀࡣ⸆Ꮫ㒊࡜ࡋ࡚ࡣࢃࡀᅜ࡛ࡣ
ࡣࡌࡵ࡚ࡢヨࡳ࡛࠶ࡿࠋ
㸦ࡑࡢ௚ࡢάື㸧
ከᩘࡢ㞟఍ࠊ◊✲఍ࢆ㛤ദࡋᣐⅬ࡜ࡋ࡚ࡢ◊✲஺ὶࢆᅗࡿ࡜ඹ࡟♫఍ⓗၨⵚࢆ⾜ࡗ࡚࠸ࡿࠋ
ୡ⣖&2(ⱝᡭ◊✲⪅◊✲ウㄽ఍͒
ᖹᡂᖺ᭶᪥ᮌ ி㒔኱Ꮫ⸆Ꮫ㒊ᵓෆ
බ㛤ࢩ࣏ࣥࢪ࣒࢘ࠕࢤࣀ࣒᝟ሗ⛉Ꮫࡢ⮫ᗋ࣭๰⸆࡬ࡢᒎ㛤ࠖ͒
ᖹᡂᖺ᭶᪥Ỉ ி㒔኱Ꮫ⸆Ꮫ㒊グᛕㅮᇽ>࣏ࢫࢱ࣮@
➨ᅇࠕ⸆Ꮫࡢᮍ᮶ࢆ⪃࠼ࡿி㒔ࢩ࣏ࣥࢪ࣒࢘๰࡜⒪ࡢఏ⤫࡜㠉᪂ࠖඹദ͒
ᖹᡂᖺ᭶Ỉ ி㒔኱Ꮫ⸆Ꮫ㒊グᛕㅮᇽ>࣏ࢫࢱ࣮@
᭱⤊ᖺᗘබ㛤ࢩ࣏ࣥࢪ࣒࢘6\PSRVLXPRQ%LRLQIRUPDWLFVDQG&KHPLFDO*HQRPLFV͒
ᖹᡂᖺ᭶᪥ᮌ㹼᪥㔠 ࡥࡿࡿࣉࣛࢨி㒔>࣏ࢫࢱ࣮@
WK,QWHUQDWLRQDO:RUNVKRSRQ%LRLQIRUPDWLFVDQG6\VWHPV%LRORJ\͒
ᖹᡂᖺ᭶᪥ⅆ㹼᭶᪥ᮌ ᮾி኱Ꮫ་⛉Ꮫ◊✲ᡤ͒
− 77 −
ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷタ⨨グᛕ⾜஦͒
ᖹᡂᖺ᭶㔠 ி㒔኱Ꮫ⸆Ꮫ㒊グᛕㅮᇽ
➨ᅇࠕ᪥ᮏࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲఍ࠖᖺ఍㸦ඹദ㸧͒
ᖹᡂᖺ᭶Ỉ㹼᪥ᮌ ி㒔኱Ꮫⓒ࿘ᖺ᫬ィྎグᛕ㤋ⓒ࿘ᖺグᛕ࣮࣍ࣝ
බ㛤ᅜ㝿ࢩ࣏ࣥࢪ࣒࢘͒
ᖹᡂᖺ᭶᪥㹼᪥᭶ ி㒔኱Ꮫ་Ꮫ㒊Ⱚ⹒఍㤋>࣏ࢫࢱ࣮@
➨ᅇࠕࢣࣔࢤࣀ࣑ࢡࢫ◊✲఍ࠖ͒
ᖹᡂᖺ᭶᪥᭶ ி㒔኱Ꮫ⸆Ꮫ㒊グᛕㅮᇽ>࣏ࢫࢱ࣮@
WK,QWHUQDWLRQDO:RUNVKRSRQ%LRLQIRUPDWLFVDQG6\VWHPV%LRORJ\͒
ᖹᡂᖺ᭶᪥᭶㹼᪥Ỉ ࣎ࢫࢺࣥ኱Ꮫ͒
➨ᅇࠕࢣࣔࢤࣀ࣑ࢡࢫ◊✲఍ࠖ͒
ᖹᡂᖺ᭶᪥ᅵ ி㒔኱Ꮫ⸆Ꮫ㒊グᛕㅮᇽ>࣏ࢫࢱ࣮@
➨ᅇࠕୡ⣖&2(ⱝᡭ◊✲⪅◊✲ウㄽ఍ࠖ͒
ᖹᡂᖺ᭶᪥Ỉ ி㒔኱Ꮫ⸆Ꮫ㒊グᛕㅮᇽ>࣏ࢫࢱ࣮@
ᖹᡂᖺᗘ&2(◊✲ဨⓎ⾲఍͒
ᖹᡂᖺ᭶᪥Ỉ ி㒔኱Ꮫ⸆Ꮫ㒊ㅮ⩏ᐊ
➨ᅇࠕࢣࣔࢤࣀ࣑ࢡࢫ◊✲఍ࠖ͒
ᖹᡂᖺ᭶᪥ᮌ ி㒔኱Ꮫ⸆Ꮫ㒊グᛕㅮᇽ>࣏ࢫࢱ࣮@
.(**$QQLYHUVDU\6\PSRVLXP)URP*HQRPLFVWR&KHPLFDO*HQRPLFV͒
ᖹᡂᖺ᭶᪥ᮌ㹼᪥㔠 ࡥࡿࡿࣉࣛࢨி㒔>࣏ࢫࢱ࣮@
WK,QWHUQDWLRQDO:RUNVKRSRQ%LRLQIRUPDWLFVDQG6\VWHPV%LRORJ\͒
ᖹᡂᖺ᭶᪥᭶㹼᪥ᮌ ࣇࣥ࣎ࣝࢺ኱Ꮫ࣋ࣝࣜࣥ>࣏ࢫࢱ࣮@
➨ᅇࠕࢣࣔࢤࣀ࣑ࢡࢫ◊✲఍ࠖ͒
ᖹᡂᖺ᭶᪥Ỉ ி㒔኱Ꮫ⸆Ꮫ㒊グᛕㅮᇽ>࣏ࢫࢱ࣮@
− 78 −
− 79 −
− 80 −
− 81 −
− 82 −
Ϫ㸫㸯 ᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲㈝⿵ຓ㔠
㸦ᖺ ᗘ㸧
ᖹᡂ ᖺᗘ
㸦༢఩㸸༓෇㸧
ᖹᡂ ᖺᗘ
᥇
᥇
ᖹᡂ ᖺᗘ
᥇
ᖹᡂ ᖺᗘ
᥇
ᖹᡂ ᖺᗘ
᥇
௳ᩘ࣭㔠㢠
ᢥ
ᢥ
㔠㢠
ᢥ
㔠㢠
ᢥ
㔠㢠
ᢥ
㔠㢠
㔠㢠
௳
௳
௳
௳
௳
ᩘ
ᩘ
ᩘ
ᩘ
ᩘ
◊✲㢟┠
⛉
Ꮫ
≉ᐃ㡿ᇦ◊✲
≉ู᥎㐍◊✲
᪂Ꮫ⾡㡿ᇦ◊✲
ᇶ┙◊✲㸦6㸧
ᇶ┙◊✲㸦$㸧
ᇶ┙◊✲㸦%㸧
ᇶ┙◊✲㸦&㸧
◊
✲
㈝
ⴌ ⱆ ◊ ✲
⿵
㸦ᣮᡓⓗⴌⱆ
ຓ
◊✲㸧
㔠
ⱝᡭ◊✲㸦$㸧
ⱝᡭ◊✲㸦%㸧
ⱝᡭ◊✲㸦ࢫࢱ࣮ࢺ
࢔ࢵࣉ㸧
ࢹ࣮ࢱ࣮࣋ࢫ
㸦◊✲ᡂᯝࢹ࣮ࢱ
࣮࣋ࢫ㸧
Ꮫ⾡๰ᡂ◊✲㈝
≉ู◊✲ဨዡບ㈝
ィ
− 83 −
Ϫ㸫㸰 ཌ⏕ປാ⛉Ꮫ◊✲㈝⿵ຓ㔠
༢఩㸸༓෇
༊ศ
௳ᩘ
ᖺᗘ 㔠㢠
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ィ
Ϫ㸫㸱 㸰㸯ୡ⣖㹁㹍㹃ࣉࣟࢢ࣒ࣛ
ᖺᗘ
ᖹᡂ ᖺᗘ ᖹᡂ ᖺᗘ
㸰㸯ୡ⣖㹁㹍㹃
ࣉࣟࢢ࣒ࣛ
ᖹᡂ ᖺᗘ
༢఩㸸༓෇
ᖹᡂ ᖺᗘ ᖹᡂ ᖺᗘ
Ϫ㸫㸲 ◊✲ᣐⅬᙧᡂ㈝➼⿵ຓ㔠
ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
༢఩㸸༓෇
ᖹᡂ ᖺᗘ ᖹᡂ ᖺᗘ
㨩ຊ࠶ࡿ኱Ꮫ㝔ᩍ⫱
㸦࢖ࢽࢩ࢔ࢸ࢕ࣈ㸧
ᐇ㊶ⓗ๰⸆ᡓ␎ᐙ
㣴ᡂࣉࣟࢢ࣒ࣛ
㸦་⒪⣔㸧
ࣘࣅ࢟ࢱࢫ೺ᗣ♫఍
ࡢ᭱᪂ࢽ࣮ࢬ࡟ᑐᛂ
ࡋࡓᐇ㊶ᆺேᮦ⫱ᡂ
− 84 −
Ϫ㸫㸳 ኱Ꮫᨵ㠉᥎㐍➼⿵ຓ㔠
ᖺᗘ
ᖹᡂ ᖺᗘ ᖹᡂ ᖺᗘ
༢఩㸸༓෇
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ඛ➃་⒪ࡢ⫱࣭๰
⸆ࢆඛᑟࡍࡿ
⸆๣ᖌ⫱ᡂ
Ϫ㸫㸴 ⏘ᴗᢏ⾡◊✲ຓᡂ஦ᴗ㈝ຓᡂ㔠㸦㹌㹃㹂㹍ຓᡂ㔠㸧
༢఩㸸༓෇ ༊ศ
ᖺᗘ ௳ᩘ
㔠㢠
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ィ
Ϫ㸫㸵 ⛉Ꮫᢏ⾡⥲ྜ᥎㐍㈝⿵ຓ㔠㸦ඛ➃ᢏ⾡ࢢ࣮ࣟࣂ࣮ࣝࣜࢲ࣮㣴ᡂࣉࣟࢢ࣒ࣛ㸧
ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
༢఩㸸༓෇
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᗘ
ᗘ
ඛ➃ᢏ⾡ࢢ࣮ࣟࣂࣝ
࣮ࣜࢲ࣮
㣴ᡂࣉࣟࢢ࣒ࣛ
Ϫ㸫㸶 ᅜ㝿໬ᣐⅬᩚഛ஦ᴗ㈝⿵ຓ㔠㸦㹅㸱㸮㸧
ᖺᗘ
ி㒔኱Ꮫᅜ㝿໬
ᣐⅬᩚഛ஦ᴗ
༢఩㸸༓෇
ᖹᡂ ᖺᗘ ᖹᡂ ᖺᗘ ᖹᡂ ᖺᗘ
− 85 −
ᖹᡂ ᖺᗘ ᖹᡂ ᖺᗘ
Ϫ㸫㸷 ⛉Ꮫᢏ⾡᣺⯆ㄪᩚ㈝
ᖺᗘ
㸦༢఩㸸༓෇㸧
ㄢ㢟ྡ
ศ㔝
ᚤᑠࢱࣥࣃࢡ㉁⤖ᬗ ; ⥺ᅇᯒ⿦⨨
ᖹᡂ ᖺ
ࡢ㛤Ⓨ
ᵓ㐀⏕≀⸆Ꮫศ㔝
᪂つཷᐜయ≉␗ⓗ⸆≀ࡢ㛤Ⓨ࡜⮫
ᗋᛂ⏝
ࢤࣀ࣒๰⸆⛉Ꮫศ㔝
ィ
Ϫ㸫㸯㸮 ໬Ꮫ⣔◊✲タഛ᭷ຠά⏝ࢿࢵࢺ࣮࣡ࢡᵓ⠏ඹྠ஦ᴗ
༢఩㸸༓෇ ༊ศ
ᖺᗘ ௳ᩘ
㔠㢠
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ィ
༢఩㸸༓෇ Ϫ㸫㸯㸯 ஧ᅜ㛫஺ὶ஦ᴗ
༊ศ
ᖺᗘ ௳ᩘ
㔠㢠
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ィ
− 86 −
㔠㢠
Ϫ㸫㸯㸰 ཷク◊✲ဨ◊✲ᩱ
༢఩㸸༓෇
༊ศ
ᖺᗘ ௳ᩘ
㔠㢠
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ᖹᡂ ᖺ
ィ
Ϫ㸫㸯㸱 እ㒊㈨㔠ࡢཷධࢀ≧ἣ
༊ศ
ᐤ㝃㔠
㸦༢఩㸸෇㸧
ཷク◊✲
ඹྠ◊✲
ᑠィ
௳
ᖺᗘ ᩘ
ᖹᡂ
ᖺ
ᖹᡂ
ᖺ
ᖹᡂ
ᖺ
ᖹᡂ
ᖺ
ᖹᡂ
ᖺ
ィ
㔠㢠
௳
ᩘ
㔠㢠
௳ᩘ
㔠㢠
௳
ᩘ
㔠㢠
− 87 −
Ϫ㸫㸯㸲 ᐤ㝃ㅮᗙ
๰⸆⚄⤒⛉Ꮫㅮᗙ 㸦ᖹᡂ ᖺ ᭶㹼ᖹᡂ ᖺ ᭶㸧
་⸆ရ⌮ㄽタィᏛㅮᗙ 㸦ᖹᡂ ᖺ ᭶㹼ᖹᡂ ᖺ ᭶㸧
ࢼࣀࣂ࢖࢜་⸆๰ᡂ⛉Ꮫㅮᗙ
㸦ᖹᡂ ᖺ ᭶㹼ᖹᡂ ᖺ ᭶㸧
ࢩࢫࢸ࣒๰⸆⛉Ꮫㅮᗙ
㸦ᖹᡂ ᖺ ᭶㹼ᖹᡂ ᖺ ᭶㸧
㸦༢఩㸸෇㸧
− 88 −
Ϫ㸫㸯㸳♫఍ⓗάື
࣭㈈ᅋἲே኱Ꮫᇶ‽༠఍ᑓ㛛ጤဨ㸦ᖹᡂ Ѹ⌧ᅾ㸧
࠙⸆ရ᭷ᶵ〇㐀Ꮫศ㔝࣭ࢣࣔࢤࣀ࣑ࢡࢫศ㔝ࠚ
࣭⊂❧⾜ᨻἲே་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓᑓ㛛ጤ
ဨ㸦ᖹᡂ ̽⌧ᅾ㸧
⸨஭ಙᏕᩍᤵ
࣭㈈ᅋἲே᪥ᮏ⸆๣ᖌ◊ಟࢭࣥࢱ࣮ㄆᐃᐇົᐇ
࣭᪥ᮏᏛ⾡఍㆟㐃ᦠ఍ဨ㸦ᖹᡂ㸯㸶ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍๰⸆⛉Ꮫ㈹㑅⪃ጤဨ㸦ᖹᡂ㸯㸶ᖺ㸧
⩦ᣦᑟ⸆๣ᖌ㣴ᡂ࣮࣡ࢡࢩࣙࢵࣉᑠጤဨ఍ጤဨ
࣭᪥ᮏ⸆Ꮫ఍ᵓ㐀άᛶ┦㛵㒊఍➨ ᅇᵓ㐀άᛶ
㸦ᖹᡂ ᖹᡂ ᖺ㸧
┦㛵ࢩ࣏ࣥࢪ࣒࢘ᐇ⾜ጤဨ㛗㸦ᖹᡂ㸯㸷ᖺ㸧
࣭➨ ᅇ᪥ᮏࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲఍ᖺ఍
࣭᪥ᮏ໬Ꮫ఍௦㆟ဨ㸦ᖹᡂ Ѹ⌧ᅾ㸧
࣭᪥ᮏ⸆Ꮫ఍ᩍ⫱㒊఍ᖖ௵ᖿ஦㸦ᖹᡂ Ѹ⌧ᅾ㸧
࣭᪥ᮏࣉࣟࢭࢫ໬Ꮫ఍๪఍㛗㸦ᖹᡂ Ѹᖹᡂ ᖺ఍㛗㸦ᖹᡂ㸯㸷ᖺ㸧
ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍๰⸆ࢭ࣑ࢼ࣮ጤဨ఍ጤဨ㸦ᖹᡂ㸯㸷
࣭᪥ᮏࣉࣟࢭࢫ໬Ꮫ఍఍㛗㸦ᖹᡂ ᖺѸ⌧ᅾ㸧
ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍ᅜ㝿஺ὶጤဨ఍ጤဨ㸦ᖹᡂ㸯㸷ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍໬Ꮫ⣔⸆Ꮫ㒊఍㒊఍㛗㸦ᖹᡂ Ѹ
ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍་⸆໬Ꮫ㒊఍㒊఍㛗㸦ᖹᡂ㸰㸯ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍๰⸆⛉Ꮫ㈹ᖿ஦㸦ᖹᡂ㸰㸯ᖺ㸧
࣭ᅜ㝿」⣲⎔໬Ꮫ఍⌮஦
㸦ᖹᡂ ᖺѸᖹᡂ ᖺ㸧
࣭㈈ᅋἲே࢔ࢫࢸࣛࢫ⑓ែ௦ㅰ◊✲఍⌮஦㸦ᖹᡂ
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊㛗㸦ᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍⌮஦㸦ᖹᡂ ᖺ㸧
㸰㸯ᖺ㸧
኱㔝ᾈ❶෸ᩍᤵ
࣭᪥௖་⸆⢭ᐦ໬Ꮫ఍㆟㛗㸦ᖹᡂ ᖺ㸧
࣭ḟୡ௦ࢆᢸ࠺᭷ᶵ໬Ꮫࢩ࣏ࣥࢪ࣒࢘ୡヰே㸦ᖹ
࣭7HWUDKHGURQDQG7HWUDKHGURQ/HWWHUV ⦅㞟㢳
ၥ㸦ᖹᡂ Ѹ⌧ᅾ㸧
ᡂ㸯㸴ᖺ㹼⌧ᅾ㸧
࣭᭷ᶵྜᡂ໬Ꮫ༠఍㛵すᨭ㒊ᖿ஦㸦ᖹᡂ㸯㸷ᖺ㹼
࣭7KH,QWHUQDWLRQDO6RFLHW\RI+HWHURF\FOLF
&KHPLVWU\ 㐠Ⴀ㢳ၥ㸦ᖹᡂ Ѹ⌧ᅾ㸧
⌧ᅾ㸧
࣭➨㸶ᅇḟୡ௦ࢆᢸ࠺᭷ᶵ໬Ꮫࢩ࣏ࣥࢪ࣒࢘ᐇ
࣭/HWWHUVLQ2UJDQLF&KHPLVWU\ ⦅㞟ጤဨ㸦ᖹ
⾜ጤဨ㛗㸦ᖹᡂ㸰㸰ᖺ㸧
ᡂ ᖺѸᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍໬Ꮫ⣔⸆Ꮫ㒊఍ᙺဨ㸦ᖹᡂ㸰㸰ᖺ㸧
࣭7HWUDKHGURQ ⦅㞟ጤဨ㸦ᖹᡂ ᖺѸ⌧ᅾ㸧
࣭$&60HGLFLQDO&KHPLVWU\/HWWHUV ⦅㞟ጤဨ㸦ᖹ
࠙⸆ရྜᡂ໬Ꮫศ㔝ࠚ
ᡂ ᖺѸ⌧ᅾ㸧
ᐩᒸΎᩍᤵ
㣤⏣ᙲ෸ᩍᤵ
࣭᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ➼ᑂᰝ఍ᑓ㛛ጤဨ
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ጤဨ
㸦ᖹᡂ Ѹ ᖺ㸧
࣭ኳ↛᭷ᶵ໬ྜ≀ㄯヰ఍ୡヰே
࣭㈈ᅋἲேࢧࣥࢺ࣮ࣜ⏕≀᭷ᶵ⛉Ꮫ◊✲ᡤホ㆟
ဨ㸦ᖹᡂ Ѹ⌧ᅾ㸧
ᒣ⏣೺୍෸ᩍᤵ
࣭ኳ↛᭷ᶵ໬ྜ≀ㄯヰ఍ୡヰே
࣭㈈ᅋἲேࣀࣂࣝࢸ࢕ࢫ⛉Ꮫ᣺⯆㈈ᅋ㑅⪃ጤဨ
࣭᪥ᮏ⸆Ꮫ఍ḟୡ௦ࢆᢸ࠺᭷ᶵ໬Ꮫࢩ࣏ࣥࢪ࢘
㸦ᖹᡂ Ѹᖹᡂ ᖺ㸧
࣒ୡヰே
࣭㈈ᅋἲே⛉Ꮫᢏ⾡ᩍ⫱༠఍㢳ၥ㸦ᖹᡂ Ѹ⌧ᅾ㸧
࣭᭷㝈㈐௵୰㛫ἲே⸆Ꮫᩍ⫱༠㆟఍⌮஦㸦ᖹᡂ
࠙⸆ရศᏊ໬Ꮫࠚ
ᖺѸᖹᡂ ᖺ㸧
➉ᮏెྖᩍᤵ
− 89 −
ࠥ⌧ᅾ㸧
࣭᭷ᶵྜᡂ໬Ꮫ༠఍㛵すᨭ㒊ᖿ஦㸦ᖹᡂ ࠥ
ᖺ㸧
࣭㏆␥໬Ꮫ༠఍஦ᴗ௻⏬ጤဨ఍ጤဨ㸦ᖹᡂ ࠥ
࠙⸆ရ㈨※Ꮫศ㔝ࠚ
ఀ⸨⨾༓✑෸ᩍᤵ
ᖺ㸧
࣭᭷ᶵྜᡂ໬Ꮫ༠఍⦅㞟༠ຊጤဨ㸦ᖹᡂ ࠥ
࣭᪥ᮏ⏕⸆Ꮫ఍ホ㆟ဨ㸦ᖹᡂ 㹼 ᖺ㸧
࣭᪥ᮏ⏕⸆Ꮫ఍㛵すᨭ㒊ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
ᖺ㸧
࣭᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ➼ᑂᰝ఍ᑓ㛛ጤဨ
࣭᪥ᮏ⏕⸆Ꮫ఍ -RXUQDORI1DWXUDO0HGLFLQHV
⦅㞟ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
㸦ᖹᡂ ࠥ ᖺ㸧
࣭኱Ꮫタ⨨࣭Ꮫᰯἲேᑂ㆟఍኱Ꮫタ⨨ศ⛉఍ᑓ㛛
࣭᪥ᮏ⸆Ꮫ఍ࣇ࢓࣐ࣝࢩ࢔ࢺࣆࢵࢡࢫᑓ㛛ᑠጤ
ဨ㸦ᖹᡂ 㹼 ᖺ㸧
ጤဨ㸦ᖹᡂ ࠥ ᖺ㸧
࣭᭷ᶵྜᡂ໬Ꮫ༠఍㛵すᨭ㒊๪ᨭ㒊㛗㸦ᖹᡂ ࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏᏛ⾡᣺⯆఍⛉Ꮫ◊✲㈝ጤဨ఍ᑓ㛛ጤဨ㸦ᖹ
ࠥ ᖺ㸧
ᡂ 㹼 ᖺ㸧
࣭➨㸰ᅇ᭷ᶵゐ፹ࢩ࣏ࣥࢪ࣒࢘ᐇ⾜ጤဨ㛗㸦ᖹᡂ
࣭ཌ⏕ປാ┬་⸆ရࡢᡂศᮏ㉁࡟㛵ࡍࡿ࣮࣡࢟
ᖺ㸧
ࣥࢢࢢ࣮ࣝࣉጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏᏛ⾡᣺⯆఍⛉Ꮫ◊✲㈝ጤဨ఍ᑓ㛛ጤဨ㸦ᖹ
࣭⊂❧⾜ᨻἲே་⸆ᇶ┙◊✲ᡤᐇ⏝໬◊✲ホ౯
ᡂ ࠥ ᖺ㸧
ጤဨ఍ᑓ㛛ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ໬Ꮫ఍ &KHPLVWU\/HWWHUV ⦅㞟ጤဨ㸦ᖹᡂ
࣭⊂❧⾜ᨻἲே་⸆ᇶ┙◊✲ᡤᇶ♏ⓗ◊✲ホ౯
ࠥ⌧ᅾ㸧
ጤဨ఍ᑓ㛛ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ⸆Ꮫ఍Ḣᩥㄅ &KHP3KDU%XOO⦅㞟ጤဨ
࣭⏕⸆ศᯒࢩ࣏ࣥࢪ࣒࢘ᖿ஦㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
㸦ᖹᡂ ࠥ⌧ᅾ㸧
࣭⸆⏝᳜≀᱂ᇵ◊✲఍ ⸆⏝᳜≀◊✲ ⦅㞟ጤ
࣭᪥ᮏ໬Ꮫ఍௦㆟ဨ㸦ᖹᡂ ࠥ⌧ᅾ㸧
ဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
㧗㡲Ύㄔ෸ᩍᤵ
࣭⸆Ꮫඹ⏝ヨ㦂 &%7 ၥ㢟⢭㑅ጤဨ㸦ᖹᡂ ࣭,QWHUQDWLRQDO 3KDUPDFHXWLFDO )HGHUDWLRQ
%RDUGRI3KDUPDFHXWLFDO6FLHQFHV&RFKDLURI
ᖺ㸧
࣭ḟୡ௦ࢆᢸ࠺᭷ᶵ໬Ꮫࢩ࣏ࣥࢪ࣒࢘ ୡヰே
WKH 6SHFLDO ,QWHUHVW *URXS RQ 1DWXUDO
㸦ᖹᡂ ᖺ㸧
3URGXFWV㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧㸧
࣭᪥ᮏ⸆Ꮫ఍໬Ꮫ⣔⸆Ꮫ㒊఍ᙺဨ㸦ᖹᡂ ᖺ㸧
࣭᪥ᮏᏛ⾡᣺⯆఍⛉Ꮫ◊✲㈝ᑂᰝ఍ ᑓ㛛ጤဨ
㸦ᖹᡂ ᖺ㸧
࠙⸆ရᶵ⬟ゎᯒᏛศ㔝ࠚ
ᯇᓮ຾ᕭᩍᤵ
࣭➨㸳ᅇḟୡ௦ࢆᢸ࠺᭷ᶵ໬Ꮫࢩ࣏ࣥࢪ࣒࢘ᐇ
⾜ጤဨ㸦ᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍࣭㏆␥ᨭ㒊ᗢົᖿ஦㸦ᖹᡂ ᖺࠥ
ᖺ㸧
࣭➨㸴ᅇḟୡ௦ࢆᢸ࠺᭷ᶵ໬Ꮫࢩ࣏ࣥࢪ࣒࢘ᐇ
⾜ጤဨ㛗㸦ᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍࣭≀⌮⣔⸆Ꮫ㒊఍ୡヰே㸦ᖹᡂ ᖺࠥ㸧
࣭㏆␥໬Ꮫ༠఍ⱝᡭࣇ࢛࣮࣒ࣛ ௻⏬ጤဨ㸦ᖹᡂ
ᖺࠥ⌧ᅾ㸧
࣭᪥ᮏ⸆Ꮫ఍࣭⸆Ꮫ◊✲ࣅࢪࣙࣥ㒊఍ᖖ௵ୡヰே
㸦ᖹᡂ ᖺࠥ ᖺ㸧
࣭᭷ᶵྜᡂ໬Ꮫ༠఍ ⦅㞟༠ຊጤဨ㸦ᖹᡂ ᖺ
− 90 −
࣭᪥ᮏ⸆Ꮫ఍࣭➨ ᅇ๰⸆ࣅࢪࣙࣥࢩ࣏ࣥࢪ࣒࢘
࣭᪥ᮏ⮚ჾಖᏑ⏕≀་Ꮫ఍┘஦ཬࡧホ㆟ဨ㸦+
ᐇ⾜ጤဨ㛗㸦ᖹᡂ ᖺ㸧
ࠥ+㸧
࣭᪥ᮏ⸆Ꮫ఍࣭Ꮫ఍㈹➨ ḟ㑅⪃ጤဨ㸦ᖹᡂ ࣭ࣂ࢖࢜࢖ࣥࢲࢫࢺ࣮ࣜ༠఍⏘Ꮫ஺ὶ㒊఍ጤဨ
ᖺ㸧
+ࠥ+
࣭᪥ᮏ⸆Ꮫ఍࣭ᙺဨ➼ೃ⿵⪅㑅⪃ጤဨ㸦ᖹᡂ ࣭᪥ᮏ⸆Ꮫ఍⸆Ꮫ◊✲ࣅࢪࣙࣥ㒊఍ᖖ௵ୡヰ
ᖺ㸧
ே+ࠥ⌧ᅾ
࣭᪥ᮏ⸆Ꮫ఍࣭ᗈሗጤဨ఍ጤဨ㸦ᖹᡂ ᖺ㸧
࣭᪥ᮏ║⸆⌮Ꮫ఍┘஦ཬࡧホ㆟ဨ+ࠥ+
࣭᪥ᮏ⸆Ꮫ఍࣭࣓࣮࣐ࣝ࢞ࢪࣥⓎ⾜ጤဨ఍ጤဨ㸦ᖹ
࣭᪥ᮏ⸆⌮Ꮫ఍௦㆟ဨ+ࠥ⌧ᅾ
ᡂᖺࠥᖺ㸧
࣭᪥ᮏே㢮㑇ఏᏛ఍ホ㆟ဨ+ࠥ+
࣭᪥ᮏ࣌ࣉࢳࢻᏛ఍࣭ホ㆟ဨ㸦ᖹᡂᖺࠥ㸧
࣭᪥ᮏᑠඣ⮫ᗋ⸆⌮Ꮫ఍㐠Ⴀጤဨ
࣭᪥ᮏ⏕≀≀⌮Ꮫ఍࣭ศ㔝ูᑓ㛛ጤဨ㸦ᖹᡂᖺ
࣭ᅜ㝿⛉Ꮫ᣺⯆㈈ᅋව௵◊✲ဨ
ࠥ㸧
࣭⊂࢚ࢿࣝࢠ࣮࣭⏘ᴗᢏ⾡⥲ྜ㛤Ⓨ
࣭≀ᛶ≀⌮໬Ꮫ◊✲఍࣭஦ົᒁ㸦ᖹᡂᖺࠥ㸧
࣭㸦1('2㸧ࠕඛ㐍ࢼࣀࣂ࢖࢜ࢹࣂ࢖ࢫࣉࣟࢪ࢙ࢡ
࣭≀ᛶ≀⌮໬Ꮫ◊✲఍࣭ୡヰே㸦ᖹᡂᖺࠥᖺ㸧
ࢺࠖᢏ⾡ጤဨ+ࠥ+
࣭%LRFKLPLFDHW%LRSK\VLFD$FWDㄅ࣭(GLWRU㸦ᖹ
࣭⊂࢚ࢿࣝࢠ࣮࣭⏘ᴗᢏ⾡⥲ྜ㛤Ⓨᶵᵓ㸦1('2㸧
ᡂᖺࠥ㸧
ࠕ⮫ᗋ㑇ఏᏊデ᩿ࢩࢫࢸ࣒ᶵჾࠖศ⛉఍ホ౯ጤ
࣭ -RXUQDO RI 3HSWLGH 6FLHQFH ㄅ ࣭ (GLWRULDO
ဨ+ࠥ⌧ᅾ
$GYLVRU\%RDUG㸦ᖹᡂᖺࠥ㸧
࣭(GLWRULDO%RDUG+\SHUWHQVLRQ+ࠥ⌧ᅾ
࣭⛉Ꮫ◊✲㈝ጤဨ఍ᑓ㛛ጤဨ㸦ᖹᡂᖺࠥᖺ㸧
࣭(GLWRULDO%RDUG/LIH6FLHQFHV+ࠥ⌧ᅾ
࣭⊂❧⾜ᨻἲே㎰ᴗ࣭㣗ရ⏘ᴗᢏ⾡⥲ྜ◊✲ᶵᵓ
࣭-+XPDQ*HQHWLFV$VVRFLDWH(GLWRU+ࠥ
ࠕ⏕≀⣔⏘ᴗ๰ฟࡢࡓࡵࡢ␗ศ㔝⼥ྜ◊✲ᨭ᥼
⌧ᅾ
஦ᴗࠖ୰㛫ホ౯࡟ಀࡿᑓ㛛ጤဨ㸦ᖹᡂᖺ㸧
࣭ 7UHQG LQ (QGRFULQRORJ\ DQG 0HWDEROLVP ࣭⊂❧⾜ᨻἲே㎰ᴗ࣭㣗ရ⏘ᴗᢏ⾡⥲ྜ◊✲ᶵ
$VVRFLDWH(GLWRU ⦅㞟ጤဨ+ࠥ⌧ᅾ
ᵓࠕ⏕≀⣔⏘ᴗ๰ฟࡢࡓࡵࡢ␗ศ㔝⼥ྜ◊✲ᨭ᥼
࣭ 1DXQ\Q6FKPLHGHEHUJ
V $UFK 3KDUPDFRO ஦ᴗࠖ⤊஢᫬ホ౯࡟ಀࡿᑓ㛛ጤဨ㸦ᖹᡂᖺ㸧
$VVRFLDWH(GLWRU ⦅㞟ጤဨ+ࠥ⌧ᅾ
࣭⊂❧⾜ᨻἲே㎰ᴗ࣭㣗ရ⏘ᴗᢏ⾡⥲ྜ◊✲ᶵᵓ
࣭ࣂ࢖࢜ࢸࢡࣀࣟࢪ࣮ࢪ࣮ࣕࢼࣝ⦅㞟ጤဨ
ࠕ࢖ࣀ࣮࣋ࢩࣙࣥ๰ฟᇶ♏ⓗ◊✲᥎㐍஦ᴗࠖ࡟
࣭ࣇ࢓࣐ࣝࣇࣟࣥࢸ࢕࢔ᰴᘧ఍♫ᙺဨ+ࠥ
ಀࡿ᭩㢮ᑓ㛛ጤဨ㸦ᖹᡂᖺࠊᖺ㸧
⌧ᅾ
▮㔝⩏᫂ຓᩍ
࣭ࣇ࢓࣐ࣝࣇࣟࣥࢸ࢕࢔ᰴᘧ఍♫ᢏ⾡ᣦᑟຓゝ
࣭᪥ᮏ⸆Ꮫ఍࣭ࣇ࢓࣐ࣝࢩ࢔ጤဨ఍ᨭ㒊࢔ࢻࣂ࢖
⪅+ࠥ⌧ᅾ࣭⮫ᗋ⸆⌮◊✲᣺⯆㈈ᅋホ㆟ဨ
ࢨ࣮㸦ᖹᡂᖺࠥᖺ㸧
+ࠥ⌧ᅾ
࣭⮫ᗋ⸆⌮◊✲᣺⯆㈈ᅋ㑅⪃ጤဨ+ࠥ⌧ᅾ
࠙ࢤࣀ࣒๰⸆⛉Ꮫศ㔝ࠚ
࣭᪥ᮏᏛ⾡఍㆟஦ົᒁ᪥ᮏᏛ⾡఍㆟㐃ᦠ఍ဨ
㎷ᮏ㇦୕ᩍᤵ
+ࠥ
࣭࣐࢖ࢡࣟ࢔ࣞ࢖◊✲఍௦⾲
࣭ᩥ㒊⛉Ꮫ㈹◊✲᣺⯆ᒁࢱࣥࣃࢡ ࣉࣟࢪ
࣭ࢤࣀ࣒๰⸆ࣇ࢛࣮࣒ࣛᖿ஦
࢙ࢡࢺホ౯ጤဨ఍ጤဨ+ࠥ+
− 91 −
࣭ி㒔ᕷ་࣭ᕤ࣭ࣛ࢖ࣇࢧ࢖࢚ࣥࢫ㐃ᦠࣉࣟࢪ
༙⏣ဴ㑻ᩍᤵ
࣭᪥ᮏ⭷Ꮫ఍๪఍㛗㸦ᖹᡂ㸯㸵ᖺ㹼㸯㸷ᖺ㸧
࢙ࢡࢺ᳨ウጤဨ఍ጤဨ+ࠥ+
࣭⊂᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ➼ᑂᰝ఍ᑓ㛛
ጤဨ࠾ࡼࡧᅜ㝿஦ᴗጤဨ఍᭩㠃ᑂᰝဨ+ࠥ
࣭᪥ᮏ⭷Ꮫ఍఍㛗㸦ᖹᡂ㸰㸯ᖺ㹼㸧
࣭᪥ᮏ໬Ꮫ఍ࢥࣟ࢖ࢻ࠾ࡼࡧ⏺㠃໬Ꮫ㒊఍ጤဨ
㸦ᖹᡂ㸯㸴ᖺ㹼㸧
+
࣭኱Ꮫᇶ‽༠఍኱Ꮫホ౯ጤဨ఍ጤဨ+ࠥ⌧
࣭᪥ᮏ⸆Ꮫ఍᝟ሗࢩࢫࢸ࣒ጤဨ㛗㸦ᖹᡂ㸯㸴ᖺ㹼㸧
࣭᪥ᮏ⸆Ꮫ఍Ḣᩥㄅ⦅㞟ጤဨ㸦ᖹᡂ㸯㸳ᖺ㹼㸧
ᅾ
࣭኱Ꮫᇶ‽༠఍኱Ꮫホ౯ጤဨ఍඲Ꮫホ౯ศ⛉఍
࣭≀ᛶ≀⌮໬Ꮫ◊✲఍ጤဨ࣭ጤဨ㛗㸦᫛࿴㸴㸰ᖺ
㹼㸧
➨ ⩌୺ᰝ+ࠥ⌧ᅾ
࣭኱Ꮫᇶ‽༠఍኱Ꮫホ౯ጤဨ఍඲Ꮫホ౯ศ⛉఍
࣭⭷ࢩ࣏ࣥࢪ࣒࢘ጤဨ㸦ᖹᡂ㸶ᖺ㹼㸧
୰㔝ᐇ෸ᩍᤵ
➨ ⩌୺ᰝ+ࠥ⌧ᅾ
࣭ཌ⏕ປാ┬་⸆㣗ရᒁ་㐨ᑂ㆟఍ᑓ㛛ጤဨ
࣭᪥ᮏ⸆Ꮫ఍ࣇ࢓࣐ࣝࢩ࢔ጤဨ఍ᨭ㒊࢔ࢻࣂ࢖
ࢨ࣮㸦ᖹᡂ㸯㸴ᖺࠥ㸯㸶ᖺ㸧
⸆๣ᖌศ⛉఍+ࠥ⌧ᅾ
࣭⊂࢚ࢿࣝࢠ࣮࣭⏘ᴗᢏ⾡⥲ྜ㛤Ⓨᶵᵓ㸦1('2㸧
࣭᪥ᮏ⭷Ꮫ఍⦅㞟ጤဨ㸦ᖹᡂ㸰㸯ᖺࠥ㸧
ᢏ⾡ጤဨ+ࠥ⌧ᅾ
࣭᪥ᮏᚠ⎔⸆⌮Ꮫ఍ᖿ஦+ࠥ+
࠙⢭ᐦ᭷ᶵྜᡂศ㔝ࠚ
࣭᪥ᮏ⸆Ꮫ఍๰⸆⛉Ꮫ㈹㑅⪃ጤဨ+
ᕝ➃⊛ኵᩍᤵ
࣭⊂᪥ᮏᏛ⾡᣺⯆఍⛉Ꮫ◊✲㈝ጤဨ఍ࠕ་ṑ
࣭㏆␥໬Ꮫ༠఍ホ㆟ဨ㸦ࠥ㸧
࣭ ᪥ ᮏ ໬ Ꮫ ఍ &KHPLVWU\ /HWWHUV ⦅ 㞟 ጤ ဨ
⸆Ꮫ , ᑠጤဨ఍ࠖᑓ㛛ጤဨ+ࠥ⌧ᅾ
ᖹ⃝᫂෸ᩍᤵ
ࠥ
࣭᪥ᮏ⸆⌮Ꮫ఍ホ㆟ဨ+㹼⌧ᅾ
࣭୕⳻໬Ꮫ⛉Ꮫᢏ⾡ࢭࣥࢱ࣮ᢏ⾡㢳ၥ㸦
࣭᪥ᮏ⸆Ꮫ఍ဨ ㏆␥ᨭ㒊ጤဨ+㹼⌧ᅾ
ࠥ㸧
㍿Ỉᓫ㙾ຓᩍ
࣭᪥ᮏ⸆Ꮫ఍௦㆟ဨ㸦ࠥ㸧
࣭᪥ᮏ⸆⌮Ꮫ఍ホ㆟ဨ
࣭᭷ᶵྜᡂ໬Ꮫ༠఍㛵すᨭ㒊ᖿ஦㸦ࠥ㸧
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ᖿ஦㸦ࠥ㸧
࠙〇๣ᶵ⬟ゎᯒᏛศ㔝ࠚ
࣭㏆␥໬Ꮫ༠఍஦ᴗ௻⏬ጤဨ㸦ࠥ㸧
▼℈Ὀᩍᤵ
࣭-RXUQDO RI &KURPDWRJUDSK\ $ (GLWRULDO
࠙⏕యศᏊㄆ㆑Ꮫศ㔝ࠚ
➉ᓥᾈᩍᤵ
%RDUG㸦ᖹᡂ㸯 ᖺ㹼㸧
࣭㟁ẼὋືศᯒ◊✲᠓ㄯ఍ᙺဨ㸦ᖹᡂ ᖺ㹼㸧
࣭ࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮⛉Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺ
࣭᪥ᮏᏛ⾡᣺⯆఍➨㸯ẁᑂᰝဨ㸦ᖹᡂ㸯㸴ᖺ㹼⌧
ᅾ㸧
࣭ᅜ㝿⏕⌮Ꮫ఍ࣉࣟࢢ࣒ࣛጤဨ㸦ᖹᡂ㸰㸯ᖺ㸧
㹼㸧
࣭᪥ᮏศᯒ໬Ꮫ఍ᮾ໭ᨭ㒊ᙺဨ㸦ᖹᡂ ᖺ㹼
ᰠ⃝ᫀ෸ᩍᤵ
࣭᪥ᮏ⸆⌮Ꮫ఍ホ㆟ဨ㸦ᖹᡂ㸯㸶ᖺ㹼⌧ᅾ㸧
ᖺ㸧
࣭᪥ᮏࣉࣟࢸ࣮࣒࢜Ꮫ఍ +832 ‽ഛጤဨ఍ጤ
ဨ㸦ᖹᡂ ᖺ㹼㸧
࣭᪥ᮏᚠ⎔⸆⌮Ꮫ఍➨ ᅇ኱఍ࣉࣟࢢ࣒ࣛጤ
ဨ㛗ᖹᡂ ᖺ
− 92 −
ᖺᗘ㸧
࣭᪥ᮏ⸆⌮Ꮫ఍➨ ᅇ㛵ᮾ㒊఍ࣉࣟࢢ࣒ࣛጤ
࣭᪥ᮏᏛ⾡఍㆟ ⏕≀⣔⸆Ꮫ◊✲㐃⤡ጤဨ 㸦ᖹ
ဨ㛗ᖹᡂ ᖺ
ᡂ ᖺᗘࠥ ᖺᗘ㸧
࣭᪥ᮏᏛ⾡᣺⯆఍ ⛉Ꮫ◊✲㈝ጤဨ఍ᑓ㛛ጤဨ
࠙⏕యᶵ⬟ゎᯒᏛศ㔝ࠚ
㸦ᖹᡂ ᖺᗘࠥ ᖺᗘ㸧
㔠Ꮚ࿘ྖᩍᤵ
࣭㸦♫㸧᪥ᮏ⸆⌮Ꮫ఍⦅㞟ጤဨ㸦ᖹᡂ ᖺࠥ⌧
ᅾ㸧ᩍ⫱௻⏬ጤဨ㸦ᖹᡂ ᖺࠥ㸧
࠙⏕⌮άᛶไᚚᏛศ㔝ࠚ
࣭㸦♫㸧᪥ᮏ⸆⌮Ꮫ఍ホ㆟ဨ㸦ࠥ⌧ᅾ㸧
ᑠሐಖ๎ᩍᤵ
࣭㸦♫㸧᪥ᮏ⸆Ꮫ఍᝟ሗࢩࢫࢸ࣒ጤဨ㸦ᖹᡂ ෆ⸨⿱Ꮚຓᩍ
ᖺࠥ⌧ᅾ㸧
࣭ᖹᡂ ᖺ㸰᭶㸰᪥ࠊࢫ࣮ࣃ࣮ࢧ࢖࢚ࣥࢫࣁ࢖
࣭᪥ᮏ⚄⤒⛉ᏛᏛ఍㟁Ꮚ໬᥎㐍ጤဨ㸦ࠥ⌧ᅾ㸧
ࢫࢡ࣮ࣝ㸦ᒣཱྀ┴Ᏹ㒊㧗➼Ꮫᰯ㸧
ࠊㅮ⩏ࠊᐇ㦂ᣦ
࣭ࣛ࢖ࣇࢧ࢖࢚ࣥࢫ㎡᭩ࣉࣟࢪ࢙ࢡࢺ௦⾲
ᑟ
୰ᕝ㈗அ෸ᩍᤵ
࣭㸦♫㸧᪥ᮏ⸆⌮Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭
࠙⏕య᝟ሗไᚚᏛศ㔝ࠚ
௦㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭ḟୡ௦ࡢ఍㸦ᖹᡂ ୰ᒣ࿴ஂᩍᤵ
ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ⣽⬊⏕≀Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭㸦♫㸧᪥ᮏ⸆Ꮫ఍⸆⌮⣔⸆Ꮫ㒊఍ⱝᡭୡヰே㸦ᖹ
࣭᪥ᮏ⏕໬Ꮫ఍ࠕ⏕໬Ꮫࠖㄅ௻⏬ጤဨ㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
ᡂ ᖺ㹼⌧ᅾ㸧
࣭㸦♫㸧᪥ᮏ⦆࿴་⒪⸆Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺ
࣭᪥ᮏ⣽⬊⏕≀Ꮫ఍ &HOO6WUXFWXUH)XQFWLRQ
ㄅ ⦅㞟ጤဨ㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
㹼⌧ᅾ㸧࣭௻⏬ᩍ⫱ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭㸦132㸧᪥ᮏ⦆࿴་⒪Ꮫ఍⦆࿴་⒪࢞࢖ࢻࣛ࢖
࣭᪥ᮏ⣽⬊⏕≀Ꮫ఍఍ィ┘ᰝ㸦ᖹᡂ ᖺࠥᖹᡂ
ᖺ㸧
ࣥసᡂጤဨ㸦ᖹᡂ ᖺ㹼 ᖺ㸧
࣭ࢺࣛࣥࢫ࣏࣮ࢱ࣮◊✲఍ୡヰே㸦ᖹᡂ ᖺ㹼
࣭᪥ᮏ⸆Ꮫ఍ᑗ᮶ၥ㢟᳨ウጤဨ㸦ᖹᡂ ᖺࠥᖹ
ᡂ ᖺ㸧
⌧ᅾ㸧
࣭᪥ᮏ⣽⬊⏕≀Ꮫ఍ &HOO6WUXFWXUH)XQFWLRQ
ⓑᕝஂᚿຓᩍ
࣭㸦♫㸧᪥ᮏ⸆⌮Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
ㄅ ๪⦅㞟ጤဨ㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
࣭㸦♫㸧᪥ᮏ⸆Ꮫ఍ࣇ࢓࣐ࣝࢩ࢔࢔ࢻࣂ࢖ࢨ࣮㸦ᖹ
࣭᪥ᮏ⸆Ꮫ఍ -RXUQDORI+HDOWK6FLHQFHㄅ ⦅
㞟ጤဨ㸦ᖹᡂᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
ᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ ᮏ ⏕ ໬ Ꮫ ఍ -RXUQDO RI %LRFKHPLVWU\ ㄅ
$GYLVRU\%RDUG㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࠙㑇ఏᏊ⸆Ꮫศ㔝ࠚ
ఀ⸨ಙ⾜ᩍᤵ
࣭᪥ᮏ⣽⬊⏕≀Ꮫ఍㐠Ⴀጤဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭᪥ᮏ⏕໬Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺᗘࠥ⌧ᅾ㸧
࣭᪥ᮏ⣽⬊⏕≀Ꮫ఍ᖖ௵⦅㞟ጤဨ㸦ᖹᡂ ᖺࠥ
࣭᪥ᮏᛂ⏝㓝⣲༠఍ホ㆟ဨ㸦ᖹᡂ ᖺᗘࠥ⌧ᅾ㸧
࣭㛵すࢧ࢖࢚ࣥࢫ࣭ࣇ࢛࣮࣒ࣛ ጤဨ ᖹᡂ ᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ᗢົᖿ஦㸦ᖹᡂ ᖺࠥ⌧
ᅾ㸧
ᖺᗘࠥ⌧ᅾ
࣭ி㒔኱ᏛᏛ⾡ฟ∧఍ ⌮஦ 㸦ᖹᡂ ᖺᗘࠥ
ᮡᮏᖾᙪ෸ᩍᤵ
− 93 −
࣭᪥ᮏ⸆⌮Ꮫ఍Ꮫ⾡ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭᪥ᮏ⏕໬Ꮫ఍ ⦅㞟༠ຊጤဨ㸦ᖹᡂ ᖺᗘࠥ
⌧ᅾ㸧
࠙⚄⤒ᶵ⬟ไᚚᏛศ㔝ࠚ
᰿ᓊᏛᩍᤵ
࠙⸆ရືែไᚚᏛศ㔝ࠚ
࣭᪥ᮏ⏕໬Ꮫ఍Ꮫ఍ホ㆟ဨ㸦㹆㸯㸵Ѹ㸧
ᶫ⏣඘ᩍᤵ
࣭᪥ᮏ⸆Ꮫ఍኱఍⤌⧊ጤဨ㸦㹆㸯㸷Ѹ㸰㸯ᖺ㸱᭶㸧
࣭ᅜ㝿⸆Ꮫ㐃ྜ㸦),3㸧๪఍㛗㸦ᖹᡂ ᖺ㹼ᖹᡂ
࣭ (GLWRULDO %RDUG PHPEHU RI 7KH -RXUQDO RI
ᖺ㸧
%LRORJLFDO&KHPLVWU\
࣭᪥ᮏ་⒪⸆Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭⛉Ꮫ◊✲㈝ጤဨ఍ᑓ㛛ဨ㸦㹆㸯㸷Ѹ㸧
࣭᪥ᮏ෌⏕་⒪Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭⛉Ꮫᢏ⾡ᨻ⟇◊✲ᡤᑓ㛛ㄪᰝဨ㸦㹆㸯㸵Ѹ㸯㸷㸧
࣭᪥ᮏᏛ⾡఍㆟㐃ᦠ఍ဨ
㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
࣭⑓ែ௦ㅰ◊✲఍ホ㆟ဨ㸦㹆㸯㸷Ѹ㸧
࣭᪥ᮏ ''6 Ꮫ఍⌮஦㛗㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆๣Ꮫ఍๪఍㛗㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
࠙⏕యᶵ⬟໬Ꮫศ㔝ࠚ
࣭᪥ᮏ⒴Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
஧ᮌྐᮁᩍᤵ
࣭⸆๣ᖌㄆᐃไᗘㄆドᶵᵓ⌮஦㸦ᖹᡂ ᖺ㹼ᖹ
࣭ࢥࣥࣅࢼࢺࣜ࢔ࣝࣂ࢖࢚࢜ࣥࢪࢽ࢔ࣜࣥࢢ◊✲
࣭ୖཎグᛕ⏕࿨⛉Ꮫ㈈ᅋ㑅⪃ጤဨ㸦ᖹᡂ ᖺ㹼
఍ ᖿ஦㸦ᖹᡂᖺᗘࠥ⌧ᅾ㸧
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ጤဨ㸦ᖹᡂ ᖺᗘࠥ⌧ᅾ㸧
࣭㏆␥໬Ꮫ༠఍ࣂ࢖࢜㒊఍ ┘஦㸦ᖹᡂ ᖺᗘࠥ
࣭᪥ᮏ࣌ࣉࢳࢻᏛ఍ ホ㆟ဨ㸦ᖹᡂ ᖺᗘࠥ ᖺ
࣭᪂࢚ࢿࣝࢠ࣮࣭⏘ᴗᢏ⾡⥲ྜ㛤Ⓨᶵᵓ◊✲ホ
ࣟࢪ࢙ࢡࢺศ⛉఍ጤဨ㛗㸦ᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆๣Ꮫ఍⌮஦㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
ᗘ㸧
࣭᪥ᮏ࣌ࣉࢳࢻᏛ఍⌮஦㸦➨ ᮇࠊࠥᖹᡂ ᖺ
࣭ཌ⏕ປാ┬⸆๣ᖌࡢ⾜ᨻฎศࡢ࠶ࡾ᪉➼࡟㛵
ࡍࡿ᳨ウ఍ጤဨ㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
ᗘ㸧
࣭᪥ᮏ໬Ꮫ఍ ࣇࣟࣥࢸ࢕࢔⏕࿨໬Ꮫ◊✲఍⌮஦
ᖺ㹼ᖹᡂ ᖺ㸧
࣭᪥ᮏ࣌ࣉࢳࢻᏛ఍⌮஦㸦➨㸯㸯ᮇࠊࠥ⌧ᅾ㸧
$GYLVRU\
࣭᪥ᮏ⸆๣Ꮫ఍఍㛗㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
࣭୕ඹ⏕࿨⛉Ꮫ◊✲᣺⯆㈈ᅋ㑅⪃ጤဨ㸦ᖹᡂ 㸦ᖹᡂᖺᗘࠥᖹᡂᖺᗘ㸧
%RDUG
RI
࣭ᩥ㒊⛉Ꮫ┬⸆Ꮫ⣔ேᮦ⫱ᡂࡢ࠶ࡾ᪉࡟㛵ࡍࡿ
᳨ウ఍ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
%LRSRO\PHUV3HSWLGH6FLHQFHࠥ⌧ᅾ
࣭(GLWRULDO %RDUG RI &XUUHQW 3URWHLQ DQG
࣭་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓᑓ㛛ጤဨ㸦ᖹᡂ ᖺ
㹼⌧ᅾ㸧
3HSWLGH6FLHQFHࠥ⌧ᅾ
࣭(GLWRULDO $GYLVRU\ %RDUG RI %LRFRQMXJDWH
&KHPLVWU\ࠥ⌧ᅾ
࣭ṊᗜᕝዪᏊ኱Ꮫ㝃ᒓ୰Ꮫᰯ㧗➼Ꮫᰯࢫ࣮ࣃ࣮
ࢧ࢖࢚ࣥࢫࣁ࢖ࢫࢡ࣮ࣝ㐠Ⴀᣦᑟጤဨ㸦ᖹᡂ ࣭$VVRFLDWH(GLWRURI0ROHFXODU7KHUDS\
ᖺ㹼⌧ᅾ㸧
࣭UG3KDUPDFHXWLFDO6FLHQFHV:RUOG&RQJUHVV
ࠥ⌧ᅾ
࣭(GLWRULDO%RDUGRI%LRPROHFXOHV㸦ࠥ⌧ᅾ㸧
௒すᮍ᮶ຓᩍ
⌧ᅾ㸧
౯ጤဨ఍ࢼࣀ࢝ࣉࢭࣝᆺேᕤ㓟⣲㐠ᦙయ〇㐀ࣉ
⌧ᅾ㸧
࣭(GLWRULDO
ᡂ ᖺ㸧
36:&3URJUDP&RFKDLU㸦ᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍⌮஦㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
− 94 −
࣭⸆Ꮫ◊✲ዡບ㈈ᅋ◊✲ຓᡂ㑅⪃ጤဨ㸦ᖹᡂ ࣭୕ඹ⏕࿨⛉Ꮫ◊✲᣺⯆㈈ᅋホ㆟ဨ㸦ᖹᡂ ᖺ
㹼⌧ᅾ㸧
ᖺ㹼ᖹᡂ ᖺ㸧
࣭᪥ᮏᏛ⾡᣺⯆఍኱Ꮫ㝔ᩍ⫱ᨵ㠉ᨭ᥼ࣉࣟࢢࣛ
࣒ጤဨ఍ศ㔝ูᑂᰝ㒊఍ᑓ㛛ጤဨ㸦ᖹᡂ ᖺ㹼
࣭᪥ᮏᏛ⾡᣺⯆఍᭱ඛ➃࣭ḟୡ௦◊✲㛤Ⓨᨭ᥼
ࣉࣟࢢ࣒ࣛᑂᰝጤဨ఍ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ➼ᑂᰝ఍ᑓ㛛ጤဨ
ᖹᡂ ᖺ㸧
࣭ᣢ⏣グᛕ་Ꮫ⸆Ꮫ᣺⯆㈈ᅋ㑅⪃ጤဨ㸦ᖹᡂ ཬࡧᅜ㝿஦ᴗጤဨ఍᭩㠃ᑂᰝဨ㸦ᖹᡂ ᖺ㹼⌧
ᅾ㸧
ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏᏛ⾡᣺⯆఍⛉Ꮫ◊✲㈝ጤဨ఍ᑓ㛛ጤဨ
࣭➨୍୕ඹ⏕࿨⛉Ꮫ◊✲᣺⯆㈈ᅋ⌮஦㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
࣭ᮍ᮶ᕤᏛ◊✲ᡤᩥ㒊⛉Ꮫ┬➨ ᅇ⛉Ꮫᢏ⾡ண
࣭᪂࢚ࢿࣝࢠ࣮࣭⏘ᴗᢏ⾡⥲ྜ㛤Ⓨᶵᵓᇶ♏◊
1R ศ⛉఍ጤဨ㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
✲࠿ࡽ⮫ᗋ◊✲࡬ࡢᶫΏࡋಁ㐍ᢏ⾡㛤Ⓨ㸦๰
࣭་⸆ᇶ┙◊✲ᡤᐇ⏝໬◊✲ホ౯ጤဨ఍ᑓ㛛ጤ
⸆࣭デ᩿ศ㔝㸧ホ౯ጤဨ఍ጤဨ㸦ᖹᡂ ᖺ㹼⌧
ဨཬࡧᇶ♏ⓗ◊✲ホ౯ጤဨ఍ᑓ㛛ጤဨ㸦ᖹᡂ ᅾ㸧
࣭᪥ᮏ⸆Ꮫ఍Ꮫ఍㈹➼㑅⪃ጤဨ㛗㸦ᖹᡂ ᖺ㹼
ᖺ㹼⌧ᅾ㸧
࣭ᅜ㝿⸆Ꮫ㐃ྜ㸦),3㸧Ꮫ⾡㒊㛛㸦%36㸧㆟㛗㸦ᖹ
⌧ᅾ㸧
࣭᪥ᮏࣞࢠࣗࣛࢺ࣮ࣜࢧ࢖࢚ࣥࢫᏛ఍⌮஦㸦ᖹᡂ
ᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏᏛ⾡఍㆟఍ဨ㸦➨஧㒊㸧
㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭ᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲㈝⿵ຓ㔠ホ౯ጤဨ㸦ᖹᡂ
ᖺ㹼⌧ᅾ㸧
࣭ཌ⏕ປാ┬⸆஦࣭㣗ရ⾨⏕ᑂ㆟఍ጤဨ㸦ᖹᡂ
ᖺ㹼⌧ᅾ㸧
ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍๪఍㢌㸦ᖹᡂ ᖺ㹼ᖹᡂ ᖺ㸧
ᒣୗᐩ⩏෸ᩍᤵ
࣭⸆Ꮫ◊✲ዡບ㈈ᅋ㐠Ⴀጤဨ㸦ᖹᡂ ᖺ㹼ᖹᡂ
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ⸆๣Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
ᖺ㸧
࣭ཌ⏕ປാ┬⸆஦࣭㣗ရ⾨⏕ᑂ㆟఍⮫᫬ጤဨ㸦ᖹ
㹼ᖹᡂ ᖺ㸧
ᡂ ᖺ㹼ᖹᡂ ᖺ㸧
࣭᭱㧗⿢ุᡤᮾி㧗➼⿢ุᡤ࣭ᮾிᆅ᪉⿢ุ
ᡤ࣭኱㜰ᆅ᪉⿢ุᡤᡤᒓᑓ㛛ጤဨ㸦▱ⓗ㈈⏘㛵
࣭᪥ᮏ⸆Ꮫ఍ᵓ㐀άᛶ┦㛵㒊఍ᖖ௵ᖿ஦㸦ᖹᡂ
ᖺ㹼⌧ᅾ㸧
࣭3KDUPDFHXWLFDO
ಀ㸧㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
5HVHDUFK
(GLWRULDO
$GYLVRU\%RDUG㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ ''6 Ꮫ఍㢳ၥ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭'UXJ 0HWDEROLVP DQG 3KDUPDFRNLQHWLFV
࣭᪥ᮏ ''6 Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭WK3KDUPDFHXWLFDO6FLHQFHV:RUOG&RQJUHVV
(GLWRULDO$GYLVRU\%RDUG㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ ''6 Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
36:&3URJUDP&RFKDLU㸦ᖹᡂ ᖺ㸧
࣭᪂࢚ࢿࣝࢠ࣮࣭⏘ᴗᢏ⾡⥲ྜ㛤Ⓨᶵᵓ1('2 ᢏ
࣭๰๣ࣇ࢛࣮࣒ࣛୡヰே㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
ᕝୖⱱㅮᖌ
⾡ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪂࢚ࢿࣝࢠ࣮࣭⏘ᴗᢏ⾡⥲ྜ㛤Ⓨᶵᵓࢸ࣮࣐
බເᆺ஦ᴗ࡟ಀࡿ⏦ㄳ᭩ࡢ஦๓᭩㠃ᑂᰝ㸦ࣆ࢔
ࣞࣅ࣮ࣗ㸧ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ⸆Ꮫ఍ᵓ㐀άᛶ┦㛵㒊఍ᖿ஦㸦ᖹᡂ ᖺ
࣭㑇ఏᏊ࣭ࢹࣜࣂ࣮ࣜ◊✲఍ᙺဨ㸦ᖹᡂ ᖺ㹼
⌧ᅾ㸧
࣭-RXUQDO RI %LRPHGLFDO 1DQRWHFKQRORJ\
− 95 −
࣭᪥ᮏ་⒪⸆Ꮫ఍ホ㆟ဨ㸦ᖹᡂ 14 ᖺࠥᖹᡂ 21
$VVRFLDWH(GLWRU㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭㑇ఏᏊ࣭ࢹࣜࣂ࣮ࣜ◊✲఍➨ ᅇࢩ࣏ࣥࢪ࣒࢘
ᖺ㸧
࣭᪥ᮏ་⒪⸆Ꮫ఍௦㆟ဨ㸦ᖹᡂ 21 ᖺࠥ㸧
㐠Ⴀጤဨ㸦ᖹᡂ ᖺ㸧
࣭㑇ఏᏊ࣭ࢹࣜࣂ࣮ࣜ◊✲఍➨ ᅇࢩ࣏ࣥࢪ࣒࢘
࣭᪥ᮏ⸆≀ືែᏛ఍ホ㆟ဨ㸦ᖹᡂ 14 ᖺࠥ㸧
࣭᪥ᮏ TDM Ꮫ఍ホ㆟ဨ㸦ᖹᡂ 16 ᖺࠥ⌧ᅾ㸧
㐠Ⴀጤဨ㸦ᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆๣Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ⮫ᗋ⸆⌮Ꮫ఍♫ဨ㸦ホ㆟ဨ㸧
㸦ᖹᡂ 21 ᖺ
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ጤဨ㸦ᖹᡂ ᖺ㹼⌧ᅾ㸧
ࠥ㸧
࣭㑇ఏᏊ࣭ࢹࣜࣂ࣮ࣜ◊✲఍➨ ᅇኟᮇࢭ࣑ࢼ
࣮ᐇ⾜ጤဨ㛗㸦ᖹᡂ ᖺ㸧
࠙⑓ែᶵ⬟ศᯒᏛศ㔝ࠚ
బ἞ⱥ㑻ᩍᤵ
࠙⸆ရస⏝ゎᯒᏛศ㔝ࠚ
࣭᪥ᮏ⸆Ꮫ఍୺ദ➨㸴ᅇ㔠ᒓࡢ㛵୚ࡍࡿ⏕య㛵㐃
㉥ụ᫛⣖ᩍᤵ
཯ᛂࢩ࣏ࣥࢪ࣒࢘ᐇ⾜ጤဨ㛗㸦㸧
࣭᪥ᮏ⸆⌮Ꮫ఍⌮஦㸦ᖹᡂ ᖺ ᭶ࠥ⌧ᅾ㸧
࣭ 6HYHQWK -DSDQ&KLQD -RLQW 6HPLQDU RQ
࣭᪥ᮏ 12 Ꮫ఍⌮஦㸦ᖹᡂ ᖺ ᭶ࠥ⌧ᅾ㸧
5DGLRSKDUPDFHXWLFDO&KHPLVWU\&KDLU3HUVRQᐇ
࣭᪥ᮏ║⸆⌮Ꮫ఍⌮஦㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
⾜ጤဨ㛗 ࣭᪥ᮏ║⸆⌮Ꮫ఍⌮஦㛗㸦ᖹᡂ ᖺ㸲᭶ࠥ⌧ᅾ㸧
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊఍ィᖿ஦㸦㹼㸧
࣭᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ホ㆟ጤဨ㸦ᖹᡂ ᖺ ᭶
࣭᪥ᮏ⸆Ꮫ఍≀⌮⣔⸆Ꮫ㒊఍㛗㸦㹼㸧
ࠥ⌧ᅾ㸧
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ጤဨ㸦㹼㸧
࣭᪥ᮏ⸆Ꮫ఍⸆⌮⣔⸆Ꮫ㒊఍㛗㸦ᖹᡂ ᖺ ᭶
࣭᪥ᮏ࢔࢖ࢯࢺ࣮ࣉ༠఍⌮஦ 㹼
ࠥ⌧ᅾ㸧
࣭᪥ᮏ࢔࢖ࢯࢺ࣮ࣉ༠఍་Ꮫ࣭⸆Ꮫ㒊఍๪㒊఍㛗
࣭ෆ㛶ᗓ㣗ရᏳ඲ጤဨ఍ᖿ஦㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
㸦㹼㸧
࣭ཌ⏕ປാ┬⸆๣ᖌᅜᐙヨ㦂ฟ㢟ጤဨ㸦ᖹᡂ ࣭᪥ᮏ᰾་Ꮫ఍⌮஦㸦㹼㸧
ᖺ ᭶ࠥ ᖺ ᭶㸧
࣭᪥ᮏศᏊ࢖࣓࣮ࢪࣥࢢᏛ఍⌮஦㹼
࣭ཌ⏕ປാ┬⸆๣ᖌᅜᐙヨ㦂ไᗘ᳨ウ఍ጤဨ㸦ᖹ
࣭᪥ᮏᚤ㔞ඖ⣲Ꮫ఍⌮஦㹼
ᡂ ᖺ ᭶ࠥᖹᡂ ᖺ ᭶㸧
࣭኱Ꮫ➼ᨺᑕ⥺᪋タ༠㆟఍⌮஦㸦㹼㸧
࣭ཌ⏕ປാ┬་㐨ᑂ㆟఍ጤဨ㸦ᖹᡂ ᖺ ᭶ࠥ
┘஦㸦㹼㸧
⌧ᅾ㸧
࣭᪥ᮏᏛ⾡᣺⯆఍⛉Ꮫ◊✲㈝ጤဨ఍ᑓ㛛ጤဨ
࣭᪥ᮏᏛ⾡఍㆟㐃ᦠ఍ဨ㸦ᖹᡂ ᖺ ᭶ࠥ⌧ᅾ㸧
㸦㹼㹼㸧
ஂ⡿฼᫂෸ᩍᤵ
࣭ᨺᑕ⥺་Ꮫ⥲ྜ◊✲ᡤศᏊ࢖࣓࣮ࢪࣥࢢࢭࣥࢱ
࣭᪥ᮏ⸆⌮Ꮫ఍Ꮫ⾡ホ㆟ဨ㸦ᖹᡂ ᖺ ᭶ࠥ⌧
࣮ホ౯ጤဨ఍ ጤဨ㛗 㹼
ᅾ㸧
࣭ᩥ㒊⛉Ꮫ┬⛉Ꮫᢏ⾡ᨻ⟇◊✲ᡤ⛉Ꮫᢏ⾡ᑓ㛛
࣭᪥ᮏ⸆⌮Ꮫ఍௦㆟ဨ㸦ᖹᡂ ᖺ ᭶ࠥ⌧ᅾ㸧
ᐙࢿࢵࢺ࣮࣡ࢡᑓ㛛ㄪᰝဨ㹼
࣭⌮໬Ꮫ◊✲ᡤ⚄ᡞ◊✲ᡤศᏊ࢖࣓࣮ࢪࣥࢢ◊✲
࠙⮫ᗋ⸆Ꮫᩍ⫱ศ㔝ࠚ
ࣉࣟࢢ࣒ࣛ ࢔ࢻࣂ࢖ࢨ࣮࣭ࣜ࢝࢘ࣥࢩࣝጤဨ
▮㔝 ⫱Ꮚ ෸ᩍᤵ
㹼
࣭ᮾ໭኱Ꮫࢧ࢖ࢡࣟࢺ࣭ࣟࣥࣛࢪ࢜࢔࢖ࢯࢺ࣮ࣉ
− 96 −
࣭'UXJ 0HWDEROLVP DQG 3KDUPDFRNLQHWLFV
ࢭࣥࢱ࣮ እ㒊ホ౯ጤဨ 㹼ࠊ
࣭
,QWHUQDWLRQDO
6\PSRVLXP
(GLWRULDO$GYLVRU\%RDUG㸦ᖹᡂ ᖺ㹼㸧
RQ
࣭$GYDQFHG'UXJ'HOLYHU\5HYLHZV([HFXWLYH
5DGLRSKDUPDFHXWLFDO&KHPLVWU\ (GLWRU㸦ᖹᡂ ᖺ㹼㸧
࣭)RXQGLQJ&RPPLWWHH㹼
࣭
-/DEHOOHG
&RPSRXQGV
DQG
すᕝඖஓ෸ᩍᤵ
࣭᪥ᮏ⸆๣Ꮫ఍ ホ㆟ဨ㸦ᖹᡂ ᖺ㹼㸧ࠊⱥㄒࢭ
5DGLRSKDUPDFHXWLFDOV
࣑ࢼ࣮すᆅ༊ጤဨ㛗㸦ᖹᡂ ᖺ㹼㸧
࣭(GLWRULDO$GYLVRU\%RDUG㹼
࣭$QQ1XFO0HG(GLWRULDO%RDUG㹼
࣭᪥ᮏ ''6 Ꮫ఍ ホ㆟ဨ㸦ᖹᡂ ᖺ㹼㸧
࣭ &XUUHQW $QDO\WLFDO &KHP (GLWRULDO
$GYLVRU\%RDUG㹼
࠙་⒪⸆๣Ꮫศ㔝ࠚ
࣭ᚤ㔞ඖ⣲ ⦅㞟ጤဨ㛗㹼
஝㈼୍ᩍᤵ
࣭᪥ᮏ⸆Ꮫ఍⸆Ꮫᩍ⫱ᨵ㠉኱Ꮫே఍㆟࣓ࣥࣂ࣮
ᑠ㔝ṇ༤෸ᩍᤵ
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ጤဨ㸦ᖹᡂ ᖺᗘࠥ⌧ᅾ㸧
㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
࣭᪥ᮏ᰾་Ꮫ఍ᑓ㛛་ᩍ⫱ᑂᰝጤဨ㸦ᖹᡂ ᖺᗘ ࣭᪥ᮏ⸆Ꮫ఍⸆Ꮫᩍ⫱ᨵ㠉኱Ꮫே఍㆟➨୕⪅ホ౯
᳨ウጤဨ㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
ࠥ⌧ᅾ㸧
࣭᪥ᮏ⭷Ꮫ఍⌮஦㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
࠙⑓ែ᝟ሗ⸆Ꮫศ㔝ࠚ
࣭᪥ᮏ⭈⮚Ꮫ఍Ꮫ⾡ホ㆟ဨ㸦ᖹᡂ ᖺ㸧
㧗಴႐ಙᩍᤵ
࣭᪥ᮏ⭈⮚Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭᪥ᮏ ''6 Ꮫ఍ ⌮஦㸦ᖹᡂ ᖺ㹼㸧ࠊᖿ஦㸦ᖹ ࣭᪥ᮏ⭈⮚Ꮫ఍ࢥ࣓ࢹ࢕࢝ࣝࢫࢱࢵࣇ⫱ᡂጤဨ
㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
ᡂ ᖺ㹼 ᖺ㸧ࠊホ㆟ဨ㸦ᖹᡂ ᖺ㹼㸧
࣭᪥ᮏ⸆๣Ꮫ఍ ⌮஦㸦ᖹᡂ ᖺ㹼㸧ࠊホ㆟ဨ㸦ᖹ ࣭᪥ᮏ⸆≀ືែᏛ఍⌮஦㸦ᖹᡂ ᖺࠥ ᖺ㸧
࣭᪥ᮏ⸆≀ືែᏛ఍๪఍㛗㸦ᖹᡂ ᖺࠥ ᖺ㸧
ᡂ ᖺ㹼㸧
࣭᪥ᮏ⸆≀ືែᏛ఍ ホ㆟ဨ㸦ᖹᡂ ᖺ㹼㸧
࣭᪥ᮏ⸆≀ືែᏛ఍ᖺ఍㛗㸦ᖹᡂ ᖺ㸧
࣭ཌ⏕ປാ┬⸆๣ᖌᅜᐙヨ㦂ฟ㢟ጤဨ㸦ᖹᡂ ࣭᪥ᮏ⸆≀ືែᏛ఍఍㛗㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭᪥ᮏ⸆๣Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
ᖺ ᭶ࠥ ᖺ ᭶㸧
࣭୕ඹ⏕࿨⛉Ꮫ◊✲᣺⯆㈈ᅋ㑅⪃ጤဨ㸦ᖹᡂ ࣭᪥ᮏ⸆๣Ꮫ఍Ꮫ఍㈹㑅⪃ጤဨ㸦ᖹᡂ ᖺ㸧
࣭᪥ᮏ⮫ᗋ⸆⌮Ꮫ఍⌮஦㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
ᖺ㹼⌧ᅾ㸧
࣭*3(1 *OREDOL]DWLRQ RI 3KDUPDFHXWLFV ࣭᪥ᮏ་⒪⸆Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
(GXFDWLRQ1HWZRUN0HPEHUDW/DUJH㸦ᖹᡂ ࣭᪥ᮏ་⒪⸆Ꮫ఍⌮஦㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭᪥ᮏ་⒪⸆Ꮫ఍ἲே໬‽ഛ≉ูጤဨ㸦ᖹᡂ ᖺ
ᖺ㹼㸧
࣭3KDUPDFHXWLFDO
5HVHDUFK
(GLWRULDO
ࠥᖹᡂ ᖺ㸧
࣭᪥ᮏ་⒪⸆Ꮫ఍་⒪⸆Ꮫᩍ⫱ጤဨ㸦ᖹᡂ ᖺࠥ
$GYLVRU\%RDUG㸦ᖹᡂ ᖺ㹼㸧
࣭(XURSHDQ-RXUQDORI3KDUPDFHXWLFDO6FLHQFHV ᖹᡂ ᖺ㸧
࣭᪥ᮏ་⒪⸆Ꮫ఍་⒪⸆Ꮫᩍ⫱ጤဨጤဨ㛗㸦ᖹᡂ
(GLWRULDO$GYLVRU\%RDUG㸦ᖹᡂ ᖺ㹼㸧
࣭-RXUQDORI%LRFKHPLVWU\(GLWRULDO$GYLVRU\
%RDUG㸦ᖹᡂ ᖺ㹼㸧
ᖺࠥᖹᡂ ᖺ㸧
࣭᪥ᮏ 7'0 Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
− 97 −
࣭᪥ᮏ 7'0 Ꮫ఍⌮஦㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
࣭ࠕ་⒪⸆Ꮫࠖ๪⦅㞟ጤဨ㛗㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭᪥ᮏ 7'0 Ꮫ఍┘஦㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭᪥ᮏ⸆≀ືែᏛ఍ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭᪥ᮏ་⸆ရ᝟ሗᏛ఍๪఍㛗㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧 ࣭᪥ᮏ⸆≀ືែᏛ఍άືάᛶ໬ጤဨ఍ጤဨ㸦ᖹᡂ
࣭7R[LFRORJ\0HFKDQLVPVDQG0HWKRGV(GLWRULDO
࣭᪥ᮏ⸆๣Ꮫ఍ホ㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
%RDUG㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭%LRSKDUPDFHXWLFV
ᖺࠥ⌧ᅾ㸧
'UXJ
'LVSRVLWLRQ ࣭᪥ᮏ⸆๣Ꮫ఍ᑗ᮶ࣅࢪࣙࣥጤဨ఍ጤဨ㸦ᖹᡂ ᖺࠥᖹᡂ ᖺࠊᖹᡂ ᖺࠥ⌧ᅾ㸧
(GLWRULDO%RDUG㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭3KDUPDFHXWLFDO 5HVHDUFK )LHOG (GLWRU ࣭᪥ᮏ⑓㝔⸆๣ᖌ఍ࡀࢇᑓ㛛⸆๣ᖌ㒊㛛◊ಟጤဨ
0ROHFXODU%LRSKDUPDFHXWLFV㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
఍ጤဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭%LRFKHPLFDO3KDUPDFRORJ\(GLWRULDO$GYLVRU\ ࣭ி㒔ᗓ⑓㝔⸆๣ᖌ఍⌮஦㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭ி㒔ᗓ⑓㝔⸆๣ᖌ఍Ꮫ⾡ጤဨ఍ጤဨ㛗㸦ᖹᡂ %RDUG㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭(XURSHDQ-RXUQDORI3KDUPDFHXWLFDO6FLHQFHV
ᖺࠥ⌧ᅾ㸧
(GLWRULDO%RDUG㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭3KDUPDFRORJ\ DQG 7KHUDSHXWLFV $VVRFLDWH
࠙ࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮ศ㔝ࠚ
ᒸᮧᆒᩍᤵ
(GLWRU㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭ி㒔ᗓ⑓㝔⸆๣ᖌ఍఍㛗㸦ᖹᡂ ᖺࠥᖹᡂ ࣭᪥ᮏ᫬㛫⏕≀Ꮫ఍ ⌮஦㸦 ᖺ㹼㸧
࣭᪥ᮏ⚄⤒⛉Ꮫ఍ ホ㆟ဨ㸦 ᖺ㹼㸧
ᖺ㸧
࣭-RXUQDORI%LRORJLFDO5K\WKPV$GYLVRU\%RDUG
࣭ி㒔ᗓ⸆๣ᖌ఍఍㛗㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭ி㒔ᗓ་⒪ᑂ㆟఍ጤဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
㸦 ᖺ㹼㸧
࣭⊂❧⾜ᨻἲே་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓᑓ㛛ጤဨ
ᅵᒃ㞞ኵ෸ᩍᤵ
࣭᪥ᮏ᫬㛫⏕≀Ꮫ఍ホ㆟ဨ ᖺ ᭶ࡼࡾ
㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭ᩥ㒊⛉Ꮫ┬኱Ꮫタ⨨࣭Ꮫᰯἲேᑂ㆟఍ᑓ㛛ጤဨ ࣭᪥ᮏᏛ⾡᣺⯆఍᪥⊂ඛ➃⛉Ꮫ఍㆟SODQQLQJ
JURXSPDQDJHU ᖺ ᭶ࡼࡾ
㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭
࣭᪥ᮏᏛ⾡఍㆟㐃ᦠ఍ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࣭⊂❧⾜ᨻἲே᪥ᮏᏛ⾡᣺⯆఍⛉Ꮫ◊✲㈝ጤဨ఍
࠙ไᚚศᏊᏛศ㔝ࠚ
ᑓ㛛ጤဨ㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
᥃㇂⚽᫛ᩍᤵ
᱇ᩄஓ෸ᩍᤵ
࣭᪥ᮏࡀࢇศᏊᶆⓗ἞⒪Ꮫ఍ ホ㆟ဨ㸸
㸦 ᖺ
࣭᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ጤဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
㹼⌧ᅾ㸧
࣭᪥ᮏ་⒪⸆Ꮫ఍ホ㆟ဨ
㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
࣭᪥ᮏࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮Ꮫ఍ ୡヰே㸸
࣭᪥ᮏ་⒪⸆Ꮫ఍௦㆟ဨ㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
㸦 ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ་⒪⸆Ꮫ఍௻⏬࣭ࢩ࣏ࣥࢪ࣒࢘ᑠጤဨ఍ጤ
࣭᪥ᮏ⏕⸆Ꮫ఍ ㈈ົᖿ஦㸸㸦 ᖺ㹼⌧ᅾ㸧
ဨ㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
࣭᪥ᮏ⸆Ꮫ఍ ㏆␥ᨭ㒊ጤဨ㸸㸦 ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ་⒪⸆Ꮫ఍௻⏬࣭ࢩ࣏ࣥࢪ࣒࢘ጤဨ఍ጤဨ
㸦ᖹᡂ ᖺࠥ⌧ᅾ㸧
࡜࢖ࣥࢲࢫࢺ࣮࣭ࣜࢺࣆࢵࢡࢫጤဨ㸸
㸦㹼 ᖺ㸧
࣭᪥ᮏ་⒪⸆Ꮫ఍ㄽᩥ㈹㑅⪃ጤဨ఍ጤဨ㸦ᖹᡂ ᖺࠥᖹᡂ ᖺ㸧
࣭ࣂ࢖࢜࢖ࣥࢲࢫࢺ࣮ࣜ༠఍࣭ࣂ࢖࢜ࢧ࢖࢚ࣥࢫ
࣭(GLWRULDO%RDUG%LRO3KDUP%XOO
ᖺ㹼⌧ᅾ
− 98 −
࣭ (GLWRULDO %RDUG 2QFRORJ\ 5HVHDUFK ࣭᝟ሗฎ⌮Ꮫ఍ㄽᩥㄅ⦅㞟ጤဨ㸦 ᖺ ᖺ㸧
ᖺ㹼⌧ᅾ
࣭᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍࢜ࣥࢺࣟ
ࢪ࣮◊✲఍୺ᰝ㸦 ᖺ ᖺ㸧
࣭᪥ᮏ᭷ᶵྜᡂ໬Ꮫ༠఍࣭᪥ᮏ᭷ᶵྜᡂ໬Ꮫ༠఍
࣭132 ἲே ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢪࣕࣃࣥ
ㄅ࣭⦅㞟ጤဨ㸸㸦 ᖺ㹼 ᖺ㸧
⌮஦
࣭᪥ᮏ㎰ⱁ໬Ꮫ఍࣭⦅㞟ᖿ஦㸸㸦㹼 ᖺ㸧
࣭ $VVRFLDWH (GLWRU %LRVFL %LRWHFKQRO
%LRFKHP㹼 ᖺ
࠙ศᏊタィ᝟ሗศ㔝ࠚ
࣭➨ ᅇ᪂⸆๰〇ㄯヰ఍㸦ᖹᡂ ᖺ㸧
࣭ᐇ⾜ጤ
㤿ぢሯᣅᩍᤵ
࣭᝟ሗฎ⌮Ꮫ఍ ᩘ⌮ࣔࢹࣝ໬࡜ၥ㢟ゎỴ◊✲
ဨ㛗
࣭᪥ᮏ⸆Ꮫ఍➨ ᅇᖺ఍㸦ᖹᡂ ᖺ㸧⤌⧊ጤ
఍ 㐠Ⴀጤဨ㸦ᖹᡂ ̽ᖺ㸧
࣭᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍ ホ㆟ဨ
ဨ
࣭➨ ᅇ 22752UJDQL]DWLRQIRU2QFRORJ\DQG
7UDQVODWLRQDO5HVHDUFKᖺḟᏛ఍㸦ᖹᡂ 㸦ᖹᡂ ̽ᖺ㸧
࣭᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍ ࣂ࢖࢜
࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᩍ⫱᳨࣒࢝ࣜ࢟ࣗࣛウጤဨ
ᖺ㸧⤌⧊ጤဨ
࣭᪥ᮏᏛ⾡᣺⯆఍ ⛉Ꮫ◊✲㈝ጤဨ఍ᑓ㛛ጤဨ
఍ጤဨཬࡧᖿ஦㸦ᖹᡂ 㹼 ᖺ㸧
࣭᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍ ᖿ஦㸦ᖹ
㸦ᖹᡂ 㹼 ᖺ㸧
ᡂ ᖺ㸧
᭹㒊᫂෸ᩍᤵ
࣭᪥ᮏ⸆Ꮫ఍ ㏆␥ᨭ㒊ጤဨ㸸㸦 ᖺ㹼⌧ᅾ㸧
࣭᪥ᮏ⸆Ꮫ఍➨ ᅇᖺ఍㸦ᖹᡂ ᖺ㸧⤌⧊ጤ
࣭9LVLWLQJ6FLHQWLVW,QVWLWXWHIRU,QIRFRPP
5HVHDUFK ,5 $JHQF\ IRU 6FLHQFH
7HFKQRORJ\DQG5HVHDUFK$67$56LQJDSRUH
ဨ
࣭➨ ᅇ᪂⸆๰〇ㄯヰ఍㸦ᖹᡂ ᖺ㸧
࣭ᐇ⾜๪
㸦ᖹᡂ 㹼 ᖺࠊᖹᡂ ᖺ㸧
࣭9LVLWLQJ5HVHDUFKHU6FKRRORI&RPSXWLQJ
ጤဨ㛗
1DWLRQDO8QLYHUVLW\RI6LQJDSRUH㸦ᖹᡂ ࠙⤫ྜࢤࣀ࣑ࢡࢫศ㔝ࠚ
ᖺ㸧
࣭6HQLRU9LVLWLQJ6FKRODU)XGDQ8QLYHUVLW\
㔠ஂᐿᩍᤵ
࣭,8%0%,83$&
%LRFKHPLFDO
1RPHQFODWXUH
&KLQD㸦ᖹᡂ ᖺ㹼㸧
࣭9LVLWLQJ
&RPPLWWHH ጤဨ
࣭8QL3URWGDWDEDVHDGYLVRU\FRPPLWWHHጤဨ
࣭%0&%LRLQIRUPDWLFV ࡞࡝㸳ࡘࡢᅜ㝿ㄅࡢ⦅㞟
࣭132 ἲே ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢪࣕࣃࣥ
8QLYHUVLW\
࣭*XHVW&RHGLWRU$VLD3DFLILF%LRWHFK1HZV
1R
6SHFLDO
LVVXH
%LRLQIRUPDWLFV LQ -DSDQ %LRWHFK 6HUYLFHV
37(/WG㸦ᖹᡂ ᖺ㸧
⌮஦㛗
࣭(GLWRULDO$GYLVRU\%RDUG7KH2SHQ0HGLFDO
஬ᩯ㐍෸ᩍᤵ
࣭᝟ሗฎ⌮Ꮫ఍௦⾲఍ဨ ᖺ
,QIRUPDWLFV
࣭᝟ሗฎ⌮Ꮫ఍ࣂ࢖࢜᝟ሗᏛ◊✲఍ᖿ஦ ᖺ
3XEOLVKHUV㸦ᖹᡂ ᖺ㹼㸧
ࠊ୺ᰝ ᖺ
RI
6WUDVERXUJ)UDQFH㸦ᖹᡂ ᖺ㸧
9RO
ጤဨ
3URIHVVRU
-RXUQDO
%HQWKDP
6FLHQFH
࣭(GLWRULDO$GYLVRU\5HYLHZ%RDUG%LRORJLFDO
− 99 −
'DWD0LQLQJLQ3URWHLQ,QWHUDFWLRQ1HWZRUNV
DQG 6\VWHPV %LRORJ\ 3URJUDP &RPPLWWHH
(GLWRUV;LDR/L/LDQG6HH.LRQJ1J,*,
0HPEHU㸦ᖹᡂ 㹼 ᖺ㸧
࣭,(((
*OREDO㸦ᖹᡂ ᖺ㸧
,QWHUQDWLRQDO
&RQIHUHQFH
RQ
࣭$VVRFLDWH(GLWRU,QWHUQDWLRQDO-RXUQDORI
%LRLQIRUPDWLFVDQG%LRPHGLFLQH:RUNVKRSRQ
.QRZOHGJH'LVFRYHU\DQG%LRLQIRUPDWLFV,*,
$SSOLFDWLRQV RI 0DFKLQH /HDUQLQJ LQ
*OREDO㸦ᖹᡂ ᖺ㹼㸧
%LRLQIRUPDWLFV3URJUDP&RPPLWWHH0HPEHU㸦ᖹ
ᡂ ᖺ㸧
࣭$VVRFLDWH(GLWRU.QRZOHGJHDQG,QIRUPDWLRQ
࣭,QWHUQDWLRQDO&RQIHUHQFHRQ%LRLQIRUPDWLFV
6\VWHPV6SULQJHU㸦ᖹᡂ ᖺ㹼㸧
3URJUDP&RPPLWWHH0HPEHU㸦ᖹᡂ ᖺ㸧
࣭$VVRFLDWH (GLWRU %0& %LRLQIRUPDWLFV
࣭,QWHUQDWLRQDO &RQIHUHQFH RQ ,QWHOOLJHQW
%LR0HG&HQWUDO㸦ᖹᡂ ᖺ㹼㸧
6\VWHPV IRU 0ROHFXODU %LRORJ\ 3URJUDP
࣭1LQWK ,((( ,QWHUQDWLRQDO &RQIHUHQFH RQ
&RPPLWWHH0HPEHU㸦ᖹᡂ 㹼 ᖺ㸧
%LRLQIRUPDWLFVDQG%LRHQJLQHHULQJ3URJUDP
,QWHUQDWLRQDO &RQIHUHQFH RQ 'DWD 0LQLQJ
&RPPLWWHHFR&KDLU㸦ᖹᡂ ᖺ㸧
࣭$VLDQ &RQIHUHQFH RQ 0DFKLQH /HDUQLQJ
'DWD㸦ᖹᡂ ᖺ㸧
3URJUDP&RPPLWWHH0HPEHU㸦ᖹᡂ ᖺ㹼㸧
࣭$&0
,QWHUQDWLRQDO
&RQIHUHQFH
:RUNVKRSRQ0LQLQJDQG0DQDJHPHQWRI%LRORJLFDO
RQ
%LRLQIRUPDWLFV DQG &RPSXWDWLRQDO %LRORJ\
࠙ࢼࣀࣂ࢖࢜་⸆๰ᡂ⛉Ꮫศ㔝ࠚ
3URJUDP&RPPLWWHH0HPEHU㸦ᖹᡂ ᖺ㹼㸧
ᅵᒇ๰೺ຓᩍ
࣭$&0 6\PSRVLXP RQ $SSOLHG &RPSXWLQJ
࣭ࣇ࢓࣐ࣝࢩ࢔ࢺࣆࢵࢡࢫᑓ㛛ᑠጤဨ㸦᪥ᮏ⸆Ꮫ
%LRLQIRUPDWLFV 7UDFN 3URJUDP &RPPLWWHH
఍㸧
0HPEHU㸦ᖹᡂ ᖺ㹼㸧
࣭$VLD 3DFLILF %LRLQIRUPDWLFV &RQIHUHQFH
࠙ࢩࢫࢸ࣒๰⸆⛉Ꮫศ㔝ࠚ
ዟ㔝ᜤྐᩍᤵ
3URJUDP&RPPLWWHH0HPEHU㸦ᖹᡂ ᖺ㹼㸧
࣭$&0,QWHUQDWLRQDO&RQIHUHQFHRQ,QIRUPDWLRQ
࣭᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍ ホ㆟ဨ
㸦ᖹᡂ ᖺᗘ㹼㸧
DQG.QRZOHGJH0DQDJHPHQW3URJUDP&RPPLWWHH
࣭᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍ 㛵す㒊
0HPEHU㸦ᖹᡂ ᖺ㸧
఍࣭㒊఍㛗㸦ᖹᡂ ᖺᗘ㹼㸧
࣭,QWHUQDWLRQDO&RQIHUHQFHRQ&RPSXWDWLRQDO
0HWKRGV LQ 6\VWHPV %LRORJ\ 3URJUDP
࣭᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍ࣂ࢖࣓࢜
ࢹ࢕࢝ࣝ◊✲఍ 㐠Ⴀጤဨ㸦ᖹᡂ 㹼 ᖺᗘ㸧
&RPPLWWHH0HPEHU㸦ᖹᡂ ᖺ㸧
࣭(XURSHDQ &RQIHUHQFH RQ &RPSXWDWLRQDO
࣭᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍ -6%L ஦඾
࢚ࢹ࢕ࢱ࣮㸦ᖹᡂ ᖺᗘ㸧
%LRORJ\3URJUDP&RPPLWWHH0HPEHU㸦ᖹᡂ ᖺࠊᖹᡂ ᖺ㸧
࣭,QWHUQDWLRQDO
&RQIHUHQFH
RQ
*HQRPH
,QIRUPDWLFV3URJUDP&RPPLWWHH0HPEHU㸦ᖹᡂ
㹼 ᖺ㸧
࣭,QWHUQDWLRQDO :RUNVKRS RQ %LRLQIRUPDWLFV
− 100 −
ϫ ⫋ဨ⤌⧊
㹙ϫ㹛⫋ဨ⤌⧊
㸦㸯㸧ᩍဨࡢ㓄⨨ࠊ඘㊊࣭௵⏝≧ἣ
ᖹᡂ㸯㸵ᖺᗘ࠿ࡽ㸰㸯ᖺᗘࡲ࡛ࡢ㸳ᖺ㛫ࡢࠊ⸆Ꮫ◊✲⛉ࡢᖖ໅ᩍ⫋ဨࡢ඘㊊≧ἣࢆ㈨ᩱ ,9㸫 ࡟ᣲ
ࡆࡿࠋᖹᡂ㸯㸵ᖺᗘࢆ㝖ࡁࠊ࠸ࡎࢀࡢᖺᗘࡶ⌧ဨᩘࡀᐃဨᩘࢆୗᅇࡗ࡚࠸ࡿࠋ
ᖖ໅ᩍဨࡣࠊᖹᡂ㸯㸷ᖺࡢ་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࡢ᪂タ࡟ࡼࡾ㸲ྡࡢᐃဨቑࡀᐇ⌧ࡋࠊ㸳㸱ྡࡢ⌧
ဨ࡟࡞ࡗࡓࡀࠊ⩣㸰㸮ᖺ࡟ࡣὶ⏝ᐃဨゎᾘࡢࡓࡵ㸯ྡῶ࡟࡞ࡾࠊᖹᡂ㸰㸱ᖺ㸯᭶㸯᪥⌧ᅾࡢ⌧ဨ⥲ᩘ
ࡣ㸳㸮ྡ㸦㈨ᩱ ,9㸫㸰㸧
ࠊࡑࡢෆヂࡣᩍᤵ㸯㸴ྡࠊ෸ᩍᤵ㸯㸶ྡࠊㅮᖌ㸱ྡࠊຓᩍ㸯㸱ྡ࡛࠶ࡿࠋࡇࡢ
࠺ࡕዪᛶࡣ㸱ྡ㸦෸ᩍᤵ㸰ྡࠊㅮᖌ㸯ྡ㸧࡛࠶ࡾࠊࡑࡢ๭ྜࡣࡲࡔప࠸ࠋࡲࡓࠊᖖ໅ᩍဨࡢ࠺ࡕ㸳㸲㸣
ࡣᮏᏛ⸆Ꮫ◊✲⛉ฟ㌟࡛࠶ࡿࡀࠊᖹᡂ㸵ᖺ㸱᭶ࡢ㸶㸵㸣ࠊᖹᡂ㸯㸲ᖺ㸳᭶ࡢ㸵㸱㸣ࠊᖹᡂ㸯㸵ᖺ㸯㸮
᭶㸴㸵㸣࡟ẚ࡭ࡿ࡜ࠊࡑࡢ๭ྜࡣᖺࠎῶᑡࡋ࡚࠸ࡿࠋ
ᖹᡂ㸷ᖺ㸲᭶࡟ࠊ኱Ꮫ㝔㔜Ⅼ໬࡟ࡼࡾ⸆Ꮫ◊✲⛉ࡢ⤌⧊ࡣࠊ㸱ᑓᨷ㸦㸶ᇶᖿㅮᗙࠊ㸱༠ຊㅮᗙ㸧࡜
㸯㝃ᒓ᪋タࠊ㸱༠ຊㅮᗙ࡜࡞ࡗࡓࡀࠊࡑࡢᚋࠊᖹᡂ㸯㸶ᖺᗘ࡟㝃ᒓ⤫ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥࢱ
࣮ࡀタ⨨ࡉࢀࠊᖹᡂ㸯㸷ᖺᗘ࡟ࢼࣀࣂ࢖࢜་⸆๰〇⛉Ꮫㅮᗙࠊᖹᡂ㸰㸮ᖺᗘ࡟ࢩࢫࢸ࣒๰⸆⛉Ꮫㅮᗙ
ࡢ㸰ᐤ㝃ㅮᗙࢆ㛤タࡋࠊ⊂❧ᑓᨷ࡜ࡋ࡚་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࡀ᪂タࡉࢀࡓࠋᖹᡂ㸰㸯ᖺᗘ࡟ࡣ㠉᪂
ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬ࠾ࡼࡧ᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮ࡀ᪂タࠊᖹᡂ㸰㸰ᖺᗘ࡟ࡣ⊂❧ᑓᨷࢆ㝖ࡃ
ಟኈㄢ⛬ࡢᑓᨷࢆ㸱ᑓᨷ࠿ࡽ㸯ᑓᨷ࡟ᨵ⤌ࡋ⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮ࡀタ⨨ࡉࢀࡓࠋ
㸦㈨ᩱ ,9㸫㸱㸧
ࠋ
ᖹᡂ㸰㸲ᖺ࡟ࡣ༤ኈᚋᮇㄢ⛬ࡢᑓᨷࡶྠᵝ࡟ᨵ⤌ࡋࠊᏛ㒊㸴ᖺไ༞ᴗ⪅ࡀ㐍Ꮫࡍࡿ༤ኈㄢ⛬ࡶタ⨨ࡍ
ࡿࡇ࡜࡜࡞ࡗ࡚࠸ࡿࠋࡇࢀࡽࡣࠊ㏆ᖺࡢ⸆Ꮫ◊✲㡿ᇦࡢᗈࡀࡾ࡟ᑐᛂࡋࡓࡶࡢ࡛࠶ࡿࠋ
㸦㈨ᩱ ,9㸫㸱㸧ࠋ
ࡲࡓ㔜Ⅼ໬࡟క࠸ࠊ⸆Ꮫ◊✲⛉ࡢ኱Ꮫ㝔Ꮫ⏕ࡢᐃဨࡣ኱ᖜ࡟ቑຍࡋࠊಟኈㄢ⛬㸴㸲ྡࠊ༤ኈㄢ⛬㸱
㸴ྡ࡜࡞ࡗࡓࡀࠊࡇࢀࢆ㔜Ⅼ໬௨๓㸦ಟኈㄢ⛬㸲㸴ྡࠊ༤ኈㄢ⛬㸰㸰ྡ㸧࡜ẚ㍑ࡍࡿ࡜ࠊ⣙㸯㸬㸲ಸ
࡜࡞ࡗ࡚࠾ࡾࠊࡇࢀࡣࡑࡢࡲࡲᩍဨࡢ◊✲ᣦᑟࡢ㈇ᢸቑ࡜࡞ࡗ࡚࠸ࡿࠋ
Ꮫ㒊࡟ࡘ࠸࡚ࡣࠊᖹᡂ㸯㸶ᖺᗘ࡟⥲ྜ⸆Ꮫ⛉ࢆ㸴ᖺไࡢ⸆Ꮫ⛉࡜㸲ᖺไࡢ⸆⛉Ꮫ⛉࡟ᨵ⤌ࡋࡓࠋ
㸦㸰㸧ᩍ⫱࣭◊✲ᨭ᥼⫋ဨᩘ
⸆Ꮫᩍ⫱࡛ࡣࠊ⸆Ꮫ◊✲⪅ࡸᐇົᢸᙜ⪅ࡢ⫱ᡂ࡜࡜ࡶ࡟ࠊ⸆๣ᖌࡢ㣴ᡂࢆ┠ⓗ࡜ࡍࡿⅬ࡟≉ᚩࡀ࠶
ࡿࡢ࡛ࠊ⮬ࡎ࡜◊✲࣭ᩍ⫱ࡢ⠊ᅖࡀከᒱ࡟ࢃࡓࡿࠋࡲࡓࠊ᪂ࡓ࡞ㅮ⩏ࡸᐇ⩦ࡀᚲせ࡜࡞ࡗ࡚ࡁ࡚࠾ࡾࠊ
㝶᫬ࡑࢀࡽࡢ඘ᐇࢆ⾜ࡗ࡚ࡁࡓࠋᏛ㒊Ꮫ⏕ᐃဨࡣࠊᖹᡂ㸯㸶ᖺᗘࡼࡾ⸆๣ᖌ㣴ᡂࡢࡓࡵࡢ㸴ᖺไᩍ⫱
ࡀ㛤ጞࡉࢀࠊ㸲ᖺไࡢ⸆⛉Ꮫ⛉ᐃဨ㸦㸳㸮ྡ㸧࡜㸴ᖺไࡢ⸆Ꮫ⛉ᐃဨ㸦㸱㸮ྡ㸧࡜࡞ࡗࡓࠋࡲࡓࠊ኱
Ꮫ㝔Ꮫ⏕ᩘ࡟ࡘ࠸࡚ࡶࠊᖹᡂ㸰㸰ᖺᗘࡢಟኈㄢ⛬ࡢᨵ⤌ࠊཬࡧᖹᡂ㸰㸲ᖺᗘ࠿ࡽࡢ༤ኈᚋᮇㄢ⛬ࡢᨵ
⤌ࠊ༤ኈㄢ⛬ࡢ᪂タ࡟ࡼࡾࠊಟኈㄢ⛬⸆⛉Ꮫᑓᨷ㸦㸳㸮ྡ㸧ࠊ་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷ㸦㸯㸲ྡ㸧ࠊ༤ኈ
ᚋᮇㄢ⛬⸆⛉Ꮫᑓᨷ㸦㸰㸰ྡ㸧ࠊ༤ኈㄢ⛬⸆Ꮫᑓᨷ㸦㸯㸳ྡ㸧࡜ቑຍࡋ࡚࠸ࡿࠋ
ࡋ࠿ࡋࠊᮏᏛ࡛ࡣᩍ⫱ࡸ◊✲㐙⾜ࡢୖ࡛ࠊᚲせ࡜ࡍࡿᖖ໅ᩍ⫋ဨࡀ඘㊊ࡉࢀ࡚࠸ࡿ࡜ࡣ࠸࠼࡞࠸ࠋ
ࡑࢀࢆ⿵࠺ࡓࡵ࡟ࠊࡇࢀࡲ࡛ࡣ㠀ᖖ໅ㅮᖌࢆ௵⏝ࡋ࡚ࡇࢀ࡟ᑐᛂࡋ࡚ࡁࡓࠋ㠀ᖖ໅ㅮᖌࡢᩘࡣᖺࠎቑ
ຍࡋ࡚ࠊᖹᡂ㸯㸳ᖺᗘ࡟ࡣ㸰㸮㸱ྡ㸦Ꮫෆࡼࡾ㸷㸵ྡࠊᏛእࡼࡾ㸯㸮㸴ྡ㸧࡟ୖࡗࡓࠋࡋ࠿ࡋࠊࡑࡢ
⩣ᖺࡢ㸯㸴ᖺᗘ࡟ࡣ㸷㸰ྡ㸦Ꮫෆ㸲㸲ྡࠊᏛእ㸲㸶ྡ㸧࡜⃭ῶࡋࠊࡑࡢᚋྠỈ‽ࡀ⥆࠸ࡓࡀࠊ㸰㸯ᖺ
− 101 −
ᗘ࡟ࡣ㸴㸱ྡ㸦Ꮫෆ㸰㸮ྡࠊᏛእ㸲㸱ྡ㸧࡜ࡉࡽ࡟⃭ῶࡋࡓ㸦㈨ᩱϫ㸲㸧ࠋࡇࢀࡣࠊி㒔኱Ꮫࡢ⊂❧
⾜ᨻἲே໬࡟క࠸ࠊ㠀ᖖ໅ㅮᖌ࡟ᑐࡍࡿண⟬㓄ศࡀ↓ࡃ࡞ࡗࡓࡓࡵ࡛࠶ࡿࠋࡇࡢࡇ࡜ࡣࠊᖖ໅ᩍ⫋ဨ
࡟ᑐࡍࡿᩍ⫱㈇ᢸቑ࡜࡞ࡗ࡚࠸ࡿࠋᩍ⫱࣭◊✲ᨭ᥼⤌⧊ࡣࠊᖹᡂ㸯㸰ᖺᗘ࡟ᅗ᭩⣔ࡀ㸯ྡᐃဨ๐ῶ࡜
࡞ࡾ㸰ྡ࡜࡞ࡗࡓ࡯࠿ࠊᢏ⾡⣔ࡶ㸱ྡ࡜࡞ࡗࡓࠋࡋ࠿ࡋࠊ⸆Ꮫ◊✲⛉඲య࡜ࡋ࡚ฎ⌮ࡍ࡭ࡁᴗົ㔞ࡣ
኱ᖜ࡟ቑຍࡋ࡚࠸ࡿࠋ≉࡟㈈ົ఍ィࢩࢫࢸ࣒ࡢᑟධࡣࠊ஦ົ⣔ࡢࡳ࡞ࡽࡎྛศ㔝࡟࠾࠸࡚ࡶࡑࡢฎ⌮
࡟㈇ᢸࡀ࠿࠿ࡾࠊ᫬㛫㞠⏝ࡢ㠀ᖖ໅⫋ဨࡢ኱㔞㞠⏝࡟ࡼࡗ࡚ࡇࢀࢆ⿵ࡗ࡚࠸ࡿࠋࡇࢀࡣ᫂ࡽ࠿࡞㈈ᨻ
ⓗ㈇ᢸቑ࡛ࡶ࠶ࡾࠊᮏ᮶ࡢ◊✲㈝ࢆᅽ㏕ࡍࡿ⤖ᯝ࡜࡞ࡗ࡚࠸ࡿࠋ㸦㈨ᩱ ,9㸫㸳㸧
ࠋ
௨ୖ㏙࡭࡚ࡁࡓࡼ࠺࡟ࠊ㏆ᖺࡢ⸆Ꮫᩍ⫱࣭◊✲ࡣ㡿ᇦࡢᣑ኱࣭ከᵝ໬ࡀᛴ㏿࡟㐍ࢇ࡛࠸ࡿࡀࠊ⊂❧
ἲே໬࡟ࡼࡿࢩࢫࢸ࣒ᨵ㠉ࡢᙳ㡪ࡶ኱ࡁࡃࠊࡲࡓࠊᖹᡂ㸯㸶ᖺᗘ࠿ࡽጞࡲࡗࡓ㸴ᖺไᩍ⫱ࡢᑟධࡣࠊ
ࡉࡽ࡞ࡿ㈇ᢸቑ࡜࡞ࡾࠊ㔜኱࡞ၥ㢟࡜࡞ࡗࡓࠋ
㸦㸱㸧ࢸ࢕࣮ࢳࣥࢢ࣭࢔ࢩࢫࢱࣥࢺࠊࣜࢧ࣮ࢳ࣭࢔ࢩࢫࢱࣥࢺࠊ࠾ࡼࡧ᪥ᮏᏛ⾡᣺
⯆఍≉ู◊✲ဨ᥇⏝≧ἣ
ࢸ࢕࣮ࢳࣥࢢ࣭࢔ࢩࢫࢱࣥࢺไᗘࡣᖹᡂ㸲ᖺᗘ࠿ࡽタࡅࡽࢀࡓࠋ᥇⏝⪅ᩘࡣᖺࠎቑຍࡋ࡚࠸ࡿࡀࠊ
ᖹᡂ㸯㸶ᖺᗘ࡟ࡣࠊಟኈㄢ⛬㸯㸴㸯ྡࠊ༤ኈㄢ⛬㸱㸯ྡ࡜᭱኱࡜࡞ࡗࡓࠋࡇࡢᖺࢆ㝖ࡅࡤྜィᩘ࡜ࡋ
࡚ࡣ⃭ῶࡋ࡚࠾ࡾࠊ㐣༙ᩘࡀ◊✲࣭ᩍ⫱ᣦᑟࡢ⿵ຓ࡟࠶ࡓࡗ࡚࠸ࡿ࡜࠸࠺⤖ᯝ࡛࠶ࡿ㸦㈨ᩱ IV㸫㸴㸧
ࠋ
ࣜࢧ࣮ࢳ࣭࢔ࢩࢫࢱࣥࢺไᗘࡣᖹᡂ㸶ᖺᗘ࡟ጞࡲࡗࡓࡀࠊᖹᡂ㸰㸮ᖺᗘ࡟ࡣ㸰㸯ୡ⣖㹁㹍㹃࡟ࡼࡾ
᥇⏝⪅ࡣቑຍࡋࡓ㸦㈨ᩱ IV㸫㸵㸧ࠋ
᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ࡟ࡣࠊᖹᡂ㸯㸶ᖺ࠿ࡽ㸰㸯ᖺᗘࡲ࡛ࡢ㸲ᖺ㛫࡟ࠊ㸯ᖺࢆ༢఩࡜ࡋ࡚ࡢ࡭
㸶㸶ྡࡀ᥇⏝ࡉࢀࠊࡇࢀࡣᖺᖹᆒ㸰㸰ྡ࡜࡞ࡿ㸦㈨ᩱ IV㸫㸶㸧ࠋ
− 102 −
ϫ㸫㸯 ᩍဨᐃဨࡢ඘㊊≧ἣ
㸦ྛᖺᗘᮎ⌧ᅾ㸧
ᖹᡂ㸯㸶ᖺᗘ
⫋ྡ
༊ศ
ᩍᤵ ෸ᩍᤵ ㅮᖌ ຓᩍ ィ
ே
ே
ே
ே
ே
ᐃ ဨ
⌧ ဨ
⌧ ဨ
๰⸆⛉Ꮫᑓᨷ
⏕࿨⸆⛉Ꮫᑓᨷ
་⒪⸆⛉Ꮫᑓᨷ
㝃ᒓ⸆⏝᳜≀ᅬ
㉁㔞ศᯒᐊ
ᖹᡂ㸯㸷ᖺᗘ
⫋ྡ
༊ศ
ᖹᡂ㸰㸮ᖺᗘ
ᩍᤵ ෸ᩍᤵ ㅮᖌ ຓᩍ ィ
ᖹᡂ㸰㸯ᖺᗘ
ᩍᤵ
෸ᩍᤵ
ㅮᖌ
ຓᩍ
ィ
ᩍᤵ ෸ᩍᤵ ㅮᖌ ຓᩍ
ィ
ே
ே
ே
ே
ே
ே
ே
ே
ே
ே
ே
ே
ே
ே
ே
ᐃ ဨ
⌧ ဨ
⌧ ဨ
๰⸆⛉Ꮫᑓᨷ
⏕࿨⸆⛉Ꮫᑓᨷ
་⒪⸆⛉Ꮫᑓᨷ
་⸆๰ᡂ᝟ሗ⛉Ꮫ
ᑓᨷ
⤫ྜ⸆Ꮫ
ࣇࣟࣥࢸ࢕࢔ᩍ⫱
ࢭࣥࢱ࣮
㝃ᒓ⸆⏝᳜≀ᅬ
㉁㔞ศᯒᐊ
− 103 −
ϫ̿㸰ᩍဨࡢฟ㌟◊✲⛉
㸦ᖹᡂ ᖺ㸯᭶㸯᪥⌧ᅾ㸧
༊ ศ
⌧ ဨ
ி኱⸆Ꮫ
ࡑࡢ௚
ࡑࡢ௚ࡢෆヂ
◊✲⛉
ே
ே
ே
ி኱་ ࠊி኱㎰ ࠊி኱ᕤ ࠊ㜰኱⸆ ࠊ໭኱་ ࠊ
ᩍ ᤵ
෸ᩍᤵ
ㅮ ᖌ
ຓ ᩍ
኱㜰ᕷ኱⌮ ࠊி㒔ᗓ❧་኱ ࠊ៞᠕኱⌮ᕤ ி኱㎰ ࠊி኱ᕤ ࠊᮾ኱⌮ ࠊᮾ኱⸆ ࠊ㜰኱⌮ ࠊ
ᒱ㜧⸆⛉኱ ி኱⌮ ࠊி኱ᕤ ࠊி኱⏕࿨ ࠊᮾ኱㎰ ࠊ
ᮾ໭኱⏕࿨ ィ
㸦㸧
㸦㸧
ி኱⸆Ꮫ
ࡑࡢ௚
㸦≉ᐃᩍဨ㸧
༊ ศ
⌧ ဨ
ࡑࡢ௚ࡢෆヂ
◊✲⛉
ே
ே
ே
ᩍ ᤵ
෸ᩍᤵ
ி኱་ ࠊᒣཱྀ኱་ ㅮ ᖌ
ຓ ᩍ
໭኱⸆ ࠊྡ኱ᕤ ࠊ஑኱㺚㺛㺡㺯⏕࿨ ࠊᮾᕤ኱⌮ᕤ ⁠㈡་኱ ࠊᐩᒣ┴❧኱ᕤ ࠊྡྂᒇᕷ኱⸆ ィ
㸦㸧
㸦㸧
− 104 −
⎇ⓥಽ㊁㧕
Φ࡯㧟‫❱⚵ޓ‬࿑
⮎ຠ᦭ᯏ⵾ㅧቇ
⮎ຠวᚑൻቇ
⮎ຠഃ⵾ൻቇ⻠ᐳ
⮎ຠಽሶൻቇ
⮎ຠ⾗Ḯቇ
⮎ຠᯏ⢻⸃ᨆቇ
⮎ຠᯏ⢻⛔ᓮቇ⻠ᐳ
᭴ㅧ↢‛⮎ቇ
ࠥࡁࡓഃ⮎⑼ቇ
⮎ຠ⵾೷⸳⸘ቇ⻠ᐳ
⵾೷ᯏ⢻⸃ᨆቇ
̪↢‛᦭ᯏวᚑൻቇ
♖ኒ᦭ᯏวᚑൻቇ㧖
↢૕ಽሶ⹺⼂ቇ
↢૕ಽሶ⮎ቇ⻠ᐳ
ಽሶᓸ↢‛ቇ
↢૕ᯏ⢻⸃ᨆቇ
⮎⑼ቇኾ᡹
ᄢቇ㒮⮎ቇ⎇ⓥ⑼
↢૕ᯏ⢻⮎ቇ⻠ᐳ
ㆮવሶ⮎ቇ
̪↢ℂᵴᕈ೙ᓮቇ٨
↢૕ᖱႎ೙ᓮቇ
↢૕ᖱႎ⮎ቇ⻠ᐳ
̪␹⚻ᯏ⢻೙ᓮቇ٨
̪↢૕ᯏ⢻ൻቇ
↢૕ᯏ⢻ൻቇ㧖
⮎ຠേᘒ೙ᓮቇ
⮎ຠേᘒක≮⮎ቇ⻠ᐳ
⮎ຠ૞↪⸃ᨆቇ
⥃ᐥ⮎ቇᢎ⢒
∛ᘒᯏ⢻ಽᨆቇ
∛ᘒᯏ⢻⸃ᨆቇ⻠ᐳ
∛ᘒᖱႎ⮎ቇ
̪ක≮⮎೷ቇ
ක≮⮎೷ቇ‫ڎ‬
⮎ℂࠥࡁࡒࠢࠬ
ࠤࡕࠥࡁࡒࠢࠬ
ࠪࠬ࠹ࡓࡃࠗࠝࡠࠫ࡯
ක⮎ഃᚑᖱႎ⑼ቇኾ᡹
ක⮎ഃᚑᖱႎ⑼ቇ⻠ᐳ
ࠪࠬ࠹ࡓࠤࡕ࠮࡜ࡇ࡯㧔೙ᓮಽሶቇ㧕
ࠪࠬ࠹ࡓࠤࡕ࠮࡜ࡇ࡯㧔ഃ⮎⸘▚ൻቇ㧕
⛔วࠥࡁࡒࠢࠬ
ಽሶ⸳⸘ᖱႎ
ነ㒝⻠ᐳ‫ࠝࠗࡃࡁ࠽ޓ‬ක⮎ഃᚑ⑼ቇ⻠ᐳ
ነ㒝⻠ᐳ‫ࡓ࠹ࠬࠪޓ‬ഃ⮎⑼ቇ⻠ᐳ
⛔ว⮎ቇᢎ⢒㐿⊒
⛔ว⮎ቇࡈࡠࡦ࠹ࠖࠕᢎ⢒࠮ࡦ࠲࡯
వ┵⮎ቇᢎ⢒㐿ᜏ
⥃ᐥ⮎ቇᢎ⢒㐿ᜏ
ක⮎ຠᢎ⢒㐿⊒
⛔ว⮎ቇᢎ⢒㐿⊒࠮ࡦ࠲࡯
ഃ⮎⑼ቇᢎ⢒
ታ〣⥃ᐥ⮎ቇ
ㅪ៤ᡰេ࡙࠾࠶࠻
5%7
వㅴ࠽ࡁࡃࠗࠝ⎇ⓥ࡙࠾࠶࠻
0$7
㕟ᣂ⊛࠽ࡁࡃࠗࠝഃ⮎⎇ⓥ᜚ὐ
⮎‛ㅍ㆐⎇ⓥ⃰
&5)
ක⮎ഃ಴⎇ⓥ⃰
5*)
߇ࠎ⎇ⓥࠣ࡞࡯ࡊ
ᦨవ┵ഃ⮎⎇ⓥ࠮ࡦ࠲࡯
ࠕ࡞࠷ࡂࠗࡑ࡯⎇ⓥࠣ࡞࡯ࡊ
㒝ዻ⮎↪ᬀ‛࿦
̪දജ⻠ᐳ㧩㧖ൻቇ⎇ⓥᚲ‫ڎޓ‬කቇㇱ㒝ዻ∛㒮
‫⎇ࠬ࡞ࠗ࠙ڎޓޓޓޓޓޓޓޓޓޓޓޓ‬ⓥᚲ‫ޓ‬٨↢๮⑼ቇ⎇ⓥ⑼
⮎⑼ቇ⑼
⮎ቇ⑼
⮎ቇㇱ
✚ോដ
⚻ℂដ
⎇ⓥផㅴដ
੐ോㇱ
ᢎോដ
᦭ᯏᓸ㊂ర⚛ಽᨆ✚ว⎇ⓥᣉ⸳
࿑ᦠដ
− 105 −
ϫ㸫㸲 㠀ᖖ໅ㅮᖌᅾ⡠⪅ᩘ
Ꮫ㒊
༊ศ
ᖺᗘ
኱Ꮫ㝔
ィ
Ꮫෆ
Ꮫእ
Ꮫෆ
Ꮫእ
Ꮫෆ
Ꮫእ
ᖹᡂ㸯㸶ᖺᗘ
ᖹᡂ㸯㸷ᖺᗘ
ᖹᡂ㸰㸮ᖺᗘ
ᖹᡂ㸰㸯ᖺᗘ
ϫ㸫㸳 ᩍ⫱࣭◊✲ᨭ᥼⫋ဨᩘ㸦ᖹᡂ ᖺᗘࠥ ᖺᗘ㸧
㸦ྛᖺᗘ ᭶ ᪥⌧ᅾ㸧
஦ົ⫋ဨ
㠀ᖖ໅⫋ဨ
㸦⾜୍㸧 㸦⾜஧㸧
ィ
ィ
ປົ⣔
ᢏ⾡࣭ᢏ⬟⣔
ᅗ᭩⣔
ᩍᐊ
஦ົᐊ
ᖺᗘ
஦ົ⣔
ᩍົ⣔
◊✲ဨ
ィ
ປົ⣔
ᢏ⬟⣔
ᢏ⾡⣔
ィ
ᅗ᭩⣔
㸦⾜୍㸧
஦ົ⣔
ᩍົ⫋ဨ
ᢏ⾡⫋ဨ
༊ศ
ᖹᡂ
ᖺᗘ
ᖹᡂ
ᖺᗘ
ᖹᡂ
ᖺᗘ
ᖹᡂ
ᖺᗘ
− 106 −
ϫ㸫㸴 ࢸ࢕࣮ࢳࣥࢢ࣭࢔ࢩࢫࢱࣥࢺ᥇⏝⪅୍ぴ⾲
ᖺᗘ
ಟኈ㸭༤ኈ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ே
ே
ே
ᖹᡂ ᖺᗘ
ே
ಟኈ
༤ኈ
ィ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ே
ே
ே
ϫ㸫 ࣜࢧ࣮ࢳ࣭࢔ࢩࢫࢱࣥࢺ᥇⏝⪅୍ぴ⾲
ᖺᗘ
ಟኈ㸭༤ኈ
ே
༤ኈ
ィ
㹂㹁㸰
㹂㹁㸯
ϫ㸫㸶 ᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨᅾ⡠≧ἣ
༊ศ
ᖺᗘ
ᖹᡂ㸯㸶ᖺᗘ
ᖹᡂ㸯㸷ᖺᗘ
ᖹᡂ㸰㸮ᖺᗘ
ᖹᡂ㸰㸯ᖺᗘ
㹎㹂
㹂㹁㸱
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝ ࠞࡣᙜヱᖺᗘࡢ᥇ᢥ⪅ᩘ࡛ෆᩘ
− 107 −
Ϭ ⟶⌮࣭㐠Ⴀ
㹙Ϭ㹛⟶⌮࣭㐠Ⴀ
኱Ꮫ࡟࠾࠸࡚ࡣࠊ◊✲࣭ᩍ⫱࡜⟶⌮࣭㐠Ⴀࡀ⾲⿬୍య࡜࡞ࡗ࡚ຠ⋡ⓗ࠿ࡘ෇⁥࡟ᶵ⬟ࡍࡿࡇ࡜࡟ࡼ
ࡾࠊ⤌⧊ࡢάຊࡀ⏕ࡲࢀࡿ࡜࠸࠺ㄆ㆑࡟ᇶ࡙࠸࡚ࠊ⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊࡛ࡣᩍဨ࡜஦ົ⫋ࡢ༠ຊ࣭㐃
ᦠࢆᇶ┙࡜ࡋࡓ⟶⌮࣭㐠Ⴀ⤌⧊ࡀタࡅࡽࢀ࡚࠸ࡿࠋ≉࡟ࠊᑠつᶍ㒊ᒁࡢᑠᘔࡾࡢຠࡃ≉ᚩࢆ⏕࠿ࡋ࡚ࠊ
ᖹᡂ㸷ᖺࡢ኱Ꮫ㝔㔜Ⅼ໬ᚋࡶ෇⁥࡞㐠Ⴀࡀ⾜ࢃࢀ࡚ࡁࡓࠋࡋ࠿ࡋࠊᩘḟ࡟΅ࡿᐃဨ๐ῶ࡜஦ົ㔞ࡢᛴ
⃭࡞ቑຍ࡟కࡗ࡚ࠊ㟁⟬໬➼࡟ࡼࡿྜ⌮໬࡟ࡼࡗ࡚ࡶ⟶⌮࣭㐠Ⴀࡢ㐺ṇᇳ⾜࡟ᅔ㞴ࢆక࠺≧ἣ࡜࡞ࡾࠊ
୍᪉ࠊᅜ❧኱Ꮫἲே໬࡟క࠺ᗈ⠊࡞஦ົࢩࢫࢸ࣒ࡢኚ᭦ࡀ⾜ࢃࢀࡓࡇ࡜࠿ࡽࠊ⟶⌮࣭㐠Ⴀయไࡢᙉ໬
ࡀႚ⥭ࡢㄢ㢟࡜࡞ࡾࠊࡑࡢᡂྰ࡟ࡼࡗ࡚ᮏ᮶ࡢ◊✲࣭ᩍ⫱࡬ࡢᙳ㡪ࡶᠱᛕࡉࢀࡿ≧ែ࡟࠶ࡿࠋ
(㸯) ⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ࡢ⤌⧊
⸆Ꮫ◊✲⛉࡟ࡣࠊ⸆⛉Ꮫᑓᨷ㸦㸶ᇶᖿㅮᗙ㸰㸱ศ㔝㸧
ࠊ་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷ㸦㸯ᇶᖿㅮᗙ㸵ศ㔝㸧
ࠊ
ࡀタ⨨ࡉࢀ࡚࠸ࡿࠋྛᑓᨷ࡟ࡣᑓᨷ㛗ࡀ⨨࠿ࢀࠊྛᑓᨷᅛ᭷ࡢၥ㢟ࢆᑂ㆟ࡋࠊᑓᨷࡢ㐠Ⴀ࡟ᙜࡓࡿࠋ
ࡲࡓࠊ㸷ࡢᇶᖿㅮᗙ࡟ຍ࠼࡚ࠊ኱Ꮫ㝔࠶ࡿ࠸ࡣᏛ㒊ࡢ◊✲ᩍ⫱ࢆጤკࡋࡓᮏᏛ௚◊✲⛉ࡢ㸱༠ຊㅮᗙ ศ㔝ࡀཧ⏬ࡋ࡚࠸ࡿࠋ㈨ᩱϬ㸫㸯
ࡇࢀࡽࢆ⟶⌮࣭㐠Ⴀࡍࡿ⤌⧊࡜ࡋ࡚◊✲⛉ᩍᤵ఍ࠊ◊✲⛉఍㆟࠾ࡼࡧ◊✲⛉༠㆟఍ࡀタ⨨ࡉࢀ࡚࠸
ࡿࠋ◊✲⛉ᩍᤵ఍ࡣ◊✲⛉ᇶᖿㅮᗙࡢᩍᤵ࡛ᵓᡂࡉࢀࠊ◊✲⛉ே஦㸦◊✲⛉㛗ೃ⿵⪅ࡢ㑅⪃ࠊྛ✀ጤ
ဨ఍ጤဨࡢ㑅ฟࠊᑓᨷ㛗ࡢ㑅ฟࠊ◊✲⛉ᩍဨೃ⿵⪅ࡢ㑅⪃➼㸧
ࠊ◊✲⛉ண⟬㛵㐃஦㡯➼ࢆᑂ㆟ࡍࡿࠋ◊
✲⛉఍㆟ࡣࠊ◊✲⛉ᇶᖿㅮᗙࠊ༠ຊㅮᗙཬࡧ኱Ꮫ㝔◊✲ᩍ⫱ࢆጤკࡋࡓᮏᏛᩍᤵ࡛ᵓᡂࡉࢀࠊ኱Ꮫ㝔
ࡢᩍົࠊᏛ఩㸦ಟኈ࠾ࡼࡧ༤ኈ㸧࡟㛵㐃ࡍࡿ஦㡯ࢆᑂ㆟ࡍࡿࠋ◊✲⛉༠㆟఍ࡣࠊ◊✲⛉ᇶᖿㅮᗙࡢᩍ
ᤵࠊ෸ᩍᤵࠊᑓ௵ㅮᖌ࠾ࡼࡧ༠ຊㅮᗙࡢᩍᤵ࡛ᵓᡂࡉࢀࠊ඲Ꮫ࠾ࡼࡧ⸆Ꮫ◊✲⛉ㅖ఍㆟ࡢሗ࿌ࢆཷࡅ
ࡿ࡜࡜ࡶ࡟ࠊ◊✲⛉࣭Ꮫ㒊ෆࡢㅖ஦㡯ࢆᑂ㆟ࡍࡿࠋ
⸆Ꮫ◊✲⛉㛗௵ᮇ㸰ᖺࡣ⸆Ꮫ㒊㛗ࢆව௵ࡋࠊ⸆Ꮫ◊✲⛉ᩍᤵ఍ࠊ⸆Ꮫ㒊ᩍᤵ఍ࠊ⸆Ꮫ◊✲⛉఍㆟ࠊ
⸆Ꮫ◊✲⛉༠㆟఍ࡢ㆟㛗ࢆົࡵࡿࠋࡲࡓࠊᇶᖿㅮᗙࡢᩍᤵ࠿ࡽ㸰ேࡀ๪◊✲⛉㛗࡜ࡋ࡚◊✲⛉㛗࡟ࡼ
ࡾᣦྡࡉࢀࠊ◊✲⛉㛗ࡢᰯົࢆ⿵బࡍࡿࠋ⸆Ꮫ◊✲⛉ᩍᤵ఍ࠊ◊✲⛉఍㆟ࠊ◊✲⛉༠㆟఍ࡣཎ๎࡜ࡋ
࡚᭶㸯ᅇ㛤ദࡉࢀࠊ஦ົ㛗ࠊ⥲ົ᥃㛗ࠊ఍ィ᥃㛗ࠊ◊✲᥎㐍᥃㛗࠾ࡼࡧᩍົ᥃㛗ࡀ㝙ᖍࡍࡿࠋ
⸆Ꮫ◊✲⛉ᩍဨࡣ⥲࡚⸆Ꮫ㒊ᩍဨࢆවᢸࡋࠊ◊✲⛉࠾ࡼࡧᏛ㒊ࡢᩍ⫱࣭◊✲ࢆศᢸࡋ࡚࠸ࡿࠋ⸆Ꮫ
◊✲⛉ࡀ㛵୚ࡍࡿᙧ࡛ࠊ⌧ᅾከࡃࡢ඲Ꮫጤဨ఍ࠊ௚㒊ᒁཬࡧ㒊ᒁෆጤဨ఍ࡀタ⨨ࡉࢀ࡚࠾ࡾࠊ㈨ᩱϬ
㸫㸰࡟ࡣෆ୺せ࡞ࡶࡢࢆᣲࡆࡓࠋࡇࢀࡽࡢጤဨ఍ࡢ࡯࡜ࢇ࡝࡟ᩍᤵࡀጤဨ࡜ࡋ࡚㛵୚ࡍࡿࡢ࡛ࠊྛᩍ
ᤵࡣ」ᩘࡢጤဨ఍ࡢጤဨ࡜࡞ࡿᚲせࡀ࠶ࡾࠊྛጤဨ఍ࡢᖺ㛫㛤ദᅇᩘࢆ⪃៖ࡍࡿ࡜ࠊᑠつᶍ㒊ᒁ࡟࡜
ࡗ࡚ࡣᴟࡵ࡚኱ࡁ࡞㈇ᢸ࡜࡞ࡗ࡚࠸ࡿࠋ
Ꮫ㒊࡟࠾࠸࡚ࡣࠊᖹᡂ ᖺࡢ኱Ꮫ㝔㔜Ⅼ໬࡟క࠸ࠊࡑࢀࡲ࡛ࡢ⸆Ꮫ⛉࣭〇⸆໬Ꮫ⛉࡟ࡼࡿ㸰Ꮫ⛉ไ
ࢆᗫࡋࠊ⥲ྜ⸆Ꮫ⛉ࡢ㸯Ꮫ⛉࡜ࡋࡓࠋᏛ㒊ࢆවᢸࡍࡿ◊✲⛉ᇶᖿㅮᗙࡢᩍᤵ࡛ᵓᡂࡉࢀࡿ⸆Ꮫ㒊ᩍᤵ
఍࡟࠾࠸࡚ࠊᏛ㒊ே஦㸦Ꮫ㒊㛗ೃ⿵⪅ࡢ㑅⪃ࠊホ㆟ဨࡢ㑅ฟࠊᩍဨೃ⿵⪅ࡢ㑅⪃㸧ࠊධᏛ⪅ࡢ㑅ᢤࠊᏛ
㒊Ꮫ⏕ࡢᩍົࠊᏛ㒊ண⟬➼ࡢ㛵㐃஦㡯ࢆᑂ㆟ࡍࡿࠋࡋ࠿ࡋᖹᡂ㸯㸶ᖺ㸲᭶ࡼࡾࠊ⸆Ꮫ㒊ࡣ෌ᗘ⸆⛉Ꮫ
⛉࡜⸆Ꮫ⛉ࡢ㸰Ꮫ⛉ไ࡜࡞ࡗࡓࡓࡵࠊ୧Ꮫ⛉࡟Ꮫ⛉㛗ࢆ⨨ࡁࠊᏛ⛉ࡢ㐠Ⴀ࡟ᙜࡓࡿయไ࡜࡞ࡗ࡚࠸ࡿࠋ
− 109 −
㸦㸰㸧஦ົ㒊⤌⧊࣭ᢏ⾡㒊⤌⧊
⸆Ꮫ◊✲⛉࠾ࡼࡧ⸆Ꮫ㒊࡟ࡣඹ㏻ࡢ஦ົ㒊࠾ࡼࡧᢏ⾡㒊ࡀ⨨࠿ࢀ࡚࠸ࡿࠋ஦ົ㒊࡟ࡣ⥲ົ᥃ࠊ఍ィ
᥃ࠊ◊✲᥎㐍᥃ࠊᩍົ᥃ࠊᅗ᭩᥃ࡀ⨨࠿ࢀࠊ஦ົ㛗ࡀࡇࢀࢆ⤫ᣓࡋ࡚࠸ࡿࠋࡲࡓࠊᐃဨ๐ῶ࡜஦ົ㔞
ࡢቑ኱࡟ᑐᛂࡍࡿࡓࡵࠊᚲせᩘࡢ㠀ᖖ໅⫋ဨࢆ㞠⏝ࡋ࡚࠸ࡿࠋᢏ⾡㒊࡟ࡣ᭷ᶵᚤ㔞ඖ⣲ศᯒᐊࡀ⨨࠿
ࢀࠊᑓ㛛ᢏ⾡࡟ࡼࡿ◊✲࣭ᩍ⫱ࡢᨭ᥼ᴗົࢆ⾜࡞ࡗ࡚࠸ࡿࠋ◊✲⛉㛗ࡀᢏ⾡㒊㛗ࢆව௵ࡋࠊࡑࡢୗ࡟
ᑓ௵ᢏ⾡ᑓ㛛⫋ဨ࠾ࡼࡧᢏ⾡⫋ဨࡀ㓄⨨ࡉࢀ࡚࠸ࡿࠋ
⸆Ꮫ◊✲⛉࡟ࡣ㒊ᒁ㝃ᒓ᪋タ࡜ࡋ࡚⸆⏝᳜≀ᅬࡀ⨨࠿ࢀࠊ⸆Ꮫ◊✲⛉㛗ࡀᅬ㛗ࢆවᢸࡋ࡚࠸ࡿࠋࡲ
ࡓࠊ◊✲⛉ෆ⤌⧊࡜ࡋ࡚ᖹᡂ㸯㸶ᖺᗘࡼࡾ⤫ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥࢱ࣮ࠊᖹᡂ㸯㸷ᖺᗘ࡟ࢼࣀ
ࣂ࢖࢜་⸆๰〇⛉Ꮫㅮᗙࠊᖹᡂ㸰㸮ᖺᗘ࡟ࢩࢫࢸ࣒๰⸆⛉Ꮫㅮᗙࡢ㸰ᐤ㝃ㅮᗙࢆ㛤タࡋࠊ⊂❧ᑓᨷ࡜
ࡋ࡚་⸆๰ᡂ᝟ሗ⛉Ꮫᑓᨷࡀ᪂タࡉࢀࡓࠋᖹᡂ㸰㸯ᖺᗘ࡟ࡣ㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬ࠾ࡼࡧ᭱
ඛ➃๰⸆◊✲ࢭࣥࢱ࣮ࡀ᪂タࠊᖹᡂ㸰㸰ᖺᗘ࡟ࡣ⊂❧ᑓᨷࢆ㝖ࡃಟኈㄢ⛬ࡢᑓᨷࢆ㸱ᑓᨷ࠿ࡽ㸯ᑓᨷ
࡟ᨵ⤌ࡋࠊ⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮ࡀタ⨨ࡉࢀࡓࠋ
㸦㸱㸧ᩍဨೃ⿵⪅ࡢ㑅⪃᪉ἲ
⸆Ꮫ◊✲⛉ࡢᩍဨ㸦ᩍᤵࠊ෸ᩍᤵࠊㅮᖌࠊຓᩍ㸧ࡢ㑅⪃ࡣ⸆Ꮫ◊✲⛉ෆつ࡟ᚑࡗ࡚ᩍᤵ఍࡟࠾࠸࡚
⾜࡞ࢃࢀࡿࠋᩍဨ࡟Ḟဨࡀ⏕ࡌࡓ㸦ᡈ࠸ࡣ⏕ࡌࡿࡇ࡜ࡀ☜ᐇ࡞㸧ሙྜࠊᩍᤵ఍࡟㑅⪃ጤဨ఍ࡀタ⨨ࡉ
ࢀࠊཎ๎࡜ࡋ࡚බເ࡟ࡼࡾೃ⿵⪅ࢆເ㞟ࡋࠊ᭩㠃ᑂᰝ࠾ࡼࡧᚲせ࡟ᛂࡌ࡚㠃᥋ࢆ⾜࡞ࡗࡓᚋࠊೃ⿵⪅
ࢆ㑅ᐃࡋࠊᩍᤵ఍࡟ሗ࿌ࡍࡿࠋᩍᤵ఍ࡣෆつ࡟ᚑࡗ࡚ᢞ⚊࡟ࡼࡾೃ⿵⪅ࢆỴᐃࡍࡿࠋຓᩍࡢ௵ᮇࡣ㸳
ᖺ㸦෌௵ྍ㸧࡜ࡍࡿࡇ࡜ࢆ⏦ࡋྜࢃࡏ࡚࠸ࡿࠋ
− 110 −
− 111 −
Ϭ㸫㸰ྛ✀ጤဨ఍
㸦◊✲⛉ෆ㸧
ጤ
ဨ
఍
ྡ
ᩍົጤဨ఍
ᵓ
ᡂ
ᡤ
⟶
஦
㡯 ጤဨ㛗ࠊྛㅮᗙᩍᤵཪࡣ෸ᩍ
Ꮫ㒊࣭኱Ꮫ㝔ࡢ࣒࢝ࣜ࢟ࣗࣛ⦅ᡂ➼
ᤵ㸯ྡ
࡟㛵ࡍࡿ஦㡯
◊✲⛉㛗ࠊ๓◊✲⛉㛗ࠊ๪◊
ᑗ᮶ィ⏬ጤဨ఍
✲⛉㛗ࠊホ㆟ဨࠊᑓᨷ㛗ࠊᏛ
ᑗ᮶ィ⏬࠾ࡼࡧᴫ⟬せồ࡟㛵ࡍࡿ
⛉㛗ࠊ◊✲⛉㛗ࡢᣦྡࡍࡿ
஦㡯
⪅ࠊ஦ົ㛗
ධヨ➼ၥ㢟᳨ウጤဨ఍
኱Ꮫ㝔ᑠጤဨ఍
ධヨ➼ၥ㢟᳨ウጤဨ఍
Ꮫ㒊ᑠጤဨ఍
ᅗ᭩ጤဨ఍
Ᏻ඲⎔ቃጤဨ఍
⮬ᕫホ౯➼ㄪᰝ᳨ウጤ
ဨ఍
වᴗᑂᰝጤဨ఍
ྛᑓᨷ㛗ࠊྛᑓᨷᩍᤵ㸯ྡ
ྛᑓᨷ㛗ࠊ඲ᩍᤵ࠿ࡽ㸯ྡࠊ
ධᏛ⪅㑅ᢤ᪉ἲ᳨ウጤဨ఍
ጤဨ
኱Ꮫ㝔ධᏛ⪅㑅ᢤ᪉ἲ➼࡟㛵ࡍࡿ
஦㡯
Ꮫ㒊ධᏛ⪅㑅ᢤ᪉ἲ➼࡟㛵ࡍࡿ஦
㡯
ጤဨ㛗ࠊྛㅮᗙᩍᤵཪࡣ෸ᩍ
ᅗ᭩ࡢ㑅ᐃ࣭㉎ධཬࡧᅗ᭩㈝ࡢண
ᤵ㸯ྡ
⟬࣭Ỵ⟬࡟㛵ࡍࡿ஦㡯
Ᏻ඲ጤဨ఍ጤဨࠊྛㅮᗙᩍဨ
᪋タ࣭タഛࡢᏳ඲⟶⌮ཬࡧᏛ⏕࣭⫋
㸯ྡ
ဨ➼ࡢᏳ඲࡟㛵ࡍࡿ஦㡯
◊✲⛉㛗ࠊ๪◊✲⛉㛗ホ౯
ᢸᙜࠊホ㆟ဨࠊᑓᨷ㛗ࠊᩍ
⮬ᕫⅬ᳨࣭ホ౯ࡢᐇ᪋࡟㛵ࡍࡿ஦㡯
ົጤဨ㛗ࠊ஦ົ㛗
◊✲⛉㛗ࠊ๪◊✲⛉㛗ࠊ஦ົ
Ⴀ฼௻ᴗ➼ࡢ஦ᴗ࡟㛵୚ࡍࡿවᴗ
㛗
ࢆᑂᰝࡍࡿ஦㡯
◊✲⛉㛗ࠊ࢚ࢿࣝࢠ࣮⟶⌮୺
࢚ࢿࣝࢠ࣮⟶⌮ጤဨ఍ ௵⪅ࠊᑓᨷ㛗ࠊ⏕࿨⛉Ꮫ◊✲
࢚ࢿࣝࢠ࣮⟶⌮࡟㛵ࡍࡿ஦㡯
⛉ᩍᤵࠊ஦ົ㛗
ᅜ㝿஺ὶጤဨ఍
◊✲⛉㛗ࠊᑓᨷ㛗ࠊᅜ㝿஺ὶ
ጤဨ఍ጤဨ
− 112 −
ᅜ㝿஺ὶ࡟㛵ࡍࡿ஦㡯
◊✲⛉㛗ࠊ⸆ရ๰ᡂ໬Ꮫㅮᗙ
ඖ⣲ศᯒ࣭㉁㔞ศᯒ◊
ᩍᤵࠊ෸ᩍᤵཪࡣຓᩍⱝᖸ
᭷ᶵᚤ㔞ඖ⣲ศᯒ⥲ྜ◊✲᪋タࡢ
✲᪋タ㐠Ⴀጤဨ఍
ྡࠊ஦ົ㛗ࠊඖ⣲ศᯒ⥲ྜ◊
⟶⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦㡯
✲᪋タࡢᢏ⾡⫋ဨ
㛵ಀㅮᗙࡢᩍᤵཪࡣ෸ᩍᤵ
ື≀ᐇ㦂ጤဨ఍
ⱝᖸྡ
ື≀㣫⫱ᐊ㐠Ⴀጤဨ఍ 㛵ಀㅮᗙࡢᩍဨⱝᖸྡ
ື≀ᐇ㦂ࡢᐇ᪋࡟㛵ࡍࡿ஦㡯
ື≀㣫⫱ᐊࡢ⟶⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦
㡯
ጤ
ဨ
఍
ྡ
ᵓ
ᡂ
ᡤ
⟶
஦
㡯 ㉸ఏᑟ 105 ࢫ࣌ࢡࢺࣟ
⸆Ꮫ㒊ࡢᩍᤵⱝᖸྡࠊ⸆Ꮫ㒊
Ꮫෆඹྠ฼⏝࡜ࡋ࡚ࡢ㉸ఏᑟ 105 ࢫ
࣓࣮ࢱ࣮ᐊ㐠Ⴀ⟶⌮ጤ
௨እࡢᩍᤵཪࡣ෸ᩍᤵⱝᖸ
࣌ࢡࢺ࣓࣮ࣟࢱ࣮ᐊࡢ⟶⌮࣭㐠Ⴀ࡟
ဨ఍
ྡ
㛵ࡍࡿ஦㡯
ᐇ㦂᤼Ỉ⣔⟶⌮ጤဨ఍ ྛㅮᗙᩍᤵཪࡣ෸ᩍᤵ㸯ྡ
ᐇ㦂᤼Ỉࡢ⟶⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦㡯
᭷ᶵᗫᾮฎ⌮ᐇ⾜ጤဨ 㛵ಀㅮᗙࡢᩍဨⱝᖸྡ
᭷ᶵᗫᾮࡢ⟶⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦㡯
↓ᶵᶵᗫᾮฎ⌮ᐇ⾜ጤ
ဨ
㛵ಀㅮᗙࡢᩍဨⱝᖸྡ
◊✲⛉㛗ࠊ5, ⟶⌮ጤဨ఍ጤ
ᨺᑕ⥺㞀ᐖ㜵Ṇጤဨ఍ ဨࠊ5, ண㜵ᑠጤဨ఍ጤဨࠊ
5, ྲྀᢅ୺௵⪅ࠊ5, 㛵㐃ㅮᗙ
ᨺᑕ⥺㞀ᐖ㜵Ṇ㐠Ⴀᑠ
ጤဨ఍
ࡢᩍᤵ
་⸆๰ᡂ⛉Ꮫㅮᗙࠖ㐠
Ⴀጤဨ఍
ᐖࡢ㜵Ṇ࡟㛵ࡍࡿ஦㡯
඲⟶⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦㡯
⸆⏝᳜≀ᅬ⟶⌮ጤဨ఍ ᅬ⟶⌮⪅ࠊ஦ົ㛗ࠊ㛵ಀㅮᗙ
ᐤ㝃ㅮᗙࠕࢼࣀࣂ࢖࢜
ᨺᑕᛶྠ఩ඖ⣲➼࡟ࡼࡿᨺᑕ⥺㞀
ᨺᑕᛶྠ఩ඖ⣲➼ࡢ౑⏝᪋タࡢᏳ
ྛㅮᗙᩍဨ㸯ྡ
᳜≀ᅬ㛗ࠊᑓᨷ㛗ࠊ⸆⏝᳜≀
ᐤ㝃ㅮᗙ᳨ウጤဨ఍
↓ᶵᗫᾮࡢ⟶⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦㡯
◊✲⛉㛗ࠊ๓◊✲⛉㛗ࠊ๪◊
✲⛉㛗ࠊホ㆟ဨࠊᑓᨷ㛗
㝃ᒓ⸆⏝᳜≀ᅬࡢ⟶⌮࣭㐠Ⴀ࡟㛵ࡍ
ࡿ஦㡯
ᐤ㝃ㅮᗙࡢタ⨨࡟㛵ࡍࡿ஦㡯
◊✲⛉㛗ࠊ㛵ಀㅮᗙࡢᩍᤵⱝ
ᐤ㝃ㅮᗙࠕࢼࣀࣂ࢖࢜་⸆๰ᡂ⛉Ꮫ
ᖸྡ
ㅮᗙࠖࡢ⟶⌮➼࡟㛵ࡍࡿ஦㡯
− 113 −
ᐤ㝃ㅮᗙࠕࢩࢫࢸ࣒๰
◊✲⛉㛗ࠊ㛵ಀㅮᗙࡢᩍᤵⱝ
ᐤ㝃ㅮᗙࠕࢩࢫࢸ࣒๰⸆⛉Ꮫㅮᗙࠖ
ᖸྡ
ࡢ⟶⌮➼࡟㛵ࡍࡿ஦㡯
ேᶒጤဨ఍ጤဨࠊ◊✲⛉㛗ࡀ
ேᶒၥ㢟࡟㛵ࢃࡿㅖၥ㢟࡟㛵ࡍࡿ
ᣦྡࡍࡿᩍဨⱝᖸྡ
஦㡯
◊✲⛉㛗ࠊ㛵ಀㅮᗙࡢᩍᤵⱝ
⤫ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔ᩍ⫱ࢭࣥࢱ
ᖸྡ
࣮ࡢ⟶⌮➼࡟㛵ࡍࡿ஦㡯
⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥ
◊✲⛉㛗ࠊ㛵ಀㅮᗙࡢᩍᤵⱝ
⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮ࡢ⟶⌮
ࢱ࣮㐠Ⴀ༠㆟఍
ᖸྡ
➼࡟㛵ࡍࡿ஦㡯
㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆
◊✲⛉㛗ࠊ㛵ಀㅮᗙࡢᩍᤵⱝ
㠉᪂ⓗࢼࣀࣂ࢖࢜๰⸆◊✲ᣐⅬࡢ
◊✲ᣐⅬ㐠Ⴀ༠㆟఍
ᖸྡ
⟶⌮➼࡟㛵ࡍࡿ஦㡯
᭱ඛ➃๰⸆◊✲ࢭࣥࢱ
◊✲⛉㛗ࠊ㛵ಀㅮᗙࡢᩍᤵⱝ
᭱ඛ➃๰⸆◊✲ࢭࣥࢱ࣮ࡢ⟶⌮➼
࣮㐠Ⴀ༠㆟఍
ᖸྡ
࡟㛵ࡍࡿ஦㡯
᝟ሗࢩࢫࢸ࣒ጤဨ఍
㛵ಀㅮᗙࡢᩍဨⱝᖸྡ
᝟ሗࢩࢫࢸ࣒࡟㛵ࡍࡿ஦㡯
⸆⛉Ꮫㅮᗙࠖ㐠Ⴀጤဨ
఍
ேᶒၥ㢟ᑐ⟇ጤဨ఍
⤫ྜ⸆Ꮫࣇࣟࣥࢸ࢕࢔
ᩍ⫱ࢭࣥࢱ࣮㐠Ⴀ༠㆟
఍
ጤ
ဨ
఍
ྡ
ᵓ
ᡂ
ᡤ
⟶
஦
ᘓ≀⟶⌮㐠Ⴀጤဨ఍
ᩍᤵ ྡ
ᘓ≀⟶⌮࡟㛵ࡍࡿ஦㡯
ඹ㏻ᶵჾጤဨ఍
ᩍᤵ ྡ
ඹ㏻ᶵჾ࡟㛵ࡍࡿ஦㡯
࣮࣒࣮࣍࣌ࢪᗈሗጤဨ
఍
ᐇົᐇ⩦ጤဨ఍
ඹ⏝ヨ㦂ጤဨ఍
฼┈┦཯ጤဨ఍
㡯 ᗈሗጤဨ఍ጤဨࠊ෸ᩍᤵཪࡣ
ຓᩍⱝᖸྡࠊ஦ົ㛗ࠊ⥲ົ᥃
࣮࣒࣮࣍࣌ࢪ➼ᗈሗ࡟㛵ࡍࡿ஦㡯
㛗ࠊᩍົ᥃㛗
㸴ᖺ⏕ࡢᏛ⏕ࡀ㓄ᒓࡉࢀࡓ
ศ㔝୺௵
ྛศ㔝ᩍဨࠊ஦ົ㛗ࠊᩍົ᥃
㛗
◊✲⛉㛗ࠊ๪◊✲⛉㛗ࠊ஦ົ
㛗
− 114 −
ᐇົᐇ⩦࡟㛵ࡍࡿ஦㡯
ඹ⏝ヨ㦂࡟㛵ࡍࡿ஦㡯
฼┈┦཯࡟㛵ࡍࡿ஦㡯
㸦඲Ꮫጤဨ఍㸧
ጤ
ဨ
఍
ྡ
኱Ꮫホ౯ጤဨ఍
኱Ꮫホ౯ጤဨ఍
Ⅼ᳨࣭ホ౯ᐇ⾜ጤဨ఍
Ꮫ⏕㒊ጤဨ఍
኱Ꮫධヨࢭࣥࢱ࣮ヨ㦂
ᐇ᪋ጤဨ఍
ᵓ
Ꮫ⏕ࡢཌ⏕⿵ᑟ࡟㛵ࡍࡿ஦㡯
኱Ꮫධヨࢭࣥࢱ࣮ヨ㦂ࡢᐇ᪋࡟㛵
ᩍᤵ
ᩍᤵཪࡣ෸ᩍᤵ
ࡍࡿ஦㡯
ᩍ⫋ᩍ⫱ࡢᅾࡾ᪉࡟㛵ࡍࡿ஦㡯
ேᶒၥ㢟࡟㛵ࢃࡿㅖၥ㢟࡟㛵ࡍࡿ
஦㡯
Ꮫෆእ࡟ᑐࡋ࡚⾜࠺ᗈሗάື࡟㛵
ࡍࡿ஦㡯
᝟ሗබ㛤࣭ಶே᝟ሗಖㆤ࡟㛵ࢃࡿㅖ
ᩍᤵཪࡣ෸ᩍᤵ
ၥ㢟࡟㛵ࡍࡿ஦㡯
ᅜ㝿஺ὶጤဨ఍
ཎᏊຊ◊✲ᩚഛጤဨ఍
ᅜ㝿஺ὶ࡟㛵ࢃࡿㅖၥ㢟࡟㛵ࡍࡿ
ᩍᤵཪࡣ෸ᩍᤵ
஦㡯
ᩍᤵཪࡣ෸ᩍᤵ
ᅜ㝿ᩍ⫱ࣉࣟࢢ࣒ࣛ࡟㛵ࡍࡿ஦㡯
⥲㛗ࡀጤკࡍࡿ⪅
ཎᏊຊ◊✲ࡢᩚഛ࡟㛵ࡍࡿ஦㡯
␃Ꮫ⏕ࢭࣥࢱ࣮ࡢ⟶⌮࣭㐠Ⴀ࡟㛵ࡍ
␃Ꮫ⏕ᢸᙜᩍဨ㐃⤡఍ ᩍᤵཪࡣ෸ᩍᤵ
ࡿ஦㡯
⎔ቃᏳ඲⾨⏕ጤဨ఍
ᢸᙜ⌮஦ࡀᚲせ࡜ㄆࡵࡿ⪅
ື≀ᐇ㦂ጤဨ఍
ᩍᤵཪࡣ෸ᩍᤵ
⤌᥮࠼㹂㹌㸿ᐇ㦂Ᏻ඲
ጤဨ఍
Ⓨ᫂ホ౯ጤဨ఍
㡯 ᩍᤵ
ᗈሗጤဨ఍
ဨ఍
஦
Ⅼ᳨࣭ホ౯࡟㛵ࡍࡿ஦㡯
ᩍᤵཪࡣ෸ᩍᤵ
఍
ᅜ 㝿 ᩍ ⫱ࣉࣟ ࢢ ࣛ ࣒ጤ
⟶
ᩍᤵࠊ⥲㛗ࡀጤკࡍࡿ⪅
ேᶒጤဨ఍
වᅜ㝿஺ὶ఍㤋ጤဨ
ᡤ
኱Ꮫホ౯࡟㛵ࡍࡿ஦㡯
ᩍᤵ
ጤဨ఍
㒊ᒁ㛗ࠊ⥲㛗ࡀጤკࡍࡿ⪅
ᩍ⫋ᩍ⫱ጤဨ఍
᝟ሗබ㛤࣭ಶே᝟ሗಖㆤ
ᡂ
Ꮫ⏕࣭⫋ဨࡢᏳ඲ಖᣢࠊಖ೺⾨⏕࣭
Ᏻ඲⾨⏕ᩍ⫱࣭⎔ቃಖ඲࡟㛵ࡍࡿ஦
ື≀ᐇ㦂ࡢィ⏬࣭❧᱌࣭ᐇ᪋ࡢ㝿ࡢ
ຓゝ➼ࢆ⾜࠺
ᩍᤵࠊ⥲㛗ࡀጤკࡍࡿ⪅
ᩍᤵࠊ⥲㛗ࡀጤკࡍࡿ⪅
− 115 −
⤌᥮࠼㹂㹌㸿ᐇ㦂࡟㛵ࡍࡿ஦㡯
Ⓨ᫂ࠊホ౯࡟㛵ࢃࡿㅖၥ㢟࡟㛵ࡍࡿ
஦㡯
ᅗ᭩㤋༠㆟఍
ᨺᑕᛶྠ఩ඖ⣲➼⟶⌮
ጤဨ఍
ᩍᤵ
㝃ᒓᅗ᭩㤋ࡢண⟬➼࡟㛵ࡍࡿ஦㡯
⥲㛗ࡀጤკࡍࡿ⪅
ᨺᑕ⥺㞀ᐖࡢ㜵Ṇ࡟㛵ࡍࡿ஦㡯
᰾⇞ᩱ≀㉁⟶⌮ጤဨ఍ ᩍᤵཪࡣ෸ᩍᤵ
᰾⇞ᩱ≀㉁➼࡟㛵ࡍࡿ஦㡯
㺓㺎㺪㺽㺻㺕㺊㺻㺨㺽㺛ࡢᐇ᪋࡟㛵ࢃࡿㅖၥ㢟
㺓㺎㺪㺽㺻㺕㺊㺻㺨㺽㺛ጤဨ఍
ᩍᤵࠊ⥲㛗ࡀጤკࡍࡿ⪅
᝟ሗ㺜㺕㺋㺶㺡㺆ጤဨ఍
㒊ᒁ㛗ࠊ⥲㛗ࡀጤკࡍࡿ⪅
᝟ሗ㺜㺕㺋㺶㺡㺆࡟㛵ࡍࡿ஦㡯
᝟ሗ⎔ቃᩚഛጤဨ఍
㒊ᒁ㛗ࠊ⥲㛗ࡀጤკࡍࡿ⪅
᝟ሗ⎔ቃᩚഛ࡟㛵ࡍࡿ஦㡯
ࢪࣗࢽ࢔࢟ࣕࣥࣃࢫᐇ
ᩍᤵཪࡣ෸ᩍᤵࠊ⥲㛗ࡀጤკ
ࢪࣗࢽ࢔࢟ࣕࣥࣃࢫࡢᐇ᪋࡟㛵ࢃ
᪋᳨ウ఍
ࡍࡿ⪅
ࡿㅖၥ㢟࡟㛵ࡍࡿ஦㡯
ྜྷ⏣࢟ࣕࣥࣃࢫᩚഛᑓ
ᩍᤵཪࡣ෸ᩍᤵࠊ⥲㛗ࡀጤკ
ྜྷ⏣࢟ࣕࣥࣃࢫࡢᩚഛ࡟㛵ࢃࡿㅖ
㛛ጤဨ఍
ࡍࡿ⪅
ၥ㢟࡟㛵ࡍࡿ஦㡯
ᩍ⫱ไᗘጤဨ఍
ᩍᤵࠊ⥲㛗ࡀጤკࡍࡿ⪅
⏘ᐁᏛ㐃ᦠᮏ㒊㐠Ⴀ༠
㆟఍
㒊ᒁ㛗ࠊ⥲㛗ࡀጤკࡍࡿ⪅
ᩍ⫱ไᗘ࡟㛵ࢃࡿㅖၥ㢟࡟㛵ࡍࡿ
஦㡯
⏘ᐁᏛ㐃ᦠᮏ㒊ࡢ㐠Ⴀ࡟㛵ࡍࡿ஦
㡯
ྜྷ⏣஦ᴗሙࡢᏳ඲⾨⏕⟶⌮࡟㛵ࡍ
ྜྷ⏣஦ᴗሙ⾨⏕ጤဨ఍ ᩍᤵཪࡣ෸ᩍᤵ
㹄㹂◊✲᳨ウጤဨ఍
࡟㛵ࡍࡿ஦㡯
ࡿ஦㡯
㹄㹂ᐤ㝃ㅮᗙࡢタ⨨࣭᭦᪂࡟㛵ࡍࡿ
ᩍᤵཪࡣ෸ᩍᤵ
஦㡯
ಖ೺⾨⏕ጤဨ఍
ࣄ ࢺ ࢤ ࣀ࣒࣭ 㑇 ఏ Ꮚゎ
ᯒ◊✲⟶⌮ጤဨ఍
㑅᭩ᑠጤဨ఍
‫‮‬ᕝ࣭ᮅỌዡບ㈹ᑂᰝ
ጤဨ఍
໬Ꮫ≀㉁⟶⌮ᑓ㛛ጤဨ
఍
㒊ᒁ㛗ࠊ⥲㛗ࡀጤკࡍࡿ⪅
ᩍᤵࠊ⥲㛗ࡀጤკࡍࡿ⪅
ᩍᤵཪࡣ෸ᩍᤵ
ಖ೺⾨⏕࡟㛵ࡍࡿ஦㡯
ࣄࢺࢤࣀ࣒࣭㑇ఏᏊゎᯒ◊✲࡟㛵
ࡍࡿ஦㡯
㑅᭩࡟㛵ࡍࡿ஦㡯
ᩍᤵࠊ⥲㛗ࡀጤკࡍࡿ⪅
ᩍᤵཪࡣ෸ᩍᤵ
‫‮‬ᕝ࣭ᮅỌዡບ㈹ࡢᑂᰝ࡟㛵ࡍࡿ஦
㡯
໬Ꮫ≀㉁ࡢ⟶⌮࡟㛵ࡍࡿ஦㡯
− 116 −
ධᏛ⪅㑅ᢤ᪉ἲ◊✲ጤ
ဨ఍
⎔ቃᏳ඲ಖ೺ᶵᵓ㐠Ⴀ
ጤဨ఍
ᅜ㝿஺ὶጤဨ఍
ᩍົ஦ົ㟁⟬⟶⌮㐠Ⴀ
ጤဨ఍
ᩍᤵཪࡣ෸ᩍᤵ
ධᏛ⪅㑅ᢤヨ㦂➼࡟㛵ࡍࡿ஦㡯
⎔ቃᏳ඲ಖ೺ᶵᵓࡢ㐠Ⴀ࡟㛵ࡍࡿ
ᩍᤵཪࡣ෸ᩍᤵ
஦㡯
ᩍᤵ
ᅜ㝿஺ὶ࡟㛵ࡍࡿ஦㡯
ᩍᤵࠊ෸ᩍᤵཪࡣㅮᖌ
㟁Ꮚィ⟬ᶵ࡟ࡼࡿᩍົ஦ົࡢฎ⌮
࡟㛵ࡍࡿ஦㡯
᝟ሗࢿࢵࢺ࣮࣡ࢡ༴ᶵ
᭱㧗᝟ሗࢭ࢟ࣗࣜࢸ࢕㈐௵
᝟ሗࢭ࢟ࣗࣜࢸ࢕ᑐ⟇࡟㛵ࡍࡿ஦
⟶⌮ጤဨ఍
⪅ࡀᣦྡࡍࡿ⪅
㡯
Ꮫ⾡᝟ሗ࣓ࢹ࢕࢔ࢭࣥ
ࢱ࣮༠㆟఍
⥲ྜ༤≀㤋༠㆟ဨ
ᨺᑕᛶྠ఩ඖ⣲⥲ྜࢭ
ࣥࢱ࣮༠㆟఍
⎔ቃಖ඲ࢭࣥࢱ࣮༠㆟
఍
ᅜ㝿஺ὶࢭࣥࢱ࣮༠㆟
఍
㌟య㞀ᐖᏛ⏕┦ㄯᐊ⟶
⌮㐠Ⴀጤဨ఍
㧗➼ᩍ⫱ࢩࢫࢸ࣒㛤Ⓨ
ࢭࣥࢱ࣮༠㆟఍
ప ≀㉁⛉Ꮫ◊✲ࢭࣥ
ࢱ࣮༠㆟ဨ఍
ཎᏊ⅔ᐇ㦂ᡤ㐠Ⴀጤဨ
఍
ඹ㏻ᩍ⫱ࢩࢫࢸ࣒ጤဨ
఍
Ꮫ⾡᝟ሗ࣓ࢹ࢕࢔ࢭࣥࢱ࣮ࡢ⟶
ᩍᤵཪࡣ෸ᩍᤵ
⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦㡯
⥲ྜ༤≀㤋ࡢ⟶⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦
ᩍᤵ
㡯
ᨺᑕᛶྠ఩ඖ⣲⥲ྜࢭࣥࢱ࣮ࡢ⟶
ᩍᤵཪࡣ෸ᩍᤵ
⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦㡯
⎔ቃಖ඲ࢭࣥࢱ࣮ࡢ⟶⌮࣭㐠Ⴀ࡟㛵
ᩍᤵ
ࡍࡿ஦㡯
ᅜ㝿஺ὶࢭࣥࢱ࣮ࡢ⟶⌮࣭㐠Ⴀ࡟㛵
ᩍᤵཪࡣ෸ᩍᤵ
ࡍࡿ஦㡯
㌟య㞀ᐖᏛ⏕┦ㄯᐊࡢ⟶⌮࣭㐠Ⴀ࡟
ᩍᤵཪࡣ෸ᩍᤵ
㛵ࡍࡿ஦㡯
㧗➼ᩍ⫱ࢩࢫࢸ࣒㛤Ⓨࢭࣥࢱ࣮ࡢ
ᩍᤵཪࡣ෸ᩍᤵ
⟶⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦㡯
ప ≀㉁⛉Ꮫ◊✲ࢭࣥࢱ࣮ࡢ⟶
ᩍᤵ
⌮࣭㐠Ⴀ࡟㛵ࡍࡿ஦㡯
ཎᏊ⅔ᐇ㦂ᡤࡢ⟶⌮࣭㐠Ⴀ࡟㛵ࡍࡿ
ᩍᤵཪࡣ෸ᩍᤵ
஦㡯
඲Ꮫඹ㏻ᩍ⫱ࢩࢫࢸ࣒࡟㛵ࡍࡿ஦
ᩍᤵཪࡣ෸ᩍᤵ
㡯
− 117 −
ϭ ㈈ᨻ
㹙ϭ㹛㈈ᨻ
ண⟬ᴫἣ࡜᭱㏆ࡢືྥ
⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ࡢṓධ࡟㛵ࡍࡿ㈨ᩱࢆ㈨ᩱϭ㸫ࠊϭ㸫㸰࡟♧ࡍࠋ㈨ᩱϭ㸫 ࡟♧ࡋࡓࡼ࠺࡟⸆
Ꮫ◊✲⛉࣭⸆Ꮫ㒊࡟ࡣᖹᡂ㸰㸯ᖺ㸳᭶⌧ᅾ㸱㸳㸰ྡࡢᏛ㒊Ꮫ⏕࡜㸰㸵㸷ྡࡢ኱Ꮫ㝔Ꮫ⏕࠾ࡼࡧ㸵ྡࡢ
◊✲⏕ࡀᅾ⡠ࡋ࡚࠸ࡿࠋࡇࢀࡽࡢᏛ⏕➼ࡀ⣡௜ࡍࡿᤵᴗᩱ➼࡟ࡼࡿ཰ධண⟬ࡀࠕᤵᴗᩱཬධᏛ᳨ᐃᩱࠖ
࡛࠶ࡿࠋࠕࡑࡢ௚ࡢ཰ධࠖࡢ୺࡞ࡶࡢࡣࠊᏛእ࠿ࡽࡢࠕ⿵ຓ㔠➼ࠖ
ࠊ
ࠕᐤ㝃㔠➼ࠖ࡜ࠕ⏘Ꮫ㐃ᦠ➼◊✲ࠖ
࡛࠶ࡿࠋ
⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ࡢᨭฟண⟬ࡢᴫせࢆ㈨ᩱϭ㸫㸰࡟♧ࡍࠋᅜ❧኱Ꮫἲேி㒔኱Ꮫ࡟࡞ࡗࡓࠊᖹᡂ
㸯㸴ᖺᗘ௨㝆ࡣࠊᅜ࠿ࡽࡣࠊ㐠Ⴀ㈝஺௜㔠࡜ࡋ࡚㓄ศࡉࢀࡿࡶࡢ㸦ᚑ๓ࡢᰯ㈝➼㸧
ࠊᩥ㒊⛉Ꮫ┬⛉Ꮫ◊
✲㈝⿵ຓ㔠࠾ࡼࡧᐤ㝃㔠ࠊཷク◊✲㈝ཬࡧඹྠ◊✲㈝➼࡟ࡼࡾ㐠Ⴀࢆ⾜࠺ࡇ࡜࡟࡞ࡗࡓࠋ㐠Ⴀ㈝஺௜
㔠ࡢ࠺ࡕࠊ୺࡞ࡶࡢࡣࠊᩍ⫋ဨࡢே௳㈝ཬࡧᩍဨཬࡧᏛ⏕ࡢேဨᩘ࡟ࡼࡾ୍ᐃࡢᇶ‽ࡢࡶ࡜࡟㓄ศࡉ
ࢀࡿ≀௳㈝࡛࠶ࡿࠋᅉࡳ࡟ᖹᡂ㸰㸯ᖺᗘỴ⟬㢠ࡣ࠾ࡼࡑ㸰㸷൨෇࡛࠶ࡾࠊࡑࡢෆࠊ㐠Ⴀ㈝஺௜㔠ࡀ⣙
㸱㸴㸣ࠊᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲㈝⿵ຓ㔠ࠊཌ⏕ປാ⛉Ꮫ◊✲㈝⿵ຓ㔠ࡀేࡏ࡚⣙㸯㸳㸣ࠊᐤ㝃㔠ࡀ⣙㸯
㸮㸣ࠊ᪋タᩚഛ⿵ຓ㔠㸦኱ᆺタഛ㸧㸯㸲㸣ࠊཷク◊✲ࠊඹྠ◊✲ࡀྜࢃࡏ࡚㸰㸯㸣࡛࠶ࡿࠋ
ࡲࡓࠊᅜ❧Ꮫᰯண⟬ࡢ࠺ࡕே௳㈝ࡢ༨ࡵࡿ๭ྜࡣࠊᩍဨࡢࢩ࣮ࣜࣥࢢࡸ⫋ဨࡢ๐ῶ࡟ࡼࡾࠊே௳㈝
࡜ࡋ࡚ࡣᖹᡂ㸯㸵ᖺࡢ㸵㸵㸣࠿ࡽᖹᡂ㸰㸯ᖺᗘ㸴㸳㸣࡜ῶᑡࡋࠊṧࡾࢆ༨ࡵࡿ≀௳㈝ࡣ㢠࡜ࡋ࡚ᚤቑ
ࡋ࡚࠸ࡿࠋࡇࡢண⟬࠿ࡽග⇕Ỉᩱ㈝ࠊᅗ᭩㛵ಀ⤒㈝ཬࡧ᪋タ⥔ᣢ⟶⌮㈝➼ࡢඹ㏻ⓗ࡞⤒㈝ࡀ┦ᙜ㒊ศ
ᕪࡋᘬ࠿ࢀࡿࡢ࡛ࠊ◊✲㈝࡜ࡋ࡚㓄ศࡉࢀࡿண⟬ࡣ⌧ᅾ࡜ࡶഹ࠿࡛࠶ࡿࠋࡋࡓࡀࡗ࡚ᐇ㝿࡟◊✲࣭ᩍ
⫱࡟౑⏝࡛ࡁࡿ㈈※࡜ࡋ࡚ࡣ⛉Ꮫ◊✲㈝࡜እ㒊㈨㔠ࡀ㠀ᖖ࡟኱ࡁ࡞๭ྜࢆ༨ࡵࠊࡇࡢ஧ࡘࡢ㈈※ࡢ᭷
↓ࡀ◊✲࣭ᩍ⫱ࡢ㐍ᒎ࡟኱ࡁࡃᙳ㡪ࡍࡿࠋ
⛉Ꮫ◊✲㈝࠾ࡼࡧእ㒊㈨㔠ࡢཷධࢀ≧ἣࡢ᥎⛣࡟ࡘ࠸࡚ࡣ㈨ᩱϪ㸫 ࠾ࡼࡧϪ㸫 ࡟♧ࡉࢀ࡚࠸ࡿࠋ
ᴫ⟬せồ஦㡯ࡢỴᐃ
⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊࡟࠾࠸࡚ࡣࠊẖᖺࠊᴫ⟬せồࡢ᪂つ஦㡯ࡢ↷఍ࡀࡃࡿࡀࠊ≉࡟㒊ᒁ඲య࡟㛵ࢃ
ࡿ㔜せ஦㡯㸦⤌⧊ࡢᨵ⦅ࠊ᪋タࡢᩚഛ➼㸧࡟ࡘ࠸࡚ࡣࠊᑗ᮶ィ⏬ጤဨ఍࡟࠾࠸࡚᪩࠸᫬ᮇ࠿ࡽᑗ᮶ᵓ
᝿࡟ᇶ࡙ࡃ஦㡯ࡢ᳨ウࢆ⾜࠸ࠊᩍᤵ᠓ㄯ఍ࡢ㆟ㄽࢆ⤒࡚ཎ᱌ࡀసᡂࡉࢀࠊࡉࡽ࡟ᩍᤵ఍࡟ࡼࡾᢎㄆࢆ
ᚓࡿࠋ㏻ᖖ㸯᭶୰࡟ࠊᑗ᮶ィ⏬ጤဨ఍࡟࠾࠸࡚Ꮫ㒊඲యࡢ᪂つせồ஦㡯ࡀᑂ㆟ࡉࢀࠊࡉࡽ࡟㸰᭶࡟⾜
࡞ࢃࢀࡿ⥲㛗࣭஦ົᒁ࡬ࡢᴫ⟬ㄝ᫂㸦ࣄࣖࣜࣥࢢ㸧ࢆ⤒࡚ࠊせồ㡰఩ࡢỴᐃ➼ࡀ◊✲⛉㛗࡟ࡼࡗ࡚⾜
ࢃࢀࡿࠋせồෆᐜࡸ༠㆟≧ἣࡣࠊ㝶᫬༠㆟఍ࡸᩍᤵ᠓ㄯ఍࡟࠾࠸࡚ሗ࿌ࡉࢀࠊ㆟ㄽࡉࢀࡿࠋ
ண⟬㓄ศ᪉㔪
⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊࡛ࡣࠊග⇕Ỉᩱ㈝ࠊᅗ᭩㛵ಀ⤒㈝ཬࡧ᪋タ⥔ᣢ⟶⌮㈝➼ࡢඹ㏻ⓗ࡞⤒㈝ࡢ᥎⟬
࡟ᇶ࡙࠸࡚ࠊḟࡢ஦㡯࡟ࡘ࠸࡚ᡤᐃࡢ㓄ศ᪉ᘧ࡟ᇶ࡙ࡁண⟬㸦᱌㸧ࢆసᡂࡋࠊᩍᤵ఍࡟ㅎࡾᢎㄆࢆཷ
ࡅࡿࠋ
− 119 −
ᩍ⫱◊✲ᇶ┙⤒㈝㸦Ꮫ⏕ศ㸧 㸳᭶㸯᪥⌧ᅾࡢᐃဨཬࡧ⌧ဨࢆᇶ♏࡜ࡋ࡚✚⟬ࡉࢀࡓᇶ‽㓄ศ㢠࠿ࡽࠊᮏ㒊᥍㝖㢠ࠊ⠇⣙ぢ㎸㢠ཬ
ࡧᏛ⏕㛵ಀඹ㏻㛵ಀ⤒㈝ࢆ᥍㝖ࡋࡓṧ㢠ࢆࠊேဨ๭㓄ศ㢠࡜ᆒ➼㓄ศ㢠࡟ศࡅ࡚ྛศ㔝࡟㓄ศࡍࡿࠋ
ᩍ⫱◊✲ᇶ┙⤒㈝㸦ᩍဨศ㸧
㸲᭶㸯᪥⌧ᅾ⌧ဨࢆᇶ♏࡜ࡋ࡚✚⟬ࡉࢀࡓᇶ‽㓄ศ㢠࠿ࡽࠊᮏ㒊᥍㝖㢠ࠊ⠇⣙ぢ㎸㢠ཬࡧඹ㏻⤒㈝
㸦ᮏ㒊ཬࡧᏛ㒊ෆ㸧ࢆ᥍㝖ࡋࡓṧ㢠ࢆࠊᡤᐃࡢ㓄ศ᪉ᘧ࡟ᇶ࡙࠸࡚ྛศ㔝࡟㓄ศࡍࡿࠋ
ᩍဨ◊✲᪑㈝
㸲᭶㸯᪥⌧ᅾࡢ⌧ဨࢆᇶ♏࡜ࡋ࡚✚⟬ࡉࢀࡓᇶ‽㓄ศ㢠࠿ࡽࠊᮏ㒊᥍㝖㢠ࠊ⠇⣙ぢ㎸㢠ཬࡧᏛ㒊ඹ
㏻㛵ಀ⤒㈝ࢆ᥍㝖ࡋࡓṧ㢠ࢆࠊᡤᐃࡢ㓄ศ᪉ᘧ࡟ᇶ࡙࠸࡚ྛศ㔝࡟㓄ศࡍࡿࠋ
㛫᥋⤒㈝
ᙜヱᖺᗘࡢ㛫᥋⤒㈝➼ཷධ㢠࠿ࡽࠊᩍဨ⤒㈝㑏ඖ࡜ࡋ࡚㸱㸮㸣ࠊ᪋タᨵಟ➼⮫᫬⤒㈝࡜ࡋ࡚㸱
㸮㸣ࠊඹ㏻⤒㈝࡜ࡋ࡚㸲㸮㸣ࢆࡑࢀࡒࢀ࡟㓄ศࡍࡿࠋ
− 120 −
− 121 −
ϭ㸫㸱 ⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊Ꮫ⏕➼ᅾ⡠⪅ᩘ
ᖹᡂ ᖺᗘ
Ꮫ㒊
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
኱Ꮫ㝔ಟኈㄢ⛬
኱Ꮫ㝔༤ኈᚋᮇㄢ⛬
◊✲⏕
◊ಟဨ
᪥ᮏᏛ⾡᣺⯆఍
ࠝࠞ
ࠝࠞ
ࠝࠞ
ࠝࠞ
ཷク◊✲ဨ
ࡑࡢ௚
≉ู◊✲ဨ
㸦 㸧ࡣእᅜே␃Ꮫ⏕࡛ࠊෆᩘ
ࠝ ࠞࡣᙜヱᖺᗘࡢ᥇ᢥ⪅ᩘ࡛ࠊෆᩘ
ᩍ⫱⫋ဨ 㸦ྛᖺᗘᮎ⌧ᅾ㸧
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᩍᤵ
෸ᩍᤵ
ㅮᖌ
ຓᩍ
஦ົ⫋ဨ 㸦ྛᖺᗘ ᭶ ᪥⌧ᅾ㸧
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
஦ົ⣔⫋ဨ
ᢏ⾡⣔⫋ဨ
− 122 −
Ϯ ᪋タ࣭タഛ
㹙Ϯ㹛᪋タ࣭タഛ
㸦㸯㸧 ᪋タࡢ⌧≧
⌧᭷ࡢᘓ≀ࡢಖ᭷㠃✚ࡣࠊᖹᡂ㸰㸰ᖺ㸳᭶⌧ᅾࠊ ੍࡛࠶ࡾࠊ୺࡟⸆Ꮫ㒊ᮏ㤋ࠊ⥲ྜ◊✲Ჷࠊ
ᩍ⫱Ჷࠊู㤋࠿ࡽ࡞ࡿࠋ
ᖹᡂ㸯㸲ᖺࡲ࡛ࡣ୺࡞ᘓ≀࡜ࡋ࡚ࡣ⸆Ꮫ㒊ᮏ㤋࡜ู㤋࡛࠶ࡗࡓࡀࠊᚑ᮶࠿ࡽࡢ኱Ꮫ㝔⏕ࡢ₞ቑ࡟ຍ
࠼ࠊᖹᡂ㸲ᖺᗘࡢ኱Ꮫ㝔⊂❧ᑓᨷタ⨨࠾ࡼࡧᖹᡂ㸷ᖺᗘࡢ኱Ꮫ㝔㔜Ⅼ໬࡟కࡗ࡚኱Ꮫ㝔ࡢᏛ⏕ᐃဨࡢ
⣙ ಸࡢቑຍ࡞࡝࡟ࡼࡿࠊ኱Ꮫ㝔ࡢつᶍࡢᣑ኱ࠊࡉࡽ࡟᭱㏆ࡢ◊✲ศ㔝࣭つᶍ࣭タഛࡢᣑ኱࡞࡝࡟
ࡼࡾࠊ᪋タࡢ⊃㝼໬ࠊ⪁ᮙ໬ࠊᏳ඲ᛶࠊᶵ⬟ᛶ࡞࡝࡟኱ࡁ࡞ၥ㢟ࡀ⏕ࡌࠊࡑࢀࡽࡢၥ㢟Ⅼࢆᨵၿࡋࠊ
ຍ࠼࡚ࠊ኱Ꮫ㝔኱Ꮫ࡜ࡋ࡚ࡢᩍ⫱࣭◊✲ࢆ୍ᒙ㧗ᗘ໬ࠊ඘ᐇࡍࡿࡓࡵ࡟ࠊ㛗ᖺ࡟ࢃࡓࡾࠊᘓ≀ࡢቑ⠏ࠊ
࠾ࡼࡧ⪏㟈ᙉ໬ࢆྵࡴ᪤Ꮡࡢᘓ≀ࡢᨵಟ࡞࡝ࢆᙉࡃせồࡋ࡚ࡁࡓࠋࡑࡢ⤖ᯝࠊᖹᡂ㸯㸲ᖺ㸯㸮᭶࡟⸆
Ꮫ㒊ᮏ㤋ࡢ༡ഃ࡟ ੍ࡢ⥲ྜ◊✲Ჷࠊᖹᡂ㸯㸳ᖺ㸯㸯᭶࡟⸆Ꮫ㒊ᮏ㤋ࡢᨵಟ㸦༡໭Ჷ㒊ศࡣ㝖ࡃ㸧
࡜ᮏ㤋ࡢ໭ᮾ๓࡟ ੍ࡢᩍ⫱Ჷࡀ᪂Ⴀࡉࢀࡓࠋ
⌧᭷᪋タ୰࡛᭱ࡶ㧗࠸๭ྜࢆࡋࡵࡿ⸆Ꮫ㒊ᮏ㤋㸦 ੍㸧ࡣᆅୖ㸲㝵ᆅୗ㸯㝵ࡢᘓ≀࡛ࠊ᫛࿴㸱㸶
㹼㸲㸯ᖺ࡟ᘓタࡉࢀࡓࡶࡢ࡛࠶ࡗࡓࡀࠊᶵ⬟㠃ࡢᑐᛂࠊ⊃㝼໬ࡢゎᾘ࡞࡝ࡢࡓࡵ࡟ᖹᡂ㸯㸳ᖺ㸳᭶࡟
༡໭࡟ࡢࡧࡿ㒊ศ௨እࡢ኱㒊ศࢆ⪏㟈ᙉ໬ࡶ࠿ࡡ࡚඲㠃ⓗ࡞ᨵಟࡀ⾜ࢃࢀࠊᖹᡂ㸯㸴ᖺ㸱᭶࡟❹ᕤࡋࠊ
༡໭Ჷࡣ୍㒊ྲྀࡾቯࡋࡶྵࡵᖹᡂ㸯㸷ᖺ㸱᭶࡟⪏㟈ᨵಟࢆ⾜࠸ࠊ⌧ᅾ࡟⮳ࡗ࡚࠸ࡿࠋࡇࡢᮏ㤋࡟ࡣࠊ
⸆Ꮫ◊✲⛉ࡢ㸯㸮ศ㔝ࠊ㸯ᐤ㝃ㅮᗙࡢᑓᨷ◊✲ᐇ㦂ᐊࠊ⏕࿨⛉Ꮫ◊✲⛉ࡢ㸯ศ㔝ࡢᑓᨷ◊✲ᐇ㦂ᐊࠊ
஦ົᐊࠊඹྠ฼⏝ᐇ㦂ᐊࠊື≀᪋タࠊㅮ⩏ᐊࠊᏛ⏕ᐇ⩦‽ഛᐊࠊ఍㆟ᐊࠊࢭ࣑ࢼ࣮ᐊ࡞࡝ࡀ࠶ࡿࠋ⥲
ྜ◊✲Ჷ㸦 ੍㸧ࡣᆅୖ㸳㝵ᆅୗ㸯㝵ࡢᘓ≀࡛ࠊᖹᡂ㸯㸲ᖺ㸯㸮᭶࡟⸆Ꮫ㒊ᮏ㤋ࡢ༡ഃ࡟ᘓ࡚ࡽࢀ
ࡓࠋࡇࡢ⥲ྜ◊✲Ჷ࡟ࡣ⸆Ꮫ◊✲⛉ࡢ㸶ศ㔝ࠊ㸯ᐤ㝃ㅮᗙࡢᑓᨷ◊✲ᐇ㦂ᐊࠊඹྠ฼⏝ᐇ㦂ᐊࠊ᭷ᶵ
ᚤ㔞ඖ⣲ศᯒ⥲ྜ◊✲᪋タࠊ105 ᐃᐊࠊ㉁㔞ศᯒᐊࠊㅮ⩏ᐊ࡞࡝ࡀ࠶ࡿࠋ⸆Ꮫ㒊ᩍ⫱Ჷ㸦 ੍㸧
ࡣᆅୖ㸰㝵ᆅୗ㸯㝵ࡢᘓ≀࡛ࠊᖹᡂ㸯㸳ᖺ㸯㸯᭶࡟⸆Ꮫ㒊ᮏ㤋ࡢ໭ᮾ๓࡟ᘓ࡚ࡽࢀࡓࠋࡇࡢᩍ⫱Ჷࡣ
Ꮫ⏕ࡢᩍ⫱ࡢࡓࡵ࡟⏝࠸ࡽࢀ࡚࠸ࡿᘓ≀࡛࠶ࡾࠊ㸯ࠊ㸰㝵࡟ࡣㅮ⩏ᐊࠊ᝟ሗฎ⌮₇⩦ᐊࠊ࣐ࣝࢳ࣓ࢹ
࢕࢔ㅮ⩏ᐊࠊᆅୗ࡟ࡣᏛ⏕ᐇ⩦ᐊࠊࡉࡽ࡟㸯㝵࡟ࡣᏛ⏕ࡀ⮬⩦ࡸㄯヰ࡞࡝ࠊ⮬⏤࡟ࡃࡘࢁࡄࡇ࡜ࡢ࡛
ࡁࡿ࣮࢜ࣉࣥࢫ࣮࣌ࢫࡀ࠶ࡿࠋࡲࡓࠊ⸆Ꮫ㒊ู㤋㸦 ੍㸧ࡣᖹᡂ㸲ᖺ࡟ᮏ㤋ࡢすഃ࡟ᘓタࡉࢀࡓࡶࡢ
࡛࠶ࡾࠊ኱ᆺࣉࣟࢪ࢙ࢡࢺ◊✲ࡢᐇ㦂ᐊࠊඹྠ฼⏝ᐇ㦂ᐊࠊ⸆⏝᳜≀ᅬ⟶⌮ᐊ࡞࡝ࡀ࠶ࡿࠋࡇࢀ௨እ
࡟ࠊ5, Ꮫ⏕ᐇ⩦ᐊ㸦᫛࿴㸲㸰ᖺࠊ᫛࿴㸳㸵ᖺቑ⠏㸧
ࠊ᱂ᇵ ᐊ㸦᫛࿴㸲㸲ᖺ㸧
ࠊᐤ௜ᘓ≀࡛࠶ࡿグᛕㅮ
ᇽࠊᅗ᭩ᐊ㸦᫛࿴㸲㸯ᖺ㸧ࡀ࠶ࡿࠋグᛕㅮᇽࡣࠊ᫛࿴㸲㸯ᖺ࡟ᘓ࡚ࡽࢀࡓࡀࠊ᭱㏆ࡢ࣐ࣝࢳ࣓ࢹ࢕࢔
࡟ࡼࡿㅮ₇ࠊㅮ⩏࡞࡝࡬ࡢᑐᛂࢆྵࡵ࡚ࠊᖹᡂ㸯㸴ᖺ㸯㸮᭶࡟ᨵ⿦ࡉࢀࠊ⣙㸱㸮㸮ᖍࡢㅮ₇఍ࡸㅮ⩏
ࢆ㛤ദࡍࡿࡇ࡜ࡀྍ⬟࡜࡞ࡾࠊᮏ◊✲⛉࣭Ꮫ㒊ࢆࡣࡌࡵࠊᏛෆ௚◊✲⛉࣭Ꮫ㒊ࢆྵࡵ࡚ࠊࡑࢀࡽࡀ୺
ദࡍࡿࢩ࣏ࣥࢪ࣒࢘ࠊㅮ₇఍ࠊㅮ⩏࡞࡝࡟ᗈࡃ฼⏝ࡉࢀ࡚࠾ࡾࠊ኱Ꮫࡢ㐠Ⴀ࡟ࡶ㈉⊩ࡋ࡚࠸ࡿࠋ
ࡇࢀࡽࡢ᪋タࡢタィࡢᇶᮏࡣࠊඛ➃ᩍ⫱࣭◊✲࡬ᑐᛂ࡛ࡁࡿࡼ࠺࡟ࠊ◊✲ࡢὶືᛶ࡟ᛂࡌࡓࣇࣞ࢟
ࢩࣅࣜࢸ࢕ࡢ࠶ࡿከ┠ⓗ࣭ඹྠ฼⏝◊✲ᐇ㦂ࢫ࣮࣌ࢫࢆ඘ᐇࡍࡿ࡭ࡃࠊ࣮࢜ࣉࣥࢫ࣮࣌ࢫࢆࢥ࢔࣮࡜
ࡋ࡚ᑓᨷ◊✲ᐇ㦂ᐊࠊඹྠᐇ㦂ᐊࢆ᭷ᶵⓗ࡟⧅ࡆࠊࡲࡓྛᑓᨷ◊✲ᐇ㦂ᐊࡣཎ๎࡜ࡋ࡚㝸ቨࢆྲྀࡾ㝖
࠸࡚࣮࢜ࣉ࣭ࣥࣛ࣎໬ࡍࡿࡇ࡜࡟ࡼࡾࠊ㧗ᶵ⬟໬ࡋࡓࢫ࣮࣌ࢫࡢ᭷ຠ฼⏝ࢆᅗࡗ࡚࠸ࡿࠋࡲࡓࠊᩍ⫱࣭
− 123 −
◊✲ࡢ࣐ࣝࢳ࣓ࢹ࢕࢔໬࡬ࡢᑐᛂࢆಁ㐍ࡍࡿࡓࡵ࡟ࠊࢥࣥࣆ࣮ࣗࢱ࣮࣭ࢿࢵࢺ࣮࣡ࢡࡢ㧗ᗘ฼⏝ࡀྍ
⬟࡞᪋タࡢ඘ᐇࡶᅗࡗ࡚࠸ࡿࠋ
ࡇࡢࡼ࠺࡟ࠊᮏ㤋ࡢ⪏㟈ᨵಟࠊ⥲ྜ◊✲Ჷࠊᩍ⫱Ჷࡢ᏶ᡂ࡟ࡼࡾࠊ௨๓࡟ẚ࡭ࢀࡤ᪋タࡢ⊃㝼໬ࠊ
⪁ᮙ໬ࡣ࠿࡞ࡾᨵၿࡉࢀࡓࡶࡢࡢࠊᮏ◊✲⛉ࡀ┠ᶆ࡜ࡋ࡚࠸ࡿ኱Ꮫ㝔኱Ꮫ࡜ࡋ࡚ࡢᩍ⫱࣭◊✲ࡢ୍ᒙ
ࡢ㧗ᗘ໬࡜඘ᐇࡢࡓࡵࡢᩍ⫱࣭◊✲యไࡢ᥎㐍ࠊຍ࠼࡚་⒪⸆Ꮫᩍ⫱࣭◊✲࡟ᐇ㊶࣭඘ᐇࡢࡓࡵ࡟ࡣࠊ
᪩ᛴ࡟ࠊ᪋タࡉࡽ࡞ࡿ඘ᐇࠊᶵ⬟ᛶ࡜Ᏻ඲ᛶࡢ☜ಖࠊタഛࡢ඘ᐇࡀ୙ྍḞ࡞≧ែ࡜࡞ࡗ࡚࠸ࡿࠋ
㸦㸰㸧 ᑗ᮶ィ⏬
ᮏ㤋ࡢ⪏㟈ᨵಟࠊ⥲ྜ◊✲Ჷࠊᩍ⫱Ჷࡢ᏶ᡂ࡟ࡼࡾࠊ௨๓࡟ẚ࡭ࢀࡤ᪋タࡢ⊃㝼໬ࠊ⪁ᮙ໬ࡣ࠿࡞
ࡾᨵၿࡉࢀࡓࡶࡢࡢࠊ኱Ꮫ㝔኱Ꮫ࡜ࡋ࡚ࡢᩍ⫱࣭◊✲ࡢ୍ᒙࡢ㧗ᗘ໬࡜඘ᐇࡢࡓࡵࡢᩍ⫱࣭◊✲యไ
ࡢ᥎㐍ࡢࡓࡵ࡟ࠊࡉࡽ࡟⌧ἣࢆ᪩ᛴ࡟ᨵၿࡋࠊ᪋タ࠾ࡼࡧタഛࢆ඘ᐇࡍࡿࡇ࡜ࡀ୙ྍḞ࡞≧ែ࡜࡞ࡗ
࡚࠸ࡿࠋࡑࡢࡓࡵࠊᏳ඲ᛶ☜ಖࡢࡓࡵࡢᮏ㤋༡໭Ჷ㒊ศࡢ⪏㟈ᕤ஦㸦⪏㟈⿵ᙉᩚഛ㸧ࠊࡉࡽ࡟ࠊ㸯㸶ᖺ
ᗘࡼࡾࡢ㸴ᖺไࡢᑟධ࡬ࡢᑐᛂ࡞࡝ࢆྵࡵ࡚㧗ᗘ࡞ᩍ⫱࣭◊✲ࢆ⾜࠾࠺࡜ࡍࡿ⸆Ꮫ◊✲⛉ࡢᑗ᮶ᵓ᝿
࡟┦ᛂࡋ࠸᪋タ࡜ࡍࡿࡓࡵ࡟ࠊ◊✲ᐇ㦂ᐊࡢᨵಟᩚഛࠊᩍ⫱᪋タࡢᨵಟᩚഛࢆ⾜࠸ࠊ࣮࢜ࣉࣥࢫ࣮࣌
ࢫࢆࢥ࢔࣮࡜ࡋ࡚ࠊ⟶⌮㒊㛛ࠊᑓᨷ◊✲ᐇ㦂ᐊࠊඹྠᐇ㦂ᐊࠊᩍ⫱㒊㛛ࡀ᭷ᶵⓗ࡟⧅ࡀࡿࡼ࠺࡟ᩚഛ
ࢆ⾜ࡗࡓࠋ㸦㈨ᩱϮ㸫㸯ࠊϮ㸫㸰㸧
ࡇࢀࡽࡢ᪋タࡢタィ࡟࠶ࡗ࡚ࡣࠊࡇࢀࡲ࡛ࡢタィᴫᛕࢆࡉࡽ࡟᥎㐍ࡋࠊඛ➃ᩍ⫱࣭◊✲࡬ᑐᛂࡍࡿ
ࡓࡵ࡟ࠊ◊✲ࡢὶືᛶ࡟ᛂࡌࡓࣇࣞ࢟ࢩࣅࣜࢸ࢕ࡢ࠶ࡿከ┠ⓗ࣭ඹྠ฼⏝◊✲ᐇ㦂ࢫ࣮࣌ࢫࢆ඘ᐇࡍ
ࡿ࡭ࡃࠊ࣮࢜ࣉࣥࢫ࣮࣌ࢫࢆࢥ࢔࣮࡜ࡋ࡚ᑓᨷ◊✲ᐇ㦂ᐊࠊඹྠᐇ㦂ᐊࢆ᭷ᶵⓗ࡟⧅ࡆࠊࡲࡓྛᑓᨷ
◊✲ᐇ㦂ᐊࡣཎ๎࡜ࡋ࡚㝸ቨࢆྲྀࡾ㝖࠸࡚࣮࢜ࣉ࣭ࣥࣛ࣎໬ࡍࡿࡇ࡜࡟ࡼࡾࠊ㧗ᶵ⬟໬ࡋࡓࢫ࣮࣌ࢫ
ࡢ᭷ຠ฼⏝ࢆᅗࡿࡇ࡜࡜ࡋ࡚࠸ࡿࠋࡲࡓࠊᩍ⫱࣭◊✲ࡢ࣐ࣝࢳ࣓ࢹ࢕࢔໬࡬ࡢᑐᛂࡓࡵ࡟ࠊࢥࣥࣆࣗ
࣮ࢱ࣮࣭ࢿࢵࢺ࣮࣡ࢡࡢ㧗ᗘ฼⏝ࡀྍ⬟࡞᪋タࢆィ⏬ࡋ࡚࠸ࡿࠋ
ࡇࢀࡽࡢᨵಟ࡟ࡼࡾࠊ᭱᪂◊✲ᶵჾࡢᑟධ࡜ࡑࡢ᭷ຠ㓄ഛࠊ◊✲᪋タ࣭ᶵჾࡢຠ⋡ⓗ࡞౑⏝ࠊඹྠ
◊✲ࡢࢫ࣮࣌ࢫࡢ☜ಖ࡟ࡼࡿᅜ㝿ඹྠ◊✲ࣉࣟࢪ࢙ࢡࢺࡸ⏘Ꮫᐁඹྠ◊✲࡞࡝ࡀ᥎㐍ࡉࢀࠊ◊✲ຠ
⋡࣭⬟ຊࡢྥୖࡸእ㒊࠿ࡽࡢ➇தⓗ㈨㔠ᑟධࡢಁ㐍࡞࡝࡟ࡼࡾࠊ◊✲ᇶ┙ࡢ඘ᐇࠊඛ➃◊✲࡟ᑐᛂࡋ
ࡓᐇ㦂ᩍ⫱ࠊ㸴ᖺไᑟධ࡟క࠺་⒪⸆Ꮫᩍ⫱ࡢᐇ㊶࣭඘ᐇ࡞࡝ࡀᮇᚅࡉࢀࡿࠋࡲࡓࠊ⸆Ꮫᩍ⫱ࠊ๰⸆
◊✲ࡢᇶ┙࡜࡞ࡿ᝟ሗࢿࢵࢺ࣮࣡ࢡࠊ᝟ሗฎ⌮ᶵ⬟ࡢ㣕㌍ⓗ࡞ᩚഛࡶᮇᚅࡉࢀࡿ࡜࡜ࡶ࡟ࠊࡉࡽ࡟ࠊ
࣮࢜ࣉࣥࢫ࣮࣌ࢫࢆ฼⏝ࡋࡓࠊᏛ㒊ࠊ኱Ꮫ㝔⏕ࡢ⮬୺ⓗ࡞Ꮫ⩦ࢆ᥎㐍ࡍࡿ࣮࢜ࣉࣥ࢝ࣥࣇ࢓ࣞࣥࢫࡸ
ᩍᐁࠊᏛ⏕ࠊእᅜே◊✲⪅࡞࡝࡜ࡢࢥ࣑ࣗࢽࢣ࣮ࢩࣙࣥࡢᶵ఍ࡢᜏᖖⓗ☜ಖ࡟ࡼࡾࠊ᪂ࡋ࠸኱Ꮫ࣭኱
Ꮫ㝔ീ࡟ᇶ࡙ࡃ◊✲⪅ࠊ⸆Ꮫ㛵㐃ᴗົᚑ஦⪅࡞࡝ࠊᑗ᮶ࡢ⸆Ꮫ࠾ࡼࡧ㛵㐃ศ㔝ࢆᢸ࠺ேᮦࡢ㣴ᡂࡶྍ
⬟࡜࡞ࡿࠋ
㸦㸱㸧 Ᏻ඲࣭㜵⅏ᑐ⟇
ᘓ≀ࡢ㜵≢࣭㜵⅏⟶⌮࡟ࡘ࠸࡚ࡣࠊᖹ᪥ࡣ༗ᚋ㸴᫬࠿ࡽ⩣ᮅ㸶᫬㸱㸮ศࡲ࡛ࠊఇ᪥ࡣ⤊᪥ᘓ≀ࡢฟ
ධࡾཱྀࢆ᪋㘄ࡋࠊ᪋㘄୰ࡢ㜵ⅆ࣭㜵≢ᑐ⟇ࡣ㆙ഛಖ㞀఍♫࡜㆙ഛጤクᴗົዎ⣙ࢆ⾜ࡗ࡚࠾ࡾࠊ⥭ᛴ஦
ែⓎ⏕ࡢሙྜࡣ㜵ⅆ⟶⌮⪅࡞࡝࡬ࡢ㐃⤡యไࢆ࡜ࡗ࡚࠸ࡿࠋࡲࡓࠊ᪋㘄ᚋࡢᘓ≀࡬ࡢධ㏥㤋ࡣ☢Ẽ࢝
− 124 −
࣮ࢻ࡟ࡼࡿಶே㆑ู࡟ࡼࡾᶵᲔ⟶⌮ࢆ⾜ࡗ࡚࠾ࡾࠊ㛵ಀ⪅௨እࡣධ㤋࡛ࡁ࡞࠸ࢩࢫࢸ࣒ࢆ࡜ࡗ࡚࠸ࡿࠋ
ᮏᏛ㒊ࡢ᪋タ࣭タഛࡢⅆ⅏ࠊᆅ㟈࡞࡝ࡢሙྜࡢ㜵⅏࡟ᑐࡋ࡚ࡣࠊ⸆Ꮫ㒊㜵ⅆጤဨࢆ୰ᚰ࡟ࠊ᪥ᖖⓗ
࡞Ᏻ඲࡟ົࡵ࡚࠸ࡿࠋࡲࡓࠊ⥭ᛴ᫬㐃⤡⥙ࢆᐃࡵࠊྛศ㔝࡟ࡇࢀࢆᚭᗏࡍࡿ࡜࡜ࡶ࡟ࠊᾘ㜵⨫ࡢ༠ຊ
ࢆᚓ࡚ࠊ㸰ᖺ࡟㸯ᅇ௨ୖࡢ㢖ᗘ࡛ࠊ඲Ꮫ㒊ⓗ࡟ᾘ㜵カ⦎ࢆ⾜࠺࡜࡜ࡶ࡟ࠊタഛⓗ࡟ࡶᾘ໬ჾࡢタ⨨࡞
࡝ࡢᑐ⟇ࢆㅮࡌࠊ༑ศ࡞Ᏻ඲࣭㜵⅏ᑐ⟇࡟ດࡵ࡚࠸ࡿࠋࡉࡽ࡟ࠊ೵㟁᫬࡟ഛ࠼ࠊᮏᏛ㒊࡟ᑓ⏝ࡢ⮬ᐙ
Ⓨ㟁⿦⨨ࢆᩚഛࡋࠊ೵㟁᫬࡛ࡢタഛࡢᏳ඲ᑐ⟇࡟ࡶດࡵ࡚࠸ࡿࠋࡓࡔࡋࠊ⮬ᐙⓎ㟁⿦⨨࡬ࡢษࡾ᭰࠼
ࡣ⮬ືⓗ࡛ࡣ࡞ࡃࠊࡲࡓ⮬ᐙⓎ㟁࡬ࡢษࡾ᭰࠼ࡀᚲせ࡞ᮏ◊✲⛉ࡢタഛࡢ୍㒊࡟ࡋ࠿ᑐᛂࡍࡿ⬟ຊࢆ
᭷ࡋ࡚ࡣ࠸࡞࠸ࡢ࡛ࠊ㈗㔜࡞ヨᩱࡸ◊✲ࡢᜏᖖⓗ࡞᥎㐍ࡢࡓࡵ࡟ࡣࠊࡑࡢ᪩ᛴ࡞ᨵၿࡀ୙ྍḞ࡞≧ែ
࡛࠶ࡿࠋ
ྛタഛࡢ㐠Ⴀ࣭⟶⌮࣭Ᏻ඲ᑐ⟇ࡣࠊᮏᏛ㒊ࡢᶵჾ⟶⌮࣮࣡࢟ࣥࢢࢢ࣮ࣝࣉࢆ୰ᚰ࡟⾜ࡗ࡚࠸ࡿࡀࠊ
ࡉࡽ࡟ࠊ᰾☢Ẽඹ㬆⿦⨨࡞࡝ࡢ኱ᆺタഛ࡟ࡘ࠸࡚ࡣྛᶵჾ࡟㐠Ⴀ⟶⌮ጤဨ఍ࢆタ⨨ࡋࠊᢏ⾡ⓗ࡞ࡇ࡜
ࡶྵࡵ࡚Ᏻ඲⟶⌮࡟ດࡵ࡚࠸ࡿࠋࡲࡓࠊᩍဨࠊ஦ົ⫋ဨࠊᏛ⏕࡞࡝ࡢປാࡢᏳ඲ᛶࡢ☜ಖࡢࡓࡵ࡟ࠊ
Ᏻ඲⎔ቃጤဨ఍ࢆタ⨨ࡋࠊ⾨⏕⟶⌮⪅ࢆ㑅௵ࡋ࡚ࠊປാ⾨⏕Ᏻ඲ἲ࡟ᇶ࡙࠸ࡓᏳ඲⾨⏕⟶⌮࠾ࡼࡧᩍ
⫱࡟ດࡵ࡚࠸ࡿࠋ5, ᐇ⩦ᐊ࡟ࡘ࠸࡚ࡣࠊᮏᏛ㒊ࡢᨺᑕ⥺㞀ᐖ㜵Ṇጤဨ఍࠾ࡼࡧᨺᑕ⥺ྲྀᢅ୺௵⪅ࢆ୰
ᚰ࡟ࠊࡑࡢᏳ඲࣭㜵⅏ᑐ⟇࡟ດࡵ࡚࠸ࡿࠋ
ࡲࡓࠊヨ⸆ࡢ⟶⌮࡟࠶ࡓࡗ࡚ࡣࠊ඲Ꮫⓗ࡞ࢥࣥࣆ࣮ࣗࢱ࡟ࡼࡿ໬Ꮫ≀㉁⟶⌮ࢩࢫࢸ࣒ .8&56 ࢆᑟධ
ࡋࠊࡑࢀࢆ฼⏝ࡋ࡚ࠊࡑࡢ⟶⌮࣭ಖ⟶࡟ດࡵ࡚࠸ࡿࠋࡉࡽ࡟ࠊ๻≀࣭ẘ≀ࡢಖ⟶࡟࠶ࡗ࡚ࡣࠊ◊✲⛉
ࡢ⟶⌮㈐௵⪅ࡢࡶ࡜ࠊྛศ㔝࡟㈐௵⪅ࢆᐃࡵࠊࡑࡢᏳ඲࣭ಖ⟶⟶⌮࡟ດࡵ࡚࠸ࡿࠋ
ࡉࡽ࡟ࠊᏛ⏕࡟ᑐࡋ࡚ࡣࠊㅮ⩏࣭ᐇ㦂࣭ᐇ⩦ࢆ㏻ࡌ࡚ࠊᏳ඲⟶⌮యไࡢᴫせࠊヨ⸆ࠊ༴㝤≀ࠊ⏕≀
ヨᩱࠊᨺᑕᛶ≀㉁➼ࡢྲྀᢅ࡜༴㝤㜵Ṇࠊᐇ㦂᤼Ỉ࡟࠾ࡅࡿ᤼Ỉᇶ‽࡜ࡑࡢ㑂Ᏺ࡟㛵ࡋ࡚ᩍ⫱ࡋࠊ࿘▱
ᚭᗏࢆᅗࡗ࡚࠸ࡿࠋࡲࡓࠊᩍဨࠊ஦ົ⫋ဨ࡞࡝ࡢປാࡢᏳ඲⾨⏕ᩍ⫱࡟ࡘ࠸࡚ࡣࠊி㒔኱Ꮫࡀ⾜࠺Ᏻ
඲ࠊ⾨⏕࡟㛵ࡍࡿᩍ⫱ࠊカ⦎ࢆཷㅮࡋࠊ࿘▱࡟ດࡵ࡚࠸ࡿࠋ
㸦㸲㸧タഛࡢ඘㊊≧ἣ࡜ᑗ᮶ィ⏬
ᮏ◊✲⛉࡟࠾࠸࡚ࡣࠊ་⸆ရࢆ⥲ྜⓗ࡟◊✲ࡍࡿࡓࡵ࡟ࠊ㑇ఏᏊࠊࢱࣥࣃࢡ㉁࡞࡝ࡢⓎ⌧ࡸᶵ⬟ࡢ
ゎᯒࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢵࢡࢫࠊ⏕యศᏊ࡜⸆≀࡜ࡢ┦஫స⏝ࡢゎᯒࠊ᪂つྜᡂ཯ᛂࡢ㛤Ⓨࠊࢣ
࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮ࠊ᪂つ་⸆ရࡢ๰〇ࠊ⸆⌮స⏝࠾ࡼࡧయෆືែࡢゎᯒ࡜ไᚚ࡞࡝ࡢ◊✲ࢆ᥎㐍ࡍ
ࡿ஦ࢆ┠ⓗ࡜ࡋ࡚࠾ࡾࠊࡑࡢࡓࡵ࡟ࣛ࢖ࣇࢧ࢖࢚ࣥࢫ㛵㐃ศᯒᶵჾࠊࣂ࢖࢜㛵㐃タഛࠊྜᡂ㛵㐃࠾ࡼ
ࡧᵓ㐀ゎᯒᶵჾࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢵࢡࢫࢆྵࡵࡓ᝟ሗฎ⌮㛵㐃ᶵჾ࣭タഛࠊ᝟ሗࢿࢵࢺ࣮࣡ࢡ
࡞࡝ࡢタഛࡢ඘ᐇࡀ୙ྍḞ࡛࠶ࡿࠋ
⌧ᅾࡲ࡛࡟ࠊ⛉Ꮫ◊✲㈝ࠊ⛉Ꮫᢏ⾡᣺⯆ㄪᩚ㈝ࠊ኱ᆺ≉ูᶵᲔᩚഛ㈝ࠊ≉ูᩍ⫱◊✲஦ᴗ㈝ࠊ኱Ꮫ
㝔㔜Ⅼ≉ู⤒㈝➼࡞࡝࡟ࡼࡾࠊୖグ㛵㐃ࡢタഛ࡜ࡋ࡚ࠊᩘྎࡢ᰾☢Ẽඹ㬆⿦⨨㸦105㸧ࠊ㉸㧗ᛶ⬟㉁㔞
ศᯒ⿦⨨ࢆྵࡴᩘྎࡢ㉁㔞ศᯒ⿦⨨ࠊࣂ࢖࢜࢖࣓࣮ࢪࣥࢢ࢔ࢼࣛ࢖ࢨࠊࢤࣀ࣒㓄ิゎᯒ⿦⨨ࠊᩘྎࡢ
࣮ࣞࢨ㉮ᰝᆺ㢧ᚤ㙾ࠊ᭷ᶵඖ⣲ศᯒ⿦⨨ࠊࢼࣀࣞ࣋ࣝ⣽⬊࣓࢝ࢽࢡࢫィ ࢩࢫࢸ࣒࡞࡝ࡢ኱ᆺタഛࡀࠊ
ྛศ㔝ࠊඹྠ฼⏝◊✲ᐊࢆ୰ᚰ࡟タ⨨ࡉࢀࠊ฼⏝ࡉࢀ࡚࠸ࡿ㸦㈨ᩱϮ㸫㸱ࠊϮ㸫㸲㸧ࠋࡲࡓࠊྛᑓᨷ◊
✲ᐇ㦂ᐊ࡟ࡣࡑࢀࡒࢀࡢᑓ㛛࡜ࡍࡿ◊✲࡟ᚲせ࡞ᶵჾࡀタ⨨ࡉࢀ࡚࠸ࡿࠋࡇࡢࡼ࠺࡟ࠊ⌧ᅾࠊ◊✲࡟
− 125 −
᭱ᑠ㝈ᚲせ࡞タഛࡣ࠶ࡿ⛬ᗘࡣタ⨨ࡉࢀ࡚ࡣ࠸ࡿࡀࠊࡲࡔ୙㊊ࡋ࡚࠸ࡿ㒊ศࡶከ࠸ࠋ≉࡟ࠊ⸆Ꮫศ㔝
ࡢ◊✲ࡀ῝ࡃ㛵ࢃࡿࣛ࢖ࣇࢧ࢖࢚ࣥࢫࠊࢼࣀࢸࢡࣀࣟࢪ࣮ࠊࢤࣀ࣒࣭ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢵࢡࢫࠊ
་⒪⸆Ꮫศ㔝ࡀᛴ㏿࡟㐍ᒎࡍࡿ⌧ᅾࠊࡇࢀࡽࡢ◊✲࣭ᩍ⫱࡟ᚲせ࡞タഛࡀḟࠎ࡜㛤Ⓨࡉࢀ࡚࠸ࡿࡀࠊ
ࡇࢀࡽࡢ᭱᪂タഛࡢタ⨨ࡣ౯᱁ࠊண⟬ࡢ㛵ಀࡶ࠶ࡾࠊࡑࡢタ⨨࡟ࡣከࡃࡢᅔ㞴ࢆ࡜ࡶ࡞ࡗ࡚࠸ࡿࠋࡲ
ࡓࠊࡍ࡛࡟タ⨨ࡉࢀ࡚࠸ࡿᶵჾࡶ⪏⏝ᖺᩘ࠿ࡽ᭦᪂ࡍ࡭ࡁࡶࡢࡶከࡃ࡞ࡗ࡚࠸ࡿࠋࡲࡓࠊ୍᪉࡛ࠊࡇ
ࢀࡽࡢᶵჾࡢ⥔ᣢ࡟ࡣከ㢠ࡢ㈝⏝ࡀ࠿࠿ࡾࠊࡇࢀࡶ኱ࡁ࡞ၥ㢟࡜࡞ࡗ࡚࠸ࡿࠋࡑࡇ࡛ࠊᮏ◊✲⛉࡟࠾
ࡅࡿᩍ⫱࣭◊✲ࡢ୍ᒙࡢ㧗ᗘ໬࡜඘ᐇࡢࡓࡵ࡟ࠊ⌧ᅾࠊࣛ࢖ࣇࢧ࢖࢚ࣥࢫࠊࢼࣀࢸࢡࣀࣟࢪ࣮ࠊࢤࣀ
࣒࣭ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢵࢡࢫࠊ་⒪⸆Ꮫ࡞࡝ࡢ◊✲࡟ᚲせ࡞᭱᪂タഛࡢ᪩ᛴ࡞タ⨨ࠊ105ࠊ㉁㔞ศ
ᯒ⿦⨨ࠊ㟁Ꮚ㢧ᚤ㙾࡞࡝ࡢ᪤Ꮡ኱ᆺタഛࡢ᭦᪂ࠊື≀᪋タ࡟࠾ࡅࡿ㣫⫱タഛࡢ඘ᐇࠊ5, ᐇ㦂᪋タ࣭タ
ഛࡢᩚഛ࣭඘ᐇࠊ᝟ሗタഛࡢ඘ᐇࠊ⥔ᣢ㈝ࢆྵࡵࡓຠ⋡ⓗ࡞⥔ᣢ⟶⌮ࢩࢫࢸ࣒ࡢᵓ⠏࡞࡝ࢆィ⏬ࡋ࡚
࠸ࡿࠋ
ࡲࡓࠊᩍ⫱⎔ቃ࡟㛵ࡋ࡚ࡣࠊ᪤タࡢㅮ⩏ᐊࠊࢭ࣑ࢼ࣮ᐊ࡟ຍ࠼ࠊᖹᡂ㸯㸳ᖺ㸯㸯᭶࡟⸆Ꮫ㒊ᩍ⫱Ჷ
ࢆ᪂⠏ࡋࠊ࣐ࣝࢳ࣓ࢹ࢕࢔ᑐᛂᆺㅮ⩏ᐊࠊ᝟ሗฎ⌮₇⩦ᐊࠊᏛ⏕ᐇ⩦ᐊࢆタࡅࠊᩍ⫱⎔ቃࡢ඘ᐇ࡟ດ
ࡵ࡚࠸ࡿࠋࡉࡽ࡟ࠊ᝟ሗฎ⌮₇⩦ᐊ࡟ࡣ㸲㸮ྎࡢࣃࢯࢥࣥࢆタ⨨ࡍࡿࡇ࡜࡟ࡼࡾࠊ᝟ሗ㛵㐃ᐇ⩦ࡢ඘
ᐇࡶᅗࡾࠊ᝟ሗ♫఍࣭་⒪࡟ᑐᛂࡋࠊ࣮ࣜࢻ࡛ࡁࡿேᮦࡢ⫱ᡂ࡟ࡶດຊࡋ࡚࠸ࡿࠋ௒ᚋࠊࡼࡾ୍ᒙࡢ
ᩍ⫱タഛࡢ඘ᐇࠊཌ⏕᪋タࢆྵࡵࡓᩍ⫱⎔ቃࡢᩚഛ࣭඘ᐇࢆᅗࡿணᐃ࡛࠶ࡿࠋ
− 126 −
VII-䠍㻌 ⸆Ꮫ◊✲⛉᪋タ㓄⨨䛾ᇶᮏ䝁䞁䝉䝥䝖
䛆ᴫᛕᅗ䛇㻌
ᩍ⫱᪋タ
⟶⌮㒊㛛
䜸䞊䝥䞁䝇䝨䞊䝇
ᑓᨷ◊✲ᐇ㦂ᐊ
ඹྠ฼⏝ᐇ㦂ᐊ
䛆㓄⨨ᅗ䛇㻌
ㅮ⩏ᐊ䚸䝉䝭䝘䞊ᐊ䚸ᐇ⩦ᐊ
ㅮ⩏ᐊ䚸ᐇ⩦ᐊ䛺䛹䛾ᩍ⫱᪋タ
ඹྠ฼⏝ᐇ㦂ᐊ䚸ື≀㣫⫱᪋タ
䠄ᆅୗ䠅
ඹྠ฼⏝ᐇ㦂ᐊ
RIᐇ㦂᪋タ
⟶⌮㒊㛛䠄䠍㝵䠅
䜸䞊䝥䞁
䝇䝨䞊䝇
ㅮᇽ䚸
⸆Ꮫ᝟ሗ᪋タ
ᑓᨷ◊✲ᐇ㦂ᐊ
䠄䠎㝵௨ୖ䠅
䜸䞊䝥䞁
䝇䝨䞊䝇
ඹྠ฼⏝ᐇ㦂ᐊ
䠄䠍㝵䚸ᆅୗ䠅
− 127 −
ᑓᨷ◊✲ᐇ㦂ᐊ
9,, ⸆Ꮫ◊✲⛉᪋タᇶᮏᴫせ
࣭࣮࢜ࣉࣥ࡞ࢫ࣮࣌ࢫࡢ☜ಖ
Ꮫ㒊࣭኱Ꮫ㝔⏕ࡢᑓᨷᩍ⛉࠾ࡼࡧᑓ㛛◊✲㡿ᇦࡢ⮬୺ⓗ࡞Ꮫ⩦ࢆ᥎㐍ࡍࡿࡇ࡜ࢆ
┠ⓗ࡜ࡋࠊ࣮࢜ࣉࣥ࡞࢝ࣥࣇ࢓ࣞࣥࢫࢫ࣮࣌ࢫࢆ☜ಖࠋ
࣭࢖ࣥࣇࣛ㸦࣮࣍ࣝࠊࣟࣅ࣮ࠊᗯୗ➼㸧ࡢ᭷ຠ฼⏝ࢆ᰾࡜ࡋࡓ࣮࢜ࣉࣥࢫ࣮࣌ࢫࡢ☜
ಖࠊ࢖ࣥࣇࣛ㸦࣮࣍ࣝࠊࣟࣅ࣮ࠊᗯୗ➼㸧ࢆ࣮࢜ࣉࣥࢫ࣮࣌ࢫ࡜ࡋ࡚☜ಖࡍࡿࡔ
ࡅ࡛࡞ࡃࠊᏛ⏕ࠋ♫఍ேࠊ◊✲⏕࡞࡝ࡀᩍ⫱࣭◊✲┠ⓗ࡛ከ┠ⓗ࡟฼⏝ฟ᮶ࡿሙ
ᡤ࡜ࡋ࡚ᩚഛࠋ
࣭ᑓᨷ◊✲ᐊࡢ࣮࢜ࣉ࣭ࣥࣛ࣎໬
ᑓᨷศ㔝࡟࠾࠸࡚ᐇ᪋ࡍࡿ኱Ꮫ㝔ᩍ⫱࣭◊✲ࡢከᵝ໬࡜ὶື໬࡟ᑐᛂࡋࠊ⮬⏤ᗘ
ࡀ㧗ࡃ࠿ࡘ㛤ᨺᛶࡢ࠶ࡿ◊✲ࢫ࣮࣌ࢫࢆᩚഛࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚ࠊᑓᨷ◊✲ᐊ
ࡣཎ๎࡜ࡋ࡚㝸ቨࢆྲྀࡾ㝖࠸ࡓᐇ㦂ᐊ㸦࣮ࣉ࣭ࣥࣛ࣎㸧࡜ࡍࡿࠋ
࣭ከ┠ⓗ࣭ඹྠ฼⏝ᐇ㦂ᐊࡢ☜ಖ
◊✲ࡢὶືᛶ࡟ᑐᛂࡉࡏࡿࡓࡵ࡟ࠊࣇࣞ࢟ࢩࣅࣜࢸ࢕ࡢ࠶ࡿከ┠ⓗ࣭ඹྠ฼⏝◊
✲ᐇ㦂ࢫ࣮࣌ࢫࢆ඘ᐇࠋ
࣭኱Ꮫ㝔ᑓ⏝ࡢㅮ⩏ᐊࠊࢭ࣑ࢼ࣮ᐊࡢᩚഛ
኱Ꮫ㝔࡟࠾ࡅࡿᩍ⫱࣭◊✲ࡢ㧗ᗘ໬࡟ᑐᛂࡋࠊ኱Ꮫ㝔ᑓ⏝ㅮ⩏ᐊࠊࢭ࣑ࢼ࣮ᐊ࡞
࡝ࡢᩍ⫱タഛࢆ඘ᐇࡉࡏࠊࡉࡽ࡟ᑓ㛛㡿ᇦࢆ㉸࠼ࡓ⮬⏤࡞஺ὶ࣭᝟ሗ஺᥮ࢆ᥎㐍
ࡍࡿࠋ
࣭◊✲ᐊࡢᯟࢆ㉸࠼ࡓᩍ⫱◊✲ࡢሙࡢ☜ಖ
ᩍ⫱࣭◊✲ࡢᅜ㝿໬࣭ከᵝ໬࡟ᑐᛂࡋࠊ◊✲ᐊࡢᯟࢆ㉸࠼ࡓ኱Ꮫ㝔࡟࠾ࡅࡿᩍ⫱࣭
◊✲ࡢሙࢆᩚഛࠋ
࣭࢔࣓ࢽࢸ࢕✵㛫ࡢᩚഛ
࢔࣓ࢽࢸ࢕ࡀ☜ಖࡉࢀࡓᩍ⫱࣭◊✲ࡢሙࢆᩚഛࠋ
− 128 −
− 129 −
− 130 −
− 131 −
ϯ Ꮫ⾡᝟ሗ
㹙ϯ㹛Ꮫ⾡᝟ሗ
㸦㸯㸧ᅗ᭩ᐊ
ᮏ◊✲⛉࣭Ꮫ㒊࡛ࡣࠊྛศ㔝ࡼࡾ㑅ฟࡉࢀࡓጤဨࡼࡾᵓᡂࡉࢀࡓᅗ᭩ጤဨ఍࡟࠾࠸࡚ࠊᏛ⾡ᅗ᭩ࡢ㉎
ධ࡟࠿࠿ࢃࡿண⟬࠾ࡼࡧỴ⟬࡞࡝ࡢ஦㡯ࢆᑂ㆟ࡋỴᐃࡋ࡚࠸ࡿࠋᅗ᭩ᐊ࡟࠾࠸࡚㠀ᖖ໅⫋ဨࢆྵࡴ㸱
ྡࡢ⫋ဨࡀ㑅ᐃࡉࢀࡓᏛ⾡ᅗ᭩ࡢ㉎ධࠊ㈚ฟࠊಖ⟶➼ࡢᴗົࢆ⾜ࡗ࡚࠸ࡿࠋ
ᖹᡂ㸰㸰ᖺ㸲᭶㸯᪥⌧ᅾࠊⶶ᭩ᩘࡣ⣙ ෉ࠊ࠺ࡕᏛ⾡㞧ㄅࡀ ๭ࠊ༢⾜ᮏࡀ㸱๭ࢆ༨ࡵ࡚࠾ࡾࠊ
㞧ㄅࡢ⥲ࢱ࢖ࢺࣝᩘࡣ ࡛࠶ࡿࠋᅗ᭩ࡢ㈚ฟ෉ᩘࡣᖹᡂ㸯㸴ᖺᗘࡲ࡛ࡣῶᑡഴྥ࡛࠶ࡗࡓࡀࠊᖹᡂ
㸯㸵ᖺᗘ௨㝆࡯ࡰቑຍഴྥ࡟࠶ࡿࠋ
Ꮫ⾡㞧ㄅࡢ㟁Ꮚࢪ࣮ࣕࢼࣝ໬࡟క࠸ࠊ㝃ᒓᅗ᭩㤋ࡢ࣮࣒࣮࣍࣌ࢪࡼࡾࠊ㟁Ꮚࢪ࣮ࣕࢼࣝࡣᘏ࡭㸴୓
ࢱ࢖ࢺࣝ௨ୖࡀᥦ౪ࡉࢀࠊ㟁Ꮚࣈࢵࢡࡶᘏ࡭㸰㸲୓ࢱ࢖ࢺࣝ௨ୖࠊࢹ࣮ࢱ࣮࣋ࢫࡶ㸯㸮㸮✀㢮௨ୖᥦ
౪ࡉࢀ࡚࠸ࡿࠋ⸆Ꮫศ㔝࡟ᚲせ࡞࡯࡜ࢇ࡝ࡢ㞧ㄅࡀ࢜ࣥࣛ࢖࡛ࣥ㜀ぴྍ⬟࡜࡞ࡗ࡚࠾ࡾࠊᮏ◊✲⛉࣭
Ꮫ㒊ࡢ㟁Ꮚࢪ࣮ࣕࢼࣝ฼⏝ᗘࡣ௚㒊ᒁ࡜ẚ㍑ࡋ࡚ࡶ㠀ᖖ࡟㧗࠸ഴྥ࡟࠶ࡿࠋᅗ᭩ᐊ࡟ࡶ㟁Ꮚࢪ࣮ࣕࢼ
࣭ࣝ᝟ሗ᳨⣴⏝ࣃࢯࢥࣥ㸲ྎࢆタ⨨ࡋࠊ฼⏝⪅ࡢ౽ᐅࢆࡣ࠿ࡗ࡚࠸ࡿࠋ௚࡟㸲㸮ྎࡢ↓⥺ /$1 ᑐᛂࣀ
࣮ࢺࣃࢯࢥࣥࢆᤵᴗ⏝㈚ฟࡢ࡯࠿ࠊᏛ⏕࡟ࡶ᫬㛫ࢆ㝈ࡗ࡚㈚ฟࡋ࡚࠸ࡿࠋ
⸆Ꮫ⛉㸳࣭㸴ᖺḟᏛ⏕࡜◊✲⛉ࡢ㝔⏕࣭ᩍ⫋ဨ➼ࡣࠊ,& ࣮࢝ࢻ࡟ࡼࡾᅗ᭩ᐊ࡬ࡢ᫬㛫እධᐊࡀྍ⬟
࡛࠶ࡾࠊᅗ᭩ࡢ㜀ぴ࣭㈚ฟ࣭」෗࣭᝟ሗ᳨⣴ࢆࡍࡿࡇ࡜ࡀ࡛ࡁࡿࠋ
⸆Ꮫ㒊ᅗ᭩ᐊࡢ≉ᚩࡢ୍ࡘࡣከᩘࡢᖹᡂࠕᮏⲡ᭩ࠖ㢮ࢆᡤⶶࡋ࡚࠸ࡿࡇ࡜࡛࠶ࡿࠋᮏⲡ᭩ࡣ᭷ྐ௨
๓ࡼࡾᩘ༓ᖺ࡟ࢃࡓࡗ࡚⵳࠼ࡽࢀࡓ₎ⲡࡢ▱㆑ࡀ㞟✚ࡉࢀࡓ᭩⡠࡛࠶ࡿࠋᮏⲡ㛵ಀ࡛ࡣࠊ୰ᅜห Ⅼࠊ᪥ᮏห Ⅼ࡟㐩ࡋ࡚࠾ࡾࠊ඲ᅜ࡛ࡶ᭷ᩘࡢ཰㞟࡛࠶ࡾࠊ⸆⣔኱Ꮫ࡛ࡣࡇࢀ࡟ඃࡿࡶࡢࡣ࡞࠸ࠋ
୺ὶᮏⲡ᭩ࡢ୍ࡘࠕ⤒ྐㆇ㢮኱ほᮏⲡࠖ
㸦ᰓẶᮏ㸧ࡀ࠶ࡾࠊࡲࡓࠊ
ࠕᮏⲡ㏻୵ド᭩ࠖ
㸦 ᖺᐩᒣ⸬ࠊ๓
⏣฼ಖ⦅㸧ࡣ㈗㔜࡞㑥⏘⸆ⲡᙬⰍᅗ࡛࠶ࡿࠋ᫂ࡢᮤ᫬⌋㑅ࡢࠕᮏⲡ⥙┠ࠖࡣ ᖺࡢỤす∧ࢆึࡵ㸵
✀ᡤⶶࡋ࡚࠾ࡾࠊ⨾㯇࡞኱ṇᮏࡢࠕᮏⲡᅗ㆕ࠖ
㸦ᒾᓮᖖṇ㸧ࡣᨾ∾㔝ᐩኴ㑻༤ኈࡢඖⶶ᭩࡛ࠊ༤ኈ⮬➹
ࡢヲ⣽࡞ᤄ⏬ࡸὀ㔘ࡀぢࡽࢀࡿࠋࡲࡓࠊ㣤἟៣ᩧࡢࠕᮏⲡᅗㄝࠖࡣ㈗㔜࡞Ᏻᨻ ᖺหࡢࡶࡢ࡛࠶ࡿࠋ
㸦㸰㸧ᶆᮏ
⏕⸆ࡢᶆᮏࡣከࡃࡢ㢮⦕໬ྜ≀ࡀᏑᅾࡍࡿ᳜≀⏺࡟࠾࠸࡚ࠊ᳜≀ࡸ⏕⸆ࡢ㚷ᐃࡸྠᐃ࡟Ḟࡃ࡭࠿ࡽ
ࡎࡶࡢ࡛࠶ࡿࠋ⌧ᅾධᡭࡋࡀࡓ࠸㈗㔜࡞୰ᅜ⏘ࡉࡃⴥᶆᮏ Ⅼࡢ௚ࠊ⏕⸆ᶆᮏ࡜ࡋ࡚୰ᅜࠊ࢖ࢫ
࣒ࣛᅪࠊᮾ༡࢔ࢪ࢔⏘ࡢࡶࡢ⣙ Ⅼࢆಖ᭷ࡋ࡚࠸ࡿ㸦㈨ᩱϯ㸫㸰㸧
ࠋ
㸦㸱㸧᝟ሗࢩࢫࢸ࣒
⌧ᅾࡢ⸆Ꮫ◊✲࡟ࡣࢥࣥࣆ࣮ࣗࢱ࣮ࢿࢵࢺ࣮࣡ࢡࢆ฼⏝ࡋࡓ᝟ሗฎ⌮ᶵ⬟ࢆ᭷ࡍࡿ◊✲ᨭ᥼᪋タࡀ
ᚲ㡲࡛࠶ࡿࠋ⸆Ꮫ㒊࡟࠾࠸࡚ࡣᮏ㤋ࠊู㤋࠾ࡼࡧ⥲ྜ◊✲Ჷࡢྛ◊✲ᐊ࠾ࡼࡧඹ㏻ᶵჾᐊࠊᅗ᭩ᐊࢆ
⤖ࡪࠊ⸆Ꮫ㒊඲㤋࡟ࢃࡓࡿᇶᖿ࣮ࣝࣉࡀᩜ࠿ࢀ࡚࠸ࡿࠋࡇࡢ /$1 ࡣி㒔኱ᏛᏛ⾡᝟ሗࢿࢵࢺ࣮࣡ࢡᶵ
ᵓ .8,16 ࡢࣀ࣮ࢻ࡟᥋⥆ࡉࢀࠊ඲ୡ⏺ࡢᏛ⾡㛵ಀ᪋タ࡜ࡢ᝟ሗ஺᥮ࠊඹྠ◊✲ࢆྍ⬟࡟ࡋ࡚࠸ࡿࠋ⸆
Ꮫ㒊ࡢࣀ࣮ࢻ࡟๭ᙜ࡚ࡽࢀ࡚࠸ࡿ ,3 ࢔ࢻࣞࢫᩘࡣ ࡛࠶ࡿࠋྛศ㔝ᙜࡓࡾ⣙ ࡢ࢔ࢻࣞࢫࡀ๭ᙜ
− 133 −
࡚ࡽࢀࡿࠋࡇࡢࢿࢵࢺ࣮࣡ࢡ࡟ࡘ࠸࡚ࡣࠊ⸆Ꮫ㒊⊂⮬࡛ࣇ࢓࢖࣮࢛࣮ࣖ࢘ࣝࢆタᐃࡋࢭ࢟ࣗࣜ࢕ࢸ࢕
࣮ࡢ☜ಖ࡟ດࡵ࡚࠸ࡿࠋࡉࡽ࡟ࠊ,3 ࢔ࢻࣞࢫᩘࡢ୙㊊ࡀ኱ࡁ࡞ၥ㢟࡜࡞ࡾࡘࡘ࠶ࡗࡓࡀࠊᖹᡂ㸯㸲ᖺ
ᗘ࠿ࡽࡢࠊ.8,16 ࡢᑟධ࡟క࠸ࠊ,3 ࢔ࢻࣞࢫᩘࡀ㣕㌍ⓗ࡟ቑຍࡋࡓࠋ.8,16 ࡛ࡣྛ◊✲ᐊẖ࡟ 9/$1
ࢆタᐃࡋࠊࡑࢀࡒࢀ࡟㈐௵⪅࡜⟶⌮⪅ࢆ⨨ࡃ㐠⏝యไࢆ࡜ࡗ࡚࠸ࡿࠋࡲࡓࠊ㸰㸯ୡ⣖ &2( ࣉࣟࢢ࣒ࣛ
ࠕࢤࣀ࣒໬Ꮫࡢ▱ⓗᇶ┙ᙧᡂ࣭◊✲ᣐⅬᙧᡂࠖࡢ୍⎔࡜ࡋ࡚ࠊ㑇ఏᏊ㓄ิゎᯒ⏝ࡢࢧ࣮ࣂࢆタ⨨ࡋࠊ
⸆Ꮫ㒊ෆ࠿ࡽࡢ฼⏝ࢆྍ⬟࡟ࡋ࡚࠸ࡿࠋ
ୖグࡢ◊✲⏝᝟ሗࢩࢫࢸ࣒ࡢ࡯࠿࡟ࠊ᝟ሗᩍ⫱⏝᪋タ࡜ࡋ࡚ࠊி㒔኱ᏛᏛ⾡᝟ሗ࣓ࢹ࢕࢔ࢭࣥࢱ࣮
ࡢ➃ᮎ࡛࠶ࡿ࣮࣡ࢡࢫࢸ࣮ࢩࣙࣥ㸲㸮ྎࡀ᝟ሗฎ⌮₇⩦ᐊ࡟タ⨨ࡉࢀࠊ.8,16 ࢆ㏻ࡌ࡚ࠊᩍ⫱⏝࡟฼⏝
ࡉࢀ࡚࠸ࡿࠋ᝟ሗฎ⌮₇⩦ᐊ࡛ࡣ᝟ሗฎ⌮ᩍ⫱࠾ࡼࡧࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ࡟㛵ࡍࡿᩍ⫱ࡀ⾜
ࢃࢀ࡚࠸ࡿࠋ
− 134 −
9,,,⸆Ꮫ㒊ᅗ᭩ᐊࡢ⌧ἣ
ᡤⶶ㞧ㄅࡢ
ⶶ᭩෉ᩘ෉㸧
㈚ฟ෉ᩘ㸦෉㸧
⫋ဨᩘ㸦ே㸧
✚
ᗙ
ᖍ
㸦੍㸧
ᗘ
ᩘ
ᩍ
ᖺ
⫋
࿴
ὒ
ィ
࿴
ὒ
ィ
ဨ
ᐃ
Ꮫ⏕
ィ
ဨ
ࣃ 䤀 ࢺ
㠃
ࢱ࢖ࢺࣝᩘ
ᘏ
ィ
+
ᖺ
+
ᖺ
+
ᖺ
+
ᖺ
+
ᖺ
㸦ͤᅗ᭩㤋ࡢ⤫ィ࡛ࡣ ੍㸧
ὀ㸸+ ࡣ + ⌧ᅾࡢᩘ್
ὀ㸸+ ࡼࡾᐃဨࡢ ྡࡣ෌㞠⏝
9,,, ௚኱Ꮫࡀಖ᭷ࡋ࡞࠸ᶆᮏࠊ㈨ᩱ➼
༊ ศ
ྡ ⛠
཰㞟ᖺ
ဨ ᩘ
ഛ ⪃
ࢺࣝࢥ⸆⏝᳜≀
ࠥ
Ⅼ
ᾏእㄪᰝ࡟ࡼࡾ཰㞟
ࡉࡃⴥᶆᮏ
୰ᅜ⏘⸆⏝᳜≀
ࠥ
Ⅼ
୰ኸ࢔ࢪ࢔⏘
ࠥ
Ⅼ
ᾏእㄪᰝ࡟ࡼࡾ཰㞟
࣋ࢺࢼ࣒⏘⸆⏝᳜≀
ࠥ
Ⅼ
ᾏእㄪᰝ࡟ࡼࡾ཰㞟
୰ᅜᶆᮏ
ࠥ
Ⅼ
ࡇࢀࡽࡣ⥲ྜ༤≀㤋
⏕⸆ᶆᮏ
࢖ࢫ࣒ࣛᅪ⏕⸆
Ⅼ
࡬⛣⟶ࡋಖᏑࡋ࡚࠸
Ⅼ
ࡿ
⸆⏝᳜≀
ᮾ༡࢔ࢪ࢔⏕⸆
ࠥ
ࠥ
ͤୖグࡢ௚࡟⏕⸆ᶆᮏ㸦୰ᅜ⏘࠾ࡼࡧᮾ༡࢔ࢪ࢔⏘㸧ࡢᩚ⌮୰ࡢࡶࡢࡀ⣙ Ⅼ࠶ࡿࠋ
− 135 −
ϰ ᅜ㝿஺ὶ
㹙ϰ㹛ᅜ㝿஺ὶ
㸦㸯㸧 ␃Ꮫ⏕ࡢཷධࢀ≧ἣ࣭␃Ꮫ⏕ᩍ⫱࣭◊✲ᣦᑟ
⸆Ꮫ㒊࡬ࡢᏛ㒊Ꮫ⏕ࡢ␃Ꮫチྍࡣᅜ㈝ࠊ⚾㈝࡛␗࡞ࡗ࡚࠸ࡿࠋᅜ㈝␃Ꮫ⏕ࡣࠊᖹᡂ㸰㸯ᖺᗘ࠿ࡽࡣ
㠃᥋ࢆ⾜࠸ࠊಟᏛࡢពᚿࢆ☜ㄆࡋࠊᩍᤵ఍ࡢᑂᰝࢆ⤒࡚ධᏛࢆチྍࡍࡿࡇ࡜࡜ࡋ࡚࠸ࡿࠋ⚾㈝␃Ꮫ⏕
ࡣ᪥ᮏㄒ⬟ຊヨ㦂㸦୍⣭㸧
ࠊ⚾㈝እᅜே␃Ꮫ⏕ヨ㦂㸦⌮⛉⣔㸧࠾ࡼࡧ≉ู㑅⪃࡜ࡋ࡚ධヨ➼ၥ㢟᳨ウጤ
ဨ఍Ꮫ㒊ᑠጤဨ఍࡟ࡼࡾసᡂࡉࢀࡓ➹グヨ㦂࡜ཱྀ㢌ㅎၥ࡟ྜ᱁ࡋࡓ⪅࡟ධᏛࢆチྍࡋ࡚࠸ࡿࠋ␃Ꮫ⏕
ࡣධᏛᐃဨᯟእ࡛ධᏛࡉࡏ࡚࠸ࡿࠋ౛ᖺࠊᅜ㈝ࠊ⚾㈝ྜࢃࡏ࡚㸯ࠥ㸰ྡࡢ࢔ࢪ࢔ᆅᇦ࠿ࡽࡢ␃Ꮫ⏕ࡀ
ධᏛࡋ࡚࠸ࡿ㸦㈨ᩱϰѸ㸯ཧ↷㸧ࠋ㏆ᖺࠊᅜ㝿໬ࡢἼ࡟ࡼࡾࠊධᏛᕼᮃ⪅ࡀᛴቑࡋ࡚ࡁࡓࡇ࡜ࡶ࠶ࡾࠊ
ᖹᡂ㸰㸰ᖺᗘ࠿ࡽࡢ≉ู㑅⪃࡛ࡣฟ㢪஦๓ᑂᰝࢆタࡅࠊཷ㦂⪅ࡢ㉁ࡢ☜ಖ࡜࡜ࡶ࡟ᚿ㢪⪅ࡢ㈇ᢸ㍍ῶ
࡟㓄៖ࡋ࡚࠸ࡿࠋᩍ⫱࡟㛵ࡋ࡚ࡣࠊᏛ⏕࠶ࡿ࠸ࡣᩍဨࡀࢳ࣮ࣗࢱ࣮࡜ࡋ࡚┦ㄯ࡟ࡢࡿࢩࢫࢸ࣒ࢆ᥇⏝
ࡋ࡚࠸ࡿࡀࠊࡑࢀ௨እࡣ≉࡟᪥ᮏேᏛ⏕࡜␗࡞ࡗࡓࡇ࡜ࡣ⾜ࡗ࡚࠸࡞࠸ࠋ
⸆Ꮫ◊✲⛉࡬ࡢධᏛࡣࠊ⸆Ꮫ◊✲⛉ࡢධヨ➼ၥ㢟᳨ウጤဨ఍኱Ꮫ㝔ᑠጤဨ఍࡟ࡼࡾ⾜ࢃࢀࡿ➹グヨ
㦂࠾ࡼࡧཱྀ㢌ㅎၥࡢྜ᱁⪅࡟ධᏛࢆチྍࡋ࡚࠸ࡿࠋ␃Ꮫ⏕ࡣධᏛᐃဨᯟእ࡛ධᏛࡉࡏ࡚࠸ࡿࠋಟኈㄢ
⛬ࠊ༤ኈᚋᮇㄢ⛬ࡢ࠸ࡎࢀࡶ㸲㹼㸵ྡࡢᏛ⏕ࡀධᏛࡋ࡚࠸ࡿ㸦㈨ᩱϰѸ㸰㸧ࠋධᏛᚋࡢᩍ⫱ࠊ◊✲ᣦᑟ
࡟㛵ࡋ࡚ࡣࠊᏛ⏕࠶ࡿ࠸ࡣᩍဨࡀࢳ࣮ࣗࢱ࣮࡜ࡋ࡚┦ㄯ࡟ࡢࡿࢩࢫࢸ࣒ࢆ᥇⏝ࡋ࡚࠸ࡿࡀࠊࡑࢀ௨እ
ࡣ≉࡟᪥ᮏேᏛ⏕࡜␗࡞ࡿࡇ࡜ࡣ⾜ࡗ࡚࠸࡞࠸ࠋ
㸦㸰㸧ᅜ㝿஺ὶጤဨ఍ࡢάື
⸆Ꮫ㒊ᅜ㝿஺ὶጤဨ఍ࡣ◊✲⛉㛗ࠊᑓᨷ㛗ࠊி㒔኱Ꮫᅜ㝿஺ὶጤဨ఍ጤဨ࡟ࡼࡾᵓᡂࡉࢀࡿࠋᏛ㒊ࠊ
◊✲⛉࡟࠾ࡅࡿᅜ㝿஺ὶ࡟㛵ࡍࡿㅖၥ㢟ࠊ౛࠼ࡤᏛ㒊㛫஺ὶ༠ᐃࡢ⥾⤖ࠊி㒔኱Ꮫᅜ㝿஺ὶጤဨ఍࡟
࠾࠸࡚ᥦ㉳ࡉࢀࡓၥ㢟ࡢ᳨ウ࡞࡝ࠊ㝶᫬ጤဨ఍ࢆ㛤ദࡋ࡚ᑐᛂࡋ࡚࠸ࡿࠋ
㸦㸱㸧ᾏእࡢ኱Ꮫ࣭ᩍ⫱ᶵ㛵࡜ࡢᩍ⫱࣭◊✲ࡢ஺ὶ
ᅜ㝿஺ὶࡣ୺࡜ࡋ࡚◊✲㠃࡛ಶேࡲࡓࡣࢢ࣮ࣝࣉࢆ༢఩࡜ࡋ࡚እᅜࡢ኱Ꮫࡲࡓࡣ◊✲ᡤ࡜ඹྠ◊✲
ࢆ⾜ࡗ࡚࠸ࡿࡶࡢ࡛ࠊ⸆Ꮫ㒊ࡢᅜ㝿஺ὶጤဨ఍ࡀ୺య࡜࡞ࡗ࡚ᐇ㉁ⓗ࡞άືࢆ⾜ࡗ࡚࠸ࡿࡶࡢ࡛ࡣ࡞
࠸ࠋᏛ㒊㛫஺ὶ༠ᐃࡣࢳࣗࣛࣟࣥࢥࣥ኱Ꮫࠊ༡࢝ࣜࣇ࢛ࣝࢽ࢔኱Ꮫࠊࢯ࢘ࣝ኱Ꮫᰯ࡜⥾⤖ࡋ࡚࠾ࡾࠊ
ᖺ㸰ࠥ㸱ᅇࡢᩍᐁࡢ◊✲஺ὶࠊⱝᡭ◊✲⪅ࡢࡓࡵࡢྜྠࢩ࣏ࣥࢪ࣒࢘࡞࡝ࢆ⾜ࡗ࡚࠸ࡿࠋᩍ⫱ᨭ᥼ࡣ
࢝ࣈ࣮ࣝ኱Ꮫ࡟ᑐࡍࡿ᚟⯆ᨭ᥼࡟ྲྀࡾ⤌ࢇ࡛࠾ࡾࠊࡇࢀࡲ࡛࡟ᩘᅇࡢ஺ὶࢆ㔜ࡡ࡚࠸ࡿࠋᑗ᮶ࡉࡽ࡟
άືࡀᙉ໬ࡉࢀࡿࡇ࡜ࡀᮃࡲࢀࡿࠋ ᖹᡂ㸰㸯ᖺᗘ࡟ࡣࠊᅜ㝿໬ᣐⅬᩚഛ஦ᴗ㸦ࢢ࣮ࣟࣂࣝ㸱㸮㸧ࡀ᥇ᢥࡉࢀࠊඃࢀࡓ␃Ꮫ⏕⋓ᚓࡢࡓࡵ
࡟ⱥㄒࡢࡳ࡛Ꮫ఩ࢆྲྀᚓ࡛ࡁࡿ *OREDO)URQWLHULQ/LIH6FLHQFH ࢥ࣮ࢫࢆ᪂タࡋࠊᖹᡂ㸰㸱ᖺᗘධ
Ꮫ⪅ࡼࡾເ㞟ࡍࡿࠋ
ࡲࡓࠊಶேࡲࡓࡣ◊✲ᐊ༢఩࡛⾜ࡗ࡚࠸ࡿࡶࡢ㸦⣙㸯㸮㸮௳㸧࡞࡝ࡀ࠶ࡾࠊᑗ᮶ⓗ࡟ቑຍࡋ࡚࠸ࡃ
ࡶࡢ࡜ᮇᚅࡉࢀ࡚࠸ࡿࠋ
− 137 −
㸦㸲㸧ᩍဨࡢᅾእ◊✲ࡢ≧ἣ࣭ᾏእฟᙇࡢ≧ἣ
ᖹᡂ㸯㸶ᖺᗘ௨㝆⌧ᅾࡲ࡛࡟ࠊᅾእ◊✲㸦Ꮫ఍ฟᖍࠊ◊✲࣭ㄪᰝ㸧ࢆ⾜ࡗࡓᩍဨࡣᘏ࡭㸰㸲㸵ྡ㸦ᖺ
ᖹᆒ㸴㸯ྡ㸧࡛ࠊ඲ᩍဨࡢ⣙㸯㸮㸮㸣ࡀᅾእ◊✲ࢆ⾜ࡗ࡚࠸ࡿࡇ࡜࡟࡞ࡿ㸦㈨ᩱϰѸ㸱㸧ࠋ
㸦㸳㸧ᣍ࡬࠸እᅜேᏛ⪅࠾ࡼࡧ◊✲⪅ࡢཷධࢀ≧ἣ
ᖹᡂ㸯㸶ᖺᗘ௨㝆⌧ᅾࡲ࡛ࠊᣍ࡬࠸௳ᩘࡣ㸯㸰௳㸦㸯㸰ྡ㸧࡛࠶ࡿࠋ୰⳹ேẸඹ࿴ᅜ㸰ྡࠊ࢖ࣛࣥ
㸰ྡࠊ࣋ࣝࢠ࣮㸰ྡࠊⱥᅜࠊࢻ࢖ࢶࠊࣇࣛࣥࢫࠊ࣎ࣜࣅ࢔ࠊࣈࣛࢪࣝࠊࢱ࢖ ྛ㸯ྡࠊ࡞࡝ࡀ࠶ࡿ㸦㈨
ᩱϰѸ㸲㸧
ࠋ
− 138 −
ϰ㸫㸯 እᅜே␃Ꮫ⏕ࡢཷධࢀ≧ἣ 㸦Ꮫ㒊㸧
ᖹᡂ㸯㸶ᖺᗘ
༊ศ
ᖹᡂ㸯㸷ᖺᗘ
ᖹᡂ㸰㸮ᖺᗘ
ᖹᡂ㸰㸯ᖺᗘ
ᖹᡂ㸰㸰ᖺᗘ
ᚿᮃ⪅
ධᏛ⪅
ᚿᮃ⪅
ධᏛ⪅
ᚿᮃ⪅
ධᏛ⪅
ᚿᮃ⪅
ධᏛ⪅
ᚿᮃ⪅
ධᏛ⪅
ᩘ
ᩘ
ᩘ
ᩘ
ᩘ
ᩘ
ᩘ
ᩘ
ᩘ
ᩘ
ᅜ㈝
⚾㈝
ィ
ϰ㸫㸰 እᅜே␃Ꮫ⏕ࡢཷධࢀ≧ἣ 㸦Ꮫ㒊㸧
㸦ಟኈㄢ⛬㸧
༊ศ
ᖹᡂ㸯㸶ᖺᗘ
ᖹᡂ㸯㸷ᖺᗘ
ᖹᡂ㸰㸮ᖺᗘ
ᖹᡂ㸰㸯ᖺᗘ
ᖹᡂ㸰㸰ᖺᗘ
ᅜ㈝
⚾㈝
ィ
㸦༤ኈㄢ⛬㸧
༊ศ
ᖹᡂ㸯㸶ᖺᗘ
ᖹᡂ㸯㸷ᖺᗘ
ᖹᡂ㸰㸮ᖺᗘ
ᖹᡂ㸰㸯ᖺᗘ
ᖹᡂ㸰㸰ᖺᗘ
ᅜ㈝
⚾㈝
ィ
ϰ㸱 ᩍဨࡢᅾእ◊✲ࡢ≧ἣ
ᖹᡂ ᖺᗘ
༊ศ
Ꮫ఍
◊✲
ฟᖍ
ㄪᰝ
௳
௳
ᩍᤵ
෸ᩍᤵ
ᖹᡂ ᖺᗘ
Ꮫ఍
◊✲
ฟᖍ
ㄪᰝ
௳
௳
௳
ㅮᖌ
ຓᩍ
ィ
ᖹᡂ ᖺᗘ
ᖹᡂ ᖺᗘ
Ꮫ఍
◊✲
ฟᖍ
ㄪᰝ
௳
௳
௳
௳
௳
௳
௳
ィ
ͤ≉ᐃ᭷ᮇ㞠⏝ᩍဨࠊᐤ㝃ㅮᗙᩍဨࢆྵࡴ
ィ
ィ
Ꮫ఍
◊✲
ฟᖍ ㄪᰝ
ィ
ͤᖹᡂ ᖺᗘ࠿ࡽຓᩍᤵЍ෸ᩍᤵࠊຓᡭЍຓᩍ
− 139 −
− 140 −
ϱ ♫఍࡜ࡢ㐃ᦠ
㹙ϱ㹛♫఍࡜ࡢ㐃ᦠ
⸆Ꮫ࡟࠾ࡅࡿᩍ⫱࣭◊✲ࡣ⸆๣ᖌ࠾ࡼࡧ๰⸆◊✲⪅ࡢ㣴ᡂࢆ୺ࡓࡿ┠ᶆ࡜ࡋ࡚࠸ࡿࡇ࡜࠿ࡽࠊ⸆Ꮫ
࡜♫఍࡜ࡢ㐃ᦠࡶ୍⯡࡟ᗈ⠊࡞⛉Ꮫ㡿ᇦ࠿ࡽ་⒪㛵ಀ࡟ཬࡪᗈ࠸⠊ᅖ࡟ࡲࡓࡀࡗ࡚࠸ࡿࠋ
ᮏᏛࡢ⸆Ꮫ◊✲⛉ࡣ〇⸆௻ᴗࡢ◊✲⪅࠾ࡼࡧᢏ⾡⪅ࡢ㣴ᡂࢆ┠ⓗ࡟タ⨨ࡉࢀࡓ⤒⦋ࢆࡶࡘṔྐⓗ࡞
⫼ᬒࡶ࠶ࡗ࡚ࠊᚑ᮶࠿ࡽࠊ་⸆ရ◊✲ࢆ࣮࣮࢟࣡ࢻ࡜ࡍࡿ♫఍࡜ࡢ㐃ᦠ࡟ຊࢆὀ࠸࡛ࡁ࡚࠾ࡾࠊ୰࡛
ࡶ〇⸆௻ᴗࢆ୺࡜ࡍࡿ་⸆ရ◊✲㛵㐃ᶵ㛵࡜ࡢ㛵ಀ࡟࠾࠸࡚ࠊ◊✲ဨࡢཷࡅධࢀࠊඹྠ◊✲୪ࡧ࡟◊
✲஺ὶ➼ࡀᴟࡵ࡚✚ᴟⓗ࡟㐍ࡵࡽࢀ࡚ࡁࡓࠋࡇࢀࡽࡢ◊✲㠃࡟࠾ࡅࡿ♫఍࡜ࡢ㐃ᦠࢆ㏻ࡋ࡚ࠊ⸆Ꮫ◊
✲⛉ࡢ◊✲ᡂᯝࡸ㧗ᗘ࡞◊✲ᢏ⾡ࢆ௚ࡢ◊✲ᶵ㛵ࡸ〇⸆௻ᴗ࡟ᗈࡃ㑏ඖࡋ࡚࠾ࡾࠊᡃࡀᅜࡢ་⒪ࠊ་
⸆ရ◊✲࡟኱ࡁࡃ㈉⊩ࡋ࡚ࡁࡓࠋ
ࡉࡽ࡟ࠊ㏆ᖺ࡟࠾ࡅࡿ་⸆ရࡢ⸆⌮ᶵ⬟ࡢ㧗ᗘ໬ࠊᗈ⠊໬࠾ࡼࡧ㧗㱋♫఍➼ࡢ་⸆ရࢆྲྀࡾࡲࡃ♫
఍ⓗኚື࡟క࠸ࠊ⸆⣔኱Ꮫࠊ⸆Ꮫ㒊࡟ᑐࡋ࡚ࠊ◊✲㠃࡛ࡢ㐃ᦠ࡟ຍ࠼࡚⫋⬟⸆๣ᖌ࡜ࡢ⫋ົ㐃ᦠ୪ࡧ
࡟෌ᩍ⫱ࡉࡽ࡟ࡣ୍⯡ᕷẸ࡬ࡢ་⸆ရࡢ᝟ሗᥦ౪࡞࡝ࡢ་⸆ရࡢ♫఍ⓗほⅬ࠿ࡽࡢ㐃ᦠࢆᐦ᥋࡟ࡶࡘ
ࡇ࡜ࡀ㔜せ࡞ㄢ㢟࡜ࡉࢀ࡚࠸ࡿࠋࡇ࠺ࡋࡓ᪂ࡋ࠸ゅᗘ࠿ࡽࡢ♫఍࡜ࡢ㐃ᦠ࡟ᑐࡍࡿᮏᏛ◊✲⛉ࡢྲྀࡾ
⤌ࡳ࡜ࡋ࡚ࡣࠊᑐᛂࡍࡿ⏕ᾭᩍ⫱ㅮ₇఍ࡢ㛤ദ࡞࡝ࢆ⾜࠸ࠊࡑࡢᐇ⦼ࢆᣲࡆࡘࡘ࠶ࡿ࡜ࡇࢁ࡛࠶ࡿࠋ
ࡇࡇ࡛ࡣᮏᏛ㒊࡟࠾ࡅࡿ♫఍࡜ࡢ㐃ᦠࡢ⌧≧ࢆࠊ◊✲ဨࡢཷࡅධࢀࠊ⏕ᾭᩍ⫱ㅮ₇఍࣭බ㛤ㅮ₇఍ࠊ
ඹྠ◊✲ࡢ㡯┠ู࡟ㄝ᫂ࡍࡿࠋ
㸦㸯㸧◊✲ဨࡢཷࡅධࢀ
⸆Ꮫ◊✲⛉࡬ࡢ◊✲ဨࡢཷࡅධࢀࡣࠊཷク◊✲ဨࠊ◊ಟဨ࠾ࡼࡧ◊✲⏕ࡢไᗘୗ࡟⾜ࢃࢀ࡚࠸ࡿࠋ
㈨ᩱϱ㸫㸯࡟㐣ཤ㸲ᖺ㛫ࡢேဨࡢືྥࢆ♧ࡍࠋẖᖺࠊከᩘࡢ◊✲ဨࢆཷࡅධࢀࡿࡇ࡜࡟ࡼࡾࠊᩍ⫱࣭
◊✲ࢆ㏻ࡋ࡚ࡢ♫఍࡜ࡢ㐃ᦠࢆ῝ࡵ࡚࠸ࡿࠋ
♫఍ேࡢ◊✲ဨࡢཷࡅධࢀࡣࠊ〇⸆௻ᴗ࠿ࡽࡢཷࡅධࢀࢆ୺࡜ࡍࡿཷク◊✲ဨࡀ୺య࡜࡞ࡾࠊ◊ಟ
ဨࡀࡇࢀ࡟ຍ࠼ࡽࢀࡿࠋ᭱㏆◊ಟဨࡢ୰࡟ࠊ௻ᴗ➼ࢆ㏥⫋ᚋࠊࡉࡽ࡟◊✲άືࢆ⥆ࡅࡓ࠸࡜ࡢᕼᮃࢆ
ᣢࡘேᮦࡀ⌧ࢀ࡚࠸ࡿࠋ᪂ࡋ࠸ഴྥ࡜ࡋ࡚ὀ┠ࡉࢀࡿ࡜ࡇࢁ࡛࠶ࢁ࠺ࠋࡉࡽ࡟ࠊࡇࢀ௨እ࡟Ẹ㛫➼࡜
ࡢඹྠ◊✲࡟ὴ㐵ࡉࢀ࡚࠸ࡿ◊✲ဨࡢᅾ⡠ࡀ࠶ࡿࠋ〇⸆௻ᴗ➼࠿ࡽࡢ◊✲ဨࢆ✚ᴟⓗ࡟ཷࡅධࢀࡿࡇ
࡜࡟ࡼࡾࠊ⸆Ꮫ◊✲⛉࡟࠾ࡅࡿ◊✲ࡢᡂᯝࡸ᭱ඛ➃ࡢ◊✲ᢏ⾡ࡢ♫఍࡬ࡢ㑏ඖࡀ኱ࡁࡃಁ㐍ࡉࢀ࡚࠾
ࡾࠊ◊✲㠃࡛ࡢ♫఍࡜ࡢ㐃ᦠ࡟኱ࡁ࡞ᙺ๭ࢆᯝࡓࡋ࡚࠸ࡿࠋ
୍᪉ࠊ◊✲⏕࡟㛵ࡋ࡚ࡣࠊᐇ㉁ⓗ࡟Ꮫෆ࠶ࡿ࠸ࡣ௚኱Ꮫฟ㌟⪅࠿ࡽࡢ኱Ꮫ㝔㐍Ꮫᕼᮃ⪅࡛༨ࡵࡽࢀ
࡚࠸ࡿࠋ௚኱Ꮫ࠶ࡿ࠸ࡣᏛෆࡢ኱Ꮫ㝔㐍Ꮫᕼᮃ⪅ࢆ◊✲⏕࡜ࡋ࡚ཷࡅධࢀࡿࡇ࡜࡟ࡼࡾࠊ኱Ꮫ㝔࡛ࡢ
ᩍ⫱ࡢ㛛ᡞࢆᗈࡆࠊᗈ࠸⠊ᅖࡢᏛ⏕ࡢ㧗ᗘඛ➃ᩍ⫱࡟ᑐࡍࡿࢽ࣮ࢬ࡟ᛂ࠼ࡿࡇ࡜ࢆྍ⬟࡟ࡋ࡚࠸ࡿࠋ
♫఍࡟ඃ⚽࡞ேᮦࢆ㍮ฟࡍࡿࡓࡵࡢ኱Ꮫ㝔ࡢ◊✲࣭ᩍ⫱ࡢ඘ᐇ࡟ࡣࠊ㐺ᙜ࡞➇த࡟ࡼࡿධᏛ⪅㑅ᢤࢆ
ᐇ᪋ࡋ࡚ᗈ࠸⠊ᅖ࠿ࡽࡢඃ⚽࡞Ꮫ⏕࣭♫఍ேࡢເ㞟ࡀ୙ྍḞ࡛࠶ࡾࠊ⌧ᅾࡢ◊✲⏕ࡢཷධࢀ≧ἣࡣࠊ
ᮏไᗘࡀࡇࡢࡼ࠺࡞ไᗘࢆᨭ᥼ࡍࡿࡓࡵࡢ᭷ຠ࡞ࢩࢫࢸ࣒࡜ࡋ࡚ᶵ⬟ࡋ࡚࠸ࡿࡇ࡜ࢆ♧ࡍࡶࡢ࡛࠶ࡿࠋ
− 141 −
㸦㸰㸧◊✲஺ὶ
㸰㸯ୡ⣖ࡢ⸆Ꮫࢆ᥈ࡿி㒔ࢩ࣏ࣥࢪ࣒࢘࠾ࡼࡧ⸆Ꮫࡢᮍ᮶ࢆ⪃࠼ࡿி㒔ࢩ࣏ࣥࢪ࣒࢘ࡢ㛤ദ
⸆Ꮫ◊✲⛉࠾ࡼࡧ㛵㐃㡿ᇦࡢྛศ㔝࣭㒊㛛ࡢ◊✲ࡣࠊᚑ᮶࠿ࡽᏛ఍άື➼ࢆ㏻ࡋ࡚✚ᴟⓗ࡟බ⾲ࡉ
ࢀࠊ࠿ࡘẸ㛫௻ᴗ➼ࡢᏛ㒊እᶵ㛵࡜ࡢ◊✲஺ὶࡶ㠀ᖖ࡟άⓎ࡟⾜ࢃࢀ࡚ࡁࡓࠋࡇࡢጼໃࡣ௒ᚋࡶỴࡋ
࡚ኚࢃࡿࡶࡢ࡛ࡣ࡞ࡃࠊࡼࡾάⓎ࡟ᒎ㛤ࡉࢀࡿࡶࡢ࡜⪃࠼ࡽࢀࡿࠋ
ࡇࢀࡽࡢศ㔝࣭㒊㛛༢఩࡛ࡢ◊✲஺ὶ࡜ࡣ⊂❧࡟ࠊࡉࡽ࡟ࠊ◊✲⛉࡜ࡋ࡚⊂⮬ᛶࢆࡶࡘ◊✲஺ὶࡢ
ሙࢆࡶࡕࠊྠ᫬࡟බ㛤ㅮᗙࡢᛶ᱁ࢆࡶࡓࡍ⪃࠼࡛ࠊ⾲グࡢࢩ࣏ࣥࢪ࣒࢘ࡀ௻⏬ࡉࢀࠊᖹᡂ㸱ᖺ࠿ࡽ㛤
ദࡉࢀࠊᖹᡂ㸯㸯ᖺ㹼㸯㸵ᖺࡢᮇ㛫࡟㸷ᅇࡢࢩ࣏ࣥࢪ࣒࢘ࡀ㛤ദࡉࢀ࡚ࡁࡓࠋ
ᮏࢩ࣏ࣥࢪ࣒࢘ࡣࠊᮏ⸆Ꮫ㒊๰タ㸳㸮࿘ᖺࢆグᛕࡋ࡚タ❧ࡉࢀࡓグᛕ஦ᴗ఍ࡢ஦ᴗࡢ୍㈏࡜ࡋ࡚ጞ
ࡵࡽࢀࡓࡶࡢ࡛࠶ࡿࠋ⸆Ꮫ㒊ᇶᖿศ㔝࡟ຍ࠼ࠊ໬Ꮫ◊✲ᡤ࠿ࡽࡢ᭷ᶵྜᡂᇶ♏◊✲㒊㛛࡜⏕య཯ᛂタ
ィ◊✲㒊㛛ࡢ㸰㒊㛛ࠊ⏕࿨⛉Ꮫ◊✲⛉࠿ࡽࡢ⏕యࢩࢫࢸ࣒Ꮫศ㔝࡜ࢩࢫࢸ࣒ᶵ⬟Ꮫศ㔝ࡢ㸰ศ㔝ࠊ་
Ꮫ㒊㝃ᒓ⑓㝔⸆๣㒊࠿ࡽࡢ་⒪⸆๣Ꮫࡢ኱Ꮫ㝔༠ຊㅮᗙࢆྵࡵࡓ඲ศ㔝࣭㒊㛛ࡀࡑࢀࡒࢀᐇ㉁ⓗ࡞୺
ദẕయ࡜࡞ࡾࠊྛศ㔝࣭㒊㛛ࡢ◊✲࠾ࡼࡧ㛵㐃ࡍࡿᑓ㛛ศ㔝ࡢ◊✲࡟㛵ࡍࡿ୍⯡බ㛤ࢩ࣏ࣥࢪ࣒࢘ࢆ
㛤ദࡍࡿࡇ࡜ࡀ௻⏬ࡉࢀࡓࡶࡢ࡛࠶ࡿࠋ
ᖹᡂ㸯㸶ᖺ㹼㸰㸰ᖺࡢࢩ࣏ࣥࢪ࣒࢘ࡢ㛤ദෆᐜࡣ㈨ᩱϱ㸫㸰࡟♧ࡍࠋẖᖺࠊྛᑓ㛛ศ㔝ࡢ୰࠿ࡽ㑅
ࡤࢀࡓ◊✲㡿ᇦࡢ᭱ඛ➃ࡢ◊✲ෆᐜࢆࢩ࣏ࣥࢪ࣒࢘ࡢ࣓࢖࣭ࣥࢸ࣮࣐࡜ࡋ࡚ྲྀࡾୖࡆࠊࡑࢀࡒࢀࡢศ
㔝࡛ᅜ㝿ⓗ࡟ά㌍ࡋ࡚࠸ࡿ◊✲⪅ࢆࢩ࣏ࣥࢪࢫࢺ࡜ࡋ࡚ᣍ⮴ࡋ࡚ࡁࡓࠋᮏᏛᅾᰯ⏕ࠊ༞ᴗ⏕࠾ࡼࡧ㛵
㐃㡿ᇦࡢ◊✲⪅ࡀከᩘཧຍࡋ࡚࠾ࡾࠊ⸆Ꮫㅖ㡿ᇦࡢⓎᒎ࡟㈉⊩ࡍࡿ࡜࡜ࡶ࡟ࠊ኱Ꮫࠊ◊✲ᶵ㛵ࠊẸ㛫
௻ᴗࡢ◊✲⪅ࡢ஺ὶࢆಁ㐍ࡍࡿሙࢆᥦ౪ࡋ࡚࠸ࡿࠋ
㸦㸱㸧⏕ᾭᩍ⫱ㅮ₇఍
ඛ࡟㏙࡭ࡓࡼ࠺࡟་⸆ရࡢ኱ࡁ࡞㉁ⓗኚ໬࡟క࠸ࠊ་⸆ရࡢ♫఍ᛶࢆ࣮࣮࢟࣡ࢻ࡜ࡍࡿ♫఍࡜ࡢ㐃
ᦠࡀᏛ㒊࡟኱ࡁࡃၥࢃࢀࡿ࡜ࡇࢁ࡜࡞ࡗࡓࡀࠊ⌧≧࡟࠾࠸࡚ࡣࡇࡢㄢ㢟ࡣ⸆Ꮫ඲య࡜ࡋ࡚඲ᅜⓗど㔝
࠿ࡽࡢάືࢆᚲせ࡜ࡍࡿ㠃ࢆᙉࡃࡶࡗ࡚࠸ࡿࠋ஦ᐇࠊ⸆Ꮫ఍ࠊ⸆๣ᖌ఍➼ࡢ㛵ಀᏛ఍࡛ࡇࢀ࡟㛵ࡍࡿ
✚ᴟⓗ࡞ྲྀࡾ⤌ࡳࡀ⾜ࢃࢀ࡚࠾ࡾࠊࡇࢀࡽࡢᏛ఍άື࡟ᮏᏛ㒊ࡢᩍဨࡢ኱ከᩘࡀ୰ᚰⓗ࡞ᙺ๭ࢆᢸࡗ
࡚ά㌍ࡋ࡚࠸ࡿ࡜ࡇࢁ࡛࠶ࡿࠋ୍᪉ࠊࡇࢀࡽࡢ඲ᅜⓗ࡞άື࡜㐃ᦠࡋࡓᏛ㒊࡜ࡋ࡚ࡢάື࡜ࡋ࡚ྠ᫬
࡟ࠊ⏕ᾭᩍ⫱ㅮ₇఍ࢆ㛤ദࡍࡿ࡞࡝ࡢ♫఍άືࢆヨࡳ࡚࠸ࡿࠋࡇࡢ⏕ᾭᩍ⫱ㅮ₇఍ࡶࡲࡓࠊ๓㏙ࡢ㸳
㸮࿘ᖺ๰タグᛕ஦ᴗ఍ࡢ஦ᴗࡢ୍⎔࡜ࡋ࡚⾜ࢃࢀࡿᙧᘧࢆ࡜ࡾࠊ୍⯡බ㛤ࡀཎ๎࡜ࡉࢀ࡚࠸ࡿࠋࡇࢀ
ࡲ࡛࡟Ꮫእ࡛ά㌍ࡋ࡚࠸ࡿ༞ᴗ⏕ࢆㅮᖌ࡜ࡋࠊ་⸆ရࠊ་⒪࡜♫఍࡜ࡢ㛵ಀࢆᖜᗈࡃ⪃࠼ࡿ㸯㸱ᅇࡢ
ㅮ₇఍ࡀ㛤ദࡉࢀࡓࠋᖹᡂ㸯㸶ᖺ㹼㸰㸰ᖺ࡟ࡣ㈨ᩱϱ㸫㸰࡟♧ࡍෆᐜ࡛ㅮ₇఍ࡀᐇ᪋ࡉࢀࠊ㧗࠸ᐇ⦼
ࡀಟࡵࡽࢀ࡚࠸ࡿࠋᮏㅮ₇఍ࡣࠊ⏕ᾭᩍ⫱ㅮ₇఍ࢆ㏻ࡌ࡚ࡼࡾຠᯝⓗ࡟♫఍࡜ࡢ㐃ᦠࢆ῝ࡵࡿࡓࡵ࡟ࠊ
ᩘᅇ࡟୍ᗘࡢ๭ྜ࡛ᮾி࡟࠾࠸࡚㛤ദࡉࢀ࡚࠾ࡾࠊᖹᡂ㸰㸮ᖺᗘࡣᮾி㛤ദ࡜ࡋࡓࠋ⏕ᾭᩍ⫱ㅮ₇఍
࡟ࡣࠊᮏᏛࡢ༞ᴗ⏕ࡢฟᖍࡀከ࠸ࡇ࡜ࡣゝ࠺ࡲ࡛ࡶ࡞࠸ࡀࠊ୍᪉࡛ࠊ୍⯡ཧຍ⪅ࡢฟᖍࡶ㠀ᖖ࡟┠❧
ࡕࠊᡤᮇࡢ┠ⓗࡀ㐩ᡂࡉࢀ࡚࠸ࡿ࡜ホ౯ࡋ࡚࠸ࡿࠋ
௒ᚋࠊࡇ࠺ࡋࡓ⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ࡢ♫఍࡜ࡢ㐃ᦠ࡟㛵ࡋ࡚ࠊࡉࡽ࡟✚ᴟⓗ࡞άືࢆᒎ㛤ࡍ࡭ࡃࠊ
᳨ウࡋ࡚࠸ࡿ࡜ࡇࢁ࡛࠶ࡿࠋ
− 142 −
㸦㸲㸧 ࿘ᖺグᛕ஦ᴗ
ᖹᡂ ᖺ ᭶ ᪥㸦㔠㸧ி㒔኱Ꮫⓒ࿘ᖺ᫬ィྎグᛕ㤋ⓒ࿘ᖺグᛕ࣮࣍ࣝ࡟࡚ࠕி㒔኱Ꮫ⸆Ꮫ㒊๰
タ ࿘ᖺグᛕㅮ₇఍࣭グᛕᘧ඾ࠖࡀ㛤ദࡉࢀࡓࠋ⸆Ꮫ㒊ࡣ᫛࿴ ᖺ㸦㸧࡟་Ꮫ㒊⸆Ꮫ⛉࡜ࡋ࡚
๰タࡉࢀࠊ᫛࿴ ᖺ㸦㸧⸆Ꮫ㒊࡬ࡢ⛣⾜ࢆ⤒࡚ࠊᮏᖺࢆࡶࡗ࡚ ࿘ᖺࢆ㏄࠼ࡓࠋᮏ⾜஦ࡣࡇࢀ
ࢆグᛕࡋ࡚㛤ദࡉࢀࡓࡶࡢ࡛࠶ࡿࠋ
グᛕㅮ₇఍࡛ࡣࠊ᭱ึ࡟ࠊṊ⏣⸆ရᕤᴗ㸦ᰴ㸧ྲྀ⥾ᙺ◊✲㛤Ⓨ⤫ᣓ
⫋኱ᕝ⁠⣖༤ኈ㸦➨ ᅇ༞㸧ࡀࠕ᪂⸆๰〇࡟ྥࡅࡓᣮᡓ̿ࢢ࣮ࣟ
ࣂࣝ໬࡜࢖ࣀ࣮࣋ࢩࣙࣥ̿ࠖ
㸦ྖ఍㸸⏕࿨⛉Ꮫ◊✲⛉ᑠሐಖ๎ᩍᤵ㸧
࡜㢟ࡍࡿㅮ₇ࡀ⾜ࢃࢀࡓࠋࡲࡎࠊࡇࡢ ᖺ㛫ࡢ๰⸆◊✲ࡢṔྐࡢ⤂
௓ࡀࡉࢀࡓᚋࠊ๰⸆◊✲ࡢࣃࣛࢲ࢖࣒ࢩࣇࢺࡸཝࡋࡉࢆቑࡍ〇⸆⏘ᴗ
ࢆྲྀࡾᕳࡃ⎔ቃࡢ⌧≧ࡀ㏙࡭ࡽࢀࡓࠋ⥆࠸࡚ࠊṊ⏣⸆ရࡀࢢ࣮ࣟࣂࣝ
໬࡜࢖ࣀ࣮࣋ࢩࣙࣥࢆ࣮࣮࢟࣡ࢻ࡟㐍ࡵ࡚ࡁࡓ๰⸆⏕⏘ᛶྥୖ࡬ࡢྲྀࡾ⤌ࡳࡀලయⓗ࡞౛ࢆᣲࡆ࡚⤂
௓ࡉࢀࡓࠋ᭱ᚋ࡟⏬ᮇⓗ᪂⸆ࡢ㛤Ⓨ࡟⧅ࡀࡿ⸆Ꮫᩍ⫱࡬ࡢᙉ࠸ᮇᚅࡀ㏙࡭ࡽࢀࡓࠋ
ᘬࡁ⥆ࡁࠊ
㸦㈈㸧ඛ➃་⒪᣺⯆㈈ᅋ⌮஦㛗㸦ඖி㒔኱Ꮫ⥲㛗㸧஭ᮧ⿱ኵ༤ኈ࡟ࡼࡾࠕ ୡ⣖ࡢ་⒪̿
་Ꮫ࠿ࡽ⸆Ꮫ࡬ࡢ࣓ࢵࢭ࣮ࢪ̿ࠖ
㸦ྖ఍㸸⸆Ꮫ◊✲⛉ᶫ⏣඘ᩍᤵ㸧࡜㢟ࡍࡿㅮ₇ࡀ⾜ࢃࢀࡓࠋ࢔ࣝ
ࢶࣁ࢖࣐࣮⑓ࡸ⢾ᒀ⑓࡞࡝ຍ㱋࡟క࠺⑌ᝈࢆ౛࡟ࠊⓎ⑕ࡸ⑓ែ㐍⾜ࡢ
ᶵᵓࢆᢕᥱࡋࡓୖ࡛ண㜵ࡸ἞⒪ࢆ⪃࠼ࡿ 3UHHPSWLYH0HGLFLQH㸦ᮍ⑓ࡢ
་⒪㸧ࡢ㔜せᛶࠊL36 ⣽⬊ࢆ฼⏝ࡋࡓ෌⏕་⒪࡬ࡢᮇᚅࡸㄢ㢟࡞࡝ࡀ㏙
࡭ࡽࢀࡓࠋࡲࡓࠊ࣐࢖ࢡࣟࢻ࣮ࢪࣥࢢἲࡸ 3(7 ࡢ་⸆ရ㛤Ⓨ࡬ࡢᛂ⏝
ࡢ⌧≧ࡸ⚄ᡞ⮫ᗋ◊✲᝟ሗࢭࣥࢱ࣮࡛ࡢྲྀࡾ⤌ࡳ࡞࡝ࡶ⤂௓ࡉࢀࡓࠋ
᭱ᚋ࡟ࠊ⸆Ꮫ࡬ࡢᮇᚅࢆ⇕ࡃㄒࡽࢀࡓࠋㅮ₇఍࡟ࡣ ྡ௨ୖࡢཧຍ⪅ࡀ࠶ࡾ఍ሙࡣ❧ࡕぢࡀฟࡿ࡯
࡝┒ἣ࡛࠶ࡗࡓࠋ
ᘬࡁ⥆ࡁࠊྠ࣮࣍ࣝ࡟࡚グᛕᘧ඾ࡀ⾜ࢃࢀࡓࠋఀ⸨ಙ⾜⸆Ꮫ◊✲⛉㛗ࡢ㛤఍ࡢᣵᣜ࡟⥆ࡁࠊி㒔኱
Ꮫᯇᮏ⣫⥲㛗࠿ࡽ᭱ึ࡟⚃㎡ࡀ㏙࡭ࡽࢀࡓࠋᘬࡁ⥆ࡁࠊᩥ㒊⛉Ꮫ┬㧗➼ᩍ⫱ᒁᚨỌಖᒁ㛗ࡢ⚃㎡௦
ㄞࡀ་Ꮫᩍ⫱ㄢྜྷ⏣༤அ⸆Ꮫᩍ⫱ᑓ㛛ᐁ࡟ࡼࡾ⾜ࢃࢀࠊࡉࡽ࡟ࠊ᪥ᮏ⸆Ꮫ఍ᯇᮌ๎ኵ఍㢌ࠊி㒔኱
Ꮫ་Ꮫ◊✲⛉ගᒣṇ㞝◊✲⛉㛗ࠊ⏣㎶୕⳻〇⸆ᰴᘧ఍♫௦⾲ྲྀ⥾ᙺ♫㛗ᅵᒇ⿱ᘯẶ㸦➨ ᅇ༞㸧ࡼ
ࡾ⚃㎡ࡀ࠶ࡾࠊᮏᏛ㒊࡬ࡢ኱ࡁ࡞ᮇᚅࡀ㏙࡭ࡽࢀࡓࠋ
ࡇࡢᚋࠊྠグᛕ㤋ᅜ㝿஺ὶ࣮࣍ࣝ࡟࡚グᛕ⚃㈡఍ࡀ㛤ദࡉࢀࡓࠋఀ⸨◊✲⛉㛗ࡢ㛤఍ࡢᣵᣜ࡟⥆ࡁࠊ
኱㜰኱Ꮫᑠᯘ㈨ṇ⸆Ꮫ◊✲⛉㛗ࠊி㒔኱Ꮫྡ㄃ᩍᤵ▮ᓥ἞᫂ඛ⏕ࠊࢩ࣑ࢵࢡᰴᘧ఍♫௦⾲ྲྀ⥾ᙺ఍
㛗ව♫㛗୰ᮧ࿴⏨Ặ
㸦➨ ᅇ༞㸧ࠊ
ᑠ㔝⸆ရᕤᴗᰴᘧ఍♫◊✲ᮏ㒊㛗ᕝ⁕࿴୍༑Ặࡼࡾ⚃㎡ࡀ࠶ࡾࠊ
ி㒔኱Ꮫ⌮஦࣭๪Ꮫ㛗⸨஭ಙᏕඛ⏕ࡢ஝ᮼࡢⓎኌ࡟ࡼࡾ⚃㈡఍ࡀጞࡲࡗࡓࠋி㒔኱Ꮫ㛵ಀ⪅ࠊ௻ᴗ㛵
ಀ⪅ࠊ௚኱Ꮫ㛵ಀ⪅ࠊ༞ᴗ⏕➼ࠊከᩘࡢཧຍࡀ࠶ࡾࠊబ἞ⱥ㑻⸆Ꮫ๪◊✲⛉㛗ࡢㅰ㎡ࡢᚋࠊ㛢఍ࡢ㎡
ࢆࡶࡗ࡚┒఍ࡢ࠺ࡕ࡟⚃㈡఍ࡣ⤊஢ࡋࡓࠋᮏ⾜஦ཧຍ⪅࡟ࡣࠊグᛕ஦ᴗ఍ࡀ⦅⧩ࡋࡓࠕி㒔኱Ꮫ⸆Ꮫ
㒊๰タ ࿘ᖺグᛕㄅࠖࡀ㓄ᕸࡉࢀࡓࠋ
− 143 −
‫ۑ‬ி㒔኱Ꮫ⸆Ꮫ㒊๰タ ࿘ᖺグᛕㅮ₇఍࣭ᘧ඾࣭⚃㈡఍ḟ➨
᪥ ᫬ ᖹᡂ ᖺ ᭶ ᪥㸦㔠㸧༗ᚋ㸯᫬㸱㸮ศ㛤ሙ
ሙ ᡤ ி㒔኱Ꮫⓒ࿘ᖺ᫬ィྎグᛕ㤋
グᛕㅮ₇఍ ༗ᚋ㸰᫬㸮㸮ศ㹼㸲᫬㸮㸮ศ㸦ⓒ࿘ᖺグᛕ࣮࣍ࣝ㸧
⥲ྜྖ఍ 㧗಴ ႐ಙ
࣭ㅮ ₇ࠕ᪂⸆๰〇࡟ྥࡅࡓᣮᡓ̿ࢢ࣮ࣟࣂࣝ໬࡜࢖ࣀ࣮࣋ࢩࣙࣥ̿ࠖ
Ṋ⏣⸆ရᕤᴗ㸦ᰴ㸧ྲྀ⥾ᙺ◊✲㛤Ⓨ⤫ᣓ⫋ ኱ᕝ⁠⣖
ྖ ఍ ி㒔኱Ꮫ⏕࿨⛉Ꮫ◊✲⛉ᩍᤵ ᑠሐಖ๎
࣭ㅮ ₇ࠕ㸰㸯ୡ⣖ࡢ་⒪̿་Ꮫ࠿ࡽ⸆Ꮫ࡬ࡢ࣓ࢵࢭ࣮ࢪ̿ࠖ
㸦㈈㸧ඛ➃་⒪᣺⯆㈈ᅋ⌮஦㛗㸦ඖி㒔኱Ꮫ⥲㛗㸧஭ᮧ⿱ኵ
ྖ ఍ ி㒔኱Ꮫ⸆Ꮫ◊✲⛉ᩍᤵ ᶫ⏣඘
グᛕᘧ඾ ༗ᚋ㸲᫬㸯㸳ศ㹼㸳᫬㸯㸳ศ㸦ⓒ࿘ᖺグᛕ࣮࣍ࣝ㸧
࣭㛤఍ࡢ㎡
࣭ᣵ ᣜ ி㒔኱Ꮫ⸆Ꮫ◊✲⛉㛗 ఀ⸨ಙ⾜
࣭⚃ ㎡ ி㒔኱Ꮫ⥲㛗 ᯇᮏ ⣫
ᩥ㒊⛉Ꮫ┬㧗➼ᩍ⫱ᒁ㛗 ᚨỌಖ
⚃㎡௦ㄞ㸸་Ꮫᩍ⫱ㄢ⸆Ꮫᩍ⫱ᑓ㛛ᐁ ྜྷ⏣༤அ
᪥ᮏ⸆Ꮫ఍఍㢌 ᯇᮌ๎ኵ
ி㒔኱Ꮫ་Ꮫ◊✲⛉㛗 ගᒣṇ㞝
⏣㎶୕⳻〇⸆ᰴᘧ఍♫௦⾲ྲྀ⥾ᙺ♫㛗 ᅵᒇ⿱ᘯ グᛕ⚃㈡఍ ༗ᚋ㸳᫬㸱㸮ศ㹼㸵᫬㸱㸮ศ㸦ᅜ㝿஺ὶ࣮࣍ࣝ㸧
࣭ᣵ ᣜ ி㒔኱Ꮫ⸆Ꮫ◊✲⛉㛗 ఀ⸨ಙ⾜
࣭⚃ ㎡ ኱㜰኱Ꮫ⸆Ꮫ◊✲⛉㛗 ᑠᯘ㈨ṇ
ி㒔኱Ꮫྡ㄃ᩍᤵ ▮ᓥ἞᫂
ࢩ࣑ࢵࢡᰴᘧ఍♫௦⾲ྲྀ⥾ᙺ఍㛗ව♫㛗 ୰ᮧ࿴⏨
ᑠ㔝⸆ရᕤᴗᰴᘧ఍♫◊✲ᮏ㒊㛗 ᕝ⁕࿴୍༑
࣭஝ ᮼ ி㒔኱Ꮫ⌮஦࣭๪Ꮫ㛗 ⸨஭ಙᏕ
࣭ᣵ ᣜ ி㒔኱Ꮫ⸆Ꮫ๪◊✲⛉㛗 బ἞ ⱥ㑻
− 144 −
㸦㸳㸧ඹྠ◊✲
ඹྠ◊✲ࡣࠊ◊✲ᐊ㸦ศ㔝㸧༢఩࡛ཷク◊✲ࠊẸ㛫➼࡜ࡢඹྠ◊✲࡜ࡋ࡚⾜ࢃࢀࡿ௚࡟ࠊእᅜࡢ◊
✲ᶵ㛵ࡸᅜෆࡢ௚኱Ꮫࠊ௚ᶵ㛵࡜ࡢ㛫࡛ከࡃࡢඹྠ◊✲ࡀ㐍ࡵࡽࢀ࡚࠸ࡿࠋ㈨ᩱϱ㸱࡟ᖹᡂ㸯㸵ᖺᗘ
㹼㸰㸯ᖺᗘࡢඹྠ◊✲ࡢ≧ἣࢆཷク◊✲࡜ඹྠ◊✲ࡢู࡟ࡲ࡜ࡵࡓࠋ
ཷク◊✲࡟ࡘ࠸࡚ࡣࠊᖹᡂ㸯㸵ᖺᗘࡀ㸯㸵௳ࠊᖹᡂ㸯㸶ᖺᗘࡀ㸰㸶௳ࠊᖹᡂ㸯㸷ᖺᗘࡀ㸰㸵௳ࠊᖹ
ᡂ㸰㸮ᖺᗘࡀ㸰㸲௳ࠊᖹᡂ㸰㸯ᖺᗘࡀ㸰㸳௳࡜࡞ࡗ࡚࠾ࡾࠊࡇࢀࡽࡢཷク◊✲ࡢᐇ᪋࡟ࡼࡗ࡚ከࡃࡢ
ᴗ⦼ࡀ࠶ࡆࡽࢀࡿࠋ≉࡟᭱㏆ࡢ㸲ᖺ㛫ࡣྛᖺ࡜ࡶ㸰㸲௳௨ୖࡢཷク◊✲ࡀᐇ᪋ࡉࢀ࡚࠸ࡿࡀࠊ⸆Ꮫ◊
✲⛉࡟ᡤᒓࡍࡿᐇാ◊✲ᐊᩘ➼ࢆ຺᱌ࡍࡿ࡜ࠊ㠀ᖖ࡟㧗࠸๭ྜ࡛ཷク◊✲ࡀᐇ᪋ࡉࢀࠊ◊✲ᡂᯝࡢ♫
఍࡬ࡢ㑏ඖࡀ✚ᴟⓗ࠿ࡘ᭷ຠ࡟⾜ࢃࢀ࡚࠸ࡿ࡜ホ౯࡛ࡁࡿࠋཷク◊✲ࡢ◊✲౫㢗⪅ࡣ〇⸆௻ᴗࠊ௚┬
ᗇࠊᅜබ❧◊✲ᶵ㛵ࠊ⛉Ꮫᢏ⾡᣺⯆㈈ᅋ࡞࡝ከᒱ࡟ࢃࡓࡗ࡚࠸ࡿࠋࡲࡓࠊཷク◊✲஦㡯࡟ࡘ࠸࡚ࡣྛ
◊✲ᐊࡢ◊✲ෆᐜ࡜ᐦ᥋࡜ᐦ᥋࡟㛵㐃ࡋࡓࡶࡢࡀከࡃࠊ〇⸆௻ᴗ࡟࠾ࡅࡿ་⸆ရ㛤Ⓨ◊✲ࡸᐁබᗇ࡛
ࡢ་⒪㛵㐃◊✲ࡢ᥎㐍࡟㈉⊩ࡍࡿࡓࡵ࡟㔜せ࡞ᙺ๭ࢆᯝࡓࡋ࡚ࡁ࡚࠾ࡾࠊࡲࡓࠊ኱ࡁ࡞ᡂᯝࡀᣲࡆࡽ
ࢀ࡚࠸ࡿࠋ
Ẹ㛫࡜ࡢඹྠ◊✲࡟ࡘ࠸࡚ࡶࠊཷク◊✲࡯࡝௳ᩘࡣከࡃࡣ࡞࠸ࡶࡢࡢࠊ⸆Ꮫ◊✲⛉ࡢ◊✲ᐊ⥲ᩘ࡜
ẚ㍑ࡍࡿ࡜ከࡃࡢ◊✲ࡀ⾜ࢃࢀ࡚࠸ࡿࠋࡑࡢෆヂࡣࠊᖹᡂ㸯㸵ᖺᗘࡀ㸯㸴௳ࠊᖹᡂ㸯㸶ᖺᗘࡀ㸰㸮௳ࠊ
ᖹᡂ㸯㸷ᖺᗘࡀ㸰㸳௳ࠊᖹᡂ㸰㸮ᖺᗘࡀ㸱㸮௳ࠊᖹᡂ㸰㸯ᖺᗘࡀ㸰㸲௳࡜࡞ࡗ࡚࠸ࡿࠋඹྠ◊✲ඛࡢ
Ẹ㛫ࡢᶵ㛵࡜ࡋ࡚ࡣ〇⸆௻ᴗࡀከࡃࠊ◊✲㢟┠࡟ࡶศᏊ⸆⌮ⓗ࡞◊✲ࡸデ᩿἞⒪⸆ࡢ㛤Ⓨ◊✲࡞࡝๰
⸆࡟㛵㐃ࡋࡓᇶ♏◊✲࠶ࡿ࠸ࡣᛂ⏝◊✲ࡀ኱༙ࢆ༨ࡵ࡚࠾ࡾࠊ⸆Ꮫ◊✲⛉ࡢ◊✲ᡂᯝࢆ㏻ࡌࡓ♫఍࡬
ࡢ㈉⊩ࡢࡓࡵ࡟㔜せ࡞ᙺ๭ࢆᯝࡓࡋ࡚࠸ࡿࠋ
ࡉࡽ࡟ࠊୖグࡢ㸰✀㢮ࡢඹྠ◊✲௨እ࡟ࡶከࡃࡢඹྠ◊✲ࡀ㐍ࡵࡽࢀ࡚ࡁ࡚࠾ࡾࠊᖹᡂ㸯㸵ᖺᗘ㹼
㸰㸰ᖺᗘࡢᐇ⦼ࢆ㈨ᩱϱ㸲࡟ࡲ࡜ࡵࡓࠋእᅜࡢ኱Ꮫࠊㅖ✀◊✲ᶵ㛵࡜⸆Ꮫ◊✲⛉ࡢ㸯㸲ࡢศ㔝࡜ࡢ㛫
࡛ඹྠ◊✲ࡀ⾜ࢃࢀ࡚ࡁ࡚࠾ࡾࠊඹྠ◊✲ᶵ㛵ࡢᡤᅾᆅࡶḢ⡿࣭࢔ࢪ࢔࣭ኴᖹὒࠊᆅᇦࢆྵࡴከࡃࡢ
ᅜ࡟ࡲࡓࡀࡗ࡚࠸ࡿࠋ୍᪉ࠊᅜෆ࡛ࡢඹྠ◊✲࡜ࡋ࡚ࡣࠊி㒔኱Ꮫࡢ௚◊✲⛉㸦་Ꮫ◊✲⛉ࠊᕤᏛ◊
✲⛉ࠊ㎰Ꮫ◊✲⛉௚㸧ࠊ◊✲㒊㛛㸦໬Ꮫ◊✲ᡤࠊ࢘࢖ࣝࢫ◊✲ᡤ௚㸧ࢆ┦ᡭ࡜ࡍࡿ◊✲ࢆࡣࡌࡵ࡜ࡋ࡚ࠊ
௚኱Ꮫࠊ௚◊✲ᶵ㛵ࢆ┦ᡭ࡜ࡍࡿ◊✲ࡀᐇ᪋ࡉࢀ࡚ࡁࡓࠋࡇࡢࡼ࠺࡞⤖ᯝࡣࠊᗈ࠸Ꮫၥ㡿ᇦ࡟࠾࠸࡚
✚ᴟⓗ࡞஺ὶࡀ㐍ࡵࡽࢀ࡚࠸ࡿࡇ࡜ࢆ཯ᫎࡋࡓࡶࡢ࡛࠶ࡾࠊࢢ࣮ࣟࣂࣝ࡞ど㔝࡟❧ࡗࡓ◊✲ࡢ᥎㐍࡜
Ꮫၥࡢ஺ὶ࡟ࡼࡾ኱ࡁ࡞ᡂᯝࡀ࠶ࡆࡽࢀ࡚࠸ࡿ࡜ホ౯ࡉࢀࡿࠋ
− 145 −
㨄㧙㧝 ⎇ⓥ↢╬ߩฃߌ౉ࠇ⁁ᴫ
඙ಽ
ᐕᐲ
⎇ⓥ↢
⎇ୃຬ
ฃ⸤
ᄖ࿖ੱฃ
⎇ⓥຬ
⸤⎇ୃຬ
ੱ
ੱ
ੱ
ੱ
ᐔᚑ㧝㧤ᐕᐲ
ᐔᚑ㧝㧥ᐕᐲ
ᐔᚑ㧞㧜ᐕᐲ
ᐔᚑ㧞㧝ᐕᐲ
− 146 −
㨄㧟 ฃ⸤⎇ⓥ࡮᳃㑆╬ߣߩ౒ห⎇ⓥߩ⁁ᴫ
㧔㧝㧕 ฃ⸤⎇ⓥ − 147 −
− 148 −
− 149 −
− 150 −
− 151 −
㧔㧞㧕᳃㑆╬ߣߩ౒ห⎇ⓥ 㧔න૏ ౞㧕
− 152 −
− 153 −
− 154 −
− 155 −
− 156 −
− 157 −
㹖Ѹ㸲 ࡑࡢ௚ࡢඹྠ◊✲
㸦㸯㸧እᅜࡢ◊✲ᶵ㛵࡜ࡢඹྠ◊✲㸦◊✲ࢸ࣮࣐㸸ᢸᙜศ㔝࣭ඹྠ◊✲ࡢ┦ᡭ᪉㸧
࣭&;&5 ࢔ࣥࢱࢦࢽࢫࢺ࡟㛵ࡍࡿඹྠ◊✲㸸⸆ရ᭷ᶵ〇㐀Ꮫ
࢖ࢫ࢚ࣛࣝ
*HQH7KHUDS\,QVWLWXWH
$PQRQ3HOHG ༤ኈ
࢖ࢫ࢚ࣛࣝ
:HL]PDQQ,QVWRI6FLHQFH 2ULW.ROOHW ༤ኈ
࢖ࢱࣜ࢔ ,QVW'HUPRSDWLFRGHOO
,PPDFRODWD
0RQLFD1DSROLWDQR ༤ኈ
࢖ࢱࣜ࢔ 8QLYHUVLW¢GL3DYLD
6HUJLR6FKLQHOOL ᩍᤵ
࢖ࣥࢻ
,QGLDQ,QVWLWXWHRI&KHPLFDO7HFKQRORJ\5DMNXPDU%DQHUMHH ༤ኈ
࢖ࣥࢻ
7DWD0HPRULDO&HQWUH
-\RWL$.RGH ༤ኈ
࢜ࣛࣥࢲ 7KH1HWKHUODQGV&DQFHU,QVWLWXWH
)LMV:%YDQ/HHXZHQ ༤ኈ
࣮࢜ࢫࢺࣛࣜ࢔ 8QLY$GHODLGH
$QGUHZ&:=DQQHWWLQR ༤ኈ
࢝ࢼࢲ
8QLY0RQWUHDO
1LNRODXV+HYHNHU ༤ኈ
࢝ࢼࢲ
)LUHVWRQH,QVWLWXWHIRU5HVSLUDWRU\+HDOWK5RPD6HKPL ༤ኈ
ࢻ࢖ࢶ
8QLYHUVLW\&OLQLFRI)UHLEXUJ
ࢻ࢖ࢶ
&KDULW«&DPSXV%HQMDPLQ)UDQNOLQ
2ODI3HQDFN ༤ኈ
ࢻ࢖ࢶ
'LUHFWHXUGHUHFKHUFKHV,QVHUP
)DZ]LD/RXDFKH ༤ኈ
ࢻ࢖ࢶ
8QLYHUVLW\2I)UHLEXUJ
)DLVDO<XVXI ༤ኈ
ࣇࣛࣥࢫ 8QLYHUVLW«3DXO6DEDWLHU
2OID0]RXJKL Ặ
ⱥᅜ
8QLYHUVLW\RI([HWHU
5RQQ\YDQ$HUOH ༤ኈ
⡿ᅜ 0HGLFDO&ROOHJHRI*HRUJLD 9DGLYHO*DQDSDWK\ ༤ኈ
⡿ᅜ 7KRPDV-HIIHUVRQ8QLY
6WHSKHQ&3HLSHU ᩍᤵ
⡿ᅜ 0'$QGHUVRQ&DQFHU&HQWHU
-DQ$%XUJHU ༤ኈ
⡿ᅜ 8&6)
-DVRQ&\VWHU ༤ኈ
⡿ᅜ
8QLYHUVLW\RI&DOLIRUQLD%HUNHOH\
5RQDOG0HLHU ༤ኈ
⡿ᅜ
8QLY1HEUDVND
+XDQJXL;LRQJ ༤ኈ
⡿ᅜ
&HQWHUIRU1HXURYLURORJ\DQG1HXURGHJHQHUDWLYH'LVRUGHUV -LDOLQ=KHQJ ༤ኈ
⡿ᅜ
8&/$
⡿ᅜ
7KH8QLYHUVLW\RI7HQQHVVHH
⡿ᅜ
8QLYHUVLW\RI$UNDQVDVIRU0HGLFDO6FLHQFHV5DQG\6+DXQ ༤ኈ
⡿ᅜ
(PRU\8QLYHUVLW\
⡿ᅜ
3XUGXH8QLYHUVLW\ 0HLNH%XUJHU ༤ኈ
0DULD*&DVWUR ᩍᤵ
%ULDQ.:KLWORFN ༤ኈ
+\XQVXN6KLP ༤ኈ
&KDQJ+.LP ༤ኈ ࣭1056WXGLHVRID7HUQDU\&RPSOH[5HDJHQWRI/LWKLXP(VWHU(QRODWH&KLUDO'LHWKHUDQG/LWKLXP
'LLVRSURS\ODPLGHLQDQ$V\PPHWULF0LFKDHO5HDFWLRQ㸸⸆ရྜᡂ໬Ꮫ
ࣇࣛࣥࢫᅜ ࣮ࣝ࢔ࣥ኱Ꮫ 3URI-0DGGDOXQR㸸
࣭ᢠ⳦ᛶ࣌ࣉࢳࢻ┦஌ຠᯝࡢᶵᵓ㸸⸆ရᶵ⬟ゎᯒᏛศ㔝
− 158 −
࢝ࢼࢲ &DOJDU\ ኱Ꮫ +DQV-9RJHO ᩍᤵ
࣭㞴⁐ᛶ⸆≀ࡢ⁐ゎᗘᨵၿᶵᵓ㸸⸆ရᶵ⬟ゎᯒᏛศ㔝
࢔࣓ࣜ࢝ 3XUGXH ኱Ꮫ 5RGROIR3LQDO ᩍᤵ
࣭ࣜࣥ㓟໬ࣉࣟࢸ࣑࢜ࢡࢫ࡜ PL51$ ࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
࣐ࢵࢡࢫࣉࣛࣥࢡ◊✲ᡤ㸦ࢻ࢖ࢶ㸧 ῝ᑿኴ㑻 ༤ኈ
࣭ࣂࢡࢸࣜ࢔ࡢࣜࣥ㓟໬ࣉࣟࢸ࣑࢜ࢡࢫ࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ᅜ❧ࢩ࣏࣮ࣥ࢞ࣝ኱Ꮫ㸦ࢩ࣏࣮ࣥ࢞ࣝ㸧 6DQMD\6ZDUXS෸ᩍᤵ
࣭࣓࢝ࣀࣂ࢖࢜ࣟࢪ࣮࡜ࣜࣥ㓟໬ࣉࣟࢸ࣑࢜ࢡࢫ࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ᅜ❧ࢩ࣏࣮ࣥ࢞ࣝ኱Ꮫ㸦ࢩ࣏࣮ࣥ࢞ࣝ㸧 ⃝⏣Ὀᏹ෸ᩍᤵ
࣭ࣆࣟࣜ⳦࡜ࣜࣥ㓟໬ࣉࣟࢸ࣑࢜ࢡࢫ࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
୰ኸ◊✲㝔㸦ྎ‴㸧 6KLK+VLXQJ:Xᩍᤵ
࣭⬻⭘⒆࡟࠾ࡅࡿࣜࣥ㓟໬ࣉࣟࢸ࣑࢜ࢡࢫ࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
࢜ࣁ࢖࢜ᕞ❧኱Ꮫ㸦⡿ᅜ㸧 ୰㔝ఀ▱㑻෸ᩍᤵ
࣭࢔࣏࣏ࣜࢱࣥࣃࢡ࡜⬡㉁ࡢ┦஫స⏝࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
࣌ࣥࢩࣝࣂࢽ࢔኱Ꮫ࣭་Ꮫ㒊㸦⡿ᅜ㸧 ࣐࢖ࢡ ࣇ࢕ࣜࢵࣉࢫ ᩍᤵ
࣭⬡㉁Ѹ࣌ࣉࢳࢻ┦஫స⏝࡟࠾ࡅࡿ⺯ග࢚ࢿࣝࢠ࣮⛣ື࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ࣁࣜࢥࣇ኱Ꮫ㸦࢘ࢡࣛ࢖ࢼ㸧 *DO\QD*RUEHQNR ༤ኈ
࣭࢝࢖࣑ࣟࢡࣟࣥࣔࢹࣝ⢏Ꮚ࡜ᇵ㣴⣽⬊ࡢ┦஫స⏝࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
&156㸦ࣇࣛࣥࢫ㸧 $OLQH9HUWXW'RL ༤ኈ
࣭⬡㉁㍺㏦ࢱࣥࣃࢡ㉁ࡢ⭷࡜ࡢ┦஫స⏝࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ࣀ࣮ࢫ࢝ࣟࣛ࢖ࢼ኱Ꮫ࣭་Ꮫ㒊㸦⡿ᅜ㸧 9\WDV%DQNDLWLV ᩍᤵ
࣭࢔࣏࣏ࣜࢱࣥࣃࢡ࡜⬡㉁ࡢ┦஫స⏝㸸〇๣ᶵ⬟ゎᯒᏛ
⡿ᅜ ࣌ࣥࢩࣝࣂࢽ࢔኱Ꮫ་Ꮫ㒊 ࣐࢖ࢡ࣭ࣇ࢕ࣜࢵࣉࢫᩍᤵ
࣭⬡㉁DSR$ ࣔࢹࣝ࣌ࣉࢳࢻ┦஫స⏝࡟࠾ࡅࡿ⺯ග࢚ࢿࣝࢠ࣮⛣ື㸸〇๣ᶵ⬟ゎᏛ
࢘ࢡࣛ࢖ࢼ ࣁࣜࢥࣇ኱Ꮫ ࣮࢞ࣜࢼ࣭ࢦࣝ࣋ࣥࢥ༤ኈ
࣭࢝࢖࣑ࣟࢡࣟࣥࣔࢹࣝ⢏Ꮚ࡜ᇵ㣴⣽⬊ࡢ┦஫స⏝㸸〇๣ᶵ⬟ゎᯒᏛ
ࣇࣛࣥࢫ &156 ࢔࣭ࣜࣥ࣋ࣝࢳ࣮ࣗࢺ࣭ࢻ࢖༤ኈ
࣭࢚࢟ࣛࣝࣀ࣮ࣛࢺࡢ ;⥺ᵓ㐀ゎᯒ㸸⢭ᐦ᭷ᶵྜᡂ
⡿ᅜࣈࣛ࢘ࣥ኱Ꮫ࣭࣏࣮ࣝ ࢘࢕࣮ࣛࢻᩍᤵ
࣭75,& ࢳࣕࢿࣝ࡟㛵ࡍࡿඹྠ◊✲㸸⏕యศᏊㄆ㆑Ꮫ
⡿ᅜ 5REHUW:RRG-RKQVRQ0HGLFDO6FKRRO1HZ-HUVH\3URI0D
ⱥᅜ 8QLYHUVLW\RI%ULVWRO6FKRRORI0HGLFDO6FLHQFHV%ULVWRO3URI6LWVDSHVDQ
࣭0* ࡟㛵ࡍࡿඹྠ◊✲㸸⏕యศᏊㄆ㆑Ꮫ
⡿ᅜ 5REHUW:RRG-RKQVRQ0HGLFDO6FKRRO1HZ-HUVH\3URI0D
ⱥᅜ 8QLYHUVLW\RI%ULVWRO6FKRRORI0HGLFDO6FLHQFHV%ULVWRO3URI6LWVDSHVDQ
࣭0* ࡟㛵ࡍࡿඹྠ◊✲㸸⏕యศᏊㄆ㆑Ꮫ
− 159 −
⡿ᅜ 5REHUW:RRG-RKQVRQ0HGLFDO6FKRRO1HZ-HUVH\3URI0D
୰ᅜ 3HNLQJ8QLYHUVLW\3URI;LDR3URI&KHQJ
࣭753 ࢳࣕࢿࣝࡢ⚄⤒ᶵ⬟࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎᯒᏛ
࢔࣓ࣜ࢝ྜ⾗ᅜ2KLR6WDWH ኱Ꮫ 'U0LNH;=KX
࣭ࣄࢺ㹌ᆺ㟁఩౫Ꮡᛶ &Dࢳࣕࢿࣝࣂࣜ࢔ࣥࢺ࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎᯒᏛ
࢝ࢼࢲ &DOJDU\ ኱Ꮫ 3URI*HUDOG:=DPSRQL
࣭࢘࢖ࣝࢫ࣋ࢡࢱ࣮ࢆ⏝࠸ࡓࢭࣟࢺࢽࣥ⚄⤒≉␗ⓗ㑇ఏᏊᑟධἲࡢ㛤Ⓨ࡜ᛂ⏝㸸⏕యᶵ⬟ゎᯒᏛ
ⱥᅜ %ULVWRO ኱Ꮫ 3URI6HUJH\.DVSDURY
࣭࢜ࣜࢦࢹࣥࢻࣟࢧ࢖ࢺࡢᶵ⬟␗ᖖ࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎᯒᏛ
⡿ᅜ ࣁ࣮ࣂ࣮ࢻ኱Ꮫ་Ꮫ㒊࣐ࢧࢳ࣮ࣗࢭࢵࢶ⥲ྜ⑓㝔 3URI(QJ+/R$VVLVWDQW3URI.HQ$UDL
࣭753 ࢳࣕࢿࣝࡢ㟁Ẽ⏕⌮Ꮫⓗゎᯒ࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎᯒᏛ
⡿ᅜ ࣁ࣮ࣂ࣮ࢻ኱Ꮫ་Ꮫ㒊ࢳࣝࢻࣞࣥࢬ⑓㝔 3URI'DYLG(&ODSKDP
࣭ࢩࢼࣉࢫᑠ⬊ࢺࣛࣥࢫ࣏࣮ࢱ࣮ࡢᶵ⬟ゎᯒ࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎᯒᏛ
⡿ᅜ ࣑ࢩ࢞ࣥ኱Ꮫ0ROHFXODU%HKDYLRUDO1HXURVFLHQFH,QVWLWXWH3URI7HWVXIXPL8HGD
࣭⬨㧊ࢫࣛ࢖ࢫࢆ⏝࠸ࡓ ZKROHFHOOSDWFKFODPS ἲ㸸⏕యᶵ⬟ゎᯒᏛ
࢝ࢼࢲ ࢙࢘ࢫࢱࣥ࢜ࣥࢱࣜ࢜኱Ꮫ5REDUWV5HVHDUFK,QVWLWXWH3URI-RKQ)0DF'RQDOG
࣭6ROLGVXSSRUWHGPHPEUDQH ࢆ⏝࠸ࡿࢺࣛࣥࢫ࣏࣮ࢱάᛶ ᐃἲ㸸⏕యᶵ⬟ゎᯒᏛ
ࢻ࢖ࢶ ࣐ࢵࢡࢫࣉࣛࣥࢡ◊✲ᡤ0D[3ODQN,QVWLWXWH 3URI.ODXV)HQGOHU
࣭)*) ࢩࢢࢼࣝ࡜ᚰ⮚ᙧᡂ㸸㑇ఏᏊ⸆Ꮫ
⡿ᅜ ࣡ࢩࣥࢺࣥ኱Ꮫ 'DYLG2UQLW]
࣭)*) ཷᐜయ࡜࢚ࢿࣝࢠ࣮௦ㅰ㸸㑇ఏᏊ⸆Ꮫ ⡿ᅜ /LOOL\5HVHDUFK/DERUDWRULHV$OH[HL.KDULWRQHQNRY
࣭)*) ࡜௦ㅰㄪ⠇㸸㑇ఏᏊ⸆Ꮫ
ࢩ࣏࣮ࣥ࢞ࣝ ,0&%'PLWU\%XODYLQ
࣭)*) ࡜௦ㅰㄪ⠇㸸㑇ఏᏊ⸆Ꮫ
࣍ࣥࢥࣥ ࣍ࣥࢥࣥ኱Ꮫ $LPLQ;X
࣭)*) ࡜௦ㅰㄪ⠇㸸㑇ఏᏊ⸆Ꮫ
⡿ᅜ ࢩࣥࢩ࢔ࢸ࢕኱Ꮫ 0DWWKLDV7VFKRS
࣭)*) ࡜௦ㅰㄪ⠇㸸㑇ఏᏊ⸆Ꮫ
࣍ࣥࢥࣥ ࣍ࣥࢥࣥ኱Ꮫ .DWK\&KHDWK
࣭)*) ࡜௦ㅰㄪ⠇㸸㑇ఏᏊ⸆Ꮫ
㡑ᅜ 6KXQJN\XQNZDQ ኱Ꮫ .RRN+ZDQ.LP
࣭)*) ࡜௦ㅰㄪ⠇㸸㑇ఏᏊ⸆Ꮫ
ⱥᅜ ,QVWLWXWHRI&DQFHU&HQWHU 5LFKDUG*URVH
࣭)*) ࡢᵓ㐀࡜ᶵ⬟㸸㑇ఏᏊ⸆Ꮫ
⡿ᅜ ࢽ࣮࣮ࣗࣚࢡ኱Ꮫ 0RRVD0RKDPPDGL
− 160 −
࣭ࢩ࢔ࣝ㓟ಟ㣭୙඲࣐࢘ࢫࡢゎᯒ㸸⏕⌮άᛶไᚚᏛ
࢔࣓ࣜ࢝ ࢝ࣜࣇ࢛ࣝࢽ࢔኱ࢧࣥࢹ࢕࢚ࢦᰯ ᩍᤵ $MLW9DUNL
࣭⬻ࡢᛶศ໬࡟㛵୚ࡍࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయ࡟㛵ࡍࡿ◊✲㸸⏕య᝟ሗไᚚᏛ
⡿ᅜ ࣓࣮ࣜࣛࣥࢻ኱Ꮫ 3URIHVVRU0DUJDUHW00F&DUWK\
࣭ື⬦⟶཰⦰࡟㛵୚ࡍࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయ࡟㛵ࡍࡿ◊✲㸸⏕య᝟ሗไᚚᏛ
⡿ᅜ ࢣࣥࢱࢵ࣮࢟኱Ꮫ 3URIHVVRU&KDUOHV/RIWLQ
࣭ࣉࣟࢫࢱࢢࣛࣥࢪࣥ ) ཷᐜయḞᦆ࣐࢘ࢫࢆ⏝࠸ࡓྠཷᐜయࡢⓎ⌧㒊఩◊✲㸸⏕య᝟ሗไᚚᏛ
⡿ᅜ ࣂࣥࢲࣅࣝࢺ኱Ꮫ 3URIHVVRU0DWKHZ'%UH\H
࣭ࣉࣟࢫࢱࢢࣛࣥࢪࣥ ) ཷᐜయḞᦆ࣐࢘ࢫࡢ㯤య㏥⦰࡟࠾ࡅࡿ㌿෗ᅉᏊ◊✲㸸⏕య᝟ሗไᚚᏛ
⡿ᅜ ࢖ࣜࣀ࢖኱Ꮫ 3URIHVVRU*HXOD*LERUL
࣭ࣉࣟࢫࢱࢢࣛࣥࢪࣥ ) ཷᐜయḞᦆ࣐࢘ࢫࡢ㯤య㏥⦰࡟࠾ࡅࡿ㑇ఏᏊⓎ⌧ࣉࣟࣇ࢓࢖ࣝࡢ◊✲㸸⏕య
᝟ሗไᚚᏛ
⡿ᅜ ࢚࣮ࣝ኱Ꮫ 3URIHVVRU&DUORV6WRFFR
࣭⫢⮚ .XSIIHU ⣽⬊࡟࠾ࡅࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢᙺ๭㸸⏕య᝟ሗไᚚᏛ
⊂ᅜ࣏ࢶࢲ࣒኱Ꮫ 3URIHVVRU*HUKDUG33¾VFKHO
࣭ࢩࣥࢢࣝࢭࣝⓎ⌧ࣉࣟࣇ࢕࣮ࣝゎᯒࢆ⏝࠸ࡓࣉࣟࢫࢱࣀ࢖ࢻཷᐜయḞᦆ࣐࢘ࢫࡢゎᯒ㸸⏕య᝟ሗไ
ᚚᏛ
⡿ᅜ ࣌ࣥࢩࣝ࣋ࢽ࢔኱Ꮫ 3URIHVVRU-DPHV+(EHUZLQH
࣭ࣉࣟࢫࢱࢢࣛࣥࢪࣥ㹃ཷᐜయḞᦆ࣐࢘ࢫ࡟࠾ࡅࡿⓎ⇕཯ᛂࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
⡿ᅜ ࣁ࣮ࣂ࣮ࢻ኱Ꮫ 3URIHVVRU&OLIIRUG6DSHU
࣭ࣉࣟࢫࢱࢢࣛࣥࢪࣥ ) ཷᐜయḞᦆ࣐࢘ࢫᏊᐑ࡟࠾ࡅࡿච␿⣽⬊ᾐ₶ࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
⡿ᅜ ࣐ࣟࣜࣥࢲ኱Ꮫ 3URIHVVRU6WHYHQ0<HOORQ
࣭᰾㓟ࡢຠ⋡ⓗ⣽⬊ෆ㏦㐩ἲࡢ㛤Ⓨ㸸⏕యᶵ⬟໬Ꮫ ࢫ࢙࣮࢘ࢹࣥࠊࢫࢺࢵࢡ࣒࣍ࣝ኱ᏛࠊžOR/DQJHO ᩍᤵ
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻࡢ⣽⬊⛣⾜ᶵᗎ㸸⏕యᶵ⬟໬Ꮫ
㐃ྜ⋤ᅜࠊ࢚࣮࢘ࣝࢬ኱Ꮫࠊ$UZ\Q7-RQHV ୖ⣭ㅮᖌ
࣭࢔ࣝࢸ࣑ࢩࢽࣥ࡜⒴ࢱ࣮ࢤࢵࢸ࢕ࣥࢢ㸸⏕యᶵ⬟໬Ꮫ
⡿ᅜࠊ࣡ࢩࣥࢺࣥ኱Ꮫࠊ7RPLND]X6DVDNL ᩍᤵ
࣭᪂つ⣽⬊ෆ⛣⾜࣋ࢡࢱ࣮ࡢ㛤Ⓨ㸸⏕యᶵ⬟໬Ꮫ
኱㡑Ẹᅜࠊᾆ㡯ᕤ⛉኱Ꮫࠊ6XQJ.HH&KXQ ᩍᤵ
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻࡢຠ⋡ⓗ⭷㏱㐣㸸⏕యᶵ⬟໬Ꮫ
ࢫ࢖ࢫࠊࢪࣗࢿ࣮ࣈ኱Ꮫࠊ6WHIDQ0DWLOH ᩍᤵ
࣭ศᏊ࣮ࣔࢱ࣮ࢱࣥࣃࢡ㉁ࡢᶵ⬟ゎᯒ㸸⏕యᶵ⬟໬Ꮫ
⡿ᅜࠊ࢝ࣜࣇ࢛ࣝࢽ࢔኱Ꮫࢧࣥࣇࣛࣥࢩࢫࢥᰯࠊ5RQ9DOHᩍᤵ
࣭ࢪࣥࢡࣇ࢕࣮ࣥ࢞ࢱࣥࣃࢡ㉁ࡢ⣽⬊ෆᣲື㸸⏕యᶵ⬟໬Ꮫ
⡿ᅜࠊ࢔࣓ࣜ࢝ᅜ❧⾨⏕◊✲ᡤࠊ-LP0F1DOO\ᩍᤵ
− 161 −
࣭᰾㓟ࢼࣀࢹࣂ࢖ࢫࡢ㛤Ⓨ࡟㛵ࡍࡿ◊✲㸸⑓ែ᝟ሗ⸆Ꮫ
⡿ᅜࢥ࣮ࢿࣝ኱Ꮫ
࣭ࣜ࣎ࣇࣛࣅࣥࢺࣛࣥࢫ࣏࣮ࢱ 5)7 ࡢ㑇ఏᏊከᆺ࡜⑓ែ⏕⌮࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
࣮࢜ࢫࢺࣛࣜ࢔ &KLOGUHQ
V+RVSLWDO:HVWPHDG8QLYHUVLW\RI6\GQH\ 'U-RKQ&KULVWRGRXORX
࣭1DWLRQDO,QVWLWXWHRI+HDOWK㸸ࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮
2NODKRPD6WDWH8QLYHUVLW\ (UDVPXV8QLYHUVLW\5RWWHUGDP
࣭⏕⌮άᛶᑠศᏊࡢࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮࡟㛵ࡍࡿඹྠ◊✲㸸ไᚚศᏊᏛ
⡿ᅜ -RKQV+RSNLQV6FKRRORI0HGLFLQHV'U-XQ2/LX
⡿ᅜ 1&,'U/HQ1HFNHUV
⡿ᅜ 8QLY:LVFRQVLQ0LOZDXNHH'U-DPHV0&RRN
࢝ࢼࢲ 0F*LOO8QLYHUVLW\'U-HUU\3HOOHWLHU
㡑ᅜ .5,%%'U-RQJ6$KQ
ࢻ࢖ࢶ (0%/+HLGHOEHUJ'U-RH/HZLV
࣭࢔࣑ࣀ࣌ࣉࢳࢲ࣮ࢮࡢᶵ⬟࡟㛵ࡍࡿ◊✲㸸ไᚚศᏊᏛ
ࢠࣜࢩࣕ 1DWLRQDO&HQWUHIRU6FLHQWLILF5HVHDUFK'HPRNULWRV'U6WUDWLNRV(IVWDWLRV
࣭ࣇࣛࢢ࣓ࣥࢺศᏊ㌶㐨ἲࡢᶵ⬟ᣑᙇ࡟㛵ࡍࡿ◊✲㸸๰⸆ィ⟬໬Ꮫ
,RZD6WDWH8QLYHUVLW\
࣭1&%,.(** ࢹ࣮ࢱ࣮࣋ࢫ㛫ࡢ㐃ᦠ㸸⤫ྜࢤࣀ࣑ࢡࢫ
⡿ᅜࠊࣂ࢖࢜ࢸࢡࣀࣟࢪ࣮᝟ሗࢭࣥࢱ࣮㸦1&%,㸧
࣭ඹྠ◊✲ࣉࣟࢪ࢙ࢡࢺ 9LV$17㸸⤫ྜࢤࣀ࣑ࢡࢫ
⡿ᅜࠊ࣎ࢫࢺࣥ኱Ꮫ
࣭⒴ࡢࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ࡟࠾ࡅࡿ࢔ࣝࢦࣜࢬ࣒࡜ࢹ࣮ࢱ࣮࣋ࢫࡢ㛤Ⓨ㸸⤫ྜࢤࣀ࣑ࢡࢫ
ࣇࣛࣥࢫࠊ࣮࢟ࣗࣜ◊✲ᡤ
࣭࣐ࣛࣜ࢔ཎ⹸ 3ODVPRGLXPIDOFLSDUXP ࢤࣀ࣒ࡢゎᯒ㸸⤫ྜࢤࣀ࣑ࢡࢫ
ࢫ࢙࣮࢘ࢹࣥࠊ࢝ࣟࣜࣥࢫ࢝◊✲ᡤ
࣭࢔ࢸ࣮࣒ࣟᛶື⬦◳໬⑕ࢆ⌮ゎࡍࡿࡓࡵࡢࢩࢫࢸ࣒⏕≀Ꮫⓗ࢔ࣉ࣮ࣟࢳ㸸⤫ྜࢤࣀ࣑ࢡࢫ
ࢫ࢙࣮࢘ࢹࣥࠊ࢝ࣟࣜࣥࢫ࢝◊✲ᡤ
࣭.(**$WODV ࡢ㛤Ⓨ㸸⤫ྜࢤࣀ࣑ࢡࢫ
ࢻ࢖ࢶࠊ(0%/
ศᏊタィ᝟ሗศ㔝
6FKRRORI&RPSXWHU6FLHQFH)XGDQ8QLYHUVLW\&KLQD
6KDQJKDL.H\/DERUDWRU\RI,QWHOOHFWXDO,QIRUPDWLRQ3URFHVVLQJ)XGDQ8QLYHUVLW\&KLQD
'HSDUWPHQWRI&RPSXWHU6FLHQFH+RQJ.RQJ%DSWLVW8QLYHUVLW\+RQJ.RQJ
'HSDUWPHQWRI0DWKHPDWLFV8QLYHUVLW\RI+RQJ.RQJ
/DERUDWRU\RI,PPXQRJHQHWLFVDQG9LUDO+RVW3DWKRJHQ*HQRPLFV6LQJDSRUH,PPXQRORJ\1HWZRUN
6LQJDSRUH
− 162 −
<RQJ/RR/LQ6FKRRORI0HGLFLQH1DWLRQDO8QLYHUVLW\RI6LQJDSRUH6LQJDSRUH
'DWD0LQLQJ'HSDUWPHQW,QVWLWXWHIRU,QIRFRPP5HVHDUFK6LQJDSRUH
'HSDUWPHQWRI&RPSXWHU6FLHQFHDQG6RIWZDUH(QJLQHHULQJ8QLYHUVLW\RI0HOERXUQH$XVWUDOLD
'HSDUWPHQWRI0HGLFLQH.DUROLQVND,QVWLWXWHW6ZHGHQ
㸦㸰㸧ᅜෆ࡛ࡢඹྠ◊✲㸦◊✲ࢸ࣮࣐㸸ᢸᙜศ㔝࣭ඹྠ◊✲ࡢ┦ᡭ᪉㸧
࣭⺯ග &;&5 ཷᐜయࣉ࣮ࣟࣈࡢᛂ⏝㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ᑠᕝ ಟᩍᤵ
࣭⺯ග &;&5 ཷᐜయࣉ࣮ࣟࣈࡢᛂ⏝㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ⏣➃Ὀᙪᩍᤵ
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻࡢᶵ⬟ゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ஧ᮌྐᮁᩍᤵ
࣭ᢠ +,9 άᛶ໬ྜ≀ࡢ᥈⣴㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ᯇᒸ㞞㞝ᩍᤵ
࣭6')&;&5 ⣔ࡢ⣽⬊እ⎔ቃ࡟࠾ࡅࡿᙺ๭ࡢゎ᫂㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ 㛗⃝ୣྖᩍᤵ
࣭ᢠ +&9 άᛶ໬ྜ≀ࡢ᥈⣴㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ᅵ᪉ ㄔ෸ᩍᤵ
࣭*35 ࣜ࢞ࣥࢻࡢᛂ⏝㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ᅵ஭㝯୍㑻ㅮᖌ
࣭㌾㦵⣽⬊࡟࠾ࡅࡿࢥ࣮ࣛࢤࣥศᏊࡢᙺ๭ࡢゎ᫂㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ᑠᯘ㞞ᙪㅮᖌ
࣭㌿෗ᢚไᅉᏊࡢไᚚศᏊ᥈⣴㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ᱓ཎᏹ୍㑻ㅮᖌ ࣭ᛶ࿘ᮇ࡟࠾ࡅࡿ⾑୰࣓ࢱࢫࢳࣥ⃰ᗘࡢኚ໬ࡢゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ᵽཱྀኖᏹㅮᖌ
࣭㦵ಟ᚟࡟࠾ࡅࡿ 6')&;&5 ⣔ࡢᙺ๭ࡢゎ᫂㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ி㒔኱Ꮫ ఀ⸨ ᐉຓᩍ
࣭+,9 ࡢឤᰁ౵ධ࣓࢝ࢽࢬ࣒ࡢゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ᮾ໭኱Ꮫ ᭹㒊ಇኵᩍᤵ
࣭+,9 ⭷⼥ྜ㜼ᐖ๣ࡢ⪏ᛶ⋓ᚓ࣓࢝ࢽࢬ࣒ࡢゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ᮾ໭኱Ꮫ ඣ⋢ᰤ୍ຓᩍ
࣭ࡣࡋ࠿἞⒪⸆ࡢ㛤Ⓨ◊✲㸸⸆ရ᭷ᶵ〇㐀Ꮫ
⚟ᓥ┴❧་⛉኱Ꮫ ᶫᮏᾈ୍ㅮᖌ
࣭࢟ࢫ࣌ࣉࢳࣥࡢ⏕⌮స⏝࡜ཷᐜయᶵ⬟ゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
㎰ᴗ⏕≀㈨※◊✲ᡤ ᒸᮧ⿱᫛ࣘࢽࢵࢺ㛗
− 163 −
࣭ࢥ࣮ࣛࢤࣥ⤖ྜࢱࣥࣃࢡ㉁㜼ᐖ๣ࡢ᥈⣴㸸⸆ရ᭷ᶵ〇㐀Ꮫ
᪩✄⏣኱Ꮫ ᑠฟ㝯つᩍᤵ ࣭4%3 㜼ᐖ๣ࡢ㛤Ⓨ◊✲㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮ Ọ஭⩏㝯ᐊ㛗
࣭࢟ࢫ࣌ࣉࢳࣥࡢ⏕⌮స⏝࡜ཷᐜయᶵ⬟ゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ᮾி኱Ꮫ ᒸ Ⰻ㝯ᩍᤵ
࣭ࢥࣞࢫࢸ࣮ࣟࣝㄏᑟయࢆ⏝࠸ࡓ '1$ ㍺㏦࡟㛵ࡍࡿ◊✲㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ᫍ⸆⛉኱Ꮫ ᭹㒊႐அㅮᖌ ࣭࢟ࢫ࣌ࣉࢳࣥࡢ⾑୰⃰ᗘᐃ㔞⣔ࡢ㛤Ⓨ࡜ᛂ⏝㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ᮾி⸆⛉኱Ꮫ ∦᱒ᩥᙪຓᩍ
࣭&;&5 ཷᐜయᣕᢠ⸆ࡢ⭘⒆ື≀ࣔࢹ࡛ࣝࡢゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ಙᕞ኱Ꮫ ᯈ㔝┤ᶞ෸ᩍᤵ ࣭6') ࡢᚠ⎔⾑ᾮ୰ࡢືែゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
㟼ᒸ┴❧኱Ꮫ ᕝᓥ༤ே෸ᩍᤵ
࣭(J 㜼ᐖ๣ࡢ㛤Ⓨ◊✲㸸⸆ရ᭷ᶵ〇㐀Ꮫ
㟼ᒸ┴❧኱Ꮫ ὸ஭❶Ⰻᩍᤵ ࣭*35 ཷᐜయࣜ࢞ࣥࢻࡢయෆືែゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
὾ᯇ་⛉኱Ꮫ 㛫㈡⏣Ὀᐶᩍᤵ
࣭࢟ࢫ࣌ࣉࢳࣥࡢ⏕⌮స⏝࡜ཷᐜయᶵ⬟ゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ྡྂᒇ኱Ꮫ ๓ከᩗ୍㑻ᩍᤵ
࣭㦵෌⏕࡟࠾ࡅࡿ &;&5 ࡢᙺ๭ࡢゎ᫂㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ྡྂᒇ኱Ꮫ ᒣᮏᮁோ෸ᩍᤵ ࣭⫵ᑠ⣽⬊⒴࡟࠾ࡅࡿ 6')&;&5 ⣔ࡢᙺ๭ࡢゎ᫂㸸⸆ရ᭷ᶵ〇㐀Ꮫ
኱㜰኱Ꮫ ᮌᓥ㈗ᚿຓᩍ
࣭/2; 㜼ᐖ๣ࡢ᥈⣴㸸⸆ရ᭷ᶵ〇㐀Ꮫ
ᅜ❧ᚠ⎔ჾ⑓ࢭࣥࢱ࣮ ἑᮧ㐩ஓ㒊㛗
࣭/7& 㜼ᐖ๣ࡢ㛤Ⓨ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
⌮໬Ꮫ◊✲ᡤ ᐑ㔝㞞ྖ୺௵◊✲ဨ
࣭ᢠ +,9 άᛶ໬ྜ≀ࡢ᥈⣴㸸⸆ရ᭷ᶵ〇㐀Ꮫ
⇃ᮏ኱Ꮫ ‶ᒇ⿱᫂ᩍᤵ
࣭+,9 ࡢឤᰁࡢ౵ධ㐣⛬࡟࠾ࡅࡿཷᐜయศᏊ⩌ࡢᣲືࡢゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
⇃ᮏ኱Ꮫ ๓⏣ὒຓ෸ᩍᤵ ࣭+,9 ࡢឤᰁࡢ౵ධ㐣⛬ࡢゎᯒ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
⇃ᮏ኱Ꮫ ྜྷᮧ࿴ஂㅮᖌ
࣭๰യ἞⒵ಁ㐍๣ࡢ㛤Ⓨ㸸⸆ရ᭷ᶵ〇㐀Ꮫ
⌰⌫኱Ꮫ 㧗ᶫ೺㐀෸ᩍᤵ
− 164 −
࣭)5 ࡟ྵࡲࢀࡿ>@࢜࢟ࢧࢪࣀࣥᵓ㐀ࡢ୙ᩧྜᡂ◊✲㸸⸆ရศᏊ໬Ꮫ ᇛす኱Ꮫ⸆Ꮫ㒊
࣭㔠ゐ፹ࢆ⏝࠸ࡓ࢔ࣝ࢟ࢽࣝ࢝ࣝࣂ࣐࣮ࢺࡢࣛࢡࢺࣥ໬࡟㛵ࡍࡿ◊✲㸸⸆ရศᏊ໬Ꮫ
⚄ᡞ⸆⛉኱Ꮫ
࣭1ࢺࣜࣇࣝ࢜ࣟ࢔ࢭࢳ࢚ࣝࣥࣄࢻࣛࢪࣥࢆ⏝࠸ࡓ࢖ࣥࢻ࣮ࣝྜᡂ◊✲㸸⸆ရศᏊ໬Ꮫ
⚄ᡞ⸆⛉኱Ꮫ
࣭࢔ࣝࢶࣁ࢖࣐࣮⑓࢔࣑ࣟ࢖ࢻșࢱࣥࣃࢡ㉁ኚ␗యࡢᵓ㐀㸸⸆ရᶵ⬟ゎᯒᏛ
ி㒔⸆⛉኱Ꮫ
࣭࢔ࣝࢶࣁ࢖࣐࣮⑓࢔࣑ࣟ࢖ࢻșࢱࣥࣃࢡ㉁จ㞟ᢚไἲࡢ㛤Ⓨ㸸⸆ရᶵ⬟ゎᯒᏛ
ᮾி་⛉ṑ⛉኱Ꮫ
࣭࢔ࣝࢶࣁ࢖࣐࣮⑓࢔࣑ࣟ࢖ࢻșࢱࣥࣃࢡ㉁จ㞟ᢚไἲࡢ㛤Ⓨ㸸⸆ရᶵ⬟ゎᯒᏛ
⚟஭኱Ꮫ་Ꮫ㒊
࣭ࣂࢡࢸࣜ࢜ࢩࣥࡢస⏝ᶵᵓ㸸⸆ရᶵ⬟ゎᯒᏛ
஑ᕞ኱Ꮫ㎰Ꮫ㒊
࣭࢔ࣝࢶࣁ࢖࣐࣮⑓࢔࣑ࣟ࢖ࢻșࢱࣥࣃࢡ㉁จ㞟ᶵᵓ㸸⸆ရᶵ⬟ゎᯒᏛ
㛗ᑑ་⒪◊✲ࢭࣥࢱ࣮
࣭ᢠ࢞ࣥᛶ࣌ࣉࢳࢻࡢస⏝ᶵᵓ㸸⸆ရᶵ⬟ゎᯒᏛ
ி㒔኱Ꮫ་Ꮫ㒊
࣭ዲ⇕⳦࡟ࡼࡿ㞴ศゎᛶື≀ࢱࣥࣃࢡ㉁ศゎࡢ᪂ᒎ㛤㸸ᵓ㐀⏕≀⸆Ꮫ
ி㒔ᗓ❧኱Ꮫ㎰Ꮫ◊✲⛉
࣭$%& ࢺࣛࣥࢫ࣏࣮ࢱ࣮ࡢ≉␗ⓗ㜼ᐖ๣ࡢタィ࡜ྜᡂ㸸ᵓ㐀⏕≀⸆Ꮫ
ி㒔኱Ꮫ໬Ꮫ◊✲ᡤ
࣭ࢺࣛࣥࢫ࣏࣮ࢱ࣮⭷ࢱࣥࣃࢡ㉁ࡢᵓ㐀⏕≀Ꮫⓗ◊✲㸸ᵓ㐀⏕≀⸆Ꮫ
⌮໬Ꮫ◊✲ᡤ᧛☻◊✲ᡤࠊ⏘ᴗᢏ⾡⥲ྜ◊✲ᡤ
࣭⚄⤒⣽⬊ᴟᛶᙧᡂ࡟࠾ࡅࡿ⥙⨶ⓗࢱࣥࣃࢡ㉁ࣜࣥ㓟໬◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ዉⰋඛ➃⛉Ꮫᢏ⾡኱Ꮫ㝔኱Ꮫࣂ࢖࢜ࢧ࢖࢚ࣥࢫ◊✲⛉
࣭⚄⤒ᖿ⣽⬊࡟࠾ࡅࡿ⥙⨶ⓗࢱࣥࣃࢡ㉁ࣜࣥ㓟໬◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
៞᠕⩏ሿ኱Ꮫ་Ꮫ㒊
࣭ࣂࢡࢸࣜ࢔ཬࡧ㓝ẕ⣽⬊࡟࠾ࡅࡿࢩࣕ࣌ࣟࣥࢱࣥࣃࢡ㉁ᇶ㉁᥈⣴◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ᮾிᕤᴗ኱Ꮫ኱Ꮫ㝔⏕࿨⌮ᕤᏛ◊✲⛉
࣭⚄⤒⣽⬊࡟࠾ࡅࡿࣜࣥ㓟໬ࣉࣟࢸ࣮࣒࢜◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ᮾி኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉
࣭ᖿ⣽⬊ࡢศ໬᢬ᢠᛶᅉᏊ࡟࠾ࡅࡿࣜࣥ㓟໬ࣉࣟࢸ࣮࣒࢜◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
኱㜰኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉
࣭ኳ↛⏤᮶⏕⌮άᛶ໬ྜ≀ࡢᶆⓗศᏊ᥈⣴࡟࠾ࡅࡿࣉࣟࢸ࣮࣒࢜◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
኱㜰኱Ꮫ኱Ꮫ㝔⌮Ꮫ◊✲⛉
− 165 −
࣭᳜≀ࡢࣜࣥ㓟໬ࣉࣟࢸ࣮࣒࢜◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
⌮໬Ꮫ◊✲ᡤ᳜≀⛉Ꮫ◊✲ࢭࣥࢱ࣮
࣭$SR$, ࡟ࡼࡿ +'/ ⏕ᡂᶵᵓ࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ྡྂᒇᕷ❧኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉
࣭$%&$㸯ࢱࣥࣃࢡ➼ࡢ⣽⬊ࡢࢥࣞࢫࢸ࣮ࣟࣝ᤼ฟᶵᵓ࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ி㒔኱Ꮫ኱Ꮫ㝔㎰Ꮫ◊✲⛉
࣭$SR( ࡜⣽⬊⾲㠃ࣉࣟࢸ࢜ࢢࣜ࢝ࣥࡢ┦஫స⏝࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
⚄ᡞ⸆⛉኱Ꮫ
࣭࢔࣏࣏ࣜࢱࣥࣃࢡ㉁࡜⬡㉁⢏Ꮚ࡜ࡢ┦஫స⏝࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
⚄ᡞ⸆⛉኱Ꮫ
࣭⬡㉁⢏Ꮚࡢᵓ㐀࡜ࢲ࢖ࢼ࣑ࢡࢫ࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ᮾி኱Ꮫ≀ᛶ◊✲ᡤ
࣭⬡㉁̾ࢱࣥࣃࢡ㉁」ྜయࡢᵓ㐀ホ౯࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
໭ᾏ㐨኱Ꮫ኱Ꮫ㝔᝟ሗ⛉Ꮫ◊✲⛉
࣭⬡㉁ᾮᬗศᩓ⣔ࡢ㹖⥺ᑠゅᩓ஘࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ி㒔኱Ꮫ኱Ꮫ㝔ᕤᏛ◊✲⛉
࣭ᒁᡤ㯞㓉๣࡟ࡼࡿࢳࣟࢩࣥ࢟ࢼ࣮ࢮ㜼ᐖస⏝࡟㛵ࡍࡿ◊✲㸸〇๣ᶵ⬟ゎᯒᏛ
ி㒔ᗓ❧་⛉኱Ꮫ
࣭୙ᩧ㸲⨨᥮Ⅳ⣲ྵ᭷」⣲⎔໬ྜ≀ࣛ࢖ࣈ࣮ࣛࣜࡢᵓ⠏࡜⏕⌮άᛶ≀㉁ࡢ᳨⣴㸸⢭ᐦ᭷ᶵྜᡂ໬Ꮫ
༓ⴥ኱⸆ ▼ᶫṇᕫᩍᤵ
࣭ከᯫᶫᆺ࢜ࣜࢦࢼࣇࢱࣞࣥ㢮ࡢྜᡂ࡜ᶵ⬟㸸⢭ᐦ᭷ᶵྜᡂ໬Ꮫ
ி㒔ᗓ❧኱Ꮫ ಴ᣢᖾྖ෸ᩍᤵ
࣭୙ᩧグ᠈ᆺ཯ᛂࡢ⌮ㄽゎᯒ㸸⢭ᐦ᭷ᶵྜᡂ໬Ꮫ
ᮾி኱Ꮫ ኱࿴⏣ᬛᙪᩍᤵ
࣭75,& ࢳࣕࢿࣝ࡟㛵ࡍࡿ◊✲㸸⏕యศᏊㄆ㆑Ꮫศ㔝
ᇸ⋢་⛉኱Ꮫ 㥖ᓮ ఙ஧ ෸ᩍᤵ
ᮾி኱Ꮫ ⏣ཱྀ Ⰻ ᩍᤵࠊ୰す ᗈᶞ ༤ኈ
ᐩᒣ኱Ꮫ 㓇஭ ⚽⣖ ᩍᤵࠊ⸨஭ ᣅே ຓᩍ
ྡྂᒇᕷ❧኱Ꮫ ௒Ἠ ♸἞ ᩍᤵࠊᒣᮧ ᑑ⏨ ㅮᖌ
ி㒔኱Ꮫ ➉ෆ ⥤Ꮚ ຓᩍࠊ∾ᒣ Ṋ ຓᩍ
኱㜰኱Ꮫ ⚄ฟ ィ ㅮᖌ
ឡ፾኱Ꮫ ୕ᮌ ဴ㑻 ᩍᤵࠊ⏣ཎ ᗣ⋞ ㅮᖌ
஑ᕞ኱Ꮫ す⏣ ᇶᏹ ෸ᩍᤵ
⚟ᒸ኱Ꮫ ᒾᮏ 㝯ᏹ ᩍᤵࠊᒣᮏ ಙኴ㑻 ෸ᩍᤵࠊ႐ከ ⣪ᩯ⨾ ㅮᖌ
⏘ᴗᢏ⾡⥲ྜ◊✲ᡤ బ⸨ ୺⛯ ࢢ࣮ࣝࣉ࣮ࣜࢲ࣮ࠊᑠ᳚ ಇᙪ ◊✲ဨࠊ୕ᑿ ࿴ᘯ ◊✲ဨ
ᅜ❧ᚠ⎔ჾ⑓ࢭࣥࢱ࣮◊✲ᡤ ᐑ⏣ ᩄ⾜ 㒊㛗ࠊἙ㔝 㞝ᖹ 㒊㛗ࠊⰼ⏣ ⿱඾ ◊✲ဨ
− 166 −
࣭ࢪࣕࣥࢡࢺࣇ࢕ࣜࣥࡢ୰ᯡ⚄⤒⣔ᶵ⬟࡟㛵ࡍࡿ◊✲㸸⏕యศᏊㄆ㆑Ꮫ
໭ᾏ㐨኱Ꮫ Ώ㎶ 㞞ᙪ ᩍᤵࠊ῝㇂ ᫀᘯ ຓᩍࠊᐑᓮ ኴ㍜ ຓᩍ
ᮾ໭኱Ꮫ ⚟Ọ ᾈྖ ᩍᤵࠊ㏆⸨ ᑦṊ ᩍᤵࠊඵᑿ ᐶ ᩍᤵࠊ㜰ୖ ὒ⾜ ෸ᩍᤵ
᳃ཱྀ ⱱᶞ ຓᩍ
ᮾி኱Ꮫ 㣤㔝 ṇග ᩍᤵ
ᇸ⋢་⛉኱Ꮫ 㥖ᓮ ఙ஧ ෸ᩍᤵ
኱㜰኱Ꮫ ⊁㔝 ᪉ఙ ᩍᤵࠊᶫᮏ ᾈ୍ ຓᩍ
ᚨᓥᩥ⌮኱Ꮫ㤶ᕝ⸆Ꮫ㒊 ᓊᮏ Ὀྖ ຓᩍ
࣭άᛶ㓟⣲ࢩࢢࢼࣝ࡟ࡼࡿ୰ᯡ⚄⤒⣔ᶵ⬟ㄪ⠇࡟㛵ࡍࡿ◊✲㸸⏕యศᏊㄆ㆑Ꮫ
໭ᾏ㐨኱Ꮫ Ώ㎶ 㞞ᙪ ᩍᤵ
ᮾி኱Ꮫ 㣤㔝 ṇගᩍᤵࠊ㰺⸨ ᘏே ᩍᤵࠊᒣ⃝ ᚨᚿᏊ ຓᩍ
㡰ኳᇽ኱Ꮫ ᱜ஭ 㝯 ᩍᤵࠊ࿋ᯘ ࡞ࡈࡳ ෸ᩍᤵࠊᮧᒣ ᑦ ෸ᩍᤵ
㛗ᓮ኱Ꮫ ᳃ ᮃ ᩍᤵࠊᰘᓮ ᬗᙪ ຓᩍ
࣭0* ࡟㛵ࡍࡿඹྠ◊✲㸸⏕యศᏊㄆ㆑Ꮫ
㡰ኳᇽ኱Ꮫ ࿋ᯘ ࡞ࡈࡳ ෸ᩍᤵ
⏘ᴗᢏ⾡⥲ྜ◊✲ᡤ బ⸨ ୺⛯ࢢ࣮ࣝࣉ࣮ࣜࢲ࣮ࠊᑠ᳚ ಇᙪ ◊✲ဨࠊ
୕ᑿ ࿴ᘯ ◊✲ဨ
ᅜ❧ᚠ⎔ჾ⑓ࢭࣥࢱ࣮◊✲ᡤ ᐮᕝ ㈼἞ ᡤ㛗
࣭0* ࡢᶵ⬟࡟㛵ࡍࡿ◊✲㸸⏕యศᏊㄆ㆑Ꮫ
ᮾ໭኱Ꮫ ᰗἑ ㍤⾜ ᩍᤵ
ᮾ㑥኱Ꮫ ㉥⩚ ᝅ⨾ ෸ᩍᤵ
᪩✄⏣኱Ꮫ ༡ἑ ா ᩍᤵ
ᕝᓮ་⛉኱Ꮫ ◁⏣ ⰾ⚽ ᩍᤵ
ᅜ❧ᚠ⎔ჾ⑓ࢭࣥࢱ࣮◊✲ᡤ ᐮᕝ ㈼἞ ᡤ㛗
ᮾி㒔⮫ᗋ་Ꮫ⥲ྜ◊✲ᡤ ᯇ⏣ ᠇அ ◊✲ဨ
࣭75,0 ࡢᶵ⬟࡟㛵ࡍࡿ◊✲㸸⏕యศᏊㄆ㆑Ꮫ
ᐩᒣ኱Ꮫ 㓇஭ ⚽⣖ ᩍᤵ
ᐑᓮ኱Ꮫ ⃝ཱྀ ᮁ ᩍᤵ
࣭&DOXPLQࡢ⏕⌮ⓗᙺ๭ࡢゎ᫂㸸⏕యศᏊㄆ㆑Ꮫ
ᇸ⋢་⛉኱Ꮫ 㥖ᓮ ఙ஧ ෸ᩍᤵ
኱㜰኱Ꮫ 㧗಴ ఙᖾ ᩍᤵ ᮌᡞᒇ ᾈᗣ ຓᩍ
࣭ཷᐜయ࢔ࢲࣉࢱ࣮ศᏊ࡟ࡼࡿ୰ᯡ⚄⤒⣔ᶵ⬟ไᚚ࡟㛵ࡍࡿ◊✲㸸⏕యศᏊㄆ㆑Ꮫ
ᚨᓥᩥ⌮኱Ꮫ㤶ᕝ⸆Ꮫ㒊 ᓊᮏ Ὀྖ ຓᩍ
㛗ᓮ኱Ꮫ ᳃ ᮃ ᩍᤵ
࣭⚄⤒⣔ࡢ 753 ࢳࣕࢿࣝ࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎᯒᏛ
ி㒔኱ᏛᕤᏛ◊✲⛉⏕≀໬Ꮫᩍᐊ
− 167 −
࣭⬻ෆࢣࣔ࢝࢖ࣥ࡟ࡼࡿࢢࣜ࢔Ѹࢽ࣮ࣗࣟࣥᶵ⬟㐃㛵ࡢ᫬㛫ⓗ࣭✵㛫ⓗㄪ⠇ᶵᵓࡢゎ᫂㸭⑊③᝟ື཯
ᛂ࡟㛵୚ࡍࡿᡥ᱈యࢆ୰ᚰ࡜ࡋࡓ⚄⤒ᅇ㊰⥙ࡢゎᯒ㸸⏕యᶵ⬟ゎᯒᏛ
໭ᾏ㐨኱Ꮫ⸆Ꮫ◊✲⛉⸆⌮Ꮫศ㔝
࣭㑇ఏᏊᨵኚ࣐࢘ࢫࢆ⏝࠸ࡓ⥙⨶ⓗ⾜ືゎᯒ࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎᯒᏛ
⸨⏣ಖ೺⾨⏕኱Ꮫ ⥲ྜ་⛉Ꮫ◊✲ᡤ ࢩࢫࢸ࣒་⛉Ꮫ◊✲㒊㛛
࣭࢝ࣉࢧ࢖ࢩࣥཷᐜయ 7539 ࡢ୰ᯡ⚄⤒⣔࡟࠾ࡅࡿᶵ⬟࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎᯒᏛ ⮬↛⛉Ꮫ◊✲ᶵᵓᒸᓮ⤫ྜࣂ࢖࢜ࢧ࢖࢚ࣥࢫࢭࣥࢱ࣮ ⣽⬊⏕⌮◊✲㒊㛛
࣭㑇ఏᏊኚ␗ࣛࢵࢺ࡟Ⓨ⌧ࡍࡿኚ␗ᆺ࢖࢜ࣥࢳࣕࢿࣝࡢ㟁Ẽ⏕⌮Ꮫⓗゎᯒ࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎ
ᯒᏛ
ி㒔኱Ꮫ་Ꮫ㒊௜ᒓື≀ᐇ㦂᪋タ
࣭㦵㧊⏤᮶⣽⬊࡟Ⓨ⌧ࡍࡿ 7530 ࡢ⑊③Ⓨ⑕࣭⥔ᣢᶵᵓ࡟࠾ࡅࡿᶵ⬟ゎᯒ㸸⏕యᶵ⬟ゎᯒᏛ
ி㒔኱Ꮫᨺᑕ⥺⏕≀◊✲ࢭࣥࢱ࣮
࣭ᒀ㓟ࢺࣛࣥࢫ࣏࣮ࢱ࣮࡟㛵ࡍࡿ◊✲㸸⏕యᶵ⬟ゎᯒᏛ
ᮥᯘ኱Ꮫ་Ꮫ㒊⸆⌮Ꮫᩍᐊ
࣭(FRGLQ ࡜ච␿㸸㑇ఏᏊ⸆Ꮫ
ᮾி኱Ꮫ ᯇᓥ⥘἞
࣭)*) ࡜⏕యࣜࢬ࣒㸸㑇ఏᏊ⸆Ꮫ
⏘ᴗᢏ⾡⥲ྜ◊✲ᡤ ኱▼຾㝯
࣭%URULQ ࡜⭈ᶵ⬟㸸㑇ఏᏊ⸆Ꮫ
ி㒔኱Ꮫ ᰗ⏣⣲Ꮚ
࣭% ⣽⬊ࡢάᛶ໬࡟࠾ࡅࡿࢩ࢔ࣝ㓟ࡢᙺ๭㸸⏕⌮άᛶไᚚᏛ
ᮾி་⛉ṑ⛉኱Ꮫ኱Ꮫ኱Ꮫ㝔 㘥⏣Ṋᚿᩍᤵ
࣭␗✀⛣᳜࡟᪊ࡅࡿࢩ࢔ࣝ㓟ศᏊ✀ࡢᙺ๭㸸⏕⌮άᛶไᚚᏛ
ᗈᓥ኱Ꮫ኱Ꮫ㝔་ṑ⸆Ꮫ⥲ྜ◊✲⛉ ኱ẁ⚽ᶞᩍᤵ
࣭࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡ࡟㛵୚ࡍࡿࢱࣥࣃࢡ㉁ࡢ ; ⥺⤖ᬗᵓ㐀ゎᯒ㸸⏕య᝟ሗไᚚᏛ
㧗࢚ࢿࣝࢠ࣮ຍ㏿ჾ◊✲ᶵᵓ≀㉁ᵓ㐀⛉Ꮫ◊✲ᡤ ᩍᤵ ⱝᵳኊᕷ
࣭࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡ࡟㛵୚ࡍࡿࢱࣥࣃࢡ㉁ࡢ⣽⬊ෆᒁᅾࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
⚟ᓥ་⛉኱Ꮫᩍᤵ ࿴ᰩ ⪽
࣭ࢩࣥࢢࣝࢭࣝⓎ⌧ࣉࣟࣇ࢕࣮ࣝゎᯒࢆ⏝࠸ࡓங⭢ศ໬ࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
ᮾி኱Ꮫ་Ꮫ㒊᪂㡿ᇦ◊✲⛉ᩍᤵ Ⳣ㔝⣧ኵ
࣭ࢩࣥࢢࣝࢭࣝⓎ⌧ࣉࣟࣇ࢕࣮ࣝゎᯒࢆ⏝࠸ࡓᛶ⏕Ṫ⭢ศ໬ࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
஑ᕞ኱Ꮫ་Ꮫ◊✲㝔ᩍᤵ ㅖᶫ᠇୍
࣭ࢩࣥࢢࣝࢭࣝⓎ⌧ࣉࣟࣇ࢕࣮ࣝゎᯒࢆ⏝࠸ࡓ 3$&$3 ࡢ⏕⌮ᶵ⬟ゎᯒ㸸⏕య᝟ሗไᚚᏛ
኱㜰኱Ꮫ⸆Ꮫ◊✲⛉ᩍᤵ 㤿ሙ᫂㐨
࣭ࢩࣥࢢࣝࢭࣝⓎ⌧ࣉࣟࣇ࢕࣮ࣝゎᯒࢆ⏝࠸ࡓ⫢⒴Ⓨ⑕ᶵᵓࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
ྡྂᒇᕷ❧኱Ꮫ⸆Ꮫ◊✲⛉෸ᩍᤵ 㛗⏣ⱱᏹ
− 168 −
࣭ཷᐜయḞᦆ࣐࢘ࢫࢆ⏝࠸ࡓࣉࣟࢫࢱࣀ࢖ࢻࡢ⏕⌮ⓗᙺ๭࡟㛵ࡍࡿ◊✲㸸⏕య᝟ሗไᚚᏛ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ᩍᤵ ᡂᐑ ࿘
࣭ື⬦⟶ᖹ⁥➽ࡢᡂ⇍࡟࠾ࡅࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
᪩✄⏣኱Ꮫ⌮ᕤᏛ⾡㝔ᩍᤵ ༡ἑ ா
࣭⾑⟶᪂⏕࡟࠾ࡅࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
໭㔛኱Ꮫ་Ꮫ㒊⸆⌮Ꮫᩍᤵ 㤿ᔱṇ㝯
࣭⭈ᶵ⬟࡟㛵୚ࡍࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
᪫ᕝ་⛉኱Ꮫ⸆⌮Ꮫᩍᤵ ∵㤳ᩥ㝯
࣭ࣉࣟࢫࢱࢢࣛࣥࢪࣥ㹄ཷᐜయḞᦆ࣐࢘ࢫ࡟࠾ࡅࡿ࢜࢟ࢩࢺࢩࣥࡢᙺ๭࡟㛵ࡍࡿ◊✲㸸⏕య᝟ሗᏛ
ᮾ໭኱Ꮫ኱Ꮫ㝔㎰Ꮫ◊✲⛉ᩍᤵ す᳃ඞᙪ
࣭࣐ࢫࢺ⣽⬊ࡢศ໬࡟㛵୚ࡍࡿ࢔ࣛ࢟ࢻࣥ㓟௦ㅰ≀ࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
᫛࿴኱Ꮫ⸆Ꮫ㒊ᩍᤵ ᕤ⸨୍㑻
࣭⭡⭍࣐ࢡࣟࣇ࢓࣮ࢪ࡟࠾ࡅࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢⓎ⌧ゎᯒ㸸⏕య᝟ሗไᚚᏛ
࣭኱㜰⸆⛉኱Ꮫ⸆Ꮫ㒊ᩍᤵ ኳ㔝ᐩ⨾ኵ
࣭໬ᏛⓎ⒴࡟㛵୚ࡍࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
ᅜ❧ࡀࢇࢭࣥࢱ࣮◊✲ᡤࡀࢇண㜵◊✲㒊㒊㛗 ⱝᯘᩗ஧
࣭࢔ࣟࢹ࢕ࢽ࢔࡟㛵୚ࡍࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢゎᯒ㸸⏕య᝟ሗไᚚᏛ
㛵す་⛉኱Ꮫ་⛉Ꮫᩍᐊᩍᤵ ఀ⸨ㄔ஧
࣭⑊③ᛂ⟅࡟࠾ࡅࡿ 753 ࢳࣕࢿࣝ࡜ࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢᙺ๭㸸⏕య᝟ሗไᚚᏛ
⮬↛⛉Ꮫ◊✲ᶵᵓᩍᤵ ᐩỌ┿⍆
࣭*$%$ ࢽ࣮ࣗࣟࣥ࡟㛵ࡍࡿࢩࣥࢢࣝࢭࣝⓎ⌧ࣉࣟࣇ࢓࢖ࣝゎᯒ㸸⏕య᝟ሗไᚚᏛ
⇃ᮏ኱Ꮫ⏕࿨⛉Ꮫ◊✲㒊ᩍᤵ ⋢ᕳఙ❶
࣭࢔ࣝࢶࣁ࢖࣐࣮⑓㐍ᒎ࡟࠾ࡅࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢᙺ๭ゎᯒ㸸⏕య᝟ሗไᚚᏛ
⇃ᮏ኱Ꮫ⏕࿨⛉Ꮫ◊✲㒊ᩍᤵ Ỉᓥᚭ
࣭࣐ࢫࢺ⣽⬊ࡢศ໬࣭ᡂ⇍࡟࠾ࡅࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥࡢᙺ๭ゎᯒ㸸⏕య᝟ሗไᚚᏛ
ᮾி㒔❧⮫ᗋ་Ꮫ⥲ྜ◊✲ᡤ๪ཧ஦◊✲ဨ ᮧୖㄔ
࣭⬡㉁࣓ࢹ࢕࢚࣮ࢱ࣮ཷᐜయࡢᵓ㐀࡜ᶵ⬟࡟㛵ࡍࡿ◊✲㸸⏕య᝟ሗไᚚᏛ
஑ᕞ኱Ꮫ་Ꮫ◊✲㝔ᩍᤵ ᶓ⁁ᓅ
࣭⬡㉁࣓ࢹ࢕࢚࣮ࢱ࣮ཷᐜయࡢᙺ๭࡟㛵ࡍࡿ◊✲㸸⏕య᝟ሗไᚚᏛ
ᮾ໭኱Ꮫ⸆Ꮫ◊✲⛉ᩍᤵ 㟷ᮌ῟㈼
࣭ࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయḞᦆ࣐࢘ࢫ࡟࠾ࡅࡿ⬡㉁࣓ࢱ࣮࣒࣎ࣟゎᯒ㸸⏕య᝟ሗไᚚᏛ
ᮾி኱Ꮫ⸆Ꮫ⣔◊✲⛉෸ᩍᤵ ᭷⏣ㄔ
࣭⢭ᕢᚤᑠᵓ㐀ࡢⓎ⌧ࣉࣟࣇ࢓࢖ࣝゎᯒ㸸⏕య᝟ሗไᚚᏛ
⮬↛⛉Ꮫ◊✲ᶵᵓᩍᤵ ྜྷ⏣ᯇ⏕ ࣭ᛶ⾜ືⓎ⌧࡟࠾ࡅࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥࡢᙺ๭ゎᯒ㸸⏕య᝟ሗไᚚᏛ
ᮾி኱ᏛศᏊ⣽⬊⏕≀Ꮫ◊✲ᡤᩍᤵ ຍ⸨ⱱ᫂
− 169 −
࣭࣐ࢫࢺ⣽⬊ࡢศ໬ᡂ⇍࡟క࠺Ⓨ⌧ࣉࣟࣇ࢓࢖ࣝゎᯒ㸸⏕య᝟ሗไᚚᏛ
ᒸᒣ኱Ꮫ⸆Ꮫ㒊෸ᩍᤵ ⏣୰ᬛஅ
࣭ࢭ࣐ࣇ࢛ࣜࣥ࡟ࡼࡿ⚄⤒㍈⣴࢞࢖ࢲࣥࢫࡢศᏊᶵᵓ㸸⚄⤒ᶵ⬟ไᚚ
኱㜰኱Ꮫ⺮ⓑ㉁◊✲ᡤ
࣭࢔ࣝࢠࢽࣥಟ㣭࣏ࣜࢯ࣮࣒࡟ࡼࡿ㑇ఏᏊᑟධ㸸⏕యᶵ⬟໬Ꮫ
໭ᾏ㐨኱Ꮫ⸆Ꮫ◊✲⛉
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻࢆ⏝࠸ࡓᶵ⬟᰾㓟ࡢ⣽⬊ෆᑟධ㸸⏕యᶵ⬟໬Ꮫ
ᮾ໭኱Ꮫከඖ≀㉁⛉Ꮫ◊✲ᡤ
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻ࡜ࢩࢢࢼࣝఏ㐩㸸⏕యᶵ⬟໬Ꮫ
ி㒔኱Ꮫ⏕࿨⛉Ꮫ◊✲⛉
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻࢆ⏝࠸ࡓᢠ࢞ࣥ๣ࡢ㏦㐩㸸⏕యᶵ⬟໬Ꮫ
ᒸᒣ኱Ꮫ⮬↛⛉Ꮫ◊✲⛉㸭⇃ᮏ኱Ꮫ⮬↛⛉Ꮫ◊✲⛉
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻࢆ⏝࠸ࡓ⣽⬊ෆ 105㸸⏕యᶵ⬟໬Ꮫ
ி㒔኱ᏛᕤᏛ◊✲⛉
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻ࡜ᢠయ㏦㐩㸸⏕యᶵ⬟໬Ꮫ
༓ⴥ኱Ꮫ⸆Ꮫ◊✲㝔
࣭5HY ࣌ࣉࢳࢻ࡜ +,9 ࡢឤᰁ㜵ᚚ㸸⏕యᶵ⬟໬Ꮫ
ᮾ໭኱Ꮫ་Ꮫ◊✲⛉
ி㒔኱Ꮫ࢘࢖ࣝࢫ◊✲ᡤ
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻࡢ⭠⟶㏱㐣㸸⏕యᶵ⬟໬Ꮫ
ி㒔⸆⛉኱Ꮫ
ᮾி⸆⛉኱Ꮫ
࣭ࢱࣥࣃࢡ㉁ࢹࢨ࢖ࣥ㸸⏕యᶵ⬟໬Ꮫ
᪥ᮏཎᏊຊ◊✲㛤Ⓨᶵᵓ
࣭ேᕤࢱࣥࣃࢡ㉁࡟ࡼࡿᴫ᪥ࣜࢬ࣒ไᚚ㸸⏕యᶵ⬟໬Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
࣭ࢪࣥࢡࣇ࢕࣮ࣥ࢞ࡢᶵ⬟ゎᯒ㸸⏕యᶵ⬟໬Ꮫ
ྠᚿ♫ዪᏊ኱Ꮫ⸆Ꮫ㒊
࣭࣌ࣉࢳࢻࡢ࣐࢘ࢫయෆືែ㸸⏕యᶵ⬟໬Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
࣭࢔ࣝࢸ࣑ࢩࢽࣥ࡜⒴ࢱ࣮ࢤࢸ࢕ࣥࢢ㸸⏕యᶵ⬟໬Ꮫ
ṊᗜᕝዪᏊ኱Ꮫ
࣭࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻࢆ⏝࠸ࡓ≉␗ⓗ࢜ࣝ࢞ࢿࣛ㏦㐩㸸⏕యᶵ⬟໬Ꮫ
ᮾி་⛉ṑ⛉኱Ꮫ㞴἞⑌ᝈ◊✲㒊
࣭ࢥ࣮ࣛࢤࣥᵝ࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻࡢ⣽⬊ෆ㏦㐩㸸⏕యᶵ⬟໬Ꮫ
᪩✄⏣኱Ꮫඛ㐍⌮ᕤᏛ㒊
− 170 −
࣭୰ᯡ⚄⤒⣔⑌ᝈ࡟ᑐࡍࡿ࢔ࣝࢠࢽࣥ࣌ࣉࢳࢻ࢟ࣕࣜ࢔ࡢᛂ⏝㸸⏕యᶵ⬟໬Ꮫ
ᚨᓥ኱Ꮫ኱Ꮫ㝔࣊ࣝࢫࣂ࢖࢜ࢧ࢖࢚ࣥࢫ◊✲㒊
࣭⮬ᕫ⤌⧊໬ᆺ㑇ఏᏊᑟධ࢟ࣕࣜ࢔ࡢ㛤Ⓨ㸸⸆ရືែไᚚᏛ
㛗ᓮ኱Ꮫ་Ꮫ㒊⸆๣㒊࣭ᩍᤵ బࠎᮌᆒ
࣭࢔ࢹࣀ࢘࢖ࣝࢫ࣋ࢡࢱ࣮ࡢච␿ᛂ⟅ไᚚ໬㸸⸆ရືែไᚚᏛ
㸦⊂㸧་⸆ᇶ┙◊✲ᡤ࣭ࣉࣟࢪ࢙ࢡࢺ࣮ࣜࢲ࣮ Ỉཱྀ⿱அ
࣭㧗ศᏊ࣑ࢭࣝ〇๣࡟ࡼࡿᨺฟไᚚἲࡢ㛤Ⓨ㸸⸆ရືែไᚚᏛ
㸦㈈㸧⚄ዉᕝ⛉Ꮫᢏ⾡࢔࢝ࢹ࣑࣮࣭ࣉࣟࢪ࢙ࢡࢺ࣮ࣜࢲ࣮ ᶓᒣᫀᖾ
࣭⸆≀ືែ≉ᛶࡢྍど໬ࢹ࣮ࢱ࣐࢖ࢽࣥࢢ
࠾ⲔࡢỈዪᏊ኱Ꮫ⌮Ꮫ㒊࣭෸ᩍᤵ ఀ⸨㈗அ
࣭⢾ಟ㣭ࢱࣥࣃࢡ㉁ࡢ㹂㹂㹑ホ౯㸸⸆ရືែไᚚᏛ
⇃ᮏ኱Ꮫ⸆Ꮫ㒊࣭ᩍᤵ ᑠ⏣ษඃᶞ
࣭యෆᇙ㎸ᆺ࣐࢖ࢡࣟࢹࣂ࢖ࢫࢆ⏝࠸ࡓ⤌⧊ᢲ᰾㓟ᑟධἲࡢ᳨ウ㸸⸆ရືែไᚚᏛ
❧࿨㤋኱Ꮫ⌮ᕤᏛ㒊࣭ᩍᤵ ᑠす ⪽
࣭⢾㙐ಟ㣭⬡㉁ࡢ㛤Ⓨ࡜㹂㹂㹑ᒎ㛤㸸⸆ရືែไᚚᏛ
ᒱ㜧኱Ꮫᛂ⏝⏕≀⛉Ꮫ㒊࣭ᩍᤵ ᮌ᭮ ┿
࣭⢾㙐ಟ㣭ࣂࣈ࣏ࣝࣜࢯ࣮࣒ࡢ㛤Ⓨ㸸⸆ရືែไᚚᏛ
ᖇி኱Ꮫ⸆Ꮫ㒊࣭ᩍᤵ ୸ᒣ୍㞝
࣭࣮࢝࣎ࣥࢼࣀࢳ࣮ࣗࣈࡢ㹂㹂㹑ᛂ⏝㸸⸆ရືែไᚚᏛ
ி㒔኱ᏛᕤᏛ◊✲⛉࣭ᩍᤵ ௒ᇼ༤
࣭࣮࢝࣎ࣥࢼࣀࢳ࣮ࣗࣈࢆ⏝࠸ࡓග⥺ ⇕⒪ἲࡢ㛤Ⓨ㸸⸆ရືែไᚚᏛ
ி㒔኱Ꮫ≀㉁̿⣽⬊⤫ྜࢩࢫࢸ࣒ᣐⅬ࣭ຓᩍ ᮧୖ㐩ஓ
࣭ࢹࣥࢻ࣐࣮ࣜࢆ⏝࠸ࡓ᰾㓟㹂㹂㹑㛤Ⓨ㸸⸆ရືែไᚚᏛ
஑ᕞ኱ᏛᕤᏛ◊✲⛉࣭෸ᩍᤵ ᪂␃⌶㑻
࣭་⸆ရࡢ㐺ṇ౑⏝࡟㛵ࡍࡿ◊✲㸸⮫ᗋ⸆Ꮫᩍ⫱
ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔⸆๣㒊
࣭ᢠ࡚ࢇ࠿ࢇ⸆ࡢయෆືែ࡜⸆ຠࡢಶேᕪ࡟㛵ࡍࡿ◊✲㸸⮫ᗋ⸆Ꮫᩍ⫱
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉⮫ᗋ⚄⤒Ꮫ
࣭ච␿ᢚไ๣ࡢಶูᢞ୚タィ࡟㛵ࡍࡿ◊✲㸸⮫ᗋ⸆Ꮫᩍ⫱
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉⫢⫹⮅࣭⛣᳜እ⛉
࣭ᢠࡀࢇ๣ࡢ⸆≀ືែ࡜ࣇ࢓࣮࣐ࢥࢤࣀ࣑ࢡࢫ࡟㛵ࡍࡿ◊✲㸸⮫ᗋ⸆Ꮫᩍ⫱
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ங⭢እ⛉
࣭࣡ࣝࣇ࢓ࣜࣥࡢ㐺ṇ౑⏝࡟㛵ࡍࡿ◊✲㸸⮫ᗋ⸆Ꮫᩍ⫱
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ᚠ⎔ჾෆ⛉
࣭ࣞࢽ࣒࢘ ᶆ㆑໬ྜ≀ࡢ᪂つ㛤Ⓨ㸸⑓ែᶵ⬟ศᯒᏛ
᪥ᮏཎᏊຊ◊✲㛤Ⓨᶵᵓ
− 171 −
࣭᰾་Ꮫデ᩿⸆ࡢ㛤Ⓨ◊✲ࠊศᏊ࢖࣓࣮ࢪࣥࢢ◊✲㸸⑓ែᶵ⬟ศᯒᏛ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉
࣭ࢱࣥࣃࢡ㉁ࠊ࣌ࣉࢳࢻᶆ㆑ᨺᑕᛶ⸆ရࡢ㛤Ⓨ◊✲㸸⑓ែᶵ⬟ศᯒᏛ
༓ⴥ኱Ꮫ⸆Ꮫ◊✲㝔
࣭ศᏊ࢖࣓࣮ࢪࣥࢢ◊✲㸸⑓ែᶵ⬟ศᯒᏛ
⚟஭኱Ꮫ㧗࢚ࢿࣝࢠ࣮་Ꮫ◊✲ࢭࣥࢱ࣮
࣭ș࢔࣑ࣟ࢖ࢻ࢖࣓࣮ࢪࣥࢢศᏊࣉ࣮ࣟࣈࡢ⸆๣タィ㸸⑓ែᶵ⬟ศᯒᏛ
㛗ᓮ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
࣭⭘⒆ቑṪ⬟ࠊ⾑ᰦデ᩿ࡢࡓࡵࡢᨺᑕᛶ⸆๣ࡢ㛤Ⓨ◊✲㸸⑓ែᶵ⬟ศᯒᏛ
໭ᾏ㐨኱Ꮫ࢔࢖ࢯࢺ࣮ࣉ⥲ྜࢭࣥࢱ࣮
ᅜ❧ᚠ⎔ჾ⑓ࢭࣥࢱ࣮
࣭ࢱࣥࣃࢡ㉁ᶆ㆑ᨺᑕᛶ⸆ရࡢ㛤Ⓨ◊✲㸸⑓ែᶵ⬟ศᯒᏛ
὾ᯇ་⛉኱Ꮫග㔞Ꮚ་Ꮫ◊✲ࢭࣥࢱ࣮
࣭ෆ⏝ᨺᑕᛶ἞⒪⸆ࡢ㛤Ⓨ◊✲㸸⑓ែᶵ⬟ศᯒᏛ
㔠ἑ኱ᏛᏛ㝿⛉Ꮫᐇ㦂ࢭࣥࢱ࣮
࣭ࢱࣥࣃࢡ㉁ࠊ࣌ࣉࢳࢻᶆ㆑ᨺᑕᛶ⸆ရࡢ㛤Ⓨ◊✲㸸⑓ែᶵ⬟ศᯒᏛ
஑ᕞ኱Ꮫ⸆Ꮫ◊✲㝔
࣭& ᆺ⫢⅖࢘࢖ࣝࢫࢆᶆⓗ࡜ࡋࡓ࢖ࣥࢱ࣮ࣇ࢙ࣟࣥ㑇ఏᏊ἞⒪ἲࡢ㛤Ⓨ㸸⑓ែ᝟ሗ⸆Ꮫ
ᗈᓥ኱Ꮫ኱Ꮫ㝔་ṑ⸆Ꮫ⥲ྜ◊✲⛉ ࣭⣒⌫య⭈⅖἞⒪ἲࡢ㛤Ⓨ࡟㛵ࡍࡿ◊✲㸸⑓ែ᝟ሗ⸆Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ ࣭࢔ࢺࣆ࣮ᛶ⓶⭵⅖࡟ᑐࡍࡿ࢖ࣥࢱ࣮ࣇ࢙ࣟࣥ㑇ఏᏊ἞⒪◊✲㸸⑓ែ᝟ሗ⸆Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ ࣭࢖ࣥࢱ࣮ࣇ࢙ࣟࣥ㑇ఏᏊ἞⒪࡟࠾ࡅࡿ ,'2 ࡢ㛵୚࡟㛵ࡍࡿ◊✲㸸⑓ែ᝟ሗ⸆Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ ࣭ྜᡂᑠศᏊ࡟ࡼࡿ⣽⬊⏕Ꮡࡢᨵၿ࡟㛵ࡍࡿ◊✲㸸⑓ែ᝟ሗ⸆Ꮫ
ி㒔኱Ꮫ໬Ꮫ◊✲ᡤ ࣭⮚ჾ⛣᳜ᝈ⪅࡟࠾ࡅࡿᑠ⭠ 3⢾⺮ⓑ㉁ࠊ&<3$ 㑇ఏᏊⓎ⌧᝟ሗ࡜ࢱࢡ࣒ࣟࣜࢫయෆືែ࡟㛵ࡍࡿ
◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉⛣᳜ච␿་Ꮫ
࣭ච␿ᢚไ๣ࡢಶูᢞ୚タィ࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉⛣᳜ච␿་Ꮫ
࣭᭷ᶵ࢔ࢽ࢜ࣥࢺࣛࣥࢫ࣏࣮ࢱࡢᵓ㐀࣭ᶵ⬟࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ᮾ໭኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ศᏊ⾑⟶⑓ែᏛ
࣭⸆๣᤼ἥࢱࣥࣃࢡ㉁⩌ࡢⓎ⌧ኚື࡜㑇ఏᏊከᆺ࣭ኚ␗ゎᯒ࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ᚨᓥ኱Ꮫ་Ꮫ㒊⮫ᗋ᳨ᰝ་Ꮫ
− 172 −
࣭ຍ㱋࣭⸆๣ᛶ⭈㞀ᐖ࡟క࠺⸆๣᤼ἥࢱࣥࣃࢡ㉁ࡢච␿⤌⧊Ꮫⓗゎᯒ࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔ேᕤ⭈⮚㒊
࣭⭈୙඲࣭⭈⭘⒆࡟࠾ࡅࡿ⸆๣᤼ἥࢱࣥࣃࢡ㉁⩌ࡢ㑇ఏᏊⓎ⌧ゎᯒ㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉Ἢᒀჾ⑓ែᏛ
࣭ᾘ໬⟶⭘⒆࡟࠾ࡅࡿ⸆≀ࢺࣛࣥࢫ࣏࣮ࢱ⩌ࡢ㑇ఏᏊⓎ⌧ゎᯒ㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ᾘ໬⟶እ⛉Ꮫࠊ⫢⫹⮅࣭⛣᳜እ⛉Ꮫ
࣭⤒ཱྀᢠࡀࢇ๣ࢆ⏝࠸ࡓ໬Ꮫ⒪ἲࡢᏳ඲ᛶ࣭᭷ຠᛶࡢྥୖࢆ┠ᣦࡋࡓ⸆≀ືែཬࡧ⸆⌮ࢤࣀ࣒ゎᯒ࡟
㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉࿧྾ჾෆ⛉Ꮫࠊங⭢እ⛉ᏛࠊἪᒀჾ⛉Ꮫࠊ⫢⫹⮅࣭⛣᳜እ⛉Ꮫࠊᾘ໬ჾෆ
⛉Ꮫࠊ་Ꮫ㒊㝃ᒓ⑓㝔እ᮶໬Ꮫ⒪ἲ㒊
࣭⫢⣽⬊ቑṪᅉᏊࡢయෆືែ࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔᥈⣴་⒪ࢭࣥࢱ࣮᥈⣴་⒪㛤Ⓨ㒊
࣭࣓ࢺ࣑࣍ࣝࣥࡢయෆືែ࡜⸆ຠ࣭ẘᛶ࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉⢾ᒀ⑓࣭ᰤ㣴ෆ⛉Ꮫ
࣭E)*) ྵ᭷ࢮࣛࢳࣥࣁ࢖ࢻࣟࢤࣝ࡟ࡼࡿ⹫⾑ୗ⫥࡟ᑐࡍࡿ⾑⟶᪂⏕⒪ἲ࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ་Ꮫ◊✲⛉ᚰ⮚⾑⟶እ⛉Ꮫࠊி㒔኱Ꮫ෌⏕་⛉Ꮫ◊✲ᡤࠊி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔᥈⣴་⒪
ࢭࣥࢱ࣮
࣭ᛴᛶ㧗ᗘ㞴⫈࡟ᑐࡍࡿෆ⪥ ,*) ᢞ୚ࡢ᭷ຠᛶ࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ་Ꮫ◊✲⛉⪥㰯ဗႃ⛉࣭㢌㢕㒊እ⛉Ꮫࠊி㒔኱Ꮫ෌⏕་⛉Ꮫ◊✲ᡤࠊி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓
㝔᥈⣴་⒪ࢭࣥࢱ࣮
࣭ࢱࢡ࣒ࣟࣜࢫࡢࢡ࣮ࣟࣥ⑓࡟ᑐࡍࡿຠᯝ࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ་Ꮫ◊✲⛉ᾘ໬ჾෆ⛉Ꮫ
࣭඲㌟ᛶᙉ⓶⑕ᾘ໬⟶㞀ᐖ࡟ᑐࡍࡿࢢࣞࣜࣥࡢ⮫ᗋຠᯝ࡟㛵ࡍࡿ◊✲㸸་⒪⸆๣Ꮫ
ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔᥈⣴་⒪ࢭࣥࢱ࣮
࣭᪂つ⏕⌮άᛶኳ↛᭷ᶵศᏊࡢࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮࡟㛵ࡍࡿ◊✲㸸ไᚚศᏊᏛ
⊂❧⾜ᨻἲே⌮໬Ꮫ◊✲ᡤ 㛗⏣⿱அ ༤ኈ
ᮾி኱Ꮫ኱Ꮫ㝔㎰Ꮫ⏕࿨⛉Ꮫ◊✲⛉ ᯇỌⱱᶞ ᩍᤵ
ᮾி⌮⛉኱Ꮫᕤᴗ㒊 ᯘ㞝஧㑻 ᩍᤵ
ᮾிᕤᴗ኱Ꮫ኱Ꮫ㝔⌮ᕤᏛ◊✲⛉ 㕥ᮌၨ௓ ᩍᤵ
ᮾிᕤᴗ኱Ꮫ⏕࿨⌮ᕤᏛ◊✲⛉ 㛵᰿ග㞝 ᩍᤵ
࣭ᚰ⑌ᝈ἞⒪⸆㛤Ⓨ࡟㛵ࡍࡿࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲㸸ไᚚศᏊᏛ
ᅜ❧⑓㝔ᶵᵓி㒔་⒪ࢭࣥࢱ࣮ 㛗㇂ᕝᾈ஧ ༤ኈ
㟼ᒸ┴❧኱Ꮫ⸆Ꮫ㒊 ᳃ᮏ㐩ஓ ᩍᤵ
࣭ឤᰁ⑕἞⒪⸆㛤Ⓨ࡟㛵ࡍࡿࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲㸸ไᚚศᏊᏛ
὾ᯇ་⛉኱Ꮫ་Ꮫ㒊 㕥ᮌဴᮁ ᩍᤵ
࣭⬡㉁⭷స⏝≀㉁ࡢస⏝ᶵᗎゎᯒ࡟㛵ࡍࡿ◊✲㸸ไᚚศᏊᏛ
− 173 −
኱㜰኱Ꮫ኱Ꮫ㝔⌮Ꮫ◊✲⛉ ᮧ⏣㐨㞝 ᩍᤵ
࣭࢔࣑ࣀ࣌ࣉࢳࢲ࣮ࢮࡢᶵ⬟࡟㛵ࡍࡿ◊✲㸸ไᚚศᏊᏛ
⊂❧⾜ᨻἲே⌮໬Ꮫ◊✲ᡤ㸦⌧࣭ᖹᡂᖇி኱Ꮫ㸧㎷ᮏ㞞ᩥ ༤ኈ
࣭ࣇࣛࢢ࣓ࣥࢺศᏊ㌶㐨ἲࡢ㛤Ⓨ࡟㛵ࡍࡿ◊✲㸸๰⸆ィ⟬໬Ꮫ
⏘ᴗᢏ⾡⥲ྜ◊✲ᡤ ࣭ࣇࣛࢢ࣓ࣥࢺศᏊ㌶㐨ἲࡢ㧗㏿໬࡟㛵ࡍࡿ◊✲㸸๰⸆ィ⟬໬Ꮫ
ศᏊ⛉Ꮫ◊✲ᡤ ࣭࢖ࣥࢩࣜࢥࢻࣛࢵࢢࢹࢨ࢖ࣥᡭἲࡢ㛤Ⓨ࡟㛵ࡍࡿ◊✲㸸๰⸆ィ⟬໬Ꮫ
㏆␥኱Ꮫ ࣭ࢤࣀ࣒᝟ሗ࡟ᇶ࡙ࡃ࢔ࣈ࣒ࣛࢩࡢࣃࢫ࢙࢘࢖෌ᵓ⠏㸸⤫ྜࢤࣀ࣑ࢡࢫ
ᇶ♏⏕≀Ꮫ◊✲ᡤ ࣭㧗⢭ᗘ࢖ࢿ࢔ࣀࢸ࣮ࢩࣙࣥ᝟ሗࢆ฼⏝ࡋࡓ࢖ࢿ௦ㅰ⤒㊰ᵓ⠏㸸⤫ྜࢤࣀ࣑ࢡࢫ
㎰ᴗ⏕≀㈨※◊✲ᡤ ࣭࢔࣐࢝ࢶᯘࡢ೺඲ᛶホ౯㸸⤫ྜࢤࣀ࣑ࢡࢫ
ி㒔኱Ꮫ⏕Ꮡᅪ◊✲ᡤ ࣭࢝ࣝࣃ࢖ࣥᇶ㉁ࢹ࣮ࢱ࣮࣋ࢫࡢᵓ⠏ࠊ࢝ࣝࣃ࢖ࣥᇶ㉁ษ᩿㒊఩ண ᡭἲࡢ☜❧࡟㛵ࡍࡿ◊✲㸸ศᏊ
タィ᝟ሗ
ᮾி㒔⮫ᗋ་Ꮫ⥲ྜ◊✲ᡤ ࣭㓄ิୖࡢ཯᚟㒊఩ࡸ㢖ฟ㒊఩ࡢຠ⋡ⓗⓎぢ࡟㛵ࡍࡿ◊✲㸸ศᏊタィ᝟ሗ
໭ᾏ㐨኱Ꮫ᝟ሗ⛉Ꮫ◊✲⛉ ࣭໬ྜ≀໬Ꮫᵓ㐀ᘧࡸ㓄ิ➼ࡢ༙ᵓ㐀໬ࢹ࣮ࢱ࠿ࡽࡢಖᏑ㒊఩ࡢຠ⋡ⓗ࡞Ⓨぢᡭἲ࡟㛵ࡍࡿ◊✲㸸ศ
Ꮚタィ᝟ሗ
⏘ᴗᢏ⾡⥲ྜ◊✲ᡤ⏕࿨᝟ሗᕤᏛࢭࣥࢱ࣮ ࣭0+& ⤖ྜ࣌ࣉࢳࢻࡢ⥙⨶ⓗண ᡭἲ࡟㛵ࡍࡿ◊✲㸸ศᏊタィ᝟ሗ
㧗▱኱Ꮫ་Ꮫ◊✲⛉ − 174 −
◊✲ᴗ⦼┠㘓
⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊ᩍဨ୍ぴ 㸦ᖹᡂ㸰㸱ᖺ㸰᭶⌧ᅾ㸧
⸆ရ᭷ᶵ〇㐀Ꮫศ㔝
ᩍᤵ
⸨஭ಙᏕ
෸ᩍᤵ኱㔝ᾈ❶
ㅮᖌ
኱▼┿ஓ
⸆ရྜᡂ໬Ꮫศ㔝
෸ᩍᤵ ᒣ⏣ ೺୍
⸆ရศᏊ໬Ꮫศ㔝
ᩍᤵ
➉ᮏెྖ
෸ᩍᤵ 㧗㡲 Ύㄔ
ຓᩍ
ሯ㔝 ༓ᑜ
⸆ရ㈨※Ꮫศ㔝
෸ᩍᤵ ఀ⸨⨾༓✑
⸆ရᶵ⬟ゎᯒᏛศ㔝
ᩍᤵ
෸ᩍᤵ ᫍ㔝 ኱
ຓᩍ
▮㔝⩏᫂
ᵓ㐀⏕≀⸆Ꮫศ㔝
ᩍᤵ
ຍ⸨༤❶
෸ᩍᤵ ୰ὠ ஽
ຓᩍ
ᒣཱྀ▱ᏹ
ࢤࣀ࣒๰⸆⛉Ꮫศ㔝
ᩍᤵ
㎷ᮏ㇦୕
෸ᩍᤵ ᖹ⃝ ᫂
ຓᩍ
ᮌᮧ 㑳ኵ
〇๣ᶵ⬟ゎᯒᏛศ㔝
ᩍᤵ
▼℈ Ὀ
෸ᩍᤵ ୰㔝 ᐇ
ᯇᓮ຾ᕭ
− 175 −
⢭ᐦ᭷ᶵྜᡂศ㔝
ᩍᤵ
ᕝ➃⊛ኵ
෸ᩍᤵ ྂ⏣ ᕦ
ຓᩍ
ྜྷᮧ ᬛஅ
⏕యศᏊㄆ㆑Ꮫศ㔝
ᩍᤵ
➉ᓥ ᾈ
෸ᩍᤵ ᰠ⃝ ᫀ
ຓᩍ
ᒣᮏ ఙ୍㑻
ຓᩍ
ᒣᓮ ኱ᶞ
ศᏊᚤ⏕≀Ꮫศ㔝
෸ᩍᤵ Ώ㒊ዲᙪ
⏕యᶵ⬟ゎᯒᏛศ㔝
ᩍᤵ
෸ᩍᤵ ୰ᕝ㈗அ
ຓᩍ
ⓑᕝஂᚿ
㑇ఏᏊ⸆Ꮫศ㔝
ᩍᤵ
ఀ⸨ಙ⾜
ㅮᖌ
୕Ꮿ Ṍ
ຓᩍ ᒣෆ ⫕
㔠Ꮚ࿘ྖ
⏕⌮άᛶไᚚᏛศ㔝
ᩍᤵ
ᑠሐಖ๎
෸ᩍᤵ ➉ᯇ ᘯ
ຓᩍ
⏕య᝟ሗไᚚᏛศ㔝
ᩍᤵ ୰ᒣ࿴ஂ
ຓᩍ ຍ⸨ ὒᖹ
ෆ⸨ ⿱Ꮚ
⚄⤒ᶵ⬟ไᚚᏛศ㔝
ᩍᤵ ᰿ᓊ Ꮫ
෸ᩍᤵ ຍ⸨⿱ᩍ
ຓᩍ
− 176 −
⏕἟ Ἠ
⏕యᶵ⬟໬Ꮫศ㔝
ᩍᤵ
஧ᮌྐᮁ
ຓᩍ ௒すᮍ᮶
ຓᩍ ୰℩ ⏕ᙪ
⸆ရືែไᚚᏛศ㔝
ᩍᤵ
ᶫ⏣ ඘
෸ᩍᤵ ᒣୗᐩ⩏
ㅮᖌ
ᕝୖ ⱱ
⸆ရస⏝ゎᯒᏛศ㔝
ᩍᤵ
㉥ụ᫛⣖
෸ᩍᤵ ஂ⡿ ฼᫂
ຓᩍ
Ἠ Ᏻᙪ
⮫ᗋ⸆Ꮫᩍ⫱ศ㔝
෸ᩍᤵ ▮㔝 ⫱Ꮚ
⑓ែᶵ⬟ศᯒᏛศ㔝
ᩍᤵ
బ἞ⱥ㑻
෸ᩍᤵ ᑠ㔝 ṇ༤
ຓᩍ
≉ᐃຓᩍ
ኳ⁹ ᩗ
బ㔝 ⣫ᖹ
⑓ែ᝟ሗ⸆Ꮫศ㔝
ᩍᤵ
㧗಴႐ಙ
෸ᩍᤵ すᕝඖஓ
ຓᩍ
㧗ᶫ ᭷ᕫ
་⒪⸆๣Ꮫศ㔝
෸ᩍᤵ ᱇ ᩄஓ
ㅮᖌ
ቑ⏣ᬛඛ
ຓᩍ
ᮏᶫ⚽அ
ຓᩍ
⡿⃝ ῟
ຓᩍ ⚟ኈ ᑗ⚽
− 177 −
ࠪࠬ࠹ࡓࡃࠗࠝࡠࠫ࡯ಽ㊁
ᢎ᝼
ጟ᧛ ဋ
ಎᢎ᝼ ࿯ዬ 㓷ᄦ
ഥᢎ
ጊญ ⾐┨
ࠪࠬ࠹ࡓࠤࡕ࠮࡜ࡇ࡯
ᢎ᝼
ដ⼱ ⑲ᤘ
㧔೙ᓮಽሶቇ㧕ಽ㊁
ಎᢎ᝼ ᦯ㇱ ᣿
ഥᢎ
⷏᧛ ᘕ৻
ࠪࠬ࠹ࡓࠤࡕ࠮࡜ࡇ࡯
ᢎ᝼
ർᶆ๺ᄦ
㧔ഃ⮎⸘▚ൻቇ㧕ಽ㊁
⛔วࠥࡁࡒࠢࠬಽ㊁
ᢎ᝼ ㊄ਭ ኪ
ಎᢎ᝼ ੖᢯ ㅴ
․ቯഥᢎ ᤨ᧻ ᢅ᣿
․ቯഥᢎ ዊኹ ᱜ᣿
ಽሶ⸳⸘ᖱႎቇಽ㊁
ᢎ᝼
ഥᢎ ἏᎹ ৻ቇ
ഥᢎ ᔒ⾐ ర♿
㚍⷗Ⴆ ᜏ
࠽ࡁࡃࠗࠝක⮎ഃᚑ⑼ቇ⻠ᐳ ቴຬᢎ᝼ ᷡ᳓ ৻ᴦ
․ቯಎᢎ᝼ ૒⮮ ผ㗼
․ቯഥᢎ ࿯ደ ഃஜ
ࠪࠬ࠹ࡓഃ⮎⑼ቇ⻠ᐳ
․ቯᢎ᝼ ᅏ㊁ ᕶผ
․ቯಎᢎ᝼ἑᧁ ᕺ㉿
․ቯഥᢎ ᣂፉ ⡡
ഃ⮎␹⚻⑼ቇ⻠ᐳ㧔ᐔᚑ ᐕ ᦬⚳ੌ㧕
ක⮎ຠℂ⺰⸳⸘ቇ⻠ᐳ㧔ᐔᚑ ᐕ ᦬⚳ੌ㧕
⛔ว⮎ቇᢎ⢒㐿⊒࠮ࡦ࠲࡯
ᢎ᝼
− 178 −
ᩕ↰ ᢅਯ
⸆ရ᭷ᶵ〇㐀Ꮫศ㔝ࢣࣔࢤࣀ࣑ࢡࢫศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧⸨஭ ಙᏕ㸦ࡩࡌ࠸ ࡢࡪࡓ࠿㸧
᫛࿴㸲㸶ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸳㸯ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬
୰㏥
෸ᩍᤵ㸦⸆Ꮫ༤ኈ㸧኱㔝 ᾈ❶㸦࠾࠾ࡢ ࡦࢁ࠶ࡁ㸧
ᖹᡂ㸶ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸯ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬୰㏥
ㅮ ᖌ㸦⸆Ꮫ༤ኈ㸧኱▼ ┿ஓ㸦࠾࠾࠸ࡋ ࡋࢇࡸ㸧
ᖹᡂ㸯㸮ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸳ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ
஢
◊✲ࡢᴫせ
ᙜ⸆ရ᭷ᶵ〇㐀Ꮫศ㔝㸭ࢣࣔࢤࣀ࣑ࢡࢫศ㔝ࡣࠊ๰⸆ࢆぢᤣ࠼ࡓ࣌ࣉࢳࢻ/ࢱࣥࣃࢡ㉁໬Ꮫ࣭᭷ᶵ໬Ꮫ
࡜ࡇࢀࡽࢆᇶ┙࡟ࡋࡓ⏕≀᭷ᶵ໬Ꮫ◊✲࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋࡇࢀࡽࡢ◊✲ࢆ㏻ࡋ࡚ࠊ་⸆ရ໬Ꮫ࣭ྜᡂ
໬Ꮫ࣭⏕໬Ꮫࡢ⼥ྜⓗ᪼⳹࡟ࡼࡿ᪂ࡋ࠸Ꮫ㝿㡿ᇦࡢ㛤ᣅࢆᐇ⌧ࡍࡿேᮦࡢ⫱ᡂ࡟ᑾຊࡋ࡚࠸ࡿࠋ
GPCR ࢆᶆⓗ࡜ࡍࡿ๰⸆◊✲
ᙜ◊✲ᐊ࡛ࡣୡ⏺࡟ඛ㥑ࡅ࡚ HIV ࢘࢖ࣝࢫࡢ➨஧ཷᐜయ࡜ࡋ࡚ᶵ⬟ࡍࡿ GPCR ࡛࠶ࡿ CXCR4 ࡟
ᑐࡍࡿ㑅ᢥⓗᣕᢠ๣ࢆぢฟࡋ࡚࠸ࡿࠋ㏆ᖺࠊSDF-1/CXCR4 ࡀ⭘⒆ࡢ⮚ჾ≉␗ⓗ㌿⛣࡜ᐦ᥋࡟㛵ࢃ
ࡿࡇ࡜ࡀሗ࿌ࡉࢀࠊ㌿⛣ᛶ⭘⒆ࡢ≉␗ⓗ᳨ฟࢆྍ⬟࡟ࡍࡿྛ✀ CXCR4 ཷᐜయ≉␗ⓗࣉ࣮ࣟࣈࡢ㛤
Ⓨ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓࠊGPR54 ࢆᶆⓗ࡜ࡍࡿ࢟ࢫ࣌ࣉࢳࣥ࠾ࡼࡧ㢮⦕ࡢ⚄⤒࣌ࣉࢳࢻ㢮ࡢᵓ㐀
άᛶ┦㛵◊✲ࢆ㏻ࡋ࡚⏕ṪෆศἪ࣍ࣝࣔࣥࡢศἪㄪ⠇࡟㛵ࢃࡿࣜ࢞ࣥࢻ࣭ཷᐜయࡢྠᐃࢆヨࡳࡿ࡜
࡜ࡶ࡟ࠊᛶ࣍ࣝࣔࣥศἪ␗ᖖ࡟㉳ᅉࡍࡿྛ✀⑌ᝈ࡟ᑐࡍࡿ἞⒪⸆㛤Ⓨ◊✲ࢆᐇ᪋ࡋ࡚࠸ࡿࠋ
᪂つ」⣲⎔㦵᱁ᵓ⠏ἲࡢ㛤Ⓨ࡜๰⸆ࢸࣥࣉ࣮ࣞࢺ࡬ࡢᛂ⏝
⎔ቃ㐺ᛂᆺ᭷ᶵྜᡂࡀᙉࡃᮃࡲࢀࡿ௒᪥ࠊ⏕≀άᛶ໬ྜ≀࡟Ꮡᅾࡍࡿ」㞧࡞」⣲⎔㦵᱁ࢆ୍ᣲ࡟
ᵓ⠏ࡍࡿ᪉ἲㄽࡢ㛤Ⓨࡣᴟࡵ࡚㔜せ࡞◊✲ㄢ㢟࡛࠶ࡿࠋᙜ◊✲ᐊ࡛ࡣࠊ୙㣬࿴Ⅳ⣲࡜㑄⛣㔠ᒓ➼ࡢ
᪂ࡋ࠸཯ᛂᛶࢆ㛤ᣅࡋ࡞ࡀࡽࠊ」ᩘࡢ⤖ྜࢆ㐃⥆ⓗ࡟⏕ᡂࡋ࡚」⣲⎔㦵᱁ࢆ୍ᣲ࡟ᵓ⠏࡛ࡁࡿ཯ᛂ
ࡢ㛤Ⓨࢆ⾜࠸ࠊ᪂つ㦵᱁๰ฟࡸ๰⸆◊✲࡬ࡢᒎ㛤ࢆ┠ᣦࡋ࡚࠸ࡿࠋ
᪂つ࣌ࣉࢳࢻྜᡂᢏ⾡ࡢ㛤Ⓨ࡜⏕≀άᛶ࣌ࣉࢳࢻྜᡂ࡬ࡢᛂ⏝
㑇ఏᏊ⤌ࡳ᥮࠼ᢏ⾡ࡀ㧗ᗘ࡟Ⓨᒎࡋࡓ⌧ᅾ࡟࠾࠸࡚ࡶࠊ␗ᖖ࢔࣑ࣀ㓟ࡸ N-࣓ࢳࣝ࢔࣑ࣀ㓟ࢆྵࡴ
࣌ࣉࢳࢻࡢྜᡂࡸࠊ⏕≀άᛶ࣌ࣉࢳࢻࡢᵓ㐀άᛶ┦㛵◊✲ࢆ⾜࠺ୖ࡛ࠊ࣌ࣉࢳࢻࡢ໬Ꮫྜᡂᢏ⾡ࡢ
㛤Ⓨࡣᴟࡵ࡚㔜せ࡛࠶ࡿࠋᙜ◊✲ᐊ࡛ࡣࠊ㛗㙐࣌ࣉࢳࢻࡸ⎔≧࣌ࣉࢳࢻࡢྜᡂ࡟㐺ᛂ࡛ࡁࡿ⊂⮬ࡢ
࣌ࣉࢳࢻྜᡂἲࡢ㛤Ⓨ࡜⏕≀άᛶ࣌ࣉࢳࢻྜᡂ࡬ࡢᒎ㛤ࢆ⾜ࡗ࡚࠸ࡿࠋ
࣌ࣉࢳࢻ࣭࣌ࣉࢳࢻ㢮⥳యࢆࣉ࣮ࣟࣈ࡜ࡍࡿࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲
⏕⌮άᛶ࣌ࣉࢳࢻࢆᨵኚ࣭ಟ㣭ࡋࡓྛ✀ㄏᑟయࡣࠊศᏊࣉ࣮ࣟࣈ࡜ࡋ࡚๰⸆ᶆⓗࡢ᥈⣴ࡸ⏕యᶵ
⬟ࡢゎ᫂࡟⏝࠸ࡿࡇ࡜ࡀྍ⬟࡛࠶ࡿࠋᙜ◊✲ᐊ࡛ࡣࠊ᭷ᶵྜᡂ໬Ꮫᢏ⾡࡟ࡼࡾࡉࡲࡊࡲ࡞࣌ࣉࢳࢻ
➼౯యࡢࢹࢨ࢖࣭ࣥྜᡂࢆ⾜࠸ࠊ⏕⌮άᛶ࣌ࣉࢳࢻࡢᵓ㐀άᛶ┦㛵◊✲࡟ᛂ⏝ࡍࡿ࡜࡜ࡶ࡟ࠊ㛤Ⓨ
ࡋࡓࣉ࣮ࣟࣈศᏊࢆά⏝ࡋࡓ⏕యᶵ⬟ゎᯒ◊✲ࡸ᪂つࢫࢡ࣮ࣜࢽࣥࢢ⣔ࡢ㛤Ⓨ࡟ࡼࡿ๰⸆ࢩ࣮ࢬ
᥈⣴◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ
⏕≀άᛶኳ↛≀ࡢྜᡂ◊✲࡜๰⸆ᒎ㛤
ୖグ࣌ࣉࢳࢻྜᡂ◊✲࡜᪂つ」⣲⎔㦵᱁ᵓ⠏ἲ࡟㛵ࡍࡿ◊✲ᡂᯝࢆᇶ┙࡜ࡋ࡚ࠊ࣌ࣉࢳࢻᛶ࠾ࡼ
ࡧ」⣲⎔⣔⏕≀άᛶኳ↛≀ࡢྜᡂ◊✲࡜๰⸆ᒎ㛤ࢆ⾜ࡗ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
⸨஭ᩍᤵࡀ᫛࿴㸳㸵ᖺ᪥ᮏ⸆Ꮫ఍ዡບ㈹ࠊ኱㔝෸ᩍᤵࡀᖹᡂ㸯㸵ᖺ᪥ᮏ⸆Ꮫ఍ዡບ㈹ࠊ኱▼ㅮᖌࡀᖹ
ᡂ㸰㸯ᖺ᪥ᮏ⸆Ꮫ఍ዡບ㈹ࢆཷ㈹ࡋࡓࠋᙜ◊✲ᐊฟ㌟⪅࣭ᩍဨ࠿ࡽࡣ㐣ཤ㸯㸳ᖺ㛫࡟㸶ேࡢ᪥ᮏ⸆Ꮫ఍
ዡບ㈹ཷ㈹⪅ࢆ㍮ฟࡋࡓࡇ࡜ࡣࠊ⸆Ꮫ◊✲࡟࠾ࡅࡿᙜ◊✲ᐊࡢ◊✲ࣞ࣋ࣝࡢ㧗ࡉࢆ♧ࡋ࡚࠸ࡿࠋࡉࡽ࡟
᭱㏆㸳ᖺ㛫ࡢᅾ⡠Ꮫ⏕ࡢ࠺ࡕࠊ㸯㸴ேࡢ༤ኈㄢ⛬Ꮫ⏕ࡀ᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ࡜ࡋ࡚ά㌍ࡋࠊᖹᡂ
㸯㸷ᖺཬࡧ㸰㸯ᖺᗘ᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ዡບ㈹ࢆཷ㈹ࡍࡿ࡞࡝ࠊᡤᒓᏛ⏕ࡢ◊✲ᡂᯝࡀᴟࡵ࡚㧗ࡃホ౯
ࡉࢀ࡚࠸ࡿࠋ
GPCR ࢆᶆⓗ࡜ࡍࡿ๰⸆◊✲
CXCR4 ≉␗ⓗ⺯ගࣉ࣮ࣟࣈ࣭ᨺᑕάᛶࣉ࣮ࣟࣈࢆసᡂࡋࠊCXCR4 Ⓨ⌧⣽⬊ࡢ㧗ឤᗘ᳨ฟ⣔ࢆ☜
− 179 −
❧ࡋࡓࠋIn vitro ࢫࢡ࣮ࣜࢽࣥࢢ⣔࡬ࡢᛂ⏝࡜࡜ࡶ࡟ࠊin vivo ࣔࢹࣝ࡟ࡼࡾ⭘⒆⣽⬊᳨ฟࡢᐇ⏝ᛶࢆ
☜ㄆࡋࡓࠋ࢟ࢫ࣌ࣉࢳࣥ㢮ࡢᵓ㐀άᛶ┦㛵◊✲࡟ࡼࡾ GPR54 ཷᐜయ㑅ᢥⓗ࢔ࢦࢽࢫࢺࢆぢฟࡍ࡜
࡜ࡶ࡟ࠊ࣌ࣉࢳࢲ࣮ࢮ⪏ᛶ࣌ࣉࢳࢻ➼౯యࡢᛂ⏝࡟ࡼࡾ in vivo ࡟࠾࠸࡚ᣢ⥆ⓗ࡞ຠᯝࡀᮇᚅ࡛ࡁࡿ
᪂つ࢔ࢦࢽࢫࢺࢆྠᐃࡋࡓࠋ
᪂つ」⣲⎔㦵᱁ᵓ⠏ἲࡢ㛤Ⓨ࡜๰⸆ࢸࣥࣉ࣮ࣞࢺ࡬ࡢᛂ⏝
C-H ⤖ྜάᛶ໬ࡸከᡂศ཯ᛂ࡞࡝ࠊ㧗࠸ཎᏊຠ⋡ࢆ᭷ࡍࡿ⣲཯ᛂࢆ㐃⥆ⓗ࡟⾜࠺ᩘ✀ࡢ᪂つ཯ᛂ
ࡢ㛤Ⓨ࡟ᡂຌࡋࠊ࢝ࣝࣂࢰ࣮ࣝࡸș-࢝ࣝ࣎ࣜࣥㄏᑟయࢆྵࡴ⦰⎔ᆺ࢖ࣥࢻ࣮ࣝ㢮ࠊ⦰⎔ᆺ࢖ࢯ࢟ࣀ
ࣜࣥ㢮࡞࡝ࠊࢻࣛࢵࢢࣛ࢖ࢡ࡞ከ⎔ᘧ」⣲⎔㦵᱁ࡢ୍ᣲᵓ⠏࡟ᡂຌࡋࡓࠋࡲࡓࠊ࣊ࢸࣟࢡ࣒ࣞࣥࢆ
⏝࠸ࡓ㐃⥆ⓗồ᰾཯ᛂ㸫SNAr ཯ᛂࢆ㥑౑ࡋࡓᵓ㐀άᛶ┦㛵◊✲࡟ࡼࡾࠊᢠ࢘࢖ࣝࢫάᛶࢆ᭷ࡍࡿ⦰
⎔ᆺ࣋ࣥࢰࢳ࢔ࢪࣥㄏᑟయࢆぢฟࡋࡓࠋ
᪂つ࣌ࣉࢳࢻྜᡂᢏ⾡ࡢ㛤Ⓨ࡜⏕≀άᛶ࣌ࣉࢳࢻྜᡂ࡬ࡢᛂ⏝
⤌᥮࠼ᢏ⾡࡟ࡼࡾㄪ〇ࡉࢀࡿࢱࣥࣃࢡ㉁࣭࣌ࣉࢳࢻࡢ⏕≀άᛶࣇࣛࢢ࣓ࣥࢺࡢ୧ᮎ➃ഃ࡟ࠊ໬Ꮫ
ヨ⸆࡟ࡼࡾ≉␗ⓗ࡟ษ᩿ࡉࢀࡿࢪ࣌ࣉࢳࢻࣘࢽࢵࢺࢆᑟධࡋࠊ⏕యෆ࡛Ᏻᐃ࡞࢚ࣥࢻ࢟ࣕࢵࣉᵓ㐀
ࢆ࣌ࣉࢳࢻ୧ᮎ➃࡟௜ࡋࡓάᛶ࣌ࣉࢳࢻ᩿∦ࢆຠ⋡ⓗ࡟ᚓࡿ᪉ἲࢆ☜❧ࡋࡓࠋࢱࣥࣃࢡ㉁࣭࣌ࣉࢳ
ࢻ㧗⏕⏘ᇵ㣴ᚤ⏕≀ࡢ฼⏝࡟ࡼࡾࠊHIV ᖥ⼥ྜ㜼ᐖ๣➼ࡢ⎔ቃㄪ࿴ᆺ⏕≀άᛶ࣌ࣉࢳࢻྜᡂἲࢆᐇ
⌧ࡋࡓࠋ
࣌ࣉࢳࢻ࣭࣌ࣉࢳࢻ㢮⥳యࢆࣉ࣮ࣟࣈ࡜ࡍࡿࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲
᭷ᶵ㖡ヨ⸆࡟ࡼࡿ❧య㑅ᢥⓗ࢔ࣝ࢟ࣝ໬཯ᛂࢆᇶ┙࡜ࡋ࡚ࠊࢪࢣࢺࣆ࣌ࣛࢪ࣑࣓ࣥࢸ࢕ࢡࢫ࡜ࡋ
࡚ࡢࢪࣄࢻࣟࣆࣜࢪࣀࣥࡢྜᡂࠊ࣌ࣉࢳࢻ⤖ྜ࣑࣓ࢸ࢕ࢡࢫ࡜ࡋ࡚ࡢࣇࣝ࢜ࣟ࢔ࣝࢣࣥ࢖ࢯࢫࢱ࣮
ࡢྜᡂ➼࡟ᡂຌࡋࡓࠋࡲࡓࠊᚓࡽࢀࡓ࣌ࣉࢳࢻ㢮⦕యࢆࣉ࣮ࣟࣈ࡜ࡋ࡚ࠊ࣌ࣉࢳࢻࢺࣛࣥࢫ࣏࣮ࢱ
࣮ࡢ࣌ࣉࢳࢻᇶ㉁ᵓ㐀ㄆ㆑࡟㛵ࡍࡿ㔜せ࡞▱ぢࢆᚓࡓࠋ
⭷⼥ྜ㐣⛬ࢆᶆⓗ࡜ࡍࡿᢠ࢘࢖ࣝࢫάᛶ࣌ࣉࢳࢻࡢ㛤Ⓨ◊✲
⸆๣⪏ᛶᰴ࡟᭷ຠ࡞ HIV ⭷⼥ྜ㜼ᐖ๣ࢆ HIV ⸆๣⪏ᛶᰴࡢࢤࣀ࣒᝟ሗ࠿ࡽຠ⋡ⓗ࡟ศᏊタィࡍ
ࡿ᪉ἲࢆ☜❧ࡋࠊࡑࡢ࢔ࣉ࣮ࣟࢳࡢྜ⌮ᛶࢆᵓ㐀໬Ꮫⓗᡭἲ࡟ࡼࡾド᫂ࡋࡓࠋࡲࡓࠊ໬Ꮫྜᡂ࣌ࣉ
ࢳࢻ࡟ࡼࡾ⭷⼥ྜ㐣⛬ࡢ㜼ᐖຠᯝࢆᐃ㔞ࡍࡿホ౯⣔ࢆ☜❧ࡋࠊHIV ࢘࢖ࣝࢫࢆ⏝࠸࡞࠸⡆౽࡞ᢠ
HIV άᛶ໬ྜ≀ࡢࢫࢡ࣮ࣜࢽࣥࢢࢆᐇ⌧ࡋࡓࠋ
⏕≀άᛶኳ↛≀ࡢྜᡂ◊✲࡜๰⸆ᒎ㛤
ᙜ◊✲ᐊ࡟࠾࠸࡚㛤Ⓨࡋࡓ࢔ࣞࣥ⣔໬ྜ≀ࡢ㐃⥆⎔໬཯ᛂࢆᇶ┙࡜ࡋ࡚ࠊErgot ࢔ࣝ࢝ࣟ࢖ࢻ㢮
ࡸᢠ⭘⒆άᛶࢫࣇ࢕ࣥࢦ⬡㉁ࡢ▷ᕤ⛬ྜᡂ࡟ᡂຌࡋࡓࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ㸯ᅇ⏕㓄ᙜࡢ⸆Ꮫ㒊ᥦ౪඲Ꮫඹ㏻⛉┠ࠕᇶ♏᭷ᶵ໬Ꮫ Aࠖࠊ㸰ᅇ⏕㓄ᙜࡢ⸆Ꮫ㒊
ᑓ㛛⛉┠ࠕ๰⸆᭷ᶵ໬Ꮫ࢚ࢡࢧࢧ࢖ࢬࠖࡢ୍㒊ࠊ㸱ᅇ⏕㓄ᙜࡢྠࠕ᭷ᶵ໬Ꮫ㸱㸦๰⸆໬Ꮫ㸧ࠖཬࡧࠕ᪂
⸆ㄽ࣭་⸆ရ໬Ꮫࠖࢆᢸᙜࡋ࡚࠸ࡿࠋㅮ⩏┠ⓗ࣭Ꮫ⩦┠ᶆࢆタᐃࡋ࡚Ꮫ⏕࡟ࡶఏ࠼ࠊࡋ࠿ࡶ୍᪉㏻⾜ࡢ
ㅮ⩏࠿ࡽ཮᪉ྥࡢᏛ⩦࡜࡞ࡿࡼ࠺࡟ࠊ₇⩦ᙧᘧࢆධࢀ࡞ࡀࡽᑐヰ࡟㔜Ⅼࢆ࠾࠸ࡓㅮ⩏ᙧᘧ࡜ࡋ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗᖺḟ㓄ᒓࡢᏛ⏕࡟ࡶྛಶே࡟ࢸ࣮࣐ࢆ୚࠼ࠊ⮬ศ࡛◊✲ィ⏬ࡢ❧᱌࡜
ᒎ㛤ࢆ⪃࠼ࡿ⬟ຊࡢ㛤Ⓨ࡟㔜Ⅼࢆ࠾࠸࡚࠸ࡿࠋᙜศ㔝ࡢ◊✲ᣦᑟࡢ᭱኱ࡢ≉㛗ࡣࠊ◊✲ᐊ඲ᵓᡂဨࡀ㝸
㐌ྠࡌࢸ࣮ࣈࣝ࡟ࡘ࠸࡚ᐇ㦂ࡢሗ࿌࡜ሗ࿌ෆᐜ࡟㛵ࡍࡿ㆟ㄽࢆ⾜࠸ࠊᏛၥࣞ࣋ࣝࡢᙉ໬ࢆᅗࡿᶵ఍ࢆᣢ
ࡘ࡜࡜ࡶ࡟ࠊ◊✲ࡢ㐍ࡵ᪉࡟㛵ࡍࡿ Q & A ࢆ㏻ࡌ࡚ࠊಶࠎࡢ኱Ꮫ㝔⏕ࡀᑗ᮶⸆Ꮫ◊✲⪅࡜ࡋ࡚⮬❧ฟ᮶
ࡿࡼ࠺ᣦᑟࡋ࡚࠸ࡿⅬ࡟࠶ࡿࠋࡲࡓࠊᡂᯝࡀฟ࡚࠸ࡿ㝔⏕࡟ࡣ◊✲ᡂᯝࡢྲྀࡾࡲ࡜ࡵ࡟ࡘ࠸࡚ᣦᑟࡋࠊ
Ꮫ⾡㞧ㄅ࡬ࡢㄽᩥⓎ⾲ࢆ✚ᴟⓗ࡟⾜ࡗ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊ࡯ࡰẖᅇᑠヨ㦂ࢆ⾜࠸㐩ᡂᗘࢆ☜ㄆࡍࡿᙧᡂⓗホ౯ࢆྲྀࡾධࢀ࡚࠸ࡿࠋ
ᙜヱศ㔝࡛ࡣ⥲ྜ⛉Ꮫ࡛࠶ࡿ⸆Ꮫࡢ≉Ṧ஦᝟ࢆ⪃៖ࡋ࡚ࠊ་⸆ရ໬Ꮫ࣭᭷ᶵྜᡂ໬Ꮫࡢࡳ࡞ࡽࡎ⸆Ꮫ㡿
ᇦ඲⯡࡟Ώࡿᗈ࠸⣲㣴ࡢ⩦ᚓ࡟ࡶ᪥ᖖⓗ࡟ὀពႏ㉳ࡋ࡚࠸ࡿࡇ࡜࠿ࡽࠊ⸆๣ᖌᅜᐙヨ㦂ࡢྜ᱁⋡ࡀᴟࡵ
࡚㧗࠸ࠋ
◊✲ᣦᑟࡣࠊ⊂๰ᛶ࠾ࡼࡧ㞴᫆ᗘࡢ㧗࠸◊✲ㄢ㢟ࢆタᐃࡋࠊᩍဨ࡜Ꮫ⏕ࡢ⮬⏤࡞Ⓨ᝿࡜⮬୺ⓗ࡞ྲྀࡾ
⤌ࡳࢆᑛ㔜ࡋࡓ཮᪉ྥࡢᑐヰࢆ✚ᴟⓗ࡟⾜࠺ࡇ࡜࡛ࠊಶேࡢ◊✲⣲㣴ࡢྥୖࢆ┠ᣦࡋ࡚࠸ࡿࠋ࡯ࡰ඲ဨ
ࡀᖺ࡟୍ᗘࡢᏛ⾡㞟఍࡛ࡢⓎ⾲ࢆ⤒㦂ࡍࡿࡇ࡜࡛◊✲ᡂᯝࡢⓎಙࢆ✚ᴟⓗ࡟⾜࠺࡜࡜ࡶ࡟ࠊᅜෆእࡢ㛵
㐃◊✲ศ㔝ࡢ᭱᪂ࡢ᝟ሗࢆᩍဨ࡜Ꮫ⏕ࡀ༠ྠࡋ࡚ㄪᰝࡍࡿࡇ࡜࡛ࠊྛಶேࡢ◊✲⬟ຊࡢྥୖ࡟ᙺ❧ࡗ࡚
࠸ࡿࠋ
኱Ꮫ㝔ಟ஢⪅ࡣࠊ〇⸆௻ᴗࡢ◊✲⫋ཬࡧ࢔࢝ࢹ࣑ࢵࢡ࣏ࢪࢩࣙࣥࡢ⋓ᚓࢆ┠ᣦࡋ࡚ᾏእ␃Ꮫࡍࡿ⪅ࡀ
− 180 −
ከࡃࠊ♫఍ࡢࢽ࣮ࢬ࡟ྜ⮴ࡋࡓᅜ㝿ⓗ࡟ࡶ㧗࠸ࣞ࣋ࣝࡢᩍ⫱࡜◊✲ࢆ⥔ᣢࡋ࡚࠸ࡿࠋ
㸦ཎⴭ㸧
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Gravel, S.; Malouf, C.; Boulais, P.E.; Berchiche, Y.A.; Oishi, S.; Fujii, N.; Leduc, R.; Sinnett, D.; Heveker,
N. The peptidomimetic CXCR4 antagonist TC14012 recruits E-arrestin to CXCR7 roles of receptor
domains. J. Biol. Chem. in press.
Oishi, S.; Misu, R.; Setsuda, S.; Masuda, R.; Ohno, H.; Naniwa, Y.; Ieda, N.; Inoue, N.; Ohkura, S.;
Uenoyama, Y.; Tsukamura, H.; Maeda, K.; Hirasawa, A.; Tsujimoto, G.; Fujii, N. Activation of
neuropeptide FF receptors by kisspeptin receptor ligands. ACS Med. Chem. Lett. in press.
Noda, M.; Omatsu, Y.; Sugiyama, T.; Oishi, S.; Fujii, N.; Nagasawa, T. CXCL12-CXCR4 chemokine
signaling is essential for NK cell development in adult mice. Blood in press.
Shimura, K.; Nameki, D.; Kajiwara, K.; Watanabe, K.; Sakagami, Y.; Oishi, S.; Fujii, N.; Matsuoka, M.;
Sarafianos, S. G.; Kodama, E. Resistance profiles of novel electrostatically constrained HIV-1 fusion
inhibitors. J. Biol. Chem. in press.
Ohta, Y.; Tokimizu, Y.; Oishi, S.; Fujii, N.; Ohno, H. Direct synthesis of quinazolines through
copper-catalyzed reaction of aniline-derived benzamidines. Org. Lett. 2010, 12(17), 3963-3965.
Oishi, S.; Watanabe,K.; Ito, S.; Tanaka, M.; Nishikawa, H.; Ohno, H.; Shimane, K.; Izumi, K.; Sakagami,
Y.; Kodama, E. N.; Matsuoka, M.; Asai, A.; Fujii, N. Affinity selection and sequence-activity relationships
of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants. Med. Chem. Commun. 2010,
1(4), 276-281.
Ding, S.; Nishizawa, K.; Kobayashi, T.; Oishi, S.; Lv, J.; Fujii, N.; Ogawa, O.; Nishiyama, H. A Potent
Chemotherapeutic strategy for bladder cancer: (S)-methoxytrityl-L-cysteine, a novel Eg5 inhibitor. J. Urol.
2010, 15(7), 314-318.
Oishi, S.; Watanabe, T.; Sawada, J.; Asai, A.; Ohno, H.; Fujii, N. Kinesin spindle protein (KSP) inhibitors
with 2,3-fused indole scaffolds. J. Med. Chem. 2010, 53(13), 5054-5058.
Inuki, S.; Yoshimitsu, Y.; Oishi, S.; Fujii, N.; Ohno, H. Ring-construction/stereoselective functionalization
cascade: total synthesis of pachastrissamine (jaspine B) through palladium-catalyzed bis-cyclization of
propargyl chlorides and carbonates. J. Org. Chem. 2010, 75(11), 3831-3842.
Izumi, K.; Nakamura, S.; Nakano, H.; Shimura, K.; Sakagami, Y.; Oishi, S.; Uchiyama, S.; Ohkubo, T.;
Kobayashi, Y.; Fujii, N.; Matsuoka, M.; Kodama, E.N. Characterization of HIV-1 resistance to a fusion
inhibitor, N36, derived from the gp41 amino terminal heptad repeat. Antiviral Res. 2010, 87(2), 179-186.
Yoshimitsu, Y.; Inuki, S.; Oishi, S.; Fujii, N.; Ohno, H. Stereoselective divergent synthesis of four
diastereomers of pachastrissamine (jaspine B). J. Org. Chem. 2010, 75(11), 3843-3846.
Okano, A.; Oishi, S.; Tanaka, T.; Fujii, N.; Ohno, H. Construction of linked nitrogen heterocycles by
palladium(0)-catalyzed intramolecular domino cyclization of 2-alkynylaziridines bearing a 2-aminoethyl
group via ring expansion with isocyanate. J. Org. Chem. 2010, 75(10), 3396-3400.
Okano, A.; Tsukamoto, K.; Kosaka, S.; Maeda, H.; Oishi, S.; Tanaka, T.; Fujii, N.; Ohno, H. Synthesis of
fused and linked bicyclic nitrogen heterocycles by palladium-catalyzed domino cyclization of propargyl
bromides. Chem. Eur. J. 2010, 16(28), 8410-8418.
Melchionna, R.; Di Carlo, A.; De Mori, R.; Cappuzzello, C.; Barberi, L.; Musaro, A.; Cencioni, C.; Fujii,
N.; Tamamura, H.; Crescenzi, M.; Capogrossi, M.C.; Napolitano, M.; Germani, A. Induction of myogenic
differentiation by SDF-1 via CXCR4 and CXCR7 receptors. Muscle Nerve. 2010, 41 828-835.
Hirano, K.; Inaba, Y.; Watanabe, T.; Oishi, S.; Fujii, N.; Ohno, H. Gold-catalyzed intramolecular alkyne
cycloisomerization cascade: direct synthesis of aryl-annulated[a]carbazoles from aniline-substituted
diethynylarenes. Adv. Synth. Cat. 2010, 352(2), 368-372.
Nishizawa, K.; Nishiyama, H.; Oishi, S.; Tanahara, N.; Kotani, H.; Mikami, Y.; Toda, Y.; Evans, B. J.;
Peiper, S. C.; Saito, R.; Watanabe, J.; Fujii, N.; Ogawa, O. Fluorescent imaging of high grade bladder
cancer using a specific antagonist for chemokine receptor CXCR4. Int. J. Cancer 2010, 127(5), 1180-1187.
Mizuhara, T.; Oishi, S.; Fujii, N.; Ohno, H. Efficient synthesis of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles by SNAr-type C-S, C-N, or C-O bond formation with
heterocumulenes. J. Org. Chem. 2010, 75(1), 265-268.
Narumi, T.; Hayashi, R.; Tomita, K.; Kobayashi, K.; Tanahara, N.; Ohno, H.; Naito, T.; Kodama, E.;
Matsuoka, M.; Oishi, S.; Fujii, N. Synthesis and biological evaluation of selective CXCR4 antagonists
containing alkene dipeptide isosteres. Org. Biomol. Chem. 2010, 8(3), 616-621.
− 181 −
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
Kajiwara, K.; Watanabe, K.; Tokiwa, R.; Kurose, T.; Ohno, H.; Tsutsumi, H.; Hata, Y.; Izumi, K.; Kodama,
E.; Matsuoka, M.; Oishi, S.; Fujii, N. Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor,
SC35EK, with an N-terminal pyroglutamate capping group. Bioorg. Med. Chem. 2009, 17(23), 7964-7970.
Tanaka, M.; Kajiwara, K.; Tokiwa, R.; Watanabe, K.; Ohno, H.; Tsutsumi, H.; Hata, Y.; Izumi, K.; Kodama,
E.; Matsuoka, M.; Oishi, S.; Fujii, N. Bioorganic synthesis of end-capped anti-HIV peptides by
simultaneous cyanocysteine-mediated cleavages of recombinant proteins. Bioorg. Med. Chem. 2009, 17(21),
7487-7492.
Inuki, S.; Yoshimitsu, Y.; Oishi, S.; Fujii, N.; Ohno, H. Ring-construction/stereoselective functionalization
cascade: total synthesis of pachastrissamine (jaspine B) through palladium-catalyzed bis-cyclization of
bromoallenes. Org. Lett. 2009, 11(19), 4478-4481.
Ohta, Y.; Chiba, H.; Oishi, S.; Fujii, N.; Ohno, H. Construction of nitrogen heterocycles bearing an
aminomethyl group by copper-catalyzed domino three-component coupling-cyclization. J. Org. Chem.
2009, 74(18), 7052-7058.
Watabe, T.; Terakawa, Y.; Watanabe, K.; Ohno, H.; Nakano, H.; Nakatsu, T.; Kato, H.; Izumi, K.; Kodama,
E.; Matsuoka, M.; Kitaura, K.; Oishi, S.; Fujii, N. X-ray crystallographic study of an HIV-1 fusion inhibitor
with the gp41 S138A substitution. J. Mol. Biol. 2009, 392(3), 657-665.
Arthur, A.; Shi, S.; Zannettino, A. C.; Fujii, N.; Gronthos, S.; Koblar, S. A. Implanted adult human dental
pulp stem cells induce endogenous axon guidance. Stem Cells 2009, 27(9) 2229-2237.
Ohta, Y.; Kubota, Y.; Watabe, T.; Chiba, H.; Oishi, S.; Fujii, N.; Ohno, H. Rapid access to
3-(aminomethyl)isoquinoline-fused polycyclic compounds by copper-catalyzed four-component coupling,
cascade cyclization, and oxidation. J. Org. Chem. 2009, 74(16), 6299-6302.
Tanaka, T.; Nomura, W.; Narumi, T.; Esaka, A.; Oishi, S.; Ohashi, N.; Itotani, K.; Evans, B. J.; Wang, Z.;
Peiper, S. C.; Fujii, N.; Tamamura, H. Structure-activity relationship study on artificial CXCR4 ligands
possessing the cyclic pentapeptide scaffold: the exploration of amino acid residues of pentapeptides by
substitutions of several aromatic amino acids. Org. Biomol. Chem. 2009, 7(18), 3805-3809.
Oishi, S.; Kodera, Y.; Nishikawa, H.; Kamitani, H.; Watabe, T.; Ohno, H.; Tochikura, T.; Shimane, K.;
Kodama, E.; Matsuoka, M.; Mizukoshi, F.; Tsujimoto, H.; Fujii, N. Design and synthesis of membrane
fusion inhibitors against the feline immunodeficiency virus. Bioorg. Med. Chem. 2009, 17(14), 4916-4920.
Evans, B.J.; Wang, Z.; Broach, J.R.; Oishi, S.; Fujii, N.; Peiper S.C. Expression of CXCR4, a
G-protein-coupled receptor for CXCL12 in yeast identification of new-generation inverse agonists.
Methods Enzymol. 2009, 460, 399-412.
Oishi, S.; Kamitani, H.; Kodera, Y.; Watanabe, K.; Kobayashi, K.; Narumi, T.; Tomita, K.; Ohno, H.; Naito,
T.; Kodama, E.; Matsuoka, M.; Fujii, N. Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide
isosteres: synthesis and bioevaluation of D-helical anti-HIV peptide analogues. Org. Biomol. Chem. 2009,
7(14), 2872-2877.
Kobayashi, K.; Narumi, T.; Oishi, S.; Ohno, H.; Fujii, N. Amino acid-based synthesis of
trifluoromethylalkene dipeptide isosteres by alcohol-assisted nucleophilic trifluoromethylation and
organozinc-ccopper-mediated SN2' alkylation. J. Org. Chem. 2009, 74(12), 4626-4629.
Suzuki, Y.; Ohta, Y.; Oishi, S.; Fujii, N.; Ohno, H. Efficient synthesis of aminomethylated pyrroloindoles
and dipyrrolopyridines via controlled copper-catalyzed domino multi-component coupling and
bis-cyclization. J. Org. Chem. 2009, 74(11), 4246-4251.
Watanabe, T.; Oishi, S.; Fujii, N.; Ohno, H. Palladium-catalyzed direct synthesis of carbazoles via one-pot
N-arylation and oxidative biaryl coupling: synthesis and mechanistic study. J. Org. Chem. 2009, 74(13),
4720-4726.
Mizuhara, T.; Inuki, S.; Oishi, S.; Fujii, N.; Ohno, H. Cu(II)-mediated oxidative intermolecular ortho C-H
functionalisation using tetrahydropyrimidine as the directing group. Chem. Commun. 2009, (23),
3413-3415.
Navenot, J.M.; Fujii, N.; Peiper, S.C. KiSS1 Metastasis Suppressor Gene Product Induces Suppression of
Tyrosine Kinase Receptor Signaling to Akt, TNF Family Ligand Expression, and Apotosis. Mol. Pharmacol.
2009, 75(5) 1074-1083.
Navenot, J.M.; Fujii, N.; Peiper, S.C. Activation of Rho and ROCK by GPR54 and KiSS1 Metastasis
Suppressor Gene Product Induces Changes of Cell Morphology and Contributes to Apotosis. Mol.
Pharmacol. 2009, 75(6) 1300-1306.
− 182 −
36.
Diamond, P.; Labrinidis, A.; Martin, S.K.; Farrugia, A.N.; Gronthos, S.; To, L.B.; Fujii, N.; O̓Loughlin,
P.D.; Evdokiou, A.; Zannettino, A.C.W. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis
in a murine model of myeloma-associated bone loss. J. Bone Miner. Res. 2009, 24(7) 1150-1561.
37.
Ohta, Y.; Oishi, S.; Fujii, N.; Ohno, H. Facile synthesis of 1,2,3,4-tetrahydro-E-carbolines by one-pot
domino three-component indole formation and nucleophilic cyclization. Org. Lett. 2009, 11(9), 1979-1982.
Ueno, M.; Kodama, E.N.; Shimura, K.; Sakurai, Y.; Kajiwara, K.; Sakagami, Y.; Oishi, S.; Fujii, N.;
Matsuoka, M. Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1
replication impaired by primary mutations for resistance to enfuvirtide. Antiviral Res. 2009, 82(1), 67-72.
Katagiri, F.; Nagai, K.; Kida, A.; Tomita, K.; Oishi, S.; Takeyama, M.; Doi, R.; Fujii, N. Clinical
significance of plasma metastin level in pancreatic cancer patients. Oncol. Rep. 2009, 21, 815-819.
Yamaki, Y.; Shigenaga, A.; Tomita, K.; Narumi, T.; Fujii, N.; Otaka, A. Synthesis of fluoroalkene dipeptide
isosteres by intramolecular redox reaction utilizing N-heteorocyclic carbenes (NHCs). J. Org. Chem. 2009,
74, 3272-3277.
Nagai, K.; Doi, R.; Katagiri, F.; Ito, T.; Kida, A.; Koizumi, M.; Masui, T.; Kawaguchi, Y.; Tomita, K.; Oishi,
S.; Fujii, N.; Uemoto, S. Prognostic value of metastin expression in human pancreatic cancer. J. Exp. Clin.
Cancer Res. 2009, 28, 9.
Naito, T.; Izumi, K.; Kodama, E.; Sakagami, Y.; Kajiwara, K.; Nishikawa, H.; Watanabe, K.; Sarafianos,
S.G.; Oishi, S.; Fujii, N.; Matsuoka, M. SC29EK, a peptide fusion inhibitor with enhanced D-helicity,
inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob.
Agents Chemother. 2009, 53(3) 1013-1018.
Izumi, K.; Kodama, E.; Shimura, K.; Sakagami, Y.; Watanabe, K.; Ito, S.; Watabe, T.; Terakawa, Y.;
Nishikawa, H.; Sarafianos, S. G.; Kitaura, K.; Oishi, S.; Fujii, N.; Matsuoka, M. Design of peptide-based
inhibitors of HIV-1 strains resistant to T-20. J. Biol. Chem. 2009, 284(8) 4914-4920.
Tomita, K.; Popiel, H.A.; Nagai, Y.; Toda, T.; Yoshimitsu, Y.; Ohno, H.; Oishi, S.; Fujii, N.
Structure-activity relationship study on polyglutamine binding peptide QBP1. Bioorg. Med. Chem. 2009,
17(3) 1259-1263.
Kitaori, T.; Ito, H.; Schwarz, E.M.; Tsutsumi, R.; Yoshitomi, H.; Oishi, S.; Nakano, M.; Fujii, N.; Nagasawa,
T.; Nakamura, T. SDF-1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the
fracture site during skeletal repair. Arthritis Rheum. 2009, 60(3) 813-823.
Mizukoshi, F.; Baba, K.; Goto-Koshino, Y.; Setoguchi-Mukai, A.; Fujino, Y.; Ohno, K.; Tamamura, H.;
Oishi, S.; Fujii, N.; Tsujimoto, H. Inhibitory effect of newly developed CXC-chemokine receptor 4
antagonists on the infection with feline immunodeficiency virus. Vet. Microbiol. 2009, 136(1-2) 155-159.
Mizukoshi, F.; Baba, K.; Goto, Y.; Setoguchi, A.; Fujino, Y.; Ohno, K.; Oishi, S.; Kodera, Y.; Fujii, N.;
Tsujimoto, H. Antiviral activity of membrane fusion inhibitors that target gp40 of the feline
immunodeficiency virus envelope protein. J. Vet. Med. Sci. 2009, 71(1) 121-124.
Nishikawa, H.; Nakamura, S.; Kodama, E.; Ito, S.; Kajiwara, K.; Izumi, K.; Sakagami, Y.; Oishi, S.;
Ohkubo, T.; Kobayashi, Y.; Otaka, A.; Fujii, N.; Matsuoka, M. Electrostatically constrained D-helical
peptide inhibitors replication of HIV-1 resistant to enfuvirtide. Int. J. Biochem. Cell Biol. 2009, 41(4)
891-899.
Evans, B.J.; Wang, Z.; Mobley, L.; Khosravi, D.; Fujii, N.; Navenot, J.M.; Peiper, S.C. Physical association
of GPR54 C-terminal with protein phosphatase 2A. Biochem. Biophys. Res. Commun. 2008, 377(4)
1067-1071.
Tanaka, T.; Tsutsumi, H.; Nomura, W.; Tanabe, Y.; Ohashi, N.; Esaka, A.; Ochiai, C.; Sato, J.; Itotani, K.;
Murakami, T.; Ohba, K.; Yamamoto, N.; Fujii, N.; Tamamura, H. Structure-activity relationship study of
CXCR4 antagonists bearing the cyclic pentapeptide scaffold: identification of the new pharmacophore. Org.
Biomol. Chem. 6(23) 4374-4377 (2008).
Tomita, K.; Oishi, S.; Ohno, H.; Peiper, S.C.; Fujii, N. Development of novel G protein-coupled receptor 54
agonists with resistance to degradation by matrix metalloproteinase. J. Med. Chem. 2008, 51(23),
7645–7649.
Inuki, S.; Oishi, S.; Fujii, N.; Ohno, H. Total synthesis of (±)-lysergic acid, lysergol, and isolysergol by
palladium-catalyzed domino cyclization of amino allenes bearing a bromoindolyl group. Org. Lett. 2008,
10(22), 5239-5242.
Iwasaki, H.; Eguchi, T.; Tsutsui, N.; Ohno, H.; Tanaka, T. Samarium(II)-mediated spirocyclization by
Intramolecular aryl radical addition onto an aromatic ring. J. Org. Chem. 2008, 73(18), 7145-7152.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
− 183 −
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
Nishikawa H.; Oishi S.; Fujita M.; Watanabe K.; Tokiwa R.; Ohno H.; Kodama E.; Izumi K.; Kajiwara K.;
Naitoh T.; Matsuoka M.; Otaka A.; Fujii N. Identification of minimal sequence for HIV-1 fusion inhibitors.
Bioorg. Med. Chem. 2008, 16(20), 9184-9187.
Mikami, S.; Nakase, H.; Yamamoto, S.; Takeda, Y.; Yoshino, T.; Kasahara, K.; Ueno, S.; Uza, N.; Oishi, S.;
Fujii, N.; Nagasawa, T.; Chiba, T. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental
colitis. J. Pharmacol. Exp. Ther. 2008, 327(2), 383-392.
Ohta, Y.; Chiba, H.; Oishi, S.; Fujii, N.; Ohno, H. Concise synthesis of indole-fused 1,4-diazepines through
copper(I)-catalyzed domino three-component coupling-cyclization-N-arylation under microwave irradiation. Org. Lett. 2008, 10(16), 3535-3538.
Ueda, S.; Kato, M.; Ohno, H.; Evans, B.; Wang, Z.; Peiper, S. C.; Izumi, K.; Kodama, E.; Matsuoka, M.;
Nagasawa, H.; Oishi, S.; Fujii, N. Identification of novel nonpeptide CXCR4 antagonists by ligand-based
design approach. Bioorg. Med. Chem. Lett. 2008, 18(14), 4124-4129.
Yano, Y.; Yano, A.; Oishi, S.; Sugimoto, Y.; Tsujimoto, G.; Fujii, N.; Matsuzaki, K. Coiled-coil tag-robe
system for quick labeling of membrane receptors in living cells. ACS Chem. Biol. 2008, 3(6) 341-345.
Okano, A.; Mizutani, T.; Oishi, S.; Tanaka, T.; Ohno, H.; Fujii, N. Palladium-catalysed biscyclisation of
allenic bromoalkenes through zipper-mode cascade. Chem. Commun. 2008, (30) 3534-3536.
Nishikawa, H.; Kodama, E.; Sakakibara, A.; Fukudome, A.; Izumi, K.; Oishi, S.; Fujii, N.; Matsuoka, M.
Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41. Antivir.
Res. 2008, 80(1), 71-76.
Nakata, H.; Steinberg, S.M.; Koh, Y.; Maeda, K.; Takaoka, Y.; Tamamura, H.; Fujii, N.; Mitsuya, H. Potent
synergistic anti-HIV effects using combinations of a CCR5. Antimicrob. Agents. Chemother. 2008, 52(6)
2111-2119.
Watanabe, T.; Oishi, S.; Fujii, N.; Ohno, H. Palladium-catalyzed sp3 C-H activation of simple alkyl groups:
direct preparation of indoline derivatives from N-alkyl-2-bromoanilines. Org. Lett. 2008, 10(9), 1759-1762.
Inokuchi, E.; Narumi, T.; Niida, A.; Tomita, K.; Oishi, S.; Ohno, H.; Fujii, N. Efficient synthesis of
trifluoromethyl and related trisubstituted alkene dipeptide isosteres by palladium-catalyzed carbonylation
of amino acid-derived allylic carbonates. J. Org. Chem. 2008, 73(10), 3942-3945.
Suzuki, Y.; Cluzeau, J.; Hara, T.; Hirasawa, A.; Tsujimoto, G.; Oishi, S.; Ohno, H.; Fujii, N.
Structure-activity relationship of pyrazine-based CK2 inhibitors: synthesis and evaluation of
2,6-disubstituted pyrazines and 4,6-disubstituted pyrimidines. Arch. Pharm. 2008, 341(9) 554-561.
Narumi, T.; Tomita, K.; Inokuchi, E.; Kobayashi, K.; Oishi, S.; Ohno, H.; Fujii, N. Diastereoselective
synthesis of highly functionalized fluoroalkene dipeptide isosteres and its application to Fmoc-based solid
phase synthesis of a cyclic pentapeptide mimetic. Tetrahedron 2008, 64(19), 4332-4346.
Tomita, K.; Oishi, S.; Ohno, H.; Fujii, N. Structure-activity relationship study and NMR analysis of
fluorobenzoyl pentapeptide GPR54 agonists. Biopolymers 2008, 90(4): 503-511.
Oishi, S.; Masuda, R.; Evans, B.; Ueda, S.; Goto, Y.; Ohno, H.; Hirasawa, A.; Tsujimoto, G.; Wang, Z.;
Peiper, S. C.; Naito, T.; Kodama, E.; Matsuoka, M.; Fujii, N. Synthesis and application of fluorescein- and
biotin-labeled molecular probes for chemokine receptor CXCR4. ChemBioChem 2008, 9(7), 1154-1158.
Driessen, W.H.; Fujii, N.; Tamamura, H.; Sullivan, S.M. Development of peptide-targeted lipoplexes to
CXCR4-expressing rat glioma cells and rat proliferating endothelial cells. Mol. Ther. 2008, 16(3) 516-524.
Ohta, Y.; Oishi, S.; Fujii, N.; Ohno, H. Facile synthesis of 3-(aminomethyl)isoquinolines by
copper-catalysed domino four-component coupling and cyclisation. Chem. Commun. 2008, (7),!835-837.
Kasiyanov, A.; Fujii, N.; Tamamura, H.; Xiong, H. Modulation of network-driven, GABA-mediated giant
depolarizing potentials by SDF-1Ș in the developing hippocampus. Dev. Neurosci. 2008, 30(4) 285-292.
Oishi, S.; Ito, S.; Nishikawa, H.; Watanabe, K.; Tanaka, M.; Ohno, H.; Izumi, K.; Sakagami, Y.; Kodama,
E.; Matsuoka, M.; Fujii, N. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for
binding affinity. J. Med. Chem. 2008, 51(3), 388-391.
Liapi, A.; Pritchett, J.; Jones, O.; Fujii, N.; Parnavelas J.G.; Nadarajah B. Stromal-derived factor 1
signalling regulates radial and tangential migration in the developing cerebral cortex. Dev. Neurosci. 2008,
30(1-3) 117-131.
Ujike, M.; Nishikawa, H.; Otaka, A.; Yamamoto, N.; Yamamoto, N.; Matsuoka, M.; Kodama, E.; Fujii, N.;
Taguchi, F. Heptad repeat-derived peptides block the protease-mediated direct entry from cell surface of
SARS coronavirus but not entry via endosomal pathway. J. Virol. 2008, 82(1) 588-592.
Sasaki, Y.; Fujii, N.; Otaka, A. Development of copper-mediated allylation of J-activated-D,E-unsaturated
lactam toward peptide mimetic synthesis. Tetrahedron Lett. 2007, 48(18) 3221-3224.
− 184 −
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
Watanabe, T.; Oishi, S.; Fujii, N.; Ohno, H. Gold-catalyzed hydroarylation of allenes: a highly
regioselective carbon-carbon bond formation producing six-membered rings. Org. Lett.!2007,!9(23),
4821-4824.
Watanabe, T.; Ueda, S.; Inuki, S.; Oishi, S.; Fujii, N.; Ohno, H. One-pot synthesis of carbazoles by
palladium-catalyzed N-arylation and oxidative coupling. Chem. Commun. 2007, (43) 4516-4518.
Ohno, H.; Iuchi, M.; Fujii, N.; Tanaka, T. Zipper-mode double C-H activation: palladium-catalyzed direct
construction of highly-fused heterocyclic systems. Org. Lett. 2007, 9(23) 4813-4815.
Kohara, H.; Omatsu, Y.; Sugiyama, T.; Noda, M.; Fujii, N.; Nagasawa, T. Development of plasmacytoid
dendritic cells in bone marrow stromal cell niches requires CXCL12-CXCR4 chemokine signaling. Blood
2007, 110(13) 4153-4160.
Kabashima, K.; Shiraishi, N.; Sugita, K.; Mori, T.; Onoue, A.; Kobayashi, M.; Sakabe, J.I.; Yoshiki, R.;
Tamamura, H.; Fujii, N.; Inaba, K.; Tokura, Y. CXCL12-CXCR4 engagement is required for migration of
cutaneous dendritic cells. Am. J. Pathol. 2007, 171(4) 1249-1257.
Zhang, W.; Navenot, J.M.; Frilot, N.M.; Fujii, N.; Peiper, S.C. Association of nucleophosmin negatively
regulates CXCR4-mediated G protein activation and chemotaxis. Mol. Pharmacol. 2007, 72(5) 1310-1321.
Tamamura, H.; Tanaka, T.; Tsutsumi, H.; Nemoto, K.; Mizokami, S.; Ohashi, N.; Oishi, S.; Fujii, N.
Versatile use of acid-catalyzed ring-opening of E-aziridinyl-D,E-enoates to stereoselective synthesis of
peptidomimetics. Tetrahedron 2007, 63(37), 9243-9254.
Kabashima, K.; Sugita, K.; Shiraishi, N.; Tamamura, H.; Fujii, N.; Tokura, Y. CXCR4 engagement
promotes dendritic cell survival and maturation. Biochem. Biophys. Res. Commun. 2007, 361(4) 1012-1016.
Narumi, T.; Tomita, K.; Inokuchi, E.; Kobayashi, K.; Oishi, S.; Ohno, H.; Fujii, N. Facile synthesis of
fluoroalkenes by palladium-catalyzed reductive defluorination of allylic gem-difluorides. Org. Lett. 2007,
9(17), 3465-3468.
Ohno, H.; Aso, A.; Kadoh, Y.; Fujii, N.; Tanaka, T. Heck-type cyclization of oxime ethers: stereoselective
carbon-carbon bond formation with aryl halides to produce heterocyclic oximes. Angew. Chem. Int. Ed.
2007, 46(33) 6325-6328.
Kubonishi, S.; Kikuchi, T.; Yamaguchi, S.; Tamamura, H.; Fujii, N.; Watanabe, T.; Arenzana-Seisdedos, F.;
Ikeda, K.; Matsui, T.; Tanimoto, M.; Katayama, Y. Rapid hematopoietic progenitor mobilization by sulfated
colominic acid. Biochem. Biophys. Res. Commun. 2007, 355(4) 970-975.
Tomita, K.; Oishi, S.; Cluzeau, J.; Ohno, H.; Navenot, J.-M.; Wang, A.; Peiper, S. C.; Akamatsu, M.; Fujii,
N. SAR and QSAR studies on the N-terminally acylated pentapeptide agonists for GPR54. J. Med. Chem.
2007, 50(14), 3222-3228.
Ogo, N.; Oishi, S.; Matsuno, K.; Sawada, J.; Fujii, N.; Asai, A. Synthesis and biological evaluation of
L-cysteine derivatives as mitotic kinesin Eg5 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17(14),
3921-3924.
Cluzeau, J.; Oishi, S.; Ohno, H.; Wang, Z.; Evans, B.; Peiper, S. C.; Fujii, N. Design and synthesis of all
diastereomers of cyclic pseudo-dipeptides as mimic of cyclic CXCR4 pentapeptide antagonist. Org. Biomol.
Chem. 2007, 5(12), 1915-1923.
Ohno, H.; Mizutani, T.; Kadoh, Y.; Aso, A.; Miyamura, K.; Fujii, N.; Tanaka, T. A highly regio- and
stereoselective formation of bicyclo[4.2.0]oct-5-ene derivatives through thermal intramolecular [2 + 2]
cycloaddition of allenes. J. Org. Chem. 2007, 72(12) 4378-4389.
Ono, Y.; Kashiwagi, H.; Esaki, T.; Tadakatsu, T.; Sato, H.; Fujii, N. Systematic solution-phase parallel
synthesis of active vitamin D3 analogs with elongated side chains and their cell differentiation activities. J.
Comb. Chem. 2007, 9(4) 711-716.
Katagiri, F.; Tomita, K.; Oishi, S.; Takeyama, M.; Fujii, N. Establishment and clinical application of
enzyme immunoassays for determination of luteinizing hormone releasing hormone and metastin. J. Pept.
Sci. 2007, 13(6), 422-429.
Juarez, J.; Dela Pena, A.; Baraz, R.; Hewson, J.; Khoo, M.; Cisterne, A.; Fricker, S.; Fujii, N.; Bradstock,
K.F.; Bendall, L.J. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the
peripheral blood and inhibit engraftment. Leukemia 2007, 21(6) 1249-1257.
Berchiche, Y.A.; Chow, K.Y.; Lagane, B.; Leduc, M.; Percherancier, Y.; Fujii, N.; Tamamura, H.; Bachelerie,
F.; Heveker, N. Direct assessment of CXCR4 mutant conformations reveals complex link between receptor
structure and GȘi activation. J. Biol. Chem. 2007, 282(8) 5111-5115.
− 185 −
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
Kang, S.-U.; Choi, W. J.; Oishi, S.; Lee, K.; Karki, R. G.; Worthy, K. M.; Bindu, L. K.; Nicklaus, M. C.;
Fisher, R. J.; Burke, T. R., Jr. Examination of acylated 4-aminopiperidine-4-carboxylic acid residues in the
pTyr+1 position of Grb2 SH2 domain-binding tripeptides. J. Med. Chem. 2007, 50(8), 1978-1982.
Ohno, H; Ohta, Y.; Oishi, S.; Fujii, N. Direct synthesis of 2-(aminomethyl)indoles through
copper(I)-catalyzed domino three-component coupling and cyclization reactions. Angew. Chem. Int. Ed.
2007, 46(13), 2295-2298.
Tomita, K.; Narumi, T.; Niida, A.; Oishi, S.; Ohno, H.; Fujii, N. Fmoc-based solid-phase synthesis of
GPR54-agonistic pentapeptide derivatives containing alkene- and fluoroalkene-dipeptide isosteres.
Biopolymers 2007, 88(2), 272-278.
Hamaguchi, H.; Kosaka, S.; Ohno, H.; Fujii, N.; Tanaka, T. Bromoallenes as allyl dication equivalents in
the presence or absence of palladium(0): direct construction of bicyclic sulfamides containing five- to
eight-membered rings by tandem cyclization of bromoallenes. Chem. Eur. J. 2007, 13(6) 1692-1708.
Tanaka, M.; Oishi, S.; Ohno, H.; Fujii, N. A novel oxazolidine linker for the synthesis of peptide aldehydes.
Int. J. Pep. Res. Ther. 2007, 13(1-2), 271-279.
Sasaki, Y.; Shigenaga, A.; Fujii, N.; Otaka, A. Synthesis of (Z)-alkene-containing cis-proline dipeptide
mimetics using samarium (II) diiodide (SmI2)-mediated reductive-alkylation reaction. Tetrahedron 2007,
63(9) 2000-2008.
Kato-Takagaki, K.; Suzuki, N.; Yokoyama, F.; Takaki, D.; Umezawa, K.; Higo, J.; Mochizuki, M.; Kikkawa,
Y.; Oishi, S.; Utani, A.; Nomizu, M. Cyclic peptide analysis of the biologically active loop region in the
laminin R3 chain LG4 module demonstrates the importance of peptide conformation on biological activity.
Biochemistry 2007, 46(7), 1952-1960.
Ueda, S.; Oishi, S.; Wang, Z.-X.; Araki, T.; Tamamura, H.; Cluzeau, J.; Ohno, H.; Kusano, S.; Nakashima,
H.; Trent, J.O.; Peiper, S.C.; Fujii, N. Structure-activity relationships of cyclic peptide-based chemokine
receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J. Med.
Chem. 2007, 50(2), 192-198.
Narumi, T.; Niida, A.; Tomita, K.; Oishi, S.; Otaka, A.; Ohno, H.; Fujii, N. A novel one-pot reaction
involving organocopper-mediated reduction/transmetalation/asymmetric alkylation, leading to the
diastereoselective synthesis of functionalized (Z)-fluoroalkene dipeptide isosteres. Chem. Commun. 2006,
(45), 4720-4722.
Baba, M.; Hong, S.-B.; Sharma, N.; Warren, M.B.; Nickerson, M.L.; Iwamatsu, A.; Esposito, D.; Gillette,
W.K.; Hopkins, R.F., III; Hartley, J.L.; Furihata, M.; Oishi, S.; Zhen, W.; Burke, T.R., Jr.; Linehan, W.M.;
Schmidt, L.S.; Zbar, B. Folliculin encoded by the BHD gene interacts with a novel binding protein, FNIP1,
and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl. Acad. Sci. 2006, 103(42),
15552-15557.
Tomita, K.; Niida, A.; Oishi, S.; Ohno, H.; Cluzeau, J.; Navenot, J.-M.; Wang, Z.; Peiper, S.C.; Fujii, N.
Structure-activity relationship study on small peptidic GPR54 agonists. Bioorg. Med. Chem. 2006, 14(22),
7595-7603.
Sasaki, Y.; Niida, A.; Tsuji, T.; Shigenaga, A.; Fujii, N.; Otaka, A. Stereoselective synthesis of
(Z)-alkene-containing proline dipeptide mimetics. J. Org. Chem. 2006, 71(13) 4969-4979.
Niida, A.; Mizumoto, M.; Narumi, T.; Inokuchi, E.; Oishi, S.; Ohno, H.; Otaka, A.; Kitaura, K.; Fujii, N.
Synthesis of (Z)-alkene and (E)-fluoroalkene containing diketopiperazine mimetics utilizing
organocopper-mediated reduction-alkylation and diastereoselectivity examination using DFT calculations. J.
Org. Chem. 2006, 71(11), 4118-4129.
Hanaoka, H.; Mukai, T.; Tamamura, H.; Mori, T.; Ishino, S.; Ogawa, K.; Iida, Y.; Doi, R.; Fujii, N.; Saji, H.
111
Development of a In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging
tumors. Nucl. Med. Biol. 2006, 33(4) 489-494.
Tamamura, H.; Ojida, A.; Ogawa, T.; Tsutsumi, H.; Masuno, H.; Nakashima, H.; Yamamoto, N.; Hamachi,
I.; Fujii, N. Identification of a new class of low molecular weight antagonists against the chemokine
receptor CXCR4 having the dipicolylamine-zinc(II) complex structure. J. Med. Chem. 2006, 49(11)
3412-3415 .
Tamamura, H.; Tsutsumi, H.; Masuno, H.; Mizokami, S.; Hiramatsu, K.; Wang, Z.; Trent, J.O.; Nakashima,
H.; Yamamoto, N.; Peiper, S.C.; Fujii, N. Development of a linear type of low molecular weight CXCR4
antagonists based on T140 analogs. Org. Biomol. Chem. 2006, 4(12) 2354-2357.
Tsuda, M.; Terada, T.; Irie, M.; Katsura, T.; Niida, A.; Tomita, K.; Fujii, N.; Inui, K. Transport
characteristics of a novel PEPT1 substrate, antihypotensive drug midodrine, and its amino acid derivatives.
J. Pharmacol. Exp. Ther. 2006, 318(1) 455-460.
− 186 −
111. Menu, E.; Asosingh, K.; Indraccolo, S.; De Raeve, H.; Van Riet, I.; Van Valckenborgh, E.; Van de Broek, I.;
Fujii, N.; Tamamura, H.; Van Camp, B.; Vanderkerken, K. The involvement of stromal derived factor 1D in
homing and progression of multiple myeloma in the 5TMM model. Haematologica 2006, 91(5) 605-612.
112. Kasyanov, A.; Tamamura, H.; Fujii, N.; Xiong, H. HIV-1 gp120 enhances giant depolarizing potentials via
chemokine receptor CXCR4 in neonatal rat hippocampus. Eur. J. Neurosci. 2006, 23(5) 1120-1128.
113. Niida, A.; Tanigaki, H.; Inokuchi, E.; Sasaki, Y.; Oishi, S.; Ohno, H.; Tamamura, H.; Wang, Z.; Peiper, S.
C.; Kitaura, K.; Otaka, A.; Fujii, N. Stereoselective synthesis of 3,6-disubstituted-3,6-dihydropyridin-2-ones as potential diketopiperazine mimetics using organocopper-mediated anti-SN2' reactions and
their use in the preparation of low molecule CXCR4 antagonists. J. Org. Chem. 2006, 71(10), 3942-3951.
114. Niida, A.; Tomita, K.; Mizumoto, M.; Tanigaki, H.; Terada, T.; Oishi, S.; Otaka, A.; Inui, K.-I.; Fujii, N.
Uequivocal synthesis of (Z)-alkene and (E)-fluoroalkene dipeptide isosteres to probe structural
requirements of the peptide transporter PEPT1. Org. Lett. 2006, 8(4), 613-616.
115. Ohta, Y.; Itoh, S.; Shigenaga, A.; Shintaku, S.; Fujii, N.; Otaka, A. Cysteine-derived S-protected
oxazolidinones: potential chemical devices for the preparation of peptide thioesters. Org. Lett. 2006, 8(3)
467-470.
116. Ohno, H.; Kadoh, Y.; Fujii, N.; Tanaka, T. Potassium carbonate-promoted stereospecific 5-endo-trig
cyclization of unactivated allenes in the absence of any transition metals. Org. Lett. 2006, 8(5) 947-950.
117. Oishi, S.; Miyamoto, K.; Niida, A.; Yamamoto, M.; Ajito, K.; Tamamura, H.; Otaka, A.; Kuroda, Y.; Asai,
A.; Fujii, N. Application of tri- and tetrasubstituted alkene dipeptide mimetics to conformational studies of
cyclic RGD peptides. Tetrahedron 2006, 62(7), 1416-1424.
118. Avniel, S.; Arik, Z.; Maly, A.; Sagie, A.; Basst, H.B.; Yahana, M.D.; Weiss, I.D.; Pal, B.; Wald, O.; Ad-El,
D.; Fujii, N.; Arenzana-Seisdedos, F.; Jung, S.; Galun, E.; Gur, E.; Peled, A. Involvement of the
CXCL12/CXCR4 pathway in the recovery of skin following burns. J. Invest. Dermatol. 2006, 126(2)
468-476.
119. Dewan, M.Z.; Uchihara, J.N.; Terashima, K.; Honda, M.; Sata, T.; Ito, M.; Fujii, N.; Uozumi, K.; Tsukasaki,
K.; Tomonaga, M.; Kubuki, Y.; Okayama, A.; Toi, M.; Mori, N.; Yamamoto, N. Efficient intervention of
growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood
2006, 107(2) 716-724.
120. Niida, A.; Wang, Z.; Tomita, K.; Oishi, S.; Tamamura, H.; Otaka, A.; Navenot, J.-M.; Broach, J. R.; Peiper,
S. C.; Fujii, N. Design and synthesis of downsized metastin (45-54) analogs with maintenance of high
GPR54 agonistic activity. Bioorg. Med. Chem. Lett. 2006, 16(1), 134-137.
㸦⥲ㄝ㸧
1
2
3
4
5
6
኱▼┿ஓࠊ⸨஭ಙᏕ ࢣࣔ࢝࢖ࣥཷᐜయ CXCR4 ࡜ࡑࡢ࢔ࣥࢱࢦࢽࢫࢺ ࿴ග⣧⸆᫬ሗ 2010, 78(1)
2-5.
Hyunsuk, S.; Oishi, S.; Fujii, N. Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal
tumors. Semin. Cancer Biol. 2009, 19(2) 123-134.
Oishi, S.; Narumi, T.; Ohno, H.; Otaka, A.; Fujii, N. Synthesis of highly functionalized alkene dipeptide
isosteres and its application to the structure-activity relationship study on bioactive peptides. J. Synth. Org.
Chem. Jpn. 2008, 66(9), 846-857.
Tamamura, H.; Tsutsumi, H.; Masuno, H.; Fujii, N. Development of low molecular weight CXCR4
antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the
treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Curr. Med. Chem. 2007, 14(1)
93-102.
Tsutsumi, H.; Tanaka, T.; Ohashi, N.; Masuno, H.; Tamamura, H.; Hiramatsu, K.; Araki, T.; Ueda, S.; Oishi,
S.; Fujii, N. The therapeutic potential of the chemokine receptor CXCR4 antagonists as multi-functional
agents. Biopolymers 2007, 88(2), 279-289.
Tsutsumi, H.; Tamamura, H.; Fujii, N. Inhibitors of the chemokine receptor CXCR4: chemotherapy of
AIDS, metastatic cancer, leukemia and rheumatoid arthritis. Lett. Drug Design Discov. 2007, 4(1) 20-26.
7
኱▼┿ஓࠊ⸨஭ಙᏕ ࣌ࣉࢳࢻࢆ࣮ࣜࢻ࡜ࡋࡓ๰⸆ Tanpakushitsu Kakusan Koso 2007, 52(13, zokan)
1696-1701.
8
኱▼┿ஓࠊ⸨஭ಙᏕ ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮ࢆᇶ┙࡜ࡍࡿ࣌ࣉࢳࢻ๰⸆ Idenshi Igaku Mook 2007, 8
87-91.
Tamamura, H.; Tsutumi, H.; Fujii, N. The chemokine receptor CXCR4 as a therapeutic target for several
diseases. Mini Rev. Med. Chem. 2006, 6(9) 989-995 (2006).
9
− 187 −
10
Otaka, A.; Fujii, N. Development of antiviral fusion inhibiting peptides. Kagaku Kogyo 2006, 57(10)
797-801.
㸦ⴭ᭩㸧
1
኱▼┿ஓࠊ⸨஭ಙᏕ ࣁ࢖ࢫ࣮ࣝࣉࢵࢺࢫࢡ࣮ࣜࢽࣥࢢ ࢖ࣥࢩࣜࢥ๰⸆⛉Ꮫ㸦3.3 ⠇࣭ி㒔ᘅᕝ
᭩ᗑ㸧2008, 63-74
2
᥃㇂⚽᫛ࠊ኱▼┿ஓࠊ▮಴ᚭࠊ⸨஭ಙᏕ ໬ྜ≀ࣛ࢖ࣈ࣮ࣛࣜ ࢖ࣥࢩࣜࢥ๰⸆⛉Ꮫ㸦3.2 ⠇࣭ி
㒔ᘅᕝ᭩ᗑ㸧2008, 46-63
3
⸨஭ಙᏕࠊ኱▼┿ஓࠊ኱㧗❶ ࣉࣟࢸ࣑࢜ࢡࢫࢆᇶ┙࡜ࡍࡿࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮ؐ᝟ሗ࠿ࡽไ
ᚚ࡬ ࣂ࢖࢜ࢽࢡࢫ, 2006, 3(10), 46-51.
− 188 −
⸆ရྜᡂ໬Ꮫศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧ᐩᒸ Ύ㸦࡜ࡳ࠾࠿ ࡁࡼࡋ㸧(2010.3 ྠᚿ♫ዪᏊ኱Ꮫ⸆
Ꮫ㒊ᩍᤵ࡟㌿ฟ)
᫛࿴㸰㸱ᖺ㸯᭶㸯㸲᪥⏕
᫛࿴㸲㸴ᖺᮾி኱Ꮫ༞ࠊ᫛࿴㸳㸯ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧ᒣ⏣೺୍㸦ࡸࡲࡔ ࡅࢇ࠸ࡕ㸧(2006.7 ᪼௵)
᫛࿴㸲㸶ᖺ㸳᭶㸰㸰᪥⏕
ᖹᡂ㸶ᖺᮾி኱Ꮫ༞ࠊᖹᡂ㸯㸱ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ⣔◊✲⛉༤ኈㄢ⛬ಟ஢
ຓᩍᤵ㸦⸆Ꮫ༤ኈ㸧㣤⏣ ᙲ㸦࠸࠸ࡔ ࠶ࡁࡽ㸧(2006.3 㧗ᓮ೺ᗣ⚟♴኱Ꮫ⸆
Ꮫ㒊ᩍᤵ࡟㌿ฟ)
᫛࿴㸱㸳ᖺ㸶᭶㸯㸰᪥⏕
᫛࿴㸳㸶ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸴㸱ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
ຓ ᩍ㸦ಟኈ㸦⸆Ꮫ㸧㸧ᒣᮏᗣ཭㸦ࡸࡲࡶ࡜ ࡸࡍ࡜ࡶ㸧(2010.3 ྠᚿ♫ዪᏊ኱Ꮫ⸆Ꮫ㒊ຓᩍ࡟㌿ฟ)
᫛࿴㸳㸲ᖺ㸯㸮᭶㸯㸲᪥⏕
ᖹᡂ㸯㸲ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸶ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ⣔◊✲⛉༤ኈㄢ⛬୰㏥㸦2006.11 ᥇⏝㸧
ᖹᡂ㸰㸰ᖺ ༤ኈ㸦⸆Ꮫ㸧ྲྀᚓ
◊✲ࡢᴫせ
⸆ရྜᡂ໬Ꮫศ㔝ࡣศᏊ⛉Ꮫࡢ┿⌮ࢆ᥈ồࡋࠊ་⸆ရ࡜࡞ࡿศᏊࡢ๰〇᪉ἲㄽࡢⓎ᫂࡜ࠊࡑࢀࢆᐇ㊶
ࡍࡿ◊✲⪅ࡢ⫱ᡂࢆ┠ⓗ࡜ࡋ࡚࠸ࡿࠋ୰࡛ࡶࠊ་⸆ရศᏊࡢ๰〇໬Ꮫࡣ๰⸆⛉Ꮫࡢ୰ᚰ࡛࠶ࡿ࡜ࡢㄆ㆑
ࡢୗࠊ୙ᩧྜᡂ཯ᛂࡢ㛤ᣅࠊ᪂཯ᛂࡢ㛤ᣅࠊ⏕≀άᛶ໬ྜ≀ࡢタィ࡜඲ྜᡂࠊศᏊㄆ㆑࡜㉸ศᏊᙧᡂࡢ
໬Ꮫ࡟ᣮᡓࡋ࡚࠸ࡿࠋ
୙ᩧྜᡂ཯ᛂࡢ㛤ᣅ
᭷ᶵࣜࢳ࣒࢘཯ᛂ๣ࢆάᛶ໬ࡋ࡚୙ᩧ໬ࡍࡿ࢟ࣛࣝ㓄఩Ꮚࠊ᭷ᶵ࣐ࢢࢿࢩ࣒࢘཯ᛂ๣ࢆάᛶ໬ࡋ࡚୙
ᩧ໬ࡍࡿ㖡-࢟ࣛࣝ࢝ࣝ࣋ࣥ㓄఩Ꮚࠊ᭷ᶵள㖄཯ᛂ๣ࢆάᛶ໬ࡋ࡚୙ᩧ໬ࡍࡿ㖡-࢟ࣛࣝ࣍ࢫࣇ࢕ࣥ㓄఩
Ꮚࠊ᭷ᶵ࣍࢘㓟཯ᛂ๣ࢆ୙ᩧ໬ࡍࡿࣟࢪ࣒࢘-࢟ࣛࣝ࣍ࢫࣇ࢕ࣥ㓄఩Ꮚࠊࣜࢳ࣒࢚࢘ࣀ࣮ࣛࢺ཯ᛂ๣ࢆά
ᛶ໬ࡋ࡚୙ᩧ໬ࡍࡿ࢟ࣛࣝ㓄఩Ꮚࠊ࢚ࣥ࢖ࣥ໬ྜ≀ࢆάᛶ໬ࡋ࡚୙ᩧ໬ࡍࡿ㔠-࢟ࣛࣝ࢝ࣝ࣋ࣥ㓄఩Ꮚࠊ
◲㯤཯ᛂ๣ࢆάᛶ໬ࡋ࡚୙ᩧ໬ࡍࡿ࢟ࣛࣝ㓄఩Ꮚࠊ㓟⣲཯ᛂ๣ࢆάᛶ໬ࡋ࡚୙ᩧ໬ࡍࡿ࢟ࣛࣝ㓄఩Ꮚࠊ
❅⣲཯ᛂ๣ࢆάᛶ໬ࡋ࡚୙ᩧ໬ࡍࡿ࢟ࣛࣝ㓄఩Ꮚࠊ➼ࡢゐ፹ⓗ࡞୙ᩧ௜ຍ཯ᛂࢆάᛶ໬࡜୙ᩧ໬ࢆ㍈࡜
ࡋ࡚㐩ᡂࡋࡓࠋ
᪂཯ᛂࡢ㛤ᣅ
୧ᮎ➃࡟άᛶ໬ࡉࢀࡓ࢜ࣞࣇ࢕ࣥࢆᣢࡘศᏊࡢࢱࣥࢹ࣒ᆺ❧య㑅ᢥⓗ⎔໬཯ᛂࠊ஧ಶࡢ࢜ࣞࣇ࢕ࣥࢆ
ᣢࡘศᏊࡢࢱࣥࢹ࣒ᆺ❧య㑅ᢥⓗ⎔໬཯ᛂࠊ࢔ࣝࢹࣄࢻ࠿ࡽࡢ┤᥋ⓗ࢔ࢩࣝࣛࢪ࢝ࣝⓎ⏕࡜࢜ࣞࣇ࢕ࣥ
࡬ࡢ௜ຍ⎔໬཯ᛂࠊ᭷ᶵள㖄ࢆࣛࢪ࢝ࣝ㛤ጞ๣࡜ࡍࡿ࢚࣮ࢸࣝ㢮ࡢ࢖࣑ࣥࠊ୙㣬࿴࢝ࣝ࣎ࢽࣝ࡬ࡢ❧య
㑅ᢥⓗ௜ຍ཯ᛂࠊ➼ࡢ໬Ꮫⓗ࡟ࡋ࠿ࡶྜᡂⓗ࡟౯್࠶ࡿ཯ᛂࢆ㛤Ⓨ୰࡛࠶ࡿࠋ
⏕≀άᛶ໬ྜ≀ࡢタィ࡜ྜᡂ
ࢻࣃ࣑ࣥ㹂㸯࢔ࢦࢽࢫࢺ࡛࠶ࡿࢪࣄࢻࣞ࢟ࢩࢪࣥࠊ࠾ࡼࡧࡑࡢ㢮⦕య A-86929ࠊ࢔࣏ࢺ࣮ࢩࢫㄏᑟά
ᛶࢆ♧ࡍࣜࢥࣜࣥ㢮ࡢタィ࡜඲ྜᡂ࡟ᡂຌࡋࠊάᛶࡢቑᙉࢆ᳨ウ୰࡛࠶ࡿࠋ
⏕≀άᛶኳ↛᭷ᶵ໬ྜ≀ࡢ୙ᩧ඲ྜᡂ
㛤ᣅࡋࡓ୙ᩧ཯ᛂࢆᇶ┙࡜ࡋ࡚ࠊᙼᓊⰼ⛉࢔ࣝ࢝ࣟ࢖ࢻࡸᾏὒ⏘ኳ↛᭷ᶵ໬ྜ≀ࡢ඲ྜᡂ࡟ᒎ㛤୰࡛
࠶ࡿࠋ
ศᏊㄆ㆑ࠊ㉸ศᏊᙧᡂࡢ໬Ꮫ
ศᏊᶵ⬟Ⓨ⌧ࡢඖ࡜࡞ࡿ㉸ศᏊᙧᡂࢆ᫂ࡽ࠿࡟ࡍࡿࡓࡵ࡟ࠊ⮬ᕫㄆ㆑ศᏊ࡛࠶ࡿࢪ࢔࣑ࢻࡢ⮬ᕫศᏊ
ㄆ㆑㞟ྜ࡜௚ศᏊ࡜ࡢ㉸ศᏊᙧᡂࢆࢤࣝ໬ࢆྍど໬ᡭẁ࡜ࡋ࡚ᣮᡓࡋ࡚࠸ࡿࠋ┤ิỈ⣲⤖ྜศᏊ࡟ࡼࡿ
Ỉ⣲⤖ྜࡢ⛉Ꮫ࡟ࡶᣮᡓࡋ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯୪ࡧ࡟ࢫࢱࢵࣇࡢཷ㈹͌ ᰤ㌿
㣤⏣ᙲຓᩍᤵࡀ௚኱Ꮫ࡟ᰤ㌿࡛ࡁࡓࡇ࡜ࠊᒣᮏᗣ཭ຓᩍࡀ 2009 ᖺᗘ᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ዡບ㈹ࢆཷ
㈹ࡋࡓࡇ࡜ࠊᒣ⏣೺୍෸ᩍᤵࡀ 2007 ᖺᗘ᪥ᮏ⸆Ꮫ఍ዡບ㈹ࢆཷ㈹ࡋ࡚࠸ࡿࡇ࡜࠿ࡽࡶ◊✲άື࡟ᑐࡍ
ࡿホ౯ࡣࡁࢃࡵ࡚㧗࠸ࠋࡲࡓࠊ◊✲ㄽᩥࡀ Angew. Chem. Int. Ed.ࡢ Hot Paper ࡟᥇⏝ࡉࢀࡓࡇ࡜ࠊཬࡧὀ
┠ࡢㄽᩥ࡜ࡋ࡚ Synfact ࡛⤂௓ࡉࢀࡓࡇ࡜ࡶ◊✲ࣞ࣋ࣝࡢ㧗ࡉࡀᐈほⓗ࡟ホ౯ࡉࢀࡓࡶࡢ࡛࠶ࡿࠋ㸲ே
− 189 −
ࡢ㝔⏕ࡀᏛ⾡᣺⯆఍≉ู◊✲ဨ࡟᥇⏝ࡉࢀࠊᩍ⫱࡜◊✲ࡢࣞ࣋ࣝࡢ㧗ࡉࡢᐈほⓗド࡛࠶ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ 2 ᅇ⏕๓ᮇㄢ⛬ࡢኳ↛≀⸆Ꮫ I㸦ኳ↛≀໬Ꮫ㸧ཬࡧ 3 ᅇ⏕ᚋᮇㄢ⛬ࡢ᭷ᶵ໬Ꮫ IV
㸦⢭ᐦ᭷ᶵྜᡂ㸧ࢆᢸᙜࡋ࡚࠸ࡿࠋタᐃࡋࡓᏛ⩦┠ᶆࢆᏛ⏕࡟ᥦ♧ࡋࠊࡋ࠿ࡶ୍᪉㏻⾜ࡢㅮ⩏࠿ࡽ཮᪉
ྥࡢᏛ⩦࡜࡞ࡿࡼ࠺࡟₇⩦ᙧᘧࢆྲྀධࢀࡓㅮ⩏࡟ྲྀ⤌ࢇ࡛࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗ㓄ᒓࡢᏛ⏕࡟ࡶࠊಶࠎ࡟ࢸ࣮࣐ࢆ୚࠼ࠊ⮬ศ࡛௙஦ࢆ㐍ࡵࡿ⬟ຊ㛤Ⓨ
ࡢᶵ఍ࢆ୚࠼࡚࠸ࡿࠋᙜศ㔝ࡢ᭱኱ࡢ≉㛗ࡣࠊಶࠎࡢ㝔⏕ࡀಶࠎࡢࢸ࣮࣐ࢆᣢࡕ୍ே࡛❧ࡕྥ࠿࠺Ⅼ࡟
࠶ࡿࠋẖ㐌ࡢᐇ㦂ሗ࿌఍࡛Ꮫၥࣞ࣋ࣝࡢᙉ໬ࢆᅗࡿᶵ఍ࢆᣢࡘ࡜࡜ࡶ࡟ඹྠ◊✲ࡢ㐍ࡵ᪉ࢆᏛࢇ࡛ࡶࡽ
ࡗ࡚࠸ࡿࠋᡂᯝࡀฟ࡚࠸ࡿ㝔⏕࡟ࡣ 15 ศ௨ୖࡢ⧳ࡲࡗࡓヰࡀฟ᮶ࡿᏛ㒊ࡢᯟࢆ㉸࠼ࡓウㄽ఍࡛Ⓨ⾲ࡍ
ࡿᶵ఍ࢆᣢࡘࡇ࡜ࢆዡບࡋ࡚࠸ࡿࠋ
ࡉࡽ࡟ࠊⓎ⾲ⱥㄒㄽᩥࢆྛಶேࡀ᭩ࡃࡇ࡜ࢆ┠ᶆ࡜ࡋ࡚࠾ࡾࠊᵓ᝿ຊ࡜Ⓨ⾲ຊࡢ⦎☻ࢆᐇ⾜ࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊ࡯ࡰẖᅇᑠヨ㦂ࢆ⾜࠸㐩ᡂᗘࢆ☜ㄆࡍࡿᙧᡂⓗホ౯ࢆྲྀࡾධࢀ࡚࠸ࡿࠋࡉ
ࡽ࡟ᤵᴗホ౯ࡶಶேⓗ࡟⾜ࡗ࡚ཧ⪃࡟ࡋࠊㅮ⩏ࡢᨵၿࢆᚰࡀࡅ࡚࠸ࡿࠋ
ᐩᒸࡀ㉱௵ࡋࡓ 1996 ᖺ௨㝆ࡢ 15 ᖺ㛫࡛ࠊ༤ኈㄢ⛬ಟ஢⪅ࡣ 35 ྡ࡟㐩ࡍࡿࠋࡑࡢᚋࡢ㐍㊰ࡣࠊእᅜ
࣏ࢫࢻࢡ␃Ꮫ 6 ྡࠊᅜෆ࣏ࢫࢻࢡ 2 ྡࠊ኱Ꮫཬࡧබⓗ◊✲ᶵ㛵 6 ྡ࡛࠶ࡾࠊࡲࡓࡑࡢ௚ࡣ〇⸆࠾ࡼࡧ໬
Ꮫ⣔࣓࣮࣮࢝ࡢ◊✲⫋࡟ࡘ࠸࡚࠾ࡾࠊᩍ⫱࡜◊✲ࡢ㧗࠸ࣞ࣋ࣝࡀホ౯ࡉࢀ࡚࠸ࡿ⤖ᯝ࡛࠶ࡿࠋ
㸦ཎⴭ㸧
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Stereoselective Formal Synthesis of (+)-Allokainic Acid via Thiol-mediated Acyl Radical Cyclization. K.
Yamada, T. Sato, M. Hosoi, Y. Yamamoto & K. Tomioka, Chem. Pharm. Bull. 2010, 58 (11), 1511-1516.
NMR Studies of a Ternary Complex Reagent of Lithium Ester Enolate, Chiral Diether, and Lithium
Diisopropylamide in an Asymmetric Michael Reaction. Y. Yamamoto, Y. Yasuda, H. Oulyadi, J. Maddaluno
& K. Tomioka, Tetrahedron 2010, 66 (13), 2470-2473.
Stereoselective Radical Addition of an Acetal to Sterically Tuned Enantiomerically Pure N-Sulfinyl Imines.
T. Akindele, K. Yamada, T. Sejima, M. Maekawa, Y. Yamamoto, M. Nakano & K. Tomioka, Chem. Pharm.
Bull. 2010, 58 (2), 265-269.
Chiral Carbene Approach to Gold-Catalyzed Asymmetric Cyclization of 1,6-Enynes. Y. Matsumoto, K. B.
Selim, H. Nakanishi, K. Yamada, Y. Yamamoto & K. Tomioka, Tetrahedron Lett. 2010, 51 (2), 404-406.
Efficient Chiral N-Heterocyclic Carbene/Copper(I)-Catalyzed Asymmetric Allylic Arylation with Aryl
Grignard Reagents. K. B. Selim, Y. Matsumoto, K. Yamada & K. Tomioka, Angew. Chem. Int. Ed. 2009, 48
(46), 8733-8735.
Steric Tuning of the Amidomonophosphane-Rhodium(I) Catalyst in Asymmetric Addition of Arylboroxines
to N-Phosphinoyl Aldimines. X. Hao, M. Kuriyama, Q. Chen, Y. Yamamoto, K. Yamada & K. Tomioka, Org.
Lett. 2009, 11 (19), 4470-4473.
Iron Chloride Enhancement of Dimethylzinc-Mediated Radical Conjugate Addition of Ethers and an Amine
to Alkylidenemalonates. K. Yamada, M. Maekawa, Y. Yamamoto, M. Nakano, T. Akindele & K. Tomioka,
Tetrahedron Lett. 2009, 50 (44), 6040-6043.
Chiral Amidophosphane-Rhodium(I)-Catalyzed Asymmetric Conjugate Arylation of Acyclic Enones with
Arylboronic Acids. Q. Chen, M. Kuriyama, X. Hao, T. Soeta, Y. Yamamoto, K. Yamada & K. Tomioka,
Chem. Pharm. Bull. 2009, 57 (9), 1024-1027.
Asymmetric Construction of Binaphthyl by the Chiral Diether-Mediated Conjugate Addition of
Naphthyllithium to Naphthalenecarboxylic Acid BHA Ester. M. Shindo, Y. Yamamoto, K. Yamada & K.
Tomioka, Chem. Pharm. Bull. 2009, 57 (7), 752-754.
Asymmetric Construction of Three Contiguous Stereogenic Centers by Conjugate Addition-Alkylation of
Lithium Ester Enolate. Y. Yamamoto, Y. Yasuda, H. Nasu & K. Tomioka, Org. Lett. 2009, 11 (9), 2007-2009.
Enantioselective Conjugate Addition of a Lithium Ester Enolate Catalyzed by Chiral Lithium Amides: a
Possible Intermediate Characterized. Baptiste Lecachey, Nicolas Duguet, Hassan Oulyadi, Catherine
Fressigné, Anne Harrison-Marchand, Y. Yamamoto, K. Tomioka & J. Maddaluno, Org. Lett. 2009, 11 (9),
1907-1910.
Accessing the Amide Functionality by the Mild and Low-Cost Oxidation of Imine. M. A. Mohamed, K.
Yamada & K. Tomioka, Tetrahedron Lett. 2009, 50 (26), 3436-3438.
Total Synthesis of (–)-Lycorine and (–)-2-epi-Lycorine by Asymmetric Conjugate Addition Cascade. K.
Yamada, M. Yamashita, T. Sumiyoshi, K. Nishimura & K. Tomioka, Org. Lett. 2009, 11 (7), 1631-1633.
Asymmetric Construction of Quaternary Carbon Centers by Sequential Conjugate Addition of Lithium
− 190 −
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
Amide and in situ Alkylation: Utility in the Synthesis of (–)-Aspidospermidine. M. Suzuki, Y. Kawamoto, T.
Sakai, Y. Yamamoto & K. Tomioka, Org. Lett. 2009, 11 (3), 653-655.
Tandem Conjugate Addition-Aldol Cyclization of 2-Formylbenzylidenemalonate with Ether Radicals by the
Mediation of Dimethylzinc. K. Yamada, M. Maekawa, T. Akindele, Y. Yamamoto, M. Nakano & K. Tomioka,
Tetrahedron 2009, 65 (4), 903-908.
Catalytic Asymmetric Intramolecular Allylation of Aldehyde. T. Sato & K. Tomioka, Heterocycles 2009, 77
(1), 587-593.
Chemoselective Conjugate Addition of Dimethylzinc-Mediated Ether and Acetal Radicals to
Alkylidenemalonates and Asymmetric Reactions. K. Yamada, M. Maekawa, T. Akindele, M. Nakano, Y.
Yamamoto & K. Tomioka, J. Org. Chem. 2008, 73 (24), 9535-9538.
Tin-free Radical Addition of Acyloxymethyl to Imines. K. Yamada, M. Nakano, M. Maekawa, T. Akindele
& K. Tomioka, Org. Lett. 2008, 10 (17), 3805-3808.
Copper-Catalyzed Asymmetric Allylic Substitution with Aryl and Ethyl Grignard Reagents. K. B. Selim, K.
Yamada & K. Tomioka, Chem. Commun. 2008, (41), 5140-5142.
Consecutive Cyclization of Allylaminoalkene by Intramolecular Aminolithiation-Carbolithiation. S.
Tsuchida, A. Kaneshige, T. Ogata, H. Baba, Y. Yamamoto & K. Tomioka, Org. Lett. 2008, 10 (16),
3635-3638.
A Ternary Complex Reagent for An Asymmetric Michael Reaction of Lithium Ester Enolates with Enoates.
Y. Yamamoto, H. Suzuki, Y. Yasuda, A. Iida & K. Tomioka, Tetrahedron Lett. 2008, 49 (31), 4582-4584.
Conjugate Addition of THF-2-yl Radical with Ș,ș-Unsaturated N-Tosyl Imines Using a Dimethylzinc-Air
Initiator. K. Yamada, H. Umeki, M. Maekawa, Y. Yamamoto, T. Akindele, M. Nakano & K. Tomioka,
Tetrahedron 2008, 64 (30-31), 7258-7265.
C2 Symmetric Chiral NHC Ligand for Asymmetric Quaternary Carbon Constructing Copper-Catalyzed
Conjugate Addition of Grignard Reagents to 3-Substituted Cyclohexenones. Y. Matsumoto, K. Yamada & K.
Tomioka, J. Org. Chem. 2008, 73 (12), 4578-4581.
Base-Induced Sequential Cyclization-Rearrangement of Enantioenriched 3-Aminoalkanoates to Five- and
Seven-Membered Lactam. T. Sakai, K. Yamada & K. Tomioka, Chem. Asian J. 2008, 3 (8), 1486-1493.
Amidophosphane-Copper(I)-Catalyzed Asymmetric Conjugate Addition of Dialkylzinc Reagents to Racemic
6-Substituted Cyclohexenones to Form 2,5-Di- and 2,2,5-Trisubstituted Cyclohexanones. K. Selim, T. Soeta,
K. Yamada & K. Tomioka, Chem. Asian J. 2008, 3 (2), 342-350.
Catalytic Asymmetric Intramolecular Hydroamination of Aminoalkenes. T. Ogata, A. Ujihara, S. Tsuchida, T.
Shimizu, A. Kaneshige & K. Tomioka, Tetrahedron Lett. 2007, 48 (38), 6648-6650.
Asymmetric Synthesis of 3-Amino-2-hydroxyalkanoates by Mannich Reaction of Menthyl Acetate with
Imines and Subsequent Oxidation. S. Hata and K. Tomioka, Tetrahedron 2007, 63 (35), 8514-8520.
Kinetic Resolution of 5-Substituted Cycloalkenones by Peptidic Amidophosphane-Copper-Catalyzed
Asymmetric Conjugate Addition of Dialkylzinc. T. Soeta, K. Selim, M. Kuriyama and K. Tomioka,
Tetrahedron 2007, 63 (28), 6573-6576.
Peptidic Amidomonophosphane Ligand for Copper-Catalyzed Asymmetric Conjugate Addition of
Diorganozincs to Cycloalkenones. T. Soeta, K. Selim, M. Kuriyama & K. Tomioka, Adv. Synth. Catal. 2007,
349 (4-5), 629-635.
Asymmetric Radical Addition of Ethers to Enantiopure N-p-Toluenesulfinyl Aldimines, Mediated by
Dimethylzinc-Air. T. Akindele, Y. Yamamoto, M. Maekawa, H. Umeki, K. Yamada & K. Tomioka, Org. Lett.
2006, 8 (25), 5729-5732.
Enantioselective Conjugate Addition of a Lithium Ester Enolate Catalyzed by Chiral Lithium Amides. N.
Duguet, A. Harrison-Marchand, J. Maddaluno & K. Tomioka, Org. Lett. 2006, 8 (25), 5745-5748.
Efficient Catalytic Asymmetric Synthesis of trans-2-substituted 5-Arylcyclohexanones by
Rhodium-Catalyzed Conjugate Arylation of Racemic 6-Substituted Cyclohexenones. Q. Chen, T. Soeta, M.
Kuriyama, K. Yamada & K. Tomioka, Adv. Synth. Catal. 2006, 348 (18), 2604-2608.
C2 Symmetric Chiral N-Heterocyclic Carbene Catalyst for Asymmetric Intramolecular Stetter Reaction. Y.
Matsumoto & K. Tomioka, Tetrahedron Lett. 2006, 47 (33), 5843-5846.
Chiral Ligand-Controlled Asymmetric Conjugate Amination of Enoates with Lithium
Mesitylmethyl(trimethylsilyl)amide. T. Sakai, H. Doi & K. Tomioka, Tetrahedron 2006, 62 (35), 8351-8359.
Asymmetric Synthesis of Intermediates for Otamixaban and Premafloxacin by the Chiral Ligand-Controlled
Asymmetric Conjugate Addition of a Lithium Amide. T. Sakai, Y. Kawamoto & K. Tomioka, J. Org. Chem.
2006, 71 (12), 4706-4709.
Tin-free Intermolecular Addition of Primary Alkyls to Imines via Dimethylzinc-Air Radical Process. K.
Yamada, Y. Yamamoto, M. Maekawa, T. Akindele, H. Umeki & K. Tomioka, Org. Lett. 2006, 8 (1), 87-89.
㸦⥲ㄝ㸧
− 191 −
1.
2.
3.
4.
5.
6.
Dimethylzinc Initiated Radical Reactions. T. Akindele, K. Yamada & K. Tomioka, Acc. Chem. Res. 42 (2),
345-355 (2009).
Aminolithiation of Carbon-Carbon Double Bonds as A Powerful Tool in Organic Synthesis. K. Tomioka,
T. Sakai, T. Ogata & Y. Yamamoto, Pure Appl. Chem. 81 (2), 247-253 (2009).
Copper-catalyzed Asymmetric Alkylation of Imines with Dialkylzinc and Related Reactions. K. Yamada &
K. Tomioka, Chem. Rev. 108 (8), 2874-2886 (2008).
ືࡁฟࡍࠕ໬ྜ≀ࣂࣥࢡࠖ࡬ࡢᮇᚅ. ᐩᒸ Ύࠊ⸨஭ಙᏕࠊ໬Ꮫࠊ62 (5)ࠊ18-20 (2007).
་⸆ရࡢࣉࣟࢭࢫ໬Ꮫ࡜ゐ፹. 㛫℩ಇ᫂ࠊᐩᒸ Ύࠊゐ፹ࠊ49 (3)ࠊ184-188 (2007).
Asymmetric Synthesis of Intermediates for Otamixaban and Premafloxacin by the Chiral
Ligand-Controlled Asymmetric Conjugate Addition of a Lithium Amide. K. Tomioka, Pure Appl. Chem. 78
(11), 2029-2034 (2006).
㸦ⴭ᭩㸧
1.
2.
᭷ᶵ໬Ꮫ̾ ࡇࡢ ᖺࡢ㐍Ṍࢆ᣺ࡾ㏉ࡾ㸪ࡑࡢᮍ᮶ࢆㄒࡿᐩᒸ Ύ㸦໬Ꮫྠே⦅㞟㒊⦅ࠊඹⴭ㸧
ࠊ
໬Ꮫྠே
Cumulenes and Allenes, Synthesis by Substitution. H. Ohno & K. Tomioka, Science of Synthesis, Vol. 44,
71–174, Houben-Weyl (2007).
㸦ヂ᭩㸧
ࣈ࣮ࣝࢫ᭷ᶵ໬Ꮫ➨㸳∧ୖୗ኱⯪Ὀྐࠊ㤶᭶ ູࠊす㒓࿴ᙪࠊᐩᒸ Ύ㸦┘ヂ㸸2UJDQLF&KHPLVWU\
93DXOD<%UXLFH3UHQWLFH+DOO㸧
ࠊ໬Ꮫྠே
ࣈ࣮ࣝࢫ᭷ᶵ໬Ꮫᴫㄝ኱⯪Ὀྐࠊ㤶᭶ ູࠊす㒓࿴ᙪࠊᐩᒸ Ύ㸦┘ヂ㸸(VVHQWLDO2UJDQLF
&KHPLVWU\3DXOD<%UXLFH3UHQWLFH+DOO㸧
ࠊ໬Ꮫྠே
ேྡ཯ᛂ࡟Ꮫࡪ᭷ᶵྜᡂᡓ␎ᐩᒸ Ύ㸦┘ヂ㸸6WUDWHJLF$SSOLFDWLRQVRI1DPHG5HDFWLRQVLQ
2UJDQLF6\QWKHVLV/£V]Oµ.¾UWL%DUEDUD&]DNµ(OVHYLHU㸧
ࠊ୸ၿ
− 192 −
N
%&X
Ŵ ŬɬȉĝèĐɭǣƌ ºóɬ9.RA U23ɭɬ
ſ²ɭ
ƂüɵɸĿĔɖĔĝæƂüɶɳĿõĔĝĔĝəȉĝǗǠǜèĐȨǞ¾£
ËŴŬɬȉĝèĐɭĤɊ ȰªɬOSK H@Aɭ
ſ² É
ŅâǍĔĝȉĝɊŴŬ@ȸÌ
ľśɳĿĔɖĔĝæľśɸĿõĔĝĔĝəȉĝǗǠǜèĐȨǞ¾£
ËŴŬɬèĐɬȉĝɭɭɪɢ ƱȦɬ9)4 +U6%ɭ
ɬ ƏáĔĝĔ
ĝəȉĝǗǠǜȬļ)VNjÞɭ
ľśɵĿ©ɋĔĝæľś ĿõĔĝĔĝəȉĝǗǠǜèĐȨǞ¾£
ÙŴɬèĐɬDžĝɭ
ɭ Ч ǹǪɬS4% U25OɭŮLj
ƏáĔĝêĚÍĚƍŸǜĝɪǥǗǠơƞÙŴ@ȸÌ
ľśɱɱĿƏ©ĸƛĔĝæľś ĿõĔĝĔĝəDžĸĝǗǠǜèĐȨǞ¾£
ÙŴɬèĐɬLJûǜĝɭɭčɎ äĮɬ=)E ;HZɭɬ ƏáĔĝĔĝəDžĝǗǠǜÙŴ)
VNjÞɭ
ľśɱɳĿƏ©ĔĝæľśɱɸĿƏáĔĝĔĝəLJûǜĝǗǠǜèĐȨǞ¾£
ÙŴɬ¾Đɬȉĝɭɭǀƹ ǻɬ%E,N =G1ɭɬ ŮLjɭ
ľśɱɷĿ©ɋĔĝæľśɱɹĿ©ɋĔĝĔĝəȉĝǗǠǜ¾ĐȨǞ¾£
BD6P
ňȉýÍĚàĝÍɎFÕȉǗǠEƗŀACXƇơàĝ\ǗǠ™ŴȀ4X0A\»ûA2ˆ—sqǗ
ǠA{`o~•kŽq|”šEŸɠ)VâȉýɓǎǗǠDȱǁ@+X"‘>,W#Dɕ4Xź2%
ƝŒAŠȌ\ÕɁ2N97Y\Ģȶ@+XÕȉǗǠǽEȀś\ǓǐA2?%X 7E @Ƈơɏĵ
àôƼEƽŔ\ÒLj29ź2%ÍĚđŰƬEɓŦdžĎȩüĉȘęôśîőEɓǎLJƼƯŔĕƸƇơ
àôƼEÆôśǗǠơȂŔÍĚEÕȎ\¢ȑǗǠȨɣA2NJƉǐC‘>,WEŠȌÕÌAźȓơ
ȂŔÍĚEÕȎ\ȿ2?Ǜ´JEȱǁ\Ǔũ2?%X 37Y);<-?1Q,Z@
CBEɇǝɏĵ\ǗǠīȯA2?źȓîőEɓǎ\ƚȚ2?%X ƶǫšƶǫ
ɦüDZôJEȖüŔ*ɪ%u†|C•aqɍ@$X S \Lj%?âȉýA2?
¼ÀEɪ%„}—aug”˜ɥSaui—‘˜ɥEÜǂǐ)=ƩLjŔE$XȘęǐôśƬ\ǘǢ2
9 N9¶êĚ¼ Șę*›ȅǐDFƯŔ@$Xƶǫšƶǫ$X%FƶǫšƧǫDZôEÎŹD
ƇÜ@$X0A\ȒÌ2ÅŞĦƁCo_hɍ_Ž}Shɍ_Ž}\ÌǎêŸA29ǟ!E ǸŰĉ
egoa˜}š•Ȥį¸E“a‡“ašôśCVIDȘęǐŷôśJAĴɓ29 ="U!37.,Z/
ŽěE¢ȑîő\LJ¸(UIdžĎDƇĥCɏĵȠȉSƇơƴę\Lj%C%źȓîőJ¯Ƅ4X0A
FɫÖǐCǗǠȨɣ@$X 7EȗƪƬEɱ=A2?ɏĵÃǫ\»[C%ƇơÍĚȘęA2?ēơȂ
Ŕxeb–_ȘęEÕȎA7EŷôśîőJEőLjD=%?ïWǯ]: 7EDZƑ_Žxeb–
_Șę*ak•îő°ĒDRēƟFƨƖ®ØîőDÒLjñȂ@$X0A\ƀV)D2Ţ&=ÔCB
Ł=)EâȉýEŷôśDőLj29 1VD0YN@ƨƖÔA2?ÒLj@+C)<9_•k•Ċ
E®Øîő\ñȂA4X9Q_Ž_•lš•ƞɁ\ǯOȺ]:źȓxeb–_Șę\ź9Dɓ
ǎ2ƇơŠbǫȠȉ\Lj%?g”˜Ȥį¸EɲµJǟ!E_•k•Ċ\įÅ@+XȘęǐŷô
śîő\ǘǢ29 .*CAHK
VF,Z@
ȏɞCÍĚƞɁ\Ũ=LJDžƯŔƼȳFŵē,ěć27EȏɞŔDȴă2?ÎYúEU%ơȂŔ\ǚ
4Čô*ē% 2)2ŎƎEŻƬȫ@FÍĚEȏɞŔ*ď4D=YôśDȑ4XȋǞŵFď'XA%
&Ĕ+Cÿɣ*$X ňǗǠģ@F•xvqiơȂ\R=ȘęDǕǓ2Ɵ!CÍĚđŰ\ɂdzǐ
DɄȋ16Xɂdzîőˆ—sqEɓŦDŪŝ2?%X DŽćŇÖC‡–˜qzy}ɍ*‚“dz`D
Ĩ]:ÍĚƯŔàȂÖ\Ũ=0A\ȒÌ4AARD7YVEîőƽŔ\ĹODÒLj29ɂdzîőDU
− 193 −
ࡿ㧗ᗘศᏊኚ᥮࡟ᡂຌࡋ࡚࠸ࡿࠋ௒ᚋࡣࠊ␗࡞ࡿ࣐ࣝࢳࢱࢫࢡᶵ⬟ゐ፹ࡢ᥈⣴ࢆྵࡵࠊ཯ᛂࡢ㏿ᗘㄽ࠾
ࡼࡧ⇕ຊᏛㄽⓗ≉ᛶࢆά⏝ࡋ࡚ࡼࡾ㧗ᗘ࡞㐃⥆཯ᛂࣉࣟࢭࢫࡢ㛤Ⓨࢆ┠ᣦࡍ࡜࡜ࡶ࡟ࠊ௜ຍ౯್ࡢ㧗࠸
᭷⏝≀㉁ࡢຠ⋡ⓗ࡞ྜᡂἲ࡜ࡋ࡚ࡢᛂ⏝ࢆ᳨ウ୰࡛࠶ࡿࠋ
‫≀⏕ۑ‬άᛶኳ↛᭷ᶵ໬ྜ≀ࡢ඲ྜᡂ◊✲
⯆࿡῝࠸⏕≀άᛶࢆ᭷ࡍࡿኳ↛≀ࡣ❅⣲ཎᏊࢆྵࡴ」㞧࡞㦵᱁࠿ࡽ࡞ࡿࡇ࡜ࡀከ࠸ࠋ⌧ᅾࠊ࢟ࣀࣜࢪ
ࢪࣥ㦵᱁࡜ࢫࣆࣟ࢜࢟ࢩ࢖ࣥࢻ࣮ࣝ㦵᱁࡞࡝ࢆྲྀࡾୖࡆࠊࡇࢀࡽྵ❅⣲㦵᱁ࢆຠ⋡ⓗ࡟ྜᡂࡍࡿࡓࡵ࡟
᪂つྜᡂ᪉ἲㄽࡢ㛤Ⓨࢆ⾜ࡗ࡚࠸ࡿࠋࡇࢀࡲ࡛࡟㑏ඖⓗ⎔໬࡟ࡼࡿ࢟ࣀࣜࢪࢪࣥ㦵᱁ࡢᵓ⠏ἲࡸࠊࣃࣛ
ࢪ࣒࢘ゐ፹ࢆ⏝࠸ࡓ཯ᛂ࡟ࡼࡿࢫࣆࣟ࢜࢟ࢩ࢖ࣥࢻ࣮ࣝ㦵᱁ᵓ⠏ἲࢆ㛤Ⓨࡋ࡚࠾ࡾࠊࡲࡓࠊࣜࢥࢪࣥࡢ
඲ྜᡂࡸ࢚ࣛࢥ࣑ࣥ㢮ࡢᙧᘧྜᡂࢆ㐩ᡂࡋ࡚࠸ࡿࠋ⌧ᅾࠊࡇࢀࡲ࡛࡟㛤Ⓨࡋࡓᡭἲࢆ⏝࠸࡚࣍ࣔࣉ࣑ࣜ
࢜ࢺ࢟ࢩࣥ㢮ࡸ⣽⬊ẘᛶࢆ᭷ࡍࡿࢥ࣒ࢿࢩࣥ㢮ࡢ඲ྜᡂ◊✲ࢆᒎ㛤୰࡛࠶ࡿࠋࡲࡓࠊ⊂⮬࡟㛤Ⓨࡋࡓྜ
ᡂ᪉ἲㄽ࡜඲ྜᡂ⤒㊰ࢆຠ⋡ࡼࡃ฼⏝ࡋ࡚ࠊከ✀ࡢᵓ㐀㢮⦕యྜᡂ࡜ᵓ㐀άᛶ┦㛵◊✲ࡉࡽ࡟ࡣ་⸆ရ
㛤Ⓨ࡬ࡢࢩ࣮ࢻ໬ྜ≀ࡢ᥈⣴࡬࡜ᒎ㛤ࡍࡿࡇ࡜ࢆ┠ᣦࡋ࡚࠸ࡿࠋ
‫ۑ‬ᶵ
ᶵ⬟ᛶศᏊࡢ๰〇
࠶ࡿ✀ࡢపศᏊࡣࠊ⏕యෆ࡟࠾࠸࡚ࢱࣥࣃࢡ㉁ࡸ㹂㹌㸿ࠊ⢾㙐➼࡜≉␗࡞┦஫స⏝ࢆ㉳ࡇࡍࡇ࡜࡛ࠊ
ࡑࢀࡒࢀᅛ᭷ࡢ⏕యᛂ⟅ࢆ♧ࡍࠋᙜ◊✲ᐊ࡛ࡣࠊ⏕య㧗ศᏊ࡜ඹ᭷⤖ྜࡸ㠀ඹ᭷⤖ྜࢆ௓ࡋ࡚≉␗ⓗ࠿
ࡘ㑅ᢥⓗ࡞┦஫స⏝ࡀ࡛ࡁࡿపศᏊ໬ྜ≀ࡢタィ࡜㛤Ⓨ࡟ྲྀ⤌ࢇ࡛࠸ࡿࠋ᭱㏆≉࡟ὀ┠ࡉࢀ࡚࠸ࡿศᏊ
࢖࣓࣮ࢪࣥࢢศ㔝࡛ࡣࠊ⏕య㧗ศᏊࢆ㧗㑅ᢥⓗ࡟໬Ꮫಟ㣭ࡋࡓ࠺࠼࡛㧗ឤᗘ࡟ྍど໬࡛ࡁࡿపศᏊࡢ㛤
Ⓨࡀᮃࡲࢀ࡚࠸ࡿࠋ㧗࠸᭷ᶵྜᡂຊࢆࣂࢵࢡ࣮࣎ࣥ࡜ࡋ࡚ࠊᅛ᭷ࡢ⏕య⎔ቃ࡟ᛂ⟅ࡋ࡚ᶵ⬟ኚ໬ࡍࡿࡇ
࡜࡛≉␗ⓗ࡟ࢱࣥࣃࢡ㉁➼ࢆ໬Ꮫಟ㣭࡛ࡁࡿపศᏊࡢ㛤Ⓨࢆᒎ㛤୰࡛࠶ࡿࠋᑗ᮶ⓗ࡟ࡣࠊ㠀౵くᛶデ᩿
⸆ࡸ㹂㹂㹑ᢏ⾡࡟ᒎ㛤࡛ࡁࡿᶵ⬟ᛶపศᏊࡢ㛤Ⓨࢆ┠ᣦࡍணᐃ࡛࠶ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ࡇࡢ㸳ᖺ㛫࡟㸰ྡࡢᩍဨࡀ᪼㐍㌿ฟࡋࡓࡓࡵ෸ᩍᤵࠊຓᩍ࡜ࡶධࢀ᭰ࢃࡗࡓࡀࠊศ㔝ࡢᩍ⫱࡜◊✲య
ไࢆ⥔ᣢࡋࡘࡘ◊✲ㄢ㢟ࡢ㌿᥮ࢆᅗࡿࡇ࡜ࡀ࡛ࡁࡓࠋㄽᩥ⥲ᩘࡣῶᑡࡋࡓࡀࠊᖺᖹᆒࡢㄽᩥⓎ⾲ᩘࡣ ሗ࡜άⓎ࡞◊✲άືࢆ⥅⥆ࡋ࡚࠸ࡿࠋ୍᪉ࠊᏛ఍Ⓨ⾲࡟㛵ࡋ࡚ࡣࠊᩍဨࡢᣍᚅㅮ₇㸦 ௳࠿ࡽ ௳㸧
࡜Ꮫ⏕ࡢᅜ㝿Ꮫ఍࡛ࡢⓎ⾲௳ᩘ㸦 ௳࠿ࡽ ௳㸧ࡀ࡜ࡶ࡟ቑຍഴྥ࡟࠶ࡾࠊᡃࠎࡢ◊✲ᡂᯝࡀᅜෆእ࡛
ㄆࡵࡽࢀ࡚ࡁࡓࡇ࡜ࢆ♧ࡋ࡚࠸ࡿࠋࡲࡓࠊඹྠ◊✲άື࡜ࡋ࡚᪂ࡓ࡞௻ᴗ࡜ࡢඹྠ◊✲࣭ཷク◊✲ࢆ㛤
ጞࡋࠊࡑࡢᡂᯝ࡜ࡋ࡚㸲௳ࡢ≉チྲྀᚓ࠾ࡼࡧ㸰௳ࡢ≉チฟ㢪ࢆ⾜࠸ࠊ♫఍࠿ࡽせᮃࡢᙉ࠸◊✲ศ㔝࡟ࡶ
㈉⊩ࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋࡇࡢ㸳ᖺ㛫࡛඲࡚ࡢᩍဨࡀ᪥ᮏ⸆Ꮫ఍ࢆࡣࡌࡵᅜෆእ࠿ࡽ᣺⯆㈹ࡸዡບ㈹ࢆཷ
㈹ࡋ࡚࠸ࡿࡇ࡜ࠊࡉࡽ࡟኱Ꮫ㝔Ꮫ⏕ࡶ➨ ᅇᅜ㝿」⣲⎔໬Ꮫ఍㆟㸦 ᖺ㸧࡜➨ ᅇ᭷ᶵྜᡂⱝᡭࢭ
࣑ࢼ࣮࡟࠾࠸࡚࣏ࢫࢱ࣮㈹㸦 ᖺ㸧ࢆཷ㈹ࡋࡓࡇ࡜࠿ࡽ㧗࠸◊✲ホ౯ࢆᚓ࡚࠸ࡿ࡜⪃࠼࡚࠸ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ㸯ᅇ⏕ᚋᮇࡢᇶ♏᭷ᶵ໬Ꮫ %ࠊ㸰ᅇ⏕ᚋᮇࡢ᭷ᶵ໬Ꮫ㸰࡜㸱ᅇ⏕ᚋᮇࡢ๰⸆᭷ᶵ
໬Ꮫ࢚ࢡࢧࢧ࢖ࢬࡢㅮ⩏ࢆᢸᙜࡋ࡚࠸ࡿࠋᏛ⏕࠿ࡽࡢᤵᴗ࢔ࣥࢣ࣮ࢺࡢホ౯ࢆཧ⪃࡟ࡋ࡚ࠊศ࠿ࡾ࡟ࡃ
࠸࡜ᢈุࡢᝏ࠿ࡗࡓศᏊࡢ❧యᵓ㐀࡜཯ᛂᛶ࡟ࡘ࠸࡚ࡣࠊศᏊᶍᆺࡸど⫈ぬᶵჾࢆ฼⏝ࡋ࡚య㦂࡛ࡁࡿ
ㅮ⩏ᙧែࢆ୍㒊ᑟධࡋࡓࠋᩍ⛉᭩ࡢࡳ࡛ࡣ୙༑ศ࡞Ⅼࡣࣉࣜࣥࢺࢆసᡂ࣭㓄௜ࡋࠊᑠࢸࢫࢺࢆ࡛ࡁࡿ㝈
ࡾẖᅇࡢㅮ⩏࡛ᐇ᪋ࡋ࡚Ꮫ⏕ࡢ⌮ゎᗘࢆᢕᥱࡋ࡞ࡀࡽㅮ⩏ࢆ㐍ࡵࡿࡼ࠺ᚰ᥃ࡅ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸Ꮫ㒊⏕࡜኱Ꮫ㝔⏕ࡣࡍ࡭࡚ᩍဨࡀᢸᙜࡍࡿᗄࡘ࠿ࡢࢢ࣮ࣝࣉ࡟㓄ᒓࡋࠊࡑ
ࡢࢢ࣮ࣝࣉෆ࡛ಶࠎࡢ⊂❧ࡋࡓࢸ࣮࣐ࢆ୚࠼◊✲ࡢึᮇẁ㝵࠿ࡽ⮬❧࡜⮬୺ᛶࢆព㆑ࡉࡏ࡚࠸ࡿࠋ୍᪉ࠊ
Ꮫ⏕ࡢᏙ❧໬ࢆ㜵ࡄࡓࡵ㛵㐃ࢸ࣮࣐ࢆࢢ࣮ࣝࣉ໬ࡋࠊᩍဨࡔࡅ࡛࡞ࡃᏛ⏕㛫࡛ࡶ◊✲ࡢ᝟ሗ஺᥮ࡸ㆟ㄽ
ࡀ࡛ࡁࡿᕤኵࢆࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊ㝸㐌ࡢಶูᐇ㦂ሗ࿌఍ࠊ㸲༙ᮇࡢ◊✲Ⓨ⾲఍ࠊ༙ᮇࡢ◊✲࣏࣮ࣞࢺ
సᡂ࡞࡝ࢆ㏻ࡌ࡚ࠊᐇ㦂ࢹ࣮ࢱࡢㄽ⌮ⓗ⪃ᐹ࡜ࢹ࢕ࢫ࢝ࢵࢩࣙࣥࡸࣉࣞࢮࣥࢸ࣮ࢩࣙࣥࡢ᪉ἲ࡟ࡘ࠸࡚
㐺ᐅᣦᑟࡋ࡚࠸ࡿࠋᏛ㒊⏕࡟ᑐࡋ࡚ࡣࠊᶵჾศᯒ₇⩦࡜᭷ᶵ໬Ꮫ₇⩦ࢆᩍဨࡀ୺య࡜࡞ࡗ࡚⾜࠸ࠊ኱Ꮫ
㝔⏕࡟ᑐࡋ࡚ࡣຮᙉ఍࡜㍯ㄞࢆ⮬୺ⓗ࡟㛤ദࡉࡏࠊⱥㄒㄽᩥࡢㄞゎຊ࡜᭷ᶵ໬Ꮫࡢᇶ♏Ꮫຊࡢࣞ࣋ࣝᙉ
໬ࢆᅗࡗ࡚࠸ࡿࠋࡲࡓẖ㐌⾜࠺ࢭ࣑ࢼ࣮࡛ࡣࠊㄽᩥ⤂௓ࡔࡅ࡛࡞ࡃࠊ㏿ሗ⤂௓࡜඲ྜᡂࡢ₇⩦ၥ㢟ࡶྲྀ
ࡾධࢀ࡚ᐇ㊶ⓗ࡞ᑓ㛛▱㆑࡜໬ྜ≀ࡢ㏫ྜᡂゎᯒࢆ⪃᱌ࡍࡿᛮ⪃ຊࡀ㌟࡟௜ࡃࡼ࠺࡟ᕤኵࡋ࡚࠸ࡿࠋ༤
ኈㄢ⛬ࡢᏛ⏕࡟ࡣࠊⱥㄒ࡛ࡢࢭ࣑ࢼ࣮Ⓨ⾲࡜ⱥㄒ࡟ࡼࡿㄽᩥసᡂ࡞࡝ࢆㄢࡋ࡚ⱥㄒຊࡢᙉ໬࡟ࡶດࡵ࡚
࠸ࡿࠋࡲࡓࠊ඲࡚ࡢ኱Ꮫ㝔⏕࡟ࡣᏛእ࡛ࡢᏛ఍࣭ウㄽ఍࡟ཧຍࠊⓎ⾲ࡍࡿᶵ఍ࢆ୚࠼࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟㛵ࡋ࡚ࡣࠊ࡯ࡰẖᅇᑠࢸࢫࢺࢆ⾜ࡗ࡚᥇Ⅼᚋ⟅᱌ࢆ㏉༷ࡋᩍဨ࡜Ꮫ⏕୧⪅ࡀ㐩ᡂᗘ
− 194 −
ࢆ☜ㄆࡍࡿᙧᡂⓗホ౯ࢆྲྀࡾධࢀࡓࠋࡇࢀ࡟ࡼࡾⴠ➨⋡ࡀᚎࠎ࡟࡛ࡣ࠶ࡿࡀῶᑡഴྥ࡟࠶ࡿࡇ࡜࠿ࡽࠊ
௒ᚋࡶᮏヨࡳࢆ⥅⥆ࡋ࡚ᐇ᪋ࡋ࡚ࡺࡃணᐃ࡛࠶ࡿࠋ
኱Ꮫ㝔ㅮ⩏࡟㛵ࡋ࡚ࡣࠊᴫㄽ࡜≉ㄽࡢ఩⨨௜ࡅࢆኚ࠼ㅮ⩏య⣔ࡢᢤᮏⓗ࡞ᨵ㠉ࢆ⾜ࡗࡓࠋ኱Ꮫ㝔ㅮ⩏
࡜ศ㔝ෆࡢຮᙉ఍ࢆ᭷ᶵⓗ࡟㐃ᦠࡉࡏࡿࡇ࡜࡛ࠊᖜᗈ࠸Ꮫၥศ㔝࡟ᑐࡍࡿ⌮ゎᗘࢆ῝ࡵࠊࡑࢀࢆᑓ㛛ศ
㔝ࡢ◊✲࡟ά࠿ࡋࠊࡉࡽ࡟᪂ࡋ࠸Ⓨ᝿࡬࡜ᒎ㛤ࡉࡏ࡚ࡺࡃࡇ࡜ࡢ኱ษࡉ࡜ᴦࡋࡉࢆ⌮ゎࡋᐇឤࡋ࡚ࡶࡽ
࠼ࡿࡼ࠺ࡉࡽ࡟ດຊࡋ࡚ࡺࡁࡓ࠸ࠋ
ࡇࡢ㸳ᖺ㛫ࡢ኱Ꮫ㝔ಟ஢⪅ࡢṤ࡝ࡀᕼᮃࡍࡿ኱Ꮫ࣭〇⸆㛵㐃௻ᴗࡢ◊✲⫋࡟ᑵ⫋ࡋ࡚࠸ࡿࡇ࡜࠿ࡽ
㸦༤ኈㄢ⛬ಟ஢⪅㸴ྡࡢ࠺ࡕࠊ኱Ꮫ◊✲⫋ ྡࠊ௻ᴗ◊✲⫋ ྡ㸸ಟኈㄢ⛬ಟ஢⪅㸯㸱ྡࡢෆࠊ༤ኈㄢ
⛬㐍Ꮫ⪅㸳ྡࠊ௻ᴗ◊✲⫋㸳ྡࠊᐁබᗇᶵ㛵㸰ྡࠊࡑࡢ௚㸯ྡ㸧ࠊᙜศ㔝ࡢᩍ⫱࡜◊✲ࡀホ౯ࡉࢀࡓ⤖
ᯝ࡛࠶ࡿ࡜⪃࠼࡚࠸ࡿࠋࡋ࠿ࡋࠊ༤ኈᚋᮇㄢ⛬࡬ࡢ㐍Ꮫ⪅ᩘ࡟㛵ࡋ࡚ࡣࠊᚎࠎ࡟ቑຍࡋ࡚ࡣ࠸ࡿࡶࡢࡢ
ᮍࡔ୙༑ศ࡛࠶ࡾࠊࡉࡽ࡟༤ኈㄢ⛬㐍Ꮫ⪅ᩘࡢቑຍ࡟ດࡵࡓ࠸ࠋ
ཎⴭ
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Kamisaki, H.; Kobayashi, Y.; Kimachi, T.; Yasui, Y.; Takemoto, Y., Synthetic Studies of Salinosporamide A
through Intramolecular Hydroamidation of Alkynes. J. Organomet. Chem. 2010, in press.
Kamisaki, H.; Nanjo, T.; Tsukano, C.; Takemoto Y., Tandem Pd-Catalyzed Heck-Type Cyclization and
Bi-Catalyzed Hydroamination: Formal Syntheses of Elacomine and Isoelacomine. Chem. Eur. J., 2010, in
press.
Shindoh, N.; Takemoto, Y.; Takasu, K., Unprecedented Synthesis of N,N-Divinylamines by
Tf2NH-Catalyzed Reaction of Ynamide with Ketimine. Heterocycles 2010,in press.
Takasu, K.; Azuma, T.; Enkhtaivan, I.; Takemoto, Y., Synthesis and Properties of Chiral Thioureas Bearing
an Additional Function at a Remote Position Tethered by a 1,5-Disubstituted Triazole. Molecules 2010, 15,
8327-8348.
Yoshida, K.; Inokuma, T.; Takasu, K.; Takemoto, Y., Catalytic Asymmetric Synthesis of Both Enantiomers
of 4-Substituted 1,4-Dihydropyridines with the Use of Bifunctional Thiourea-Ammonium Salts Bearing Different Counterions. Molecules 2010, 15, 8305-8326.
Takasu, K.; Tanaka, T.; Azuma, T.; Takemoto, Y., Auto-tandem Catalysis: Facile Synthesis of Substituted
Alkylidenecyclo-hexanones by Domino (4 + 2) Cycloaddition-Elimination Raction. Chem. Commun., 2010,
46, 8246-8248.
Takasu, K.; Nagamoto, Y.; Takemoto, Y., Stereocontrolled Synthesis of Spiro[n.2]alkenes by Ring Contraction of Fused-Cyclobutanols. Chem. Eur. J., 2010, 16, 8427-8432.
Enomoto, T.; Yasui, Y.; Takemoto, Y., Synthetic Study toward Ecteinascidin 743: Concise Construction of
the Diazabicyclo[3.3.1]nonane Skeleton and Assembly of the Pentacyclic Core. J. Org. Chem., 2010, 75,
4876-4879.
Yasui, Y.; Kamisaki, H.; Ishida, T.; Takemoto, Y., Synthesis of 3,3-disubstituted oxindoles through
Pd-catalyzed intramolecular cyanoamidation. Tetrahedron, 2010, 66, 1980-1989.
Yoshida, K.; Inokuma, T.; Takasu, K.; Takemoto, Y., Brønsted AcidʊThiourea Co-catalysis: Asymmetric
Synthesis of Functionalized 1,4-Dihydropyridines from Į-Enaminoesters and Į,ȕ-Unsaturated Aldehydes.
Synlett, 2010, 1865-1869.
Tsukano, C.; Zhao, L.; Takemoto, Y.; Hirama, M., Concise Total Synthesis of (±)-Lycodine. Eur. J. Org.
Chem., 2010, 4198-4200.
Takasu, K.; Azuma, T.; Takemoto, Y., Synthesis of trifunctional thioureas bearing 1,5-disubstituted triazole
tether by Ru-catalyzed Huisgen cycloaddition. Tetrahedron Lett. 2010, 51, 2737-2740.
Kuwahara, A.; Yamamori, M.; Nishiguchi, K.; Okuno, T.; Chayahara, N.; Miki, I.; Tamura, T.; Kadoyama,
K.; Inokuma, T.; Takemoto, Y.; Nakamura, T.; Kataoka, K.; Sakaeda, T.; Effect of dose-escalation of
5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma. Int. J. Med. Sci., 2010, 7, 48-54.
Enantioselective Total Synthesis of (–)- and (+)-Petrosin. Toya, H.; Okano, K.; Takasu, K.; Ihara, M.; Takahashi, A.; Tanaka H.; Tokuyama, H. Org. Lett. 2010, 12, 5196-5199.
Selective Accumulation of Rhodacyanine in the Plasmodial Mitochondria is Related to the Growth Inhibition
of Malaria Parasites. D. Morisaki, H.-S. Kim, H. Inoue, H. Terauchi, S. Kuge, A. Naganuma, H. Tokuyama,
M. Ihara, K. Takasu, Chem. Sci. 2010, 1, 206-209.
Total Synthesis of (±)-Lepadiformine A via Radical Translocation/Cyclization Reaction. Fujitani, M.; Tsuchiya, M.; Okano, K.; Takasu, K.; Ihara, M.; Tokuyama, H. Synlett 2010, 822-826.
Fluorinated Rhodacyanine (SJL-01) Possessing High Efficacy for Visceral Leishmaniasis (VL). Yang, M.;
Arai., C.; Baker, Md. A.; Lu, J.; Ge, J.-F.; Pudhom, K.; Takasu, K.; Kasai, K.; Kaiser, M.; Brun, R.; Yardley,
− 195 −
B.; Itoh, I.; Ihara, M. J. Med. Chem. 2010, 53, 368-373.
18. Inokuma, T.; Takasu, K.; Sakaeda, T.; Takemoto Y., Hydroxyl Group-Directed Organocatalytic Asymmetric
Michael Addition of Į,ȕ-Unsaturated Ketones with Alkenylboronic Acids. Org. Lett., 2009, 11, 2425-2428.
19. Shindoh, N.; Takemoto, Y.; Takasu, K.; Atropisomerism of .alpha.,.beta.-Unsaturated Amidines: Stereoselective Synthesis by Catalytic Cascade Reaction and Optical Resolution. Chem. Eur. J., 2009, 15, 7026-7030.
20. Yasui, Y.; Kinugawa, T.; Takemoto, Y., Synthetic studies on vincorine: access to the
3a,8a-dialkyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole skeleton. Chem. Commun., 2009, 4275-4277.
21. Enomoto, T.; Girard, A.-L.; Yasui, Y.; Takemoto, Y.; Gold(I)-Catalyzed Tandem Reactions Initiated by Hydroamination of Alkynyl Carbamates: Application to the Synthesis of Nitidine. J. Org. Chem., 2009, 74,
9158-9164.
22. Miyabe, H.; Yoshida, K.; Reddy, V. K.; Takemoto, Y.; Palladium or Iridium-Catalyzed Allylic Substitution
of Guanidines: Convenient and Direct Modification of Guanidines. J. Org. Chem., 2009, 74, 305-311.
23. Kamisaki, H.; Yasui, Y.; Takemoto, Y.; Pd-catalyzed intramolecular amidation of
2-(buta-1,3-dienyl)phenylcarbamoyl chloride: a concise synthesis of spiro[indoline-3,3'-pyrrolidine]. Tetrahedron Lett., 2009, 50, 2589-2592.
24. Miyabe, H.; Matsumura, A.; Yoshida, K.; Takemoto, Y. Synthesis of chiral oxime ethers based on regio- and
enantioselective allylic substitution catalyzed by iridium-pybox complex. Tetrahedron, 2009, 65, 4464-4470.
25. Inokuma, T.; Sakamoto, S.; Takemoto, Y.; Enantioselective nitrocyclopropanation of DE-unsaturated
D-cyanoimides catalyzed by bifunctional thiourea. Synlett, 2009, 1627-1630.
26. Yasui, Y.; Kakinokihara, I.; Takeda, H.; Takemoto, Y.; Preparation of Į,ȕ-Unsaturated Lactams through Intramolecular Electrophilic Carbamoylation of Alkenes. Synthesis, 2009, 3989-3993.
27. Takeda, H.; Ishida, T.; Takemoto, Y.; Synthesis of indolo[2,3-b]quinolines by palladium-catalyzed annulation of unsaturated isothioureas. Chem. Lett., 2009, 38, 772-773.
28. Inokuma, T.; Nagamoto, Y.; Sakamoto, S.; Miyabe, H.; Takasu, K.; Takemoto, Y., Asymmetric Synthesis of
4-Substituted 2,6-Dioxopiperidine-3-carbonitrile by Using Thiourea-Catalyzed Asymmetric Michael Addition. Heterocycles, 2009, 79, 573-582.
29. Shindoh, N.; Tokuyama, H.; Takemoto, Y.; Takasu, K., Triflic Imide Catalyzed [3+2] Cycloaddition of Aldimines with Į,Į-Dimethylallylsilane. Heterocycles, 2009, 77, 187-192.
30. Kuwahara, A.; Yamamori, M.; Nishiguchi, K.; Okuno, T.; Chayahara, N.; Miki, I.; Tamura, T.; Inokuma, T.;
Takemoto, Y.; Nakamura, T.; Kataoka, K.; Sakaeda, T., Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell
carcinoma. Int. J. Med. Sci., 2009, 6, 305-311.
31. Shindoh, N.; Takemoto, Y.; Takasu, K.; Auto-Tandem Catalysis: A Single Catalyst Activating Mechanistically Distinct Reactions in a Single Reactor. Chem. Eur. J., 2009, 15, 12168-12179.
32. Yasui, Y.; Takeda, H.; Takemoto, Y.; Toward General Access to the Aspidosperma-Type Terpenoid Indole
Alkaloids: Synthesis of the Key 3,3-Disubstituted Piperidones through Enantioselective Intramolecular
Heck-Type Reaction of Chloroformamides. Chem. Pharm. Bull. 2008, 56, 1567-1574.
33. Xie, J.; Yoshida, K.; Takasu, K.; Takemoto, Y., Thiourea-Catalyzed Asymmetric Formal [3 + 2] Cycloaddition of Azomethine Ylides with Nitroolefins. Tetrahedron Lett. 2008, 49, 6910-6913.
34. Shindoh, N.; Tokuyama, H.; Takemoto, Y.; Takasu, K., Auto-Tandem Catalysis in the Synthesis of Substituted Quinolines from Aldimines and Electron-rich Olefins: Cascade Povarov-Hydrogen Transfer Reaction. J.
Org. Chem. 2008, 73, 7451-7456.
35. Yasui, Y.; Kamisaki, H.; Takemoto, Y.; Enantioselective Synthesis of 3,3-Disubstituted Oxindoles through
Pd-Catalyzed Cyanoamidation. Org. Lett. 2008, 10, 3303-3306.
36. Enomoto, T.; Obika, S.; Yasui, Y.; Takemoto, Y., Gold(I)-Catalyzed Hydroamination as a General Approach
toward the Synthesis of Substituted Hydroisoquinolines: Remarkable Acceleration by Ethanol. Synlett 2008,
1647-1650.
37. Obika, S.; Yasui, Y.; Yanada, R.; Takemoto, Y., Concise Synthesis of the CDE Ring System of Tetrahydroisoquinoline Alkaloids Using Carbophilic Lewis Acid-Catalyzed Hydroamidation and Oxidative
Friedel-Crafts Cyclization. J. Org. Chem. 2008, 73, 5206-5209.
38. Yanada, R.; Hashimoto, K.; Tokizane, R.; Miwa, Y.; Minami, H.; Yanada, K.; Ishikura, M.; Takemoto, Y.,
Indium(III)-Catalyzed Tandem Reaction with Alkynylbenzaldehydes and Alkynylanilines to Heteroaromatic
Compounds. J. Org. Chem. 2008, 73, 5135-5138.
39. Reddy, V. K.; Miyabe, H.; Yamauchi, M.; Takemoto, Y., Enantioselective Synthesis of [1,2]-oxazinone
scaffolds and [1,2]-oxazine core structures of FR900482. Tetrahedron, 2008, 64, 1040-1048.
40. (2 + 2) Cycloaddition Reaction of Alkyl Enol Ethers with Acrylates by in situ Generated Silyl Trifric Imide
Catalyst, Takasu, K; Miyakawa, Y.; Ihara, M.; Tokuyama, H. Chem. Pharm. Bull., 2008, 56, 1205-1206.
41. Catalytic Multicomponent Cycloaddition Assembling Three Different Substances to Form Highly Substituted
Bicyclo[4.2.0]octanes, Takasu, K; K. Inanaga, K.; Ihara, M. Tetrahedron Lett., 2008, 49, 4220-4222.
− 196 −
42. Miyabe, H.; Sami, Y.; Naito, T.; Takemoto, Y.; Gold-Catalyzed Cyclization Reaction of Alkynyl
tert-Butylcarbamates. Heterocyles, 2007, 73, 187-190.
43. Yamaoka, Y.; Miyabe, H.; Yasui, Y.; Takemoto, Y., Chiral Thiourea-catalyzed Direct Mannich Reactions.
Synthesis, 2007, 2571-2575.
44. Miyabe, H.; Takemoto, Y., Enantioselective Radical Cyclizations: A New Approach to Stereocontrol of
Cascade Reactions. Chem. Eur. J., 2007, 13, 7280-7286.
45. Miyabe, H.; Toyoda, A.; Takemoto, Y., Enantioselective Cascade Radical Addition-Cyclization of Oxime
Ethers. Synlett, 2007, 1885-1888.
46. Yasui, Y.; Tuschida, S.; Miyabe, H.; Takemoto, Y.; One-Pot Amidation of Olefins through Pd-Catalyzed
Coupling of Alkylboranes and Carbamoyl Chlorides. J. Org. Chem., 2007, 72, 5898-5900.
47. Obika, S.; Kono, H.; Yasui, Y.; Yanada, R.; Takemoto, Y., Concise Synthesis of 1,2-Dihydroisoquinolines
and 1H-Isochromones by Carbophilic Lewis Acid-Catalyzed Tandem Nucleophilic Addition and Cyclization
of 2-(1-Alkynyl)arylaldimines and 2-(1-Alkynyl)aryaldehydes. J. Org. Chem., 2007, 72, 4462-4468.
48. Yamaoka, Y.; Miyabe, H.; Takemoto, Y., Catalytic Enantioselective Petasis-Type Reaction of Quinolines
Catalyzed by a Newly Designed Thiourea Catalyst. J. Am. Chem. Soc., 2007, 129, 6686-6687.
49. Kobayashi, Y.; Kamisaki, H.; Takeda, H.; Yasui, Y.; Yanada, R.; Takemoto, Y., Intramolecular Cyanoamidation of Unsaturated Cyanoformamides Catalyzed by Palladium: An Efficient Synthesis of Multi-Functionalized Lactams. Tetrahedron, 2007, 63, 2978-2989.
50. Miyabe, H.; Tuchida, S.; Yamauchi, M.; Takemoto, Y.; Reaction of Nitro Organic Compounds Using Thiourea Catalysts Anchored to Polymer Support. Synthesis, 2006, 3295-3300.
51. Miyabe, H.; Asada, R.; Toyoda, A.; Takemoto, Y., Enantioselective Cascade Radical Addition-Cyclization-Trapping Reactions. Angew. Chem. Int. Ed., 2006, 45, 5863-5866.
52. Inokuma, T.; Hoashi, Y.; Takemoto, Y., Thiourea-Catalyzed Asymmetric Michael Addition of Activated
Methylene Compounds to DE-Unsaturated Imides: Dual Activation of Imide by Intra- and Intermolecular
Hydrogen-bonding. J. Am. Chem. Soc., 2006, 128, 9413-9419.
53. Kobayashi, Y.; Kamisaki, H.; Yanada, R.; Takemoto, Y., Palladium-Catalyzed Intramolecular Cyanoamidation of Alkynyl and Alkenyl Cyanoformamides. Org. Lett., 2006, 8, 2711-2713.
54. Miyata, O.; Takeda, N.; Kimura, Y.; Takemoto, Y.; Tohnai, N.; Miyata, M.; Naito, T., Efficient Synthesis of
Indoles Using [3,3]-Sigmatropic Rearrangement of N-Trifluoroacetyl Enehydrazines. Tetrahedron, 2006, 62,
3629-3647.
55. Yanada, R.; Obika, S.; Kono, H.; Takemoto, Y.; In(OTf)3-catalyzed Tandem Nucleophilic Addition and Cyclization of ortho-Alkynylarylaldimines to 1,2-Dihydroisoquinolines. Angew. Chem. Int. Ed., 2006, 45,
3822-3825.
56. Miyabe, H.; Yamaoka, Y.; Takemoto, Y.; Reactive Ketimino Radical Acceptors: Intermolecular Alkyl Radical Addition to Imines with a Phenolic Hydroxyl Group. J. Org. Chem., 2006, 71, 2099-2106.
57. Xu, X.; Yabuta, T.; Yuan, P.; Takemoto, Y., Organocatalytic Enantioselective Hydrazination of
1,3-Dicarbonyl Compounds: Asymmetric Synthesis of Į,Į-Disubstituted Į-Amino Acids. Synlett, 2006,
137-140.
58. Xu, X.; Furukawa, T.; Okino, T.; Miyabe, H.; Takemoto, Y., Bifunctional Thiourea-Catalyzed Diastereo- and
Enantioselective Aza-Henry Reaction. Chem. Eur. J., 2006, 12, 466-476.
59. Hoashi, Y.; Yabuta, T.; Yuan, P.; Miyabe, H.; Takemoto, Y., Enantioselective Tandem Michael Reaction to
Nitroalkene Catalyzed by Bifunctional Thiourea: Total Synthesis of (-)-Epibatidine. Tetrahedron, 2006, 62,
365-374.
⥲ㄝࠊ᭩⡠
1.
2.
3.
4.
5.
6.
7.
8.
9.
Takemoto, Y., Development of Chiral Thiourea Catalysts and Its Application to Asymmetric Catalytic Reactions. Chem. Pharm. Bull., 2010, 58, 593-601.
Inokuma, T.; Takemoto, Y., BROMONITROMETHANE. Electronic Encyclopedia of Reagents for Organic
Synthesis, Wiley, 2010.
➉ᮏెྖࠊ᭷ᶵ࣍࢘⣲ヨ⸆ࢆ฼⏝ࡋࡓ୙ᩧࢳ࢜ᒀ⣲ゐ፹཯ᛂࡢ㛤Ⓨࣇ࢓࢖ࣥࢣ࣑࢝ࣝ 2010, 39, (8),
22-32.
➉ᮏెྖࠊከᶵ⬟ᛶࢳ࢜ᒀ⣲ゐ፹࡜୙ᩧ཯ᛂࡢ㛤Ⓨ໬Ꮫ࡜ᕤᴗ2010, 84, (7), 24-34.
ሯ㔝༓ᑜࠊSiegel, D. R.; Danishefsky, S. J., ከ⎔≧ከࣉࣞࢽࣝ࢔ࢩࣝࣇࣟࣟࢢࣝࢩࣀ࣮ࣝ㢮ࡢ඲ྜᡂ.
᭷ᶵྜᡂ໬Ꮫ༠఍ㄅ, 2010, 68, 592-600.
Takasu, K., Triflic Imide Catalyzed Cycloaddition Reactions. Synlett, 2009, 1905-1914.
ᰗ⏣⋹Ꮚࠊ➉ᮏెྖ,࢖ࣥࢪ࣒࢘ࢆ⏝࠸ࡿྜᡂ཯ᛂࡢ㛤Ⓨ.᭷ᶵྜᡂ໬Ꮫ༠఍ㄅ, 2009, 67, 239-247.
➉ᮏెྖ⊦⇃⩼ࢳ࢜ᒀ⣲ᆺゐ፹ࡢ㛤Ⓨࠕ㐍໬ࢆ⥆ࡅࡿ᭷ᶵゐ፹ࠖ⦅㞟 ୸ᒸၨ஧໬Ꮫྠே
2009, Kyoto, 75-86.
బࠎᮌㄔࠊሯ㔝༓ᑜ, ᕧ኱࣏࢚࣮ࣜࢸࣝኳ↛≀࣭ࢠ࣒ࣀࢩࣥ㸫A ࡢ඲ྜᡂ ࠕኳ↛≀඲ྜᡂࡢ᭱᪂
ືྥࠖ,┘ಟ ໭Ὀ⾜ࠊࢩ࣮࢚࣒ࢩ࣮ฟ∧, 2009, Tokyo, 228-243.
− 197 −
10. Yasui, Y.; Takemoto, Y., Intra- and Intermolecular Amidation of C-C Unsaturated Bonds Through Palladium-Catalyzed Reactions of Carbamoyl Derivatives. Chem. Rec. 2008, 8, 386-394.
11. Miyabe, H.; Takemoto, Y., Discovery and Application of Asymmetric Reaction by Multi-Functional Thioureas. Bull. Chem. Soc. Jpn., 2008, 81, 785-795.
12. 㧗㡲Ύㄔࠊ㐃⥆཯ᛂ࠾ࡼࡧከᡂศ཯ᛂࢆᇶ┙࡜ࡍࡿከ⨨᥮ࢩࢡࣟࣈࢱࣥࡢ㎿㏿ྜᡂἲࡢ㛤Ⓨࠊ᭷ᶵ
ྜᡂ໬Ꮫ༠఍ㄅࠊ2008, 66, 554-563.
13. Takemoto, Y.; Miyabe, H., The Amino Thiourea-Catalyzed Asymmetric Nucleophilic Reactions. Chimia,
2007, 61, 269-275.
14. Takemoto, Y.; Miyabe H., C-N Bond Formation through Amination. In Comprehensive Organometallic
Chemistry III. Eds. Crabtree, R. H.; Mingos, D. M. P.; Elsevier: Oxford, Vol. 10.15, 2006, 695-724.
15. Takemoto, Y., Development of Amino Thiourea Catalysts as an Artificial Enzyme: Their Application to
Catalytic Enantioselective Reactions. J. Synth. Org. Chem. Jpn., 2006, 64, 1139-1147.
16. Ᏻ஭⩏⣧, ➉ᮏెྖ,⏕≀άᛶ≀㉁ࡢ㎿㏿ྜᡂࢆᣦྥࡋࡓ㔠ᒓ཯ᛂ๣࡟ࡼࡿࣛࢡࢱ࣒ᙧᡂ཯ᛂࡢ㛤
Ⓨࠊ໬Ꮫ࡜ᕤᴗ, 2006, 57, 729-733.
17. ➉ᮏెྖࢳ࢜ᒀ⣲⣔୙ᩧ᭷ᶵศᏊゐ፹ࡢ๰〇ࠕ᭷ᶵศᏊゐ፹ࡢ᪂ᒎ㛤ࠖ┘ಟᰘᓮṇ຾ࢩ࣮࢚
࣒ࢩ࣮ฟ∧, 2006, Tokyo, 167-179.
≉チฟ㢪
㸯㸧」⣲⎔㦵᱁ࢆ᭷ࡍࡿ໬ྜ≀࠾ࡼࡧヱ໬ྜ≀ࢆ୙ᩧゐ፹࡜ࡋ࡚⏝࠸ࡿගᏛάᛶ໬ྜ≀ࡢ〇㐀᪉ἲ㸸≉
㢪 㸦ฟ㢪᪥㸸 ᖺ ᭶ ᪥㸧
㸰㸧୙ᩧࢳ࢜ᒀ⣲໬ྜ≀࠾ࡼࡧࡇࢀࢆゐ፹࡜ࡋ࡚⏝࠸ࡿ୙ᩧඹᙺ௜ຍ཯ᛂ࡟ࡼࡿ୙ᩧ໬ྜ≀ࡢ〇㐀᪉
ἲ㸸≉チ➨ ྕ㸦Ⓩ㘓᪥㸸 ᖺ ᭶ ᪥㸧
㸱㸧ከ⨨᥮ࢩࢡࣟࣈࢱࣥཬࡧከ⨨᥮ࢩࢡࣟࣈࢸࣥ໬ྜ≀ࡢ〇㐀᪉ἲ㸸≉チ➨ ྕ㸦Ⓩ㘓᪥㸸
ᖺ ᭶ ᪥㸧
㸳㸧ࢺࣜࣃࣀࢯ࣮࣐ཎ⹸ᐤ⏕ឤᰁ⑕ࡢண㜵ཪࡣ἞⒪⏝་⸆⤌ᡂ≀㸸≉チ ྕ㸦Ⓩ㘓᪥ ᖺ㸵
᭶㸰㸱᪥㸧
㸴㸧ᢠࢺࣜࣃࣀࢯ࣮࣐๣㸸≉チ ྕ㸦Ⓩ㘓᪥ ᖺ㸵᭶㸰㸱᪥㸧
㸵㸧࢔ࢨࣟࢲࢩ࢔ࢽࣥ໬ྜ≀ࢆ᭷ຠᡂศ࡜ࡋ࡚ྵ᭷ࡍࡿ་⸆⤌ᡂ≀㸸㹕㹍㸰㸮㸮㸴㸭㸯㸱㸵㸰㸳㸶㸸ᑂ
ᰝㄳồ῭
㸶㸧ࣇ࢙ࣀ࢟ࢧࢪࢽ࣒࢘໬ྜ≀ࢆάᛶᡂศ࡜ࡋ࡚ྵ᭷ࡍࡿ་⸆⤌ᡂ≀㸸㹕㹍㸰㸮㸮㸴㸭㸮㸶㸵㸷㸱㸳㸸
ᑂᰝㄳồ῭
㸵㸧ࢩ࢚ࣜࣝࣀ࣮ࣝ㢮ࡢ〇㐀ἲ㸸≉㢪 㸦ฟ㢪᪥㸸 ᖺ ᭶ ᪥㸧
− 198 −
⸆ရ㈨※Ꮫศ㔝
ᩍᤵ㸦⸆Ꮫ༤ኈ㸧ᮏከ⩏᫛㸦࡯ࢇࡔ ࡂࡋࡻ࠺㸧(2007.3 ᐃᖺ㏥⫋)
᫛࿴㸯㸶ᖺ㸷᭶㸵᪥⏕
᫛࿴㸲㸰ᖺ ி㒔኱Ꮫ༞ࠊ᫛࿴㸲㸶ᖺ ྠ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧ఀ⸨⨾༓✑㸦࠸࡜࠺ ࡳࡕ࡯㸧(2003.5 ᪼௵㸧
᫛࿴㸲㸲ᖺ㸵᭶㸯㸮᪥⏕
ᖹᡂ㸲ᖺ ி㒔኱Ꮫ༞ࠊᖹᡂ㸶ᖺ ྠ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬୰㏵㏥Ꮫ
ຓᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧▮಴ᚭ㸦ࡸࡄࡽ ࡜࠾ࡿ㸧(2008.12 ㏥⫋)
᫛࿴㸳㸯ᖺ㸳᭶㸰㸲᪥⏕
ᖹᡂ㸯㸯ᖺ ி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸴ᖺ ྠ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
WHO ࡟ࡼࢀࡤࠊ་Ꮫࡀ㧗ᗘ࡟Ⓨ㐩ࡋࡓ௒᪥࡟࠾࠸࡚ࡶࠊᆅ⌫ୖࡢ⣙㸴๭ࡢே㐩ࡢ೺ᗣࡣఏ⤫་⒪࡟
ࡼࡗ࡚ᨭ࠼ࡽࢀ࡚࠸ࡿࠋኳ↛⸆≀࡟ࡼࡿ἞⒪ࡣࡑࡢఏ⤫་⒪ࡢ୰ᚰ࡟఩⨨ࡋ࡚࠸ࡿࡀࠊ㏆௦໬ࡸᆅ⌫つ
ᶍ࡛ࡢ⮬↛◚ቯ࣭㛤Ⓨ࡟᰿ࡊࡋࡓࠊ㈨※ࠊ⏕⏘ࠊရ㉁࡞࡝࡟ಀࡿከᵝ࡞ၥ㢟ࡀᄇฟࡋ࡚ࡁ࡚࠸ࡿࠋࡲࡓࠊ
ඛ㐍ᅜ࡟࠾࠸࡚ࡶࠊ୙ᐃឋッࡸᮎᮇࡀࢇ࡞࡝㏆௦་Ꮫࡢ⢋ࢆࡶࡗ࡚ࡋ࡚ࡶᩆࢃࢀ࡞࠸ᝈ⪅ࡀఏ⤫་Ꮫࡸ
೺ᗣ㣗ရ➼ࢆྵࡴ⿵᏶௦᭰་⒪ࢆ฼⏝ࡍࡿࡇ࡜ࡀቑຍࡋ࡚࠾ࡾࠊ⸆ⲡ἞⒪ࡸኳ↛⸆≀ࡢຠ⬟ຠᯝࡀὀ┠
ࡉࢀࡿᶵ఍ࡶከ࠸ࠋࡇ࠺ࡋࡓኳ↛⸆≀ࡢ౑⏝㔞ࡢቑຍࠊࡲࡓ࢖ࣥࢱ࣮ࢿࢵࢺࢆ฼⏝ࡋࡓᅜ㝿ⓗ࡞≀㈨ࡢ
ὶ㏻ࡀάⓎ࡟࡞ࡿ࡟క࠸ࠊᅜ㝿ㄪ࿴ࢆព㆑ࡋࡓኳ↛⸆≀㢮ࡢᏳ඲ᛶࠊ᭷ຠᛶ࡞࡝࡟㛵ࡍࡿಖドࡸᇶ‽ᩚ
ഛࡀᛴົ࡛࠶ࡿ࡜࠸ࢃࢀ࡞ࡀࡽࠊࡑࡢᇶ┙࡜࡞ࡿྛ⏕⸆㢮࡟ࡘ࠸࡚ࡢᇶ♏ⓗ◊✲ࢹ࣮ࢱࡀ‶㊊࡟ᥞࡗ࡚
࠸ࡿ࡜ࡣゝ࠸㞴࠸࡜࠸࠺ࡢࡀ⌧≧࡛࠶ࡿࠋᙜศ㔝࡛ࡣኳ↛⸆≀ࡢ≉㉁ࢆ⛉Ꮫⓗ࡟✲᫂ࡍࡿ࡜࠸࠺❧ሙ࠿
ࡽࠊୗグ࡟↔Ⅼࢆ࠶࡚࡚◊✲ࢆᒎ㛤ࡋ࡚࠸ࡿࠋ
‫⏝⸆ۑ‬᳜≀ࡢ⏕ྜᡂ࡟㛵ࡍࡿ◊✲
᳜≀ࡣேయࡢ⏕⌮ᶵᵓ࡟స⏝ࡍࡿ஧ḟ௦ㅰᡂศࢆ⏘⏕ࡍࡿ≉Ṧ࡞ᶵ⬟ࢆᣢࡗ࡚࠸ࡿࠋᙜศ㔝࡛ࡣ⸆⏝
࡟౪ࡉࢀࡿ᳜≀ࡢࡑࢀࡽ≉Ṧᡂศࡢ⏕ྜᡂ࡟㛵ࡋࠊ⊂⮬ࡢᮦᩱࢆ⏝࠸࡚◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋࢱ࣮ࢤࢵࢺ
࡜ࡍࡿᡂศࡣ୺࡟⢭Ἔࡸᶞ⬡ࡢᡂศ࡛㤶ࡾࡀ࠶ࡿࡶࡢࡀ୰ᚰ࡛࠶ࡿࠋࡇࢀࡽࡢ㤶ࡾᡂศࡣᚋ㏙ࡢ⏕⸆⸆
⌮Ꮫⓗ◊✲ࡢᮦᩱ࡛ࡶ࠶ࡿࠋලయⓗ࡟ࡣ௨ୗࡢ㸰Ⅼ࡛࠶ࡿࠋ(1) ࢩࢯ⛉᳜≀ࡣ≉ᚩⓗ࡞⏕⌮άᛶࢸࣝ࣌
ࣀ࢖ࢻࢆ⏘⏕࣭⵳✚ࡍࡿࡀࠊࡑࢀࡽࡢᶵ⬟Ⓨ⌧ࡣཝ᱁࡞㑇ఏⓗไᚚࢆཷࡅ࡚࠸ࡿࡇ࡜ࡀࠊᙜศ㔝ࡢ◊✲
࡟ࡼࡗ࡚᫂ࡽ࠿࡟࡞ࡗ࡚࠸ࡿࠋ⌧ᅾࠊࣔࣀࢸࣝ࣌ࣥࡸࢭࢫ࢟ࢸࣝ࣌ࣥࡢ⏕ྜᡂ࡟㛵ಀࡍࡿ㘽㓝⣲㑇ఏᏊ
ࡢ༢㞳ࡸᶵ⬟ゎᯒࢆ⾜࠺࡜࡜ࡶ࡟ࠊኚ␗㑇ఏᏊࡢᵓ⠏࡜ࡑࢀࡽࡢᶵ⬟ゎᯒ࠿ࡽࠊ≉࡟❧యไᚚᶵᵓࡢゎ
᫂ࢆ┠ᣦࡋࡓ◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋᮦᩱ࡜ࡍࡿࢩࢯࡣᅜෆእࡼࡾ཰㞟ࡋࡓ㑇ఏᏊ㈨※࡛ࠊ⿄࠿ࡅ࡟ࡼࡿ⮬
Ṫࢆ⧞ࡾ㏉ࡋ࡚⫱✀ࡋࡓ 5800 ㉸⣔⤫ࢆ᭷ࡍࡿ⣧⣔ࣛ࢖ࣈ࣮࡛ࣛࣜ࠶ࡾࠊୡ⏺࡟ࡶ㢮ࢆぢ࡞࠸࢜ࣜࢪࢼ
ࣝ⣲ᮦ࡛࠶ࡿࠋ(2) ỿ㤶࡟ࡣ≉␗࡞ࢸࣝ࣌ࣥ࡜ࢡࣟࣔࣥㄏᑟయࡀྵࡲࢀࡿࠋࡇࢀࡽ໬ྜ≀ࡣ೺ᖖ࡞⤌⧊
࡛ࡣ᳨ฟࡉࢀࡎࠊയᐖࢆཷࡅࡓ⤌⧊➼࡟⵳✚ࡉࢀࡿࠋࡑࡇ࡛ࠊࡇࡢ≉␗࡞໬ྜ≀ࡢ⏘⏕ᶵᵓࡢゎ᫂ࢆ┠
− 199 −
ᣦࡋࠊ⏕ᮌࡸᇵ㣴⣽⬊ࢆ⏝࠸࡚ࠊ✀ࠎࡢㄏᑟᐇ㦂ࢆ⾜ࡗ࡚࠸ࡿࠋ≉࡟ᇵ㣴⣽⬊ࢆ⏝࠸ࡓᐇ㦂⣔ࡣࠊỿ㤶
ࡢࡼ࠺࡞ᮌᮏ᳜≀㢮ࡢ⏕ྜᡂ◊✲࡟㐺ࡋࡓᮦᩱ࡜࠸࠼ࡿࡀࠊࢱ࣮ࢤࢵࢺ࡜ࡍࡿ஧ḟ௦ㅰ⏘≀ࢆ⏘⏕ࡋ࡞
࠸ሙྜࡶ࠶ࡗ࡚ࠊ฼⏝࡟ࡣࡌࡹ࠺ࡪࢇ࡞⤒㦂್ࡀせồࡉࢀࡿࠋᙜศ㔝ࡢ◊✲ࡢṔྐⓗ⤒⦋ࢆࡶ㋃ࡲ࠼ࠊ
ỿ㤶ᇵ㣴⣽⬊ࢆ฼⏝ࡋࡓⰾ㤶ᛶᶞ⬡ᡂศࡢ⏕ྜᡂ◊✲ࡣ࢜ࣜࢪࢼࣜࢸ࢕࣮ࡢ㧗࠸ࡶࡢ࡛࠶ࡿࠋ
‫ۑ‬ኳ↛⸆≀ࡢ⏕⸆⸆⌮Ꮫⓗ◊✲
ࡑࢀࡒࢀࡢኳ↛⸆≀࡟ఏ࠼ࡽࢀࡿ⸆Ꮫⓗ࡞ព࿡࡟ࡘ࠸࡚ࠊ⛉Ꮫⓗ࡞⿬௜ࡅࢆᚓࠊ๰⸆◊✲࡟⧅ࡀࡿྍ
⬟ᛶࢆồࡵࡿ◊✲ࡢ㔜せᛶࡣப࠺ࡲ࡛ࡶ࡞࠸ࠋࡋ࠿ࡋ࡞ࡀࡽࠊ᫬௦ࡢὶࢀ࡜࡜ࡶ࡟ᚑ᮶ᆺࡢࢫࢡ࣮ࣜࢽ
ࣥࢢ࡟ࡼࡿ᪂つάᛶᡂศࡢ᥈⣴◊✲ࡣ࠶ࡲࡾ⾜ࢃࢀ࡞ࡃ࡞ࡗ࡚ࡁ࡚࠸ࡿࠋᙜศ㔝࡛ࡣࠊࣔࣀࢸࣝ࣌ࣥࡸ
ࢭࢫ࢟ࢸࣝ࣌ࣥ࡞࡝ࡢ᥹Ⓨᛶ໬ྜ≀ࢆ⏕ྜᡂ◊✲࡞࡝࡛ࡶྲྀࡾᢅࡗ࡚࠸ࡿࡇ࡜࠿ࡽࠊ⢭Ἔᡂศࡢ྾ධᢞ
୚࡟ࡼࡿ㙠㟼άᛶࢆ୰ᚰ࡟◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋ࢔࣐ࣟࢸࣛࣆ࣮࡜࠸࠺ゝⴥࡣ㏆ᖺ࡛ࡣࡼࡃ⪺࠿ࢀࡿࡼ࠺
࡟࡞ࡗࡓࡶࡢࡢࠊࡑࡢ⛉Ꮫⓗ࡞◊✲ࡣពእ࡟ᑡ࡞ࡃࠊᮍ▱ࡢ㡿ᇦࡀከࡃṧࡉࢀ࡚࠸ࡿࠋࡑࡇ࡛ࠊᐇ㦂ື
≀ࢆ౑ࡗ࡚⌧㇟ࢆ☜ㄆࡍࡿᐇ㦂⣔ࡢ☜❧࠿ࡽ╔ᡭࡋࠊ᥹Ⓨᛶ໬ྜ≀ࡢ໬Ꮫᵓ㐀࡜㙠㟼άᛶࡢᵓ㐀άᛶ┦
㛵࡞࡝࡟ࡘ࠸࡚ࡶ◊✲ࢆᒎ㛤ࡋ࡚࠸ࡿࠋࡲࡓࠊኳ↛⸆≀ࡢ୰࡟ࡣ㛗ᮇ㛫㐃⥆ࡋ࡚᭹⏝ࡉࢀࡿࡶࡢࡶ࠶ࡿࠋ
ࡇࡢࡼ࠺࡞㛗ᮇ⥅⥆ⓗᢞ୚࡟ࡘ࠸࡚ࡢ◊✲ࡶ㐍⾜୰࡛࠶ࡿࠋ
‫⏝⸆ۑ‬㈨※᳜≀࣭ఏ⤫⸆≀ࡢᾏእᏛ⾡ㄪᰝ
⏕⸆Ꮫࡣ㠀ᖖ࡟ࡍࡑ㔝ࡢᗈ࠸ศ㔝࡛ࠊ⏕⸆࡟ࡲࡘࢃࡿࡍ࡭࡚ࡢ஦㇟ࡀ◊✲ᑐ㇟࡜࡞ࡿ࡜ゝࡗ࡚ࡶ㐣ゝ
࡛ࡣ࡞࠸ࠋ࠶ࡿ⏕⸆࡟ࡘ࠸࡚◊✲ࡍࡿ㝿࡛ࡶࠊ◊✲ᮦᩱࡢࣛ࢖ࣇࢧ࢖ࢡࣝࡸศ㢮ࠊ᱂ᇵ≧ἣ࡞࡝ࢆ▱ࡿ
ࡇ࡜࡛᪂ࡓ࡞◊✲ࡢ࣋ࢡࢺࣝࡸ᪂ࡋ࠸Ⓨ᝿࡟ࡘ࡞ࡀࡿࡇ࡜ࡀከࡃ࠶ࡿࠋࡲࡓࠊఏ⤫⸆≀ࡣே㢮ࡀ⮬ࡽࡢ
⤒㦂࡟ࡼࡾ⮬↛⏺࠿ࡽ㑅ࡧฟࡋࡓࡶࡢ࡛࠶ࡾࠊୡ⏺ྛᆅ࡟ࡣࡲࡔࡲࡔ▱ࡽࢀࡊࡿఏ⤫⸆ࡀྛᆅ࡟ఏ࠼ࡽ
ࢀ࡚࠸ࡿࠋࡉࡽ࡟ࠊ㏆ᖺࠊ㈨※ಖ᭷ᅜ࡟࠾࠸࡚ࡣࠊ⮬ᅜ㈨※࡟ᑐࡍࡿಖㆤᨻ⟇ࡸ㍺ฟつไ࡞࡝ࡀ㧗ࡲࡾ
ࢆぢࡏ࡚࠾ࡾࠊ⏕⸆ᇶཎࢆእᅜ⏘࡟኱ࡁࡃ౫Ꮡࡋ࡚࠸ࡿࢃࡀᅜ࡜ࡋ࡚ࡣࠊᅜෆ⏕⏘ࡢྍ⬟ᛶࢆ᥈ࡾࡘࡘࠊ
ࡉࡲࡊࡲ࡞㠀ᖖ஦ែ࡟ࡶᑐᛂྍ⬟࡞ࡔࡅࡢ᝟ሗ཰㞟࡜▱㆑ࡢ㞟✚ࠊ‽ഛࡀ⫢せ࡜࠸ࢃࢀ࡚࠸ࡿࠋୖグࡢ
ࡼ࠺࡞ほⅬ࠿ࡽᙜศ㔝࡛ࡣ⸆⏝㈨※᳜≀࡟㛵ࡍࡿ⌧ᆅㄪᰝࢆ⥅⥆ⓗ࡟⾜ࡗ࡚ࡁ࡚࠸ࡿࠋࡇࡢ 5 ᖺ㛫ࡢ≉
࡟๓༙ᮇ㛫࡛ࡣࠊ࢖ࣥࢻࢩࢼ༙ᓥ㒊ࡢ⸆⏝᳜≀㈨※ㄪᰝ◊✲ࢆ⢭ຊⓗ࡟ᒎ㛤ࡋࡓࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ୖグࡢ◊✲ࡣ࠸ࡎࢀࡶᮏ◊✲ศ㔝ࡀ⊂⮬࡟㛤Ⓨࡋ㐍ࡵ࡚᮶ࡓࡶࡢ࡛࠶ࡿࠋࡲࡓࠊࡇࢀࡽࡢࢸ࣮࣐ࡣࠊ
ࡑࢀࡒࢀ⊂⮬ࡢ◊✲࣋ࢡࢺࣝࢆ᭷ࡍࡿࡶࡢࡢ┦஫࡟ᐦ᥋࡟㛵㐃ࡋ࡚࠸ࡿࠋᚑࡗ࡚ࠊഐ࠿ࡽᐇ㦂ᡭἲࡔࡅ
ࢆぢࢀࡤ㠀ᖖ࡟ከᒱ࡟ࢃࡓࡗ࡚࠸ࡿ࡜ᛮࢃࢀࡿ࠿ࡶࡋࢀ࡞࠸ࡀࠊศ㔝඲య࡜ࡋ࡚ࡣࣂࣛࣥࢫⰋࡃࡲ࡜ࡲ
ࡾࡢ࠶ࡿࡶࡢ࡟࡞ࡗ࡚࠸ࡿ࡜⪃࠼࡚࠸ࡿࠋࡲࡓࠊ௚኱Ꮫࡸ௻ᴗ࡜ࡢඹྠ◊✲࡟ࡼࡾࠊ◊✲ࡢ㍯ࡶᗈࡀࡾ
ࢆࡶࡘࡶࡢ࡜࡞ࡾࡘࡘ࠶ࡿࠋ
ࡇࡢ㸳ᖺ㛫࡟ᮏከᩍᤵࡀᮏᏛࢆᐃᖺ㏥⫋㸦ጲ㊰⊂༠኱Ꮫ⸆Ꮫ㒊࡟෌ᑵ⫋㸧ࠊ▮಴ຓᩍࡀ㏥⫋㸦Ṋ⏣⸆
ရᰴᘧ఍♫ி㒔⸆⏝᳜≀ᅬ࡟㌿⫋㸧ࡋࠊᮇ㛫ࡢ࡯࡜ࢇ࡝ࡣఀ⸨෸ᩍᤵࡀ༢⊂࡛Ꮫ㒊Ꮫ⏕࣭኱Ꮫ㝔⏕ࡢᩍ
⫱࣭◊✲ᣦᑟ࡜◊✲άື࡟క࠺㞧ົ୍ษࢆᢸᙜࡋ࡞ࡀࡽ⌧ᅾ࡟⮳ࡗ࡚࠸ࡿࠋࡇࢀࡲ࡛ᾏእ⌧ᆅㄪᰝࢆ◊
✲ࡢࢶ࣮ࣝࡢࡦ࡜ࡘ࡜ࡋ࡚኱ࡁࡃ఩⨨࡙ࡅ࡚ࡁ࡚࠸ࡓࡀࠊᮏከᩍᤵࡢᐃᖺ㏥⫋ᚋࠊࡉࡽ࡟▮಴ຓᩍࡶ㏥
⫋ࡋ࡚࠿ࡽࡣࠊㄪᰝฟᙇ୰ࡢ␃Ᏺࢆ㡸࠿ࡿᩍဨࡀ඲ࡃ↓࠸࡜࠸࠺≧ἣࡀ⥆࠸࡚࠾ࡾࠊ⌧ᆅㄪᰝࡢᐇ᪋ࡀ
− 200 −
ᅔ㞴࡜࡞ࡗ࡚࠸ࡿࠋ
ᩍ⫱ࡢᴫせ
‫ۑ‬Ꮫ㒊Ꮫ⏕ࡢᩍ⫱㸸ᙜศ㔝ࡣࠊᮏከᩍᤵᅾ௵୰ࡣࠕ⸆⏝᳜≀Ꮫࠖ
㸦ᮏከᩍᤵᢸᙜ㸧
ࠊ
ࠕ⸆⏝㈨※Ꮫࠖ
㸦ఀ⸨
෸ᩍᤵᢸᙜ㸧
ࠊࠕኳ↛≀⸆Ꮫ㸱㸦ᪧ ⏕⸆Ꮫ㸧ࠖ㸦ᮏከᩍᤵᢸᙜ㸧ࡢ㸱ࡘࡢㅮ⩏ࢆᢸᙜࡋࡓࠋᮏከᩍᤵᐃᖺ
㏥⫋ᚋࡣఀ⸨෸ᩍᤵࡀࠕ⸆⏝᳜≀Ꮫࠖࠊࠕኳ↛≀⸆Ꮫ㸱ࠖࡢ㸰ࡘࡢㅮ⩏ࢆᢸᙜࡋ࡚࠸ࡿࠋࠕ⸆⏝᳜≀Ꮫࠖ
ࡣ⌮⣔ᩥ⣔ࢆၥࢃࡎ඲Ꮫ㒊඲Ꮫᖺᑐ㇟ࡢ඲Ꮫඹ㏻⛉┠࡜ࡋ࡚㛤ㅮࡉࢀ࡚࠸ࡿࠋ⸆⏝᳜≀࡟ᑐࡍࡿ㛵ᚰࡣ
Ꮫ㒊ࢆ㉺࠼ࡓࡶࡢ࡛ࠊᒚಟ⪅ᩘࡣẖᖺ㸯㸴㸮ࠥ㸯㸷㸮ྡࢆᩘ࠼ࠊ඲Ꮫ㒊࠿ࡽᒚಟⓏ㘓ࡀ࠶ࡿࡀࠊ࡞࠿࡛
ࡶ་Ꮫ㒊࠿ࡽࡢᒚಟ⪅ࡀ᭱ࡶከࡃࠊḟ࠸࡛⸆Ꮫ㒊࡜࡞ࡗ࡚࠸ࡿࠋࡸࡣࡾ⌮⣔Ꮫ㒊ࡢᒚಟ⪅ᩘࡀከ࠸ࡀࠊ
ᩥ⣔Ꮫ㒊ᒚಟ⪅ᩘࡶ 2 ࢣࢱ࡟࡞ࡿࡇ࡜ࡀከࡃࠊࡲࡓ඲Ꮫㅮ⩏࡛࠶ࡿ࡜࠸࠺ࡇ࡜࠿ࡽࠊ⸆⏝᳜≀࡟㛵ࡍࡿ
ึṌ࠿ࡽᛂ⏝ࡲ࡛ࢆᖜᗈࡃࠊ࠶ࡲࡾ⸆Ꮫࡢᑓ㛛ᛶࡀᙉࡃฟࡍࡂ࡞࠸ࡼ࠺㓄៖ࡋࡘࡘࠊᐇ≀ࡢᅇぴࡸ⸆⏝
᳜≀ᅬぢᏛ࡞࡝ࢆ⤌ࡳධࢀ࡚ࠊᗙᏛ࡟ࡼࡿ▱㆑⩦ᚓࡔࡅ࡛࡞ࡃࠊ஬ឤ࡟ࡶッ࠼࡚グ᠈࡟ṧࡿࡼ࠺࡞ㅮ⩏
ࢆᒎ㛤ࡋ࡚࠸ࡿࠋ
ࠕኳ↛≀⸆Ꮫ㸱ࠖࡣ⸆Ꮫ㒊 3 ᅇ⏕๓ᮇ㓄ᙜ⛉┠࡛࠶ࡾࠊ඲Ꮫㅮ⩏ࡢࠕ⸆⏝᳜≀Ꮫࠖࠊ㸰
ᅇ⏕๓ᮇࡢࠕኳ↛≀⸆Ꮫ㸯ࠖࠊ㸰ᅇ⏕ᚋᮇࡢࠕኳ↛≀⸆Ꮫ㸰ࠖࢆᒚಟࡋࡓᚋ࡟⏝ពࡉࢀ࡚࠸ࡿ㑅ᢥ⛉┠
࡛࠶ࡿࠋᚑࡗ࡚ࠊࡇࢀࡽࡢ⛉┠࡛Ꮫ⩦ࡋ࡚࠸ࡿࡣࡎࡢෆᐜࡢᛂ⏝࡜ࡋ࡚ࡢ⏕⸆Ꮫࢆ୰ᚰ࡟ࠊ⏕⸆࣭ኳ↛
≀ࢆ࡜ࡾࡲࡃୡ⏺ⓗ࡞₻ὶࠊつ᱁ᇶ‽ࡸᏳ඲ᛶ࡟㛵ࡍࡿ஦㡯ࡢࣁ࣮ࣔࢼ࢖ࢮ࣮ࢩࣙࣥࠊ⸆Ꮫ⛉Ꮫ⏕࡟ࡣ
≉࡟㔜せ࡜࡞ࡿ₎᪉ࡢ⌮ㄽ࡜ᐇ㝿࡞࡝ࡶྵࡲࢀࡿࡼ࠺ព㆑ࡋ࡞ࡀࡽᤵᴗィ⏬ࢆࡓ࡚࡚࠸ࡿࠋ
‫ۑ‬኱Ꮫ㝔Ꮫ⏕ࡢᩍ⫱㸸ᙜศ㔝࡛ࡣࠊᏛ⏕ಶࠎேࡢ⮬❧ࢆಁࡍ┠ⓗ࡛ࠊᙜศ㔝ࡀ㐙⾜ࡋ࡚࠸ࡿࢸ࣮࣐ࡢ୰
࠿ࡽྛᏛ⏕ࡀᕼᮃࡍࡿࢸ࣮࣐ࢆ㑅ᢥࠊᣦᑟᩍဨ࡜┦ㄯࡋ࡞ࡀࡽ◊✲ィ⏬➼ࢆ⟇ᐃࡋᐇ᪋ࡍࡿ࡜࠸࠺ᙧࢆ
࡜ࡗ࡚࠸ࡿࠋࡇࢀࡣࡲࡓࠊி㒔኱Ꮫࡢ⢭⚄࡛࠶ࡿࠕ⮬⩦⮬ᚓࠖࡢᐇ㊶ࡑࡢࡶࡢ࡛ࡶ࠶ࡿࠋᐇ㝿ࠊᩍဨࡢ
ࡳ࡞ࡽࡎඛ㍮ᚋ㍮࡜ࡢᐇ㦂࡟㛵ࡍࡿ┦ㄯࡸウㄽࠊᢏ⾡ᣦᑟࡀ᪥ᖖ⾜ࢃࢀ࡚࠾ࡾࠊ◊✲ሗ࿌఍࡛ࡣࠊ⮬㌟
ࡢ⾜ࡗࡓᐇ㦂⤖ᯝࡀᙉ࠸ᢈุࡢ║࡟ࡉࡽࡉࢀࠊ◊✲⪅࡜ࡋ୍࡚ே❧ࡕࡍࡿࡓࡵࡢカ⦎ࡢሙ࡜࡞ࡗ࡚࠸ࡿࠋ
ࡲࡓࠊฟ᮶ࡿ㝈ࡾᏛ⏕࡟Ꮫ఍Ⓨ⾲ࡢᶵ఍ࢆ୚࠼ࠊ◊✲ㄽᩥࡶᏛ⏕⮬ࡽࡀⱥㄒ࡛᭩ࡃࡇ࡜ࢆ┠ᶆ࡟ࡋ࡚࠸
ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ࡘ࠸࡚ࡣࠊᏛ㒊ࡀᐇ᪋ࡋ࡚࠸ࡿㅮ⩏ෆᐜ࡟㛵ࡍࡿ࢔ࣥࢣ࣮ࢺㄪᰝ࡛ࠊᖹᡂ 20 ᖺᗘ
ࡢࠕ⸆⏝᳜≀Ꮫࠖ࡟ᑐࡍࡿᏛ⏕ࡢホ౯ࡀ⸆Ꮫ㒊㛤ㅮࡢ඲ㅮ⩏ࡢ୰࡛᭱ࡶ㧗࠸࡜ࡉࢀࡓࠋࡇࢀࢆཷࡅࠊࣇ
࢓࢝ࣝࢸ࢕࣮ࢹ࢕࣋ࣟࢵࣉ࣓ࣥࢺࡢ୍⎔࡜ࡋ࡚ࠊᖹᡂ 21 ᖺᗘ๓ᮇ㛤ㅮࡢᙜヱㅮ⩏ࢆ⸆Ꮫ◊✲⛉ᡤᒓࡢ
ㅮ⩏ࢆᢸᙜࡍࡿࡍ࡭࡚ࡢᩍဨࡀ⫈ㅮࡋࠊྛಶேࡢᤵᴗෆᐜ࡜ẚ㍑ࡋࠊྥୖ࡟ᙺ❧࡚ࡿ୍ຓ࡜ࡍࡿ࡜࠸࠺
ࡇ࡜ࡀ⾜ࢃࢀࡓࠋࡇࢀࡣᏛ㒊ึࡢヨࡳ࡛࠶ࡗࡓࠋ⌮⣔ᩥ⣔ࢆၥࢃࡎ኱Ꮫෆࡢ඲Ꮫ㒊ࠊ඲Ꮫᖺࢆᑐ㇟࡜ࡋࠊ
ᐇ㝿࡟ࡍ࡭࡚ࡢᏛ㒊࠿ࡽࡢཷㅮ⪅ࡀ࠶ࡾࠊཷㅮ⪅ᩘࡶ 180 ྡࢆ㉸࠼ࡿ࡜࠸࠺≧ἣࡢ୰࡛⾜ࡗ࡚࠸ࡿ⸆⏝
᳜≀Ꮫࡢㅮ⩏ࡀ᭱㧗ホ౯ࢆᚓࡓ࡜࠸࠺ࡇ࡜ࡢෆᐜ࡟ࡣࠊᤵᴗ୰࡟ᐇ≀ࡢ⸆⏝᳜≀ࢆᅇぴࡋࡓࡾ⸆⏝᳜≀
ᅬࢆ౑ࡗ࡚ᐇ㝿࡟⸆⏝᳜≀࡟ゐࢀ࡞ࡀࡽ஬ឤ࡛Ꮫࡪᶵ఍ࢆࡘࡃࡗࡓࡾࡍࡿ࡞࡝ࠊ⏕⸆ࡸ᳜≀ࡢ⏕ࡁࡓ▱
㆑ࡀ㌟࡟╔ࡃࡼ࠺㓄៖ࡋࡓᤵᴗィ⏬ࡀຠᯝⓗ࡛࠶ࡗࡓ࡜࠸࠺ࡇ࡜ࡀ࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋ
ࠕኳ↛≀⸆Ꮫ㸱ࠖ
ࡣࠊᪧ࣒࡛࢝ࣜ࢟ࣗࣛࡣ⏕⸆Ꮫ࡟┦ᙜࡋࠊ࠿ࡘ࡚ࡣ࡜࠿ࡃ⏕⸆ྛㄽ࡟⤊ጞࡋࡀࡕ࡛࠶ࡗࡓㅮ⩏ෆᐜࢆぢ
− 201 −
┤ࡋࠊᩍ⛉᭩ࢆࡦࡶ࡜ࡅࡤぢࡘࡅࡽࢀࡿ㡯┠࡟๭ࡃ᫬㛫ࡣ᭱ᑠ㝈࡟࡜࡝ࡵࠊ▱㆑ࡀ᭷ᶵⓗ࡟ࡘ࡞ࡀࡾࠊ
Ꮫ⏕⮬㌟ࡀ⪃࠼ࡿᶵ఍ࢆᣢࡕࡸࡍ࠸ࡼ࠺㓄៖ࡋࡓㅮ⩏ࢆ⾜ࡗࡓࠋࡑࡢ⤖ᯝࠊᤵᴗ࢔ࣥࢣ࣮ࢺࡸࢸࢫࢺవ
ⓑ࡞࡝ࡢ⮬⏤グ㏙࡛ࠊ⏕⸆ࡣྂ⮯࠸ࡶࡢ࡜࠸࠺࢖࣓࣮ࢪࡀኚࢃࡗࡓࠊࡉࡽ࡟⏕⸆ᏛࢆᏛࡧࡓ࠸ࠊ࡞࡝ࡢ
ឤ᝿ࡀከࡃࡳࡽࢀࡓࡇ࡜࠿ࡽࠊᪧ᮶ࡢᐃᆺࢱ࢖ࣉࡢෆᐜ࡛ࡣ࡞ࡃࠊ᪂ࡓ࡞࣋ࢡࢺࣝࡀࡳ࠼ࡿࡼ࠺࡞ㅮ⩏
ෆᐜ࡟ࣜࣇࣞࢵࢩ࡛ࣗࡁࡓࡢ࡛ࡣ࡞࠸࠿࡜ᛮࡗ࡚࠸ࡿࠋ
ศ㔝ࡢ኱Ꮫ㝔Ꮫ⏕ࡣࠊᇶᮏⓗ࡟ࡔࢀࡶࡀಟኈㄢ⛬࡛ࡣᖹᆒ㸯ᅇࠊ༤ኈㄢ⛬࡛ࡣẖᖺᏛ఍Ⓨ⾲ࡋ࡚࠸ࡿࠋ
ࡦ࡜ࡾ㸯ࢸ࣮࣐࡛◊✲ࢆࡍࡍࡵ࡚࠸ࡿࡇ࡜ࡢ⾲ࢀ࡜ࡋ࡚ࠊ◊✲ᡂᯝࡢㄽᩥࢆฟ∧ࡍࡿ㝿ࡢඹⴭ⪅ᩘࡀ㏆
ᖺࡣ㠀ᖖ࡟ᑡ࡞࠸ࡇ࡜ࡀᣲࡆࡽࢀࡿࠋከࡃࡢሙྜࠊᐇ㦂ࢆᢸᙜࡋࡓᏛ⏕࡜ᣦᑟᩍဨࡢྜィ㸰ࠊ㸱ྡ࡛࠶
ࡿࠋࡲࡓࠊ₇⩦ࡢ୍⎔࡜ࡋ࡚⾜ࡗ࡚࠸ࡿࠊ᳜≀᥇㞟ࡸ᱂ᇵᆅぢᏛࠊ⏕⸆㛵ಀ఍♫ࡢぢᏛ࡞࡝ࡶࠊᐇ㝿▱
㆑ࡢಟᚓ࡟኱ࡁ࡞ຠᯝࡀ࠶ࡿࡶࡢ࡜☜ಙࡋ࡚࠸ࡿࠋ
㸦ཎⴭ㸧
(1)
Characterization of ˺-guaiene synthases from cultured cells of Aquilaria, responsible for the
formation of the sesquiterpenes in agarwood
Yukie Kumeta, Michiho Ito
Plant Physiology, 154 (4), 1998-2007 (2010)
(2)
Geraniol and linalool synthases from wild species of perilla
Naoko Masumoto, Miyuki Korin, Michiho Ito
Phytochemistry, 71, 1068-1075 (2010)
(3)
Germintaion rates of perilla (Perilla frutescens (L.) Britton) mericarps stored at 4C for 1–20 years
Naoko Masumoto, Michiho Ito
J. Natural Medicines, 64, 378-382 (2010)
(4)
A candidate cDNA clone for (–)-limonene-7-hydroxylase from Perilla frutescens
Christopher J.D. Mau, Frank Karp, Michiho Ito, Gisho Honda, Rodney Croteau
Phytochemistry, 71, 373-379 (2010)
(5)
Evaluation of volatile components from spikenard: valerena-4,7(11)-diene is a highly active sedative
compound
Hiroaki Takemoto, Toru Yagura, Michiho Ito
J. Natural Medicines, 63, 380-385 (2009)
(6)
Production of agarwood fragrant constituents in Aquilaria calli and cell suspension cultures
Yukie Okudera, Michiho Ito
Plant Biotechnology, 26, 307-315 (2009)
(7)
Influence of composition upon the variety of tastes in Cinamomi Cortex
Naoka Yokomi, Michiho Ito
J. natural Medicines, 63, 261-266 (2009)
(8)
Production of the monoterpene limonene and modulation of apoptosis-related proteins in NIH3T3
− 202 −
cells by introduction of the limonene synthase gene isolated from the plant Schizonepeta tenuifolia
Yoshiko Satomi, Kazuaki Ohara, Kazufumi Yazaki, Michiho Ito, Gisho Honda, Hoyoku, Nishino
Biotechnology and Applied Biochemistry,52, 185-190 (2009)
(9)
Perilla frutescens var. frutescens in northern Laos
Michiho Ito, Gisho Honda, Kongmany Sydara
J. Natural Medicines, 62 (2), 251-258 (2008)
(10)
Anticarcinogenic compounds in the Uzbek medicinal plant, Helichrysum maracandicum
Toru Yagura, Tomoko Motomiya, Michiho Ito, Gisho Honda, Akira Iida, Fumiyuki Kiuchi, Harukuni
Tokuda, Hoyoku Nishino
J. Natural Medicines, 62 (2), 174-178 (2008)
(11)
Sedative effect of vapor inhalation of agarwood oil and spikenard extract and identification of their
active components
Hiroaki Takemoto, Michiho Ito, Tomohiro Shiraki, Toru Yagura, Gisho Honda
J. Natural Medicines, 62 (1), 41-46 (2008)
(12)
A new phenolic gludoside from an Uzbek medicinal plant, Origanum tyttanthum
Yoshio Takeda, Maki Tomonari, Shihoko Arimoto, Toshiya Matsuda, Hideaki Otsuka, Katsuyoshi
Matsunami, Gisho Honda, Michiho Ito, Yoshihisa Takaishi, Fumiyuki Kiuchi, Olimjon K.
Khodzhimatov, Ozodbek A. Ashurmetov
J. Natural Medicines, 62 (1), 71-74 (2008)
(13)
Sesquiterpene lactones from the roots of Ferula varia and their cytotoxic activity
Kyoko Suzuki, Mamoru Okasaka, Yoshiki Kashiwada, Yoshihisa Takaishi, Gisho Honda, Michiho
Ito, Yoshio Takeda, Olimjon K. Kodzhimatov, Ozodbek Ashurmetov, Michiko Sekiya, Yasumasa
Ikeshiro
J. Nat. Prod. 70, 1915-1918 (2007)
(14)
Chemical composition of the essential oil of Microtoena patchoulii [(C.B. Clarke ex J.D. Hooker)
C.Y. Wu & Hsuan]
Manami Senpuku, Kazuya Nonaka, Michiho Ito, Gisho Honda
J. Essential Oil Research, 19 (July/August), 336-337 (2007)
(15)
Geraniol syntheses from perilla and their taxonomical significance
Michiho Ito, Gisho Honda
Phytochemistry, 68 (4), 446-453 (2007)
(16)
Chemical constituents of an Uzbek medicinal plant, Perovskia scrophularifolia
Yoshio Takeda, Takaaki Hayashi, Toshiya Masuda, Gisho Honda, Yoshihisa Takaishi, Michihoh Ito,
Hideaki Otsuka, Katsuyoshi Matsunami, Olimjon K. Khodzhimatov, Ozodbek A. Ashurmetov
J. Natural Medicines, 61 (1), 84-85 (2007)
− 203 −
㸦⥲ㄝ㸧
Analysis of essential oils–Recent techniques and advances in GC-MS eqyupment, Michiho Ito, Foods
& Food Ingredients Journal of Japan, 215 (2), 170-175 (2010)
┠࡛ぢࡿ₎᪉⸆࣭⏕⸆ࠕ᱇⓶ࠖఀ⸨⨾༓✑་⸆ࢪ࣮ࣕࢼࣝ 㔜せ⸆⏝᳜≀࡟㛵ࡍࡿㄅୖウㄽ ࡑࡢ㸲 ᱇⓶࡟㛵ࡍࡿヰ㢟ఀ⸨⨾༓✑⸆⏝᳜≀◊✲
Research and educational activities through perspective of pharmacognosy, Michiho Ito, Yakugaku
Zasshi, 130 (5), 687-695 (2010)
⸅≀࠿ࡽ⪺㤶ࠊࡑࡋ࡚⥺㤶࡬ఀ⸨⨾༓✑ࠊ㫽ẟ㐓ᖹ໬Ꮫ࡜ᕤᴗࠊ
Relaxing with fragrant vapor of natural medicine; its sedative effects on mice, Michiho Ito, Aroma
Research, 39, 234-241 (2009)
Studies on perilla, agarwood, and cinnamon through a combination of fieldwork and laboratory work,
Michiho Ito, J. Nat. Med. 62 (4), 387-395 (2008)
Agarwood–its sedative effect on mice and current state in the production sites, Michiho Ito, Gisho
Honda, Aroma Research, 34, 122-127 (2008)
ࢩࢯࡢ㤶ࡾࡢࣂ࢚ࣛࢸ࢕࣮ఀ⸨⨾༓✑࿴ග⣧⸆᫬ሗࠊ
㸦ⴭ᭩㸧
⏕⸆Ꮫ࡬ࡢ࠸ࡊ࡞࠸ఀ⸨⨾༓✑⦅ⴭி㒔ᘅᕝ᭩ᗑࠊ0DU
⸆Ꮫ⏕ࡢࡓࡵࡢ⸆⏝᳜≀Ꮫ࣭⏕⸆Ꮫࢸ࢟ࢫࢺ㧗▼ၿஂࠊ㤿ሙࡁࡳỤࠊᮏከ⩏᫛⦅㞟ࠊ㸦ศᢸᇳ➹㸸⸆
⏝᳜≀ࡢศᕸ࡜⏕ែ㸧ᘅᕝ᭩ᗑࠊ)HE
㓝⣲ࣁࣥࢻࣈࢵࢡ➨㸱∧ඵᮌ㐩ᙪࠊ⚟஭ಇ㑻ࠊ୍ᓥⱥ἞ࠊ㙾ᒣ༤⾜ࠊ⹡㇂ဴኵ⦅ࠊ㸦ศᢸᑵ➹㸧ᮅ
಴᭩ᗑࠊ-XQH
Studies on perilla relating to its essential oil and taxonomy in Phytochemistry Research Progress,
Michiho Ito, Takumi Matsumoto ed., Nova Publishers, 13-30 (2008)
− 204 −
⸆ရᶵ⬟ゎᯒᏛศ㔝
ᩍ ᤵ ி㒔኱Ꮫ༤ኈ㸦⸆Ꮫ㸧ᯇᓮ ຾ᕭ㸦ࡲࡘࡊࡁ ࠿ࡘࡳ㸧㸦2003.5 ╔௵㸧
᫛࿴ 57 ᖺி㒔኱Ꮫ༞ࠊ᫛࿴ 59 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬
ಟ஢ࠊᖹᡂ 4 ᖺி㒔኱Ꮫ༤ኈ㸦⸆Ꮫ㸧ྲྀᚓ
෸ᩍᤵ ኱㜰኱Ꮫ༤ኈ㸦⌮Ꮫ㸧ᫍ㔝 ኱㸦࡯ࡋࡢ ࡲࡉࡿ㸧㸦2004.9 ╔௵㸧
ᖹᡂ 5 ᖺ ኱㜰኱Ꮫ⌮Ꮫ㒊༞ࠊᖹᡂ 10 ᖺ኱㜰኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
ຓ ᩍ ி㒔኱Ꮫ༤ኈ㸦⸆Ꮫ㸧▮㔝 ⩏᫂㸦ࡸࡢ ࡼࡋ࠶ࡁ㸧㸦2005.5 ╔௵㸧
ᖹᡂ 12 ᖺி㒔኱Ꮫ⸆Ꮫ㒊༞ࠊᖹᡂ 17 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬
ಟ஢
◊✲ࡢᴫせ
⸆ရᶵ⬟ゎᯒᏛศ㔝࡛ࡣࠊ⏕య⭷ࡢ⏕≀≀⌮໬Ꮫࠊࢱࣥࣃࢡ㉁ࡢࣇ࢛࣮ࣝࢹ࢕ࣥࢢ࡟ࡘ࠸࡚◊✲ࢆᒎ
㛤ࡋ࡚࠸ࡿࠋ
㸯㸬⏕య⭷ࡢ⏕≀≀⌮໬Ꮫ
⏕య⭷ࡣ࢚ࢿࣝࢠ࣮࣭≀㉁ࡢ௦ㅰ࣭㍺㏦ࠊ᝟ሗఏ㐩࡜࠸ࡗࡓ⏕࿨άືࡢ⯙ྎ࡛࠶ࡾࠊࡑࡢᵓ㐀࣭ᶵ
⬟ࢆゎ᫂ࡍࡿࡇ࡜ࡣ⏕࿨⌧㇟ࡢ⌮ゎ࡜࠸࠺ᇶ♏ⓗほⅬࡢࡳ࡞ࡽࡎࠊ་⸆ရࡢ๰〇➼ࡢᛂ⏝㠃࡛ࡶ㔜
せ࡛࠶ࡿࠋ⏕య⭷ࡢᇶᮏᵓ㐀ࡣ 1 ୓✀㢮௨ୖ࡟ࡶ࠾ࡼࡪ⬡㉁ࡀᙧᡂࡍࡿ஧ศᏊ⭷࡟✀ࠎࡢᶵ⬟ᛶ⺮
ⓑ㉁ࡀ᪉ྥᛶࢆᣢࡗ࡚ᇙࡵ㎸ࡲࢀࡓࠕᕧ኱㉸ศᏊ」ྜయ࡛ࠖ࠶ࡾࠊከᩘࡢᵓᡂศᏊࡀືⓗ࡟┦஫స
⏝ࡋ࠶࠺ࡇ࡜࡟ࡼࡗ࡚」㞧࡞ᶵ⬟ࢆᐇ⌧ࡋ࡚࠸ࡿࠋᙜศ㔝࡛ࡣࠊ⏕≀≀⌮໬Ꮫⓗᡭἲࢆ࣮࣋ࢫ࡟ࠊ
ឤᰁ⑕ࡸ࢔ࣝࢶࣁ࢖࣐࣮⑓࡞࡝ࢱࣥࣃࢡ㉁㸦࣌ࣉࢳࢻ㸧-⬡㉁┦஫స⏝ࡢ㛵୚ࡍࡿ⑌ᝈ࡟ᑐࡍࡿ๰⸆
◊✲ࢆ⾜࠺࡜ྠ᫬࡟ࠊGPCR ࡞࡝ࡢ⭷ࢱࣥࣃࢡ㉁ࡢᵓ㐀ᙧᡂ࣭ࢲ࢖ࢼ࣑ࢡࢫ࡜ᶵ⬟Ⓨ⌧࣭⬡㉁㸦࣑
ࢡࣟࢻ࣓࢖ࣥᙧᡂࢆྵࡴ㸧࡟ࡼࡿࡑࢀࡽࡢไᚚࡢ◊✲ࢆ⾜࠸ࠊ⏕య⭷ࡢᵓ㐀࣭ᶵ⬟ࢆỴᐃࡋ࡚࠸ࡿ
ཎ⌮ཎ๎ࢆศᏊ࡛ࣞ࣋ࣝゎ᫂ࡋ࡚࠸ࡿࠋ
㸰㸬ࢱࣥࣃࢡ㉁ࡢࣇ࢛࣮ࣝࢹ࢕ࣥࢢ
࢔ࣝࢶࣁ࢖࣐࣮⑓㛵㐃࢔࣑ࣟ࢖ࢻșࢱࣥࣃࢡ㉁࡞࡝ࢱࣥࣃࢡ㉁ࡢࣇ࢛࣮ࣝࢹ࢕ࣥࢢ␗ᖖ࡟ࡼࡗ࡚
⏕ᡂࡍࡿ࢔࣑ࣟ࢖ࢻ⥺⥔ࡢᵓ㐀ࡸࣇ࢛࣮ࣝࢹ࢕ࣥࢢ࣓࢝ࢽࢬ࣒ࠊኳ↛ኚᛶࢱࣥࣃࢡ㉁ࡢᵓ㐀ᙧᡂ࡟
ࡘ࠸࡚ NMR ࡞࡝ࡢศගᏛࢆ⏝࠸࡚◊✲ࡋ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᙜศ㔝࡟࠾࠸࡚ࡣࠊ⸆Ꮫ㡿ᇦࡢ⏕≀≀⌮໬Ꮫ࡜ࡋ࡚ࠊ⑌⑓ࡢཎᅉゎ᫂ࡸ๰⸆ࢆᖖ࡟ど㔝࡟࠸ࢀࡘࡘࠊ
࠿ࡘᏛ⾡ⓗ࡟ࡶ㉁ࡢ㧗࠸◊✲ࢆ┠ᣦࡋ࡚ࡁࡓࠋࡑࡢ◊✲ᡂᯝࡣࠊᅜ㝿ㄅ࡟Ⓨ⾲ࡉࢀࠊㄽᩥࡢ⥲ᘬ⏝ᩘࡀ
5000 ᅇࢆ㛫㏆࡟ࡋ࡚࠸ࡿࠋࡲࡓࠊᅜෆእ࡛ࡢᣍᚅㅮ₇ࠊ⥲ㄝᇳ➹ࡢ౫㢗ࡸ᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊ዡບ㈹࣭
ྛ✀Ꮫ఍࡛ࡢඃ⚽Ⓨ⾲㈹ཷ㈹࠿ࡽࡳ࡚ࡶࠊ୍ᐃࡢእ㒊ホ౯ࢆཷࡅ࡚࠸ࡿ࡜ᛮࢃࢀࡿࠋࡋ࠿ࡋࠊࡲࡔࡲࡔ
୙༑ศ࡛࠶ࡾࠊࡉࡽ࡟㧗࠸┠ᶆࢆᣢࡗ࡚ࠊᖜᗈ࠸◊✲⪅࡟ᙳ㡪ࢆ୚࠼ࡿࡼ࠺࡞⏬ᮇⓗ࡞◊✲ࢆ┠ᣦࡍᚲ
せࡀ࠶ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣศᯒ໬Ꮫ 1㸦2 ᅇ⏕๓ᮇ㸧ࠊศᯒ໬Ꮫ 3㸦2 ᅇ⏕ᚋᮇ㸧ࠊ๰⸆≀⌮໬Ꮫ࢚ࢡࢧࢧ࢖ࢬ
1㸦2 ᅇ⏕๓ᮇ㸧ࠊ๰⸆≀⌮໬Ꮫ࢚ࢡࢧࢧ࢖ࢬ 2㸦2 ᅇ⏕ᚋᮇ㸧ࠊ⏕≀≀⌮໬Ꮫ㸦3 ᅇ⏕ᚋᮇ㸧࠾ࡼࡧ⸆Ꮫ
ᑓ㛛ᐇ⩦Ϩ㸦㸱ᅇ⏕๓ᮇࠊศᢸ㸧ࢆᢸᙜࡋ࡚࠸ࡿࠋศᯒ໬Ꮫ 1࣭3 ࡣࡍ࡭࡚ࡢᏛ⏕ࡀ⩦ᚓࡍ࡭ࡁᇶ♏Ꮫ
ၥ࡛࠶ࡿࡢ࡛ࠊ࢚ࢡࢧࢧ࢖ࢬ࡛ࡢ₇⩦࡜㐃ᦠࡋ࡚ࠊᖹᆒⓗᏛຊࡢྥୖ࡟ດࡵ࡚࠸ࡿࠋ⏕≀≀⌮໬Ꮫࡣ
advanced ࡞Ꮫၥ㡿ᇦ࡛࠶ࡿࡢ࡛ࠊ༢࡟ᩍ⛉᭩ⓗ▱㆑ࢆワࡵ㎸ࡴࡢ࡛ࡣ࡞ࡃࠊࡑ࠺ࡋࡓ▱㆑ࡀ࡝ࡢࡼ࠺࡟
ࡋ࡚⏕ࡲࢀ࡚ࡁࡓ࠿ࡢ⫼ᬒࡸⓎ᝿ἲࢆᩍ࠼ࡿࡢࡀ㔜せ࡛࠶ࡿ࡜⪃࠼ࠊᩍဨ⮬㌟ࡢయ㦂ࡶ஺࠼࡚ࠊࢧ࢖࢚
ࣥࢫࡢᴦࡋࡉࢆఏ࠼ࡿࡼ࠺࡟ດࡵ࡚࠸ࡿࠋ
༞ᴗᐇ⩦࠾ࡼࡧ኱Ꮫ㝔ᩍ⫱㸸ಶࠎࡢ◊✲ㄢ㢟ࢆ㏻ࡌࠊᇶ♏ⓗ࡞ᐇ㦂ᡭἲࠊ◊✲ࡢὶࢀ㸦సᴗ௬ㄝࡢタ
ᐃ--㸼ᐇ㦂--㸼⤖ᯝࡢゎ㔘--㸼సᴗ௬ㄝࡢಟṇ㸧ࢆಟᚓࡉࡏࡿࡼ࠺ᣦᑟࡋ࡚࠸ࡿࠋࢭ࣑ࢼ࣮࡛ࡣ⮬⏤࡛ά
Ⓨ࡞㆟ㄽࡀ࡛ࡁࡿ㞺ᅖẼసࡾࢆࡋ࡚࠸ࡿࠋ༤ኈᚋᮇㄢ⛬ࡢᏛ⏕࡟ࡣ⥲ㄝࢭ࣑ࢼ࣮ࢆㄢࡋ࡚ࠊ⮬㌟ࡢ◊✲
㡿ᇦࢆᴫほࡍࡿຊࢆ㣴࠺ࡼ࠺࡟ࡋ࡚࠸ࡿࠋࡲࡓࠊⱥㄒ࡟ࡼࡿࣉࣞࢮࣥࢸ࣮ࢩࣙࣥࡶᐇ᪋ࡋ࡚࠾ࡾࠊᅜ㝿
− 205 −
఍㆟࡛ࡢཱྀ㢌Ⓨ⾲ࢆዡບࡋ࡚࠸ࡿࠋࡇࢀࡽࡢᩍ⫱ࢆ㏻ࡌࠊᅜ㝿ⓗ࡟࣮ࣜࢲ࣮ࢩࢵࣉࢆ࡜ࡗ࡚ࡺࡅࡿேᮦ
ࢆ⫱ᡂࡋࡓ࠸ࠋࡲࡓࠊ኱Ꮫ㝔ㅮ⩏࡛ࡣࠊయ㦂ࢆࡶ࡜࡟ࠊ࡝ࡢࡼ࠺࡟ၥ㢟Ⅼࢆᤕࡽ࠼࡚ゎỴࡍࡿ࠿࡟㔜Ⅼ
ࢆ⨨࠸ࡓㅮ⩏ࢆᚰࡀࡅ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊ᩍ⫱㸸Ꮫຊྥୖࡢࡓࡵศ࠿ࡾࡸࡍ࠸ㅮ⩏࡜ཝṇ࡞᥇Ⅼࢆᚰࡀࡅ࡚࠸ࡿࡀࠊᏛᖺẖࡢᏛ⩦ពḧࡸ฿
㐩ᗘ࡟ᕪࡀ࠶ࡿࡢ࡛ࠊᘬࡁ⥆ࡁᕤኵ࡜ດຊࡀᚲせ࡛࠶ࡿࠋࡲࡓࠊࢧ࢖࢚ࣥࢫ࡟ᑐࡍࡿ⯆࿡ࢆᣢࡓࡏࡿⅬ
࡛ࡣࠊ≉࡟Ꮫไᨵ㠉௨㝆ࠊពḧⓗ࡛ඃ⚽࡞Ꮫ⏕ࡀ◊✲ᐊ࡟㓄ᒓࡉࢀࡿࡼ࠺࡟࡞ࡗ࡚ࡁ࡚࠾ࡾࠊᡂᯝࢆᣲ
ࡆ࡚࠸ࡿࡶࡢ࡜ᛮࢃࢀࡿࠋ
◊✲ᐊᩍ⫱㸸ࢭ࣑ࢼ࣮᫬ࡢ㆟ㄽࡣάⓎ࡛࠶ࡾࠊከࡃࡢᏛ⏕ࡣ✚ᴟⓗ࡟◊✲࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࡶࡢࡢࠊ
ᇶ♏Ꮫຊࡣࡲࡔࡲࡔ୙㊊ࡋ࡚࠸ࡿࠋࡲࡓࠊⱥㄒຊࡢఙࡧ࡟ࡶಶேᕪࡀ኱ࡁ࠸ࠋࡲࢃࡾ࡟ὶࡉࢀࡿࡇ࡜࡞
ࡃࠊࡋࡗ࠿ࡾ࡜┠ᶆࢆࡶࡗ࡚◊㛑ࡉࡏࡿ⢭⚄ⓗ࡞㘫㘐ࡀᚲせ࡛࠶ࡿࠋ
㸦ཎⴭ㸧
1. A novel hybrid peptide targeting EGFR-expressing cancers. M. Kohno, T. Horibe, M. Haramoto, Y. Yano, K.
Ohara, O. Nakajima, K. Matsuzaki, and K. Kawakami, Eur. J. Cancer, in press (2010).
2. Solubility enhancement of hydrophobic compounds by cosolvents: Role of solute hydrophobicity on the
solubilization effect. Y. Miyako, N. Khalef, K. Matsuzaki, and R. Pinal, Int. J. Pharm., 393,48-54 (2010).
3. Ganglioside-mediated aggregation of amyloid ș-proteins (Aș): Comparison between Aș-(1-40) and Aș
-(1-42). M. Ogawa, M. Tsukuda, T. Yamaguchi, K. Ikeda, T. Okada, Y. Yano, M. Hoshino, and K. Matsuzaki,
J. Neurochem. in press (2010).
4. A disulfide-linked amyloid-beta peptide dimer forms a protofibril-like oligomer through a distinct pathway
from amyloid fibril formation. T. Yamaguchi, H. Yagi, Y. Goto, K. Matsuzaki and M. Hoshino Biochemistry,
49, 7100-7107 (2010).
5. Chaperonin-encapsulation of proteins for NMR. S. Tanaka, Y. Kawata, G. Otting, N.E. Dixon, K. Matsuzaki
and M. Hoshino Biochim. Biophys. Acta, 1804,866-871 (2010).
6. Design of a soluble transmembrane helix for measurements of water-membrane partitioning. Y. Yano, N.
Shimai, and K. Matsuzaki, J. Phys. Chem. B., 114,1925-1931 (2010).
7. "Click peptide": pH-triggered in situ production and aggregation of monomer Abeta1-42. A. Taniguchi, Y.
Sohma, Y. Hirayama, H. Mukai, T. Kimura, Y. Hayashi, K. Matsuzaki, and Y. Kiso, Chembiochem, 10,
710-715 (2009).
8. Lacticin Q, a lactococcal bacteriocin, causes high-level membrane permeability in the absence of specific
receptors. F. Yoneyama, Y. Imura, S. Ichimasa, K. Fujita, T. Zendo, J. Nakayama, K. Matsuzaki, and K.
Sonomoto, Appl. Environ. Microbiol., 75, 538-541 (2009).
9. Peptide-lipid huge toroidal pore: a new antimicrobial mechanism mediated by a lactococcal bacteriocin,
lacticin F. Yoneyama, Y. Imura , K. Ohno , T. Zendo , J. Nakayama , K. Matsuzaki, and K. Sonomoto,
Antimicrob. Agents Chemother 53, 3211-3217 (2009).
10. Ganglioside-induced formation of amyloid fibrils by hIAPP in lipid rafts. M. Wakabayashi and K.
Matsuzaki, FEBS Lett., 583, 2854-2858 (2009).
11. Controlled production of amyloid beta peptide from a photo-triggered, water-soluble precursor "click peptide.
A. Taniguchi, M. Skwarczynski, Y. Sohma, T. Okada, K. Ikeda, H. Prakash, H. Mukai, Y. Hayashi, T. Kimura,
S. Hirota, K. Matsuzaki, and Y. Kiso, ChemBioChem, 9, 3055-3065 (2008).
12. Magainin 2 in Action: Distinct Modes of Membrane Permeabilization in Living Bacterial and Mammalian
Cell A. Y. Imura, N. Choda, and K. Matsuzaki, Biophys. J., 95, 5757-5765 (2008).
13. Formation of toxic Aș-(1-40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts :
Polymorphisms in Aș-(1-40) fibrils. T. Okada, K. Ikeda, M. Wakabayashi, M. Ogawa, K. Matsuzaki,
Antimicrob. J. Mol. Biol., 382, 1066-1074 (2008).
14. Coiled-coil tag-probe system for quick labeling of membrane receptors in living cells. N. Y. Yano, A. Yano, S.
Oishi, Y. Sugimoto, G. Tsujimoto, N. Fujii, & K. Matsuzaki, ACS Chem. Biol., 6, 341-345 (2008).
15. Intracellular third loop-C-terminal tail interaction in prostaglandin EP3beta receptor. Y. Yano, T. Shimbo, Y.
Sugimoto, and K. Matsuzaki, Biochim. Biophys. Res. Commun., 371, 846-849 (2008).
16. Design, synthesis and biophysical properties of a helical Abeta1-42 analogue: Inhibition of fibrillogenesis
and cytotoxicity. K. Matsuzaki, T. Okada, M. Tsukuda, K. Ikeda, Y. Sohma, Y. Chiyomori, A. Taniguchi, S.
Nakamura, N. Ito, Y. Hayashi, and Y. Kiso, Biochim. Biophys. Res. Commun., 371, 777-780 (2008).
17. Driving force of binding of amyloid beta-protein to lipid bilayers. K. Ikeda and K. Matsuzaki, Biochim.
− 206 −
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Biophys. Res. Commun., 370, 525-529 (2008).
Interaction of a Magainin-PGLa Hybrid Peptide with Membranes: Insight into the Mechanism of
Synergism., M. Nishida, Y. Imura, M. Yamamoto, S. Kobayashi, Y. Yano, and K. Matsuzaki, Biochemistry,
46, 14284-14290 (2007).
Action Mechanism of PEGylated Magainin 2 Analogue Peptide. Y. Imura, M. Nishida, and K. Matsuzaki,
Biochim. Biophys. Acta, 1768, 2578-2585 (2007).
Formation of Amyloids by Abeta-(1-42) on NGF-Differentiated PC12 Cells: Roles of Gangliosides and
Cholesterol. M. Wakabayashi and K. Matsuzaki. J. Mol. Biol., 371, 924-933 (2007).
Formation of toxic fibrils of Alzheimer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a
neuronal membrane component.. T. Okada, M. Wakabayashi, K. Ikeda, K. Matsuzaki J. Mol. Biol., 371,
481-489 (2007).
Action Mechanism of Tachyplesin I and Effects of PEGylation. Y. Imura, M. Nishida, Y. Ogawa, Y. Takakura,
and K. Matsuzaki, Biochim. Biophys. Acta, 1768, 1160-1169 (2007).
Cores and pH-dependent Dynamics of Ferredoxin-NADP+ Reductase Revealed by Hydrogen/Deuterium
Exchange. Y-H. Lee, K. Tamura, M. Maeda, M. Hoshino, K. Sakurai, S. Takahashi, T. Ikegami, T. Hase, and
Y. Goto, J. Biol. Chem., 282, 5959-5967 (2007).
Inhibitors of amyloid beta-protein aggregation mediated by GM1-containing raft-like membranes, K.
Matsuzaki, T. Noguch, M. Wakabayashi, K. Ikeda, T. Okada, Y. Ohashi, M. Hoshino, and H. Naiki, Biochim.
Biophys. Acta, 1768, 122-130 (2007).
Click Peptide" Based on the "O-Acyl Isopeptide Method": Control of Abeta1-42 Production from a
Photo-Triggered Abeta1-42 Analogue. A. Taniguchi, Y. Sohma, M. Kimura, T. Okada, K. Ikeda, Y. Hayashi,
T. Kimura, S. Hirota, K. Matsuzaki, and Y. Kiso, J. Am. Chem. Soc., 128, 696-697 (2006).
Measurement of Thermodynamic Parameters for Hydrophobic Mismatch 1-Self-Association of a
Transmembrane Helix. Y. Yano and K. Matsuzaki, Biochemistry, 45, 3370-3378 (2006).
Measurement of Thermodynamic Parameters for Hydrophobic Mismatch 2-Intermembrane Transfer of a
Transmembrane Helix. Y. Yano, M. Ogura, and K. Matsuzaki, Biochemistry, 45, 3379-3385 (2006).
Biantennary glycans as well as genetic variants of alpha1-acid glycoprotein control the enantioselectivity and
binding affinity of oxybutynin. T. Kimura, A. Shibukawa, and K. Matsuzaki, Pharm. Res., 23, 1038-1042
(2006).
Inhibition of the formation of amyloid ș -protein fibrils using biocompatible nanogels as artificial
chaperones. K. Ikeda, T. Okada, S. Sawada, K. Akiyoshi, and K. Matsuzaki, FEBS Lett., 580, 6587-6595
(2006).
㸦⥲ㄝ㸧
1. ᪂つ⺯ගࣛ࣋ࣝἲ࡟ࡼࡿ⭷ཷᐜయࡢෆᅾ໬ࡢྍど໬. ᯇᓮ຾ᕭࠊ▮㔝⩏᫂, ⏕໬Ꮫ 82ࠊ494-497
(2010).
2. Abeta polymerization through interaction with membrane gangliosides . K. Matsuzaki, K. Kato, and K.
Yanagisawa, Biochim. Biophys. Acta, 1801, 868-877 (2010).
3. Effects of macromolecular crowding on intracellular diffusion from a single particle perspective" D. Hall,
and M. Hoshino Biophys Rev, 2, 39-53(2010).
4. ࢞ࣥࢢࣜ࢜ࢩࢻࢡࣛࢫࢱ࣮ࢆ௓ࡋࡓ࢔࣑ࣟ࢖ࢻș࣌ࣉࢳࢻࡢจ㞟࣭ẘᛶⓎ⌧ ࡢ࣓࢝ࢽࢬ࣒࡜
ࡑࡢ㜼ᐖ. ᯇᓮ຾ᕭ, ⸆ㄅ 130, 511-515 (2010).
5. Control of cell selectivity of antimicrobial peptides. K. Matsuzaki, Biochim. Biophys. Acta, 1788, 1687-1692
(2009).
6. Solution NMR studies of amphibian antimicrobial peptides: Linking structure to function?㸬E.F. Haney, H.N.
Hunter, 1, K.Matsuzaki, and H. J. Vogel, Biochim. Biophys. Acta, 1788, 1639-1655 (2009).
7. Tag-probe fluorescent labeling methods for live-cell imaging of membrane proteins㸬Y. Yano and K.
Matsuzaki㸪Biochim. Biophys. Acta, 1788, 2124-2131 (2009).
8. ࢔ࣝࢶࣁ࢖࣐࣮⑓࢔࣑ࣟ࢖ࢻșࢱࣥࣃࢡ㉁ࡢจ㞟࡟࠾ࡅࡿ⏕య⭷ࡢᙺ๭, ᯇᓮ ຾ᕭ, ⭷, 32,
185-189 (2007).
9. Physicochemical interactions of amyloid beta-peptide with lipid bilayers. K. Matsuzaki Biochim. Biophys.
Acta ,1768, 1935-1942 (2007).
10. Dimethylsulfoxide-quenched hydrogen/deuterium exchange method to study amyloid fibril structure." M.
Hoshino, H. Katou, K. Yamaguchi, and Y. Goto Biochim. Biophys. Acta ,1768, 1886-99(2007).
11. 㸿ș࢔࣑ࣟ࢖ࢻᙧᡂ࡟࠾ࡅࡿ⏕య⭷ࡢᙺ๭. ᯇᓮ຾ᕭ, ⣽⬊ᕤᏛ㸪26㸪173-176㸦2007㸧.
12. ⏕⣽⬊ࢱࣥࣃࢡ㉁ࡢྍど໬--⺯ගࢱࣥࣃࢡ㉁࠿ࡽࢣ࣑࢝ࣝࣛ࣋ࣝ࡬. ᯇᓮ຾ᕭ࣭▮㔝⩏᫂, ໬Ꮫ,
61, 66-67 (2007).
− 207 −
13. Click peptide: a novel ͂O-acyl isopeptide method̓ for peptide synthesis and chemical biology-oriented
synthesis of amyloid ș peptide analogues㸬Y. Sohma, A. Taniguchi, T. Yoshiya, Y. Chiyomori, F. Fukao, S.
Nakamura, M. Skwarczynski, T. Okada, K. Ikeda, Y. Hayashi, T. Kimura, S. Hirota, K. Matsuzaki, and Y.
Kiso㸪J. Pept. Sci. 12, 823-828 (2006).
㸦ⴭ᭩㸧
1. ≉␗ⓗ⺯ගࣛ࣋ࣝἲ࡟ࡼࡿ⏕⣽⬊࡛ࡢཷᐜయ࢖࣓࣮ࢪࣥࢢ. ᯇᓮ຾ᕭࠊ▮㔝⩏᫂, ⸆Ꮫศᯒ⛉Ꮫࡢ
᭱๓⥺, 170-171㸪ࡌ࡯࠺㸦2009㸧
2. Accumulation of Alzheimer beta-amyloid via Ganglioside Clusters. Katsumi Matsuzaki,
Experimental Glycoscience. Glycobiology, Springer, Tokyo, pp.185-187, (2008)
3. ⏕య㜵ᚚࡢ௙⤌ࡳࢆ฼⏝ࡋ࡚ᢠ⳦๣ࢆ๰ࡿ㸸ᖹᡂ∧ࡀࡲࡢἜࡢヰ. ᯇᓮ຾ᕭ, ᪂ࡋ࠸⸆ࢆ࡝࠺๰ࡿ
࠿ ๰⸆◊✲ࡢ᭱๓⥺ ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉⦅㸪ㅮㄯ♫ࣈ࣮ࣝࣂࢵࢡࢫ㸪➨ 8 ❶㸦2007㸧
4. ⬡㉁⭷࣏ࣜ࣌ࣉࢳࢻ┦஫స⏝. ᯇᓮ຾ᕭ, ⏕≀≀⌮Ꮫࣁࣥࢻࣈࢵࢡ㸪➨ 3 ❶ 8 ⠇㸪ᮅ಴᭩ᗑ㸦2007㸧
5. (SBO 19)⏕య⭷ࡢ❧యᵓ㐀ࢆつᐃࡍࡿ┦஫స⏝࡟ࡘ࠸࡚ࠊㄝ࡛᫂ࡁࡿࠋ
㸬ᯇᓮ຾ᕭ㸪≀⌮⣔⸆Ꮫ㸦Ϫ㸬
⏕యศᏊ࣭໬Ꮫ≀㉁ࡢᵓ㐀Ỵᐃ㸧᪥ᮏ⸆Ꮫ఍⦅, ᮾி໬Ꮫྠே, 106-209 (2006)
6. Folding Intermediates: Turning Points to the Native State, Amyloid Fibrils and Aggregation. M. Hoshino, Y.
O. Kamatari, S. Ohnishi, Protein Folding: New Research, Tony R. Obalinsky ed., Nova Science Publishers,
pp. 51-87 (2006)
− 208 −
ᵓ㐀⏕≀⸆Ꮫศ㔝
ᩍᤵ(㎰Ꮫ༤ኈ) ຍ⸨ ༤❶(࠿࡜࠺ ࡦࢁ࠶ࡁ)(2002.4 ╔௵)
᫛࿴ 58 ᖺᒣᙧ኱Ꮫ༞ࠊ᫛࿴ 63 ᖺி㒔኱Ꮫ኱Ꮫ㝔㎰Ꮫ◊✲⛉༤ኈ
ㄢ⛬ಟ஢
෸ᩍᤵ(༤ኈ(㎰Ꮫ)) ୰ὠ ஽(࡞࠿ࡘ ࡜࠾ࡿ)(2003.4 ╔௵)
ᖹᡂ 3 ᖺ኱㜰኱Ꮫ༞ࠊᖹᡂ 8 ᖺி㒔኱Ꮫ኱Ꮫ㝔㎰Ꮫ◊✲⛉༤ኈㄢ
⛬ಟ஢
ຓᩍ(༤ኈ(⌮Ꮫ)) ᒣཱྀ ▱ᏹ(ࡸࡲࡄࡕ ࡜ࡶࡦࢁ)(2008.9 ╔௵)
ᖹᡂ 10 ᖺி㒔኱Ꮫ༞ࠊᖹᡂ 16 ᖺி㒔኱Ꮫ኱Ꮫ㝔⌮Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
ຓᩍ(༤ኈ(⸆Ꮫ)) ୰㔝 ༤᫂(࡞࠿ࡢ ࡦࢁ࠶ࡁ)(2008.3 ㏥⫋)
ᖹᡂ 9 ᖺ኱㜰኱Ꮫ༞ࠊᖹᡂ 14 ᖺ኱㜰኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
ᙜᵓ㐀⏕≀⸆Ꮫศ㔝࡛ࡣࠊᮍゎ᫂ࡢ⏕࿨⌧㇟ࡢ௙⤌ࡳࢆࡑࡢᢸ࠸ᡭ࡛࠶ࡿศᏊࡢ❧యᵓ
㐀࠿ࡽ᫂ࡽ࠿࡟ࡍࡿ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ᪂ࡓ࡞⏕࿨⌧㇟ࡢศᏊᵓ㐀ᇶ┙ࡢ⌮ゎࡣࠊ⏕యᶵ
⬟ࡢㄪ⠇໬ྜ≀ࡍ࡞ࢃࡕ⸆ࢆ๰ᡂࡍࡿࡓࡵࡢタィཎ⌮ࡢⓎぢ࡟ᐤ୚ࡍࡿ࠿ࡽ࡛࠶ࡿࠋࡑࡇ
࡛ࠊゎ᫂ࢆ┠ⓗ࡜ࡍࡿศᏊࡢ㑇ఏᏊࢆྲྀᚓࡋࠊ㐺ษ࡞⣽⬊࡟࡚⩻ヂࡉࢀࡓࢱࣥࣃࢡ㉁ࢆ༢
㞳⢭〇ࡋ࡚⤖ᬗ໬ࢆ⾜࠸ࠊX ⥺⤖ᬗゎᯒࢆᐇ᪋ࡋ࡚❧యᵓ㐀ࢆỴᐃࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊࡑ
ࡢ❧యᵓ㐀࡟ᇶ࡙࠸ࡓ㑇ఏᏊᨵኚࡸ໬Ꮫ⏕≀Ꮫⓗ࡞࢔ࣉ࣮ࣟࢳ࠿ࡽၥ㢟ࡢศᏊࡢ௙⤌ࡳࢆ
⌮ゎࡋࡼ࠺࡜ࡋ࡚࠸ࡿࠋࡍ࡞ࢃࡕࠊX ⥺⤖ᬗᏛࢆ୰᰾࡜ࡋ࡚ࠊศᏊ⏕≀Ꮫࠊ⏕໬Ꮫࠊ⣽⬊
⏕≀Ꮫࠊ≀⌮໬Ꮫࠊ⏕≀᝟ሗᏛ࡟Ώࡿᗈ⠊࡞᪉ἲࢆ⤌ࡳྜࢃࡏ࡚ཎᏊᵓ㐀࡛ࣞ࣋ࣝ⏕≀Ꮫ
ࡢ␲ၥ࡟⟅࠼ࡼ࠺࡜ࡍࡿ࡜ࡇࢁ࡟ᙜศ㔝ࡢ◊✲ࡢ≉ᚩࡀ࠶ࡿࠋࡉࡽ࡟ࠊX ⥺⤖ᬗᏛ࡛ࡣࠊ
⌮໬Ꮫ◊✲ᡤ᧛☻◊✲ᡤ࠾ࡼࡧ኱ᆺᨺᑕග᪋タ SPring-8 ࡜ࡢ㐃ᦠ࡟ࡼࡾࠊୡ⏺᭱㧗ࡢ❧య
ᵓ㐀ゎᯒ⎔ቃࢆά⏝࡛ࡁࡿయไ࡟࠶ࡿࠋࡇࡢࡼ࠺࡞◊✲ᡭἲࡢ≉ᚩࢆά࠿ࡋ࡚᭱ඛ➃ࡢ◊
✲࡜◊✲⪅⫱ᡂࡀ⾜ࢃࢀ࡚࠸ࡿࠋ
ཎᏊᵓ㐀ࢆᇶ┙ࡋࡓ⏕≀Ⓨග࣓࢝ࢽࢬ࣒ࡢゎ᫂
㓝⣲ࡣࠊ໬Ꮫ཯ᛂࢆ㦫␗ⓗ࡞ࢫࣆ࣮ࢻ࡬࡜ຍ㏿ࡍࡿࡇ࡜ࡀ࡛ࡁࡿࢱࣥࣃࢡ㉁ࡢゐ፹࡛࠶
ࡾࠊ㔜せ࡞๰⸆ᶆⓗ࡛࠶ࡿࠋࡑࡇ࡛ࠊࡑࡢᶵ⬟ࡢ௙⤌ࡳࢆᢸ࠺ᵓ㐀せᅉࢆࠊX ⥺⤖ᬗᵓ㐀
ゎᯒࢆ⏝࠸࡚᫂ࡽ࠿࡟ࡍࡿࡇ࡜ࢆ┠ⓗ࡟ࠊ࣍ࢱࣝࡢⓎග㓝⣲ࣝࢩࣇ࢙࣮ࣛࢮࡢ❧యᵓ㐀ゎ
ᯒࢆ⾜ࡗ࡚࠸ࡿࠋ࣍ࢱࣝࡢࣝࢩࣇ࢙࣮ࣛࢮࡣ㯤⥳Ⰽ࡟Ⓨගࡍࡿ཯ᛂࢆゐ፹ࡍࡿࠋᡃࠎࡣࣝ
ࢩࣇ࢙࣮ࣛࢮ࡜ࡑࡢ཯ᛂ୰㛫య࢔ࢼࣟࢢ㸦DLSA㸧」ྜయࡢᵓ㐀ゎᯒࢆ⾜࠺ࡇ࡜࡛Ⓨග཯ᛂ
࡟క࠺ࣝࢩࣇ࢙࣮ࣛࢮࡢᵓ㐀ኚ໬ࢆᤕࡽ࠼ࡿࡇ࡜࡟ᡂຌࡋࡓ(Nature, 2006)ࠋࡇࡢ◊✲࡟ࡼࡾࠊ
− 209 −
Ⓨග⏕ᡂ≀࢜࢟ࢩࣝࢩࣇ࢙ࣜࣥࡀ㓝⣲୰࡟⤖ྜࡋ࡚࠸ࡿጼࢆึࡵ࡚ᤊ࠼ࡿࡇ࡜࡟ᡂຌࡍࡿ
࡜࡜ࡶ࡟ࠊࣝࢩࣇ࢙࣮ࣛࢮࡢⓎගⰍࡢไᚚࡢ௙⤌ࡳࢆゎ᫂ࡋࡓࠋ௒ᚋࡣࠊࣝࢩࣇ࢙࣮ࣛࢮ
࡟ࡼࡿⓎග཯ᛂࡢ㔞Ꮚ཰⋡ࡀ᭱ࡶ㧗࠸⌮⏤ࢆゎ᫂ࡍࡿணᐃ࡛࠶ࡿࠋ
᳜≀࣍ࣝࣔࣥࢪ࣋ࣞࣜࣥ࡜ࡑࡢཷᐜయࡢ┦஫స⏝࠾ࡼࡧศᏊ㐍໬ࡢ❧యᵓ㐀ᇶ┙ࡢゎ᫂
᝟ሗఏ㐩≀㉁࡜ཷᐜయ࡜ࡢ┦஫స⏝࣓࢝ࢽࢬ࣒ࡢ◊✲࡜ࡋ࡚ࠊ᳜≀ᡂ㛗ㄪ⠇ᅉᏊࢪ࣋ࣞ
ࣜࣥ(GA)࡜ࡑࡢཷᐜయ GID1 ࡜ࡢ」ྜయࡢ❧యᵓ㐀ࢆỴᐃࡋࠊࢪ࣋ࣞࣜࣥಙྕཷᐜࡢ௙⤌ࡳ
ࢆゎ᫂ࡋࡓ(Nature, 2008)ࠋGA ࡣࠊ࣌ࢽࢩࣜࣥࡼࡾࡶྂࡃࠊ1920 ᖺ௦࡟ᡃࡀᅜ࡛࢝ࣅ࠿ࡽⓎ
ぢࡉࢀࡓ⏕≀ᶵ⬟ㄪ⠇໬ྜ≀࡛࠶ࡾࠊࡑࡢಙྕཷᐜࡢ௙⤌ࡳࡣࠊ2005 ᖺ࡟ཷᐜయࡀྠᐃࡉ
ࢀࡿࡲ࡛࡞ࡒ࡟ໟࡲࢀ࡚࠸ࡓࠋࡲࡓࠊGID1 ࡣࣜࣃ࣮ࢮ࡜࠸࠺⬡㉁ศゎ㓝⣲ࡢ❧యᵓ㐀࠿ࡽ
ཷᐜయ࡬࡜㐍໬ࢆ㐙ࡆࡓ࡜⪃࠼ࡽࢀࡿ᪂つࡢᵓ㐀㦵᱁ࡶࡘ᰾ෆཷᐜయ࡛࠶ࡾࠊ㐍໬ࡢ㐣⛬
࡟⯆࿡ࡀᣢࡓࢀ࡚࠸ࡓࠋGA-GID1 」ྜయࡢ❧యᵓ㐀Ỵᐃ࡟ࡼࡾࠊ」㞧࡞」⣲⎔໬ྜ≀࡛࠶
ࡿ GA ࢆᕦࡳ࡟ㄆ㆑ࡍࡿཷᐜయࡢ࣓࢝ࢽࢬ࣒ࡀゎ᫂ࡉࢀࡿ࡜࡜ࡶ࡟ࠊศᏊ㐍໬࡜❧యᵓ㐀࡜
ࡢ㛵ಀࡀุ᫂ࡋࡓࠋ
࣌ࣝ࢜࢟ࢩࢯ࣮࣒⭷ࢱࣥࣃࢡ㉁ࡢ㐠ᦙయ࡜ཷᐜయ┦஫స⏝ࡢ❧యᵓ㐀ᇶ┙ࡢゎ᫂
࣌ࣝ࢜࢟ࢩࢯ࣮࣒ࡣ༢୍ࡢ⭷ᵓ㐀ࢆ᭷ࡍࡿ࢜ࣝ࢞ࢿ࡛ࣛ࠶ࡾࠊࡑࡢḞ㝗ࡣ㔜⠜࡞⑌ᝈࡢ
ཎᅉ࡜࡞ࡿࠋ࣌ࣝ࢜࢟ࢩࢯ࣮࣒≉␗ⓗ࡞⭷ࢱࣥࣃࢡ㉁(PMP)ࡢ㍺㏦࡟ࡣࠊ࣌ࣝ࢜࢟ࢩࣥ㸦Pex㸧
࡜࿧ࡤࢀࡿ࣌ࣝ࢜࢟ࢩࢯ࣮࣒ᙧᡂᅉᏊࢱࣥࣃࢡ㉁ࡀ」ᩘ㛵୚ࡋ࡚࠸ࡿ࡜ࡉࢀ࡚࠸ࡿࡀࠊࡑ
ࢀࡽࡢᙺ๭࡜┦஫స⏝ࡢ௙⤌ࡳࡣㅦࡢࡲࡲ࡛࠶ࡗࡓࠋᡃࠎࡣ PMP 㐠ᦙయ Pex19p ࡜ࡑࡢཷ
ᐜయ Pex3p ࡢ」ྜయࢆㄪ〇ࡋࠊX ⥺⤖ᬗゎᯒࢆ⾜࠺ࡇ࡜࡟ึࡵ࡚ᡂຌࡋࡓ(EMBO J., 2010)ࠋ
ࡲࡓࠊศᏊ㛫┦஫స⏝ࡢ௙⤌ࡳ࡜⣽⬊୰࡛ࡢ࣌ࣝ࢜࢟ࢩࢯ࣮࣒ᙧᡂࡀ┦㛵ࡍࡿࡇ࡜ࡶ᫂ࡽ
࠿࡟ࡋࡓࠋ
$%& ࢺࣛࣥࢫ࣏࣮ࢱ࣮ࡢ⤖ᬗᏛⓗ◊✲
ABC㸦ATP Binding Cassette㸧ࢱࣥࣃࢡ㉁࡜ࡣࠊศᏊෆ࡟ࡼࡃಖᏑࡉࢀࡓ ATP ⤖ྜ㒊఩ࢆ
㸰ࡘ᭷ࡍࡿ⭷ࢱࣥࣃࢡ㉁ࡢ⥲⛠࡛࠶ࡿࠋண᝿ࡉࢀࡿ㸰ḟᵓ㐀ࡣ㠀ᖖ࡟Ⰻࡃఝ࡚࠸ࡿ࡟ࡶ㛵
ࢃࡽࡎࠊࢺࣛࣥࢫ࣏࣮ࢱ࣮ࠊࣞࢭࣉࢱ࣮ࠊࢳࣕࣥࢿࣝ࡜࠸ࡗࡓከᵝ࡞⏕⌮ᶵ⬟ࢆ♧ࡋࠊ⏕
࿨⥔ᣢ࡟ᚲ㡲࡞ᙺ๭ࢆᯝࡓࡋ࡚࠸ࡿࠋࡋࡓࡀࡗ࡚ ABC ࢱࣥࣃࢡ㉁ࡢ❧యᵓ㐀ࢆ㧗࠸ศゎ⬟
࡛Ỵᐃࡍࡿࡇ࡜ࡣᶵ⬟ࡢ㐪࠸ࢆ᫂ࡽ࠿࡟ࡍࡿࡓࡵ࡟ᚲ㡲࡛࠶ࡿࠋࡋ࠿ࡋࠊࡇࢀࡽ⭷ࢱࣥࣃ
ࢡ㉁ࡣࠊศᏊᵓ㐀ࣞ࣋ࣝࡢ◊✲ࡀᅔ㞴࡛࠶ࡾࠊ࡯࡜ࢇ࡝◊✲ࡀ㐍ࢇ࡛࠸࡞࠸ࠋࡑࡇ࡛ࠊ࢞
ࣥࡢከ๣⪏ᛶࡢཎᅉ࡟࡞ࡗ࡚࠸ࡿ ABC ࢺࣛࣥࢫ࣏࣮ࢱ࣮࡛࠶ࡿ P ⢾ࢱࣥࣃࢡ㉁࡜ࡑࡢ┦ྠ
ࢱࣥࣃࢡ㉁ࢆࢱ࣮ࢤࢵࢺ࡜ࡋ࡚㑅ࡧࠊ⤖ᬗ໬ࢆ┠ᣦࡋࡓ኱㔞⢭〇ἲࡢ☜❧࡜⭷ࢱࣥࣃࢡ㉁
⤖ᬗ໬ἲࡢ㛤Ⓨࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓࠊ㧗ᗘ࡟⢭〇ࡋࡓᶆⓗ⭷ࢱࣥࣃࢡ㉁ࢆ⏝࠸࡚ࡑࡢᶵ⬟
ࢆ⏕໬Ꮫⓗ࡟◊✲ࡋ࡚࠸ࡿࠋ᭱㏆ࠊ㐙࡟ X ⥺⤖ᬗゎᯒ࡟㐺ࡋࡓ⤖ᬗࢆྲྀᚓࡍࡿᡭἲࢆ☜❧
ࡍࡿࡇ࡜ࡀ࡛ࡁࡓࡓࡵࠊ௒ᚋࡣ X ⥺⤖ᬗᵓ㐀ゎᯒ࡜❧యᵓ㐀࡟ᇶ࡙࠸ࡓ࣓࢝ࢽࢬ࣒ࡢゎᯒ
− 210 −
ࢆᐇ᪋ࡍࡿணᐃ࡛࠶ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᩘ༑ᖺ௨ୖ࡟ࢃࡓࡾㅦ࡜ࡉࢀ࡚ࡁࡓ୕ࡘࡢᮍゎ᫂ࡢ⏕≀⌧㇟࡟ゎ⟅ࢆ୚࠼ࡿࡇ࡜ࡀ࡛ࡁ
ࡓࠋࡑࡢᡂᯝࡣࠊNature, EMBO J.࡜࠸ࡗࡓୡ⏺ⓗ࡟ホ౯ࡢ㧗࠸㞧ㄅ࡟Ⓨ⾲ࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋ
ࡲࡓࠊከᩘࡢ⛉ᏛㄅࡸᏛ఍ㄅࡢࢽ࣮ࣗࢫࡸ⥲ㄝ࡛⤂௓ࡉࢀᑓ㛛ᐙ࠿ࡽࡢ㧗࠸ホ౯ࢆཷࡅࡿ
ࡔࡅ࡛࡞ࡃࠊࢸࣞࣅࡢᨺᫎࡸࠊᅜෆእࡢ᪂⪺ࠊ୍⯡㞧ㄅ࡞࡝࡟ࡶグ஦ࡀᥖ㍕ࡉࢀࠊࡉࡽ࡟
NHK 㧗ᰯ⏕≀ㅮᗙࡢ㢟ᮦ࡟ྲྀࡾୖࡆࡽࢀࡿ࡞࡝ࠊ♫఍ⓗ࡞཯㡪ࡶ኱ࡁ࠿ࡗࡓࠋࡇࢀࡽ◊✲
࡟ࡼࡗ࡚ಶࠎࡢタၥ࡟ゎ⟅ࡀᚓࡽࢀࡓࡔࡅ࡛࡞ࡃࠊస⏝࣓࢝ࢽࢬ࣒࡟క࠺ࢱࣥࣃࢡ㉁ศᏊ
ࡢᵓ㐀ኚ໬࡟ࡼࡗ࡚ฟ⌧ࡍࡿ≉␗࡞ศᏊ㛫┦஫స⏝ࢆ᪂ࡓ࡟ⓎぢࡋࡓࠋࡲࡓࠊࡇࡢⓎぢࡢ
㐣⛬࡛᪂ࡋ࠸ᵓ㐀ゎᯒᡭἲࢆ☜❧࡛ࡁࡓࠋࡇࢀࡽࡣࠊ௒ᚋࡢ⸆⌮స⏝◊✲ࡸᶵ⬟ไᚚศᏊ
ࡢタィ࡟ᛂ⏝ࡍࡿࡇ࡜࡟ࡼࡗ࡚๰⸆࡟㈉⊩ࡍࡿ࡜⪃࠼ࡽࢀࡿࠋࡉࡽ࡟ࠊ2002 ᖺࡢ◊✲ᐊタ
❧௨᮶ 8 ᖺ࡟Ώࡾྲྀࡾ⤌ࢇ࡛ࡁࡓ⭷ࢱࣥࣃࢡ㉁ࡢ⤖ᬗ໬ࡀ₞ࡃᐇ⌧࡛ࡁࡓࠋ୍᪉ࠊ2005 ᖺ
ᗘࡲ࡛࡟⛉Ꮫᢏ⾡᣺⯆ㄪᩚ㈝ࡢ᥼ຓ࡛ᰴᘧ఍♫ࣜ࢞ࢡ࡜ඹྠ㛤Ⓨࡋࡓᚤᑠࢱࣥࣃࢡ㉁⤖ᬗ
⏝ࡢ㉸㧗⢭ᗘ X ⥺ゎᯒ⿦⨨ࡣࠊࡇࢀࡽᡂᯝ࡟୙ྍḞࡢᇶ┙タഛ࡜ࡋ࡚ά㌍ࡋࡓࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ 1 ᅇ⏕๓ᮇࡢ⸆Ꮫ೔⌮࣭ᴫㄽ㸦඲Ꮫඹ㏻ࠊศᢸ㸧
ࠊ2 ᅇ⏕๓ᮇㄢ⛬ࡢ
≀⌮໬Ꮫ 1㸦㔞Ꮚ໬Ꮫ㸧
㸦2007 ᖺᗘࡲ࡛㸧ࠊᇶ♏᝟ሗฎ⌮(඲Ꮫඹ㏻)ࠊᇶ♏᝟ሗฎ⌮₇⩦(඲
Ꮫඹ㏻)ࠊ2 ᅇ⏕ᚋᮇㄢ⛬ࡢ≀⌮໬Ꮫ 3㸦ᵓ㐀໬Ꮫ㸧ࠊ๰⸆≀⌮໬Ꮫ࢚ࢡࢧࢧ࢖ࢬ 2㸦ศᢸ㸧ࠊ
3 ᅇ⏕ᚋᮇㄢ⛬ࡢ≀⌮໬Ꮫ 4㸦⏕≀≀⌮໬Ꮫ㸧
㸦ศᢸ㸧ࠊ⏕≀ᵓ㐀᝟ሗᏛ㸦2008 ᖺᗘࡲ࡛ศᢸ㸧
ࢆᢸᙜࡋ࡚࠾ࡾࠊศᏊࡢ❧యᵓ㐀࡟㛵ࡍࡿㅮ⩏ࢆᖜᗈࡃ⾜ࡗ࡚࠸ࡿࠋ᭱㏆Ⓨᒎࡢⴭࡋ࠸ X
⥺⤖ᬗゎᯒ࡟ࡼࡗ࡚ࠕ࡞ࡐࢱࣥࣃࢡ㉁ࡢ❧యᵓ㐀ࢆỴᐃࡍࡿࡇ࡜ࡀ࡛ࡁࡿࡢ࠿ࠖ
ࠊ⤖ᬗゎᯒ
࡟ࡼࡿᵓ㐀Ỵᐃཎ⌮ࢆṇࡋࡃ⌮ゎࡋࠊ❧యᵓ㐀ࢆ㐺ษ࡟฼⏝࡛ࡁࡿࡼ࠺࡟ᩍ⫱ࢆ⾜ࡗ࡚࠸
ࡿࠋࡲࡓࠊࢹ࣮ࢱ࣮࣋ࢫୖࡢ❧యᵓ㐀᝟ሗࢆࢥࣥࣆ࣮ࣗࢱ࣮ୖ࡟⾲♧ࡍࡿᡭἲࢆྛᏛ⏕ࡀ
⩦ᚓࡋ࡚ࠊ༞ᴗᐇ⩦௨㝆࡟ࡑࢀࡒࢀࡢศ㔝࡟࠾࠸࡚ά⏝࡛ࡁࡿࡼ࠺࡟ࠊㅮ⩏࡜ᐇ⩦ࢆ⤌ࡳ
ྜࢃࡏࡓᣦᑟࢆࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊ≀⌮໬Ꮫⓗཎ⌮࡟ᇶ࡙࠸࡚⏕≀Ꮫⓗ࡞ᶵ⬟ࢆ⪃ᐹࡍࡿ
ࡇ࡜ࡀ㐩ᡂ࡛ࡁࡿࡼ࠺࡟࡞ࡿࡇ࡜ࢆ┠ᶆ࡜ࡋ࡚ᣦᑟ࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
༞ᴗᐇ⩦࠾ࡼࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗ㓄ᒓࡢᏛ⏕࡟ࡶࠊಶࠎே࡟ࢸ࣮࣐ࢆ୚࠼⮬ศ⮬㌟࡛◊
✲ࢆ㐙⾜ࡍࡿ⬟ຊࢆ⩦ᚓࡉࡏࡿࡇ࡜ࢆ┠ᶆ࡜ࡋ࡚࠸ࡿࠋ኱Ꮫ㝔⏕࡟ᑐࡋ࡚ࡣࠊ༢࡟ X ⥺⤖
ᬗゎᯒ࡞࡝ࡢ◊✲ᡭẁ࡟⢭㏻ࡍࡿࡔࡅ࡛࡞ࡃࠊࡑࡢᵓ㐀ゎᯒἲࢆ࠸࠿࡟⏝࠸࡚ಶࠎࡢၥ㢟
Ⅼࢆゎ᫂ࡋ࡚࠸ࡃࡢ࠿ࢆⓎ᝿࡛ࡁࡿࡼ࠺࡟ࠊ◊✲ࡢᡓ␎࡟ࡘ࠸࡚ࡶᏛࡪᶵ఍ࢆタࡅ࡚࠸ࡿࠋ
− 211 −
ⱥㄒㄽᩥ࡟ࡘ࠸࡚ࡣྛಶேࡀ⮬㌟࡛᭩ࡃࡇ࡜ࢆᐇ㊶ࡋ࡚࠸ࡿࠋಟኈㄢ⛬࡟࠾࠸࡚ࡣࠊ᭱᪂
ࡢ◊✲ᡭἲࡢ⩦ᚓ࡜ᚓពศ㔝ࡢ☜❧ࢆ┠ᶆ࡜ࡋ࡚ࡢᣦᑟࢆࠊ୍᪉ࠊ༤ኈㄢ⛬࡟࠾࠸࡚ࡣࠊ
⊂⮬ࡢ◊✲ࣉࣛࣥࢆᥦ᱌ࡋ࡚ᐇ⾜ࡍࡿࡇ࡜ࢆㄢࡋ࡚ࠊ⮬ࡽࢸ࣮࣐ࢆ❧᱌ࡍࡿ⬟ຊࢆ㣴࠼ࡿ
ࡼ࠺࡟ᣦᑟࢆ⾜ࡗ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ࡘ࠸࡚ࡣࠊᑠࢸࢫࢺࡸ࣏࣮ࣞࢺࡢᥦฟࢆಁࡋࠊᤵᴗ࡟ᑐࡍࡿ㐩ᡂᗘࢆ☜
ㄆࡋ࡚࠸ࡿࠋㅮ⩏ࡢ㛫࡟ఱᅇ࠿ᤵᴗホ౯ࢆᏛ⏕࡟⾜ࡗ࡚ࡶࡽ࠸ࡇࢀࢆཧ⪃࡟ࡋ࡚࠸ࡿࠋ኱
Ꮫ㝔⏕ࡢ◊✲ᣦᑟ࡟ࡘ࠸࡚ࡣࠊಟኈㄢ⛬࡛ࡣᖹᆒ୍ᅇࠊ༤ኈㄢ⛬࡛ࡣẖᖺࡢᏛ఍Ⓨ⾲ࢆዡ
ບࡋ࡚࠾ࡾࠊಶேࡢ◊✲⬟ຊࡣㄢ⛬ࡀࡍࡍࡴ࡟ࡘࢀࠊ☜ᐇ࡟ࣞ࣋ࣝ࢔ࢵࣉࡋ࡚࠸ࡿࠋ◊✲
ᐊ๰タ 2 ᖺ┠࡜࡞ࡿ 2003 ᖺᗘ࡟㸲ᅇ⏕࡜ಟኈㄢ⛬ࡢ኱Ꮫ㝔Ꮫ⏕ࢆཷࡅධࢀጞࡵ࡚௨᮶ࠊ
2010 ᖺࡲ࡛࡟ 4 ྡࡢ༤ኈㄢ⛬ಟ஢⪅ࢆ㍮ฟࡋࡓࠋࡑࡢ࠺ࡕࠊ2 ྡࡣ኱Ꮫ࡟࠾࠸࡚ࠊ2 ྡࡣࠊ
〇⸆௻ᴗ࡟࠾࠸࡚๰⸆ᇶ┙◊✲࡟ᚑ஦ࡋ࡚࠾ࡾࠊ࠸ࡎࢀࡶᵓ㐀⏕≀Ꮫࡢᑓ㛛ᐙ࡜ࡋ࡚ά㌍
ࡋ࡚࠸ࡿࠋࡲࡓࠊ㐣ཤ 5 ᖺ㛫࡟༤ኈ◊✲ဨ࡜ࡋ࡚ 4 ྡࠊ௻ᴗ࠿ࡽࡢ◊✲⏕࡜ࡋ࡚ 2 ྡࡀ◊
✲࡟ᚑ஦ࡋ࡞ࡀࡽࠊ໬Ꮫࡢゝⴥ࡛⏕≀⌧㇟ࢆグ㏙ࡍࡿࡓࡵࡢ࢔ࣉ࣮ࣟࢳ࡜࢜ࣜࢪࢼࣝࡢ◊
✲ᡭἲࢆ⩦ᚓࡍࡿࡓࡵ࡟ᅾ⡠ࡋ࡚࠾ࡾࠊᡃࠎࡢ◊✲ᡂᯝ࡜◊✲ᡭἲ࡟ᑐࡍࡿ㧗࠸ホ౯ࡢ⌧
ࢀ࡛࠶ࡿ࡜ᛮࢃࢀࡿࠋ
(ཎⴭ)
1. Structural basis for docking of peroxisomal membrane protein carrier Pex19p onto its receptor
Pex3p., Sato, Y., Shibata, H., Nakatsu, T., Nakano, H., Kashiwayama, Y., Imanaka, T., and Kato,
H., EMBO J., 29, 4083 – 4093 (2010).
2. The Exquisite Structure and Reaction Mechanism of Bacterial Pz-peptidase A toward
Collagenous Peptides – X-RAY CRYSTALLOGRAPHIC STRUCTURE ANALYSIS OF
PZ-PEPTIDASE
A
REVEALS
DIFFERENCES
FROM
MAMMALIAN
THIMET
OLIGOPEPTIDASE–., Kawasaki, A., Nakano, H., Hosokawa, A., Nakatsu, T., Kato, H., and
Watanabe, K., J. Biol. Chem., 285, 34972 – 34980 (2010).
3. Deleting two C-terminal Ș-helices is effective to crystallize the bacterial ABC transporter
Escherichia coli MsbA complexed with AMP-PNP. Terakado, K., Kodan, A., Nakano, H.,
Kimura, Y., Ueda, K., Nakatsu, T., & Kato, H., Acta Cryst., D66, 319-323 (2010).
4. Structure of the membrane domain of human erythrocyte anion exchanger 1 revealed by electron
crystallography., Yamaguchi, T., Ikeda, Y., Abe, Y., Kuma, H., Kang, D., Hamasaki, N. & Hirai,
− 212 −
T., J. Mol. Biol., 397, 179-189 (2010).
5. Helical image reconstruction of the outward-open human erythrocyte band 3 membrane domain
in tubular crystals., Yamaguchi, T., Fujii, T., Abe, Y., Hirai, T., Kang, D., Namba, K., Hamasaki,
N. & Mitsuoka, K. J. Struct. Biol., 169, 406-412 (2010).
6. Mutation of His 834 in human anion exchanger 1 affects substrate binding., Takazaki, S., Abe,
Y., Yamaguchi, T., Yagi, M., Ueda, T., Kang, D. & Hamasaki, N., Biochim. Biophys. Acta, 1798,
903-908 (2010).
7. Functional role of the linker region in purified human P-glycoprotein., Sato, T., Kodan, A.,
Kimura, Y., Ueda, Nakatsu, T., & K., Kato, H., FEBS J., 276, 3504-3516 (2009).
8. Improved expression and purification of human multidrug resistance protein MDR1 from
baculovirus-infected insect cells., Kodan, A., Shibata, H., Matsumoto, T., Terakado, K.,
Kakiyama, K., Matsuo, M., Ueda, & K., Kato, H., Protein Expr. Purif., 64, 47-54 (2009).
9. X-ray Crystallographic Study of an HIV-1 Fusion Inhibitor with the gp41 S138A Substitution.,
Watabe, T., Terakawa, Y., Watanabe, K.,Ohno, H., Nakano, H., Nakatsu, T., Kato, H., Iumi, K.,
Kodama, E., Matsuoka, M., Kitaura, K., Oishi, S., & Fujii, N., J. Mol. Biol., 392, 657 – 665
(2009).
10. Overexpression and purification of rat peroxisomal membrane protein 22, PMP22, in Pichia
pastoris., Egawa, K., Shibata, H., Yamashita, S., Yurimoto, H., Sakai, Y., & Kato, H., Protein
Expr. Purif., 64, 47-54 (2008).
11. Structural basis for gibberellin recognition by its receptor GID1., Shimada, A.,
Ueguchi-Tanaka, M., Nakatsu, T., Nakajima, M., Naoe, Y., Ohmiya, H., Kato, H., & Matsuoka,
M., Nature, 456, 520-523 (2008).
12. Mechanism of Efficient Firefly Bioluminescence via Adiabatic Transition State and Seam of
Sloped Conical Intersection., L.W. Chung, S. Hayashi, M. Lundberg, T. Nakatsu, H. Kato, & K.
Morokuma, J. Am. Chem. Soc., 130, 12880-12881 (2008).
13. Characterization of the Interaction between Recombinant Human Peroxin Pex3p and
Pex19p-IDENTIFICATION OF TRP-104 IN Pex3p AS A CRITICAL RESIDUE FOR THE
INTERACTION-., Sato, Y., Shibata, H., Nakano, H., Matsuzono, Y., Kashiwayama, Y.,
Kobayashi, Y., Fujiki, Y., Imanaka, T., & Kato, H., J. Biol. Chem., 283, 6136-6144 (2008)
14. A direct repeat of E-box-like elements is required for cell-autonomous circadian rhythm of clock
genes., Nakahata, Y., Yoshida, M., Takano, A., Soma, H., Yamamoto, T., Yasuda, A., Nakatsu, T.,
& Takumi, T., BMC Mol. Biol., 9, 1-11 (2008).
15. Crystallization and preliminary X-ray crystallographic studies of Pz peptidase A from
− 213 −
Geobacillus collagenovorans MO-1., Kawasaki, A., Nakano, H., Tsujimoto, Y., Matsui, H.,
Shimizu, T., Nakatsu, T., Kato, H., Watanabe, K., Acta Crystallogr., F63, 142 – 144, (2007)
16. Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol
Kimura, Y., Kioka, N., Kato, H., Matsuo, M., Ueda, K., Biochem. J., 401, 597 – 605. (2007)
17. New insights into the binding mode of coenzymes: structure of Thermus thermophilus
Delta1-pyrroline-5-carboxylate dehydrogenase complexed with NADP+., Inagaki, E., Ohshima,
N., Sakamoto, K., Babayeva, N.D., Kato, H., Yokoyama, S., & Tahirov, T.H., Acat Crystallogr.,
F63, 462-465, (2007).
18. Clearance of oxidized erythrocytes by macromphages: Involvement of caspases in the
generation of clearance signal at band 3 glycoprotein., Miki Y., Tazawa T., Hirano K.,
Matsushima H., Kumamoto S., Hamasaki N., Yamaguchi T., and Beppu M., Biochem. Biophys.
Res. Commun., 363, 57-62, (2007).
19. Structural basis for the spectral difference in luciferase bioluminescence., Nakatsu, T., Ichiyama,
S., Hiratake, J., Saldanha, A., Kobashi, N., Sakata, K., and Kato, H., Nature, 440, 372 – 376
(2006).
20. Overexpression, purification, crystallization and preliminary X-ray crystallographic studies of a
proline-specific aminopeptidase from Aneurinibacillus sp. strain AM-1., Akioka, M., Nakano, H.,
Horikiri, A., Tsujimoto, Y., Masui, H., Shimizu, T., Nakatsu, T., Kato, H., Watanabe, K., (2006)
Acta Crystallogr., F62, 1266 – 11268.
(⥲ㄝ)
1. ࢪ࣋ࣞࣜࣥཷᐜయ GID1 ࡟ࡼࡿࢪ࣋ࣞࣜࣥㄆ㆑࡜ࡑࡢศᏊ㐍໬ࠊຍ⸨༤❶ࠊబ⸨཭⨾ࠊ
ୖཱྀ㸦⏣୰㸧⨾ᘺᏊࠊ᪥ᮏ⤖ᬗᏛ఍ㄅࠊ52, 31 – 36 (2010)
2. 㧗ᶵ⬟໬࣍ࢱ࣭ࣝࣝࢩࣇ࢙࣮ࣛࢮ๰〇࡟ྥࡅ࡚ࠊ୰ὠ஽ࠊ᪥ᮏ⤖ᬗᏛ఍ㄅࠊ52, 81 – 88
(2010)
3. ┿᰾⏕≀⏤᮶⭷⺮ⓑ㉁ࡢ⤖ᬗ໬ᨭ᥼ἲࡢ㛤ⓎѸGFP ⼥ྜᢏ⾡ࢆ⏝࠸ࡓ⤖ᬗ໬⬟ุᐃ⣔࡜
㓝ẕ࡟ࡼࡿ⺮ⓑ㉁⏕⏘⣔Ѹ㸪ຍ⸨༤❶㸪ᒣୗᩔᏊ㸪Ụᕝ㡪Ꮚ㸪ᓮᒣ៞ኴ㸪⺮ⓑ㉁᰾㓟㓝
⣲㸪54㸪1461-1467 (2009)
4. ࣍ࢱࣝࡢⓎගⰍࢆไᚚࡍࡿ௙⤌ࡳѸⓎග㓝⣲ࣝࢩࣇ࢙࣮ࣛࢮࡢ⤖ᬗᵓ㐀࡜࣓࢝ࢽࢬ࣒Ѹࠊ
ຍ⸨༤❶ࠊ୰ὠ஽ࠊி㒔኱Ꮫప ≀㉁⛉Ꮫ◊✲ࢭࣥࢱ࣮ㄅࠊ11, 44 – 51 (2007)
5. ࢤࣥࢪ࣎ࢱ࣭ࣝࣝࢩࣇ࢙࣮ࣛࢮ࡟࠾ࡅࡿⓎගⰍไᚚᶵᵓࡢᵓ㐀⏕≀Ꮫⓗ◊✲ࠊ୰ὠ஽
᪥ᮏ⤖ᬗᏛ఍ㄅ 49, 186-191 (2007)
6. ࣍ࢱࣝⓎගࡢ࡞ࡒࠊຍ⸨༤❶ࠊ୰ὠ஽ࠊ⏕໬Ꮫࠊ7, 697-701 (2007)
− 214 −
7. ࣍ࢱࣝࡢⓎගⰍࢆไᚚࡍࡿ௙⤌ࡳࠊຍ⸨༤❶ࠊ୰ὠ஽ࠊ໬Ꮫ࡜⏕≀ࠊ45, 239-245 (2007)
8. Ⓨග㓝⣲ࠕࣝࢩࣇ࢙࣮ࣛࢮࠖࡢ཯ᛂ㐣⛬ࡢ❧యᵓ㐀ࠊຍ⸨༤❶ࠊ୰ὠ஽ࠊᐇ㦂་Ꮫࠊ24(17)ࠊ
2595-2600 (2006)
(ⴭ᭩)
1. ᫬ィไᚚᵓ㐀⏕≀Ꮫࠊຍ⸨༤❶ࠊ⌧௦⏕≀⛉Ꮫධ㛛ࠊ➨ 3 ᕳ➨ 5 ❶ࠊᒾἼ᭩ᗑࠊ(2011)
2. ⸆ࡢࢱ࣮ࢤࢵࢺ⺮ⓑ㉁ࡢᵓ㐀ࢆỴᐃࡍࡿࠊຍ⸨༤❶ࠊ᪂ࡋ࠸⸆ࢆ࡝࠺๰ࡿ࠿̿๰⸆◊✲
ࡢ᭱๓⥺̿㸦ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉⦅㸧ࠊ77-107ࠊㅮㄯ♫ࠊ(2007)
3. ࣝࢩࣇ࢙࣮ࣛࢮࡢ❧యᵓ㐀ࡢゎ᫂ࠊຍ⸨༤❶ࠊ୰ὠ஽ࠊู෉໬ᏛࠕศᏊ࢖࣓࣮ࢪࣥࢢࠖࠊ
໬Ꮫྠேࠊ(2007)
− 215 −
䝀䝜䝮๰⸆⛉Ꮫศ㔝
ᩍ㻌 ᤵ䠄་Ꮫ༤ኈ䠅㎷ᮏ㻌 ㇦୕䠄䛴䛨䜒䛸㻌 䛤䛖䛮䛖䠅
㻌 㻌 ᫛࿴ 28 ᖺ 2 ᭶ 13 ᪥⏕
㻌 㻌 ᫛࿴ 53 ᖺ໭ᾏ㐨኱Ꮫ་Ꮫ㒊༞ᴗ
㻌 㻌 ᫛࿴ 60 ᖺಙᕞ኱Ꮫ㻌 ་Ꮫ༤ኈྲྀᚓ
෸ᩍᤵ䠄་Ꮫ༤ኈ䠅ᖹ⃝㻌 㻌 ᫂䠄䜂䜙䛥䜟㻌 䛒䛝䜙䠅
㻌 㻌 ᫛࿴ 40 ᖺ 2 ᭶ 15 ᪥⏕
㻌 㻌 ᫛࿴ 62 ᖺᮾி኱Ꮫ⌮Ꮫ㒊⏕≀໬Ꮫ⛉༞ᴗ
ᖹᡂඖᖺᮾி኱Ꮫ኱Ꮫ㝔⌮Ꮫ⣔◊✲⛉⏕≀໬Ꮫᑓᨷಟኈㄢ⛬ಟ஢
ᖹᡂ 7 ᖺᒣ᲍་⛉኱Ꮫ㻌 ༤ኈ(་Ꮫ)ྲྀᚓ
ㅮ㻌 ᖌ䠄་Ꮫ༤ኈ䠅㍿Ỉ㻌 ᓫ㙾䠄䛣䛧䜏䛪㻌 䛯䛛䛒䛝䠅䠄2007.3 ⮬἞་⛉኱Ꮫ䜈
㌿ฟ䠅
㻌 㻌 ᫛࿴ 41 ᖺ 9 ᭶ 19 ᪥⏕
㻌 㻌 ᖹᡂ 4 ᖺ᪂₲኱Ꮫ་Ꮫ㒊༞ᴗ
ᖹᡂ 8 ᖺᒣ᲍་⛉኱Ꮫ኱Ꮫ㝔་Ꮫᑓᨷ⛉ಟ஢䚸༤ኈ(་Ꮫ)ྲྀᚓ
ຓ㻌 ᩍ䠄ே㛫䞉⎔ቃᏛ༤ኈ䠅㊊㐩㻌 ဴஓ䠄䛒䛰䛱㻌 䛶䛴䜔䠅䠄2007.7 ⚄ᡞ኱Ꮫ䜈㌿ฟ䠅
㻌 㻌 ᖹᡂ 12 ᖺி㒔኱Ꮫ኱Ꮫ㝔ே㛫䞉⎔ቃ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢䚸༤ኈ䠄ே㛫䞉⎔ቃᏛ䠅ྲྀᚓ
≉ᐃຓᩍ䠄⌮Ꮫ༤ኈ䠅ᑎ⃝㻌 ࿴ဢ䠄䛶䜙䛥䜟㻌 䛛䛪䜔䠅䠄2010.4 ྠ኱Ꮫ㝔᭱ඛ➃๰⸆◊✲䝉䞁䝍䞊䜈␗ື䠅
㻌 㻌 ᫛࿴ 49 ᖺ 12 ᭶ 12 ᪥⏕
㻌 㻌 ᖹᡂ 10 ᖺி㒔኱Ꮫ༞
㻌 㻌 ᖹᡂ 15 ᖺி㒔኱Ꮫ኱Ꮫ㝔⌮Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢䚸༤ኈ(⌮Ꮫ)ྲྀᚓ
㻌 㻌 ᖹᡂ 19 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉≉ㄆຓᩍ╔௵
ຓ㻌 ᩍ䠄⸆Ꮫ༤ኈ䠅ᮌᮧ㻌 㑳ኵ䠄䛝䜐䜙㻌 䛔䛟䛚䠅
㻌 㻌 ᫛࿴ 51 ᖺ 6 ᭶ 15 ᪥⏕
㻌 㻌 ᖹᡂ 13 ᖺி㒔኱Ꮫ༞
㻌 㻌 ᖹᡂ 18 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢䚸༤ኈ䠄⸆Ꮫ䠅ྲྀᚓ
㻌 㻌 ᖹᡂ 20 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉⸆⌮䝀䝜䝭䜽䝇ຓᩍ
◊✲䛾ᴫせ
๰⸆◊✲䛿ᚑ᮶䛾ศᏊ㑏ඖ୺⩏䛛䜙䝀䝜䝮䚸㑇ఏᏊⓎ⌧䚸䝍䞁䝟䜽⥲య䜢䜘䜚ໟᣓⓗ䚸⤫ྜⓗ䛻ᤊ䛘䜛᪉ྥ
䠄䝀䝜䝮䝽䜲䝗䠅䛻䝟䝷䝎䜲䝮䝅䝣䝖䛧䛴䛴䛒䜛䚹䝫䝇䝖䞉䝀䝜䝮䛾䝀䝜䝮ᶵ⬟⛉Ꮫ䛾₻ὶ䛾୰䚸᪂䛯䛺᪉ἲㄽ䛻䜘䜛
䝀䝜䝮䝽䜲䝗䛺䝃䞊䝏◊✲䜢ຍ䛘䛯䝸䝃䞊䝏䜢ᚿྥ䛧䛶䛔䜛䚹⥙⨶ⓗⓎ⌧ゎᯒ䛻䜲䞁䝣䜷䝬䝔䜱䜽䝇ᢏ⾡䜢⤌䜏
ྜ䜟䛫䚸ᚑ᮶ᆺ䛾๰⸆ᡭἲ䛷䛿䜰䝥䝻䞊䝏䛾ᅔ㞴䛺ከᅉᏊ⑌ᝈ䛻ᑐ䛩䜛๰⸆ೃ⿵㑇ఏᏊ䛾⤠䜚㎸䜏䜢⾜䛔䚸
in vitro 䛚䜘䜃 in vivo 䛷䛾ᶵ⬟ゎᯒ䛻䜘䜚䚸⤠䜚㎸䜣䛰㑇ఏᏊ䛾ホ౯䜢⾜䛖䛣䛸䛷䚸䝀䝜䝮๰⸆䛾୍㐃䛾◊✲䜢
㐙⾜䛧䛶䛔䜛䚹䛣䛾䝀䝜䝮๰⸆◊✲䜰䝥䝻䞊䝏䛿䚸ᐇ㝿䛻ᡂᯝ䜢ୖ䛢䛴䛴䛒䜛䚹୍౛䛸䛧䛶䚸䜸䞊䝣䜯䞁ཷᐜయ
GPR120 䛾䝸䜺䞁䝗᥈⣴䛸䚸GLP-1 ศἪ䜢௓䛩䜛௦ㅰㄪ⠇ᶵᵓ䜢ゎ᫂䛧䚸GPR120 䛜⢾ᒀ⑓䛾἞⒪ᶆⓗ䛸䛺䜚䛖
䜛䛣䛸䜢♧䛧䛯䚹䜎䛯䚸䜒䛖୍䛴䛾౛䛸䛧䛶䚸⭈⅖䝰䝕䝹ື≀䛾⥙⨶ⓗⓎ⌧䝥䝻䝣䜯䜲䝹ゎᯒ䛛䜙䚸᪂つ἞⒪ᶆⓗ
ೃ⿵㑇ఏᏊ䛸䛧䛶⺮ⓑ㉁䝸䞁㓟໬㓝⣲ CK2 䜢ぢฟ䛧䛯䚹䛣䛾䝀䝜䝮๰⸆◊✲䜢䛥䜙䛻Ⓨᒎ䛥䛫䚸Ⓨぢ䛧䛯἞⒪ᶆ
ⓗ㑇ఏᏊ䛻ᑐ䛩䜛⸆≀㛤Ⓨ䜢௻ᴗ䛸䛾ඹྠ◊✲➼䛻䜘䜚㐍䜑䚸๰⸆䛾㐩ᡂ䜢䜑䛦䛧䛶䛔䜛䚹䛣䜜䜙䛾䝀䝜䝮๰
⸆◊✲䜢୰ᚰ䛸䛧䛶䚸௨ୗ䛾◊✲䜢⾜䛳䛶䛔䜛䚹
㑇ఏᏊⓎ⌧䝺䝧䝹䛻䛚䛡䜛䝀䝜䝮ᶵ⬟ゎᯒ
኱㔞䛾㑇ఏᏊ䛾Ⓨ⌧䜢ᚤ㔞䛛䛴㧗ຠ⋡䛻ゎᯒ䛩䜛䝬䜲䜽䝻䜰䝺䜲䚸DNA 䝏䝑䝥䜢⏝䛔䚸ྛ✀⑌ᝈ䚸⸆
≀ᛂ⟅䛻䛚䛡䜛㑇ఏᏊⓎ⌧䝥䝻䝣䜯䜲䝹䜢ໟᣓⓗ䛻ゎᯒ䛧䚸᪂䛯䛺䜛㑇ఏᏊᶵ⬟䛾Ⓨぢ䚸๰⸆ᶆⓗ䛾᥈
⣴䜢⾜䛳䛶䛔䜛䚹䝬䜲䜽䝻䜰䝺䜲 DNA 䝏䝑䝥ゎᯒᢏ⾡䜢᪤䛻☜❧䛧䚸䝷䝑䝖➼ᐇ㦂ື≀䛾ᶆ‽໬㑇ఏᏊ䝷䜲
䝤䝷䝸䞊DNA 䝏䝑䝥䜢⏝䛔䛶ྛ✀⑓ែ䝰䝕䝹ື≀䛻䛚䛡䜛㑇ఏᏊⓎ⌧ゎᯒ䛸ᚑ᮶䛾⏕⌮䚸⏕໬Ꮫ཯ᛂ䚸
⸆≀ᛂ⟅ᛶ䛸䛾┦㛵䜘䜚䚸๰⸆ᶆⓗ⤠䜚㎸䜏䜢⾜䛳䛶䛔䜛䚹䛣䛾ᡭἲ䜢⏝䛔䛶䚸⭈⅖἞⒪ᶆⓗ㑇ఏᏊ䛾᥈
⣴䛾⤖ᯝ䚸⺮ⓑ㉁䝸䞁㓟໬㓝⣲ CK2 䛾ྠᐃ䚸ㄽᩥⓎ⾲≉チ໬䛻ᡂຌ䛧䛯䚹⌧ᅾ䛣䛾ᡂᯝ䛾๰⸆ᛂ⏝䜢௻
ᴗ䛸䛾ඹྠ◊✲䛷㐍䜑䛶䛔䜛ẁ㝵䛷䛒䜛䚹
䜸䞊䝣䜯䞁ཷᐜయ䛾䝸䜺䞁䝗᥈⣴䛛䜙䛾๰⸆
ྛ✀⺮ⓑ⺯ගᶆ㆑ᢏ⾡䜔㧗ឤᗘ᳨ฟᢏ⾡䛾ⴭ䛧䛔㐍Ṍ䛻䜘䜚䚸ཷᐜయ䛾䜘䛖䛺⛥ᑡⓎ⌧⺮ⓑ䛾⣽⬊
ෆᒁᅾ䚸ືែ䛜ྍど໬ฟ᮶䜛䜘䛖䛻䛺䜚䚸༢୍⣽⬊䝺䝧䝹䛷⣽⬊ෆ䛾ྛ✀⏕໬Ꮫ཯ᛂ䚸⣽⬊ෆᒁᅾ䛜ྍ
ど໬䛷䛝䜛䜘䛖䛻䛺䛳䛶䛝䛯䚹䛣䛾䛄ྍど໬⣽⬊⏕≀Ꮫ䛅ᢏ⾡䜢䜸䞊䝣䜯䞁䠣䠬䠟䠮䛾䝸䜺䞁䝗᥈⣴䛻ᛂ⏝䜢⾜
− 216 −
䛳䛶䛔䜛䚹᪂つ䜸䞊䝣䜯䞁ཷᐜయ GPR120 䛜㛗㙐୙㣬࿴⬡⫫㓟䜢䝸䜺䞁䝗䛸䛧䚸⭠⟶ෆศἪ⣽⬊䛻Ⓨ⌧䛩
䜛⬡⫫㓟䝉䞁䝃䞊䛸䛧䛶䚸⾑୰䛻 GLP-1 䛾ศἪㄪ⠇䜢⾜䛖䛣䛸䜢ぢฟ䛧䛯䚹䛣䛾ᡂᯝ䛿䚸䝀䝜䝮᝟ሗ䛛䜙䛾
᪂つ䛾⢾ᒀ⑓἞⒪ᶆⓗ㑇ఏᏊ䛾ព࿡䛧䛶䛚䜚䚸๰⸆ᛂ⏝䜢┠ᣦ䛧䛯◊✲䜢䚸௻ᴗ➼䛸䛾ඹྠ◊✲䛷ᘬ䛝
⥆䛝㐍䜑䛶䛔䜛䚹
㑇ఏᏊᨵኚື≀䜢⏝䛔䛯ཷᐜయᶵ⬟䛾ゎᯒ
GPCR 䛾ᶵ⬟䜢⏕య䛻䛚䛔䛶ヲ⣽䛻ゎ᫂䛩䜛䛯䜑䚸ཷᐜయ㑇ఏᏊᨵኚື≀䜢స〇䛧ゎᯒ䜢⾜䛳䛶䛔䜛䚹
≉ᐃ䛾㑇ఏᏊ䜢ᨵኚ䛧䛯ಶయ䛻䛚䛔䛶⏕⌮ᶵ⬟䜔㑇ఏᏊⓎ⌧䝥䝻䝣䜯䜲䝹䛾ኚ໬䜢ྠᐃ䛩䜛䛣䛸䛻䜘䜚䚸
᪂䛯䛺἞⒪ᶆⓗ䛾Ⓨぢ䜔ணᮇ䛧䛺䛔๪స⏝䛾ཎᅉゎ᫂䛻⧅䛜䜛䛸⪃䛘䜛䚹ᐇ㝿䛣䜜䜎䛷䛻⾑ᅽㄪ⠇䚸⾑
⢾್䚸ෆศἪᶵ⬟䚸⾜ື␗ᖖ䛻㛵䛩䜛ཷᐜయᶵ⬟䜢ྠᐃ䛧䛯䚹䜎䛯㑇ఏᏊᨵኚື≀䛻ᑐ䛧䛶⸆≀䛾ຠᯝ
䜔⑌ᝈឤཷᛶ䜢ㄪ䜉䛯䛸䛣䜝䚸Ḟᦆ䛧䛯ཷᐜయ䛸䛿୍ぢ㛵ಀ䛾䛺䛔௚䛾ཷᐜయᶵ⬟䛻ኚ໬䛜⌧䜜䜛䛣䛸
䜢⤒㦂䛧䛶䛚䜚䛣䜜䜎䛷ゎ᫂䛥䜜䛶䛔䛺䛛䛳䛯ཷᐜయᶵ⬟䛾඲యീ䜢᫂䜙䛛䛻䛩䜛䛣䛸䛜ฟ᮶䜛䛸⪃䛘䜛䚹
䝔䞊䝷䞊䝯䜲䝗་⒪䜢┠ᣦ䛧䛯⮫ᗋ䝀䝜䝮๰⸆◊✲
䝀䝜䝮⛉Ꮫ䛻䜘䜚䚸⸆≀ᛂ⟅ᛶ䛾㑇ఏⓗ⫼ᬒ䛻ྜ䜟䛫䛯䝔䞊䝷䞊䝯䜲䝗་⒪䛜ྍ⬟䛸䛺䜝䛖䛸䛧䛶䛔䜛䚹
䝀䝜䝮⮫ᗋ◊✲䛾㔜せᛶ䛻╔┠䛧䚸1996 ᖺ䜘䜚་⸆ရᶵᵓ䛾ฟ㈨஦ᴗ䛸䛧䛶䚸ከᅉᏊ⑌ᝈ䛾⑓ែ㛵㐃㑇
ఏᏊ䚸἞⒪㛵㐃㑇ఏᏊ䛾᥈⣴䚸᭦䛻䛿䝀䝜䝮๰⸆᝟ሗ䜢ᥦ౪䛩䜛䝥䝻䝆䜵䜽䝖䚸Genox ๰⸆◊✲ᡤ䜢ᐁẸ
ඹྠ䛷タ❧䛧䛯䚹䛣䛾䝥䝻䝆䜵䜽䝖䛻䛚䛔䛶䚸᪤䛻 30 ௨ୖ䛾᪂つ䛾⑌ᝈ䞉἞⒪㛵㐃㑇ఏᏊ䛾ྠᐃ䛻ᡂຌ䛧
䛶䛔䜛䚹䛣䛾ᡂᯝ䜢Ⓨᒎ䛥䛫䚸⊂⮬䛻☜❧䛧䛯㉸㧗ឤᗘ DNA 䝏䝑䝥ᢏ⾡䛸䚸䝀䝜䝮ゎᯒ᝟ሗ䜢䝞䜲䜸䜲䞁
䝣䜷䝬䝔䜱䝑䜽䝇䛷⤫ྜⓗ䛻ゎᯒ䛩䜛䛣䛸䛷䚸⑌ᝈ㛵㐃㑇ఏᏊ䚸デ᩿䝬䞊䜹䞊䜔⸆≀ᶆⓗ䛾἞⒪㛵㐃㑇ఏ
Ꮚ䜢ᢳฟ䛩䜛⮫ᗋ◊✲䜢䚸ྛ✀⑌ᝈ䛻ᑐ䛧䛶ᗈ䛟ᒎ㛤䛧䛶䛔䜛䚹
ᶵ⬟ᛶ RNA ゎᯒ䛻ᇶ䛵䛟䝀䝜䝮་Ꮫ◊✲
⫢⒴䜔⮅⒴䛺䛹䛾㞴἞ᛶ⒴䜔 ES ⣽⬊䛾Ⓨ⏕䞉ศ໬䛚䜘䜃య⣽⬊䛾⬺ศ໬䜢◊✲ᑐ㇟䛸䛧䚸㧗ឤᗘ䝬
䜲䜽䝻䜰䝺䜲ᢏ⾡䞉䝞䜲䜸䜲䞁䝣䜷䝬䝔䜱䜽䝇ᢏ⾡䜢㥑౑䛧䛯 RNA ⥙⨶ⓗ᥈⣴ἲ䛾㛤Ⓨ䛻䜘䜛᪂つ䛺ᶵ⬟ᛶ
RNA 䛾⥙⨶ⓗ᥈⣴䛸ྠᐃ䚸䛚䜘䜃䝀䝜䝮་Ꮫ䞉෌⏕་Ꮫ䛻ᇶ䛵䛟 in vitro, in vivo ᶵ⬟ゎᯒ䛻䜘䜛᪂つᶵ
⬟ᛶ RNA 䛾ศᏊ䝯䜹䝙䝈䝮䞉⑓ែ䝯䜹䝙䝈䝮䛾ゎ᫂䜢┠ᣦ䛧䛶䛔䜛䚹⒴ᢚไ䛾䝍䞊䝀䝑䝖䛸䛺䜛ᶵ⬟ᛶ
RNA䚸⒴デ᩿䝬䞊䜹䞊䛸䛺䜛ᶵ⬟ᛶ RNA䚸䛺䜙䜃䛻⣽⬊䛾ศ໬䞉⬺ศ໬ㄏᑟ䛻㔜せ䛺ᶵ⬟ᛶ RNA 䛺䛹
䛾ྛ✀᪂つ RNA 䛾Ⓨぢ䛸䛭䛾≉チ໬䜢┠ᶆ䛸䛧䚸Ⓨぢ䛥䜜䛯᪂つ RNA 䛾ศᏊ䝯䜹䝙䝈䝮䞉⑓ែ䝯䜹䝙䝈
䝮䛾ゎ᫂䛛䜙䚸䛭䜜䜙䜢ᶆⓗ䛸䛩䜛᰾㓟་⸆ရ䛻䜘䜛㞴἞ᛶ⒴἞⒪䞉෌⏕་⒪䜈䛾ᛂ⏝䜔᪂つ䛺෌⏕་
⒪ᢏ⾡䛾㛤Ⓨ䜢䜑䛦䛧䛶䛔䜛䚹
䜿䝭䜹䝹䝀䝜䝭䜽䝇䛾䛯䜑䛾䝞䜲䜸䜲䞁䝣䜷䝬䝔䜱䜽䝇◊✲
䝫䝇䝖䝀䝜䝮᫬௦䛸࿧䜀䜜䜛௒᪥䚸䝀䝜䝮䛸䝍䞁䝟䜽㉁䜢୰ᚰ䛸䛧䛯Ⳙ኱䛺⏕≀Ꮫ䝕䞊䝍䛜ሗ࿌䛥䜜䜛䜘䛖
䛻䛺䜚䚸䛣䜜䜙⥙⨶ⓗ䝕䞊䝍䜢ᢅ䛖䝞䜲䜸䜲䞁䝣䜷䝬䝔䜱䜽䝇䛜ὀ┠䛥䜜䛶䛔䜛䚹䛧䛛䛧䛺䛜䜙䚸௒᪥⚾䛯䛱䛜
┠䛻䛩䜛⥙⨶ⓗ⏕≀Ꮫ◊✲䛿䛸䛛䛟㑇ఏᏊ䞉䝍䞁䝟䜽㉁䜢୰ᚰ䛻⪃䛘䜙䜜䛜䛱䛷䛒䜚䚸⏕య㛵㐃໬Ꮫ≀㉁
䜢⥙⨶ⓗ䛻ᢅ䛳䛯䝞䜲䜸䜲䞁䝣䜷䝬䝔䜱䜽䝇◊✲䛿ᮍ䛰ⓙ↓䛻➼䛧䛔䚹ቑຍ䛧⥆䛡䜛䝀䝜䝮䞉䝥䝻䝔䜸䞊䝮䛺
䛹䛾䝞䜲䜸᝟ሗ䛸໬Ꮫ≀㉁᝟ሗ䛸䛾䝀䝜䝮䝇䜿䞊䝹䛷䛾⼥ྜᡭἲ䛾㛤Ⓨ䛚䜘䜃䛭䜜䛻ᇶ䛵䛟⏕≀Ꮫⓗᶵ
⬟䛾▱㆑Ⓨぢ䜢┠ᶆ䛸䛧䛶◊✲䜢㐍䜑䛶䛔䜛䚹ලయⓗ䛻䛿䚸䝍䞁䝟䜽㉁䛸໬Ꮫ≀㉁䛸䛾┦஫స⏝䜢䝀䝜䝮
䝇䜿䞊䝹䛷ண 䛩䜛䛯䜑䛾᝟ሗᏛⓗᡭἲ䛾㛤Ⓨ䚸ཬ䜃䛭䛾䝍䞁䝟䜽㉁䠉໬Ꮫ≀㉁㛫䛾┦஫స⏝᝟ሗ䜢
⏝䛔䛯᪂䛧䛔䝟䝇䜴䜵䜲ゎᯒᡭἲ䛾㛤Ⓨ䜢⾜䛳䛶䛔䜛䚹䜎䛯⌧ᅾ᪤䛻䚸GPCR 䝣䜯䝭䝸䞊䛸⸆≀䛸䛾┦஫స
⏝䝕䞊䝍䝧䞊䝇䛾㛤Ⓨ䛻ᡂຌ䛧䚸ㄽᩥⓎ⾲䛸≉チබ㛤䛻⮳䛳䛶䛔䜛䚹
◊✲άື䛻ᑐ䛩䜛⮬ᕫⅬ᳨䞉ホ౯
䝀䝜䝮๰⸆◊✲䛻ᑐ䛩䜛䚸୍⯡䛾ὀ┠䛿኱䛝䛟䚸ᙜศ㔝䛾◊✲ᡂᯝ䛻䛴䛔䛶䛯䜃䛯䜃᪂⪺䚸TV ➼䛷ሗ㐨䛜
䛺䛥䜜䛶䛔䜛䚹䜎䛯䚸㐣ཤ䛻䛿䚸኱Ꮫ㝔⏕䛻䜘䜛ᴗ⦼䛻ᑐ䛧ᚠ⎔⸆⌮Ꮫ఍䛛䜙㈹䛜ᤵ୚䛥䜜䛶䛚䜚䚸ከ䛟䛾Ꮫ఍
䛛䜙䝅䞁䝫䝆䝇䝖➼䛸䛧䛶ᣍᚅ䛥䜜䛶䛔䜛䛣䛸䛛䜙䚸Ꮫ఍䛻䛚䛔䛶䜒䛭䛾◊✲ෆᐜ䛾⛉Ꮫᛶ䛿㧗䛟ホ౯䛥䜜䛶䛔䜛
䛸⪃䛘䜙䜜䜛䚹
㻌
ᩍ⫱䛾ᴫせ
㻌 Ꮫ㒊ᩍ⫱:䝫䝇䝖䞉䝀䝜䝮᫬௦䜢㐍䜣䛷䛔䛟䛾䛻ᚲ㡲䛸䛺䜛▱㆑䜔ᛮ⪃య⣔䜢య⣔ⓗ䛛䛴ໟᣓⓗ䛻ᩍ⫱䛧䛶
䛔䛝䛯䛔䛸ᛮ䛳䛶䛔䜛䚹ᙜศ㔝䛿 2 ᅇ⏕㓄ᙜ䛾䛂⏕⌮Ꮫ 3䠄⑓ែ⏕⌮Ꮫ䠅䛃䛸 3 ᅇ⏕㓄ᙜ䛾䛂⏕⌮Ꮫ 4䠄⑓ែ䝀䝜
䝮Ꮫ䠅䛃䛾ㅮ⩏䜢ᢸᙜ䛧䛶䛔䜛䚹䜎䛯䚸䛂ᇶ♏᝟ሗฎ⌮䛃䛾ㅮ⩏䛸₇⩦䜢ศᢸ䛧䛶䛔䜛䚹་⒪⸆Ꮫ䚸๰⸆⛉Ꮫ䛾
ᇶ♏䛸䛺䜛䜒䛾䛷䛒䜚䚸Ꮫ⏕䛸䛾ᑐヰ䜢㔜ど䛧䚸Ꮫ⩦ពḧ䛸⌮ゎ䛾⛬ᗘ䜢ᢕᥱ䛧䛴䛴⾜䛳䛶䛔䜛䚹
༞ᴗᐇ⩦ཬ䜃኱Ꮫ㝔ᩍ⫱:༞ᴗ㓄ᒓ䛾Ꮫ⏕䜒ྵ䜑ಶேಶே䛻◊✲䝔䞊䝬䜢୚䛘䚸⮬ศ⮬㌟䛾ຊ䛻䜘䛳䛶௙
஦䜢㐍䜑䛶䛔䛟⬟ຊ䜢㧗䜑䛶䛔䛟ᶵ఍䜢୚䛘䜛䜘䛖䛴䛸䜑䛶䛔䜛䚹ᐇ㦂ᐊ䛻䛚䛡䜛◊✲άື䜢㏻䛨䛶▱㆑䞉ᢏ
⾡䛾ಟᚓ䛸䛸䜒䛻㛵㐃䛩䜛◊✲䛸⮬ᕫ䛾◊✲䛸䛾఩⨨௜䛡䜔ព⩏䛸䛔䛳䛯䜒䛾䜢⮬ぬ䛥䛫䛶䛔䜛䚹䜎䛯༢䛻䝀
− 217 −
䝜䝮ゎᯒ䛾ᡭἲ䛻⢭㏻䛩䜛䛰䛡䛷䛺䛟䚸䛭䛾ᡭἲ䜢䛔䛛䛻⏝䛔䛶ಶ䚻䛾ၥ㢟Ⅼ䜢ゎ᫂䛧䛶䛔䛟䛛䛸䛔䛖◊✲
ᡓ␎䛻䛴䛔䛶䜒Ꮫ䜣䛷䛔䛡䜛䜘䛖䛺⎔ቃస䜚䜢䛧䛶䛔䜛䚹
ᩍ⫱άື䛻ᑐ䛩䜛⮬ᕫⅬ᳨䞉ホ౯
㻌 Ꮫ㒊Ꮫ⏕䛾ㅮ⩏䛻ᑐ䛧䛶䛿䚸ᤵᴗホ౯䜒ಶேⓗ䛻⾜䛳䛶䚸ㅮ⩏䛻ྲྀ䜚ධ䜜䜛䜘䛖ཧ⪃䛻䛧䛶䛔䜛䚹⌮ゎ
䜢ຓ䛡䜛ᕤኵ䜢䛥䜜䛯䝥䝸䞁䝖䚸䝇䝷䜲䝗䜢౑⏝䛧䚸Ꮫ⏕䛾ホ౯䜒㧗䛔䚹
◊✲ᐊෆ䛾ᩍ⫱䛿䚸䜋䜌඲ဨ䛜ᖺ䛻୍ᗘ䛿ᅜෆᏛ఍Ⓨ⾲䛧䚸䜎䛯䚸ᅜ㝿Ꮫ఍䛷䛾Ⓨ⾲䜢⾜䛖ಟኈᏛ⏕
䜒ฟ䛶䛔䜛䛣䛸䛛䜙ุ᩿䛧䛶䚸ྛಶே䛾ᐇຊ䜢㧗䜑䜛䛣䛸䛻ᙺ❧䛳䛶䛔䜛䚹
2006 ᖺ௨㝆䛻䛚䛡䜛኱Ꮫ㝔ಟ஢⪅䛾䛖䛱䚸බົဨ䛸䛧䛶་⸆ရ䛻ᦠ䜟䜛䜒䛾䠍ྡ䚸኱Ꮫ䛾ᩍ⫋䛻ᑵ䛔
䛯䜒䛾 1 ྡ䚸௻ᴗ䛾◊✲⫋䛻ᑵ䛔䛯䜒䛾 5 ྡ䚸኱Ꮫ䛾◊✲⫋䛻ᑵ䛔䛯䜒䛾䛜 1 ྡฟ䛶䛚䜚䚸ᩍ⫱䛸◊✲䛾
㧗䛔䝺䝧䝹䛜ホ౯䛥䜜䛶䛔䜛䚹
䠄ཎⴭ䠅
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Sun Q, Hirasawa A, Hara T, Kimura I, Adachi T, Awaji T, Ishiguro M, Suzuki T, Miyata N, Tsujimoto G.
Structure-Activity Relationships of GPR120 Agonists Based on a Docking Simulation. Mol Pharmacol. 78:
804-810, 2010.
Tsujimoto G. [Overview and future vision of drug discovery based on the genomic science]. Nippon Rinsho.
688670-675, 2010.
Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G. MicroRNA-210
regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J
Biol Chem. 2010.
Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T,
Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, Narumiya S, Ogawa O. Identification
of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft
model. Cancer Res. 70(4): 1606-1615, 2010.
Tamba S, Yodoi R, Morimoto K, Inazumi T, Sukeno M, Segi-Nishida E, Okuno Y, Tsujimoto G, Narumiya S,
Sugimoto Y. Expression profiling of cumulus cells reveals functional changes during ovulation and central
roles of prostaglandin EP2 receptor in cAMP signaling. Biochimie. 92(6): 665-675, 2010.
Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G. Genome-wide analysis of aberrant methylation in
human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput
sequencing. BMC Genomics. 11137, 2010
Oikawa R, Hosoda C, Nasa Y, Daicho T, Tanoue A, Tsujimoto G, Takagi N, Tanonaka K, Takeo S. Decreased
susceptibility to salt-induced hypertension in subtotally nephrectomized mice lacking the vasopressin V1a
receptor. Cardiovasc Res. 87(1): 187-194, 2010.
Kimura I, Nakayama Y, Konishi M, Kobayashi T, Mori M, Ito M, Hirasawa A, Tsujimoto G, Ohta M, Itoh N,
Fujimoto M. Neuferricin, a novel extracellular heme-binding protein, promotes neurogenesis. J Neurochem.
112: 1156-1167, 2010.
Miyauchi S, Hirasawa A, Ichimura A, Hara T, Tsujimoto G. New frontiers in gut nutrient sensor research:
free fatty acid sensing in the gastrointestinal tract. J Pharmacol Sci. 112: 19-24, 2010.
Koshimizu T A, Tsuchiya H, Tsuda H, Fujiwara Y, Shibata K, Hirasawa A, Tsujimoto G, Fujimura A.
Inhibition of heat shock protein 90 attenuates adenylate cyclase sensitization after chronic morphine
treatment. Biochem Biophys Res Commun. 392: 603-607, 2010.
Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G,
Kanematsu A, Ogawa O, Todo T, Tsutsui K, van der Horst G T, Okamura H. Salt-sensitive hypertension in
circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med. 16(1): 67-74,2010.
Ichimura A, Ruike Y, Terasawa K, Shimizu K, Tsujimoto G. MicroRNA-34a inhibits cell proliferation by
repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells.
Mol Pharmacol. 77(6): 1016-1024, 2010.
Daimon T, Hirayama C, Kanai M, Ruike Y, Meng Y, Kosegawa E, Nakamura M, Tsujimoto G, Katsuma S,
Shimada T. The silkworm Green b locus encodes a quercetin 5-O-glucosyltransferase that produces green
cocoons with UV-shielding properties. Proc Natl Acad Sci U S A. 107(25): 11471-11476, 2010.
Hara T, Hirasawa A, Sun Q, Sadakane K, Itsubo C, Iga T, Adachi T, Koshimizu T A, Hashimoto T, Asakawa
Y, Tsujimoto G. Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn
Schmiedebergs Arch Pharmacol. 380: 247-255, 2009.
Ichimura A, Hirasawa A, Hara T, Tsujimoto G. Free fatty acid receptors act as nutrient sensors to regulate
energy homeostasis. Prostaglandins Other Lipid Mediat. 89: 82-88, 2009.
Kojima Y, Sasaki S, Oda N, Koshimizu T A, Hayashi Y, Kiniwa M, Tsujimoto G, Kohri K. Prostate growth
inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
Prostate. 69: 1521-1528, 2009.
− 218 −
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
Sanbe A, Tanaka Y, Fujiwara Y, Miyauchi N, Mizutani R, Yamauchi J, Cotecchia S, Koike K, Tsujimoto G,
Tanoue A. Enhanced vascular contractility in alpha1-adrenergic receptor-deficient mice. Life Sci. 84:
713-718, 2009.
Kimura I, Konishi M, Asaki T, Furukawa N, Ukai K, Mori M, Hirasawa A, Tsujimoto G, Ohta M, Itoh N,
Fujimoto M. Neudesin, an extracellular heme-binding protein, suppresses adipogenesis in 3T3-L1 cells via
the MAPK cascade. Biochem Biophys Res Commun. 381: 75-80, 2009.
Sekiguchi Y, Nakaniwa T, Kinoshita T, Nakanishi I, Kitaura K, Hirasawa A, Tsujimoto G, Tada T. Structural
insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 19:
2920-2923, 2009.
Tsujimoto G. [Cutting edge of drug discovery based on genomic science]. Nippon Rinsho. 67: 1170-1174,
2009.
Terasawa K, Ichimura A, Sato F, Shimizu K, Tsujimoto G. Sustained activation of ERK1/2 by NGF induces
microRNA-221 and 222 in PC12 cells. Febs J. 276: 3269-3276, 2009.
Tsuchiya S, Oku M, Imanaka Y, Kunimoto R, Okuno Y, Terasawa K, Sato F, Tsujimoto G, Shimizu K.
MicroRNA-338-3p and microRNA-451 contribute to the formation of basolateral polarity in epithelial cells.
Nucleic Acids Res. 37: 3821-3827, 2009.
Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami
K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N. Identification of novel microRNA targets based on
microRNA signatures in bladder cancer. Int J Cancer. 125: 345-352, 2009.
Shimada Y, Sato F, Shimizu K, Tsujimoto G, Tsukada K. cDNA microarray analysis of esophageal cancer:
discoveries and prospects. Gen Thorac Cardiovasc Surg. 57: 347-356, 2009.
Kojima Y, Sasaki S, Hayashi Y, Tsujimoto G, Kohri K. Subtypes of alpha1-adrenoceptors in BPH: future
prospects for personalized medicine. Nat Clin Pract Urol. 6: 44-53, 2009.
Hara T, Hirasawa A, Sun Q, Koshimizu T A, Itsubo C, Sadakane K, Awaji T, Tsujimoto G. Flow
cytometry-based binding assay for GPR40 (FFAR1; free fatty acid receptor 1). Mol Pharmacol. 75: 85-91,
2009.
Tsujimoto G, Takano Y. New topics in vasopressin receptors and approach to novel drugs: preface. J
Pharmacol Sci. 109: 32, 2009.
Koshimizu T A, Tsujimoto G. New topics in vasopressin receptors and approach to novel drugs: vasopressin
and pain perception. J Pharmacol Sci. 109: 33-37, 2009.
Nakaniwa T, Kinoshita T, Sekiguchi Y, Tada T, Nakanishi I, Kitaura K, Suzuki Y, Ohno H, Hirasawa A,
Tsujimoto G. Structure of human protein kinase CK2alpha2 with a potent indazole-derivative inhibitor. Acta
Crystallogr Sect F Struct Biol Cryst Commun. 65: 75-79, 2009.
Miyauchi S, Hirasawa A, Iga T, Liu N, Itsubo C, Sadakane K, Hara T, Tsujimoto G. Distribution and
regulation of protein expression of the free fatty acid receptor GPR120. Naunyn Schmiedebergs Arch
Pharmacol. 379: 427-434, 2009.
Michel M C, Wieland T, Tsujimoto G. How reliable are G-protein-coupled receptor antibodies? Naunyn
Schmiedebergs Arch Pharmacol. 379: 385-388, 2009.
Sato F, Tsuchiya S, Terasawa K, Tsujimoto G. Intra-platform repeatability and inter-platform comparability
of microRNA microarray technology. PLoS One. 4: e5540, 2009.
Tsuchiya S, Tachida Y, Segi-Nishida E, Okuno Y, Tamba S, Tsujimoto G, Tanaka S, Sugimoto Y.
Characterization of gene expression profiles for different types of mast cells pooled from mouse stomach
subregions by an RNA amplification method. BMC Genomics. 10: 35, 2009.
Feng C, Araki M, Kunimoto R, Tamon A, Makiguchi H, Niijima S, Tsujimoto G, Okuno Y. GEM-TREND: a
web tool for gene expression data mining toward relevant network discovery. BMC Genomics. 10411, 2009.
Suzuki Y, Cluzeau J, Hara T, Hirasawa A, Tsujimoto G, Oishi S, Ohno H, Fujii N. Structure-activity
relationships of pyrazine-based CK2 inhibitors: synthesis and evaluation of 2,6-disubstituted pyrazines and
4,6-disubstituted pyrimidines. Arch Pharm (Weinheim). 341: 554-561, 2008.
Hirasawa A, Hara T, Katsuma S, Adachi T, Tsujimoto G. Free fatty acid receptors and drug discovery. Biol
Pharm Bull. 31: 1847-1851, 2008.
Tsujimoto G. In silico drug discovery science-research and education. Yakugaku Zasshi. 128: 1519-1523,
2008.
Tsuruo T, Tsujimoto G, Yamamoto H. [Introduction to the symposium "bio-informatics for pharmaceutical
sciences and pharmacy education". Foreword]. Yakugaku Zasshi. 128: 1517, 2008.
Oishi S, Masuda R, Evans B, Ueda S, Goto Y, Ohno H, Hirasawa A, Tsujimoto G, Wang Z, Peiper S C, Naito
T, Kodama E, Matsuoka M, Fujii N. Synthesis and application of fluorescein- and biotin-labeled molecular
probes for the chemokine receptor CXCR4. Chembiochem. 9: 1154-1158, 2008.
Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T, Myoumoto A, Akiyama H, Ito N,
Kamoto T, Manabe T, Nobumasa H, Tsujimoto G, Ogawa O. Microarray-based identification of
CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J
− 219 −
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
Cancer Res Clin Oncol. 2008.
Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K, Nishiyama H, Kamoto T, Mikami Y,
Tanaka Y, Jung G, Akiyama H, Nobumasa H, Guilford P, Reeve A, Okuno Y, Tsujimoto G, Nakamura E,
Ogawa O. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin
Cancer Res. 14: 2579-2587, 2008.
Adachi T, Yanaka H, Kanai H, Nozaki M, Takahara Y, Tsuda M, Jonouchi T, Tsuda K, Hirasawa A,
Tsujimoto G. Administration of perilla oil coated with Calshell increases glucagon-like peptide secretion.
Biol Pharm Bull. 31: 1021-1023, 2008.
Takahara Y, Kobayashi T, Takemoto K, Adachi T, Osaki K, Kawahara K, Tsujimoto G. Pharmacogenomics
of cardiovascular pharmacology: development of an informatics system for analysis of DNA microarray data
with a focus on lipid metabolism. J Pharmacol Sci. 107: 1-7, 2008.
Sanbe A, Takagi N, Fujiwara Y, Yamauchi J, Endo T, Mizutani R, Takeo S, Tsujimoto G, Tanoue A. Alcohol
preference in mice lacking the Avpr1a vasopressin receptor. Am J Physiol Regul Integr Comp Physiol. 294:
R1482-1490, 2008.
Kojima Y, Sasaki S, Kubota Y, Hayase M, Hayashi Y, Shinoura H, Tsujimoto G, Kohri K. Expression of
alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor
antagonists in the management of benign prostatic hyperplasia. J Urol. 179: 1040-1046, 2008.
Nakamura K, Fujiwara Y, Mizutani R, Sanbe A, Miyauchi N, Hiroyama M, Yamauchi J, Yamashita T,
Nakamura S, Mori T, Tsujimoto G, Tanoue A. Effects of vasopressin V1b receptor deficiency on ACTH
release from anterior pituitary cells in response to oxytocin stimulation. Endocrinology. 2008.
Yano Y, Yano A, Oishi S, Sugimoto Y, Tsujimoto G, Fujii N, Matsuzaki K. Coiled-coil tag--probe system for
quick labeling of membrane receptors in living cell. ACS Chem Biol. 3: 341-345, 2008..
Tanaka T, Katsuma S, Adachi T, Koshimizu T A, Hirasawa A, Tsujimoto G. Free fatty acids induce
cholecystokinin secretion through GPR120. Naunyn Schmiedebergs Arch Pharmacol. 377: 523-527, 2008.
Ito M, Shikano T, Oda S, Horiguchi T, Tanimoto S, Awaji T, Mitani H, Miyazaki S. Difference in Ca2+
oscillation-inducing activity and nuclear translocation ability of PLCZ1, an egg-activating sperm factor
candidate, between mouse, rat, human, and medaka fish. Biol Reprod. 78: 1081-1090, 2008.
Tanaka T, Yano T, Adachi T, Koshimizu T A, Hirasawa A, Tsujimoto G. Cloning and characterization of the
rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation
of pancreatic beta cells. Naunyn Schmiedebergs Arch Pharmacol. 377: 515-522, 2008.
Hirasawa A, Itsubo C, Sadakane K, Hara T, Shinagawa S, Koga H, Nose H, Koshimizu T A, Tsujimoto G.
Production and characterization of a monoclonal antibody against GPR40 (FFAR1; free fatty acid receptor
1). Biochem Biophys Res Commun. 365: 22-28, 2008.
Kikkou T, Matsumoto O, Ohkubo T, Kobayashi Y, Tsujimoto G. NMR structure of an intracellular third loop
peptide of human GABA(B) receptor. Biochem Biophys Res Commun. 366: 681-684, 2008.
Suzuki T, Igari S, Hirasawa A, Hata M, Ishiguro M, Fujieda H, Itoh Y, Hirano T, Nakagawa H, Ogura M,
Makishima M, Tsujimoto G, Miyata N. Identification of G protein-coupled receptor 120-selective agonists
derived from PPARgamma agonists. J Med Chem. 51: 7640-7644, 2008.
Bexis S, Cleary L, McGrath J C, Tanoue A, Tsujimoto G, Docherty J R. Alpha(1D)-adrenoceptors mediate
nerve and agonist-evoked contractions in mouse vas deferens: evidence obtained from knockout technology.
Auton Autacoid Pharmacol. 28: 81-85, 2008.
Takano H, Nakazawa S, Okuno Y, Shirata N, Tsuchiya S, Kainoh T, Takamatsu S, Furuta K, Taketomi Y,
Naito Y, Takematsu H, Kozutsumi Y, Tsujimoto G, Murakami M, Kudo I, Ichikawa A, Nakayama K,
Sugimoto Y, Tanaka S. Establishment of the culture model system that reflects the process of terminal
differentiation of connective tissue-type mast cells. FEBS Lett. 582: 1444-1450, 2008.
Ichimura A, Kadowaki T, Narukawa K, Togiya K, Hirasawa A, Tsujimoto G. In silico approach to identify
the expression of the undiscovered molecules from microarray public database: identification of odorant
receptors expressed in non-olfactory tissues. Naunyn Schmiedebergs Arch Pharmacol. 377: 159-165, 2008.
Zhang H, Ohmi K, Hirasawa A, Enosawa S, Hara Y, Tamura A, Tsujimoto G. Immunological
tolerance-related genes in a spontaneous tolerant model of rat liver transplantation explored by suppression
subtractive hybridization. Cell Transplant. 17: 195-201, 2008.
Ruike Y, Ichimura A, Tsuchiya S, Shimizu K, Kunimoto R, Okuno Y, Tsujimoto G. Global correlation
analysis for micro-RNA and mRNA expression profiles in human cell lines. J Hum Genet. 53: 515-523,
2008.
Kojima Y, Sasaki S, Shinoura H, Hayase M, Kubota Y, Hayashi Y, Tsujimoto G, Kohri K. Change of
expression levels of alpha1-adrenoceptor subtypes by administration of
alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients.
Prostate. 67: 1285-1292, 2007.
Daikoku R, Kunitake T, Kato K, Tanoue A, Tsujimoto G, Kannan H. Body water balance and body
temperature in vasopressin V1b receptor knockout mice. Auton Neurosci. 136: 58-62, 2007.
− 220 −
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi J, Yamauchi J, Tsujimoto G, Tanoue A. Insulin
hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol. 584: 235-244, 2007.
Matsunaga T, Yasuda K, Adachi T, Gu N, Yamamura T, Moritani T, Tsujimoto G, Tsuda K. Association of
beta-adrenoceptor polymorphisms with cardiac autonomic modulation in Japanese males. Am Heart J. 154:
759-766, 2007.
Sanbe A, Tanaka Y, Fujiwara Y, Tsumura H, Yamauchi J, Cotecchia S, Koike K, Tsujimoto G, Tanoue A.
Alpha1-adrenoceptors are required for normal male sexual function. Br J Pharmacol. 152: 332-340, 2007.
Ikeda A, Miyazaki T, Kakizawa S, Okuno Y, Tsuchiya S, Myomoto A, Saito S Y, Yamamoto T, Yamazaki T,
Iino M, Tsujimoto G, Watanabe M, Takeshima H. Abnormal features in mutant cerebellar Purkinje cells
lacking junctophilins. Biochem Biophys Res Commun. 363: 835-839, 2007.
Faber J E, Szymeczek C L, Cotecchia S, Thomas S A, Tanoue A, Tsujimoto G, Zhang H.
Alpha1-adrenoceptor-dependent vascular hypertrophy and remodeling in murine hypoxic pulmonary
hypertension. Am J Physiol Heart Circ Physiol. 292: H2316-2323, 2007.
Gotoh C, Hong Y H, Iga T, Hishikawa D, Suzuki Y, Song S H, Choi K C, Adachi T, Hirasawa A, Tsujimoto
G, Sasaki S, Roh S G. The regulation of adipogenesis through GPR120. Biochem Biophys Res Commun.
354: 591-597, 2007.
Oikawa R, Nasa Y, Ishii R, Kuwaki T, Tanoue A, Tsujimoto G, Takeo S. Vasopressin V1A receptor enhances
baroreflex via the central component of the reflex arc. Eur J Pharmacol. 558: 144-150, 2007.
Egashira N, Tanoue A, Matsuda T, Koushi E, Harada S, Takano Y, Tsujimoto G, Mishima K, Iwasaki K,
Fujiwara M. Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor
knockout mice. Behav Brain Res. 178: 123-127, 2007.
Yasuda K, Adachi T, Gu N, Matsumoto A, Matsunaga T, Tsujimoto G, Tsuda K, Ishihara A. Effects of
hyperbaric exposure with high oxygen concentration on glucose and insulin levels and skeletal muscle-fiber
properties in diabetic rats. Muscle Nerve. 35: 337-343, 2007.
Adachi T, Kikuchi N, Yasuda K, Anahara R, Gu N, Matsunaga T, Yamamura T, Mori C, Tsujimoto G, Tsuda
K, Ishihara A. Fibre type distribution and gene expression levels of both succinate dehydrogenase and
peroxisome proliferator-activated receptor-gamma coactivator-1alpha of fibres in the soleus muscle of
Zucker diabetic fatty rats. Exp Physiol. 92: 449-455, 2007.
Kawanishi H, Takahashi T, Ito M, Matsui Y, Watanabe J, Ito N, Kamoto T, Kadowaki T, Tsujimoto G, Imoto
I, Inazawa J, Nishiyama H, Ogawa O. Genetic analysis of multifocal superficial urothelial cancers by
array-based comparative genomic hybridisation. Br J Cancer. 97: 260-266, 2007.
Hosoda C, Hiroyama M, Sanbe A, Birumachi J, Kitamura T, Cotecchia S, Simpson P C, Tsujimoto G,
Tanoue A. Blockade of both alpha1A- and alpha1B-adrenergic receptor subtype signaling is required to
inhibit neointimal formation in the mouse femoral artery. Am J Physiol Heart Circ Physiol. 293: H514-519,
2007.
Kikkou T, Matsumoto O, Ohkubo T, Kobayashi Y, Tsujimoto G. NMR structure of a human homologous
methuselah gene receptor peptide. Biochem Biophys Res Commun. 352: 17-20, 2007.
Gu N, Adachi T, Matsunaga T, Tsujimoto G, Ishihara A, Yasuda K, Tsuda K. HNF-1alpha participates in
glucose regulation of sucrase-isomaltase gene expression in epithelial intestinal cells. Biochem Biophys Res
Commun. 353: 617-622, 2007.
Fujiwara Y, Hiroyama M, Sanbe A, Yamauchi J, Tsujimoto G, Tanoue A. Mutual regulation of vasopressinand oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice. J Endocrinol. 192:
361-369, 2007.
Kadowaki T, Wheelock C E, Adachi T, Kudo T, Okamoto S, Tanaka N, Tonomura K, Tsujimoto G,
Mamitsuka H, Goto S, Kanehisa M. Identification of endocrine disruptor biodegradation by integration of
structure-activity relationship with pathway analysis. Environ Sci Technol. 41: 7997-8003, 2007.
Koshimizu T A, Tanoue A, Tsujimoto G. Clinical implications from studies of alpha1 adrenergic receptor
knockout mice. Biochem Pharmacol. 73: 1107-1112, 2007
Naito Y, Takematsu H, Koyama S, Miyake S, Yamamoto H, Fujinawa R, Sugai M, Okuno Y, Tsujimoto G,
Yamaji T, Hashimoto Y, Itohara S, Kawasaki T, Suzuki A, Kozutsumi Y. Germinal center marker GL7 probes
activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative
modulation of B-cell activation. Mol Cell Biol. 27: 3008-3022, 2007.
Ruike Y, Katsuma S, Hirasawa A, Tsujimoto G. Glucocorticoid-induced alternative promoter usage for a
novel 5' variant of granzyme A. J Hum Genet. 52: 172-178, 2007.
Ito T, Tanaka E, Kadowaki T, Kan T, Higashiyama M, Shiojima S, Tomoda S, Myoumoto A, Akiyama H,
Nobumasa H, Matsumoto S, Miyamoto S, Mitsumori M, Sato F, Watanabe G, Itami A, Meltzer S J,
Tsujimoto G, Shimada Y. An ultrasensitive new DNA microarray chip provides gene expression profiles for
preoperative esophageal cancer biopsies without RNA amplification. Oncology. 73: 366-375, 2007.
Matsunaga T, Yasuda K, Adachi T, Gu N, Yamamura T, Moritani T, Tsujimoto G, Tsuda K.
Alpha-adrenoceptor gene variants and autonomic nervous system function in a young healthy Japanese
− 221 −
population. J Hum Genet. 52: 28-37, 2007.
Myoumoto A, Nakatani K, Koshimizu T A, Matsubara H, Adachi S, Tsujimoto G. Glucocorticoid-induced
granzyme A expression can be used as a marker of glucocorticoid sensitivity for acute lymphoblastic
leukemia therapy. J Hum Genet. 52: 328-333, 2007.
83. Yamamoto H, Takematsu H, Fujinawa R, Naito Y, Okuno Y, Tsujimoto G, Suzuki A, Kozutsumi Y.
Correlation index-based responsible-enzyme gene screening (CIRES), a novel DNA microarray-based
method for enzyme gene involved in glycan biosynthesis. PLoS ONE. 2: e1232, 2007.
84. Hashida R, Ohkura N, Saito H, Tsujimoto G. The NR4A nuclear receptor family in eosinophils. J Hum
Genet. 52: 13-20, 2007.
85. Yasuda K, Matsunaga T, Adachi T, Aoki N, Tsujimoto G, Tsuda K. Adrenergic receptor polymorphisms and
autonomic nervous system function in human obesity. Trends Endocrinol Metab. 17: 269-275, 2006.
86. Tanaka Y, Nakamura K, Matsumoto S, Kimoto Y, Tanoue A, Tsujimoto G, Endo F. Gene expression profiles
of homogentisate-treated Fah-/- Hpd-/-mice using DNA microarrays. Mol Genet Metab. 89: 203-209, 2006.
87. Nishikino M, Matsunaga T, Yasuda K, Adachi T, Moritani T, Tsujimoto G, Tsuda K, Aoki N. Genetic
variation in the renin-angiotensin system and autonomic nervous system function in young healthy Japanese
subjects. J Clin Endocrinol Metab. 91: 4676-4681, 2006.
88. Yasuda K, Aoki N, Adachi T, Tsujimoto G, Gu N, Matsunaga T, Kikuchi N, Tsuda K, Ishihara A. Hyperbaric
exposure with high oxygen concentration inhibits growth-associated increase in the glucose level of diabetic
Goto-Kakizaki rats. Diabetes Obes Metab. 8: 714-715, 2006.
89. Koshimizu T A, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori
T, Takeo S, Okamura H, Tsujimoto G. V1a vasopressin receptors maintain normal blood pressure by
regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A. 103: 7807-7812,
2006.
90. Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, Kohri K. Quantification of alpha1-adrenoceptor
subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia
patients. Prostate. 66: 761-767, 2006.
91. Tomita T, Masuzaki H, Iwakura H, Fujikura J, Noguchi M, Tanaka T, Ebihara K, Kawamura J, Komoto I,
Kawaguchi Y, Fujimoto K, Doi R, Shimada Y, Hosoda K, Imamura M, Nakao K. Expression of the gene for
a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40
expression in pancreatic beta cells and implications for insulin secretion. Diabetologia. 49: 962-968, 2006.
92. Koshimizu T A, Kretschmannova K, He M L, Ueno S, Tanoue A, Yanagihara N, Stojilkovic S S, Tsujimoto
G. Carboxyl-terminal splicing enhances physical interactions between the cytoplasmic tails of purinergic
P2X receptors. Mol Pharmacol. 69: 1588-1598, 2006.
93. Yasuda K, Adachi T, Kikuchi N, Tsujimoto G, Aoki N, Tsuda K, Ishihara A. Effects of running exercise on
fibre-type distribution of soleus and plantaris muscles in diabetic Otsuka Long-Evans Tokushima fatty rats.
Diabetes Obes Metab. 8: 311-321, 2006.
94. Kikkou T, Matsumoto O, Ohkubo T, Kobayashi Y, Tsujimoto G. NMR structure of an intracellular loop
peptide derived from prostaglandin EP3alpha receptor. Biochem Biophys Res Commun. 345: 933-937,
2006.
95. Itoh S, Yamada S, Mori T, Miwa T, Tottori K, Uwahodo Y, Yamamura Y, Fukuda M, Yamamoto K, Tanoue A,
Tsujimoto G. Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor.
Am J Physiol Endocrinol Metab. 291: E147-151, 2006.
96. Okuno Y, Yang J, Taneishi K, Yabuuchi H, Tsujimoto G. GLIDA: GPCR-ligand database for chemical
genomic drug discovery. Nucleic Acids Res. 34: D673-677, 2006.
97. Adachi T, Tanaka T, Takemoto K, Koshimizu T A, Hirasawa A, Tsujimoto G. Free fatty acids administered
into the colon promote the secretion of glucagon-like peptide-1 and insulin. Biochem Biophys Res Commun.
340: 332-337, 2006.
98. Fukunaga S, Setoguchi S, Hirasawa A, Tsujimoto G. Monitoring ligand-mediated internalization of G
protein-coupled receptor as a novel pharmacological approach. Life Sci. 80: 17-23, 2006.
99. Osada S, Naganawa A, Misonou M, Tsuchiya S, Tamba S, Okuno Y, Nishikawa J, Satoh K, Imagawa M,
Tsujimoto G, Sugimoto Y, Nishihara T. Altered gene expression of transcriptional regulatory factors in tumor
marker-positive cells during chemically induced hepatocarcinogenesis. Toxicol Lett. 167: 106-113, 2006.
100. Gu N, Adachi T, Matsunaga T, Takeda J, Tsujimoto G, Ishihara A, Yasuda K, Tsuda K. Mutant HNF-1alpha
and mutant HNF-1beta identified in MODY3 and MODY5 downregulate DPP-IV gene expression in
Caco-2 cells. Biochem Biophys Res Commun. 346: 1016-1023, 2006.
101. Kawanishi H, Takahashi T, Ito M, Watanabe J, Higashi S, Kamoto T, Habuchi T, Kadowaki T, Tsujimoto G,
Nishiyama H, Ogawa O. High throughput comparative genomic hybridization array analysis of multifocal
urothelial cancers. Cancer Sci. 97: 746-752, 2006.
102. Koshimizu T A, Tsujimoto G. Functional role of spliced cytoplasmic tails in P2X2-receptor-mediated
cellular signaling. J Pharmacol Sci. 101: 261-266, 2006.
82.
− 222 −
103. Tsuchiya S, Okuno Y, Tsujimoto G. MicroRNA: biogenetic and functional mechanisms and involvements in
cell differentiation and cancer. J Pharmacol Sci. 101: 267-270, 2006.
104. Nagino K, Nomura O, Takii Y, Myomoto A, Ichikawa M, Nakamura F, Higasa M, Akiyama H, Nobumasa H,
Shiojima S, Tsujimoto G. Ultrasensitive DNA chip: gene expression profile analysis without RNA
amplification. J Biochem. 139: 697-703, 2006.
105. Gu N, Adachi T, Takeda J, Aoki N, Tsujimoto G, Ishihara A, Tsuda K, Yasuda K. Sucrase-isomaltase gene
expression is inhibited by mutant hepatocyte nuclear factor (HNF)-1alpha and mutant HNF-1beta in Caco-2
cells. J Nutr Sci Vitaminol (Tokyo). 52: 105-112, 2006.
106. Egashira N, Tanoue A, Tsujimoto G, Mishima K, Takano Y, Iwasaki K, Fujiwara M. [Vasopressin receptor
knockout mice as an animal model of psychiatric disorders]. Nihon Shinkei Seishin Yakurigaku Zasshi. 26:
101-105, 2006.
107. Herath C B, Ishiwata H, Shiojima S, Kadowaki T, Katsuma S, Ushizawa K, Imai K, Takahashi T, Hirasawa
A, Takahashi S, Izaike Y, Tsujimoto G, Hashizume K. Developmental aberrations of liver gene expression in
bovine fetuses derived from somatic cell nuclear transplantation. Cloning Stem Cells. 8: 79-95, 2006.
108. Koshimizu T, Kretschmannova K, He ML, Ueno S, Tanoue A, Yanagihara N, Stojilkovic SS, Tsujimoto G.
Carboxy-terminal splicing enhances physical interactions between the cytoplasmic tails of purinergic P2X
receptors. Mol. Pharmacol. 69: 1588-1598, 2006.
䠄࿴ᩥ䠅
ヱᙜ䛺䛧
䠄⥲ㄝ䠅䠄Ḣᩥ䠅
1.
Miyauchi S, Hirasawa A, Ichimura A, Hara T, Tsujimoto G. Free fatty acid sensing in the gastrointestinal
tract. Journal of Pharmacological Sciences : 2009. in press.
Ichimura A, Hirasawa A, Hara T, Tsujimoto G. Free fatty acid receptors act as nutrient sensors to regulate
energy homeostasis. Prostaglandins & Other Lipid Mediators 89 : 82-88, 2009.
2.
䠄࿴ᩥ䠅
1.
⬡⫫㓟ཷᐜయ䛸ᾘ໬྾཰ㄪ㐩ᶵ⬟. ᖹ⃝᫂䚸㎷ᮏ㇦୕. ᾘ໬䛸྾཰ vol.32 np.1’09 :17-23,2010
2.
3.
4.
ከ౯୙㣬࿴⬡⫫㓟䛸⣽⬊ෆ䝅䜾䝘䝹ఏ㐩. ཎ㈗ᩥ䚸ᖹ⃝᫂䚸㎷ᮏ㇦୕. ἞⒪Ꮫ 43: 824-828, 2009
䃨3 ከ౯୙㣬࿴⬡⫫㓟䛸 G ⺮ⓑ㉁ඹᙺᆺཷᐜయ. ᖹ⃝᫂䚸㎷ᮏ㇦୕ The Lipid 19: 374-378, 2008
ᾘ໬⟶⬡⫫㓟ཷᐜయ◊✲䛿⢾ᒀ⑓἞⒪⸆๰⸆䛾䝠䞁䝖䛸䛺䜚䛖䜛䛛. ᖹ⃝᫂䚸㎷ᮏ㇦୕. G.I.Research
16 : 396-402, 2008
䜻䞊䝽䞊䝗ゎㄝ䛂㐟㞳⬡⫫㓟ཷᐜయ / Free fatty acids receptor䛃. ᖹ⃝᫂䚸㎷ᮏ㇦୕. ᪥ᮏ⸆⌮Ꮫ㞧ㄅ
132: 370-375, 2008
⬡⫫㓟ཷᐜయ GPR120 䜢௓䛩䜛 GLP-1 䛾ศἪ. ᖹ⃝᫂䚸㎷ᮏ㇦୕. Diabetes Frontier 18: 676-680,
2007
5.
6.
䠄ⴭ᭩䠅䠄Ḣᩥ䠅
ヱᙜ䛺䛧
䠄࿴ᩥ䠅
1. ➨ 2 ❶. G 䝍䞁䝟䜽㉁ඹᙺᆺཷᐜయ䛸䝀䝜䝮๰⸆. ㎷ᮏ㇦୕ ᐇ㦂་Ꮫቑห, (2006)
− 223 −
〇๣ᶵ⬟ゎᯒᏛศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧▼℈ Ὀ㸦࠸ࡋࡣࡲ ࡸࡍࡋ㸧㸦 ╔௵㸧
ᖹᡂ ᖺி㒔኱Ꮫ༞ࠊᖹᡂ ᖺྠ኱Ꮫ኱Ꮫ㝔ᕤᏛ◊✲⛉ಟኈㄢ⛬ಟ஢
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧༙⏣ ဴ㑻㸦ࡣࢇࡔ ࡚ࡘࢁ࠺㸧㸦 ᐃᖺ㏥⫋ࠊ
㕥㮵་⒪⛉Ꮫ኱Ꮫ⸆Ꮫ㒊࣭ᩍᤵ࡟㌿ฟ㸧
᫛࿴ ᖺி㒔኱Ꮫ༞ࠊ᫛࿴ ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ ୰㏵㏥Ꮫ
ຓᩍᤵ㸦⸆Ꮫ༤ኈ㸧㯮⏣ ⩏ᘯ㸦ࡃࢁࡔ ࡼࡋࡦࢁ㸧
㸦 ጲ㊰⋊༠኱Ꮫ
⸆Ꮫ㒊࣭ᩍᤵ࡟㌿ฟ㸧
᫛࿴ ᖺி㒔኱Ꮫ༞ࠊ᫛࿴ ᖺྠ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬⤊஢
෸ᩍᤵ㸦ᕤᏛ༤ኈ㸧୰㔝 ᐇ㸦࡞࠿ࡢ ࡳࡢࡿ㸧㸦 ᪼௵㸧
ᖹᡂ ᖺி㒔኱Ꮫ༞ࠊᖹᡂ ᖺྠ኱Ꮫ኱Ꮫ㝔ᕤᏛ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢ 㸦▼℈ᩍᤵ㸧
◊✲ࡢᴫせ
〇๣ᶵ⬟ゎᯒᏛศ㔝ࡣࠊศᏊࣞ࣋ࣝ࠾ࡼࡧ⣽⬊࡛ࣞ࣋ࣝ⏕యᵓᡂᅉᏊࢆィ ࣭ゎᯒࡋࠊᶵ⬟ゎ᫂ࡍࡿ
ࡇ࡜ࢆ◊✲┠ᶆ࡜ࡋࠊศ㞳࣭ศᯒ⛉Ꮫࢆ㥑౑ࡋࡓศᏊ⣽⬊ィ ࠊ࠾ࡼࡧ⏺㠃࣭≀⌮⛉Ꮫࢆᇶ┙࡜ࡋࡓศ
Ꮚ㞟ྜయゎᯒࢆ㏻ࡌ࡚ࠊ⸆Ꮫࡢ᪂ᆅᖹࢆษࡾ㛤ࡃࡇ࡜ࢆᶆᴶࡋ࡚࠸ࡿࠋ୰࡛ࡶࠊ㉁㔞ศᯒࠊᚤ㔞ศ㞳ศ
ᯒ࣭࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ➼ࢆ㥑౑ࡋࡓࣉࣟࢸ࣮࣒࢜ゎᯒࡢ᪉ἲㄽ㛤Ⓨࡸࡑࢀ࡟ᇶ࡙ࡃ⣽⬊ᶵ⬟ゎᯒࡸ་
⸆ရ㛤Ⓨ࡬ࡢᛂ⏝ࠊ࠾ࡼࡧ⏕యෆ⬡㉁࣭࢔࣏࣏ࣜࢱࣥࣃࢡ㉁ࡢᵓ㐀ᶵ⬟ゎᯒࡸࡑࢀ࡟ᇶ࡙ࡃ〇๣㛤Ⓨ࡞
࡝࡟ᣮᡓࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊࡇࢀࡽࡢ◊✲ࢆ㏻ࡌ࡚⸆Ꮫ◊✲⪅ࡢ⫱ᡂࢆ⾜ࡗ࡚࠸ࡿࠋ
Ⓨ⌧ࣉࣟࢸ࣑࢜ࢡࢫ୍ᩧゎᯒἲࡢ㛤Ⓨ
⣽⬊ෆ࡛Ⓨ⌧ࡋ࡚࠸ࡿࢱࣥࣃࢡ㉁ࡢࡍ࡭࡚ࢆィ ᑐ㇟࡜ࡋࠊ㉁㔞ศᯒ࠾ࡼࡧᚤ㔞ศ㞳ศᯒࢆ㥑౑
ࡋ࡞ࡀࡽࠊ㠀ᖖ࡟」㞧࡛ࢲ࢖ࢼ࣑ࢵࢡࣞࣥࢪࡢᗈ࠸ヨᩱࢆ✲ᴟࡢศ㞳ศᯒἲ࡛࢜ࣥࣛ࢖ࣥศ㞳ࡋ࡞
ࡀࡽ㉁㔞ศᯒィ࡛ ᐃࡋࠊ⊂⮬ࡢࢹ࣮ࢱฎ⌮ࢩࢫࢸ࣒࡛ゎᯒࡍࡿࢩࢫࢸ࣒ࡢ㛤Ⓨ࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
࣓࣮ࢺࣝ㛗࢟ࣕࣆ࣮࣒ࣛࣜ࢝ࣛࢆ⏝࠸ࡓ㉸㧗ศ㞳⬟ࢩࢫࢸ࣒ࢆ⏝࠸࡚ࡍ࡛࡟኱⭠⳦࡞࡝ࡢ⏕≀࡛
ࡣⓎ⌧ࡋ࡚࠸ࡿ඲ࢱࣥࣃࢡ㉁ࡢ୍ᩧศᯒࡀྍ⬟࡟࡞ࡗ࡚࠾ࡾࠊࣄࢺ࡞࡝ࡢ㧗➼⏕≀ࡢࣉࣟࢸ࣮࣒࢜
ゎᯒ࡬ࡢᒎ㛤ࡀ኱࠸࡟ᮇᚅࡉࢀ࡚࠸ࡿࠋ
ࢩࢢࢼࣝఏ㐩ࣉࣟࢸ࣮࣒࢜࡟㛵ࡍࡿ◊✲
⣽⬊ෆࢩࢢࢼࣝఏ㐩ࢿࢵࢺ࣮࣡ࢡ࡟࠾࠸࡚ࠊ࢟ࢼ࣮ࢮࡸ࣍ࢫࣇ࢓ࢱ࣮ࢮ࡟ࡼࡿྍ㏫ⓗࣜࣥ㓟໬཯
ᛂࡣ୰ᚰⓗ࡞ᙺ๭ࢆᯝࡓࡋ࡚࠸ࡿࠋ⊂⮬ࡢࣜࣥ㓟໬࣌ࣉࢳࢻ㧗㑅ᢥⓗ⃰⦰ᢏ⾡ࢆ㛤Ⓨࡋࠊࣜࣥ㓟໬
ࢱࣥࣃࢡ㉁ࡢゎᯒࢆࣉࣟࢸ࣮࣒࢜つᶍ࡛⾜࠺ࡇ࡜ࡀྍ⬟࡜࡞ࡗࡓࠋᮏࢩࢫࢸ࣒ࢆ࢟ࢼ࣮ࢮ㜼ᐖ⸆➼
ࡢศᏊᶆⓗ⸆ࡢ LQYLYR ࣉࣟࣇ࢓࢖ࣜࣥࢢ࡟ᛂ⏝ࡋ๰⸆ᨭ᥼ࢶ࣮ࣝ࡜ࡋ࡚㛤Ⓨࡍࡿ࡜࡜ࡶ࡟ࠊ⒴➼
ࡢᵝࠎ࡞⑌⑓࡟࠾ࡅࡿࣜࣥ㓟໬␗ᖖࢆࢫࢡ࣮ࣜࢽࣥࢢࡍࡿࢩࢫࢸ࣒࡜ࡋ࡚ࡢᛂ⏝◊✲ࡶᒎ㛤୰࡛
࠶ࡿࠋࡉࡽ࡟ࠊ᪂つ࡟ぢࡘ࠿ࡗ࡚ࡁࡓᶵ⬟ᮍ▱ࡢࣜࣥ㓟໬ࢱࣥࣃࢡ㉁ࡢࢩࢢࢼࣝࢿࢵࢺ࣮࣡ࢡゎᯒ
ࡶ⾜ࡗ࡚࠸ࡿࠋࣜࣥ㓟໬ಟ㣭࡟ຍ࠼ࠊ࢔ࢭࢳࣝ໬ಟ㣭➼ࡢ௚ࡢ⩻ヂᚋಟ㣭ࣉࣟࢸ࣑࢜ࢡࢫ࡟ࡘ࠸࡚
ࡶࡑࡢ ᐃࢩࢫࢸ࣒ࢆ㛤Ⓨ୰࡛࠶ࡿࠋ
⭷࡜ࢱࣥࣃࢡ㉁ࡢ┦஫స⏝࠾ࡼࡧ⭷⬡㉁ࡢࢲ࢖ࢼ࣑ࢡࢫ࡟㛵ࡍࡿ◊✲
㧗ᐦᗘ࣏ࣜࢱࣥࣃࢡ㉁+'/ࡢ᪂⏕཯ᛂࡢ࣓࢝ࢽࢬ࣒ࡢゎ᫂ࢆ┠ᣦࡋࠊࣔࢹࣝ⭷ࢆ⏝࠸ࡓ≀⌮໬
Ꮫⓗ࢔ࣉ࣮ࣟࢳ࡟ࡼࡾ᳨ウࢆ⾜ࡗ࡚࠸ࡿࠋ⌧ᅾࡲ࡛࡟ᵝࠎ࡞⭷⎔ቃኚ໬ࡀ࢔࣏࣏ࣜࢱࣥࣃࢡ㉁࡟
ࡼࡿ⭷ࡢ⮬Ⓨⓗ࡞ࢹ࢕ࢫࢡ໬ࢆㄏ㉳ࡍࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋࡲࡓࠊ⭷⬡㉁ࢲ࢖ࢼ࣑ࢡࢫ◊✲
࡟࠾࠸࡚ࠊ᫬ศ๭୰ᛶᏊᑠゅᩓ஘ἲࢆ⏝࠸ࡓࣜࣥ⬡㉁ࡢ⭷㛫⛣ື࡜ࣇࣜࢵࣉࣇࣟࢵࣉࡢ㏿ᗘࢆྠ
᫬࡟᳨ฟࡍࡿ᪂つᡭἲࢆ㛤Ⓨࡋࡓࠋᮏᡭἲ࡟ࡼࡾࠊSUHș+'/ ᵝࢹ࢕ࢫࢡ≧」ྜయ㛫ࡢࣜࣥ⬡㉁⛣
ືࡀ࣏ࣜࢯ࣮࣒㛫࡜ẚ࡭⣙ ಸಁ㐍ࡉࢀ࡚࠸ࡿࡇ࡜ࢆぢ࠸ࡔࡋࡓࠋ⌧ᅾࠊᑠ⬊㍺㏦ࡸࣜࣥ⬡㉁௦
ㅰ࡟㛵୚ࡍࡿࣜࣥ⬡㉁㍺㏦ࢱࣥࣃࢡ㉁ࡢάᛶホ౯ࡢඹྠ◊✲ࢆᐇ᪋ࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊ⭷ࢱࣥࣃ
ࢡ㉁ࡢࣇࣜࢵࣃ࣮ࢮάᛶ࡞࡝ࠊ⏕⌮ⓗ࡟㔜せ࡞ OLSLGWUDQVSRUW ࡢᐃ㔞ⓗホ౯ࢆ㐍ࡵ࡚࠸ࡿࠋ
⬡㉁ᚤ⢏Ꮚࡢㄪ〇࡜⏕≀≀⌮Ꮫⓗ◊✲
⬡㉁࢚࣐ࣝࢩࣙࣥࡣ⾑₢࣏ࣜࢱࣥࣃࢡ㉁⢏Ꮚࡢࣔࢹ࡛ࣝ࠶ࡾࠊࡲࡓࠊ་⸆ရࡢ㏦㐩⣔࡜ࡋ࡚฼
⏝ࡉࢀ࡚࠸ࡿࠋ஧ศᏊ⭷࣏ࣜࢯ࣮࣒࡟ẚ࡭ࠊ࢚࣐ࣝࢩࣙࣥ࡟ࡣ࢔࣏࣏ࣜࢱࣥࣃࢡ㉁ࡀ⣙ ಸࡶከ
ࡃ⤖ྜࡋࠊࡇࢀ࡟ᛂࡌ࡚⢏Ꮚࡢయෆ௦ㅰࠊᇵ㣴⣽⬊࡜ࡢ┦஫స⏝ࡀ኱ࡁࡃኚ໬ࡍࡿࡇ࡜ࢆⓎぢࡋ
ࡓࠋࡲࡓࠊ࢔࣏࣏ࣜࢱࣥࣃࢡࡢ⤖ྜࡀ⬡㉁⢏Ꮚ⾲㠃ࢺ࣏ࣟࢪ࣮࡟ࡼࡾኚ໬ࡍࡿ࣓࢝ࢽࢬ࣒ࢆ 105
ࡸ⺯ගศගἲ࡟ᇶ࡙ࡁゎ᫂ࡋࡓࠋ୍᪉ࠊᚑ᮶࠿ࡽࡑࡢ〇㐀ࡀᅔ㞴࡛࠶ࡿ࡜࠸ࢃࢀ࡚࠸ࡓࢼࣀ⢏Ꮚ
− 224 −
㸦࢟ࣗ࣎ࢯ࣮࣒ࠊ࣊࢟ࢯࢯ࣮࣒㸧ࡢㄪ〇ἲ࡜ホ౯ἲࢆୡ⏺࡟ඛ㥑ࡅ☜❧ࡋࡓࠋࡇࢀࡽࡢ᪂つ⬡㉁
⢏Ꮚࢆ฼⏝ࡋࠊ஧ศᏊ⭷࣓ࣛࣛ࠿ࡽ࣊࢟ࢧࢦࢼࣝࡸ࣮࢟ࣗࣅࢵࢡ࡬ࡢᵓ㐀㌿⛣࡟ࡼࡿ⭷ࡢ≀ᛶኚ
໬ࡸࢱࣥࣃࢡࡢᶵ⬟ㄪᩚࡢㄪᰝࢆ⾜ࡗ࡚࠸ࡿࠋࡉࡽ࡟࢔࣏࣏ࣜࢱࣥࣃࢡ㉁࡜⬡㉁ࡢ」ྜయ࡛࠶ࡿ
ࢼࣀࢹ࢕ࢫࢡࡢᚤ⣽࡞ᵓ㐀ኚ໬ࢆศගᏛⓗ࡟᳨ฟࡍࡿࡇ࡜࡟ࡶᡂຌࡋ࡚࠾ࡾࠊࡉࡽ࡞ࡿᵓ㐀ㄪᰝ
ࢆᐇ᪋୰࡛࠶ࡿࠋࡲࡓࠊࡇࢀࡽࡢᚤ⢏Ꮚࡢ་⸆ရ〇๣ᛂ⏝࡬ࡢ㐨ࡶ㛤࠿ࢀࡘࡘ࠶ࡾࠊ⌧ᅾ」ᩘࡢ
〇⸆௻ᴗ࡜ࡢඹྠ◊✲ࡶ㐙⾜ࡋ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
▼℈Ὀᩍᤵࡣ 㸫 ᖺᗘ࡟㸦⊂㸧⛉Ꮫᢏ⾡᣺⯆ᶵᵓࡉࡁࡀࡅࠕᵓ㐀ᶵ⬟࡜ィ 㡿ᇦࠖ◊✲⪅࡟
᥇ᢥࡉࢀࡓࠋࡲࡓ ᖺᗘ࡟ࡣ᪥ᮏ㉁㔞ศᯒᏛ఍ࡼࡾ఍ㄅ㈹ࢆཷ㈹ࡋ࡚࠸ࡿࠋ୰㔝෸ᩍᤵࡣ ᖺᗘ
᪥ᮏ⭷Ꮫ఍ዡບ㈹ࠊ ᖺᗘ᪥ᮏ⸆Ꮫ఍ዡບ㈹ࢆཷ㈹ࡋ࡚࠸ࡿࠋᡤᒓࡋࡓ༤ኈᚋᮇㄢ⛬ࡢᏛ⏕ࡢከࡃ
ࡣ᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ࡟᥇⏝ࡉࢀ࡚࠸ࡿࠋࡲࡓࠊ⛉Ꮫ◊✲㈝⿵ຓ㔠ࡸ་⸆ရᇶ┙◊✲ᡤᇶ♏◊✲
᥎㐍㈝࡞࡝ࢆ⥅⥆ⓗ࡟⋓ᚓࡋ࡚࠸ࡿࠋࡉࡽ࡟⛉Ꮫᢏ⾡᣺⯆ᶵᵓ◊✲ᡂᯝ᭱㐺ᒎ㛤ᨭ᥼஦ᴗࡸෆ⸨グᛕ⛉
Ꮫ᣺⯆㈈ᅋ◊✲ຓᡂ࡟᥇ᢥࡉࢀࠊࣜࣥ㓟໬ࣉࣟࢸ࣑࢜ࢡࢫ๰⸆ࡢᐇ⏝໬◊✲ࡶ⾜ࡗ࡚࠸ࡿࠋࡇࢀࡽࡢࡇ
࡜࠿ࡽࡶᮏศ㔝ࡢ◊✲ホ౯ࡣࡁࢃࡵ࡚㧗࠸ࡇ࡜ࡀࢃ࠿ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣㅮ⩏⛉┠࡜ࡋ࡚㸯ᅇ⏕ᚋᮇࡢ⸆Ꮫ≀⌮໬Ꮫ㸦໬Ꮫ⇕ຊᏛ㸧ࠊ㸰ᅇ⏕๓ᮇࡢ≀⌮໬Ꮫ
㸰㸦㟁Ẽ໬Ꮫࠊ⏺㠃໬Ꮫ㸧
ࠊᚋᮇࡢศᯒ໬Ꮫ㸱㸦ศගᏛ㸧ࠊ㸱ᅇ⏕ᚋᮇࡢ≀⌮໬Ꮫ 4㸦⏕≀≀⌮໬Ꮫ㸧ࢆࠊ
₇⩦⛉┠࡜ࡋ࡚ 2 ᅇ⏕๓ᮇࡢ๰⸆≀⌮໬Ꮫ࢚ࢡࢧࢧ࢖ࢬ㸯ࠊᚋᮇࡢ๰⸆≀⌮໬Ꮫ࢚ࢡࢧࢧ࢖ࢬ㸰ࢆࠊᐇ
⩦⛉┠࡜ࡋ࡚㸱ᅇ⏕๓ᮇࡢ⸆Ꮫᑓ㛛ᐇ⩦㸯ࢆࡑࢀࡒࢀᢸᙜࡋ࡚࠸ࡿࠋㅮ⩏⛉┠࡟ࡘ࠸࡚ࡣࠊ⏕࿨⛉Ꮫࡢ
ᇶ♏ࡢᩍ⫱࡟┠ᶆࢆタᐃࡋࠊ཮᪉ྥࡢᏛ⩦࡜࡞ࡿࡼ࠺࡟₇⩦ᙧᘧࢆධࢀ࡞ࡀࡽᩍ⫱ࡋ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗ㓄ᒓࡢᏛ⏕࡟ࡣྛಶே࡟ࢸ࣮࣐ࢆ୚࠼ࠊ⮬ศ࡛௙஦ࢆ່ࡵࡿ⬟ຊࡢ㛤Ⓨ
ࡢᶵ఍ࢆ୚࠼࡚࠸ࡿࠋࡲࡓࠊᮏศ㔝ࡢ㝔⏕ࡣࡑࢀࡒࢀࡀ◊✲㢟┠ࢆᣢࡕࠊㄢ㢟タᐃ࡜ࡑࡢゎỴࢆ⊂ຊ࡛
⾜࠺ࡼ࠺ᣦᑟࡋ࡚࠸ࡿࠋẖ㐌ࠊ◊✲࣭ᐇ㦂ࡢሗ࿌࡜඲ဨ࡟ࡼࡿウㄽ࡛◊✲ࣞ࣋ࣝࡢᙉ໬ࢆᅗࡿᶵ఍ࢆᣢ
ࡘ࡜࡜ࡶ࡟ࠊእ㒊ᶵ㛵࡜ࡢඹྠ◊✲ࡢ㐍ࡵ᪉ࢆᏛࢇ࡛ࡶࡽࡗ࡚࠸ࡿࠋ㝔⏕࡟ࡣᏛእࡢ◊✲Ꮫ఍࡛Ⓨ⾲ࡍ
ࡿᶵ఍ࢆᣢࡘࡇ࡜ࠊ≉࡟༤ኈᚋᮇㄢ⛬㝔⏕࡟ࡣᅜ㝿Ꮫ఍࡛ࡢⱥㄒ࡟ࡼࡿⓎ⾲ࢆ⩏ົ໬ࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊᑠヨ㦂ࢆᐇ᪋ࡋ࡚㐩ᡂᗘࢆ☜ㄆࡍࡿᙧᡂⓗホ౯ࢆྲྀࡾධࢀ࡚࠸ࡿࠋࡉ
ࡽ࡟Ꮫ⏕࡟ࡼࡿᤵᴗホ౯ࡶ⾜ࡗ࡚ࠊㅮ⩏࡟ྲྀࡾධࢀࡿࡼ࠺ཧ⪃࡟ࡋ࡚࠸ࡿࠋ
◊✲ᐊෆࡢ㝔⏕ࡢᩍ⫱࡟ࡘ࠸࡚ࡣࠊ඲ဨࡀ୍ᖺ࡟ᑡ࡞ࡃ࡜ࡶ୍ᗘࡣᏛ఍ཱྀ࡛㢌Ⓨ⾲ࡋ࡚࠾ࡾࠊྛಶே
ࡢᐇຊࢆ㧗ࡵࡿࡇ࡜࡟ᙺ❧ࡗ࡚࠸ࡿࠋ
኱Ꮫ㝔ಟኈㄢ⛬ಟ஢⪅ࡣ〇⸆௻ᴗࡢ〇๣࣭ศᯒศ㔝ࡢ◊✲⫋࡟ᑵࡃࡶࡢࡀᅽಽⓗ࡟ከ࠸ࠋࡲࡓ༤ኈᚋ
ᮇㄢ⛬ಟ஢⪅ࡣ኱Ꮫࡢຓᡭࠊ௻ᴗࡢ◊✲⫋࡟ࡘ࠸࡚࠸ࡿࠋࡇࢀࡣᩍ⫱࡜◊✲࡟ࡘ࠸࡚㧗࠸ᐈほⓗホ౯ࢆ
ཷࡅ࡚࠸ࡿࡇ࡜ࢆ♧ࡍࡶࡢ࡛࠶ࡿࠋ
㸦ཎⴭ㸧
1.
2.
3.
4.
5.
6.
Detection of Rap1A as a yessotoxin binding protein from blood cell membranes. S. Ujihara, T. Oishi, R.
Mouri, R. Tamate, K. Konoki, N. Matsumori, M. Murata, Y. Oshima, N. Sugiyama, M. Tomita,Y. Ishihama.
Bioorg Med Chem Lett 20, 6443-6 (2010).
A systematic survey of in vivo obligate chaperonin-dependent substrates. K. Fujiwara, Y. Ishihama, K.
Nakahigashi, T. Soga,H. Taguchi. EMBO J 29, 1552-64 (2010).
One-Dimensional Capillary Liquid Chromatographic Separation Coupled with Tandem Mass Spectrometry
Unveils the Escherichia coli Proteome on a Microarray Scale. M. Iwasaki, S. Miwa, T. Ikegami, M. Tomita,
N. Tanaka,Y. Ishihama. Anal Chem 82, 2616-20 (2010).
Quantitative proteome and phosphoproteome analyses of cultured cells based on SILAC labeling without
requirement of serum dialysis. K. Imami, N. Sugiyama, M. Tomita,Y. Ishihama. Mol Biosyst 6, 594-602
(2010).
Large-scale comparative phosphoproteomics identifies conserved phosphorylation sites in plants. H.
Nakagami, N. Sugiyama, K. Mochida, A. Daudi, Y. Yoshida, T. Toyoda, M. Tomita, Y. Ishihama,K.
Shirasu. Plant Physiol 153, 1161-74 (2010).
emPAI Calc--for the estimation of protein abundance from large-scale identification data by liquid
chromatography-tandem mass spectrometry. K. Shinoda, M. Tomita,Y. Ishihama. Bioinformatics 26, 576-7
(2010).
− 225 −
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Development of Titania Particles Used for Phosphopeptide Enrichment in Mass Spectrometry-based
Phosphoproteomics. Y. Kyono, N. Sugiyama, K. Imami, K. Miyazaki, M. Ohira, M. Tomita,Y. Ishihama. J.
Mass Spectrom. Soc. Jpn. 58, 129-138 (2010).
Chemical dephosphorylation for identification of multiply phosphorylated peptides and phosphorylation
site determination. Y. Kyono, N. Sugiyama, M. Tomita,Y. Ishihama. Rapid Commun Mass Spectrom 24,
2277-82 (2010).
Towards the systematic discovery of signal transduction networks using phosphorylation dynamics data. H.
Imamura, N. Yachie, R. Saito, Y. Ishihama,M. Tomita. BMC Bioinformatics 11, 232 (2010).
Type 2C protein phosphatases directly regulate abscisic acid-activated protein kinases in Arabidopsis. T.
Umezawa, N. Sugiyama, M. Mizoguchi, S. Hayashi, F. Myouga, K. Yamaguchi-Shinozaki, Y. Ishihama, T.
Hirayama,K. Shinozaki. Proc Natl Acad Sci U S A 106, 17588-93 (2009).
In silico analysis of phosphoproteome data suggests a rich-get-richer process of phosphosite accumulation
over evolution. N. Yachie, R. Saito, J. Sugahara, M. Tomita,Y. Ishihama. Mol Cell Proteomics 8, 1061-71
(2009).
Ser/Thr/Tyr phosphoproteome analysis of pathogenic and non-pathogenic Pseudomonas species. A.
Ravichandran, N. Sugiyama, M. Tomita, S. Swarup,Y. Ishihama. Proteomics 9, 2764-75 (2009).
Chemical Cleavage-Assisted Tryptic Digestion for Membrane Proteome Analysis. M. Iwasaki, T. Masuda,
M. Tomita,Y. Ishihama. J Proteome Res 8, 3169-3175 (2009).
Identification of DNA-dependent Protein Kinase as a Cofactor for the Forkhead Transcription Factor
FoxA2. A. Nock, J.M. Ascano, T. Jones, M.J. Barrero, N. Sugiyama, M. Tomita, Y. Ishihama,S. Malik. J
Biol Chem 284, 19915-26 (2009).
Unbiased quantitation of Escherichia coli membrane proteome using phase transfer surfactants. T. Masuda,
N. Saito, M. Tomita,Y. Ishihama. Mol Cell Proteomics 8, 2770-7 (2009).
Successive and selective release of phosphorylated peptides captured by hydroxy acid-modified metal oxide
chromatography. Y. Kyono, N. Sugiyama, K. Imami, M. Tomita,Y. Ishihama. J Proteome Res 7, 4585-93
(2008).
LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11. K. Sagane, Y. Ishihama,H. Sugimoto. Int J
Biol Sci 4, 387-96 (2008).
High-efficiency liquid chromatographic separation utilizing long monolithic silica capillary columns. K.
Miyamoto, T. Hara, H. Kobayashi, H. Morisaka, D. Tokuda, K. Horie, K. Koduki, S. Makino, O. Nunez, C.
Yang, T. Kawabe, T. Ikegami, H. Takubo, Y. Ishihama,N. Tanaka. Anal Chem 80, 8741-50 (2008).
On-line selective enrichment and ion-pair reaction for structural determination of sulfated glycopeptides by
capillary electrophoresis-mass spectrometry. K. Imami, Y. Ishihama,S. Terabe. J Chromatogr A 1194,
237-42 (2008).
Aligning LC peaks by converting gradient retention times to retention index of peptides in proteomic
experiments. K. Shinoda, M. Tomita,Y. Ishihama. Bioinformatics 24, 1590-5 (2008).
Phase Transfer Surfactant-Aided Trypsin Digestion for Membrane Proteome Analysis. T. Masuda, M.
Tomita,Y. Ishihama. J Proteome Res 7, 731-740 (2008).
Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a
calcined titania/C18 biphasic column. K. Imami, N. Sugiyama, Y. Kyono, M. Tomita,Y. Ishihama. Anal Sci
24, 161-6 (2008).
Large-scale phosphorylation mapping reveals the extent of tyrosine phosphorylation in Arabidopsis. N.
Sugiyama, H. Nakagami, K. Mochida, A. Daudi, M. Tomita, K. Shirasu,Y. Ishihama. Mol Syst Biol 4, 193
(2008).
Protein abundance profiling of the Escherichia coli cytosol. Y. Ishihama, T. Schmidt, J. Rappsilber, M.
Mann, F.U. Hartl, M.J. Kerner,D. Frishman. BMC Genomics 9, 102 (2008).
Polymer Entrapment in Polymerized Silicate for Preparing Highly Stable Capillary Coatings for CE and
CE-MS. M.R. Monton, M. Tomita, T. Soga,Y. Ishihama. Anal Chem 79, 7838-44 (2007).
Splicing factor SF3b as a target of the antitumor natural product pladienolide. Y. Kotake, K. Sagane, T.
Owa, Y. Mimori-Kiyosue, H. Shimizu, M. Uesugi, Y. Ishihama, M. Iwata,Y. Mizui. Nat Chem Biol 3,
570-5 (2007).
Simple on-line sample preconcentration technique for peptides based on dynamic pH junction in capillary
electrophoresis-mass spectrometry. K. Imami, M.R. Monton, Y. Ishihama,S. Terabe. J Chromatogr A 1148,
250-5 (2007).
Enhancement of the efficiency of phosphoproteomic identification by removing phosphates after
phosphopeptide enrichment. Y. Ishihama, F.Y. Wei, K. Aoshima, T. Sato, J. Kuromitsu,Y. Oda. J Proteome
Res 6, 1139-44 (2007).
Phosphopeptide enrichment by aliphatic hydroxy acid-modified metal oxide chromatography for
nano-LC-MS/MS in proteomics applications. N. Sugiyama, T. Masuda, K. Shinoda, A. Nakamura, M.
Tomita,Y. Ishihama. Mol Cell Proteomics 6, 1103-9 (2007).
− 226 −
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using
StageTips. J. Rappsilber, M. Mann,Y. Ishihama. Nat Protoc 2, 1896-906 (2007).
Microelectrospray interface with coaxial sheath flow for high-resolution capillary electrophoresis/mass
spectrometry separation. M. Hashimoto, Y. Ishihama, M. Tomita,T. Soga. Rapid Commun Mass Spectrom
21, 3579-84 (2007).
Multiplexed two-dimensional liquid chromatography for MALDI and nanoelectrospray ionization mass
spectrometry in proteomics. H. Saito, Y. Oda, T. Sato, J. Kuromitsu, Y. Ishihama. J Proteome Res 5,
1803-7 (2006).
Simplified gradient generator for micro- and nano-liquid chromatography. K. Murata, N. Mano, N.
Asakawa,Y. Ishihama. J. Chromatogr. A 1123, 47-52 (2006).
A protein associated with toll-like receptor 4 (PRAT4A) regulates cell surface expression of TLR4. Y.
Wakabayashi, M. Kobayashi, S. Akashi-Takamura, N. Tanimura, K. Konno, K. Takahashi, T. Ishii, T.
Mizutani, H. Iba, T. Kouro, S. Takaki, K. Takatsu, Y. Oda, Y. Ishihama, S. Saitoh, K. Miyake. J Immunol
177, 1772-9 (2006).
Modular stop and go extraction tips with stacked disks for parallel and multidimensional Peptide
fractionation in proteomics. Y. Ishihama, J. Rappsilber,M. Mann. J Proteome Res 5, 988-94 (2006).
Effects of Phospholipid and Surface Pressure on Lipoprotein Lipase–Lipolysis of Triglyceride in
Monolayers. K. Nishitsuji, M. Nakano, S. Morita, T. Handa, Membrane 35, 30-36 (2010).
Thermodynamic and Kinetic Stability of Discoidal High-Density Lipoprotein Formation from
Phosphatidylcholine/Apolipoprotein A-I Mixture. M. Fukuda, M. Nakano, M. Miyazaki, T. Handa, J. Phys.
Chem. B 114, 8228-8234 (2010).
Static and Dynamic Characterization of Nanodiscs with Apolipoprotein A-I and Its Model Peptide. M.
Miyazaki, Y. Tajima, T. Handa, M. Nakano, J. Phys. Chem. B, 114 12376-12382 (2010).
Synthetic Pentapeptides Inhibiting Autophosphorylation of Insulin Receptor in a Non-ATP-Competitive
Mechanism. M. Kato, M. Abe, Y. Kuroda, M. Hirose, M. Nakano, T. Handa, J. Pept. Sci. 15, 327-336
(2009).
Useful Modified Cellulose Polymers as New Emulsifiers of Cubosomes. M. Uyama, M. Nakano, J.
Yamashita, T. Handa, Langmuir 25, 4336-4338 (2009).
Flip-Flop of Phospholipids in Vesicles: Kinetic Analysis with Time-Resolved Small-Angle Neutron
Scattering. M. Nakano, M. Fukuda, T. Kudo, N. Matsuzaki, T. Azuma, K. Sekine, H. Endo, T. Handa, J.
Phys. Chem. B 113, 6745-6748 (2009).
Static and Dynamic Properties of Phospholipid Bilayer Nanodiscs. M. Nakano, M. Fukuda, T. Kudo, M.
Miyazaki, Y. Wada, N. Matsuzaki, H. Endo, T. Handa, J. Am. Chem. Soc. 131, 8308-8312 (2009).
The Influence of Water on the Stability of Lyophilized Formulations with Inositol and Mannitol as
Excipients. A. Terakita, H. Matsunaga, T. Handa, Chem. Pharm. Bull. 57, 459-463 (2009).
Smaller Discoidal High-Density Lipoprotein Particles Form Saddle Surfaces, but Not Planar Bilayers. M.
Miyazaki, M. Nakano, M. Fukuda, T. Handa, Biochemistry 48, 7756-7763 (2009).
Inhibition of Autophosphorylation of Epidermal Growth Factor Receptor by a Small Peptide not Employing
an ATP-Competitive Mechanism. M. Abe, Y. Kuroda, M. Hirose, M. Kato, M. Murakami, Y. Watanabe, M.
Nakano, T. Handa, Biopolymers 89, 40-51 (2008).
Role of the N- and C-terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and
Dermatan Sulfate: A Surface Plasmon Resonance Study. Y. Yamauchi, N. Deguchi, C. Takagi, M.
Tanaka, P. Dhanasekaran, M. Nakano, T. Handa, M. C. Phillips, S. Lund-Katz, H. Saito, Biochemistry 47,
6702-6710 (2008).
Effect of Polymer Type on the Dissolution Profile of Amorphous Solid Dispersions Containing Felodipine.
H. Konno, T. Handa, D. E. Alonzo, L. S. Taylor, Eur. J. Pharm. Biopharm. 70, 493-499 (2008).
Conformational Change of Apolipoprotein A-I and HDL Formation from Model Membranes under
Intracellular Acidic Conditions. M. Fukuda, M. Nakano, M. Miyazaki, M. Tanaka, H. Saito, S. Kobayashi,
M. Ueno, T. Handa, J. Lipid Res. 49, 2419-2426 (2008).
Cytotoxicity of Lipid-Free Apolipoprotein B. S. Morita, Y. Deharu, E. Takata, M. Nakano, T. Handa,
Biochim. Biophys. Acta 1778, 2594-2603 (2008).
Spontaneous Reconstitution of Discoidal HDL from Sphingomyelin-Containing Model Membranes by
Apolipoprotein A-I. M. Fukuda, M. Nakano, S. Sriwongsitanont, M. Ueno, Y. Kuroda, T. Handa, J. Lipid
Res. 48, 882-889 (2007).
Determination of Interbilayer and Transbilayer Lipid Transfers by Time-Resolved Small-Angle Neutron
Scattering. M. Nakano, M. Fukuda, T. Kudo, H. Endo, T. Handa, Phys. Rev. Lett. 98, 238101 (2007).
Bile Salt–Dependent Efflux of Cellular Phospholipids Mediated by ATP Binding Cassette Protein B4. S.
Morita, A. Kobayashi, Y. Takanezawa, N. Kioka, T. Handa, H. Arai, M. Matsuo, K. Ueda, Hepatology 46,
188-199 (2007).
− 227 −
53.
54.
55.
56.
57.
58.
59.
60.
61.
Novel Action of Apolipoprotein E (ApoE): ApoE Isoform Specifically Inhibits Lipid-Particle-Mediated
Cholesterol Release from Neurons. J-S. Gong, S. Morita, M. Kobayashi, T. Handa, S. C. Fujita, K.
Yanagisawa. M. Michikawa, Molecular Neurodegeneration 2:9 (2007).
Interaction of an Amphipathic Peptide with Phosphatidycholine/Phosphatidylethanolamine Mixed
Membranes. K. Shintou, M. Nakano, T. Kamo, Y. Kuroda, T. Handa, Biophys. J. 93, 3900-3906 (2007).
Inhibition of Autophosphorylation of Epidermal Growth Factor Receptor by Small Peptides in vitro. M.
Abe, Y. Kuroda, M. Hirose, Y. Watanabe, M. Nakano, T. Handa, Br. J. Pharmacol. 147, 402-411 (2006).
Local Anesthetics Suppress Nerve Growth Factor-Mediated Neurite Outgrowth by Inhibition of Tyrosine
Kinase Activity of TrkA. M. Takatori, Y. Kuroda, M. Hirose, Anesth. Analg. 102, 462-467 (2006).
The Antiproliferative Effect of Lidocaine on Human Tongue Cancer Cells with Inhibition of the Activity of
Epidermal Growth Factor Receptor. M. Sakaguchi, Y. Kuroda, M. Hirose, Anesth. Analg. 102, 1103-1107
(2006).
Application of Tri- and Tetrasubstituted Alkene Dipeptide Mimetics to Conformational Studies of Cyclic
RGD Peptides. S. Oishi, K. Miyamoto, A. Niida, M. Yamamoto, K. Ajito, H. Tamamura, A. Otaka, Y.
Kuroda, A. Asai, N. Fujii, Tetrahedron 62, 1416-1424 (2006).
Effect of Formulated Ingredients on Rapidly Disintegrating Oral Tablets Prepared by the Crystalline
Transition Method. M. Sugimoto, S. Narisawa, K. Matsubara, H. Yoshino, M. Nakano, T. Handa, Chem.
Pharm. Bull. 54, 175-180 (2006).
Development of Manufacturing Method for Rapidly Disintegrating Oral Tablets Using the Crystalline
Transition of Amorphous Sucrose. M. Sugimoto, S. Narisawa, K. Matsubara, H. Yoshino, M. Nakano, T.
Handa, Int. J. Pharm. 320, 71-78 (2006).
Effects of an Amphipathic Į-Helical Peptide on Lateral Pressure and Water Penetration in
Phosphatidylcholine and Monoolein Mixed Membranes. T. Kamo, M. Nakano, Y. Kuroda, T. Handa, J.
Phys. Chem. B 110, 24987-24992 (2006).
㸦⥲ㄝ㸧
1. ᾮయࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮㉁㔞ศᯒἲ(LC-MS)࡟ࡼࡿࢱࣥࣃࢡ㉁኱つᶍゎᯒ. ▼℈Ὀ. ໬Ꮫ࡜ᕤᴗ 63,
796-7 (2010).
2. ࣉࣟࢸ࣑࢜ࢡࢫ LC-MS ࢩࢫࢸ࣒ࡢ᪂ᒎ㛤. ▼℈Ὀ. ࣇ࢓࣐ࣝࢩ࢔ 46, 1130-34 (2010).
3. Development of Dual Stable Isotope Labeling by Amino Acids in Cell Culture and Application to Quantitative
Proteomics. K. Imami, M. Tomita, Y. Ishihama. J. Mass Spectrom. Soc. Jpn. 58, 81-87 (2010).
4. Sample Preparation Methods for Large-Scale Analysis of Membrane Proteins Using Shotgun Proteomics. T.
Masuda, Y. Ishihama. J. Mass Spectrom. Soc. Jpn. 57, 145-151 (2009).
5. Informatics for peptide retention properties in proteomic LC-MS. K. Shinoda, M. Sugimoto, M. Tomita, Y.
Ishihama. Proteomics 8, 787-98 (2008).
6. Development of solid phase extraction mini-columns for proteome analysis. Y. Ishihama. BUNSEKI KAGAKU
57, 1011-18 (2008).
7. ࣉࣟࢸ࣑࢜ࢡࢫ࡟࠾ࡅࡿࢼࣀ LC-MS ࢩࢫࢸ࣒ Y. Ishihama. Chromatography 29, 25-31 (2008).
8. ⣽⬊ෆࢩࢢࢼࣝఏ㐩ࢩࢫࢸ࣒࡟࠾ࡅࡿศᏊᣲືࠊ▼℈Ὀࠊ111, 578-81 (2008).
9. ࢩࢢࢼࣝఏ㐩ࣉࣟࢸ࣮࣒࢜ࡢ᭱๓⥺. Y. Ishihama, N. Sugiyama. Pharma VISION NEWS 12, 29-34 (2008).
10. Optimization of Nano-Liquid Chromatography Coupled with Mass Spectrometry for Proteomics. Y. Ishihama. J.
Mass Spectrom. Soc. Jpn. 55, 157-164 (2007).
㟼ⓗ࣭ືⓗᵓ㐀ホ౯࡟ࡼࡿ⏕య⬡㉁」ྜయᙧᡂᶵᵓࡢゎ᫂㸬୰㔝ᐇ㸪<DNXJDNX=DVVKL
࢔࣏࣏ࣜࢱࣥࣃࢡѸ ⬡㉁⭷┦஫స⏝࡟ࡼࡿࢹ࢕ࢫࢡ≧」ྜయᙧᡂ࡜㧗ᐦᗘ࣏ࣜࢱࣥࣃࢡ㉁ᙧᡂཎ
⌮ࡢ⪃ᐹ㸬୰㔝ᐇ㸬<DNXJDNX=DVVKL
6$168 ࢆ౑ࡗࡓ⬡㉁ࡢ࣋ࢩࢡࣝ㛫⛣ືࡢ◊✲㸬୰㔝ᐇ㸪Ἴ⣠
⮬Ⓨⓗ +'/ ᵝ⢏Ꮚᙧᡂ࡟࠾ࡅࡿ⭷ᵓ㐀ࡢᙳ㡪㸬୰㔝ᐇ㸪⭷
㠀஧ศᏊ⭷ᵓ㐀ࢆ᭷ࡍࡿ⬡㉁ᚤ⢏Ꮚࡢ๰ᡂ࡜ࡑࡢᵓ㐀ホ౯࡟㛵ࡍࡿ◊✲㸬୰㔝ᐇ㸪⭷
㸦⦅᭩㸧
ࣉࣟࢸ࣑࢜ࢡࢫࡀゎࡁ᫂࠿ࡍ᝟ሗఏ㐩ࢿࢵࢺ࣮࣡ࢡ ᭹㒊ᡂ௓▼℈Ὀ⦅ᐇ㦂་Ꮫ ᭶ྕ
⨺ᅵ♫ᮾி
㸦ⴭ᭩㸧
ࣜࣥ㓟໬ࢱࣥࣃࢡ㉁ࡢ⥙⨶ⓗゎᯒྜྷཎᏹᶞ▼℈Ὀࣉࣟࢸ࣑࢜ࢡࢫ⑓⌮࡜ࡢ㛵ࢃࡾ⑓⌮
࡜⮫ᗋࠊᒣ⏣ဴྖ⦅ศගᇽᮾிSS
− 228 −
᳜≀ࣜࣥ㓟໬ࣉࣟࢸ࣮࣒࢜ゎᯒࡢ᭱๓⥺୰⚄ᘯྐᮡᒣ┤ᖾ▼℈Ὀ᳜≀࡟࠾ࡅࡿࢩࢢࢼࣝ
◊✲ࡢ᪂ᒎ㛤ᰠᮏ㎮⏨㧗ᒣㄔྖ⚟⏣⿱✑ᯇᒸಙ ⦅ ඹ❧ฟ∧ᮾிSS
⩻ヂᚋಟ㣭ࣉࣟࢸ࣑࢜ࢡࢫࡢ᭱๓⥺ி㔝᏶ᮡᒣ┤ᖾ▼℈Ὀࣉࣟࢸ࣑࢜ࢡࢫࡀᣅࡃ་Ꮫ⏕≀
Ꮫࡢ᪂ᆅᖹ⣽⬊ᕤᏛࠊ୰ᒣᩗ୍ᯇᮏ㞞グ⦅Ꮫ◊࣓ࢹ࢕࢝ࣝ⚽₶♫ᮾிSS
ࣜࣥ㓟໬ࣉࣟࢸ࣮࣒࢜ゎᯒ࡟ࡼࡿศᏊᶆⓗ⸆ホ౯ᮡᒣ┤ᖾ▼℈Ὀࣉࣟࢸ࣑࢜ࢡࢫࡀゎࡁ᫂
࠿ࡍ᝟ሗఏ㐩ࢿࢵࢺ࣮࣡ࢡ᭹㒊ᡂ௓▼℈Ὀ⦅ᐇ㦂་Ꮫ ᭶ྕ ⨺ᅵ♫ᮾி9ROSS
࣓ࢱ࣑࣎ࣟࢡࢫࠊࣉࣟࢸ࣑࢜ࢡࢫࡢࡓࡵࡢࢼࣀ /&06 ࢩࢫࢸ࣒▼℈Ὀ࣓ࢱ࣑࣎ࣟࢡࢫࡢඛ➃
ᢏ⾡࡜ᛂ⏝⚟ᓮⱥ୍㑻 ⦅ࢩ࣮࢚࣒ࢩ࣮ฟ∧ᮾிSS
ࣉࣟࢸ࣮࣒࢜◊✲ࢆᡂຌࡉࡏࡿヨᩱㄪ〇࡜ゎᯒἲ ࢔ࣇ࢕ࢽࢸ࢕࣮ࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮࡟࠾ࡅࡿ
≉␗ᛶࡢホ౯࡟ࡘ࠸࡚▼℈Ὀ⏣⏿๛ᑠ⏣ྜྷဢࣂ࢖࢜ࢸࢡࣀࣟࢪ࣮ࢪ࣮ࣕࢼࣝᑠ⏣ྜྷဢ
⦅⨺ᅵ♫ᮾி9ROSS
ࣉࣟࢸ࣑࢜ࢡࢫࡢ⣽⬊ᶵ⬟ゎᯒ࡬ࡢᣮᡓ ▼℈Ὀᑠ⏣ྜྷဢ⬻ᶵ⬟ゎ᫂࡟ྥࡅࡓࣉࣟࢸ࣮࣒࢜
◊✲⣽⬊ᕤᏛࠊ♒㎶ಇ᫂㧗ᶫಙᘯ⦅⚽₶♫ᮾி9ROSS
࣮࢟ࣗ࣎ࢯ࣮࣒ࡢㄪ〇ἲ࡜ᛂ⏝㸬୰㔝ᐇ㸪ᅜṊ㇏႐┘ಟ㉸ศᏊࢧ࢖࢚ࣥࢫࢸࢡࣀࣟࢪ࣮࢚ࢾ࣭
ࢸ࢕࣮࣭࢚ࢫSS
⬡㉁࢚࣐ࣝࢩࣙࣥ㸦⾑₢࣏ࣜࢱࣥࣃࢡ㉁ࡢᛶ㉁࡜ᶵ⬟㸧㸬༙⏣ဴ㑻㸪ྂ⃝㑥ኵ┘ಟ᪂ࡋ࠸ศᩓ࣭
ங໬ࡢ⛉Ꮫ࡜ᛂ⏝ᢏ⾡ࡢ᪂ᒎ㛤ࢸࢡࣀࢩࢫࢸ࣒SS
ࢫࢱࣥࢲ࣮ࢻ⸆Ꮫࢩ࣮ࣜࢬ㸰≀⌮⣔⸆Ꮫ ,,,6%2㸬༙⏣ဴ㑻㸪୰㔝ᐇ㸪᪥ᮏ⸆Ꮫ఍⦅ᮾி
໬ᏛྠேSS
− 229 −
⢭ᐦ᭷ᶵྜᡂ໬Ꮫศ㔝
ᩍᤵ㸦⸆Ꮫ༤ኈ㸧ᕝ➃⊛ኵ㸦࠿ࢃࡤࡓ ࡓࡅ࠾㸧
᫛࿴㸳㸱ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸳㸶ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧ᳺ ୍඾㸦ࡘࡤࡁ ࠿ࡎࡢࡾ㸧
㸰㸮㸮㸶ᖺ㸲᭶ி㒔ᗓ❧኱Ꮫ⏕࿨⎔ቃᏛ㒊ᩍᤵ࡟㌿௵
᫛࿴㸴㸰ி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸯ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧ྂ⏣ ᕦ㸦ࡩࡿࡓ ࡓࡃࡳ㸧
㸰㸮㸮㸶ᖺ㸲᭶㟼ᒸ┴❧኱Ꮫ⸆Ꮫ㒊ຓᩍࡼࡾ᪼௵ࠊ
ᖹᡂ㸳ᖺᒸᒣ኱Ꮫ༞ࠊᖹᡂ㸯㸮ᖺி㒔኱Ꮫ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
ຓᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧ྜྷᮧ ᬛஅ㸦ࡼࡋࡴࡽ ࡜ࡶࡺࡁ㸧(2007.4 ᪼௵)ࠊ
ᖹᡂ㸯㸯ᖺᚨᓥ኱Ꮫ༞ࠊᖹᡂ㸯㸵ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
ᩍົ⫋ဨ㸦༤ኈ㸦⸆Ꮫ㸧
㸧ྜྷᮧ ᬛஅ㸦ࡼࡋࡴࡽ ࡜ࡶࡺࡁ㸧(2005.12 ╔௵)ࠊ
ᖹᡂ㸯㸯ᖺᚨᓥ኱Ꮫ༞ࠊᖹᡂ㸯㸵ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
ᙜ◊✲ᐊ࡛ࡣ≀㉁๰〇ࡢ᪉ἲㄽ㛤ᣅ࡟㛵ࡍࡿ௨ୗࡢ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ
㸦㸯㸧ືⓗ୙ᩧไᚚ㸸㏻ᖖ࢟ࣛࣜࢸ࢕࣮ࢆᣢࡓ࡞࠸࡜⪃࠼ࡽࢀࡿ᭷ᶵศᏊࡸ཯ᛂ୰㛫యࡶ༢఩᫬㛫ෆ࡟
ࡣ࢟ࣛࣝ࡞ศᏊ✀࡜ࡋ࡚Ꮡᅾࡍࡿ㸦ືⓗ୙ᩧ㸧ࠋ࢚ࣀ࣮ࣞࢺᵓ㐀ࡢᣢࡘືⓗ୙ᩧࢆ฼⏝ࡍࡿ࡜ᚑ᮶ࡢ୙
ᩧྜᡂࡢ࢝ࢸࢦ࣮ࣜ࡟ࡣ࡞࠿ࡗࡓ୙ᩧグ᠈ᆺ཯ᛂࡀྍ⬟࡟࡞ࡿࠋࡇࡢ᪉ἲࢆ⏝࠸࡚᪂つ࢔࣑ࣀ㓟ࡸ᪂ࡋ
࠸㦵᱁ࢆᣢࡘྵ❅⣲」⣲⎔ࠊࡉࡽ࡟㸲⨨᥮Ⅳ⣲ྵ᭷⏕⌮άᛶኳ↛≀ࡢྜᡂࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓ࢚࢟ࣛࣝ
ࣀ࣮ࣞࢺ୰㛫యࡢᑑ࿨ࡢไᚚࠊ;⥺ᵓ㐀ゎᯒࠊᶵᵓゎ᫂࡟ྥࡅࡓ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ
㸦㸰㸧᭷ᶵゐ፹㸸㔠ᒓࢆྵࡲࡎ ࿴࡞᮲௳ୗ࡛ാࡃ᭷ᶵゐ፹ࡣ⎔ቃㄪ࿴ᆺ཯ᛂࣉࣟࢭࢫ㛤ᣅ࡟᭷ᮃ࡛࠶
ࡿࠋ㐲㝸୙ᩧㄏᑟࢆᇶ┙࡜ࡍࡿゐ፹タィ࡟ࡼࡾࠊ㧗άᛶࠊ㧗㑅ᢥⓗ࡞᭷ᶵゐ፹㛤Ⓨࢆ┠ᣦࡋ࡚࠸ࡿࠋࡇ
ࢀࡲ࡛࡟࢔ࣝࢥ࣮ࣝ㢮ࡢ୙ᩧ࢔ࢩࣝ໬ゐ፹ࠊࡲࡓ↓ಖㆤ⢾ࡢ఩⨨㑅ᢥⓗᐁ⬟ᇶ໬ゐ፹ࢆ㛤Ⓨࡋ࡚࠸ࡿࠋ
⌧ᅾࡉࡽ࡟ࠊ✀ࠎࡢከᐁ⬟ᇶᛶ໬ྜ≀ࡢ఩⨨㑅ᢥⓗ࡞ᐁ⬟ᇶ໬㸦࢔ࢩࣝ໬ࠊࢺࢩࣝ໬ࠊࣜࣥ㓟໬ࠊ㓟໬㸧
࡬ࡢᒎ㛤ࡀ㐍⾜୰࡛࠶ࡿࠋ
㸦㸱㸧᪂つ㍈ᛶ୙ᩧ໬ྜ≀ࡢ๰〇㸸Ỉ⣲⤖ྜ࡟ࡼࡾ࢟ࣛࣜࢸ࢕࣮ࡀಖᣢࡉࢀࡿ᪂つ࡞㍈ᛶ୙ᩧ໬ྜ≀ࡢ
๰〇࡟ᡂຌࡋࡓࠋ⌧ᅾࠊᮏ໬ྜ≀ࢆ⏝࠸ࡿ୙ᩧ཯ᛂ࡬ࡢᒎ㛤ࡀ㐍⾜୰࡛࠶ࡿࠋ
㸦㸲㸧࢟ࣛࣝࣘࢽࢵࢺࡢ㞟✚ຠᯝ㸸࢟ࣛࣝࣘࢽࢵࢺࡢ㞟✚࡟ࡼࡿ㧗ḟᵓ㐀ไᚚࠊᶵ⬟㛤Ⓨࢆ┠ⓗ࡜ࡋࡓ
◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ'/ᆺ࢜ࣜࢦ࢚ࢫࢸࣝࡸ '/ᆺ࢜ࣜࢦ࣌ࣉࢳࢻࡢᵓ㐀ࠊᶵ⬟≉ᛶ࡟㛵ࡍࡿ◊✲ࠊ'/
ᆺ࢜ࣜࢦ࣌ࣉࢳࢻࢆᇶᮏ㦵᱁࡜ࡍࡿศᏊㄆ㆑ᆺゐ፹ࡢ㛤Ⓨࢆ⾜ࡗ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ఍άືࢆᴟࡵ࡚άⓎ࡟⾜࡞ࡗ࡚࠸ࡿࠋ኱Ꮫ㝔⏕ࡢᏛ఍Ⓨ⾲௳ᩘࡣẖᖺ㸰㸳௳ࢆ㉺࠼ࠊ㸰㸮㸯㸮ᖺ࡟
ࡣ㸲㸯௳࡟㐩ࡋࡓࠋࡇࡢ㛫ẖᖺࡢࡼ࠺࡟኱Ꮫ㝔⏕ࡀᏛ఍࡛ࡢ㈹ࢆཷ㈹ࡋ࡚࠸ࡿࠋ㸰㸮㸮㸴ᖺ࡟ࡣ᳃ᒣඞ
ᙪಟኈ࠾ࡼࡧ㡲Ụ኱㍜Ꮫኈࡀࠊࡑࢀࡒࢀ➨㸰㸱ᅇ᭷ᶵྜᡂࢭ࣑ࢼ࣮࣏ࢫࢱ࣮㈹࠾ࡼࡧ➨㸰㸯ᅇࢩࢡࣟࣇ
࢓᳨ࣥウ఍࣏ࢫࢱ࣮㈹ࢆཷ㈹ࡋࡓࠋࡲࡓᕝ➃⊛ኵᩍᤵࡀ 7HWUDKHGURQ/HWWHUV0RVW&LWHG3DSHU
$ZDUG ࢆཷ㈹ࡋࡓࠋ㸰㸮㸮㸵ᖺ࡟ࡣ௒ᮧὒᏊᏛኈࠊᮧᯇ΅ಟኈࠊ཭ཎၨ௓Ꮫኈࠊ᳃ᒣඞᙪಟ
ኈࠊ࠾ࡼࡧ㧗▼࿴ேಟኈࡀࠊࡑࢀࡒࢀ➨㸯ᅇ᭷ᶵȧ㟁Ꮚ⣔ࢩ࣏ࣥࢪ࣒࣏࢘ࢫࢱ࣮㈹ࠊ➨㸯㸮㸵ᅇ໬Ꮫ◊
✲ᡤ◊✲Ⓨ⾲఍Ꮫ⏕◊✲㈹ࠊ➨㸰㸵ᅇ᭷ᶵྜᡂⱝᡭࢭ࣑ࢼ࣮࣏ࢫࢱ࣮㈹ࠊ➨㸷㸰ᅇ᭷ᶵྜᡂࢩ࣏ࣥࢪ࢘
࣒࣏ࢫࢱ࣮㈹ࠊ࠾ࡼࡧ➨㸰ᅇ࣍ࢫࢺ࣭ࢤࢫࢺ໬Ꮫࢩ࣏ࣥࢪ࣒࣏࢘ࢫࢱ࣮㈹ࢆཷ㈹ࡋࡓࠋ㸰㸮㸮㸶ᖺ࡟ࡣ
௒ᮧὒᏊᏛኈࡀ➨㸰ᅇ᭷ᶵȧ㟁Ꮚ⣔ࢩ࣏ࣥࢪ࣒࣏࢘ࢫࢱ࣮㈹ࢆࠊ㸰㸮㸮㸷ᖺ࡟ࡣᏱ␃㔝⩏἞ಟኈࡀ➨㸰
㸷ᅇ᭷ᶵྜᡂⱝᡭࢭ࣑ࢼ࣮࣏ࢫࢱ࣮㈹ࠊ➨㸱㸷ᅇ」⣲⎔໬Ꮫウㄽ఍Ꮫ⏕ㅮ₇㈹ࠊࡉࡽ࡟➨㸳ᅇ࣍ࢫࢺ࣭
ࢤࢫࢺ໬Ꮫࢩ࣏ࣥࢪ࣒࣏࢘ࢫࢱ࣮㈹ࢆཷ㈹ࡋࡓࠋࡲࡓ㸰㸮㸯㸮ᖺ࡟ࡣྜྷ⏣ᆂభಟኈࡀ➨㸲㸮ᅇ」⣲⎔໬
Ꮫウㄽ఍࣏ࢫࢱ࣮㈹ࢆཷ㈹ࡋ࡚࠸ࡿࠋᕝ➃⊛ኵᩍᤵࡣ㸰㸮㸮㸴ᖺ௨㝆ࠊ࢔࣓ࣜ࢝໬Ꮫ఍ࡸ
3DFLIL&KHP ࡞࡝ࡢᅜ㝿Ꮫ఍࡛㸯㸮ᅇ௨ୖᣍᚅㅮ₇ࢆ⾜࡞ࡗ࡚࠸ࡿࠋࡲࡓࠊẖ᪥እᅜ࠿ࡽ༤ኈ◊✲ဨ
− 230 −
ᕼᮃࡢၥ࠸ྜࢃࡏࡀ࠶ࡾࠊᖖ᫬㸰ྡ௨ୖࡢእᅜேඹྠ◊✲⪅ࡀᅾ⡠ࡋ࡚࠸ࡿࡇ࡜ࡶᅜෆእ࡛ᙜㅮᗙࡢ◊
✲ࡀ㧗ࡃホ౯ࡉࢀ࡚࠸ࡿࡇ࡜ࢆ♧ࡋ࡚࠸ࡿࠋ
ᩍ⫱ࡢᴫせ
ᇶ♏◊✲ࢆ㐙⾜࡛ࡁࡿᇶᮏⓗ࡞ᢏ⾡࡜▱㆑ࢆ㌟࡟ࡘࡅࡿࡇ࡜ࠊ▱㆑ࡢࡓࡵࡢ▱㆑࡛ࡣ࡞ࡃ◊✲ୖࡢၥ
㢟ⅬゎỴࡢࡓࡵࡢ▱㆑࡜ࡋ࡚ࠊࡲࡓ᪂ࡓ࡞Ⓨ᝿࡟ࡘ࡞ࡀࡿ▱㆑࡜ࡋ࡚ά࠿ࡏࡿࡼ࠺ᣦᑟࡋ࡚࠸ࡿࠋ◊✲
ᐊ࡛ࡢඹྠసᴗࢆ㏻ࡌ࡚༠ㄪᛶࢆᏛࡧࡘࡘ◊✲ࡢ⊂⮬ᛶࢆᑛ㔜ࡍࡿẼ㢼ࡶ኱ษ࡟ࡋ࡚࠸ࡿࠋ኱Ꮫ㝔ಟ஢
⪅ࡣ㧗ᗘ࡞ᑓ㛛▱㆑࡜⬟ຊࢆᣢࡕࠊ⮬㈇ᚰ࡜άຊࢆࡶࡗ࡚♫఍ⓗせㄳ࡟⟅࠼ࡽࢀࡿேᮦ࡟⫱ᡂࡋࡓ࠸࡜
㢪ࡗ࡚࠸ࡿࠋࡲࡓᖖ᫬ᅾ⡠ࡍࡿእᅜேඹྠ◊✲⪅࡜✚ᴟⓗ࡟᥋ࡍࡿᶵ఍ࢆᣢࡘࡇ࡜࡛ࠊᏛ⏕㐩ࡀど㔝ࢆ
ᗈࡆࢳࣕࣞࣥࢪ⢭⚄ࢆ㣴࠼ࡿࡼ࠺ࠊྠ᫬࡟ⱥ఍ヰ࡟ぶࡋࡵࡿࡼ࠺⎔ቃ㐀ࡾ࡟໅ࡵ࡚࠸ࡿࠋẖ㐌ࠊ᭱᪂ᩥ
⊩ࡢ⤂௓࡜ウ㆟ࠊ኱Ꮫ㝔ࣞ࣋ࣝࡢⱥᩥᩍ⛉᭩ࡢ㍯ㄞࢆ⾜࡞࠸ࠊ▱㆑ࡢ⩦ᚓ࡜㆟ㄽࡢ⤌❧࡚ࢆカ⦎ࡋ࡚࠸
ࡿࠋᐇ㦂⤖ᯝࡢሗ࿌఍ࡣẖ㐌⾜࠸ࠊ◊✲ࡢ㐍ࡵ᪉ࠊၥ㢟ⅬゎỴࡢ᪉⟇ࢆᏛࢇ࡛࠸ࡿࠋࡇࡢ㝿ࠊ⮬ศ௨እ
ࡢ◊✲ࢸ࣮࣐࡟ࡘ࠸࡚ࡶពぢ஺᥮ࢆ⾜࠸どⅬࡀ೫ࡽ࡞࠸ࡼ࠺ᚰ᥃ࡅ࡚࠸ࡿࠋ㸱ࢣ᭶࡟୍ᗘࡢ◊✲࣏࣮ࣞ
ࢺࢆྛ⮬ࡀᥦฟࡋࠊᩥ❶࡛ᴗ⦼ࢆ⾲⌧ࡍࡿカ⦎ࢆ⾜࡞ࡗ࡚࠸ࡿ ࠋࡇࡢ࣏࣮ࣞࢺࡣࡲࡓ◊✲ࡢᒎᮃࡸព
⩏ࢆ⪃࠼ࡿᶵ఍࡜ࡶ࡞ࡾࠊ᪂ࡓ࡞◊✲ィ⏬ࢆᥦ᱌ࡍࡿࡇ࡜ࡶ᥎ዡࡋ࡚࠸ࡿࠋࡉࡽ࡟ᖺ୍ᅇ኱Ꮫ㝔⏕඲ဨ
ࡀ㸱㸮ศࡢㅮ₇ࢆࡍࡿ◊✲ᐊྜᐟࢭ࣑ࢼ࣮ࢆ⾜࡞ࡗ࡚࠸ࡿࠋࡇࢀࡣࠊ⮬ศ⮬㌟ࡢ◊✲ࢆぢ┤ࡋࠊ௚ࡢ◊
✲࡟ࡶࡌࡗࡃࡾ࡜ࡩࢀࠊ⮬⏤࡞ពぢ஺᥮ࢆ⾜࡞࠺ࡇ࡜࡛ࠊ㝔⏕㐩ࡢ◊✲⪅࡜ࡋ࡚ࡢ⮬㈇࡜⮬❧ᚰࠊࡑࡋ
࡚ᗈ࠸ど㔝ࢆ㣴࠺ᶵ఍࡜ࡋ࡚࠸ࡿࠋࡲࡓࠊࡇࡢࢭ࣑ࢼ࣮ྜᐟ࡛ࡣ᪥ᖖࡢ◊✲ᐊ࡛ࡢ◊✲⏕ά࠿ࡽࡣᚓࡽ
ࢀ࡞࠸ேⓗ஺ὶࢆィࡿࡇ࡜ࡶ኱ษ࡞┠ⓗࡢࡦ࡜ࡘ࡛࠶ࡿࠋࡲࡓࠊ༤ኈㄢ⛬Ꮫ⏕ࡢᾏእ▷ᮇ␃Ꮫࡶ✚ᴟⓗ
࡟ዡࡵ࡚࠾ࡾࠊ㸰㸮㸮㸶ᖺ࡟ࡣΏ㑔ಇⱥಟኈࡀ⡿ᅜ࣌ࣥࢩࣝࣂࢽ࢔኱Ꮫ࡟ࠊ㸰㸮㸮㸷ᖺ࡟ࡣᯘ୍ᗈಟኈ
ࡀࢫ࢖ࢫࡢࢫ࢖ࢫ㐃㑥ᕤ⛉኱Ꮫ࡟ࠊ㸰㸮㸯㸮ᖺ࡟ࡣ཭ཎၨ௓ಟኈࡀⱥᅜࢣࣥࣈࣜࢵࢪ኱Ꮫ࡟ࡑࢀࡒࢀ㸰
ࠥ㸱ࣨ᭶㛫␃Ꮫࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᅾ⡠ࡍࡿᏛ⏕ࡢ࡯࡜ࢇ࡝඲ဨࡀẖᖺᏛ఍Ⓨ⾲ࢆ⾜࡞࠼ࡿᡂᯝࢆ࠶ࡆࠊ኱Ꮫ㝔ಟ஢⪅ࡢ࡯࡜ࢇ࡝ࡀᕼᮃ
ࡍࡿ◊✲⫋࡟ᑵ࠸࡚࠸ࡿࠋ㸰㸮㸮㸴ᖺ࠿ࡽ㸰㸮㸯㸮ᖺᗘࡢ༞ᴗ⏕ࡣ㸯㸱ேࡀ࣓࣮࣮࢝ࡢ◊✲⫋࡟ᑵࡁࠊ
㸴ேࡀබⓗᶵ㛵ࡢ◊✲⪅㸦኱Ꮫຓᩍ㸳ྡࠊ◊✲ဨ㸯ྡ㸧࡜ࡋ࡚⌧ᅾά㌍୰࡛࠶ࡿ㸦௚ࠊ⸆ᒁ㸰ྡ㸧ࠋࡲ
ࡓᙜ◊✲ᐊ࡛༤ኈ◊✲ဨࢆ⾜ࡗࡓእᅜே◊✲⪅ࡀ㸲ྡ᪥ᮏࡢ኱ᡭ௻ᴗ࡟ᑵ⫋ࡋ࡚࠸ࡿࠋࡇࢀࡣ◊✲࡜ᩍ
⫱ࡢᡂᯝࡀ♫఍ⓗ࡟ཷࡅධࢀࡽࢀホ౯ࡉࢀࡓ⤖ᯝ࡛࠶ࡿ࡜ྠ᫬࡟ࠊᏛ⏕㐩ࡢ◊✲άື࡬ࡢ᝟⇕ࡸពḧࡀ
ᙜㅮᗙࡢ㞺ᅖẼࡢ୰࡛ᇵࢃࢀࡓ⤖ᯝ࡜⪃࠼ࡽࢀࠊᩍ⫱ホ౯ࡣ㧗࠸ࠋ
㸦ཎⴭ㸧
1.
2.
3.
4.
5.
6.
7.
Sterechemical Diversity in Asymmetric Cyclization via Memory of Chirality.
Kawabata, T.; Matsuda, S.; Kawakami, S.; Monguchi, D.; Moriyama, K.
J. Am. Chem. Soc. 2006, 128, 15394-15395.
Synthesis of Chiral 1,2-Dihydropyridines and 2,3,4-Trisubstituted Pyridines from a-Amino Acids
Monguchi, D.; Majumdar, S.; Kawabata, T.
Heterocycles. 2006, 68, 2571-2578.
Bidirectional and Colorimetric Recognition of Sodium and Potassium Ions
Tsubaki, K.: Tanima, D.; Kuroda, Y.; Fuji, K.; Kawabata, T.
Org. Lett. 2006, 8, 5797-5800.
Suzuki-Miyaura Coupling on the Three Upper Rims of Hexahomotrioxacalix[3]arenes.
Tsubaki, K.; Sakakibara, M.; Nakatani, Y.; Kawabata, T.
Tetrahedron. 2006, 62, 10321-10324.
Total Synthesis of (+)-Lasonolide A
Yoshimura, T.; Yakushiji, F.; Kondo, S.; Wu, X.; Shindo, M.; Shishido, K.
Org. Lett. 2006, 8, 475-478.
Bottom-Up Synthesis of Optically Active Oligonaphthalenes: Three Different Pathways for Controlling Axial Chirality.
Tsubaki, K.; Tanaka, H.; Takaishi, K.; Miura, M.; Morikawa, H.; Furuta, T.; Tanaka, K.; Fuji, K.; Samamori,
T.; Tokitoh, N.; Kawabata, T.
J. Org. Chem. 2006, 71, 6579-6587.
Synthesis and Optical Properties of the Helical Oligonaphthalenes.
Long-Range Exciton-Coupled Circular Dichroism: Application for Determination of Absolute Configuration
of Oligonaphthalenes.
− 231 −
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
Tsubaki, K.; Takaishi, K.; Tanaka, H.; Miura, M.; Kawabata, T.
Org. Lett. 2006, 8, 2587-2590.
Optical Properties of Oligo(2,3-dioxyfunctionalized)naphthalenes
Tsubaki, K.; Miura, M.; Nakamura, A.; Kawabata, T.;
Tetrahedron Letters, 2006, 47, 1241-1244.
Use of Zinc Enolate, Free from Other Metals, in Enantioselective Palladium-catalyzed Allylic Alkylation.
Kinoshita, N.; Kawabata, T.; Tsubaki, K.; Bando, M.; Fuji, K.
Tetrahedron, 2006, 62, 1756-1763.
Homochiral Helices of Oligonaphthalenes Inducing Opposite-Handed Cholesteric Phases
Silvia Pieraccini, Alberta Ferrarini, Kaoru Fuji, Giovanni Gottarelli, Stefano Lena, Kazunori Tsubaki, Gian
Piero Spada
Chemistry - A European Journal, 2006, 12, 1121-1126.
A Catalytic One-Step Process for the Chemo- and Regioselective Acylation of Carbohydrates.
Kawabata, T. Muramatsu, W. Nishio, T. Shibata, T. Schedel, H.
J. Am Chem Soc. 2007, 129, 12890-12895.
Regioselective acylation of 6-O-protected octyl beta-D-glucopyranosides by DMAP catalysis
Muramatsu, W. Kawabata, T.
Tetrahedron Lett., 2007, 48, 5031-5033.
Synthesis and Properties of the Chiral Oligonaphthalenes.
Tsubaki, K.
Organic & Biomolecular Chemistry. 2007, 5, 2179-2188.
Synthesis of chiral 2,2'-dimethyl-1,1'-binaphthyl-8,8'-diamine and barriers of atropisomerization of the related binaphthyls
Tsubaki, K..; Hai, D. T. T.; Reddy V. K.; Ohnishi, H.; Fuji, K.; Kawabata, T.
Tetrahedron: Asymmetry. 2007, 18, 1017-1021.
Synthesis and Determination of the Absolute Configuration of Chiral Tetracosanaphthalenes.
Tsubaki, K.; Takaishi, K.; Sue, D.; Kawabata, T.
J. Org. Chem, 2007, 72, 4238-4241.
Colorimetric Recognition of Length of a,w-Diamines in Water.
Tsubaki, K.; Tanima, D.; Sasamori, T.; Tokitoh, N.; Kawabata, T.
Tetrahedron Lett., 2007, 48, 2135-2138.
Asymmetric Dieckmann Condensation via Memory of Chirality: Synthesis of the Key Intermediate for
AS-3201, an Aldose Reductase Inhibitor
Watanabe, T.; Kawabata, T.
Heterocycles, 2008, 76, 1593-1606.
Direct Asymmetric Intramolecular Alkylation of b-Alkoxy-Į-Amino Esters via Memory of Chirality
Moriyama, K.; Sakai, H.; Kawabata, T.
Org. Lett. 2008, 10, 3883-3886.
Total Synthesis of (-)-㹑erotobenine
Koizumi, Y.; Kobayashi, H.; Wakimoto, T.; Furuta, T.; Fukuyama, T.; Kan, T.
J. Am. Chem. Soc. 2008, 130, 16854-16855.
Versatile synthesis of head group functionalized phospholipids via oxime bond formation
Furuta, T.; Mochizuki, M.; Ito, M.; Takahashi, T.; Suzuki, T.; Kan, T.
Org. Lett. 2008, 10, 4847-4850.
Efficient synthesis of optically active gallocatechin-3-gallate derivatives via 6-endo cyclization
Hirooka, Y.; Nitta, M.; Furuta, T.; Kan, T.
Synlett, 2008, 3234-3238.
Synthesis and characteristic stereostructure of biphenanthryl ether
Koizumi, Y.; Suzuki, S.; Takeda, K.; Murahashi, K.; Horikawa, M.; Katagiri, K.; Masu, H.; Kato, T.; Azumaya, I.; Fujii, S.; Furuta, T.; Tanaka, K.; Kan, T.
Tetrahedron: Asymmetry, 2008, 19, 1407-1410.
Synthesis of diazirine possessing an acetophenone derivative as a valuable intermediate for a flavonoid
photoaffinity probe
Furuta, T.; Ueda, M.; Hirooka, Y.; Tanaka, K.; Kan, T.
Heterocycles, 2008, 76, 811-817.
One-pot synthesis of carbazole via tandem Suzuki-Miyaura and amination reaction
Kitamura, Y.; Yoshikawa, S.; Furuta, T.; Kan, T.
Synlett, 2008, 377-380.
Synthetic studies on altemicidin: Stereocontrolled construction of the core framework
Kan, T.; Kawamoto, Y.; Asakawa, T.; Furuta, T.; Fukuyama, T.
− 232 −
Org. Lett. 2008, 10, 169-171.
26. Thress-component cascade energy transfer using oligonaphthalene skeletons
Tsubaki, K.; Takaishi, K.; Sue, D.; Matsuda, K.; Kanemitsu, Y.; Kawabata, T.
J. Org. Chem. 2008, 73, 4279-4282.
27. Regioselective Acylation of Octyl ȕ-D-Glucopyranoside by Chiral 4-Pyrrolidinopyridine Analogues
Kawabata, T.; Muramatsu, W.; Nishio, T.; Shibata, T.; Uruno, Y.; Stragies, R.
Synthesis, 2008, 747-753.
28. Colorimetoric Recognition Using Functional Phenolphthalein Derivatives
Tsubaki, K.
J. Incl. Phenom. Macrocyclic. Chem. 2008, 61, 217-225.
29. Powdered KOH in DMSO: An Efficient Base for Asymmetric Cyclization via Memory of Chirality at Ambient Temperature
Kawabata, T.; Moriyama, K.; Kawakami, S.; Tsubaki, K.
J. Am. Chem Soc. 2008, 130, 4153-4157.
30. Functional Group Tolerance in Organocatalytic Regioselective Acylation of Carbohydrates
Ueda, Y.; Muramatsu, W.; Mishiro, K.; Furuta, T.; Kawabata, T.
J. Org. Chem. 2009, 74, 8802-8805.
31. Solide-Supported Synthesis of Artificial Phospholipids
Furuta, T.; Onuki, H.; Mochizuki, M.; Ito, M.; Inai, M.; Wakimoto, T.; Kan, T.
Synlett 2009, 74, 3373-3377.
32. Development of highly sensitive and selective molecules for detection of spermidine and spermine
Tanima, D.; Imamura, Y.; Kawabata, T.; Tsubaki, K.
Org. Biomol. Chem. 2009, 7, 4689-4694.
33. Regioselective Synthesis of Methylated Epigallocatechin Gallate via Nitrobenzenesulfonyl (Ns) Protecting
Group
Aihara, Y.; Yoshida, A.; Furuta, T.; Wakimoto, T.; Akizawa, T.; Konishi, M.; Kan, T.
Bioorg. Med. Chem. Lett. 2009, 19, 4171-4174.
34. Identification and Characterization of Flavonoids as Sialyltransterase Inhibitors
Hidari, K. I. P. J.; Oyama, K.; Ito, G.; Nakayama, M.; Inai, M.; Goto, S.; Kanai, Y.; Watanabe, K.; Yoshida,
K.; Furuta, T.; Kan, T.; Suzuki, T.
Biochem. Biophys. Res. Commun. 2009, 382, 609-613.
35. Synthesis and Properties of S,R-alternating octinaphthalenes
Takaishi, K.; Sue, D.; Kuwahara, S.; Harada, N.; Kawabata, T.; Tsubaki, K.
Tetrahedron 2009, 65, 6135-6140.
36. Concise Synthesis of Chafurosides A and B
Furuta, T.; Nakayama, M.; Suzuki, H.; Tajimi, H.; Inai, M.; Nukaya, H.; Wakimoto, T.; Kan, T.
Org. Lett. 2009, 11, 2233-2236.
37. Synthesis of Chiral Dotriacontanaphthalenes: How many naphthalene units are we able to elaborately connect?
Sue, D.; Takaishi, K.;Harada, T.; Kuroda, R.; Kawabata, T.; Tsubaki, K.
J. Org. Chem. 2009, 74, 3940-3943.
38. Axially Chiral Binaphthyl Surrogates with an Inner N-H-N Hydrogen Bond
Kawabata, T.; Jiang, C.; Hayashi, K.; Tsubaki, K.; Yoshimura, T.; Majumdar, S.; Sasamori, T.; Tokitoh, N..
J. Am. Chem Soc. 2009, 131, 54-55.
39. Cobalt (II)-Responsive DNA Binding of a GCN4-bZIP Protein Containing Cysteine Residues Functionalized
with Iminodiacetic Acid
Azuma, Y.; Imanishi, M.; Yoshimura, T.; Kawabata, T.; Futaki, S.
Angew. Chem. Int. Ed. 2009, 48, 6853-6856.
40. High-performance Affinity Chromatography with Immobilized Albumin Column
Ishii, T.; Minoda, K.; Bae, M.-J.: Mori, T.; Uekusa, Y.; Ichikawa, T.; Aihara, Y.; Furuta, T.; Wakimoto, T.;
Kan, T.; Nakayama, T.
Mol. Nutr. Food Res. 2010, 54, 816-822.
41. Synthsis of Axially Chiral Amino Acid and Amino Alcohols via Additive-Ligand-Free Pd Catalyzed Domino
Coupling Reaction and Subsequent Transformation of the Product Amidoaza[5]helicene
Furuta, T.; Yamamoto, J.; Kitamura, Y.; Hashimoto, A.; Masu, H.; Azumaya, I.; Kan, T.; Kawabata, T.
J. Org. Chem. 2010, 75, 20, 7010-7013.
42. Insights into Origins of Configurational Stability of Axially Chiral Biaryl Amines with an Intramolecular
N-H-N Hydrogen Bond
Hayashi, K.; Matubayasi, N.; Jiang, C.; Yoshimura, T.; Majumdra, S.; Sasamori, T.; Tokitoh, N.;
Kawabata, T.
− 233 −
J. Org. Chem. 2010, 75, 5031-5036.
43. Structural Characteristics of Green Tea Catechins for Formation of Protein Carbonyl in Human Serum Albumin
Ishii, T.; Mori, T.; Ichikawa, T.; Kaku, M.; Uekusa, Y.; Akagawa, M.; Aihara, Y.; Furuta, T.; Wakimoto, T.;
Kan, T.; Nakayama, T.
Bioorg. Med. Chem. 2010, 18, 4892-4896.
44. Reaction Behavior of Cumulene: Diels-Alder, Friedel-Crafts, and Pd-Catalyzed Domino Reactions
Asakawa, T.; Iinuma, M.; Wakasugi, Y.; Kuno, M.; Furuta, T.; Fujii, S.; Tanaka, K.; Kan, T.
Heterocycles, 2010, 80, 1125-1147.
45. Perfectly Regioselective Acylation of a Cardiac Glycoside, Digitoxin, via Catalytic Amplification of the Intrinsic Reactivity
Yoshida, K.; Furuta, T.; Kawabata, T.
Tetrahedron Lett. 2010, 51, 4830-4832.
46. Axially Chiral Anilido-Aldimine Aluminum Complexes with a Pseudobinaphthyl Skeleto
Hayashi, K.; Nakajima, Y.; Ozawa, F.; Kawabata, T.
Chem. Lett. 2010, 39, 643-645.
47. Perfectly Regioselective and Sequential Protection of Glucopyranosides
Muramatsu, W.; Mishiro, K.; Ueda, Y.; Furuta, T.; Kawabata, T.
Eur. J. Org. Chem. 2010, 5, 827-831.
48. Synthesis of Spiro Compounds through Tandem Oxidative Coupling and a Framework Rearrangement Reaction
Sue, D.; Kawabata, T.; Sasamori, T.; Tokitoh, N.; Tsubaki, K,*
Org. Lett. 2010, 12, 256-258.
㸦⥲ㄝ㸧
1. ගᏛάᛶ࢜ࣜࢦࢼࣇࢱࣞࣥ㢮ࡢྜᡂ࡜ගᏛᣲື
2.
3.
4.
Takaishi, K.; Tsubaki, K.; Tanaka, H.; Miura, M.; Kawabata, T.
YAKUGAKU ZASSHI. 2006, 126, 779-786.
An Organocatalytic Regioselective Acylation of Carbohydrates: Toward the Development of Intelligent Catalysts.
T. Kawabata
J. Syn. Org. Chem.Japan, 2007, 65, 1081-1087.
㨩ຊⓗ࡞ศᏊኚ᥮࡬ࡢ࢔ࣉ࣮ࣟࢳ
ᕝ➃⊛ኵ
ࣇ࢓࣐ࣝࢩ࢔ࠊ2007, 43, 242-244.
Nonenzymatic Regioselective Acylation of Carbohydrates
Kawabata, T.; Furuta, T.
Chem. Lett. 2009, 38, 640-647.
㸦ⴭ᭩㸧
1.
2.
3.
࢔ࢩࣝ໬ゐ፹
ᕝ➃⊛ኵ
㐍໬ࢆ⥆ࡅࡿ᭷ᶵゐ፹ࠊ୸ᒸၨ஧⦅ࠊ໬Ꮫྠேࠊpp150-161 (2009)
Asymmetric Synthesis of Amino Acids with a Tetrasubstituted Carbon Center via Memory of Chirality.
Takeo Kawabata
ACS Symposium Series 1009. "Asymmetric Synthesis and Application of Į-Amino Acids". 2009. 31-56.
࢔࣑ࣀ㓟ㄏᑟయࡢศᏊෆ୙ᩧ࢔ࣝ࢟ࣝ໬
ᕝ➃⊛ኵ
౑࠼ࡿ㸟᭷ᶵྜᡂ཯ᛂ㸰㸲㸯ᐇ㊶࢞࢖ࢻࠊ୸ᒸၨ஧ࡽ⦅ࠊ໬Ꮫྠேࠊpp236-237, 268-269, 366-367
(2010).
− 234 −
⏕యศᏊㄆ㆑Ꮫศ㔝
ᩍ ᤵ㸦་Ꮫ༤ኈ㸧➉ᓥ ᾈ㸦ࡓࡅࡋࡲ ࡦࢁࡋ㸧㸦2006.1 ᥇⏝㸧
᫛࿴ 58 ᖺᮾி㎰ᕤ኱Ꮫ㎰Ꮫ㒊༞ࠊᖹᡂඖᖺி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ
◊✲⛉༤ኈㄢ⛬ಟ஢
ຓᩍᤵ㸦⸆Ꮫ༤ኈ㸧ᒸ ᫀ࿃㸦࠾࠿ ࡋࡻ࠺ࡈ㸧㸦1997.9 ᪼௵㸧
᫛࿴ 57 ᖺி㒔኱Ꮫ⸆Ꮫ㒊༞ࠊ᫛࿴ 62 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲
⛉༤ኈㄢ⛬ಟ஢
ᖹᡂ 18 ᖺ 6 ᭶ி㒔኱Ꮫ་Ꮫ⣔◊✲⛉ᩍᤵ
෸ᩍᤵ㸦་Ꮫ༤ኈ㸧ᒣᓮဴ⏨㸦ࡸࡲࡊࡁ ࡚ࡘ࠾㸧㸦2007.4 ᥇⏝㸧
ᖹᡂ 3 ᖺ༓ⴥ኱Ꮫ་Ꮫ㒊༞ࠊᖹᡂ 9 ᖺ༓ⴥ኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲
⛉༤ኈㄢ⛬ಟ஢
ᖹᡂ 21 ᖺ 12 ᭶ᚨᓥ኱Ꮫ኱Ꮫ㝔⸆Ꮫ⣔◊✲⛉ᩍᤵ
෸ᩍᤵ㸦⌮Ꮫ༤ኈ㸧ᰠ⃝ ᫀ㸦࠿ࡁࡊࢃ ࡋࡻ࠺㸧㸦2010.4 ᥇⏝㸧
ᖹᡂ 3 ᖺᮾி኱Ꮫ⌮Ꮫ㒊༞ࠊᖹᡂ 8 ᖺᮾி኱Ꮫ኱Ꮫ㝔⌮Ꮫ⣔◊✲⛉༤ኈㄢ⛬ಟ஢
ຓ ᩍ㸦⸆Ꮫ༤ኈ㸧ụ⏣⠜ྐ㸦࠸ࡅࡔ ࠶ࡘࡋ㸧㸦2006.7 ᥇⏝㸧
ᖹᡂ 8 ᖺி㒔኱Ꮫ⸆Ꮫ㒊༞ࠊᖹᡂ 13 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
ᖹᡂ 20 ᖺ 10 ᭶኱᪥ᮏఫ཭〇⸆ᰴᘧ఍♫
ຓ ᩍ㸦ᕤᏛ༤ኈ㸧ᒣᮏఙ୍㑻㸦ࡸࡲࡶ࡜ ࡋࢇ࠸ࡕࢁ࠺㸧㸦2009.4 ᥇⏝㸧
ᖹᡂ 14 ᖺ᫛࿴኱Ꮫ⸆Ꮫ㒊༞ࠊᖹᡂ 19 ᖺྠி㒔኱Ꮫ኱Ꮫ㝔ᕤᏛ◊✲⛉༤ኈㄢ⛬ಟ஢
≉௵ຓᩍ㸦⸆Ꮫ༤ኈ㸧ᒣᓮ኱ᶞ㸦ࡸࡲࡊࡁ ࡔ࠸ࡌࡹ㸧㸦2009.10 ᥇⏝㸧
ᖹᡂ 14 ᖺྡྂᒇᕷ❧኱Ꮫ⸆Ꮫ㒊༞ࠊᖹᡂ 19 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
⏕యศᏊ⩌ࡣ࠾஫࠸࡟≀⌮ⓗ࠾ࡼࡧᶵ⬟ⓗ࡟┦஫స⏝ࡋࠊከᙬ࡞໬Ꮫ཯ᛂࢆᘬࡁ㉳ࡇࡍࡇ࡜࡟ࡼࡾࠊ
ከᵝ࡛ᰂ㌾࡞⏕࿨⌧㇟ࢆᵓ⠏ࡋ࡚࠸ࡿࠋ⏕యศᏊㄆ㆑Ꮫศ㔝࡛ࡣࠊᇶᮏᡭἲ࡜ࡋ࡚⏕໬Ꮫ࣭㑇ఏᏊᐇ㦂
ἲࢆ⏝࠸ࡿࡇ࡜࡟ࡼࡾࠊࡑࡢ⏕࿨⌧㇟ࢆศᏊ࡛ࣞ࣋ࣝ᫂ࡽ࠿࡟ࡍࡿ◊✲ࢆ㐙⾜ࡋ࡚࠸ࡿࠋ◊✲άື࡟ࡼ
ࡾࡶࡓࡽࡉࢀࡿᡂᯝࡣࠊᇶ♏⏕≀ᏛࡢⓎᒎ࡟ᐤ୚ࡍࡿࡢࡳ࡛ࡣ࡞ࡃࠊ⸆≀㛤Ⓨ࡟ྥࡅࡓ᭷⏝࡞ᶆⓗศᏊ
ࡢタᐃࡸ㑇ఏᏊ⑌ᝈ➼ࡢ⑓ែゎ᫂࡞࡝࡬ࡶ㈉⊩ࡋ࡚࠸ࡿࠋ௨ୗ࡟ࠊ⌧ᅾ㐙⾜ࡋ࡚࠸ࡿලయⓗ࡞◊✲ㄢ㢟
࡟ࡘ࠸࡚ᴫㄝࡍࡿࠋ
1. ᑠ⬊య࢝ࣝࢩ࣒࢘ࢩࢢࢼࣜࣥࢢ࡟㛵ࡍࡿ◊✲
ᑠ⬊య࠿ࡽࡢ Ca2+ᨺฟࡣࠊ➽཰⦰ࠊఏ㐩≀㉁ᨺฟࠊ⭷㟁఩ㄪ⠇࡞࡝ከᙬ࡞⣽⬊ᶵ⬟࡟㛵୚ࡍࡿࠋ⣽⬊
ෆ Ca2+ࢫࢺ࢔࡜ࡋ࡚ാࡃᑠ⬊యࡣࠊᵝࠎ࡞ࢱࣥࣃࢡ㉁࡟ࡼࡾࡑࡢᶵ⬟ࡀᵓ⠏࣭ไᚚࡉࢀ࡚࠸ࡿࡀࠊࡑࡢ
ศᏊᐇయ࡟ࡘ࠸࡚ࡣ୙᫂࡞Ⅼࡀከࡃṧࡉࢀ࡚࠸ࡿࠋ⯆ዧᛶ⣽⬊࡟࠾ࡅࡿᑠ⬊యࡢᵓᡂࢱࣥࣃࢡ㉁ࡢᙺ๭
ࢆ 1 ࡘ 1 ࡘ᫂ࡽ࠿࡟ࡍࡿࡇ࡜࡟ࡼࡾࠊᑠ⬊య Ca2+ᨺฟࡢศᏊᇶ┙ࢆゎ᫂ࡍࡿࡇ࡜ࢆ┠ᣦࡋ࡚࠸ࡿࠋ≉࡟ࠊ
ࣜ࢔ࣀࢪࣥཷᐜయ࡟ࡼࡿ Ca2+ᨺฟࡢ⏕⌮ᶵ⬟ࠊࣜ࢔ࣀࢪࣥཷᐜయᶵ⬟࡟ᑐࡍࡿࢪࣕࣥࢡࢺࣇ࢕ࣜࣥࡢ㈉
⊩ࠊࡑࡢ௚ࡢᑠ⬊య Ca2+ᨺฟ࡟ᚲ㡲࡞ศᏊࡢ᳨⣴࡞࡝࡟ࡘ࠸࡚◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋ㏆ᖺࠊ⣽⬊⭷ Ca2+
ࢳࣕࢿࣝ࡜ࣜ࢔ࣀࢪࣥཷᐜయࡢᶵ⬟ⓗඹᙺ࡟ᚲせ࡞⤖ྜ⭷ᵓ㐀ࡢᙧᡂ࡟ࠊࢪࣕࣥࢡࢺࣇ࢕ࣜࣥࡀ㔜せ࡞
ᙺ๭ࢆᯝࡓࡋ࡚࠸ࡿࡇ࡜ࢆ♧ࡋࡓࠋࡲࡓࠊTRIC ࢳࣕࢿࣝࡀࠊᑠ⬊య࠿ࡽࡢ Ca2+ᨺฟ࡟కࡗ࡚Ⓨ⏕ࡍࡿ
ᑠ⬊ෆ⭍ࡢ㈇㟁Ⲵࢆ୰࿴ࡍࡿ࢝࢘ࣥࢱ࣮࢖࢜ࣥࢳࣕࢿࣝ࡜ࡋ࡚ᶵ⬟ࡋࠊຠ⋡ⓗ࡞ Ca2+ᨺฟࢆไᚚࡋ࡚࠸
ࡿࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋࡓࠋᚰ➽⣽⬊࡟࠾࠸࡚ࡇࢀࡽࡢศᏊ⩌ࡢḞᦆࡣᚰ୙඲࡟ࡼࡿಶయ⮴Ṛᛶࢆᘬࡁ㉳ࡇ
ࡋࠊⅬኚ␗ᤄධࡣࣄࢺᚰ➽⑕ࡸ୙ᩚ⬦࡞࡝ࡢཎᅉ࡜࡞ࡿࠋࡉࡽ࡟ࠊࡑࡢ୰ࡢᗄࡘ࠿ࡢࡶࡢࡣ㝆ᅽ⸆ࡸᢠ
୙ᩚ⬦⸆ࡢᶆⓗศᏊ࡜࡞ࡗ࡚࠸ࡿࠋ
2. ୰ᯡ⣔᝟ሗఏ㐩࡟㛵ࡍࡿ◊✲
㏆ᖺࡢᛴ㏿࡞⏕≀ᏛࡢⓎᒎ࡟࠾࠸࡚ࡶࠊ୰ᯡ⚄⤒⣔࡟࠾ࡅࡿ᝟ሗฎ⌮ࢆศᏊ࡛ࣞ࣋ࣝ⌮ゎࡍࡿࡓࡵࡢ
▱㆑ࢆ⌧ᅾࡢே㢮ࡣ༑ศ࡟ᣢࡕྜࢃࡏ࡚࠸࡞࠸ࠋ⌧ᅾ࡛ࡶ୰ᯡ⣔࠿ࡽࡣᶵ⬟୙᫂࡞ࢱࣥࣃࢡ㉁⩌ࡀከࡃ
ぢฟࡉࢀ࡚࠾ࡾࠊᮍྠᐃ࡞᝟ሗఏ㐩⣔ࡢᏑᅾࡀ♧၀ࡉࢀ࡚࠸ࡿࠋᚑࡗ࡚ࠊࡑࢀࡽࢱࣥࣃࢡ㉁ࡢ⬻ᵓ⠏ࡸ
⚄⤒ᶵ⬟࡬ࡢᐤ୚ࢆ᳨ウࡋࠊ⏕⌮ᶵ⬟ࢆ᫂ࡽ࠿࡟ࡍࡿ◊✲ࡣ㔜せ࡛࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋࡲࡓࠊ୰ᯡ⚄⤒
⣔࡟࠾࠸࡚ࡶᑠ⬊య Ca2+ࢩࢢࢼࣝ⣔ࡢไᚚᶵᵓࡸᶵ⬟ⓗᙺ๭࡟ࡘ࠸࡚ࡣᮍࡔ࡟ከࡃࡢⅬࡀ୙࡛᫂࠶ࡿࠋ
㏆ᖺࠊᡃࠎࡣᑠ⬊య Ca2+ࢩࢢࢼࣝ⣔࡟࠾࠸࡚㔜せ࡞ᙺ๭ࢆᢸ࠺ࣜ࢔ࣀࢪࣥཷᐜయࡸᑠ⬊యᆺ Ca2+࣏ࣥࣉ
࡞࡝ࡢ Ca2+㍺㏦యศᏊࡢ᪂つไᚚᶵᵓࢆぢฟࡋࡓࠋ⌧ᅾࠊࡇࢀࡽ Ca2+㍺㏦యศᏊࡢไᚚᶵᵓࡀ◚⥢ࡍࡿ
࡜ࢽ࣮ࣗࣟࣥࡸࢩࢼࣉࢫࡢᶵ⬟ࠊࡉࡽ࡟ࡣ㐠ືᏛ⩦࡞࡝ࡢ⬻ᶵ⬟࡟ࡶ␗ᖖࡀ⌧ࢀࡿࡇ࡜ࢆ♧ࡍ⤖ᯝࡀᚓ
ࡽࢀࡘࡘ࠶ࡾࠊCa2+㍺㏦యศᏊࡢᶵ⬟◚⥢࡟㉳ᅉࡍࡿ⑌ᝈࡢゎ᫂ࡸศᏊデ᩿ἲࡢ☜❧ࠊࡉࡽ࡟ࡣ๰⸆࡬
− 235 −
࡜◊✲ࡀⓎᒎࡍࡿࡇ࡜ࡀᮇᚅࡉࢀࡿࠋ
3. ➽⣽⬊ࡢ⭷ᵓ⠏࡜ᶵ⬟࡟㛵ࡍࡿ◊✲
⤌⧊Ꮫࡸ⣽⬊⏕≀Ꮫࡢᩍ⛉᭩ࢆ⣣ゎࡃ࡜ࠊᚰ➽ࡸ㦵᱁➽⣽⬊࡟ࡣᐇ࡟୙ᛮ㆟࡞⣽⬊⭷ࡸᑠ⬊య⭷ࡢᙧ
ែᏛⓗᵓ㐀ࡀ࠶ࡿࡇ࡜࡟㦫࠿ࡉࢀࡿࠋ౛࠼ࡤࠊᶓ⟶⣔㸦transverse tubule㸧ࠊ୕ࡘ⤌㸦triad junction㸧ࠊᑠ⬊
య⤊ᮎ㒊㸦 junctional sarcoplasmicreticulum㸧 ࡜ᶓ⾜㒊㸦longitudinal region㸧
ࠊZ-tubule㸦Z ⥺࡜ᑠ⬊యࡢ
㏆᥋⤖ྜ㸧࡞࡝࡛࠶ࡿࠋ➽ศ໬ࡢ㐣⛬࡛ࡇࢀࡽࡢᵓ㐀ࡣṇ☜࡟෌⌧ࡉࢀࡿࡢ࡛ࠊ㑇ఏᏊ⏘≀࡟ࡼࡾつᐃ
ࡉࢀ࡚࠸ࡿࡇ࡜࡟㛫㐪࠸ࡣ࡞࠸ࡀࠊࡑࡢศᏊᶵᗎࡣࡲࡗࡓࡃ୙᫂࡜ゝࡗ࡚ࡶ㐣ゝ࡛ࡣ࡞࠸⌧≧࡛࠶ࡿࠋ
ࡇࢀࡽࡢ⭷ᵓ㐀࡟୙ྍḞ࡞ศᏊ⩌ࢆྠᐃࡋࠊࡑࢀࡽࡢᶵ⬟ࡢゎ᫂ࢆ┠ᣦࡋࡓ◊✲ࢆ㐙⾜ࡋ࡚࠸ࡿࠋ⌧ᅾ
࡛ࡣࠊ࣑ࢶࢢ࣑ࣥ 23, 29, 53 ࡜࿨ྡࡋࡓศᏊ࡟ὀ┠ࡋࡓᐇ㦂࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ࣑ࢶࢢ࣑ࣥ 29 ࡣࠊᶓ⟶
⭷ࡢᚤ⣽ᵓ㐀ࢆつᐃࡍࡿ࡜࡜ࡶ࡟ࠊ➽⣽⬊ࡢ⪁໬࡟ࡶ῝ࡃ㛵୚ࡍࡿ⭷ࢱࣥࣃࢡ㉁࡛࠶ࡿࡇ࡜ࡀ᭱㏆ࡢᡂ
ᯝ࡛♧ࡉࢀࡓࠋࡲࡓࠊ࣑ࢶࢢ࣑ࣥ 53 ࡣ➽⣽⬊ࡢ⾲ᒙᦆയ᫬ࡢ⭷ಟ᚟࡟㛵୚ࡋ࡚࠸ࡿࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋ
ࡓࠋゎ᫂ࡉࢀࡓ࣑ࢶࢢ࣑ࣥ 53 ࡢ⏕⌮ᶵ⬟࠿ࡽࡣࠊ඲㌟ࡢ➽⫗ࡀ⾶࠼ࡿ➽ࢪࢬࢺࣟࣇ࢕࣮ࡢ⑓ែ✲᫂ࠊ
デ᩿ࡸ἞⒪࡬ࡢᛂ⏝࡞࡝࡬ࡢⓎᒎࡶᮇᚅࡉࢀࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
➉ᓥࡣᖹᡂ 12 ᖺᗘ⏕໬Ꮫ఍ዡບ㈹ࢆཷ㈹ࠋᒸࡣᖹᡂ 10 ᖺᗘ⸆Ꮫ఍ዡບ㈹ࠊ⢾㉁Ꮫ఍ዡບ㈹ࢆཷ㈹ࠋ
➉ᓥࡣᖹᡂ 15-19 ᖺᗘᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲㈝⿵ຓ㔠ᇶ┙◊✲(S)ࠕᑠ⬊య Ca2+ᨺฟࡢศᏊᵓ⠏ࠖࡢ◊✲௦
⾲⪅ࠊᖹᡂ 17-21 ᖺᗘ≉ᐃ㡿ᇦ◊✲ࠕ⭷㍺㏦」ྜయࠖ➨㸰⌜⌜㛗ࠊᖹᡂ 20-22 ᖺᗘᩥ㒊⛉Ꮫ┬⛉Ꮫ◊✲
㈝⿵ຓ㔠ᇶ┙◊✲(A)ࠕ᪂つᑠ⬊యࢳࣕࢿࣝ࡟㛵ࡍࡿ◊✲ࠖࡢ◊✲௦⾲⪅࡜ࡋ࡚ࠊ2008-2012 ᖺ⡿ᅜ NHI
RO1 ◊✲㈝ࠕTRIC, A Novel Modulator of Intracellular Ca Homeostasisࠖࡢඹ◊✲௦⾲⪅࡜ࡋ࡚◊✲ࢆ᥎㐍
ࡋ࡚࠸ࡿࠋᒸࡣᖹᡂ 14 ᖺ࠿ࡽᖹᡂ 18 ᖺࡲ࡛⛉Ꮫᢏ⾡᣺⯆ᶵᵓᡓ␎ⓗᇶ♏◊✲ࠕ࢘࢖ࣝࢫឤᰁ࡟࠾ࡅࡿ
⢾㙐ᶵ⬟ࡢゎ᫂࡜๰⸆࡬ࡢᛂ⏝ࠖࡢ◊✲ศᢸ⪅ࠊᖹᡂ 16 ᖺ࠿ࡽᖹᡂ 20 ᖺࡲ࡛ᩥ㒊⛉Ꮫ┬Ꮫ⾡๰ᡂ◊✲
㈝ࠕ⢾㙐⏕≀Ꮫ࡜⚄⤒⛉Ꮫࡢ⼥ྜ࡟ࡼࡿ⚄⤒⢾㙐⏕≀Ꮫ㡿ᇦࡢ๰ᡂࠖࡢ◊✲௦⾲⪅࡜ࡋ࡚ࠊᰠ⃝ࡣᖹᡂ
20-21 ᖺᗘ≉ᐃ㡿ᇦ◊✲ࠕ⭷㍺㏦」ྜయࠖ➨㸱⌜බເ◊✲௦⾲⪅࡜ࡋ࡚◊✲ࢆ᥎㐍ࡋ࡚࠸ࡿࠋᮏศ㔝࡛
ᡭ᥃ࡅࡿྛ◊✲ㄢ㢟ࡣ࠸ࡎࢀࡶ⊂๰ᛶࡢ㧗࠸◊✲࡜ࡋ࡚ᅜ㝿ⓗ࡟㠀ᖖ࡟㧗࠸ホ౯ࢆᚓ࡚࠸ࡿࠋ≉࡟ࠊ➉
ᓥࡽ࡟ࡼࡾⓎぢࡉࢀࡓ TRIC ࢳࣕࢿࣝ࡟ࡘ࠸࡚ࡢ◊✲ࡣࠊ⣽⬊ෆࢫࢺ࢔࠿ࡽࡢ Ca2+ᨺฟ࡜ྠㄪࡋ࡚ᶵ⬟
ࡍࡿ࢝࢘ࣥࢱ࣮࢖࢜ࣥࢳࣕࢿࣝࡢྠᐃ࡜ゝ࠺ࠊ⏕⌮Ꮫ㡿ᇦࡢ✚ᖺ࡟Ώࡿ㔜せ࿨㢟࡟ᑐࡋ࡚᫂☜࡞ゎ⟅ࢆ
୚࠼ࡿ◊✲࡜ࡋ࡚ᅜෆእࡼࡾᴟࡵ࡚㧗࠸ホ౯ࢆᚓ࡚࠸ࡿࠋᑦࠊ➉ᓥࡣᖹᡂ 22 ᖺ 10 ᭶ࡼࡾ኱Ꮫᮏ㒊ࡢ௻
⏬ᢸᙜᴗົࡢ⌮஦⿵ࡶවົࡋ࡚࠸ࡿࡀࠊ◊✲ࡢ㉁ࡢ᭦࡞ࡿྥୖࢆ┠ᣦࡋ࡚ࠊ୍ᒙࡢດຊࢆ㔜ࡡࡘࡘ࠶ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ㸯ᅇ⏕࡟ᑐࡍࡿࠕ⸆Ꮫ⏕≀Ꮫࠖ࠾ࡼࡧ㸰ᅇ⏕๓ᮇࡢ⏕≀໬Ꮫ I, 㸱ᅇ⏕ᚋᮇࡢ⸆
Ꮫᑓ㛛ᐇ⩦㸱࣭㸲ࢆᢸᙜࡋ࡚࠸ࡿࠋ⸆Ꮫ⏕≀Ꮫࡢㅮ⩏࡟㛵ࡋ࡚ࡣࠊ➉ᓥ࣭ᒣᓮဴ⏨࣭ᰠ⃝࣭ụ⏣ࡽ࡟ࡼ
ࡾᩍ⛉᭩ࢆᇳ➹࣭ฟ∧ࡋࡓࡀࠊ࣮࢝ࣛᅗ⾲ࢆ⏝࠸ࡓศ࠿ࡾ᫆࠸ᩍ⛉᭩࡜ࡋ࡚ホ౯ࡀ㧗ࡃࠊ඲ᅜ࡛ 4000
ྡࡶࡢᏛ⏕ࡶࡋࡃࡣᩍ⫋ဨࡀࠊࡇࡢᩍ⛉᭩ࢆㅮ⩏ࢸ࢟ࢫࢺ࡜ࡋ࡚᥇⏝ࡋ࡚࠸ࡿࠋ඲࡚ࡢㅮ⩏࡟ࡘ࠸࡚ࡣࠊ
ᩍ⛉᭩࠾ࡼࡧཧ⪃᭩ࢆᣦᐃࡍࡿ࡯࠿ࠊㅮ⩏᫬࡟ࡣࣉࣜࣥࢺࠊࣃ࣮࣏࣡࢖ࣥࢺࡶࡋࡃࡣᯈ᭩ࢆ⏝࠸࡚࠸࡚
⌮ゎࢆຓࡅ࡚࠸ࡿࠋࡲࡓ㐺ᐅࠊㅮ⩏᫬㛫ࡢ⤊ࢃࡾ࡟⾜࠺ᑠࢸࢫࢺࡶࡋࡃࡣ࣏࣮ࣞࢺㄢ㢟࡟ࡼࡾࠊ⌮ゎᗘ
ࡢࢳ࢙ࢵࢡ࡟ດࡵ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸ศ㔝㓄ᒓࡋࡓ㸲ᅇ⏕࡟ࡣࠊಶேẖ࡟ࢸ࣮࣐ࢆ୚࠼ࠊ⫋ဨ࠶ࡿ࠸ࡣୖ⣭⏕ࡢ
ᣦᑟࡢࡶ࡜࡟ࠊ⏕໬ᏛࠊศᏊ⏕≀Ꮫࠊ⣽⬊⏕≀Ꮫ࡞࡝ࡢ◊✲ᡭἲࢆᏛࡤࡏࡿ࡜࡜ࡶ࡟ࠊᐇ㦂⛉Ꮫ࡛ᡂᯝ
ࢆୖࡆࡿࡓࡵ࡟ࡣࠊᑓ㛛ⓗᇶ♏▱㆑ࠊᣢ⥆ⓗὀពຊࠊ୙᩿ࡢྥୖᚰ࡞࡝ࡀᚲせ࡛࠶ࡿࡇ࡜ࢆ⮬ࡽయᚓࡍ
ࡿࡼ࠺ᣦᑟࡋ࡚࠸ࡿࠋᏛᮇᮎ࡟ࡣࠊ༞ᴗⓎ⾲఍ࢆ⾜࠸ࠊྛே㸯㸳ศ⛬ᗘࡢཱྀ㢌Ⓨ⾲࡜ࠊ㸯㸳ࠥ㸱㸮ศ⛬
ᗘࡢ㉁␲ᛂ⟅ࢆ⾜ࡗ࡚࠸ࡿࠋ
኱Ꮫ㝔ಟኈㄢ⛬࡛ࡣࠊ୚࠼ࡽࢀࡓࡑࢀࡒࢀࡢࢸ࣮࣐ࢆ୺యⓗ࡟ゎỴࡋ࡚⾜ࡃࡓࡵࡢㄽ⌮ࢆ୰ᚰ࡟Ꮫࡤ
ࡏࡿࠋၥ㢟ⅬࡢゎỴ࡟ࡣ࠸ࡃࡘࡶࡢ࢔ࣉ࣮ࣟࢳࡀྍ⬟࡞ሙྜࡀከ࠸ࡀࠊࡑࡢ᫬Ⅼ࡛ࡢ◊✲⎔ቃࡢ୰࡛࡝
ࡢ࢔ࣉ࣮ࣟࢳࡀ᭱๓ࡢࡶࡢ࡛࠶ࡿ࠿ࢆุ᩿ࡍࡿ⬟ຊࢆ㣴࠺ࠋ༤ኈㄢ⛬࡟࠾࠸࡚ࡣࠊྛ⮬ࡢࢸ࣮࣐ࡢ῝໬
ࢆィࡿ࡜࡜ࡶ࡟ࠊࢸ࣮࣐ࡢᒎ㛤ࠊ᪂ࢸ࣮࣐ࡢタᐃࢆ⾜࠺⬟ຊࢆ㣴࠺ࠋ┤᥋㛵ಀࡋࡓᑓ㛛㡿ᇦࡢୡ⏺ࡢ㐍
ᒎࡣࡶ࡜ࡼࡾࠊᗈࡃ⏕࿨⛉Ꮫࡢ᭱᪂ࡢືྥࢆᤊ࠼࡚ࠊ⮬ᕫࡢࢸ࣮࣐࡜ࡢ㛵㐃ࠊ㛫ྜ࠸ࢆィࡿ⩦័ࢆ㌟࡟
ࡘࡅࡉࡏࡿࠋࡇࢀࡽࡣୗ⣭⏕ࡢᣦᑟ࡜⤌ࡳྜࢃࡏࡓᙧ࡛⾜ࢃࢀࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᇶᮏⓗ࡟ࡣࠊᮏᏛ㒊Ꮫ⏕ࡣᑗ᮶ࠊ♫఍࡟࠾࠸࡚ᣦᑟ⪅࡜࡞ࡿࡇ࡜ࡀせồࡉࢀ࡚࠸ࡿ࡜ࡢ⪃࠼ࡢᇶ࡟ࠊ
⮬ࡽ⪃࠼ࠊ⮬ࡽᐇ⾜ࡍࡿಶᛶ࠶ࡿ◊✲⪅ࡢ㣴ᡂࢆ┠ᶆ࡜ࡋ࡚࠸ࡿࠋࡇࢀࡲ࡛ᮏศ㔝࡟࠾ࡅࡿ༤ኈㄢ⛬ಟ
− 236 −
஢⪅ࡢ኱༙ࡀࠊ኱Ꮫࡸᅜ❧ࡢ◊✲ᡤ࡛ᩍဨ࣭◊✲⪅࡜ࡋ࡚ࠊ࠶ࡿ࠸ࡣ〇⸆௻ᴗࡢ◊✲⪅࡜ࡋ࡚ᇶ♏⏕≀
Ꮫ࠿ࡽ་⸆ရ㛤Ⓨ࡟⮳ࡿ᭱ඛ➃◊✲࡟ᚑ஦ࡋ࡚࠸ࡿࠋࡇࡢ஦ᐇࡣࠊᮏศ㔝࡟࠾ࡅࡿ◊✲άືࡢỈ‽ࡢ㧗
ࡉࢆド᫂ࡋ࡚࠸ࡿࡶࡢ࡜⪃࠼࡚࠸ࡿࠋࡋ࠿ࡋ࡞ࡀࡽࠊ௚ࡢ㡿ᇦ࡜ྠᵝ࡟ࠊ㏆ᖺ࡛ࡣ༤ኈㄢ⛬㐍Ꮫ⪅ࡀ⃭
ῶࡋ࡚࠾ࡾࠊ◊✲⪅㣴ᡂ࡟࠾࠸࡚ࡶࢢ࣮ࣟࣂࣝ࡞ᒎ㛤ࡀᚲ㡲࡞᫬௦ࢆ㏄࠼࡚࠸ࡿࠋ௒ᚋࡣ࢔ࢪ࢔ㅖᅜ࠿
ࡽࡢඃ⚽ேᮦ࡟ᑐࡋ࡚◊✲⪅⫱ᡂ࡟ᑾຊࡍࡿࡇ࡜ࡶᚲ㡲࡛࠶ࡿ࡜ᛮࢃࢀࡿࠋ
㸦ཎⴭㄽᩥ㸧
1. Kakizawa, S., Shibazaki, M. & Mori, N. Protein oxidation inhibits NO-mediated signaling pathway for
synaptic plasticity. Neurobiol. Aging, in press.
2. Li, H., Ding, X., Lopez, J. R., Takeshima, H., Ma, J., Allen, P. D. & Eltit, J. M. Imparied Orai1-mediateded
resting Ca2+ entry reduces the cytosolic [Ca2+] and SR Ca2+ loading in quitescent junctophilin1 knockout
myotubes. J. Biol. Chem. in press.
3. Yamazaki, D., Kito, H., Yamamoto, S., Ohya, S., Yamamura, H., Asai, K. & Imaizumi, Y. Contribution of Kir2
potassium channels to ATP-induced cell death in brain capillary endothelial cells and reconstituted HEK293
cell model. Am J Physiol Cell Physiol, in press.
4. Zhao, X., Yamazaki, D., Park, K-H., Komazaki, S., Tjondrokoesoemo, A., Nishi, M., Lin, P., Hirata, Y., Brotto,
M., Takeshima, H. & Ma, J. Ca2+ overload and sarcoplasmic reticulum instability in tric-a null skeletal muscle.
J. Biol. Chem. in press.
5. Cao, C-M., Zhang, Y., Weisleder, N., Ferrante, C., Wang, X., Lv, F., Zhang, Y., Song, R., Moonsun Hwang, M.,
Jin, L., Guo, J., Peng, W., Li, G., Nishi, M., Takeshima, H., Ma, J. & Xiao, R-P. MG53 constitutes a primary
determinant of cardiac ischemic preconditioning. Circulation 121, 2565-2574, 2010.
6. Miwa, M., Uchida, S., Horiba, F., Takeshima, H., Nabeshima, T. & Hiramatsu, M. Nociceptin and its metabolite
attenuate U0126-induced memory impairment through a nociceptin opioid peptide (NOP)
receptor-independent mechanism. Neurobiol. Learn. Mem. 93, 396-405, 2010.
7. Pitt, S. J., Park, K-H., Nishi, M., Urashima, T., Aoki, S., Yamazaki, D., Ma, J., Takeshima, H. & Sitsapesan, R.
Charade of the SR K+-channel: two ion-channels, TRIC-A and TRIC-B, masquerade as a single K+-channel.
Biophys. J. 99, 417-426, 2010.
8. Wang, X., Xie, W., Zhang, Y., Lin, P., Han, L., Han, P., Wang, Y., Chen, Z., Ji, G., Zheng, M., Weisleder, N.,
Xiao, R-P., Takeshima, H., Ma, J. & Cheng, H. Cardioprotection of ischemia/reperfusion injury by
cholesterol-dependent MG53-mediated membrane repair. Circ. Res. 107, 76-83, 2010.
9. Yamazaki, T., Sasaki, N., Nishi, M. & Takeshima, H. Facilitation of DNA damage- induced apoptosis by
endoplasmic reticulum protein mitsugumin23. Biochem. Biophys. Res. Commun. 392, 196-200, 2010.
10. Cai, C., Masumiya, H., Weisleder, N., Matsuda, N., Nishi, M., Hwang, M., Ko, J-K., Lin, P., Thornton, A.,
Zhao, X., Pan, Z., Komazaki, S., Brotto, M., Takeshima, H. & Ma, J. MG53 nucleates assembly of cell
membrane repair machinery. Nature Cell Biol. 11, 56-64, 2009.
11. Cai, C., Masumiya, H., Weisleder, N., Pan, Z., Nishi, M., Ko, J-K., Komazaki, S., Takeshima, H. & Ma, J.
MG53 regulates membrane budding and exocytosis in muscle cells. J. Biol. Chem. 284, 3314-3322, 2009.
12. Cai, C., Weisleder, N., Ko, J-K., Komazaki, S., Sunada, Y., Nishi, M., Takeshima, H. & Ma, J. Membrane
repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3 and dysferlin.
J. Biol. Chem. 284, 15894-15902, 2009.
13. Jiao, Q., Bai, Y., Akaike, T., Takeshima, H., Ishikawa, Y. & Minamisawa, S. Sarcalumenin is essential for
maintaining cardiac function during endurance exercise training. Am. J. Physiol. Heart Circ. Physiol. 297,
H576-582, 2009.
14. Kato, K., Kiyonaka, S., Sawaguchi, Y., Tohnish, M., Masaki, T., Yasokawa, N., Mizuno, Y., Mori, E., Inoue, K.,
Hamachi, I., Takeshima, H. & Mori, Y. Molecular characterization of flubendiamide sensitivity in
lepidopterous ryanodine receptor. Biochemistry 48, 10342-10352, 2009.
15. Lange, I., Yamamoto, S., Partida-Sanchez, S., Mori, Y., Fleig, A. & Penner, R. TRPM2 functions as lysosomal
Ca2+ release channel in ȕ-cells. Science Signaling 71, ra23 2009
16. Li, X. Q., Zheng, Y. M., Rathore, R., Ma, J., Takeshima, H. & Wang, Y. X. Genetic evidence for functional
role of ryanodine receptor 1 in pulmonary artery smooth muscle cells. Pflugers Arch. 457, 771-783, 2009.
17. Liu, Q. H., Zheng, Y. M., Korde, A. S., Li, X-Q., Ma, J., Takeshima, H. & Wang, Y-X. Protein kinase CH
regulates local calcium signaling in airway smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. 40, 663-671,
2009.
18. Masumiya, H., Asaumi, Y., Nishi, M., Minamisawa, S., Adachi-Akahane, S., Yoshida, M., Kangawa, K., Ito,
K., Kagaya, Y., Yanagisawa, T., Yamazaki, T., Ma, J. & Takeshima, H. Mitsugumin 53-mediated maintenance
of K+ currents in cardiac myocytes. Channels 3, 6-11, 2009.
19. Matsuo, N., Tanda, K., Nakanishi, K., Yamasaki, N., Toyama, K., Takao, K., Takeshima, H. & Miyakawa, T.
Comprehensive behavioral phenotyping of ryanodine receptor type 3 (RyR3) knockout mice: decreased social
− 237 −
contact duration in two social interaction tests. Front. Behav. Neurosci. 3, 3, 2009.
20. Yamazaki, D., Komazaki, S., Nakanishi, H., Mishima, A., Nishi, M., Yazawa, M., Yamazaki, T., Taguchi, R. &
Takeshima, H. Essential role of TRIC-B channel in Ca2+- handling of alveolar epithelium and perinatal lung
maturation. Development 136, 2355-2361, 2009.
21. Huddleston, T., Tang, W., Takeshima, H., Hamilton, S. L. & Klann, E. Superoxide- induced Potentiation in the
Hippocampus Requires Activation of Ryanodine Receptor Type 3 and ERK. J. Neurophysiol. 99, 1565-1571,
2008.
22. Reiss, D., Wichmann, J., Takeshima, H., Kieffer, B. L. & Ouagazzal, A-M. Effects of nociceptin/orphanin FQ
receptor (NOR) agonist, Ro64-6198, on reactivity to acute pain in mice: comparison to morphine. Eur. J.
Pharmacol. 579, 141-148, 2008.
23. Sasaki, A., Takasakib, I., Andoh, T., Shiraki, K., Takeshima, H., Takahata, H. & Kuraishi, Y. Nociceptin
receptor-deficiency prevents postherpetic pain without effects on acute herpetic pain in mice. Neuroreport 19,
83-86, 2008.
24. Shimura, M., Minamisawa, S., Takeshima, H., Jiao, Q., Bai, Y., Umemura, S. & Ishikawa, Y. Sarcalumenin
alleviates stress-induced cardiac dysfunction by improving Ca2+ handling of the sarcoplasmic reticulum.
Cardiovasc. Res. 77, 362-370, 2008.
25. Stewart, R., Song, L., Carter, S. M., Sigalas, C., Zaccai, N. R., Kanamarlapudi, V., Bhat, M. B., Takeshima, H.
& Sitsapesan, R. Single-channel characterization of the rabbit recombinant RyR2 reveals a novel inactivation
property of physiological concentrations of ATP. J. Membr. Biol. 222, 65-77, 2008.
26. Takahashi, N., Mizuno, Y., Kozai, D., Yamamoto, S., Kiyonaka, S., Shibata, T., Uchida, K. & Mori, Y.
Molecular characterization of TRPA1 channel activation by cysteine-reactive inflammatory mediators.
Channels 2, 287-298, 2008.
27. Yamamoto, S., Shimizu, S., Kiyonaka, S., Takahashi, N., Wajima, T., Hara, Y., Negoro, T., Hiroi, T., Kiuchi, Y.,
Okada, T., Kaneko, S., Lange, I., Fleig, A., Penner, R., Nishi, M., Takeshima, H & Mori, Y. TRPM2-mediated
Ca2+ influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration.
Nature Med. 14, 738-747, 2008.
28. Chugun, A., Sato, O., Takeshima, H. & Ogawa, Y. Mg2+ activates the ryanodine receptor type 2 (RyR2) at
intermediate Ca2+ concentrations. Am. J. Cell Phys. 292, C535-544, 2007.
29. Delbono, O., Xia, J., Treves, S., Wang, Z-M., Jimenez-Moreno, R., Payne, A. M., Messi, M. L., Briguet, A.,
Schaerer, F., Nishi, M., Takeshima, H. & Zorzato, F. Loss of skeletal muscle strength by ablation of the
sarcoplasmic reticulum protein JP45. Proc. Natl. Acad. Sci. USA. 104, 20108-20113, 2007.
30. Fujiwara, A., Kakizawa, S. & Iino, M. Induction of cerebellar long-term depression requires activation of
calcineurin in Purkinje cells. Neuropharmacol. 52, 1663-1670, 2007.
31. Hotta, S., Morimura, K., Ohya, S., Muraki, K., Takeshima, H. & Imaizumi, Y. Ryanodine receptor type 2
deficiency changes excitation-contraction coupling and membrane potential in urinary bladder smooth muscle.
J. Physiol. 582, 489-506, 2007.
32. Ikeda, A., Miyazaki, T., Kakizawa, S., Okuno, Y., Tsuchiya, S., Myomoto, A., Saito, S., Yamamoto, T.,
Yamazaki, T., Iino, M., Tsujimoto, G., Watanabe, M. & Takeshima, H. Abnormal features in mutant cerebellar
Purkinje cells lacking junctophilins. Biochem. Biophys. Res. Commun. 363, 835-839, 2007.
33. Kakizawa, S., Kishimoto, Y., Hashimoto, K., Miyazaki, T., Furutani, K., Shimizu, H., Fukaya, M., Nishi, M.,
Sakagami, H., Ikeda, A., Kondo, H., Kano, M., Watanabe, M., Iino, M. & Takeshima, H.
Junctophilin-mediated channel crosstalk essential for cerebellar synaptic plasticity. EMBO J. 26, 1924-1933,
2007.
34. Kamikubo, Y., Tabata, T., Kakizawa, S., Kawakami, D., Watanabe, M., Ogura, A., Iino, M. & Kano, M.
Postsynaptic GABAB Receptor Signaling Enhances LTD in Cerebellar Purkinje Cells. J. Physiol. 585,
549-563, 2007.
35. Kina, S., Tezuka, T., Kusakawa, S., Kishimoto, Y., Kakizawa, S., Hashimoto, K., Ohsugi, M., Kiyama, Y.,
Horai, R., Kakuta, S., Iwakura, Y., Iino, M., Kano, M., Manabe, T. & Yamamoto, T. Involvement of
protein-tyrosine phosphatase PTPMEG in motor learning and cerebellar long-term depression. Eur. J.
Neurosci. 26, 2269-2278, 2007.
36. Matsushita, Y., Furukawa, T., Kasanuki, H., Nishibatake, M., Kurihara, Y., Ikeda, A., Kamatani, N., Takeshima,
H. & Matsuoka, R. Mutations of junctophilin type 2 associated with hypertrophic cardiomyopathy. J. Hum.
Genet. 52, 543-548, 2007.
37. Miyakawa, K., Uchida, A., Shiraki, T., Teshima, K., Takeshima, H. & Shibata, S. ORL1 receptor-mediated
down-regulation of mRER2 in the suprachiasmatic nucleus accelerates re-entrainment of the circadian clock
following a shift in the environmental light/dark cycle. Neuropharmacol. 52, 1055-1064, 2007.
38. Nagai, J., Kurokawa, M., Takeshima, H., Kieffer, B. L. & Ueda, H. Nociceptin receptor (NOP)-deficient mice
show memory and learning enhancement in a novel KUROBOX apparatus using stress-free positive cue task.
J. Pharmacol. Exp. Ther. 321, 195-201, 2007.
39. Phimister, A. J., Lango, J., Lee, E. H., Ernst-Russell, M., Takeshima, H., Ma, J., Allen, P. D. & Pessah, I. N.
− 238 −
Conformation-dependent stability of junctophilin 1 (JP1) and ryanodine receptor type 1 (RyR1) channel
complex is mediated by their hyper-reactive thiols. J. Biol. Chem. 282, 8667-8677, 2007.
40. Uemura, T., Kakizawa, S., Yamasaki, M., Sakimura, K., Watanabe, M., Iino, M. & Mishina, M. Regulation
of Long-Term Depression and Climbing Fiber Territory by GluRG2 at Parallel Fiber Synapses through its
Carboxyl Terminal Domain in Cerebellar Purkinje Cells. J. Neurosci. 27, 12096-12108, 2007.
41. Weisleder, N., Ferrante, C., Hirata, Y., Collet, C., Chu, Y., Cheng, H., Takeshima, H. & Ma, J. Systemic
ablation of RyR3 alters Ca2+ spark signaling in adult skeletal muscle. Cell Calcium 42, 548-555, 2007.
42. Yamazaki D, Ohya S, Asai K, Imaizumi Y. Characteristics of the ATP-induced Ca2+-entry pathway in the
t-BBEC 117 cell line derived from bovine brain endothelial cells. J Pharmacol Sci, 104, 103-107, 2007.
43. Yamazaki, T., Sasaki, N., Nishi, M., Yamazaki, D., Ikeda, A., Okuno, Y., Komazaki, S. & Takeshima, H.
Augmentation of drug-induced cell death by ER protein BRI3BP. Biochem. Biophys. Res. Commun. 362,
971-975, 2007.
44. Yazawa, M., Ferrante, C., Feng, J., Mio, K., Ogura, T., Zhang, M., Lin, P-H., Pan, Z., Komazaki, S., Kato, K.,
Nishi, M., Zhao, X., Weisleder, N., Sato, C., Ma, J. & Takeshima, H. TRIC channels are essential for Ca2+
handling in intracellular stores. Nature 448, 78-82, 2007.
45. Zhang, M., Yamazaki, T., Yazawa, M., Treves, S., Nishi, M., Murai, M., Shibata, E., Zorzato, F. & Takeshima,
H. Calumin, a novel Ca2+-binding transmembrane protein on the endoplasmic reticulum. Cell Calcium 42,
83-90, 2007.
46. Furutani, K., Okubo, Y., Kakizawa, S. & Iino, M. Postsynaptic inositol 1.4.5-trisphosphate signaling
maintains presynaptic function of parallel fiber-Purkinje cell synapses via BDNF. Proc. Natl. Acad. Sci. USA.
103, 8528-8533, 2006.
47. Hirata, Y., Brotto, M., Weisleder, N., Chu, Y., Lin, P., Zhao, X., Thornton, A., Komazaki, S., Takeshima, H.,
Ma, J. & Pan, Z. Uncoupling of store-operated Ca2+ entry and altered Ca2+ release from sarcoplasmic
reticulum through silencing of junctophilins. Biophys. J. 90, 4418-4427, 2006.
48. Himukashi, S., Takeshima, H., Koyanagi, S., Shichino, T. & Fukuda, K. The involvement of the nociceptin
receptor in the antinociceptive action of nitrous oxide. Anesth. Analg. 103, 738-741, 2006.
49. Kiyoshi H, Yamazaki D, Ohya S, Kitsukawa M, Muraki K, Saito SY, Ohizumi Y, Imaizumi Y. Molecular and
electrophysiological characteristics of K+ conductance sensitive to acidic pH in aortic smooth muscle cells of
WKY and SHR. Am. J. Physiol. Heart Circ. Physiol. 291, H2723-H2734, 2006.
50. Kizuka, Y., Matsui, T., Takematsu, H., Kozutsumi, Y., Kawasaki, T., & Shogo Oka, S. Physical and functional
association of glucuronyltransferases and sulfotransferase involved in HNK-1 biosynthesis. J. Biol. Chem. 281,
13644-13651, 2006.
51. Miyazaki, T., Hashimoto, K., Uda, A., Sakagami, H., Nakamura, Y., Saito, S., Nishi, M., Kume, H., Tohgo, A.,
Kaneko, I., Kondo, H., Fukunaga, K., Kano, M., Watanabe, M. & Takeshima, H. Disturbance of cerebellar
synaptic maturation in mutant mice lacking BSRPs, a novel brain-specific receptor-like protein family. FEBS
Lett. 580, 4057-4064, 2006.
52. Moriguchi, S., Nishi, M., Komazaki, S., Sakagami, H., Miyazaki, T., Masumiya, H., Saito, S., Watanabe, M.,
Kondo, H., Yawo, H., Fukunaga, K. & Takeshima, H. Functional uncoupling between Ca2+ release and
afterhyperpolarization in mutant hippocampal neurons lacking junctophilins. Proc. Natl. Acad. Sci. USA. 103,
10811-10816, 2006.
53. Ohkubo Y, Ueta A, Ando N, Ito T, Yamaguchi S, Mizuno K, Sumi S, Maeda T, Yamazaki D, Kurono Y,
Fujimoto S, Togari T. Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method
for identifying a common mutation. J Hum Genet, 51, 118-123, 2006.
54. Okuda-Ashitaka, E., Minami, T., Matsumura, S., Takeshima, H., Reinscheid, R. K., Civelli, O. & Ito, S. The
opioid peptide nociceptin/orphanin FQ mediates prostaglandin E-induced allodynia, tactile pain associated
with nerve injury. Eur. J. Neurosci. 23, 995-1004, 2006.
55. Togho, A., Eiraku, M., Miyazaki, T., Miura, E., Kawaguchi, S., Nishi, M., Watanabe, M., Hirano, T., Kengaku,
M. & Takeshima, H. Impaired cerebellar functions in mutant mice lacking DNER. Mol. Cell. Neurosci. 31,
326-333, 2006.
56. Yamazaki D, Aoyama M, Ohya S, Muraki K, Asai K, Imaizumi Y. Novel functions of small conductance Ca2+
activated K+ channel in enhanced cell proliferation by ATP in brain endothelial cells. J Biol Chem, 281,
38430-38439, 2006.
57. Yoshida, T., Inoue, R., Morii, T., Takahashi, N., Yamamoto, S., Hara, Y., Tominaga, M., Shimizu, S., Sato, Y.,
& Mori, Y. Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nature Chem. Biol. 2, 596-607,
2006.
58. Weisleder, N., Brotto, M., Komazaki, S., Pan, Z., Zhao, X., Nosek, T., Parness, J., Takeshima, H. & Ma, J.
Muscle aging is associated with compromised Ca2+ spark signaling and segregated intracellular Ca2+ release. J.
Cell Biol. 174, 639-645, 2006.
㸦ⱥᩥ⥲ㄝ㸧
− 239 −
1. Yamamoto, S., Takahashi, N. & Mori, Y. Chemical physiology of oxidative stress-activated TRPM2 and TRPC5
channels. Prog Biophys Mol Biol 103, 18-27, 2010.
2. Yamazaki D, Yamazaki T, Takeshima H. New molecular components supporting ryanodine receptor-mediated
Ca2+ release: roles of junctophilin and TRIC channel in embryonic cardiomyocytes. Pharmacol Ther, 121,
265-272, 2009.
3. Takeshima, H. Junctophilin. Encyclopedia of movement disorders. (Elsevier Limitted, Oxford, UK. 2009)
4. Weisleder, N., Takeshima, H. &Ma, J. Mitsugumin 53 (MG53) facilitates vesicle trafficking in striated muscle
to contribute to cell membrane repair. Commun. Integr. Biol. 3, 225-226, 2009.
5. Kakizawa, S., Moriguchi, S., Ikeda, A., Iino, M. & Takeshima, H. Functional crosstalk between cell-surface and
intracellular channels mediated by junctophilins essential for neuronal functions. Cerebellum 7, 385-391,
2008.
6. Weisleder, N., Takeshima, H. & Ma, J. Immuno-proteomic approach to excitation- contraction coupling in
skeletal and cardiac muscle: molecular insights revealed by the mitsugumins. Cell Calcium 43, 1-8, 2008.
7. Yamamoto, S., Wajima, T., Hara, Y., Nishida, M. & Mori, Y. Transient receptor potential channels in
Alzheimer's disease. Biochim Biophys Acta 1772, 958-967, 2007.
8. Saito, S. & Takeshima, H. DNER as key molecule for cerebellar maturation. Cerebellum 5, 227-231, 2006.
㸦࿴ᩥ⥲ㄝ㸧
ᰠ⃝ ᫀ I ᆺ࢖ࣥࢩࣗࣜࣥᵝᡂ㛗ᅉᏊཷᐜయ ⏕యࡢ⛉Ꮫ 61, 386-387, 2010.
➉ᓥᾈ ⤖ྜ⭷ᵓ㐀࡜ࢳࣕࢿࣝᶵ⬟ඹᙺ BIO Clinica 25 1165-1170, 2010.
ᒣᓮ኱ᶞ ᑠ⬊య࡟࠾ࡅࡿ TRIC ࢳࣕࢿࣝᶵᵓ ་Ꮫࡢ࠶ࡺࡳ 235, 341, 2010.
ᒣᓮ኱ᶞࠊᒣᮏఙ୍㑻ࠊ➉ᓥᾈ ᑠ⬊య Ca2+ᨺฟ࡟࠾ࡅࡿ TRIC ࢳࣕࢿࣝࡢ⏕⌮ⓗᙺ๭ ᪥ᮏ⸆⌮Ꮫ
఍ㄅ 135, 99-103, 2010.
5. 㧗ᶫ㔜ᡂࠊᒣᮏఙ୍㑻ࠊ᳃Ὀ⏕ 㓟໬ࢫࢺࣞࢫసືᛶ TRP ࢳࣕࢿࣝࡢ໬Ꮫ⏕⌮Ꮫ ᐇ㦂་Ꮫቑห 27,
196-204, 2009.
6. ➉ᓥᾈ ⤖ྜ⭷ᵓ㐀࡜ࢪࣕࣥࢡࢺࣇ࢕ࣜࣥ ་Ꮫࡢ࠶ࡺࡳ 230, 1163-1164, 2009.
7. ἟⏣᭸኱ࠊ㤶す኱㍜ࠊ㧗ᶫ㔜ᡂࠊຍ⸨㈼ኴࠊ⎩⏕ᖾႹࠊᒣᮏఙ୍㑻ࠊ㔠Ꮚ㞝ࠊ┾ᮏ㐩⏕ࠊ᳃Ὀ⏕ TRP
ࢳࣕࢿࣝࡢᵓ㐀࡜ከᵝ࡞ᶵ⬟ ⏕໬Ꮫ 81, 962-983, 2009.
8. ᒣᓮ኱ᶞࠊᒣ㷂ဴ⏨ࠊ➉ᓥᾈ TRIC ࢳࣕࢿࣝࡢ⏕⌮ⓗᶵ⬟ ⏕໬Ꮫ 81, 1004-1008, 2009.
9. ᒣᮏఙ୍㑻ࠊΎỈಇ୍ࠊ᳃Ὀ⏕ TRPM2 ࢳࣕࢿࣝ࡟ࡼࡿάᛶ㓟⣲ࢩࢢࢼࣝቑᖜ࡜៏ᛶ⅖⑕ࡢ㛵㐃
᪥ᮏ⸆⌮Ꮫ఍ㄅ 134, 122-130, 2009.
10. ➉ᓥᾈ ᑠ⬊య Ca2+ᨺฟࢆᨭ࠼ࡿ TRIC ࢳࣕࢿࣝ ໬Ꮫ࡜⏕≀ 46, 158-160, 2008.
11. ᒣᓮဴ⏨ࠊ➉ᓥᾈ ➽ᑠ⬊య Ca2+ᨺฟࡢศᏊᶵᵓ ᚰ⮚ 40, 222-226, 2008.
12. ᒣᮏఙ୍㑻ࠊ㧗ᶫ㔜ᡂࠊΎ୰ⱱᶞࠊ᳃Ὀ⏕ ⎔ቃᛂ⟅ࢆᢸ࠺࢖࢜ࣥࢳࣕࢿࣝ άᛶ໬Ꮫ✀࡟ࡼࡾάᛶ
໬ࡉࢀࡿ TRP ࢳࣕࢿࣝࡢศᏊᶵᵓ ⺮ⓑ㉁᰾㓟㓝⣲ 54, 212–223, 2009.
13. ➉ᓥᾈ ⤖ྜ⭷ᙧᡂᅉᏊ ࢪࣕࣥࢡࢺࣇ࢕ࣜࣥ ᐇ㦂་Ꮫ 26, 462-466, 2008.
14. ụ⏣⠜ྐࠊᒣᓮဴ⏨ࠊ➉ᓥᾈ ࣜ࢔ࣀࢪࣥཷᐜయ࡟ࡼࡿᑠ⬊య Ca2+ᨺฟࡢศᏊᶵᵓ ⺮ⓑ㉁᰾㓟㓝
⣲ 52, 1965-1972, 2007.
15. ᰠ⃝ ᫀ. ᡂ⇍⬻࡟࠾ࡅࡿࢩࢼࣉࢫࡢᶵ⬟⥔ᣢ࡟ࡣ⚄⤒άືࡀᚲせ࡛࠶ࡿ. ᪥ᮏ⏕⌮Ꮫ㞧ㄅ 68,
198, 2006.
1.
2.
3.
4.
㸦ⴭ᭩㸧
1. ➉ᓥᾈࠊᰠ⃝ ᫀ ་ṑ⸆⣔Ꮫ⏕ࡢࡓࡵࡢᇶ♏⏕࿨⛉Ꮫ㸦➨஧∧㸧 ி㒔ᘅᕝ᭩ᗑ ༳ๅ୰
2. ➉ᓥᾈࠊᒣᓮဴ⏨ࠊụ⏣⠜ྐࠊ㍿Ỉᓫ㙾 ་ṑ⸆⣔Ꮫ⏕ࡢࡓࡵࡢᇶ♏⏕࿨⛉Ꮫ ி㒔ᘅᕝ᭩ᗑ, 2008.
3. ᰠ⃝ ᫀ ᪂࣍ࣝࣔࣥࣁࣥࢻࣈࢵࢡ ⚄⤒ᰤ㣴ᅉᏊ ᾆ㔝 ᫂ኸࡽ⦅ࠊ༡Ụᇽ 497-589, 2007.
− 240 −
ศᏊᚤ⏕≀Ꮫศ㔝
෸ᩍᤵ㸦་Ꮫ༤ኈ㸧Ώ㒊 ዲᙪ㸦ࢃࡓ࡞࡭ ࡼࡋࡦࡇ㸧(1989.4 ╔௵)
᫛࿴㸰㸰ᖺ㸲᭶㸰㸵᪥⏕
᫛࿴㸲㸴ᖺᮾி኱Ꮫ⌮Ꮫ㒊༞ࠊ
᫛࿴㸲㸷ᖺྠ኱Ꮫ኱Ꮫ㝔⌮Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
ศᏊᚤ⏕≀Ꮫศ㔝ࡣࠊᢠ࢘࢖ࣝࢫάᛶࢆ᭷ࡍࡿࢧ࢖ࢺ࢝࢖ࣥࠊ࢖ࣥࢱ
࣮ࣇ࢙ࣟࣥ㸦IFN㸧࡟㛵ࢃࡿㅖၥ㢟ࢆ◊✲ࢸ࣮࣐࡟ྲྀࡾୖࡆ࡚࠸ࡿࠋิᣲࡍࢀࡤࠊ࢘࢖ࣝࢫឤᰁ࡟ᑐࡍ
ࡿ⮬↛ච␿࡟࠾ࡅࡿ IFN ࡢ⏘⏕ᶵᵓࡢゎᯒࠊୖ⓶⣔⣽⬊࡟࠾ࡅࡿ IFN ⏘⏕ࡢㄏⓎ࡜ศἪ᪉ྥᛶࡢゎᯒࠊ
ࣄࢺ㑇ఏᛶ⑌ᝈ࡜ IFN ⏘⏕⬟ࡢ┦㛵ᛶࡢゎᯒࠊIFN ࡟ࡼࡿ࣐ࢡࣟࣇ࢓࣮ࢪࡢ⣽⬊Ṛㄏᑟᶵᗎࡢゎᯒࠊ࣐
ࢡࣟࣇ࢓࣮ࢪࡢṚ⣽⬊㈎㣗࡟ࡼࡿ IFN ⏘⏕ᶵᗎࡢゎᯒࠊ࣐࢘ࢫ⬇ᛶ⣽⬊ࡢศ໬࡟క࠺ IFN ࢩࢫࢸ࣒⣔
ࡢᡂ❧ᶵᗎࡢゎᯒࠊIFN 㑇ఏᏊᑟධ࡟ࡼࡿᢠ⭘⒆ຠᯝࡢゎᯒ࡞࡝࡛࠶ࡿࠋࡇࢀࡽࡢ᭱㏆ࡢ◊✲ᡂᯝࢆ௨
ୗ࡟ࡲ࡜ࡵࡿࠋ
࢘࢖ࣝࢫឤᰁ࡟ᑐࡍࡿ⮬↛ච␿࡟࠾ࡅࡿ IFN ࡢ⏘⏕ᶵᵓࡢゎᯒ
IFN ࡣ࢘࢖ࣝࢫឤᰁ࡟ࡼࡾᐟ୺⣽⬊ࡀ⏘⏕ࡍࡿᢠ࢘࢖ࣝࢫᅉᏊ࡜ࡋ࡚Ⓨぢࡉࢀࡓࢧ࢖ࢺ࢝࢖࡛ࣥࠊ
ᐟ୺ࡢ࢘࢖ࣝࢫឤᰁ࡟ᑐࡍࡿ⏕య㜵ᚚ࡟㔜せ࡞ᙺ๭ࢆᯝࡓࡋ࡚࠸ࡿࠋ㏆ᖺࠊ⮬↛ච␿ᛂ⟅࠾ࡼࡧ㐺
ᛂච␿ᛂ⟅ࡢ௙⤌ࡳࡀヲ⣽࡟᫂ࡽ࠿࡟࡞ࡾࠊIFN ࡣ࢘࢖ࣝࢫឤᰁ࡟ᑐࡍࡿ⮬↛ච␿ᛂ⟅࡜ࡋ࡚⏘⏕
ࡉࢀࡿࢧ࢖ࢺ࢝࢖ࣥ࡜ࡋ࡚఩⨨࡙ࡅࡽࢀࡿࡼ࠺࡟࡞ࡗࡓࠋ࢘࢖ࣝࢫឤᰁ࡛ᐟ୺࡟ࡼࡾឤ▱ࡉࢀࡿศ
Ꮚࡣ࢘࢖ࣝࢫ⏤᮶ࡢྛ✀᰾㓟ศᏊ࡛࠶ࡾࠊࡑࢀࡽࡢឤ▱ศᏊࡣᐟ୺㑇ఏᏊ࡟⤌ࡳ㎸ࡲࢀ࡚࠸ࡿࡇ࡜
ࡀ᫂ࡽ࠿࡟࡞ࡗ࡚ࡁࡓࠋ㏆ᖺࠊ⣽⬊㉁ෆࡢ dsDNA ࡟ᑐࡋ࡚ࡶᛂ⟅ࡋ IFN ࢆ⏘⏕ࡍࡿࡇ࡜ࡀ♧ࡉࢀ
ࡓࡀࠊࡑࡢឤ▱ศᏊࡢᮏయࡣᮍྠᐃ࡛࠶ࡾࠊIFN ⏘⏕ㄏᑟᶵᵓࡣࡲࡔ୙᫂ࡢⅬࡀከ࠸ࠋࡇࡢၥ㢟ࢆ
ゎ᫂ࡍ࡭ࡃࠊ࣐࢘ࢫࡢ⣔ࢆ୰ᚰ࡟◊✲ࢆ㐍ࡵ࡚࠾ࡾࠊ⯆࿡῝࠸⤖ᯝࡀᚓࡽࢀࡘࡘ࠶ࡿࠋ
ୖ⓶⣔⣽⬊࡟࠾ࡅࡿ IFN ⏘⏕ࡢㄏⓎ࡜ศἪ᪉ྥᛶࡢゎᯒ
ୖ⓶⣔⣽⬊ࡣከࡃࡢ⤌⧊࡛᭱እ㒊࡟୍ᒙࢆ࡞ࡋእ㒊࡬ࡢ≀㉁ࡢᨺฟ࣭ศἪࡸྲྀࡾ㎸ࡳࢆᢸࡗ࡚࠾
ࡾࠊ⣽⬊ࡢ㡬ഃ⭷ഃࡢ⣽⬊⭷࡜ᇶᗏ⭷ഃࡢࡑࢀ࡜࡛ࡣᵓᡂᡂศࡸᛶ㉁ࢆ␗࡟ࡍࡿࠋⓎ⌧࣋ࢡࢱ࣮ࡢ
ᑟධ࡟ࡼࡾ ,)1 㑇ఏᏊࢆⓎ⌧ࡉࡏࡿ࡜ࠊ㑇ఏᏊᑟධࢆ㡬ഃ⭷ഃࡍࡿሙྜ࡜ᇶᗏ⭷ഃ࠿ࡽࡍࡿሙྜ࡜
࡛ ,)1 ࡢ⏘⏕ศἪ᪉ྥࡀ㑇ఏᏊᑟධഃ࡟౫Ꮡࡍࡿࡇ࡜ࡀ♧ࡉࢀࡓࠋࡲࡓ࢘࢖ࣝࢫឤᰁࡢሙྜ࡛ࡶྠ
ᵝࡢ⤖ᯝࡀᚓࡽࢀࡓࠋࡑࡢᶵᗎࡢゎ᫂ࡣᮍゎỴ࡛࠶ࡿࠋ
࣐ࢡࣟࣇ࢓࣮ࢪ⣔⣽⬊࡟࠾ࡅࡿ IFN ࢩࢫࢸ࣒ࡢゎᯒ
࣐ࢡࣟࣇ࢓࣮ࢪࡣ⮬↛ච␿ᛂ⟅ࡢึᮇᛂ⟅ࢆᢸ࠺㔜せ࡞⣽⬊࡛࠶ࡾࠊࢢ࣒ࣛ㝜ᛶ⣽⳦ࡢ⭷ᡂศ
࡛࠶ࡿ࣏ࣜከ⢾࡟㐣ᩄ࡟ᛂ⟅ࡋ⅖⑕ࢆ㉳ࡇࡍࠋࡇࡢ࡜ࡁ IFNJࡢస⏝ࢆྠ᫬࡟ཷࡅࡿ࡜⣽⬊ࡣ⣽⬊
Ṛࢆ㉳ࡇࡍࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡓࠋࡇࡢᶵᗎࢆゎ᫂ࡍ࡭ࡃ࣐࢘ࢫࡢ࣐ࢡࣟࣇ࢓࣮ࢪᵝ⣽⬊࡛ㄪ࡭ࡓ
࡜ࡇࢁࠊ⣽⬊Ṛࢆ㉳ࡇࡍ࡟ࡣ㸱d ࡜࠸࠺㛗᫬㛫ࢆせࡍࡿࡇ࡜࡜ࠊ⣽⬊Ṛࡣ NO ⏘⏕ࢆ㜼ᐖࡍࡿ࡜㜼
Ṇ࡛ࡁࡿࡇ࡜ࡀศ࠿ࡗࡓࠋIFNJࡣ⣽⬊ᛶච␿ᛂ⟅࡟࠿࠿ࢃࡿ T ⣽⬊ࡀ⏘⏕ࡍࡿࡇ࡜࠿ࡽࠊࡇࡢ⣽
⬊Ṛࡣ࣐ࢡࣟࣇ࢓࣮ࢪࡢ⣽⬊ᶵ⬟ࢆ࠶ࡿ⛬ᗘᣢ⥆ࡉࡏࡓࡢࡕࠊ㐣๫࡞ᛂ⟅ࢆ཰᮰ࡉࡏࡿᙺ๭ࢆᢸ
ࡗ࡚࠸ࡿྍ⬟ᛶࡀ᥎ᐹࡉࢀࡓࠋ
ࡲࡓࠊ࣐ࢡࣟࣇ࢓࣮ࢪࡣ⮬ᕫṚ⣽⬊ࡢ㈎㣗ฎ⌮ࢆᢸࡗ࡚࠾ࡾࠊࡇࡢฎ⌮ࡀ୙඲࡛⣽⬊ෆ࡟ᮍฎ
⌮ DNA ࡀṧᏑࡍࡿࡼ࠺࡟࡞ࡿ࡜ IFN ⏘⏕ࡀㄏᑟࡉࢀࡿࡇ࡜ࡀ♧ࡉࢀ࡚࠸ࡿࡀࠊᐇ㝿ࠊṚ⣽⬊ࡢ㈎
㣗ฎ⌮᫬࡟ IFN ࡀㄏᑟࡉࢀࡿ࠿࡝࠺࠿ࡣ୙࡛᫂࠶ࡿࠋࡑࡇ࡛ࠊṚ⣽⬊ࢆ࣐࢘ࢫࡢ࣐ࢡࣟࣇ࢓࣮ࢪ
ᵝ⣽⬊࡟ྲྀࡾ㎸ࡲࡏ࡚ࡳࡓ࡜ࡇࢁࠊᚤ㔞࡞ࡀࡽ IFN ࢆ⏘⏕ࡍࡿࡇ࡜ࡀ♧ࡵࡉࢀࠊIFN ㄏᑟᅉᏊࡣ
DNA ࡛࠶ࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ
࣐࢘ࢫ⬇ᛶ⣽⬊ࡢศ໬࡟క࠺ IFN ࢩࢫࢸ࣒⣔ࡢᡂ❧ᶵᗎࡢゎᯒ
࣐࢘ࢫࡢ⣔࡛ IFN ⏘⏕⬟ࡣ⬇Ⓨ⏕ࡢึᮇ࡟ࡣࡳࡽࢀࡎࠊศ໬࡟కࡗ࡚ฟ⌧ࡋ࡚᮶ࡿࡇ࡜ࡀ♧ࡉࢀ
࡚࠸ࡿࡀࠊࡑࡢヲ⣽ࡣࡼࡃㄪ࡭ࡽࢀ࡚࠸࡞࠸ࠋࡑࡇ࡛࣐࢘ࢫ⬇ᛶ⭘⒆⣽⬊ࢆ⏝࠸࡚ゎᯒࢆヨࡳࡓࠋࣞ
ࢳࣀ࢖ࣥ㓟ฎ⌮࡟ࡼࡾศ໬ࡉࡏࡿ࡜ dsRNA ฎ⌮࡟ᛂ⟅ࡋ࡚ IFN ⏘⏕ࢆ♧ࡍࡼ࠺࡟࡞ࡗࡓࡀ dsDNA ࡟
ࡼࡿ⏘⏕⬟ࡣࡳࡽࢀ࡞࠿ࡗࡓࠋࡑࡢ⌮⏤ࢆศᏊⓗ࡟ゎ᫂ࡍ࡭ࡃゎᯒࢆ㐍ࡵ࡚࠸ࡿࠋ
− 241 −
ࣄࢺ㑇ఏᛶ⑌ᝈ࡜ ,)1 ⏘⏕⬟ࡢ┦㛵ᛶࡢゎᯒ
ࣄࢺ㑇ఏᛶ⑌ᝈ࡜ ,)1 ⏘⏕⬟ࡢ┦㛵ᛶࢆ᥈⣴ࡍ࡭ࡃࠊ࢙࢘ࣝࢼ࣮⑕ೃ⩌ࠊࣈ࣮࣒ࣝ⑕ೃ⩌ࠊࣟࢫ
࣒ࣥࢻࢺ࣒ࢯࣥ⑕ೃ⩌ࠊ࢔ࢱ࢟ࢩ࢔࣭ࢸࣛࣥࢪ࢙ࢡࢱࢩ࢔⑕ࠊࣇ࢓ࣥࢥࢽ࣮㈋⾑⑕ࠊ࠾ࡼࡧ➨ ␒ᰁⰍయࢺࣜࢯ࣑࣮ᝈ⪅⏤᮶⣽⬊ᰴࢆ⏝࠸࡚ࠊGV51$ ࡸ GV'1$ ࡟ࡼࡿ ,)1 ⏘⏕ㄏᑟ⬟ࢆㄪ࡭࡚ࡳࡓ
ࡀࠊࣄࢺṇᖖ㸰ಸయ⣽⬊ᰴ࡜ẚ࡭࡚ࠊ኱ࡁ࡞ᕪ␗ࡣㄆࡵࡽࢀ࡞࠿ࡗࡓࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
◊✲ᡂᯝࡣࠊ⮬↛ච␿ᛂ⟅࡟࠾ࡅࡿ IFN ࡢᙺ๭ࡢゎ᫂࡟ᐤ୚ࡍࡿ࡜࡜ࡶ࡟ࠊIFN ࡟㛵ࡍࡿ⌮ゎࢆ῝ࡵ
ࡿ࡜ᛮࢃࢀࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣࠊᚤ⏕≀Ꮫϩ㸦࢘࢖ࣝࢫᏛ㸧ࡢㅮ⩏ㄢ┠ࢆᢸᙜࡋ࡚࠸ࡿࠋ᭱㏆ࡢ◊✲ᡂᯝ࡟ࡶ
ゝཬࡋࠊཷㅮ⪅ࡢ㛵ᚰࢆ㧗ࡵࡿᕤኵࢆࡋ࡚࠸ࡿࠋ
≉ูᐇ⩦࠾ࡼࡧ኱Ꮫ㝔ᩍ⫱㸸≉ูᐇ⩦㓄ᒓࡢᏛ⏕࡟ࡣࠊྛே࡟ࢸ࣮࣐ࢆ♧ࡋࠊ◊✲ࡢព⩏ࡢ⌮ゎࢆ
῝ࡵࠊ⮬ศ࡛௙஦ࢆ㐍ࡵࡿ⬟ຊࢆ㧗ࡵࡿ࡭ࡃᣦᑟࡋ࡚࠸ࡿࠋ㝔⏕࡟ࡣࠊಶࠎே࡟ࢸ࣮࣐ࢆタᐃࡋࠊ⊂
❧ࡋ࡚◊✲࡟ᙜࡓࡽࡏ࡚࠸ࡿࠋ⥥ᐦ࡟ᐇ㦂ࡢ㐍ᤖ≧ἣࡢሗ࿌࡞ࡽࡧ࡟⤖ᯝ࡟ᑐࡍࡿ㆟ㄽࢆ⾜࠸࡞ࡀࡽ
◊✲┠ᶆࡢ㐩ᡂ࡟ྥ࠿ࢃࡏ࡚࠸ࡿࠋᙜศ㔝ࡢ◊✲ࢸ࣮࣐඲⯡ࢆ⌮ゎ࡛ࡁࡿࡼ࠺࡟ࡍࡿࡓࡵࠊᩍᐊဨ඲
ဨཧຍ࡛ᐇ㦂ሗ࿌఍ࢆẖ㐌୍ᅇ⾜ࡗ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊ㉁ၥࢆ㝶᫬ཷࡅ௜ࡅࠊㅮ⩏࡟ྲྀࡾධࢀࡿࡼ࠺࡟ࡋ࡚࠸ࡿࠋ
㝔⏕ࡢᣦᑟ࡛ࡣࠊ඲ဨࡀㄢ⛬ಟ஢ᖺ࡟㛵㐃Ꮫ఍ཱྀ࡛㢌Ⓨ⾲ࢆࡋ࡚࠸ࡿࡇ࡜࠿ࡽุ᩿ࡋ࡚ࠊྛಶேࡢ
◊✲ࡢ⬟ຊ࠾ྥୖ࡟ᐤ୚ࡋ࡚࠸ࡿ࡜ᛮࢃࢀࡿࠋ኱Ꮫ㝔ಟ஢⪅ࡣ〇⸆࣓࣮࣮࢝ࡢ◊✲⫋࡟ࡘࡃࡶࡢࡀከ
࠸ࡀࠊᆅ᪉⮬἞యࡢㅖᶵ㛵࡟࠾࠸࡚ᑓ㛛ᛶࢆ⏕࠿ࡏࡿ⫋࡟ᑵࡃࡶࡢࡶ࠾ࡾࠊᩍ⫱࡜◊✲ࡢᡂᯝࡀホ౯
ࡉࢀ࡚࠸ࡿ⤖ᯝ࡛࠶ࡿ࡜ᛮࢃࢀࡿࠋ
㸦ཎⴭ㸧
1. Persistent interferon transgene expression by RNA interference-mediated silencing of interferon receptors.
Takahashi Y, Vikman E, Nishikawa M, Ando M, Watanabe Y, Takakura Y. J Gene Med. 12:739-746 (2010)
2. Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga
mice via Th1 polarization. Hattori K, Nishikawa M, Watcharanurak K, Ikoma A, Kabashima K, Toyota H,
Takahashi Y, Takahashi R, Watanabe Y, Takakura Y. J Immunol. 184:2729-2735 (2010)
3. Effects of methyl-beta-cyclodextrin treatment on secretion profile of interferon- beta and zonula occuludin-1
architecture in Madin-Darby canine kidney cell monolayers. Maruyama M, Ishida K, Watanabe Y, Nishikawa M,
Takakura Y. Biol Pharm Bull. 32:910-915 (2009)
4. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene
expression. Mitsui M, Nishikawa M, Zang L, Ando M, Hattori K, Takahashi Y, Watanabe Y, Takakura Y. J Gene
Med. 11:435-443 (2009)
5. Enhancement of antiproliferative activity of interferons by RNA interference- mediated silencing of SOCS
gene expression in tumor cells. Takahashi Y, Kaneda H, Takasuka N, Hattori K, Nishikawa M, Watanabe Y,
Takakura Y. Cancer Sci. 99:1650-1655(2008)
6. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid
DNA. Kawano H, Nishikawa M, Mitsui M, Takahashi Y, Kako K, Yamaoka K, Watanabe Y, Takakura Y. Int J
Cancer. 121:401-406(2007)
7. Inhibition of autophosphorylation of epidermal growth factor receptor by small peptides in vitro. Abe M,
Kuroda Y, Hirose M, Watanabe Y, Nakano M, Handa T. Br J Pharmacol. 147:402-411 (2006)
− 242 −
⏕యᶵ⬟ゎᯒᏛศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧㔠Ꮚ࿘ྖ㸦࠿ࡡࡇ ࡋࡹ࠺ࡌ㸧(2004.4 ᪼௵㸪2004.3
ࡲ࡛་⒪⸆⌮Ꮫศ㔝ຓᩍᤵ)
᫛࿴㸳㸳ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸴㸮ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬
ಟ஢
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧୰ᕝ㈗அ㸦࡞࠿ࡀࢃ ࡓ࠿ࡺࡁ㸧㸦2005.7 ຓᡭࡼࡾ
᪼௵㸧
ᖹᡂ㸴ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸶ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬๓ᮇㄢ
⛬ಟ஢ࠊᖹᡂ㸷ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬୰㏵㏥Ꮫࠊᖹᡂ㸯㸰
ᖺி㒔኱Ꮫ༤ኈ㸦⸆Ꮫ㸧ྲྀᚓ
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧ⓑᕝஂᚿ㸦ࡋࡽ࠿ࢃ ࡦࡉࡋ㸧㸦2006.1 COE ◊✲ဨ
ࡼࡾ᪼௵㸧
ᖹᡂ㸯㸰ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸵ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ
஢
㸦㔠Ꮚᩍᤵ㸧
◊✲ࡢᴫせ
ᙜศ㔝ࡣ⏕࿨⛉Ꮫࡢ┿⌮ࢆ᥈ồࡋࠊ἞⒪࡟᭷⏝࡞་⸆ရ๰〇࡟㈨ࡍࡿ⸆⌮Ꮫⓗ❧ሙ࡟❧ࡗࡓ⏕యᶵ⬟
ࡢゎ᫂࡜ࠊࡑࢀࢆᐇ㊶ࡍࡿ◊✲⪅ࡢ⫱ᡂࢆ┠ⓗ࡜ࡋ࡚࠸ࡿࠋ୰࡛ࡶࠊᮍゎ᫂ࡢ㒊ศࡢከ࠸୰ᯡ⚄⤒⣔࡟
↔Ⅼࢆᙜ࡚ࠊศᏊ⏕≀Ꮫⓗ᪉ἲࢆྵࡴㅖ✀ࡢ᪉ἲㄽࢆ㥑౑ࡋ࡚ࠊCa2+㏱㐣ᛶ࢖࢜ࣥࢳࣕࢿࣝ࡞࡝ࡢ⭷㍺
㏦ࢱࣥࣃࢡ㉁ࢆᑐ㇟࡜ࡍࡿᶵ⬟ゎᯒ࡜๰⸆ࠊ៏ᛶ⑊③ᶵᵓࠊᢠ࠺ࡘ⸆࣭౫Ꮡᛶ⸆≀➼ࡢస⏝ᶵᵓࠊ⚄⤒࣭
ࢢࣜ࢔⣽⬊ᶵ⬟㐃㛵ࡢゎ᫂࡟ᣮᡓࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊ⮬↛ゝㄒฎ⌮ᢏ⾡ࢆ⏕࿨⛉Ꮫࡢᩍ⫱࠿ࡽ▱㆑Ⓨぢ
࡟ࡲ࡛ᛂ⏝ࡍࡿ⊂⮬ࡢࢸ࢟ࢫࢺゎᯒ࡜ࢹ࣮ࢱ࣮࣋ࢫᵓ⠏࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
࢖࢜ࣥࢳࣕࢿࣝ๰⸆
㓝⣲ࡸཷᐜయࢆᶆⓗ࡜ࡍࡿ๰⸆ࡀ㐍ᒎࡋ࡚࠸ࡿࡢ࡟ᑐࡋ࡚ࠊ࢖࢜ࣥࢳࣕࢿ࣭ࣝࢺࣛࣥࢫ࣏࣮ࢱࢆ
⸆≀స⏝Ⅼ࡜ࡍࡿࢤࣀ࣒๰⸆ࡣᮍⓎ㐩࡛࠶ࡿࠋࡇࡢ≧ἣࢆᡴ㛤ࡍࡿࡓࡵ࡟ࡣ⭷㍺㏦ࢱࣥࣃࢡ㉁ࡢᶵ
⬟ゎ᫂ࢆ㐍ࡵࡿ࡜࡜ࡶ࡟ ᐃᡭἲࡢᨵⰋ࡜ேᮦ⫱ᡂࡀᚲせ࡛࠶ࡿࠋࡇࡢⓎ᝿࡟ᇶ࡙࠸࡚㟁఩౫Ꮡᛶ
Ca2+ࢳࣕࢿࣝࡸ TRP ࢳࣕࢿࣝࢆጞࡵ࡜ࡍࡿ Ca2+㏱㐣ᛶ࢝ࢳ࢜ࣥࢳࣕࢿࣝ࡜୰ᯡ⚄⤒⑌ᝈ࡜ࡢ㛵㐃ࢆ
᳨ウࡍࡿ࡜࡜ࡶ࡟㸪௻ᴗ࡜ࡢඹྠ◊✲࡟ࡼࡗ࡚పศᏊࣜ࢞ࣥࢻࡢస⏝ᶵᗎゎ᫂ࢆ㐍ࡵ࡚࠸ࡿࠋࡲࡓࠊ
⣽⬊ෆᑠჾᐁ࡟Ꮡᅾࡍࡿ࢖࢜ࣥࢳࣕࢿ࣭ࣝࢺࣛࣥࢫ࣏࣮ࢱࡢᶵ⬟ホ౯ࢆ⾜࠺ࡓࡵࠊ᪂ࡓ࡞⭷㍺㏦㟁
ὶ ᐃ⣔ࢆᵓ⠏ࡋ࡚࠸ࡿࠋ
៏ᛶ⑊③ᶵᵓ
⮫ᗋୖၥ㢟࡜࡞ࡿ៏ᛶ⑊③ࡢᶵᵓゎ᫂࠾ࡼࡧ᪂つ἞⒪⸆๰〇ࢆ┠ᣦࡋࠊ⬨㧊࠾ࡼࡧ⬻ෆ࡛ࣞ࣋ࣝ
ࡢ③ぬ᝟ሗఏ㐩࣭ไᚚᶵᵓࡢゎ᫂࠾ࡼࡧ៏ᛶ⑊③᫬ࡢࡑࢀࡽࡢኚᛶᶵᵓ࡟ࡘ࠸᳨࡚ウࢆ⾜ࡗ࡚࠸ࡿࠋ
≉࡟ࠊච␿⣔⣽⬊/ࢢࣜ࢔⣽⬊࡜⚄⤒⣔࡜ࡢ┦஫㐃㛵࡟╔┠ࡋ࡚◊✲ࢆ㐍ࡵ࡚࠾ࡾࠊ༢⌫/࣐ࢡࣟࣇ
࢓࣮ࢪࡸ࣑ࢡࣟࢢࣜ࢔࡟Ⓨ⌧ࡍࡿ TRPM2 ࡀ៏ᛶ⑊③Ⓨ⑕࡟㔜せ࡞ᙺ๭ࢆᢸࡗ࡚࠸ࡿࡇ࡜ࢆึࡵ࡚
᫂ࡽ࠿࡟ࡋࠊ⌧ᅾࠊࡑࡢヲ⣽࡞ᶵᵓࢆゎᯒࡋ࡚࠸ࡿ࡜ࡇࢁ࡛࠶ࡿࠋࡲࡓࠊ࢜࢟ࢧࣜࣉࣛࢳࣥ࡞࡝ࡢ
ᢠࡀࢇ๣ࡢ㔜኱࡞๪స⏝ࡢ㸯ࡘ࡛࠶ࡿᮎᲈ⚄⤒㞀ᐖ࡟ࡘ࠸࡚ࠊࡑࡢⓎ⏕࡟ TRP ࢳࣕࢿࣝࡀᯝࡓࡍᙺ
๭ࢆゎᯒࡋ࡚࠸ࡿࠋ
ᢠ࠺ࡘ⸆࣭౫Ꮡᛶ⸆≀➼ࡢస⏝ᶵᵓ
ぬ㓰๣ࠊ㯞⸆ᛶ㙠③⸆ࠊMDMA ࡞࡝ࡢ᪂ᆺ㯞⸆࡞࡝ࡢ౫Ꮡᛶ⸆≀ࠊ࠶ࡿ࠸ࡣ SSRIࠊSNRIࠊ୕⎔
⣔ᢠ࠺ࡘ⸆࡜࠸ࡗࡓᢠ࠺ࡘ⸆ࡢస⏝ᶵᵓ࡟㛵ࡋ࡚ࠊ୰⬻⓶㉁㎶⦕⬻ษ∦ඹᇵ㣴⣔࠾ࡼࡧ⦭⥺᰾ྵ᭷
୰⬻ษ∦ᇵ㣴⣔ࢆ⏝࠸࡚ࠊࡑࢀࡽࡢ㛗ᮇฎ⨨࡟ࡼࡾࠊࡑࢀࡒࢀࢻࣃ࣑ࣥ⚄⤒࠾ࡼࡧࢭࣟࢺࢽࣥ⚄⤒
ࡢάືஹ㐍ࡀ⏕ࡌࡿࡇ࡜ࢆ in vitro ࡛ึࡵ࡚᫂ࡽ࠿࡟ࡋࠊࡑࡢヲ⣽࡞ศᏊѸ ⚄⤒ᶵᵓࡢゎ᫂ࢆ㐍ࡵ
࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
୰ᕝ෸ᩍᤵࡀ➨ 25 ᅇ᪥ᮏ⸆⌮Ꮫ఍Ꮫ⾡ዡບ㈹ࢆཷ㈹ࡋࠊࡲࡓᙜศ㔝ᡤᒓࡢ኱Ꮫ㝔⏕࠾ࡼࡧ⸆Ꮫ⛉㸴
ᖺไࡢᏛ㒊⏕ࡀྛᏛ఍࡟࠾࠸࡚ᩘࠎࡢඃ⚽Ⓨ⾲㈹࣭ඃ⚽࣏ࢫࢱ࣮㈹ࢆཷ㈹ࡋ࡚࠸ࡿࡇ࡜ࠊࡉࡽ࡟ࠊᙜศ
㔝ᡤᒓࡢ኱Ꮫ㝔༤ኈㄢ⛬Ꮫ⏕ࡀ᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ㸦㹂㹁㸧࡟᥇⏝ࡉࢀ࡚࠸ࡿࡇ࡜࠿ࡽࡳ࡚ࡶࠊ
◊✲άືࡣάⓎ࡛࠶ࡾࠊࡑࡢホ౯ࡣᴟࡵ࡚㧗࠸ࠋ
ࡲࡓࡇࡢ 7 ᖺ㛫࡟ࠊబ⸨๓ᩍᤵࡀᐃᖺ㏥ᐁ࡟క࠸ዉⰋඛ➃⛉Ꮫᢏ⾡኱Ꮫ㝔኱Ꮫ࣭┘஦࡟㌿ฟࠊ㔠Ꮚᩍ
− 243 −
ᤵࡀி㒔኱Ꮫ⸆Ꮫ◊✲⛉་⒪⸆⌮Ꮫศ㔝࠿ࡽ╔௵ࠊ༡๓ຓᩍᤵࡀ໭ᾏ㐨኱Ꮫ⸆Ꮫ◊✲⛉⸆⌮Ꮫศ㔝࡬ᩍ
ᤵ࡟㌿ฟࠊ୰ᕝຓᩍᤵࡀຓᡭ࠿ࡽ᪼௵ࡍࡿ࡞࡝ே஦㠃ࡶάⓎ࡛࠶ࡾࠊᙜศ㔝ࡀ௚࠿ࡽ㧗࠸ᐈほⓗホ౯ࢆ
ཷࡅ࡚࠸ࡿࡇ࡜ࢆ⿬௜ࡅ࡚࠸ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝࡛ࡣ⌧ᅾࠊ㔠Ꮚᩍᤵࡀ඲Ꮫඹ㏻⛉┠ࠕ⸆Ꮫᴫㄽࠖ㸦㸯ᅇ⏕๓ᮇ⛉┠㸧ࡢㅮ⩏㸯ᅇࠊࠕඛ
➃་⒪ SGD ₇⩦ࠖ㸦㸯ᅇ⏕๓ᮇ⛉┠㸧ࡢ₇⩦㸰ᅇࠊࠕ⏕⌮Ꮫ㸰㸦ศᏊ⏕⌮Ꮫ㸧ࠖ㸦㸰ᅇ⏕๓ᮇ⛉┠㸧ࡢㅮ
⩏඲࡚㸦㸯㸱ᅇ㸧ࠊࠕ⸆≀἞⒪Ꮫ㸯ࠖ㸦㸲ᅇ⏕๓ᮇ⛉┠㸧ࡢㅮ⩏㸱ᅇ࣭₇⩦㸰ᅇࢆᢸᙜࡋ࡚࠸ࡿ௚ࠊ㝃ᒓ
ᅗ᭩㤋ᥦ౪඲Ꮫඹ㏻⛉┠ࠕ᝟ሗ᥈⣴ධ㛛ࠖ㸦㸯ࠥ㸲ᅇ⏕๓ᮇ⛉┠㸧ࡢㅮ⩏࠾ࡼࡧ₇⩦㸱ᅇࢆᢸᙜࡋࠊ୰
ᕝ෸ᩍᤵࡀࠕ⸆⌮Ꮫ㸰㸦ᚠ⎔ჾ⸆⌮㸧ࠖ㸦㸱ᅇ⏕๓ᮇ⛉┠㸧ࡢㅮ⩏඲࡚㸦㸯㸱ᅇ㸧ࠊࠕ⸆≀἞⒪Ꮫ㸯ࠖ㸦㸲
ᅇ⏕๓ᮇ⛉┠㸧ࡢㅮ⩏㸳ᅇ࣭₇⩦㸰ᅇࠊ⸆Ꮫᑓ㛛ᐇ⩦ III㸦㸱ᅇ⏕ᚋᮇ⛉┠㸧ࡢ⸆⌮Ꮫᐇ⩦ࠊ࠾ࡼࡧ⏕࿨
⣔ࡢᑡேᩘࢭ࣑ࢼ࣮㸦࣏ࢣࢮ࣑㸧㸰ᅇࢆᢸᙜࡋࠊⓑᕝຓᩍࡀࠕᇶ♏ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࠖ㸦㸲ᅇ
⏕๓ᮇ⛉┠㸧ࡢ₇⩦㸯ᅇࠊ་⸆ရ㛤Ⓨࣉࣟࢪ࢙ࢡࢺ₇⩦㹇㸦㸱ᅇ⏕㞟୰⛉┠㸧ࢆᢸᙜࡍࡿ࡞࡝㠀ᖖ࡟ከ
ࡃࡢ⛉┠ࢆᢸᙜࡋ࡚࠸ࡿࠋࡲࡓࠊ⸆Ꮫᑓ㛛ᐇ⩦ V㸦⑓㝔ᐇ⩦㸧ࡢ࣏ࢫࢺࢺ࣮ࣞࢽࣥࢢ࡜ࡋ࡚ࡢ⸆๣ᖌᅜ
ᐙヨ㦂๓⿵ㅮࡸᶍᨃヨ㦂ࢆᐇ᪋ࡋࠊ⸆๣ᖌᅜᐙヨ㦂ࡢྜ᱁ࢆ┠ᣦࡍᏛ⏕ࢆᨭ᥼ࡋ࡚࠸ࡿࠋࡇࢀࡽࡢ⛉┠
ࡢࢩࣛࣂࢫࠊㅮ⩏ෆᐜࠊᑠࢸࢫࢺࠊ඲యᡂ⦼ࠊ㐣ཤࡢヨ㦂ၥ㢟ࠊ⛉┠ᡂ⦼࡜⸆๣ᖌᅜᐙヨ㦂ྜ᱁࡜ࡢ┦
㛵㛵ಀࠊᏛ⏕࢔ࣥࢣ࣮ࢺ࡞࡝ࡢ᝟ሗࡣࡍ࡭࡚ศ㔝࣮࣒࣮࣍࣌ࢪ࡛බ㛤ࡋ࡚࠾ࡾࠊ᝟ሗබ㛤࡟ດࡵ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗᐇ⩦㓄ᒓࡢᏛ⏕ࡣࠊከࡃࡢሙྜࠊඛࡎ኱Ꮫ㝔Ꮫ⏕ࡢᐇ㦂ࡢ⿵ຓࢆࡋ࡞
ࡀࡽᚲせ࡞᪉ἲㄽࢆಟᚓࡉࡏࠊ㡰ḟྛே࡟ಶูࡢࢸ࣮࣐ࢆ୚࠼ࠊᐇ㦂ࢹࢨ࢖ࣥࡢタᐃࠊ㐍ࡵ᪉࡞࡝◊✲
ࡢᇶ♏⬟ຊࡢ㛤Ⓨ࡟ດࡵࡿᶵ఍ࢆ୚࠼࡚࠸ࡿࠋ኱Ꮫ㝔Ꮫ⏕࡟࠾࠸࡚ࡣࠊಶࠎࡢࢸ࣮࣐ࢆ୚࠼ࠊ⮬୺ⓗ࡟
◊✲ࢆ⾜࠺࡜ඹ࡟ࠊࡑࢀࡒࢀࡢ◊✲࡟㐍ᤖ≧ἣࢆ㐺ᐅᩍᐁࡀࢳ࢙ࢵࢡࡋࠊ◊✲ࣞ࣋ࣝࡢ඘ᐇࠊᙉ໬ࢆᅗ
ࡗ࡚࠸ࡿࠋࡲࡓ₇⩦࡟᫬㛫࡟⧳ࡵ࡚ᩍᐊဨ඲ဨࡢ๓࡛Ⓨ⾲ࡉࡏࠊ◊✲ᡓ␎࣭ᡓ⾡ࡢ❧࡚᪉ࢆᣦᑟࡍࡿࡔ
ࡅ࡛࡞ࡃࠊ඲ဨࡀᑡ࡞ࡃ࡜ࡶᖺ࡟୍ᗘࠊ࡛ࡁࢀࡤ」ᩘᅇࠊ㛵㐃ࡍࡿᅜෆᏛ఍࣭◊✲఍➼࡛Ⓨ⾲ࡍࡿᶵ఍
ࢆ୚࠼ࠊࡉࡽ࡟༤ኈㄢ⛬኱Ꮫ㝔⏕ࡣᅜ㝿Ꮫ఍࡛ࡢⓎ⾲ࡢᶵ఍ࡶ୚࠼࡚࠸ࡿࠋࡲࡓࠊⓎ⾲ⱥㄒㄽᩥࢆྛಶ
ேࡀ᭩ࡃࡇ࡜ࢆ┠ᶆ࡜ࡋ࡚࠾ࡾࠊⓎ⾲ຊࡢ⦎☻ࢆᐇ⾜ࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕࡟ᑐࡍࡿㅮ⩏⛉┠࡟㛵ࡋ࡚ࡣࠊ⌮ゎࢆຓࡅࡿᕤኵࡉࢀࡓࣉࣜࣥࢺࢆ౑⏝ࡋࠊᏛ⏕ࡢ⯆࿡ࠊ㛵
ᚰࢆᖖ࡟ចࡁࡘࡅࡿࡼ࠺ດຊࡋࠊࡲࡓㅮ⩏ẖࡢᑠヨ㦂࠶ࡿ࠸ࡣ୰㛫ヨ㦂࡟ࡼࡿ㐩ᡂᗘࡢ☜ㄆࢆ⾜ࡗ࡚࠸
ࡿࠋࡉࡽ࡟ࠊᏛ⏕࡟ᑐࡋᩍᐁẖࡢㅮ⩏ホ౯ࡶ⾜࠸ࠊᚓࡽࢀࡓホ౯ࠊ࢔ࢻࣂ࢖ࢫ➼ࢆㅮ⩏ෆᐜࡸࢫࢱ࢖ࣝ
࡟ྲྀࡾධࢀࡿࡼ࠺ཧ⪃࡟ࡋ࡚࠸ࡿࠋ◊✲ᐊ࡟ᡤᒓࡋ࡚࠸ࡿ኱Ꮫ㝔Ꮫ⏕ࡢᩍ⫱ࡣࠊಟኈㄢ⛬ᅾᏛ୰࡟࡯࡜
ࢇ࡝඲ဨࡀᑡ࡞ࡃ࡜ࡶ୍ᗘࡣᏛ఍Ⓨ⾲ࢆࡋ࡚࠸ࡿࡇ࡜ࠊከࡃࡢ༤ኈㄢ⛬኱Ꮫ㝔⏕ࡀ᪥ᮏᏛ⾡᣺⯆఍≉ู
◊✲ဨ࡟᥇⏝ࡉࢀࠊࡲࡓᅜ㝿Ꮫ఍࡛ࡢⓎ⾲ࡢ⤒㦂ࡶ᭷ࡋ࡚࠸ࡿࡇ࡜࠿ࡽุ᩿ࡋ࡚ࠊྛಶேࡢᐇຊࢆ㧗ࡵ
ࡿࡇ࡜࡟ᙺ❧ࡗ࡚࠸ࡿࠋࡑࢀ࡜ྠ᫬࡟ࠊື≀ឡㆤࡸ⎔ቃၥ㢟࡟ࡘ࠸࡚ࡢㄆ㆑ࢆ㧗ࡵࡿດຊࢆ⾜ࡗ࡚࠸ࡿࠋ
ࡇࡢ㸳ᖺ㛫ࡢ༤ኈᚋᮇㄢ⛬ಟ஢⪅㸲ྡࡢ㐍㊰ࡣࠊ௻ᴗ◊✲ᡤ㸱ྡ㸦୰ᑿࠊฟᒣࠊ๓⏣㸧ࠊ⊂❧⾜ᨻἲ
ே㸯ྡ㸦ᒸᮧ㸧࡛࠶ࡾࠊ୰࡟ࡣ༤ኈᚋᮇㄢ⛬ࢆ୰㏵㏥Ꮫࡋ࡚ᾏእ〇⸆௻ᴗ࡟⾜ࡃࡶࡢࡶ࠸ࡿ㸦㸯ྡ㸦ᒣ
ෆ㸧㸧ࠋಟኈㄢ⛬ಟ஢⪅㸯㸵ྡࡢ㐍㊰ࡣࠊ〇⸆௻ᴗ㸯㸮ྡ㸦ᒣᒸࠊἨࠊᒸ⏣ࠊᮡୗࠊᵽཱྀࠊ୕ᖹࠊᯇ㇂ࠊ
ୖすࠊἙᮏࠊ᭦⏣㸧ࠊ⊂❧⾜ᨻἲே㸯ྡ㸦኱ᆤ㸧ࠊ኱Ꮫ⑓㝔㸯ྡ㸦⏣୰㸧ࠊࡑࡢ௚௻ᴗ㸲ྡ㸦ⱝᯇࠊᒣཱྀ
೺ࠊⲡ㔝ࠊ᱓ཎ㸧࡛࠶ࡾࠊከࡃࡀ〇⸆௻ᴗࡢ◊✲⫋ࠊᐁබᗇࠊ኱Ꮫ࡞࡝࡟㐍ࢇ࡛࠾ࡾࠊᩍ⫱࡜◊✲ࡢ㧗
࠸ࣞ࣋ࣝࡀホ౯ࡉࢀ࡚࠸ࡿ⤖ᯝ࡛࠶ࡿࠋ
㸦ཎⴭ㸧
1. TRPC3 Mediates thrombin-induced astrocyte activation and upregulates its own expression in rat cortical
astrocytes. Shirakawa, H., Sakimoto, S., Nakao, K., Sugishita, A., Konno, M., Iida, S., Kusano, A.,
Hashimoto, E., Nakagawa, T., Kaneko, S.: J. Neurosci. 30, 13116-13129 (2010)
2. Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective
serotonin reuptake inhibitors on serotonin release. Nagayasu, K., Yatani, Y., Kitaichi, M., Kitagawa, Y.,
Shirakawa, H., Nakagawa, T., Kaneko, S.: Br. J. Pharmacol., 161, 1527-1541 (2010)
3. Sustained exposure to 3,4-methylenedioxymethamphetamine induces the augmentation of exocytotic
serotonin release in rat organotypic raphe slice cultures. Nagayasu, K., Kitaichi, M., Shirakawa, H.,
Nakagawa, T., Kaneko, S.: J. Pharmacol. Sci., 113, 197-201 (2010)
4. Roles of E- and D2-adrenoceptors within the central nucleus of the amygdala in the visceral pain-induced
aversion in rats. Deyama, S., Takishita, A., Tanimoto, S., Ide, S., Nakagawa, T., Satoh, M., Minami, M.: J.
Pharmacol. Sci., 114, 123-126 (2010)
− 244 −
5. Role of enhanced noradrenergic transmission within the ventral bed nucleus of the stria terminalis in visceral
pain-induced aversion in rats. Deyama, S., Katayama, T., Kondoh, N., Nakagawa, T., Kaneko, S.,
Yamaguchi, T., Yoshioka, M., Minami, M.: Behav. Brain Res., 197, 279-283 (2009)
6. Identification of a novel planarian G-protein-coupled receptor that responds to serotonin in Xenopus laevis
oocytes. Nishimura, K., Unemura, K., Tsushima, J., Yamauchi, Y., Otomo, J., Taniguchi, T., Kaneko, S.,
Agata, K., Kitamura, Y.: Biol. Pharm. Bull., 32, 1672-1677 (2009)
7. TRPM2-mediated Ca2+ influx induces chemokine production in monocytes that aggravates inflammatory
neutrophil infiltration. Yamamoto, S., Shimizu, S., Kiyonaka, S., Takahashi, N., Wajima, T., Hara, Y.,
Negoro, T, Hiroi, T., Kiuchi, Y., Okada, T., Kaneko, S., Lange, I., Fleig, A., Penner, R., Nishi, M.,
Takeshima, H., Mori, Y.: Nat. Med., 14, 738-747 (2008)
8. Gene transfer of GLT-1, a glial glutamate transporter, into the spinal cord by recombinant adenovirus
attenuates inflammatory and neuropathic pain in rats. Maeda, S., Kawamoto, A., Yatani, Y., Shirakawa, H.,
Nakagawa, T., Kaneko, S.: Mol. Pain, 4, 65 (2008)
9. TRPV1 stimulation triggers apoptotic cell death of rat cortical neurons. Shirakawa, H., Yamaoka, T., Sanpei,
K., Sasaoka, H., Nakagawa, T., Kaneko, S.: Biochem. Biophys. Res. Commun., 377, 1211-1215 (2008)
10. Mechanisms of substrate transport-induced clustering of a glial glutamate transporter GLT-1 in
astroglial-neuronal cultures. Nakagawa, T., Otsubo, Y., Yatani, Y., Shirakawa, H., Kaneko, S.: Eur. J.
Neurosci., 28, 1719-1730 (2008)
11. Ractive oxygen species derived from NOX1/NADPH oxidase enhance inflammatory pain. Ibi, M., Matsuno,
K., Shiba, D., Katsuyama, M., Iwara, K., Kakehi, T., Nakagawa, T., Sango, K., Shirai, Y., Yokoyama, T.,
Kaneko, S., Saito, N. and Yabe-Nishimura, C.: J. Neurosci., 28, 9486-9494 (2008)
12. Activation of the E-adrenoceptor-protein kinase A signaling pathway within the ventral bed nucleus of the
stria terminalis mediates the negative affective component of pain in rats. Deyama, S., Katayama, T.,
Nakagawa, T., Kaneko, S., Yamaguchi, T., Yoshioka, M., Minami, M.: J. Neurosci., 28, 7728-7736 (2008)
13. Augmentation of serotonin release by sustained exposure to 3,4-methylenedioxymethamphetamine and
methamphetamine in rat organotypic mesencephalic slice cultures containing raphe serotonergic neurons.
Higuchi, M., Suzuki, Y., Yatani, Y., Kitagawa, Y., Nagayasu, K., Shirakawa, H., Nakagawa, T. and Kaneko,
S.: J. Neurochem., 106, 2410-2420 (2008).
14. Differential contribution of spinal mitogen-activated protein kinases to the phase of long-lasting allodynia
evoked by intrathecal administration of ATP in rats. Nakagawa, T., Wakamatsu, K., Maeda, S., Shirakawa, H.
and Kaneko, S.: Biol. Pharm. Bull., 31, 1164-1168 (2008)
15. Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic
phenotype. Kume, T., Kawato, Y., Osakada, F., Izumi, Y., Katsuki, H., Nakagawa, T., Kaneko, S., Niidome,
T., Takada-Takatori, Y., Akaike, A.: Neurosci. Lett., 443, 199-203 (2008)
16. Ca2+ mobilization mediated by transient receptor potential canonical 3 is associated with thrombin-induced
morphological changes of 1321N1 human astrocytoma cells. Nakao, K., Shirakawa, H., Sugishita, A.,
Matsutani, I., Niidome, T., Nakagawa, T. and Kaneko, S.: J. Neurosci. Res., 86, 2722-2732 (2008)
17. Acceleration of serotonin transporter transport-associated current by 3,4-methylenedioxymethanphetamine
(MDMA) under acidic conditions. Yamauchi, Y., Izumi, T., Unemura, K., Uenishi, Y., Nakagawa, T. and
Kaneko, S.: Neurosci. Lett., 428, 72-76 (2007)
18. Increased Ca2+ channel currents in cerebellar Purkinje cells of the ataxic groggy rat. Tanaka, K., Shirakawa,
H., Okada, K., Konno, M., Nakagawa, T., Serikawa, T., Kaneko, S.: Neurosci. Lett., 426, 75-80 (2007)
19. Inhibition of glutamatergic transmission by morphine in the basolateral amygdaloid nucleus reduces
pain-induced aversion. Deyama, S., Yamamoto, J., Machida, T. Tanimoto, S., Nakagawa, T., Kaneko, S.,
Satoh, M. and Minami, M.: Neurosci. Res., 59, 199-204 (2007)
20. Intrathecal administration of ATP produces long-lasting allodynia in rats: differential mechanisms in the
phase of the induction and maintenance. Nakagawa, T., Wakamatsu, K., Zhang, N., Maeda, S., Minami, M.,
Satoh, M. and Kaneko, S.: Neuroscience, 147, 445-455 (2007)
21. Involvement of the bed nucleus of the stria terminalis in the negative affective component of visceral and
somatic pain in rats. Deyama, S., Nakagawa, T., Kaneko, S., Uehara, T. and Minami, M.: Behav. Brain Res.,
176, 367-371 (2007)
22. Characterization of the tritium-labeled analog of L-threo-E-benzyloxyaspartate binding to glutamate
transporters. Shimamoto, K., Otsubo, Y., Shigeri, Y., Yasuda-Kamatani, Y., Satoh, M., Kaneko, S., and
Nakagawa, T.: Mol. Pharmacol., 71, 294-302 (2007)
23. The ataxic groggy rat has a missense mutation in the P/Q-type voltage-gated Ca2+ channel D1A subunit gene
and exhibits absence seizures. Tokuda, S., Kuramoto, K., Tanaka, K., Kaneko, S., Takeuchi, I.K., Sasa, M.,
Serikawa, T.: Brain Res., 1133, 168-177 (2007)
24. Serofendic acid, a neuroprotective substance derived from fetal calf serum, inhibits mitochondrial membrane
depolarization and caspase-3 activation. Kume, T., Taguchi, R., Katsuki, H., Akao, M., Sugimoto, H.,
Kaneko, S., Akaike, A.: Eur. J. Pharmacol., 542, 69-76 (2006)
− 245 −
25. A critical role of TRPM2 in neuronal cell death by hydrogen peroxide. Kaneko, S., Kawakami, S., Hara, Y.,
Wakamori, M., Itoh, E., Minami, T., Takada, Y., Kume, T., Katsuki, H., Mori, Y., Akaike, A.: J. Pharmacol.
Sci., 101, 66-76 (2006)
26. Aminoglutethimide prevents excitotoxic and ischemic injuries in cortical neurons. Shirakawa, H., Katsuki, H.,
Kume, T., Kaneko, S., Akaike, A.: Br. J. Pharmacol., 147, 729-736 (2006)
27. Heterologous expression of a mammalian ABC transporter in plant and its application to phytoremediation.
Yazaki, K., Yamanaka, N., Masuno, T., Konagai, S., Shitan, N., Kaneko, S., Ueda, K., Sato, F.: Plant. Mol.
Biol., 61, 491-503 (2006)
28. Inhibitory role of supraspinal P2X3/P2X2/3 subtypes on nociception in rats. Fukui, M., Nakagawa, T., Minami,
M., Satoh, M. and Kaneko, S.: Mol. Pain, 2, 19 (2006)
29. Serofendic acid, a neuroprotective substance derived from fetal calf serum, inhibits mitochondrial membrane
depolarization and caspase-3 activation. Kume, T., Taguchi, R., Katsuki, H., Akao, M., Sugimoto, H.,
Kaneko, S., Akaike, A.: Eur. J. Pharmacol., 542, 69-76 (2006)
㸦⥲ㄝ࣭ⴭ᭩㸧
1. Spinal astrocytes as therapeutic targets for pathological pain. Nakagawa, T. and Kaneko, S.: J. Pharmacol.
Sci., in press.
2. ࢜ࣆ࢜࢖ࢻ࡟ࡼࡿ⑊③἞⒪࡜౫Ꮡ 㸫ᇶ♏࡜⮫ᗋ㸫 ៏ᛶ⑊③ୗ࡟࠾ࡅࡿ࢜ࣆ࢜࢖ࢻ౫Ꮡ࣭⪏ᛶࡢ
◊✲ືྥ. ୰ᕝ㈗அ㸸࣌࢖ࣥࢡࣜࢽࢵࢡ, 31, 1425-1433 (2010)
3. ࢭࣟࢺࢽࣥࢺࣛࣥࢫ࣏࣮ࢱ࣮㜼ᐖ⸆ࡢࢭࣟࢺࢽࣥ⚄⤒࡟ᑐࡍࡿస⏝ 㹼ࢺࣛࣥࢫ࣏࣮ࢱ࣮ᶵ⬟ࡢ
᪂ࡓ࡞ഃ㠃㹼. ୰ᕝ㈗அ㸸᪥ᮏ⸆⌮Ꮫ㞧ㄅ, 136, 309 (2010)
4. ⚄⤒࣭ࢢࣜ࢔ᅇ㊰ࡢ␗ᖖ࡟ࡼࡿ៏ᛶ⑊③. ୰ᕝ㈗அ㸸་Ꮫࡢ࠶ࡺࡳ, 235, 805-806 (2010)
5. ៏ᛶ⑊③࡟࠾ࡅࡿ⸆๣㑅ᐃ࡜἞⒪⸆㛤Ⓨ㸦⦅㞟㸸ᢏ⾡᝟ሗ༠఍㸧16 ⠇ Na+ࢳࣕࢿࣝࣈࣟࢵ࣮࢝. ୰
ᕝ㈗அ (2010)
6. ៏ᛶ⑊③࡟࠾ࡅࡿ⸆๣㑅ᐃ࡜἞⒪⸆㛤Ⓨ㸦⦅㞟㸸ᢏ⾡᝟ሗ༠఍㸧20 ⠇ ࢝ࣥࢼࣅࣀ࢖ࢻཷᐜయ. ୰
ᕝ㈗அ (2010)
7. ៏ᛶ⑊③࡟࠾ࡅࡿ⬨㧊࢔ࢫࢺࣟࢧ࢖ࢺࡢᙺ๭. ୰ᕝ㈗அ㸸᪥ᮏ⸆⌮Ꮫ㞧ㄅ, 136, 122 (2010)
8. ࡀࢇ⑊③ࡢ⸆≀⒪ἲ࡟㛵ࡍࡿ࢞࢖ࢻࣛ࢖ࣥ 2010 ᖺ∧㸦⦅㞟㸸≉ᐃ㠀Ⴀ฼άືἲே ᪥ᮏ⦆࿴་⒪Ꮫ
఍ ⦆࿴་⒪࢞࢖ࢻࣛ࢖ࣥసᡂጤဨ఍㸧Ѹ ⸆⌮Ꮫⓗ▱㆑㸸࢜ࣆ࢜࢖ࢻ ࢜ࣆ࢜࢖ࢻ࡜ࡣఱ࠿㸸⸆⌮
Ꮫⓗ≉ᚩ. ኱⃝໷ᘯࠊ୰ᕝ㈗அࠊᡂ⏣ ᖺ㸸35-37 (2010)
9. ⚄⤒㸫ࢢࣜ࢔ᅇ㊰⥙ࡢᶵ⬟␗ᖖࢆཎᅉ࡜ࡍࡿ៏ᛶ⑊③ཬࡧ⸆≀౫Ꮡ࡟㛵ࡍࡿ◊✲㸦➨ 25 ᅇ᪥ᮏ⸆
⌮Ꮫ఍Ꮫ⾡ዡບ㈹ཷ㈹ㅮ₇⥲ㄝ㸧. ୰ᕝ㈗அ㸸᪥ᮏ⸆⌮Ꮫ㞧ㄅ, 135, 225-229 (2010)
10. ⬻ෆࢢࣜ࢔⣽⬊࡟࠾ࡅࡿ transient receptor potential channel ࡢ⑓ែ⏕⌮ⓗᙺ๭. ⓑᕝஂᚿࠊ୰ᕝ㈗அࠊ
㔠Ꮚ࿘ྖ㸸⸆Ꮫ㞧ㄅ, 130, 281-287 (2010)
11. ᐇ㦂⸆⌮Ꮫࢩ࣮ࣜࢬ ᐇ㊶⾜ື⸆⌮Ꮫ㸦㔠ⰾᇽ⦅㸧Ѹ ៏ᛶ③ࡢⓎ⏕ᶵᗎ࡜⑊③἞⒪ᶆⓗ. ୰ᕝ㈗அࠊ
㉥ụ᫛⣖ (2010)
12. ⚄⤒ఏ㐩࡟㛵୚ࡍࡿ≀㉁Ѹ ࢜ࣆ࢜࢖ࢻཷᐜయࡢከᵝᛶ࡜ᙺ๭ศᢸ. ୰ᕝ㈗அࠊబ⸨බ㐨㸸⏕యࡢ⛉
Ꮫ, 60, 446-447 (2009)
13. ⚄⤒ఏ㐩࡟㛵୚ࡍࡿ≀㉁Ѹ ࣀࢩࢭࣉࢳࣥ࡜ࡑࡢཷᐜయ. ୰ᕝ㈗அࠊబ⸨බ㐨㸸⏕యࡢ⛉Ꮫ, 60,
486-487 (2009)
14. ⬻⹫⾑⑌ᝈ἞⒪࡟ྥࡅࡓ᪂ࡋ࠸࢖࢜ࣥࢳࣕࢿࣝᶆⓗ. ⓑᕝஂᚿ㸸་Ꮫࡢ࠶ࡺࡳ, 228, 861-862 (2009)
15. ୰ᯡ⚄⤒⣔ࡢࢺࣛࣥࢫ࣏࣮ࢱ࣮ࢆࡵࡄࡗ࡚Ѹ ⸆≀౫Ꮡ⑕࡜ࣔࣀ࢔࣑ࣥࢺࣛࣥࢫ࣏࣮ࢱ࣮. ୰ᕝ㈗
அ㸸Clin. Neurosci., 26, 1140-1142 (2008)
16. ࢢࣝࢱ࣑ࣥ㓟ࢺࣛࣥࢫ࣏࣮ࢱ࣮࡜୰ᯡ⚄⤒⣔⑌ᝈ. ୰ᕝ㈗அ㸸་Ꮫࡢ࠶ࡺࡳ, 225, 1348-1349 (2008)
17. ⬻ษ∦ᇵ㣴⣔ࢆ⏝࠸ࡓ౫Ꮡᛶ⸆≀ࡢ⢭⚄⚄⤒ẘᛶホ౯ Ѹ ⸆≀౫Ꮡࡢ in vitro ◊✲Ѹ . ୰ᕝ㈗அࠊ㔠
Ꮚ࿘ྖ㸸᪥ᮏ࢔ࣝࢥ࣮࣭ࣝ⸆≀་Ꮫ఍㞧ㄅ, 43, 166-171 (2008)
18. Neuropsychotoxicity of abused drugs: Molecular and neural mechanisms of neuropsychotoxicity induced by
methamphetamine, 3,4-methylenedioxymethamphetamine (Ecstasy) and 5-methoxy-N,N-diisopropyl
tryptamine (Foxy). Nakagawa, T. and Kaneko, S.: J. Pharmacol. Sci., 106, 2-8 (2008)
19. ៏ᛶ⑊③἞⒪ᶆⓗ࡜ࡋ࡚ࡢࢢࣜ࢔⣽⬊. ୰ᕝ㈗அ㸸་Ꮫࡢ࠶ࡺࡳ, 218, 1096-1097 (2006)
20. ⸆≀౫Ꮡࡢ⚄⤒⛉Ꮫ 㸫㐪ἲࢻࣛࢵࢢ࡜ぬ㓰๣࡟ࡼࡿ⚄⤒⢭⚄ẘᛶ㸫MDMA ࡟ࡼࡿࢭࣟࢺࢽࣥᨺฟ
࠾ࡼࡧ⚄⤒ẘᛶⓎ⌧ࡢศᏊᶵᗎ. ୰ᕝ㈗அࠊ㔠Ꮚ࿘ྖ㸸་Ꮫࡢ࠶ࡺࡳ, 217, 4490-4493 (2006)
− 246 −
㑇ఏᏊ⸆Ꮫศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧ఀ⸨ ಙ⾜㸦࠸࡜࠺ ࡢࡪࡺࡁ㸧(1993.4 ᪼௵)
᫛࿴ 24 ᖺ 2 ᭶ 10 ᪥⏕
᫛࿴ 46 ᖺி㒔኱Ꮫ⸆Ꮫ㒊༞ࠊ᫛࿴ 51 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤
ኈㄢ⛬ಟ஢
ຓᩍᤵ㸦་Ꮫ࣭⸆Ꮫ༤ኈ㸧⸨ᯘ ᗣஂ㸦ࡩࡌࡤࡸࡋ ࡸࡍࡦࡉ㸧㸦1993.4
᪼௵㸧
᫛࿴ 30 ᖺ 10 ᭶ 3 ᪥⏕
᫛࿴ 53 ᖺி㒔኱Ꮫ⸆Ꮫ㒊⸆Ꮫ⛉༞ࠊ᫛࿴ 61 ᖺி㒔኱Ꮫ༤ኈ㸦⸆Ꮫ㸧
ྲྀᚓࠊᖹᡂ 7 ᖺி㒔኱Ꮫ༤ኈ㸦་Ꮫ㸧ྲྀᚓࠊᖹᡂ 9 ᖺ⚟஭་⛉኱Ꮫ㧗
࢚ࢿࣝࢠ࣮་Ꮫ◊✲ࢭࣥࢱ࣮ᩍᤵ࡟㌿ฟ
ຓᩍᤵ㸦་Ꮫ༤ኈ㸧኱ෆ ῄ௦㸦࠾࠾࠺ࡕ ࡜ࡋࡼ㸧㸦1998.3 ᥇⏝㸧
᫛࿴ 39 ᖺ 7 ᭶ 11 ᪥⏕
ᖹᡂඖᖺᒸᒣ኱Ꮫ་Ꮫ㒊་Ꮫ⛉༞ࠊᖹᡂ 5 ᖺᒸᒣ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲
⛉ಟ஢ࠊᖹᡂ 11 ᖺᚨᓥ኱ᏛᕤᏛ㒊⏕≀ᕤᏛ⛉ຓᩍᤵ࡟㌿ฟ
ㅮ ᖌ㸦⸆Ꮫ༤ኈ㸧୕Ꮿ Ṍ 㸦ࡳࡸࡅ ࠶ࡺࡳ㸧㸦2001.11 ᥇⏝㸧
᫛࿴ 44 ᖺ 9 ᭶ 22 ᪥⏕
ᖹᡂ 5 ᖺᒱ㜧⸆⛉኱Ꮫ༞ࠊᖹᡂ 10 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
ຓ ᡭ㸦⸆Ꮫ༤ኈ㸧ᑿᓮ ᜨ୍㸦࠾ࡊࡁ ࡅ࠸࠸ࡕ㸧㸦1993.6 ᪼௵㸧
᫛࿴ 40 ᖺ 8 ᭶ 3 ᪥⏕
ᖹᡂඖᖺி㒔኱Ꮫ⸆Ꮫ㒊〇⸆໬Ꮫ⛉༞ࠊᖹᡂ 11 ᖺ㛗ᓮ኱Ꮫ⸆Ꮫ㒊⣽⬊ไᚚᏛຓᩍᤵ࡟㌿ฟ
ຓ ᡭ㸦⸆Ꮫ༤ኈ㸧ᑠす Ᏺ࿘㸦ࡇ࡟ࡋ ࡶࡾࡕ࠿㸧㸦1999.10 ᥇⏝㸧
᫛࿴ 47 ᖺ 9 ᭶ 30 ᪥⏕
ᖹᡂ 7 ᖺி㒔኱Ꮫ⸆Ꮫ㒊༞ࠊᖹᡂ 11 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ᚋᮇㄢ⛬㏥Ꮫࠊᖹᡂ 21
ᖺ࡟⚄ᡞ⸆⛉኱Ꮫᚤ⏕≀໬Ꮫㅮᗙ෸ᩍᤵ࡟㌿ฟ
ຓᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧ᒣෆ ⫕㸦ࡸࡲ࠺ࡕ ࡣࡌࡵ㸧(2010.4 ᥇⏝)
᫛࿴ 54 ᖺ 8 ᭶ 6 ᪥⏕
ᖹᡂ 15 ᖺி㒔኱Ꮫ⸆Ꮫ㒊༞ࠊᖹᡂ 20 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ᚋᮇㄢ⛬ಟ஢
◊✲ࡢᴫせ
ᵝࠎ࡞⑓Ẽࡢཎᅉ࡟ࠊ⣽⬊እࢩࢢࢼࣝᅉᏊࡀ㛵୚ࡋ࡚࠸ࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠾ࡾࠊ⣽⬊እࢩࢢࢼࣝᅉ
Ꮚࡢ◊✲ࡣࠊ⑓ᅉࡢゎ᫂ࡸண㜵ࠊ἞⒪࡟᭷⏝࡛࠶ࡿࠋᙜ㑇ఏᏊ⸆Ꮫศ㔝ࡣࠊ⏕య࡟࠾ࡅࡿ⣽⬊㛫ࢩࢢࢼ
ࣝᅉᏊࡢാࡁࢆゎ᫂ࡍࡿࡇ࡜࡜ࠊࡑࢀࢆᐇ㊶ࡋ࠺ࡿ◊✲⪅ࡢ⫱ᡂ࡜ࢆ┠ⓗ࡜ࡋ࡚࠸ࡿࠋ
FGF㸦⥺⥔ⱆ⣽⬊ቑṪᅉᏊ㸧ࣇ࢓࣑࣮ࣜ࡟ᒓࡍࡿ⣽⬊㛫ࢩࢢࢼࣝᅉᏊࡢྠᐃ
FGF ࡣࠊ⥺⥔ⱆ⣽⬊ࢆጞࡵ࡜ࡍࡿᵝࠎ࡞⣽⬊࡟ᑐࡋቑṪάᛶࢆᣢࡘ⏕⌮άᛶ࣌ࣉࢳࢻ࡛࠶ࡾࠊ
⏕య࡟࠾࠸࡚๰യ἞⒵ࠊ⾑⟶᪂⏕ࠊ⤌⧊ᙧᡂ࡟㔜せ࡛࠶ࡿࠋᙜศ㔝࡛ࡣࠊ᪤▱ࡢ FGF ࣇ࢓࣑࣮ࣜ
ࡢᵓ㐀ୖࡢ┦ྠᛶ࡟╔┠ࡋࡓ⊂⮬ࡢᡭἲࢆ㛤Ⓨࡋࠊ᪂ࡓ࡟ 9 ✀㢮ࡢ FGF ࢆྠᐃࡋࡓࠋ
᪂つ࡞ FGF ࡢ⏕⌮ⓗព⩏ࡢゎ᫂
ᙜศ㔝࡛᪂ࡓ࡟༢㞳ࡋࡓ FGF ࡟ࡘ࠸࡚ࠊ⏕⌮ⓗព⩏ࢆ᫂ࡽ࠿࡟ࡋࡓࠋ≉࡟ࠊ⬡㉁௦ㅰㄪ⠇࡟࠾
ࡅࡿ FGF21 ࡢᙺ๭ࠊᚰ⮚ᶵ⬟࡜ಖㆤస⏝࡟࠾ࡅࡿ FGF16 ࡢᙺ๭ࠊ⬻⚄⤒ᙧᡂ࡟࠾ࡅࡿ FGF19 ࡢᙺ
๭ࢆ᫂ࡽ࠿࡟ࡋࡓࠋࡇࢀࡽࡢ᝟ሗࡣ⮫ᗋ࡟࠾࠸࡚ࡶ᭷⏝࡞▱ぢࢆᥦ౪ࡍࡿࡶࡢ࡛࠶ࡿࠋࡲࡓࡇࢀ௨
እࡢ FGF ࡢᙺ๭࡟ࡘ࠸࡚ࡶゎ᫂ࢆ㐍ࡵ࡚࠸ࡿࠋ
᪂つ࡞⣽⬊㛫ࢩࢢࢼࣝᅉᏊࡢྠᐃ࡜ᶵ⬟ゎᯒ
ᙜศ㔝࡛ࡣࠊᗄࡘ࠿ࡢ᪂つศἪᛶ㑇ఏᏊࢆⓎぢࡋࠊࡑࡢ⏕⌮ⓗᙺ๭ࢆゎ᫂ࡋࡓࠋ᪂つ Wnt ࢔ࣥ
ࢱࢦࢽࢫࢺ࡛࠶ࡿ Neucrin ࡣ⫾⏕ᮇࡢ⬻⚄⤒⣔࡛㧗Ⓨ⌧ࡋࠊ⬻ᙧᡂ࡟㔜せ࡞ᙺ๭ࢆᯝࡓࡋ࡚࠸ࡿࡇ
࡜ࢆ᫂ࡽ࠿࡟ࡋࡓࠋࡲࡓࠊ᪂つ BMP ࢔ࣥࢱࢦࢽࢫࢺ࡛࠶ࡿ Brorin ࡜ Brorin-like ࢆⓎぢࡋࡓࠋBrorin
ࡣ⫾⏕ᮇࡢ⬻ࠊ⭈⮚࡜⏕ᚋࡢ⬻࡛㧗Ⓨ⌧ࡋࠊ⬻ࠊ⭈⮚ࡢᙧᡂ࡟㔜せ࡞ᙺ๭ࢆᯝࡓࡋ࡚࠸ࡿࡇ࡜ࢆ᫂
ࡽ࠿࡟ࡋࡓࠋBrorin-like ࡣ Brorin ࡜࡜ࡶ࡟ࠋ⫾⏕ᮇ࡜⏕ᚋࡢ⬻࡛㧗Ⓨ⌧ࡋࠊ⬻ᙧᡂ࡟㔜せ࡞ᙺ๭ࢆ
ᯝࡓࡋ࡚࠸ࡿ࡜ᮇᚅࡉࢀ࡚࠸ࡿࠋ
− 247 −
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
᪂つ࡟༢㞳ࡋ࡚ࡁࡓ FGFࠊ࠶ࡿ࠸ࡣ᪂つ⣽⬊እࢩࢢࢼࣝᅉᏊࡢⓎ⌧࡜⏕⌮ⓗព⩏࡟㛵ࡋ࡚ࠊᅜෆእ
ࡢ◊✲⪅࡜✚ᴟⓗ࡟ඹྠ◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋࡇࢀࡽࡢᡂᯝࡣᅜ㝿ⓗ࡟ホ౯ࡢ㧗࠸㞧ㄅ࡟ᩘከࡃሗ࿌ࡋ࡚
࠸ࡿࠋࡲࡓ」ᩘࡢ㞧ㄅ࡟౫㢗ࢆཷࡅࠊࣞࣅ࣮ࣗࢆᇳ➹ࡋ࡚࠸ࡿࡇ࡜࠿ࡽࠊ◊✲ホ౯ࡣᴟࡵ࡚㧗࠸ࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ 2 ᅇ⏕ᚋᮇㄢ⛬ࡢ⏕≀໬Ꮫ 3㸦ᇶ♏㑇ఏᏊᏛ㸧ࠊ3 ᅇ⏕๓ᮇㄢ⛬ࡢ⏕≀໬Ꮫ 4㸦ᛂ
⏝㑇ఏᏊᏛ㸧
ࠊ3 ᅇ⏕ᚋᮇㄢ⛬ࡢ⸆Ꮫᑓ㛛ᐇ⩦ 4 ࢆᢸᙜࡋ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗ㓄ᒓࡢᏛ⏕ࠊཬࡧ኱Ꮫ㝔ᅾ⡠ࡢᏛ⏕࡟ᑐࡋࠊࡑࢀࡒࢀ࡟ูಶࡢᐇ㦂
ࢸ࣮࣐ࢆ୚࠼ࠊ୍ே࡛ᐇ㦂ィ⏬ࡢ❧᱌ࠊၥ㢟ゎỴࢆ⾜࠼ࡿ⬟ຊࡢ㛤Ⓨࢆ┠ᣦࡋ࡚࠸ࡿࠋࡲࡓࠊࡇࡢࡇ࡜
࡟ࡼࡾࠊྛே࡟㈐௵ឤࢆ୚࠼ࠊ◊✲⪅࡜ࡋ࡚ࡢ⮬ぬࡀⱆ⏕࠼ࡿࡇ࡜ࢆᮇᚅࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊ₇⩦࡜ࡋ
࡚ࠊᅜෆእࡢホ౯ࡢ㧗࠸ᩥ⊩⤂௓࡜ࠊಶࠎࡢᐇ㦂⤖ᯝࡢሗ࿌ࢆ࡯ࡰ 2 ࣨ᭶࡟୍ᅇ⾜ࡗ࡚ࡶࡽ࠸ࠊ⫋ဨࢆ
ྵࡴ඲ဨ࡛ࢹ࣮ࢱ࡟ᑐࡍࡿᢈホࠊᥦ᱌ࢆ⾜ࡗ࡚࠸ࡿࠋ࠿ࡘྛ✀㛵ಀᏛ఍࡟࠾ࡅࡿ✚ᴟⓗ࡞Ⓨ⾲ࢆᐇ㊶ࡋ
࡚ࡶࡽࡗ࡚࠸ࡿࠋࡇࢀ࡟ࡼࡾࠊⓎ⾲ࠊウㄽࡢ⬟ຊࡀ㧗ࡃࠊ࠿ࡘᗈ࠸ど㔝ࢆ᭷ࡍࡿ◊✲⪅ࡢ⫱ᡂࢆ⾜ࡗ࡚
࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟㛵ࡋ࡚ࡣࠊ᭱㏆ࡢᙜヱศ㔝ࡢ㐍ᒎࡢෆᐜࢆ✚ᴟⓗ࡟ྲྀࡾධࢀᩍ⫱ࡋ࡚࠸ࡿࠋ
◊✲ᐊෆࡢᩍ⫱ࡣࠊ₇⩦࡟࠾ࡅࡿ✚ᴟⓗ࡞Ⓨゝࡀᐇ㊶ࡉࢀ࡚࠸ࡿࡇ࡜ࠊᏛ⏕࡯ࡰ඲ဨࡀ༞ᴗࡲ࡛࡟
Ꮫ఍࡛◊✲ᡂᯝࡢⓎ⾲ࢆ⾜ࡗ࡚࠸ࡿࡇ࡜࠿ࡽุ᩿ࡋ࡚ࠊ◊✲⪅࡜ࡋ࡚ࡢ⬟ຊࡢ㛤Ⓨࡀᐇ㊶ࡉࢀ࡚࠸ࡿࠋ
2006 ᖺ௨㝆ࠊ25 ྡ௨ୖࡢ༞ᴗ⏕ࡢከࡃࡣ኱Ꮫ㝔࡟㐍Ꮫࡋࠊ⸆Ꮫ㡿ᇦࡢᩍ⫱࣭◊✲ศ㔝ࠊ◊✲㛤Ⓨศ
㔝࡛ά㌍ࡋ࡚࠸ࡿࠋ
㸦ཎⴭ㸧
1. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. N.
Itoh and D.M. Ornitz, J. Biochem. (2010) in press
2. Neuferricin, a novel extracellular heme-binding protein, promotes neurogenesis. I. Kimura, Y. Nakayama,
M. Konishi, T. Kobayashi, M. Mori, M. Ito, A. Hirasawa, G. Tsujimoto, M. Ohta, N. Itoh and M.
Fujimoto, J. Neurochem. 112, 1155-1167 (2010)
3. FGF21 is dispensable for hypothermia induced by fasting in mice. K. Oishi1, K. Sakamoto1, M. Konishi,
Y. Murata, N. Itoh and H. Sei, Neuroendocrinology Lett. 31, 198-202 (2010)
4. Hormone-like (endocrine) Fgfs: Their evolutionary history and roles in development, metabolism, and
disease. N. Itoh, Cell and Tissue Research 342, 1-11 (2010)
5. Secreted bone morphogenetic protein antagonists of the Chordin family. N. Itoh and Hiroya Ohta,
BioMol. Concepts 1, 297-304 (2010)
6. Chondroitin 4-O-sulfotransferase-1 is required for somitic muscle development and motor axon guidance
in zebrafish.S. Mizumoto, T. Mikami, D. Yasunaga, N. Kobayashi, H. Yamauchi, A. Miyake, N. Itoh, H.
Kitagawa, K. Sugahara, Biochem. J. 19, 387-399 (2009)
7. Neudesin, an extracellular heme binding protein, suppresses adipogenesis in 3T3-L1 cells via the MAPK
cascade. I. Kimura, M. Konishi, T. Asaki, N. Furukawa, K. Ukai, M. Mori, A. Hirasawa, G. Tsujimoto,
M. Ohta, N. Itoh and M. Fujimoto, Biochem. Biophys. Res. Commun. 381, 75-80 (2009)
8. Fgf4 is required for left-right patterning of visceral organs in zebrafish. H. Yamauchi, N. Miyakawa, A.
Miyake and N. Itoh, Dev. Biol. 332, 177-185 (2009)
9. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis
and triglyceride clearance in liver. Y. Hotta, H. Nakamura, M. Konishi, Y. Murata, H. Takagi, S.
Matsumura, K. Inoue, T. Fushiki and N. Itoh, Endocrinology 150, 4625-4633 (2009)
10. A novel neural-specific BMP antagonist, Brorin-like, of the Chordin family. H. Miwa, A. Miyake, Y.
Kouta, A. Shimada, Y. Yamashita, Y. Nakayama, H. Yamauchi, M. Konishi and N. Itoh, FEBS Lett. 583,
3643-3648 (2009)
11. Neucrin is a novel neural-specific secreted antagonist to canonical Wnt signaling, A. Miyake, Y.
Takahashi, H. Miwa, A. Shimada, M. Konishi and N.Itoh, Biochem. Biophys. Res. Commun. 390,
1051-1055 (2009)
12. Functional evolutionary history of the mouse Fgf gene family. N. Itoh and D. M. Ornitz, Dev. Dyn.
237, 18-27 (2008)
13. Fgf19 is required for zebrafish lens and retina development. Y. Nakayama, A. Miyake, Y. Nakagawa, T.
− 248 −
Mido, M. Yoshikawa, M. Konishi and N. Itoh, Dev. Biol. 313, 752-756 (2008)
14. Neurotrophic activity of neudesin, a novel extracellular heme-binding protein, is dependent on the
binding of heme to its cytochrome b5-like heme/steroid-binding domain. I. Kimura, Y. Nakayama, H.
Yamauchi, M. Konishi, A. Miyake, M. Mori, M. Ohta, N. Itoh and M. Fujimoto, J. Biol. Chem. 238,
4323-4331 (2008)
15. Role of Fgf receptor 2c in adipocyte hypertrophy in mesenteric white adipose tissue. M. Konishi, H.
Nakamura, H. Miwa, P. Chambon, D. M. Ornitz and N. Itoh, Mol. Cell. Endo. 287, 13-19 (2008)
16. Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Y. Hotta, S. Sasaki, M.
Konishi, H. Kinoshita, K. Kuwahara, K. Nakao and N. Itoh, Dev. Dyn. 237, 3079-3087 (2008)
17. Functional evolutionary history of the mouse Fgf gene family. N. Itoh and D. M. Ornitz, Dev. Dyn. 237,
18-27 (2008)
18. Fgf19 is required for zebrafish lens and retina development.Y. Nakayama, A. Miyake, Y. Nakagawa, T.
Mido, M. Yoshikawa, M. Konishi and N. Itoh, Dev. Biol. 313, 752-756 (2008)
19. Neurotrophic activity of neudesin, a novel extracellular heme-binding protein, is dependent on the
binding of heme to its cytochrome b5-like heme/steroid-binding domain. I. Kimura, Y. Nakayama, H.
Yamauchi, M. Konishi, A. Miyake, M. Mori, M. Ohta, N. Itoh and M. Fujimoto, J. Biol. Chem. 238,
4323-4331 (2008)
20. Role of Fgf receptor 2c in adipocyte hypertrophy in mesenteric white adipose tissue. M. Konishi, H.
Nakamura, H. Miwa, P. Chambon, D. M. Ornitz and N. Itoh, Mol. Cell. Endo. 287, 13-19 (2008)
21. Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Y. Hotta, S. Sasaki, M.
Konishi, H. Kinoshita, K. Kuwahara, K. Nakao and N. Itoh, Dev. Dyn. 237, 3079-3087 (2008)
22. fibin, a novel secreted lateral plate mesoderm signal, is essential for pectoral fin bud initiation in
zebrafish. T. Wakahara, N. Kusu, H.Yamauchi, I. Kimura, M. Konishi, A. Miyake and N. Itoh, Dev. Biol.
303, 527-535 (2007)
23. Brorin, a novel secreted BMP antagonist, promotes neurogenesis in mouse neural precursor cells.
N. Koike, Y. Kassai, Y. Kouta, H. Miwa,M. Konishi and N. Itoh, J. Biol. Chem. 282, 15843-15850 (2007)
24. The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development,
metabolism, and disease. N. Itoh, Biol. Pharm. Bull. 30, 1819-1825 (2007)
25. The zebrafish fgf family. N. Itoh and M. Konishi, Zebrafish 4, 179-186 (2007)
26. Role of Fgf10 in cell proliferation in white adipose tissue. M. Konishi, T. Asaki, N. Koike, H. Miwa, A.
Miyake, and N. Itoh, Mol. Cell. Endocrinol. 249, 71-77 (2006)
27. Neudesin, a secreted factor, promotes neural cell proliferation and neuronal differentiation in mouse
neural precursor cells. I. Kimura, M. Konishi, A. Miyake, M. Fujimoto and N. Itoh, J. Neurosci. Res. 83,
1415-1424 (2006)
28. Fgf21 is essential for hematopoiesis in zebrafish. H. Yamauchi, Y. Hotta, M. Konishi, A. Miyake, A.
Kawahara and N. Itoh, EMBO Reports 7, 649-654 (2006)
29. R. Nomura, E. Kamei, Y. Hotta, M. Konishi, A. Miyake, and N. Itoh
Fgf16 is essential for pectoral fin bud formation in zebrafish
Biochem. Biophys. Res. Commun. 347, 340-346 (2006)
㸦⥲ㄝ㸧
)*)ᑠすᏲ࿘ࠊఀ⸨ಙ⾜᪥ᮏ⮫ᗋ༳ๅ୰
࢚ࢡࢺࢹ࢕ࣥᑠすᏲ࿘ࠊఀ⸨ಙ⾜ศᏊ⣽⬊἞⒪
᪂つ࡞ศἪᛶ⤌⧊ᙧᡂᅉᏊࡢ᥈⣴࡜ࡑࡢᙺ๭ࡢゎ᫂ࢆ┠ᣦࡋ࡚ఀ⸨ಙ⾜ࣇ࢓࣐ࣝࢩ࢔
⬡⫫⣽⬊ቑṪ⤌⧊ᙧᡂ࡜ )*)ᑠすᏲ࿘ఀ⸨ಙ⾜7KH/LSLG
ṑࡢᮏᩘỴᐃ㸪ṑᑤࣃࢱ࣮ࣥᙧᡂࢆไᚚࡍࡿ᪂ࡋ࠸ %03 ࢔ࣥࢱࢦࢽࢫࢺHFWRGLQⴱす⩏᫂㸪ఀ⸨ಙ
⾜ᐇ㦂་Ꮫ㸪㸪
ṑࡢᙧᡂࢆไᚚࡍࡿᅉᏊⴱす⩏᫂㸪ఀ⸨ಙ⾜⺮ⓑ㉁᰾㓟㓝⣲㸪㸪
㸦ⴭ᭩㸧
)*) ⤒㊰ఀ⸨ಙ⾜ᒾἼ ⏕≀Ꮫ㎡඾ ➨㸳∧ ༳ๅ୰
− 249 −
⏕⌮άᛶไᚚᏛศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧ᑠሐ ಖ๎㸦ࡇ࡙ࡘࡳ ࡸࡍࡢࡾ㸧㸦1997. 4 ᑵ௵ࠊ1999. 4 ᩍ
ᤵ㸧
᫛࿴㸰㸶ᖺ㸱᭶㸶᪥⏕
᫛࿴㸳㸱ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸳㸶ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
෸ ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧➉ᯇ ᘯ㸦➉ᯇ ᘯ㸧(2000.2 ᥇⏝)
᫛࿴㸲㸰ᖺ㸯㸮᭶㸯᪥⏕
ᖹᡂ㸱ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸶ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ⣔◊✲⛉༤ኈㄢ⛬ಟ஢
ຓ ᩍ㸦༤ኈ㸦⏕࿨⛉Ꮫ㸧㸧 ෆ⸨㸦ᯇ஭㸧 ⿱Ꮚ㸦࡞࠸࡜࠺㸦ࡲࡘ࠸㸧 ࡺ࠺
ࡇ㸧㸦2007.6 ᥇⏝㸧
᫛࿴㸳㸲ᖺ㸵᭶㸯㸷᪥⏕
ᖹᡂ㸯㸲ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸷ᖺྠ኱Ꮫ኱Ꮫ㝔⏕࿨⛉Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢
◊✲ࡢᴫせ
⏕⌮άᛶไᚚᏛศ㔝ࡣ⏕య⭷ࢆ୰ᚰ࡟⏕࿨⌧㇟ࢆゎ᫂ࡋ࡚࠸ࡃࡇ࡜ࢆ┠ⓗ࡜ࡋࠊ⣽⬊⏕≀ᏛࠊศᏊ⏕
≀Ꮫⓗᡭἲࢆ⏝࠸࡚ࠊ⏕య⭷ୖࡢ⬡㉁ࠊ⢾㙐ࠊࢱࣥࣃࢡ㉁ࡢ⏕⌮ᶵ⬟ࢆࢩࢫࢸ࣒࡜ࡋ࡚⌮ゎࡍࡿࡇ࡜┠
ᣦࡋ࡚࠸ࡿࠋࡉࡽ࡟ᩍ⫱㠃࡛ࡣࠊࡇࢀࡽࡢ◊✲ࢆ㏻ࡌ࡚ࠊ⣽⬊⏕≀ᏛࠊศᏊ⏕≀Ꮫ࡟ᦠࢃࡿ◊✲⪅ࡢ⫱
ᡂࢆ┠ⓗ࡜ࡋ࡚࠸ࡿࠋ
ࢫࣇ࢕ࣥࢦ⬡㉁ࢩࢢࢼࣝࡢゎ᫂
ࢫࣇ࢕ࣥࢦ⬡㉁ࡣ⏕య⭷ࡢᵓᡂ⬡㉁ᡂศࡢ୍ࡘ࡜ࡋ࡚ྂࡃ࠿ࡽ▱ࡽࢀ࡚࠸ࡿࡀࠊࡑࡢᶵ⬟ࡣ༑ศ
࡟ࡣ᫂ࡽ࠿࡟ࡉࢀ࡚࠸࡞࠸ࠋᙜ◊✲ᐊ࡛ࡣࠊࠕ෤⹸ኟⲡࠖ⏤᮶ࡢච␿ᢚไ๣ ISP-1 ࡀࠊࢫࣇ࢕ࣥࢦ⬡
㉁ྜᡂ㜼ᐖస⏝ࢆᣢࡘࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋ࡚࠸ࡿࠋࡇࢀࡲ࡛࡟ ISP-1 ࢆ㓝ẕ࡟ാ࠿ࡏ࡚ࠊࢫࣇ࢕ࣥࢦ
⬡㉁ࡢᶵ⬟࡟㛵ࡍࡿ」ᩘࡢ᪂ࡋ࠸㑇ఏᏊࡢ༢㞳࡟ᡂຌࡋ࡚࠸ࡿࠋࡇࡢ࠺ࡕ Ypk1 ࡣࢫࣇ࢕ࣥࢦ⬡㉁
࡟ࡼࡾࡑࡢࣜࣥ㓟໬ࡀஹ㐍ࡉࢀࡿࠋࡉࡽ࡟ࠊYpk1 ࡣ㓝ẕࡢቑṪ࡟ᚲせ࡞ࢭࣜࣥࢫࣞ࢜ࢽࣥ࢟ࢼ࣮ࢮ
࡛࠶ࡾࠊ❅⣲※㣚㣹࡟ࡼࡾࠊࡇࢀࡲ࡛࡟ሗ࿌ࡢ↓࠸ ESRCT 」ྜయࡀ㛵୚ࡍࡿ᪂ࡋ࠸࣮࢜ࢺࣇ࢓ࢪ
࣮࡟ࡼࡾศゎࡉࢀࡿࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋ࡚࠸ࡿࠋࡲࡓࠊ2010 ᖺ 9 ᭶ࠊISP-1 ࢆ࣮ࣜࢻ໬ྜ≀࡜ࡋ࡚ྜ
ᡂࡉࢀࡓ FTY720 ࡀ⚄⤒ච␿⑌ᝈࡢࡦ࡜ࡘከⓎᛶ◳໬⑕἞⒪⸆࡜ࡋ࡚⡿ᅜ࡛ᢎㄆࡉࢀࡓࠋ
ࢩ࢔ࣝ㓟ศᏊ✀ࡢ⏕⌮ᶵ⬟
⏕య⭷࡟Ꮡᅾࡍࡿ඲࡚ࡢࢱࣥࣃࢡ㉁ࡣࠊ⢾㙐ಟ㣭ࢆཷࡅ࡚࠾ࡾࡑࡢ⢾㙐ࡢ᭱እ➃ࡣከࡃࡢሙྜࢩ
࢔ࣝ㓟࡟そࢃࢀ࡚࠸ࡿࠋࡇࡢࢩ࢔ࣝ㓟ࡢศᏊ✀ࡣࣄࢺࡢࡳ௚ࡢື≀࡜␗࡞ࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿࠋ
ᙜ◊✲ᐊࡣࣄࢺᆺࢩ࢔ࣝ㓟ࡢศᏊ✀ࢆᣢࡘ࣐࢘ࢫࢆసᡂࡋࠊࢩ࢔ࣝ㓟ࡢศᏊ✀ࡢ㐪࠸࡟ࡼࡿᢠཎᛶ
ཬࡧ␗✀⛣᳜࡬ࡢᙳ㡪ࢆホ౯ࡋࡓࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ࢫࣇ࢕ࣥࢦ⬡㉁㛵㐃ࢩࢢࢼࣝศᏊ Ypk1 ࡢศゎᶵᵓࢆ◊✲ࡋ࡚࠸ࡃ㐣⛬࡛ࠊESRCT 」ྜయࡀ㛵୚ࡍࡿ
᪂ࡋ࠸࣮࢜ࢺࣇ࢓ࢪ࣮ᶵᵓࢆ᫂ࡽ࠿࡟ࡋࡓࡇ࡜ࡣࠊ㓝ẕࡢቑṪ࡬ࡢ Ypk1 ࡢ㛵୚ࢆ᥈ࡿୖ࡛㔜せ࡞Ⓨぢ
࡛࠶ࡿ࡜࡜ࡶ࡟ࠊ᪂ࡓ࡟ぢ࠸ࡔࡋࡓ࣮࢜ࢺࣇ࢓ࢪ࣮ᶵᵓࡀࠊࡼࡾᬑ㐢ⓗ࡞ῶᑡ࡛࠶ࡿࡇ࡜ࡀ♧ࡉࢀࢀࡤ
኱ࡁ࡞࢖ࣥࣃࢡࢺࢆ୚࠼ࡿ࡜⪃࠼ࡽࢀࡿࠋࡲࡓࠊࢩ࢔ࣝ㓟ศᏊ⭘ࡢኚ໬࡛ࠊࢩ࢔ࣝ㓟ࡢศᏊ✀ࡢ㐪࠸࡟
ࡼࡿᢠཎᛶཬࡧ␗✀⛣᳜࡬ホ౯ࢆ⾜࠼ࡓࡇ࡜ࡣࠊ௒ᚋࡢᢠయ〇๣ࢆࡣࡌࡵ࡜ࡋࡓࢱࣥࣃࢡ㉁〇๣࡟ΰධ
ࡍࡿື≀ᆺࢩ࢔ࣝ㓟ࡢၥ㢟ࢆ⪃࠼ࡿୖ࡛㔜せ࡞ᆅ᳨࡛࠶ࡿ࡜ᛮࢃࢀࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣㅮ⩏⛉┠࡜ࡋ࡚ 3 ᅇ⏕ᚋᮇㄢ⛬ࡢ⏕≀⛉Ꮫ 5㸦⣽⬊⏕≀Ꮫ㸧ࢆᢸᙜࡋ࡚࠸ࡿࠋ୍
᪉㏻⾜ࡢㅮ⩏ࢆࡉࡅࡿࡓࡵࠊẖᅇᤵᴗࡢ࢔ࣥࢣ࣮ࢺࢆྲྀࡗ࡚Ꮫ⏕ࡢ⌮ゎᗘࢆ☜࠿ࡵ࡞ࡀࡽᤵᴗࢆ⾜ࡗ࡚
࠸ࡿࠋ୍᪉ࠊᐇ⩦⛉┠࡜ࡋ࡚ࡣ⸆Ꮫᑓ㛛ᐇ⩦ 4 ࡢ୰࡛୺࡜ࡋ࡚ච␿Ꮫࡢᐇ⩦ࢆᢸᙜࡋ࡚࠸ࡿࠋᐇ⩦ෆᐜ
࡜ࡋ࡚ࡣ⸆Ꮫ㒊ࡢᏛ⏕࡜ࡋ࡚᭱ప㝈㌟࡟ࡘࡅ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ᇶ♏ᢏ⾡࡜ྠ᫬࡟ࠊ᭱᪂ࡢᢏ⾡ࡢྲྀࡾᢅ
࠸࡟ࡶ⩦⇍࡛ࡁࡿࡇ࡜ࢆᛕ㢌࡟⨨࠸࡚⾜ࡗ࡚࠸ࡿࠋᐇ⩦ᚋࡣ࣏࣮ࣞࢺᥦฟࢆࡉࡏࠊ㉁ၥࡢᅇ⟅ࠊࢥ࣓ࣥ
ࢺࢆグࡋ࡚㏉㑏ࡋ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗ㓄ᒓࡢᏛ⏕ࡶྵࡵ࡚ࠊࡍ࡭࡚ࡢᏛ⏕ಶேಶே࡟⊂⮬ࡢࢸ࣮࣐ࢆ୚࠼ࠊ
⮬ศ࡛◊✲ࢆ㐙⾜࡛ࡁࡿ⬟ຊࢆ㌟࡟ࡘࡅࡿࡇ࡜ࢆᛕ㢌࡟⨨࠸࡚ᣦᑟࢆ⾜ࡗ࡚࠸ࡿࠋศ㔝඲య࡛ࡢሗ࿌఍
ࡸࠊᑠࢢ࣮ࣝࣉ࡛ࡢ㐌༢఩࡛ࡢሗ࿌఍ࢆ⾜ࡗ࡚࠸ࡿࠋࡉࡽ࡟ࠊ◊✲ࡀࡲ࡜ࡲࡗࡓሙྜ࡟ࡣ✚ᴟⓗ࡟Ꮫ఍
➼࡛ࡢⓎ⾲ࢆ່ࡵ࡚࠸ࡿࠋࡲࡓࠊᐇ㊶ࢆ㏻ࡌ࡚ⱥㄒࡢㄽᩥࡢ᭩ࡁ᪉ࡶᣦᑟࡋ࡚࠸ࡿࠋࡲࡓࠊ㸲ᅇ⏕ࡢᩍ
− 250 −
⫱࡜ࡋ࡚ศ㔝඲య࡛ࡢሗ࿌఍ࡢࣇ࢛࣮ࣟ࢔ࢵࣉࢆ⾜࠸ࠊᙜヱศ㔝ࡢ◊✲ࢆ⌮ゎࡍࡿࡢ࡟໅ࡵ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
๓㏙ࡢࡼ࠺࡟Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊẖᅇ࢔ࣥࢣ࣮ࢺࢆ⾜࠸ࠊ⌮ゎᗘࢆ☜ㄆࡍࡿᡭἲࢆྲྀࡾධࢀ
࡚࠸ࡿࠋ␲ၥⅬࡣḟᅇࡢᤵᴗ࡛᫂ࡽ࠿࡟ࡋࠊࡑࢀ࡛ࡶศ࠿ࡽ࡞࠸Ꮫ⏕࡟ࡣಶูᣦᑟࡶ⾜ࡗ࡚࠸ࡿࠋᐇ⩦
⛉┠࡟㛵ࡋ࡚ࡣࠊ๓ᖺࡢᏛ⏕ࡢ࣏࣮ࣞࢺࢆཧ⪃࡟ࡋ࡚ࠊẖᖺᨵⰋࢆຍ࠼࡚࠸ࡿࠋ
ࡇࡢ㛫ࠊ኱Ꮫ㝔ಟ஢⪅ࡣ〇⸆࣓࣮࣮࢝ࢆጞࡵ࡜ࡋࡓ௻ᴗ࠿ࠊ࠶ࡿ࠸ࡣ༤ኈㄢ⛬ࢆ༞ᴗᚋ࢔࢝ࢹ࣑ࢵࢡ
ศ㔝࡛◊✲⫋࡟ᑵ࠸࡚࠸ࡿࠋ⌧ᅾࠊ⡿ᅜ࡟஧ே␃Ꮫ୰࡛࠶ࡾࠊ௒ᖺᗘ୰࡟ࢫ࢖ࢫ࡟୍ྡ␃Ꮫࡢணᐃ࡛࠶
ࡿࠋ
㸦ཎⴭ㸧
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Sphingosylphosphorylcholine and lysosulfatide have inverse regulatory functions in monocytic cell
differentiation into macrophages Arch Biochem Biophys. in press Yamamoto, H., Naito, Y., Okano, M.,
Kanazawa, T., Takematsu, H., and Kozutsumi, Y.(2010)
Identification of Ypk1 as a novel selective substrate for nitrogen starvation-triggered proteolysis requiring
autophagy system and ESCRT machinery components. J Biol Chem.in press Shimobayashi, M.,
Takematsu, H., Eiho, K., Yamane, Y., and Kozutsumi, Y. (2010).
Differential CXCR4 expression and function in subpopulations of the feline lymphoma cell line 3201
susceptible to feline immunodeficiency virus. J Feline Med Surg 12, 269-277. Tochikura, T.S., Motokawa,
K., Naito, Y., Kozutsumi, Y., Tanabe-Tochikura, A., and Hohdatsu, T. (2010).
Synthesis and binding analysis of unique AG2 pentasaccharide to human Siglec-2 using NMR techniques.
Bioorganic & medicinal chemistry 18, 3720-3725 Hanashima, S., Sato, K.I., Naito, Y., Takematsu, H.,
Kozutsumi, Y., Ito, Y., and Yamaguchi, Y. (2010).
Anomalous expression of Thy1 (CD90) in B-cell lymphoma cells and proliferation inhibition by anti-Thy1
antibody treatment. Biochem Biophys Res Commun 396, 329-334. Ishiura, Y., Kotani, N., Yamashita,
R., Yamamoto, H., Kozutsumi, Y., and Honke, K. (2010).
Immunological property of antibodies against N-glycolylneuraminic acid epitopes in cytidine
monophospho-N-acetylneuraminic acid hydroxylase-deficient mice. J Immunol 184, 3269-3275 Tahara,
H., Ide, K., Basnet, N.B., Tanaka, Y., Matsuda, H., Takematsu, H., Kozutsumi, Y., and Ohdan, H. (2010).
Protective effect of N-glycan bisecting GlcNAc residues on {beta}-amyloid production in Alzheimer's
disease. Glycobiology 20, 99-106 Akasaka-Manya, K., Manya, H., Sakurai, Y., Wojczyk, B.S.,
Kozutsumi, Y., Saito, Y., Taniguchi, N., Murayama, S., Spitalnik, S.L., and Endo, T. (2009).
Potent small molecule mouse CD22-inhibitors: exploring the interaction of the residue at C-2 of sialic acid
scaffold. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5573-5. Abdu-Allah HH, Watanabe K, Hayashizaki K,
Takaku C, Tamanaka T, Takematsu H, Kozutsumi Y, Tsubata T, Ishida H, Kiso M.
Synthesis of biotinylated sialoside to probe CD22-ligand interactions. Tetrahedron Lett. 2009 Aug
Vol.50(31):4488-91. Abdu-Allah HH, Watanabe K, Hayashizaki K, Iwayama Y, Takematsu H, Kozutsumi Y,
Tsubata T, Ishida H, Kiso M.
Glycosphingolipids are not pivotal receptors for Subtilase cytotoxin in vivo: Sensitivity analysis with
glycosylation-defective mutant mice. Biochem Biophys Res Commun 2009 Jan 9;378(2):179-81
Kondo Y, Tokuda N, Fan X, Yamashita T, Honke K, Takematsu H, Togayachi A, Ohta M, Kotzusumi Y,
Narimatsu H, Tajima O, Furukawa K, Furukawa K.
Tropoelastin regulates chemokine expression in fibroblasts in Costello syndrome. Biochem Biophys Res
Commun. 372(4):681-7. Tatano Y, Fujinawa R, Kozutsumi Y, Takahashi T, Tsuji D, Takeuchi N, Tsuta K,
Takada G, Sakuraba H, Itoh K. (2008).
Wheat germ agglutinin stains dispersed post-golgi vesicles after treatment with the cytokinesis inhibitor
psychosine. J Cell Physiol 215, 517-525. Kanazawa, T., Takematsu, H., Yamamoto, A., Yamamoto, H., and
Kozutsumi, Y. (2008).
Establishment of the culture model system that reflects the process of terminal differentiation of connective
tissue-type mast cells. FEBS Lett. 582, 1444-1450 Takano, H., Nakazawa, S., Okuno, Y., Shirata, N.,
Tsuchiya, S., Kainoh, T., Takamatsu, S., Furuta, K., Taketomi, Y., Naito, Y., Takematsu, H., Kozutsumi, Y,
Tsujimoto, G., Murakami, M., Kudo, I., Ichikawa, A., Nakayama, K., Sugimoto, Y., and Tanaka, S (2008).
Tropoelastin regulates chemokine expression in fibroblasts in Costello syndrome. Biochem Biophys Res
Commun 372, 681-687. Tatano, Y., Fujinawa, R., Kozutsumi, Y., Takahashi, T., Tsuji, D., Takeuchi, N.,
Tsuta, K., Takada, G., Sakuraba, H., and Itoh, K. (2008).
− 251 −
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
Correlation Index-Based Responsible-Enzyme Gene Screening (CIRES), a Novel DNA Microarray-Based
Method for Enzyme Gene Involved in Glycan Biosynthesis. PLoS ONE 2, e1232. Yamamoto, H.,
Takematsu, H., Fujinawa, R., Naito, Y., Okuno, Y., Tsujimoto, G., Suzuki, A., and Kozutsumi, Y. (2007).
Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic
acid species involved in the negative modulation of B-cell activation. Mol Cell Biol 27, 3008-3022. Naito,
Y., Takematsu, H., Koyama, S., Miyake, S., Yamamoto, H., Fujinawa, R., Sugai, M., Okuno, Y., Tsujimoto,
G., Yamaji, T., Hashimoto, Y. Itohara, S. Kawasaki, T. Suzuki, A.and Kozutsumi, Y (2007).
Human B-lymphocytes express alpha2-6-sialylated 6-sulfo-N-acetyllactosamine serving as a preferred
ligand for CD22/Siglec-2. J Biol Chem 282, 32200-32207 Kimura, N., Ohmori, K., Miyazaki, K., Izawa,
M., Matsuzaki, Y., Yasuda, Y., Takematsu, H., Kozutsumi, Y., Moriyama, A., and Kannagi, R. (2007).
Synthetic glycan ligand excludes CD22 from antigen receptor-containing lipid rafts. Biochem Biophys Res
Commun 360, 759-764. Yu, J., Sawada, T., Adachi, T., Gao, X., Takematsu, H., Kozutsumi, Y., Ishida, H.,
Kiso, M., and Tsubata, T. (2007).
N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol Cell Biol
27, 4340-4346. Hedlund, M., Tangvoranuntakul, P., Takematsu, H., Long, J. M., Housley, G. D., Kozutsumi,
Y., Suzuki, A., Wynshaw-Boris, A., Ryan, A. F., Gallo, R. L., et al. (2007).
Dihydroceramide:sphinganine C-4-hydroxylation requires Des2 hydroxylase and the membrane form of
cytochrome b5. Biochem J 397, 289-295. Enomoto, A., Omae, F., Miyazaki, M., Kozutsumi, Y., Yubisui,
T., and Suzuki, A. (2006).
Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer.
Biochem Biophys Res Commun 341, 478-482. Ide, Y., Miyoshi, E., Nakagawa, T., Gu, J., Tanemura, M.,
Nishida, T., Ito, T., Yamamoto, H., Kozutsumi, Y., and Taniguchi, N. (2006).
Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides
containing non-human sialic acid on human cancer cells. Cancer Res 66, 2937-2945. Yin, J., Hashimoto, A.,
Izawa, M., Miyazaki, K., Chen, G. Y., Takematsu, H., Kozutsumi, Y., Suzuki, A., Furuhata, K., Cheng, F. L.,
et al. (2006).
Physical and functional association of glucuronyltransferases and sulfotransferase involved in HNK-1
biosynthesis. J Biol Chem 281, 13644-13651. Kizuka, Y., Matsui, T., Takematsu, H., Kozutsumi, Y.,
Kawasaki, T., and Oka, S. (2006).
Down-regulation of caveolin-1 in mouse Lewis lung cancer P29 is a causal factor for the malignant
properties in a high-metastatic subline. Oncol Rep 16, 289-294. Zhang, Q., Furukawa, K., Chen, H. H.,
Fujinawa, R., Kozutsumi, Y., Suzuki, A., and Urano, T. (2006).
㸦⥲ㄝ㸧
➉ᯇ ᘯࠊᑠሐಖ๎㸦㸧ࢫࣇ࢕ࣥࢦ⬡㉁ࡀ㛵ࢃࡿච␿ᢚไ࡜ࢩࢢࢼࣝఏ㐩 ໬Ꮫ࡜⏕≀ ༳ๅ
୰
➉ᯇᘯࠊ%ࣜࣥࣃ⌫࡟࠾ࡅࡿࢩ࢔ࣝ㓟ಟ㣭ࡢᶵ⬟ゎ᫂࡟ྥࡅ࡚ ⏕໬Ꮫ ➨ᕳ ➨
ྕ ࡳ࡟ࢀࡧࡹ࠺
<XNR1DLWR㸦㸧$FWLYDWLRQGHSHQGHQWFKDQJHLQVLDOLFDFLGVSHFLHVLQPRXVH%FHOOV
㸦࣐࢘ࢫ%⣽⬊ࡢάᛶ໬࡟క࠺ࢩ࢔ࣝ㓟ศᏊ✀ࡢኚ໬㸧7,**7UHQGV LQ*O\FRVFLHQFHDQG
*O\FRWHFKQRORJ\9RO 1R */<&2'8%87
ෆ⸨⿱Ꮚࠊ➉ᯇᘯࠊᑠሐಖ๎%⣽⬊ࡢᶵ⬟ㄪ⠇࡟࠾ࡅࡿ⢾㙐ㄆ㆑ࡢ㔜せᛶ̿̿%⣽⬊άᛶ
໬࡟క࠺⢾㙐ࡢኚ໬ࢱࣥࣃࢡ㉁᰾㓟㓝⣲9RO1R
➉ᯇ ᘯࠊ ᑠሐಖ๎㸦㸧 ࢩ࢔ࣝ㓟௦ㅰࡢከᵝᛶ࡜⏕࿨ᶵ⬟ ⣽⬊ᕤᏛ9RO 㸦ⴭ᭩㸧
ᑠሐಖ๎⢾㙐ࢆ▱ࡿѸ ࡑࡢ⣲㢦࡜⑓Ẽ࡬ࡢᣮᡓࠊSࠊ⛉Ꮫᢏ⾡㐍⾜ᶵᵓ
<DPDPRWR+7DNHPDWVX+DQG.R]XWVXPL<'1$0LFURDUUD\LQ*O\FRELRORJ\LQ([SHULPHQWDO
*O\FRVFLHQFH6SULQJHU-DSDQ
<.R]XWVXPLDQG+7DNHPDWVX'1$PLFURDUUD\LQ*O\FRELRORJ\&RPSUHKHQVLYH*O\FRVFLHQFH
YRO
+7DNHPDWVXDQG<.R]XWVXPL㸦㸧&KDUDFWHUL]DWLRQRIJHQHVFRQIHUULQJUHVLVWDQWDJDLQVW
,630\ULRVLQHLQGXFHGVSKLQJROLSLGGHSOHWLRQLQ\HDVW͇LQ6SKLQJROLSLG%LRORJ\
6SOLQJHU
− 252 −
⏕య᝟ሗไᚚᏛศ㔝
ᩍ ᤵ㸦་Ꮫ༤ኈ㸧୰ᒣ࿴ஂ㸦࡞࠿ࡸࡲ ࠿ࡎࡦࡉ㸧㸦2003.5 ╔௵㸧
᫛࿴ 34 ᖺ 1 ᭶ 6 ᪥⏕
᫛࿴ 56 ᖺி㒔኱Ꮫ༞
᫛࿴ 58 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉㸦⸆Ꮫᑓᨷ㸧ಟኈㄢ⛬ಟ஢
᫛࿴ 62 ᖺྠ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉㸦⏕⌮⣔ᑓᨷ㸧༤ኈㄢ⛬ಟ஢
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧ᮡᮏᖾᙪ㸦ࡍࡂࡶ࡜ ࡺࡁࡦࡇ㸧(1997.9 ᪼௵)
㸦2009.4 ⇃ᮏ኱Ꮫ኱Ꮫ㝔་Ꮫ⸆Ꮫ◊✲㒊 ⸆Ꮫ⏕໬Ꮫศ㔝ᩍᤵ࡟㌿ฟ㸧
᫛࿴ 40 ᖺ 11 ᭶ 20 ᪥⏕
᫛࿴ 63 ᖺி㒔኱Ꮫ༞ࠊᖹᡂ 2 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢
ᖹᡂ 4 ᖺྠ༤ኈᚋᮇㄢ⛬㏥Ꮫࠊᖹᡂ 6 ᖺி㒔኱Ꮫ༤ኈ㸦⸆Ꮫ㸧ྲྀᚓ
㸦୰ᒣᩍᤵ㸧
ຓ ᩍ㸦༤ኈ㸦⌮Ꮫ㸧㸧⏦᝴፾㸦ࡋࢇ ࡬࠺࠽ࢇ㸧㸦2006.4 ᪼௵㸧
㸦2009.1 ி㒔኱Ꮫ⏕࿨⛉Ꮫ⣔࢟ࣕࣜ࢔ࣃࢫᙧᡂࣘࢽࢵࢺ ≉ᐃຓᩍ࡟㌿ฟ㸧
᫛࿴ 45 ᖺ 10 ᭶ 26 ᪥⏕
ᖹᡂ 5 ᖺ៞໭኱Ꮫᰯ⮬↛⛉Ꮫ኱Ꮫ⏕≀Ꮫ⛉༞ࠊᖹᡂ 7 ᖺྠ኱Ꮫ኱Ꮫ㝔ಟኈㄢ⛬ಟ஢
ᖹᡂ 11 ᖺ⟃Ἴ኱Ꮫ⏕≀໬Ꮫ◊✲⛉⏕≀ᕤᏛᏛ㝿࣒࢝ࣜ࢟ࣗࣛ༤ኈㄢ⛬ಟ஢
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧ຍ⸨ὒᖹ㸦࠿࡜࠺ ࡼ࠺࡬࠸㸧㸦2009.9 ᥇⏝㸧
᫛࿴ 54 ᖺ 4 ᭶ 21 ᪥⏕
ᖹᡂ 14 ᖺ⟃Ἴ኱Ꮫ➨஧⩌⏕≀Ꮫ㢮༞
ᖹᡂ 16 ᖺྠ኱Ꮫ኱Ꮫ㝔⏕࿨⎔ቃ⛉Ꮫ◊✲⛉᝟ሗ⏕≀⛉Ꮫᑓᨷಟኈྕྲྀᚓ
ᖹᡂ 19 ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉㸦⏕࿨⸆⛉Ꮫᑓᨷ㸧༤ኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
⣽⬊ෆࡢ࢜ࣝ࢞ࢿࣛ㛫㸦࡜ࡃ࡟ࢦࣝࢪయ࡜࢚ࣥࢻࢯ࣮࣒ࢆ୰ᚰ࡟㸧ࡢ࣓ࣥࣈ࣭ࣞࣥࢺࣛࣇ࢕ࢵࢡࡢㄪ
⠇ᶵᵓࠊ࠾ࡼࡧࣉࣟࢫࢱࢢࣛࣥࢪࣥ➼ࡢ⏕⌮άᛶ≀㉁ࡢྜᡂ࠾ࡼࡧస⏝࡟㛵ࢃࡿ㓝⣲ࡸཷᐜయࡢᵓ㐀࡜
ᶵ⬟࡟㛵ࡋ࡚◊✲ࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊࡑࢀࡽࡢᡂᯝ࡟ᇶ࡙࠸࡚㓝⣲ㄪ⠇໬ྜ≀࠶ࡿ࠸ࡣཷᐜయసື⸆ࡢ
㛤Ⓨ࡟㈉⊩ࡍࡿ࡜࡜ࡶ࡟ࠊࡑࢀࡽ୍㐃ࡢ◊✲࣭ᩍ⫱άືࢆ㏻ࡌ࡚༤ኈ࣭ಟኈㄢ⛬ࡢ኱Ꮫ㝔⏕࠾ࡼࡧᏛ㒊
༞ᴗᐇ⩦ࡢᏛ⏕࡟ᑐࡍࡿᣦᑟࢆ⾜ࡗ࡚࠸ࡿࠋ
పศᏊ㔞 *73DVH ࡟ࡼࡿ⣽⬊ෆࢱࣥࣃࢡ㉁㍺㏦ࡢㄪ⠇࡟㛵ࡍࡿ◊✲
⣙ ඙ಶࡢ⣽⬊࠿ࡽᡂࡿ⚾ࡓࡕࣄࢺࡢ࠿ࡽࡔࡀṇࡋࡃᶵ⬟ࡍࡿࡓࡵ࡟ࡣࠊྛ⣽⬊ࡀṇࡋࡃᶵ⬟ࡋ࡞
ࡅࢀࡤ࡞ࡾࡲࡏࢇࠋ⣽⬊ෆ࡟ࡣࡉࡲࡊࡲ࡞࢜ࣝ࢞ࢿࣛࡀᏑᅾࡋ࡚࠾ࡾࠊࡑࡇ࡟ࡣᅛ᭷ࡢࢱࣥࣃࢡ㉁ࡀᒁ
ᅾࡋࡲࡍࠋࡑࡋ࡚ࠊ⣽⬊ࡀṇࡋࡃᶵ⬟ࡍࡿࡓࡵ࡟ࡣࠊྛࢱࣥࣃࢡ㉁ࡀྜᡂࡉࢀࡓሙᡤ࠿ࡽᶵ⬟ࡍ࡭ࡁṇ
ࡋ࠸࢜ࣝ࢞ࢿࣛࡸ⣽⬊⭷࡬࡜㍺㏦ࡉࢀ࡞ࡅࢀࡤ࡞ࡾࡲࡏࢇࠋ
ᑠ⬊యࠊࢦࣝࢪయࠊ࢚ࣥࢻࢯ࣮࣒ࠊࣜࢯࢯ࣮࣒࡞࡝ࡢศἪ⣔࢜ࣝ࢞ࢿࣛࡢ㛫ࡸࡇࢀࡽࡢ࢜ࣝ࢞ࢿࣛ࡜
⣽⬊⭷࡜ࡢ㛫ࡢࢱࣥࣃࢡ㉁ࡢ㍺㏦ࡣࠊ㍺㏦ᑠ⬊ࢆࡣࡌࡵ࡜ࡍࡿ⭷ᵓ㐀య࡟ࡼࡾ௰௓ࡉࢀࠊ࣓ࣥࣈࣞࣥࢺ
ࣛࣇ࢕ࢵࢡ࡜⥲⛠ࡉࢀࡲࡍࠋ㍺㏦ᑠ⬊ࡣࠊ$UI ࣇ࢓࣑࣮ࣜࡢపศᏊ㔞 *73DVH ࡢไᚚୗ࡛✚ࡳⲴࢱࣥࣃࢡ
㉁ࡀ㞟✚ࡋࠊࡑࡇ࡟ࡉࡲࡊࡲ࡞ࢥ࣮ࢺࢱࣥࣃࢡ㉁ࡀ㞟ྜࡍࡿࡇ࡜࡟ࡼࡾᙧᡂࡉࢀࡲࡍࠋࡑࡋ࡚ࠊࡇࡢ㍺
㏦ᑠ⬊ࡀཷᐜ࢜ࣝ࢞ࢿࣛࡢ⭷࡜⼥ྜࡋ࡚✚ࡳⲴࢱࣥࣃࢡ㉁ࢆཷࡅΏࡋࡲࡍࠋࡇࡢ⼥ྜ㐣⛬࡟ࡣࠊ5DE ࣇ
࢓࣑࣮ࣜࡢపศᏊ㔞 *73DVH ࡀ㛵୚ࡋࡲࡍࠋ
ࢦࣝࢪయࡢࢺࣛࣥࢫഃ࡟఩⨨ࡍࡿࢺࣛࣥࢫࢦࣝࢪ⥙㸦7*1㸧ࠊ࢚ࣥࢻࢯ࣮࣒ࠊࡑࡋ࡚⣽⬊⭷࡜ࡢ㛫ࡢࢱ
ࣥࣃࢡ㉁㍺㏦ࡣᴟࡵ࡚」㞧࡛ࡍࠋࣄࢺࡢሙྜ࡟ࡣ $UI ࣇ࢓࣑࣮ࣜࡢ࣓ࣥࣂ࣮ࡣ⣙ ✀㢮ࠊ5DE ࣇ࢓࣑ࣜ
࣮ࡢ࣓ࣥࣂ࣮ࡣ⣙ ✀㢮Ꮡᅾࡍࡿࡇ࡜࠿ࡽࠊ࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡࡢ㐣⛬ࡣࠊࡇࢀࡽࡢపศᏊ㔞
*73DVH ࠾ࡼࡧࢥ࣮ࢺࢱࣥࣃࢡ㉁ࢆࡣࡌࡵ࡜ࡍࡿࡉࡲࡊࡲ࡞࢚ࣇ࢙ࢡࢱ࣮ࢱࣥࣃࢡ㉁࡟ࡼࡿ」㞧࡞ㄪ⠇
ࢆ࠺ࡅࡿ࡜⪃࠼ࡽࢀࡲࡍࠋ⏕య᝟ሗไᚚᏛศ㔝࡛ࡣࠊ⣽⬊ᶵ⬟ࡢ᰿ᖿࢆ࡞ࡍ⣽⬊ෆࡢ࣓ࣥࣈࣞࣥࢺࣛࣇ
࢕ࢵࢡ࡟㛵ࡋ࡚ࠊ$UIࠊ5DEࠊࢥ࣮ࢺࢱࣥࣃࢡ㉁࡞࡝ࡼࡿㄪ⠇ࡢほⅬ࠿ࡽゎ᫂ࢆࡵࡊࡋࡲࡍࠋ
࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡ࡟ࡼࡿ⣽⬊ศ⿣ࡢㄪ⠇࡟㛵ࡍࡿ◊✲
⣽⬊ศ⿣ࡢ㝿࡟ࡣࠊ࢜ࣝ࢞ࢿࣛࡣᔂቯࡋࡓࡾࠊ෌ᙧᡂࡉࢀࡓࡾࠊࢲ࢖ࢼ࣑ࢵࢡ࡟ᒁᅾࢆኚ໬ࡉࡏࡓࡾ
ࡍࡿࡇ࡜࡟ࡼࡾࠊ஧ࡘࡢፉ⣽⬊࡟ᆒ➼࡟ศ㓄ࡉࢀࡲࡍࠋࡇࡢࡼ࠺࡞㐣⛬࡟ࡣ⭷ࡢ౪⤥ࡸ㝖ཤࡀᚲせ࡛࠶
ࡾࠊ≉ᐃࡢࢱࣥࣃࢡ㉁ࡀ≉ᐃࡢ㒊఩࡟౪⤥ࡉࢀ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࡢ࡛ࠊ⣽⬊ศ⿣᫬ࡢ࢜ࣝ࢞ࢿࣛࡢᙧែ
ኚ໬ࡣ࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡ࡟ࡼࡿㄪ⠇ࢆ࠺ࡅࡲࡍࠋ
$UI ࣇ࢓࣑࣮ࣜࡸ 5DE ࣇ࢓࣑࣮ࣜࡢࢱࣥࣃࢡ㉁ࡸࠊࡑࢀࡽࡢ࢚ࣇ࢙ࢡࢱ࣮ࢱࣥࣃࢡ㉁ࡢ࡞࠿࡟ࡣࠊ⣽
⬊ศ⿣᫬ࡢࢦࣝࢪయࡸࣜࢧ࢖ࢡࣜࣥࢢ࢚ࣥࢻࢯ࣮࣒ࠊ୰ኸ⣳㗽యࡸ࣑ࢵࢻ࣎ࢹ࢕࣮࡞࡝࡟ᒁᅾࡍࡿࡶࡢ
− 253 −
ࡀ࠶ࡾࡲࡍࠋࡇࢀࡽࡢᒁᅾࡣࠊ᫬㛫ⓗ࣭✵㛫ⓗ࡟ࢲ࢖ࢼ࣑ࢵࢡ࡟ኚ໬ࡋࡲࡍࠋ⏕య᝟ሗไᚚᏛศ㔝࡛ࡣࠊ
⣽⬊ศ⿣ࢆྵࡴࡉࡲࡊࡲ࡞⣽⬊ᶵ⬟ࡢㄪ⠇࡟࠾ࡅࡿ࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡࡢᙺ๭࡟ࡘ࠸࡚ࠊ᫬㛫ⓗ࡞
ほⅬ࡜✵㛫ⓗ࡞ほⅬࡢ୧᪉࠿ࡽࡢゎ᫂ࢆࡵࡊࡋࡲࡍࠋ
ࣉࣟࢫࢱࢢࣛࣥࢪࣥཷᐜయࡢゎᯒ ࣉࣟࢫࢱࢢࣛࣥࢪࣥ3*࡟ࡘ࠸࡚ࡣࠊࡑࡢ⏕ྜᡂ⤒㊰࡟㛵ࡋ࡚ࡣከࡃゎ᫂ࡉࢀ࡚࠸ࡓࡀࠊ3* స⏝ࢆⓎ
᥹ࡍࡿཷᐜయ࡟㛵ࡋ࡚ࡣ࡯࡜ࢇ࡝᫂ࡽ࠿࡛ࡣ࡞࠿ࡗࡓࠋᙜヱศ㔝࡛ࡣࠊඹྠ◊✲⪅㸦ᡂᐑ ࿘ᩍᤵࠊி
኱་㸧࡜༠ຊࡋࠊୡ⏺࡟ඛ㥑ࡅ࡚඲ ✀㢮ࡢ 3* ཷᐜయ࡟ᑐᛂࡍࡿ㑇ఏᏊḞᦆ࣐࢘ࢫࢆసฟࡋࡓࠋࡉࡽ
࡟ࠊࡉࡲࡊࡲ࡞⏕⌮࣭⑓ែ᮲௳ୗ࡟࠾ࡅࡿ 3* ཷᐜయࡢ⏕⌮ᶵ⬟ࢆ᫂ࡽ࠿࡟ࡋࡘࡘ࠶ࡿࠋ
⣽⬊༢఩ࡢࢺࣛࣥࢫࢡࣜࣉࢺ࣮࣒ゎᯒ ࣐࢖ࢡࣟ࢔ࣞ࢖ࢆࡣࡌࡵ࡜ࡍࡿ⥙⨶ⓗ࡞Ⓨ⌧ࣉࣟࣇ࢓࢖ࣝゎᯒࡣࠊ⏕≀Ꮫⓗ࡞஦㇟ゎᯒ࡟ᚲ㡲ࡢࢶ࣮
࡛ࣝ࠶ࡿࡀࠊ⣽⬊༢఩ࡢⓎ⌧ࣉࣟࣇ࢓࢖ࣝゎᯒࡣᅔ㞴࡛࠶ࡗࡓࠋᙜヱศ㔝࡛ࡣࠊୡ⏺࡟ඛ㥑ࡅ࡚⣽⬊༢
఩ࡢ 51$ ࢆᅇ཰࣭ቑᖜࡋࠊ࣐࢖ࢡࣟ࢔ࣞ࢖ゎᯒ࡟౪ࡍࡿ᪉ἲࢆ☜❧ࡋࡓࠋ୰࡛ࡶࠊᙜヱศ㔝ࡢ኱ࡁ࡞ᡂ
ᯝࡣࠊ⫶࡟Ꮡᅾࡍࡿ஧✀㢮ࡢ࣐ࢫࢺ⣽⬊ࢧࣈࢡࣛࢫࡢⓎ⌧ࣉࣟࣇ࢓࢖ࣝࢆྠᐃࡋࠊࡑࢀࡽࡢ≉ᚩ࡟ᇶ࡙
ࡁࠊ୧⣽⬊ࡢ≉ᚩࢆண ࡋࡓࡇ࡜࡛࠶ࡿࠋᮏᢏ⾡ࢆᇶ┙࡜ࡋ࡚ࠊᅜෆእࡢከࡃࡢ◊✲⪅࣭௻ᴗ࡜ඹྠ◊
✲ࢆ㐍ࡵ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ಟኈㄢ⛬࠾ࡼࡧ༤ኈᚋᮇㄢ⛬ࡢᅾ⡠⪅ࡀࠊ⸆Ꮫ఍⏕≀㒊఍୺ദࣇ࢓࣮࣐࣭ࣂ࢖࢜ࣇ࢛࣮࣒࡛ࣛࠊ
ᖺᗘ᭱ඃ⚽Ⓨ⾲⪅㈹࡜ඃ⚽Ⓨ⾲⪅㈹ࠊ ᖺᗘඃ⚽Ⓨ⾲⪅㈹㸦 ྡ㸧ࢆཷ㈹ࡋ࡚࠸ࡿࠋࡇࢀࡽホ౯ࡣࠊ
᪥ᖖࡢ◊✲ᡂᯝࢆホ౯ࡢ㧗࠸ᅜ㝿ㄅ࡟ከࡃⓎ⾲ࡋࠊࡑࢀࡽࡀ௚◊✲⪅࡟ࡼࡾከࡃᘬ⏝ࡉࢀ࡚࠸ࡿ஦࡟ࡼ
ࡿ࡜⮬ᕫホ౯ࡍࡿࠋ
ᩍ⫱ᴫせ
Ꮫ㒊ᩍ⫱㸸ㅮ⩏࡜ࡋ࡚ࡣࠊ ᅇ⏕๓ᮇࡢ⏕≀໬Ꮫ 㸦௦ㅰ⏕໬Ꮫ㸧ࠊ ᅇ⏕๓ᮇࡢ⾨⏕⸆Ꮫ 㸦⎔ቃ⾨
⏕Ꮫ㸧ࠊ ᅇ⏕ᚋᮇࡢ⾨⏕⸆Ꮫ 㸦೺ᗣ໬Ꮫ㸧ࢆᢸᙜࡋ࡚࠸ࡿࠋㅮ⩏ࡢ┠ᶆ࡜Ꮫ⏕ࡢ฿㐩┠ᶆࢆ᫂♧ࡋࠊ
ࣉࣜࣥࢺࡸᾮᬗࣉࣟࢪ࢙ࢡࢱ࣮ࢆ⏝࠸࡚ຠ⋡ⓗ࡟ㅮ⩏ࢆ⾜࠺࡜࡜ࡶ࡟ࠊㅮ⩏ᚋ࡟ᑠࢸࢫࢺࢆ⾜࠺ࡇ࡜࡟
ࡼࡗ࡚⌮ゎࡢᬑཬ࡟ດࡵ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗᐇ⩦ࡢᏛ⏕࡟ࡣࠊྛேಶูࡢࢸ࣮࣐ࢆ୚࠼ࠊ⮬ศ࡛⪃࠼ࠊᐇ㦂ࢆ୺య
ⓗ࡟㐍ࡵࠊ⤖ᯝࢆホ౯࡛ࡁࡿ⬟ຊࡢ㔊ᡂ࡟ດࡵ࡚࠸ࡿࠋ◊✲⌧ሙ࡟࠾࠸࡚ࡣࠊ◊✲⪅࡜ࡋ࡚ࡢᇶᮏⓗ࡞
ែᗘࡢಟᚓࠊ࠾ࡼࡧ◊✲ᐊࢆ୍♫఍༢఩࡜ࡳ࡞ࡋ඲ဨࡢ༠ຊ࡜Ᏺࡿ࡭ࡁែᗘࡢ⫱ᡂ࡟ᚰࡀࡅ࡚࠸ࡿࠋࢭ
࣑ࢼ࣮ࡣ㐌 2 ᅇࠊ1 ᅇࡣඃࢀࡓᩥ⊩ࡢ⤂௓࡜ᐇ㦂ࡢࡲ࡜ࡵሗ࿌ࡢ඲ဨཧຍࢭ࣑ࢼ࣮ࠊ௚ࡢ 1 ᅇࡣࣀ࣮ࢺ
ࡢ⏕ࢹ࣮ࢱ࡟ࡼࡿᑠேᩘࢭ࣑ࢼ࣮ࢆᐇ᪋ࡋࠊࢸ࣮࣐ࡢᣢࡘ⫼ᬒࠊព⩏ࠊ⸆Ꮫ࡬ࡢᛂ⏝ࢆ⪃࠼ࡿࡼ࠺࡟ᣦ
ᑟࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕࡟ᑐࡍࡿㅮ⩏ࡣ㏻ᖖ 80 ே௨ୖ࡛๓ྥࡁᮘࡢㅮ⩏ᐊ࡜࠸࠺⎔ቃࡢࡓࡵࠊᏛ⏕࡜఍ヰࡋ࡞ࡀࡽ
཮᪉ྥᛶࡢᤵᴗࡀࡋ࡟ࡃ࠸ࡀࠊᏛ⏕ᮏ఩ࡢᤵᴗࢆࡍࡿࡼ࠺ᕤኵࢆࡋࡓ࠸ࠋホ౯ࡣㅮ⩏ᚋࡢᑠࢸࢫࢺ࠾ࡼ
ࡧᮇᮎヨ㦂ࡢᡂ⦼࡟ࡼࡾ⥲ྜⓗ࡟ホ౯࡛ࡁ࡚࠸ࡿ࡜ᛮ࠺ࠋ኱Ꮫ㝔ࡣࢭ࣑ࢼ࣮࡛ࡢᩍ⫱࡜Ꮫ఍ࠊㅮ₇఍࡬
ࡢ✚ᴟⓗ࡞ཧຍ࡜Ⓨ⾲ࢆಁࡋ࡚࠸ࡿࠋ
㸦ཎⴭ㸧
1. Yamamoto, H., Koga, H., Katoh, Y., Takahashi, S., Nakayama, K. & Shin, H-W. (2010) Functional crosstalk
between Rab14 and Rab4 through a㻌 dual effector, RUFY1/Rabip4. Mol. Biol. Cell, 21, 2746-2755.
2. Saitoh, A., Shin, H.-W., Yamada, A., Waguri, S. & Nakayama, K. (2009) Three homologous ArfGAPs
participate in coat protein I-mediated transport. J. Biol. Chem., 284, 13948-13957.
3. Nishimoto-Morita, K., Shin, H.-W., Mitsuhashi, H., Kitamura, M., Zhang, Q, Johannes, L. & Nakayama, K.
(2009) Differential effects of depletion of ARL1 and ARFRP1 on membrane trafficking between the trans-Golgi
network and endosomes. J. Biol. Chem., 284, 10583-10592.
4. Azuma, Y., Takada, M., Shin, H.-W., Kioka, N., Nakayama, K. & Ueda, K. (2009) The retroendocytosis
pathway of ABCA1/apoA-I contributes to HDL formation. Genes Cells, 14, 191-204.
5. Takano, H., Nakazawa, S., Shirata, N., Tamba, S., Furuta, K., Tsuchiya, S., Morimoto, K., Itano, N., Irie, A.,
Ichikawa, A., Kimata, K., Nakayama, K., Sugimoto, Y. & Tanaka, S. (2009) Involvement of CD44 in mast cell
proliferation during terminal differentiation. Lab. Invest.,89, 446-455.
6. Katoh, Y, Ritter, B, Gaffry, T, Blondeau, F, Höning, S, McPherson, PS. The clavesin family, neuron-specific
− 254 −
lipid- and clathrin-binding Sec14 proteins regulating lysosomal morphology. J Biol Chem
2009;284(40):27646-54.
7. Ishizaki, R., Shin, H.-W., Mitsuhashi, H. & Nakayama, K. (2008) Redundant Roles of BIG2 and BIG1,
Guanine-nucleotide Exchange Factors for ARFs, in Membrane Traffic between the TGN and endosomes. Mol.
Biol. Cell, 19, 2650-2660.
8. Takano, H., Nakazawa, S., Okuno, Y. Shirata, N., Tsuchiya, S., Kainoh, T., Takamatsu, S., Furuta, K.,
Taketomi, Y., Naito, Y., Takematsu, H., Kozutsumi, Y., Tsujimoto, G., Murakami, M., Kudo, I.,
Ichikawa, A., Nakayama, K., Sugimoto, Y. & Tanaka, S. (2008) Establishment of the culture model system that
reflects the process of terminal differentiation of connective tissue-type mast cells. FEBS Lett., 582,1444-1450.
9. Yanagida-Ishizaki, Y., Takei, T., Ishizaki, R., Imakagura, H., Takahashi, S., Shin, H.-W., Katoh, Y. &
Nakayama, K. (2008) Recruitment of Tom1L1/Srcasm to endosomes and the midbody by Tsg101. Cell Struct.
Funct., 33, 91-100.
10. Sakanaka, M., Tanaka, S.,Sugimoto, Y., and Ichikawa, A. Essential role of EP3 subtype in prostaglandin
E2-induced adhesion of mouse cultured and peritoneal mast cells to the Arg-Gly-Asp-enriched matrix. (2008)
Am.J.Physiol.Cell. Physiol.295, C1427-C1433.
11. Tamba, S., Yodoi, R., Segi-Nishida, E., Ichikawa, A., Narumiya, S., and Sugimoto, Y. Timely interaction
between prostaglandin and chemokine signaling is a prerequisite for successful fertilization. (2008) Proc. Natl.
Acad. Sci. USA. 105, 14539-14544.
12. Yano, Y., Yano, A., Oishi, S., Fujii, N., Sugimoto, Y., and Matsuzaki, K. Coiled-coil tag-robe system for quick
labeling of membrane receptors in living cells.(2008) ACS .Chem. Biol. 3, 341-345.
Yano, Y., Shimbo, T., Sugimoto, Y., and Matsuzaki, K. Intracellular third loop-C-terminal tail interaction in
prostaglandin EP3ȕ receptor. (2008) Biochem. Biophys. Res. Commun. 371, 846-849.
13. Takano, H., Nakazawa, S., Okuno, Y., Shirata, N., Tsuchiya, S., Kainoh, T., Takamatsu, S., Furuta, K.,
Taketomi, Y., Naito, Y., Takematsu, H., Kozutsumi, Y., Tsujimoto, G., Murakami, M., Kudo, I., Ichikawa, A.,
Nakayama, K., Sugimoto, Y., and Tanaka, A. Establishment of the culture model system that reflects the process
of terminal differentiation of connective tissue-type mast cells. (2008) FEBS. Lett. 582, 1444-1450.
14. Tsuchiya, H., Oka, T., Nakamura, K., Ichikawa, A., Saper, C. B., and Sugimoto, Y. Prostaglandin E2 attenuates
preoptic expression of GABAA receptors via EP3 receptors. (2008 ) J. Biol. Chem. 283, 11064-11071.
15. Yuhki, K.I., Ushikubi, F., Naraba, H., Ueno, A., Kato, H., Kojima, F., Narumiya, S., Sugimoto, Y., Matsushita,
M., and Oh-Ishi, S. Prostaglandin I2 plays a key role in zymosan-induced mouse pleurisy.(2008) J. Pharmacol.
Exp. Ther. 325, 601-609.
16. Esumi, S., Wu, S-X., Yanagawa, Y., Obata, K., Sugimoto, Y., and Tamamaki, N. Method for single-cell
microarray analysis and application to gene-expression profiling of GABAergic neuron progenitors. (2008)
Neurosci. Res. 60, 439-451.
17. Yellon, S. M., Ebner, C. A., and Sugimoto, Y. Parturition and recruitment of macrophages in cervix of mice
lacking the prostaglandin F receptor. (2008) Biol. Reprod. 78, 438-444.
18. Kawamata, M., Yoshida, M. Sugimoto, Y., Kimura, T., Tonomura, Y., Takayanagi, Y., Yanagisawa, T., and
Nishimori, K. Infusion of oxytocin induces successful delivery in prostanoid FP-receptor-deficient mice. (2008)
Mol. Cell. Endocrinol. 283, 32-37.
19. Yamane, J., Kubo, A., Nakayama, K., Yuba-Kubo, A. Katsuno, T., Tsukita, S. & Tsukita, S. (2007)
Functional involvement of TMF/ARA160 in Rab6-dependent retrograde membrane traffic. Exp. Cell Res.,
313,3472-3485.
20. Inoue, M., Shiba, T., Ihara, K., Yamada, Y., Hirano, S., Kamikubo,H., Kataoka, M., Kawasaki, M.,Kato, R.,
Nakayama, K., & Wakatsuki, S.(2007) Molecular basis for autoregulatory interaction between GAE domain and
hinge region of GGA1. Traffic, 8, 904-913.
21. Furuta, K., Nakayama, K., Sugimoto, Y., Ichikawa, A. & Tanaka, S. (2007) Activation of histidine
decarboxylase through post- translational cleavage by caspase-9 in a mouse mastocytoma P-815. J. Biol. Chem.,
282,13438-13446.
22. Hoshino, T., Nakaya, T., Homan, T., Tanaka, K., Sugimoto, Y., Araki, W., Narita, M., Narumiya, S., Suzuki, T.,
and Mizushima, T. Involvement of prostaglandin E2 in production of amyloid-peptides both in vitro and in vivo.
(2007) J. Biol. Chem. 282, 32676-32688.
23. Suzuki-Yamamoto, T., Sugimoto, Y, Ichikawa, A., and Ishimura, K.Co-localization of prostaglandin F
synthase, cyclooxygenase-1 and prostaglandin F receptor in mouse Leydig cells. (2007) Histochem. Cell. Biol.
128(4),317-322.
24. Taketomi, Y., Sunaga, K,. Tanaka, S., Nakamura, M., Arata, S., Okuda, T., Moon, T.C., Chang, H.W.,
Sugimoto, Y., Kokame, K., Miyata, T., Murakami, M., and Kudo, I.Impaired mast cell maturation and
degranulation and attenuated allergic responses in ndrg1-deficient mice. (2007) J. Immunol. 178, 7042-7053.
− 255 −
25. Furuta, K., Nakayama, K., Sugimoto, Y., Ichikawa, A., and Tanaka, S.Activation of histidine decarboxylase
through post-translational cleavage by caspase-9 in a mouse mastocytoma P-815. (2007) J. Biol. Chem. 282 (18),
13438-13446.
26. Sugimoto, Y., and Narumiya, S.Prostaglandin E receptors. (2007) J. Biol. Chem. 282 (16), 11613-11617.
27. Kawamata, M., Tonomura, Y., Kimura, T., Sugimoto, Y., Yanagisawa, T., and Nishimori, K.Oxytocin-induced
phasic and tonic contractions are modulated by the contractile machinery rather than the quantity of oxytocin
receptor. (2007) Am. J. Physiol. Endocrinol. Metab. 292 (4), E992-E999.
28. Shiba, T., Koga, H., Shin, H.-W., Kawasaki, M., Kato, R., Nakayama, K. & Wakatsuki, S. (2006) Structural
basis for Rab11-dependent membrane recruitment of FIP3/Arfophilin-1. Proc. Natl. Acad. Sci. USA, 103,
15416-15421
29. Yogosawa, S., Kawasaki, M., Wakatsuki, S., Kominami, E., Shiba, Y., Nakayama, K., Kohsaka, S. &
Akazawa, C. (2006) Monoubiquitylation of GGA3 by hVPS18 regulates its ubiquitin-binding ability. Biochem.
Biophys. Res. Commun., 350, 82-90.
30. Furuta, K., Ichikawa, A., Nakayama, K. & Tanaka, S. (2006) Membrane orientation of the precursor 74-kDa
form of L-histidine decarboxylase. Inflamm. Res., 55, 185-191.
31. Ishizaki, R., Shin, H.-W., Iguchi-Ariga, S.M.M., Ariga, H. & Nakayama, K. (2006) AMY-1 (associate of
Myc-1) localization to the trans-Golgi network through interacting with BIG2, a guanine-nucleotide exchange
factor for ADP-ribosylation factors. Genes Cells, 11, 949-959.
32. Yokoyama, U., Minamisawa, S., Hong, Q., Ghatak, S., Akaike, T., Segi-Nishida, E., Iwasaki, S., Iwamoto, M.,
Misra, S., Tamura, K., Hori, H., Yokota, S., Toole, B.P., Sugimoto, Y., and Ishikawa, Y.Chronic activation of the
prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. (2006)
J. Clin. Invest. 116, 3026-3034.
33. Osada, S., Naganawa, A., Misonou, M., Tsuchiya. S., Tamba, S., Okuno, Y., Nishikawa, J., Satoh, K.,
Imagawa, I, Tsujimoto, G., Sugimoto, Y., and Nishihara, T.Altered gene expression of transcriptional regulatory
factors in tumor marker-positive cells during chemically induced hepatocarcinogenesis. (2006) Toxicol. Lett.
167, 106-113.
34. Trivedi, D.B., Sugimoto, Y., and Loftin, C.D.Attenuated cyclooxygenase-2 expression contributes to patent
ductus arteriosus in preterm mice. (2006) Pediatr. Res. 60, 669-674.
35. Shioji, M., Fukuda, H., Kanzaki, T., Wasada, K., Kanagawa, T., Shimoya, K., Mu, J., Sugimoto, Y., Murata,
Y.Reduction of aquaporin-8 on fetal membranes under oligohydramnios in mice lacking prostaglandin F2 alpha
receptor. (2006) J. Obstet. Gynaecol. Res. 32, 373-378.
36. Kim, H., Arakawa, H., Hatae, N., Sugimoto, Y., Matsumoto, O., Osada, T., Ichikawa, A., and Ikai, A.
Quantification of the number of EP3 receptors on a living CHO cell surface by the AFM.(2006)
Ultramicroscopy. 106, 652-662.
37. Katoh, Y., Imakagura, H., Futatsumori, M. & Nakayama, K. (2006) Recruitment of clathrin onto endosomes
by the Tom1-Tollip complex. Biochem. Biophys. Res. Commun., 341,143-149. 㸦⥲ㄝ㸧
ᮡᮏᖾᙪ㸦㸧ࣉࣟࢫࢱࣀ࢖ࢻࡢస⏝Ⓨ⌧࡜ࢩࢢࢼ࣭ࣝࢡࣟࢫࢺ࣮ࢡ ᐇ㦂་Ꮫࠊࠊ
୰ᒣ࿴ஂ㸪⏦᝴፾$UI ࣇ࢓࣑࣮ࣜࡢపศᏊ㔞*73DVH ࡢ࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡ࡟࠾ࡅࡿᙺ
⺮ⓑ㉁᰾㓟㓝⣲
๭㸬⺮
୰ᒣ࿴ஂ࢚ࣥࢻࢧ࢖ࢺ࣮ࢩࢫࡼࡶࡸࡲヰ㸬⺮
⺮ⓑ㉁᰾㓟㓝⣲
ᮡᮏᖾᙪ㸦㸧ࣉࣟࢫࢱࣀ࢖ࢻཷᐜయࡢ⏕⌮స⏝Ⓨ⌧࣓࢝ࢽࢬ࣒ ⣽⬊ᕤᏛࠊࠊ
⏦᝴፾㸪୰ᒣ࿴ஂ$5) ࡟ࡼࡿ࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡࡢㄪ⠇㸬⣽
⣽⬊ᕤᏛ
୰ᒣ࿴ஂࣘࣅ࢟ࢳࣥ࡟ࡼࡿ࣓ࣥࣈࣞࣥࢺࣛࣇ࢕ࢵࢡࡢㄪ⠇㸬⺮
⺮ⓑ㉁᰾㓟㓝⣲
⏕యࡢ⛉Ꮫ
୰ᒣ࿴ஂࢡࣛࢫࣜࣥ౫Ꮡᛶ࢚ࣥࢻࢧ࢖ࢺ࣮ࢩࢫ㸬⏕
ᮡᮏᖾᙪ㸦㸧ዲ୰⌫ࣜࢡ࣮ࣝࢺ࡟࠾ࡅࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥ㹃㸰ࡢᙺ๭ ་Ꮫࡢ࠶ࡺࡳࠊࠊ
㸬
ᮡᮏᖾᙪ㸦㸧ࣉࣟࢫࢱࣀ࢖ࢻཷᐜయࡢⓎ⌧࡜ᶵ⬟ ⏕໬Ꮫࠊࠊ
㸦ⴭ᭩㸧
࣮ࣞࢽࣥࢪ࣮ࣕࡢ᪂⏕໬Ꮫ㸦➨㸳∧ୖ㸪ୗ㸧 ୰ᒣ࿴ஂ⦅㞟 ᘅᕝ᭩ᗑ㸬
୰ᒣ࿴ஂ&KDSWHU㸸⣽⬊ෆ≀㉁㍺㏦㸬ศᏊ⏕≀Ꮫ࢖ࣛࢫࢺࣞ࢖ࢸࢵࢻᨵゞ➨㸱∧㸬⏣ᮧ㝯
࣭᫂ᒣᮏ㞞⦅ ⨺ᅵ♫ SS㸬
୰ᒣ࿴ஂ➨୍❶ ⸆๰ࡾࡣࠗ೺ᗣ࡜⑓Ẽࡢ㐪࠸ࢆ▱ࡿࡇ࡜࠘࠿ࡽጞࡲࡿ㸬 ᪂ࡋ࠸⸆ࢆ࡝࠺
− 256 −
๰ࡿ࠿㸸๰⸆◊✲ࡢ᭱๓⥺㸬ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉⦅ ㅮㄯ♫ࣈ࣮ࣝࣂࢵࢡࢫSS㸬
࣮ࣞࢽࣥࢪ࣮ࣕࡢ᪂⏕໬Ꮫ㸦➨㸲∧ୖ㸪ୗ㸧ᕝᔘᩄ♸ࠊ୰ᒣ࿴ஂ⦅ヂ ᘅᕝ᭩ᗑ
− 257 −
⚄⤒ᶵ⬟ไᚚᏛศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧᰿ᓊ Ꮫ㸦ࡡࡂࡋ ࡲ࡞ࡪ㸧㸦1996. 4 ᪼௵㸧 ᫛࿴㸰㸷ᖺ㸯᭶㸯㸷᪥⏕
᫛࿴㸳㸰ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸳㸵ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
෸ᩍᤵ㸦⸆Ꮫ༤ኈ㸧ຍ⸨ ⿱ᩍ㸦࠿࡜࠺ ࡦࢁࡢࡾ㸧(2004. 3 ᪼௵)
᫛࿴㸲㸴ᖺ㸯㸰᭶㸰㸴᪥⏕
ᖹᡂ㸴ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸷ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈ
ㄢ⛬ᚋᮇㄢ⛬㏥Ꮫࠊ
ᖹᡂ㸯㸰ᖺி㒔኱Ꮫ༤ኈ㸦⸆Ꮫ㸧ྲྀᚓ
ຓᩍ㸦༤ኈ㸦⏕࿨⛉Ꮫ㸧
㸧⏕἟ Ἠ㸦࠾࠸ࡠࡲ ࠸ࡎࡳ㸧
᫛࿴㸳㸱ᖺ㸳᭶㸰㸲᪥⏕
ᖹᡂ㸯㸲ᖺி㒔኱Ꮫ༞ࠊ
ᖹᡂ㸯㸷ᖺி㒔኱Ꮫ኱Ꮫ㝔⏕࿨⛉Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢ࠊ༤ኈ㸦⏕࿨⛉Ꮫ㸧ྲྀᚓ
◊✲ࡢᴫせ
ᮏศ㔝࡛ࡣ⚄⤒ᅇ㊰ᙧᡂࡢศᏊᶵᵓࢆゎ᫂ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚௨ୗࡢ◊✲ࢆ⾜ࡗ࡚ࡁࡓࠋ㸯㸧⚄⤒ᅇ㊰
ᙧᡂ࡟ࠊ5KR ࣇ࢓࣑࣮ࣜࡀ㔜せ࡞ᙺ๭ࢆᯝࡓࡋ࡚࠾ࡾࠊ5KR ࣇ࢓࣑࣮ࣜࡢ୰࡛ࠊ5KR ࡣ⚄⤒✺㉳ࡢ㏥⦰ࢆࠊ5DFࠊ
&GF ࡀ✺㉳ࡢఙ㛗ࢆไᚚࡋ࡚࠸ࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿࠋ5KR ࣇ࢓࣑࣮ࣜࡢ୰࡛ࠊ୰ᯡ⚄⤒⣔࡟୺せ࡟Ⓨ⌧ࡋ
࡚࠸ࡿࡀࠊࡑࡢ⚄⤒ᶵ⬟ࡀ୙࡛᫂࠶ࡗࡓ 5QG㸦5QGࠊ5QGࠊ5QG㸧࡜࠸࠺ࢧࣈࣇ࢓࣑࣮ࣜࡀᏑᅾࡍࡿࠋ5QG
ࡣ 5KR ࡢάᛶࢆᢚไࡍࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿࡀࠊ5QG ࡟㛵ࡋ࡚ࡣ඲ࡃ୙࡛᫂࠶ࡗࡓࠋᡃࠎࡣࠊ5QG ࡢ⚄⤒ᶵ
⬟ࡢศᏊᶵᵓࢆ᫂ࡽ࠿࡟ࡍࡿࡓࡵࠊ5QG ࡟⤖ྜࡍࡿศᏊࢆ㓝ẕࡢ WZRK\EULG ἲࢆ⏝࠸࡚ࢫࢡ࣮ࣜࢽࣥࢢࡋࡓࠋ
ࡑࡢ⤖ᯝࠊ5QG ࡟≉␗ⓗ࡟⤖ྜࡍࡿ᪂つࡢ࢚ࣇ࢙ࢡࢱ࣮ศᏊࢆࢡ࣮ࣟࢽࣥࢢࡋࠊ3UDJPLQ ࡜ྡ௜ࡅࡓࠋ3UDJPLQ
ࡣ 5QG ࡀ⤖ྜࡍࡿࡇ࡜࡟ࡼࡾࠊ5KR ࢆάᛶ໬ࡋࠊ⚄⤒✺㉳ࡢ㏥⦰ࢆᘬࡁ㉳ࡇࡍࡇ࡜ࡀࢃ࠿ࡾࠊ5QG ࡜ 5QG
ࡣ 5KR ࡢάᛶࢆṇ࡜㈇࡟ไᚚࡋ࡚࠸ࡿࡇ࡜ࡀࢃ࠿ࡗࡓࠋ㸰㸧୍᪉ࠊ5QG ࡟⤖ྜࡍࡿศᏊࢆࢫࢡ࣮ࣜࢽࣥࢢࡋ
ࡓ⤖ᯝࠊ5QG ࡣ⚄⤒㍈⣴࢞࢖ࢲࣥࢫศᏊࠊ6HPD' ࡢཷᐜయࠊ3OH[LQ% ࡢ⣽⬊ෆ㡿ᇦ࡟⤖ྜࡍࡿࡇ࡜ࡀࢃ࠿
ࡗࡓࠋᡃࠎࡣࠊ3OH[LQ ࣇ࢓࣑࣮࡛ࣜඹ㏻࡟ࡼࡃಖᏑࡉࢀ࡚࠸ࡿ 3OH[LQ% ࡢ⣽⬊ෆ㡿ᇦࡀ 55DV*$3 ࡛࠶ࡾࠊ
⣽⬊⭷ࡢఙᒎࢆಁ㐍ࡍࡿ 55DV ࡢάᛶࢆ┤᥋ᢚไࡍࡿࡇ࡜࡟ࡼࡾࠊ⚄⤒㍈⣴ࡢᡂ㛗෇㗹ࡢ㏥⦰ࢆᘬࡁ㉳ࡇࡍ
ࡇ࡜ࢆぢ࠸ࡔࡋࠊ3OH[LQ% ࡜࠸࠺ཷᐜయࡀపศᏊ㔞 * ⺮ⓑ㉁ࡢ *$3 ࡛࠶ࡿ࡜࠸࠺௒ࡲ࡛࡟ሗ࿌ࡢ࡞࠸඲ࡃ
᪂ࡋ࠸᝟ሗఏ㐩ᶵᵓ࡛࠶ࡿࡇ࡜ࢆⓎぢࡋࡓࠋࡲࡓࠊ55DV*$3 άᛶⓎ⌧࡟ࡣࠊ5QG ࡢ 3OH[LQ% ࡬ࡢ⤖ྜࡀ
ᚲ㡲࡛࠶ࡗࡓࠋࡲࡓࠊ6HPD'3OH[LQ% ࡜ඹ࡟ࡼࡃ◊✲ࡉࢀ࡚࠸ࡿ 6HPD$3OH[LQ$ ࡟ࡼࡿᡂ㛗෇㗹ࡢ㏥⦰
࡟ࡶ 55DV ࡢάᛶపୗࡀᚲせ࡛࠶ࡿࡇ࡜ࢆ♧ࡋࠊ55DV*$3 άᛶࡀ 3OH[LQ ࣇ࢓࣑࣮ࣜ࡟ඹ㏻ࡢ㔜せ࡞ᶵ⬟࡛
࠶ࡿࡇ࡜ࢆ♧၀ࡋࡓࠋࡉࡽ࡟ࠊ55DV ࡣ⣽⬊ࡢ⣽⬊እ࣐ࢺࣜࢵࢡࢫ࡬ࡢ⤖ྜ࡟ࡼࡾάᛶ໬ࡉࢀࠊάᛶ໬ࡉࢀ
ࡓ 55DV ࡣ࢖ࣥࢸࢢࣜࣥࢆάᛶ໬ࡋ࡚⣽⬊⭷ࡢఙᒎࢆᘬࡁ㉳ࡇࡍࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋࡓࠋࡑࡋ࡚ࠊ3OH[LQ%
ࡣ 55DV ࡢάᛶࢆᢚไࡋࠊ55DV ࡟ࡼࡿ࢖ࣥࢸࢢࣜࣥࡢάᛶ໬ࢆ㜼ᐖࡋ࡚⣽⬊⭷ࡢఙᒎࢆᢚไࡋࠊ㍈⣴ࡢ཯
Ⓨస⏝ࡀⓎ᥹ࡉࢀࡿࡇ࡜ࡀࢃ࠿ࡗࡓࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
᰿ᓊ Ꮫ㸸㸯㸷㸷㸱ᖺࠊ᪥ᮏ⏕໬Ꮫ఍ዡບ㈹ཷ㈹
᳃ ࿴ಇ㸸㸯㸷㸷㸵ᖺࠊ᪥ᮏ⏕໬Ꮫ఍ዡບ㈹ཷ㈹
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸⏕⌮໬Ꮫࢆᢸᙜࡋ࡚࠾ࡿࠋ⏕యࡣᵝࠎ࡞⎔ቃࡢኚ໬࡟ᑐᛂࡋࠊ⮬ࡽࡢᜏᖖᛶࢆ⥔ᣢࡋ࡚࠸
ࡿࠋᮏㅮ⩏ࡣࠊ⏕࿨య࡟ᚲ㡲࡞⛛ᗎࡢ⥔ᣢ࡟㛵ࢃࡿෆศἪ⣔࡜୰ᯡ⚄⤒⣔࡟ࡘ࠸࡚ศᏊ࡛ࣞ࣋ࣝࡢ࣓࢝
ࢽࢬ࣒ࢆ⌮ゎࡉࡏ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸⚾ࡓࡕࡢ◊✲ࡢฟⓎⅬࡣࠊ⚄⤒⣽⬊ࡣ࡝࠺ࡋ࡚⣽⬊⭷ࡢ࠶ࡿỴࡵࡽࢀࡓ࡜
ࡇࢁ࠿ࡽࡁࡕࢇ࡜⚄⤒✺㉳ࢆఙࡤࡍࡢࡔࢁ࠺࠿ࠊ࡜࠸࠺ࡇ࡜࡛ࡍࠋࡇࡢ⣲ᮔ࡞␲ၥ࡟⟅࠼ࡿࡓࡵࡢ᪉ἲ
ㄽ࡜ࡋ࡚⚾ࡓࡕࡣࠊRho ࣇ࢓࣑࣮ࣜ࡟ࡼࡿ⚄⤒✺㉳ᙧᡂࡢㄪ⠇ᶵ⬟࡟㛵ࢃࡿ⚄⤒⣽⬊ෆࡢ㔜せ࡞᪂ࡋ࠸
⺮ⓑ㉁ศᏊࢆྠᐃࠊࢡ࣮ࣟࢽࣥࢢࡋࠊࡑࡢศᏊࢆࡼࡾ࡝ࡇࢁ࡟ࡋ࡚⚄⤒✺㉳ᙧᡂࢆ௓ࡋࡓ⚄⤒ᅇ㊰ᙧᡂ
ࡢ࣓࢝ࢽࢬ࣒ࢆศᏊࣞ࣋ࣝࠊ⣽⬊࡛ࣞ࣋ࣝ᥎⌮ࡋ࡚࠸ࡲࡍࠋ
⚾ࡓࡕࡢ◊✲ᐊ࡛ࡣࠊಶேࡀୖ࡟㏙࡭ࡓ◊✲ࣉࣟࢪ࢙ࢡࢺࡢ㸯ࡘ࡟ᡤᒓࡋࠊࡑࡢ୰࡛⊂⮬ࡢ◊✲ࢸ࣮
− 258 −
࣐ࢆタᐃࡋ࡚ᇶᮏⓗ࡟⊂ຊ࡛◊✲ࢆ㐍ࡵ࡚ࡶࡽ࠸ࡲࡍࠋࡲࡓࠊࡑࡢᐇ㦂⤖ᯝࡸ◊✲ࡢ㐍ࡵ᪉࡟ࡘ࠸࡚ࠊ
ࡼࡃ㆟ㄽࢆࡍࡿࡇ࡜ࢆᚰࡀࡅ࡚࠾ࡾࡲࡍࠋࡑࡋ࡚ࠊࡑࡢ㐣⛬࡛⮬ศࡢ◊✲⤖ᯝࢆㄽᩥ࡜ࡋ࡚ࡲ࡜ࡵ࡚࠸
ࡃຊࢆ㌟࡟ࡘࡅ࡚ࡶࡽ࠸ࡲࡍࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊ࡯ࡰẖᅇᑠヨ㦂ࢆ⾜࠸㐩ᡂᗘࢆ☜ㄆࡍࡿᙧᡂⓗホ౯ࢆྲྀࡾධࢀ࡚࠸ࡿࠋ
ࡉࡽ࡟ᤵᴗホ౯ࡶಶேⓗ࡟⾜ࡗ࡚ࠊㅮ⩏࡟ྲྀࡾධࢀࡿࡼ࠺ཧ⪃࡟ࡋ࡚࠸ࡿࠋ
㸦ཎⴭ㸧
1. Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism. Hiramoto-Yamaki N.,
Takeuchi S., Ueda S., Harada K., Fujmoto S., Negishi M., and Katoh H. J. Cell Biol., 190, 461-477 (2010)
2. Semaphorin 4D/plexin-B1 stimulates PTEN activity through R-Ras GAP activity, inducing growth cone
collapse in hippocampal neurons. Oinuma I., Ito Y., Katoh H., and Negishi M. J. Biol. Chem., 285,
28200-28209 (2010)
3. RhoG promotes neural progenitor cell proliferation in mouse cerebral cortex. Fujimoto, S., Negishi, M., and
Katoh, H. Mol. Biol. Cell , 20, 4941-4950 (2009)
4. Plexin-B1 is a GTPase activating protein for M-Ras, remodeling dendrite morphology. Saito, Y., Oinuma, I.,
Fujimoto, S., and Negishi, M. EMBO Rep., 10, 614-621 (2009)
5. E2-Chimaerin binds to EphA receptors and regulates cell migration. Takeuchi, S., Yamaki, N., Iwasato, T.,
Negishi, M., and Katoh, H. FEBS Leet., 583, 1237-1242 (2009)
6. Different requirement of Rnd GTPases for R-Ras GAP activity of Plexin-C1 and Plexin-D1. Uesugi, K.,
Oinuma, I., Katoh, H., and Negishi, M. J. Biol. Chem., 284, 6743-6751. (2009)
7. Regulation of dendrite growth by the Cdc42 activator Zizimin1/Dock9 in hippocampal neurons. Kuramoto, K.,
Negishi, M., and Katoh, H. J. Neurosci. Res., 87(16), 1794-1805 (2009)
8. Lysophosphatidic acid and thrombin receptors require both GD12 and GD13 to regulate axonal morphology in
hippocampal neurons. Yamazaki, J., Katoh, H., and Negishi, M. Biol. Pharm. Bull., 31(12), 2216-2222
(2008)
9. Dock4 regulates dendritic development in hippocampal neurons. Ueda, S., Fujimoto, S., Hiramoto, K.,
Negishi, M., and Katoh, H. J. Neurosci. Res., 86(16), 3052-3061 (2008)
10. Rac-GAP D-chimerin regulates motor-curcuit formation as a key mediator of Ephrin B3/EphA4 forward
signaling. Iwasato, T., Katoh, H., Nishimaru, H., Ishikawa, Y., Inoue, H., Saito, Y., Ando, R., Iwama, M.,
Takahashi, R., Negishi, M., and Itohara, S. Cell 130, 742-753 (2007)
11. RhoG regulates anoikis through a phosphatidylinositol 3-kinase-dependent mechanism. Yamaki, N., Negishi,
M., and Katoh, H. Exp. Cell Res. 313, 2821-2832 (2007)
12. Interaction of arginine-rich pepetides with membrane-associated proteoglycans is crucial for induction of
actin organization and macropinocytosis. Nakase, I., Tadokoro, A., Kawabata, N., Takeuchi, T., Katoh, H.,
Hiramoto, K., Negishi, M., Nomizu, M., Sugiura, Y., and Futaki, S. Biochemistry 46, 492-501 (2007)
13. R-Ras controls axon specification upstream of GSK-3E through integrin-linked kinase. Oinuma, I., Katoh, H.,
and Negishi, M. J. Biol. Chem. 282, 303-318 (2007)
14. Dock4 is regulated by RhoG and promotes Rac-dependent cell migration. Hiramoto, K., Negishi, M., and
Katoh, H. Exp. Cell Res. 312, 4205-4216 (2006)
15. Regulation of neuronal morphology by Toca-1, an F-BAR/EFC protein that induces plasma membrane
invagination. Kakimoto, T., Katoh, H., and Negishi, M. J. Biol. Chem. 281, 29042-29053 (2006)
16. Sema4D/Plexin-B1 activates GSK-3E via R-Ras GAP activity, inducing growth cone collapse. Ito, Y.,
Oinuma, I., Katoh, H., Kaibuchi, K., and Negishi, M. EMBO Rep. 7, 704-709 (2006)
17. PKC phosphorylates MARCKS Ser159 not only directly but also through RhoA/ROCK. Tanabe, A.,
Kamisuki, Y., Hidaka, H., Suzuki, M., Negishi, M., and Takuwa, Y. Biochem. Biophys. Res. Commun. 345,
156-161 (2006)
18. Semaphorin 4D/Plexin-B1-mediated R-Ras GAP activity inhibits cell migration by regulating E1 integrin
activity. Oinuma, I., Katoh, H., and Negishi, M. J. Cell Biol. 173, 601-613 (2006)
19. Small GTPase Rnd1 is involved in neuronal activity-dependent dendritic development in hippocampal
neurons. Ishikawa, Y., Katoh, H., and Negishi, M. Neurosci. Lett. 400, 218-223 (2006)
20. Pragmin, a novel effector of Rnd2 GTPase, stimulates RhoA activity. Tanaka, H., Katoh, H., and Negishi, M.
J. Biol. Chem. 281, 10355-10364 (2006)
21. Differential distribution of ELMO1 and ELMO2 mRNAs in the developing mouse brain. Katoh, H., Fujimoto,
S., Ishida, C., Ishikawa, Y., and Negishi, M. Brain Res. 1073-1074, 103-108 (2006)
22. In vivo function of Rnd2 in the development of neocortical pyramidal neurons. Nakamura, K., Yamashita, Y.,
Tamamaki, N., Katoh, H., Kaneko, T., and Negishi, M. Neurosci. Res. 54, 149-153 (2006)
− 259 −
23. Activation of Rac1 by RhoG regulates cell migration. Katoh, H., Hiramoto, K., and Negishi, M.
119, 56-65 (2006)
− 260 −
J. Cell Sci.
⏕యᶵ⬟໬Ꮫศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧஧ᮌ ྐᮁ㸦ࡩࡓࡁ ࡋࢁ࠺㸧(2005.4 ᪼௵)
᫛࿴㸳㸶ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸴㸰ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇ
ㄢ⛬୰㏥ࠊᖹᡂඖᖺி㒔኱Ꮫ⸆Ꮫ༤ኈྲྀᚓ
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧௒す ᮍ᮶㸦࠸ࡲ࡟ࡋ ࡳࡁ㸧(2003.7 ᥇⏝)
ᖹᡂ㸷ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸲ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇ
ㄢ⛬ಟ஢
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧୰℩ ⏕ᙪ㸦࡞࠿ࡏ ࠸ࡃࡦࡇ㸧(2006.4 ᥇⏝)
ᖹᡂ㸯㸰ᖺᒱ㜧⸆⛉኱Ꮫ༞ࠊᖹᡂ㸯㸵ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈᚋᮇㄢ⛬ಟ஢
◊✲ࡢᴫせ
⏕యෆ࡟ࡣᵝࠎ࡞≀㉁ࡀᏑᅾࡋࠊࡑࢀࡒࢀࡀᵝࠎ࡞ᶵ⬟άᛶࢆ᭷ࡋ࡚࠾
ࡾࠊࡑࡢᶵ⬟ࡀ஫࠸࡟」㞧࡟⤡ࡳྜ࠺ࡇ࡜࡟ࡼࡗ࡚⏕≀ࡢᶵ⬟ࢆᢸࡗ࡚࠸ࡿࠋ 㸦஧ᮌᩍᤵ㸧
ᙜ◊✲ᐊࡣࠊᵝࠎ࡞⏕యάᛶ≀㉁ࡢാࡁࢆࠊ⏕≀໬Ꮫⓗᡭἲࠊྜᡂ໬Ꮫⓗᡭἲࠊ
≀⌮໬Ꮫⓗᡭἲࢆ⏝࠸࡚ศᏊ࡛ࣞ࣋ࣝ⌮ゎࡋࠊ⏕≀ࢆ໬Ꮫࡢ┠࡛ぢࡿࡇ࡜ࢆ┠ᶆ࡟◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋ
⣽⬊ᶵ⬟࣭㑇ఏᏊࢆไᚚࡍࡿ⏕⌮άᛶ⺮ⓑ㉁ࡢ๰ฟࢆ┠ᣦࡋࠊ⣽⬊⭷㏱㐣࣌ࣉࢳࢻ࣋ࢡࢱ࣮ࡢ㛤Ⓨ࡜
࣓࢝ࢽࢬ࣒ࠊள㖄ࣇ࢕࣮ࣥ࢞ᆺ㌿෗ᅉᏊࡢᶵ⬟ゎᯒ࡜⣽⬊ᶵ⬟ไᚚࠊ⣽⬊ෆࢱ࣮ࢤࢸ࢕ࣥࢢࡢ໬Ꮫ࡜
ศᏊタィࠊ⎔ቃᛂ⟅ᆺᶵ⬟ᛶ࣌ࣉࢳࢻࡢࢹࢨ࢖ࣥ࡞࡝࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
⣽⬊⭷㏱㐣࣌ࣉࢳࢻ࣋ࢡࢱ࣮ࡢ㛤Ⓨ࡜࣓࢝ࢽࢬ࣒
⣽⬊ෆ᝟ሗఏ㐩࡟㛵୚ࡍࡿ࣌ࣉࢳࢻࡸࢱࣥࣃࢡ㉁ࡢຠ⋡ⓗ࡞⣽⬊ෆᑟධࡀᐇ⌧ࡉࢀࢀࡤࠊศ໬ࠊච
␿ᛂ⟅࡞࡝࡜࠸ࡗࡓࠊ⣽⬊ෆࢩࢢࢼࣝఏ㐩࡟ࡼࡗ࡚ᘬࡁ㉳ࡇࡉࢀࡿ⣽⬊ᛂ⟅ࡢไᚚࡀᮇᚅ࡛ࡁࡿࠋࡋ
࠿ࡋࠊ୍⯡࡟࣌ࣉࢳࢻ࣭ࢱࣥࣃࢡ㉁ࡣぶỈᛶࡀ㧗ࡃࠊࡲࡓศᏊ㔞ࡶ኱ࡁ࠸ࡇ࡜࠿ࡽࠊࡑࡢࡲࡲ࡛⣽⬊
⭷ࢆ㏻㐣ࡍࡿࡇ࡜ࡣᅔ㞴࡛࠶ࡿࠋ㏆ᖺࠊ⣽⬊㏱㐣ᛶࡢ࣌ࣉࢳࢻࢆࢱࣥࣃࢡ㉁ࡢ⣽⬊ෆᑟධ࣋ࢡࢱ࣮࡜
ࡋ࡚⏝࠸ࡿ᪉ἲࡀὀ┠ࡉࢀ࡚࠸ࡿࠋࡇࢀࡽࡢ᪉ἲࡣࠊ㠀ኳ↛࢔࣑ࣀ㓟ࠊ㠀ኳ↛㦵᱁ࢆศᏊෆ࡟᭷ࡍࡿ
࣌ࣉࢳࢻࡢ⣽⬊ෆᑟධࢆࡶྍ⬟࡜ࡍࡿࡶࡢ࡛࠶ࡾࠊ⣽⬊ࢆ໬Ꮫⓗ࡟⌮ゎࡍࡿࡓࡵࡢ᪉ἲㄽ࡜ࡋ࡚ࡶ㔜
せ࡛࠶ࡿࠋᙜ◊✲ᐊ࡛ࡣࠊ᪂ࡓ࡞ᶵ⬟ࢆ᭷ࡍࡿ⣽⬊㏱㐣ᛶ࣌ࣉࢳࢻࡢ๰ฟ࡜ࠊ⣽⬊ෆࢱ࣮ࢤࢸ࢕ࣥࢢ
ࡢ໬Ꮫ࡜ศᏊタィ࡞࡝࡬ࡢᒎ㛤ࢆ┠ᣦࡋࡓ◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋ
ள㖄ࣇ࢕࣮ࣥ࢞ࢱࣥࣃࢡ㉁ࡢ㹂㹌㸿ㄆ㆑࡜ᶵ⬟Ⓨ⌧ࠊᶵ⬟ኚ᥮ࡢ◊✲
ள㖄ࣇ࢕࣮ࣥ࢞ᆺࣔࢳ࣮ࣇࡣࠊࢩࢫࢸ࢖ࣥࡸࣄࢫࢳࢪࣥ࡜࠸ࡗࡓ࢔࣑ࣀ㓟ࡀள㖄࡜㓄఩ࡍࡿࡇ࡜࡟
ࡼࡗ࡚ึࡵ࡚㧗ḟᵓ㐀ࢆ᭷ࡍࡿࡇ࡜ࡀ࡛ࡁࡿࣘࢽ࣮ࢡ࡞᰾㓟⤖ྜ⬟ࢆ᭷ࡍࡿࣔࢳ࣮ࣇ࡛࠶ࡿࠋࡑࡢᵓ
㐀ୖࡢ≉ᚩࡶࡉࡿࡇ࡜࡞ࡀࡽ㹂㹌㸿ㄆ㆑ࣔࢳ࣮ࣇ࡜ࡋ࡚ࡢࣘࢽ࣮ࢡࡉࡶ⯆࿡῝࠸ࡶࡢ࡛࠶ࡿࠋ඾ᆺⓗ
࡞㹁㸰㹆㸰ᆺள㖄ࣇ࢕࣮ࣥ࢞ࡣࠊ㸯㸧㸯ࡘࡢࣇ࢕࣮ࣥ࢞ࡀ࠾ࡼࡑ㸱ࡘࡢሷᇶࢆㄆ㆑ࡋ࡚࠸ࡿࠊ㸰㸧㠀
ᑐ⛠ሷᇶ㓄ิࢆㄆ㆑ࡍࡿࠊ㸱㸧┤㙐ୖ࡟୪ࢇ࡛ㄆ㆑㡿ᇦࢆᗈࡆ࡚࠸ࡿࠋࡇࢀࡽࢆᇶ࡟ࡋࡓࠊ௵ពࡢ㹂
㹌㸿㓄ิࢆṇ☜࡟ㄆ㆑ࡍࡿศᏊࡢ๰〇ࡣࠊேᕤไ㝈㓝⣲ࡸேᕤࣜࣉࣞࢵࢧ࣮࡜ࡋ࡚᭷⏝࡛࠶ࡿ࡜⪃࠼
ࡽࢀࡿࠋᡃࠎࡣࠊள㖄ࣇ࢕࣮ࣥ࢞ࢆ⏝࠸ࡓ᪂つᶵ⬟ࢱࣥࣃࢡ㉁ࡢ๰〇࠾ࡼࡧࠊࡑࢀࢆ⏝࠸ࡓ᫬ィ㑇ఏ
Ꮚไᚚ࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
⎔ቃᛂ⟅ᆺᶵ⬟ᛶ࣌ࣉࢳࢻࡢࢹࢨ࢖ࣥ
࢖࢜ࣥࢳࣕࢿࣝࡸ '1$ ⤖ྜࢱࣥࣃࢡ㉁ࡣ⏕యෆ᝟ሗఏ㐩࡟㔜せ࡞ാࡁࢆ₇ࡎࡿࢱࣥࣃࢡ㉁࡛࠶ࡿࠋ
ᡃࠎࡣࠊேᕤⓗ࡟ࢹࢨ࢖ࣥࡋࡓྜᡂ࣌ࣉࢳࢻࢆ⏝࠸ࠊࡇࢀࡽࡢᶵ⬟Ⓨ⌧ࡢࡓࡵ࡟ࡣ࣌ࣉࢳࢻ㓄ิࡸࡑ
ࡢᵓ㐀࡟࡝ࡢࡼ࠺࡞せᅉࡀ㔜せ࡛࠶ࡿ࠿ࢆ᳨ウࡍࡿ࡜࡜ࡶ࡟ࠊ✀ࠎࡢࣜ࢞ࣥࢻࡸእⓗ่⃭࡟࿧ᛂࡋ࡚
ᵓ㐀ࡸᶵ⬟ࡀࢫ࢖ࢵࢳ࡛ࡁࡿ᪂ࡋ࠸ᶵ⬟ᛶศᏊࢆ๰ฟࡍࡿࡇ࡜ࢆ┠ᣦࡋ࡚࠸ࡿࠋ᭦࡟ࠊࡇࢀࡽࡢ⣽⬊
ෆ࡬ࡢᑟධ࡟ࡼࡿ⣽⬊ᶵ⬟ࡢไᚚࢆࡡࡽࡗ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᙜ◊✲ᐊࡢ◊✲ᡂᯝࡣࠊᅜෆእࡢ㛵㐃Ꮫ఍࡛ࡢᣍᚅㅮ₇ࡸ⥲ㄝࡢ౫㢗࡞࡝ࠊ㧗ࡃホ౯ࡉࢀ࡚࠸ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ⸆⛉Ꮫ⛉࡞ࡽࡧ࡟⥲ྜ⸆Ꮫ⛉ 3 ᅇ⏕๓ᮇࡢ᭷ᶵ໬Ꮫ㸱㸦๰⸆໬Ꮫ㸧ࠊ࡞ࡽࡧ࡟
ྠ 3 ᅇ⏕ᚋᮇࡢ᭷ᶵ໬Ꮫ㸳㸦⏕యᶵ⬟໬Ꮫ㸧ࢆᢸᙜࡋ࡚࠸ࡿࠋ๓⪅࡛ࡣࢱࣥࣃࢡ㉁ࡸ᰾㓟ࡢᵓ㐀࡜┦
஫ㄆ㆑࡜་⸆࡜ࡢ㛵㐃࡟ࡘ࠸࡚ࡢㅮ⩏ࢆศᢸࡋࠊᚋ⪅࡛ࡣࠊไ࢞ࣥ๣࡞࡝ࢆࡣࡌࡵ࡜ࡋࡓᵝࠎ࡞⏕య
άᛶศᏊࡢస⏝ᶵసࡸ᰾㓟ࡸࢱࣥࣃࢡ㉁࡞࡝ࡢ⏕యศᏊࡢᵓ㐀ᙧᡂ࡜┦஫స⏝ᵝᘧࢆࠊ᭷ᶵ໬Ꮫࠊ≀
− 261 −
⌮໬Ꮫࠊ⏕≀໬Ꮫ➼ࡢ▱㆑ࢆ⥲ྜࡋ࡚⪃ᐹࡍࡿࡇ࡜࡟ࡼࡾࠊ⏕࿨⌧㇟ࢆ໬Ꮫࡢ┠࡛ᤊ࠼ࡿ࡜࡜ࡶ࡟ࠊ
᪂ࡋ࠸⸆ࡢタィ࡟㛵ࡍࡿ╔║ⅬࢆᏛࡪࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗᐇ⩦࡛ࡣࠊಶࠎࡢࢸ࣮࣐ࢆ୚࠼ࠊᢏ⾡ࡢ⩦ᚓࡸࠊᩍᐁࠊ◊✲ᐊෆࡢ
Ꮫ⏕㛫࡛ࡢウㄽ࡞࡝ࢆ㏻ࡋ࡚ࠊ኱Ꮫ㝔࡟ྥࡅࡓ◊✲ࡢᇶ♏ࢆᇵࡗ࡚࠸ࡿࠋࡉࡽ࡟ࠊ኱Ꮫ㝔Ꮫ⏕࡟㛵ࡋ
࡚ࡣࠊ᭦࡟㧗࠸ࣞ࣋ࣝࢆ┠ᣦࡋࠊಶࠎࡢࢸ࣮࣐ࢆゎỴࡍࡿࡓࡵࡢᆅຊࢆ㣴࠸ࠊ◊✲⪅࡜ࡋ࡚⊂ࡾ❧ࡕ
࡛ࡁࡿࡼ࠺ࠊᛮ⪃ἲࠊ◊✲ᢏἲࡢ୧㠃࠿ࡽࡢᐇ㊶ⓗ࠿ࡘ⥲ྜⓗ࡞カ⦎ࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓࠊᩥ⊩㉎ㄞ
఍ࡸ◊✲ሗ࿌఍ࢆ㏻ࡋ࡚ࠊ◊✲ࡢど㔝ࢆᗈࡆࡿ࡜࡜ࡶ࡟ࠊ⮬ᕫࡢ◊✲ᡂᯝࢆ࢔ࣆ࣮ࣝࡍࡿカ⦎ࠊ࠶ࡿ
࠸ࡣࠊ≀஦ࡢᮏ㉁ࢆ⌮ゎࡋウㄽࡍࡿカ⦎ࢆ⾜ࡗ࡚࠸ࡿࠋࡉࡽ࡟ࠊ◊✲ᡂᯝࢆᏛ఍Ⓨ⾲ࠊⱥᩥㄽᩥ࡞࡝
ࡢᙧ࡛✚ᴟⓗ࡟බ⾲ࡋࠊᅜෆእࡢ◊✲⪅࡜ウㄽࡍࡿᶵ఍ࢆᣢࡘࡇ࡜ࢆዡບࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏ࡣࠊ㸱ᖺḟࡲ࡛࡟⩦ᚓࡋࡓᵝࠎ࡞ᩍ⛉ෆᐜࡀ⏕యᶵ⬟ࡸ⸆≀ࡢస⏝ᶵᗎ࡟࡝ࡢࡼ࠺
࡟㛵୚ࡋ࡚࠸ࡿ࠿ࢆࠊලయⓗ࠿ࡘ⥲ྜⓗ࡟⌮ゎࡋࠊ᭱᪂ࡢ◊✲ືྥࡶ஺࠼࡚ࠊ⸆Ꮫே࡜ࡋ࡚ࡢ⣲㣴࡜
ࢭࣥࢫࢆ㣴࠺ࡇ࡜ࢆ┠ᶆ࡟⾜ࡗ࡚࠸ࡿࠋࡉࡽ࡟ᖺᗘᮎ࡟ࡣಶࠎࡢᏛ⏕࠿ࡽᤵᴗホ౯ࢆ⾜࠸ࠊㅮ⩏ෆᐜ
ࡢ඘ᐇ࡜ᨵၿࢆᅗࡗ࡚࠸ࡿࠋ
◊✲ᐊෆࡢᩍ⫱ࡣࠊ◊✲⌧ሙ࡛ࡢᐇ㊶ⓗ࡞ウㄽࠊᖺᩘᅇࡢᩥ⊩⤂௓ࡸ◊✲⤂௓ࠊࡉࡽ࡟ࡣࠊྛಶே
࡞ࡽࡧ࡟Ꮫ⏕┦஫ࡢᐇຊࢆ㧗ࡵࡿࡇ࡜ࢆ┠ᣦࡋ࡚࠾ࡾࠊᡂᯝ࡜ࡋ࡚ᅜෆእ࡟࠾ࡅࡿᩘከࡃࡢᏛ఍ࡸᅜ
㝿୍ὶㄅ࡬ࡢⓎ⾲࡟ࡘ࡞ࡀࡗ࡚࠸ࡿࠋᩘከࡃࡢ኱Ꮫ㝔ಟ஢⪅ࡀࠊ༤ኈ◊✲ဨ࡜ࡋ࡚ᅜෆእࡢ኱Ꮫ࣭◊
✲ᶵ㛵࡛◊㛑ࢆ✚ࡳࠊࡲࡓࠊ〇⸆ࢆࡣࡌࡵ࡜ࡋࡓྛ✀௻ᴗࡢ◊✲࣭㛤Ⓨ⫋࡟ᑵࡁࠊ኱Ꮫ࡛ᚓࡓ▱㆑ࡸ
⤒㦂ࢆ᭦࡟Ⓨᒎࡉࡏࡿᙧ࡛ά㌍ࡋ࡚࠸ࡿࠋࡇࢀࡽࡣᩍ⫱࡜◊✲ࡢࣞ࣋ࣝࡀ㧗ࡃホ౯ࡉࢀ࡚࠸ࡿ⤖ᯝ࡛
࠶ࡿ࡜ゝ࠼ࡿࠋ
㸦ཎⴭ㸧
1. Enhanced Target-Specific Accumulation of Radiolabeled Antibodies by Conjugating Arginine-Rich Peptides
as Anchoring Molecules
Rei Miyamoto, Hiromichi Akizawa, Takeshi Nishikawa, Tomoya Uehara, Yusuke Azuma, Ikuhiko Nakase,
Shiroh Futaki, Hirofumi Hanaoka, Yasuhiko Iida, Keigo Endo, Yasushi Arano
Bioconjug. Chem,. in press.
2. Nanoparticles for ex vivo siRNA Delivery to Dendritic Cells for Cancer Vaccines: Programmed Endosomal
Escape and Dissociation
Hidetaka Akita, Kentaro Kogure, Rumiko Moriguchi, Yoshio Nakamura, Tomoko Higashi, Takashi
Nakamura, Satoshi Serada, Minoru Fujimoto, Tetsuji Naka, Shiroh Futaki, Hideyoshi Harashima
J. Control. Release., in press.
3. Zinc Finger-Zinc Finger Interaction between the Transcription Factors, GATA-1 and Sp1
Miki Imanishi, Chika Imamura, Chika Higashi, Wei Yan, Shigeru Negi, Shiroh Futaki, Yukio Sugiura
Biochem. Biophys. Res. Commun., 400(4), 625-630 (2010)
4. Transduction of Cell-Penetrating Peptides into Induced Pluripotent Stem Cells
Hiroshi Yukawa, Hirofumi Noguchi, Ikuhiko Nakase, Yoshitaka Miyamoto, Koichi Oishi, Nobuyuki
Hamajima, Shiroh Futaki, Shuji Hayashi
Cell Transplant, 19(6), 901-909 (2010)
5. Metal-Stimulated Transcriptional Regulation by an Artificial Zinc Finger Protein
Miki Imanishi, Tomohiro Nakaya, Tatsuya Morisaki, Daisuke Noshiro, Shiroh Futaki, Yukio Sugiura
ChemBioChem, 11(12), 1653-1655 (2010)
6. Rev-derived Peptides Inhibit HIV-1 Replication by Antagonism of Rev and a Co-receptor, CXCR4
Kazuki Shimane, Eiichi Kodama, Ikuhiko Nakase, Shiroh Futaki, Yasuteru Sakurai, Yasuko Sakagami,
Stefan G. Sarafianos, Masao Matsuoka
Int. J. Biochem. Cell Biol., 42(9), 1482-1488 (2010)
7. Contribution of the Flexible Loop Region to the Function of Staphylococcal Enterotoxin B
Saeko Yanaka, Motonori Kudou, Yoshikazu Tanaka, Takumi Sasaki, Sumiyo Takemoto, Atsuko Sakata,
Yukio Hattori, Tomoyuki Koshi, Shiroh Futaki, Kouhei Tsumoto, Toshihiro Nakashima
Protein Eng. Des. Sel., 23(5), 415-421 (2010)
− 262 −
8. Expressed Protein Ligation for the Preparation of Fusion Proteins with Cell Penetrating Peptides for
Endotoxin Removal and Intracellular Delivery
Hao-Hsin Yu, Ikuhiko Nakase, Sílvia Pujals, Hisaaki Hirose, Gen Tanaka, Sayaka Katayama, Miki
Imanishi, Shiroh Futaki
Biochim. Biophys. Acta., 798(12), 2249-2257 (2010)
9. Acylation of Octaarginine: Implication to the Use of Intracellular Delivery Vectors
Sayaka Katayama, Hisaaki Hirose, Kentaro Takayama, Ikuhiko Nakase, Shiroh Futaki
J. Control. Release, in press.
10. Nanoparticles for ex vivo siRNA Delivery to Dendritic Cells for Cancer Vaccines: Programmed Endosomal
Escape and Dissociation
Hidetaka Akita, Kentaro Kogure, Rumiko Moriguchi, Yoshio Nakamura, Tomoko Higashi, Takashi
Nakamura, Satoshi Serada, Minoru Fujimoto, Tetsuji Naka, Shiroh Futaki, Hideyoshi Harashima
J. Control. Release, 143(3), 311-317 (2010)
11. Metal-Assisted Channel Stabilization: Disposition of a Single Histidine on the N-terminus of Alamethicin
Yielded Channels with Extraordinarily Long Lifetimes
Daisuke Noshiro, Koji Asami, Shiroh Futaki
Biophys. J., 98(9), 1801-1808 (2010)
12. Cell-Penetrating d-Isomer Peptides of p53 C-Terminus: Long-term Inhibitory Effect on the Growth of
Bladder Cancer
Daiji Araki, Kentaro Takayama, Miyabi Inoue, Toyohiko Watanabe, Hiromi Kumon, Shiroh Futaki, Hideki
Matsui, Kazuhito Tomizawa
Urology, 75, 813-819 (2010)
13. Development of an Intracellularly-Acting Inhibitory Peptide Selective for PKN
Kazuhiro Shiga, Kentaro Takayama, Shiroh Futaki, Jessica E. Hutti, Lewis C. Cantley, Katsuko Ueki,
Yoshitaka Ono, Hideyuki Mukai
Biochem. J., 425(2), 445-453 (2009)
14. Elucidating Cell-Penetrating Peptide Mechanisms of Action for Membrane Interaction, Cellular Uptake, and
Translocation Utilizing the Hydrophobic Counter-Anion Pyrenebutyrate
Peter Guterstam, Fatemeh Madani, Hisaaki Hirose, Toshihide Takeuchi, Shiroh Futaki, Samir EL-Andaloussi,
Astrid Gräslund, Ülo Langel
Biochim. Biophys. Acta. – Biomembranes, 1788(12), 2509-2517 (2009)
15. Studies on the Effects of Arginine Residues Introduced to Peptide Ribonucleic Acids (PRNA) on the
Complex Stability with RNA
Akihiro Nishino, Nobuya Sawa, Keiko Onodera, Seiji Sakamoto, Yasuyuki Araki, Ikuhiko Nakase, Shiroh
Futaki, Yoshihisa Inoue, Takehiko Wada
Nucleic Acids Symp. Ser., (53), 55-56 (2009)
16. Cell Surface Accumulation of Flock House Virus-derived Peptide Leads to Efficient Internalization via
Macropinocytosis
Ikuhiko Nakase, Hisaaki Hirose, Gen Tanaka, Akiko Tadokoro, Sachiko Kobayashi, Toshihide Takeuchi,
Shiroh Futaki
Mol. Ther., 17(11), 1868-1876 (2009)
17. Positive and Negative Cooperativity of Modularly Assembled Zinc Fingers
Miki Imanishi, Atsushi Nakamura, Tatsuya Morisaki, Shiroh Futaki
Biochem. Biophys. Res. Commun., 387(3), 440-443 (2009)
18. Effect of Polyethyleneglycol Spacer on the Binding Properties of Nuclear Localization Signal-Modified
Liposomes to Isolated Nucleus
Dai Kurihara, Hidetaka Akita, Asako Kudo, Tomoya Masuda, Shiroh Futaki, Hideyoshi Harashima
Biol. Pharm. Bull., 32(7), 1303-1306 (2009)
− 263 −
19. A pH-sensitive Fusogenic Peptide Facilitates Endosomal Escape and Greatly Enhances the Gene Silencing
of siRNA-containing Nanoparticles in vitro and in vivo
Hiroto Hatakeyama, Erika Itho, Hidetaka Akita, Motoi Oishi, Yukio Nagasaki, Shiroh Futaki, Hideyoshi
Harashima
J. Control. Release, 139(2), 127-132 (2009)
20. Cobalt(II)-Responsive DNA Binding of a GCN4-bZIP Protein Containing Cysteine Residues Functionalized
with Iminodiacetic Acid
Yusuke Azuma, Miki Imanishi, Tomoyuki Yoshimura, Takeo Kawabata, Shiroh Futaki
Angew. Chem. Int. Ed., 48(37), 6853-6856 (2009)
21. Enhanced Intracellular Delivery Using Arginine-Rich Peptides by the Addition of Penetration Accelerating
Sequences (Pas)
Kentaro Takayama, Ikuhiko Nakase, Hiroyuki Michiue, Toshihide Takeuchi, Kazuhito Tomizawa, Hideki
Matsui, Shiroh Futaki
J. Control. Release, 138(2), 128-133 (2009)
22. Efficient Short Interference RNA Delivery to Tumor Cells Using a Combination of Octaarginine, GALA and
Tumor-Specific, Cleavable Polyethylene Glycol System
Yu Sakurai, Hiroto Hatakeyama, Hidetaka Akita, Motoi Oishi, Yukio Nagasaki, Shiroh Futaki, Hideyoshi
Harashima
Biol. Pharm. Bull., 32(5), 928-932 (2009)
23. Cellular Uptake, Distribution and Cytotoxicity of the Hydrophobic Cell Penetrating Peptide Sequence
PFVYLI Linked to the Proapoptotic Domain Peptide PAD
Catherine L. Watkins, Paul Brennan, Christopher Fegan, Kentaro Takayama, Ikuhiko Nakase, Shiroh Futaki,
Arwyn T. Jones
J. Control. Release, 140(3), 237-244 (2009)
24. Cytosolic Targeting of Macromolecules Using a pH-dependent Fusogenic Peptide in Combination with
Cationic Liposomes
Sachiko Kobayashi, Ikuhiko Nakase, Noriko Kawabata, Hao-Hsin Yu, Sílvia Pujals, Miki Imanishi, Ernest
Giralt, Shiroh Futaki
Bioconjug. Chem., 20 (5), 953–959 (2009)
25. Mesoporous Silica Based Delivery System for a Drug with a Peptide as a Cell-Penetrating Vector
Chuanbo Gao, Isabel Izquierdo-Barba, Ikuhiko Nakase, Shiroh Futaki, Juanfang Ruan, Kazutami Sakamoto,
Yasuhiro Sakamoto, Kazuyuki Kuroda, Osamu Terasaki, Shunai Che
Microporous and Mesoporous Materials, 122(1-3), 201-207 (2009)
26. Low Concentration Thresholds of Plasma Membranes for Rapid Energy-Independent Translocation of a Cell
Penetrating Peptide
Catherine L. Watkins, Dirk Schmaljohann, Shiroh Futaki, Arwyn T. Jones
Biochem. J., 420(2), 179-189 (2009)
27. High-resolution Multi-dimensional NMR Spectroscopy of Proteins in Human Cells
Kohsuke Inomata, Ayako Ohno, Hidehito Tochio, Shin Isogai, Takeshi Tenno, Ikuhiko Nakase, Toshihide
Takeuchi, Shiroh Futaki, Yutaka Ito, Hidekazu Hiroaki, Masahiro Shirakawa
Nature, 458(7234), 106-110 (2009)
28. Novel System to Achieve One-Pot Modification of Cargo Molecules with Oligoarginine Vectors for
Intracellular Delivery
Kentaro Takayama, Akiko Tadokoro, Sílvia Pujals, Ikuhiko Nakase, Ernest Giralt, and Shiroh Futaki
Bioconjug. Chem., 20(2), 249-257 (2009)
29. Transferrin Receptor-dependent Cytotoxicity of Artemisinin–Transferrin Conjugates on Prostate Cancer
Cells and Induction of Apoptosis
Ikuhiko Nakase, Byron Gallis, Tomoka Takatani-Nakase, Steve Oh, Eric Lacoste, Narendra P. Singh, David
R. Goodlett, Seigo Tanaka, Shiroh Futaki, Henry Lai, Tomikazu Sasaki
Cancer Lett., 274(2), 290-298 (2009)
− 264 −
30. Effects of Arginine Residue Introduction upon Interaction and Complexation Behavior of Peptide
Ribonucleic Acids (PRNAs) with RNA: Synthesis and Properties of alpha-Containing arginine
Takehiko Wada, Nobuya Sawa, Hirofumi Sato, Shiroh Futaki, Yoshihisa Inoue.
Nucleic Acids Symp. Ser., (52), 673-674 (2008)
31. Oligoarginine-Based Prodrugs with Self-Cleavable Spacers for Caco-2 Cell Permeation
Kentaro Takayama, Yuka Suehisa, Takuya Fujita, Jeffrey-Tri Nguyen, Shiroh Futaki, Akira Yamamoto,
Yoshiaki Kiso, Yoshio Hayashi
Chem. Pharm. Bull., 56(11), 1515-1520 (2008)
32. Rapid Transcriptional Activity in Vivo and Slow DNA Binding in Vitro by Artificial Multi-Zinc Finger
Protein
Tatsuya Morisaki, Miki Imanishi, Shiroh Futaki, Yukio Sugiura
Biochemistry, 47(38), 10171-10177 (2008)
33. Octaarginine- and Octalysine-Modified Nanoparticles Have Different Modes of Endosomal Escape
Ayman El-Sayed, Ikramy A. Khalil, Kentaro Kogure, Shiroh Futaki, Hideyoshi Harashima
J. Biol. Chem., 283(34), 23450-23461 (2008)
34. An Artificial Virus-like Nano Carrier System: Enhanced Endosomal Escape of Nanoparticles via Synergistic
Action of pH-sensitive Fusogenic Peptide Derivatives
Kentaro Sasaki, Kentaro Kogure, Shinji Chaki, Yoshio Nakamura, Rumiko Moriguchi, Hirofumi Hamada,
Radostin Danev, Kuniaki Nagayama, Shiroh Futaki, Hideyoshi Harashima
Anal. Bioanal. Chem., 391(8), 2717-2727 (2008)
35. Cellular Internalization and Distribution of Arginine-Rich Peptides as a Function of Extracellular Peptide
Concentration, Serum, and Plasma Membrane Associated Proteoglycans
Michie Kosuge, Toshihide Takeuchi, Ikuhiko Nakase, Arwyn Tomos Jones, Shiroh Futaki
Bioconjug. Chem. 19(3), 656-664 (2008)
36. Development of Oligoarginine-drug Conjugates Linked to New Peptidic Self-cleavable Spacers toward
Effective Intestinal Absorption
Yoshio Hayashi, Kentaro Takayama, Yuka Suehisa, Takuya Fujita, Jeffrey-Tri Nguyen, Shiroh Futaki, Akira
Yamamoto, Yoshiaki Kiso
Bioorg. Med. Chem. Lett., 17(18), 5129-5132 (2007)
37. Guanidine-Containing Molecular Transporters: Sorbitol-Based Transporters Show High Intracellular
Selectivity toward Mitochondria
Kaustabh K. Maiti, Woo Sirl Lee, Toshihide Takeuchi, Catherine Watkins, Marjan Fretz, Dong-Chan Kim,
Shiroh Futaki, Arwyn Jones, Kyong-Tai Kim, Sung-Kee Chung
Angew. Chem. Int. Ed. Engl., 46(31), 5880-5884 (2007)
38. D-Helical Linker of an Artificial 6-Zinc Finger Peptide Contributes to Selective DNA Binding to a
Discontinuous Recognition Sequence
Wei Yan, Miki Imanishi, Shiroh Futaki, Yukio Sugiura
Biochemistry, 46(29), 8517-8524 (2007)
39. New Packaging Method of Mycobacterial Cell Wall using Octaarginine-modified Liposomes: Enhanced
Uptake by and Immunostimulatory Activity of Dendritic Cells
Atthachai Homhuan, Kentaro Kogure, Hideyuki Akaza, Shiroh Futaki, Takashi Naka, Yukiko Fujita, Ikuya
Yano, Hideyoshi Harashima
J. Control. Release, 120(1-2), 60-69 (2007)
40. Octaarginine-modified Multifunctional Envelope-type Nano Device for siRNA
Yoshio Nakamura, Kentaro Kogure, Shiroh Futaki, Hideyoshi Harashima
J. Control. Release, 119(3), 360-367 (2007)
41. NMR Investigation of the Electrostatic Effect in Binding of a Neuropeptide, Achatin-I, to
Phosphatidylcholine Bilayers.
− 265 −
Tomohiro Kimura, Keiko Ninomiya, Shiroh Futaki
J. Phys. Chem. B. 111(14), 3831-3838 (2007)
42. Octaarginine-modified Multifunctional Envelope-type Nanoparticles for Gene Delivery
I. A. Khalil1, K. Kogure, S. Futaki, S. Hama, H. Akita, M. Ueno, H. Kishida, M. Kudoh, Y. Mishina, K.
Kataoka, M. Yamada, H. Harashima
Gene Ther., 14(8), 682-689 (2007)
43. The Use of Acid Wash in Determining Cellular Uptake of Fab/Cell-Permeating Peptide Conjugates
Shouju Kameyama, Mayo Horie, Takeo Kikuchi, Takao Omura, Akiko Tadokoro, Toshihide Takeuchi,
Ikuhiko Nakase, Yukio Sugiura, Shiroh Futaki
Biopolymers (Peptide Science), 88(2), 98-106 (2007)
44. Temperature, Concentration and Cholesterol Dependent Translocation of L- and D-octaarginine across the
Plasma and Nuclear membrane of CD34+ Leukaemia Cells
Marjan M. Fretz, Neal A. Penning, Saly Al-Taei, Shiroh Futaki, Toshihide Takeuchi, Ikuhiko Nakase, Gert
Storm, Arwyn T. Jones
Biochem. J., 403(2), 335-342 (2007)
45. Activation of JNK Pathway during Islet Transplantation and Prevention of Islet Graft Loss by Intraportal
Injection of JNK Inhibitor
H. Noguchi, Y. Nakai, M. Ueda, Y. Masui, S. Futaki, N. Kobayashi, S. Hayashi, S. Matsumoto
Diabetologia, 50(3), 612-619 (2007)
46. Interaction of Arginine-Rich Peptides with Membrane-Associated Proteoglycans Is Crucial for Induction of
Actin Organization and Macropinocytosis
Ikuhiko Nakase, Akiko Tadokoro, Noriko Kawabata, Toshihide Takeuchi, Hironori Katoh, Kiyo Hiramoto,
Manabu Negishi, Motoyoshi Nomizu, Yukio Sugiura, Shiroh Futaki
Biochemistry, 46(2), 492-501 (2007)
47. RNA Recognition and Recognition Control of D-Peptide Ribonucleic Acids Containing Arginine Residue by
External Factors.
Takehiko Wada, Yoshiki Maeda, Nobuya Sawa, Hirofumi Sato, Shiroh Futaki, Yoshihisa Inoue
Nucleic Acids Symp. Ser., (50), 75-76 (2006)
48. Oligomers of E-Amino Acid Bearing Non-planar Amides Form Ordered Structures
Yuko Otani, Shiroh Futaki, Tatsuto Kiwada, Yukio Sugiura, Atsuya Muranaka, Nagao Kobayashi, Masanobu
Uchiyama, Kentaro Yamaguchi, Tomohiko Ohwada
Tetrahedron, 62(50), 11635-11644 (2006)
49. Effects of Na+/H+ Exchanger Inhibitors on Subcellular Localisation of Endocytic Organelles and
Intracellular Dynamics of Protein Transduction Domains HIV-TAT Peptide and Octaarginine
Marjan Fretz, Jing Jin, Robin Conibere, Neal A. Penning, Saly Al-Taei, Gert Storm, Shiroh Futaki, Toshihide
Takeuchi, Ikuhiko Nakase, Arwyn T. Jones
J. Control. Release, 116(2), 247-254 (2006)
50. Direct and Rapid Cytosolic Delivery Using Cell-Penetrating Peptides Mediated by Pyrenebutyrate
Toshihide Takeuchi, Michie Kosuge, Akiko Tadokoro, Yukio Sugiura, Mayumi Nishi, Mitsuhiro Kawata,
Naomi Sakai, Stefan Matile, Shiroh Futaki
ACS Chem. Biol., 1(5), 299–303 (2006)
51. Effects of Cell-Permeating Peptide Binding on the Distribution of 125I-Labeled Fab Fragment in Rats
Shouju Kameyama, Mayo Horie, Takeo Kikuchi, Takao Omura, ToshihideTakeuchi, Ikuhiko Nakase, Yukio
Sugiura, Shiroh Futaki
Bioconjug. Chem., 17(3), 597-602 (2006)
52. Design, Synthesis, and Membrane-Translocation Studies of Inositol-Based Transporters
Kaustabh K. Maiti, Ock-Youm Jeon, Woo Sirl Lee, Dong-Chan Kim, Kyong-Tai Kim, Toshihide Takeuchi,
Shiroh Futaki, Sung-Kee Chung
Angew. Chem. Int. Ed. Engl., 45(18), 2907-2912 (2006)
− 266 −
53. Cellular Uptake and Subsequent Intracellular Trafficking of R8-liposomes Introduced at Low Temperature
Akitada Iwasa, Hidetaka Akita, Ikramy Khalil, Kentaro Kogure, Shiroh Futaki, Hideyoshi Harashima
Biochim. Biophys. Acta – Biomembranes, 1758(6), 713-720 (2006)
54. Transmission of Extramembrane Conformational Change into Current; Construction of Metal-gated Ion
Channel
Tatsuto Kiwada, Kazuhiro Sonomura, Yukio Sugiura, Koji Asami, Shiroh Futaki
J. Am. Chem. Soc., 128(18), 6010-6011 (2006)
55. Delivery of Condensed DNA by Liposomal Non-viral Gene Delivery System into Nucleus of Dendritic
Cells
Takashi Nakamura, Rumiko Moriguchi, Kentaro Kogure, Arisa Minoura, Tomoya Masuda, Hidetaka Akita,
Kazunori Kato, Hirofumi Hamada, Masaharu Ueno, Shiroh Futaki, Hideyoshi Harashima
Biol. Pharm. Bull. 29(6), 1290-1293 (2006)
56. Significant and Prolonged Antisense Effect of a Multifunctional Envelope-type Nano Device Encapsulating
Antisense Oligodeoxynucleotide
Yoshio Nakamura, Kentaro Kogure, Yuma Yamada, Shiroh Futaki, Hideyoshi Harashima,
J. Pharm. Pharmacol., 58(4), 431-437 (2006)
57. Intracellular Traffic and Fate of Protein Transduction Domains HIV-1 TAT Peptide and Octaarginine.
Implications for their Utilization as Drug Delivery Vectors
Saly Al Taei, Neal A. Penning, Jeremy C. Simpson, Shiroh Futaki, Toshihide Takeuchi, Ikuhiko Nakase,
Arwyn T. Jones
Bioconjug. Chem., 17(1), 90-100 (2006)
58. High Density of Octaarginine Stimulates Macropinocytosis Leading to Efficient Intracellular Trafficking for
Gene Expression
Ikramy A. Khalil, Kentaro Kogure, Shiroh Futaki, Hideyoshi Harashima
J. Biol. Chem., 281(6), 3544-3551 (2006)
59. Evaluation of the Nuclear Delivery and Intra-nuclear Transcription of Plasmid DNA Condensed with P (mu)
and NLS-P by Cytoplasmic and Nuclear Microinjection: A Comparative Study with Poly-L-lysine
Hidetaka Akita, Mitsuhide Tanimoto, Tomoya Masuda, Kentaro Kogure, Susumu Hama, Keiko Ninomiya,
Shiroh Futaki, Hideyoshi Harashima
J. Gene Med., 8(2), 198-206 (2006)
60. Distribution of Immunoglobulin Fab Fragment Conjugated with HIV-1 REV Peptide Following Intravenous
Administration in Rats
Shouju Kameyama, Ritsuko Okada, Takeo Kikuchi, Takao Omura, Ikuhiko Nakase, Toshihide Takeuchi,
Yukio Sugiura, Shiroh Futaki
Mol. Pharm. 3(2), 174-180 (2006)
㸦⥲ㄝ㸧
1. Endosome-disruptive Peptides for Improving Cytosolic Delivery of Bioactive Macromolecules
Ikuhiko Nakase, Sachiko Kobayashi, Shiroh Futaki
Biopolymers (Peptide Science), in press
2. ⭷㏱㐣ᛶሷᇶᛶ࣌ࣉࢳࢻࢆ⏝࠸ࡿ⣽⬊ෆ㏦㐩ᢏ⾡ࠥࡑࡢศᏊᶵᵓ࡜ᛂ⏝㹼
஧ᮌྐᮁ, ୰℩⏕ᙪ
⏕≀≀⌮, 50(3), 137-140 (2010)
3. ࣐ࣝࢳள㖄ࣇ࢕࣮ࣥ࢞ᆺேᕤ㌿෗ᅉᏊࡢ๰〇࡜ᶵ⬟
(Artificial Transcription Factors Based on Multi-Zinc Finger Motifs)
᳃ᓮ㐩ஓ, ௒すᮍ᮶, ஧ᮌྐᮁ, ᮡᾆᖾ㞝
⸆Ꮫ㞧ㄅ, 130(1), 45-48 (2010)
4. ⭷㏱㐣࣌ࣉࢳࢻ࣋ࢡࢱ࣮ࡢ㛤Ⓨ࡜࣓࢝ࢽࢬ࣒
− 267 −
୰℩⏕ᙪ, ஧ᮌྐᮁ
⏕໬Ꮫ, 81(11), 992-995 (2009)
5. Delivery of Macromolecules using Arginine-rich Cell Penetrating Peptides: Ways to Overcome Endosomal
Entrapment
Ayman El-Sayed, Shiroh Futaki, Hideyoshi Harashima
AAPS J., 11(1), 13-22 (2009)
6. Membrane Permeable Peptide Vectors: Chemistry and Functional Design for the Therapeutic Applications
Shiroh Futaki
Adv. Drug Deliv. Rev., 60(4-5), 447 (2008)
7. Methodological and Cellular Aspects that Govern the Internalization Mechanisms of Arginine-rich
Cell-penetrating Peptides
Ikuhiko Nakase, Toshihide Takeuchi, Gen Tanaka, Shiroh Futaki
Adv. Drug Deliv. Rev., 60(4-5), 598–607 (2008)
8. Arginine-rich Peptides and their Internalization Mechanisms
Shiroh Futaki, Ikuhiko Nakase, Akiko Tadokoro, Toshihide Takeuchi Arwyn Tomos Jones
Biochem. Soc. Trans., 35(Pt 4), 784-787 (2007)
9. Ligand-Induced Extramembrane Conformation Switch Controlling Alamethicin Assembly and the Channel
Current
Shiroh Futaki, Koji Asami
Chem. Biodiv., 4(6), 1313-1322 (2007)
10.ศᏊ㞟ྜయࡢ⣽⬊ෆࢹࣜࣂ࣮ࣜ
஧ᮌྐᮁ
⮫ᗋ᳨ᰝ, 50(12), 1439-1546 (2006)
㸦⮫ᗋ᳨ᰝቑหྕ,ࢼࣀࢸࢡࣀࣟࢪ࣮࡜ࣂ࢖࢜ࢭࣥࢧ㸧
11.࣌ࣉࢳࢻ࡟ࡼࡿ⣽⬊ෆ⛣㏦ไᚚ,
஧ᮌྐᮁ,
㧗ศᏊ, 55(5), 345 (2006)
12. Anion Hopping of (and on) Functional Oligoarginines: From Chloroform to Cells,
Naomi Sakai, Shiroh Futaki, Stefan Matile,
Soft Matter, 2(8), 636 – 641 (2006)
13. Oligoarginine Vectors for Intracellular Delivery: Design and Cellular-uptake Mechanisms,
Shiroh Futaki
Biopolymers (Peptide Science), 84(3), 241-249 (2006)
㸦ⴭ᭩㸧
1. ໬Ꮫࣇࣟࣥࢸ࢕࢔
⏕࿨⌧㇟ࢆ⌮ゎ
ࡍࡿศᏊࢶ࣮ࣝ㸸࢖࣓࣮ࢪࣥࢢ࠿ࡽ⏕యᶵ⬟ゎᯒࡲ࡛
὾ᆅ᱁ࠊ஧ᮌྐᮁ⦅
໬Ꮫྠேࠊி㒔ࠊ2010
➨㸯㸲❶࣌ࣉࢳࢻࢆࢶ࣮ࣝ࡜ࡋ࡚⏝࠸ࡓ⣽⬊ෆ࡬ࡢ≀㉁㍺㏦ (pp111-118)
஧ᮌྐᮁ
2. Immunoglobulin Binding Factor in Human Seminal Plasma and Uterine Cerivical Mucus
Masaharu Kamada, Masahiko Maegawa, Nobuhiko Maeda, Satoshi Yamamoto, Shuji Yoshikawa, Hidetoshi
Mori, Yu Tanaka, Masumi Okada, Keiji Shitukawa, Minoru Irahara1, Toshihiro Aono, Hiroshi Kido,
− 268 −
Fumitaka Ogushi, Saburo Sone, Naoomi Kanayama, Susumu Kagawa, Yasukazu Ohmoto, Shiroh Futaki, Zhi
Guo Liang, Samuel S. Koide
In Current Paradigm of Reproductive Immunology
Ed. by A. H. Bandivdekar and C. P. Puri
Research Signpost, Kerala, India, pp 95-104, 2009
3. Ligand-Induced Extramembrane Conformation Switch Controlling Alamethicin Assembly and the Channel
Current
Shiroh Futaki, Koji Asami
In Peptaibols: Fungal Peptides Containing D-Dialkyl D-Amino Acids
Ed. by Claudio Toniolo and Hans Bruckner,
Verlag Helvetica Chimica Acta, Zurich, pp 344-352, 2009
4. ᶵ⬟ᛶ DDS ࢟ࣕࣜ࢔ࡢ〇ᮦタィ
ᒸ⏣ᘯ᫭┘ಟ
ࢩ࣮࢚࣒ࢩ࣮ฟ∧ࠊ኱㜰ࠊ2008
➨ 2 ❶ DDS ࢟ࣕࣜ࢔⣲ᮦࡢᇶᮏタィ
13 ⭷㏱㐣࣌ࣉࢳࢻ (pp142-149)
஧ᮌྐᮁ
5. ➨༑஬ᨵṇ᪥ᮏ⸆ᒁ᪉ゎㄝ᭩
ᘅᕝ᭩ᗑ, ᮾி, 2006
་⸆ရྛ᮲
஧ᮌྐᮁ㸦ศᢸ㸧
6. 㑇ఏᏊ་Ꮫ MOOK5
ඛ➃⏕≀་Ꮫ◊✲࣭་⒪ࡢࡓࡵࡢ㑇ఏᏊᑟධࢸࢡࣀࣟࢪ࣮
࢘࢖ࣝࢫࢆ⏝࠸࡞࠸㑇ఏᏊᑟධἲࡢᮦᩱࠊᢏ⾡ࠊ᪉ἲㄽࡢ᪂ࡓ࡞ᒎ㛤
ཎᓥ⚽ྜྷࠊ⏣⏿Ὀᙪ⦅㞟
࣓ࢹ࢕࢝ࣝࢻࢗ, ኱㜰, 2006
➨㸲❶㸲㸬⣽⬊ෆᑟධ㸦pp202-206㸧
஧ᮌྐᮁ
− 269 −
⸆ရືែไᚚᏛศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧ᶫ⏣ ඘㸦ࡣࡋࡔ ࡳࡘࡿ㸧㸦1992.4 ᪼௵㸧
᫛࿴㸲㸷ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸳㸲ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
ຓᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧ᒣୗ ᐩ⩏㸦ࡸࡲࡋࡓ ࡩࡳࡼࡋ㸧(1997.9 ᪼௵)
᫛࿴㸴㸱ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸰ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
ಟኈㄢ⛬ಟ஢
ㅮ ᖌ㸦༤ኈ㸦⸆Ꮫ㸧㸧ᕝୖ ⱱ㸦࠿ࢃ࠿ࡳ ࡋࡆࡿ㸧(2009.6 ᪼௵)
ᖹᡂ㸵ᖺ㛗ᓮ኱Ꮫ༞ࠊᖹᡂ㸷ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
㸦ᶫ⏣ᩍᤵ㸧
⸆ရືែไᚚᏛศ㔝࡛ࡣࠊࢻࣛࢵࢢࢹࣜࣂ࣮ࣜࢩࢫࢸ࣒ࡢ㛤Ⓨࢆ୰ᚰ࡟◊✲
ࡀ㐍ࡵࡽࢀ࡚࠸ࡿࠋಶࠎࡢ◊✲ࡣࠊ㸯㸧◊✲ࡢ┠ⓗ㸦ືែゎᯒἲ࣭⌮ㄽࡢ㛤Ⓨࠊືែไᚚᢏ⾡ࡢ㛤Ⓨ࡞
࡝㸧ࠊ㸰㸧ᑐ㇟་⸆ရ㸦ࢱࣥࣃࢡ㉁་⸆ရࠊ㑇ఏᏊ་⸆ࠊ୍⯡పศᏊ⸆≀࡞࡝㸧ࠊ㸱㸧἞⒪ᑐ㇟㸦⒴ࠊ⫢
㞀ᐖ࡞࡝㸧ࠊ㸲㸧ᑐ㇟ືែࣞ࣋ࣝ㸦඲㌟ࠊ⮚ჾࠊ⣽⬊㸧ࠊ㸳㸧ᑐ㇟㒊఩㸦⫢⮚ࠊ⒴ࠊ⫵࡞࡝㸧
ࠊ㸴㸧ᇶ┙
࡜࡞ࡿࢧ࢖࢚ࣥࢫ㸦㑇ఏᏊ᧯సᢏ⾡ࠊ᝟ሗゎᯒᢏ⾡࡞࡝㸧ࠊ㸵㸧฼⏝ࡍࡿ〇๣ᢏ⾡㸦㧗ศᏊᢸయࠊᚤ⢏
Ꮚ〇๣࡞࡝㸧ࡢࡼ࠺࡟ࠊከゅⓗ࡞どⅬࡼࡾᩚ⌮ศ㢮ࡉࢀࠊྛࠎࡢ◊✲ࢸ࣮࣐ࡣࡑࢀࡒࢀࡢ஺Ⅼ࡟఩⨨࡙
ࡅࡽࢀࡿࠋ௦⾲ⓗ࡞◊✲ࢸ࣮࣐ࢆ௨ୗ࡟ᣲࡆࡿࡀࠊ࠸ࡎࢀࡶᅜ㝿Ꮫ఍࠾ࡼࡧᅜ㝿Ꮫ⾡ㄅ࡟ᡂᯝࡀሗ࿌ࡉ
ࢀὀ┠ࢆ㞟ࡵ࡚࠸ࡿࠋ㸯㸧⣽⬊≉␗ⓗ㧗ศᏊ࢟ࣕࣜ࢔࠾ࡼࡧᚤ⢏Ꮚ〇๣ࡢ㛤Ⓨࠊ㸰㸧ࡀࢇ἞⒪ࢆ┠ⓗ࡜
ࡋࡓಟ㣭ࢱࣥࣃࢡ㉁་⸆ရࡢ㛤Ⓨࠊ㸱㸧㑇ఏᏊ་⸆ရࡢ㑇ఏᏊⓎ⌧ྥୖࢆ┠ⓗ࡜ࡋࡓ〇๣㛤Ⓨࠊ㸲㸧ࡀ
ࢇච␿⒪ἲࡢࡓࡵࡢ㑇ఏᏊ་⸆ရࡢタィࠊ㸳㸧㑇ఏᏊ㸭࢟ࣕࣜ࢔」ྜయࡢศᏊ㛫࠾ࡼࡧ⣽⬊࡟࠾ࡅࡿ┦
஫స⏝ࡢゎᯒࠋ㸴㸧㧗ศᏊ࣭ᚤ⢏Ꮚࡢືែ≉ᛶࡢゎᯒࠊ㸶㸧⸆≀ືែ࡟㛵ࡍࡿ In silico ண ࠊ㸷㸧ືែ
ホ౯ࡢࡓࡵࡢ᝟ሗゎᯒᢏ⾡ࡢ㛤Ⓨࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
㐣ཤ 5 ᖺ㛫ࡢ㛫࡟ࡶࠊᶫ⏣ᩍᤵࡀ 2007 ᖺ࡟⡿ᅜ⸆Ꮫ఍ AAPS ࡼࡾ Research Achievement Award, 2010
ᖺ࡟᪥ᮏ⸆≀ືែᏛ఍㈹ࠊྠᖺ Controlled Release Society (CRS) ࠿ࡽ Fellow of the CRS, International
Pharmaceutical Federation (FIP) ࠿ࡽ FIP Fellow Award 2010 ࢆࠊᕝୖㅮᖌࡀ 2006 ᖺ࡟୓᭷⸆๣Ꮫዡບ㈹ࠊ
᪥ᮏ⸆≀ືែᏛ఍ዡບ㈹ࠊ2008 ᖺ࡟᪥ᮏ⸆Ꮫ఍ዡບ㈹ࠊࢆཷ㈹ࡋࠊࡲࡓࠊ◊✲ဨࡸ኱Ꮫ㝔⏕ࡀ᪥ᮏ⸆Ꮫ
఍㏆␥ᨭ㒊ዡບ㈹ࡸ᪥ᮏ⸆๣Ꮫ఍ Postdoctoral Presentation Award ࢆጞࡵࠊከࡃࡢ㈹ࢆཷ㈹ࡋ࡚࠸ࡿࡇ࡜
࡟㇟ᚩࡉࢀࡿࡼ࠺࡟ࠊ◊✲άືࡣࡁࢃࡵ࡚άⓎ࡛࠶ࡾࠊ㧗࠸ホ౯ࢆཷࡅ࡚࠸ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣㅮ⩏⛉┠࡜ࡋ࡚ࠊ⸆๣Ꮫ㸯㸦⁐ᾮ〇๣ㄽ㸧ࠊ⸆๣Ꮫ㸰㸦ᅛᙧ〇๣ㄽ㸧ࠊ⸆ᒁ᪉࣭⸆
஦㛵㐃ἲつ࡞࡝ࢆᢸᙜࡋ࡚࠸ࡿࠋࡇࢀࡽࡣ་⸆ရࡢᢞ୚ἲࢆ⪃✲ࡍࡿ⸆๣Ꮫ࡜ࡑࢀ࡟㛵㐃ࡍࡿ⛉┠࡛࠶
ࡾࠊࡑࡢ୰࡛ࡣࠊ〇๣◊✲࡟࠿࠿ࡿ≀⌮Ꮫࠊ໬Ꮫࠊ⏕≀Ꮫⓗᇶ♏ࠊ་⸆ရ〇๣ࡢ〇㐀ἲࠊࣞࢠࣗࣛࢺࣜ
࣮ࢧ࢖࢚ࣥࢫ࡟ࡘ࠸࡚య⣔ⓗ࡟ㅮ⩏ࡋ࡚࠸ࡿࠋ
Ꮫ㒊⏕≉ูᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸≉ูᐇ⩦㓄ᒓࡢᏛ㒊⏕࡟ࡣಶࠎ࡟◊✲ࢸ࣮࣐ࢆ୚࠼ࠊ༤ኈᚋᮇㄢ⛬
Ꮫ⏕ࠊ༤ኈ◊✲ဨ࡟ࡼࡿ༠ຊࢆᚓ࡞ࡀࡽࠊᇶ♏ᢏ⾡ࡢ⩦ᚓ࡟ຍ࠼ᐇ㦂ィ⏬࠾ࡼࡧ⤖ᯝศᯒࢆ⮬ࡽ⾜࠺ᶵ
఍ࢆᣢࡘࡼ࠺㓄៖ࡋ࡚࠸ࡿࠋ኱Ꮫ㝔⏕࡟ࡣࠊࡉࡽ࡟㧗ᗘ࡞◊✲⬟ຊࢆせồࡍ࡭ࡃࠊ◊✲ࢸ࣮࣐ࡢ᪉ྥ௜
ࡅ࠾ࡼࡧ❧᱌ࢆ⾜࠸࠿ࡘᐇ㦂ィ⏬ࡶ⮬㌟࡛❧࡚࡚◊✲ࢆ㐙⾜ࡍࡿࡼ࠺࡟⎔ቃࢆᩚ࠼ࡿ࡜ඹ࡟ࠊࢢ࣮ࣝࣉ
࣑࣮ࢸ࢕ࣥࢢࡸࢭ࣑ࢼ࣮࡟࠾ࡅࡿⓎ⾲ࠊ㆟ㄽࢆዡບࡋⓎ⾲ຊࡢᾰ㣴࡟ດࡵ࡚࠸ࡿࠋࢭ࣑ࢼ࣮࡛ࡣࠊᩥ⊩
᝟ሗࢆ⥲ㄝⓗ࡟ᩚ⌮ࡍࡿᶵ఍࡜୍⯡ㄽᩥࢆⱥㄒ࡛⤂௓ࡍࡿᶵ఍ࢆ୚࠼ࠊ⥲ྜⓗ࡞ุ᩿ຊ࡜◊✲㐙⾜࡟ᚲ
せ࡞ㄒᏛ⬟ຊࡢྥୖࢆᅗࡗ࡚࠸ࡿࠋࡲࡓࠊᏛ఍➼࡟ࡶᅜෆእࢆၥࢃࡎ✚ᴟⓗ࡟ཧຍࡍࡿࡇ࡜ࢆዡບࡋࠊ
▱㆑ࣞ࣋ࣝࡢྥୖ࡜ඹ࡟ᅜ㝿Ỉ‽࡟࠿࡞ࡗࡓ⾲⌧⬟ຊࡢ⋓ᚓࢆ┠ᣦࡍ࡜ඹ࡟ࠊᅜ㝿ⓗ࡞◊✲⪅ࢥ࣑ࣗࢽ
ࢸ࢕࣮ࡢ୍ဨ࡜ࡋ࡚ᑗ᮶ά㌍࡛ࡁࡿࡼ࠺࡟ᅜ㝿஺ὶࡢᶵ఍ᥦ౪࡟ࡶດࡵ࡚࠸ࡿࠋࡉࡽ࡟ࠊ◊✲ᡂᯝࡢⱥ
ㄒㄽᩥ࡟ࡼࡿⓎ⾲ࢆᖖ࡟๓ᥦ࡟ࡋࠊᩍᐁ࡜ࡢ㆟ㄽࢆ㏻ࡌ࡚Ⓨ⾲⾲⌧ຊࡸㄽ⌮ᛮ⪃⬟ຊࢆ☻࠸࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕࡟ᑐࡍࡿㅮ⩏⛉┠࡟࠾࠸࡚ࡣࠊྛㄽⓗ࡞▱㆑౪୚ᆺ࡛ࡣ࡞ࡃࠊᏛၥయ⣔ࡢᵓ㐀ࢆᏛ⏕ࡀ༑ศ
⌮ゎ࡛ࡁࡿࡼ࠺࡟ㅮ⩏ࡢព⩏࡜┠ᶆࢆ᫂☜࡟ࡍࡿࡇ࡜࡟ຊⅬࢆ⨨࠸࡚࠸ࡿࠋࡑࡢࡓࡵ࡟඲యീࡀ୍ᮃ࡛
ࡁࡿཧ⪃㈨ᩱࢆసᡂࡋࠊㅮ⩏๓࡟㓄ᕸࢆࡋ࡚࠸ࡿࠋࡲࡓࠊ་⸆ရ〇๣ࡢᐇ౛ࢆ⤂௓ࡍࡿࡇ࡜࡟ࡼࡗ࡚ࠊ
− 270 −
ㅮ⩏ෆᐜ࡟ලయᛶࢆࡶࡓࡏ࡚ࠊᏛ⏕ࡢ⯆࿡ࠊ㛵ᚰࢆᖖ࡟ចࡁࡘࡅࡿࡼ࠺ດຊࡋ࡚࠸ࡿࠋᖖ࡟㉁␲ᛂ⟅ࡢ
᫬㛫ࢆタࡅ࡚ࠊ཮᪉ྥࡢ஺ὶࡀᐇ⌧ࡍࡿࡼ࠺࡟ດࡵ࡚࠸ࡿࠋࡉࡽ࡟ᤵᴗホ౯ࢆ⾜࠸ࠊᚓࡽࢀࡓホ౯ࠊ࢔
ࢻࣂ࢖ࢫࢆㅮ⩏ෆᐜࡸࢫࢱ࢖ࣝ࡟ྲྀࡾධࢀࡿࡼ࠺ཧ⪃࡟ࡋ࡚࠸ࡿࠋࡲࡓࠊ኱Ꮫ㝔⏕ࢆᑐ㇟࡟ࡋࡓ≉ㄽࡸ
₇⩦⛉┠࡟࠾࠸࡚ࡣࠊᑗ᮶◊✲⪅࡜ࡋ࡚ά㌍ࡍࡿࡓࡵࡢ⣲ᆅࡢᾰ㣴࡟ດࡵࡿ࡭ࡃࠊᇶ♏▱㆑࡜ඛ➃◊✲
ࡢヰ㢟ࢆࣂࣛࣥࢫࡼࡃྲྀࡾධࢀࡽࢀ࡚࠸ࡿࠋ
◊✲ᐊ࡟࠾ࡅࡿ኱Ꮫ㝔⏕࠾ࡼࡧ㸲ᅇ⏕≉ูᐇ⩦⏕࡟ᑐࡍࡿᩍ⫱ࡣࠊಶࠎࡢ◊✲άືࢆ㏻ࡌࡓ㒊ศࡀ୰
ᚰ࡛࠶ࡿࡀࠊከࡃࡀᏛ఍࡛ࡢⓎ⾲࠾ࡼࡧㄽᩥᥖ㍕ࢆᯝࡓࡋ࡚࠸ࡿࡇ࡜࠿ࡽุ᩿ࡋ࡚ࠊ◊✲⪅࡜ࡋ࡚ᚲせ
࡞ᇶ♏⬟ຊࡢ௜୚ࡣ࡯ࡰᯝࡓࡏ࡚࠸ࡿࡶࡢ࡜⪃࠼ࡿࠋࡋ࠿ࡋࠊ◊✲ࡢᅜ㝿໬࡞࡝◊✲⪅ࢆྲྀࡾᕳࡃ⎔ቃ
ࡣᛴῶᮇ࡟ኚ໬ࡋ࡚࠾ࡾࠊᖖ࡟♫఍ࡢኚ໬ࢆ㋃ࡲ࠼ࡓᩍ⫱ࢆᐇ㊶࡛ࡁࡿࡼ࠺࡟⮬ᡄࡋ࡚࠸ࡿࠋ
ᖹᡂ 18 ᖺᗘ௨㝆ࡢᏛ㒊༞ᴗ⏕ࠊ኱Ꮫ㝔ಟ஢⏕㸦ᅾᏛ⏕ࢆ㝖ࡃ㸧࡟ࡣࠊ༤ኈྕྲྀᚓᚋ኱Ꮫᩍဨࡢ⫋࡟
࠶ࡿ⪅ 5 ྡࠊ༤ኈྕࢆᤵ୚ࡉࢀࡓእᅜே␃Ꮫ⏕ 5 ྡࢆᩘ࠼ࡿࠋ௚ࡶ኱㒊ศࡣ〇⸆௻ᴗࡑࡢ௚࡟࠾࠸࡚◊
✲࠶ࡿ࠸ࡣ㛤Ⓨᴗົࡢ➨୍⥺࡛ά㌍ࡋ࡚࠾ࡾࠊ◊✲ᐊࡢᩍ⫱◊✲ࣞ࣋ࣝࡢ㧗ࡉࡀ♧ࡉࢀ࡚࠸ࡿࠋ
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Efficient alveolar macrophage targeting of NFțB decoy by mannosylated liposomes after intratracheal
administration. W. Wijagkanalan, S. Kawakami, Y. Higuchi, F. Yamashita, and M. Hashida, Journal of
Controlled Release, in press
Improvement of insulin resistance by removal of systemic hydrogen peroxide by PEGylated catalase in
obesemice. M. Ikemura, M. Nishikawa, K. Hyoudou, Y. Kobayashi, F. Yamashita and M. Hashida, Molecular
Pharmaceutics, in press
Development of an ultrasound-responsive and mannose-modified gene vector for antigen presenting
cell-selective and efficient gene transfer. K. Un, S. Kawakami, R. Suzuki, K. Maruyama, F. Yamashita and M.
Hashida, Biomaterials, 31(30), 7813-7826, (2010)
Size control of lipid-based drug carrier by drug loading. T. Murakami, K. Tsuchida, M. Hashida and H.
Imahori, Molecular BioSystems, 6(5), 789-791, (2010)
Key physiological phenomena governing transgene expression based on tissue pressure-mediated
transfection in mice. H. Mukai, S. Kawakami, H. Takahashi, K. Satake, F. Yamashita and M. Hashida,
Biological & Pharmaceutical Bulletin, 33(9), 1627-1632, (2010)
Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer
cells. T. Miyano, W. Wijagkanalan, S. Kawakami, F. Yamashita and M. Hashida, Molecular Pharmaceutics,
7(4), 1318-1327, (2010)
Efficient gene transfection by histidine-modified chitosan through enhancement of endosomal escape. K.
Chang, Y. Higuchi, S. Kawakami, F. Yamashita and M. Hashida, Bioconjugate Chemistry, 21(6), 1087-1095,
(2010)
Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective
therapeutics. K. Hirata, T. Maruyama, H. Watanabe, H. Maeda, K. Nakajou, Y. Iwao, Y. Ishima, H. Katsumi,
M. Hashida and M. Otagiri, Journal of Controlled Release, 145(1), 9-16, (2010)
PiggyBac transposon-mediated long-term gene expression in mice. H. Nakanishi, Y. Higuchi, S. Kawakami,
F. Yamashita and M. Hashida, Molecular Therapy, 18(4), 707-714, (2010)
Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic
liposome/IL-12 pDNA complexes in mice. C. Pensri, S. Kawakami, Y. Higuchi, F. Yamashita and M. Hashida,
Cancer Gene Therapy, 17(7), 512-522, (2010)
Ȗ-Polyglutamic acid coated vectors for effective and safe gene therapy. T. Kurosaki, T. Kitahara, S.
Kawakami, Y. Higuchi, A. Yamaguchi, H. Nakagawa, Y. Kodama, T. Hamamoto, M. Hashida, and H. Sasaki,
Journal of Controlled Release, 142(3), 404-410, (2010)
Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid
DNA/doxorubicin complex in mice. Y. Mizuno, T. Naoi, M. Nishikawa, S. Rattanakiat, N. Hamaguchi, M.
Hashida and Y. Takakura, Journal of Controlled Release, 141(2), 252-259, (2010)
Enhanced transfection efficiency into macrophages and dendritic cells using the combination of
mannosylated lipoplexes and bubble liposomes with ultrasound exposure. K. Un, S. Kawakami, R. Suzuki, K.
Maruyama, F. Yamashita and M. Hashida, Human Gene Therapy, 21(1), 65-74, (2010)
A novel multi-dimensional visualization technique for understanding the design parameters of drug
formulations. F. Yamashita, T. Itoh, S. Yoshida, M. K.Haidar and M. Hashida, Computers and Chemical
Engineering, 34, 1306-1311, (2010)
Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. S. Zhou, S.
Kawakami, F. Yamashita and M. Hashida, Cancer Letters, 287(1), 75-81, (2010)
− 271 −
16. Enhanced gene transfection in macrophages by histidine-conjugated mannosylated cationic liposomes. K.
Nakamura, Y. Kuramoto, H. Mukai, S. Kawakami, Y. Higuchi and M. Hashida, Biological & Pharmaceutical
Bulletin, 32(9), 1628-1631, (2009)
17. Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of
catalase. K. Hyoudou, M. Nishikawa , M. Ikemura, Y. Kobayashi, A. Mendelsohn, N. Miyazaki, Y. Tabata, F.
Yamashita and M. Hashida, Journal of Controlled Release, 137(2), 110-115, (2009)
18. Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice. H. Katsumi, M.
Nishikawa, H. Yasui, F. Yamashita and M. Hashida, Journal of Controlled Release, 140(1), 12-17, (2009)
19. Systematic research of peptide spacers controlling drug release from macromolecular prodrug system,
carboxymethyldextran polyalcohol-peptide-drug conjugates. Y. Shiose, H. Kuga, H. Ohki, M. Ikede, F.
Yamashita and M. Hashida, Bioconjugata Chemistry, 20(1), 60-70, (2009)
20. NFkB decoy delivery using dendritic poly(L-lysine) for treatment of endotoxin-induced hepatitis in mice. Y.
Sugao, K. Watanabe, Y. Higuchi, R. Kurihara, S. Kawakami, M. Hashida, Y. Katayama and T. Niidome,
Bioorganic & Medicinal Chemistry, 17(14), 4990-4995, (2009)
21. Pressure-mediated transfection of murine spleen and liver. H. Mukai, S. Kawakami, Y. Kamiya, F. Ma, H.
Takahashi, K. Satake, K. Terao, H. Kotera, F. Yamashita, and M. Hashida, Human Gene Therapy, 20(10),
1157-1167, (2009)
22. Evaluation of proinflammatory cytokine production and liver injury induced by plasmid DNA/cationic
liposomes complexes with various mixing ratios in mice. Y. Ito, S. Kawakami, P. Charoensit, Y. Higuchi and
M. Hashida, European Journal of Pharmaceutics and Biopharmaceutics, 71(2), 303-309, (2009)
23. Suppressive effects of sugar-modified cationic liposome/NF-țB decoy complexes on adenovirus
vector-induced innate immune responses. H. Huang, F. Sakurai, Y. Higuchi, S. Kawakami, M. Hashida, K.
Kawabata and H. Mizuguchi, Journal of Controlled Release, 133(2), 139-145, (2009)
24. Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. T. Okuda, S.
Kawakami, Y. Higuchi, Y. Oka, T. Satoh, M. Yokoyama, F. Yamashita and M. Hashida, International Journal
of Pharmaceutics, 373, 100-106, (2009)
25. Immunostimulatory Characteristics Induced by LinearPolyethyleneimine/plasmid DNA Complexes in
Cultured Macrophages. Y. Saito, Y. Higuchi, S. Kawakami, F. Yamashita and M. Hashida, Human Gene
Therapy, 20(2), 137-145, (2009)
26. Encapsulation of the synthetic retinoids Am80 and LE540 into polymeric micelles and the retinoids’ release
control. T. Satoh, Y. Higuchi, S. Kawakami, M. Hashida, H. Kagechika, K. Shudo and M. Yokoyama, Journal
of Controlled Release, 136(3), 187-195, (2009)
27. Mannosylated cationic liposomes/CpG DNA complex for the treatment of hepatic metastasis after
intravenous administration in mice. Y. Kuramoto, S. Kawakami, S. Zhou, K. Fukuda, F. Yamashita and M.
Hashida, Jounal of Pharmaceutical Sciences, 98(3), 1193-1197, (2009)
28. Hydrogen perpxide-mediated nuclear KappaB activation in both liver and tumor cells during initial stages of
hepatic metastasis. Y. Kobayashi, M. Nishikawa, K. Hyoudou, F. Yamashita and M. Hashida, Cancer
Sciences, 99(8), 1546-1552, (2008)
29. Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an
endotoxin-induced lung inflammation model. W. Wijagkanalan, Y. Higuchi, S. Kawakami, M. Teshima, H.
Sasaki and M. Hashida, Molecular Pharmacology, 74(5), 1183-1192, (2008)
30. Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney. H. Mukai, S.
Kawakami and M. Hashida, Biochemical and Biophysical Research Communications, 372(3), 383-387,
(2008)
31. SOD derivatives prevent metastatic tumor gtowth aggravated by tumor removal. Kenji Hyoudou, Makiya
Nishikawa, Y. Kobayashi, M. Ikemura, F. Yamashita and M. Hashida, Clinical & Experimental Metastasis,
25(5), 531-536, (2008)
32. Block copolymer design for stable encapsulation of N-(4-hydroxyphenyl)retinamide into polymeric micelles
in mice. T. Okuda, S. Kawakami, M. Yokoyama, T. Yamamoto, F. Yamashita and M. Hashida, International
Journal of Pharmaceutics, 357, 318-322, (2008)
33. Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG
DNA/cationic liposome complex in mice. Y. Kuramoto, S. Kawakami, S. Zhou, K. Fukuda, F. Yamashita and
M. Hashida, Journal of Controlled Release, 126(3), 274-280, (2008)
34. Use of mannosylated cationic liposomes/immunostimulatory CpG DNA complex for effective inhibition of
peritoneal dissemination in mice. Y. Kuramoto, S. Kawakami, S. Zhou, K. Fukuda, F. Yamashita and M.
− 272 −
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
Hashida, Journal of Gene Medicine, 10, 392-399, (2008)
Mannosylated semiconductor quantum dots for the labeling of macrophage. Y. Higuchi, M. Oka, S.
Kawakami and M. Hashida, Journal of Controlled Release, 125(2), 131-136, (2008)
Novel hierarchical classification and visualization method for multi-objective optimization of drug
properties: application to structure-activity relationship analysis of cytochrome P450 metabolism. F.
Yamashita, H. Hara, T. Itoh and M. Hashida, Jounral of Chemical Information and Modeling, 48, 364-369,
(2008)
Incorporation of all-trans retinoic acid to lipoplexes inhibit nuclear factor kB activation mediated liver injury
induced by lipoplexes in mice. C. Pensri, S. Kawakami, Y. Higuchi and M. Hashida, Journal of Gene
Medicine, 10(1), 61-69, (2008)
Insertion of nuclear factor-țB binding sequence into plasmid DNA for increased transgene expression in
colon carcinoma cells. O. Thanaketpaisarn, M. Nishikawa, T. Okabe, F. Yamashita and M. Hashida, Journal
of Biotechnology, 133(1), 36-41, (2008)
Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats.
W. Wijagkanalan, S. Kawakami, M. Takenaga, R. Igarashi, F. Yamashita and M. Hashida, Journal of
Controlled Release, 125(2), 121-130, (2008)
Prevention of hepatic ischemia/reperfusion injury by prolonged delivery of nitric oxide to the circulating
blood in mice. H. Katsumi, M. Nishikawa, F. Yamashita and M. Hashida, Transplantation, 85(2), 264-269,
(2008)
Anti-tumor effect of all-trans retinoic acid loaded polymeric micelles in solid tumor bearing mice. N. Chansri,
S. Kawakami, M. Yokoyama, T. Yamamoto, P. Charoensit and M. Hashida, Pharmaceutical Research, 25(2),
428-434, (2008)
Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity
in several tumors. Y. Shiose, Y. Ochi, H. Kuga, F. Yamashita and M. Hashida, Biological & Pharmaceutical
Bulletin, 30(12), 2365-2370, (2007)
Automated extraction of information from the literature on chemical-CYP3A4 interactions. C. Feng, F.
Yamashita and M. Hashida, Journal of Chemical Information and Modeling, 47, 2449-2455, (2007)
Combining cisplatin with cationized catalase decreases nephrotoxicity while improving antitumor activity. S.
Ma, M. Nishikawa, K. Hyoudou, R. Takahashi, M. Ikemura, Y. Kobayashi, F. Yamashita and M. Hashida,
Kidney International, 72(12), 1474-1482, (2007)
Cationized catalase-loaded hydrogel for growth inhibition of peritoneally disseminated tumor cells. K.
Hyoudou, M. Nishikawa, M. Ikemura, Y. Kobayashi, A. Mendelsohn, N. Miyazaki, Y. Tabata, F. Yamashita
and M. Hashida, Journal of Controlled Release, 122(2), 151-158, (2007)
Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical
moddification with polyethylene glycol. A. Takagi, N. Yamashita, T. Yoshioka, Y. Takaishi, K. Sano, H.
Yamaguchi, A. Maeda, K. Saito, Y. Takakura and M. Hashida, Journal of Controlled Release, 119(3),
271-278, (2007)
Efficient protection by cationized catalase against H2O2 injury in primary cultured alveolar epithelial cells. T.
Nemoto, S. Kawakami, F. Yamashita and M. Hashida, Journal of Controlled Release, 121, 74-80, (2007)
Development of an antigen presenting cell-targeted DNA vaccine against melanoma by mannosylated
liposomes. Y. Lu, S. Kawakami, F. Yamashita and M. Hashida, Biomaterials, 28(21), 3255-3262, (2007)
Hepatocyte-selective gene transfer by galactosylated protein/linear polyethylenimine/plasmid DNA
complexes in mice. M. Hohokabe, Y. Higuchi, H. Mukai, S. Kawakami and M. Hashida, Journal of
Biomedical Nanotechnology, 3(3), 277-284, (2007)
Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer
in human hepatoma HepG2 cells. K. Shigeta, S. Kawakami, Y. Higuchi, T. Okuda, H. Yagi, F. Yamashita, M.
Hashida, Journal of Controlled Release, 118(2), 262-270, (2007)
Inhibition of peritoneal dissemination of tumor cells by cationized catalase in mice. K. Hyoudou, M.
Nishikawa, Y. Kobayashi, S. Mukai, M. Ikemura, Y. Kuramoto, F. Yamashita and M. Hashida, Journal of
Controlled Release, 119, 121-127, (2007)
Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted
PEGylated liposomes. T. Terada, M. Mizobata, S. Kawakami, F. Yamashita, and M. Hashida, Journal of
Controlled Release, 119(3), 262-270, (2007)
The potential role of fucosylated cationic liposome/NFkB decoy complexes in the treatment of
cytokine-related liver disease. Y. Higuchi, S. Kawakami, F. Yamashita and M. Hashida, Biomaterials, 28(3),
− 273 −
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
532-539, (2007)
Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic
liposomes in mice. A. Sato, M. Takagi, A. Shimamoto, S. Kawakami and M. Hashida, Biomaterials, 28(7),
1434-1442, (2007)
Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog
DX-8951f. Y. Shiose, H. Kuga, F. Yamashita and M. Hashida, Journal of Pharmacy and Biomedical Analysis,
43(4), 1290-1296, (2007)
Analysis of in vivo NF-kappaB activation during liver inflammation in mice: prevention by catalase delivery.
K. Hyoudou, M. Nishikawa, Y. Kobayashi, Y. Kuramoto, F. Yamashita and M. Hashida, Molecular
Pharmacology, 71(2), 446-453, (2007)
Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. S. Nagayama, K.
Ogawara, K. Minato, Y. Fukuoka, Y. Takakura, M. Hashida, K. Higaki and T. Kimura, International Journal
of Pharmaceutics, 329, 192-198, (2007)
PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice.
T. Okuda, S. Kawakami, N. Akimoto, T. Niidome, F. Yamashita and M. Hashida, Journal of Controlled
Release, 116(3), 330-336, (2006)
Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase. K.
Hyoudou, M. Nishikawa, Y. Kobayashi, Y. Kuramoto, F. Yamashita and M. Hashida, Clinical & Experimental
Metastasis, 23, 269-278, (2006)
Inhibition of pulmonary metastasis by all-trans retinoic acid incorporated in cationic liposomes in mice. S.
Suzuki, S. Kawakami, N. Chansri, F. Yamashita and M. Hashida, Journal of Controlled Release, 116(1),
58-63, (2006)
Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human
interleukin 11(rhIL11) A. Takagi, N. Yamashita, T. Yoshioka, Y. Takaishi, K. Nakanishi, S. Takemura, A.
Maeda, K. Saito, Y. Takakura and M. Hashida, Journal of Controlled Release, 115, 134-139, (2006)
Quantitative structure/activity relationship modelling of pharmacokinetic properties using genetic
algorithm-combined partial least squares method. F. Yamashita, S. Fujiwara, S. Wanchana and M. Hashida,
Journal of Drug Targeting, 14(7), 496-504, (2006)
PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. K. Hyoudou, M.
Nishikawa, Y. Kobayashi, Y. Umeyama, F. Yamashita and M. Hashida, Free Radical Biology & Medicine, 41,
1449-1458, (2006)
Levels and concentration ratios of polychlorinated biphenyls and polybrominated diphenyl ethers in serum
and breast milk in japanese mothers. K. Inoue, K. Harada, K. Takenaka, S. Uehara, M. Kono, T. Shimizu, T.
Takasuga, K. Senthilkumar, F. Yamashita and A. Koizumi, Environmental Health Perspectives, 114(8),
1179-1185, (2006)
Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG
oligonucleotide/cationic liposome complex. Y. Kuramoto, M. Nishikawa, K. Hyoudou, F. Yamashita and M.
Hashida, Journal of Controlled Release, 115(2), 226-233, (2006)
Intracellular trafficking is the important process that determines the optimal charge ratio on transfection by
galactosylated lipoplex in HepG2 cells. Y. Saito, S. Kawakami, Y. Yabe, F. Yamashita and M. Hashida,
Biological & Pharmaceutical Bulletin, 29(9), 1986-1990, (2006)
Role of tyrosine and tryptophan in cheimically modified serum albumin on its tissue distribution. S. Ma, M.
Nishikawa, Y. Yabe, F. Yamashita and M. Hashida, Biological & Pharmaceutical Bulletin, 29(9), 1926-1930,
(2006)
Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. T.
Terada, M. Mizobata, S. Kawakami, Y. Yabe, F. Yamashita and M. Hashida, Journal of Drug Targeting, 14(8),
536-545, (2006)
Visualization of large-scale aqueous solubility data using a novel hierarchical data visualization technique. F.
Yamashita, T. Itoh, H. Hara and M. Hashida, Journal of Chemical Information and Modeling, 46(3),
1054-1059, (2006)
Intravenous administration of mannosylated cationic liposome/NFkappa B decoy complexes effectively
prevent LPS-induced cytokine production in a murine liver failure model. Y. Higuchi, S. Kawakami, M. Oka,
Y. Yabe, F. Yamashita, M. Hashida, FEBS Letters, 580(15), 3706-3714, (2006)
Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous
administration. T. Okuda, S. Kawakami, T. Maeie, T. Niidome, F. Yamashita and M. Hashida, Journal of
− 274 −
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
Controlled Release, 114, 69-77, (2006)
Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice. N. Chansri,
S. Kawakami, F. Yamashita and M. Hashida, International Journal of Pharmaceutics, 321, 42-49, (2006)
Efficient gene transfer into macrophages and dendritic cells by in vivo gene delivery with mannosylated
lipoplex via the intraperitoneal route. Y. Hattori, S. Kawakami, K. Nakamura, F. Yamashita and M. Hashida,
Journal of Pharmacology and Experimental Therapeutics, 318(2), 828-834, (2006)
Effect of the particle size of galactosylated lipoplex on hepatocyte-selective gene transfection after intraportal
administration. Y. Higuchi, S. Kawakami, S. Fumoto, F. Yamashita and M. Hashida, Biological &
Pharmaceutical Bulletin, 29(7), 1521-1523, (2006)
Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by
macrophages. W. Yeeprae, S. Kawakami, F. Yamashita and M. Hashida, Journal of Controlled Release,
114(2), 193-201, (2006)
Improved anti-oxidant activity of superoxide dismutase by direct chemical modification. N. Ishimoto, T.
Nemoto, K. Nagayoshi, F. Yamashita and M. Hashida, Journal of Controlled Release, 111, 204-211, (2006)
Evaluation of proinflammatory cytokine production induced by linear and branched
polyethylenimine/plasmid DNA complexes in mice. S. Kawakami, Y. Ito, P. Charoensit, F. Yamashita and M.
Hashida, Journal of Pharmacology and Experimental Therapeutics, 317(3), 1382-1390, (2006)
Influence of cholesterol composition on the association of serum mannan-binding proteins with
mannosylated liposomes. T. Terada, M. Nishikawa, F. Yamashita and M. Hashida, Biological &
Pharmaceutical Bulletin, 29(4), 613-618, (2006)
Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid conntaining galactosylated liposomes for
hepatocellular carcinoma-selective targeting. T. Terada, M. Iwai, S. Kawakami, F. Yamashita and M. Hashida,
Journal of Controlled Release, 111(3), 333-342, (2006)
Analysis of the molecular interaction of glycosylated prpteins with rabbit liver asialoglycoprotein receptors
using surface plasmon resonance spectroscopy. T. Terada, M. Nishikawa, F. Yamashita and M. Hashida,
Journal of Pharmacy and Biomedical Analysis, 41, 966-972, (2006)
Analysis of the molecular interaction between mannosylated proteins and serum mannan-binding lectns. T.
Terada, M. Nishikawa, F. Yamashita and M. Hashida, International Journal of Pharmaceutics, 316, 117-123,
(2006)
Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. Y. Hattori, S.
Kawakami, Y. Lu, K. Nakamura, F. Yamashita, M. Hashida, Journal of Gene Medicine, 8, 824-834, (2006)
83. Suppression of TNFD production in LPS induced liver failure mice after intravenous injection of cationic
liposome/NFNB decoy complex. Y. Higuchi, S. Kawakami, M. Oka, F. Yamashita and M. Hashida,
Pharmazie, 61, 144-147, (2006)
84. Use of lipoplex-induced nuclear factor-țB activation to enhance transgene expression by lipoplex in mouse
lung. T. Kuramoto, M. Nishikawa, O. Thanaketpaisarn, T. Okabe, F. Yamashita and M. Hashida, Journal of
Gene Medicine, 8, 53-62, (2006)
85. Physicochemical and pharmacokinetic characteristics of cationic liposomes. W. Yeeprae, S. Kawakami, S.
Suzuki, F. Yamashita and M. Hashida, Pharmazie, 61, 102-105, (2006)
86. Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in
DOTAP/cholesterol liposomes. S. Kawakami, S. Suzuki, F. Yamashita and M. Hashida, Journal of Controlled
Release, 110(3), 514-521, (2006)
87. Liver targeting of catalase by cationization for prevention of acute liver failure in mice. S. Ma, M. Nishikawa,
H. Katsumi, F. Yamashita and M. Hashida, Journal of Controlled Release, 110(2), 273-282, (2006)
㸦⥲ㄝ㸧
1.
2.
Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. W. Wijagkanalan, S.
Kawakami, and M. Hashida, Pharmaceutical Research, in press
Strategies for In Vivo Delivery of siRNAs: Recent Progress. Y. Higuchi, S. Kawakami and M. Hashida,
BioDrugs, 24(3), 195-205, (2010)
3.
ࢺࣛࣥࢫ࣏ࢰࣥ࡟ᇶ࡙ࡃᣢ⥆Ⓨ⌧ᆺ࣋ࢡࢱ࣮ࡢ㛤Ⓨ࡜἞⒪ᛂ⏝. ୰す⚽அ, ᵽཱྀࡺࡾᏊ, ᕝୖ ⱱ,
ᒣୗᐩ⩏, ᶫ⏣ ඘, ⸆Ꮫ㞧ㄅ, 129(12), 1433-1443, (2009)
4.
Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. M. Nishikawa, M. Hashida
and Y. Takakura, Advanced Drug Delivery Reviews, 61(4), 319-326, (2009)
− 275 −
5.
In vivo ⺯ග࢖࣓࣮ࢪࣥࢢ࡟ࡼࡿ⣽⬊ࡢ㏣㊧ࢆ┠ⓗ࡜ࡋࡓከᶵ⬟ᛶ㔞Ꮚࢻࢵࢺࡢ㛤Ⓨ. ᵽཱྀࡺࡾᏊ,
ᶫ⏣ ඘, ࣓ࢹ࢕࣭࢝ࣝࢧ࢖࢚ࣥࢫ࣭ࢲ࢖ࢪ࢙ࢫࢺ, 35(13), 560-563, (2009)
6.
᰾㓟་⸆ရࢹࣜࣂ࣮ࣜࢆ┠ⓗ࡜ࡋࡓ⢾ಟ㣭ᚤ⢏Ꮚ࢟ࣕࣜ࢔ࡢ㛤Ⓨ࡜἞⒪࡬ࡢᒎ㛤. ᕝୖ ⱱ, ⸆Ꮫ
㞧ㄅ, 128(11), 1577-1586, (2008)
7.
⫵࡬ࡢ㑇ఏᏊࢹࣜࣂ࣮ࣜ. ྥ஭ⱥྐ, ᕝୖ ⱱ, ᶫ⏣ ඘, Drug Delivery System, 23(4), 454-459, (2008)
8.
⣽⬊㑅ᢥⓗ᰾㓟ࢱ࣮ࢤࢸ࢕ࣥࢢ࡟ࡼࡿࡀࢇච␿⒪ἲࡢ㛤Ⓨ. ᕝୖ ⱱ, ᵽཱྀࡺࡾᏊ, ୰す⚽அ, ಴ᮏ
ኤ㤶㔛, ᭹㒊ⰾᖾ, ᶫ⏣ ඘, Drug Delivery System, 23(2), 138-144, (2008)
9.
⅖⑕἞⒪ࢆ┠ⓗ࡜ࡋࡓ NFȡB ࢹࢥ࢖ࡢ⣽⬊㑅ᢥⓗࢱ࣮ࢤࢸ࢕ࣥࢢࢩࢫࢸ࣒ࡢ㛤Ⓨ. ᵽཱྀࡺࡾᏊ,
ᕝୖ ⱱ, ᶫ⏣ ඘, ⸆Ꮫ㞧ㄅ, 128(2), 209-218, (2008)
10. Non-viral approaches for targeted delivery of plasmid DNA and oligonucleotide. S. Kawakami, Y. Higuchi
and M. Hashida, Journal of Pharmaceutical Sciences, 97(2), 726-745, (2008)
11. Development of nitric oxide donors for the treatment of cardiovascular diseases. H. Katsumi, M. Nishikawa
and M. Hashida, Cardiovascular and Hematological Agents in Medicinal Chemistry, 5(3), 204-208, (2007)
12. ච␿άᛶ໬ CpG DNA ࡢ⭡⭷᧛✀࡟ᑐࡍࡿච␿⒪ἲ࡬ࡢᛂ⏝. ಴ᮏኤ㤶㔛㸪ᶫ⏣ ඘, ⸆Ꮫ㞧ㄅ,
127(10), 1533-1540, (2007)
13. Targeted delivery of small interfering RNA by systemic administration. S. Kawakami and M. Hashida, Drug
Metabolism and Pharmacokinetics, 22(3), 142-151, (2007)
14. Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. M. Nishikawa and M. Hashida,
Expert Opinion on Drug Delivery, 3(3), 355-369, (2006)
㸦ⴭ᭩㸧
1.
ᅗゎ࡛Ꮫࡪ㹂㹂㹑 ⸆≀἞⒪ࡢ᭱㐺໬ࢆ┠ᣦࡍඛ➃๰⸆ᢏ⾡ࠊᶫ⏣ ඘┘ಟࠊࡌ࡯࠺ (2010)
2.
⸆Ꮫ ◊✲᭱๓⥺. ᶫ⏣ ඘, ⏕࿨⣔ࠕ㏫ᘬࡁ㺁◊✲ᐊ᱌ෆ, 351-356, ᑠᐑᒣᏹ ⦅, ᮾிᅗ᭩ (2010)
3.
➨ 2 ❶ Ex vivo ࡟ࡼࡿ㹀㸿ண 1. In silico ࡟ࡼࡿࣂ࢖࢜࢔࣋࢖ࣛࣅࣜࢸ࢕ࡢண . ᒣୗᐩ⩏,
⸆≀ࡢᾘ໬⟶྾཰ண ◊✲ࡢ᭱๓⥺, 30-36, ᮡᒣ㞝୍ ⦅, ࣓ࢹ࢕࢝ࣝ ࢻࢗ (2010)
4.
࣮࣋ࢩࢵࢡ⸆Ꮫᩍ⛉᭩ࢩ࣮ࣜࢬ 18 ⸆≀ືែᏛ. ᶫ⏣ ඘ ⦅, ໬Ꮫྠே (2010)
5.
໬Ꮫᵓ㐀࡜⸆⌮స⏝ ᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣ ඘ ┘ಟ, ᘅᕝ᭩ᗑ㸦2010㸧
6.
⸆≀ືែᏛ. ᰘᓮṇ຾㸪㉥ụ᫛⣖㸪ᶫ⏣ ඘ ┘ಟ, ᘅᕝ᭩ᗑ (2010)
7.
་⸆ရ㛤Ⓨㄽ. ᰘᓮṇ຾㸪㉥ụ᫛⣖㸪ᶫ⏣ ඘ ┘ಟ, ᘅᕝ᭩ᗑ (2010)
8.
ᐇົᐇ⩦஦๓Ꮫ⩦ࡢࡓࡵࡢㄪ๣Ꮫィ⟬ࢻࣜࣝ. ᰘᓮṇ຾㸪㉥ụ᫛⣖㸪ᶫ⏣ ඘ ┘ಟ, ᘅᕝ᭩ᗑ
(2010)
9.
㹂㹂㹑἞⒪ࢩࢫࢸ࣒ࡢタィ࡜ホ౯ ᮍ᮶་⒪ࡢ㛤ᣅ࡟ྥࡅ࡚ࠊᶫ⏣ ඘⦅㞟ࠊࡌ࡯࠺ (2009)
10. 〇๣Ꮫ࣭≀⌮⸆๣Ꮫ. ᰘᓮṇ຾㸪㉥ụ᫛⣖㸪ᶫ⏣ ඘ ┘ಟ, ᘅᕝ᭩ᗑ (2009)
11. ᐇົᐇ⩦஦๓Ꮫ⩦ࡢࡓࡵࡢㄪ๣Ꮫ. ᰘᓮṇ຾㸪㉥ụ᫛⣖㸪ᶫ⏣ ඘ ┘ಟ, ᘅᕝ᭩ᗑ (2009)
12. ➨ 2 ❶ ᶵ⬟ᛶ㹂㹂㹑࢟ࣕࣜ࢔⣲ᮦࡢᇶᮏタィ 㸰 ⢾ಟ㣭ࢼࣀ࢟ࣕࣜ࢔. ᵽཱྀࡺࡾᏊ, ᕝୖ ⱱ,
ᶫ⏣ ඘, ᶵ⬟ᛶ㹂㹂㹑࢟ࣕࣜ࢔ࡢ〇๣タィ, 34-41, ᒸ⏣ᘯ᫭ ⦅, ࢩ࣮࢚࣒ࢩ࣮ฟ∧ (2008)
13. ⸆≀యෆືែࡢண 13 ⸆≀ືែ≉ᛶࡢ࢖ࣥࢩࣜࢥண . ᒣୗᐩ⩏, ᶫ⏣ ඘, ศᏊ⸆≀ືែᏛ,
248-268, ᮡᒣ㞝୍, ᴋཎὒஅ ⦅, ༡ᒣᇽ (2008)
14. Pharmacokinetics of nanocarrer-mediated drug and gene delivery. Y. Higuchi, S. Kawakami and M. Hashida,
Nanotechnology for Cancer Therapy, 43-58, Mansoor M. Amiji (Eds.), CRC PRESS, Boca Raton (2007)
15. ➨ 3 㒊 ᡃࡀᅜࡢಖ೺་⒪ࡢᑗ᮶ᒎᮃ ➨ 8 ❶ ྛศ㔝ࡢᑗ᮶ᒎᮃ ๰⸆ࡢᑗ᮶ᒎᮃ-ADME ண ࡜ DDS ࡢほⅬ࠿ࡽ. ᒣୗᐩ⩏, ᡃࡀᅜࡢಖ೺་⒪ࡢᑗ᮶ 20 ᖺᚋࡢࣄ࣮࣐ࣗࣥࣛ࢖ࣇࢆᒎᮃࡍࡿ,
285-287, ㈈ᅋἲேࣄ࣮࣐ࣗࣥࢧ࢖࢚ࣥࢫ᣺⯆㈈ᅋᑗ᮶ືྥㄪᰝጤဨ఍ ⦅, ㈈ᅋἲேࣄ࣮࣐ࣗࣥࢧ
࢖࢚ࣥࢫ᣺⯆㈈ᅋ (2007)
16. ➨ 4 ❶ ⸆≀ືែ࣭〇๣◊✲⪅࡜་⸆ရ໬Ꮫ◊✲ᡤࡢࣇ࢕࣮ࢻࣂࢵࢡ 3. ືែ≉ᛶࡢ in silico ண
. ᒣୗᐩ⩏, ᭱᪂๰⸆Ꮫ 2007 ⸆≀ືែᏛ≉ᛶࡢゎᯒࡣ๰⸆ࡢ࣮࣮࢟࣡ࢻ, 246-250, ᮡᒣ㞝୍ ⦅,
࣓ࢹ࢕࢝ࣝࢻࢗ (2007)
17. ϫ㸸ືែண ϫ-C In silico ࡟ࡼࡿ⸆≀ືែண . ᒣୗᐩ⩏, ๰⸆ືែ ་⸆ရ๰〇ࡢࡓࡵࡢ⪃࠼
− 276 −
᪉࡜᭱᪂᝟ሗ, 301-323, DMPK ㄅࢽ࣮ࣗࢫࣞࢱ࣮⦅㞟ጤဨ఍ ⦅, ᪥ᮏ⸆≀ືែᏛ఍ (2006)
18. ➨ 15 ᨵṇ᪥ᮏ⸆ᒁ᪉ゎㄝ᭩ࠊᶫ⏣ ඘ศᢸᇳ➹ࠊᘅᕝ᭩ᗑ (2006)
− 277 −
⸆ရస⏝ゎᯒᏛศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧㉥ụ ᫛⣖㸦࠶࠿࠸ࡅ ࠶ࡁࡢࡾ㸧㸦1994. 4 ╔௵㸧
᫛࿴㸲㸷ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸳㸲ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧ஂ⡿ ฼᫂㸦ࡃࡵ ࡜ࡋ࠶ࡁ㸧(1998.6 ᥇⏝)
ᖹᡂ㸴ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸮ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ᚋᮇㄢ⛬㏥Ꮫ
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧Ἠ Ᏻᙪ㸦࠸ࡎࡳ ࡸࡍࡦࡇ㸧(2007.11 ᥇⏝)
ᖹᡂ㸯㸲ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸷ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
ᙜ⸆ရస⏝ゎᯒᏛศ㔝ࡣ୰ᯡ⚄⤒స⏝⸆ࡢ⸆⌮Ꮫࢆ୺せㄢ㢟࡜ࡋ࡚ࠊ
୍㈏ࡋ࡚୰ᯡ⚄⤒⣔࡟࠾ࡅࡿ⸆≀࣭⏕⌮άᛶ≀㉁ࡢస⏝࡟㛵ࡍࡿ◊✲ࢆ
⾜࠸ࠊ⚄⤒⛉Ꮫ࠾ࡼࡧ⚄⤒⢭⚄⸆⌮Ꮫࡢศ㔝࡟࠾ࡅࡿ◊✲⪅ࡢ⫱ᡂࢆ┠
㸦㉥ụᩍᤵ㸧
ⓗ࡜ࡋ࡚ࡁࡓࠋ⬻⹫⾑ࠊ⬻ෆฟ⾑࡟క࠺ࢽ࣮ࣗࣟࣥṚࠊ࠾ࡼࡧࠊ࢔ࣝࢶࣁ࢖࣐
࣮⑓ࠊࣃ࣮࢟ࣥࢯࣥ⑓࡞࡝ࡢ㞴἞ᛶ⚄⤒ኚᛶ⑌ᝈ࡟㛵ࢃࡿࢽ࣮ࣗࣟࣥṚࢆไᚚࡍࡿෆᅾᛶಖㆤᅉᏊࡢ᥈
⣴࡜స⏝ᶵᗎࡢゎᯒ࡟ຊࢆὀࡂࠊ᪂つ⚄⤒ಖㆤ≀㉁࡛࠶ࡿࢭࣟࣇ࢙ࣥࢻ㓟(serofendic acid)ࢆ࢘ࢩ⫾௘⾑
ΎࡼࡾⓎぢࡋࠊࡑࡢ⣽⬊ಖㆤࡢศᏊᶵᵓࡢゎ᫂ࢆ㐍ࡵ࡚࠸ࡿࠋࡲࡓࠊࢽ࣮ࣗࣟࣥ⏕Ꮡ࡜⚄⤒෌⏕ࢆไᚚ
ࡍࡿపศᏊ㔞໬ྜ≀ࡢ᥈⣴ࢆ㐍ࡵ࡚࠾ࡾࠊ᳜≀ࢆࢯ࣮ࢫ࡜ࡋࡓ᳨ウࡀ⌧ᅾ㐍⾜୰࡛࠶ࡿࠋ
⫾௘⾑Ύ࡟⏤᮶ࡍࡿ⚄⤒ಖㆤ໬ྜ≀ࢭࣟࣇ࢙ࣥࢻ㓟ࡢ⣽⬊స⏝ᶵᗎࡢゎᯒ
࢘ࢩ⫾௘⾑Ύ୰࡟⚄⤒ಖㆤάᛶࢆ᭷ࡍࡿᡂศࡀᏑᅾࡍࡿ╔┠ࡋ᳨ウࢆ㐍ࡵࡓ⤖ᯝࠊ᪂つ࡞ෆᅾᛶ≀
㉁ࢆⓎぢࡋࠊserofendic acid ࡜࿨ྡࡋࡓࠋSerofendic acid ࡢ⸆⌮స⏝ࡢゎᯒࠊ⮫ᗋᛂ⏝ࡢྍ⬟ᛶࡢ᳨
ウࢆ㐍ࡵ࡚࠾ࡾࠊࡇࢀࡲ࡛࡟ࠊin vitro ᐇ㦂⣔࡟࠾࠸࡚ࡣ኱⬻⓶㉁ࠊ⥺᮲యࠊ⬨㧊࡞࡝ࡢ୰ᯡ⚄⤒⣔
ㅖ㒊఩࡟࠾࠸࡚⚄⤒ಖㆤస⏝ࢆⓎ⌧ࡍࡿ࡜࡜ࡶ࡟ࠊෆ⪥ࠊᚰ⮚࡞࡝ࡢᮎᲈ⮚ჾ࡟࠾࠸࡚ࡶࣛࢪ࢝ࣝ
ㄏⓎ㞀ᐖ࡟ᑐࡍࡿ⣽⬊ಖㆤస⏝ࢆⓎ⌧ࡍࡿࡇ࡜᫂ࡽ࠿࡟ࡋࡓࠋࡉࡽ࡟ in vivo ᐇ㦂⣔࡟࠾࠸୍࡚㐣ᛶ
⬻⹫⾑㞀ᐖࠊᚰ➽᱾ሰࣔࢹࣝື≀࡟࠾ࡅࡿ᭷ຠᛶࡶ᫂ࡽ࠿࡟ࡋࡓࠋ
㞴἞ᛶ⚄⤒ኚᛶ⑌ᝈ࡟࠾ࡅࡿࢽ࣮ࣗࣟࣥṚࡢᶵᗎࡢゎᯒ࡜ࡑࡢಖㆤᅉᏊࡢ᥈⣴
࢔ࣝࢶࣁ࢖࣐࣮⑓ࠊࣃ࣮࢟ࣥࢯࣥ⑓࡞࡝ࡢ୰ᯡ⚄⤒ኚᛶ⑌ᝈ࡟క࠺ࢽ࣮ࣗࣟࣥṚࡢᶵᗎࢆゎᯒࡍࡿ
࡜࡜ࡶ࡟ࠊࢽࢥࢳࣥᛶ࢔ࢭࢳࣝࢥࣜࣥࠊࢻࣃ࣑ࣥࠊ⬡⁐ᛶࣅࢱ࣑ࣥ⩌࡞࡝ࡢෆᅾᛶ≀㉁ࡀ⚄⤒ಖㆤ
స⏝ࢆⓎ⌧ࡍࡿࡇ࡜ࢆぢฟࡋࠊࡇࢀࡽࡢෆᅾᛶ⚄⤒ಖㆤ≀㉁ࡢࢽ࣮ࣗࣟࣥ⏕Ꮡ࡟࠾ࡅࡿᙺ๭ࡢ᳨ウ
ࢆ㐍ࡵ࡚࠸ࡿࠋ≉࡟ࠊࢽࢥࢳࣥཷᐜయࡢ⚄⤒ಖㆤᶵᵓ࡟㛵ࡍࡿ◊✲࡛ࡣࠊ࢔ࣝࢶࣁ࢖࣐࣮⑓࡟⏝࠸
ࡽࢀࡿࢻࢿ࣌ࢪࣝ࡞࡝ࡢ࢔ࢭࢳࣝࢥ࢚ࣜࣥࢫࢸ࣮ࣛࢮ㜼ᐖ⸆ࡀ⚄⤒ᆺࢽࢥࢳࣥཷᐜయࢆ௓ࡋ࡚⚄
⤒ಖㆤస⏝ࢆⓎ⌧ࡍࡿࡇ࡜ࠊࡑࡢస⏝ᶵᗎ࡜ࡋ࡚ PI3K-Akt ⤒㊰ࢆྵࡵࡓࣜࣥ㓟໬⤒㊰ࡀ㠀ᖖ࡟㔜
せ࡞ᙺ๭ࢆᯝࡓࡍࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋࡓࠋ
ࢽ࣮ࣗࣟࣥ⏕Ꮡ࡜⚄⤒෌⏕ࢆไᚚࡍࡿపศᏊ㔞໬ྜ≀ࡢ᥈⣴
⬻⑌ᝈ࡟࠾࠸࡚⚄⤒⣽⬊Ṛࡀច㉳ࡉࢀࡿ࡜୙ྍ㏫ⓗ࡞ኚᛶࡀ⏕ࡌࡿࠋࡇࢀࡽࡢ἞⒪ࢆ⾜࠺ࡓࡵ࡟ࡣ
⏕Ꮡࡋ࡚࠸ࡿࢽ࣮ࣗࣟࣥࡢ⣽⬊Ṛࢆ㜵ࡄ࡜࡜ࡶ࡟ࠊ᪂ࡓ࡞ࢽ࣮ࣗࣟࣥࢆ⿵඘ࡍࡿࠊࡲࡓࡣ⚄⤒ᢞᑕ
ࢆㄏⓎࡍࡿࡇ࡜࡟ࡼࡾᶵ⬟ⓗ࡟ᅇ᚟ࡍࡿ࡜࠸ࡗࡓ⚄⤒෌⏕ࢆಁ㐍ࡍࡿࡇ࡜ࡀ㔜せ࡛࠶ࡿࠋࡇࢀࡲ࡛
࡟ࠊ⚄⤒✺㉳ఙ㛗࡟ᑐࡍࡿ᪂ࡓ࡞ホ౯⣔ࢆ㛤Ⓨࡋࠊ⚄⤒✺㉳ఙ㛗࡟㛵୚ࡍࡿ࣓࢝ࢽࢬ࣒࡟ࡘ࠸࡚⣽
⬊᥋╔ᅉᏊࡀ㔜せ࡞ᙺ๭ࢆᯝࡓࡍࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋࡓࠋ⌧ᅾࠊࢽ࣮ࣗࣟࣥ⏕Ꮡ࠾ࡼࡧ⚄⤒෌⏕ࢆไ
ᚚࡍࡿ᳜≀࡟⏤᮶ࡍࡿపศᏊ㔞໬ྜ≀ࡢ᥈⣴ࢆ㐍ࡵ࡚࠾ࡾࠊ᭷ຠᛶࢆ♧ࡍศ⏬ࢆᚓ࡚࠾ࡾ⢭〇ࢆ㐍
ࡵᵓ㐀ゎᯒࢆ⾜࠺ࡇ࡜࡟ࡼࡾࠊ໬ྜ≀ࡢྠᐃࢆ┠ᣦࡍࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᙜ◊✲ᐊ࡛Ⓨぢࡋࡓ᪂つෆᅾᛶ⚄⤒ಖㆤ≀㉁ serofendic acid ࡢ⸆⌮స⏝ࡢゎᯒࢆ㐍ࡵࠊin vitroࠊin vivo
ᐇ㦂⣔ࡢ୧⪅࡟࠾࠸࡚᭷ຠᛶࢆ᫂ࡽ࠿࡜ࡋࠊㄽᩥⓎ⾲ࢆ⾜ࡗࡓࠋࢽࢥࢳࣥ࠾ࡼࡧ࢔ࣝࢶࣁ࢖࣐࣮⑓἞⒪
⸆ࡢ⚄⤒ಖㆤస⏝࡟㛵ࡍࡿ◊✲࡛ࡶୡ⏺ࢆ࣮ࣜࢻࡋ࡚࠾ࡾࠊࡑࡢಖㆤస⏝ᶵᗎ࡟ࡘ࠸᳨࡚ウࢆ㐍ࡵㄽᩥ
Ⓨ⾲ࢆ⾜࠸ࠊከࡃࡢ㏣ຍሗ࿌ࡀ࡞ࡉࢀ࡚࠸ࡿࠋ⚄⤒✺㉳ఙ㛗ࢆ in vitro ࡛ホ౯ࡍࡿ᪂つᐇ㦂⣔ࢆ㛤Ⓨࡋ
ࡓࠋࡲࡓࠊ᭦࡞ࡿࢽ࣮ࣗࣟࣥ⏕Ꮡ࠾ࡼࡧ⚄⤒෌⏕ࢆไᚚࡍࡿపศᏊ㔞໬ྜ≀ࡢ᥈⣴◊✲࡟╔ᡭࡋࠊ᭷ᮃ
࡞ศ⏬ࢆᚓ࡚࠾ࡾࠊ᪂つ໬ྜ≀ࡢⓎぢ࡟ࡘ࡞ࡀࡿࡇ࡜ࡀᮇᚅࡉࢀࡿࠋࡇࢀࡽࡢ◊✲ࡢホ౯ࡣ㧗࠸ࠋ
− 278 −
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ㸯ᅇ⏕ᚋᮇࡢ୍⯡⏕⌮Ꮫࠊ㸰ᅇ⏕ᚋᮇࡢ⸆⌮Ꮫ㸯㸦་⒪⸆Ꮫϩ㸦⸆⌮Ꮫ㸧㸧ࠊ㸱ᅇ
⏕ᚋᮇࡢ⸆⌮Ꮫ㸱㸦་⒪⸆Ꮫϫ㸦་⸆ရᏳ඲ᛶᏛ㸧㸧ࠊ⸆Ꮫᑓ㛛ᐇ⩦㸱㸦ϫ㸧ࠊ㸲ᅇ⏕๓ᮇࡢ⸆≀἞⒪Ꮫ
㸰ࠊ⮫ᗋ⸆Ꮫ⥲ㄽࢆᢸᙜࡋ࡚࠸ࡿࠋࡑࢀࡒࢀࡢㅮ⩏ࠊᐇ⩦࡟࠾࠸࡚᫂☜࡞┠ᶆࢆタᐃࡍࡿ࡜࡜ࡶ࡟ࠊᏛ
⏕࠿ࡽࡢࣜࣇࣞࢡࢩࣙࣥ➼ࡶྲྀࡾධࢀ࡚ࠊᏛ⏕ࡢ⯆࿡ࢆႏ㉳ࡋ⌮ゎࢆ῝ࡵࡿࡼ࠺࡟ㅮ⩏ࢆ⾜ࡗ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸ᙜศ㔝ࡢᩍ⫱࣭◊✲ࡢ≉ᚩࡣࠊ⑌ᝈࡢ἞⒪࡟ᙺ❧ࡘ◊✲ㄢ㢟ࢆタᐃࡋࠊᏛ
⏕࡟ࡶ◊✲࡟ᚑ஦ࡋ࡞ࡀࡽᏛ⩦ࡋ࡚࠸ࡃࡇ࡜࡟ࡼࡾࠊྛ⮬ࡢ◊✲ࡢព⩏ࢆ⌮ゎࡍࡿ࡜࡜ࡶ࡟ࠊ⊂๰ⓗ࡞
◊✲ࡢᐇ㊶ࢆ┠ᣦࡍࡼ࠺࡟ᣦᑟࡋ࡚࠸ࡿⅬ࡛࠶ࡿࠋࡉࡽ࡟ࠊ⮫ᗋ་Ꮫศ㔝ࠊ〇⸆௻ᴗ࡜ࡢඹྠ◊✲ࢆ✚
ᴟⓗ࡟㐍ࡵࡿࡇ࡜࡟ࡼࡾࠊ་⒪⛉Ꮫࠊ๰⸆⛉Ꮫ࡟࠾ࡅࡿ⸆⌮Ꮫ◊✲ࡢᙺ๭࡟㛵ࡍࡿ⌮ゎࢆಁ㐍ࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏ࡣ㸯ᅇ⏕࠿ࡽ㸲ᅇ⏕ࡲ࡛ࡢ඲Ꮫᖺ࡟ᑐࡋ࡚⸆≀἞⒪࡟㛵㐃ࡋࡓ⣔⤫ⓗ࡞ㅮ⩏࣭ᐇ⩦ࢆ
⾜ࡗ࡚࠾ࡾࠊㅮ⩏࡛ࡣẖᅇᑠヨ㦂ࢆ⾜࠸㐩ᡂᗘࢆ☜ㄆࡍࡿᙧᡂⓗホ౯ࢆྲྀࡾධࢀ࡚࠸ࡿࠋ◊✲ᐊෆࡢᩍ
⫱ࡣࠊከࡃࡢᏛ⏕ࡀ኱Ꮫ㝔ᅾ⡠୰࡟Ꮫ఍Ⓨ⾲ࢆ⾜࠸ㄽᩥⓎ⾲ࡶ⾜ࡗ࡚࠸ࡿࡇ࡜࠿ࡽࠊ◊✲⪅⫱ᡂࡢ┠ⓗ
ࡣ࡯ࡰ㐩ࡋ࡚࠸ࡿ࡜⪃࠼ࡽࢀࡿࠋ
2005 ᖺ㹼2010 ᖺࡢ኱Ꮫ㝔ಟ஢⪅ࡢ㐍㊰࡜ࡋ࡚ࡣࠊ〇⸆࣓࣮࣮࢝ࡢ◊✲⫋࡟ࡘࡃ⪅ࡀከࡃࠊ༤ኈ㸴ྡ
୰㸱ྡࠊಟኈ㸱㸯ྡ୰㸯㸵ྡࡀ࣓࣮࣮࢝◊✲⫋࡟ᑵ⫋ࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊಟኈಟ஢⪅ࡢ࠺ࡕ㸯㸯ྡࡣ༤
ኈㄢ⛬࡟㐍Ꮫࡋ࡚࠸ࡿࠋ኱Ꮫ➼ࡢᩍ⫱◊✲ᶵ㛵㸦኱Ꮫࡢຓᡭ㸰ྡࠊ࣏ࢫࢻࢡ㸯ྡ㸧ࠊ་⒪ᶵ㛵ࡢ⸆๣ᖌ
㸦㸰ྡ㸧࡜࡞ࡿᏛ⏕ࡶ࠾ࡾࠊᩍ⫱࡜◊✲ࡢ㧗࠸ࣞ࣋ࣝࡀホ౯ࡉࢀ࡚࠸ࡿ⤖ᯝ࡛࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋ
㸦ཎⴭ㸧
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Reconstruction and quantitative evaluation of dopaminergic innervation of striatal neurons in dissociated
primary cultures. S. Wakita, Y. Izumi, T. Matsuo, T. Kume, Y. Takada-Takatori, H. Sawada & A. Akaike, J.
Neurosci. Methods., 192, 83-89 (2010)
Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic
cultures. T. Matsuo, Y. Izumi, T. Kume, Y. Takada-Takatori, H. Sawada & A. Akaike, Neurosci. Lett., 481,
78-81 (2010)
Heme oxygenase-1 contributes to pathology associated with thrombin-induced striatal and cortical injury in
organotypic slice culture. M. Ohnishi, H. Katsuki, K. Unemura, Y. Izumi, T. Kume, Y. Takada-Takatori & A.
Akaike, Brain Res., 1347, 170-178 (2010)
Mitogen-activated protein kinases support survival of activated microglia that mediate thrombin-induced
striatal injury in organotypic slice culture. M. Ohnishi, H. Katsuki, Y. Izumi, T. Kume, Y. Takada-Takatori &
A. Akaike, J. Neurosci. Res., 88, 2155-2164 (2010)
Haloperidol, spiperone, pimozide and aripiprazole reduce intracellular dopamine content in PC12 cells and
rat mesencephalic cultures: Implication of inhibition of vesicular transport. T. Matsuo, Y. Izumi, S. Wakita, T.
Kume, Y. Takada-Takatori, H. Sawada & A. Akaike, Eur. J. Pharmacol., 640, 68-74 (2010)
Depolarizing stimuli cause persistent and selective loss of orexin in rat hypothalamic slice culture. H. Katsuki,
S. Kurosu, S. Michinaga, A. Hisatsune, Y. Isohama, Y. Izumi, T. Kume & A. Akaike, Peptides, 31,
1131-1138 (2010)
Elevation of heme oxygenase-1 by proteasome inhibision affords dopaminergic neuroprotection. N.
Yamamoto, Y. Izumi, T. Matsuo, S. Wakita, T. Kume, Y. Takada-Takatori, H. Sawada & A. Akaike, J.
Neurosci. Res., 88, 1934-1942 (2010)
Biological characterization of ADAM22 variants reveals the importance of a disintegrin domain sequence in
cell surface expression. K. Sagane, H. Sugimoto & A. Akaike, J. Recept. Signal Transduct. Res., 30, 72-77
(2010)
Abeta-induced BACE-1 cleaves N-terminal sequence of mPGES-2. T. Kihara, Y. Shimmyo, A. Akaike, T.
Niidome & H. Sugimoto, Biochem. Biophys. Res. Commun., 393, 728-733 (2010)
PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes. X. Wu, T. Kihara, A. Akaike, T.
Niidome & H. Sugimoto, Biochem. Biophys. Res. Commun., 393, 514-518 (2010)
Design, synthesis and evaluation of carbamate-modified (-)-N1-phenethylnorphysostigmine derivatives as
selective butyrylcholinesterase inhibitors. J. Takahashi, I. Hijikuro, T. Kihara, G. M. Murugesh, S. Fuse, Y.
Tsumura, A. Akaike, T. Niidome, T. Takahashi & H. Sugimoto, Bioorg. Med. Chem. Lett., 20, 1721-1723
(2010)
Design, synthesis, evaluation and QSAR analysis of N1-substituted norcymserine derivatives as selective
butyrylcholinesterase inhibitors. J. Takahashi, I. Hijikuro, T. Kihara, G. M. Murugesh, S. Fuse, R. Kunimoto,
Y. Tsumura, A. Akaike, T. Niidome, Y. Okuno, T. Takahashi & H. Sugimoto, Bioorg. Med. Chem.Lett., 20,
1718-1720 (2010)
− 279 −
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
Mechanisms of chronic nicotine treatment-induced enhancement of the sensitivity of cortical neurons to the
neuroprotective effect of donepezil in cortical neurons. Y. Takada-Takatori, T. Kume, Y. Izumi, T. Niidome,
T. Fujii, H. Sugimoto & A. Akaike, J. Pharmacol. Sci., 112, 265-272 (2010)
Dopamine facilitates D-synuclein oligomerization in human neuroblastoma SH-SY5Y cells. K. Yamakawa, Y.
Izumi, H. Takeuchi, N. Yamamoto, T. Kume, A. Akaike, R. Takahashi, S. Shimohama & H. Sawada,
Biochem. Biophys. Res. Commun., 391, 129-134 (2010)
Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of a4 and D7
receptors in neuroprotection. A. Akaike, Y. Takada-Takatori, T. Kume & Y. Izumi, J. Mol. Neurosci., 40,
211-216 (2010)
Basic fibroblast growth factor promotes the generation of microtubule-associated protein 2-positive cells
from microglia. T. Niidome, H. Nonaka, A. Akaike, T. Kihara & H. Sugimoto, Biochem. Biophys. Res.
Commun., 390, 1018-1022 (2009)
Non-fibrillar amyloid-ș peptide reduces NMDA-induced neurotoxicity, but not AMPA-induced
neurotoxicity. T. Niidome, Y. Goto, M. Kato, P.-L. Wang, S. Goh, N. Tanaka, A. Akaike, T. Kihara & H.
Sugimoto, Biochem. Biophys. Res. Commun., 386, 734-738 (2009)
Lack of tolerance to anxiolysis and withdrawal symptoms in mice repeatedly treated with AC-5216, a
selective TSPO ligand. A. Kita, T. Kinoshita, H. Kohayakawa, K. Furukawa & A. Akaike, Prog.
Neuropsychopharmacol. Biol. Psychiatry, 33, 1040-1045 (2009)
Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene. P.-L.
Wang, T. Niidome, A. Akaike, T. Kihara & H. Sugimoto, J. Neurosci. Res., 87, 2105-2114 (2009)
Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration
via BDNF-mediated signaling. H. Katsuki, E. Kurimoto, S. Takemori, Y. Kurauchi, A. Hisatsune, Y.
Isohama, Y. Izumi, T. Kume, K. Shudo & A. Akaike, J. Neurochem., 110, 707-718 (2009)
ᕤ‫ܖ‬OSCEỆấẬỦἅἱἷἝἃὊἉἹὅᏡщᚸ̖ỉࣱ̮᫂Ệ᧙ẴỦ౨᚛. ᆿဋग़औ, ჵ᣼፯ܑ, ౕஜб,
᧙ᡶ, ᭗ဋᬐጢ, ᔺஜ˦ဃ, Эဋᅎ‫܇‬, ហ൷ଯኔ & ࠯Ј૞, ᕤ‫ܖ‬ᩃᛏ, 129,(5) 609-616 (2009)
Amyloid precursor protein promotes endoplasmic reticulum stress-induced cell death via C/EBP homologous
protein-mediated pathway. K. Takahashi, T. Niidome, A. Akaike, T. Kihara & H. Sugimoto, J. Neurochem.,
109, 1324-1327 (2009)
Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor
up-regulation. Y. Takada-Takatori, T. Kume, Y. Ohgi, T. Niidome, T. Fujii, H. Sugimoto & A. Akaike, Biol.
Pharm. Bull., 32, 318-324 (2009)
A role for SOX2 in the generation of microtubule-associated protein 2-positive cells from microglia. H.
Nonaka, T. Niidome, Y. Shinozuka, A. Akaike, T. Kihara & H. Sugimoto, Biochem. Biophys. Res. Commun.,
380, 60-64 (2009)
Serofendic acid protects from iodinated contrast medium and high glucose probably against superoxide
production in LLC-PK1 cells. O. Kitamura, K. Uemura, H. Kitamura, H. Sugimoto, A. Akaike & T. Ono,
Clin. Exp. Nephrol., 13, 15-24 (2009)
AMPA reduces surface expression of NR1 through regulation of GSK3beta. T. Nishimoto, T. Kihara, A.
Akaike, T. Niidome & H. Sugimoto, Neuroreport, 20, 161-165 (2009)
Long-term treatment with nicotine suppresses neurotoxicity of, and microglial activation by, thrombin in
cortico-striatal slice cultures. M. Ohnishi, H. Katsuki, M. Takagi, T. Kume & A. Akaike, Eur. J. Pharmacol.,
602, 288-293 (2009)
Serofendic acid promotes stellation induced by cAMP and cGMP analogs in cultured cortical astrocytes. T.
Kume, R. Ito, R. Taguchi, Y. Izumi, H. Katsuki, T. Niidome, Y. Takada-Takatori, H. Sugimoto & A. Akaike,
J. Pharmacol. Sci., 109, 110-118 (2009)
Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced parkinson's disease
models. H. Takeuchi, T. Yanagida, M. Inden, K. Takata, Y. Kitamura, K. Yamakawa, H. Sawada, Y. Izumi,
N. Yamamoto, T. Kihara, K. Uemura, H. Inoue, T. Taniguchi, A. Akaike, R. Takahashi & S. Shimohama, J.
Neurosci. Res., 87, 576-585 (2009)
Functional changes induced by long-term stimulation of nicotinic acetylcholine receptors. Y.
Takada-Takatori, T. Kume, Y. Izumi, Y. Ohgi, T. Niidome, T. Fujii, H. Sugimoto & A. Akaike, Biol. Pharm.
Bull., 32, 318-324 (2009)
Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and
MAPK activation. Y. Izumi, N. Yamamoto, T. Matsuo, S. Wakita, H. Takeuchi, T. Kume, H. Katsuki, H.
Sawada & A. Akaike, J. Neurochem., 110, 745-755 (2009)
Excitotoxicity-associated p53 expression in adult rat retina is mediated by calpain activity but not by CIinflux. Y. Hama, H. Katsuki, Y. Izumi, T. Kume & A. Akaike, J. Pharmacol. Sci., 110, 493-496 (2009)
− 280 −
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with
donepezil. Y. Takada-Takatori, T. Kume, Y. Ohgi, Y. Izumi, T. Niidome, T. Fujii, H. Sugimoto & A. Akaike,
J. Neurosci. Res., 86, 3575-3583 (2008)
Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic
phenotype. T. Kume, Y. Kawato, F. Osakada, Y. Izumi, H. Katsuki, T. Nakagawa, S. Kaneko, T. Niidome, Y.
Takada-Takatori & A. Akaike, Neurosci. Lett., 443, 199-203 (2008)
ᕤ‫ܖ‬OSCEỂỉधᎍࣖ‫ݣ‬ᛢ᫆ỆấẬỦᚸ̖૾ඥỆ᧙ẴỦ౨᚛. ᆿဋग़औ, ჵ᣼፯ܑ, ౕஜб, ᭗ဋᬐጢ,
ᔺஜ˦ဃ, ᧙ᡶ, Эဋᅎ‫܇‬, ហ൷ଯኔ & ࠯Ј૞, Ҕၲᕤ‫ܖ‬, 34,(11) 1004-1010 (2008)
DJ-1 protects against neurodegeneration caused by focal cerebral ischemia and reperfusion in rats. D.
Yanagisawa, Y. Kitamura, M. Inden, K. Takata, T. Taniguchi, S. Morikawa, M. Morita, T. Inubushi, I.
Tooyama, T. Taira, M. S. Iguchi-Ariga, A. Akaike & H. Ariga, J. Cereb. Blood Flow Metab., 28, 563-578
(2008)
Phosphorylation of amyloid precursor protein (APP) at Tyr687 regulates APP processing by D-and
H-secretase. K. Takahashi, T. Niidome, A. Akaike, T. Kihara & H. Sugimoto, Biochem. Biophys. Res.
Commun., 377, 544-549 (2008)
Three destinct neuroprotective functions of myricetin against glutamate-induced neuronal cell death:
involvement of direct inhibition of caspase-3. Y. Shimmyo, T. Kihara, A. Akaike, T. Niidome & H.
Sugimoto, J. Neurosci. Res., 86, 1836-1845 (2008)
Multifunction of myricetin on Ab: neuroprotection via a conformational change of Ab and reduction of Ab
via the interference of secretases. Y. Shimmyo, T. Kihara, A. Akaike, T. Niidome & H. Sugimoto, J.
Neurosci. Res., 86, 368-377 (2008)
Toward the generation of rod and cone photoreceptors from mouse, monkey and human embryonic stem cells.
F. Osakada, H. Ikeda, M. Mandai, T. Wataya, K. Watanabe, N. Yoshimura, A. Akaike, Y. Sasai & M.
Takahashi, Nature Biotechnol., 26, 215-352 (2008)
Bromocriptine, a dopamineD2 receptor agonist with the structure of the amino acid ergot alkaloids, induces
neurite outgrowth in PC12 cells. T. Oda, T. Kume, Y. Izumi, Y. Takada-Takatori, T. Niidome & A. Akaike,
Eur. J. Pharmacol., 598, 27-31 (2008)
D-Amino-3-hydroxy-5-methyl-4-isoxazole propionate attenuates glutamate-induced caspase-3 cleavage via
regulation of glycogen synthase kinase 3b. T. Nishimoto, T. Kihara, A. Akaike, T. Niidome & H. Sugimoto,
J. Neurosci. Res., 86, 1096-1105 (2008)
Differential regulation of neurogenesis in two neurogenic regions of APPswe/PSldE9 transgenic mice. T.
Niidome, N. Taniuchi, A. Akaike, T. Kihara & H. Sugimoto, Neuroreport, 19, 1361-1364 (2008)
A molecular pathway involved in the generation of microtubule-associated protein 2-positive cells from
microglia. T. Niidome, S. Matsuda, H. Nonaka, A. Akaike, T. Kihara & H. Sugimoto, Biochemical and
Biophysical Research Communications, 370, 184-188 (2008)
Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in
rats. T. Nakamura, T. Kume, H. Katsuki, T. Niidome, H. Sugimoto & A. Akaike, Eur. J. Pharmacol., 586,
151-155 (2008)
Microtubule-associated protein 2-positive cells derived from microglia possess properties of functional
neurons. S. Matsuda, T. Niidome, H. Nonaka, Y. Goto, K. Fujimura, M. Kato, M. Nakanishi, A. Akaike, T.
Kihara & H. Sugimoto, Biochem. Biophys. Res. Commun., 368, 971-976 (2008)
Regulation of intracellular dopamine levels by dopaminergic drugs: involvement of vesicular monoamine
transporter. Y. Izumi, N. Yamamoto, T. Kume, H. Katsuki, H. Sawada & A. Akaike, Eur. J. Pharmacol., 582,
52-61 (2008)
Chloride-dependent acute excitotoxicity in adult rat retinal ganglion cells. Y. Hama, H. Katsuki, C. Suminaka,
T. Kume & A. Akaike, Neuropharm., 55, 677-686 (2008)
Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of
Alzheimer's disease. Y. Goto, T. Niidome, H. Hongo, A. Akaike, T. Kihara & H. Sugimoto, Eur. J.
Pharmacol., 583, 84-91 (2008)
Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in
rats. S. Fujimoto, H. Katsuki, M. Ohnishi, M. Takagi, T. Kume & A. Akaike, J. Cereb. Blood Flow Metab.,
28, 506-515 (2008)
Donepezil attenuates excitotoxic damage induced by membrane depolarization of cortical neurons exposed to
veratridine. S. Akasofu, K. Sawada, T. Kosasa, H. Hihara, H. Ogura & A. Akaike, Eur. J. Pharmacol., 588,
189-197 (2008)
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress. N. Yamamoto, H.
Sawada, Y. Izumi, T. Kume, H. Katsuki, S. Shimohama & A. Akaike, J. Biol. Chem. , 282, 4364-4372 (2007)
− 281 −
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
Synthesis and pharmacological profile of serofendic acids A and B. T. Terauchi, N. Asai, T. Doko, R.
Taguchi, O. Takenaka, H. Sakurai, M. Yonaga, T. Kimura, A. Kajiwara, T. Niidome, T. Kume, A. Akaike &
H. Sugimoto, Bioorg. Med. Chem., 15, 7098-7107 (2007)
Decreased proliferation of hippocampal progenitor cells in APPswe/PS1dE9 transgenic mice. N. Taniuchi, T.
Niidome, Y. Goto, A. Akaike, T. Kihara & H. Sugimoto, Neuroreport, 18, 1801-1805 (2007)
Wnt signaling promotes regeneration in the retina of adult mammals. F. Osakada, S. Ooto, T. Akagi, M.
Mandai, A. Akaike & M. Takahashi, J. Neurosci., 27, 4210-4219 (2007)
Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. M. Okawara, H.
Katsuki, E. Kurimoto, H. Shibata, T. Kume & A. Akaike, Biochem. Pharmacol., 73, 550-560 (2007)
Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury. M.
Ohnishi, H. Katsuki, S. Fujimoto, M. Takagi, T. Kume & A. Akaike, Experimental Neurology, 206, 43-52
(2007)
Donepezil potentiates nerve growth factor-induced neurite outgrowth in PC12 cells. T. Oda, T. Kume, H.
Katsuki, T. Niidome, H. Sugimoto & A. Akaike, J. Pharmacol. Sci., 104, 349-354 (2007)
Mulberry leaf extract prevents amyloid beta-peptide fibril formation and neurotoxicity. T. Niidome, K.
Takahashi, Y. Goto, S. Goh, N. Tanaka, K. Kamei, M. Ichida, S. Hara, A. Akaike, T. Kihara & H. Sugimoto,
Neuroreport, 18, 813-816 (2007)
Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural
stem/progenitor cells. M. Nakanishi, T. Niidome, S. Matsuda, A. Akaike, T. Kihara & H. Sugimoto, Eur. J.
Neurosci., 25, 649-658 (2007)
Contribution of endogenous glycine and D-serine to excitotoxic and ischemic cell death in rat cerebrocortical
slice cultures. H. Katsuki, Y. Watanabe, S. Fujimoto, T. Kume & A. Akaike, Life Sci., 81, 740-749 (2007)
Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous
dopamine-mediated excitotoxicity. Y. Izumi, H. Sawada, N. Yamamoto, T. Kume, H. Katsuki, S. Shimohama
& A. Akaike, Eur. J. Pharmacol., 557, 132-140 (2007)
Thrombin induces striatal Neurotoxicity depending on mitogen-activated protein kinase pathways in vivo. S.
Fujimoto, H. Katsuki, M. Ohnishi, M. Takagi, T. Kume & A. Akaike, Neurosci., 144, 694-701 (2007)
Serofendic Acid, a substance extracted from fetal calf serum, as a novel drug for cardioprotection. M. Akao,
T. Takeda, T. Kita, T. Kume & A. Akaike, Cardiovasc Drug Rev., 25, 333-341 (2007)
Improvement of focal ischemia-induced rat dopaminergic dysfunction by striatal transplantation of mouse
embroyonic stem cells. D. Yanagisawa, M. Qi, D.-h. Kim, Y. Kitamura, M. Inden, D. Tsuchiya, K. Takata, T.
Taniguchi, K. Yoshimoto, S. Shimohama, A. Akaike, S. Sumi & K. Inoue, Neurosci. Lett., 407, 74-79 (2006)
Synthesis and neuroprotective effects of serofendic acid analogues. T. Terauchi, T. Doko, M. Yonaga, A.
Kajiwara, T. Niidome, R. Taguchi, T. Kume, A. Akaike & H. Sugimoto, Bioorg. Med. Chem. Lett., 16,
5080-5083 (2006)
Serofendic acid, a novel substance extracted from fetal calf serum, protects against oxidative stress in
neonatal rat cardiac myocytes. T. Takeda, M. Akao, M. Matsumoto-Ida, M. Kato, H. Takenaka, Y. Kihara, T.
Kume, A. Akaike & T. Kita, J. American College. Cardiology, 47, 1882-1890 (2006)
Effects of selegiline on antioxidant systems in the nigrostriatum in rat. K. Takahata, S. Shimazu, H. Katsuki,
F. Yoneda & A. Akaike, J. Neural Transm., 113, 151-158 (2006)
Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via
nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Y. Takada-Takatori, T. Kume, M.
Sugimoto, H. Katsuki, H. Sugimoto & A. Akaike, Neuropharmacology, 51, 474-486 (2006)
Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. Y. Takada-Takatori, T.
Kume, M. Sugimoto, H. Katsuki, T. Niidome, H. Sugimoto, T. Fujii, S. Okabe & A. Akaike, Eur. J.
Pharmacol., 549, 19-26 (2006)
Nitric oxide-mediated effect of nipradilol, D - and E-adrenergic blocker, on glutamate neurotoxicity in rat
cortical cultures. R. Taguchi, H. Shirakawa, T. Yamaguchi, T. Kume, H. Katsuki & A. Akaike, Eur. J.
Pharmacol., 535, 86-94 (2006)
Aminoglutethimide prevents excitotoxic and ischemic injuries in cortical neurons. H. Shirakawa, H. Katsuki,
T. Kume, S. Kaneko & A. Akaike, British J. Pharmacol., 147, 729-736 (2006)
c-jun N-terminal kinase inhibition and a-tocopherol protect midbrain dopaminergic neurons from
interferon-g/lipopolysaccharide-induced injury without affecting nitric oxide production. H. Shibata, H.
Katsuki, M. Okawara, T. Kume & A. Akaike, J. Neruosci. Res., 83, 102-109 (2006)
Mechanisms of cell death of neural progenitor cells caused by trophic support deprivation. T. Niidome, N.
Morimoto, S. Iijima, A. Akaike, T. Kihara & H. Sugimoto, Eur. J. Pharmacol., 548, 1-8 (2006)
Glutamate excitotoxicity is involved in cell death caused by tributyltin in cultured rat cortical neurons. Y.
Nakatsu, Y. Kotake, K. Komasaka, H. Hakozaki, R. Taguchi, T. Kume, A. Akaike & S. Ohta, Toxicol. Sci.,
89, 235-242 (2006)
− 282 −
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
Serofendic acid, a neuroprotective substance derived from fetal calf serum, inhibits mitochondrial membrane
depolarization and caspase-3 activation. T. Kume, R. Taguchi, H. Katsuki, M. Akao, H. Sugimoto, S. Kaneko
& A. Akaike, Eur. J. Pharmacol., 542, 69-76 (2006)
Nitric oxide-producing microglia mediate thrombin-induced degeneration of dopaminergic neurons in rat
midbrain slice culture. H. Katsuki, M. Okawara, H. Shibata, T. Kume & A. Akaike, J. Neurochem., 97,
1232-1242 (2006)
A critical role of TRPM2 in neuronal cell death by hydrogen peroxide. S. Kaneko, S. Kawakami, Y. Hara, M.
Wakamori, E. Itoh, T. Minami, Y. Takada, T. Kume, H. Katsuki, Y. Mori & A. Akaike, J. Pharmacol. Sci.,
101, 66-76 (2006)
Contribution of endogenous glycine site NMDA agonists to excitotoxic retinal damage in vivo. Y. Hama, H.
Katsuki, Y. Tochikawa, C. Suminaka, T. Kume & A. Akaike, Neurosci. Res., 56, 279-285 (2006)
Amyloid E-peptide preconditioning reduces glutamate-induced neurotoxicity by pormoting endocytosis of
NMDA receptor. Y. Goto, T. Niidome, A. Akaike, T. Kihara & H. Sugimoto, Biochem. Biophys. Res.
Commun., 351, 259-265 (2006)
Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and
the striatum in organotypic slice cultures. S. Fujimoto, H. Katsuki, T. Kume & A. Akaike, Neurobiology of
Disease, 22, 130-142 (2006)
Preclinical evidence of neuroprotection by cholinesterase inhibitors. A. Akaike, Alzheimer Dis. Assoc.
Disord., 20, S8-S11 (2006)
Pregnenolone sulphate attenuates AMPA cytotoxicity on rat cortical neurons. H. Shirakawa, H. Katsuki, T.
Kume, S. Kaneko & A. Akaike, Eur. J. Neurosci., 21, 2329-2335 (2005)
Stimulation of nicotinic acetylcholine receptors protects motor neurons. T. Nakamizo, J. Kawamata, H.
Yamashita, R. Kanki, T. Kihara, H. Sawada, A. Akaike & S. Shimohama, Biochem. Biophys. Res. Com., 330,
1285-1289 (2005)
Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat
cortical neurons. T. Kume, M. Sugimoto, Y. Takada, T. Yamaguchi, A. Yonezawa, H. Katsuki, H. Sugimoto
& A. Akaike, Eur. J. Pharmacol., 527, 77-85 (2005)
Protective effect of serofendic acid on glutamate-induced neurotoxicity in rat cultured motor neurons. T.
Kume, Y. Kawai, K. Yoshida, T. Nakamizo, R. Kanki, H. Sawada, H. Katsuki, S. Shimohama, H. Sugimoto
& A. Akaike, Neurosci. Lett., 383, 199-202 (2005)
Serofendic acid promotes survival of auditory hair cells and neurons of mice. T. Kita, T. Nakagawa, T.-S.
Kim, K. Iwai, S. Takebayashi, A. Akaike & J. Ito, NeuroReport, 16, 689-692 (2005)
Tetraethylammonium exacerbates ischemic neuronal injury in rat cerebrocortical slice cultures. H. Katsuki, A.
Shinohara, S. Fujimoto, T. Kume & A. Akaike, Eur. J. Pharmacol., 508, 85-91 (2005)
Quinolinic acid toxicity on orexin neurons blocked by gamma aminobutyric acid type A receptor stimulation.
H. Katsuki & A. Akaike, Neuroreport, 16, 1157-1161 (2005)
Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in
SH-SY5Y cells. Y. Izumi, H. Sawada, N. Yamamoto, T. Kume, H. Katsuki, S. Shimohama & A. Akaike, J.
Neruosci. Res., 82, 126-137 (2005)
p-Quinone mediates 6-hydroxydopomine-induced dopaminergic neuronal death and ferrous iron accelerates
the conversion of p-Quinone into melanin extracellularly. Y. Izumi, H. Sawada, N. Sakka, N. Yamamoto, T.
Kume, H. Katsuki, S. Shimohama & A. Akaike, J. Neruosci. Res., 79, 849-860 (2005)
Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational
asymmetry in hemi-parkinsonian rats. M. Inden, Y. Kitamura, J.-i. Kondo, K. Hayashi, T. Yanagida, K.
Takata, D. Tsuchiya, D. Yanagisawa, K. Nishimura, T. Taniguchi, S. Shimohama, H. Sugimoto & A. Akaike,
J. Neurochem., 95, 950-961 (2005)
㸦⥲ㄝ㸧
⥙⭷⚄⤒⣽⬊Ṛࡢ෌⏕࣭ศ໬ࢆไᚚࡍࡿᅉᏊ㉥ụ᫛⣖ஂ⡿฼᫂ἨᏳᙪᑠᆏ⏣ᩥ㝯᪥ᮏ⸆
⌮Ꮫ㞧ㄅ
㛗ᮇࢽࢥࢳࣥཷᐜయ่⃭ࡣࢽ࣮ࣗࣟࣥࢆᏲࡿ㉥ụ᫛⣖ႚ↮⛉Ꮫ
⫾௘⏤᮶⚄⤒ಖㆤ≀㉁ࢭࣟࣇ࢙ࣥࢻ㓟ࡢⓎぢ࡜స⏝ᶵᗎࡢゎᯒஂ⡿฼᫂᪥⸆⌮ㄅᮾி㒔
࢔ࢭࢳࣝࢥࣜࣥཷᐜయࡢ࢖࢜ࣥసືᛶ࣭௦ㅰసືᛶࡢാࡁ㉥ụ᫛⣖⏕యࡢ⛉Ꮫ
ෆᅾᛶࢢࣜࢩࣥ⤖ྜ㒊఩ࣜ࢞ࣥࢻ࡟ࡼࡿ10'$ㄏⓎ⥙⭷㞀ᐖࡢไᚚ㤶᭶༤ᚿ㉥ụ᫛⣖὾ᗣ༤Ώ
㎶ె඾║⸆⌮
− 283 −
/HYRGRSDLQGXFHGYHVLFXODUUHOHDVHRIJOXWDPDWHDQGPHFKDQLVPVRIOHYRGRSDLQGXFHG
QHXURWR[LFLW\LQSULPDU\QHXURQFXOWXUHVLQUDWVWULDWD$NLQRUL$NDLNH7DNHKLNR0DHGD
1HXURELRORJ\RI'23$DVDQHXURWUDQVPLWWHU
⚄⤒ಖㆤ࣭෌⏕ ་⒪◊✲ࡢ᭱๓⥺㉥ụ᫛⣖ ௚ྡ་Ꮫࡢ࠶ࡺࡳ
ࢽ࣮ࣗࣟࣥࡢ࢔࣏ࢺ࣮ࢩࢫࢆไᚚࡍࡿෆᅾᛶಖㆤᅉᏊ㉥ụ᫛⣖㤶᭶༤ᚿஂ⡿฼᫂᪥ᮏ⚄⤒
⢭⚄⸆⌮Ꮫ㞧ㄅ
⫾ඣ≉␗ⓗಖㆤ≀㉁࡜⚄⤒⣽⬊Ṛ㉥ụ᫛⣖ஂ⡿฼᫂་Ꮫࡢ࠶ࡺࡳ
⚄⤒ಖㆤస⏝⸆ෆᅾᛶ⚄⤒ಖㆤ≀㉁ࡢ᥈⣴㉥ụ᫛⣖&OLQLFDO1HXURVFLHQFH
㸦ⴭ᭩㸧
➨㸱❶⑊③࣭ᥙ⑛ᶵᵓ㛵㐃ࠊṊ⏣ᘯᚿࠊ㎷⛱ࠊ㉥ụ᫛⣖ࠊᐇ㊶⾜ື⸆⌮Ꮫࠊ᪥ᮏ⸆⌮Ꮫ఍ᰴᘧ
఍♫㔠ⰾᇽ㸦ᮾி㸧
་⸆ရ㛤Ⓨㄽࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ௚ྡࠊᰤ⏣ᩄஅࠊཎⱥᙲࠊᒸᮧ᪼ ௚ྡ⦅ࠊᘅ
ᕝ᭩ᗑ㸦ᮾி㸧
⸆≀ືែᏛࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ௚ྡࠊᰤ⏣ᩄஅࠊᒣᓮᾈྐࠊℿ஭㞞⾜ ௚ྡ⦅ࠊᘅ
ᕝ᭩ᗑ㸦ᮾி㸧
ศᯒ໬Ꮫ,,ᶵჾศᯒࡢ་⒪⸆Ꮫ࡬ࡢᛂ⏝ࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊబ἞ⱥ㑻 ௚ྡࠊᒸᑦ⏨ࠊᰤ
⏣ᩄஅࠊᏳ஭⿱அ ௚ྡ⦅ࠊᘅᕝ᭩ᗑ㸦ᮾி㸧
ศᯒ໬Ꮫ,ᇶ♏໬Ꮫ࠿ࡽ་⒪⸆Ꮫ࡬ࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊబ἞ⱥ㑻 ௚ྡࠊᏳ஭⿱அࠊᰤ⏣ᩄ
அࠊᒸᑦ⏨ ௚ྡ⦅ࠊᘅᕝ᭩ᗑ㸦ᮾி㸧
〇๣Ꮫ࣭≀⌮⸆๣Ꮫࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ௚ྡࠊᰤ⏣ᩄஅࠊ၈⃝೺ࠊᒸᮏᾈ୍ ௚ྡ
⦅ࠊᘅᕝ᭩ᗑ㸦ᮾி㸧
ᐇົᐇ⩦஦๓Ꮫ⩦ࡢࡓࡵࡢㄪ๣Ꮫࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ௚ྡࠊཌ⏣ᖾ୍㑻ࠊ␇㷂ᴿࠊ
ᰤ⏣ᩄஅ ௚ྡ⦅ࠊᘅᕝ᭩ᗑ㸦ᮾி㸧
➨❶ ⾑ᾮ࠾ࡼࡧ㐀⾑ჾ⑌ᝈ ➨❶ ឤぬჾ⑌ᝈࠊ㉥ụ᫛⣖ ௚ྡࠊ᭱᪂⸆≀἞⒪Ꮫࠊ㉥ụ᫛
⣖ࠊ▼஭㑥㞝ࠊ㉺๓ᏹಇࠊ㔠Ꮚ࿘ྖ⦅ࠊᘅᕝ᭩ᗑ㸦ᮾி㸧
⛉Ꮫⱥㄒㄽᩥసᡂ࣭ᢞ✏ࡢᇶ♏▱㆑ࠊ㉥ụ᫛⣖ࠊᮌᮧ႐௦ྐࠊ$QVKRQ\):)221*ࠊ࢖࣓ࢵࢡࢫࢪࣕ
ࣃࣥᰴᘧ఍♫㸦ி㒔㸧
⸆⛉Ꮫ኱㎡඾ ➨∧ࠊ㉥ụ᫛⣖ ௚ྡࠊᮌᮧ㑥ᙪ⦅ࠊᘅᕝ᭩ᗑ㸦ᮾி㸧
/HYRGRSDLQGXFHGYHVLFXODUUHOHDVHRIJOXWDPDWHDQGPHFKDQLVPVRIOHYRGRSDLQGXFHG
QHXURWR[LFLW\LQSULPDU\QHXURQFXOWXUHVLQUDWVWULDWD$NLQRUL$NDLNH7DNHKLNR0DHGD
1HXURELRORJ\RI'23$DVDQHXURWUDQVPLWWHU\RVKLPL0LVX<RVKLR*RVKLPD%RFD5DWRQ&5&
3UHVV㸦)ORULGD86$㸧
㸦ࡑࡢ௚㸧
ෆᅾᛶࢻࣃ࣑ࣥ࡟ࡼࡿࢻࣃ࣑ࣥࢽ࣮ࣗࣟࣥṚࡢไᚚࠊἨᏳᙪࠊ㉥ụ᫛⣖ࠊ་Ꮫࡢ࠶ࡺࡳࠊ་ṑ⸆ฟ
∧ᰴᘧ఍♫ࠊࠊ
ࣉࣟࢸ࢔ࢯ࣮࣒άᛶ㜼ᐖ࡟ࡼࡿ⣽⬊ಖㆤస⏝ࠊἨᏳᙪࠊ㉥ụ᫛⣖ࠊ་Ꮫࡢ࠶ࡺࡳࠊ་ṑ⸆ฟ∧ᰴᘧ
఍♫ࠊࠊ
$O]KHLPHU⑓἞⒪⸆࡟ࡼࡿࢽࢥࢳࣥཷᐜయ࢔ࢵࣉࣞࢠ࣮ࣗࣞࢩࣙࣥࠊ㧗㫽ᝆグࠊஂ⡿฼᫂ࠊ㉥ụ᫛⣖ࠊ
་Ꮫࡢ࠶ࡺࡳࠊ་ṑ⸆ฟ∧ᰴᘧ఍♫ࠊࠊ
͆ࢭࣟࣇ࢙ࣥࢻ㓟͇Ⓨぢ࡬ࡢ㐨ࡢࡾ࣮࢘ࢩ⫾௘⾑Ύ࡟⏤᮶ࡍࡿ⚄⤒ಖㆤ≀㉁ࠊ㉥ụ᫛⣖ࠊ་Ꮫࡢ࠶
ࡺࡳࠊ་ṑ⸆ฟ∧ᰴᘧ఍♫ࠊࠊ
ࣅࢱ࣑ࣥ(㢮⦕యࡢ⚄⤒ಖㆤస⏝ࠊᑠᆏ⏣ᩥ㝯ࠊஂ⡿฼᫂ࠊ㉥ụ᫛⣖ࠊ་Ꮫࡢ࠶ࡺࡳࠊࠊ
ႚ↮࡜⸆⌮Ꮫࠊ㉥ụ᫛⣖ࠊႚ↮⛉Ꮫࠊ㈈ᅋἲேႚ↮⛉Ꮫ◊✲㈈ᅋࠊࠊ
− 284 −
⮫ᗋ⸆Ꮫᩍ⫱ศ㔝
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧▮㔝⫱Ꮚ㸦ࡸࡢ ࠸ࡃࡇ㸧㸦2008. 4 ╔௵㸧
᫛࿴ 37 ᖺ 4 ᭶ 24 ᪥⏕
᫛࿴ 60 ᖺி㒔኱Ꮫ༞ࠊ᫛࿴ 62 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢ࠊᖹᡂ 5 ᖺி㒔኱Ꮫ༤
ኈ㸦⸆Ꮫ㸧ྲྀᚓ
ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔⸆๣㒊๪⸆๣㒊㛗ࢆే௵
◊✲ࡢᴫせ
⮫ᗋ⸆Ꮫᩍ⫱ศ㔝ࡣࠊ⸆Ꮫ㒊 6 ᖺไᩍ⫱㛤ጞ࡜࡜ࡶ࡟ᖹᡂ 18 ᖺ 4 ᭶࡟᪂タࡉࢀࡓࠋ
ࠕ་⸆ရࡢ㐺ṇ
౑⏝࡟㛵ࡍࡿᩍ⫱◊✲ࠖࢆ࣓࢖ࣥࢸ࣮࣐࡟ࠊ⮫ᗋ࡛ࡢၥ㢟Ⓨぢ࡜ࡑࡢゎỴࠊ⮫ᗋ࡬ࡢࣇ࢕࣮ࢻࣂࢵ
ࢡ࡜࠸ࡗࡓ࢔ࣉ࣮ࣟࢳࢆ㏻ࡋ࡚ࠊ⸆๣ᴗົࡢ⛉Ꮫⓗᇶ┙ࡢ☜❧ࢆ┠ᣦࡋ࡚࠸ࡿࠋ
⑌ᝈ᫬࡟࠾ࡅࡿ⸆≀ືែ࡜⸆ຠゎᯒ
⮫ᗋ㛤Ⓨ࡟࠾ࡅࡿ⸆≀ືែヨ㦂ࡣࠊከࡃࡢሙྜ೺ᗣ࣎ࣛࣥࢸ࢕࢔ࢆᑐ㇟࡟ࠊే⏝⸆๣ࡢไ㝈ࡉ
ࢀࡓ᮲௳ୗ࡛⾜࡞ࢃࢀ࡚࠸ࡿࡓࡵࠊᕷ㈍ᚋ࡟⸆≀ືែ࣭⸆ຠࡢኚືᅉᏊ࡜ࡋ࡚ࠊ⸆≀㛫┦஫స
⏝ࡸ⑌ᝈࡢᙳ㡪ࢆ⪃៖ࡍࡿᚲせࡀ࠶ࡿࠋࡑࡇ࡛ࠊ⮫ᗋ࡛⤒㦂ࡋࡓ᪂つ⸆≀┦஫స⏝ࡸ⑌ᝈ᫬ࡢ
⸆≀ືែ࣭⸆ຠኚື࡟ࡘ࠸࡚ࠊࡑࡢᶵᵓࢆゎ᫂ࡋ⸆≀἞⒪࡟཯ᫎࡉࡏࡿ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ
⸆≀⾑୰⃰ᗘࣔࢽࢱࣜࣥࢢ࡜ಶู໬ᢞ୚タィ
⸆≀ືែࡢಶయᕪࡀ኱ࡁࡃࠊ࠿ࡘ἞⒪ᇦࡢ⊃࠸⸆≀࡟ࡘ࠸࡚ࡣࠊ⸆≀⾑୰⃰ᗘࣔࢽࢱࣜࣥࢢ࡟
ᇶ࡙ࡃᢞ୚タィࡀᚲせ࡜࡞ࡿࠋ㑇ఏᏊከᆺ᝟ሗࢆྵࡴ⮫ᗋࢹ࣮ࢱࢆẕ㞟ᅋ⸆≀ືែ/⸆ຠゎᯒ➼
ࡢ⤫ィᏛⓗᡭἲࢆ⏝࠸࡚ゎᯒࡋࠊᝈ⪅㞟ᅋ࡟࠾ࡅࡿ⸆≀ືែ࣭⸆ຠ≉ᛶ࡜ࡑࢀࡽࡢኚືᅉᏊࢆ
᫂ࡽ࠿࡟ࡋࠊಶู໬ᢞ୚タィἲࡢᵓ⠏ࢆ┠ᣦࡋ࡚࠸ࡿࠋ
⸆๣౑⏝ホ౯࡜⸆≀⒪ἲࡢ᭱㐺໬࡟㛵ࡍࡿ◊✲
་⸆ရ౑⏝᫬ࡢຠᯝ࣭๪స⏝࡟㛵ࡍࡿᝈ⪅᝟ሗࢆ཰㞟ࡋࠊᝈ⪅⫼ᬒᅉᏊ࡜ࡢ㛵㐃ゎᯒࢆ⾜࠺ࡇ
࡜࡛༴㝤ᅉᏊࢆᢳฟࡋࠊࡲࡓ་⒪⤒῭ⓗほⅬ࠿ࡽホ౯ࡍࡿࡇ࡜࡛ࠊ⸆≀⒪ἲࡢ᭱㐺໬ࢆࡣ࠿ࡿ
ࡓࡵࡢ⮫ᗋ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᩍဨࡣ୍ྡ࡛ࠊ኱Ꮫ㝔⏕ࡣᮍ㓄ᒓ࡛࠶ࡿࡶࡢࡢࠊᾏእḢᩥㄅࢆྵࡵᖺ㛫 3ࠥ12 ሗࡢཎⴭㄽᩥࢆⓎ
⾲ࡋ࡚࠸ࡿࡇ࡜ࠊᅜෆࡢᏛ఍࣭ࢩ࣏ࣥࢪ࣒࢘➼࡛ᣍᚅㅮ₇ࢆከࡃ⾜ࡗ࡚࠸ࡿࡇ࡜ࠊᖹᡂ 20 ᖺᗘ⮫
ᗋ⸆⌮᣺⯆㈈ᅋ➨୍ᅇ◊✲኱㈹ࢆཷ㈹ࡋ࡚࠸ࡿࡇ࡜࠿ࡽࠊᙜヱ◊✲ศ㔝࡟࠾ࡅࡿホ౯ࡣ㧗࠸࡜⪃࠼
ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸▮㔝ࡣ 4 ᅇ⏕๓ᮇ㓄ᙜࡢࠕ་⒪⸆๣Ꮫ 1ࠖࡢ༙ศཬࡧ 4 ᅇ⏕ᚋᮇ㓄ᙜࡢࠕ་⒪⸆๣Ꮫ
2ࠖࡢ඲㒊ࢆᢸᙜࡋ࡚࠸ࡿࠋࡇࢀࡽࡢᤵᴗࡣࠊ⸆๣ᖌ࡜ࡋ࡚ᚲせ࡞ᇶ♏▱㆑ࢆ⩦ᚓࡉࡏࡿ࡜࡜ࡶ࡟ࠊ
་⒪⌧ሙࡢ⮫ሙឤࡀఏࢃࡿࡼ࠺⾜ࡗ࡚࠸ࡿࠋ≉࡟ࠊ
ࠕ་⒪⸆๣Ꮫ 2࡛ࠖࡣࠊPBL Ꮫ⩦ࢆྲྀࡾධࢀࡓ₇
⩦ࡶ⾜ࡗ࡚࠸ࡿࠋࡉࡽ࡟ࠊ5 ᅇ⏕࡟࠾ࡅࡿࠕ⑓㝔ᐇົᐇ⩦࡛ࠖࡣࠊᐇ⩦㈐௵ᩍဨ࡜ࡋ࡚ி㒔኱Ꮫ་
Ꮫ㒊㝃ᒓ⑓㝔࡟ᖖ㥔ࡋࠊᐇ⩦ࡢ௻⏬࣭㐠Ⴀ࣭ホ౯ࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓࠊ௚ࡢ⸆Ꮫ㒊ᩍဨ࡜༠ຊࡋ࡚
ࠕඛ➃་⒪ SGD ₇⩦ࠖ
㸦1 ᅇ⏕ᑐ㇟㸧ཬࡧࠊ
ࠕ་⒪⸆Ꮫ࣮࣡ࢡࢩࣙࢵࣉࠖࠊ
ࠕ་⒪⸆Ꮫᐇ㦂ᢏ⾡ࠖࠊ
ࠕᏛ
⾡᝟ሗㄽࠖ㸦4ࠥ6 ᅇ⏕㸧ࢆᢸᙜࡋࠊ་⒪⸆Ꮫᩍ⫱ࡢ඘ᐇ࡟ດࡵ࡚࠸ࡿࠋࡲࡓᪧㄢ⛬࡛ࡣࠊ4 ᅇ⏕㓄
ᙜࡢ 4 㐌㛫ࡢᐇົᐇ⩦㸦ᚲಟࠊࠕ⸆Ꮫᑓ㛛ᐇ⩦ 5ࠖ㸧ࢆி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࡟࠾࠸࡚ᢸᙜࡋࡓࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸ᩍဨ㸯ྡࡢᑡேᩘศ㔝ࡢ≉ᚩࢆ⏕࠿ࡋ࡚ࠊ༞ᴗ㓄ᒓࡢᏛ⏕࡟ࡣ୎ᑀ࡞
ᣦᑟࢆᚰࡀࡅࠊಶேࢸ࣮࣐ࢆタᐃࡋ࡚◊✲⪅࡜ࡋ࡚ࡢ⣲㣴ࢆ㌟࡟௜ࡅࡉࡏࡿ࡜࡜ࡶ࡟ࠊᗈࡃ་⒪⸆
Ꮫ㛵㐃ࡢ▱㆑࣭ᢏ⬟࣭ែᗘ࡟㛵ࡍࡿᩍ⫱ࢆ⾜ࡗ࡚࠸ࡿࠋᙜศ㔝ࡢ᭱኱ࡢ≉㛗ࡣࠊ་Ꮫ㒊⮫ᗋㅮᗙࡸ
་Ꮫ㒊㝃ᒓ⑓㝔⸆๣㒊࡜ࡢඹྠ◊✲ࢆከࡃ⾜ࡗ࡚࠸ࡿⅬ࡛࠶ࡾࠊ⮫ᗋ་࣭⸆๣ᖌ࡜ࡢពぢ஺᥮ࢆ㏻
ࡋ࡚ࠊ◊✲ᡂᯝࡢ⮫ᗋⓗព⩏ࢆᖖ࡟⪃࠼࡞ࡀࡽࠊ◊✲ࡢ㐍ᒎ࡜ࣞ࣋ࣝࡢᙉ໬ࢆ┠ᣦࡋ࡚࠸ࡿࠋࢭ࣑
ࢼ࣮ࡸ◊✲Ⓨ⾲ࡣ་⒪⸆๣Ꮫศ㔝࡜ඹྠ࡛⾜࠸ࠊ⸆≀ືែ࡜⸆≀἞⒪࡟㛵ࡍࡿᑓ㛛▱㆑ࢆᗈࡃಟᚓ
ࡍࡿᶵ఍ࢆ୚࠼࡚࠸ࡿࠋࡉࡽ࡟ᪧㄢ⛬ࡢ⸆๣ᖌචチྲྀᚓᚋࡢ኱Ꮫ㝔ಟኈㄢ⛬㸦⮫ᗋ⸆Ꮫࢥ࣮ࢫ㸧࡛
ࡣࠊၥ㢟ゎỴ⬟ຊࢆᣢࡗࡓ་⒪ேࢆ㣴ᡂࡍࡿࡇ࡜ࢆ┠ⓗ࡟ࠊ⑓Ჷᴗົࢆ୰ᚰ࡜ࡋࡓࠕ⮫ᗋ⸆Ꮫᐇ⩦
ࠖ㸦6 ࣨ᭶㸧ࢆ⾜࡞ࡗ࡚ࡁࡓࠋ
− 285 −
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢᤵᴗ࡛ࡣᏛ⏕ഃ࠿ࡽࡢ࢔ࣥࢣ࣮ࢺㄪᰝࡸ⪺ࡁྲྀࡾㄪᰝࢆᐇ᪋ࡋ࡚ࠊᚓࡽࢀࡓពぢࢆཧ
⪃࡟ࡋ࡞ࡀࡽᩍ⫱ᨵၿ࡟ດࡵ࡚࠸ࡿࠋࡲࡓࠊ4 ᅇ⏕ᑐ㇟ࡢᤵᴗ࡛ࡣࠊ࡯ࡰẖᅇᑠヨ㦂ࢆᐇ᪋ࡋ㐩ᡂ
ᗘࢆ☜ㄆࡍࡿᙧᡂⓗホ౯ࢆྲྀࡾධࢀ࡚࠸ࡿࠋ௒ᖺᗘ࠿ࡽ㛤ጞࡉࢀࡓ 5 ᅇ⏕ᑐ㇟ࡢࠕ⑓㝔ᐇົᐇ⩦ࠖ
ࡣࠊᏛ⏕࠿ࡽࣂࣛࣥࢫࡢⰋ࠸඘ᐇࡋࡓᐇ⩦࡜⫯ᐃⓗ࡞ពぢࢆከࡃᚓ࡚࠸ࡿࡇ࡜࠿ࡽࠊᐇ⩦┠ᶆࡣ༑
ศ㐩ᡂࡉࢀ࡚࠸ࡿࡶࡢ࡜⪃࠼ࡽࢀࡿࠋ
◊✲ᐊ࡛ࡢᩍ⫱ࡣࠊᖹᡂ 21 ᖺᗘ࠿ࡽ⸆Ꮫ⛉ࡢ༞ᴗᐇ⩦⏕ࢆᖺ㛫㸯ྡࡎࡘཷධࢀࠊ⌧ᅾ 2 ྡࡢᏛ
⏕ࡀ㓄ᒓࡉࢀ࡚࠸ࡿࠋ᪤࡟Ꮫ㒊Ꮫ⏕ࡀᏛ఍Ⓨ⾲ࢆ⾜࠸ࠊㄽᩥసᡂࢆ⾜࠺➼ࠊ㡰ㄪ࡟◊✲ᣦᑟࡀฟ᮶
࡚࠸ࡿ࡜⪃࠼ࡽࢀࡿࠋ
㸦ཎⴭ㸧
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence
on the disposition of metformin in diabetic patients. K. Toyama, A. Yonezawa, M. Tsuda, S. Masuda, I.
Yano, T. Terada, R. Osawa, T. Katsura, M. Hosokawa, S. Fujimoto, N. Inagaki, and K. Inui, Pharmacogenet. Genomics, 20(2), 135-138 (2010).
A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients
with acute rejection. M. Fukudo, I. Yano, T. Katsura, N. Ito, S. Yamamoto, T. Kamoto, O. Ogawa, and
K. Inui, Drug Metab. Pharmacokinet., 25(5), 411-417 (2010).
Pharmacokinetics of vancomycin after intravenous administration in 3 patients implanted with vancomycin-loaded cement beads. K. Shinsako, I. Yano, Y. Okui, Y. Matsuda, and J. Kunimasa, Jpn. J. Pharm.
Care Sci., 36(11), 826-831 (2010).
A larger dosage is needed for everolimus than sirolimus to maintain the same blood concentration in
two pancreatic islet transplant patients with tacrolimus. E. Sato, I. Yano, M. Shimomura, S. Masuda, T.
Katsura, S. Matsumoto, T. Okitsu, Y. Iwanaga, S. Uemoto, and K. Inui, Drug Metab. Pharmacokinet.,
24(2), 175-179 (2009).
Prospective evaluation of the Bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation. M. Fukudo, I. Yano, K. Shinsako, T. Katsura, Y. Takada, S. Uemoto,
and K. Inui, J. Clin. Phamacol., 49(7), 789-797 (2009).
A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients
based on routine trough monitoring data. S. Omote, Y. Yano, T. Hashida, S. Masuda, I. Yano, T. Katsura,
and K. Inui, Biol. Pharm. Bull., 32(1), 99-104 (2009).
Population analysis of myelosuppression profiles using routine clinical data after combination cancer
chemotherapy. Y. Yano, T. Kodawara, H. Hongo, I. Yano, Y. Kishi, J. Takahashi, and K. Inui, J. Pharm.
Sci., 98(11), 4402-4412 (2009).
Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. A.
Yokomasu, I. Yano, E. Sato, S. Masuda, T. Katsura, and K. Inui, Biopharm. Drug Disp., 30(9), 517-523
(2009).
⸆Ꮫᐇົᐙᩍဨࡢ⌧≧࡟㛵ࡍࡿ࢔ࣥࢣ࣮ࢺㄪᰝ◊✲㸬▮㔝⫱Ꮚ㸪஭㛵 ೺㸪ᮾᾏᯘᚭ㸪㟷ᒣ㝯
ኵ㸪ᮌὠ⣧Ꮚ㸪୰ᮧ ᆒ㸪⸨஭ಇᚿ㸪Ώ㑔⨾ᬛ␃㸪㔝⏣ᖾ⿱㸪⬥ᒇ⩏ᩥ㸪᳃⏣㑥ᙪ㸪 ᡭᔱ኱
㍜㸪஧⚄ᖾḟ㑻㸪་⒪⸆Ꮫ, 35(1), 43-49 (2009).
᪂つᢠᝏᛶ⭘⒆⸆ࢸࣔࢰ࣑ࣟࢻࡢ࢝ࣉࢭࣝ㛤ᑒᚋࡢ⁐ᾮ୰࡛ࡢᏳᐃᛶ࡟㛵ࡍࡿホ౯㸬 ྂಥᏕ
᫂㸪Ỉ㔝▱⾜㸪⏣ୖ⿱⨾㸪ᶫ⏣ ஽㸪▮㔝⫱Ꮚ㸪᱇ ᩄஓ㸪஝ ㈼୍, ⸆Ꮫ㞧ㄅ, 129(3), 353-357
(2009).
㐀⾑ᖿ⣽⬊⛣᳜ᝈ⪅࡟࠾ࡅࡿ࢝ࣝࢩࢽ࣮ࣗࣜࣥ㜼ᐖ๣࡜࢔ࢰ࣮ࣝ⣔ᢠ┿⳦๣ࡢ⸆≀ືែᏛⓗ
┦஫స⏝ࡢホ౯. 㧗ᔱ⨾Ꮨ㸪㇂ཱྀ⌮Ἃ㸪▮㔝⫱Ꮚ㸪⏥㔝㈗ஂ㸪ᶫ⏣ ஽㸪ቑ⏣ᬛඛ㸪 ▼ᕝ㝯
அ㸪ෆᒣ ༟㸪஝ ㈼୍, ་⒪⸆Ꮫ, 35(4), 233-239 (2009).
ࣅࣥ࢝࢔ࣝ࢝ࣟࢻ⣔ᢠࡀࢇ๣ࡢ≀⌮໬Ꮫⓗ≉ᛶ࡟ཬࡰࡍ ᗘኚ໬ࡢᙳ㡪. ᑠᓥ୍᫭㸪ᑎ⏣ᬛ
♸㸪ὠ⏣┿ᘯ㸪ᶫ⏣ ஽㸪▮㔝⫱Ꮚ㸪஝ ㈼୍㸪᪥⑓⸆ㄅ, 45(5), 681-684 (2009).
㟁Ꮚ࢝ࣝࢸᑟධᚋࡢㄪ๣ᴗົ࡟࠾ࡅࡿ⸆Ꮫⓗ௓ධࡢ᳨ウ㸬᪂㏕ᜨᏊ㸪ⱝᮡ༤Ꮚ㸪Ᏻ⏣ᖾ௦㸪Ἑ
㷂⫱௦㸪㊊㐩ᑦ⨾㸪ᖹሯ⌮ᜨ㸪▮㔝⫱Ꮚ㸪஝ ㈼୍㸪་⒪⸆Ꮫ, 35(8), 558-563 (2009).
ᢠࡀࢇ๣㐃᪥ᢞ୚᫬ࡢไྤ⒪ἲࡢᐇែㄪᰝ࡜ホ౯㸬 ඤ⋢ᖾಟ㸪ᑎ⏣ᬛ♸㸪㧗ᶫ୍ᰤ㸪▮㔝⫱
Ꮚ㸪஝ ㈼୍㸪་⒪⸆Ꮫ, 35(9), 609-614 (2009).
እ᮶໬Ꮫ⒪ἲ㒊࡟࠾ࡅࡿ⥅⥆ⓗ࡞⸆Ꮫⓗ⟶⌮Ѹᝈ⪅ᩍ⫱ࢩࢫࢸ࣒ࡢᵓ⠏࡜ࣇ࢓࣮࣐ࢩ࣮ࣗࢸ࢕
࢝ࣝࢣ࢔࡬ࡢྲྀࡾ⤌ࡳ㸬⚃ ༓ెᏊ㸪ᑠᯘᨻᙪ㸪ᑎ⏣ᬛ♸㸪▮㔝⫱Ꮚ㸪ᯇᮏ⦾ᕭ㸪ᰗཎ୍ᗈ㸪
⚟ᓥ㞞඾㸪஝ ㈼୍㸪་⒪⸆Ꮫ. 35(12), 866-874 (2009).
− 286 −
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. M. Fukudo, I. Yano, A. Yoshimura, S. Masuda,
M. Uesugi, K. Hosohata, T. Katsura, Y. Ogura, F. Oike, Y. Takada, S. Uemoto, and K. Inui, Pharmacogenet. Genomics, 18(5) 413-423 (2008).
Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. A.
Yokomasu, I. Yano, E. Sato, S. Masuda, T. Katsura, and K. Inui, Drug Metab. Pharmacokinet., 23(6),
469-475 (2008).
㧗║ᅽᝈ⪅࡟࠾ࡅࡿ࢔ࢭࢱࢰ࣑ࣛࢻᢞ୚㔞࡜๪స⏝Ⓨ⌧ࡢ༴㝤ᅉᏊ࡟㛵ࡍࡿ᳨ウ㸬ᮌᑎᗣ⿱㸪
⏥㔝㈗ஂ㸪▮㔝⫱Ꮚ㸪⏣㎶ᬗ௦㸪ྜྷᮧ㛗ஂ㸪஝ ㈼୍㸪᪥⑓⸆ㄅ, 44(5): 744-746 (2008).
ࡀࢇ໬Ꮫ⒪ἲ࡟ࡼࡿᝏᚰ࣭჎ྤࡢᛶᕪ㸬㉥⃝㯞⾰Ꮚ㸪ᶫ⏣ ஽㸪▮㔝⫱Ꮚ㸪᱇ ᩄஓ㸪㧗ᓥᖾ
ᜨ㸪ᡭⰋྥ⪽㸪ᯇᮏ⦾ᕭ㸪ᰗཎ୍ᗈ㸪⚟ᓥ㞞඾㸪஝ ㈼୍㸪་⒪⸆Ꮫ, 34(8), 742-747 (2008).
ᢠจᅛ⸆࠾ࡼࡧ⾑ᅽ㝆ୗ⸆ࡢᡭ⾡๓ࡢ㐺ษ࡞ఇ⸆ᮇ㛫タᐃ࡬ࡢྲྀࡾ⤌ࡳ㸬 ᑿୖ㞞ⱥ㸪㇈ ᭷
⣖㸪ᑎ⏣ᬛ♸㸪ᶫ⏣ ஽㸪▮㔝⫱Ꮚ㸪ゅᒣṇ༤㸪஝ ㈼୍, ་⒪⸆Ꮫ, 34(8), 773-780 (2008).
ᡂே㞴἞ᛶ࡚ࢇ࠿ࢇᝈ⪅࡟࠾ࡅࡿࢡࣟࣂࢨ࣒࠾ࡼࡧάᛶ௦ㅰ≀ࡢయෆືែ࡟㛵ࡍࡿゎᯒ㸬Ᏻ⏣
ᖾ௦㸪▮㔝⫱Ꮚ㸪໭ᮧ᭸Ꮚ㸪ᶫ⏣ ஽㸪ᮌୗ┿ᖾᏊ㸪ụ⏣᫛ኵ㸪㧗ᶫⰋ㍜㸪஝ ㈼୍㸪TDM
◊✲, 25(4): 165-169 (2008).
⸆Ꮫᩍ⫱භᖺไ࡟ྥࡅࡓእ᮶⸆๣஺௜ᐇ⩦ࡢྲྀࡾ⤌ࡳ࡜ࡑࡢホ౯. ᏳᏞᏊⰧ⨾㸪㧗ᶫ୍ᰤ㸪ᒸ
ᮧࡳࡸᏊ㸪ᶫ⏣ ஽㸪▮㔝⫱Ꮚ㸪஝ ㈼୍, ᪥⑓⸆ㄅ, 44(11), 1629-1632 (2008).
㟁Ꮚ࢝ࣝࢸᑟධ࡟క࠺␲⩏↷఍ࡢ㉁ⓗྥୖ࡜⸆๣ᖌࡢᙺ๭. ᮌୗ㔛⣪㸪ྂ⏣♸⨾Ꮚ㸪ᒸᮧࡳࡸ
Ꮚ㸪୸ᒣᚿ✑Ꮚ㸪ᑿᓮ῟Ꮚ㸪㧗ᶫ୍ᰤ㸪▮㔝⫱Ꮚ㸪஝ ㈼୍, ᪥⑓⸆ㄅ, 44(2), 265-267 (2008).
Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine and effects of
CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. M. Jiko, I. Yano, E. Sato, K.
Takahashi, H. Motohashi, S. Masuda, M. Okuda, N. Ito, E. Nakamura, T. Segawa, T. Kamoto, O.
Ogawa, and K. Inui, Int. J. Clin. Oncol., 12(4), 284-290 (2007).
Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. K. Takahashi, I. Yano, Y. Fukuhara, T. Katsura, T. Takahashi, N. Ito, S. Yamamoto, O.
Ogawa, K. Inui, Drug Metab. Pharmacokinet., 22(6), 441-444 (2007).
㠀ᑠ⣽⬊⫵⒴ᝈ⪅࡟ᑐࡍࡿࢤࣇ࢕ࢳ࢕ࢽࣈ᭹⏝㛤ጞ᫬ࡢᝈ⪅ᩍ⫱ࢩࢫࢸ࣒ᵓ⠏ࡢヨࡳ㸬⚃ ༓
ెᏊ㸪▮㔝⫱Ꮚ㸪᱇ ᩄஓ㸪ᅬ㒊 ㄔ㸪⏣୰ᩥၨ㸪࿴⏣ὒᕭ㸪஝ ㈼୍, ་⒪⸆Ꮫ. 33(1), 1-7 (2007).
᪂つᢠ⢭⚄⑓⸆ࡢ⮫ᗋᑟධ࡟క࠺ฎ᪉ෆᐜࡢኚ໬㸸኱Ꮫ⑓㝔⢭⚄⛉እ᮶࡟࠾ࡅࡿ᳨ウ. Ṋ⏣ග
ຍ㸪ᑠᯘᨻᙪ㸪Ἑᓮ⫱௦㸪ῐ㔝ⰾஂ㸪ⱝᮡ༤Ꮚ㸪኱㔝᫂ὒ㸪▮㔝⫱Ꮚ㸪ᒸ⏣ ಇ㸪ᯘ ᣅ஧㸪
஝ ㈼୍, ་⒪⸆Ꮫ, 33(1), 60-65 (2007).
EMIT ἲ࡟ࡼࡿ࣑ࢥࣇ࢙ࣀ࣮ࣝ㓟⾑୰⃰ᗘ ᐃ࡜ HPLC ἲ࡜ࡢẚ㍑࡟ࡼࡿ⾑୰⃰ᗘホ౯㸬ྂಥ
Ꮥ᫂㸪ྜྷ⏣ඃᏊ㸪⃝⏣ிᏊ㸪ቑ⏣ᬛඛ㸪▮㔝⫱Ꮚ㸪஝ ㈼୍, ་⒪⸆Ꮫ, 33(9), 804-808 (2007).
ຍ㱋㯤ᩬኚᡂ⑕ࡢග⥺ຊᏛⓗ⒪ἲ࡟࠾ࡅࡿ⸆๣ᴗົѸ࣋ࣝࢸ࣏ࣝࣇ࢕ࣥѸࡢㄪ〇࡜ᝈ⪅ᣦᑟ.
⏥㔝㈗ஂ㸪ᶫ⏣ ஽㸪ⱝᮡ༤Ꮚ㸪▮㔝⫱Ꮚ㸪⏣ᮧ ᐶ㸪㎷ᕝ᫂Ꮥ㸪኱㇂⠜ྐ㸪ྜྷᮧ㛗ஂ㸪஝ ㈼
୍, ᪥⑓⸆ㄅ. 43(10), 1377-1380 (2007).
Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor
liver transplant recipients. M. Fukudo, I. Yano, S. Masuda, M. Goto, M. Uesugi, T. Katsura, Y. Ogura, F.
Oike, Y. Takada, H. Egawa, S. Uemoto, and K. Inui, Clin. Pharmacol. Ther., 80(4), 331-345 (2006).
Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients:
Twice daily vs. once daily dosing. M. Fukudo, I. Yano, S. Masuda, T. Katsura, Y. Ogura, F. Oike, Y.
Takada, K. Tanaka, and K. Inui, Liver Transpl., 12(2), 292-300 (2006).
Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. S. Fukatsu, M. Fukudo, S. Masuda, I. Yano, T. Katsura, Y. Ogura, F.
Oike, Y. Takada, and K. Inui, Drug Metab. Pharmacokinet., 21(2), 122-125 (2006).
Evaluation of Calvert’s formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer. E. Sato, I. Yano, M. Jiko, K. Takahashi, H. Motohashi, S. Masuda, T.
Katsura, H. Nishiyama, T. Segawa, N. Ito, T. Kamoto, O. Ogawa, and K. Inui, Biol. Pharm. Bull., 29(7),
1441-1444 (2006).
Temporal decline in sirolimus elimination immediately after pancreatic islet transplantation. E. Sato, M.
Shimomura, S. Masuda, I. Yano, T. Katsura, S. Matsumoto, T. Okitsu, Y. Iwanaga, H. Noguchi, H. Nagata, Y. Yonekawa, and K. Inui, Drug Metab. Pharmacokinet., 21(6), 492-500 (2006).
඲デ⒪⛉ࢆᑐ㇟࡜ࡋࡓࠕࡀࢇ໬Ꮫ⒪ἲㄝ᫂᭩ࠖࡢసᡂ࡜ࡑࡢά⏝㸬㧗ᰗ࿴ఙ㸪㧗ᶫ୍ᰤ㸪ᑿୖ
㞞ⱥ㸪ྂಥᏕ᫂㸪ⱝᮡ༤Ꮚ㸪ᶫ⏣ ஽㸪▮㔝⫱Ꮚ㸪ዟ⏣┿ᘯ㸪᱇ ᩄஓ㸪஝ ㈼୍, ᪥⑓⸆ㄅ, 42(1),
49-52 (2006).
እ᮶໬Ꮫ⒪ἲࣞࢪ࣓ࣥࡢⓏ㘓࡜ฎ᪉ᨭ᥼ᶵ⬟ࡢ᭷⏝ᛶ㸬㉥⃝㯞⾰Ꮚ㸪ᶫ⏣ ஽㸪▮㔝⫱Ꮚ㸪᱇
− 287 −
37.
ᩄஓ㸪໭㔝ಇ⾜㸪᳜㔝ṇஓ㸪ᯇᮏ⦾ᕭ㸪ᰗཎ୍ᗈ㸪⚟ᓥ㞞඾㸪஝ ㈼୍, ་⒪⸆Ꮫ, 32(4), 327-333
(2006).
⒴໬Ꮫ⒪ἲࡢ๪స⏝᝟ሗ⤫ྜࢆ┠ⓗ࡜ࡋࡓࢹ࣮ࢱࢩ࣮ࢺࡢᵓ⠏Ѹᢠ⭘⒆๣࣭࢖ࣥࢱ࣮ࣇ࢙ࣟࣥ
࣭ᨺᑕ⥺ే⏝⒪ἲࡢ๪స⏝᝟ሗ⤫ྜ࡜ホ౯Ѹ㸬ྂಥᏕ᫂㸪▮㔝⫱Ꮚ㸪᱇ ᩄஓ㸪∦ᒸ኱἞㸪໭
᮲㞞ே㸪㧗ᮌᗣᚿ㸪㧗ᶫ ₶㸪ᶫᮏಙኵ㸪஝ ㈼୍, ་⒪⸆Ꮫ, 32(7), 599-606 (2006).
㸦⥲ㄝ㸧
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
ච␿ᢚไ⸆࡜࢔ࢰ࣮ࣝ⣔ᢠ┿⳦⸆ࡢ⸆≀ືែᏛⓗ┦஫స⏝. ▮㔝⫱Ꮚ㸪஝ ㈼୍, ἞⒪Ꮫ㸪
43(12) 1351-1355 (2009).
Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors. I. Yano, Drug Metab. Pharmacokinet., 23(3), 150-157 (2008).
࢝ࣝࢩࢽ࣮ࣗࣜࣥ㜼ᐖ๣ࡢయෆືែ࡜⸆ຠࡢ㏿ᗘㄽⓗゎᯒ࡟ᇶ࡙ࡃಶู໬ᢞ୚タィἲ. ▮㔝⫱
Ꮚ㸪⚟ᅵᑗ⚽㸪ቑ⏣ᬛඛ㸪ᑠ಴㟹ᘯ㸪ᑿụᩥ㝯㸪⏣୰⣫୍㸪஝ ㈼୍, ⮫ᗋ⸆⌮ࡢ㐍Ṍ 2008, 29,
113-119 (2008).
ච␿ᢚไ๣ࡢయෆືែ࡜⸆ຠࡢ㏿ᗘㄽⓗゎᯒ࡟ᇶ࡙ࡃಶู໬ᢞ୚タィࢩࢫࢸ࣒ࡢ㛤Ⓨ. ▮㔝⫱
Ꮚ, ୖཎ♳ᛕ⏕࿨⛉Ꮫ㈈ᅋ◊✲ሗ࿌㞟, 22, 7 (2008).
ࢱࢡ࣒ࣟࣜࢫ⾑୰⃰ᗘࡢㄪᩚ࣓࢝ࢽࢬ࣒. ▮㔝⫱Ꮚ㸪஝ ㈼୍, ௒᪥ࡢ⛣᳜, 21(1), 17-23 (2008).
⸆≀ືែࣃ࣓࣮ࣛࢱࢆά⏝ࡋࡓ⮫ᗋ஦౛Ѹ࢝ࣝࢩࢽ࣮ࣗࣜࣥ㜼ᐖ๣࡟ࡘ࠸࡚. ▮㔝⫱Ꮚ㸪஝ ㈼
୍㸪᭶ห⸆஦, 49(9), 1359-1364 (2007).
ࡇࢀ࠿ࡽࡢ⮫ᗋ⸆๣ᖌࡢ࠶ࡾ᪉Ѹ⸆๣ᖌࡀኚ࠼ࡿ⸆≀἞⒪Ѹ. ▮㔝⫱Ꮚ, ᪥ᮏ་⒪⸆Ꮫ఍఍ሗ,
11(4), 24-29 (2007).
⏕య⫢⛣᳜⑕౛࡟࠾ࡅࡿ࢝ࣝࢩࢽ࣮ࣗࣜࣥάᛶࡢ ᐃ࡟ᇶ࡙ࡃ⸆ຠホ౯࡜ಶู໬ᢞ୚タィ. ▮
㔝⫱Ꮚ㸪஝ ㈼୍, ᭶ห⸆஦, 48(2), 269-275 (2006).
⏕య⫢⛣᳜ࡢ TDM. ▮㔝⫱Ꮚ㸪஝ ㈼୍, TDM ◊✲, 23(2), 63-64 (2006).
⮅ᓥ⛣᳜ᝈ⪅࡟࠾ࡅࡿࣛࣃ࣐࢖ࢩࣥࡢయෆືែ࡜⸆ຠ࣭๪స⏝࡟㛵ࡍࡿ᳨ウ. బ⸨ᰤ㔛Ꮚ㸪ୗ
ᮧᫀᐶ㸪ቑ⏣ᬛඛ㸪▮㔝⫱Ꮚ㸪ᅵ⏕ᗣྖ㸪᱇ ᩄஓ㸪ᯇᮏៅ୍㸪⯆ὠ ㍤㸪ᒾỌᗣ⿱㸪㔝ཱྀὒ
ᩥ㸪Ọ⏣ⱥ⏕㸪⡿ᕝᖾ⚽㸪⏣୰⣫୍㸪஝ ㈼୍㸪TDM ◊✲, 23(2)㸪85-86 (2006).
NONMEM ࢆά⏝ࡋࡓ TDM ゎᯒᨭ᥼ࢯࣇࢺ࢙࢘࢔ࡢ㛤Ⓨ. ▼ᶫ ᚭ㸪▮㔝⫱Ꮚ㸪ቑ⏣ᬛඛ㸪᱇
ᩄஓ㸪஝ ㈼୍, TDM ◊✲, 23(2), 153-154 (2006).
ᑠඣ㐀⾑ᖿ⣽⬊⛣᳜࡟࠾ࡅࡿࢩࢡࣟࢫ࣏ࣜࣥ㛫ḴⅬ⁲ἲࡢ⾑୰⃰ᗘࣔࢽࢱࣜࣥࢢ. ⃝⏣ிᏊ㸪
ᑠ㇂ᩔᏊ㸪ቑ⏣ᬛඛ㸪᱇ ᩄஓ㸪▮㔝⫱Ꮚ㸪ᯇཎ ኸ㸪ᖹᯇⱥᩥ㸪ᑠᯘ㐨ᘯ㸪㊊❧ኊ୍㸪୰⏿
㱟ಇ㸪஝ ㈼୍㸪TDM ◊✲, 23(2)㸪87-88 (2006).
⥳ෆ㞀἞⒪⸆࢔ࢭࢱࢰ࣑ࣛࢻࡢయෆືែ࡜⸆ຠࡢ㏿ᗘㄽⓗゎᯒѸ╔║Ⅼ࡜㐍ࡵ᪉ࡢ࣏࢖ࣥࢺ.
▮㔝⫱Ꮚ, ᭶ห⸆஦, 48(8)(7 ᭶⮫᫬ቑหྕࠊ஝ ㈼୍┘ಟ), 1289-1293 (2006).
࢝ࣝࢩࢽ࣮ࣗࣜࣥ㜼ᐖ๣ࡢ pharmacodynamics ࡜⮳㐺ᢞ୚タィ. ⚟ᅵᑗ⚽㸪▮㔝⫱Ꮚ㸪ቑ⏣ᬛඛ㸪
᱇ ᩄஓ, ᑠ಴㟹ᘯ, ᑿụᩥ㝯, 㧗⏣Ὀḟ, ୖᮏఙ஧, ⏣୰⣫୍, ஝ ㈼୍, ௒᪥ࡢ⛣᳜㸪
19(6)㸪658-660 (2006).
㸦ⴭ᭩㸧
1.
2.
3.
4.
5.
6.
Important drug interactions for clinical oncologists. H. Ishiguro, I. Yano, and M. Toi, In: Frontiers in
Drug Design and Discovery vol. 4, G.W. Caldwell, A. Z. Yan, and M. I. Choudhary (Eds.), Bentham
Science Publishers Ltd., pp.97-121 (2009).
Pharmacogenomic considerations in breast cancer management. H. Ishiguro, I. Yano, and M. Toi, In:
Frontiers in Drug Design and Discovery vol. 4, G.W. Caldwell, A. Z. Yan, and M. I. Choudhary (Eds.),
Bentham Science Publishers Ltd., pp.122-134 (2009).
➨ 3 ❶ࢺࣛࣥࢫ࣏࣮ࢱ࣮◊✲ࡢ⮫ᗋᛂ⏝ 2) ⸆≀┦஫స⏝ 2 ࢪࢦ࢟ࢩࣥࡢ⸆≀┦஫స⏝࡟㛵ࢃ
ࡿࢺࣛࣥࢫ࣏࣮ࢱ࣮. ▮㔝⫱Ꮚ, ⸆≀ࢺࣛࣥࢫ࣏࣮ࢱ࣮ά⏝ࣛ࢖ࣈ࣮ࣛࣜ ᶵ⬟࣭㍺㏦ᇶ㉁࠿
ࡽ๰⸆࣭⮫ᗋᛂ⏝ࡲ࡛, ஝ ㈼୍⦅, ⨺ᅵ♫, pp. 169-171 (2009).
➨ 2 ❶ ་⒪࡜⸆๣ᖌ. ▮㔝⫱Ꮚ, ་⒪⸆Ꮫ➨ 5 ∧, ᇼ ஢ᖹ┘ಟ, ஝ ㈼୍, ዟᮧ຾ᙪ⦅㞟, ᘅ
ᕝ᭩ᗑ, pp.7-28 (2009).
➨ 4 ❶ ฎ᪉ࡏࢇ࡜ㄪ๣. ▮㔝⫱Ꮚ, ་⒪⸆Ꮫ➨ 5 ∧, ᇼ ஢ᖹ┘ಟ, ஝ ㈼୍, ዟᮧ຾ᙪ⦅㞟,
ᘅᕝ᭩ᗑ, pp.49-79 (2009).
➨ 10 ❶ ⸆≀⒪ἲ࡜ฎ᪉ 10.5 ⮚ჾ⛣᳜᫬ࡢ⸆≀⒪ἲ࡜ฎ᪉.▮㔝⫱Ꮚ, ་⒪⸆Ꮫ➨ 5 ∧, ᇼ
− 288 −
஢ᖹ┘ಟ, ஝ ㈼୍, ዟᮧ຾ᙪ⦅㞟, ᘅᕝ᭩ᗑ, pp.356-368 (2009).
7. 8.2 Therapeutic drug monitoring and individualized therapy with tacrolimus in recipients of living-donor liver transplantation. I. Yano, S. Masuda, and Inui, K. In: Evolution of living-donor liver
transplantation, K. Tanaka, Y. Inomata, S. Uemoto, and T. Kiuchi (Eds), Thomson Reuters, pp. 217-231
(2008).
8. ➨ 1 ❶ ་⒪ࡢ㉁ⓗྥୖࢆࡵࡊࡋࡓ⸆๣ᖌࡢྲྀࡾ⤌ࡳ 5 ࣂࣝࣅࢶ࣮ࣞࢺ⒪ἲ᫬ࡢࢳ࢜࣌ࣥࢱ࣮
ࣝయෆືែ࡜⬻Ṛุᐃ᫬࡟࠾ࡅࡿయไᩚഛ㸬▮㔝⫱Ꮚ, ⸆๣ᖌࡀኚ࠼ࡿ⸆≀἞⒪㸰ѸᏳ඲࡞ࡀࢇ
἞⒪࡜ࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪࡟ྥࡅ࡚Ѹ, ஝ ㈼୍┘ಟ, ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔⸆๣㒊⦅ⴭ, ࡌ
࡯࠺, pp. 43-48 (2007).
9. ➨ 3 ❶ ࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪࡟ྥࡅࡓ⸆๣ᖌࡢྲྀࡾ⤌ࡳѸ⮚ჾ⛣᳜་⒪ࢆ୰ᚰ࡟ 6 ࢝ࣝࢩࢽࣗ
࣮ࣜࣥάᛶ࡟ᇶ࡙ࡃ⸆ຠホ౯࡜ಶู໬ᢞ୚タィ㸬▮㔝⫱Ꮚ, ⸆๣ᖌࡀኚ࠼ࡿ⸆≀἞⒪㸰ѸᏳ඲࡞
ࡀࢇ἞⒪࡜ࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪࡟ྥࡅ࡚Ѹ, ஝ ㈼୍┘ಟ, ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔⸆๣㒊⦅
ⴭ, ࡌ࡯࠺, pp.161-168 (2007).
10. ➨ 2 ❶ ࢳ࣮࣒་⒪࡟ὀ┠ࡍࡿ SBOs 4-6㸬▮㔝⫱Ꮚ, ஝ ㈼୍, ࢫࢱࣥࢲ࣮ࢻ⸆Ꮫࢩ࣮ࣜࢬ 10.
ᐇົᐇ⩦஦๓Ꮫ⩦㸸⑓㝔࣭⸆ᒁᐇ⩦࡟⾜ࡃ๓࡟, ᪥ᮏ⸆Ꮫ఍⦅, ᮾி໬Ꮫྠே, pp. 11-16 (2006).
11. ➨ 5 ❶ ་⒪⸆๣Ꮫ 5.1 ་⒪࡜⸆๣ᖌ㸬▮㔝⫱Ꮚ, ஝ ㈼୍, ᭱᪂⸆๣Ꮫ➨ 9 ∧, ᯘ ṇᘯ㸪
ᕝᓥ჆᫂㸪஝ ㈼୍⥲⦅㞟, ᘅᕝ᭩ᗑ, pp. 425-444 (2006).
12. ➨Ϩ㒊 ⸆⌮Ꮫࡢᇶ♏㸪2 ⸆ຊᏛ. ▮㔝⫱Ꮚ㸦ヂ㸧, ࣁ࣮ࣂ࣮ࢻ኱Ꮫࢸ࢟ࢫࢺ ⑓ែ⏕⌮࡟ᇶ࡙
ࡃ⮫ᗋ⸆⌮Ꮫ㸪Ύ㔝 ⿱㸦᪥ᮏㄒ┘ಟ㸧㸪஝ ㈼୍㸪⚟ᒣ⚽┤㸪ᇼỤ ⛱㸪㉺ᒣ⿱⾜㸪୕ᔱ⌮
᫭㸪୍ᒣ ᬛ㸪୕᳃⤒ୡ㸦ࣃ࣮ࢺ┘ヂ㸧㸪࣓ࢹ࢕࣭࢝ࣝࢧ࢖࢚ࣥࢫ࣭࢖ࣥࢱ࣮ࢼࢩࣙࢼࣝ㸪 pp.
17-27 (2006).
− 289 −
⑓ែᶵ⬟ศᯒᏛศ㔝㸦⎔ቃ⸆ရไᚚᏛศ㔝ࢆྵࡴ㸧
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧బ἞ⱥ㑻㸦ࡉࡌ ࡦ࡛࠾㸧㸦1996.4 ╔௵㸧
᫛࿴㸲㸷ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸳㸯ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬๓ᮇㄢ⛬ಟ஢ࠊ᫛࿴㸳㸯ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ᚋᮇㄢ⛬㏥Ꮫࠊ᫛࿴㸳㸳ᖺி㒔኱Ꮫ⸆Ꮫ༤ኈྲྀᚓ
෸ᩍᤵ㸦⸆Ꮫ༤ኈ㸧ஂୗ⿱ྖ㸦ࡃࡆ ࡺ࠺ࡌ㸧㸦2007.10 ໭ᾏ㐨኱
Ꮫ RI ࢭࣥࢱ࣮ᩍᤵ࡟㌿ฟ㸧᫛࿴㸴㸮ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸴㸰
ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢ࠊᖹᡂ㸶ᖺி㒔኱Ꮫ༤
ኈ㸦⸆Ꮫ㸧ྲྀᚓ
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧ᑠ㔝ṇ༤㸦࠾ࡢ ࡲࡉࡦࢁ㸧㸦2007.12 ᥇
⏝㸧ࠊᖹᡂ㸵ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸱ᖺྠ኱Ꮫ኱Ꮫ㝔
⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
ຓᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧ኳ⁹ ᩗ㸦࡚ࢇࡲ ࡓ࠿ࡋ㸧㸦2004.1 ᥇⏝㸧
ᖹᡂ㸯㸰ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸲ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢ࠊᖹᡂ㸯㸴ᖺྠ኱Ꮫ኱
Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬㏥Ꮫࠊᖹᡂ㸰㸮ᖺி㒔኱Ꮫ༤ኈ㸦⸆Ꮫ㸧ྲྀᚓ
≉ᐃຓᩍ㸦⸆Ꮫ༤ኈ㸧ᮌᮧᐶஅ㸦ࡁࡴࡽ ࡦࢁࡺࡁ㸧㸦2006.4 ᥇⏝㸧
ᖹᡂ㸯㸱ᖺி㒔⸆⛉኱Ꮫ༞ࠊᖹᡂ㸯㸳ᖺྠ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢ࠊᖹᡂ㸯㸶ᖺி㒔኱Ꮫ኱
Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢ࠊᖹᡂ㸯㸶ᖺி㒔኱Ꮫ⸆Ꮫ༤ኈྲྀᚓ
≉ᐃຓᩍ㸦⛉Ꮫᢏ⾡᣺⯆㸧㸦⸆Ꮫ༤ኈ㸧బ㔝⣫ᖹ㸦ࡉࡢ ࡇ࠺࡬࠸㸧㸦2010.4 ᥇⏝㸧
ᖹᡂ㸯㸴ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸶ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢
ᖹᡂ㸰㸯ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢ࠊᖹᡂ㸰㸯ᖺி㒔኱Ꮫ⸆Ꮫ༤ኈྲྀᚓ
◊✲ࡢᴫせ
⏕యࡣከࡃࡢศᏊࡀ┦஫స⏝ࡍࡿࡇ࡜࡟ࡼࡗ࡚ࠊከᵝ࡞ᶵ⬟ࢆႠࢇ࡛࠸ࡿࠋࡋࡓࡀࡗ࡚ࠊ⏕యࡢᶵ
⬟ࢆゎ᫂ࡍࡿࡓࡵ࡟ࡣศᏊ࡛ࣞ࣋ࣝࡢ┦஫స⏝ࡢゎᯒࡀᚲせ࡛࠶ࡿࠋᙜ⑓ែᶵ⬟ศᯒᏛศ㔝࡛ࡣࠊග
㔞Ꮚᢏ⾡ࢆ⏝࠸ࡿࡇ࡜࡟ࡼࡾࠊ⏕ࡁ࡚ᶵ⬟ࡋ࡚࠸ࡿ≧ែ࢖ࣥࣅ࣎ࡢ⏕యࢆᑐ㇟࡜ࡋ࡚ࠊࡑࡢ୰࡛㉳
ࡇࡗ࡚࠸ࡿศᏊࡢ┦஫స⏝ࢆ✵㛫ⓗ࣭᫬㛫ⓗ࡟ศᏊ࡛ࣞ࣋ࣝయእ࠿ࡽࣜ࢔ࣝࢱ࢖࣒࡛ྍど໬ࡋ࡚ᤊ࠼
ࡿ⏕యᶵ⬟ゎᯒἲ㸦ศᏊ࢖࣓࣮ࢪࣥࢢἲ㸧ࢆ㛤Ⓨࡋࠊࡑࢀࢆᇶ┙࡜ࡋ࡚⏕యᶵ⬟ࡸ⭘⒆ࠊ⬻⚄⤒⑌ᝈࠊ
ᚰ⑌ᝈࠊ⾑ᰦࠊ⢾ᒀ⑓࡞࡝ࡢ㌟యࡢᶵ⬟ኚ໬࡟ᇶ࡙ࡃෆᅉᛶ⑌ᝈࡢ⑓ែࡢ௙⤌ࡳࡢゎ᫂࡜⸆≀స⏝ᶵ
ᗎ࣭ຠᯝࡢゎᯒࠊ⑓ែࡢ≉ᛶ࡟ᇶ࡙ࡃᶵ⬟ᛶ⏬ീデ᩿⸆࠾ࡼࡧᨺᑕᛶ἞⒪⸆ࡢ๰〇࡟㛵ࡍࡿ◊✲࠾ࡼ
ࡧࡑࢀࡽࢆᐇ㊶ࡍࡿ◊✲⪅ࡢ⫱ᡂ࡟ᣮᡓࡋ࡚࠸ࡿࠋ
㸯㸧⏕యᶵ⬟ࠊ⑓ែࡢ௙⤌ࡳࠊ⸆≀స⏝ᶵᗎࢆศᏊ࡛ࣞ࣋ࣝ࢖ࣥࣅ࣎ゎᯒࡍࡿࡓࡵࡢศᏊ࢖࣓࣮ࢪࣥ
ࢢἲࡢ㛤Ⓨ
⏕యෆ࡛ࡣᖖ࡟ศᏊࡀ┦஫స⏝ࡋ࡚࠸ࢁ࠸ࢁ࡞཯ᛂࢆ㉳ࡇࡋࠊືⓗ࡟ኚ໬ࡋ࡚࠸ࡿࠋ⏕యᶵ⬟ࢆゎ
᫂ࡍࡿࡓࡵ࡟ࠊᚑ᮶ࡣᑐ㇟ศᏊࡢ཯ᛂࢆヨ㦂⟶ࡸ⣽⬊ࢆ⏝࠸࡚ゎᯒࡋ࡚ࡁࡓࡀࠊ⏕య࡜࠸࠺ࠊከࡃ
ࡢศᏊ཯ᛂࡀ஫࠸࡟㛵㐃ࡋ࡚ᖖ࡟ኚ໬ࡋ࡚࠸ࡿሙྜ࡟ࡣࠊᚑ᮶ࡢゎᯒ࡟ຍ࠼ࠊ᪂ࡓ࡟࢖ࣥࣅ࡛࣎ࡢ
ศᏊ཯ᛂࡢ᫬㛫ⓗ࣭✵㛫ⓗ࡞ゎᯒࡀᚲせ࡛࠶ࡿࠋࡑࡇ࡛ࠊᚠ⎔࣭௦ㅰᶵ⬟ࠊᚤᑠ⤌⧊⎔ቃࠊ⚄⤒ఏ
㐩ᶵ⬟࡞࡝ࡢ⏕యᶵ⬟ࢆᑐ㇟࡜ࡋ࡚ࠊᨺᑕ⥺ࢆࡣࡌࡵ࡜ࡍࡿග㔞Ꮚᢏ⾡ࢆ⏝࠸࡚ࠊศᏊ཯ᛂࢆ࢖ࣥ
ࣅ࡛࣎ᐃ㔞ゎᯒࡍࡿࡓࡵࡢ᪂つ⏕యᶵ⬟ゎᯒἲࠊศᏊ࢖࣓࣮ࢪࣥࢢἲࡢ㛤Ⓨࢆヨࡳࠊ᪂ࡋ࠸㧗ឤᗘࠊ
㧗ゎീຊ࢖࣓࣮ࢪࣥࢢࢩࢫࢸ࣒ࡢ㛤Ⓨࠊ⬻ࠊᚰ➽ࠊ⭘⒆ࠊ㦵࡞࡝ࢆᑐ㇟࡜ࡋࡓ㧗ឤᗘᶵ⬟ศᯒヨ⸆
࡛࠶ࡿศᏊࣉ࣮ࣟࣈࡢタィ࣭㛤Ⓨࠊ⏕యᶵ⬟ࡢ࢖ࣥࣅ࣎ᐃ㔞ゎᯒἲࡢ㛤Ⓨࢆ⾜ࡗࡓࠋ≉࡟ࠊ⚄⤒ఏ
㐩≀㉁ࡢࢺࣛࣥࢫ࣏࣮ࢱ࣮ࡸࣞࢭࣉࢱ࣮ࡢศᏊ࢖࣓࣮ࢪࣥࢢ࡟᭷ຠ࡞ศᏊࣉ࣮ࣟࣈࡢ㛤Ⓨ࡜ࡑࢀ࡟
ࡼࡿᶆⓗᶵ⬟ࡢᐃ㔞ゎᯒࠊ୙Ᏻᐃࣉ࣮ࣛࢡ࡟࠾ࡅࡿࢫ࢝࣋ࣥࢪ࣮ࣕࣞࢭࣉࢱ࣮ࠊ⢾௦ㅰࠊࢱࣥࣃࢡ
ศゎ㓝⣲࡟᭷ຠ࡞ศᏊࣉ࣮ࣟࣈࡢ㛤Ⓨ࡜ࡑࢀ࡟ࡼࡿᶆⓗᶵ⬟ࡢᐃ㔞ゎᯒࠊ࢔ࣝࢶࣁ࢖࣐࣮⑓࡛㉳ࡇ
ࡿș࢔࣑ࣟ࢖ࢻ࠾ࡼࡧࢱ࢘⺮ⓑࡢจ㞟࣭⵳✚㐣⛬ࡢศᏊ࢖࣓࣮ࢪࣥࢢ࡟᭷ຠ࡞ศᏊࣉ࣮ࣟࣈࡢ㛤Ⓨ
࡞࡝࡟ᡂຌࡋࡓࠋ
㸰㸧⑓ែࡢ≉ᛶ࡟ᇶ࡙ࡃᶵ⬟ᛶ⏬ീデ᩿⸆࠾ࡼࡧᨺᑕᛶ἞⒪⸆ࡢ๰〇
⮫ᗋ⏬ീデ᩿ࡣᢠ⏕≀㉁ࡢ฼⏝࡞࡝࡜࡜ࡶ࡟⌧௦་Ꮫࢆኚ࠼ࡓࡶࡢࡢࡦ࡜ࡘ࡜࠸ࢃࢀ࡚࠸ࡿࠋࡇࡢ
⏬ീデ᩿࡟ࡣ✀ࠎࡢᡭἲࡀ⏝࠸ࡽࢀ࡚࠸ࡿࡀࠊ㧗࠸≀㉁㏱㐣ᛶࢆ᭷ࡍࡿᨺᑕ⥺㸦Ț⥺㸧࡛ᶆ㆑ࡉࢀ
ࡓᨺᑕᛶ໬ྜ≀ࢆศᏊࣉ࣮ࣟࣈ࡜ࡍࡿ᰾་Ꮫ⏬ീデ᩿ࡣࡑࡢ୍ࡘ࡛࠶ࡿࠋࡑࡇ࡛ࠊ⬻ࡸᚰ➽ࡢ⑌ᝈࠊ
⭘⒆➼࡟≉␗ⓗ࡞ᚤᑠ⎔ቃࡢኚ໬ࡸⓎ⌧ࢱࣥࣃࢡ㉁ࢆᶆⓗ࡜ࡋࡓࠊ⑓ែࡢ≉ᛶ࡟ᇶ࡙ࡃᶵ⬟ᛶᨺᑕ
ᛶศᏊࣉ࣮ࣟࣈࡢ๰〇࡜ࡑࡢ⮫ᗋ฼⏝࡟㛵ࡍࡿ◊✲ࢆ⾜ࡗࡓࠋ౛࠼ࡤࠊ⬻᱾ሰࡸᚰ➽᱾ሰࡢ୺࡞ཎ
− 290 −
ᅉ࡛࠶ࡿື⬦◳໬୙Ᏻᐃࣉ࣮ࣛࢡࡢデ᩿ࡢࡓࡵ࡟ࠊ) ᶆ㆑ࢢࣝࢥ࣮ࢫㄏᑟయࣉ࣮ࣟࣈࢆ⏝࠸ࡿࡇ
࡜ࡢ᭷ຠᛶࠊ07003 ࡸ /2; ࡟⤖ྜࡍࡿ࢖ࣥࣅ࣎᰾་Ꮫ࠾ࡼࡧ⺯ග࢖࣓࣮ࢪࣥࢢ⏝ࣉ࣮ࣟࣈࢆ㛤
Ⓨࡋࡓࠋࡲࡓࠊ⸆≀⒪ἲࡸᨺᑕ⥺἞⒪࡟ᑐࡍࡿ᢬ᢠᛶ࡟㛵୚ࡍࡿ⭘⒆ࡢప㓟⣲㡿ᇦࢆ࢖࣓࣮ࢪࣥࢢ
࡛ࡁࡿ࢖ࣥࣅ࣎᰾་Ꮫ࠾ࡼࡧ⺯ග࢖࣓࣮ࢪࣥࢢ⏝ศᏊࣉ࣮ࣟࣈࡢ㛤Ⓨ◊✲࡟ࡶᡂຌࡋࡓࠋ
ࡲࡓࠊᨺᑕ⥺ș⥺ࡢ⣽⬊㞀ᐖᛶࢆ฼⏝ࡋ࡚ࠊデ᩿⸆ࡢ㛤Ⓨ࡛ᚓࡽࢀࡓ໬ྜ≀ࡢ㒊఩≉␗ⓗ㞟✚ᛶ
࡟㛵ࡍࡿ◊✲ᡂᯝ࡟ᇶ࡙࠸࡚ࠊ⣽⬊㞀ᐖᛶࡢ㧗࠸ᨺᑕᛶ᰾✀ࢆᵓᡂඖ⣲࡜ࡋ࡚ྵ᭷ࡍࡿࠊ⭘⒆ࡸ㦵
⑊③ࡢෆ⏝ᨺᑕ⥺἞⒪⸆㸦ෆ㒊↷ᑕ⸆㸧ࡢ㛤Ⓨࡶ㐍ࡵ࡚࠾ࡾࠊᡭ⾡ࡸ໬Ꮫ⒪ἲࡢ㐺ᛂࡀ㞴ࡋ࠸⭘⒆
ࡸ㦵⑊③⦆࿴἞⒪࡟᭷ຠ࡞໬ྜ≀ࡢ㛤Ⓨ࡟ᡂຌࡋࡓࠋ
㸱㸧ᚤ㔞㔠ᒓඖ⣲ࡢ⏕యస⏝ࡢゎ᫂࠾ࡼࡧࡑࢀࢆᇶ♏࡜ࡍࡿ⏕⌮άᛶ㔠ᒓ㘒໬ྜ≀ࡢ๰〇
⬻⹫⾑ࠊ࢔ࣝࢶࣁ࢖࣐࣮⑓ࠊ⢾ᒀ⑓࡞࡝࡟࠾ࡅࡿள㖄ࠊ㖡ࠊ㕲࡞࡝ࡢ⏕యෆᚤ㔞㔠ᒓඖ⣲ࡢ㛵୚ࢆ
᳨ウࡍࡿ࡜ඹ࡟ࠊ⏕యෆ࡛ࡢ㔠ᒓ࢖࢜ࣥࡸ࣮࢟ࣞࢺ໬ྜ≀ࡢ⏕⌮ⓗືែࡸ໬Ꮫಟ㣭࡟ࡼࡿయෆືែ
ࡢ≉␗ⓗ࡞ไᚚ࡟㛵ࡍࡿᇶ♏ⓗ᳨ウࢆᇶ࡟ࠊ⬻⹫⾑᫬࡛ࡢ⚄⤒⣽⬊ಖㆤࡸ ᆺ⢾ᒀ⑓ࡢ἞⒪ࡢྍ⬟
ᛶࢆᣢࡘள㖄㘒యࢆ๰〇ࡋࡓࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ஂୗ෸ᩍᤵࡀ௚኱Ꮫ࡟ᰤ㌿࡛ࡁࡓࠋࡲࡓࠊబ἞ᩍᤵࡣ 2009 ᖺ࡟➨ 1 ᅇศᏊ࢖࣓࣮ࢪࣥࢢ㈹㸦ඛ➃་
⒪ᢏ⾡◊✲ᡤ㸧ࠊᑠ㔝෸ᩍᤵࡣ᪥ᮏ⸆Ꮫ఍ዡບ㈹ࠊ᪥ᮏ᰾་Ꮫ఍ዡບ㈹ࠊኳ‶ຓᩍࡣ᪥ᮏ᰾་Ꮫ఍ዡ
ບ㈹ࢆཷ㈹ࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊబ἞ᩍᤵࡽࡢㄽᩥࡣ⡿ᅜ᰾་Ꮫ఍ᶵ㛵ㄅ Journal of Nuclear Medicine ㄅ
ࡢ Editor’s Choice Award (2007 ᖺ) ࢆཷ㈹ࡋࡓࠋࡇࢀࡽࡢࡇ࡜࠿ࡽࡶ◊✲ホ౯ࡣᴟࡵ࡚㧗࠸ࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ㸰ᅇ⏕ᚋᮇㄢ⛬ࡢศᯒᏛ II㸦ᨺᑕ໬Ꮫ㸧ࠊ㸱ᅇ⏕๓ᮇㄢ⛬ࡢศᯒ໬Ꮫ IV(⮫ᗋ໬
Ꮫ)ࢆᢸᙜࡍࡿ࡜ඹ࡟ࠊ㸰ᅇ⏕ᚋᮇㄢ⛬ࡢ๰⸆≀⌮໬Ꮫ࢚ࢡࢧࢧ࢖ࢬ㸰ࠊ㸲ᅇ⏕ᚋᮇㄢ⛬ࡢ་⒪ᐇົ஦
๓ᐇ⩦ࠊ㸲ᅇ⏕๓ᮇㄢ⛬ࡢ་⒪⸆Ꮫᴫㄽࡢ୍㒊ࢆᢸᙜࡋ࡚࠸ࡿࠋ฿㐩┠ᶆࢆタᐃࡍࡿ࡜ඹ࡟ࠊࡑࢀࢆ
Ꮫ⏕࡟ఏ࠼ࠊࡲࡓ₇⩦࡞࡝ࢆ஺࠼࡞ࡀࡽࠊㅮ⩏ෆᐜࡢ⌮ゎࡢ඘ᐇࢆᅗࡿࡼ࠺࡟ㅮ⩏ࡋ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗ≉ูᐇ⩦㓄ᒓࡢᏛ⏕࡟ࡣࠊಶࠎࡢࢸ࣮࣐ࢆ୚࠼ࠊᐇ㦂ࢹࢨ࢖ࣥࡢタ
ᐃࡢ௙᪉ࠊᐇ㦂ࡢ㐍ࡵ᪉࡞࡝ࡢ◊✲ࡢ㐍ࡵ᪉ࡢ⌮ゎ࡜◊✲ࡢᇶ♏⬟ຊࡢ㛤Ⓨ࡟ດࡵࡿᶵ఍ࢆ୚࠼࡚࠸
ࡿࠋ኱Ꮫ㝔⏕࡟࠾࠸࡚ࡣࠊྛேࡀಶࠎࡢࢸ࣮࣐ࢆᣢࡕࠊ◊✲ࢆ⾜࠺࡜ඹ࡟ࠊᩍᐁ࡜ᖖ࡟㆟ㄽࡋ࡞ࡀࡽࠊ
ࡑࡢ◊✲ࡢࣞ࣋ࣝࡢ඘ᐇࠊᙉ໬ࢆᅗࡗ࡚࠸ࡿࠋࡲࡓࠊ◊✲ᡂᯝࡣ㛵㐃Ꮫ఍࡛Ⓨ⾲ࡍࡿᶵ఍ࢆᣢࡘࡇ࡜
ࢆዡບࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊ⸆Ꮫࠊ≉࡟ศᏊ࢖࣓࣮ࢪࣥࢢࠊᨺᑕᛶ་⸆ရᏛࠊ⏕≀↓ᶵ໬Ꮫࠊ⑓ែᶵ⬟
ศᯒᏛ࡞࡝࡟㛵ࡍࡿ▱㆑ࡸᢏ⾡ࢆᗈࡃᢕᥱࡋࠊ⛉Ꮫ◊✲ࡢ᪉ἲㄽࡢ⩦ᚓ࡟ົࡵࡿ࡜࡜ࡶ࡟ࠊ◊✲ㄢ㢟
ࡢタᐃ࣭ᒎ㛤࣭ホ౯࡞࡝ࢆ୰ᚰ࡜ࡋ࡚ࠊ◊✲⪅࡜ࡋ࡚⮬❧ࡍࡿࡓࡵࡢせ௳ࢆᏛ⩦ࡋࠊ࠿ࡘ◊✲⪅࡟ᑐ
ࡍࡿ◊✲ᣦᑟ⬟ຊࢆ㣴࠺ࡓࡵ࡟ࠊᩍᐊဨ඲ဨ࡛ࡢ◊✲ᡂᯝࡢሗ࿌఍ࢆ㐌୍ᗘ⾜࠸ࠊάⓎ࡞ពぢ஺᥮ࢆ
⾜ࡗ࡚࠸ࡿࠋ
ࡉࡽ࡟ࠊⓎ⾲ⱥㄒㄽᩥࢆྛேࡀ᭩ࡃࡇ࡜ࢆ┠ᶆ࡜ࡋ࡚࠾ࡾࠊⓎ⾲ຊࡢ⦎☻ࢆᐇ⾜ࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊሙྜ࡟ᛂࡌࠊ₇⩦ᙧᘧࢆྲྀࡾධࢀࡓࡾࠊᑠࢸࢫࢺࢆ⾜࠺࡞࡝ࡋ࡚ࠊ⥲
ྜⓗホ౯࡟ຍ࠼ࠊᙧᡂⓗホ౯ࢆྲྀࡾධࢀ࡚࠸ࡿࠋ
◊✲ᐊࡢᩍ⫱ࡣࠊ࡯ࡰ඲ဨࡀᖺ࡟㸯ᅇ௨ୖᏛ఍࡛Ⓨ⾲ࢆࡋ࡚࠸ࡿࡇ࡜࠿ࡽุ᩿ࡋ࡚ࠊྛಶேࡢᐇຊ
ࢆ㧗ࡵࡿࡇ࡜࡟ᙺ❧ࡗ࡚࠸ࡿࠋࡓࡔࡋࠊᏛ఍ࡣᅜෆᏛ఍ࡀ୺࡛ࠊᅜ㝿Ꮫ఍࡛ࡢⓎ⾲ࡣ࡝࠺ࡋ࡚ࡶ㝈ࡽ
ࢀ࡚࠸ࡿࡇ࡜࠿ࡽࠊᅜ㝿Ꮫ఍࡬ࡢཧຍࡢᶵ఍ࢆ࡛ࡁࡿ㝈ࡾከࡃ୚࠼࡚ࠊ㇏࠿࡞ᅜ㝿ⓗឤぬࢆ㌟࡟ࡘࡅ
ࡽࢀࡿࡼ࠺ࠊດຊࢆࡍ࡭ࡁ࡛࠶ࡿ࡜⪃࠼࡚࠸ࡿࠋ
2006 ᖺ௨㝆ࠊ኱Ꮫ㝔ಟ஢⪅ࡣ〇⸆࣓࣮࢝ࡢ◊✲⫋࡟ࡘ࠸࡚࠸ࡿࡶࡢࡀከ࠸㸦༤ኈㄢ⛬ 5 ྡ୰ 3 ྡࠊ
ಟኈㄢ⛬ 20 ྡ୰ 16 ྡ㸧ࡀࠊ኱Ꮫ㝔ࢆಟ஢ᚋ኱Ꮫࡲࡓࡣᅜබ❧◊✲ᡤ࡞࡝ࡢ◊✲⫋࡟ᑵ࠸࡚࠸ࡿࡶࡢ
㸦1 ྡ㸧ࠊᅜᐙබົဨ㸦2 ྡ㸧ࠊ་⒪⫋࡟ࡘࡃࡶࡢࡶ࠸ࡿ㸦3 ྡ㸧ࠋࡇࢀࡣࠊᩍ⫱࡜◊✲ࡢ㧗࠸ࣞ࣋ࣝ
ࡀホ౯ࡉࢀ࡚࠸ࡿ⤖ᯝ࡛࠶ࡿ࡜⪃࠼ࡿࠋ
㸦ཎⴭ㸧
1. Quantification of regional myocardial oxygen metabolism in normal pigs using positron emission
tomography with injectable 15O-O2., Temma T, Iida H, Hayashi T, Teramoto N, Ohta Y, Kudomi N, Watabe
H, Saji H, Magata Y., Eur J Nucl Med Mol Imaging. 37(2), 377-385,(2010).
− 291 −
2. NIR fluorescent ytterbium compound for in vivo fluorescence molecular imaging., Aita K, Temma T, Kuge
Y, Seki KI, Saji H., Luminescence. 25(1), 19-24 (2010).
3. Synthesis of a new NIR fluorescent Nd complex labeling agent., Aita K, Temma T, Shimizu Y, Kuge Y, Seki
K, Saji H., J Fluoresc. 20(1), 225-34 (2010).
4. A novel strategy to tag matrix metalloproteinases-positive cells for in vivo imaging of invasive and
metastatic activity of tumor cells., Zhao T, Harada H, Teramura Y, Tanaka S, Itasaka S, Morinibu A,
Shinomiya K, Zhu Y, Hanaoka H, Iwata H, Saji H, Hiraoka M., J Control Release. 144(1), 109-114 (2010).
5. Nicotinic acetylcholine receptors expressed in the ventralposterolateral thamic nucleus play an important
role in anti-allodynic effects., Ueda M, Iida Y, Tominaga A, Yoneyama T, Ogawa M, Magata M, Nishimura
H, Kuge Y, Saji H., Br. J. Pharmacol. 159:1201-1210 (2010).
6. Development of dual functional SPECT/Fluorescent probes for imaging cerebral E-amyloid plaques., Ono M,
Ishikawa M, Kimura H, Hayashi S, Matsumura K, Watanabe H, Shimizu Y, Chen Y, Kawashima H, Saji H.,
Bioorg Med Chem Lett.0:3885-3888 (2010).
7. Synthesis and evaluation of novel chalcone derivatives with 99mTc/Re complexes as potential probes for
detection of amyloid plaques., Ono M, Ikeoka R, Watanabe H, Kimura H, Fuchigami T, Haratake M, Saji H,
Nakayama M., ACS Chemical Neuroscience.1(9), 598-607 (2010).
8. Rapid detection of hypoxia-inducible factor-1-active tumours: pretaregeted imaging with a protein
degradating a mechanism similar to hypoxia-inducible factor-1., Ueda M, Kudo T, Kuge Y, Mukai T, Tanaka
T, Konishi H, Miyano A, Ono M, Kizaka-Kondoh, Masahiro Hiraoka S, Saji H.,Eur J Nucl Med Mol
Imaging. 37(8), 1566 –1574 (2010).
9. 99mTc/Re complexes based on flavones and aurone as SPECT probes for imaging cerebral ȕ-amyloid
plaques., Ono M, Ikeoka R, Watanabe H, Kimura H, Fuchigami T, Haratake M, Saji H, Nakayama M.,
Bioorg Med Chem. Lett. 0:5743-5748 (2010).
10. A novel 18F-labeled pyridyl benzofuran derivatives for imaging of ȕ-amyloid plaques in Alzheimer’s
brains., Cheng Y, Ono M, Kimura H, Kagawa S, Nishii R, Kawashima H, Saji H., Bioorg Med Chem Lett.
20:6141-6144 (2010).
11. Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials
for characterizing atherosclerotic plaques., Kuge Y, Takai N, Ogawa Y, Temma T, Zhao Y, Nishigori K,
Ishino S, Kamihashi J, Kiyono Y, Shiomi M, Saji H., Eur J Nucl Med Mol Imaging. 7(11), 2093-2104 (2010).
12. Fluorinated benzofuran derivatives for PET imaging of ȕ-amyloid Plaques in Alzheimer’s disease brains.,
Cheng Y, Ono M, Kimura H, Kagawa S, Nishii R, Kawashima H, Saji H. ACS Med Chem Lett.1(9), 321325 (2010).
13. Novel benzofurans with 99mTc complexes as probes for imaging cerebral ȕ-amyloid plaques., Ono M, Ikeoka
R, Watanabe H, Kimura H, Fuchigami T, Haratake M, Saji H, Nakayama M., ACS Med Chem Lett. 443447 (2010).
14. Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I)
tricarbonyl core as a chelate site., Ogawa K, Kawashima H, Shiba K, Washiyama K, Yoshimoto M, Kiyono
Y, Ueda M, Mori H, Saji H., Nucl Med Biol. 36(2), 129-135 (2009).
15. 18F-labeled flavones for in vivo imaging of ȕ-amyloid plaques in Alzheimer’s brains., Ono M, Watanabe R,
Kawashima H, Kawai T, Watanabe H, Haratake M, Saji H, Nakayama M., Bioorg Med Chem. 17:68676872(2009).
16. Novel radioiodinated aurones as probes for SPECT imaging of E-amyloid plaques in the brain., Maya Y, Ono
M, Watanabe H, Haratake M, Saji H, Nakayama M., Bioconjugate Chem. 20(1), 95-101 (2009).
17. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in
HIF-1-active tumor cells., Kudo T, Ueda M, Kuge Y, Mukai T, Tanaka S, Masutani M, Kiyono Y, KizakaKondoh S, Hiraoka M, Saji H., J Nucl Med. 50(6), 942-949 (2009).
18. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging., Mukai E, Toyoda K,
Kimura H, Kawashima H, Fujimoto H, Ueda M, Temma T, Hirao K, Nagakawa K, Saji H, Inagaki N,
Biochem Biophys Res Commun. 389(3), 523-526 (2009).
19. Synthesis and biological evaluation of radioiodinated 2,5-diphenyl-1,3,4-oxadiazoles for detecting betaamyloid plaques in the brain., Watanabe H, Ono M, Ikeoka R, Haratake M, Saji H, Nakayama M.,
Bioorg Med Chem. 17(17), 6402-6406 (2009).
20. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant
tumors., Temma T, Sano K, Kuge Y, Kamihashi J, Takai N, Ogawa Y, Saji H., Biol Pharm Bull. 32(7),
1272-1277 (2009).
21. Push-pull benzothiazole derivatives as probes for detecting beta-amyloid plaques in Alzheimer's brains., Ono
M, Hayashi S, Kimura H, Kawashima H, Nakayama M, Saji H., Bioorg Med Chem. 17(19), 7002-7007
(2009).
− 292 −
22.
Fluoro-pegylated chalcones as positron emission tomography probes for in vivo imaging of beta-amyloid
plaques in Alzheimer's disease., Ono M, Watanabe R, Kawashima H, Cheng Y, Kimura H, Watanabe H,
Haratake M, Saji H, Nakayama M. J Med Chem. 52, 6394-6401 (2009).
23. Synthesis and evaluation of a radioiodinated lumiracoxib derivative for the imaging of cyclooxygenase-2
expression., Kuge Y, Obokata N, Kimura H, Katada Y, Temma T, Sugimoto Y, Aita K, Seki K, Tamaki N,
Saji H., Nucl Med Biol. 36(8), 869-876 (2009).
24. Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I)
tricarbonyl core as a chelate site., Ogawa K, Kawashima H, Kimuya S, Shiba K, Onoguchi M, Kimura H,
Hashimoto K, Odani A, Saji H., Ann Nucl Med. 17(8), 129-135 (2009).
25. 5-Iodo-A-85380, a specific ligand for D4E2 nicotinic acetylcholine receptors, prevents glutamate neurotoxicity
in rat cortical cultured neurons., Ueda M, Iida Y, Kitamura Y, Kawashima H, Ogawa M, Magata Y, Saji H.,
Brain Res. 1199, 46-52 (2008).
26. Evaluation of radioiodinated (2S,ȘS)-2-(Ș-(2-iodophenoxy)benzyl)morpholine as a radioligand for imaging
of norepinephirine transporter in the heart., Kiyono Y, Sugita T, Ueda M, Kawashima H, Kanegawa N,
Kuge Y, Fujibayashi Y, Saji H., Nucl Med Biol. 35, 213-218 (2008).
27. Tageting of lectinlike oxidized low-density lipoprotein receptor (LOX-1) with 99mTc-labeled anti-LOX-1
antibody: potential agent for imaging of vulnerable plaque., Ishino S, Mukai T, Kuge Y, Kume N, Ogawa M,
Tkai N, Kamihashi J, Shiomi M, Minami M, Kita T, Saji H., J Nucl Med. 49(10), 1677-1685 (2008).
28. Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: assessment of
infact size with 99mTc-Annexin V., Doue T, Ohtsuki K, Ogawa K, Ueda M, Azuma A, Saji H, Strauss, HW,
Matsubara H., J Nucl Med. 49(10), 1694-1700 (2008).
29. CYP2D6-mediated metabolism of a novel acyl coenzyme A: cholesterol acyltransferase inhibitor, Pactimibe,
and its unique plasma metabolite, R-125528., Kotsuma M, Tokui T, Ishizuka-Ozeki T, Honda T, Iwabuchi H,
Murai T, Ikeda T, Saji H., Drug Metab Disposition. 36(3), 529-534 (2008).
30. Development of nobel ș-amyloid probes based on 3,5-diphenyl-1,2,4-oxadiazole., Ono M, Haratake M, Saji
H, Nakayama M., Bioorg Med Chem. 16(14) , 6867-6872 (2008).
31. PET -15 cerebral blood flow and metabolism after acute stroke in spontaneously hypertensive rats., Temma
T, Kuge Y, Sano K, Kamihashi J, Obokata N, Kawashima H, Magata Y, Saji H., Brain Res., 1212, 18-24
(2008).
32. Prominent lectin-like oxidized low density lipoprotein (LDL) receptor-1 (LOX-1) expression in
atherosclerotic lesions is associated with tissue factor expression and apoptosis in hypercholesterolemic
rabbits., Kuge Y, Kume N, Ishino S, Takai N, Ogawa Y, Mukai T, Minami M, Shiomi M, Saji H., Biol
Pharm Bull. 31(8), 1475-1482 (2008).
33. Therapeutic effects for the palliation of metastatic bone pain of a rhenium-186 complex-conjugated
bisphosphonate in an animal model., Ogawa K, Mukai T, Asano D, Kawashima H, Kinuya S, Shiba K,
Hashimoto K, Mori H, Saji H., J Nucl Med. 48(1), 122-127 (2007).
34. Is MIBG a substrate of P-glycoprotein?., Kiyono Y, Yamashita T, Doi H, Kuge Y, Katsura T, Inui K, Saji H.,
Eur J Nucl Med Mol Imaging. 34(3), 448-452(2007).
35. Qunatification of nicotinic acetylcholine receptors in Parkinson’s disease with 123I-5IA SPECT., Oishi N,
Hashikawa K, Yoshida H, Ishizu K, Ueda M, Kawashima H, Saji H, Fukuyama H., J Neurol Sci. 256, 52-60
(2007).
36. Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instabilityanalysis in hypercholesterolemic rabbits., Ishino S, Mukai T, Kume N, Asano D, Ogawa M, Kuge Y,
Minami M, Kita T, Shiomi M, Saji H., Atherosclerosis. 195, 48-56 (2007).
37. 99mTc-Annexin A5 for noninvasive characterization of atherosclerotic lesions: imaging and histological
studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits., Ishino S, Kuge Y, Takai
N, Tamaki N, Strauss HW, Blankenberg FG, Shiomi M, Saji H., Eur J Nucl Med Mol Imaging. 34(6), 889899 (2007).
38. Development of a novel neodymium compound for in vivo fluorescence imaging., Aita K, Temma T, Kuge
Y, Saji H., Luminescence. 22, 455-461 (2007).
39. Effect of carboxy-group of D-glutamic acid or Ȗ-carboxy-D-glutamic acid as N-terminal amino acid of 111In diethylenetriaminepentaacetic acid-octreotide on accumulation of radioactivity in kidney., Akizawa H,
Saito M, Tsukamoto I, Ohkura T, Shimizu T, Kitamura Y, Mifune M, Saito Y, Arano Y, Saji H., Biol
Pharm Bull. 30 (11), 2226-2228 (2007).
40. Synthesis and evaluation of radioiodinated (S,S)-2-(a-(2-idodphenoxy)benzyl)morpholine for imaging brain
norepinephrine transporter., Kanegawa N, Kiyono Y, Kimura H, Sugita T, Kajiyama S, Kawashima H, Ueda
M, Kuge Y, Saji H., Eur J Nucl Med Mol Imaging. 34(6), 636-647 (2007).
41. Applicability of a high-resolution small semiconductor gamma camera to small animal imaging., Kiyono Y,
Yamashita T, Doi H, Kuge Y, Katsura T, Inui K, Saji H., Nucl Med Commun. 28(4), 736-741(2007).
42. Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study.,
− 293 −
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
Mamede M, Ishizu K, Ueda M, Mukai T, Iida Y, Kawashima H, Fukuyama H, Togashi H, Saji H., J Nucl
Med. 48(11), 1829-1835 (2007).
Distribution profiles of membrane Type-1 Matrix Metalloproteinase (MT1-MMP), Matrix Metalloproteinase2 (MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis: comparison with plaque instability
analysis., Kuge Y, Takai N, Ishino S, Takai N, Temma T, Shiomi M, Saji H., Biol Pharm Bull. 30(9), 16341640 (2007).
Synthesis and evaluation of radioiodinated cyclooxygenase-2 inhibitors as potential SPECT tracers for
cyclooxygenase-2 expression., Kuge Y, Katada Y, Shimonaka S, Temma T, Kimura H, Kiyono Y, Yokota C,
Minematsu K, Seki K, Tamaki N, Ohkura K, Saji H., Nucl Med Biol. 33(1) , 21-27 (2006).
Reduced 123I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice
with MPTP-induced parkinsonism., Fukumitsu N, Suzuki M, Fukuda T, Kiyono Y, Kajiyama S, Saji H.,
Nucl Med Biol. 33(1), 37- 42 (2006).
Change of central cholinergic receptors following lesions of nucleus basalis magnocellularis in rats: search
for an imaging index suitable for the early detection of Alzheimer’s disease., Ogawa M, Iida Y, Nakagawa
M, Kuge Y, Kawasima H, Tominaga A, Ueda M, Magata Y, Saji H., Nucl Med Biol. 33(2), 249-254 (2006).
rhenium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. ,
Ogawa K, Mukai T, Arano Y, Otaka A, Ueda M, Uehara T, Magata Y, Hashimoto K, Saji H., Nucl Med
Biol. 33(5) , 513-520 (2006).
Protective effect of zinc against ischemic neuronal injury in a middle cerebral artery occusion model.,
Kitamura Y, Iida Y, Ueda M, Mifune M, Kasuya F, Ohta M, Igarashi K, Saito Y, Saji H., J Pharmacol Sci.
100, 142-148 (2006).
In vivo measurement of presynaptic Zn2+ release during forebrain ischemia in rats., Kitamura Y, Iida Y, Abe
J, Mifune J, Kasuya F, Ohta M, Igarashi K, Saito Y, Saji H., Biol Pharm Bull. 29(4), 821-823 (2006).
Synthesis and evaluation of radioiodinated (S,S)-2-(alpha-(2-iodophenoxy)benzyl)morpholine for imaging
brain norepinephrine transporter., Kanegawa N, Kiyono Y, Kimura H, Sugita T, Kajiyama S, Kawashima H,
Ueda M, Kuge Y, Saji H., Eur J Nucl Med Mol Imaging. 33(6), 639-47 (2006).
Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains., Ono
M, Kawashima H, Nonaka A, Kawai T, Haratake M, Mori H, Kung MP, Kung HF, Saji H, Nakayama M., J
Med Chem. 49(9), 2725-30 (2006).
Release of vesicular Zn2+ in a rat transient middle cerebral artery occlusion model., Kitamura Y, Iida Y, Abe
J, Mifune M, Kasuya F, Ohta M, Igarashi K, Saito Y, Saji H., Brain Res Bull. 69(6), 622-5 (2006).
Detection of maleate-induced Fanconi syndrome by decreasing accumulation of 125I-3-iodo-alpha-methyl-Ltyrosine in the proximal tubule segment-1 region of renal cortex in mice: a trial of separate evaluation of
reabsorption., Shikano N, Nakajima S, Kotani T, Itoh Y, Nishii R, Yoshimoto M, Flores LG 2nd, Saji H,
Ishikawa N, Kawai K., Ann Nucl Med. 20(3), 175-81 (2006).
Development of a 111-In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging
tumors., Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, Iida Y, Doi R, Fujii N, Saji H.,
Nucl Med Biol. 33(3), 486-494 (2006).
Estimation of oxygen metabolism in a rat model of permanent ischemia using positron emission tomography
with injectable 15O-O2., Temma T, Magata Y, Kuge Y, Shimonaka S, Sano K, Katada Y, Kawashima H,
Mukai T, Watabe H, Iida H, Saji H., J Cereb Blood Flow Metab. 26, 1577-1583 (2006).
A catheter-based intravascular radiation detector of vulnerable plaques., Hosokawa R, Kambara N, Ohba M,
Mukai T, Ogawa M, Motomura H, Kume N, Saji H, Kita T, Nohara R., J Nucl Med.,47(5) 863-867 (2006).
Development of a novel technetium-99m-chelate-conjugated bisphosphonate with high affinity for bone as a
bone Scintigraphic Agent., Ogawa K, Mukai T, Inoue Y, Ono M, Saji H., J Nucl Med. 47(12), 2042-2047
(2006).
Application of [18F]FDG-PET for monitoring the therapeutic effect of anti-inflammatory drugs on
stabilization of vulnerable atherosclerotic plaques., Ogawa M, Magata Y, Kato T, Hatano K, Ishino S,
Mukai T, Shiomi M, Ito K, Saji H., J Nucl Med. 48(11) , 1822-1827 (2006).
Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains., Ono
M, Kawashima H, Nonaka A, Kawai T, Haratake M, Mori H, MP.Kung P,HF. Kung, Saji H, Nakayama M.,
J Med Chem. 49(9) , 2725-30 (2006).
Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic
nerves: implications for heterogeneous accumulation of MIBG., Kiyono Y, Kajiyama S, Fujiwara H,
Kanegawa N, Saji H., Eur J Nucl Med Mol Imaging. 32(4), 438-442 (2005).
Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic
nerves: implications for heterogeneous accumulation of MIBG., Kiyono Y, Kajiyama S, Fujiwara H,
Kanegawa N, Saji H., Eur J Nucl Med Mol Imaging. 32(4), 993-997 (2005).
Alternation of striatal [11C]raclopride and 6-[18F]fluoro-L-3,3-dihydoxyphenylalanine uptake precedes., Ishida
Y, Kawai K, Magata Y, Abe H, Yoshimoto M, Takeda R, Hashiguchi H, Mukai T, Saji H., Development of
− 294 −
63.
64.
methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain
bundle in rats. Neurosci. Lett. 389, 30-34 (2005).
Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic
bone pain based on the concept of bifunctional radiopharmaceuticals., Ogawa K, Mukai T, Arano Y, Ono M,
Hanaoka H, Ishino S, Hashimato K, Nishimura H, Saji H., Bioconjugate Chem. 16(4), 751-757 (2005).
In vivo system to estimate renal brush border enzyme-mediated cleavage of peptide linkages for designing.,
Fujioka Y, Satake S, Uehara T, Mukai T, Akizawa H, Ogawa K, Saji H, Endo K, Arano Y., Radiolabeled
antibody fragments of low renal radioactivity levels. Bioconjugate Chem. 16, 1610-1616 (2005).
(⥲ㄝ)
1.
2.
3.
4.
5.
ࣄࢺ⬻ࢽࢥࢳࣥཷᐜయࡢ࢖࣓࣮ࢪࣥࢢ. బ἞ⱥ㑻ࠊୖ⏣┿ྐ, THE LUNG, 18(1), 62-66 (2010).
ᨺᑕᛶศᏊࣉ࣮ࣟࣈࡢ㛤Ⓨࡢㄢ㢟. బ἞ⱥ㑻, Bio Clinica, 25(9), 752-757 (2010).
᭱㏆ࡢᨺᑕᛶ⸆ရ㛤Ⓨ. బ἞ⱥ㑻, Isotope News, 660, 2-9 (2009).
་⒪⏝ PET ⸆๣㸸⸆๣ྜᡂရ㉁⟶⌮, బ἞ⱥ㑻, Radiosotopes, 58(3), 115-120 (2009).
⣽⬊ෆᚤ㔞ඖ⣲,బ἞ⱥ㑻, ⮫ᗋ᳨ᰝࠊ53(2)ࠊ167-170 (2009).
6. Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and
single photon emission computed tomography (SPECT)., Ogawa M, Tsukada H,Hatano K, Ouchi Y, S
aji H, Magata Y., Biol Pharm Bull. 32(3), 337-340 (2009).
7. ⚄⤒ఏ㐩ᶵ⬟ࡣ࡝ࡇࡲ࡛ゎ᫂ࡉࢀࡓ࠿㸫⬻⚄⤒ᶵ⬟ࡢศᏊ࢖࣓࣮ࢪࣥࢢ㸸࢔ࢭࢳࣝࢥࣜࣥ⚄⤒ఏ
㐩ᶵ⬟. ୖ⏣┿ྐࠊబ἞ⱥ㑻, PET journalࠊNo.6ࠊ167-170 (2009).
8. ୙Ᏻᐃᛶື⬦◳໬ࣉ࣮ࣛࢡ࢖࣓࣮ࢪࣥࢢࡢࡓࡵࡢศᏊࣉ࣮ࣟࣈ㛤Ⓨ◊✲. ኳ‶ᩗࠊబ἞ⱥ㑻, PE
9.
10.
11.
12.
13.
14.
T journal, No.7, 10-11 (2009).
PET᳨ᰝ࡟౑ࢃࢀࡿศᏊࣉ࣮ࣟࣈࡢ㛤Ⓨ. బ἞ⱥ㑻, ⌧௦໬Ꮫ, No.464, 28-32 (2009).
࢖ࣥࣅ࣎࢖࣓࣮ࢪࣥࢢゎᯒ࡜DDSホ౯. బ἞ⱥ㑻, PHARM TECH JAPAN, 25(13), 83-89 (2009).
ື⬦◳໬ࣉ࣮ࣛࢡࡢ㉁ⓗデ᩿࡜ศᏊ࢖࣓࣮ࢪࣥࢢ. బ἞ⱥ㑻, Bio Clinica, 23(2), 145-150 (2008).
PET〇๣. బ἞ⱥ㑻,ᨺᑕ⥺↷ᑕ฼⏝ಁ㐍༠㆟఍, 23(2), 145-150 (2008).
࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢ㛤Ⓨ࡜ᛂ⏝. బ἞ⱥ㑻, Drug Delivery System, 23(1), 24-32 (2008).
㔠ᒓᨺᑕᛶྠ఩ඖ⣲ࡢデ᩿࣭἞⒪࡬ࡢᛂ⏝.బ἞ⱥ㑻, YAKUGAKU ZASSHI, 128(3), 323-332 (2
008).
15. ᨺᑕ⥺἞⒪ࢆᣦྥࡋࡓPET/SPECTࣉ࣮ࣟࣈࡢ㛤Ⓨ㸫ప㓟⣲࢖࣓࣮ࢪࣥࢢࢆ୰ᚰ࡟㸫. ஂୗ⿱ྖࠊ
ୖ⏣┿ྐࠊ㉿ᯇྜྷࠊᕤ⸨ႛࠊ㏆⸨⛉Ụࠊ⏣୰ṇኴ㑻ࠊ⋢ᮌ㛗Ⰻࠊᖹᒸ┾ᐶࠊబ἞ⱥ㑻, ⒴ࡢ⮫ᗋ,
54(2), 105-108 (2008).
16. ⮫ᗋデ᩿࡬ࡢ฼⏝ࡀᮃࡲࢀ࡚࠸ࡿPET⸆๣࡜⮬ືྜᡂ⿦⨨ࡢ㐍Ṍ㸸᪂ࡋ࠸⸆๣. Ἑᔱ⚽࿴ࠊబ἞
ⱥ㑻, PET journal, No.4, 17-19 (2008).
17. ࢽࢥࢳࣥᛶཷᐜయ࢖࣓࣮ࢪࣥࢢ๣ࡢ㛤Ⓨ࡜ࡑࢀࢆ⏝࠸ࡓ៏ᛶ⑊③᫬ࡢࢽࢥࢳࣥ⚄⤒ᶵ⬟ゎᯒႚ↮
⛉Ꮫ◊✲ࡢ࠶ࡺࡳ㸫1996ᖺ࠿ࡽ2005ᖺ㸫.బ἞ⱥ㑻,ႚ↮⛉Ꮫ◊✲㈈ᅋ⦅, 96-100 (2007).
18. ศᏊ࢖࣓࣮ࢪࣥࢢ࡛ࡳࡓ⏕యෆ⸆≀ືែ. బ἞ⱥ㑻, ᪥ᮏ⮫ᗋ, 65(2), 363-369 (2007).
19. ⑌ᝈࡢデ᩿࡜἞⒪࡟⏝࠸ࡿᨺᑕᛶ㔠ᒓ໬ྜ≀. బ἞ⱥ㑻, 㔠ᒓ, 77(3), 61-67 (2007).
20. ࡀࢇデ᩿࡜἞⒪࡟࠾ࡅࡿศᏊ࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢタィ࡜᭷⏝ᛶ. బ἞ⱥ㑻, ᪂་⒪, No.389. 7
5-78 (2007).
21. Chemical contraol of biological activity and biodistribution of metal compounds : Drug design of metal co
mplexes with biological activity and target-specific biodistribution., Saji H, Ogawa K, Kitamura Y, Kubot
a-Akizawa M, Kawashima H., Biomed Res Trace Elements. 18(3), 255-263 (2007).
22. ື⬦◳໬ࡢ㉁ⓗデ᩿ࡢࡓࡵࡢศᏊ࢖࣓࣮ࢪࣥࢢ. బ἞ⱥ㑻ࠊஂୗ⿱ྖࠊྥ㧗ᘯࠊከ⏣ᮧᰤ஧ࠊஂ⡿
඾᫛ࠊ㔝ཎ㝯ྖ, Innervision, 21 (7), 27 (2006).
23. ศᏊࣉ࣮ࣟࣈࡢᙺ๭࡜◊✲ࡢ⌧≧. బ἞ⱥ㑻, ࢖ࣥࢼ࣮ࣅࢪࣙࣥ, 21(12), 4-9 (2006).
24. ศᏊ࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈ. బ἞ⱥ㑻,ࣄ࣮࣐ࣗࣥࢧ࢖࢚ࣥࢫ, 18(4), 22-28 (2007).
25. ື⬦◳໬⏬ീデ᩿ࡢ᭱๓⥺㸫㉸㡢Ἴ.᰾་Ꮫ, 㹁㹒㸪MRI࡛ᐄ࣮࣐ࣟࢆ࡝࠺ぢࡿ࠿㸽㸫.ᒣᐊṇᶞࠊ
ከ⏣ᮧᰤ஧ࠊ㔠ᑿᫀኴ㑻ࠊ୰⃝࿴ᬛࠊబ἞ⱥ㑻ࠊྥ㧗ᘯࠊᒸ㔝჆᫂ࠊᮌᮧ๛ࠊ໭ᚭࠊᐩᶔ࠿࠾ࡾ,
⏬ീデ᩿, 25(8): 963-973 (2005).
− 295 −
㸦ⴭ᭩㸧
1. ศᏊࣉ࣮ࣟࣈࡢศᏊタィ.బ἞ⱥ㑻,㸦௒Ἠຮ ┘ಟࠊ⏣ཎᐉᗈ⦅㸧ᚰ࣭⾑⟶⑓ࡢศᏊ࢖࣓࣮ࢪࣥ
ࢢ͇ p.13-20, Ọ஭᭩ᗑ (2010).
2. PET ⸆๣. బ἞ⱥ㑻,㸦᪥ᮏᨺᑕ⥺ᢏ⾡Ꮫ఍⦅㸧ᨺᑕ⥺་⒪ᢏ⾡Ꮫྀ᭩(26)͆PET ࠾ࡼࡧ PET/CT
᳨ᰝᢏ⾡ࡢᇶ♏͇ p.4-8,᪥ᮏᨺᑕ⥺ᢏ⾡Ꮫ఍ (2009).
3. デ᩿⸆.బ἞ⱥ㑻 (㎷ᮏ㇦୕ࠊᑠụ຾ኵ⦅) ᶆ‽་⒪⸆Ꮫ͆⸆⌮Ꮫ͇p.450-467,་Ꮫ᭩㝔(2009).
4. ࣏ࢪࢺࣟࣥ CT (PET)࡟ࡼࡿ⭘⒆ࡢ࢖ࣥࣅ࣎࢖࣓࣮ࢪࣥࢢ. బ἞ⱥ㑻(᪥ᮏ⸆Ꮫ఍≀⌮⣔⸆Ꮫ㒊
఍࣭ศᯒ໬Ꮫᢸᙜᩍဨ఍㆟⦅)⸆Ꮫศᯒ⛉Ꮫࡢ᭱๓⥺, p.178-179,ࡌ࡯࠺,(2009).
5. ࣑ࢿࣛࣝྵ᭷⸆๣ࡢ་⒪࡬ࡢᛂ⏝. బ἞ⱥ㑻 (⣒ᕝ჆๎⦅)࣑͆ࢿࣛࣝࡢ⛉Ꮫ࡜᭱᪂ᛂ⏝ᢏ⾡͇,
p.278-289, ࢩ࣮࢚࣒ࢩ࣮ฟ∧ (2008).
6. ࢫࢱࣥࢲ࣮ࢻ⸆Ꮫࢩ࣮ࣜࢬ㸰͆≀⌮⣔⸆Ꮫ IV ₇⩦⦅͇. బ἞ⱥ㑻 (᪥ᮏ⸆Ꮫ఍⦅)p.33-35,
ᮾி໬Ꮫྠே(2008).
7. ࣑ࢿࣛࣝྵ᭷⸆๣ࡢ་⒪࡬ࡢᛂ⏝. బ἞ⱥ㑻,(⣒ᕝ჆๎⦅)࣑͆ࢿࣛࣝࡢ⛉Ꮫ࡜᭱᪂ᛂ⏝ᢏ⾡͇
p.278-289, ࢩ࣮࢚࣒ࢩ࣮ฟ∧(2008).
8. PET ⸆๣ࡢ〇㐀࠾ࡼࡧရ㉁ࡢ⟶⌮ᇶ‽. బ἞ⱥ㑻 (ఀ⸨ṇᩄࠊ㐲⸨ၨ࿃ࠊబ἞ⱥ㑻ࠊ⋢ᮌ㛗Ⰻࠊ⏿
⃝㡰ࠊ⚟⏣ᐶࠊᑎ⏣ᘯྖ ⦅)͆⮫ᗋ་ࡢࡓࡵࡢࢡࣜࢽ࢝ࣝ㹎㹃㹒㸫⑓ᮇ࣭⑓ែデ᩿ࡢࡓࡵࡢ࢞
࢖ࢻࣈࢵࢡ㸫͇p.19-22. ඛ➃་⒪ᢏ⾡◊✲ᡤ (2007).
9. ศᏊ࢖࣓࣮ࢪࣥࢢࡢࡓࡵࡢศᏊࣉ࣮ࣟࣈ. బ἞ⱥ㑻 (ఀ⸨ṇᩄࠊ㐲⸨ၨ࿃ࠊబ἞ⱥ㑻ࠊ⋢ᮌ㛗Ⰻࠊ
⏿⃝㡰ࠊ⚟⏣ᐶࠊᑎ⏣ᘯྖ ⦅)͆⮫ᗋ་ࡢࡓࡵࡢࢡࣜࢽ࢝ࣝ㹎㹃㹒㸫⑓ᮇ࣭⑓ែデ᩿ࡢࡓࡵࡢ࢞
࢖ࢻࣈࢵࢡ㸫͇p.36-39. ඛ➃་⒪ᢏ⾡◊✲ᡤ(2007).
10. ➨ 33 ❶ ࠺ࡗ⾑ᛶᚰ୙඲ࡢ⸆≀⒪ἲ. బ἞ⱥ㑻(㧗ᢡಟ஧ࠊ⚟⏣ⱥ⮧ࠊ㉥ụ᫛⣖ࠊ▼஭㑥㞝┘ヂ)
͆ࢢࢵࢻ࣐࣭ࣥࢠ࣐ࣝࣥ ⸆⌮᭩㹙ୖ㹛-➨ 11 ∧-͇,p.1084-1120. , ᘅᕝ᭩ᗑ (2007).
12. ➨ 56 ❶ ⏥≧⭢࠾ࡼࡧᢠ⏥≧⭢⸆. బ἞ⱥ㑻(㧗ᢡಟ஧ࠊ⚟⏣ⱥ⮧ࠊ㉥ụ᫛⣖ࠊ▼஭㑥㞝┘ヂ)
͆ࢢࢵࢻ࣐࣭ࣥࢠ࣐ࣝࣥ ⸆⌮᭩㹙ୗ㹛-➨ 11 ∧-͇,p.1928-1967.ᘅᕝ᭩ᗑ(2007).
13. ͆ࡲࡍࡲࡍᗈࡀࡿศᏊ࢖࣓࣮ࢪࣥࢢᢏ⾡͇ బ἞ⱥ㑻 (బ἞ⱥ㑻ࠊ⏣⏿Ὀᙪ⦅)࣓ࢹ࢕࢝ࣝࢻ ࣮ࢗ
(2007).
14.
࣏ࢪࢺࣟࣥᨺᑕᛶ⸆๣. బ἞ⱥ㑻 (᪥ᮏ᰾་Ꮫᢏ⾡Ꮫ఍⦅)࣏ࢪࢺ᩿ࣟࣥᒙ᧜ᙳ㸦PET㸧ᢏ⾡࣐ࢽ
ࣗ࢔ࣝ, p.65-80, ᪥ᮏ᰾་Ꮫᢏ⾡Ꮫ఍ (2006).
15. 18F-FDG 〇๣࡟㉳ᅉࡍࡿࡶࡢ. బ἞ⱥ㑻 (ஂಖᩔྖ⦅)͆FDG-PET ᳨ᰝࡢṇᖖീ࡜ࣆࢵࢺࣇ࢛࣮
͇ࣝ, p.55-64, 㔠ཎฟ∧(2005).
16.
ᨺᑕᛶ་⸆ရ. బ἞ⱥ㑻(኱᱈ၿᮁࠊ㛫㈡⏣Ὀᐶࠊబ἞ⱥ㑻ࠊ๓⏣⛱ࠊᑠᔱ࿘஧⦅)͆᪂ᨺᑕ໬
Ꮫ࣭ᨺᑕᛶ་⸆ရ͇, p.127-189, ༡Ụᇽ (2005).
17. ᨺᑕᛶ≀㉁ࡢ⸆Ꮫ㡿ᇦ࡬ࡢᛂ⏝. బ἞ⱥ㑻 (బ἞ⱥ㑻ࠊ๓⏣⛱ࠊᑠᔱ࿘஧⦅)͆᪂ᨺᑕ໬Ꮫ࣭ᨺᑕ
ᛶ་⸆ရ͇, p.122-125, ༡Ụᇽ(2005).
18. ௦⾲ⓗ࡞ᨺᑕᛶ᰾✀ࡢ≀⌮ⓗᛶ㉁࡟ࡘ࠸࡚ㄝ࡛᫂ࡁࡿ. బ἞ⱥ㑻 (᪥ᮏ⸆Ꮫ఍⦅)ࢫࢱࣥࢲ࣮ࢻ⸆
Ꮫࢩ࣮ࣜࢬ㸰͆≀⌮⣔⸆Ꮫ I㸬≀㉁ࡢ≀⌮ⓗᛶ㉁͇, p.100-111., ᮾி໬Ꮫྠே (2005).
19. ᰾཯ᛂ࠾ࡼࡧᨺᑕᖹ⾮࡟ࡘ࠸࡚ㄝ࡛᫂ࡁࡿ. బ἞ⱥ㑻, (᪥ᮏ⸆Ꮫ఍⦅)ࢫࢱࣥࢲ࣮ࢻ⸆Ꮫࢩ࣮ࣜࢬ
㸰͆≀⌮⣔⸆Ꮫ I㸬≀㉁ࡢ≀⌮ⓗᛶ㉁͇, p.112-115, ᮾி໬Ꮫྠே (2005).
20.
ᨺᑕ⥺ࡢ ᐃཎ⌮࡟ࡘ࠸࡚ㄝ࡛᫂ࡁࡿ. బ἞ⱥ㑻, (᪥ᮏ⸆Ꮫ఍⦅)ࢫࢱࣥࢲ࣮ࢻ⸆Ꮫࢩ࣮ࣜࢬ㸰
͆≀⌮⣔⸆Ꮫ I㸬≀㉁ࡢ≀⌮ⓗᛶ㉁͇, p.116-120, ᮾி໬Ꮫྠே (2005).
21. ௦⾲ⓗ࡞ᨺᑕᛶ་⸆ရࡢ✀㢮࡜⏝㏵࡟ࡘ࠸࡚ㄝ࡛᫂ࡁࡿ. బ἞ⱥ㑻, (᪥ᮏ⸆Ꮫ఍⦅)ࢫࢱࣥࢲ࣮ࢻ
⸆Ꮫࢩ࣮ࣜࢬ㸯㸮͆ᐇົᐇ⩦஦๓Ꮫ⩦͇, p.206-211, ᮾி໬Ꮫྠே(2005).
22. ᨺᑕᛶ་⸆ရࡢ⟶⌮࡜ྲྀᢅ࠸㸦ᢞ⸆ࠊᗫᲠ࡞࡝㸧࡟ࡘ࠸࡚ㄝ࡛᫂ࡁࡿ. బ἞ⱥ㑻 (᪥ᮏ⸆Ꮫ఍⦅)
ࢫࢱࣥࢲ࣮ࢻ⸆Ꮫࢩ࣮ࣜࢬ㸯㸮͆ᐇົᐇ⩦஦๓Ꮫ⩦͇, p.212-214, ᮾி໬Ꮫྠே(2005).
− 296 −
⑓ែ᝟ሗ⸆Ꮫศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧㧗಴႐ಙ㸦ࡓ࠿ࡃࡽ ࡼࡋࡢࡪ㸧㸦1997. 5 ╔௵㸧
᫛࿴ 56 ᖺி㒔኱Ꮫ༞ࠊ᫛࿴ 58 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
ಟኈㄢ⛬ಟ஢
෸ᩍᤵ㸦⸆Ꮫ༤ኈ㸧ᒣᒸ Ύ㸦ࡸࡲ࠾࠿ ࡁࡼࡋ㸧㸦1997.5 ╔௵ࠊ2010.6
㏥⫋㸧
᫛࿴ 46 ᖺᐩᒣ኱Ꮫ༞ࠊ᫛࿴ 51 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
෸ᩍᤵ㸦⸆Ꮫ༤ኈ㸧すᕝඖஓ㸦࡟ࡋ࠿ࢃ ࡲࡁࡸ㸧㸦2002.8 ╔௵㸧
ᖹᡂ 2 ᖺி㒔኱Ꮫ༞ࠊᖹᡂ 4 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
ಟኈㄢ⛬ಟ஢
ຓᩍ㸦⸆Ꮫ༤ኈ㸧㧗ᶫ᭷ᕫ㸦ࡓ࠿ࡣࡋ ࡺ࠺ࡁ㸧㸦2009.4 ╔௵㸧
ᖹᡂ 13 ᖺி㒔኱Ꮫ༞ࠊᖹᡂ 18 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
⑓ែ᝟ሗ⸆Ꮫศ㔝ࡣࠊ⑌⑓἞⒪ࡢࡓࡵ࡟⏕య࡟ᢞ୚ࡉࢀࡿࠕࣔࣀࠖ࡜ࡋ࡚ࡢ͆ࡃࡍࡾ͆࡜ᢞ୚ࡉࢀࡿ
ഃࡢࠕࣄࢺࠖ࡜ࡢ㛵ࢃࡾࢆࠊ⏕≀⸆๣Ꮫࠊ⸆≀ືែᏛࠊࢻࣛࢵࢢࢹࣜࣂ࣮ࣜࢩࢫࢸ࣒࡞࡝ࡢᏛၥⓗࣂࢵ
ࢡࢢࣛࣥࢻ࡟ᇶ࡙ࡁ⤫ྜⓗ࡟㏣ồࡋࠊ⌮᝿ⓗ࡞⸆≀἞⒪ࡀ⾜࠺ࡇ࡜ࡀ࡛ࡁࡿ ͆⸆≀ᢞ୚͇ࡢ᭱㐺໬ࡢ
ᐇ⌧ࢆ┠ⓗ࡟◊✲άືࢆ⾜ࡗ࡚࠸ࡿࠋࡇ࠺ࡋࡓάືࢆ㏻ࡌࠊ⸆≀἞⒪ࢆከゅⓗ࡞どⅬ࠿ࡽᩜ⾝ࡋࠊၥ㢟
ࡢタᐃ࡜௬ㄝࡢᥦ♧ࠊᐇ㦂࡟ࡼࡿᐇド࡞࡝༑ศ࡞◊✲⬟ຊ࡜࣮ࣜࢲ࣮ࢩࢵࣉࢆවࡡഛ࠼ࡓ◊✲⪅ࡢ⫱ᡂ
ࢆ┠ⓗ࡜ࡋ࡚࠸ࡿࠋ
㑇ఏᏊ἞⒪࣭DNA ࣡ࢡࢳࣥ⒪ἲࡢ᭱㐺໬ࢆ┠ᣦࡋࡓ᰾㓟་⸆ရ㛤Ⓨ
㑇ఏᏊ἞⒪ࡸ DNA ࣡ࢡࢳࣥ⒪ἲࡢᐇ⌧࡟ࡣࠊ㑇ఏᏊ⏘≀࡛࠶ࡿࢱࣥࣃࢡ㉁ࡢయෆືែไᚚࡀᚲ
せ࡛࠶ࡿࠋ࢖ࣥࢱ࣮ࣇ࢙ࣟࣥ㑇ఏᏊࢆ฼⏝ࡋࡓ᳨ウ࡛ࡣࠊ㛗ᮇⓎ⌧ࡀྍ⬟࡞ࣉࣛࢫ࣑ࢻࡢ㛤Ⓨ࡟ᡂ
ຌࡋࠊࡇࢀࡀ⒴ࡸ࢔ࢺࣆ࣮ᛶ⓶⭵⅖἞⒪࡟᭷ຠ࡛࠶ࡿࡇ࡜ࢆᐇドࡋࡓࠋࡲࡓࠊᵓ㐀ᨵኚᆺࢱࣥࣃࢡ
㉁ࢆタィࡋࠊ㑇ఏᏊᑟධ࣭Ⓨ⌧ᚋࡢࢱࣥࣃࢡ㉁యෆືែไᚚ࡟ࡼࡿ἞⒪ຠᯝቑᙉ࣭๪స⏝㍍ῶ࡟ࡶ
ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋᢠཎᥦ♧⣽⬊࡟ຠ⋡ࡼࡃྲྀࡾ㎸ࡲࢀࡿࡇ࡜࡛⣽⬊ࢆάᛶ໬ࡍࡿ⇕ࢩࣙࢵࢡࢱࣥࣃ
ࢡ㉁ࢆᇶ┙࡜ࡍࡿᢠ⭘⒆ච␿἞⒪ࢩࢫࢸ࣒ࡢ㛤Ⓨ࡛ࡣࠊ⭷㏱㐣࣌ࣉࢳࢻࢆ฼⏝ࡋࡓືែไᚚᢏ⾡࡟
ࡼࡾࠊᢠཎࢆ⏝࠸ࡎ࡟ᢠཎ≉␗ⓗ࡞ᢠ⭘⒆ච␿ࡢㄏᑟ࡟ᡂຌࡋࡓࠋ
᰾㓟ࢼࣀࢹࣂ࢖ࢫ࣭ࣁ࢖ࢻࣟࢤࣝࡢ㛤Ⓨ
CpG ࣔࢳ࣮ࣇࢆྵࡴ DNA ࡣࠊTLR9 ࢆ௓ࡋ࡚ࢧ࢖ࢺ࢝࢖ࣥ⏘⏕ࢆㄏᑟࡍࡿࡇ࡜࠿ࡽࠊ⒴ࡸ⮬ᕫ
ච␿⑌ᝈࠊ࢔ࣞࣝࢠ࣮⑌ᝈ࡞࡝࡟ᑐࡍࡿ἞⒪⸆࡜ࡋ࡚ࡢᛂ⏝ࡀᮇᚅࡉࢀࡿࠋᡃࠎࡣࠊ┦⿵㙐࡜ 2 㔜
㙐ࢆᙧᡂࡍࡿ᰾㓟ࡢᶵ⬟ࢆᕦࡳ࡟฼⏝ࡍࡿࡇ࡜࡛ࠊኳ↛࡟ࡣᏑᅾࡋ࡞࠸ࣘࢽ࣮ࢡ࡞ᵓ㐀ࢆ᭷ࡍࡿ
DNA ᵓ㐀య㸦polypodna㸧ࢆᵓ⠏ࡍࡿࡇ࡜࡟ᡂຌࡋࡓࠋࡇࢀࡣࠊ୰ᚰ࠿ࡽ」ᩘࡢ㊊㸦pod㸧ࡀ✺ࡁฟ
ࡿᙧࡢศᒱᆺ DNA ࡛࠶ࡾࠊࡇࡢࡼ࠺࡞ᵓ㐀య࡜ࡍࡿࡇ࡜࡛ CpG ࣔࢳ࣮ࣇ࡟ࡼࡿච␿άᛶ໬ࡀቑᙉ
ࡉࢀࡿࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋ࡚࠸ࡿࠋࡉࡽ࡟ࡇࡢ polypodna ࢆ㓝⣲ࢆ⏝࠸࡚㐃⤖ࡍࡿࡇ࡜࡛ࠊࢹࣥࢻࣜ
࣐࣮ᆺ DNA ࡸ DNA ࣁ࢖ࢻࣟࢤࣝࡢㄪ〇࡟ᡂຌࡋࡓࠋDNA ࣁ࢖ࢻࣟࢤࣝࡣෆໟࡋࡓ⸆≀ࢆᚎᨺ࡛
ࡁࡿࡇ࡜࠿ࡽࠊ⌧ᅾࠊ⸆≀࣭ච␿἞⒪ࢩࢫࢸ࣒࡬࡜ࡋ࡚ࡢ㛤Ⓨ࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
RNA ᖸ΅ࢆ฼⏝ࡋࡓ⑌ᝈ἞⒪ࢩࢫࢸ࣒ࡢ㛤Ⓨ
ሷᇶ㓄ิ≉␗ⓗ࡟ mRNA ࢆศゎࡍࡿ RNA ᖸ΅ࡣࠊ㑇ఏᏊⓎ⌧ᢚไάᛶࡢ㧗ࡉ࠿ࡽ࢘࢖ࣝࢫឤᰁ
ࡸ⒴࡞࡝࡟ᑐࡍࡿ⏬ᮇⓗ἞⒪ἲ࡜ࡋ࡚ᮇᚅࡉࢀ࡚࠸ࡿࠋࡇࢀࢆ἞⒪࡟⏝࠸ࡿ࡟ࡣάᛶᮏయ࡛࠶ࡿ
small interfering RNA㸦siRNA㸧ࡲࡓࡣ࣊࢔ࣆࣥᆺ RNA ࢆຠ⋡Ⰻࡃᶆⓗ⣽⬊ෆ࡟ࢹࣜࣂ࣮ࣜࡍࡿᚲせ
ࡀ࠶ࡿࠋᡃࠎࡣࠊin vivo ࡛ RNA ᖸ΅ࢆㄏᑟࡍࡿࡇ࡜࡟ࡼࡿ⑌ᝈ἞⒪ࡢᐇ⌧࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋࣞ
࣏࣮ࢱ࣮㑇ఏᏊᑟධ⒴⣽⬊ࢆ⏝࠸ࡓᐃ㔞ⓗ࡞ RNA ᖸ΅ຠᯝࡢゎᯒἲࢆ☜❧ࡍࡿ࡜࡜ࡶ࡟ࠊ⣽⬊ቑ
Ṫࡸ⾑⟶᪂⏕ࢆಁ㐍ࡍࡿ HIF-1Į ࢆࣀࢵࢡࢲ࢘ࣥࡍࡿࡇ࡜࡛㧗࠸ᢠ⭘⒆ຠᯝࢆᚓ࡚࠸ࡿࠋࡑࡢ἞⒪
ࡢᐇ⌧࡟ࡣ㑇ఏᏊⓎ⌧ᢚไຠ⋡ࡢᨵၿࡀᚲせ࡛࠶ࡿࡇ࡜࠿ࡽࠊࡉࡽ࡟㧗ຠ⋡࡟ RNA ᖸ΅ࢆㄏᑟྍ
⬟࡞ࢩࢫࢸ࣒ࡢ㛤Ⓨ࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
ከᶵ⬟⣽⬊἞⒪๣ࡢ㛤Ⓨ
㏆ᖺࠊ⬇ᛶᖿ⣽⬊ࡸேᕤከ⬟ᛶᖿ⣽⬊ࢆጞࡵࠊᵝࠎ࡞⣽⬊ࢆㄪ〇࣭ᇵ㣴ࡍࡿᢏ⾡ࡀ㣕㌍ⓗ࡟㐍Ṍ
ࡋࡓࡇ࡜ࢆཷࡅࠊ⣽⬊ࢆᢞ୚ࡍࡿࡇ࡜࡟ࡼࡿ⑌ᝈ἞⒪࡟኱ࡁ࡞ᮇᚅࡀᐤࡏࡽࢀ࡚࠸ࡿࠋࡋ࠿ࡋ࡞ࡀ
− 297 −
ࡽࠊ⣽⬊ࢆ฼⏝ࡋࡓ἞⒪ࡢ᭷ຠᛶࡣࠊᢞ୚ࡍࡿ⣽⬊ࡢᶵ⬟ᛶ࡟ຍ࠼࡚ࠊ⏕యෆ㐠࿨࡟౫Ꮡࡍࡿࠋᡃࠎ
ࡣࠊḟୡ௦἞⒪࡟฼⏝ྍ⬟࡞ከᶵ⬟⣽⬊἞⒪๣ࡢ㛤Ⓨ࡟ྥࡅ᳨࡚ウࢆ㐍ࡵ࡚࠸ࡿࠋᢞ୚⣽⬊ࡢ⏕య
ෆ࡛ࡢṧᏑᛶྥୖࢆ┠ⓗ࡜ࡋࡓ᳨ウ࡟࠾࠸࡚ࡣࠊྜᡂᑠศᏊ⣽⬊᥋╔ศᏊࢆ฼⏝ࡍࡿࡇ࡜࡛ࠊ⛣᳜
⣽⬊ࡢ⏕Ꮡᮇ㛫ࢆᘏ㛗ࡋࠊ⓶⭵ᦆയࡢ἞⒵ಁ㐍࡟ᡂຌࡋࡓࠋ௒ᚋࠊ⣽⬊࡟ᚲせ࡞✀ࠎࡢᶵ⬟ࢆ௜୚
ࡍࡿࡇ࡜࡛ࠊ⣽⬊἞⒪࡟฼⏝ྍ⬟࡞⣽⬊἞⒪๣ࡢ㛤Ⓨ࡟ྲྀࡾ⤌ࡴணᐃ࡛࠶ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᅜෆእࡢᏛ఍࣭ࢩ࣏ࣥࢪ࣒࢘➼࡛㧗಴ᩍᤵࠊすᕝ෸ᩍᤵࡀࢤࢫࢺࢫࣆ࣮࣮࢝࡜ࡋ࡚ከᩘㅮ₇ࢆ⾜ࡗ࡚
࠸ࡿࠋࡲࡓࠊ㧗಴ᩍᤵࡀ 2009 ᖺᗘ࡟ AAPS (American Association of Pharmaceutical Scientists) Fellow ࢆࠊ
すᕝ෸ᩍᤵࡀ 2007 ᖺᗘ᪥ᮏ⸆๣Ꮫ఍ዡບ㈹ࢆࠊ
㧗ᶫຓᩍࡀ 2006 ᖺᗘ࡟᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲ဨ㸦DC2㸧
࡟᥇ᢥࡉࢀࠊ኱Ꮫ㝔༤ኈᚋᮇㄢ⛬㝔⏕ࡢẟ฼ᾈኴࡀ 2009 ᖺ࡟ Nucleic Acids Research/ASJ Poster Award ࢆ
ཷ㈹ࡋ࡚࠸ࡿࡇ࡜࠿ࡽࡶ◊✲ホ౯ࡣࡁࢃࡵ࡚㧗࠸ࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ 3 ᅇ⏕๓ᮇㄢ⛬ࡢ⸆๣Ꮫ㸰㸦ᅛᙧ〇๣ㄽ㸧ࠊ3 ᅇ⏕ᚋᮇㄢ⛬ࡢ⸆๣Ꮫ㸱㸦⸆≀ືែ
Ꮫ㸧ࠊ⸆Ꮫᑓ㛛ᐇ⩦㸱ࢆᢸᙜࡋ࡚࠸ࡿࠋ฿㐩┠ᶆࢆタᐃࡋࠊ⌮ゎࡀ῝ࡲࡿࡼ࠺₇⩦ᙧᘧࢆ⤌ࡳ㎸ࢇ࡛ㅮ
⩏ࡋ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗ㓄ᒓࡢᏛ⏕࡟ࡣಶேࡢࢸ࣮࣐ࡢࡳ࡞ࡽࡎࠊᗈࡃ㛵㐃ࡢ▱㆑࣭ᢏ⾡ࢆ⩦
ᚓ࡛ࡁࡿᶵ఍ࢆ୚࠼࡚࠸ࡿࠋᙜศ㔝ࡢ᭱኱ࡢ≉㛗ࡣࠊ㝔⏕ࡀ⊂⮬ࡢࢸ࣮࣐ࢆᣢࡕ⮬୺ⓗ࡟ィ⏬ࢆ❧᱌ࠊ
ᐇ⾜ࡍࡿⅬ࡟࠶ࡿࠋ኱ࡁ࡞ࢸ࣮࣐ࡈ࡜࡟ࠊ㸲㹼㸳ேࡢࢢ࣮ࣝࣉ༢఩࡛ࠊ㐌࡟㸯ᅇᩍဨ࡜ࡢࢹ࢕ࢫ࢝ࢩࣙ
ࣥࠊពぢ஺᥮ࢆ⾜࠸ࠊ◊✲ࡢ㐍ᒎ࡜ࣞ࣋ࣝࡢᙉ໬ࢆᅗࡿᶵ఍ࢆᣢࡘࡼ࠺࡟ࡋ࡚࠸ࡿࠋ≉࡟༤ኈㄢ⛬ࡢ㝔
⏕࡟ࡣࠊࢢ࣮ࣝࣉ඲యࡢ◊✲ീࢆᢕᥱࡉࡏࠊ◊✲ࡢ㐍ࡵ᪉ࢆᵓ⠏ࡍࡿ㝿ࡢ࣮ࣜࢲ࣮ࢩࢵࣉ⬟ຊࡢ㣴ᡂ࡟
ࡶ↔Ⅼࢆ⨨࠸࡚࠸ࡿࠋࡲࡓࠊᩍᐊဨ඲ဨࡀ⮬ศ௨እࡢ◊✲ࢸ࣮࣐ࢆ⌮ゎࡍࡿࡓࡵࢭ࣑ࢼ࣮࡛ࡣ◊✲ሗ࿌
఍ࢆ㐌୍ᗘ⾜࠺࡜࡜ࡶ࡟ࠊ⮬ศࡢ◊✲ࢸ࣮࣐࡟㛵㐃ࡋࡓᩥ⊩ࢆ⥲ㄝⓗ࡟ࡲ࡜ࡵࡿⓎ⾲ࢆ⾜࡞ࡗ࡚࠸ࡿࠋ
ࡲࡓࠊ㸰㸮㸮㸶ᖺᗘ࠾ࡼࡧ㸰㸮㸯㸮ᖺᗘࡢ⸆๣Ꮫ఍ࡢ SNPEE ࡟࠾࠸࡚ࠊᏛ⏕࡟ࡼࡿ㉁␲ᛂ⟅ࡀࡶࡗ࡜
ࡶάⓎ࡛༳㇟ⓗ࡞◊✲ᐊ࡟㑅ࡤࢀࡓࡇ࡜࠿ࡽࠊࡇࢀࡽࡢ◊✲ᐊάືࢆ㏻ࡌ࡚㝔⏕ࡢࢹ࢕ࢫ࢝ࢵࢩࣙࣥ⬟
ຊࢆྥୖࡉࡏࡿࡇ࡜࡟ᡂຌࡋ࡚࠸ࡿࠋ
ࡉࡽ࡟ࠊㄒᏛຊࡢ඘ᐇࢆ┠ⓗ࡟ಟኈㄽᩥࡣᚲࡎⱥㄒ࡛᭩ࡃࡼ࠺ᣦᑟࡋ࡚࠸ࡿࠋ༤ኈㄢ⛬ࡢ㝔⏕࡟ࡣࠊ
ⱥㄒㄽᩥࢆྛಶேࡀ⊂ຊ࡛௙ୖࡆࡿ⬟ຊࡢ⫱ᡂࡶ⾜ࡗ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊᤵᴗホ౯ࢆಶேⓗ࡟⾜ࡗ࡚ㅮ⩏࡟ྲྀࡾධࢀࡿࡼ࠺ཧ⪃࡟ࡋ࡚࠸ࡿࠋ◊✲
ᐊෆࡢᩍ⫱ࡣࠊ࡯ࡰ඲ဨࡀᖺ࡟୍ᗘࡣᅜ㝿Ꮫ఍ࡶྵࡵࡓᏛ఍࡛Ⓨ⾲ࢆࡋ࡚࠸ࡿࡇ࡜࠿ࡽุ᩿ࡋ࡚ࠊྛಶ
ேࡢᐇຊࢆ㧗ࡵࡿࡇ࡜࡟ᙺ❧ࡗ࡚࠸ࡿࠋᮏศ㔝ࡢ኱Ꮫ㝔ಟ஢⪅ࡣ〇⸆࣓࣮࣮࢝ࡢ◊✲⫋࡟ࡘࡃࡶࡢࡀከ
ࡃࠊ༤ኈㄢ⛬㸶ྡ㸦〇⸆㛵㐃࣓࣮࣮࢝◊✲⫋㸲ྡࠊ኱Ꮫㅮᖌ㸯ྡࠊ኱Ꮫຓᩍ㸰ྡࠊᅜ❧⾨◊㸯ྡࠊ㸧ࠊಟ
ኈㄢ⛬㸰㸴ྡ㸦〇⸆࣓࣮࣮࢝◊✲⫋㸰㸳ྡࠊ⑓㝔⸆๣ᖌ㸯ྡ㸧࡛࠶ࡾࠊᩍ⫱࡜◊✲ࡢ㧗࠸ࣞ࣋ࣝࡀホ౯
ࡉࢀ࡚࠸ࡿ⤖ᯝ࡜⪃࠼ࡽࢀࡿࠋ
㸦ཎⴭ㸧
1. 5’-phosphate oligodeoxynucleotides enhance the phosphodiester-CpG DNA-induced inflammatory response
in macrophages. Yoshida H, Nishikawa M, Kiyota T, Uno S, Toyota H, Takahashi R, Narita M, Takakura Y.
Euro J Immunol., in press
2. Positive correlation between the generation of reactive oxygen species and activation/reactivation of
transgene expression after hydrodynamic injection into mice. Takiguchi N, Takahashi Y, Nishikawa M,
Matsui Y, Fukuhara Y, Oushiki D, Kiyose K, Hanaoka K, Nagano T, Takakura Y. Pharm Res., in press
3. Improvement of insulin resistance by removal of systemic hydrogen peroxide by PEGylated catalase in obese
mice. Ikemura M, Nishikawa M, Hyoudou K, Kobayashi Y, Yamashita F, Hashida M. Mol Pharm., in press
4. Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in
tumor-bearing mice. Nishikawa M, Mizuno Y, Mohri K, Matsuoka N, Rattanakiat S, Takahashi Y, Funabashi
H, Luo D, Takakura Y. Biomaterials., in press
5. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and
phosphorothioate oligodeoxynucleotides. Matsuoka N, Nishikawa M, Mohri K, Rattanakiat S, Takakura Y. J
Control Release., in press
6. Persistent interferon transgene expression by RNA interference-mediated silencing of interferon receptors.
Takahashi Y, Vikman E, Nishikawa M, Ando M, Watanabe Y, Takakura Y. J Gene Med., 12(9), 739-746
− 298 −
(2010)
7. Enhanced generation of cytotoxic T lymphocytes by heat shock protein 70 fusion proteins harboring both
CD8+ T Cell and CD4+ T cell epitopes. Takemoto S, Nishikawa M, Guan X, Ohno Y, Yata T, Takakura Y. Mol
Pharm., in press
8. Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in
NC/Nga mice via Th1 polarization. Hattori K, Nishikawa M, Watcharanurak K, Ikoma A, Kabashima K,
Toyota H, Takahashi Y, Takahashi R, Watanabe Y, Takakura Y. J Immunol., 184(5), 2729-2735 (2010)
9. Injection site-dependent induction of immune response by DNA vaccine: comparison of skin and spleen as a
target for vaccination. Guan X, Nishikawa M, Takemoto S, Ohno Y, Yata T, Takakura Y. J Gene Med., 12(3),
301-309 (2010)
10. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in
macrophages. Yasuda S, Yoshida H, Nishikawa M, Takakura Y. Mol Pharm., 7(2), 533-542 (2010)
11. Development of a novel Hsp70-based DNA vaccine as a multifunctional antigen delivery system. Yamaoka A,
Guan X, Takemoto S, Nishikawa M, Takakura Y. J Control Release., 142(3), 411-415 (2010).
12. Bootstrap method-based estimation of the minimum sample number for obtaining pharmacokinetic
parameters in preclinical experiments. Takemoto S, Yamaoka K, Nishikawa M, Yano Y, Takakura Y. J Pharm
Sci., 99(4), 2176-2184 (2010)
13. Control of hypoxia-induced tumor cell adhesion by cytophilic human catalase. Yata T, Nishikawa M,
Nishizaki C, Oku M, Yurimoto H, Sakai Y, Takakura Y. Free Radic Biol Med., 47(12), 1772-1778 (2009)
14. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid
DNA/doxorubicin complex in mice. Mizuno Y, Naoi T, Nishikawa M, Rattanakiat S, Hamaguchi N, Hashida
M, Takakura Y. J Control Release., 141(2), 252-259 (2010)
15. Induction of tumor-specific immune response by gene transfer of Hsp70-cell-penetrating peptide fusion
protein to tumors in mice. Nishikawa M, Otsuki T, Ota A, Guan X, Takemoto S, Takahashi Y, Takakura Y.
Mol Ther., 18(2), 421-428 (2010)
16. Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice. Katsumi H, Nishikawa
M, Yasui H, Yamashita F, Hashida M. J Control Release., 140(1), 12-17 (2009)
17. The assembly of a short linear natural cytosine-phosphate-guanine DNA into dendritic structures and its
effect on immunostimulatory activity. Rattanakiat S, Nishikawa M, Funabashi H, Luo D, Takakura Y.
Biomaterials., 30(29), 5701-5706 (2009)
18. The aldo-keto reductase Akr1b7 gene is a common transcriptional target of xenobiotic receptors pregnane X
receptor and constitutive androstane receptor. Liu MJ, Takahashi Y, Wada T, He J, Gao J, Tian Y, Li S, Xie W.
Mol Pharmacol., 76(3), 604-611 (2009) TLR9-dependent systemic interferon-beta production by intravenous
injection of plasmid DNA/cationic liposome complex in mice. Yoshida H, Nishikawa M, Yasuda S, Mizuno Y,
Toyota H, Kiyota T, Takahashi R, Takakura Y. J Gene Med., 11(8), 708-717 (2009)
19. Effects of methyl-beta-cyclodextrin treatment on secretion profile of interferon-beta and zonula occuludin-1
architecture in Madin-Darby canine kidney cell monolayers. Maruyama M, Ishida K, Watanabe Y, Nishikawa
M, Takakura Y. Biol Pharm Bull. 32(5), 910-915 (2009)
20. Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of
catalase. Hyoudou K, Nishikawa M, Ikemura M, Kobayashi Y, Mendelsohn A, Miyazaki N, Tabata Y,
Yamashita F, Hashida M. J Control Release., 137(2), 110-115 (2009)
21. Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA
vaccination. Isaji K, Kawase A, Matono M, Guan X, Nishikawa M, Takakura Y. J Control Release., 135(3),
227-233 (2009)
22. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene
expression. Mitsui M, Nishikawa M, Zang L, Ando M, Hattori K, Takahashi Y, Watanabe Y, Takakura Y. J
Gene Med., 11(5), 435-443 (2009)
23. Enhanced generation of cytotoxic T lymphocytes by increased cytosolic delivery of MHC class I epitope
fused to mouse heat shock protein 70 via polyhistidine conjugation. Takemoto S, Nishikawa M, Otsuki T,
Yamaoka A, Maeda K, Ota A, Takakura Y. J Control Release., 135(1), 11-18 (2009)
24. Hydrogen peroxide-mediated nuclear factor kappaB activation in both liver and tumor cells during initial
stages of hepatic metastasis. Kobayashi Y, Nishikawa M, Hyoudou K, Yamashita F, Hashida M. Cancer Sci.,
99(8), 1546-1552 (2008)
25. Gene silencing of beta-catenin in melanoma cells retards their growth but promotes the formation of
pulmonary metastasis in mice. Takahashi Y, Nishikawa M, Suehara T, Takiguchi N, Takakura Y. Int J Cancer.,
123(10), 2315-2320 (2008)
26. Reactivation of silenced transgene expression in mouse liver by rapid, large-volume injection of isotonic
solution. Nishikawa M, Nakayama A, Takahashi Y, Fukuhara Y, Takakura Y. Hum Gene Ther., 19(10),
1009-1020 (2008)
27. Unique cytokine production profile following stimulation with DNA in macrophages from NZB/W F1 mice.
− 299 −
Ogawa Y, Yoshinaga T, Nishikawa M, Takakura Y. Biol Pharm Bull., 31(6), 1244-1249 (2008)
28. Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or
short hairpin RNA expressed from plasmid vectors. Takahashi Y, Yamaoka K, Nishikawa M, Takakura Y. J
Pharm Sci., 98(1), 74-80 (2009)
29. SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Hyoudou K, Nishikawa M,
Kobayashi Y, Ikemura M, Yamashita F, Hashida M. Clin Exp Metastasis., 25(5), 531-536 (2008)
30. Cellular activation by plasmid DNA in various macrophages in primary culture. Yoshida H, Nishikawa M,
Yasuda S, Mizuno Y, Takakura Y. J Pharm Sci., 97(10), 4575-4585 (2008)
31. Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation. Nishikawa M,
Matono M, Rattanakiat S, Matsuoka N, Takakura Y. Immunology., 124(2), 247-255 (2008)
32. Prevention of hepatic ischemia/reperfusion injury by prolonged delivery of nitric oxide to the circulating
blood in mice. Katsumi H, Nishikawa M, Yamashita F, Hashida M. Transplantation., 85(2), 264-269 (2008)
33. Effects of inflammatory response on in vivo transgene expression by plasmid DNA in mice. Kako K,
Nishikawa M, Yoshida H, Takakura Y. J Pharm Sci., 97(8), 3074-3083 (2008)
34. Insertion of nuclear factor-kappaB binding sequence into plasmid DNA for increased transgene expression in
colon carcinoma cells. Thanaketpaisarn O, Nishikawa M, Okabe T, Yamashita F, Hashida M. J Biotechnol.,
133(1), 36-41 (2008)
35. Cationized catalase-loaded hydrogel for growth inhibition of peritoneally disseminated tumor cells. Hyoudou
K, Nishikawa M, Ikemura M, Kobayashi Y, Mendelsohn A, Miyazaki N, Tabata Y, Yamashita F, Hashida M.
J Control Release., 122(2), 151-158 (2007)
36. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification
with polyethylene glycol. Takagi A, Yamashita N, Yoshioka T, Takaishi Y, Sano K, Yamaguchi H, Maeda A,
Saito K, Takakura Y, Hashida M. J Control Release., 119(3), 271-278 (2007)
37. Design of PCR-amplified DNA fragments for in vivo gene delivery: size-dependency on stability and
transgene expression. Hirata K, Nishikawa M, Kobayashi N, Takahashi Y, Takakura Y. J Pharm Sci., 96(9),
2251-2261 (2007)
38. Inhibition of peritoneal dissemination of tumor cells by cationized catalase in mice. Hyoudou K, Nishikawa
M, Kobayashi Y, Mukai S, Ikemura M, Kuramoto Y, Yamashita F, Hashida M. J Control Release., 119(1),
121-127 (2007)
39. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid
DNA. Kawano H, Nishikawa M, Mitsui M, Takahashi Y, Kako K, Yamaoka K, Watanabe Y, Takakura Y. Int J
Cancer., 121(2), 401-406 (2007)
40. Action mechanism of tachyplesin I and effects of PEGylation. Imura Y, Nishida M, Ogawa Y, Takakura Y,
Matsuzaki K. Biochim Biophys Acta., 1768(5), 1160-1169 (2007)
41. Plasmid DNA uptake and subsequent cellular activation characteristics in human monocyte-derived cells in
primary culture. Fukuhara Y, Naoi T, Ogawa Y, Nishikawa M, Takakura Y. J Pharm Sci., 96(6), 1576-1584
(2007)
42. Histogram analysis of pharmacokinetic parameters by bootstrap resampling from one-point sampling data in
animal experiments. Takemoto S, Yamaoka K, Nishikawa M, Takakura Y. Drug Metab Pharmacokinet., 21(6),
458-464 (2006)
43. DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells.
Yoshinaga T, Yasuda K, Ogawa Y, Nishikawa M, Takakura Y. Immunology., 120(3), 295-302 (2007)
44. Analysis of in vivo nuclear factor-kappaB activation during liver inflammation in mice: prevention by
catalase delivery. Hyoudou K, Nishikawa M, Kobayashi Y, Kuramoto Y, Yamashita F, Hashida M. Mol
Pharmacol., 71(2), 446-453 (2007)
45. Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase.
Hyoudou K, Nishikawa M, Kobayashi Y, Kuramoto Y, Yamashita F, Hashida M. Clin Exp Metastasis.,
23(5-6), 269-278 (2006)
46. Suppression of tumor growth by intratumoral injection of short hairpin RNA-expressing plasmid DNA
targeting beta-catenin or hypoxia-inducible factor 1alpha. Takahashi Y, Nishikawa M, Takakura Y. J Control
Release., 116(1), 90-95 (2006)
47. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Hyoudou K, Nishikawa
M, Kobayashi Y, Umeyama Y, Yamashita F, Hashida M. Free Radic Biol Med., 41(9), 1449-1458 (2006)
48. Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. Nagayama S,
Ogawara K, Minato K, Fukuoka Y, Takakura Y, Hashida M, Higaki K, Kimura T. Int J Pharm., 329(1-2),
192-198 (2007)
49. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG
oligonucleotide/cationic liposome complex. Kuramoto Y, Nishikawa M, Hyoudou K, Yamashita F, Hashida
M. J Control Release., 115(2), 226-233 (2006)
50. Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human
− 300 −
51.
52.
53.
54.
55.
56.
57.
58.
59.
interleukin 11 (rhIL11). Takagi A, Yamashita N, Yoshioka T, Takaishi Y, Nakanishi K, Takemura S, Maeda A,
Saito K, Takakura Y, Hashida M. J Control Release., 115(2), 134-139 (2006)
Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble
antigen through scavenger receptor-mediated delivery. Yamasaki Y, Ikenaga T, Otsuki T, Nishikawa M,
Takakura Y. Vaccine., 25(1), 85-91 (2007)
Role of tyrosine and tryptophan in chemically modified serum albumin on its tissue distribution. Ma SF,
Nishikawa M, Yabe Y, Yamashita F, Hashida M. Biol Pharm Bull., 29(9), 1926-1930 (2006)
Enhanced antigen-specific antibody production following polyplex-based DNA vaccination via the
intradermal route in mice. Kawase A, Isaji K, Yamaoka A, Kobayashi N, Nishikawa M, Takakura Y. Vaccine.,
24(27-28), 5535-5545 (2006)
Analysis of the molecular interaction between mannosylated proteins and serum mannan-binding lectins.
Terada T, Nishikawa M, Yamashita F, Hashida M. Int J Pharm., 316(1-2), 117-123 (2006)
Influence of cholesterol composition on the association of serum mannan-binding proteins with
mannosylated liposomes. Terada T, Nishikawa M, Yamashita F, Hashida M. Biol Pharm Bull., 29(4), 613-618
(2006)
Analysis of the molecular interaction of glycosylated proteins with rabbit liver asialoglycoprotein receptors
using surface plasmon resonance spectroscopy. Terada T, Nishikawa M, Yamashita F, Hashida M. J Pharm
Biomed Anal., 41(3), 966-972 (2006)
Liver targeting of catalase by cationization for prevention of acute liver failure in mice. Ma SF, Nishikawa M,
Katsumi H, Yamashita F, Hashida M. J Control Release., 110(2), 273-282 (2006)
Moment analysis for kinetics of gene silencing by RNA interference. Takahashi Y, Yamaoka K, Nishikawa M,
Takakura Y. Biotechnol Bioeng., 93(4), 816-819 (2006)
Use of lipoplex-induced nuclear factor-kappaB activation to enhance transgene expression by lipoplex in
mouse lung. Kuramoto T, Nishikawa M, Thanaketpaisarn O, Okabe T, Yamashita F, Hashida M. J Gene Med.,
8(1), 53-62 (2006)
㸦⥲ㄝ㸧㸦Ḣᩥ㸧
1. DNA-based nano-sized systems for pharmaceutical and biomedical applications. Nishikawa M, Rattanakiat S,
Takakura Y. Adv Drug Deliv Rev.,62(6), 626-32 (2010)
2. Towards therapeutic application of RNA-mediated gene regulation. Preface. Takakura Y. Adv Drug Deliv
Rev., 61(9), 667 (2009)
3. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to
achieve RNAi-based gene therapy. Takahashi Y, Nishikawa M, Takakura Y. Adv Drug Deliv Rev., 61(9),
760-766 (2009)
4. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Nishikawa M, Hashida M,
Takakura Y. Adv Drug Deliv Rev., 61(4), 319-326 (2009)
5. Reactive oxygen species in tumor metastasis. Nishikawa M. Cancer Lett., 266(1), 53-59 (2008)
6. Pharmacokinetic considerations regarding non-viral cancer gene therapy. Nishikawa M, Takakura Y, Hashida
M. Cancer Sci., 99(5), 856-862 (2008)
7. Heat shock protein derivatives for delivery of antigens to antigen presenting cells. Nishikawa M, Takemoto S,
Takakura Y. Int J Pharm., 354(1-2), 23-27 (2008)
8. Hsp-based tumor vaccines: state-of-the-art and future directions. Takakura Y, Takemoto S, Nishikawa M.
Curr Opin Mol Ther., 9(4), 385-391 (2007)
9. Development of nitric oxide donors for the treatment of cardiovascular diseases. Katsumi H, Nishikawa M,
Hashida M. Cardiovasc Hematol Agents Med Chem., 5(3), 204-208 (2007)
10. Role of immunostimulatory DNA and TLR9 in gene therapy. Yasuda K, Wagner H, Takakura Y. Crit Rev
Ther Drug Carrier Syst., 23(2), 89-110 (2006)
11. Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. Nishikawa M, Hashida M.
Expert Opin Drug Deliv., 3(3), 355-369 (2006)
㸦⥲ㄝ㸧㸦࿴ᩥ㸧
1.
2.
3.
4.
࢜ࣜࢦ᰾㓟ࢆᇶ┙࡜ࡍࡿࢼࣀࢧ࢖ࢬDDS㛤Ⓨ㸬ẟ฼ᾈኴ㸪すᕝඖஓ㸪㧗ᶫ᭷ᕫ㸪㧗಴႐ಙ㸪Drug
Delivery System㸪25: 573-578 (2010).
࢜ࣜࢦ᰾㓟་⸆࡬ࡢDDSࡢᒎ㛤㸬㧗಴႐ಙ, Drug Delivery System, 25: 549 (2010).
㑇ఏᏊ࣭⣽⬊〇๣ࣇ࢛࣮࢝ࢫࢢ࣮ࣝࣉࡢάື࡟ࡘ࠸࡚㸬㧗಴႐ಙ, すᕝඖஓ, ⸆๣Ꮫ, 70: 214-215
(2010).
⫢ࢱ࣮ࢤࢸ࢕ࣥࢢ㸬すᕝඖஓ㸪DDS἞⒪ࢩࢫࢸ࣒ࡢタィ࡜ホ౯㸪ᶫ⏣ ඘ ⦅㸪ࡌ࡯࠺㸪pp. 67-71
(2009).
− 301 −
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
⸆≀యෆືែࡢゎᯒ࡜ホ౯㸬㧗಴႐ಙ, ࣇ࢓࣮࣒ࢸࢡࢪࣕࣃࣥ, 25: 37-40 (2009).
㑇ఏᏊࢹࣜࣂ࣮ࣜࢩࢫࢸ࣒ࡢ᭱㐺໬㸬すᕝඖஓ㸪໬Ꮫᕤᴗ㸪59: 27-31 (2008).
㧗ศᏊ໬Ꮫ࡟ᮇᚅࡍࡿ㸬㧗಴႐ಙ, Drug Delivery System, 23: 608 (2008).
DDSࢆ⏝࠸ࡓsiRNAࢹࣜࣂ࣮ࣜ㸬㧗಴႐ಙ, ⅖⑕࡜ච␿, 16: 23-28 (2008).
DDSࡢᇶ♏. 㧗಴႐ಙ, ໬Ꮫᕤᴗ, 59: 3-6 (2008).
ࡀࢇ἞⒪ࡢࡓࡵࡢshort hairpin RNAⓎ⌧࣋ࢡࢱ࣮ࡢࢹࣜࣂ࣮ࣜ㸬すᕝඖஓ, 㧗ᶫ᭷ᕫ, 㧗಴႐ಙ,
Drug Delivery System, 22: 123-130 (2007).
㑇ఏᏊ࣭᰾㓟་⸆ရࡢࢹࣜࣂ࣮ࣜ㸬㧗಴႐ಙ, Drug Delivery System, 22: 103 (2007).
ᣢ⥆ⓗ㑇ఏᏊⓎ⌧ࡢࡓࡵࡢ࢔ࣉ࣮ࣟࢳ㸬すᕝඖஓ, 㧗಴႐ಙ, 㑇ఏᏊ་ᏛMOOK 5ྕࠕඛ➃⏕≀་Ꮫ
◊✲࣭་⒪ࡢࡓࡵࡢ㑇ఏᏊᑟධࢸࢡࣀࣟࢪ࣮࢘࢖ࣝࢫࢆ⏝࠸࡞࠸㑇ఏᏊᑟධἲࡢᮦᩱࠊᢏ⾡ࠊ᪉ἲ
ㄽࡢ᪂ࡓ࡞ᒎ㛤ࠖࠊཎᓥ⚽ྜྷࠊ⏣⏿Ὀᙪ⦅ࠊ 118-123 (2006).
ࡀࢇ⣽⬊࡬ࡢsiRNAࢹࣜࣂ࣮ࣜ࡜ࡀࢇ㑇ఏᏊ἞⒪࡬ࡢ㐺⏝㸬㧗ᶫ᭷ᕫ, すᕝඖஓ, 㧗಴႐ಙ,⸆Ꮫ㞧
ㄅ, 127: 1525-1531 (2007).
యෆ࣭⣽⬊ෆືែไᚚᶵ⬟ࢆᦚ㍕ࡋࡓ⇕ࢩࣙࢵࢡࢱࣥࣃࢡ㉁ࡢ㛤Ⓨ࡜࣡ࢡࢳࣥࢹࣜࣂ࣮ࣜ࡬ࡢᛂ⏝㸬
すᕝඖஓࠊ➉ᮏㄔ஧ࠊ㧗಴႐ಙ, ⸆Ꮫ㞧ㄅ, 127: 293-300 (2007).
㸦ⴭ᭩㸧㸦࿴࣭ⱥᩥ㸧
1.
2.
3.
4.
㸯❶ ⸆ࡢ㐠࿨㸬すᕝඖஓ㸪࣮࣋ࢩࢵࢡ⸆Ꮫᩍ⛉᭩ࢩ࣮ࣜࢬ㸯㸶 ⸆≀ືែᏛ㸪ᶫ⏣ ඘ ⦅㸪໬
Ꮫྠே㸪pp. 1-24 (2010).
ᅗゎ࡛Ꮫࡪ DDS㸸⸆≀἞⒪ࡢ᭱㐺໬ࢆ┠ᣦࡍඛ➃๰⸆ᢏ⾡㸬㧗಴႐ಙ ⦅㞟㸪ᶫ⏣ ඘ ┘ಟ㸪ᒸᮏ
ᾈ୍㸪ᰤ⏣ᩄஅ㸪బஂ㛫ಙ⮳㸪㧗಴႐ಙ㸪すᕝඖஓ㸪ᶫ⏣ ඘㸪୸ᒣ୍㞝㸪ᒣୗᐩ⩏㸪ᒣᮏ ᫀ㸪
ᶓᒣᫀᖾ ඹⴭ ࡌ࡯࠺♫ (2010).
2-9 ࢼࣀ࣓ࢹ࢕ࢩࣥ࡜ࡋ࡚ࡢ siRNA㸬すᕝඖஓ㸪ࢼࣀ࣓ࢹ࢕ࢩࣥ㸪Ᏹ⌮㡲ᜏ㞝 ⦅㸪࣮࣒࢜♫㸪pp.
195-205 (2008)㸬
PK consideration of Biodrugs. Y. Takakura, Biodrug Delivery Systems: Fundamentals, Applications and
Clinical Development, eds. M.Morishita, K.M. Park, pp.40-49, Informa Healthcare, New York (2009)
− 302 −
་⒪⸆๣Ꮫศ㔝
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧஝ ㈼୍㸦࠸ࡠ࠸ ࡅࢇ࠸ࡕ㸧
㸦1994. 1 ╔௵ࠊ2010. 3 ᐃᖺ㏥⫋ࠊி㒔⸆⛉኱ᏛᏛ㛗
࡟㌿ฟ㸧
᫛࿴㸰㸰ᖺ㸰᭶㸰㸱᪥⏕
᫛࿴㸲㸲ᖺி㒔኱Ꮫ༞ࠊ᫛࿴㸲㸴ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢ࠊ᫛࿴㸲㸵ᖺྠ኱Ꮫ኱Ꮫ
㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬㏥Ꮫࠊ᫛࿴㸳㸰ᖺி㒔኱Ꮫ⸆Ꮫ༤ኈྲྀᚓ
෸ᩍᤵ㸦༤ኈ㸦⸆Ꮫ㸧㸧᱇ ᩄஓ㸦࠿ࡘࡽ ࡜ࡋࡸ㸧㸦2004. 12 ᪼௵㸧
᫛࿴㸲㸮ᖺ㸲᭶㸰㸵᪥⏕
᫛࿴㸴㸱ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸳ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢
ㅮ ᖌ㸦༤ኈ㸦⸆Ꮫ㸧㸧ቑ⏣ᬛඛ㸦ࡲࡍࡔ ࡉ࡜ࡦࢁ㸧㸦2005. 1 ᪼௵㸧
᫛࿴㸲㸲ᖺ㸴᭶㸰㸵᪥⏕
ᖹᡂ㸲ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸮ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧ᑎ⏣ᬛ♸㸦࡚ࡽࡔ ࡜ࡶࡦࢁ㸧㸦2000. 4 ᥇⏝ࠊ2008. 3 ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔
๪⸆๣㒊㛗࡟㓄⨨᥮㸧
᫛࿴㸲㸳ᖺ㸯㸯᭶㸳᪥⏕
ᖹᡂ㸴ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸯ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧ᮏᶫ⚽அ㸦ࡶ࡜ࡣࡋ ࡦ࡛ࡺࡁ㸧㸦2002. 4 ᥇⏝㸧
᫛࿴㸲㸴ᖺ㸷᭶㸯㸮᪥⏕
ᖹᡂ㸵ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸱ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧ୖ஭ඃ୍㸦࠺ࢃ࠸ ࡺ࠺࠸ࡕ㸧
㸦2005. 1 ᥇⏝ࠊ2007. 3 ឡ▱Ꮫ㝔኱Ꮫㅮᖌ࡟㌿ฟ
㸧
᫛࿴㸲㸷ᖺ㸯㸮᭶㸰㸴᪥⏕
ᖹᡂ㸷ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸲ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧⡿⃝ ῟㸦ࡼࡡࡊࢃ ࠶ࡘࡋ㸧㸦2007. 4 ᥇⏝㸧
᫛࿴㸳㸳ᖺ㸰᭶㸯㸶᪥⏕
ᖹᡂ㸯㸲ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸷ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢
ຓ ᩍ㸦༤ኈ㸦⸆Ꮫ㸧㸧⚟ᅵᑗ⚽㸦ࡩࡃ࡝ ࡲࡉࡦ࡛㸧㸦2008. 4 ᥇⏝㸧
᫛࿴㸳㸰ᖺ㸶᭶㸯㸯᪥⏕
ᖹᡂ㸯㸱ᖺ㔠ἑ኱Ꮫ༞ࠊᖹᡂ㸯㸶ᖺி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉༤ኈᚋᮇㄢ⛬ಟ஢
◊✲ࡢᴫせ
ᙜ་⒪⸆๣Ꮫศ㔝ࡣࠊ
ࠕ་⸆ရࡢయෆືែ࡜᭷ຠᛶ࣭Ᏻ඲ᛶ࡟㛵ࡍࡿᇶ♏࡜⮫ᗋࠖࢆ࣓࢖ࣥࢸ࣮࣐࡟ࠊ
⛉Ꮫⓗ᰿ᣐ࡟ᇶ࡙࠸ࡓ་⸆ရ㐺ṇ౑⏝ࡢᐇ㊶ࢆ┠ᣦࡋ࡚◊✲࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
་⸆ရࡢయෆືែ࡜⸆ຠ࣭ẘᛶ࡟㛵ࡍࡿᇶ♏࡜⮫ᗋ
⣽⬊Ⓨ⌧⣔ࠊin vivo ᐇ㦂⣔࠾ࡼࡧ⮫ᗋ᳨యࢆ⏝࠸ࡓືែゎᯒࢆ⾜࠸ࠊ་⸆ရࡢయෆືែࡸࡑࡢኚື
せᅉ࡟ࡘ࠸࡚◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓࠊ⸆๣ᛶ⭈㞀ᐖⓎ⌧ᶵᵓ࡟㛵ࡍࡿ◊✲ࡸࠊ⸆๣ᛶ⭈㞀ᐖࡢࣂ
࢖࣐࣮࣮࢜࢝ࡢ᥈⣴ࢆ⾜࠸ࠊ᪩ᮇデ᩿ἲࡸ⭈㞀ᐖᅇ㑊ᡭἲࡢ㛤Ⓨ࡬ࡢᒎ㛤ࢆ┠ᣦࡋ࡚࠸ࡿࠋ
⸆≀ࢺࣛࣥࢫ࣏࣮ࢱࡢศᏊ࣭⣽⬊⏕≀Ꮫⓗゎᯒ࡜⮫ᗋᛂ⏝࡟㛵ࡍࡿ◊✲
ࢺࣛࣥࢫ࣏࣮ࢱࢆ௓ࡋࡓ⸆≀ࡢᾘ໬⟶྾཰࣭⭈᤼ἥᶵᵓ࡟↔Ⅼࢆ࠶࡚ࠊ᭷ᶵ࢖࢜ࣥࢺࣛࣥࢫ࣏࣮ࢱ
ࡢᶵ⬟ゎᯒࡸⓎ⌧ㄪ⠇ᶵᵓࡢゎᯒࢆ㐍ࡵ࡚࠸ࡿࠋࡉࡽ࡟ࠊ⸆≀ࢺࣛࣥࢫ࣏࣮ࢱࢆ฼⏝ࡋࡓ⸆≀㏦㐩
ࢩࢫࢸ࣒ࡢ㛤Ⓨࡸ⸆≀┦஫స⏝ண ⣔ࡢᵓ⠏࡞࡝ࠊࡑࡢ⮫ᗋᛂ⏝ࢆ┠ᣦࡋࡓ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ
⑓ែ᫬ࡢ⸆≀ືែ࣭⸆ຠࡢኚືせᅉゎᯒ࡜ᝈ⪅ಶูᢞ୚タィ࡟㛵ࡍࡿ◊✲
ᛴᛶ࣭៏ᛶ⭈୙඲ࡸ⏥≧⭢ᶵ⬟ஹ㐍⑕࡞࡝ࠊᵝࠎ࡞⑓ែࣔࢹࣝື≀ࢆసᡂࡋࠊ⭈⮚ࡸᑠ⭠࡟࠾ࡅࡿ
⸆≀ࢺࣛࣥࢫ࣏࣮ࢱ⩌ࡢⓎ⌧ኚື࡟ࡘ࠸࡚ゎᯒࡋࠊࡉࡽ࡟ࡑࢀࡽ⑓ែ᫬࡟࠾ࡅࡿ⭠⟶྾཰ࠊ⭈᤼ἥ
࡞࡝ࡢ in vivo ⸆≀ືែࡢኚ໬࡜ࡢ┦㛵࡟ࡘ࠸᳨࡚ウࢆ⾜࠺ࡇ࡜࡟ࡼࡗ࡚ࠊ㐺ษ࡞⸆≀ᢞ୚タィࡢ☜
❧ࢆ┠ᣦࡋ࡚࠸ࡿࠋ
⸆≀┦஫స⏝ࡢ in vitro ண ࣭ホ౯⣔ࡢ㛤Ⓨ࡟㛵ࡍࡿ◊✲
⮫ᗋୖぢ࠸ࡔࡉࢀࡓ⸆≀┦஫స⏝࡟ࡘ࠸࡚ࠊࡑࡢᶵᵓࢆᇶ♏ⓗ࡟ゎ᫂ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚ࠊࣄࢺ
᭷ᶵ࢝ࢳ࢜ࣥ㍺㏦⣔ࢆᑟධࡋࡓᒀ⣽⟶ୖ⓶⣽⬊ࣔࢹࣝ࡞࡝ࢆᵓ⠏ࡋ࡚ゎᯒࢆ㐍ࡵ࡚࠸ࡿࠋ
⸆≀ࢺࣛࣥࢫ࣏࣮ࢱ࣭௦ㅰ㓝⣲ࡢ㑇ఏᏊከᆺ࡜ࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪
⸆≀ࡢ⾑୰⃰ᗘ ᐃ࡜ẕ㞟ᅋゎᯒἲ㸦population pharmacokinetics/pharmacodynamics㸧࡟ᇶ࡙࠸࡚㐺
− 303 −
ษ࡞ᢞ୚タィࢆ⾜࠺ࡇ࡜࡟ࡼࡾࠊࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪ࡢᐇ㊶ࢆヨࡳ࡚࠸ࡿࠋࡲࡓࠊ⸆≀ࢺࣛࣥࢫ࣏
࣮ࢱࡸ௦ㅰ㓝⣲ࡢ㑇ఏⓗከᆺ࡜యෆືែ࡜ࡢ┦㛵࡟ࡘ࠸࡚ゎᯒࢆ⾜࠸ࠊ㑇ఏᏊデ᩿࡟ᇶ࡙ࡃಶูᢞ
୚タィἲࡢᵓ⠏ࢆ㐍ࡵ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᖹᡂ 18ࠥ22 ᖺᗘࡲ࡛ࡢ 5 ᖺ㛫࡟ࠊ་⒪⸆๣Ꮫศ㔝ࡢᩍဨࡀ᪥ᮏ⸆Ꮫ఍ዡບ㈹ࠊ᪥ᮏ⸆Ꮫ఍㏆␥ᨭ㒊
ዡບ㈹ࢆཷ㈹ࡋࠊࡲࡓ஝ࡀ᪥ᮏ⸆Ꮫ఍㈹ࠊ᪥ᮏ⸆๣Ꮫ఍㈹ࠊ᪥ᮏ⸆≀ືែᏛ఍ࣇ࢙࣮ࣟࡢ⛠ྕࠊ⡿ᅜ⸆
Ꮫ఍ Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism ࢆཷ㈹ࡋ࡚
࠸ࡿࡇ࡜࠿ࡽ◊✲ホ౯ࡣᴟࡵ࡚㧗࠸ࡶࡢ࡜࠸࠼ࡿࠋࡲࡓࠊ஝ࡀከࡃࡢᅜ㝿Ꮫ఍࣭ࢩ࣏ࣥࢪ࣒࡛࢘ࡢㅮ₇
࡟ᣍ⪸ࡉࢀ࡚࠸ࡿࡇ࡜࠿ࡽࠊᅜ㝿ⓗ࡟ࡶ㧗࠸ホ౯ࢆᚓ࡚࠸ࡿࡶࡢ࡜⪃࠼ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ་⒪⸆๣Ꮫ㸯㸦་⒪⸆Ꮫ V㸧ࡢㅮ⩏ࢆ⮫ᗋ⸆Ꮫᩍ⫱ศ㔝࡜ศᢸࡋ࡚࠸ࡿࠋ་⒪ࡢ
ሙ࡟࠾࠸࡚ᚲせ࡜࡞ࡿᇶ♏▱㆑ࢆ⩦ᚓࡉࡏࡿ࡜࡜ࡶ࡟ࠊ་⒪⌧ሙࡢ⮫ሙឤࡀఏࢃࡿࡼ࠺ㅮ⩏ࡋ࡚࠸ࡿࠋ
ࡲࡓࠊ⸆Ꮫ⛉ 6 ᖺไࡢᏛ⏕࡟ᑐࡋ࡚ࠊ㸯ᅇ⏕ࡢ᫬࡟᪩ᮇయ㦂Ꮫ⩦ࢆ⾜ࡗ࡚࠸ࡿࠋࡉࡽ࡟ࠊᖹᡂ 22 ᖺᗘ
࠿ࡽ 10 ྡࡎࡘ 3 ᅇ࡟ศࡅ࡚ 11 㐌࡟࠾ࡼࡧ⑓㝔ᐇົᐇ⩦ࢆᐇ᪋ࡋࠊ་⒪ே࡜ࡋ࡚ࡢ⮬ぬࢆಁࡍࡼ࠺࡟ດ
ࡵ࡚࠸ࡿࠋࡲࡓࠊᪧㄢ⛬࡛ࡣ 3 ᅇ⏕ᚋᮇࠥ4 ᅇ⏕๓ᮇ࡟࠿ࡅ࡚ࡢ⸆Ꮫᑓ㛛ᐇ⩦㹔࡟࠾࠸࡚ࠊ40 ேࡎࡘࡢ
Ꮫ⏕࡟ᑐࡋ࡚ 4 㐌㛫࡟ཬࡪ⑓㝔ᐇ⩦ࢆ 2 ᅇᐇ᪋ࡋ࡚࠸ࡓࠋࡑࡢ௚࡟ࠊ௚ࡢ⸆Ꮫ㒊ᩍဨ࡜༠ຊࡋ࡚⾜࠺ࣜ
࣮ࣞㅮ⩏㸦⸆Ꮫ೔⌮࣭ᴫㄽ㸦⸆Ꮫᴫㄽ㸧ࠊ⮫ᗋ⸆Ꮫ⥲ㄽ㸧ࡶᢸᙜࡋࠊ⥲ྜ⛉Ꮫ࡜ࡋ࡚ࡢ⸆Ꮫࡢᩍ⫱࡟ࡶ
ດࡵ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗ㓄ᒓࡢᏛ⏕࡟ࡶಶࠎ࡟ࢸ࣮࣐ࢆ୚࠼ࠊྛ⮬࡛ၥ㢟ゎỴࢆᅗࡿ࡜࡜ࡶ࡟
ࠊࢢ࣮ࣝࣉෆࠊࢢ࣮ࣝࣉ㛫࡛༠ຊࡋ࠶࠸࡞ࡀࡽ◊✲ᐊ࡜ࡋ࡚ࡢඹ㏻┠ᶆࡢ㐩ᡂ࡟ྥࡅ࡚௙஦ࢆ㐍ࡵࡉࡏ
࡚࠸ࡿࠋᡂᯝࡀᚓࡽࢀࡓᏛ⏕࡟ࡣ✚ᴟⓗ࡟Ꮫ఍➼࡛◊✲Ⓨ⾲ࢆ⾜ࢃࡏࡿ࡜࡜ࡶ࡟ࠊⱥㄒㄽᩥࢆྛಶே࡛
᭩࠿ࡏࡿࡼ࠺࡟ᣦᑟࡋ࡚࠸ࡿࠋࢭ࣑ࢼ࣮࡛ࡣྛேࡢ✚ᴟⓗ࡞ⓎゝࢆಁࡋࠊάⓎ࡞ウㄽࡀ⾜ࢃࢀࡿࡼ࠺࡟
ດࡵ࡚࠸ࡿࠋᪧㄢ⛬࡟࠾࠸࡚ࡣࠊ6 ᖺไࡢඛ㥑ࡅ࡜ࡋ࡚⮫ᗋ⸆Ꮫࢥ࣮ࢫ኱Ꮫ㝔⏕ࡢཷࡅධࢀࢆᖹᡂ 13 ᖺ
ᗘࡼࡾ㛤ጞࡋࠊデ⒪⛉࡟࠾ࡅࡿ⸆๣⟶⌮ᣦᑟᴗົ࡟ᦠࢃࡏࡿࡇ࡜࡟ࡼࡗ࡚ࠊ⮫ᗋ⸆Ꮫ࡟㛵ࡍࡿ㧗ᗘ࡞ᑓ
㛛ⓗ▱㆑࡜ᢏ⾡ࢆ⩦ᚓࡉࡏࠊၥ㢟ゎỴ⬟ຊࢆᣢࡗࡓ་⒪ேࡢ⫱ᡂ࡟ດࡵ࡚࠸ࡓࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࣭ᐇ⩦࡛ࡣᏛ⏕ഃ࠿ࡽࡢホ౯ࢆᐇ᪋ࡋ࡚ࠊᚓࡽࢀࡓពぢࢆཧ⪃࡟ࡋ࡞ࡀࡽᩍ⫱ᨵၿ࡟
ດࡵ࡚࠸ࡿࠋᐇ⩦࡟㛵ࡋ࡚ࡣࠊ⸆๣㒊࡜࠸࠺་⒪⌧ሙ࡟࠾ࡅࡿ⮫ሙឤࠊ㈐௵ࡢ㔜ࡉࢆᙉࡃឤࡌࡓ࡜࠸࠺
ពぢࡀࠊᐇ⩦⤊஢ᚋࡢ࢔ࣥࢣ࣮ࢺㄪᰝ࡟࠾࠸࡚ከᩘᚓࡽࢀ࡚࠸ࡿࡇ࡜࠿ࡽࠊึᮇࡢ┠ᶆࡣ༑ศ㐩ᡂࡉࢀ
࡚࠸ࡿࡶࡢ࡜⪃࠼࡚࠸ࡿࠋ6 ᖺไᏛ⏕࡟ᑐࡍࡿ㛗ᮇᐇົᐇ⩦࡟㛵ࡋ࡚ࡣࠊ㛤ጞᚋ 2 ᮇࡀ⤊஢ࡋࡓ࡜ࡇࢁ
࡛࠶ࡿࡀࠊྠᵝࡢ㧗࠸ホ౯ࡀᏛ⏕ഃࡼࡾᚓࡽࢀ࡚࠸ࡿࠋ
◊✲ᐊෆࡢᩍ⫱ࡣࠊ࡯ࡰ඲ဨࡀᖺ࡟୍ᗘࡣᏛ఍Ⓨ⾲ࢆ⾜࠸ࠊಟኈಟ஢ࡲ࡛࡟ㄽᩥᥖ㍕࡟⮳ࡿ౛ࡶከ࠸
ࡇ࡜࠿ࡽࠊ◊✲⪅࡜ࡋ࡚ࡢᇶ♏ࡣ㌟࡟ࡘ࠸࡚࠸ࡿࡶࡢ࡜⪃࠼࡚࠸ࡿࠋࡉࡽ࡟ࠊ᪥ᮏᏛ⾡᣺⯆఍≉ู◊✲
ဨ࡜ࡋ࡚ከᩘ᥇⏝㸦ᖹᡂ 11 ᖺ௨㝆 9 ே㸧ࡉࢀ࡚࠸ࡿࡇ࡜࠿ࡽࠊࡑࡢᐇ⦼ࡀ㧗ࡃホ౯ࡉࢀ࡚࠸ࡿ࡜࠸࠼
ࡿࠋ
ࡲࡓࠊᖹᡂ 18ࠥ22 ᖺࡲ࡛ࡢ 5 ᖺ㛫࡟ࠊಟኈㄢ⛬ࢆಟ஢ࡋࡓ 22 ྡࡢ࠺ࡕ 9 ேࡀ༤ኈᚋᮇㄢ⛬࡟㐍Ꮫࠊ
ࡲࡓ኱Ꮫ⑓㝔⸆๣ᖌ 2 ேࠊ〇⸆௻ᴗ࡟ 10 ேࠊᐁබᗇ࡟ 1 ྡࡀᑵ⫋ࡋࡓࠋࡉࡽ࡟༤ኈᚋᮇㄢ⛬ಟ஢ࡋࡓ
⪅ 9 ྡࡢ࠺ࡕࠊ3 ேࡀ኱Ꮫࡢᩍဨ㸦་⒪⣔㸧ࠊ2 ேࡀ኱Ꮫ⑓㝔⸆๣ᖌࠊ1 ேࡀ࣏ࢫࢻࢡࠊ3 ேࡀ〇⸆௻ᴗ
⫋ဨ࡜ࡋ࡚ά㌍ࡋ࡚࠸ࡿࡇ࡜࠿ࡽࠊᩍ⫱࣭◊✲ࡢ㧗࠸ࣞ࣋ࣝࢆ♧ࡍ࡜࡜ࡶ࡟་⒪⸆๣Ꮫࡢேᮦ⫱ᡂࡢ㠃
࡟࠾࠸࡚༑ศ㈉⊩ࡋ࡚࠸ࡿࠋ
ཎⴭ㸦ⱥᩥ㸧
1. Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant
sudden sensorineural hearing loss: a prospective clinical trial. T Nakagawa, T Sakamoto, H
Hiraumi, YS Kikkawa, N Yamamoto, K Hamaguchi, K Ono, M Yamamoto, Y Tabata, S
Teramukai, S Tanaka, H Tada, R Onodera, A Yonezawa, K Inui & J Ito. BMC Med, in press
2. Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is
caused by a microdeletion in the riboflavin transporter gene GPR172B. G Ho, A Yonezawa, S
Masuda, K Inui, KG Sim, K Carpenter, RK Olsen, JJ Mitchell, WJ Rhead, G Peters & J
Christodoulou. Hum Mutat, in press
− 304 −
3. Human NPC1L1 Expression is Positively Regulated by PPARalpha. Y Iwayanagi, T Takada, F
Tomura, Y Yamanashi, T Terada, K Inui & H Suzuki. Pharm Res, in press
4. A transient increase of calcineurin phosphatase activity in living-donor kidney transplant
recipients with acute rejection. M Fukudo, I Yano, T Katsura, N Ito, S Yamamoto, T Kamoto, O
Ogawa & K Inui. Drug Metab Pharmacokinet, 25(5), 411-417 (2010)
5. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell
carcinoma. T Mizuno, T Terada, T Kamba, M Fukudo, T Katsura, E Nakamura, O Ogawa & K
Inui. Ann Oncol, 21(6), 1382-1383 (2010)
6. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure
rats. S Nakagawa, S Masuda, K Nishihara & K Inui. Biochem Pharmacol, 79(1), 67-76 (2010)
7. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity.
T Nakamura, A Yonezawa, S Hashimoto, T Katsura & K Inui. Biochem Pharmacol, 80(11),
1762-1767 (2010)
8. Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal
failure rats. K Nishihara, S Masuda, S Nakagawa, A Yonezawa, T Ichimura, JV Bonventre & K
Inui. Am J Physiol Renal Physiol, 298(4), F923-934 (2010)
9. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug
transporters. K Ogasawara, T Terada, T Katsura, E Hatano, I Ikai, Y Yamaoka & K Inui. Drug
Metab Pharmacokinet, 25(2), 190-199 (2010)
10. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. K
Shinsako, T Mizuno, T Terada, J Watanabe, T Kamba, E Nakamura, O Ogawa & K Inui. Int J
Clin Oncol, 15(5), 512-514 (2010)
11. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with
central nervous system metastases of non-small cell lung cancer. Y Togashi, K Masago, M
Fukudo, T Terada, S Fujita, K Irisa, Y Sakamori, YH Kim, T Mio, K Inui & M Mishima. J
Thorac Oncol, 5(7), 950-955 (2010)
12. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell
lung cancer and chronic renal failure who are undergoing hemodialysis. Y Togashi, K Masago,
M Fukudo, T Terada, Y Ikemi, YH Kim, S Fujita, K Irisa, Y Sakamori, T Mio, K Inui & M
Mishima. J Thorac Oncol, 5(5), 601-605 (2010)
13. A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma
concentration. Y Togashi, K Masago, M Mishima, M Fukudo & K Inui. J Thorac Oncol, 5(6),
924-925 (2010)
14. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little
influence on the disposition of metformin in diabetic patients. Pharmacogenet Genomics. K
Toyama, A Yonezawa, M Tsuda, S Masuda, I Yano, T Terada, R Osawa, T Katsura, M Hosokawa,
S Fujimoto, N Inagaki & K Inui. Pharmacogenet Genomics, (2010)
15. Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. S
Watanabe, M Tsuda, T Terada, T Katsura & K Inui. J Pharmacol Exp Ther, 334(2), 651-656
(2010)
16. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
S Yamamoto, H Nakase, M Matsuura, Y Honzawa, S Masuda, K Inui & T Chiba. J
Gastroenterol Hepatol, 25(5), 886-891 (2010)
17. Identification and comparative functional characterization of a new human riboflavin transporter
hRFT3 expressed in the brain. Y Yao, A Yonezawa, H Yoshimatsu, S Masuda, T Katsura & K
Inui. J Nutr, 140(7), 1220-1226 (2010)
18. Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. T
Yoshino, H Nakase, Y Honzawa, K Matsumura, S Yamamoto, Y Takeda, S Ueno, N Uza, S
Masuda, K Inui & T Chiba. Inflamm Bowel Dis, (2010)
19. Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. M
Aoki, T Terada, K Ogasawara, T Katsura, E Hatano, I Ikai & K Inui. Pharmacogenet Genomics,
19(8), 647-656 (2009)
20. Prospective evaluation of the bayesian method for individualizing tacrolimus dose early after
living-donor liver transplantation. M Fukudo, I Yano, K Shinsako, T Katsura, Y Takada, S
Uemoto & K Inui. J Clin Pharmacol, 49(7), 789-797 (2009)
21. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole,
but not lansoprazole, in adult living-donor liver transplant patients. K Hosohata, S Masuda, T
Katsura, Y Takada, T Kaido, Y Ogura, F Oike, H Egawa, S Uemoto & K Inui. Drug Metab
Dispos, 37(4), 821-826 (2009)
− 305 −
22. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1
in female living-donor liver transplant patients. K Hosohata, S Masuda, A Yonezawa, T Katsura,
F Oike, Y Ogura, Y Takada, H Egawa, S Uemoto & K Inui. Pharm Res, 26(7), 1590-1595
(2009)
23. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of
tacrolimus in adult living-donor liver transplant patients: a case-control study. K Hosohata, S
Masuda, A Yonezawa, M Sugimoto, Y Takada, T Kaido, Y Ogura, F Oike, S Uemoto & K Inui.
Drug Metab Pharmacokinet, 24(5), 458-463 (2009)
24. Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete
loss of transport activity. M Kajiwara, T Terada, K Ogasawara, J Iwano, T Katsura, A Fukatsu, T
Doi & K Inui. J Hum Genet, 54(1), 40-46 (2009)
25. Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2.
N Kimura, S Masuda, T Katsura & K Inui. Biochem Pharmacol, 77(8), 1429-1436 (2009)
26. [Evaluation of stability of temozolomide in solutions after opening the capsule]. T Kodawara, T
Mizuno, H Taue, T Hashida, I Yano, T Katsura & K Inui. Yakugaku Zasshi, 129(3), 353-357
(2009)
27. Human organic anion transporter hOAT4 is a transporter of perfluorooctanoic acid. H Nakagawa,
T Terada, KH Harada, T Hitomi, K Inoue, K Inui & A Koizumi. Basic Clin Pharmacol Toxicol,
105(2), 136-138 (2009)
28. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure
rats. S Nakagawa, S Masuda, K Nishihara & K Inui. Biochem Pharmacol, 79(1), 67-76 (2009)
29. A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer
patients based on routine trough monitoring data. S Omote, Y Yano, T Hashida, S Masuda, I
Yano, T Katsura & K Inui. Biol Pharm Bull, 32(1), 99-104 (2009)
30. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in
Japanese cancer patients. M Onoue, T Terada, M Kobayashi, T Katsura, S Matsumoto, K
Yanagihara, T Nishimura, M Kanai, S Teramukai, A Shimizu, M Fukushima & K Inui. Int J Clin
Oncol, 14(2), 136-142 (2009)
31. Larger dosage required for everolimus than sirolimus to maintain same blood concentration in
two pancreatic islet transplant patients with tacrolimus. E Sato, I Yano, M Shimomura, S
Masuda, T Katsura, S Matsumoto, T Okitsu, Y Iwanaga, S Uemoto & K Inui. Drug Metab
Pharmacokinet, 24(2), 175-179 (2009)
32. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity
focusing on renal organic cation transporter OCT2. Y Tanihara, S Masuda, T Katsura & K Inui.
Biochem Pharmacol, 78(1263-1271 (2009)
33. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal
secretion of metformin. M Tsuda, T Terada, T Mizuno, T Katsura, J Shimakura & K Inui. Mol
Pharmacol, 75(6), 1280-1286 (2009)
34. Involvement of human multidrug and toxin extrusion 1 (MATE1) in the drug interaction
between cimetidine and metformin in renal epithelial cells. M Tsuda, T Terada, M Ueba, T Sato,
S Masuda, T Katsura & K Inui. J Pharmacol Exp Ther, (2009)
35. Population analysis of myelosuppression profiles using routine clinical data after the ICE
(ifosfamide/carboplatin/etoposide) regimen for malignant gliomas. Y Yano, T Kodawara, H
Hongo, I Yano, Y Kishi, J Takahashi & K Inui. J Pharm Sci, 98(4402-4412 (2009)
36. Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in
rats. A Yokomasu, I Yano, E Sato, S Masuda, T Katsura & K Inui. Biopharm Drug Disp,
30(517-523 (2009)
37. Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is
regulated by DNA methylation. M Aoki, T Terada, M Kajiwara, K Ogasawara, I Ikai, O Ogawa,
T Katsura & K Inui. Am J Physiol Renal Physiol, 295(1), F165-F170 (2008)
38. Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. J Chen, T
Terada, K Ogasawara, T Katsura & K Inui. Am J Physiol Renal Physiol, 295(1), F247-F252
(2008)
39. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal
dysfunction in adult living-donor liver transplant patients. M Fukudo, I Yano, A Yoshimura, S
Masuda, M Uesugi, K Hosohata, T Katsura, Y Ogura, F Oike, Y Takada, S Uemoto & K Inui.
Pharmacogenet Genomics, 18(5), 413-423 (2008)
40. Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and
required level of tacrolimus in pediatric living-donor liver transplantation. M Goto, S Masuda, T
Kiuchi, Y Ogura, F Oike, K Tanaka, S Uemoto & K Inui. J Pharmacol Exp Ther, 325(2),
− 306 −
610-616 (2008)
41. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver
transplant patients with defects of CYP2C19 and CYP3A5. K Hosohata, S Masuda, Y Ogura, F
Oike, Y Takada, T Katsura, S Uemoto & K Inui. Drug Metab Pharmacokinet, 23(2), 134-138
(2008)
42. Regulation of basal core promoter activity of human organic cation transporter 1
(OCT1/SLC22A1). M Kajiwara, T Terada, J Asaka, M Aoki, T Katsura, I Ikai & K Inui. Am J
Physiol Gastrointest Liver Physiol, (2008)
43. Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic
cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in
ischemia/reperfusion-induced acute kidney injury. T Matsuzaki, T Morisaki, W Sugimoto, K
Yokoo, D Sato, H Nonoguchi, K Tomita, T Terada, K Inui, A Hamada & H Saito. Drug Metab
Dispos, 36(4), 649-654 (2008)
44. Roles of organic anion transporters in the renal excretion of perfluorooctanoic acid. H
Nakagawa, T Hirata, T Terada, P Jutabha, D Miura, KH Harada, K Inoue, N Anzai, H Endou, K
Inui, Y Kanai & A Koizumi. Basic Clin Pharmacol Toxicol, 103(1), 1-8 (2008)
45. Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells. N
Nishio, T Katsura & K Inui. Pharm Res, 25(5), 1037-1042 (2008)
46. Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney.
K Ogasawara, T Terada, H Motohashi, J Asaka, M Aoki, T Katsura, T Kamba, O Ogawa & K
Inui. J Hum Genet, 53(7), 607-614 (2008)
47. Inhibitory effect of zinc on the absorption of beta-lactam antibiotic ceftibuten via the peptide
transporters in rats. M Okamura, T Terada, T Katsura & K Inui. Drug Metab Pharmacokinet,
23(6), 464-468 (2008)
48. [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction]. M Onoue
& K Inui. Gan To Kagaku Ryoho, 35(7), 1080-1085 (2008)
49. Regulatory mechanism governing the diurnal rhythm of intestinal H+/peptide cotransporter 1
(PEPT1). H Saito, T Terada, J Shimakura, T Katsura & K Inui. Am J Physiol Gastrointest Liver
Physiol, 295(2), G395-G402 (2008)
50. Transcellular transport of organic cations in double-transfected MDCK cells expressing human
organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. T Sato, S Masuda, A
Yonezawa, Y Tanihara, T Katsura & K Inui. Biochem Pharmacol, 76(7), 894-903 (2008)
51. Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with
high concentrations of a minor metabolite M-II in bile. M Shimomura, S Masuda, M Goto, T
Katsura, T Kiuchi, Y Ogura, F Oike, Y Takada, S Uemoto & K Inui. Drug Metab Pharmacokinet,
23(5), 313-317 (2008)
52. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). T
Terada & K Inui. Biochem Pharmacol, 75(9), 1689-1696 (2008)
53. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. S Yamamoto,
H Nakase, S Mikami, S Inoue, T Yoshino, Y Takeda, K Kasahara, S Ueno, N Uza, H Kitamura,
H Tamaki, M Matsuura, K Inui & T Chiba. Aliment Pharmacol Ther, 28(5), 589-597 (2008)
54. Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in
rats. A Yokomasu, I Yano, E Sato, S Masuda, T Katsura & K Inui. Drug Metab Pharmacokinet,
23(6), 469-475 (2008)
55. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of
oxaliplatin in colorectal cancer. S Yokoo, S Masuda, A Yonezawa, T Terada, T Katsura & K Inui.
Drug Metab Dispos, 36(11), 2299-2306 (2008)
56. Identification and functional characterization of a novel human and rat riboflavin transporter,
RFT1. A Yonezawa, S Masuda, T Katsura & K Inui. Am J Physiol Cell Physiol, 295(3),
C632-G641 (2008)
57. Characterization of the basal promoter element of human organic cation transporter 2 gene. J
Asaka, T Terada, K Ogasawara, T Katsura & K Inui. J Pharmacol Exp Ther, 321(2), 684-689
(2007)
58. Identification of essential histidine and cysteine residues of the H+/organic cation antiporter
multidrug and toxin extrusion (MATE). J Asaka, T Terada, M Tsuda, T Katsura & K Inui. Mol
Pharmacol, 71(6), 1487-1493 (2007)
59. Decreased renal accumulation and toxicity of a new VCM formulation in rats with chronic renal
failure. N Hodoshima, S Masuda & K Inui. Drug Metab Pharmacokinet, 22(6), 419-427 (2007)
60. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and
effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. M Jiko, I
− 307 −
Yano, E Sato, K Takahashi, H Motohashi, S Masuda, M Okuda, N Ito, E Nakamura, T Segawa,
T Kamoto, O Ogawa & K Inui. Int J Clin Oncol, 12(4), 284-290 (2007)
61. Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1.
M Kajiwara, T Terada, J Asaka, K Ogasawara, T Katsura, O Ogawa, A Fukatsu, T Doi & K Inui.
Am J Physiol Renal Physiol, 293(5), F1564-F1570 (2007)
62. Is MIBG a substrate of P-glycoprotein? Y Kiyono, T Yamashita, H Doi, Y Kuge, T Katsura, K
Inui & H Saji. Eur J Nucl Med Mol Imaging, 34(4), 448-452 (2007)
63. A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by
sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an
initial report of the phase I-IIa study. A Marui, Y Tabata, S Kojima, M Yamamoto, K Tambara, T
Nishina, Y Saji, K Inui, T Hashida, S Yokoyama, R Onodera, T Ikeda, M Fukushima & M
Komeda. Circ J, 71(8), 1181-1186 (2007)
64. Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced
acute renal failure. T Matsuzaki, H Watanabe, K Yoshitome, T Morisaki, A Hamada, H
Nonoguchi, Y Kohda, K Tomita, K Inui & H Saito. Kidney Int, 71(6), 539-547 (2007)
65. Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure
rats. K Nishihara, S Masuda, L Ji, T Katsura & K Inui. Biochem Pharmacol, 73(9), 1482-1490
(2007)
66. Hepatocyte nuclear factor-4Ș regulates the human organic anion transporter 1 gene in the
kidney. K Ogasawara, T Terada, J Asaka, T Katsura & K Inui. Am J Physiol Renal Physiol,
292(6), F1819-F1826 (2007)
67. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a
kidney transplant recipient. K Takahashi, I Yano, Y Fukuhara, T Katsura, T Takahashi, N Ito, S
Yamamoto, O Ogawa & K Inui. Drug Metab Pharmacokinet, 22(6), 441-444 (2007)
68. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin
extrusions/H+-organic cation antiporters. Y Tanihara, S Masuda, T Sato, T Katsura, O Ogawa &
K Inui. Biochem Pharmacol, 74(2), 359-371 (2007)
69. Gene expression and regulation of drug transporters in the intestine and kidney. T Terada & K
Inui. Biochem Pharmacol, 73(3), 440-449 (2007)
70. Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter
MATE1. M Tsuda, T Terada, J Asaka, M Ueba, T Katsura & K Inui. Am J Physiol Renal Physiol,
292(2), F593-F598 (2007)
71. Cl--dependent upregulation of human organic anion transporters: different effects on transport
kinetics between hOAT1 and hOAT3. H Ueo, H Motohashi, T Katsura & K Inui. Am J Physiol
Renal Physiol, 293(1), F391-F397 (2007)
72. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1,
hOAT3, and hOCT2). Y Uwai, H Ida, Y Tsuji, T Katsura & K Inui. Pharm Res, 24(4), 811-815
(2007)
73. Interaction and transport characteristics of mycophenolic acid and its glucuronide via human
organic anion transporters hOAT1 and hOAT3. Y Uwai, H Motohashi, Y Tsuji, H Ueo, T
Katsura & K Inui. Biochem Pharmacol, 74(1), 161-168 (2007)
74. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum
agent-induced nephrotoxicity. S Yokoo, A Yonezawa, S Masuda, A Fukatsu, T Katsura & K Inui.
Biochem Pharmacol, 74(3), 477-487 (2007)
75. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+
leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. A
Yokota, S Kimura, S Masuda, E Ashihara, J Kuroda, K Sato, Y Kamitsuji, E Kawata, Y Deguchi,
Y Urasaki, Y Terui, M Ruthardt, T Ueda, K Hatake, K Inui & T Maekawa. Blood, 109(1),
306-314 (2007)
76. Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for
rOCT1 and rOCT3. J Asaka, T Terada, M Okuda, T Katsura & K Inui. Pharm Res, 23(4),
697-704 (2006)
77. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in
a living-donor liver transplant recipient. S Fukatsu, M Fukudo, S Masuda, I Yano, T Katsura, Y
Ogura, F Oike, Y Takada & K Inui. Drug Metab Pharmacokinet, 21(2), 122-125 (2006)
78. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric
living-donor liver transplant recipients. M Fukudo, I Yano, S Masuda, M Goto, M Uesugi, T
Katsura, Y Ogura, F Oike, Y Takada, H Egawa, S Uemoto & K Inui. Clin Pharmacol Ther, 80(4),
331-345 (2006)
79. Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant
− 308 −
patients: twice daily vs. once daily dosing. M Fukudo, I Yano, S Masuda, T Katsura, Y Ogura, F
Oike, Y Takada, K Tanaka & K Inui. Liver Transpl, 12(2), 292-300 (2006)
80. Prediction of glycylsarcosine transport in Caco-2 cell lines expressing PEPT1 at different levels.
M Irie, T Terada, M Tsuda, T Katsura & K Inui. Pflügers Arch, 452(1), 64-70 (2006)
81. Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates
liver cirrhosis but causes albuminuria in rats. K Kusumoto, A Ido, A Moriuchi, T Katsura, I Kim,
Y Takahama, M Numata, M Kodama, S Hasuike, K Nagata, H Uto, K Inui & H Tsubouchi. Int J
Mol Med, 17(3), 503-509 (2006)
82. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in
living-donor liver transplant patients. S Masuda, M Goto, S Fukatsu, M Uesugi, Y Ogura, F
Oike, T Kiuchi, Y Takada, K Tanaka & K Inui. Clin Pharmacol Ther, 79(1), 90-102 (2006)
83. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ
transplant patients. S Masuda & K Inui. Pharmacol Ther, 112(1), 184-198 (2006)
84. Identification and functional characterization of a new human kidney-specific H+/organic cation
antiporter, kidney-specific multidrug and toxin extrusion 2. S Masuda, T Terada, A Yonezawa, Y
Tanihara, K Kishimoto, T Katsura, O Ogawa & K Inui. J Am Soc Nephrol, 17(8), 2127-2135
(2006)
85. Unequivocal synthesis of (Z)-alkene and (E)-fluoroalkene dipeptide isosteres to probe structural
requirements of the peptide transporter PEPT1. A Niida, K Tomita, M Mizumoto, H Tanigaki, T
Terada, S Oishi, A Otaka, K Inui & N Fujii. Org Lett, 8(4), 613-616 (2006)
86. The PDZ domain protein PDZK1 interacts with human peptide transporter PEPT2 and enhances
its transport activity. R Noshiro, N Anzai, T Sakata, H Miyazaki, T Terada, HJ Shin, X He, D
Miura, K Inui, Y Kanai & H Endou. Kidney Int, 70(2), 275-282 (2006)
87. Human organic anion transporter 3 gene is regulated constitutively and inducibly via a
cAMP-response element. K Ogasawara, T Terada, J Asaka, T Katsura & K Inui. J Pharmacol
Exp Ther, 319(1), 317-322 (2006)
88. Interactions of fluoroquinolone antibacterials, DX-619 and levofloxacin, with creatinine
transport by renal organic cation transporter hOCT2. M Okuda, N Kimura & K Inui. Drug
Metab Pharmacokinet, 21(5), 432-436 (2006)
89. Temporal decline in sirolimus elimination immediately after pancreatic islet transplantation. E
Sato, M Shimomura, S Masuda, I Yano, T Katsura, S Matsumoto, T Okitsu, Y Iwanaga, H
Noguchi, H Nagata, Y Yonekawa & K Inui. Drug Metab Pharmacokinet, 21(6), 492-500 (2006)
90. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with
hormone refractory prostate cancer. E Sato, I Yano, M Jiko, K Takahashi, H Motohashi, S
Masuda, T Katsura, H Nishiyama, T Segawa, N Ito, T Kamoto, O Ogawa & K Inui. Biol Pharm
Bull, 29(7), 1441-1444 (2006)
91. Induction of intestinal peptide transporter 1 expression during fasting is mediated via
peroxisome proliferator-activated receptor alpha. J Shimakura, T Terada, H Saito, T Katsura &
K Inui. Am J Physiol Gastrointest Liver Physiol, 291(5), G851-G856 (2006)
92. The transcription factor Cdx2 regulates the intestine-specific expression of human peptide
transporter 1 through functional interaction with Sp1. J Shimakura, T Terada, Y Shimada, T
Katsura & K Inui. Biochem Pharmacol, 71(11), 1581-1588 (2006)
93. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation
antiporter MATE1. T Terada, S Masuda, J Asaka, M Tsuda, T Katsura & K Inui. Pharm Res,
23(8), 1696-1701 (2006)
94. Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug
midodrine, and its amino acid derivatives. M Tsuda, T Terada, M Irie, T Katsura, A Niida, K
Tomita, N Fujii & K Inui. J Pharmacol Exp Ther, 318(1), 455-460 (2006)
95. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver
transplant recipients. M Uesugi, S Masuda, T Katsura, F Oike, Y Takada & K Inui.
Pharmacogenet Genomics, 16(2), 119-127 (2006)
96. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic
cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). A Yonezawa, S
Masuda, S Yokoo, T Katsura & K Inui. J Pharmacol Exp Ther, 319(2), 879-886 (2006)
ཎⴭ㸦࿴ᩥ㸧
1. ࢚ࣝࣟࢳࢽࣈ᭹⏝⥅⥆࡟ᙳ㡪ࢆཬࡰࡍᅉᏊࡢ᥈⣴㸬୕㟢ஂ⏕ࠊᑿୖ㞞ⱥࠊᑎ⏣ᬛ♸ࠊ᱇
ᩄஓࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㞧ㄅࠊ༳ๅ୰㸬
2. ࢤ࣒ࢩࢱࣅࣥ༢๣⒪ἲ࡟ࡼࡿ⾑ᾮẘᛶࡢᛶᕪ. ୕ᾆ⠜ྐࠊᑿୖ㞞ⱥࠊᑎ⏣ᬛ♸ࠊ㧗ᶫ୍
− 309 −
ᰤࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 36(1), 57-60 (2010)
3. ᡭ⾡㒊࡟࠾ࡅࡿ⸆๣ᖌࡢᖖ㥔యไࡢᩚഛ࡜⤒῭ຠᯝ࡟㛵ࡍࡿ᳨ウ. ụぢὈ᫂ࠊᑿୖ㞞ⱥࠊ
ᅵ⏕ᗣྖࠊෆᇼ⪽Ꮚࠊᯇ⏣⿱ஓࠊ㧗ᶫ୍ᰤࠊᑎ⏣ᬛ♸ࠊⲨ஭ಇஅࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ,
36(3), 157-162 (2010)
4. ஙࡀࢇ໬Ꮫ⒪ἲ FEC100 ࡟࠾ࡅࡿ G-CSF 〇๣ࡢ౑⏝ホ౯. ⸨⃝ᾈ⨾ࠊᶫ⏣ ஽ࠊᑎ⏣ᬛ
♸ࠊ᱇ ᩄஓࠊ▼㯮 ὒࠊⰾᯘᾈྐࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 35(1), 31-36 (2009)
5. ᪂つᢠᝏᛶ⭘⒆⸆ࢸࣔࢰ࣑ࣟࢻࡢ࢝ࣉࢭࣝ㛤ᑒᚋࡢ⁐ᾮ୰࡛ࡢᏳᐃᛶ࡟㛵ࡍࡿホ౯.
ྂಥᏕ᫂ࠊỈ㔝▱⾜ࠊ⏣ୖ⿱⨾ࠊᶫ⏣ ஽ࠊ▮㔝⫱Ꮚࠊ᱇ ᩄஓࠊ஝ ㈼୍ࠊ⸆Ꮫ㞧ㄅ,
129(3), 353-357 (2009)
6. 㐀⾑ᖿ⣽⬊⛣᳜ᝈ⪅࡟࠾ࡅࡿ࢝ࣝࢩࢽ࣮ࣗࣜࣥ㜼ᐖ๣࡜࢔ࢰ࣮ࣝ⣔ᢠ┿⳦๣ࡢ⸆≀ື
ែᏛⓗ┦஫స⏝ࡢホ౯. 㧗ᔱ⨾Ꮨࠊ㇂ཱྀ⌮Ἃࠊ▮㔝⫱Ꮚࠊ⏥㔝㈗ஂࠊᶫ⏣ ஽ࠊቑ⏣ᬛ
ඛࠊ▼ᕝ㝯அࠊෆᒣ ༟ࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 35(4), 233-239 (2009)
7. ࣋ࣂࢩࢬ࣐ࣈࡢᢠ⭘⒆ຠᯝ࡟ཬࡰࡍࣞࢽ࣮ࣥ࢔ࣥࢪ࢜ࢸࣥࢩࣥ⣔ᢚไ⸆ࡢᙳ㡪. ໭⃝
ᩥ❶ࠊᑎ⏣ᬛ♸ࠊ㧗ᶫ୍ᰤࠊᯇᮏ⦾ᕭࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 35(5), 337-342 (2009)
8. ࣅࣥ࢝࢔ࣝ࢝ࣟ࢖ࢻ⣔ᢠࡀࢇ๣ࡢ≀⌮໬Ꮫⓗ≉ᛶ࡟ཬࡰࡍ ᗘኚ໬ࡢᙳ㡪. ᑠᓥ୍᫭ࠊ
ᑎ⏣ᬛ♸ࠊὠ⏣┿ᘯࠊᶫ⏣ ஽ࠊ▮㔝⫱Ꮚࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㞧ㄅ, 45(5),
681-684 (2009)
9. 㟁Ꮚ࢝ࣝࢸᑟධᚋࡢㄪ๣ᴗົ࡟࠾ࡅࡿ⸆Ꮫⓗ௓ධࡢ᳨ウ. ᪂㏕ᜨᏊࠊⱝᮡ༤ᏊࠊᏳ⏣ᖾ
௦ࠊἙᓮ⫱௦ࠊ㊊㐩ᑦ⨾ࠊᖹሯ⌮ᜨࠊ▮㔝⫱Ꮚࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 35(8), 558-564 (2009)
10. ᢠࡀࢇ๣㐃᪥ᢞ୚᫬ࡢไྤ⒪ἲࡢᐇែㄪᰝ࡜ホ౯. ඤ⋢ᖾಟࠊᑎ⏣ᬛ♸ࠊ㧗ᶫ୍ᰤࠊ▮
㔝⫱Ꮚࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 35(9), 609-614 (2009)
11. ࢚ࣝࣟࢳࢽࣈ᭹⏝ᝈ⪅࡟ᑐࡍࡿእ᮶ㄪ๣ᐊ࡛ࡢ᭹⸆ᣦᑟయไࡢ☜❧࡜௒ᚋࡢㄢ㢟. ᒸ
ᮧࡳࡸᏊࠊ㧗ᶫ୍ᰤࠊ୸ᒣᚿ✑ᏊࠊྂಥᏕ᫂ࠊụぢὈ᫂ࠊ⚃༓ెᏊࠊ῝ὠ⚈ኸࠊᑠᯘᨻ
ᙪࠊᑎ⏣ᬛ♸ࠊᰗཎ୍ᗈࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㞧ㄅ, 45(10), 1347-1351 (2009)
12. ࡀࢇ་⒪ࡢᆒ࡚ࢇ໬࡟ྥࡅࡓி㒔ࡀࢇ⸆๣ᴗົ㐃ᦠ༠㆟఍ࡢྲྀࡾ⤌ࡳѸಖ㝤⸆ᒁ࡟࠾ࡅ
ࡿࡀࢇ་⒪ࡢᐇែㄪᰝѸ. ᮏከఙ஧ࠊ኱㔝ᜨ୍ࠊ⚟⏣ග἞ࠊ௒ᕝᩥ඾ࠊᒸ㔝⨾⮧ࠊⴕᢤ
୍㑻ࠊᑠཎᘏ❶ࠊ୰すᘯ࿴ࠊྥ஭ᛅᬕࠊ୕ୖ ṇࠊᒸ⏣⪔஧ࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣
ᖌ఍㞧ㄅ, 45(10), 1352-1356 (2009)
13. እ᮶໬Ꮫ⒪ἲ㒊࡟࠾ࡅࡿ TS-1 ᭹⏝ᝈ⪅࡟ᑐࡍࡿ⥅⥆ⓗ࡞⸆Ꮫⓗ⟶⌮ࠥᝈ⪅ᩍ⫱ࢩࢫࢸ
࣒ࡢᵓ⠏࡜✚ᴟⓗ࡞ࣇ࢓࣮࣐ࢩ࣮ࣗࢸ࢕࢝ࣝࢣ࢔࡬ࡢྲྀࡾ⤌ࡳࠥ. ⚃ ༓ెᏊࠊᑠᯘᨻ
ᙪࠊᑎ⏣ᬛ♸ࠊ▮㔝⫱Ꮚࠊᯇᮏ⦾ᕭࠊᰗཎ୍ᗈࠊ⚟ᓥ㞞඾ࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 35(12),
866-874 (2009)
14. ᢠ⒴๣୰ኸㄪ๣࡟ࡼࡿࢲ࢝ࣝࣂࢪࣥᢞ୚᫬࡟⾑⟶③ࢆ⏕ࡌࡓ 2 ౛. ୸⏣┤ᶞࠊ㇂ᒸᮍᶞࠊ
ᯇᮧ⏤⨾ࠊ᫝ᯞ ဴࠊᐑᆅⰋᶞࠊᒸᮧࡳࡸᏊࠊ஝ ㈼୍ࠊ⮫ᗋ⓶⭵⛉, 63(2), 100-102 (2009)
15. 㟁Ꮚ࢝ࣝࢸᑟධ࡟క࠺␲⩏↷఍ࡢ㉁ⓗྥୖ࡜⸆๣ᖌࡢᙺ๭. ᮌୗ㔛⣪ࠊྂ⏣♸⨾Ꮚࠊᒸ
ᮧࡳࡸᏊࠊ୸ᒣᚿ✑Ꮚࠊᑿᓮ῟Ꮚࠊ㧗ᶫ୍ᰤࠊ▮㔝⫱Ꮚࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍
㞧ㄅ, 44(2), 265-267 (2008)
16. ⫵ࡀࢇᝈ⪅࡟ᑐࡍࡿሷ㓟࢔࣒ࣝࣅࢩࣥࡢእ᮶໬Ꮫ⒪ἲ࡟࠾ࡅࡿ౑⏝ᐇែㄪᰝ࡜⾑ᾮẘ
ᛶࡢホ౯. ୕Ꮿ▱ᏹࠊᶫ⏣ ஽ࠊᑠᯘᨻᙪࠊᑎ⏣ᬛ♸ࠊ᱇ ᩄஓࠊᏳ⏣ᾈᗣࠊ୕ᑿ┤ኈࠊ
ᰗཎ୍ᗈࠊ⚟ᓥ㞞඾ࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 34(3), 268-273 (2008)
17. 㧗║ᅽᝈ⪅࡟࠾ࡅࡿ࢔ࢭࢱࢰ࣑ࣛࢻᢞ୚㔞࡜๪స⏝Ⓨ⌧ࡢ༴㝤ᅉᏊ࡟㛵ࡍࡿ᳨ウ. ᮌ
ᑎᗣ⿱ࠊ⏥㔝㈗ஂࠊ▮㔝⫱Ꮚࠊ⏣㎶ᬗ௦ࠊྜྷᮧ㛗ஂࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㞧ㄅ,
44(5), 744-746 (2008)
18. ࡀࢇ໬Ꮫ⒪ἲ࡟ࡼࡿᝏᚰ࣭჎ྤⓎ⌧ࡢᛶᕪ. ㉥⃝㯞⾰Ꮚࠊᶫ⏣ ஽ࠊ▮㔝⫱Ꮚࠊ᱇ ᩄ
ஓࠊ㧗ᓥᖾᜨࠊᡭⰋྥ⪽ࠊᯇᮏ⦾ᕭࠊᰗཎ୍ᗈࠊ⚟ᓥ㞞඾ࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 34(8),
742-747 (2008)
19. ᢠจᅛ⸆࠾ࡼࡧ⾑ᅽ㝆ୗ⸆ࡢᡭ⾡๓ࡢ㐺ษ࡞ఇ⸆ᮇ㛫タᐃ࡬ࡢྲྀࡾ⤌ࡳ. ᑿୖ㞞ⱥࠊ㇈
᭷⣖ࠊᑎ⏣ᬛ♸ࠊᶫ⏣ ஽ࠊ▮㔝⫱Ꮚࠊゅᒣṇ༤ࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 34(8), 773-780 (2008)
20. እ᮶໬Ꮫ⒪ἲ࡟࠾ࡅࡿᦠᖏᆺᣢ⥆ὀධჾࡢ⢭ᗘㄪᰝ. ᮌᮧ ⥳ࠊᑠᯘᨻᙪࠊᶫ⏣ ஽ࠊ
ᑎ⏣ᬛ♸ࠊ᱇ ᩄஓࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㞧ㄅ, 44(10), 1507-1510 (2008)
21. ᡂே㞴἞ᛶ࡚ࢇ࠿ࢇᝈ⪅࡟࠾ࡅࡿࢡࣟࣂࢨ࣒࠾ࡼࡧάᛶ௦ㅰ≀ࡢయෆືែ࡟㛵ࡍࡿゎ
ᯒ. Ᏻ⏣ᖾ௦ࠊ▮㔝⫱Ꮚࠊ໭ᮧ᭸Ꮚࠊᶫ⏣ ஽ࠊᮌୗ┿ᖾᏊࠊụ⏣᫛ኵࠊ㧗ᶫⰋ㍜ࠊ஝
㈼୍ࠊTDM ◊✲, 25(4), 165-169 (2008)
22. ⸆Ꮫᩍ⫱භᖺไ࡟ྥࡅࡓእ᮶⸆๣஺௜ᐇ⩦ࡢྲྀࡾ⤌ࡳ࡜ࡑࡢホ౯. ᏳᏞᏊⰧ⨾ࠊ㧗ᶫ୍
ᰤࠊᒸᮧࡳࡸᏊࠊᶫ⏣ ஽ࠊ▮㔝⫱Ꮚࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㞧ㄅ, 44(11), 1629-1632
(2008)
23. 㠀ᑠ⣽⬊⫵ࡀࢇᝈ⪅࡟ᑐࡍࡿࢤࣇ࢕ࢳࢽࣈ᭹⏝㛤ጞ᫬ࡢᝈ⪅ᩍ⫱ࢩࢫࢸ࣒ᵓ⠏ࡢヨࡳ.
⚃ ༓ెᏊࠊ▮㔝⫱Ꮚࠊ᱇ ᩄஓࠊᅬ㒊 ㄔࠊ⏣୰ᩥၨࠊ࿴⏣ὒᕭࠊ஝ ㈼୍ࠊ་⒪⸆
Ꮫ, 33(1), 1-7 (2007)
24. ᪂つᢠ⢭⚄⑓⸆ࡢ⮫ᗋᑟධ࡟క࠺ฎ᪉ෆᐜࡢኚ໬㸸኱Ꮫ⑓㝔⢭⚄⛉እ᮶࡟࠾ࡅࡿ᳨ウ.
− 310 −
Ṋ⏣ගຍࠊᑠᯘᨻᙪࠊἙᓮ⫱௦ࠊῐ㔝ⰾஂࠊⱝᮡ༤Ꮚࠊ኱㔝᫂ὒࠊ▮㔝⫱Ꮚࠊᒸ⏣ಇࠊ
ᯘ ᣅ஧ࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 33(1), 60-65 (2007)
25. EMIT ἲ࡟ࡼࡿ࣑ࢥࣇ࢙ࣀ࣮ࣝ㓟⾑୰⃰ᗘ ᐃ࡜ HPLC ἲ࡜ࡢẚ㍑࡟ࡼࡿ⾑୰⃰ᗘホ౯.
ྂಥᏕ᫂ࠊྜྷ⏣ඃᏊࠊ⃝⏣ிᏊࠊቑ⏣ᬛඛࠊ▮㔝⫱Ꮚࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 33(9), 804-808
(2007)
26. ᪂ࡓ࡞⸆๣ᖌᴗົᒎ㛤࡜ࡋ࡚ࡢ UGT1A1 㑇ఏᏊከᆺゎᯒ㸸⡆౽࠿ࡘᏳ౯࡞᪉ἲㄽࡢ☜
❧. ᑎ⏣ᬛ♸ࠊᑿୖ㞞ⱥࠊᑠᯘᨻᙪࠊᯇᮏ⦾ᕭࠊᰗཎ୍ᗈࠊ⚟ᓥ㞞඾ࠊ஝ ㈼୍ࠊ་⒪
⸆Ꮫ, 33(10), 858-862 (2007)
27. ຍ㱋㯤ᩬኚᛶ⑕ࡢග⥺ຊᏛⓗ⒪ἲ࡟࠾ࡅࡿ⸆๣ᴗົѸ࣋ࣝࢸ࣏ࣝࣇ࢕ࣥࡢㄪ〇࡜ᝈ⪅ᣦ
ᑟѸ. ⏥㔝㈗ஂࠊᶫ⏣ ஽ࠊⱝᮡ༤Ꮚࠊ▮㔝⫱Ꮚࠊ⏣ᮧ ᑄࠊ㎷ᕝ᫂Ꮥࠊ኱㇂⠜ྐࠊྜྷ
ᮧ㛗ஂࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㞧ㄅ, 43(10), 1377-1380 (2007)
28. ඲デ⒪⛉ࢆᑐ㇟࡜ࡋࡓࠕࡀࢇ໬Ꮫ⒪ἲㄝ᫂᭩ࠖࡢసᡂ࡜ࡑࡢ㐠⏝. 㧗ᰗ࿴ఙࠊ㧗ᶫ୍ᰤࠊ
ᑿୖ㞞ⱥࠊྂಥᏕ᫂ࠊⱝᮡ༤Ꮚࠊᶫ⏣ ஽ࠊ▮㔝⫱Ꮚࠊዟ⏣┿ᘯࠊ᱇ ᩄஓࠊ஝ ㈼୍ࠊ
᪥ᮏ⑓㝔⸆๣ᖌ఍㞧ㄅ, 42(1), 49-52 (2006)
29. እ᮶໬Ꮫ⒪ἲࣞࢪ࣓ࣥࡢⓏ㘓࡜ฎ᪉ᨭ᥼ᶵ⬟ࡢ᭷⏝ᛶ. ㉥⃝㯞⾰Ꮚࠊᶫ⏣ ஽ࠊ▮㔝⫱
Ꮚࠊ᱇ ᩄஓࠊ໭㔝ಇ⾜ࠊ᳜㔝ṇஓࠊᯇᮏ⦾ᕫࠊᰗཎ୍ᗈࠊ⚟ᓥ㞞඾ࠊ஝ ㈼୍ࠊ་⒪
⸆Ꮫ, 32(4), 327-333 (2006)
30. ⭘⒆እ⛉እ᮶࡟࠾ࡅࡿᣢཧ⸆ࢳ࢙ࢵࢡ࡜ࡑࡢホ౯Ѹ⸆๣ᖌ࡟ࡼࡿᝈ⪅㠃ㄯ࠿ࡽෆ᭹ᣦ♧
⡙ࡲ࡛ࡢ↷ྜࢆ㏻ࡋ࡚Ѹ. ᑿୖ㞞ⱥࠊ㉥⃝㯞⾰Ꮚࠊᑎ⏣ᬛ♸ࠊⱝᮡ༤Ꮚࠊ▼ὠ㞞ᘯࠊ஝
㈼୍ࠊ་⒪⸆Ꮫ, 32(5), 424-428 (2006)
31. ⒴໬Ꮫ⒪ἲࡢ๪స⏝᝟ሗ⤫ྜࢆ┠ⓗ࡜ࡋࡓࢹ࣮ࢱࢩ࣮ࢺࡢᵓ⠏Ѹᢠ⭘⒆๣࣭࢖ࣥࢱ࣮ࣇ
࢙࣭ࣟࣥᨺᑕ⥺ే⏝⒪ἲࡢ๪స⏝᝟ሗ⤫ྜ࡜ホ౯Ѹ. ྂಥᏕ᫂ࠊ▮㔝⫱Ꮚࠊ᱇ ᩄஓࠊ
∦ᒸ኱἞ࠊ໭᮲㞞ேࠊ㧗ᮌᗣᚿࠊ㧗ᶫ ₶ࠊᶫᮏಙኵࠊ஝ ㈼୍ࠊ་⒪⸆Ꮫ, 32(7), 599-606
(2006)
⥲ㄝ㸦ⱥᩥ㸧
1. Terada T and Inui K. Physiological and pharmacokinetic roles of H+/organic cation antiporters
(MATE/SLC47A). Biochem Pharmacol 75: 1689-1696, 2008.
2. Terada T and Inui K. Gene expression and regulation of drug transporters in the intestine and
kidney. Biochem Pharmacol 73: 440-449, 2007.
3. Masuda S and Inui K. An up-date review on individualized dosage adjustment of calcineurin
inhibitors in organ transplant patients. Pharmacol Ther 112: 184-198, 2006.
⥲ㄝ㸦࿴ᩥ㸧
1. 20 ║⛉⑌ᝈ㸸⥙⭷⑕࣭㯤ᩬ⑕. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2010. ⏥㔝㈗ஂࠊ஝ ㈼୍ࠊ
⸆ᒁቑหྕ, 61(4), 1214-1216 (2010)
2. 24 ᝏᛶ⭘⒆㸸⫢⒴. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2010. ᑿୖ㞞ⱥࠊ஝ ㈼୍ࠊ⸆ᒁቑห
ྕ, 61(4), 1570-1573 (2010)
3. 27 ⛣᳜་⒪㸸⛣᳜་⒪࡟࠾ࡅࡿ⸆≀⒪ἲ. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2010. ῝ὠ⚈ኸࠊ
஝ ㈼୍ࠊ⸆ᒁቑหྕ, 61(4), 1738-1740 (2010)
4. 29 ᅗゎ ⸆⌮స⏝㸸ච␿ᢚไ⸆. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2010. ⚟ᅵᑗ⚽ࠊ஝ ㈼
୍ࠊ⸆ᒁቑหྕ, 61(4), 110-112 (2010)
5. ࡣࡌࡵ࡚ࡢᡭ⾡ᐊ ⸆ရ⟶⌮ࡢ࣏࢖ࣥࢺ㸦≉㞟㸸࿘⾡ᮇᝈ⪅ࡢ⸆Ꮫⓗ⟶⌮㸧. ᑿୖ㞞ⱥࠊ
஝ ㈼୍ࠊ⸆ᒁู෉, 61(5), 52-58 (2010)
6. ་⒪Ᏻ඲ࡢ☜ಖ࡜་⸆ရ㐺ṇ౑⏝࡟ྥࡅࡓᣢཧ⸆⟶⌮ࡢྲྀࡾ⤌ࡳ ᝈ⪅㠃ㄯ࠿ࡽ୚⸆
ᣦ♧ᐇ᪋⡙ࡢ↷ྜࡲ࡛ࢆ㏻ࡋࡓᣢཧ⸆⟶⌮㸦≉㞟㸸15 ࡢ஦౛࠿ࡽᏛࡪᣢཧ⸆⟶⌮㸧. ᑿ
ୖ㞞ⱥࠊᐙỌ჆Ꮚࠊ῝ὠ⚈ኸࠊ᱇ ᩄஓࠊ஝ ㈼୍ࠊ⸆ᒁู෉, 61(9), 3021-3025 (2010)
7. ࣏࢖ࣥࢺࣞࢡࢳ࣮ࣕ་⸆ရᏳ඲㸦➨ 13 ᅇ㸧
㸸⤒ཱྀᢠࡀࢇ๣἞⒪࡛Ⓨ⏕ࡍࡿ࢚࣮ࣛ㸦≉㞟㸸
ᚋⓎ་⸆ရ—⸆๣ᖌࡢ㛵ࢃࡾࢆ᥈ࡿ㸧. ᑿୖ㞞ⱥࠊ῝ὠ⚈ኸࠊᒣ⏣࿴ྖࠊ᱇ ᩄஓࠊ஝
㈼୍ࠊ᭶ห⸆஦, 52(10), 1535-1538 (2010)
8. ⸆≀ࢺࣛࣥࢫ࣏࣮ࢱ◊✲࡜௒ᚋࡢᒎ㛤. ஝ ㈼୍ࠊᑎ⏣ᬛ♸ࠊ⭷, 33(5), 201-207 (2009)
9. ᣦᑟ⸆๣ᖌࡢㄆᐃࢆཷࡅࡿ ղ᪥ᮏ་⒪⸆Ꮫ఍ㄆᐃ⸆๣ᖌ࣭ᣦᑟ⸆๣ᖌ㸦➨Ϫ❶ ᣦᑟ
⸆๣ᖌ࣭ㄆᐃ⸆๣ᖌ࢞࢖ࢻ㸧. ஝ ㈼୍ࠊ᭶ห⸆஦(㸷᭶⮫᫬ቑหྕ), 50, 1577-1581 (2008)
10. ➨㸯ᅇ࢖ࣜࣀࢸ࢝ࣥሷ㓟ሷࡢ௦ㅰࡢಶయᕪࢆ᥈ࡿ㸸⸆๣ᖌࡀⓎಙࡍࡿࡀࢇ⸆≀⒪ἲࡢ࢚
ࣅࢹࣥࢫ. ᑿୖ㞞ⱥࠊᑎ⏣ᬛ♸ࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 51(1), 97-103 (2009)
11. ➨㸰ᅇẼࢆࡘࡅࡓ࠸࢖ࣥࣇ࣮ࣗࢨ࣮࣏ࣥࣉࡢṧᾮ㸸⸆๣ᖌࡀⓎಙࡍࡿࡀࢇ⸆≀⒪ἲࡢ࢚
ࣅࢹࣥࢫ. ᮌᮧ ⥳ࠊᑠᯘᨻᙪࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 51(2), 243-248 (2009)
12. ➨㸱ᅇᢠࡀࢇ๣๪స⏝Ⓨ⌧ࡢᛶᕪ㸸⸆๣ᖌࡀⓎಙࡍࡿࡀࢇ⸆≀⒪ἲࡢ࢚ࣅࢹࣥࢫ. ㉥⃝
㯞⾰Ꮚࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 51(3), 381-384 (2009)
− 311 −
13. ➨㸲ᅇሷ㓟࢔࣒ࣝࣅࢩࣥࡢ๪స⏝ゎᯒ࠿ࡽࡳ࠼࡚ࡁࡓࡇ࡜㸸⸆๣ᖌࡀⓎಙࡍࡿࡀࢇ⸆≀
⒪ἲࡢ࢚ࣅࢹࣥࢫ. ୕Ꮿ▱ᏹࠊᑎ⏣ᬛ♸ࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 51(4), 541-546 (2009)
14. ᩍ⫱㈹ཷ㈹ ⥴᪉ᏹὈẶࡢᴗ⦼. ஝ ㈼୍ࠊࣇ࢓࣐ࣝࢩ࢔, 45(5), 482 (2009)
15. ➨㸳ᅇࣉࣛࢳࢼ⣔ᢠࡀࢇ๣ࡢ⭈ẘᛶ࡟㏕ࡿ㸸⸆๣ᖌࡀⓎಙࡍࡿࡀࢇ⸆≀⒪ἲࡢ࢚ࣅࢹࣥ
ࢫ. ⡿⃝ ῟ࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 51(5), 725-729 (2009)
16. ➨㸴ᅇஙࡀࢇ໬Ꮫ⒪ἲ FEC100 ࡛ࡢ G-CSF 〇๣ࡢண㜵ⓗᢞ୚࡟ࡘ࠸࡚㸸⸆๣ᖌࡀⓎಙ
ࡍࡿࡀࢇ⸆≀⒪ἲࡢ࢚ࣅࢹࣥࢫ. ⸨⃝ᾈ⨾ࠊᑎ⏣ᬛ♸ࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 51(6),
859-863 (2009)
17. ⮚ჾ෌⏕࡜⸆≀యෆືែࡢ┦㛵࡟ࡘ࠸࡚▱ࡾࡓ࠸Ѹ⫢⛣᳜ᝈ⪅࡟࠾ࡅࡿࢱࢡ࣒ࣟࣜࢫࢡ
ࣜ࢔ࣛࣥࢫࡢኚ໬Ѹ. ῝ὠ⚈ኸࠊ஝ ㈼୍ࠊ἞⒪Ꮫ, 43(6), 693-694 (2009)
18. ⏕య⫢⛣᳜ᝈ⪅࡟࠾ࡅࡿ࣓࢜ࣉࣛࢰ࣮ࣝ࡜ࢱࢡ࣒ࣟࣜࢫࡢ┦஫స⏝࡟ཬࡰࡍᑠ⭠
CYP2C19 㑇ఏᏊከᆺࡢᙳ㡪. ⣽⏿ᆂᏊࠊቑ⏣ᬛඛࠊୖᮏఙ஧ࠊ஝ ㈼୍ࠊ௒᪥ࡢ⛣᳜㸪
22(3), 283-287 (2009)
19. 19 ║⛉⑌ᝈ㸸⥙⭷⑕࣭㯤ᩬ⑕. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2009. ⏥㔝㈗ஂࠊ஝ ㈼୍ࠊ
⸆ᒁቑหྕ, 60(4), 1663-1665 (2009)
20. 24 ᝏᛶ⭘⒆㸸⫢⒴. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2009. ᑿୖ㞞ⱥࠊ஝ ㈼୍ࠊ⸆ᒁቑห
ྕ, 60(4), 1972-1980 (2009)
21. 27 ⛣᳜་⒪㸸⛣᳜་⒪࡟࠾ࡅࡿ⸆≀⒪ἲ. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2009. ῝ὠ⚈ኸࠊ
஝ ㈼୍ࠊ⸆ᒁቑหྕ, 60(4), 2138-2141 (2009)
22. 29 ᅗゎ ⸆⌮స⏝㸸ච␿ᢚไ⸆. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2009. ⚟ᅵᑗ⚽ࠊ஝ ㈼
୍ࠊ⸆ᒁቑหྕ, 60(4), 2258-2260 (2009)
23. ච␿ᢚไ⸆ࡢືែ࡜⸆ຠ࣭ẘᛶ. ቑ⏣ᬛඛࠊ஝ ㈼୍ࠊ἞⒪Ꮫ㸪43(12), 1303-1307 (2009)
24. ච␿ᢚไ⸆࡜࢔ࢰ࣮ࣝ⣔ᢠ┿⳦⸆ࡢ⸆≀ືែᏛⓗ┦஫స⏝. ▮㔝⫱Ꮚࠊ஝ ㈼୍ࠊ἞⒪
Ꮫ, 43(12), 1351-1355 (2009)
25. ࢱࢡ࣒ࣟࣜࢫ⾑୰⃰ᗘࡢㄪᩚ࣓࢝ࢽࢬ࣒. ▮㔝⫱Ꮚࠊ஝ ㈼୍ࠊ௒᪥ࡢ⛣᳜, 21(1), 17-23
(2008)
26. ච␿ᢚไ⸆㸸➨Ϫ㒊 ἞⒪࡟࠾ࡅࡿ᭱㏆ࡢ᪂⸆ࡢ఩⨨௜ࡅࠑ⸆ຠูࠒࠥ᪂⸆ࡢᗈሙࠥ. ⚟
ᅵᑗ⚽ࠊ஝ ㈼୍ࠊ᪂⸆ᒎᮃ 2008(ቑหྕ), 44, 327-331 (2008)
27. TS-1 ࡬࡯࠿ࡢ 5-FU ⣔ᢠ⒴๣࠿ࡽษࡾ᭰࠼ࡿ㝿ࡢ᭹⸆⟶⌮ୖࡢὀពⅬࡣ࠶ࡾࡲࡍ࠿㸽
㸦≉㞟㸸ࣇࢵ໬ࣆ࣑ࣜࢪࣥ⣔ᢠ⒴๣ࡢ᭹⸆⟶⌮ Q&Aձ㸧. ㉥⃝㯞⾰Ꮚࠊ஝ ㈼୍ࠊ⸆
ᒁู෉, 59(5), 2246-2249 (2008)
28. ࢝ࣝࢩࢽ࣮ࣗࣜࣥ㜼ᐖ๣ࡢయෆືែ࡜⸆ຠࡢ㏿ᗘㄽⓗゎᯒ࡟ᇶ࡙ࡃಶู໬ᢞ୚タィἲ.
▮㔝⫱Ꮚࠊ⚟ᅵᑗ⚽ࠊቑ⏣ᬛඛࠊᑠ಴㟹ᘯࠊᑿụᩥ㝯ࠊ⏣୰⣫୍ࠊ஝ ㈼୍ࠊ⮫ᗋ⸆⌮
ࡢ㐍Ṍ, 29, 113-119 (2008)
29. ࠙⭈ࡢ≀㉁㍺㏦࡜௦ㅰࠚ SLC (solute carrier)ࢺࣛࣥࢫ࣏࣮ࢱ࡜≀㉁௦ㅰ. ᑎ⏣ᬛ♸ࠊ஝
㈼୍ࠊ⭈࡜㏱ᯒ, 65(5), 657-663 (2008)
30. Irinotecan ࡢ๪స⏝Ⓨ⌧࡟ᑐࡍࡿ UGT1A1*28 ࡜ UGT1A1*6 ࡢᙺ๭. ᑿୖ㞞ⱥࠊ஝ ㈼୍ࠊ
⒴࡜໬Ꮫ⒪ἲ, 35(7), 1080-1085 (2008)
31. 19 ║⛉⑌ᝈ㸸⥙⭷⑕࣭㯤ᩬ⑕㸬⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2008. ⏥㔝㈗ஂࠊ஝ ㈼
୍ࠊ⸆ᒁቑหྕ, 59(4), 1635-1637 (2008)
32. 24 ᝏᛶ⭘⒆㸸⫢⒴. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2008. ᑿୖ㞞ⱥࠊ஝ ㈼୍ࠊ⸆ᒁቑห
ྕ, 59(4), 1938-1945 (2008)
33. 27 ⛣᳜་⒪㸸⛣᳜་⒪࡟࠾ࡅࡿ⸆≀⒪ἲ. ⑓Ẽ࡜⸆ࣃ࣮ࣇ࢙ࢡࢺࣈࢵࢡ 2008. ῝ὠ⚈ኸࠊ
஝ ㈼୍ࠊ⸆ᒁቑหྕ, 59(4), 2111-2114 (2008)
34. ᅜෆእ࡟࠾ࡅࡿᶆ‽ࡀࢇ⸆≀⒪ἲ㸸⫶ࡀࢇ㸦≉㞟㸸▱ࡗ࡚࠾ࡁࡓ࠸ᶆ‽ࡀࢇ⸆≀⒪ἲ㸧.
ᑎ⏣ᬛ♸ࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 49(2), 199-206 (2007)
35. ⸆⌮ࢤࣀ࣑ࢡࢫ࡟ࡼࡿᢞ୚タィ㸸⮚ჾ⛣᳜㸳. ቑ⏣ᬛඛࠊ஝ ㈼୍ࠊ⮫ᗋ᳨ᰝ, 51(5),
547-552 (2007)
36. ዡບ㈹ཷ㈹ ᑎ⏣ᬛ♸Ặࡢᴗ⦼. ஝ ㈼୍ࠊࣇ࢓࣐ࣝࢩ࢔, 43(6), 585 (2007)
37. ⭈⸆≀ࢺࣛࣥࢫ࣏࣮ࢱ⩌ࡢ rSNP ࡟╔┠ࡋࡓⓎ⌧㔞ኚືせᅉࡢゎ᫂. ஝ ㈼୍ࠊቑ⏣ᬛ
ඛࠊᑎ⏣ᬛ♸ࠊᮏᶫ⚽அࠊ⮫ᗋ⸆⌮ࡢ㐍Ṍ, 28, 42-48 (2007)
38. ᑓ㛛⸆๣ᖌࡢ඘ᐇ㸦ࡀࢇ໬Ꮫ⒪ἲ㸧
㸸ᖹᡂ 19 ᖺᗘᅜබ⚾❧኱Ꮫ⑓㝔⸆๣㒊⫋ဨ◊ಟ. ᑎ
⏣ᬛ♸ࠊ஝ ㈼୍ࠊ⸆஦᪂ሗ, 2484, 13-15 (2007)
39. ⸆≀ືែࣃ࣓࣮ࣛࢱ࣮ࢆά⏝ࡋࡓ⮫ᗋ஦౛—࢝ࣝࢩࢽ࣮ࣗࣜࣥ㜼ᐖ๣࡟ࡘ࠸࡚㸦≉㞟㸸
⸆ᏛⓗどⅬ࠿ࡽ⸆ࢆࡳࡿຊ㸧. ▮㔝⫱Ꮚࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 49(9), 1359-1364 (2007)
40. ⫶ࡀࢇ㸸➨㸱❶ ࣞࢪู࣓ࣥ⸆≀⒪ἲࣔࢽࢱࣜࣥࢢࡢ࣏࢖ࣥࢺ. ᑿୖ㞞ⱥࠊ஝ ㈼୍ࠊ
᭶ห⸆஦(9 ᭶⮫᫬ቑหྕ), 49(10), 1567-1575 (2007)
41. H+/organic cation antiporter (MATE/SLC47A)㸦≉㞟㸸ࡇࢀࡔࡅࡣ▱ࡗ࡚࠾ࡁࡓ࠸ศᏊ⭈⮚
Ꮫ 2007. ⡿⃝ ῟ࠊ஝ ㈼୍ࠊ⭈࡜㏱ᯒ, 63(4), 466-469 (2007)
42. ⸆๣ᖌ࠿ࡽࡢࡦ࡜ࡇ࡜Ѹᢠࡀࢇ๣࡟ࡼࡿ஦ᨾࢆ㜵ࡄࡓࡵ࡟Ѹ. ᑿୖ㞞ⱥࠊᑎ⏣ᬛ♸ࠊ஝
− 312 −
㈼୍ࠊ⮫ᗋ◊ಟࣉࣛࢡࢸ࢕ࢫ, 4(6), 28 (2007)
43. ➨㸶ᅇ⭈⸆≀ࢺࣛࣥࢫ࣏࣮ࢱ࣮ࡢⓎ⌧ኚື࡜⸆≀⭈᤼ἥ࡟࠾ࡅࡿᙺ๭㸸⸆๣ᖌࡀኚ࠼ࡿ
⸆≀἞⒪ Part 2. ᮏᶫ⚽அࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 48(1), 99-105 (2006)
44. ➨㸷ᅇ⏕య⫢⛣᳜⑕౛࡟࠾ࡅࡿ࢝ࣝࢩࢽ࣮ࣗࣜࣥάᛶࡢ ᐃ࡟ᇶ࡙ࡃ⸆ຠホ౯࡜ಶู
໬ᢞ୚タィ㸸⸆๣ᖌࡀኚ࠼ࡿ⸆≀἞⒪ Part 2. ▮㔝⫱Ꮚࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 48(2),
269-276 (2006)
45. ➨㸯㸮ᅇ᪂つࡀࢇ໬Ꮫ⒪ἲ࡟࠾ࡅࡿ๪స⏝᝟ሗࡢ཰㞟࣭ホ౯࠿ࡽ࢚ࣅࢹࣥࢫࢆᚓࡿѸ⬻
⭘⒆ᝈ⪅ࢆ౛࡜ࡋ࡚㸸⸆๣ᖌࡀኚ࠼ࡿ⸆≀἞⒪ Part 2. ྂಥᏕ᫂ࠊ஝ ㈼୍ࠊ᭶ห⸆஦,
48(3), 417-424 (2006)
46. ➨㸯㸯ᅇࡀࢇࡢ㞟Ꮫⓗ἞⒪࠾ࡅࡿ⸆Ꮫⓗ௓ධ౛Ѹ㢕㒊ࡀࢇᝈ⪅࡟࠾ࡅࡿ㧗ࢥࣞࢫࢸ࣮ࣟ
ࣝ⾑⑕ࡣᨺᑕ⥺἞⒪࡟㉳ᅉࡍࡿሙྜࡀ࠶ࡿ㸸⸆๣ᖌࡀኚ࠼ࡿ⸆≀἞⒪ Part 2. 㷇⇃ᐜᏊࠊ
஝ ㈼୍ࠊ᭶ห⸆஦, 48, 595-600 (2006)
47. ࢩ࣮ࣜࢬࡀࢇ໬Ꮫ⒪ἲࡢᇶ♏㸸մ⫶ࡀࢇࡢᴫせ࡜໬Ꮫ⒪ἲ. ᑿୖ㞞ⱥࠊ஝ ㈼୍ࠊ᪥ᮏ
⑓㝔⸆๣ᖌ㞧ㄅ, 42(2), 467-470 (2006)
48. ➨㸯㸰ᅇ(᏶)⮚ჾ⛣᳜ᝈ⪅࡟࠾ࡅࡿࢸ࣮࣮࣓ࣛ࢖ࢻච␿ᢚไ⒪ἲ࡟ྥࡅ࡚Ѹ㑇ఏᏊከᆺ
ゎᯒࡢᐇ᪋࡜⮫ᗋⓗព⩏࡟ࡘ࠸࡚㸸⸆๣ᖌࡀኚ࠼ࡿ⸆≀἞⒪ Part 2. ቑ⏣ᬛඛࠊ஝ ㈼
୍ࠊ᭶ห⸆஦, 48(5), 747-753 (2006)
49. ி㒔኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔ࡢྲྀࡾ⤌ࡳ ⸆๣ᖌࡢࢳ࢙ࢵࢡࢆᚲ㡲࡜ࡋࡓᣢཧ⸆ࡢᏳ඲⟶
⌮㸦≉㞟㸸ධ㝔᫬ᣢཧ⸆ࡢᏳ඲⟶⌮࡟ྥࡅ࡚㸧. ▼ὠ㞞ᘯࠊ஝ ㈼୍ࠊ᭶ห⸆஦, 48(6),
863-868 (2006)
50. ձ㝔ෆឤᰁᑐ⟇ࢳ࣮࣒(ICT)㸦≉㞟㸸ࢳ࣮࣒་⒪㸧. 㧗ᰗ࿴ఙࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣
ᖌ㞧ㄅ, 42(8), 1025-1026 (2006)
51. ᚠ⎔ჾ⸆ࡢే⏝౑⏝᫬ࡢὀពⅬ㸸௒᭶ࡢ୺㢟 ᚠ⎔ჾ⸆ࡢ౑࠸᪉ 2006. ⱝᮡ༤Ꮚࠊ஝
㈼୍ࠊmedicina, 43(9), 1497-1501 (2006)
52. ࢝ࣝࢩࢽ࣮ࣗࣜࣥ㜼ᐖ๣ࡢ Pharmacodynamics ࡜⮳㐺ᢞ୚タィ. ⚟ᅵᑗ⚽ࠊ▮㔝⫱Ꮚࠊቑ
⏣ᬛඛࠊ᱇ ᩄஓࠊᑠ಴㟹ᘯࠊᑿụᩥ㝯ࠊ㧗⏣Ὀḟࠊୖᮏఙ஧ࠊ⏣୰⣫୍ࠊ஝ ㈼୍ࠊ
௒᪥ࡢ⛣᳜, 19(6), 658-660 (2006)
53. ࡀࢇ໬Ꮫ⒪ἲࡢᇶ♏ ⫵ࡀࢇࡢᴫせ࡜໬Ꮫ⒪ἲ. ⚃ ༓ెᏊࠊ஝ ㈼୍ࠊ᪥ᮏ⑓㝔⸆๣
ᖌ఍㞧ㄅ, 42(8), 1037-1041 (2006)
ⴭ᭩㸦ⱥᩥ㸧
1. Terada T and Inui K. Impact of Drug Transport Proteins. In Drug Absorption Studies In Situ,
In Vitro and In Silico Models, ed by C. Ehrhardt and K-J. Kim, pp.559-576, Springer, New York
(2008)
2. Yano I, Masuda S, and Inui K. Therapeutic drug monitoring and individualized therapy with
tacrolimus in recipients of living-donor liver transplantation. In Evolution of living-donor
liver transplantation, ed by K. Tanaka, Y. Inomata, S. Uemoto and T. Kiuchi, pp.217-232,
Thomson Reuters, New York (2008)
ⴭ᭩㸦࿴ᩥ㸧
1. ᮏᶫ⚽அ㸪஝ ㈼୍㸸➨㸯❶ ࢺࣛࣥࢫ࣏࣮ࢱ࣮◊✲ࡢᇶ♏.
2.
3.
4.
5.
6.
7.
8.
9.
10.
1.ࢺࣛࣥࢫ࣏࣮ࢱ࣮ࡢ✀
㢮 1) SLC ࡢᵓ㐀࡜ᶵ⬟. 㑇ఏᏊ་Ꮫ MOOK12 ᭱᪂ࢺࣛࣥࢫ࣏࣮ࢱ࣮◊✲ 2009, ᮡ
ᒣ㞝୍⦅㞟, 287-292, ࣓ࢹ࢕࢝ࣝࢻࢗ (2009)
ᇼ ஢ᖹ┘ಟ㸪஝ ㈼୍㸪ዟᮧ຾ᙪ⦅㞟㸸་⒪⸆Ꮫ➨ 5 ∧, ᘅᕝ᭩ᗑ (2009)
஝ ㈼୍┘ಟ㸸⸆๣ᖌࡀⓎಙࡍࡿࡀࢇ⸆≀⒪ἲࡢ࢚ࣅࢹࣥࢫ,ࡌ࡯࠺ (2009)
஝ ㈼୍⦅㞟㸸⸆≀ࢺࣛࣥࢫ࣏࣮ࢱά⏝ࣛ࢖ࣈ࣮ࣛࣜ㸪⨺ᅵ♫㸦2009㸧
㧗ஂྐ㯢┘ಟ㸪ᇼ ṇ஧㸪Ⳣ㔝೺ኴ㑻㸪㛛⬥ Ꮥ㸪஝ ㈼୍㸪ᯘ ᫀὒ⦅㞟㸸἞⒪⸆ࣁ
ࣥࢻࣈࢵࢡ 2009, ࡌ࡯࠺ (2009)
ᑎ ⏣ ᬛ ♸ 㸪 ஝ ㈼ ୍ 㸸 I. Basic Nephrology 6. H+/ ᭷ ᶵ ࢝ ࢳ ࢜ ࣥ ࢔ ࣥ ࢳ ࣏ ࣮ ࢱ
(MATE/SLC47A). Annual Review ⭈⮚, ᚚᡭὙဴஓ, ᮾཎⱥ஧, ⛅⃝ᛅ⏨, ஬༑ᔒ 㝯,
㔠஭ዲඞ⦅㞟, 36-42, ୰እ་Ꮫ♫ (2008)
㧗ஂྐ㯢┘ಟ㸪ᇼ ṇ஧㸪Ⳣ㔝೺ኴ㑻㸪㛛⬥ Ꮥ㸪஝ ㈼୍㸪ᯘ ᫀὒ⦅㞟㸸἞⒪⸆ࣁ
ࣥࢻࣈࢵࢡ 2008, ࡌ࡯࠺ (2008)
⚟ᅵᑗ⚽㸪஝ ㈼୍㸸➨㸳❶ ๓⮫ᗋ࠿ࡽ⮫ᗋ࡬ࡢࢺࣛࣥࢫ࣮ࣞࢩࣙࣥ. 3.ࢤࣀ࣒᝟ሗ
ࢆᇶ┙࡜ࡋࡓࢱࢡ࣒ࣟࣜࢫయෆືែゎᯒ࡜ಶู໬ච␿ᢚไ⒪ἲ࡬ࡢᛂ⏝. 㑇ఏᏊ་Ꮫ
MOOK7 ᭱᪂๰⸆Ꮫ 2007, ᮡᒣ㞝୍⦅㞟, 287-292, ࣓ࢹ࢕࢝ࣝࢻࢗ (2007)
ᶫ⏣ ஽㸪஝ ㈼୍㸸➨㸳❶ ⸆ᒁ࡟࠾ࡅࡿ⚗↮ᨭ᥼ 2.⑓㝔⸆ᒁ࡟࠾ࡅࡿ⚗↮ᨭ᥼ࡢ
࣏࢖ࣥࢺ. ⚗↮ᣦᑟ㺃ᨭ᥼⪅ࡢࡓࡵࡢ⚗↮⛉Ꮫ, ྜྷ⏣ ಟ┘ಟ, ᐩỌ♸Ẹ㸪୰ཎಇ㝯㸪
㧗ᶫ⿱Ꮚ⦅㞟, ᪥ᮏ⚗↮⛉Ꮫ఍⦅, 247-251, ᩥගᇽ (2007)
஝ ㈼୍┘ಟ㸸⸆๣ᖌࡀኚ࠼ࡿ⸆≀἞⒪㸰-Ᏻ඲࡞ࡀࢇ἞⒪࡜ࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪࡟ྥ
− 313 −
ࡅ࡚,ࡌ࡯࠺ (2007)
11. Ύ㔝 ⿱┘ಟ㸪ࣃ࣮ࢺ┘ヂ ஝ ㈼୍㸪⚟ᒣ⚽┤㸪ᇼỤ ⛱㸪㉺ᒣ⿱⾜㸪୕ᔱ⌮᫭㸪୍
12.
13.
14.
15.
16.
ᒣ ᬛ㸪୕᳃⤒ୡ㸸⑓ែ⏕⌮࡟ᇶ࡙ࡃ⮫ᗋ⸆⌮Ꮫ, ࣓ࢹ࢕࢝ࣝ㺃ࢧ࢖࢚ࣥࢫ࣭࢖ࣥࢱ࣮
ࢼࢩࣙࢼࣝ(2006)
஝ ㈼୍㸪ᅵ஭ಇኵ ⦅ⴭ㸸ᨵゞ➨㸰⭈ᶵ⬟ู⸆๣౑⏝࣐ࢽࣗ࢔ࣝ, ࡌ࡯࠺ (2006)
▮㔝⫱Ꮚ㸪஝ ㈼୍㸸➨㸰❶ ࢳ࣮࣒་⒪࡟ὀ┠ࡍࡿ SB04-6 ͆ࢫࢱࣥࢲ࣮ࢻ⸆Ꮫࢩ
࣮ࣜࢬ 10. ᐇົᐇ⩦஦๓Ꮫ⩦㸸⑓㝔࣭⸆ᒁᐇ⩦࡟⾜ࡃ๓࡟͇㸪 ᪥ᮏ⸆Ꮫ఍⦅㸪ᮾி⛉
Ꮫྠே㸪ᮾி㸪11-16 (2006)
▮㔝⫱Ꮚ㸪஝ ㈼୍㸸➨㸳❶ ་⒪⸆๣Ꮫ㸦ศᢸᇳ➹㸧. ͆᭱᪂⸆๣Ꮫ➨㸷∧͇㸪 ᯘ
ṇᘯ㸪ᕝᓥ჆᫂㸪஝ ㈼୍⥲⦅㞟㸪ᘅᕝ᭩ᗑ㸪ᮾி(2006)
ᑎ⏣ᬛ♸㸪஝ ㈼୍㸸࣌ࣉࢳࢻࢺࣛࣥࢫ࣏࣮ࢱ PEPTs. ͆๰⸆ືែ ་⸆ရ๰〇ࡢࡓࡵ
ࡢ⪃࠼᪉࡜᭱᪂஦᝟͇㸪⸆≀ືែᏛ఍㸪ᮾி(2006)
஝ ㈼୍┘ಟ㸸⸆๣ᖌ࡟ࡼࡿ⮫ᗋ◊✲ࡢ㐍ࡵ᪉Ѹ᪥ᖖᴗົ࠿ࡽ་⒪⸆Ꮫ◊✲ࡢࢩ࣮ࢬࢆ
⫱࡚ࡿ㸬᭶ห⸆஦ 7 ᭶⮫᫬ቑหྕ㸪ࡌ࡯࠺ (2006)
− 314 −
ࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮ศ㔝
ᩍ ᤵ㸦་Ꮫ༤ኈ㸧ᒸᮧ ᆒ㸦࠾࠿ࡴࡽ ࡦ࡜ࡋ㸧㸦2007.5 ╔௵㸧
᫛࿴ 54 ᖺி㒔ᗓ❧་⛉኱Ꮫ༞
෸ᩍᤵ㸦⌮Ꮫ༤ኈ㸧ᅵᒃ 㞞ኵ㸦࡝࠸ ࡲࡉ࠾㸧㸦2011.1.1 ᪼௵ࠊ
2007.6̿2010.12 ㅮᖌ㸧ᖹᡂ 10 ᖺᮾி኱Ꮫ⌮Ꮫ㒊༞ࠊ
ᖹᡂ 15 ᖺྠ኱Ꮫ኱Ꮫ㝔⌮Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
ຓ ᩍ㸦⏕࿨⛉Ꮫ༤ኈ㸧ᒣཱྀ ㈡❶㸦ࡸࡲࡄࡕ ࡼࡋ࠶ࡁ㸧
㸦2007.11 ╔௵㸧ࠊᖹᡂ 11 ᖺி㒔኱Ꮫ⸆Ꮫ㒊༞
ᖹᡂ 16 ᖺྠ኱Ꮫ኱Ꮫ㝔⏕࿨⛉Ꮫ◊✲⛉༤ኈㄢ⛬ಟ஢
㸦
㸦ᒸᮧᩍᤵ㸧
◊✲ࡢᴫせ
⏕యࣜࢬ࣒ Biological Rhythm ࡣࠊᆅ⌫ࡢ⮬㌿࡟࡜ࡶ࡞࠺᫨ኪࡢつ๎ṇࡋ࠸ኚື࡟ᇶ࡙ࡁᙧᡂࡉࢀࡓࠊ
⏕࿨࡟࡜ࡗ࡚᭱ࡶ᰿※ⓗ࡞ࠕ᫬㛫ࠖࡢ௙⤌ࡳ࡛࠶ࡿࠋᡃࠎࡣ့ங㢮᫬ィ㑇ఏᏊࡢࢡ࣮ࣟࢽࣥࢢ㸦Naure 1997,
Cell 1997㸧࠿ࡽࣜࢬ࣒⏕ᡂࡢศᏊࣞ࣋ࣝࡢゎ᫂㸦Science 1999, 2001㸧ࢆඛᑟࡋࠊ⏕యෆ࡛᫬ィࡀᐇ㝿ື
࠸࡚࠸ࡿ஦ࢆ᫂ࡽ࠿࡟ࡋࡓ㸦Nature 2001; Science 2003a㸧ࠋࡍ࡞ࢃࡕࠊ⏕యࣜࢬ࣒ࡢศ㔝࡜ࡣࠊ๓ୡ⣖ࡢ
᭱ᚋ࡟࡞ࡉࢀࡓ⏕≀Ꮫࡢ᭱ᚋࡢࣇࣟࣥࢸ࢕࢔࡛࠶ࡾࠊᡃࠎࡣࡑࡢ㛤ᣅ࡟ᐇ㝿ཧຍࡋࠊ⣽⬊ࠊ⤌⧊ࠊ⾜ື
࡜⏕࿨ࡢ㝵ᒙᛶ࡟ࢃࡓࡾಖᏑࡉࢀ࡚࠸ࡿࠕศᏊ᫬ィ molecular clockࠖࡢᴫᛕࡢ☜❧࡟㈉⊩ࡋࡓࠋ
ࡇࡢศᏊ࡛ࣞ࣋ࣝࡢゎ᫂࡜⏕࿨ཎ⌮࡛ࡢ㔜せᛶࡣࠊ⏕యࣜࢬ࣒◊✲ࡣࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮ⓗᡭἲࡀ
㠀ᖖ࡟᭷ຠ࡞ศ㔝࡜࡞ࡗࡓࠋࡑࡢ࡞࠿࡛ࠊᡃࠎࡣࡇࢀࡽࡢከࡃࡢ㑇ఏᏊ࣭⣽⬊ࣞ࣋ࣝࡢᡂᯝࢆࠊಶయࣞ
࣋ࣝ࡟ᒎ㛤ࡋ࡚࠸ࡿࠋ᭱㏆࡛ࡣࠊ㑇ఏᏊ࠿ࡽ⾜ືࡲ࡛ࡢⓎ⌧ᶵᵓࡀࢃ࠿ࡗ࡚࠸ࡿ⏕࿨ཎ⌮ࡢ୍ࡘ࡛
࠶ࡿศᏊ᫬ィࢆ⏝࠸࡚ࢤࣀ࣑ࢡࢫࠊࣉࣟࢸ࣑࢜ࢡࢫࢆ㥑౑ࡋ࡚ࠊཎᅉࡢゎ᫂ࡉࢀ࡚࠸࡞࠸៏ᛶ⑌ᝈ
ࡢ⑓ᅉࡢゎ᫂࡟ᣮࡳࠊࡇࡢ᪂ࡋ࠸ษࡾཱྀ࠿ࡽࠊ๰⸆ࡢ㐩ᡂࢆ┠ᣦࡋ࡚࠸ࡿࠋࡇࢀࡽࡢᡂᯝࡣ௨㝆ࡢ
ࡼ࠺࡟ࡲ࡜ࡵࡽࢀࡿࠋ
ศᏊ᫬ィࡢᴫᛕࡢ☜❧
᫬ィ㑇ఏᏊࡢⓎぢ࡜ศᏊ᫬ィࡢᴫᛕࡢ☜❧࡜࡜ࡶ࡟ࠊ᭱㏆ 10 ᖺ࡛ࠊ⏕యࣜࢬ࣒ࡢᴫᛕࡣ᰿ᗏ࠿
ࡽኚࢃࡗࡓࠋ᪂ࡋ࠸ぢ᪉࡛ࡣࠊ⏕యࣜࢬ࣒ࡣ඲㌟ࡢ⣽⬊ෆ࡛⏕ࡲࢀ࡚࠸ࡿࠋࡍࡲࢃࡕࠊࣜࢬ࣒ࡣࠊ
᫬ィ㑇ఏᏊ࡛࡛ࡁࡓᩘ༑඙ࡢ⣽⬊᫬ィ࡟ࡼࡗ࡚⏕ࡲࢀࡿࡢ࡛࠶ࡿࠋ᫬ィࡢ୰ᚰ࡟࠸ࡿࡢࡣ Per 㑇ఏ
Ꮚ⩌࡛ࠊࡑࡢࣉ࣮ࣟࣔࢱ࣮㒊఩ࡢไᚚ࡛ᙉ࠸㌿෗ࣜࢬ࣒ࢆ㉳ࡇࡍࠋࡇࡢࣜࢬ࣑ࢵࢡ࡞㌿෗࡟ࡼࡗ࡚
⏘⏕ࡉࢀࡓ PER ⺮ⓑ㉁⩌㸦PER1, PER2ࠊPER3㸧ࡣࠊᙉຊ࡞㌿෗ᢚไᅉᏊ࡛࠶ࡿ CRY ⺮ⓑ㉁⩌㸦CRY1,
CRY2㸧࡜⤖ྜࡋ࡚ࠊ⮬ศ⮬㌟ࡢ㌿෗ࢆᢚไࡋࠊࣇ࢕࣮ࢻࣂࢵࢡ࣮ࣝࣉࡀ㛢ࡌ࡚㌿෗ࡀῶᑡࡍࡿࠋ
ࡍ࡞ࢃࡕࠊࡇࡢᢚไᅉᏊ」ྜయࡀᙧᡂࡍࡿ㌿෗ࣜࢬ࣒ࡀᇶᮏ࡟࡞ࡾࠊ᫬ィ⺮ⓑ㉁ࡢᙉ࠸᣺ືࢆᘬࡁ
㉳ࡇࡋࠊࡘ࠸࡟ࡣ⣽⬊άື࡟ࣜࢬ࣒ࡀ⏕ࡲࢀࡿࡢ࡛࠶ࡿࠋ࡛ࡣࠊ᫬ィ㑇ఏᏊࡢ㌿෗ࣜࢬ࣒ࡣ᫬ィ⺮
ⓑ㉁ࣜࢬ࣒ࢆᘬࡁ㉳ࡇࡍࡢ࡟ᚲ㡲࡛࠶ࢁ࠺࠿㸽ᡃࠎࡣࠊᜏᖖⓗ࡟୍ᐃ㔞Ⓨ⌧ࡍࡿࡼ࠺࡟ᑟධࡋࡓእ
᮶ᛶࡢ Per2 㑇ఏᏊࡀ mRNA ࡛ࣞ࣋ࣝࡣࣜࢬ࣒ࡀ↓࠸ࡀࠊ⺮ⓑ㉁࡛ࣞ࣋ࣝࡣࣜࢬ࣒ࢆ♧ࡍࡇ࡜ࢆ᫂
ࡽ࠿࡟ࡋࡓࠋࡇࢀࡣࠊᚑ᮶ᚲ㡲࡜ᛮࢃࢀ࡚࠸ࡓ㌿෗ࣞ࣋ࣝࡢࣜࢬ࣒ࡣᚲ㡲࡛࡞ࡃࠊ㌿෗ᚋࡢࣉࣟࢭ
ࢫࡔࡅ࡛ࡶ᫬ィ⺮ⓑ㉁ࡢࣜࢬ࣒ࠊࡦ࠸࡚ࡣ⣽⬊άືࡢࣜࢬ࣒ࢆច㉳ࡋ࠺ࡿࡇ࡜ࢆጞࡵ࡚♧ࡋࡓࠋࡇ
ࡢࡼ࠺࡞㑇ఏᏊࣞ࣋ࣝࠊ⺮ⓑ㉁ࣞ࣋ࣝࡢࡉࡲࡊࡲ࡞㝵ᒙࢆࢱ࣮ࢤࢵࢺ࡜ࡋࡓ᪂ࡋ࠸ࣜࢬ࣒ㄪᩚ๣ࡢ
㛤Ⓨࡀᮇᚅࡉࢀࡿࠋ
୰ᯡ᫬ィ࡜ SCN-Gene Project
ࡇࢀࡽࡢᩘ༑඙ಶࡶࡢ⣽⬊࡟࠶ࡿᮎᲈ㸦⣽⬊㸧᫬ィࡣࠊࡤࡽࡤࡽ࡟᫬ࢆ้ࢇ࡛࠸ࡿࡢ࡛࠶ࢁ࠺࠿㸽
ࡑ࠺࡛ࡣ࡞ࡃࠊ⏕య࡟ࡣࡇࢀࡽࢆ⤫ྜࡍࡿ᫬ィࡀᏑᅾࡋࠊࡑࢀࡀ⬻ࡢᑠ⚄⤒᰾࡛࠶ࡿど஺ཫୖ᰾
㸦suprachiasmatic nucleus: SCN㸧࡟࠶ࡿ୰ᯡ᫬ィ࡛࠶ࡿࠋSCN ࡣᩘ༓ಶࡢ⣽⬊࠿ࡽ࡞ࡿ᫬㛫Ⓨ᣺࡟
≉໬ࡋࡓ⚄⤒᰾࡛࠶ࡾࠊᴟࡵ࡚ᙉຊ࡞ࣜࢬ࣒ࢆ඲㌟ࡢ⣽⬊࡟Ⓨ᣺ࡋࠊࣜࢬ࣒ࢆㄪᚊࡍࡿࠋࡇࡢ SCN
᫬ィࢆእ⏺ࡢ᫂ᬯ࿘ᮇ࡟ྠㄪࡉࡏࡿࡢࡀࠊ║⌫࠿ࡽࡢගධຊ࡛࠶ࡾࠊගࡀ NMDA ᆺࡢࡳ࡞ࡽࡎࠊ
AMPA ᆺࢢࣝࢱ࣑ࣥ㓟ཷᐜయࢆ௓ࡋ SCN ᫬ィ⣽⬊ෆࡢศᏊ᫬ィࢆ⎔ቃ࿘ᮇ࡟ྠㄪࡉࡏ࡚࠸ࡿࠋ
2006 ᖺࡼࡾࠊࡇࡢᑠ⚄⤒᰾ࡢࣜࢬ࣒⏘⏕ᶵᵓࢆศᏊ࡛ࣞ࣋ࣝ᫂ࡽ࠿࡟ࡍࡿࡓࡵࠊGene Chip / in situ
hybridization / Knockout-mice సᡂࢆ⥙⨶ⓗ࠿ࡘໟᣓⓗ࡟⾜࠺ࣉࣟࢪ࢙ࢡࢺ࡛࠶ࡿ SCN-Gene Project
− 315 −
ࢆ㛤ጞࡋࡓࠋ⌧ᅾࡲ࡛࡛༑ᩘಶࡢᮍ▱ࡢ SCN ≉␗ⓗ㑇ఏᏊࢆ᳨ฟࡋࡓࡀࠊࡑࡢ୰࡟ࡣ」ᩘࡢ࣮࢜
ࣇ࢓ࣥ G ⺮ⓑ㉁ඹᙺᆺཷᐜయࡀ࠶ࡾࠊࡑࡢࣜ࢞ࣥࢻ㛤Ⓨ࠾ࡼࡧࡑࡢ㛵㐃ࡢ๰⸆ࢆᐇ⾜୰࡛࠶ࡿࠋ
᫬㛫ࡢ⚄⤒ఏ㐩ᶵᵓ㸸⮬ᚊ⚄⤒⣔࡜᫬㛫ࡢ⚄⤒ࢩࢢࢼࣝ࠿ࡽ࣍ࣝࣔࣥࢩࢢࢼࣝ࡬ࡢኚ᥮
SCN ࡢࢩࢢࢼࣝࡀ࡝ࡢࡼ࠺࡟ࡋ࡚඲㌟ࡢ᫬ィࢆ⤫ᣓࡍࡿࡢ࠿ࡣࠊ⌧ᅾゎ᫂ࡉࢀ࡚࠸࡞࠸ࠋࡓࡔࠊ
ከࡃࡢࡇࢀࡲ࡛ࡢࢹ࣮ࢱࡣࠊSCN ࡢ⚄⤒ฟຊࡀࡑࢀࢆᢸࡗ࡚࠸ࡿࡇ࡜ࢆ♧ࡋ࡚࠸ࡿࠋࡑࢀࡣࠊど
ᗋୗ㒊ࡢᐊഐ᰾ୗ㒊㡿ᇦࢆ௓ࡋࠊ୰⬻୰ᚰ⅊ⓑ㉁ࠊᶫഃ⭎᰾ࠊᘼ᮰᰾ࠊ㏞㉮⚄⤒⫼ഃ᰾ࠊᘏ㧊⥙ᵝ
యࠊ⬨㧊୰㛫㉁ഃ᰾࡞࡝୰ᯡࡢ⮬ᚊ⚄⤒⣔ࡢ᰾⩌࡟⮳ࡾࠊ୰ᯡ࠿ࡽฟ࡚஺ឤ⚄⤒ࠊ๪஺ឤ⚄⤒࡜࡞
ࡗ࡚඲㌟ࡢ⣽⬊࡟᫬㛫ࡀ࠸ࡁࢃࡓࡿࠋᡃࠎࡣᾘ໬⟶࣭࿧྾ჾ⣔࡟ከᩘศᕸࡍࡿ⭢ᵓ㐀㸦እศἪ⭢ࠊ
ෆศἪ⭢㸧ࡢศᏊ᫬ィࡀ㏞㉮⚄⤒ࢆ௓ࡋ࡚ࠊ᫬ィ࡛⟶⌮ࡉࢀ࡚࠸ࡿࡇ࡜ࢆ♧ࡋࡓࠋࡇࢀࡽࡣࠊႍᜥ
࡞࡝ࡢ⑕≧Ⓨ⑕࡟ศᏊ᫬ィࡀᐦ᥋࡟㛵୚ࡋ࡚࠸ࡿࡇ࡜ࢆ♧ࡋ࡚࠸ࡿࠋ
ࡲࡓࠊ⏕యࣜࢬ࣒ࡣෆศἪࢩࢢࢼࣝࢆ௓ࡋ࡚ࡶࠊ඲㌟ࡢࣜࢬ࣒ࢆไᚚࡍࡿࠋࡑࡢ୰࡛ SCN̿஺
ឤ⚄⤒̿๪⭈⣔ࡣࠊ඲㌟ࣞ࣋ࣝࡢ⣽⬊ࡢ᫬ࡢㄪᚊ࡟㔜せ࡛࠶ࡿࠋࡇࡢ⣔࡛ࡣ๪⭈࡟⮳ࡗࡓ஺ឤ⚄⤒
࢖ࣥࣃࣝࢫࡣ࣍ࣝࣔࣥࢩࢢࢼࣝ࡬᫬㛫᝟ሗࡀኚ᥮ࡉࢀ࡚࠸ࡓࠋ๪⭈⓶㉁࣍ࣝࣔࣥࡣᮎᲈ⣽⬊ࡢ
glucocorticoid ཷᐜయࢆ௓ࡋࠊPer1 ࣉ࣮ࣟࣔࢱ࣮ࡢ GRE ࢆ⤒࡚ Per1 ㌿෗ࢆୖࡆࠊ᫬ࡀㄪᚊࡉࢀࡿ
ࡢ࡛࠶ࡿࠋࡇࡢ⣔ࡣࠊ๪⭈⓶㉁࣍ࣝࣔࣥࢆึࡵ࡜ࡍࡿྛ✀⸆๣ࡢ᫬㛫⸆⌮Ꮫ࡜⏕య཯ᛂࡢ᫬㛫≉␗
ᛶࡢゎ᫂࡟ᐤ୚ࡍࡿᡤぢ࡜⪃࠼ࡽࢀࡿࠋ
඲㌟ࡢ⣽⬊᫬ィ࡜ࡣ
඲㌟㸴㸮඙ࡶࡢ⣽⬊࡟ࡣ᫬ィࡀ࠶ࡾࠊࡑࡢస⏝ᶵᵓ࡟㛵ࡋ࡚ࡶ◊✲ࢆ㐍ࡵࡓࠋࡓ࡜࠼ࡤࠊ⓶⭵࡟
࠾࠸࡚ࡣࠊ௦ㅰ࣭⾑⟶࣭㐠ື࣭❧ẟ࣭Ⓨờ࣭⣽⬊ศ⿣ീࡀ᪥ෆࣜࢬ࣒ࢆ࿊ࡍࡿ஦ࡣ▱ࡽࢀ࡚࠸ࡿࡀࠊ
య⣔ⓗ࡟᳨⣴ࡣࡉࢀ࡚࠸࡞࠸ࠋᡃࠎࡣࠊṇᖖ࣐࢘ࢫࡢ⓶⭵࡟ศᏊ᫬ィᶵᵓࡀ᏶ഛࡋ࡚࠸ࡿࡇ࡜ࠊ≉
࡟ࠊࢣࣛࢳࣀࢧ࢖ࢺ࡟ⴭ᫂࡞ࣜࢬ࣒ࢆㄆࡵࡿࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋࡓࠋ⓶⭵ࡣ┤᥋ගࡀ࠶ࡓࡿ⮚ჾ࡛࠶
ࡿࡀࠊࡇࡢศᏊ᫬ィࡣࠊ⓶⭵ࡢཷࡅࡿග࡟ࡣ඲ࡃ཯ᛂࡋ࡞࠿ࡗࡓࡀࠊ୰ᯡ᫬ィ࡛࠶ࡿ SCN ࢆ◚ቯ
ࡍࡿ࡜ࠊ⓶⭵࡟┤᥋ගࡢᙜࡓࡿ᫂ᬯ᮲௳ୗ࡛ࡶࡇࢀࡽࡢࣜࢬ࣒ࡀ᏶඲࡟ᾘኻࡍࡿࡢ࡛ࠊ⓶⭵ࡢ᫬ィ
ࡣእ⏺ࡢග࡛ࡣ࡞ࡃࠊయࡢ୰ࡢ᫬ィ࡟ᨭ㓄ࡉࢀ࡚࠸ࡿ࡜ゝ࠼ࡿࠋ⓶⭵ࡢ⣽⬊ศ⿣ࡶࡇࡢᒁᡤ᫬ィ࡟
ไᚚࡉࢀ࡚࠸ࡿྍ⬟ᛶࡀ࠶ࡿࡢ࡛ࠊ⓶⭵ࣜࢬ࣒ࡢ⓶⭵ࡢ⏕⌮ࠊ⪁໬ࠊⓎ⒴ᶵᵓ࡬ࡢ㛵୚ࡀ⯆࿡῝࠸
ㄢ㢟࡛࠶ࡿࠋ
᫬ィʊ⑌ᝈ䝥䝻䝆䜵䜽䝖 Chrono-disease Project
᭱㏆䚸䝸䝈䝮␗ᖖ䝬䜴䝇䛾⑓⌮䞉⑓ែ䜢⥲ྜⓗ䛻᥈ồ䛧䚸ᐇ㝿䛾䝠䝖䛾⑌⑓䜢ศᏊ᫬ィ䛸䛔䛖඲䛟᪂
䛧䛔ษ䜚ཱྀ䛛䜙ゎ᫂䛩䜛䛂᫬ィʊ⑌ᝈ䝥䝻䝆䜵䜽䝖 Chrono-disease Project䛃䜢❧䛱ୖ䛢䚸⏕య䝸䝈䝮␗
ᖖ䛻䜘䜛⑌⑓ᶵᵓ䜢ศᏊ䝺䝧䝹䛷䛾ゎ᫂䛻ὀຊ䛧䛶䛔䜛䚹䝸䝈䝮␗ᖖ䛸ᚑ᮶䛛䜙㛵ಀ䛜῝䛔䛸䛥䜜䜛
⬻ᶵ⬟㞀ᐖ䠄╧╀ぬ㓰␗ᖖ䞉ኪ㛫ᚔᚉ䠅䛾䜏䛺䜙䛪䚸≉䛻ὀ┠䛩䜛䛾䛿㧗⾑ᅽ⑕䚸Ⓨ⒴䚸䛺䛹䛾⏕
ά⩦័⑓䜔⪁໬䛷䛒䜛䚹⌧ᅾ䚸㛵⠇䝸䜴䝬䝏䚸Ⓨ⒴䛺䛹䜢⾜䛳䛶䛔䜛䛜䚸୍㐃䛾◊✲䛾୰䛷䚸┠ぬ䛧
䛔ᡂᯝ䜢䛒䛢䛯䛾䛿䚸ࣜࢬ࣒ࡀ᏶඲࡟ᾘኻࡋࡓ Cry1, Cry2 㑇ఏᏊࢆḞኻࡋࡓ Cry-null ࣐࢘ࢫࡀࠊ๪
⭈⌫≧ᒙ࠿ࡽࡢ㐣๫࡞࢔ࣝࢻࢫࢸࣟࣥศἪ࡟ࡼࡗ࡚㣗ሷឤཷᛶ㧗⾑ᅽࢆ♧ࡍ࡜࠸࠺Ⓨぢ࡛࠶ࡿࠋ
DNA ࣐࢖ࢡࣟ࢔ࣞ࢖ゎᯒ࡞ࡽࡧ࡟࣮ࣞࢨ࣮࣐࢖ࢡࣟࢲ࢖ࢭࢡࢩࣙࣥἲࢆ⏝࠸࡚ࠊ๪⭈⌫≧ᒙ࡟≉
␗ⓗ࡟Ⓨ⌧ࡋࠊ᫬ィ㑇ఏᏊ࡟ࢥࣥࢺ࣮ࣟࣝࡉࢀࡿࠊ᪂ࢱ࢖ࣉ 3ș-HSD ࡀ㐣๫⏘⏕ࡉࢀ࢔ࣝࢻࢫࢸ
ࣟࣥࡢ␗ᖖ⏘⏕ࢆᘬࡁ㉳ࡇࡋ࡚࠸ࡓࠋCry-null ࣐࢘ࢫ࡟࠾ࡅࡿ㣗ሷឤཷᛶ㧗⾑ᅽࡢⓎぢ࡜๪⭈⌫≧
ᒙ≉␗ⓗ 3ș-HSD ࢧࣈࢱ࢖ࣉࡢྠᐃࡣࠊ᫬ィ⑌ᝈ࡛ึࡵ࡚ࡢ≀㉁ྠᐃ࡛࠶ࡾࠊ◊✲ࡢ᪂ᒁ㠃ࢆษ
ࡾ㛤࠸ࡓᴟࡵ࡚㔜せ࡞ᡤぢ࡛࠶ࡿࠋࡇࡢ᪂ᆺ 3ș-HSD ࡣࣄࢺ࡟ࡶᏑᅾࡋࠊࡑࢀࡀࠊHSD3B1 ࡛࠶
ࡗࡓࠋ⯆࿡῝࠸ࡇ࡜࡟ࠊ᭱㏆ࠊࢤࣀ࣒ゎᯒ◊✲࡟࡚ HSD3B1 ࡢ㑇ఏᏊከᆺࡀᮏែᛶ㧗⾑ᅽ⑕ࡸ⾑
୰࢔ࣝࢻࢫࢸࣟࣥ⃰ᗘ࡟┦㛵ࡍࡿࡇ࡜ࡀሗ࿌ࡉࢀࡓࠋ㧗࢔ࣝࢻࢫࢸࣟࣥ⾑⑕ࡢ἞⒪࡟ HSD3B1 ≉
␗ⓗ࡞㜼ᐖ๣ࡀ᭷ຠ࡛࠶ࡿ࡜⪃࠼ࡽࢀࠊࡑࡢ㛤Ⓨࡀᮇᚅࡉࢀࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
᫬ィࡢࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮◊✲࡟ᑐࡍࡿᅜẸ୍⯡ࡢὀ┠ࡣ኱ࡁࡃࠊᡃࠎࡢᩍᐊࡣࠊࡇࡢ 5 ᖺ㛫࡟᪂
⪺࡟ 10 ᅇ௨ୖࠊࢸࣞࣅ࡟ 5 ᅇࡢྲྀᮦࢆཷࡅࡓࠋࡲࡓࠊከࡃࡢᅜෆእࡢᏛ఍࠿ࡽᖺ㛫༑ᩘᅇࡢᣍᚅㅮ₇
ࡢ౫㢗ࢆཷࡅ࡚࠾ࡾࠊ㞧ㄅࡢ⏕యࣜࢬ࣒≉㞟ࡢ⦅⪅౫㢗ࡀᖺ୍ᗘࡣ࠶ࡿࡇ࡜࠿ࡽࠊ⏕≀Ꮫࠊ་Ꮫࠊ⸆Ꮫ
ࡢᗈ࠸◊✲ศ㔝࠿ࡽࠊᮏศ㔝ࡢ◊✲ෆᐜࡣ㧗ࡃホ౯ࡉࢀ࡚࠸ࡿ࡜࠸࠼ࡿࠋᾏእ࡛ࡣᏛ఍ࡢࡳ࡞ࡽࡎࠊBBC
News㸦ⱥᅜ㸧ࠊ࣮࢞ࢹ࢕࢔ࣥ㸦ⱥᅜ㸧
ࠊTimes India㸦࢖ࣥࢻ㸧࡞࡝኱ᡭࢽ࣮ࣗࢫ࣓ࢹ࢕࢔࡛኱ࡁࡃྲྀࡾୖ
ࡆࡽࢀࡓࠋᒸᮧᩍᤵࡣ 2007 ᖺᗘ⣸⥓〔❶ࠊ2009 ᖺᗘ Aschoff Rule Award (Society for Biological
Rhythms:USA)ࢆཷ㈹ࡋࡓࠋᅵᒃ෸ᩍᤵࡣ 2010 ᖺᗘ᪥ᮏෆศἪᏛ఍➨ 11 ᅇⱝᡭ◊✲ዡບ㈹ࢆཷ㈹ࡋ࡚࠸
ࡿࠋ௨ୖࡢࡼ࠺࡟ࠊᡃࠎࡢᩍᐊࡣࠊᅜෆࡢࡳ࡞ࡽࡎᅜእ࠿ࡽࡶ㧗࠸ホ౯ࢆཷࡅ࡚࠸ࡿࠋ
− 316 −
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜᩍᐊࡣࠊ1 ᖺ⏕ᚋᮇࡢ⏕⌮Ꮫ㸯㸦ゎ๗⏕⌮Ꮫ㸧ࠊ2 ᖺ⏕ᚋᮇࡢ⏕⌮Ꮫ㸱㸦⑓ែ⏕⌮Ꮫ㸧ࠊ3
ᖺ⏕๓ᮇࡢ⏕⌮Ꮫ㸲㸦⑓ែࢤࣀ࣒Ꮫ㸧࠾ࡼࡧ 3 ᖺ⏕ᚋᮇࡢ⸆Ꮫᑓ㛛ᐇ⩦㸱㸦⚄⤒ゎ๗Ꮫ㸧ࢆᢸᙜࡋ࡚࠸
ࡿࠋ⏕⌮Ꮫ㸯࡛ࡣࠊ⏕࿨⛉Ꮫࡢᇶ♏࡛࠶ࡿேయࡢᙧែࢆ⣽⬊࣭⤌⧊࣭ჾᐁ࡜㝵ᒙᛶ࡟ㅮ⩏ࡋࠊேయࡢᵓ
ᡂཎ⌮࡜ᶵ⬟࡜ࡢ㛵ಀࢆ⌮ゎࡉࡏ࡚࠸ࡿࠋ⏕⌮Ꮫ㸱࡛ࡣࠊ⏕࿨άືࡢ␗ᖖ࡟ࡼࡿ⑌⑓Ⓨ⑕ࡢ࣓࢝ࢽࢬ࣒
ࢆ⣽⬊࣭⤌⧊࣭ჾᐁ࡛ࣞ࣋ࣝㅮ⩏ࡋࠊࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮ࡢどⅬ࠿ࡽ๰⸆⛉Ꮫࡢᇶ♏࡜࡞ࡿ⏕⌮࣭⑓
ែ⏕⌮ࢆ⌮ゎࡉࡏࡿࠋ⏕⌮Ꮫ㸲࡛ࡣࠊ⑓Ẽࡢ࣓࢝ࢽࢬ࣒࡟ᇶ࡙࠸ࡓ἞⒪Ꮫ㸦⸆≀἞⒪ࢆ୰ᚰ࡟㸧࡟ࡘ࠸
࡚ㄽ㏙ࡍࡿࠋࡇࡢ 3 ᖺ୍㈏ᩍ⫱࡛ࠊேయࢆ⣽⬊࠿ࡽ⑓Ẽ࣭἞⒪ࡲ୍࡛㈏ࡋࡓ⸆Ꮫᩍ⫱ࢆ┠ᣦࡋ࡚࠸ࡿࠋ
ᐇ⩦ࡣᩍᐊࢆ࠶ࡆ࡚ࠊᐇ㝿ࡢᐇ⩦᫬㛫ࡢᩘಸࡢ᪥᫬ࢆ࠿ࡅ࡚‽ഛࡋ࡚࠾ࡾࠊ㑇ఏᏊᨵኚ࣐࢘ࢫ࡞࡝᭱᪂
ࡢᡂᯝ࡟ゐࢀࡽࢀࡿࡼ࠺࡟ᩍᮦࢆᕤኵࡋ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸ᙜࢩࢫࢸ࣒ࣂ࢖࢜ࣟࢪ࣮ศ㔝ࡢ୺ࡓࡿ◊✲┠ᶆ࡛࠶ࡿࠕ᫬㛫ࡢ་⸆⛉Ꮫࠖ
ࢆ༞ᴗ㓄ᒓࡢᏛ⏕࠿ࡽጞࡵࡿࠋศᏊ⏕≀Ꮫࠊ㑇ఏᏛࠊ⣽⬊⏕≀Ꮫࠊ⺮ⓑ㉁⛉Ꮫࠊ⚄⤒⛉Ꮫࠊ᫬㛫⸆⌮Ꮫࠊ
╧╀⛉Ꮫࠊ⾜ື⛉Ꮫ࡞࡝㠀ᖖ࡟ᗈ⠊࡞ศ㔝࡛㛤Ⓨࡉࢀࡓ✀ࠎࡢࢸࢡࢽࢵࢡࢆ⏝࠸࡚ࠊ୰ᯡ⚄⤒⣔ࡸᚠ⎔
ჾࡢṇᖖ⏕⌮ࡢࡳ࡞ࡽࡎࠊ៏ᛶ⑌ᝈࡢ⑌⑓㸦Ⓨ⒴ࠊ㧗⾑ᅽ࡞࡝㸧࡟㏕ࡿࠋಟኈㄢ⛬࠾ࡼࡧ༤ኈㄢ⛬࡛ࡣࠊ
᪂ࡋ࠸⑌ᝈᶵᵓࢆⓎぢࡋ࡚ࠊ๰⸆࡟⤖ࡧ௜ࡅࡿࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚࠸ࡿࠋ༤ኈㄢ⛬ࡢᏛ⏕࡟ࡣࠊࡇࢀ࠿ࡽ
ࡢᏛ⾡ࡔࡅ࡛࡞ࡃẸ㛫ࡢ◊✲ືྥࢆ࡝ࡢࡼ࠺࡟ぢᴟࡵࡿࡢ࠿ࡢࣀ࢘ࣁ࢘ࢆᩍ⫱ࡍࡿࠋࡲࡓࠊᢏἲࡔࡅ࡛
࡞ࡃࠊㄽ⌮ࡢ⤌ࡳ❧࡚᪉ࡸࠊㄽᩥࡢࡲ࡜ࡵ᪉ࢆᣦᑟࡍࡿࠋᐇ㊶࡜ࡋ࡚ࠊᚋ㐍ࢆᣦᑟࡍࡿࡇ࡜࡛ࠊࣄࢺ࡜
ࡢࢳ࣮࣒࣮࣡ࢡࡢసࡾ᪉ࡸࠊඹྠ୍࡛ࡘࡢࡇ࡜ࢆᡂࡋ㐙ࡆࡿࡓࡵࡢࢳ࣮࣒ࡢసࡾ᪉ࢆᣦᑟࡍࡿࠋ㐌࡟୍
ᅇࡢࣉࣞࢮࣥࢸ࣮ࢩࣙࣥᣦᑟ࡟ࡣ≉࡟ຊࢆධࢀ࡚࠸ࡿࠋᅜ㝿ⓗ࡞ά㌍ࡢࡓࡵࠊᏛ⏕ࡢ⮬୺ⓗ࡞ⱥᩥᢒㄞ
఍ࢆྵࡴࠊⱥᩥࢆㄞࡳࠊⱥᩥࢆ᭩ࡃᣦᑟࢆࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟࠶ࡓࡗ࡚ࡣࠊᑐヰᘧㅮ⩏࡟ດࡵࠊᏛ⏕ࡢ⌮ゎࢆᖖ࡟㧗ࡃಖ࡜࠺࡜ດຊࡋ࡚࠸ࡿࠋㅮ
⩏ࣉࣜࣥࢺࡣᚲࡎΏࡋࠊ᚟⩦ࡀྍ⬟࡞ࡼ࠺࡟ࡋ࡚࠾ࡾࠊ㝶᫬ᤵᴗホ౯ࢆಶேⓗ࡟⾜ࡗ࡚ㅮ⩏࡟ྲྀࡾධࢀ
ࡿࡼ࠺࡟ࡋ࡚࠸ࡿࠋ◊✲ᐊࡢ኱Ꮫ㝔⏕࡟㛵ࡋ࡚ࡣࠊᅜ㝿Ꮫ఍ࡸᅜෆᏛ఍࡛ࡢⓎ⾲ࡀ࡛ࡁࡿࡼ࠺࡟ᣦᑟࡋ
࡚࠸ࡿࠋ2007 ᖺ࡟᪂タࡉࢀࡓᙜᩍᐊࡢ༞ᴗ⏕ࡢᐇ⦼ࡣࡲࡔᑡ࡞࠸ࡀࠊ༤ኈㄢ⛬ 3 ྡ㸦኱ᡭ࣓࣮࣮࢝◊✲
⫋ 1 ྡࠊ࣏ࢫࢻࢡ 2 ྡ㸧ࠊಟኈㄢ⛬ 3 ྡ㸦኱ᡭ࣓࣮࣮࢝◊✲⫋ 3 ྡ㸧࡛ࠊ඲ဨ࡯ࡰᕼᮃ㏻ࡾࡢ⫋✀ࢆᚓ
࡚࠾ࡾࠊᙜᩍᐊࡢ◊✲࣭ᩍ⫱ࡀ㧗࠸࡛ࣞ࣋ࣝホ౯ࡉࢀ࡚࠸ࡿ⤖ᯝ࡜⪃࠼ࡽࢀࡿࠋ
㸦ཎⴭ㸧
1. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G,
Kanematsu A, Ogawa O, Todo T, Tsutsui K, van der Horst GTJ, Okamura H: Salt-sensitive hypertension in
circadian clock-deficient mice involves dysregulated adrenal Hsd3b6. Nature Medicine, 16, 67-74, 2010.
2. Hashiramoto A, Yamane T, Tsumiyama K, Yoshidam K, Komai K., Yamada H, Yamazaki F, Doi M, Okamura
H, Shiozawa S: Mammalian clock gene Cryptochrome regulates arthritis via proinflammatory cytokine
TNF-D. J Immunol. 184:1560-1560, 2010.
3. Mizoro Y, Yamaguchi Y, Kitazawa R, Yamada H, Matsuo M, Fustin JM, Doi M, Okamura H: Activation of
AMPA receptors in the suprachiasmatic nucleus: Phase-shifts the mouse circadian clock in vivo and in vitro,
Plos ONE; 5(6):e10951., 2010 (http://dx.plos.org/10.1371/journal.pone.0010951).
4. Sato M, Mizoro Y, Atobe Y, Fujimoto Y, Yamaguchi Y, Fustin JM, Doi M, Okamura H: Transportin 1 in the
mouse brain: appearance in regions of neurogenesis, cerebrospinal fluid production/sensing, and circadian
clock. J. Comp. Neurol., in press.
5. Tanioka M, Yamada H, Doi M, Bando H, Yamaguchi Y, Nishigori C, Okamura H: Molecular clocks in mouse
skin. J. Invest. Dermatol. 129, 1225-1231, 2009. (J Invest Dermatol advance online publication, November
27, 2008; doi:10.1038/jid.2008.345)
6. Masuda Y, Emoto N, Nonaka H, Yagita K, Todo T, Okamura H, Yokoyama M, Hirata K. Role of angiotensin
and the clock system in the circadian regulation of plasminogen activator inhibitor-1. Kobe J Med Sci. 54,
E264-271, 2009.
7. Nishinaga H, Komatsu R, Doi M, Fustin JM, Yamada H, Okura R, Yamaguchi Y, Matsuo M, Emoto N,
Okamura H: Circadian expression of the Na+/H+ exchanger NHE3 in the mouse renal medulla. Biomed. Res.
30, 87-93, 2009.
8. Fukatsu Y, Noguchi T, Hosooka T, Ogura T, Kotani K, Abe T, Shibakusa T, Inoue K, Sakai M, Tobimatsu K,
Inagaki K, Yoshioka T, Matsuo M, Nakae J, Matsuki Y, Hiramatsu R, Kaku K, Okamura H, Fushiki T,
Kasuga M: Muscle-specific overexpression of heparin-binding epidermal growth factor (EGF)-like growth
factor increases peripheral glucose disposal and insulin sensitivity. Endocrinology. 150, 2683-2691, 2009.
9. Moriya T, Aida R, Kudo T, Akiyama M, Doi M, Hayasaka N, Nakahata N, Mistlberger R, Okamura H,
− 317 −
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
Shibata S: The dorsomedial hypothalamic nucleus is not necessary for food-anticipatory circadian rhythms of
behavior, temperature or clock gene expression in mice. Eur. J. Neurosci. 29, 1447-1460 , 2009.
Kobayashi M, Kikuchi D, Okamura H: Imaging of ultraweak spontaneous photon emission from human body
displaying diurnal rhythm. Plos ONE, 2009 4(7):e6256.
Westermark PO, Welsh DK, Okamura H, Herzel H: Quantification of circadian rhythms in single cells. PLoS
Computational Biol, 2009 5(11):e1000580. Epub 2009 Nov 26
Uchio N, Doi M, Matsuo M, Yamazaki F, Mizoro Y, Hondo M, Sakurai T, Okamura H: Circadian
characteristics of mice depleted with GPR7. Biomed Res. 30, 357-364, 2009
Fukuyama T, Doi M, Matsuo M, Nishinaga H, Miyake S, Okamura H: Circadian expression of 86- and
84-kDa heat shock proteins in the mouse suprachiasmatic nucleus. Biomed Res. 29:93-98, 2008.
Nishio T, Bando H, Bamba H, Hisa Y, Okamura H. Circadian gene expression in the murine larynx. Auris
Nasus Laryn. 35:539-544, 2008.
Nishino N, Tamori Y, Tateya S, Kawaguchi T, Shibakusa T, Mizunoya W, Inoue K, Kitazawa R, Kitazawa S,
Matsuki Y, Hiramatsu R, Masubuchi S, Omachi A, Kimura K, Saito M, Amo T, Ohta S, Yamaguchi T, Osumi
T, Cheng J, Fujimoto T, Nakao H, Nakao K, Aiba A, Okamura H, Fushiki T, Kasuga M: FSP27 contributes to
efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J.
Clin. Invest. 118, 2808-2821, 2008
Bando H, Nishio T, van der Horst GTJ, Masubuchi S, Hisa Y, Okamura H: Vagal regulation of airway clocks
in mice. J. Neurosci., 27, 4359-4365, 2007.
Cheng H-YM, Papp JW, Verlamova O, Dziema H, Russell B, Curfman JP, Nakazawa T, Shimizu K, Okamura
H, Impey S, Obrietan K: MicroRNA modulation of circadian clock period and entrainment. Neuron,
54:813-829, 2007.
Fukuya H, Emoto N, Nonaka H, Yagita K, Okamura H, Yokoyama M: Circadian expression of clock genes in
human peripheral leukocytes. Biochem Biophys Res Commun., 354, 924-928, 2007.
Doi M, Cho S, Yujnovsky I, Hirayama J, Cermakian N, Cato A, Sassone-Corsi P: Light-Inducible and
Clock-Controlled Expression of MAP Kinase Phosphatase 1 in the Mouse Central Pacemaker Neurons. J.
Biol. Rhythms 22, 127-139, 2007.
Masamizu Y, Ohtsuka T, Takashima Y, Nagahara H, Takenaka Y, Yoshikawa K, Okamura H, Kageyama R:
Real-time imaging of the somite segmentation clock: reveration of unstable oscillators in the individual
presomitic mesoderm cells. Proc. Natl. Acad. Sci. USA. 103, 1313-1318, 2006.
Chaves I, Yagita K, Barnhoon S, Okamura H, van der Horst TJ, Tamanini F: Functional evolution of the
photolyase/chryptochrome protein family: importance of the C terminus of mammalian CRY1 for circadian
core oscillator performance, Mol. Cell. Biol., 26, 1743-1753, 2006.
Koyanagi S, Okazawa S, Kuramoto Y, Ushijima K, Shimeno H, Soeda S, Okamura H, Ohdo S: Chronic
treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral
tissues. Mol. Endocrinol. 20, 573-583, 2006.
Maywood ES, Reddy AB, Wong GKY, O’Nelill JS, O’Brien JA, McMahon DG, Harmar AJ, Okamura H,
Hastings MH: Synchronization and maintenance of timekeeping in suprachiasmatic circadian clock cells by
neuropeptidergic signaling. Current Biology 16, 599-605, 2006.
Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M, Teshigawara K, Matsuki Y,
Watanabe E, Hiramatsu R, Notohara K, Katayose K, Okamura H, Kahn CR, Noda T, Takeda K, Akira S, Inui
A, Kasuga M: Role of hepatic STAT3 in brain insulin action on hepatic glucose production, Cell Metabolism
3, 267-275, 2006.
Fujimoto Y, Yagita K, Okamura H: Does mPER2 protein oscillate without its coding mRNA cycling?—
Post-transcriptional regulation by cell clock, Genes Cells 11, 525-530, 2006.
Maeda A, Tsujiya S, Higashide T, Toida K, Todo T, Ueyama T, Okamura H, Sugiyama K: Circadian
intraocular pressure rhythm is generated by clock genes. Invest. Ophtalmol. Vis Sci., 47, 4050-4052, 2006.
Koshimizu T, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T,
Takeo S, Okamura H, and Tsujimoto G, V1a vasopressin receptors maintain normal blood pressure by
regulating circulating blood volume and baroreflex sensitivity. Proc. Natl. Acad. Sci. USA, 103, 7807-7812,
2006.
Hashimoto N, Kido Y, Uchida T, Asahara S, Shigeyama Y, Matsuda T, Takeda A, Tsuchihashi D, Nishizawa
A, Ogawa W, Fujimoto Y, Okamura H, Karen C. Arden KC, Herrera P, Noda T, and Kasuga M: Ablation of
PDK1 in pancreatic E cells induces diabetes as a result of loss of E-cell mass. Nature Genetics, 38, 589-593,
2006.
Hatori M, Okano T, Nakajima Y, Doi M, Fukada Y: Lcg is a light-inducible and clock-controlled gene
expressed in the chicken pineal gland. J. Neurochem. 96, 1790-1800, 2006.
Doi M, Yujnovsky I, Hirayama J, Malerba M, Titorra E, Sassone-Corsi P, Borrelli E: Impaired light-masking
in dopamine D2 receptor-null mice. Nature Neurosci. 9, 732-734, 2006.
Doi M, Hirayama J, Sassone-Corsi P: Circadian regulator CLOCK is a histone acetyltransferase. Cell 125,
− 318 −
497-508, 2006.
32. Yujnovsky I, Hirayama J, Doi M, Borrelli E, Sassone-Corsi P: Signaling mediated by the dopamine D2
receptor potentiates circadian regulation by CLOCK:BMAL1. Proc. Natl. Acad. Sci. USA 103, 6386-6391
2006.
33. Tan EM#, Yamaguchi Y#, Horwitz GD, Gosgnach S, Lein ES, Goulding M, Albright TD, Callaway EM. (#
equal contribution): Selective and quickly reversible inactivation of mammalian neurons in vivo using the
Drosophila allatostatin receptor. Neuron 51, 157-170, 2006.
㸦⥲ㄝ࣭ⱥᩥ㸧
1. Okamura H, Doi M, Fustin JM, Yamaguchi Y, Matsuo M: Mammalian circadian clock system: Molecular
mechanisms for pharmaceutical and medical sciences. Adv Drug Deliv Rev 62, 876-884, 2010.
2. Okamura H, Doi M, Fustin JM, Yamaguchi Y: Hypertension due to loss of clock. Curr hypertension Rep In
press.
3. Okamura H, Doi M: Dissection of hypertension with molecular clock: Mol Cell Endocrinol In press.
4. Okamura H: Brain comes to light. Nature 452, 294-295, 2008.
5. Okamura H: Suprachiasmatic nucleus clock time in mammalian circadian system. Cold Spring Harb Symp
Quant Biol 72, 551-556, 2007.
6. Tominaga-Yoshino K, Ueyama T, Okamura H: Suprachiasmatic nucleus cultures that maintain rhythmic
properties in vitro. Methods Mol Biol 362, 481-492, 2007.
㸦⥲ㄝ࣭࿴ᩥ㸧
1. ᒸᮧ ᆒ㸸⏕య᫬ィ࡜㌟㏆࡞⑓Ẽ 㸦௻⏬࡜࣮࢝ࣛࢢࣛࣅ࢔㸧 ⬻ 21ࠊ13(4)ࠊ362-365ࠊ2010.
2. ᅵᒃ㞞ኵࠊᒸᮧ ᆒ㸸᫬ィ㑇ఏᏊ࡜㧗⾑ᅽࠊ⬻ 21ࠊ13(4)ࠊ367-371ࠊ2010.
3. ᒸᮧ ᆒࠊᅵᒃ㞞ኵ㸸⾑ᅽㄪ⠇࡟࠿࠿ࢃࡿෆศἪ࣭௦ㅰ࣭⮬ᚊ⚄⤒ࢿࢵࢺ࣮࣡ࢡࠊ⾑ᅽࠊ17 (10)ࠊ13-18ࠊ
2010.
4. ᒸᮧ ᆒ㸸⏕య᫬ィ࡟ࡼࡿ⾑ᅽㄪ⠇ࡢ࣓࢝ࢽࢬ࣒࣮᪂ࡓ࡞㧗⾑ᅽ἞⒪⸆ࡢ㛤Ⓨ࡟ྥࡅ࡚ࠊࣇ࢓࣐ࣝࢩ
࢔ࠊ46(12)ࠊ1125-1129ࠊ2010.
5. ᒣ⏣⿱அࠊᅵᒃ㞞ኵࠊᒸᮧ ᆒ㸸⓶⭵࡟࠾ࡅࡿ⏕యࣜࢬ࣒ࡢศᏊᶵᵓ ࣇࣞࢢࣛࣥࢫࢪ࣮ࣕࢼࣝࠊ38
(1)ࠊ32-40ࠊ2010.
6. ᒣཱྀ㈡❶ࠊᒸᮧ ᆒ㸸యෆ᫬ィ࡜ࡣ㸽 ⫧‶࡜⢾ᒀ⑓ࠊ9(2)ࠊ197-201ࠊ2010.
7. ᅵᒃ 㞞ኵ, ᒸᮧ ᆒ: యࣜࢬ࣒␗ᖖ࡟క࠺㧗⾑ᅽⓎ⑕࣓࢝ࢽࢬ࣒, ᐇ㦂་Ꮫ 28, 1742-1746, 2010.
8. ᯇᑿ㞞༤ࠊᒸᮧ ᆒ㸸⢭⚄⑌ᝈ࡜⏕యࣜࢬ࣒㸸⢭⚄⑌ᝈ࡬ࡢ⏕య᫬ィ࠿ࡽࡢ࢔ࣉ࣮ࣟࢳࠊᐇ㦂་Ꮫࠊ
28(14)ࠊ2224-2228ࠊ2010.
9. ᒸᮧ ᆒ㸸့ங㢮࡟࠾ࡅࡿ⏕యࣜࢬ࣒ࡢ௙⤌ࡳ ⏕≀≀⌮ࠊ49(5)ࠊ232-237ࠊ2009.
10. ᒣᓮᩥ⩏ࠊᅵᒃ㞞ኵࠊᒸᮧ ᆒ㸸యෆ᫬ィࡢศᏊᶵᵓ࡜⑌⑓἞⒪࡬ࡢᒎᮃ 㸦≉㞟㸸᫬㛫⸆⌮Ꮫ㸧 ་
⸆ࢪ࣮ࣕࢼࣝࠊ45ࠊ(6) 86-91ࠊ2009.
11. ᒸᮧ ᆒ㸸 ᫬㛫࡜⑓Ẽ㸸⏕య᫬ィ࠿ࡽ᫬㛫་Ꮫ࡬㸦≉㞟࡟࠶ࡓࡗ࡚㸧 ࣓ࢹ࢕࢝ࣝࣂ࢖࢜ࠊ6 (6)ࠊ
12-15ࠊ2009.
12. ᅵᒃ㞞ኵࠊᒸᮧ ᆒ㸸ศᏊ࠿ࡽぢࡓ⏕యࣜࢬ࣒ࡢ᫬㛫ᶵᵓ ࣓ࢹ࢕࢝ࣝࣂ࢖࢜ࠊ6 (6)ࠊ16-20ࠊ2009.
13. ᒸᮧ ᆒ㸸ᆅ⌫࡜᫬࡜᫬ィ㑇ఏᏊ ⬻࡜Ⓨ㐩ࠊ40ࠊ97-102ࠊ2008.
14. ᒸᮧ ᆒ㸸యෆ᫬ィࡢ᪂ࡋ࠸⌮ゎ ᑠඣ⛉ࠊ49ࠊ1357-1364ࠊ2008.
15. ᒸᮧ ᆒࠊᅵᒃ㞞ኵ㸸⏕≀᫬ィࢩࢫࢸ࣒࡟࠾ࡅࡿࢿ࢞ࢸ࢕ࣈࣇ࢕࣮ࢻࣂࢵࢡ⌮ㄽࡢ☜❧࡜ᒎ㛤
Clinical Neuroscienceࠊ25ࠊ1094-1099ࠊ2007.
16. ᒸᮧ ᆒ㸸᫬㛫᝟ሗࢆ࡟࡞࠺๪⭈ࢫࢸࣟ࢖ࢻ࣍ࣝࣔࣥ Clinical Neuroscienceࠊ25ࠊ1134-1137ࠊ2007.
17. ᒸᮧ ᆒ㸸యෆ᫬ィࡢศᏊᶵᵓ࡜ࡑࡢ⑓ែ ᭱᪂་Ꮫࠊ62ࠊ2407-2413ࠊ2007.
18. ᒣཱྀ㈡❶: ࢸࢡࣀ࣭ࢺࣞࣥࢻ ⏕ࡁࡓື≀࡛౑࠼ࡿ㎿㏿࡛ྍ㏫ⓗ࡞ AlstR/AL ⚄⤒⣽⬊୙
άᛶ໬ἲࡢ㛤Ⓨ. ࣂ࢖࢜ࢸࢡࣀࣟࢪ࣮ࢪ࣮ࣕࢼࣝ 7, 70-73, 2007.
19. ᒸᮧ ᆒ㸸ࡣࡌࡵ࡟ ࣮ ⏕≀࡟࡜ࡗ࡚᫬ィ࡜ࡣ࡞࡟࠿ࠊ་Ꮫࡢ࠶ࡺࡳࠊ216ࠊ199-204ࠊ2006.㸦➨
216 ᕳ 3 ྕࠊ2006/1/21 ྕࠊ࠶ࡺࡳࠕ᫬ィ㑇ఏᏊࠖ
㸧
20. ᒸᮧ ᆒ㸸ࣄࢺࡣ࡞ࡐ╀ࡿࡢ࠿㸽 ࠕ≉㞟㸸᫬ィ㑇ఏᏊ࠿ࡽ⑌ᝈʊ╧╀㞀ᐖࠖ ࣓ࢹ࢕࣭࢝ࣝࢧ࢖
࢚ࣥࢫ࣭ࢲ࢖ࢪ࢙ࢫࢺ 32ࠊ57-58ࠊ2006.
21. ቑῲᝅࠊᒸᮧ ᆒ㸸᫬ィ㑇ఏᏊ࡜యෆࣜࢬ࣒ ࠕ≉㞟㸸᫬ィ㑇ఏᏊ࠿ࡽ⑌ᝈʊ╧╀㞀ᐖࠖ ࣓ࢹ࢕
࣭࢝ࣝࢧ࢖࢚ࣥࢫ࣭ࢲ࢖ࢪ࢙ࢫࢺ 32ࠊ59-64ࠊ2006.
22. ୖᒣ཭Ꮚࠊᒸᮧ ᆒ: ど஺ཫୖ᰾࠿ࡽ๪⭈⓶㉁ࢆ௓ࡋࡓ඲㌟࡬ࡢ᫬้ࢩࢢࢼࣝఏ㐩 ᐇ㦂་Ꮫ, 24,
472-478, 2006.
− 319 −
23. ᒸᮧ ᆒࠊቑῲ ᝅ㸸᫬ィ㑇ఏᏊࠊ⮫ᗋᩚᙧእ⛉ 41 (6)ࠊ652-655ࠊ2006.
24. ⸨ᮏ ⩏ேࠊᒸᮧ ᆒ㸸ື≀ࡢᴫ᪥᫬ィ࡜ࣘࣅ࢟ࢳࣥ ⺮ⓑ㉁᰾㓟㓝⣲ 51 (10)ࠊ1316-1320ࠊ2006.
㸦ⴭ᭩࣭ⱥᩥ㸧
1. Okamura H, Ueyama T, Masubuchi S, Kitahama K: Morphology of DOPAergic neurons in mammals. In
Neurobiology of DOPA as a Neurotransmitter, Edited by Y. Misu and Y. Goshima, CRC Press in Taylor &
Francis, Boca Raton, 2006, pp 47-62.
㸦ⴭ᭩࣭ⱥᩥ㸧
1. ᒸᮧ ᆒࠊᅵᒃ㞞ኵ㸸⏕యࣜࢬ࣒␗ᖖ࡜࢔ࣝࢻࢫࢸࣟࣥ⏘⏕㐣๫ࢆక࠺㧗⾑ᅽࠊAnuual Review ᚠ
⎔ჾ 㸰㸮㸯㸯ࠊ୰እ་Ꮫ♫ࠊ2011, ༳ๅ୰.
2. ᒸᮧ ᆒࠊᅵᒃ㞞ኵ㸸⏕యࣜࢬ࣒࡜㧗⾑ᅽࠊAnnual Review ⢾ᒀ⑓࣭௦ㅰ࣭ෆศἪ 2011ࠊ୰እ་
Ꮫ♫ࠊ2011, ༳ๅ୰.
3. ᒸᮧ ᆒࠊᅵᒃ㞞ኵ㸸⏕యࣜࢬ࣒␗ᖖ࡜ཎⓎᛶ࢔ࣝࢻࢫࢸࣟࣥ⑕ࠊཎⓎᛶ࢔ࣝࢻࢫࢸࣟࣥ⑕デ⒪࣐
ࢽࣗ࢔ࣝ ᨵゞ➨ ∧㸦ᡂ℩ගᰤࠊᖹ⏣⤖႐⥴㸧ࠊデ᩿࡜἞⒪♫ࠊ2012, ༳ๅ୰.
4. ᒸᮧ ᆒ㸸့ங㢮ࡢ᫬ィ㑇ఏᏊࠊ᫬㛫⏕≀Ꮫ஦඾㸦▼⏣┤⌮㞝ࠊᮏ㛫◊୍⦅㸧
ࠊᮅ಴᭩ᗑࠊpp186-187
㡫ࠊ2008. ISBN 978-4-254-1730-3
5. ᒸᮧ ᆒ㸸ග࡜యෆ᫬ィࠊ୍෉࡛ࢃ࠿ࡿග⓶⭵⛉㸦⓶⭵⛉ࢧࣈࢫ࣌ࢩࣕࣜࢸ࢕࣮ࢩ࣮ࣜࢬ㸧㸦᳃⏣
᫂⌮ࠊᐑᆅⰋᶞࠊΎỈᏹ⦅㸧ࠊᩥගᇽࠊpp54-56ࠊ2008. ISBN978-4-8306-3451-2
6. ዟᮧᜤྐࠊᒸᮧ ᆒ㸸๰⸆ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢵࢡࢫࠊ࢖ࣥࢩࣜࢥ๰⸆⛉Ꮫ㸦⸨஭ಙᏕࠊ㎷ᮏ㇦
୕ࠊዟᮧᜤྐ⦅㸧ࠊி㒔ᘅᕝ᭩ᗑࠊpp9-36 㡫ࠊ2008ࠋISBN978-4-901789-03-5
7. ᒸᮧ ᆒࠊᑠᯇ᲍ᜨ㸸 ⮬ᚊ⚄⤒ᶵ⬟ࡢ᫬㛫⏕≀Ꮫࠋ᪥ᮏ⮬ᚊ⚄⤒⛉Ꮫ఍ࠕ⮬ᚊ⚄⤒ᶵ⬟᳨ᰝ ➨
㸲∧ࠖ ᩥගᇽࠊᮾிࠊ 82 㡫ʊ88 㡫ࠊ2007 ࠋ
8. ᒸᮧ ᆒࠊ⸨ᮏ⩏ேࠊⴷ ᪂㸸ࣘࣅ࢟ࢳࣥ࡜యෆ᫬ィࠊู෉་Ꮫࡢ࠶ࡺࡳࠕࣘࣅ࢟ࢳࣥ◊✲ࡢ᪂ᒎ
㛤ʊ࣓࢝ࢽࢬ࣒࠿ࡽ⑌ᝈ◊✲࡬࣮ࠖpp142-146ࠊ2006ࠊ་ṑ⸆ฟ∧ᰴᘧ఍♫ࠊ145 㡫ࠋ
− 320 −
ࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮㸦ไᚚศᏊᏛ㸧ศ㔝
ᩍ ᤵ ༤ኈ㸦ᕤᏛ㸧᥃㇂⚽᫛㸦࠿ࡅࡸ ࡦ࡛࠶ࡁ㸧㸦2007. 4 ╔௵㸧
ᖹᡂඖᖺ៞ᛂ⩏ሿ኱Ꮫ༞ࠊᖹᡂ 6 ᖺྠ኱Ꮫ኱Ꮫ㝔⌮ᕤᏛ◊✲⛉
༤ኈㄢ⛬ಟ஢
෸ᩍᤵ ༤ኈ㸦⸆Ꮫ㸧᭹㒊 ᫂㸦ࡣࡗ࡜ࡾ ࠶ࡁࡽ㸧㸦2007. 6 ╔௵㸧
ᖹᡂ 3 ᖺᒱ㜧⸆⛉኱Ꮫ༞ࠊᖹᡂ 8 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
ຓ ᩍ ༤ኈ㸦㎰Ꮫ㸧すᮧៅ୍㸦࡟ࡋࡴࡽ ࡋࢇ࠸ࡕ㸧㸦2009.4 ╔௵㸧
ᖹᡂ 11 ᖺᮾி኱Ꮫ༞ࠊᖹᡂ 16 ᖺྠ኱Ꮫ኱Ꮫ㝔㎰Ꮫ⏕࿨⛉Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
≉ᐃຓᩍ ༤ኈ㸦ᕤᏛ㸧ᯘ ㇏㸦ࡣࡸࡋ ࡺࡓ࠿㸧㸦2009.6 ╔௵㸧
ᖹᡂ 14 ᖺ᪥ᮏ኱Ꮫ༞ࠊᖹᡂ 19 ᖺᐩᒣ┴❧኱Ꮫ኱Ꮫ㝔ᕤᏛ◊✲⛉
༤ኈㄢ⛬ಟ஢
◊✲ࡢᴫせ
ᙜࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮㸦ไᚚศᏊᏛ㸧ศ㔝ࡣࠊኳ↛≀໬Ꮫ㸦ኳ↛≀⸆Ꮫ㸧ࠊ࣓ࢹ࢕ࢩࢼࣝࢣ࣑
ࢫࢺ࣮ࣜ㸦๰⸆໬Ꮫ㸧ࢆᶵ㍈࡜ࡋ࡚ࠊࣇ࢛࣮࣡ࢻࢣ࣑࢝ࣝࢪ࢙ࢿࢸ࢕ࢡࢫ࠾ࡼࡧࣜࣂ࣮ࢫࢣ࣑࢝
ࣝࢪ࢙ࢿࢸ࢕ࢡࢫࡢ཮᪉ྥ࠿ࡽࡢ᭷⏝࡞᪂つ⏕⌮άᛶᑠศᏊࡢ㛤ᣅ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋࡉࡽ࡟ࠊ
ࡑࢀࡽࢆ฼⏝ࡋ࡚⣽⬊ࡢࠕቑṪ࣭ศ໬࣭Ṛࠖ࡞࡝ࡢㄪ⠇ᶵᵓࡢゎ᫂◊✲࡟ྲྀ⤌ࡳࠊ㠉᪂ⓗ་⸆ရ
࣮ࣜࢻ໬ྜ≀๰〇ࢆᣦྥࡋࡓ⊂๰ᛶࡢ㧗࠸ඛ➃ⓗࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲࠾ࡼࡧࢣ࣑࢝ࣝࢤࣀ
࣑ࢡࢫ◊✲ࢆᒎ㛤ࡋ࡚࠸ࡿࠋࡲࡓᩍ⫱㠃࡛ࡣࠊኳ↛≀໬Ꮫࠊ࣓ࢹ࢕ࢩࢼࣝࢣ࣑ࢫࢺ࣮ࣜࠊࢣ࣑࢝
ࣝࣂ࢖࢜ࣟࢪ࣮࡞࡝ࡢ⼥ྜⓗ᪼⳹ࢆᇶ┙࡜ࡍࡿඛᑟⓗᏛ㝿㡿ᇦࡢ⣲㣴ࢆ᭷ࡍࡿேᮦ⫱ᡂ࡟ດࡵ࡚
࠸ࡿࠋ
ከᅉᏊ⑌ᝈ㸦ࡀࢇࠊᚰ⑌ᝈࠊឤᰁ⑕ࠊ⚄⤒ኚᛶ⑌ᝈࠊච␿⑌ᝈࠊ⢾ᒀ⑓࡞࡝㸧࡟ᑐࡍࡿḟୡ௦໬
Ꮫ⒪ἲࡢ㛤Ⓨࢆᣦྥࡋࡓඛ➃ⓗࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲
᪂つ⏕⌮άᛶᑠศᏊࡢヲ⣽࡞స⏝ᶵᵓゎᯒ◊✲ࠊᵓ㐀άᛶ┦㛵◊✲ࠊᶵ⬟ᛶศᏊࣉ࣮ࣟࣈࢆ฼
⏝ࡋࡓᶆⓗࢱࣥࣃࢡ㉁㸦⤖ྜࢱࣥࣃࢡ㉁㸧ࡢྠᐃ࣭ゎᯒ◊✲ࢆᒎ㛤ࡋ࡚࠸ࡿࠋ౛࠼ࡤࠊ㑇ఏᏊⓎ
⌧ゎᯒἲࡸࢱࣥࣃࢡ㉁Ⓨ⌧ゎᯒἲࢆ㥑౑ࡋ࡚ࠊ⾑⟶᪂⏕ᢚไ๣࢚࣏࢟ࢩ࢟ࣀ࣮ࣝ Bࠊ࢔ࢨࢫࣆࣞ
ࣥࠊࢧ࢖ࢺࢺ࢚ࣜࢽࣥ A ࡞࡝ࡢ⣽⬊ෆᶆⓗࢿࢵࢺ࣮࣡ࢡࢆྠᐃࡋࡓࠋࡲࡓࠊ⏕య⭷ࡢᵓ㐀࡜ᶵ⬟
ࡢ⌮ゎࢆ┠ᣦࡋࡓࢣ࣑࢝ࣝࢤࣀ࣑ࢡࢫ◊✲ࢆ⾜࠸ࠊ⏕య⭷ᶵ⬟ไᚚ≀㉁ࡢ㛤Ⓨ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ
ࡉࡽ࡟ࠊࣜࣂ࣮ࢫࢣ࣑࢝ࣝࢪ࢙ࢿࢸ࢕ࢡࢫࡢ◊✲ᇶ┙࡜ࡋ࡚ࠊM1 ࢔࣑ࣀ࣌ࣉࢳࢲ࣮ࢮࣇ࢓࣑ࣜ
࣮ࡢ⏕⌮ᶵ⬟ゎᯒࠊ⬺ࣘࣅ࢟ࢳࣥ໬㓝⣲(DUB)ࡢ⏕⌮ⓗᙺ๭ࡢゎ᫂ࢆ┠ᣦࡋࡓ DUB άᛶ᳨ฟ⏝
ࢶ࣮ࣝࡢ㛤Ⓨ࡞࡝ࢆ⾜ࡗ࡚࠸ࡿࠋ
๰⸆࣮ࣜࢻ໬ྜ≀ࡢ㛤ᣅࢆᣦྥࡋࡓ᪂つ⏕⌮άᛶ≀㉁ࡢኳ↛≀໬Ꮫ࣭࣓ࢹ࢕ࢩࢼࣝࢣ࣑ࢫࢺ࣮ࣜ
◊✲
ࡀࢇ≉␗ⓗᚤᑠ⎔ቃࠊᚰ୙඲ࠊឤᰁ⑕ࠊ⚄⤒ኚᛶ⑌ᝈࠊච␿⑌ᝈࠊ⢾ᒀ⑓ࠊᖿ⣽⬊࡞࡝ࢆไᚚ
− 321 −
ᶆⓗ࡜ࡋࡓ᪂つኳ↛᭷ᶵศᏊࡢ㛤ᣅ࣭๰〇⸆⌮άᛶホ౯ࡢࡓࡵࡢࣁ࢖ࢥࣥࢸࣥࢶ࣭ࢫࢡ࣮ࣜࢽࣥ
ࢢ(HCS)࠾ࡼࡧࣁ࢖ࢫ࣮ࣝࣉࢵࢺ࣭ࢫࢡ࣮ࣜࢽࣥࢢ(HTS)ࡢᵓ⠏ࠊ᥈⣴◊✲ࢆᒎ㛤ࡋࡓࠋࡉࡽ࡟ࠊ
LC-MS/MS ➼ࢆ฼⏝ࡋࡓ࣓ࢱ࣮࣒࣎ࣟゎᯒ◊✲ࡢ⤖ᯝࠊᚤ⏕≀௦ㅰ⏘≀⏤᮶ࡢ」ᩘࡢ᪂つ⏕⌮ά
ᛶ≀㉁ࢆぢฟࡋࡓࠋࡲࡓࠊHCS ࠾ࡼࡧ HST ࡟࠾ࡅࡿࣄࢵࢺ໬ྜ≀㸦ྜᡂ໬ྜ≀ࠊ⏕⸆࣭₎᪉⏤
᮶໬ྜ≀ࠊ⏕యෆᶵ⬟ศᏊ࡞࡝㸧࠿ࡽࡢ๰⸆࣮ࣜࢻೃ⿵໬ྜ≀࡬ࡢྜᡂᒎ㛤ࢆ⾜࠸ࠊ」ᩘࡢ⯆࿡
῝࠸ࣇ࢓࣮࣐ࢥ࣍࢔ࡢ㛤Ⓨࢆ⾜ࡗࡓࠋ࡞࠾ࠊ≉ᐃࡢᶆⓗࢱࣥࣃࢡ㉁࡟ᑐࡋ࡚ࡣࠊin silico ࢫࢡࣜ
࣮ࢽࣥࢢ◊✲ࢆ⾜ࡗࡓࠋ
ࢣࣔ࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࠊࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢆά⏝ࡋࡓࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮◊✲
࣏ࢫࢺࢤࣀ࣒᫬௦ࡢ௒᪥࡛ࡉ࠼ࠊ⏕⌮άᛶᑠศᏊࡢᶆⓗࣃࢫ࢙࢘࢖࣭ᶆⓗศᏊࢆྠᐃࡍࡿࡇ࡜
ࡣᐜ࡛᫆ࡣ࡞࠸ࡀࠊࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮㸦ከᅉᏊ⑌ᝈ࡟ᑐࡍࡿከඖⓗ໬Ꮫ⒪ἲ㸧ࢆ☜❧ࡍࡿࡓ
ࡵ࡟ࡣ⏕⌮άᛶᑠศᏊࡢᶆⓗࣃࢫ࢙࢘࢖࣭ᶆⓗศᏊࢆ㎿㏿࡟ྠᐃ࣭ゎᯒྍ⬟࡞ࣉࣛࢵࢺࣇ࢛࣮࣒
ࡢ☜❧ࡣ୙ྍḞ࡛࠶ࡿࠋࡑࡇ࡛ࠊᙜศ㔝࡛ࡣࠊᶵ⬟ᛶศᏊࣉ࣮ࣟࣈࡢ๰〇࣭ά⏝ࢆᇶ┙࡜ࡋࡓࣉ
ࣛࢵࢺࣇ࢛࣮࣒㛤Ⓨ◊✲ࠊ࠾ࡼࡧศ⿣㓝ẕ࣭ฟⱆ㓝ẕࢆ฼⏝ࡋࡓຠᯝⓗ࡞స⏝ᶵᗎண ࢩࢫࢸ࣒
ࡢ㛤Ⓨ◊✲ࢆᒎ㛤ࡋ࡚࠸ࡿࠋ
᭷⏝≀㉁⏕⏘࣭๰〇ࡢࡓࡵࡢ⏕ྜᡂᕤᏛⓗ◊✲
⎔ቃㄪ࿴ᆺࡢ᭷ᶵ໬ྜ≀๰〇ࡀᙉࡃᮃࡲࢀࡿ௒᪥ࠊ≉␗࡞໬Ꮫᵓ㐀ࢆຠ⋡ࡼࡃᵓ⠏ྍ⬟࡞ᚤ⏕
≀㸦ᨺ⥺⳦ࠊ⣒≧⳦࡞࡝㸧ࡸ᳜≀ࡢ⏕ྜᡂ㑇ఏᏊࢆά⏝ࡋࡓ͆ࡶࡢ࡙ࡃࡾ◊✲͇ࡣ㔜せ࡞◊✲ㄢ
㢟࡛࠶ࡿࠋᙜศ㔝࡛ࡣࠊ᭷⏝⏕⌮άᛶ≀㉁ࢆ⏕⏘ࡍࡿᚤ⏕≀ࡢࢤࣀ࣒ୖࡢタィᅗࢆゎㄞࡋ࡞ࡀࡽࠊ
⏕ྜᡂᕤᏛⓗ࡟࢜ࣜࢪࢼࣜࢸ࢕࣮ࡢ㧗࠸᪂つ㦵᱁๰ฟ◊✲ࡸ๰⸆◊✲࡬ࡢᒎ㛤ࢆ⾜ࡗ࡚࠸ࡿࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
᥃㇂ᩍᤵࡀఫᮌ࣭ᱵ⃝グᛕ㈹㸦ᖹᡂ 18 ᖺ, ᪥ᮏᢠ⏕≀㉁Ꮫ⾡༠㆟఍㸧
ࠊ⏕࿨⛉Ꮫၨ᫂㈹㸦ᖹᡂ
19 ᖺ, (㈈)ၨ᫂఍㸧ࠊ኱Ꮫ㝔⏕ࡀᅜ㝿఍㆟㸦➨ 6 ᅇ(2010 ᖺ) OOTR (Organization for Oncology and
Translational Research)ᖺḟᏛ఍) ࡟࠾ࡅࡿඃ⚽࣏ࢫࢱ࣮㈹ࢆཷ㈹ࡋ࡚࠸ࡿࡇ࡜࡞࡝࠿ࡽࡶࠊ◊
✲ホ౯ࡣᴟࡵ࡚㧗࠸ࠋࡲࡓࠊᙜ◊✲ศ㔝ࡣ 2007 ᖺࡢタ❧௨᮶ࠊඛᑟⓗᏛ㝿◊✲㡿ᇦ࡟㐺ࡋࡓ◊
✲ᇶ┙ࢆࡋࡗ࠿ࡾ࡜ᵓ⠏ࡋࠊ㡰ㄪ࡟◊✲ᡂᯝࢆᣲࡆࡘࡘ࠶ࡿࠋࡉࡽ࡟ࠊ኱Ꮫ㝔⏕ࡀᏛ⾡᣺⯆఍≉
ู◊✲ဨ࡟᥇⏝ࡉࢀ࡚࠸ࡿࡇ࡜ࡶࠊᩍ⫱࡜◊✲ࡢࣞ࣋ࣝࡢ㧗ࡉࡢᐈほⓗド࡛࠶ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ 2 ᅇ⏕㓄ᙜࡢኳ↛≀⸆Ꮫ 2㸦⸆⏝㈨※Ꮫ㸧ࢆᢸᙜࡋ࡚࠸ࡿࠋࡲࡓࠊ་⸆ရ
໬Ꮫ࣭᪂⸆ㄽࠊ⸆Ꮫᑓ㛛ᐇ⩦ IIࠊ๰⸆᭷ᶵ໬Ꮫ࢚ࢡࢧࢧ࢖ࢬࠊ་⸆ရ㛤Ⓨࣉࣟࢪ࢙ࢡࢺ₇⩦ Iࠊ
ᇶ♏໬Ꮫᐇ㦂ࠊ࣏ࢣࢵࢺࢮ࣑ࠕࡃࡍࡾࡢ໬Ꮫࠖ࡞࡝ࢆศᢸࡋ࡚࠸ࡿࠋタᐃࡋࡓㅮ⩏┠ⓗ࣭Ꮫ⩦┠
ᶆࢆᏛ⏕࡟ࡶఏ࠼ࠊࡋ࠿ࡶ୍᪉㏻⾜ࡢㅮ⩏࠿ࡽ཮᪉ྥࡢᏛ⩦࡜࡞ࡿࡼ࠺࡟ࠊ₇⩦᪉ᘧࢆ✚ᴟⓗ࡟
ྲྀࡾධࢀࡓㅮ⩏࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
༞ᴗᐇ⩦࠾ࡼࡧ኱Ꮫ㝔ᩍ⫱㸸༞ᴗ㓄ᒓࡢᏛ⏕࡟ࡶಶࠎ࡟◊✲ࢸ࣮࣐ࢆ୚࠼ࠊ⮬ศ࡛⪃࠼࡚◊✲
ࢆ㐙⾜ྍ⬟࡞⬟ຊ㛤Ⓨࡢᶵ఍ࢆ୚࠼࡚࠸ࡿࠋᙜศ㔝ࡢ᭱኱ࡢ≉㛗ࡣࠊ」ᩘࡢ◊✲ࢢ࣮ࣝࣉయไୗࠊ
㝔⏕ࡀಶࠎࡢ◊✲ࢸ࣮࣐ࢆᣢࡕࠊᏛ㝿◊✲㡿ᇦ࡛࠶ࡿࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲ศ㔝࡟࠾࠸࡚ࠊ
− 322 −
஫࠸࡟ษ☩⌶☻ࡋ࡞ࡀࡽ◊✲ࢆ㐙⾜ࡋ࡚࠸ࡿⅬ࡛࠶ࡿࠋࡲࡓࠊ⮬ศ௨እࡢ◊✲ࢸ࣮࣐ࡶ⌮ゎ࡛ࡁ
ࡿࡼ࠺࡟ࡍࡿࡓࡵࠊẖ㐌㸯ᅇࠊྛேࡢ◊✲ሗ࿌఍ࠊᩥ⊩ሗ࿌఍࡞࡝ࢆ⾜ࡗ࡚࠸ࡿࠋࡉࡽ࡟ࠊ◊✲
ᡂᯝࡀฟ࡚࠸ࡿ㝔⏕࡟ࡣࠊᅜෆእࡢᏛ఍Ⓨ⾲ࡢ᥎ዡࠊ࡞ࡽࡧ࡟ཎⴭㄽᩥࡢᇳ➹ᣦᑟࢆ✚ᴟⓗ࡟⾜
ࡗ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊ᭱᪂ࡢ◊✲ෆᐜࢆ஺࠼ࡘࡘࠊẖᅇᑠヨ㦂ࢆ⾜࠸㐩ᡂᗘࢆ☜ㄆࡍࡿᙧ
ᘧホ౯ࢆྲྀࡾධࢀ࡚࠸ࡿࠋࡉࡽ࡟ᤵᴗホ౯ࡶಶேⓗ࡟ࡶ⾜ࡗ࡚ཧ⪃࡟ࡋࠊㅮ⩏ࡢᨵၿࢆᚰࡀࡅ࡚
࠸ࡿࠋ
◊✲ᐊෆࡢᩍ⫱ࡣࠊ◊✲ᐊࡢබᘧຮᙉ఍௨እ࡟ࡶ໬Ꮫ㡿ᇦ࡜⏕≀Ꮫ㡿ᇦࡢྛᑓ㛛ศ㔝࡟↔Ⅼࢆ
⤠ࡗࡓຮᙉ఍ࡀ⮬୺ⓗ࡟㛤ദࡉࢀ࡚࠸ࡿࡇ࡜ࠊከࡃࡢᏛ⏕ࡀ༞ᴗࡲ࡛࡟ᅜෆእࡢᏛ఍࡛◊✲ᡂᯝ
ࡢⓎ⾲ࢆ⾜ࡗ࡚࠸ࡿࡇ࡜࡞࡝࠿ࡽุ᩿ࡋ࡚ࠊ◊✲⪅࡜ࡋ࡚ࡢ⬟ຊ㛤Ⓨࡀᐇ㊶ࡉࢀ࡚࠸ࡿࠋࡲࡔᏛ
㒊༞ᴗ⏕ࡣᩘᑡ࡞࠸ࡀࠊ༞ᴗ⏕ࡢከࡃࡣ኱Ꮫ㝔࡟㐍Ꮫࡋࠊ⸆Ꮫ㡿ᇦࡢ◊✲㛤Ⓨศ㔝࡛ά㌍ࡋ࡚࠸
ࡿࠋ
࡞࠾ࠊᩍ⫱Ⅼ᳨άືࡢ୍⎔࡜ࡋ࡚⸆Ꮫᩍ⫱⪅࣮࣡ࢡࢩࣙࢵࣉ࡞࡝࡟ࡶཧຍࡋ࡚࠾ࡾࠊ⮬ᕫ◊㛑
࡟ྲྀࡾ⤌ࢇ࡛࠸ࡿࠋ
㸦ཎⴭ㸧
1.
L. Lindqvist, F. Robert, W. Merrick, H. Kakeya, C. Fraser, H. Osada. J. Pelletier. Inhibition of
translation by cytotrienin A –a member of the ansamycin family. RNA. 16, 2404-2413 (2010).
2.
S. Nishimura, Y. Arita, M. Honda, K. Iwamoto, A. Matsuyama, A. Shirai, H. Kawasaki, H. Kakeya, T.
Kobayashi, S. Matsunaga, M. Yoshida. Marine antifungal theonellamides target 3beta-hydroxysterol
to activate Rho1 signaling. Nature Chem. Biol. 6(7), 519-526 (2010).
3.
R. Waditee-Sirisattha, J. Shibato, R. Rakwal, S. Sirisattha, A. Hattori, T. Nakano, T. Takabe, M.
Tsujimoto. The Arabidopsis Aminopeptidase LAP2 Regulates Plant Growth, Leaf Longivity and Stress
Response PLoS ONE in press (2010).
4.
Y. Goto, R. Yoshioka, N. Arisaka, A. Hattori, M. Tsujimoto. Involvement of Gln-238 in the substrate
specificity of human laeverin/aminopeptidase Q. Biol Pharm Bull in press (2010).
5.
N. Kato, H. Suzuki, H. Takagi, Y. Asami, H. Kakeya, M. Uramoto, T. Usui, S. Takahashi, Y.
Sugimoto, H. Osada. Identification of cytochrome P450s required for fumitremorgen biosynthesis in
Aspergillus fumigatus. ChemBioChem. 10, 920-928 (2009).
6.
Y. Hayashi, K. Sankar, H. Ishikawa, Y. Nozawa, K. Mizoue, H. Kakeya. Total synthesis and
determination of the absolute configuration of FD-838, a naturally occurring azaspirobicyclic product.
Bioorg. Med. Chem. Lett., 19, 3863-3865 (2009).
7.
N. Kato, H. Suzuki, H. Takagi, Y. Asami, H. Kakeya, M. Uramoto, T. Usui, S. Takahashi, Y.
Sugimoto, H. Osada. Identification of Cytochrome P450s Required for Fumitremorgin Biosynthesis in
Aspergillus fumigates. ChemBioChem. 10, 920-928 (2009).
8.
M. Maruyama, N. Arisaka, Y. Goto, Y. Osawa, H. Inoue, H. Fujiwara, A. Hattori, M. Tsujimoto.
Histidine-379 of human laeverin/aminopeptidase Q, a non-conserved residue within the exopeptidase
motif, defines its distinctive enzymatic properties. J. Biol. Chem. 284, 34692-34702 (2009).
− 323 −
9.
M. Ishii, A. Hattori, Y. Numaguchi, X. Ma, T. Nagasaka, M. sujimoto, T. Murohara, H. Kobayashi, S.
Mizutani. The effect of recombinant aminopeptidase A (APA) on hypertension in pregnant
spontaneously hypertensive rats (SHRs). Early Hum. Dev. 85, 589-594 (2009).
10. C.H. Ho, L. Magtanong, S.L. Barker, D. Gresham, S. Nishimura, P. Natarajan, J.L. Koh, J. Porter, C.A.
Gray, R.J. Andersen, G. Giaever, C. Nislow, B. Andrews, D. Botstein, T.R. Graham, M. Yoshida, C.
Boone. A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive
compounds. Nat. Biotechnol. 27, 369-377 (2009).
11. Y. Asami, H. Kakeya, Y. Komi, S. Kojima, K. Nishikawa, K. Beebe, L. Neckers, H. Osada.
Azaspirene, a fungal product, inhibits angiogenesis by blocking Raf-1 activation. Cancer Sci. 99(9),
1853-1858 (2008).
12. Y. Hayashi, M. Shoji, H. Ishikawa, J. Yamaguchi, T. Tamura, H. Imai, Y. Nishigaya, K. Takabe, H.
Kakeya, H. Osada. The Asymmetric Total Synthesis of (+)-Cytotrienin A, an Ansamycin-Type
Anticancer Drug. Angew. Chem. Int. Ed. 47, 6657-6660 (2008).
13. H. Kamiyama, T. Usui, H. Sakurai, M. Shoji, Y. Hayashi, H. Kakeya, H. Osada. Epoxyquinol B, a
naturally ocuuring pentaketide dimer, inhibits NF-kB signaling by crosslinking TAK1. Biosci.
Bitechnol. Biochem. 72(7), 1894-1900 (2008).
14. H. Kamiyama, H. Kakeya, T. Usui, K. Nishikawa, M. Shoji, Y. Hayashi, H. Osada. Epoxyquinol B
shows antiangiogenic effects in vitro and in vivo by inhibiting VEGFR, and EGFR, FGFR, and PDFR.
Oncol. Res. 17, 11-21 (2008).
15. H.D. Jain, C. Zhang, S. Zhou, H. Zhou, J. Ma, X. Liu, A.M. Deveau, C.M. Dieckhaus, M.A. Johnson,
K.S. Smith, T.L. Macdonald, H. Kakeya, H. Osada, J.M. Cook. Synthesis and structure-activity
relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein. Bioorg. Med.
Chem. 16, 4626-4651 (2008).
16. H. Kamiyama, T. Usui, M. Uramoto, H. Takagi, M. Shoji, Y. Hayashi, H. Kakeya, H.Osada. Fungal
metabolite, epoxyquinol B crosslinks proteins by epoxyquinol-thiol conjugation. J. Antibiot. 61, 94-97
(2008).
17. Y. Goto, H. Tanji, A. Hattori, M. Tsujimoto. Glutamine-181 is crucial in the enzymatic activity and
substrate specificity of human endoplasmic-reticulum aminopeptidase-1. Biochem. J. 416, 109-116
(2008).
18. Y. Hayashi, T. Toyomasu, Y. Hirose, Y. Onodera, W. Mitsuhashi, H. Yamane, T. Sassa, T. Dairi.
Comparison of the enzymatic properties of ent-copalyl diphosphate synthases in the biosynthesis of
phytoalexins and gibberellins in rice, Biosci. Biotech. Biochem., 72, 523-530 (2008).
19. Y. Hayashi, N. Matsuura, H. Toshima, N. Itoh, J. Ishikawa, Y. Mikami, T. Dairi. Cloning of the gene
cluster responsible for biosynthesis of brasilicardin A, a unique diterpenoid. J. Antibiot., 61, 164-174
(2008).
20. M. Ishii, A. Hattori, Y. Numaguchi, M. Tsujimoto, S. Ishiura, H. Kobayashi, T. Murohara, J.W.
Wright, S. Mizutani. The effect of recombinant aminopeptidase A on hypertension in spontaneously
hypertensive rats: its effect in comparison with candesartan. Horm. Metab. Res. 40, 887-891 (2008).
21. M. Maruyama, A. Hattori, Y. Goto, M. Ueda, M. Maeda, H. Fujiwara, M. Tsujimoto.
Laeverin/aminopeptidase Q, a novel bestatin-sensitive leucine aminopeptidase belonging to the M1
family of aminopeptidases. J. Biol. Chem. 282, 20088-20096 (2007).
22. Y. Goto, A. Hattori, S. Mizutani, M. Tsujimoto. Asparatic acid 221 is critical in the calcium-induced
modulation of the enzymatic activity of human aminopeptidase A. J. Biol.Chem. 282, 37074-37081
(2007).
23. C.W. Lo, D. Kaida, S. Nishimura, A. Matsuyama, Y. Yashiroda, H. Taoka, K. Ishigami, H. Watanabe,
− 324 −
H. Nakajima, T. Tani, S. Horinouchi, M. Yoshida. Inhibition of splicing and nuclear retention of
pre-mRNA by spliceostatin A in fission yeast. Biochem. Biophys. Res. Commun. 364, 573-577
(2007).
24. C. Ikeda, Y. Hayashi, N. Itoh, H. Seto, T. Dairi. Functional analysis of eubacterial ent-copalyl
diphosphate synthase and pimara-9(11),15-diene synthase with unique primary sequences. J. Biochem.,
141, 37-45 (2007).
25. Y. Hayashi, H. Onaka, N. Itoh, H. Seto, T. Dairi. Cloning of the gene cluster responsible for
biosynthesis of KS-505a (longestin), a unique tetraterpenoid, Biosci. Biotech. Biochem., 71,
3072-3081 (2007).
26. Y. Asami, H. Kakeya, G. Okada, M. Toi, H. Osada. RK-95113, a new angiogenesis inhibitor produced
by Aspergillus fumigatus. J. Antibiot. 59, 724-728 (2006).
27. H. Tomiki, T. Saito, M. Ueki, H. Konno, T. Asaoka, R. Suzuki, M. Uramoto, H. Kakeya, H. Osada.
RIKEN natural products encyclopedia (RIKEN NPEdia), a chemical database of RIKEN natural
products depository (RIKEN NPDepo). J. Comput. Aided Chem. 7, 156-161 (2006).
28. M. Matsuzawa, H. Kakeya, J. Yamaguchi, M. Shoji, R. Onose, H. Osada, Y. Hayashi. Enantio- and
diastereoselective total synthesis of (+)-panepophenanthrin, an ubiquitin-activating enzyme inhibitor,
and biological properties of its new derivatives. Chem. Asian J. 1, 845-851 (2006).
29. N. Watanabe, Y. Nishihara, T. Yamaguchi, A. Koito, H. Miyoshi, H. Kakeya, H. Osada. Fumagillin
suppresses HIV-1 infection of macrophages through the inhibition of VPR activity. FEBS Lett. 580,
2598-2602 (2006).
30. H. Taguchi, A. Ohkubo, M. Sekine, K. Seio, H. Kakeya, H. Osada, T. Sasaki. Synthesis and biological
properties of new phosmidosine analogs having an N-acylsulfamate linkage. Nucleos. Nucleot. Nucl.
25, 647-654 (2006).
31. I. Shiina, T. Uchimaru, M. Shoji, H. Kakeya, H. Osada, Y. Hayashi. Computational study on the
reaction mechanism of the key thermal [4+4] cycloaddition reaction in the biosynthesis of
epoxytwinol A. Org. Lett. 8, 1041-1044 (2006).
32. J. Yamaguchi, M. Toyoshima, M. Shoji, H. Kakeya, H. Osada, Y. Hayashi. Concise, enantio- and
diastereo-selective total syntheses of fumagillol, RK-805, FR65814, ovalicin and 5-demethylovalicin,
using the proline-mediated, catalytic, asymmetric D-aminoxylation. Angew. Chem. Int. Ed. 45,
789-793 (2006).
33. Y. Goto, A. Hattori, Y. Ishii, S. Mizutani, M. Tsujimoto. Enzymatic properties of human
aminopeptidase A. Regulation of its enzymatic activity by calcium and angiotensin IV. J. Biol. Chem.
281, 23503-23513 (2006).
34. Y. Goto, A. Hattori, Y. Ishii, M. Tsujimoto. Reduced activity of the hypertension-associated
Lys528Arg
mutant
of
human
adipocyte-derived
leucine
aminopeptidase
(A-LAP)/ER-aminopeptidase-1. FEBS Lett. 580, 1833-1838 (2006).
35. F. Shido, T. Ito, S. Nomura, E. Yamamoto, S. Sumigama, K. Ino, A. Itakura, A. Hattori, M. Tsujimoto,
S. Mizutani, F. Kikkawa. Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory
factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells.
Endocrinology 147, 1780-1788 (2006).
36. D. Fruci, S. Ferracuti, M.Z. Limongi, V. Cunsolo, E. Giorda, R. Fraioli, L. Sibilio, O. Carroll, A.
Hattori, P.M. Van Endert, & P. Giacomini. Expression of endoplasmic reticulum aminopeptidases in
EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell
lines. J. Immunol. 176, 4869-4879 (2006).
37. K.-H. Lee, S. Nishimura, S. Matsunaga, N. Fusetani, H. Ichijo, S. Horinouchi, M. Yoshida. Induction
− 325 −
of a Ribotoxic Stress Response that Stimulates Stress-Activated Protein Kinases by
13-Deoxytedanolide, an Antitumor Marine Macrolide. Biosci. Biotechnol. Biochem. 70, 161-171
(2006).
38. T. Kawasaki, Y. Hayashi, T. Kuzuyama, K. Furihata., N. Itoh, H. Seto, T. Dairi. Biosynthesis of a
natural polyketide-isoprenoid hybrid compound furaquinocin A: Identification and heterologous
expression of the gene cluster. J. Bacteriol., 188, 1236-1244 (2006)
㸦⥲ㄝ㸧
᥃㇂⚽᫛ࠊすᮧៅ୍. ≉㞟ྕࠕ᪥ᮏࡢኳ↛≀໬Ꮫࡢᒎᮃ 㸫⏕࿨⛉Ꮫゎ᫂ࡢᶵ⬟ศᏊࠊ᪂ࡓ
࡞๰⸆ศᏊ࡜ࡋ࡚㸫ࠖ
㸹 ᪂つ᭷⏝ኳ↛᭷ᶵ໬ྜ≀ࡢ㛤ᣅ࡜ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲. ᭷ᶵ
ྜᡂ໬Ꮫ༠఍ㄅ, 68, 490-500 (2010).
኱ᵳࡉࡘࡁࠊ᥃㇂⚽᫛Meeting Report㸸➨ᅇ᪥ᮏࡀࢇศᏊᶆⓗ἞⒪Ꮫ఍Ꮫ⾡㞟఍ࡀࢇศ
Ꮚᶆⓗ἞⒪ࠊ࣓ࢹ࢕࢝ࣝࣞࣅ࣮ࣗ♫
すᮧៅ୍ࠊྜྷ⏣⛱ࣉࣟࣇ࢓࢖ࣜࣥࢢ࡟ࡼࡿ໬ྜ≀ࡢస⏝ゎᯒ໬Ꮫ༳ๅ୰
4.
Nishimura, S., Yashiroda, Y., Yoshida, M. Chemical genomics based on yeast genetics. Osada, H. Ed.
Chemical Biology: Small Molecules for Protein Targeting. Wiley pp. 223-238 (2009).
すᮧៅ୍ࠊྜྷ⏣⛱.㓝ẕࢆ⏝࠸ࡓ኱つᶍࣉࣟࣇ࢓࢖ࣝゎᯒ࡟ࡼࡿࢣ࣑࢝ࣝࢪ࢙ࢿࢸ࢕ࢡࢫ
⣽⬊ᕤᏛ
6.
᥃㇂⚽᫛. ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲࡟ࡼࡿ᪂ࡓ࡞๰⸆ᶆⓗࡢᥦ♧. ໬Ꮫ 63(5), 68-69 (2008).
7.
M. Tsujimoto, Y. Goto, M. Maruyama, A. Hattori. Biochemical and enzymatic properties of the M1
family of aminopeptidases involved in the regulation of blood pressure. Heart Fail Rev. 13, 285-91.
(2008).
8.
᥃㇂⚽᫛. ᭷⏝ኳ↛᭷ᶵ໬ྜ≀ࡢ㛤ᣅ࡜ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲. ᖹᡂ19ᖺᗘᚋᮇ㸦⛅Ꮨ㸧
᭷ᶵྜᡂ໬Ꮫㅮ⩦఍ࢸ࢟ࢫࢺ-᭷ᶵྜᡂ໬Ꮫࡢࢲ࢖ࢼ࣑ࢬ࣒㸸ࡑࡢᇶ♏࠿ࡽᗈ⠊࡞ᛂ⏝ࡲ࡛.
89-100 (2007).
9.
᥃㇂⚽᫛ࠊ 㛗⏣⿱அ. ኳ↛≀໬Ꮫ࣭⏕࿨⛉Ꮫࢹ࢕ࣅࢪ࣏࣮ࣙࣥࣞࢺ㸫་⸆ရ᥈⣴࡜๰⸆◊
✲㸹ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲. ᪥ᮏ໬Ꮫ఍. (2007).
10. ᥃㇂⚽᫛. ᚤ⏕≀ࡀ⏕⏘ࡍࡿ᪂つ⏕⌮άᛶ≀㉁ࡢ㛤ᣅ࡜ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲. Jpn. J.
Antibiotics. 181-187 (2007).
11. ᥃㇂⚽᫛ࠊ㰻⸨Ᏻ㈗Ꮚࠊ㛗⏣⿱அ. ᚤ⏕≀௦ㅰ⏘≀⏤᮶ࡢᑠศᏊࣛ࢖ࣈ࣮ࣛࣜࡢ฼⏝ᢏ⾡㸫
ࢫࢡ࣮ࣜࢽࣥࢢ࡜ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲㸫, BIO INDUSTRY㸦ࣂ࢖࢜࢖ࣥࢲࢫࢺ࣮ࣜ㸧, 24,
48-54 (2007).
12. ᥃㇂⚽᫛. Natural products-based chemical biology 㸫⊂๰ⓗ࡞ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮◊✲ࢆ┠
ᣦࡋ࡚㸫. ࣂ࢖࢜ࢧ࢖࢚ࣥࢫ࡜࢖ࣥࢲࢫࢺ࣮ࣜ, 65, 75 (2007).
13. S. Mizutani, K. Shibata, F. Kikkawa, A. Hattori, M. Tsujimoto, M. Ishii, H. Kobayashi. Essential role
of placental leucine aminopeptidase in gynecologic malignancy. Expert. Opin. Ther. Targets 11,
453-461 (2007).
14. 㛗⏣⿱அࠊ ᥃㇂⚽᫛. ᅛᙧࡀࢇࡢᚁᅽࢆ┠ᣦࡋࡓᢠࡀࢇ๣ࡢ㛤Ⓨ. ࡀࢇศᏊᶆⓗ἞⒪. 4,
24-31 (2006).
᥃㇂⚽᫛. Researcher’s eye“ࡶࡢ࡜ࡾ”࡜“໶”. ୕⏣ホㄽ (៞᠕⩏ሿ኱Ꮫฟ∧఍), 1093, 64 (2006).
− 326 −
᭹㒊᫂ࠊ㎷ᮏ㞞ᩥ0࢔࣑ࣀ࣌ࣉࢳࢲ࣮ࢮࣇ࢓࣑࣮ࣜࡢ᪂ࡓ࡞⏕⌮ᶵ⬟⾑ᰦṆ⾑ㄅ
すᮧៅ୍ࠊᯇᒣ᫭ஂࠊྜྷ⏣⛱.㓝ẕࢆᇶ┙࡜ࡋࡓࢣ࣑࢝ࣝࢤࣀ࣑ࢡࢫ.BIONICS
18. K. Kikuchi, H. Kakeya. A bridge between chemistry and biology. Nature Chem. Biol. 2, 392-394
(2006).
㸦᭩⡠㸧
1.
すᮧៅ୍ࠊ᥃㇂⚽᫛. ᪂つ⣲ᮦ᥈⣴㸫་⸆ရ࣮ࣜࢻ໬ྜ≀࣭㣗ရ⣲ᮦࢆồࡵ࡚㸫. ୖᮧ኱㍜㸦┘
ಟ㸧ࢩ࣮࢚࣒ࢩ࣮ฟ∧ࠊpp85-94 (2008).
2.
᥃㇂⚽᫛. “ᚤ⏕≀”࠿ࡽࡢ㉗ࡾ≀. ධ㛛 ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮㸫⏕࿨ࡢ୙ᛮ㆟ࢆ᥈ࡿ໬Ꮫ≀
㉁ࡢ≀ㄒ㸫. ධ㛛ࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮⦅㞟ጤဨ఍㸦⦅㸧ࠊ࣮࣒࢜♫ࠊpp.11-25 (2008).
3.
᥃㇂⚽᫛ࠊ኱▼┿ஓࠊ▮಴ᚭࠊ⸨஭ಙᏕ. ๰⸆◊✲࡟࠾ࡅࡿ໬ྜ≀ࣛ࢖ࣈ࣮ࣛࣜ. ࢖ࣥࢩࣜࢥ
๰⸆⛉Ꮫ㸫ࢤࣀ࣒᝟ሗ࠿ࡽ๰⸆࡬㸫㸦⸨஭ಙᏕ, ㎷ᮏ㇦୕, ዟ㔝ᜤྐ㸦⦅㸧ࠊி㒔ᘅᕝ᭩ᗑ㸧ࠊ
pp46-62 (2008).
᭹㒊᫂ࠊ᥃㇂⚽᫛. ࢣ࣑࢝ࣝࢪ࢙ࢿࢸ࢕ࢡࢫࢆᇶ┙࡜ࡋࡓࢣࣔࢤࣀ࣑ࢡࢫ࠾ࡼࡧࢣ࣑࢝ࣝࣂ
࢖࢜ࣟࢪ࣮. ࢖ࣥࢩࣜࢥ๰⸆⛉Ꮫ㸫ࢤࣀ࣒᝟ሗ࠿ࡽ๰⸆࡬㸫㸦⸨஭ಙᏕࠊ ㎷ᮏ㇦୕ࠊዟ㔝ᜤ
ྐ㸦⦅㸧ࠊி㒔ᘅᕝ᭩ᗑ㸧
ࠊpp37-46 (2008).
− 327 −
ࢩࢫࢸ࣒ࢣࣔࢭࣛࣆ࣮㸦๰⸆ィ⟬໬Ꮫ㸧
ᩍᤵ㸦⌮Ꮫ༤ኈ㸧໭ᾆ࿴ኵ㸦ࡁࡓ࠺ࡽ ࠿ࡎ࠾㸧㸦2007.4 ╔௵㸧
᫛࿴ 46 ᖺ኱㜰ᕷ❧኱Ꮫ༞ࠊ᫛࿴ 51 ᖺྠ኱Ꮫ኱Ꮫ㝔⌮Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
ຓᩍ㸦༤ኈ࣭⌮Ꮫ㸧ᮧ⏣ඞ⨾㸦ࡴࡽࡓ ࠿ࡘࡳ㸧㸦2008.8 ╔௵ࠊ2010.3 ㏥⫋㸧
ᖹᡂ 11 ᖺ༓ⴥ኱Ꮫ༞ࠊᖹᡂ 15 ᖺ⥲ྜ◊✲኱Ꮫ㝔኱Ꮫᩘ≀⛉Ꮫ◊✲⛉
༤ኈㄢ⛬୰㏥
◊✲ࡢᴫせ
ᮏศ㔝ࡣࠊ໭ᾆᩍᤵࡀᢸᙜᩍᤵࢆ໅ࡵ࡚࠸ࡓᐤ㝃ㅮᗙ࣭་⸆ရ⌮ㄽタィᏛ
ㅮᗙ㸦2003 ᖺ 8 ᭶㹼2008 ᖺ 7 ᭶㸧ࡢᩍ⫱࣭◊✲ࢆཷࡅ⥅ࡄᙧ࡛ 2007 ᖺ 4 ᭶
࡟Ⓨ㊊ࡋࠊStructure-Based Drug Design (SBDD)ࡢࡓࡵࡢィ⟬໬Ꮫⓗ࡞ᡭἲࡢ㛤
Ⓨ࡜ࠊࡇࢀࡽࢆᛂ⏝ࡋࡓ་⸆ရศᏊタィ◊✲ࢆ⾜ࡗ࡚࠸ࡿࠋ≉࡟ࠊ⚾ࡓࡕࡀⓎ 㸦໭ᾆᩍᤵ㸧
᱌ࡋࡓ኱つᶍ⣔ࡢ㔞Ꮚ໬Ꮫィ⟬ἲࢆά⏝ࡋ࡚ࠊࢻࣛࢵࢢࢹࢨ࢖࡛ࣥせ࡜࡞ࡿࢱࣥࣃࢡ㉁࡜ࣜ࢞ࣥࢻࡢ」
ྜయᵓ㐀࡜࢔ࣇ࢕ࢽࢸ࢕ࡢ㧗⢭ᗘィ⟬ண ἲࢆ☜❧ࡍࡿࡇ࡜ࢆ┠ᶆ࡜ࡋ࡚◊✲άືࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓࠊ
ィ⟬໬Ꮫࡢ⌮ㄽⓗᇶ♏ࢆ⇍▱ࡍࡿ࡜࡜ࡶ࡟㧗ᗘ࡞ィ⟬ᢏ⾡ࢆయᚓࡋ࡚ࠊ๰⸆◊✲ࡢࡉࡲࡊࡲ࡞ࢫࢸ࣮ࢪ
࡟࠾࠸࡚ⓗ☜࡞ᡭἲࢆ㥑౑ࡋ࡚◊✲ࢆᒎ㛤࡛ࡁࡿ⬟ຊࢆ᭷ࡍࡿ◊✲⪅ࡢ⫱ᡂࢆ┠ⓗ࡜ࡋ࡚࠸ࡿࠋ
㔞Ꮚ໬Ꮫィ⟬࡟ࡼࡿࢱࣥࣃࢡ㉁࡜ࣜ࢞ࣥࢻࡢศᏊ㛫┦஫స⏝ࡢ⢭ᐦゎᯒ
⚾ࡓࡕࡀ㛤Ⓨࡋࡓࣇࣛࢢ࣓ࣥࢺศᏊ㌶㐨(FMO)ἲࡣࠊࢱࣥࣃࢡ㉁㸫ࣜ࢞ࣥࢻ」ྜయ඲⣔ࢆ㔞Ꮚ໬Ꮫ
ィ⟬࡛ࡁࡿ᪉ἲ࡛࠶ࡿࠋࡇࡢ᪉ἲ࡟ࡼࡾࠊFK506 ⤖ྜࢱࣥࣃࢡ㉁ࢆ㢟ᮦ࡟ࡋ࡚ࠊ㟁Ⲵ⛣ື┦஫స⏝
ࢆࡣࡌࡵ CH/ȧ࡞࡝ศᏊຊሙィ⟬࡛ࡣホ౯ࡍࡿࡇ࡜ࡀᅔ㞴࡞ᙅ࠸ศᏊ㛫┦஫స⏝ࢆヲ⣽࡟ゎᯒࡋࠊ
ࡇࡢࢱࣥࣃࢡ㉁ࡢࣜ࢞ࣥࢻㄆ㆑ᵝᘧࢆ᫂ࡽ࠿࡟ࡋࡓࠋ
᪂つ࢖ࣥࢩࣜࢥࢫࢡ࣮ࣜࢽࣥࢢἲࡢ㛤Ⓨ
ศᏊືຊᏛࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡾồࡵࡓࢱࣥࣃࢡ㉁⤖ྜࢧ࢖ࢺࡢỈ࿴ᵓ㐀࡟ᇶ࡙ࡃ᪂つ࢖ࣥࢩ
ࣜࢥࢫࢡ࣮ࣜࢽࣥࢢἲࢆ㛤Ⓨࡋࡓࠋ᪤ᡂࡢ᪉ἲࡢࣄࢵࢺ⋡ࡀ࠾࠾ࡴࡡ 10㸣࡛࠶ࡿࡢ࡟ẚ࡭࡚ࠊᮏ᪉
ἲࡣ⣙ 30%࡜࠸࠺㧗࠸ࣄࢵࢺ⋡ࢆᣢࡘຠ⋡ࡢⰋ࠸᪉ἲ࡛࠶ࡿࡇ࡜ࢆ♧ࡋࡓࠋ
ࢻࣛࢵࢢࢹࢨ࢖ࣥࡢࡓࡵࡢィ⟬໬Ꮫᡭἲࡢ㛤Ⓨ
ࢻࣛࢵࢢࢹࢨ࢖࡛ࣥࡣࠊࢩ࣮ࢻ໬ྜ≀ࡢࢫࢡ࣮ࣜࢽࣥࢢ࠿ࡽ໬ྜ≀ࡢ᭱㐺໬ࡲ࡛ྛ◊✲ࢫࢸ࣮ࢪ࡛ࠊ
㧗㏿㸦ప⢭ᗘ㸧࠿ࡽ㧗⢭ᗘ㸦ప㏿㸧ࡲ࡛ࡢࡉࡲࡊࡲ࡞ィ⟬ἲࡀせồࡉࢀࡿࠋࡇࢀࡽ࡟ᑐᛂ࡛ࡁࡿィ
⟬᪉ἲࡢᯟ⤌ࡳࡢࡦ࡜ࡘࡀࠊ㔞Ꮚ(QM)ィ⟬࡜ྂ඾ຊሙ(MM)ィ⟬ࢆ⼥ྜࡋࡓ QM/MM ἲ࡛࠶ࡿࠋ⚾
ࡓࡕࡣ FMO ἲ࡜ྂ඾ຊሙࡢ⼥ྜἲࢆ㛤Ⓨࡋࠊせồࡉࢀࡿィ⟬㏿ᗘ࡜ィ⟬⢭ᗘ࡟ᛂࡌ࡚㐺ษ࡞ QM
㡿ᇦࡢࢧ࢖ࢬࢆ㑅ᢥ࡛ࡁࡿ᪉ἲࢆ㛤Ⓨࡋࡓࠋࡇࡢ᪉ἲ࡟ࡼࡾࢱࣥࣃࢡ㉁࡜ࣜ࢞ࣥࢻࡢ」ྜయᵓ㐀ࡢ
ィ⟬ࢆ⾜ࡗࡓ⤖ᯝࠊᐇ㦂ᵓ㐀࡟ᴟࡵ࡚㏆࠸ᵓ㐀ࡀᚓࡽࢀࡓࡇ࡜࠿ࡽࠊSBDD ࡟࠾࠸࡚᭷⏝࡞ィ⟬ἲ
࡜࡞ࡿࡇ࡜ࢆ♧ࡋࡓࠋ
ィ⟬໬Ꮫᡭἲ࡟ࡼࡿ་⸆ရ໬ྜ≀ࡢ᥈⣴◊✲
ᐇ㦂ࢢ࣮ࣝࣉ࡜ඹྠ࡛⾜ࡗࡓ⭈⅖἞⒪⸆ࡢ᥈⣴◊✲࡟࠾࠸࡚ࠊ࢖ࣥࢩࣜࢥࢫࢡ࣮ࣜࢽࣥࢢ࡟ࡼࡾࢱ
࣮ࢤࢵࢺࢱࣥࣃࢡ㉁࡟άᛶࢆᣢࡘ࠸ࡃࡘ࠿ࡢ໬ྜ≀ࢆぢฟࡋࠊࡑࢀࡽࢆࢩ࣮ࢻ໬ྜ≀࡜ࡋ࡚ィ⟬໬
Ꮫᡭἲࢆ㥑౑ࡋ࡚ SBDD ࢆ⾜࠸ࠊ100 ಸ㧗࠸άᛶࢆᣢࡘ᪂つ㜼ᐖ๣ࡢ๰〇࡟ᡂຌࡋࡓࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
◊✲ㄽᩥࠊ⥲ㄝࠊⴭ᭩࡞࡝ࢆከᩘⓎ⾲ࡋ࡚࠾ࡾࠊ◊✲άືࡣάⓎ࡛࠶ࡿ࡜ゝ࠼ࡿࠋࡲࡓࠊ໭ᾆᩍᤵࡀ
ᅜෆእࡢᏛ఍࣭ࢩ࣏ࣥࢪ࣒࢘➼࡛ࢤࢫࢺࢫࣆ࣮࣮࢝࡜ࡋ࡚ከᩘࡢㅮ₇ࢆ⾜ࡗ࡚࠸ࡿࡇ࡜ࡣࠊෆእ࠿ࡽ㧗
࠸ホ౯ࢆཷࡅ࡚࠸ࡿࡇ࡜ࡢド࡛࠶ࡿ࡜⪃࠼࡚࠸ࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣࠊ2 ᅇ⏕๓ᮇࡢ≀⌮໬ᏛϨ㸦㔞Ꮚ໬Ꮫ㸧ࠊ๰⸆≀⌮໬Ꮫ₇⩦ 1ࠊ3 ᅇ⏕๓ᮇࡢ⸆Ꮫ
ᑓ㛛ᐇ⩦Ϩ㸦ศᏊ㌶㐨ἲィ⟬ᐇ⩦㸧ࢆᢸᙜࡋ࡚࠸ࡿࠋศᏊࡢᵓ㐀࣭཯ᛂ࣭ᛶ㉁ࡉࡽ࡟ࡣࢻࣛࢵࢢࢹࢨ࢖
࡛ࣥ㔜せ࡞ᙅ࠸ศᏊ㛫┦஫స⏝ࢆ⌮ゎࡍࡿࡓࡵࡢᇶ♏࡜ࡋ࡚ࡢ㔞Ꮚ໬Ꮫࢆศ࠿ࡾࡸࡍࡃㅮ⩏ࡋ࡚࠸ࡿࠋ
ᤵᴗࡣࠊ㝶᫬ᑠࢸࢫࢺࢆ⾜࠸₇⩦࡜࠶ࢃࡏ࡚ࠊ⌮ゎᗘࢆᢕᥱࡋ࡞ࡀࡽ㐍ࡵ࡚࠸ࡿࠋࡲࡓࠊศᏊ㌶㐨ἲィ
⟬ᐇ⩦ࢆᥦ౪ࡋࠊㅮ⩏ࠊ₇⩦ࠊᐇ⩦ࢆ⤌ࡳྜࢃࡏ࡚⌮ゎࡀ῝ࡲࡿࡼ࠺࡟ᕤኵࡋ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸Ꮫ㒊Ꮫ⏕࡟ࡣࠊ᭱ึ࡟ 3 ࣨ᭶⛬ᗘࡢ㛫࡟㞟୰ⓗ࡟ศᏊືຊᏛἲ࡜ศᏊ㌶㐨
ἲࡢ⌮ㄽࡢᏛ⩦࡜ィ⟬₇⩦ࢆㄢࡋࠊᇶᮏⓗ࡞▱㆑࡜ᢏ⾡ࢆ⩦ᚓ࡛ࡁࡿࡼ࠺࡟ࡋ࡚࠸ࡿࠋࡑࡢᚋ࡟◊✲ㄢ
− 328 −
㢟ࢆ୚࠼ࠊㄢ㢟࡟ᐦ᥋࡟㛵㐃ࡍࡿㄽᩥࢆཧ⪃࡟ࡋ࡚ࠊࡉࡽ࡟ㄢ㢟◊✲㐙⾜࡛ᚲせ࡜࡞ࡿಶูලయⓗ࡞▱
㆑࡜ィ⟬ᡭἲࢆ⩦ᚓ࡛ࡁࡿࡼ࠺࡟ࡋ࡚࠸ࡿࠋࡑࡢᚋࡣྛ⮬ࡢⓎ᝿࡟ᇶ࡙࠸࡚ࠊ⮬⏤࡟◊✲ࢆ⾜࠺ࡼ࠺࡟
ᣦᑟࡋ࡚࠸ࡿࠋẖ㐌ࢢ࣮ࣝࣉࢭ࣑ࢼ࣮࡟࠾࠸࡚ྛ⮬ࡀ◊✲ࡢ㐍ᤖ≧ἣࢆሗ࿌ࡋࠊ࣓ࣥࣂ࣮඲ဨ࡟ࡼࡿ㆟
ㄽࢆ㏻ࡌ࡚◊✲ࡢ㐍ࡵ᪉ࢆᣦᑟࡋ࡚࠸ࡿࠋ୍᪉ࠊ㐌 1 ᅇ㞧ㄅ఍࡛ྛ⮬ࡢㄢ㢟࡟㛵㐃ࡋࡓㄽᩥ⤂௓ࢆㄢࡋࠊ
᭱᪂ࡢ◊✲ືྥࢆᢕᥱࡍࡿ࡜࡜ࡶ࡟ࠊ௚ࡢ࣓ࣥࣂ࣮ࡢㄽᩥ⤂௓ࢆ⪺࠸࡚ᖜᗈࡃ᭱᪂ࡢ◊✲ᡂᯝࢆᏛࡪࡇ
࡜ࡀ࡛ࡁࡿࡼ࠺࡟ࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊࣉࣞࢮࣥࢸ࣮ࢩࣙࣥ⬟ຊࢆྥୖࡉࡏࡿࡓࡵ࡟ࠊࢢ࣮ࣝࣉࢭ࣑ࢼ࣮
࡛ࡣࣃ࣮࣏࣡࢖ࣥࢺཎ✏ࢆసᡂࡋ࡚Ⓨ⾲ࡍࡿࡇ࡜࡟ࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ࡘ࠸࡚ࡣࠊᏛ⏕ࡢᤵᴗホ౯ࡢ⤖ᯝࢆཧ⪃࡟ࡋ࡚ᨵၿࢆᅗࡗ࡚࠸ࡿࠋ◊✲ᐊ࡜ࡋ࡚ࡣࠊ
་⸆ရ⌮ㄽタィᏛㅮᗙศࢆྵࡵ࡚ࠊࡇࢀࡲ࡛࡟ಟኈㄢ⛬ 5 ྡ㸦࠺ࡕᅾᏛ୰ 1 ྡ㸧ࠊ༤ኈㄢ⛬ 1 ྡ㸦ᅾᏛ
୰㸧ࡢᏛ⏕ࢆཷࡅධࢀ࡚ࡁࡓࠋ◊✲ᐊ࡛ࡢᩍ⫱ࡣࠊ᪩ࡅࢀࡤಟኈ 1 ᖺࠊᶆ‽ⓗ࡟ࡣಟኈ 2 ᖺ࡛Ꮫ఍Ⓨ⾲
ࢆ⾜࠺ࡇ࡜ࢆ┠ᶆ࡟ᣦᑟࡋࠊ඲ဨࡇࢀࢆ㐩ᡂࡋ࡚࠸ࡿࠋࡉࡽ࡟ࠊࡇࢀࡽࡢⓎ⾲࡛Ꮫ⏕ࡢ࡯࡜ࢇ࡝඲ဨࡀ
࣏ࢫࢱ࣮㈹࡞࡝ࢆཷ㈹ࡋࠊ࠺ࡕ 2 ྡࡀಟኈㄢ⛬ᅾᏛ୰࡟ㄽᩥ࡜ࡋ࡚ࡲ࡜ࡵ࡚ᅜ㝿ㄅ࡟ᥖ㍕ࡉࢀࡓࠋࡲࡓࠊ
ᅜ㝿఍㆟࡛ࡢⓎ⾲ࢆ᥎ዡࡋ࡚࠾ࡾࠊࡇࢀࡲ࡛࡟ᅾ⡠ࡋࡓ㝔⏕ࡢ࠺ࡕ 3 ྡࡀᅜእ࡛㛤࠿ࢀࡓᅜ㝿఍㆟࡛Ⓨ
⾲ࢆ⾜ࡗࡓࠋಟኈㄢ⛬ಟ஢⪅ࡣࠊ኱Ꮫຓᡭ㸦㸯ྡ㸧ࠊ௚◊✲⛉༤ኈㄢ⛬Ꮫ⏕㸦1 ྡ㸧ࠊ〇⸆௻ᴗ◊✲⫋㸦1
ྡ㸧ࠊ⸆๣ᖌ㸦1 ྡ㸧࡜ࡋ࡚ά㌍ࡋ࡚࠸ࡿࠋࡇࢀࡽࡢࡇ࡜ࡣࠊᮏศ㔝ࡢᩍ⫱࡜◊✲ࡀᖜᗈࡃ࠿ࡘ㧗࠸ࣞ࣋
ࣝ࡟࠶ࡿࡇ࡜ࡀホ౯ࡉࢀࡓド࡛࠶ࡿࠋ
㸦ཎⴭ㸧
1. A combined effective fragment potential–fragment molecular orbital method II. Analytic gradient and
application to the geometry optimization of solvated tetraglycine and chignolin, Takeshi Nagata, Dmitri G.
Fedorov, Toshihiko Sawada, Kazuo Kitaura, Mark S. Gordon, J. Chem. Phys. in press.
2. Role of the key mutation in the selective binding of avian and human influenza hemagglutinin to sialosides
revealed by quantum-mechanical calculations, Toshihiko Sawada, Dmitri G. Fedorov, Kazuo Kitaura, J. Am.
Chem. Soc., in press.
3. Binding of influenza A virus hemagglutinin to the sialoside receptor is not controlled by the homotropic
allosteric effect, Toshihiko Sawada, Dmitri G. Fedorov, Kazuo Kitaura, J. Phys. Chem. B, in press.
4. Energy gradients in combined fragment molecular orbital and polarizable continuum model
(FMO/PCM) calculations, Hui Li, Dmitri G. Fedorov, Takashi Nagata, Kazuo Kitaura, Jan H. Jensen, and
Mark S. Gordon, J. Comp. Chem., 31, 778-790 (2010).
5. Fragment molecular orbital study of the electronic excitations in the photosynthetic reaction center of
Blastochloris viridis, Tsutomu Ikegami, Toyokazu Ishida, Dmitri G. Fedorov, Kazuo Kitaura, Yuichi Inadomi,
Hiroaki, Umeda, Mitsuo Yokokawa, Satoshi Sekiguchi, J. Comp. Chem., 31, 447-454 (2010).
6. Open-shell formulation of the fragment molecular orbital method, Spencer R. Pruitt, Dmitri G. Fedorov,
Kazuo Kitaura, Mark S. Gordon, J. Chem. Theo. Comp., 6, 1-5 (2010).
7. Ligand shape emerges in solvent dipole ordering region at ligand binding site of protein, Katsumi Murata,
Naoya Nagata, Isao Nakanishi, Kazuo Kitaura, J. Comp. Chem., 31, 791-796 (2010).
8. Fragment-molecular-orbital-based ab initio NMR chemical-shift calculations for large molecular systems,
Satoshi Yokojima, Qi Gao, Dmitri G. Fedorov, Kazuo Kitaura, Minoru Sakurai, Shinichiro Nakamura, J.
Chem. Theor. Comp., 6, 1428-1444 (2010)
9. Importance of the hybrid orbital operator derivative term for the energy gradient in the fragment molecular
orbital method, Takeshi Nagata, Dmitri G. Fedorov, Kazuo Kitaura, Chem. Phys. Lett., 492, 302-308 (2010).
10. SDOVS: A solvent dipole ordering-based method for virtual screening, Katsumi Murata, Naoya Nagata, Isao
Nakanishi, Kazuo Kitaura, J. Comp. Chem., 31, 2714-2722 (2010).
11. Systematic Study of the Embedding Potential Description in the Fragment Molecular Orbital Method, Dmitri
G. Fedorov, Lyudmila V. Slipchenko, Kazuo Kitaura, J. Phys. Chem. A, 114, 8742-8753, (2010).
12. Amide–ʌ Interactions between Formamide and Benzene, Yumi N. Imai, Yoshihisa Inoue, Isao Nakanishi,
Kazuo Kitaura, J. Comp. Chem., 30, 2267-2276 (2009).
13. Cluster Hydration Model for Binding Energy Calculations of Protein-Ligand Complexes, Kaztumi Murata,
Dmitri G. Fedorov, Isao Nakanishi, Kazuo Kitaura, J. Phys.Chem B, 113, 809-817 (2009).
14. Design of peptide-based inhibitors for Human Immunodeficience virus typr 1 strains resistant to T-20,
Kazuki Izumi, Eiichi Kodama1, Kazuya Shimura, Yasuko Sakagami, Kentaro Watanabe, Saori Ito, Tsuyoshi
Watabe, Yukihiro Terakawa, Hiroki Nishikawa, Stefan G. Sarafianos, Kazuo Kitaura, Shinya Oishi,
Nobutaka Fujii, Masao Matsuoka, J. Biol. Chem., 284, 4914-4920 (2009).
15. Structural and interaction analysis of helical heparin oligosaccharides with the fragment molecular orbital
method, Toshihiko Sawada, Dmitri G. Fedorov, Kazuo Kitaura, Int. J. Quantum. Chem. , 109, 2033-2045
− 329 −
(2009).
16. Binding Free Energy Calculations of Adenosine Deaminase-inhibitor and Effects of Methyl Substitution in
Inhibitors, Takahiro Kosugi, Isao Nakanishi, Kazuo Kitaura, J. Chem. Inf. Model., 45, 615-622 (2009).
17. Excited state geometry optimizations by the fragment molecular orbital based time-dependent density
functional theory, Mahito Chiba, Dmitri G. Fedorov, Takeshi Nagata, Kazuo Kitaura, Chem. Phys. Lett., 474,
227-232 (2009).
18. Derivatives of the approximated electrostatic potentials in the fragment molecular orbital method, Takeshi
Nagata, Dmitri G. Fedorov, Kazuo Kitaura, Chem. Phys. Lett.,475, 124-131 (2009).
19. A Combined Effective Fragment Potential - Fragment Molecular Orbital Method. I. The Energy Expression
and Initial Applications, Takeshi Nagata, Dmitri Fedorov, Kazuo Kitaura, and Mark S. Gordon, J. Chem.
Phys., 131, 024101-024112 (2009).
20. X-ray crystallographic study of HIV-1 fusion inihibitor with the gp41 S138A substitution, Tsuyoshi Watabe,
Yukihiro Terakawa, Kentaro Watanabe, Hiroaki Ohno, Hiroaki Nakano, Toru Nakatsu, Hiroaki Kato, Kazuki
Izumi, Eiichi Kodama, Masao Matsuoka, Kazuo Kitaura, Shinya Oishi, Nobutaka Fujii, J. Mol. Biol. 392,
657-665 (2009).
21. Structural insight into human CK2Į in complex with the potent inhibitor ellagic acid, Yusuke Sekiguchi,
Tetsuko Nakaniwa, Takayoshi Kinoshita, Isao Nakanishi, Kazuo Kitaura, Akira Hirasawa, Gozoh Tsujimoto,
Toshiji Tada, Bioorg. Med. Chem. Lett., 2920-2923 (2009).
22. Analytic gradient for the adaptive frozen orbital bond detachment in the fragment molecularorbital method,
Dmitri G. Fedorov, Pavel V. Avramov, Jan H. Jensen, Kazuo Kitaura, Chem. Phys. Lett., 477, 169-175
(2009).
23. The role of the exchange in the embedding electrostatic potential for the fragment molecular orbital method,
Dmitri G. Fedorov, Kazuo Kitaura, J. Chem. Phys., 131, 171106-171109 (2009).
24. Structure of human protein kinase CK2D 2 with a potent indazole-derivative inhibitor, Tetsuko Nakaniwa,
Yakayoshi Kinoshita, Yusuke Sekiguchi, Toshiji Toda, Isao Nakanishi, Kazuo Kitaura, Yamato Suzuki,
Hiroaki Ohno, Akira Hirasawa, Gozoh Tsujimoto, Acta Cryst., F65, 75-79 (2009).
25. Cl-S interactions in Protein-Ligand Complexes, Yumi N. Imai, Yoshihisa Inoue, Isao Nakanishi, Kazuo
Kitaura, Protein Science, 17, 1129-1137 (2008).
26. Ab initio fragment molecular orbital study of ligand binding to human progesterone receptor ligand-binding
domain, Takanori Harada, Kenji Yamagishi, Tatsuya Nakano, Kazuo Kitaura, Hiroaki Tokiwa, NaunynSchmiedeberg’s Arch Pharmacol ., 377, 607–615 (2008).
27. Polarizable continuum model with the fragment molecular orbita-based time-dependent density functional
theory, Mahito Chiba, Dmitri G. Fedorov, Kazuo Kitaura, J. Comp. Chem., 29, 2667-2676 (2008).
28. Theoretical Analysis of Intermolecular Interaction Effect on the Excitation Energy of Organic Pigments;
Solid State Quinacridone, Hiroo Fukunaga, Dmitri G. Fedorov, Mahito Chiba, Kazumi Nii, Kazuo Kitaura,
J.Phys.Chem. A ,112, 10887-10894 (2008).
29. Covalent bond fragmentation suitable to describe solids in the fragment molecular orbital method, Dmitri G.
Fedorov, Jan H. Jensen, Ramesh C. Deka, Kazuo Kitaura, J. Phys. Chem. A, 112, 11808-11816 (2008).
㸦⥲ㄝ㸧
1. Cl-S interactions in protein-ligand complexes, YN. Imai, Y Inoue, I. Nakanishi, K. Kitaura, QSAR &
Combinatorial Science 28, 869-873 (2009).
2. ࣇࣛࢢ࣓ࣥࢺศᏊ㌶㐨ἲ࡟ࡼࡿࢱࣥࣃࢡ㉁㸫ࣜ࢞ࣥࢻ」ྜయࡢ┦஫స⏝ゎᯒ࡜࢔ࣇ࢕ࢽࢸ࢕ィ⟬,
௰すຌ, ໭ᾆ࿴ኵ, ᐇ㊶㸸࢖ࣥࢩࣜࢥ๰⸆ࡢ᭱๓⥺㸦㑇ఏᏊ་Ꮫ MOOK14㸧,➉⏣-ᚿ㮚┿⏤Ꮚ, ᱵᒣ
⚽᫂⦅, ࣓ࢹ࢕࢝ࣝࢻࢗ, pp. 84-89 (2009).
㸦ⴭ᭩㸧
1. Theoretical Background of the Fragment Molecular Orbital (FMO) Method and Its Implementation in
GAMESS, D.G.Fedorov, K.Kitaura, D.G.Fedorov, In The Fragment Molecular Orbital Method: Practical
Applications to Large Molecular Systems, D.G.Fedorov and K.Kitaura (Eds.), CRC press (Boca Raton), pp.
5-36 (2009).
2. The Fragment Molecular Orbital-Based Time-Dependent Density Functional Theory for Excited States in
Large Systems, M.Chiba, D.G.Fedorov, K.Kitaura, In The Fragment Molecular Orbital Method: Practical
Applications to Large Molecular Systems, D.G.Fedorov, K.Kitaura (Eds.), CRC press (Boca Raton), pp.
91-118 (2009). 3. Detailed Electronic Structure Studies Revealing the Nature of Protein-Ligand Binding, I.Nakanishi,
D.G.Fedorov, K.Kitaura, In The Fragment Molecular Orbital Method: Practical Applications to Large
Molecular Systems, D.G.Fedorov, K.Kitaura (Eds.), CRC press (Boca Raton), pp. 171-192, (2009).
− 330 −
4. FMO ἲ࡟ࡼࡿ኱つᶍ⏕యศᏊ㔞Ꮚ໬Ꮫィ⟬, ໭ᾆ࿴ኵ, ィ⟬ຊᏛࢩ࣑࣮ࣗࣞࢩࣙࣥࣁࣥࢻࣈࢵࢡ,
᪥ᮏィ⟬ᕤᏛ఍࣭ィ⟬⛉Ꮫ᣺⯆㈈ᅋ⦅, ୸ၿ, pp. 139-147 (2009).
5. ศᏊࣔࢹࣜࣥࢢ࡜ࢩ࣑࣮ࣗࣞࢩࣙࣥ, ௰す ຌ, ໭ᾆ࿴ኵ, ࢖ࣥࢩࣜࢥ๰⸆⛉Ꮫ, ⸨஭ಙᏕ, ㎷ᮏ㇦
୕ዟ㔝ᜤྐ⦅ி㒔ᘅᕝ᭩ᗑpp. 95-124 (2008).
− 331 −
Ơ ÊJ]jHO°Ǹ
ĪħȎŬïÁâȏǺ‚÷Ȏ&) /'7ȏȎ ž“ȏ
ĴÐ ċ ĸ IJŮ
ĴÐ ċľæï¿ĴÐ ċËæïæïȂŬïƗƁƍƈ
ÁâǏƊ¡†
­ĪħȎÁâȎĄïȏȏŠĭǩȎ" 0ȏȎ ž“ȏ
ĴÐ ċ ĸ IJŮ
Ċğ¦ċƒăæï¿Ċğ ċËæïæïȂĄïƁƍƈÁâ
ǏƊ¡†
¸ĪȎÁâȎŬïȏȏĺDZŏŖȎ("6 .)9ȏȎ ž“ ǟƧȏ
ĴÐ ċ ĸ IJŮ
Ċğ ċDzæï¿Ċğ ċËæïæïȂŬïƁƍƈNjñǣïĊğ ċÁâÉ
Æē
ŧ“¸ĪȎÁâȎŬïȏȏāƾƲƼȎ3.% 4)9ȏȎ ž“ ǟƧȏ
ĴÐ ċ ĸ IJŮ
Ċğ ċĂāæï¿Ċğ ċDzæïæïȂŬïƁƍƈÁâǏƊ¡†
ŧ“¸ĪȎÁâȎŬïȏȏ”ƷŽƙȎ" ./ȏȎ ž“ ǟƧȏ
ĴÐ ċ ĸ IJŮ
Ċğ ċ¼śǫæï¿Ċğ ċDzæïæïȂŬïƁƍƈNjñǣïĊğ ċÁ
âÉÆē
ŧñ¸ĪȎÁâȎǠïȏȏĵĿĩijȎ". "ȏ
Ȏ ž“Ȏŧ“¸Īȏ
ŧñ¸Īȏ
ĴÐ ċ ĸ IJŮ
Ċğ ċDzæï¿Ċğ ċËæïæïȂǠïƁƍƈÁâǏƊ¡†
ŧñ¸ĪȎÁâȎŬïȏȏýøŏijȎ
5 .ȏȎ ž“ȏ
ĴÐ ċ ĸ IJŮ
Ċğ ċƎÏȉæï¿Ċğ ċDzæïæïȂŬïƁƍƈÁâǏƊNjñǣïĊ
ğ ċÁâÉÆē
hOYHȎÁâȎƶïȏȏ ۀǫĐȎ$ /)9ȏȎ ž“ȏ
ĴÐ ċ ĸ IJŮ
Ċğ ċǢŴæï¿Ċğ ċDzæïæïȂƶïƁƍƈÁâǏƊ¡†
hOYHȎÁâȎƶïȏȏ ǖDZûîȎ5, .ȏȎ ž“ȏ
ĴÐ ċ ĸ IJŮ
Ċğ ċæȁĎƎæï¿Ċğ ċDzæïæïȂƶïƁƍƈÁâǏƊ¡† − 332 −
Ɓ ƍ'Ňƿ
ƠÊJ]jHO°Ǹ(`X;(1"7ŮŦ;¢'DZÑȎǯ–ì3Sw_Hǘ»
ÊŦ$#ȏ'ȅ.65MOVk©™Ȏƛƪ7(ŮŦ¢™ȏ;ĝÞïŸ%¬ňƔ
Ů
Ï'(5;MOVk'(5"
ů7ęůƁƍ;ƹ
Ŭǂ7ÝƃƁƍ
4*8;¶ƶƈï%
7đƁƍó!ǾŶ
7ABdLzaOJ]k\TX
!(ű€'ƁƍƦ%46Ƶƌ8Ʈæ$ŮÏƈï'ƀǓ;ż‰›ůĝÞ"ǁţ
5™Ɨ»KwbozS»7"Ëĵ%'ĝÞ;ǂŀ7Ģƺ'ǾŶ2ƹ
7 J ]k\TX¾ƶÑWzSfzO'ǾŶ
ĠǾŶ
7J]k\TX¾ƶÑWzSfzO( ¾ƶÑŜ‘ĬĶĝÞ
¾ŵůÄ*{Ʊů ; %7ʼn$ĝÞ"ƠÊWzSfzO!6Ɓƍ
'ķ§Ə"¾ŵ'ūß5%({ƱƄ•";$";Żĥ
7
Ǵ ƚÅę_Szw'ǂŀ"ĕŮŦ%47Ů°ǂƞǚ‡ş
ŽǿƄ•'ŶǬ%—ʼn$Ŧǘŭà€%Ĩ¯8
Ê(ÛáĕŮŦ$#%4
Ů°ǂ;Ç
7''µ
7ŭà+'ǕƳ;ǜŞ71%(
'Ů°ǂŌň;m[Sz7"ėƿ!6'´ŐȄ"
Ů°ǂƞǚ'‡ş
}Èō!7Ġ(ŭàǕƳŦǘ'ĹŌ»ÊŦ;ùǔ"ıƀ'Ů°ǂƞǚ%
Í.87ǴƚÅę;ǂŀŮÊğ$#'S@e'ǴƚÅę"(ijƂ%½±!7_
Szw%4
ňğ8
7";ǀ.'ƀǀ;ęů
“Ğ'
ĹŌ»ÊŦ5Ů°ǂƞǚ;‡ş7įŕ;ƂƎūÜ('įŕ'Džƒ¹Ū'Ì
|3ŃŦ%47çŤŦÊğƞǚ'‡ş+'ęů$#;ƹ
7
Ƭ ǘÊğǴƚc=jrz"rwƬǘňǦ"'Ȁǧǂŀ
IrQurwƬǘ(ƛƪƭ;ňğ7ƿ$Ƭǘ!6MIZs–Ǭ3°ìNjǓ%
Ɛ{7(ƐˆlTQwNnz"
¤IrQurwƬǘ('»Ê
Ŧ'ơƉ!6ٙƭ€'íÜŒ(ƛƪ3ƛƪ«ý×ð'ƋȈ%4
ų$7'
í Ü Œ ( ƞ ǚ " !" ƞ ǚ % 4 7 '
!" ƞ ǚ % Í . 8 7 Ǵ ƚ " ²Ĕ8
ķ Ǣ Ë ñ 8 #$%&$%&!%!
'*#+'$:'$$ (Ýǘ"7IrQurwƬǘ'»ïňǦ^rCzMpw"'ùę
ȀŸ2Í1Řěij5%8òȊŸ%ƂNj8'(ýī'ŮŦƋ'/!
Ġ(J]kǂǎ8ȔȕƋ'ŽłŮŦ%ù'Ǵƚc=jrz'ƗƠǂŀ;
ƹ'ƟŁȑȔ'LdS@e%°Ȉ!Ƭǘ^rCzMpw"'Ȁǧij
5%$ūÜ('Ɓƍ;Ŷÿ
7"ƥ58
Hǘ%
ǂŀ
-"<#'ԅȈ%"
ėȇƬƨǵ!
7>qGYwǵ3'njü™'ÊğǴƚ
4*tQeSzSw_
ŽłŮŦ€'°Ć;ǐ,7"!Ƭǘ%47MIZs–ǬlF[Pk;
7
ƶŦǿż‰›ůƶŦyŊŸǿż‰›ů'\TXvzHǂŀ
− 333 −
ƽī'ų$7¾ƶÑ;œů7"Àũ!ů"%(Ǚ5$Ĺô$›ůǀ5
87"71¾ƶÑ'Âȃ$Ɲ/Ê:;Ŭǂ7"(Ƿƿ!7'ƶ
Ŧǿż‰›ů'ı%ƀ58
72'(¾ƶÑ'Ŝ‘ĬĶ%œůƅĘ$#"
LJǞ8
'¾ƶÑ'Ŝ‘ĬĶ%ù©
8
7:!($.ļƀ'ż‰›ůíÜ7Âȃ2ƥ587!Ġ
7©
(ǖÙŕŽIJĽ¾ƶĝÞQwSz%4
8
7©
ƓŬ8
'ż‰›ůLJǞ
7IJĽÚ«!Ǘã
'¾ƶÑ'Ŝ‘ĬĶWzS;2"%;<= WzSfzO€'
»ÊŦtfs'¾ƶÑWzS;ƠÊJ]k\TX¾ƶÑWzSfzO;ňƔ
8;2"%ƶŦż‰›ů_Szw'ǂŀ;ƹƟŁ"
ĥñ8¾ƶÑ%ù
8"ż‰›ů;ǙÂȃ'7¾ƶÑ;‡ş7įŕ'ǾŶ%ğ·.
¢'ĜƦ%ù
®į87ƶ'rOX;ƓŬż‰›ů'Èƫě'7ƶ;ÞÎ
7ABdMOVk
6ġć'ǾŶ%ğ·
ƁƍŘº%ù7ƯąţńyLjž
Ú«ä'ï•yMwhNAkƑ!Ǻ‚ĪħyŠĭŠĪħJOXObzFz"
ǒš;ƹ
7".Ġ'ǾŶ
ǿƘȓ¥Ø>HQO8
åī
7J]k\TXLzaO(Ú«ä5ċ
6'į;ñĻŸ%ǒšyĶƕ"
7"52Ġ'ƁƍŅƣ%ù7Ljž(ņ1
¯ť$#;
ȋ"DŽ7
ĪƩ'Ňƿ
¿ŅòƤÄ*æïȂĪƩȖđ°Ǹ(ó"
"ĝÞƗ'ƀǓ;Ĥ
¡âǏƊ'ïŮ5dzĀ872"2
$ïŮå^@E@wcDiV?HO'úǽõ"
œ1587Ɗď'ƀǓ3Ģƺ(ŮŦïƗyĝÞïƗ"2%čƤē!7Ō•;~
7.đƁƍó!(å'Ɓƍó!Ǿ£8 7ȆNJ•
ȎƯ5'Ɓƍ«ö%Ȁ
ǧ'7þī'ǑĬ;ljƛ%ǎ/ǂƜ7ȏ"(ǭOS@s'ǥÞ
ȎȀǧ°Ǹ'
ȆNJ5ĥñ8Ļǿ%Ŷƻ8ķĮ'ǑĬ;čƜ7ȏ;ƹ
78
(ĉ%ķĮ'ĝÞ;ġ%¨87""2%æǹ'ĝÞ;ǎ/ǂǶ7^@E@wcDi
V?HO"ïÕ'ěǘ%2Êư7OS@s!ïŮ+'ĪƩ%2ķǮ!7"ƥ
7.Ɓƍ'ǩĦŨŔ;ÞÎ
OSTc3'ïŮ"džǑ;ƹQjZz(őǨ'
2'"őĸ'2'6ŒǝŸ.".«ö'2';´Ʀ!ƁƍĚ4%ǩ.
.6ÞÎ7«ö$ßÊ(ĒƦ!Ŷƻ7"!ƁƍŘº'ǩÿ; 7
ĪƩŘº%ù7ƯąţńyLjž
đ°Ǹ'ŧǼ"
^@E@wcDiV?HOQwSz«'ŬïyƶïyĝÞïƗ'Ɓ
ƍóǿ'ŒřŹ<!ċȒØ'ïŮŶƻ•;(1ċȑØ'hOYHŶƻ•
4*
− 334 −
QwSz©™!ǒĈ;ģQjZz}ñĻ!ċ%šďǾ£871^@E@w
cDiV?HOȀǧ°Ǹ;€Ė%ķĮ'ƁƍÞÎ%ǃ87Ō•(å. ċ ĸ
5òİ
7 > euIqk%46QwSz«!', Ž'ïŮ>lrF'gO
XwY@U'fsrwcqwO'_r%Ƙȓxĸ'ƁƍŲï;ƞȊ
ïŮ%2Ō•~58
6đ°Ǹ'
7'4%đ°Ǹ(śä%Ǥů7ƁƍƦ'Ʃğ%å
'òƣ7
Ȏ Ãƴȏ
"?@ F@ J'++!@ Q@ +@ W@ ' '&!$'@ QX &''*+![!" *
$?\$+?*+?$:!"'$:<%+!$?\:'!!$:'+!*$@
]
+'@Q@\'#'$&!@>@J'++!@Q@>^!'+$?@>@+@W@Q!&''@J@'
'&!$'@QX%&$!"!*''#$!$:$?:?]'#%'+&_'#"$
:'+!*$@]
Q![?+'!@ W@ >''^'@ Q@ `&*^@ @ '&!$'@ Q@ ' +@ WX
&#"+!*''#$!$:!%!!'+<$:'+!*$@]
q!$&!?'@ {@ >^!'+$?@ >@ +'@ Q@ +@ W@ ' '&!$'@ QX
]_! ''#$!$ : %'+ => :'!# \'$ $|?* ' $?\$+'+
!:'+!:'+!*$@]
>'?'@ >@ {''!$&!@ {@ >''\@ Q@ +@ W@ '&!$'@ Q@ J!+@ @
' ^?+$?@ >X +" %"'!"]\'$ +& : *%+!" $!"'!"
%'+&_'#$ ' !+$ '%%!*'+! + ''#$!$ : **+' *'* :'+!*$@]
{''!$&!@{@+'@Q@'&!$'@Q@'+@WX;?"]+'"+!+'*+!
%!*+! : *&!*'@ "!* ' %&''*"!*' '+' ! ' !+"'+
:'_^F!!:'+!*$@!]!
J'++!@ Q@ >''^'@ q@ '&!$'@ Q@ ' +@ WX WQ}Q~W=F}Q
*&!*'$+?*+?$'*&$$:+_^''#$$q?*!**!$<$@
`
]`
Q!#'@{@W&!"![?@;@J'++!@Q@>^!'+$?@>@+'@Q@+@W@'
'&!$'@ QX '+& ' [#]*'+'#[ +'\!* %'+&_'# %!*+!
$q?*!**!$<$@`]`
''@ Q@ '_'$&!'@ W@ '&!$'@ Q@ >'^?*&!@ >@ ' $'!@ >X
&''*+!['+! : '%&']%&$%&"?*?+'$ !$[#$ : >€%'$'
"!!''$!++
@]
− 335 −
;![@ ;@ `&*^@ Q@ +@ W@ J'""$+@ @ '?$$]F@ @
J'$$@ @ J!@ =@ '\!$@ @ ' `&*^@ X >& ?$ :
+_^ ''#$$ : ?*!'+!" *&'!$$ ! *'!'$*?' !$'$ Q
F!$#$+@]
;![@ ;@ J'#$@ q@ '!@ q@ q'^@ @ '&!$'@ Q@ `'&"@ Q@
`&*^@@'+@WX';F''+'\'$:'+!"!*'!'+$|?*$
]]*?+$+'+?$':?+?%$%*+$*+'>%@]
'&!$'@ Q@ +@ W@ ‚??!*&!@ Q@ >''\@ Q@ ' J!'^'_'@ QX : %$+'+! ' ''#$!$ : *?' +_^$ !!" !$'$$ '
?"$q?*!**!$<$@;
];
J'#$@q@;![@;@'!@q@'&!$'@Q@`'&"@Q@`&*^@@
' +@ WX >$ : !$+!"'+!" *&'!$$ : '+!"!* '!'+! _
€+$!$+';F:'+!*$@]
}?^!@ <@ W&!\?#'@ >@ ' '&!$'@ QX q_ ^ +&$ : %&+#%
%!*+!:"+#%'+':'+!*$@]
>'^''\@ Q@ W&!"![?@ ;@ +'@ Q@ +@ W@ ' '&!$'@ QX
&''*+!['+! ' *'$$!:!*'+! : '$ ?" !+'*+!$ :'+!*$@]
>''^'@ Q@ Q!#'@ {@ +@ W@ ' '&!$'@ QX '#$!$ : ' !%!
\!$#+&$!$ %+! :'!# ' %&$%&!%! $+?*+?' '!'+!$ :'+!*$@]
`&*^@@+@W@{+?^?!@ƒ@;„€'!@‚ƒ@?^'$@@W*&!\@
‚@'}$!*@QXF!!:'+!*$$+'+"!$:+&''#$!$:!%!$Q+&$
QF!
@]
‚^$@ƒ@;![@;@`&*^@@J'""$+@@+@W@!^$$@@
' '\!$@ X <"!W*' ' F!*?*+ %'*^'" : %\]
''#$!$:$%*!:!*@$'"!$:+&"F!!:'+!*$
@]
{''!$&!@ {@ J'++!@ Q@ +'@ Q@ +@ W@ ' '&!$'@ QX ][#
%!*+!" %++!' ?\$ : +& *&!*' +'$:'+! %'++ :
$?\$+'+]%?*+%'!$F!!:'+!*$
@!]!
`&*^@ @ `&*^@ Q@ '_'$&!'@ W@ ;![@ ;@ '&!$'@ Q@ '
^@ Q@ '@ <@ J'""$+@ @ ' +@ WX W#$+$ \!"#
'%%'*&$ ' %'+&_'# +$ : !$+!"'+!" *'!'$*?' !$'$ Q
F!$#$+
@
]
'_'$&!'@ >@ '_'$&!'@ W@ >''^'@ @ Q?'!@ Q@ {'@ Q@ ?+?@
− 336 −
qJ@ <^&$'@ ;W@ '&!$'@ Q@ W'+&@ q@ ' `'' JX ;'! $&?::!"
'+&?+!:+\'+$<$@]
W&!"![?@;@'^!@Q@}^?'@W@+@W@''&!$'@QX€+'*+!'
''#$!$ : *&!*' !:!*'+! %'++$ ! ?" %+ & :
Q@]
J'$&!+@@>^!'+$?@>@'_'@W@{$&!['_'@@}^?'@W@+@W@
''&!$'@QX%&$!''#$!$:"#*$#+'$:'$$!?^'#+!*
"$ : $+?*+?' ' :?*+!' *&''*+!['+! : "#*'$ '\&#
<$@]
J!'^'_'@ Q@ q!$&!&''@ J@ '&!$'@ Q@ ' }^''@ qX &''*+!['+!
' ?+!'# '$*'% : Wq ! !+' "$ @
]
W&!![?@ {@ J'++!@ Q@ +@ W@ ' '&!$'@ QX '![ '*+!
%'++$:%!*+!:?^_[#'+!*'*+!$:'+!*$@
]
>'^''\@ Q@ }^?'@ W@ +&@ Q@ >^!'+$?@ >@ +@ W@ ' '&!$'@ QX
q+_^''#$!$:'$?"!+'*+!$:'+!*$@
]
J'#$@ q@ ;![@ ;@ '!@ q@ J'@ `@ '&!$'@ Q@ `'&"@ Q@
`&*^@@'+@WX';F'%'+&"]$%*!:!*$|?*'+'\'$:
%+! :'!!$ ! ! '+!"!* '!'+! F!!:'+!*$ @ ]
J'$&!+@ @ >'^!"'_'@ @ W&!"'@ Q@ '&!$'@ Q@ ' Q'!+$?^'@ JX
Q!!"$!"!:!*'++%'++$!*'\&#'+$?"'*&'!$F!!:'+!*$@
!]!
{''!$&!@ {@ '^!@ Q@ ?++!"@ @ J'@ `@ ' '&!$'@ QX
!*+!:?"]+'"+!+'*+!+_^$:+&!+"'+!:*&!*'
'"!*$%'*$F!!:'+!*$@!]!
}^?'@W@{'''@>@J''…!'@Q@+&@Q@'+'#''@>@F^@@+@W@
' '&!$'@ QX +'$ '%%!" : "\' ''#$!$ : +'\!*
%'+&_'#$q?*!**!$<$@`]`
…!'@''&!$'@QXW#$+'+!*$?#:+#%$:%^'#+!*
++$\'$"!"&\&'%+!'*&!+*+?QF!
@
]
ƒ+?!*@@{'''@>@'&!$'@Q@'F^X!'+&!+'*+!€%'+!
:\!*&!*'%'+&_'#$'+_^$>$F!*&W*!@] − 337 −
'&!$'@ Q@ '^!@ Q@ +@ W@ J'++!@ Q@ J!'^'_'@ Q@ +&@ Q@
'+'#''@ >@ '_'$&!'@ W@ }^?'@ W@ >^!'+$?@ >@ ' {''!$&!@ {X
:!^!""$+!:'+&!+q?*!**!$<$@
;];
'_'$&!'@W@^'_$^!@@^'_$^'@Q@!$^!@@'+'#''@>@'
'&!$'@ QX !€ '! '*! !€ '+'\'$@ %"$$ %+ q?*!**!$<$@;];
J'$&!+@@{$&!['_'@@}^?'@W@?'@@+@W@''&!$'@
QX>&%+!:$'+?'$$'"'$$'$:'++#'*!'!'+!$!
?^'#+!*"$ƒ!%!<$@] J?'"@@J'@`@''&!$'@QX!*+!"F*%!+%$!?$_!+&
+_^ +%"# \'$ '! '*! !!*$ :'+!*$ @ ]
'_'$&!'@ W@ '_'$&!'@ >@ ?+'@ qJ@ <^&$'@ ;W@ `''@ J@ '
'&!$'@ QX %''+! %'!]_!$ '!]*\!'+!$ : $*!" +&
*'$%*!:!*'!]'*&!+*+?$!+'['"$:'+!*$
@
]
J?'"@@'_'$&!'@W@''&!$'@QXq_'!'*!!!*$\'$
$!?+_^+%"#:'+!*$@
]
W?"'@@{''!$&!@{@J'$&!+@@+@W@''&!$'@QX!%
$*!" $*& : %!*+!" "#*' $+?*+?$ : " €%$$!$ '+'
:'+!*$@] Q?+@@J'++!@Q@''&!$'@QX'#$!$:*$?\$+?*+?$:
+'\!**%?$_!+&!+&!::+"'!$"?%$:'+!*$
@]
'_'^!@ >@ `&*^@ @ '*&!@ >@ ?@ >@ }^'+@ W@ >''^'@ q@
>?'@ @ >$?…!+@ @ Q'!+$?^'@ J@ +@ W@ ' '&!$'@ QX
+!:!*'+! : *! !$?%+ \!"''+! \# !+"'+! :
$+?*+?]'*+!!+#'+!$&!%_!+&%'+&_'#''#$!$!W*!>*&@
]
‚?…!+'@ Q@ Q!&''@ J@ +@ W@ $'^!@ q@ ' '&!$'@ QX Q!!"
%^'#+!* "$ : ?^_ '! '*!$ ' $+%]*]\'$ '%%'*&
FQF!!:'+!*$@
W*&_'+[@ ]Q@ '?"'!@ @ q'*&@ @ ;'?'@ @ ' '&!$'@ QX
}\$!" +'\!* :?*+!$ '+ +& " $*' F! @ <
− 338 −
+&@ Q@ q'*&@ @ ?'@ @ +@ W@ ' '&!$'@ QX ?+!'#
&!$+#':?*+!'!%!*'+!$:%+!'!$'+&!*\!'+!$!
?^'#+$F!@<
ƒ!!%&?'&@ †@ >''^'@ W@ +@ W@ ='@ @ ' '&!$'@ QX >&
*'!+#:%+!!+'*+!+_^$+!!q?"'+!
!$$q;;$F!!:'+!*$@]
J?@@q"@;Q@{'''@>@&@@'_'$&!'@W@Q@@ƒ!"&?@F@
'&!$'@ Q@ W+?'+@ Q@ ' ;!$!@ X †!$q>  _ ?$ :
%'+&_'#!$?'!['+!@!+!"@%!*+!'*$+?*+!q?*!**!$<$
@`
]`
Q!#'@ {@ +&@ Q@ }^?'@ W@ {$&!['_'@ @ ' '&!$'@ QX W '
'?+'+!*"'+'+!'%'+&_'#*$+?*+!$q?*!**!$
<$
@`]`
}&@Q@{'''@>@J'++!@Q@+@W@''&!$'@QXW#$+'+!*''#$!$
: [#]*'+'#[ '*+! %'++$ ' %!*+! : !*\!'
\!"''+!%'+&_'#$&:Q@]
J?@ @ Q@ @ `?@ @ '&!$'@ Q@ W+?'+@ Q@ ' ;ƒ!$!@ X >_'
$*''\?+!!$!''%$:+&*q'+F!+*&
@
]
Q'$?!]q…'@ @ +@ W@ '?"?!@ <@ +@ Q@ '_'$&!'@ W@ Q!#'@ {@
@><@''&!$'@QXqW>'$*!%+]\'$%'+'+'\'$:
"$ _!+& +'\!* %'+&_'# !:'+! ' W> !!*$ ! '+
&#$!@
]
Q!_'@{@'^!@Q@''&!$'@QX%&$!''#$!$:!$+!*+!
%#^+! ' !\$' %%+! $+?*+?' +!:$ * ! !*\!'
"$QF!@
]
{''!$&!@ {@ Q!&''@ J@ }$'^!@ Q@ Q?''+$?@ J@ $'^!@ q@ W'+@ >@
J![?^?!@{@+@W@''&!$'@QX!*+!:!$$!"[#"$!
\'*+!'+'\!*+_^'*$+?*+!:#$!"''+!%'+&_'#:
$?'$'?"!$'‚FW@]
}^'+@ W@ {''!$&!@ {@ &!'@ W@ '_'$&!'@ W@ >?'@ @ '
'&!$'@QX!*+!:!+"+'\!$]'+"$!'\''\#
^]\'$+_^''#$!$+!*$@]
?++!"@@'&!$'@Q@'+@WX<"?'+!:+'\!*+_^$\#
$'*?+'\!+$FQF!!:'+!*$@
}^?'@ W@ '_'$&!'@ W@ \'#'$&!@ @ }"'$'_''@ q@ '&!$'@ Q@ '
+@ WX &''*+!['+! : '+!$&!%$ \+_ +'$*!%+!' ?!+$ '
− 339 −
%$+?*+?$!F'*!?$$?\+!!$'$*&!*&!'*!FQ!*$@
W?"!+'@ @ }"'+'@ @ W&!^'+'@ Q@ !^?#'@ J@ >'^'@ @ ‚??!*&!@ Q@
'&!$'@ Q@ }'+'@ >@ W?!?'@ Q@ ' W?"!+'@ QX %+ ?*+!
$|?*:+&:$&_'+?!*?'*#'\'*+!?W#*&***?$"'+?$
*&$ *++ ' "'!['+! &+$#+& <$ @
]
Ȏ ơǍȏ
Šĭǩ Ǻ‚÷ "J]k\TX%
7¾ƶÑ"ŮÏĝÞ'ƠÊ Ŏ
’¶ƶVH]uNzȐòǛȖ@wMrK¶ƶ'ķ´Ƣ@ ǯ–ì¾ï Q}}kT
H
Šĭǩ F<q; ǴƚÅęWzSfzO ^@ErRzOȍWzSfzOŘ
ůƺ ZMpZs^@ErRzOeuNBHXĝÞǪÖëҕź¡@ %%
]@ Ƈ
ŢƄ
Ľå ŝŰǡȌéſǸ‹ŗìǺ‚ ÷^@E@wcDiV?HOyMOVk
^@EuNz" Ů»ï @]
ŋĽŚŠĭ ǩǺ‚ ÷ƒ{q WzSfzO"Ɩǻ@wcDiV
?HOƸŷǘ łǵ Ǵƚ @]
ŋĽŚŠĭ ǩǺ‚ ÷ ŮÏMOVkĝÞƠÊWzSfzOòȊ
¾ï @]
Ǻ‚ ÷”ƷŽƙêŰ¡ˆǰŠĭ ǩèŰƆì¾ƶÑ'ƠÊWzSfzO
Ƹŷǘ łǵ Ǵƚ @]
˜ƷӄāƾƲƼǺ‚ ÷Ʒ ÁČSw_Hǘǿż‰›ů'ªǩ»ĝÞ%Ý
‡şŮŦŦŬ @]
ȎƴĶȏ
>^!'+$?@>@+'@Q@+@W@''&!$'@QX'q+
$?*$ : %!*+!" %+! :?*+! : !*$ '+' !*?!" ƒq>$?*‡+!‚?*+!!*+!!+!*$'‡!&''@;@
J'_^!$@ >@ ƒ?\'@ W@ ƒ!@ F@ <''!@ @ ' "'_'@ Q@ $@ W%!"
W'+@>@{''!$&!@{@'&!$'@Q@J!+@@'>&@JX%+
:+&!++&\#€+'*+!"?+!'#!:'+!‡W|?*
''#$!$Q+&$'%%!*'+!$‡&'@@@!*%+$$
− 340 −
^!]!$&!+'@ ‚ ' '&!$!'@ QX F!!:'+!*$ ''#$!$ : "#*'
$+?*+?$:'"!*%$%*+!‡F!!:'+!*$:#*\!"#'
#*!*$'+?*+!‡ƒ!+&@]`@ƒ?++^@>@'‚'^@Q@
$@%%
]
J'$&!+@ ' '&!$'@ QX ƒ{q : !+"'+ ''#$!$ :
%'+&_'#$@"$@'"#*'$+?*+?$‡J'\^:#*!*$‡?!"$@
<;'!*@Q@$@%%]@*'!*$$
'&!$'@Q@ƒ!!%&?'&@†@'>''\@QX_"\'$''#$!$:
%+!
!+'*+!
+_^$
!
?"'+!
!$'$$
‡q?%+!*$‡['+@}@@%%]@<$$
^!]!$&!+'@ ‚ ' '&!$'@ QX =$!" ! +& +'$!+! :
"!*$ + *&!*' "!*$ ‡F!!:'+!*$ : W#$+$ F!"#‡
'_+[@W@@%%]
@J?''$$
J'$&!+@ ' '&!$'@ QX ƒ{q : !+"'+ ''#$!$ :
%'+&_'#$@"$@'$+?*+?$‡€%!+'#*$*!*‡>'!"?*&!@q@
W?[?^!@@+@{@q'!'+$?@J@'_'$'^!@>@'J'$@W@$@%%]@
W%!"
^!]!$&!+'@ ‚ ' '&!$'@ QX W#$+$ '%%'*& + +'\!$ ‡`!#*#*%!':&!*'F!"#‡F"#@>@_*\
J'$&!+@@^!]!$&!+'@‚@='@q@'&!$'@Q@'Q'!+$?^'@
JX_::!*!+%\'\!!$+!*:!!"'\+$'%%!
+"#*\!"#Q>;;@†?@$$?@+!*q ^!]!$&!+'@‚''&!$'@QX'+'+!'%'+&_'#'%%!"
!‡%''+!!*$†?‡F"'@qJ@@J?''
$$@Q+&$QF!@]
Q'$?!]q…'@ @ +@ W@ @ ><@ ' '&!$'@ QX \!!:'+!*$ $?* : %'+ "!*$ $'*& ‡'+ F!!:'+!*$‡
_'$@;@@J?''$$@Q+&$QF!@]
− 341 −
œ ÍżŹîƜƛ
Ą ýƳ­ÊƳĸÐƴƴƯųÈ ÷Ƴ-. )8ƴƳ2006. 4 ł„ƴ
č¿ 63 áĘ~ÌЫàð 3 á·ÌÐÌÐƤÜÐńŋň
‘Êƀʼn‘{
£ĄƳ­ÊƳÜÐƴƴįÛ vÐƳ9 ƴƳ2006. 4 ł„ƴ
àð 11 á¨ĩƔÌЫàð 16 á·ÌÐÌÐƤÜÐńŋň
­Êƀʼn‘{
£ĄƳ­ÊƳÜÐƴƴëƉ “ŔƳ 1"ƴƳ2008. 4 ł„ƴ
àð 13 áÚƣÌЫàð 18 á·ÌÐÌÐƤÜÐńŋň
­Êƀʼn‘{
ńŋ&ĞŲ
ƳƯųÈĄýƴ
Ĺ¾ňÐ!'ÒƱóŮ&Ɠģ"ÌÄapLAEV&ƓØ%35Ġ$
åï&UuQÌƜ%ūŊ7674UuQ4Źŏġ%35Ēĺ$Ńƅ:è6UuQf?
YrF'Ĺ¾ňÐ%
6ƚŲ$ƀƬ!6Ĺ¾ňÐUuQ&ijé'ůåã&UuQ!'$
ªğƐ§UuQ"½(7635űƨ$åï&UuQË"!6Œ(Ɨ†Íƙž&3$Ć
Ξ-Ɨ†ÍZRVquEƄ]M@A?´†ƕZRVquEŎ&Fl_2ZRVquE
·Ġ%œÍğƐ2œƝğƐ&3$ē2Fl_û476ķÃůUuQ%Ô Ġ$f?Y
rFòĦĊ%ƠĽ7 6vĈ!wŻ&3$ªğƐ§UuQ%Ô6f?YrFòĦ-
űąUuQ:ř¶f?YrF6òĦ'ĔŅŌ!6ç ÔƇ"6UuQ%¶9
¶ĸľ¤Ķľ$f?YrFòĦ:ğŐ6"'Ĺ¾ňÐ&ŃƅĽų%Ì%ƈĵ6&.$4
îÆňÐ&ƓØ%1ƈĵ6&3$Ŷİ4ćf?YrFòĦ&ğŐ
3*Ĺ¾ňÐw
&ŃƅĽų:ŭÐÀ&ĪŢ¯*ńŋšţð%ƈĵ 6
ƄZRVquE"Ɨ†ÍĽķUuQ4&f?YrF
űą&ÒƱĖƒx!ĬÑ7Ɨ†ÍĽķUuQy47Ƕ%µÒƱĖƒx!#&3
$Ƅ]M¥ 6"ÀƬ'Ĺ¾ňÐwƩÞ%Ŧ¼ĪÀƬ!6!Ɨ†Í
ĽķUuQ4ƄZRVquE%
ƑŚ–Ľķ 6Ɨ†Íž:-±54
%µÒƱĖƒx!è476űą&Ɨ†Íž:”¡"ÒƱĖƒĤ%ƄZRVquE&z&
#&J`ZRVquE¥ 6:ÿÑ6òĦ:ğŐŘĚ:Ŵŵľ%ůŇ6P_V@
A=: R ]RGuL" ÒŰĕòĦ'ªğƐ§UuQƳƄZRVquEƴ"ğƐ§U
uQƳĽķƴ:ř¶œƭ6"%ŀäġěЊòĦ" 1ć-MGul^
mT>:ùç UuQbuMw&ƄZRVquE•‰%Ɩĺ³Ť!5Ɨ†ÍĽķU
uQ4ħĿ6ĖƒƳ;Ŏ&Ļļƴx!¥ 6Ƅ]M:ÓČ%Ĝ›tůŇ³Ť!6
Ɨ†ÍZRVquE"Ɨ†ÍĽķUuQ&ř¶%36Ɨ†ÍElMQmrF
Ɨ†ÍElMQmrF'Ɨ†ÍġŤ:ÿÑ6w!Ēĺ!57-!ĽķUuQ4&ElM
QmrFƫĺ7 !ĊŃ&Ɨ†ÍZRVquE:ĽķUuQ"ř¶ElMQmr
FŒâ:Ìß%¹w6òĦ:ğŐĕòĦ&e?rV'UuQ:ř¶6&!'$El
MQmrFIMV:ř¶6"!5• &ĊÏòĦ:Œâ"ŹŏIMV%
šư
űąƗ†ÍZRVquE&ř¶%36Ɨ†ÍElMQmrF
Ɨ†ÍZRVquE" Ɨ†ÍĽķ&.$4Qr]EƊŀ}Šĺ2ƙžŀ·í$#Ġ$Z
RVquEğŐ7 674ZRVquE:ř¶ElMQmrF6òĦ:ğŐ
òĦ&e?rV'v&ZRVquE%ķ7$3$ElMQ1ùElMQ
mrF›ė6İ!5òĦ&ƪ’í2íŤ'·ÀƬżÑ&ĊÏòĦ:šư
œƝ2§¶IJğƐ%
6ƫ›]Qr&¤Ķľõ›òĦ
ƫ›]Qr"'y47|Œ&z!vÑą‚w&|Œ%›ķ6Ƙœ:ú 66Ƙœ
Ƴ]Qrƴƫ›]Qr"$7(&Ƙœľ$]Qr', ƫ›]Qr%$6ƳƘœľ$]Q
r', vÑą‚w›ķ6"³Ť$0ƴ0ƩÞ%™ƞ!6&™ƞí:ŝ¿
6òĦ:ğŐy47űą&ēƳœƝƴ2Fl_Ƴ§¶IJğƐƴ474%—Ã6ƫ
›]Qr:™ƞí:Ł õ›6òĦ:ğŐÒŰğŐòĦ'ƫ›]Qr&™ƞí:
ƍī6"%35Ŵŵľ$ĸŷ:¹w6&.$4è47ƫ›]Qr:‹ĺœƭ%
1ĊÏòĦ&šư³Ť!6"Ň7
− 342 −
ń ŋĨ¥%Ô6ťÝİĜtŽŽ
UuQf?YrFġěЊ\?C?r_BfT>EM&VRaLjuXn
3*VRaDr_<
orM%ƂĆ:Ľů 6ij%UuQf?YrF&VRaDr_<orM!6 KDD %
2006,2007 á%ƑŚ þô7 6KDD &þôĶ' 15%ʼnâ!52 áƑŚ!þô7ċĕ
&Fnua'äœƛ&.!67%¢ ƯųÈĄýÂƧЅtKreL@hŎ!ÅƁƃĮš
2øæƃĮš" ËąƃĮ:ŭ 6"41ńŋŽŽ'90 Ʋ
Ąţ&ĞŲ
ÌÐƤĄţƵÌÐƤƃş" îÆňÐĞƂ"©Ŭ ð IT ^LZMijƂ:öäÌÐƤŬÐń
ŋň%
6îÆňÐĄţ:ö 6äœƛ!'‘Êƀʼn&ÐĹ:ÔƇ%ÕƟď6'ƂĆ
&Ǝƃ:ŭ 57'ÕƟľŃƅ&º°"Ľů&ġ…:yńŋš" &ņ:Á06Ąţ&
v!6ÌÐƤÐĹ&ńŋTuf'ƯųÈĄý"&ƆƂ%35ĥÑ7ńŋ'ŕ 2 ƒơ%vâ&
guT>rF%350ŗƓ0476-­ÊƀʼnÌÐƤłw'ƒ%vâ&ldguT>
rF!ƓüÆ»ş¦47 5ƓüÆ»Ď'œƛ&&ir\u4ƊÀ2IirV:²
Ď%' 30 œ:ƌ6ƆƂ"$6ldguT>rF'Ľů
3*ňÐľƆƂ:ŭŤ¡:Ʈŧ
ġ…:y 6-ldguT>rF!‹976Ÿž'ũž!6-‘ÊƂĆ:ƥ•
&ƂĆ'ũž!ŻƏ63úÖ 64%œƛñÙ6§Ðńŋñ\?C?r_BfT
>EMOrQuÒĉ 6Ũòńŋš?rQuXKkXnVouYrFapFlhƳITPƴ
Ƶ\?
C?r_BfT>EM"KMThN\?CpLu&ÂƧƑĂĄţńŋapFlh%35]uVXu
ġƢ!6őÂdMVrÌÐtW?SbnmrKMThN\?CpLuFnuat_lrM]mMTR
E%ŕ 3 sđ&ĭÃ&ġ…è476
ĄţĨ¥%Ô6ťÝİĜtŽŽ
ÌÐƤƃş'¬‡±è&ı%Ј 4 cuL&oeuVĀ›:Ĥƒş¦€ 6ç oeu
V&Šð%35ŃƅŠè&Ç:Ā6&.$4ňÐľĆōŠð&źŞ:1ƀ 6àð 19
á%ĕœƛ'ćż70«ĝĹ'-‘Êƀʼn 2 ¸&.!62 ¸'77©ÐƘ˜”Ð
"Ƌĝ: 5ĕńŋœƛ&ĄţĴŌê:ƮŘĚ"²Ģ0 6
Ƴ®Ūƴ
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Hancock, T., Takigawa, I. and Mamitsuka, H., Mining Metabolic Pathways through Gene Expression
Bioinformatics 26 (17), 2128-2135 (2010).
Hu, X., Zhou, W., Udaka, K., Mamitsuka, H. and Zhu, S., MetaMHC: A Meta Approach to Predict Peptides
Binding to MHC Molecules Nucleic Acids Research 38, W474-W479 (2010).
Hancock, T. and Mamitsuka, H., Boosted Optimization for Network Classification Proceedings of the
Thirteenth International Conference on Artificial Intelligence and Statistics (AISTATS 2010) (JMLR
Workshop and Conference Proceedings, 9), 305-312 (2010).
Hancock, T. and Mamitsuka, H., A Markov Classification Model for Metabolic Pathways Algorithms for
Molecular Biology 5, 10 (2010)
Nakamura, A., Saito, T., Takigawa, I., Mamitsuka, H. and Kudo, M., Algorithms for Finding a Minimum
Repetition Representation of a String Lecture Notes in Computer Science 6393 (Proceedings of the
Seventeenth Symposium on String Processing and Information Retrieval (SPIRE 2010)), 185-190 (2010)
Shiga, M. and Mamitsuka, H., Variational Bayes Learning over Multiple Graphs Proceedings of the IEEE
International Workshop on Machine Learning for Signal Processing (MLSP 2010) , 166-171 (2010)
Lam, T. H., Mamitsuka, H., Ren, E. C., and Tong, J. C., TAP Hunter: A SVM-based System for Predicting
TAP Ligands using Local Description of Amino Acid Sequence Immunome Research 6 (Suppl. 1), S6
(2010)
Kayano, M., Takigawa, I., Shiga, M., Tsuda, K. and Mamitsuka, H., On the Performance of Methods for
Finding a Switching Mechanism in Gene Expression Genome Informatics 24 (Proceedings of the Tenth
Annual Workshop on Bioinformatics and Systems Biology), 69-83 (2010)
Kayano, M., Takigawa, I., Shiga, M., Tsuda, K. and Mamitsuka, H., Efficiently Finding Genome-wide
Three-way Gene Interactions from Transcript- and Genotype-Data Bioinformatics 25 (21), 2735-2743
(2009)
Zhu, S., Zeng, J. and Mamitsuka, H., Enhancing MEDLINE Document Clustering by Incorporating MeSH
Semantic Similarity Bioinformatics 25 (15), 1944-1951 (2009).
− 343 −
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
Zhu, S., Takigawa, I., Zeng, J. and Mamitsuka, H., Field Independent Probabilistic Model for Clustering
Multi-Field Documents Information Processing and Management 45 (5), 555-570 (2009). [ScienceDirect]
Hancock, T. and Mamitsuka, H., A Markov Classification Model for Metabolic Pathways Lecture Notes in
Bioinformatics 5724 (Proceedings of the Ninth Workshop on Algorithms in Bioinformatics (WABI 2009)),
121-132 (2009) [SpringerLink]
Wan, R., Kiseleva, L., Harada, H., Mamitsuka, H. and Horton, P., HAMSTER: Visualizing Microarray
Experiments as a Set of Minimum Spanning Trees Source Code for Biology and Medicine 4 8 (2009)
Ching, W-K., Li, L.., Chan, Y-M. and Mamtisuka, H., A Study of Network-based Kernel Methods on
Protein-Protein Interaction for Protein Functions Prediction Lecture Notes in Operations Research
(Proceedings of the Third International Symposium on Optimization and Systems Biology (OSB 2009)) 11,
25-32 (2009)
Wan, R, Vo, A. N. and Mamitsuka, H., Efficient Probabilistic Latent Semantic Analysis Through
Parallelization Lecture Notes in Computer Science 5839 (Proceedings of the Fifth Asian Information
Retrieval Symposium (AIRS 2009)), 432-443 (2009)
Hancock, T. and Mamitsuka, H., Active Pathway Identification and Classification with Probabilistic
Ensembles Genome Informatics 22 (Proceedings of the Ninth Annual Workshop on Bioinformatics and
Systems Biology), 30-40 (2009)
duVerle, D., Takigawa, I., Ono, Y., Sorimachi, H. and Mamitsuka, H., CaMPDB: a Resource for Calpain and
Modulatory Proteolysis Genome Informatics 22 (Proceedings of the Ninth Annual Workshop on
Bioinformatics and Systems Biology), 202-214 (2009)
Li, L., Shiga, M., Ching, W.-K. and Mamitsuka, H., Annotating Gene Functions with Integrative Spectral
Clustering on Microarray Expressions and Sequences Genome Informatics 22 (Proceedings of the Ninth
Annual Workshop on Bioinformatics and Systems Biology), 95-120 (2009)
Hashimoto, K., Takigawa, I., Shiga, M., Kanehisa, M. and Mamitsuka, H., Mining Significant Tree Patterns
in Carbohydrate Sugar Chains Bioinformatics 24 (16) (Proceedings of the Seventh European Conference on
Computational Biology (ECCB 2008)) , i167-i173 (2008)
Hashimoto, K., Aoki-Kinoshita, K. F., Ueda, N., Kanehisa, M. and Mamitsuka, H., A New Efficient
Probabilistic Model for Mining Labeled Ordered Trees Applied to Glycobiology ACM Transactions on
Knowledge Discovery From Data 2 (1), Article No.6 (2008)
Takigawa, I. and Mamitsuka, H., Probabilistic Path Ranking Based on Adjacent Pairwise Coexpression for
Metabolic Transcripts Analysis Bioinformatics 24 (2), 250-257 (2008)
Hancock, T. and Mamitsuka, H., Semi-Supervised Graph Partitioning with Decision Trees Genome
Informatics 20 (Proceedings of the Eighth Annual Workshop on Bioinformatics and Systems Biology),
102-111 (2008)
Wan, R, Wheelock, Å. and Mamitsuka, H., A Framework for Determining Outlying Microarray Experiments
Genome Informatics 20 (Proceedings of the Eighth Annual Workshop on Bioinformatics and Systems
Biology), 64-76 (2008)
Shiga, M., Takigawa, I. and Mamitsuka, H., A Spectral Clustering Approach to Optimally Combining
Numerical Vectors with a Modular Network Proceedings of the Thirteenth ACM SIGKDD International
Conference On Knowledge Discovery and Data Mining (KDD 2007), 647-656 (2007)
Shiga, M., Takigawa, I. and Mamitsuka, H., Annotating Gene Function by Combining Expression Data with
a Modular Gene Network Bioinformatics 23 (13) (Proceedings of the Fifteenth International Conference on
Intelligent Systems for Molecular Biology (ISMB 2007)) , i468-i478 (2007)
Yoneya, T. and Mamitsuka, H., A Hidden Markov Model-based Approach for Identifying Timing
Differences in Gene Expression under Different Experiment Bioinformatics 23 (7), 842-849 (2007)
Zhu, S., Takigawa, I., Zhang, S. and Mamitsuka, H., A Probabilistic Model for Clustering Text Documents
with Multiple Fields Lecture Notes in Computer Science 4425 (Proceedings of the Twenty-Ninth European
Conference on Information Retrieval (ECIR 2007)), 331-342 (2007)
Kadowaki, T., Wheelock, C. E., Adachi, T., Kudo, T., Okamoto, S., Tanaka, N., Tonomura, K., Tsujimoto,
G., Mamitsuka, H., Goto, S. and Kanehisa, M., Identification of Endocrine Disruptor Biodegradation by
Integration of Structure-activity Relationship with Pathway Analysis Environmental Science & Technology
41 (23), 7997-8003 (2007)
Yoneya, T. and Mamitsuka, H., PURE: A PubMed Article Recommendation System Based on Content-based
Filtering Genome Informatics 18 (Proceedings of the Seventh Annual Workshop on Bioinformatics and
Systems Biology), 267-276 (2007)
Mamitsuka, H., Selecting Features in Microarray Classification Using ROC Curves Pattern Recognition 39
(12), 2393-2404 (2006)
Wan, R., Takigawa, I. and Mamitsuka, H., Applying Gaussian Distribution-dependent Criteria to Decision
Trees for High-Dimensional Microarray Data Lecture Notes in Bioinformatics 4316 (Proceedings of 2006
VLDB Workshop on Data Mining in Bioinformatics), 40-49 (2006)
− 344 −
32.
33.
34.
35.
36.
Hashimoto, K., Aoki-Kinoshita, K. F., Ueda, N., Kanehisa, M. and Mamitsuka, H., A New Efficient
Probabilistic Model for Mining Labeled Ordered Trees Proceedings of the Twelfth ACM SIGKDD
International Conference On Knowledge Discovery and Data Mining (KDD 2006), 177-186 (2006)
Aoki-Kinoshita, K. F., Ueda, N., Mamitsuka, H. and Kanehisa, M., ProfilePSTMM: Capturing Tree-structure
Motifs in Carbohydrate Sugar Chains Bioinformatics 22 (14) (Proceedings of the Fourteenth International
Conference on Intelligent Systems for Molecular Biology (ISMB 2006)) , e25-e34 (2006).
Zhu, S., Okuno, Y., Tsujimoto, G. and Mamitsuka, H., Application of a New Probabilistic Model for Mining
Implicit Associated Cancer Genes from OMIM and Medline Cancer Informatics 2, 361-371 (2006)
Zhu, S., Udaka, K., Sidney, J., Sette, A., Aoki-Kinoshita, K. F. and Mamitsuka, H., Improving MHC Binding
Peptide Prediction by Incorporating Binding Data of Auxiliary MHC Molecules Bioinformatics 22 (13),
1648-1655 (2006)
Mamitsuka, H., Query-Learning-Based Iterative Feature-Subset Selection for Learning from
High-Dimensional Data Sets Knowledge and Information Systems 9 (1), 91-108 (2006)
Ƴ śſƴ
1. Mamitsuka, H., Informatic Innovations in Glycobiology: Relevance to Drug Discovery Drug Discovery
Today 13 (3/4), 118-123 (2008)
2. ëƉ “ŔįÛ vÐƯųÈ ÷, ËĠ$H[hUuQ&ř¶ľElMQmrFŷę ĹIJIJĸ
48(3), 190-194 (2008)
ƳŪďƴ
1. Ng, S.-K., Mamitsuka, H. and Wong, L., Genome Informatics, Vol. 19, Imperial College Press (2007)
ISBN-10: 1-86094-984-3 (ISBN-13: 978-1-86094-984-3).
2. Wan, R. and Mamitsuka, H., Discovering Network motifs in Protein Interaction Networks. Biological Data
Mining in Protein Interaction Networks. Chapter 8, pp. 117–143, Eds. Li, X.-L. and Ng, S.-K., IGI Global
(2009) ISBN: 978-1-60566-398-2.
3. ƯųÈ ÷ő× Ʀ, PURE: PubMed ĆĵĜŖăāKMTh ÒƱ©Ðɝ 26(7):Ĺ¾ńŋ+&
ìĺ"ƠĽƓ/\?CUuQbuM"P_V@A=ПŜ, 201-206 (2008)
− 345 −
ࢼࣀࣂ࢖࢜་⸆๰ᡂ⛉Ꮫㅮᗙ
ᐈဨᩍᤵ㸦ᕤᏛ༤ኈ㸧 ΎỈ୍἞㸦ࡋࡳࡎ࠿ࡎࡣࡿ㸧
㸦2007.5 ╔௵㸧
᫛࿴ 45 ᖺ ᮾி኱Ꮫ༞ࠊ᫛࿴ 50 ᖺ ྠ኱Ꮫ኱Ꮫ㝔ᕤᏛ⣔◊✲⛉ ༤ኈㄢ⛬ಟ஢
≉ᐃ෸ᩍᤵ 㸦་Ꮫ༤ኈ㸧బ⸨ྐ㢧㸦ࡉ࡜࠺ࡩࡳ࠶ࡁ㸧
㸦2007.10 ╔௵㸧
ᖹᡂ 3 ᖺ ி㒔኱Ꮫ༞ࠊᖹᡂ 12 ᖺ ྠ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ ༤ኈㄢ⛬ಟ஢
≉ᐃຓᩍ 㸦⸆Ꮫ༤ኈ㸧 ᅵᒇ๰೺㸦ࡘࡕࡸࡑ࠺ࡅࢇ㸧
㸦2007.7 ╔௵㸧
ᖹᡂ 11 ᖺ ி㒔኱Ꮫ༞ࠊᖹᡂ 16 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ ༤ኈㄢ⛬ಟ஢
◊✲ᴫせ
㸦ΎỈᐈဨᩍᤵ㸧
ᮏࢼࣀࣂ࢖࢜་⸆๰ᡂ⛉Ꮫㅮᗙ࡛ࡣࠊ⏕యᶵ⬟࡞ࡽࡧ࡟⑓ែࡢᮏ㉁ゎ᫂ࢆ┠ᣦࡋ࡚ࠊࣂ࢖࢜ࢸࢡࣀࣟࢪ࣮࡜ࢼ
ࣀࢹࣂ࢖ࢫ࣭ࢩࢫࢸ࣒◊✲ࢆ⼥ྜࡋࠊࡉࡽ࡟᭱ඛ➃ࢼࣀࣂ࢖࢜ࢸࢡࣀࣟࢪ࣮ࢆά⏝ࡋ࡚᪂ࡓ࡞デ᩿ࠊ་⒪ࠊ་⸆
ࡢ๰ᡂࢆᅗࡗ࡚࠸ࡿࠋ
≉࡟ DNA ࣐࢖ࢡࣟ࢔ࣞ࢖ࠊ㧗ឤᗘ㉁㔞ศᯒࢩࢫࢸ࣒➼ࡢඛ➃ศᯒᢏ⾡ࢆᇶ┙࡜ࡋࠊࡑࢀ࠿ࡽᚓࡽࢀࡿࢹ࣮ࢱࡢ
⤫ྜゎᯒ࡟ࡼࡾᚑ᮶ࡣᚓࡽࢀ࡞࠿ࡗࡓ᪂ࡓ࡞᝟ሗࡢ⋓ᚓ࡟ὀຊࡋࠊ་Ꮫ◊✲⛉࡜ࡢ㐃ᦠࢆ୰ᚰ࡟ࠊ㉁ࡢ㧗࠸⮫ᗋ
᳨య࡜㧗࠸ࣞ࣋ࣝࡢ⮫ᗋ᝟ሗࢆゎᯒᑐ㇟࡜ࡍࡿࡇ࡜࡟ࡼࡾࠊྛ✀ࡀࢇࡢデ᩿ࠊࢸ࣮࣮࣓࣮ࣛࢻ་⒪ࠊศᏊᶆⓗ་
⸆ࡢ๰ᡂࢆ┠ᣦࡋ࡚࠸ࡿࠋ
DNA ࢳࢵࣉ࡟ࡼࡿࡀࢇࡢ᭱㐺἞⒪ἲ㑅ᢥ
ி኱⑓㝔࡜㐃ᦠࡋ࡚◊✲ࢆ㐍ࡵ࡚ࠊ⫢⣽⬊⒴ࡢ⭘⒆㒊࡜㠀⭘⒆㒊ࡢ୧᪉ࡢ࣐࢖ࢡࣟ RNA ࣉࣟࣇ࢓࢖ࣝࢆゎᯒ
ࡍࡿࡇ࡜࡛ࠊ᪩ᮇ࠿ࡽᬌᮇࡲ࡛ࡢ෌Ⓨࢆ㧗⋡࡟ண ࡋࡓࠋࡇࡢ෌Ⓨண ࢔ࣝࢦࣜࢬ࣒ࡣࠊ⫢ࡀࢇᝈ⪅ࡢ⫢ษ㝖
ᚋࡢ᳨ᰝ࣭἞⒪᪉㔪ࢆỴࡵࡿ㝿ࡢ᪉㔪࡜࡞ࡿࠋ
㣗㐨ࡀࢇ࡟࠾ࡅࡿ࣐࢖ࢡࣟ RNA ࡟ࡼࡿࡀࢇ⣽⬊ቑṪᢚไ
࣐࢖ࢡࣟ㹐㹌㸿ࡢ࣐࢖ࢡࣟ࢔ࣞ࢖ࢆ㥑౑ࡋ࡚ࠊmiR-210 ࡢⓎ⌧ࡀ㣗㐨ᡥᖹୖ⓶⒴࡟࠾࠸࡚᭷ព࡟పୗࡋ࡚࠾ࡾࠊ
ࡑࡢᗘྜ࠸ࡣᮍศ໬࡞ᙧែࢆ♧ࡍࡀࢇ⣽⬊࡟࠾࠸࡚㢧ⴭ࡛࠶ࡿࡇ࡜ࠊmiR-210 ࡣ G1/G0 ཬࡧ G2/M ᮇ࡟࠾ࡅࡿ
⣽⬊࿘ᮇ೵Ṇ࡜࢔࣏ࢺ࣮ࢩࢫࡢஹ㐍ࢆㄏᑟࡍࡿࡇ࡜࡟ࡼࡾࠊ⒴⣽⬊ࡢቑṪࢆ㈇࡟ไᚚࡍࡿࡇ࡜ࢆぢ࠸ࡔࡋࡓࠋ
ࡲࡓࡑࡢຠᯝࡢ୍㒊ࡣ FGFRL1 ࡢⓎ⌧పୗࢆ௓ࡋ࡚࠸ࡿࡇ࡜ࡶ♧ࡋࡓࠋ
ୖ⓶⣽⬊ഃᗏ⭷ࡢᴟᛶᙧᡂ࡟࠾ࡅࡿ࣐࢖ࢡࣟ RNA ࡢᐤ୚
ୖ⓶⣽⬊ศ໬ㄏᑟࣔࢹࣝ࡟࠾࠸࡚ࠊศ໬࡟క࠸᭷ព࡟Ⓨ⌧ࡀஹ㐍ࡍࡿ microRNA ࡜ࡋ࡚ 250 ✀ࡢ୰࠿ࡽ
miR-210ࠊmiR-338-3p ཬࡧ miR-451 ࡢ㸱✀ࢆྠᐃࡋࡓࠋࡉࡽ࡟ࠊࡇࡢ࠺ࡕࡢ miR-338-3p ࡜ miR-451 ࡀ༠ㄪⓗ
࡟స⏝ࡋ࡚ୖ⓶⣽⬊ഃᗏ⭷ࡢᴟᛶᙧᡂ࡟ᐤ୚ࡋ࡚࠸ࡿࡇ࡜ࢆぢ࠸ࡔࡋࡓࠋ
◊✲άື⮬ᕫⅬ᳨࣭ホ౯
◊✲㈝ࢆ❧ࡕୖࡆ࡚ 3 ᖺ 6 ࢝᭶࡟࡞ࡿࡀࠊ◊✲άືࡀ㌶㐨࡟஌ࡾࠊ◊✲ㄽᩥࡀホ౯ࡢ㧗࠸ᅜ㝿ㄅ࡟╔ᐇ࡟ᥖ㍕
ࡉࢀጞࡵ࡚ࡁࡓࠋࡀࢇࡢ࣐࢖ࢡࣟ㹐㹌㸿ࡢ◊✲࡟࠾࠸࡚ඛ➃ࢆ㉮ࡾࡘࡘ࠶ࡿ࡜࠸࠼ࡿࠋ
ᩍ⫱ᴫせ
㝔⏕ࡢಶู◊✲ㄢ㢟ࢆ㏻ࡌ࡚◊✲ࡢᇶᮏⓗࣉࣟࢭࢫࢆ⩦ᚓ࡛ࡁࡿᵝ࡟ࡋ࡚࠸ࡿࠋྜࢃࡏ࡚་⒪ࢆྲྀࡾࡲࡃ♫఍ࠊ
⤒῭≧ἣࡢࡳ࡞ࡽࡎ⛉Ꮫᢏ⾡ࠊ⤒῭ᨻ⟇࡬ࡢ㛵ᚰࢆႏ㉳ࡋࠊ༞ᴗᚋࡢ♫఍ே࡜ࡋ࡚ࡢ▱㆑ࠊάືຊࡢ୍ຓ࡜࡞ࡿ
ᵝ࡟ດຊࡋ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ࡇࢀࡲ࡛ࡢ㝔⏕ࡣ㸲ྡ࡛࠶ࡿࡀࠊࡑࢀࡒࢀ◊✲ࡢᇶᮏࣉࣟࢭࢫࠊ⪃࠼᪉࡜ඹ࡟་⒪ࢆྲྀࡾᕳࡃ♫఍ࠊ⤒῭᝟ໃ࡟
ࡘ࠸࡚࠶ࡿ⛬ᗘࡢ▱㆑ࢆ㌟࡟ࡘࡅࡓ࡜⪃࠼ࡽࢀࡿࠋ
− 346 −
㸦ཎⴭ㸧
1.
Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G䠊
MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1).
J Biol Chem. (2010) Nov 2. [Epub ahead of print]
2. Nomura H., and Shimizu K.
Stress in Tin-Doped Indium Oxide Thin Films Formed on Substrates by Sputtering. Jpn.J.Appl.Phys.49 025501 (2010)
3. Tetsuo Ito, Fumiaki Sato, Takatsugu Kan, Yulan Cheng, Stefan David, Rachana Agarwal, Bogdan C.
Paun, Zhe Jin, Alexandru V. Olaru, James P. Hamilton, Florin M. Selaru, Jian Yang, Nobutoshi
Matsumura, Kazuharu Shimizu, John M. Abraham, Yutaka Shimada, Yuriko Mori, and Stephen J.
Meltzer.
Polo-like Kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer
International Journal of Cancer, accepted on Nov. 19, 2010, currently in press.
4. Ortiz CM, Ito T, Hashimoto Y, Nagayama S, Iwai A, Tsunoda S, Sato F, Martorell M, Garcia JA, Perez A,
Shimada Y.
Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell
lines.
Diagn Pathol. 2010 Jun 21;5:41.
5. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G.
Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA
immunoprecipitation combined with high-throughput sequencing.
BMC Cancer, 2010, 11:137.
6. Shimada Y, Sato F, Shimizu K, Tsujimoto G, Tsukada K.
cDNA microarray analysis of esophageal cancer: discoveries and prospects.
Gen Thorac Cardiovasc Surg. 2009 Jul;57(7):347-56. Epub 2009 Jul 14.
7. Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y, Mori Y, Agarwal R, Paun BC, Jin Z, Olaru AV, Seralu FM,
Hamilton JP, Yang J, Abraham JM, Meltzer SJ.
The miR-25-93-106b cluster members function as oncomiRs regulating p21 and Bim in Barrett’s neoplasia.
Gastroenterology, 136(5), 1689-1700, 2009.
8. Terasawa K; Ichimura A; Sato F; Shimizu K; Tsujimoto G.
Sustained activation of ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells.
FEBS Journal, 276(12): 3269-76, 2009.
9. Tsuchiya S; Oku M; Imanaka Y; Kunimoto R; Okuno Y; Terasawa K; Sato F; Tsujimoto G; Shimizu K.
MicroRNA-338-3p and microRNA-451 contribute to the formation of basolateral polarity in epithelial cells.
Nucleic Acids Res. 2009 Apr 22. e-pub.
10. Sato F, Tsuchiya S, Terasawa K, Tsujimoto G.
Intra-platform Repeatability and Inter-platform Comparability of MicroRNA Microarray Technology.
PLoS ONE. 2009;4(5):e5540. Epub 2009 May 14.
11. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, Olaru AV, Paun BC, Yang J, Kan T, Ito T, Hamilton JP, Selaru FM,
Agarwal R, David S, Abraham JM, Wolfsen HC, Wallace MB, Shaheen NJ, Washington K, Wang J, Canto MI,
Bhattacharyya A, Nelson MA, Wagner PD, Romero Y, Wang KK, Feng Z, Sampliner RE, Meltzer SJ.
A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett’s
Esophagus.
Cancer Res, 69(10), 4112-15, 2009.
12. Tsuchiya S., Tachida Y., Segi-Nishida E., Okuno Y., Tamba S., Tsujimoto G., Tanaka S. and Sugimoto Y.
Characterization of gene expression profiles for different types of mast cells pooled from mouse stomach subregions by
an RNA amplification method.
BMC Genomics 10, 35, 2009.
− 347 −
13. Takano H., Nakazawa S., Shirata N., Tamba S., Furuta K., Tsuchiya S., Morimoto K., Itano N., Irie A., Ichikawa A.,
Kimata K., Nakayama K., Sugimoto Y. and Tanaka S.
Involvement of CD44 in mast cell proliferation during terminal differentiation.
Lab. Invest. 89, 446-455, 2009.
14. Iwaisako K, Hatano E, Taura K, Nakajima A, Tada M, Seo S, Tamaki N, Sato F, Ikai I, Uemoto S, Kinoshita M.
Loss of Sept4 exacerbates liver fibrosis through the dysregulation of hepatic stellate cells.
Journal of Hepatology, 2008;49(5):768-78. Epub: 2008 Jul 15.
15. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal R, Selaru FM, Sato F, Abraham
JM, Beer DG, Mori Y, Shimada Y, Meltzer SJ.
Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and
correlates with clinical risk factors.
Int J Cancer. 2008 Nov 15;123(10):2331-6.
16. Jin Z, Mori Y, Hamilton JP, Olaru A, Sato F, Yang J, Ito T, Kan T, Agarwal R, Meltzer SJ.
Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis.
Cancer. 112(1):43-9, 2008.
17. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Beer DG, Agarwal R,
Abraham JM, Meltzer SJ.
Hypermethylation of the AKAP12 promoter is a biomarker of Barrett&apos;s-associated esophageal neoplastic
progression.
Cancer Epidemiol Biomarkers Prev. 17(1):111-7, 2008.
18. Ito T, Tanaka E, Kadowaki T, Kan T, Higashiyama M, Shiojima S, Tomoda S, Myoumoto A, Akiyama H, Nobumasa H,
Matsumoto S, Miyamoto S, Mitsumori M, Sato F, Watanabe G, Itami A, Meltzer SJ, Tsujimoto G, Shimada Y.
An ultrasensitive new DNA microarray chip provides gene expression profiles for preoperative esophageal cancer
biopsies without RNA amplification.
Oncology, 2008 May 30;73(5-6):366-375.
19. Ito T, Shimada Y, Kan T, David S, Cheng Y, Mori Y, Agarwal R, Paun B, Jin Z, Olaru A, Hamilton JP, Yang J,
Abraham JM, Meltzer SJ, Sato F.
Pituitary Tumor-transforming gene 1 (PTTG1) increases cell motility and promotes lymph node metastasis in esophageal
squamous cell carcinoma.
Cancer Res, 2008, 68(9):3214-24.
20. Sato F, Jin Z, Schulmann K, Wang J, Greenwald BD, Ito T, Kan T, Hamilton JP, Yang J, Paun B, David S, Olaru A,
Cheng Y, Mori Y, Abraham JM, Yfantis HG, Wu TT, Fredericksen MB, Wang KK, Canto M, Romero Y, Feng Z,
Meltzer SJ.
Three-tiered Risk Stratification Model to Predict Progression in Barrett&apos;s Esophagus Using Epigenetic and Clinical
Features.
PLoS ONE. 2008 Apr 2;3(4):e1890.
21. Ruike Y., Ichimura A., Tsuchiya S., Shimizu K., Kunimoto R., Okuno Y. and Tsujimoto G.
Global correlation analysis for micro-RNA and mRNA expression profiles in human cell lines.
J. Hum. Genet. 53, 515-523, 2008.
22. Takano H., Nakazawa S., Okuno Y., Shirata N., Tsuchiya S., Kainoh T., Takamatsu S., Furuta K., Taketomi Y., Naito Y.,
Takematsu H., Kozutsumi Y., Tsujimoto G., Murakami M., Kudo I., Ichikawa A., Nakayama K., Sugimoto Y. and
Tanaka S.
Establishment of the culture model system that reflects the process of terminal differentiation of connective tissue-type
mast cells.
FEBS Lett. 582, 1444-1450, 2008.㻌
− 348 −
ࢩࢫࢸ࣒๰⸆⛉Ꮫㅮᗙ
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧ዟ㔝ᜤྐ㸦࠾ࡃࡢ ࡸࡍࡋ㸧㸦2008. 10 ╔௵㸧
ᖹᡂ 5 ᖺி㒔኱Ꮫ༞ࠊᖹᡂ 7 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
ಟኈㄢ⛬ಟ஢
෸ᩍᤵ㸦⸆Ꮫ༤ኈ㸧℩ᮌ(す⏣)ᜨ㔛㸦ࡏࡂ(࡟ࡋࡔ)࠼ࡾ㸧㸦2008.10 ╔௵㸧
ᖹᡂ 7 ᖺி㒔኱Ꮫ༞ࠊᖹᡂ 12 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
ຓ ᩍ㸦ࢩࢫࢸ࣒⏕࿨⛉Ꮫ༤ኈ㸧᪂ᓥ ⪽㸦࡟࠸ࡌࡲ ࡉ࡜ࡋ㸧
㸦2009.2 ╔௵㸧
ᖹᡂ 10 ᖺ஑ᕞ኱Ꮫ༞ࠊᖹᡂ 12 ᖺྠ኱Ꮫ኱Ꮫ㝔
ࢩࢫࢸ࣒᝟ሗ⛉Ꮫ◊✲⛉ ಟኈㄢ⛬ಟ஢
㸦ዟ㔝ᩍᤵ㸧
◊✲ࡢᴫせ
ࣄࢺࢤࣀ࣒ゎㄞ᏶஢ࢆཷࡅ࡚ࠊ⏕࿨⛉Ꮫࡢ◊✲ᑐ㇟ࡣࠊಶࠎࡢ㑇ఏᏊࡢᶵ⬟ゎ᫂࠿ࡽࠊከᩘࡢᅉᏊࡢ
┦஫స⏝ࡀ⏕ࡳฟࡍ」㞧࡞ࠕࢩࢫࢸ࣒ࠖ࡜ࡋ࡚ࡢᣲືࢆ᫂ࡽ࠿࡟ࡍࡿࡇ࡜࡟⛣⾜ࡋࡘࡘ࠶ࡿࠋࡇࡢࡇ࡜
ࡣࠊࢤࣀ࣑ࢡࢫࢆฟⓎⅬ࡜ࡋ࡚ࠊᶵ⬟ࢤࣀ࣑ࢡࢫࠊࢣ࣑࢝ࣝࣂ࢖࢜ࣟࢪ࣮ࠊࢩࢫࢸ࣒ࢬࣂ࢖࢜ࣟࢪ࣮࡜
࠸ࡗࡓ᪂ࡋ࠸◊✲ศ㔝ࠕࢩࢫࢸ࣒⏕࿨⛉Ꮫ㸦Systems Bioscience㸧ࠖࡢ๰ฟࢆࡶࡓࡽࡋࡓࠋ୍᪉ࠊ௒᪥࡟
࠾ࡅࡿ๰⸆⛉Ꮫࡣࠊ༢୍ࡢ⑌ᝈཎᅉࢱࣥࣃࢡ㉁ࢆ≉ᐃࡋࠊࡑࡢ༢୍ᶆⓗศᏊࡢᶵ⬟ไᚚࢆ┠ⓗ࡜ࡋࡓࠕศ
Ꮚᶆⓗ๰⸆ࠖࡀ୺ὶ࡜࡞ࡗ࡚࠸ࡿࠋࡋ࠿ࡋ࡞ࡀࡽࠊ་⸆ရ㛤Ⓨ࡟࠾ࡅࡿ㔜せㄢ㢟࡛࠶ࡿ๪స⏝Ⓨ⌧ࡢཎ
ᅉࡢ୍ࡘࡀ⸆≀࡜ணᮇࡏࡠ⏕యศᏊ࡜ࡢస⏝࡟㉳ᅉࡍࡿࡇ࡜࠿ࡽࡶࢃ࠿ࡿࡼ࠺࡟ࠊ⸆≀࡟ࡼࡿ༢୍ࡢࢱ
ࣥࣃࢡ㉁ࡢᶵ⬟ኚ໬࠿ࡽࡑࡢ⸆⌮άᛶࡢ඲࡚ࢆㄒࡾᑾࡃࡋ࡚๰⸆࡬࡜⧅ࡆࡿࡇ࡜ࡣ஦ᐇୖ୙ྍ⬟࡛࠶
ࡾࠊࣈ࣮ࣞࢡࢫ࣮ࣝ࡜࡞ࡿ㠉᪂ⓗ๰⸆ࡀᚅࡕᮃࡲࢀ࡚ࡁࡓࠋ
ࡇࡢࡼ࠺࡞⫼ᬒ࠿ࡽࠊᮏㅮᗙ࡛ࡣࠊࢩࢫࢸ࣒⏕࿨⛉Ꮫࡢ◊✲ᢏ⾡ࢆ๰⸆◊✲ࡢᐇ㊶ⓗၥ㢟࡟㐺⏝ࡋࠊ๰
⸆࡟≉໬ࡋࡓࢩࢫࢸ࣒⏕࿨⛉Ꮫࡢ◊✲㛤Ⓨࢆ⾜࠺ࡇ࡜࡟ࡼࡾࠊ᪂ࡓ࡞๰⸆⛉Ꮫ⌮ㄽࠕࢩࢫࢸ࣒๰⸆⛉Ꮫࠖ
ࡢ๰ᡂࢆ┠ᣦࡋ࡚࠸ࡿࠋලయⓗ࡟ࡣࠊḟࡢ 3 㡯┠࡟ࡘ࠸࡚◊✲ࢆᐇ᪋ࡋ࡚࠸ࡿࠋ
1. ⑓ែⓎ⑕ࣉࣟࢭࢫࡸ⸆⌮స⏝ࣉࣟࢭࢫࡢࢩࢫࢸ࣒ࢩ࣑࣮ࣗࣞࢩࣙࣥ࡟ࡼࡿ⑓ែཎᅉ㑇ఏᏊࠊ⸆≀ᶆ
ⓗ㑇ఏᏊࡢ᥈⣴࡜࣓࢝ࢽࢬ࣒ࡢゎ᫂
Ⳙ኱࡞໬ྜ≀⩌࡜ࢱࣥࣃࢡ㉁⩌࡜ࡢ┦஫స⏝᝟ሗ࡛࠶ࡿࢣ࣑࢝ࣝࢤࣀ࣑ࢡࢫ᝟ሗ࡜ࠊ㑇ఏᏊⓎ⌧
ࢹ࣮ࢱࠊ๪స⏝᝟ሗ࡞࡝࡜ࡢࢹ࣮ࢱ⤫ྜ࡟ࡼࡾࠊ⸆≀㸫ᶆⓗࢱࣥࣃࢡ㉁㸫⑌ᝈ㛵㐃ࢱࣥࣃࢡ㉁㸫⑌
ᝈ࡬࡜⧅ࡄ⸆≀㸫⑌ᝈ⤫ྜࢿࢵࢺ࣮࣡ࢡࢆᵓ⠏ࡋࠊࡑࢀ࡟ᇶ࡙ࡃࢿࢵࢺ࣮࣡ࢡ๰⸆ࢩ࣑࣮ࣗࣞࢱࡢ
◊✲㛤Ⓨࢆ⾜࠸ࡲࡍࠋࡲࡓࠊࢿࢵࢺ࣮࣡ࢡ๰⸆ࢩ࣑࣮ࣗࣞࢱࢆ⏝࠸࡚ࠊ⸆≀άᛶ࢔ࢵࢭ࢖ࢹ࣮ࢱ࠾
ࡼࡧ㑇ఏᏊⓎ⌧ࢹ࣮ࢱ࠿ࡽࠊ⑌ᝈ≉␗ⓗ࣭⸆≀≉␗ⓗ࡞ศᏊࢿࢵࢺ࣮࣡ࢡࢆ᥎ᐃࡋࠊ⏕యࢩࢫࢸ࣒
ࡢᣲືไᚚ࡟᭱㐺࡞⑌ᝈཎᅉࢱࣥࣃࢡ㉁ࡸ⸆≀ᶆⓗࢱࣥࣃࢡ㉁ࡢ᥈⣴ࢆ⾜࠺࡜࡜ࡶ࡟ࠊ⑓ែࣉࣟࢭ
ࢫࡸ⸆⌮స⏝࣭ẘᛶⓎ⌧࣓࢝ࢽࢬ࣒ࢆࢩࢫࢸ࣐ࢸ࢕ࢵࢡ࡟᫂ࡽ࠿࡟ࡋࡲࡍࠋ
2.
⸆⌮ຠᯝಁ㐍࡜Ᏻ඲ᛶྥୖࢆᚿྥࡋࡓྜ⌮ⓗ⸆≀᥈⣴ᡭἲࡢ㛤Ⓨ࡜ࠊከ㔜ᶆⓗ⸆⌮స⏝࡟ᇶ࡙ࡃࢻ
ࣛࢵࢢࢹࢨ࢖ࣥ⌮ㄽࡢᵓ⠏
᝟ሗ⛉Ꮫᢏ⾡ࡢ୍ࡘ࡛࠶ࡿᶵᲔᏛ⩦࡟ᇶ࡙࠸࡚ࠊࢣ࣑࢝ࣝࢤࣀ࣑ࢡࢫ᝟ሗ࡜ࡋ࡚㞟✚ࡉࢀࡓ኱㔞
ࡢ┦஫స⏝᝟ሗ࠿ࡽ໬ྜ≀㸫ࢱࣥࣃࢡ㉁ࡢ┦஫స⏝࣮ࣝࣝࢆᢳฟࡍࡿࡇ࡜࡟ࡼࡾࠊྜ⌮ⓗ࡞໬ྜ≀
᥈⣴ࢆᐇ⌧ࡋࠊࡉࡽ࡟ࡣ┦஫స⏝せᅉ࡜࡞ࡿ໬Ꮫᵓ㐀ࢆ๰ฟࡋࡲࡍࠋࡲࡓࠊᐃ㔞ᛶ᝟ሗࡢᑟධ࡟ࡼ
ࡿ໬Ꮫᵓ㐀̺ᶆⓗࢱࣥࣃࢡ㉁̺άᛶ್ࡢከḟඖᵓ㐀άᛶ┦㛵ࣔࢹࣝࡢᵓ⠏࡜ࠊ⸆⌮άᛶᵓ㐀ࡢᢳฟࠊ
ࡑࡋ࡚ከ㔜ᶆⓗ⸆⌮స⏝㸦≉࡟ᶆⓗ㑅ᢥᛶ㸧࡟ᇶ࡙ࡃࢻࣛࢵࢢࢹࢨ࢖ࣥ⌮ㄽࡢᵓ⠏ࢆ⾜࠸ࡲࡍࠋࡇ
ࢀ࡟ࡼࡾࠊຠᯝⓗ࠿ࡘᏳ඲ᛶࡢ㧗࠸་⸆ရࡢ๰〇ࡀຍ㏿໬ࡉࢀࡿࡇ࡜ࡀᮇᚅࡉࢀࡲࡍࠋ
3.
࠺ࡘ⑓ࣔࢹࣝࡸᢠ࠺ࡘ἞⒪ࣔࢹࣝ࡟ࡼࡿ⬻㒊఩≉␗ⓗ㑇ఏᏊࢿࢵࢺ࣮࣡ࢡࡢゎᯒ࡜⅖⑕ᛶ࣓ࢹ࢕
࢚࣮ࢱ࣮ࡢ㛵୚࡟ࡘ࠸࡚ࡢࢩࢫࢸ࣒ⓗゎᯒ
࠺ࡘ⑓ࡢⓎ⑕ᶵᗎࡸᢠ࠺ࡘ⸆἞⒪ࡢస⏝ᶵᗎ࡟ࡘ࠸࡚ࡣᮍࡔ୙᫂࡞Ⅼࡀከ࠸ࡢࡀ⌧≧࡛ࡍࠋ࠺ࡘ
⑓ࡢⓎ⑕࣓࢝ࢽࢬ࣒ࡢ୍ࡘ࡜ࡋ࡚ࠕࣔࣀ࢔࣑ࣥ௬ㄝࠖ㸦ࢩࢼࣉࢫ㛫㝽࡟࠾ࡅࡿࢭࣟࢺࢽ࣭ࣥ࢔ࢻࣞ
ࢼࣜࣥ⃰ᗘࡢῶᑡ㸧ࡀᥦၐࡉࢀ࡚࠸ࡲࡍࡀࠊ࠺ࡘ⑓ែ࡛ࡣࡇࢀࡽ⚄⤒ఏ㐩≀㉁ࡢ⃰ᗘࡀῶᑡࡍࡿࡢ
ࡳ࡞ࡽࡎࠊ⚄⤒ࡀྍረⓗ࡟ኚ໬ࡍࡿ࡜⪃࠼ࡽࢀ࡚࠸ࡲࡍࠋࡑࡇ࡛ࠊ⬻ෆࡢ⣽⬊࣭ศᏊ࡛ࣞ࣋ࣝ࡝ࡢ
ࡼ࠺࡞ኚ໬ࡀ㉳ࡁ࡚࠸ࡿ࠿ࢆ᫂ࡽ࠿࡟ࡍࡿࡓࡵ࡟ࠊ࣐࢘ࢫ࣭ࣛࢵࢺࢆ⏝࠸࡚ࠊ࠺ࡘ⑓⑓ែࣔࢹࣝࡸ
ᢠ࠺ࡘ἞⒪ࣔࢹࣝࢆసᡂࡋࠊࡑࡢ⬻ෆኚ໬ࢆศᏊ⏕≀Ꮫⓗࠊ⤌⧊Ꮫⓗ࡟ゎᯒࡋࡲࡍࠋලయⓗ࡟ࡣࠊ
− 349 −
⬻ษ∦࠿ࡽ≉ᐃࡢ⬻㒊఩ࢆษࡾฟࡋࠊ㑇ఏᏊⓎ⌧ኚ໬ࢆ⥙⨶ⓗ࡟ゎᯒࡋࠊ࠺ࡘ⑓ࡢⓎ⑕ࡸ἞⒪࡟࡜
ࡶ࡞࠺⣽⬊ࡢኚ໬ࢆ㑇ఏᏊⓎ⌧ࢿࢵࢺ࣮࣡ࢡ࡜ࡋ࡚ᤊ࠼ࠊ࠺ࡘ⑓ែ࡟ඹ㏻ࡋ࡚ࡳࡽࢀࡿᶵ⬟ࡢኚ໬
ࢆ᫂ࡽ࠿࡟ࡋࡲࡍࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᅜෆእࡢᏛ఍࣭ࢩ࣏ࣥࢪ࣒࢘➼࡛ዟ㔝ᩍᤵࡀࢤࢫࢺࢫࣆ࣮࣮࢝࡜ࡋ࡚ከᩘㅮ₇ࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓዟ
㔝ᩍᤵࡣᖹᡂ 21 ᖺᗘᩥ㒊⛉Ꮫ኱⮧⾲ᙲ࣭⛉Ꮫᢏ⾡㈹㸦⛉Ꮫᢏ⾡᣺⯆㒊㛛㸧ࠊᖹᡂ 20 ᖺᗘ᪥ᮏ⸆Ꮫ఍࣭
ዡບ㈹ࠊᖹᡂ 19 ᖺᗘ᪥ᮏ⸆Ꮫ఍࣭⸆Ꮫࣅࢪࣙࣥ㒊఍ 㒊఍㈹ࢆཷ㈹ࡋ࡚࠾ࡾࠊ℩ᮌ෸ᩍᤵࡀᖹᡂ 22 ᖺ
ᗘ᪥ᮏ⸆Ꮫ఍࣭ዡບ㈹ࢆཷ㈹ࡋ࡚࠸ࡿࡇ࡜࠿ࡽࡶ◊✲ホ౯ࡣࡁࢃࡵ࡚㧗࠸ࠋ᭦࡟ࠊዟ㔝ᩍᤵࡢ◊✲ᡂᯝ
ࡣࠊி㒔኱Ꮫ་Ꮫ㡿ᇦࡢᨭ᥼ࢆཷࡅ࡚኱ᏛⓎ࣋ࣥࢳ࣮ࣕ࡜ࡋ࡚㉳ᴗ໬ࡉࢀࠊᐇ⏝໬࡟⮳ࡗ࡚࠾ࡾࠊ௒᪥
ᙉࡃồࡵࡽࢀࡿ◊✲ᡂᯝࡢ♫఍㑏ඖ࡟࠾࠸࡚ࡶ㧗ࡃホ౯࡛ࡁࡿࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜศ㔝ࡣ 4 ᅇ⏕๓ᮇㄢ⛬ࡢᇶ♏ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࢆᢸᙜࡋ࡚࠸ࡿࠋ≉࡟ࠊཷㅮ⏕
୍ே୍ேࡀ PC ➃ᮎ࡛ᐇ㝿࡟ࣉࣟࢢ࣑ࣛࣥࢢࢆࡋ࡞ࡀࡽࠊᤵᴗࢆ⾜࠺ᐇ㊶ⓗ࡞₇⩦ᙧᘧࢆྲྀࡾධࢀࡿ௚ࠊ
༑ศ࡞᚟⩦ࡀฟ᮶ࡿࡼ࠺࡟ e㸫࣮ࣛࢽࣥࢢᩍᮦ࡜ࡋ࡚ᤵᴗᩍᮦࡢ࢔࣮࢝࢖ࣈ໬ࡶ⾜ࡗ࡚࠸ࡿࠋ
༞ᴗᐇ⩦ཬࡧ኱Ꮫ㝔ᩍ⫱㸸ᙜ◊✲ᐊ࡛ࡣࠊ㝔⏕ࡀ⊂⮬ࡢࢸ࣮࣐ࢆᣢࡕᖖ࡟⮬ࡽ◊✲ィ⏬ࢆ❧᱌ࠊ㐙⾜
ࡍࡿ࡜࠸࠺ࠊ㝔⏕ࡢ⮬୺ᛶࢆ᭱኱㝈ᑛ㔜ࡋࡓ◊✲ᣦᑟ᪉㔪ࢆྲྀࡗ࡚࠸ࡿࠋࡲࡓࠊ◊✲ࢸ࣮࣐ࡈ࡜࡟ࠊ㸱
㹼㸲ேࡢࢢ࣮ࣝࣉ༢఩࡛ࠊ㐌࡟㸯ᅇᩍဨ࡜ࡢࢹ࢕ࢫ࢝ࢩࣙࣥࠊពぢ஺᥮ࢆ⾜࠸ࠊ◊✲ࡢ㐍ᒎ࡜ࣞ࣋ࣝࡢ
ᙉ໬ࢆᅗࡿᶵ఍ࢆᣢࡘࡼ࠺࡟ࡋ࡚࠸ࡿࠋ᭦࡟ࠊẖ㐌 1 ᅇࠊᐃ౛ࢭ࣑ࢼ࣮ࢆ㛤ദࡋࠊ◊✲ᐊ඲ဨࡀཧຍࡢ
ࡶ࡜⮬ࡽࡢ◊✲௨እࡢࢸ࣮࣐ࢆⓎ⾲࣭ウㄽࡍࡿ◊✲ሗ࿌఍࡜⮬ࡽࡢ◊✲ࢸ࣮࣐࡟㛵㐃ࡋࡓ᭱᪂ᩥ⊩ࢆ⤂
௓ࡋࠊ῝ࡃ㆟ㄽࡍࡿᩥ⊩⤂௓ࢆ⾜ࡗ࡚࠸ࡿࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
Ꮫ㒊Ꮫ⏕ࡢㅮ⩏࡟ᑐࡋ࡚ࡣࠊẖᅇࡢㅮ⩏ᚋ࡟ㄢࡍㄢ㢟࡜࡜ࡶ࡟ᤵᴗࡢឤ᝿ࢆ࣓࣮ࣝᙧᘧ࡛ཷࡅ௜ࡅ࡚
࠾ࡾࠊྛᏛ⏕ࡢࡑࡢ᪥ࡢ⌮ゎᗘࢆ㏲ḟᢕᥱࡍࡿࡼ࠺࡟ᚰࡀࡅ࡚࠸ࡿࠋࡲࡓࠊᏛ⏕ࡢᤵᴗ⌮ゎᗘ࡟୙Ᏻࡀ
ឤࡌࡽࢀࡿሙྜࡣࠊḟࡢㅮ⩏࡛᚟⩦ࢆྲྀࡾධࢀࡿ࡞࡝࡛ᑐᛂࡋ࡚࠸ࡿࠋ◊✲ᐊෆࡢᩍ⫱ࡣࠊ࡯ࡰ඲ဨࡀ
ᖺ࡟୍ᗘࡣᅜ㝿Ꮫ఍ࡶྵࡵ࡚Ꮫ఍࡛Ⓨ⾲ࢆࡋ࡚࠸ࡿࡇ࡜࠿ࡽุ᩿ࡋ࡚ࠊྛಶேࡢᐇຊࢆ㧗ࡵࡿࡇ࡜࡟ᙺ
❧ࡗ࡚࠸ࡿࠋࡲࡓࠊᙜ◊✲ᐊࡢᑓ㛛ศ㔝ࡣࠊ⸆Ꮫ࡜᝟ሗᏛ࡜ࡢᏛ㝿ศ㔝࡟఩⨨࡙ࡅࡽࢀࡿࡇ࡜࠿ࡽࠊ⫱
ᡂேᮦീ࡜ࡋ࡚⊃࠸ど㔝࡟㝗ࡾࡀࡕ࡞◊✲⪅࡟㝈ࡽࡎࠊከ᪉㠃࡛ά㌍ࡍࡿ࣮ࣜࢲ࣮⫱ᡂࢆ┠ᣦࡋ࡚ࡁࡓࠋ
ᐇ㝿ࠊ༞ᴗ⏕ࡢ㐍㊰ࡣࠊ〇⸆࣓࣮࣮࢝ࡢ◊✲⫋௨እ࡟ࠊཌ⏕ປാ┬ࡸ⤒῭⏘ᴗ┬ࡢᐁ൉ࡸ኱ᡭ IT ௻ᴗ
࡬㐍ࢇࡔᏛ⏕ࡶ࠾ࡾࠊᩍ⫱࡜◊✲ࡢ㧗࠸ࣞ࣋ࣝࡀホ౯ࡉࢀ࡚࠸ࡿ⤖ᯝ࡜⪃࠼ࡽࢀࡿࠋ
㸦ཎⴭ㸧
1.
2.
3.
4.
5.
6.
Niijima, S., Yabuuchi, H., Okuno, Y., A cross-target view to feature selection: identification of molecular
interaction features in ligand-target space, J. Chem. Inf. Model., in press, 2010
Kusaka, M., Katoh-Fukui, Y., Ogawa, H., Miyabayashi, K., Baba, T., Shima, Y., Sugiyama, N.,
Sugimoto, Y., Okuno, Y., Kodama, R., Iizuka-Kogo, A., Senda, T., Sasaoka, T., Kitamura, K., Aizawa,
S., Morohashi, KI. “Abnormal Epithelial Cell Polarity and Ectopic Epidermal Growth Factor Receptor
(EGFR) Expression Induced in Emx2 KO Embryonic Gonads” Endocrinology, 151(12), 5893-5904,
2010
van der Horst, E., Peironcely, JE., Ijzerman, AP., Beukers, MW., Lane, JR., van Vlijmen, HW.,
Emmerich, MT., Okuno, Y., Bender, A. “A novel chemogenomics analysis of G protein-coupled
receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization” BMC
Bioinformatics, 11:316, 2010
Tamba, S., Yodoi, R., Morimoto, K., Inazumi, T., Sukeno, M., Segi-Nishida, E., Okuno, Y., Tsujimoto,
G., Narumiya, S., Sugimoto, Y. “Expression profiling of cumulus cells reveals functional changes during
ovulation and central roles of prostaglandin EP2 receptor in cAMP signaling” Biochimie, 92, 665-675,
2010
Hagihara, M., Yoneda, K., Yabuuchi, H., Okuno, Y., Nakatani, K. “A reverse transcriptase stop assay
revealed diverse quadruplex formations in UTRs in mRNA” Bioorg Med Chem Lett, 20, 2350-2353,
2010
Terada, N., Shimizu, Y., Kamba, T., Inoue, T., Maeno, A., Kobayashi, T., Nakamura, E., Kamoto, T.,
Kanaji, T., Maruyama, T., Mikami, Y., Toda, Y., Matsuoka, T., Okuno, Y., Tsujimoto, G., Narumiya, S.,
Ogawa, O. “Identification of EP4 as a potential target for the treatment of castration-resistant prostate
− 350 −
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
cancer using a novel xenograft model” Cancer Res, 70, 1606-1615, 2010
Takahashi, J., Hijikuro, I., Kihara, T., Murugesh, M.G., Fuse, S., Kunimoto, R., Tsumura, Y., Akaike, A.,
Niidome, T., Okuno, Y., Takahashi, T., Sugimoto, H. “Design, synthesis, evaluation and QSAR analysis
of N(1)-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors” Bioorg Med
Chem Lett, 20, 1718-1720, 2010
Doi, M., Takahashi, Y., Komatsu, R., Yamazaki, F., Yamada, H., Haraguchi, S., Emoto, N., Okuno, Y.,
Tsujimoto, G., Kanematsu, A., Ogawa, O., Todo, T., Tsutsui, K., van der Horst, G.T., Okamura, H.
“Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal
Hsd3b6” Nat Med, 16, 67-74, 2010
Esaki, Y., Li, Y., Sakata, D., Yao, C., Segi-Nishida, E., Matsuoka, T., Fukuda, K., and Narumiya, S. Dual
roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc Natl Acad Sci
U S A 107:12233-12238, 2010
Kondo, C., Minowa, Y., Uehara, T., Okuno, Y., Nakatsu, N., Ono, A., Maruyama, T., Kato, I., Yamate, J.,
Yamada, H., Ohno, Y., Urushidani, T. “Identification of genomic biomarkers for concurrent diagnosis of
drug-induced renal tubular injury using a large-scale toxicogenomics database” Toxicology, 265, 15-26,
2009
Feng, C., Araki, H., Kunimoto, R., Tamon, A., Makiguchi, H., Niijima, S., Tsujimoto, G., Okuno, Y.
“GEM-TREND: a web tool for Gene Expression data Mining Toward Relevant Network Discovery”
BMC Genomics, 10:411, 2009
Tsuchiya, S., Oku, M., Imanaka, Y., Kunimoto, R., Okuno, Y., Terasawa, K., Sato, F., Tsujimoto, G.,
Shimizu, K. “MicroRNA-338-3p and microRNA-451 contribute to the formation of basolateral polarity
in epithelial cells” Nucleic Acids Res. 37, 3821-3827, 2009
Ichimi, T., Enokida, H., Okuno, Y., Kunimoto, R., Chiyomaru, T., Kawamoto, K., Kawahara, K., Toki,
K., Kawakami, K., Nishiyama, K., Tsujimoto, G., Nakagawa, M., Seki, N. “Identification of novel
microRNA targets based on microRNA signatures in bladder cancer ” Int. J. Cancer 125, 345-352, 2009
van der Horst, E., Okuno, Y., Bender, A., Ijzerman, A.P. “Substructure mining of GPCR ligands reveals
activity-class specific functional groups in an unbiased manner” J. Chem. Inf. Model. 49, 348-60, 2009
Tsuchiya, S., Tachida, Y., Segi-Nishida, E., Okuno, Y., Tamba, S., Tsujimoto, G., Tanaka, S., Sugimoto,
Y. “Characterization of gene expression profiles for different types of mast cells pooled from mouse
stomach subregions by an RNA amplification method” BMC Genomics 10: 35, 2009
Niijima, S., Okuno, Y. “Laplacian linear discriminant analysis approach to unsupervised feature
selection” IEEE/ACM Trans. Comput. Biol. Bioinform.,
6, 605-614, 2009
Yodoi, R., Tamba, S., Morimoto, K., Segi-Nishida, E., Nishihara, M., Ichikawa, A., Narumiya, S., and
Sugimoto, Y. 2009. RhoA/Rho kinase signaling in the cumulus mediates extracellular matrix assembly.
Endocrinology 150:3345-3352.
Yamaoka, K., Yano, A., Kuroiwa, K., Morimoto, K., Inazumi, T., Hatae, N., Tabata, H., Segi-Nishida, E.,
Tanaka, S., Ichikawa, A., and Sugimoto, Y. 2009. Prostaglandin EP3 receptor superactivates adenylyl
cyclase via the Gq/PLC/Ca2+ pathway in a lipid raft-dependent manner. Biochem Biophys Res Commun
389:678-682.
Ruike, Y., Ichimura, A., Tsuchiya, S., Shimizu, K., Kunimoto, R., Okuno, Y., Tsujimoto, G. “Global
correlation analysis for micro-RNA and mRNA expression profiles in human cell lines” J. Hum. Genet.
53, 515-23, 2008
Kawanishi, H., Matsui, Y., Ito, M., Watanabe, J., Takahashi, T., Nishizawa, K., Nishiyama, H., Kamoto,
T., Mikami, Y., Tanaka, Y., Jung, G., Akiyama, H., Nobumasa, H., Guilford, P., Reeve, A., Okuno, Y.,
Tsujimoto, G., Nakamura, E., Ogawa, O. “Secreted CXCL1 is a potential mediator and marker of the
tumor invasion of bladder cancer” Clin. Cancer Res. 14, 2579-87, 2008
Takano, H., Nakazawa, S., Okuno, Y., Shirata, N.,Tsuchiya, S., Kainoh, T., Takamatsu, S., Furuta, K.,
Taketomi, Y., Naito, Y., Takematsu, H., Kozutsumi, Y., Tsujimoto, G., Murakami, M., Kudo, I., Ichikawa,
A., Nakayama, K., Sugimoto, Y., Tanaka, S. “Establishment of the culture model system that reflects the
process of terminal differentiation of connective tissue-type mast cells” FEBS Lett. 582, 1444-50, 2008
Okuno, Y., Tamon, A., Yabuuchi, H., Niijima, S., Minowa, Y., Tonomura, K., Kunimto, R., Feng, C.
“GLIDA: GPCR-ligand database for chemical genomics drug discovery – Database and tools update”
Nucleic Acids Res. 36, D907-12, 2008
Tamba, S., Yodoi, R., Segi-Nishida, E., Ichikawa, A., Narumiya, S., and Sugimoto, Y. 2008. Timely
interaction between prostaglandin and chemokine signaling is a prerequisite for successful fertilization.
Proc Natl Acad Sci U S A 105:14539-14544.
Suda, S., Segi-Nishida, E., Newton, S.S., and Duman, R.S. 2008. A postpartum model in rat: behavioral
and gene expression changes induced by ovarian steroid deprivation. Biol Psychiatry 64:311-319.
Segi-Nishida, E., Warner-Schmidt, J.L., and Duman, R.S. 2008. Electroconvulsive seizure and VEGF
− 351 −
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
increase the proliferation of neural stem-like cells in rat hippocampus. Proc Natl Acad Sci U S A
105:11352-11357.
Kitajima, M., Minowa, Y., Matsuda, H., Okuno, Y. “Compound-transporter interaction studies using
canonical correlation analysis” Chem-Bio Inform. J. 7, 24-34, 2007
Yamamoto, H., Takematsu, H., Fujinawa, R., Naito, Y., Okuno, Y., Tsujimoto, G., Suzuki, A., Kozutsumi,
Y. “Correlation index-based responsible-enzyme gene screening (CIRES), a novel DNA
microarray-based method for glycan biosynthesis enzyme gene” PLoS ONE, 2, e1232, 2007
Ikeda, A., Miyazaki, T., Kakizawa, S., Okuno, Y., Tsuchiya, S., Myomoto, A., Saito, SY., Yamamoto, T.,
Yamazaki, T., Iino, M., Tsujimoto, G., Watanabe, M., Takeshima, H. “Abnormal features in mutant
cerebellar Purkinje cells lacking junctophilins” Biochem. Biophys. Res. Commun. 363, 835-9, 2007
Yamazaki, T., Sasaki, N., Nishi, M., Yamazaki, D., Ikeda, A., Okuno, Y., Komazaki, S., Takeshima, H.
“Augmentation of drug-induced cell death by ER protein BRI3BP” Biochem. Biophys. Res. Commun.
362, 971-5, 2007
Naito, Y., Takematsu, H., Koyama, S., Miyake, S., Yamamoto, H., Fujinawa, R., Sugai, M., Okuno, Y.,
Tsujimoto, G., Yamaji, T., Hashimoto, Y., Itohara, S., Kawasaki, T., Suzuki, A., Kozutsumi, Y. “Germinal
center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid
species involved in the negative modulation of B cell activation” Mol. Cell Biol. 27, 3008-22, 2007
Nagamachi, M., Sakata, D., Kabashima, K., Furuyashiki, T., Murata, T., Segi-Nishida, E., Soontrapa, K.,
Matsuoka, T., Miyachi, Y., and Narumiya, S. 2007. Facilitation of Th1-mediated immune response by
prostaglandin E receptor EP1. J Exp Med 204:2865-2874.
Zhu, S., Okuno, Y., Tsujimoto, G., Mamitsuka, H. “Application of a new probabilistic model for mining
implicit associated cancer genes from OMIM and Medline” Cancer Inform. 2, 361-71, 2006
Osada, S., Naganawa, A., Misonou, M., Tsuchiya, S., Tamba, S., Okuno, Y., Nishikawa, J., Satoh, K.,
Imagawa, I., Tsujimoto, G., Sugimoto, Y., Nishihara, T. “Altered gene expression of transcriptional
regulatory factors in tumor marker-positive cells during chemically induced hepatocarcinogenesis”
Toxicol. Lett. 167, 106-13, 2006
Tsuchiya, S., Okuno, Y., Tsujimoto, G. “MicroRNA: biogenetic and functional mechanisms and
involvements in cell differentiation and cancer” J. Pharmacol. Sci. 101, 267-70, 2006
Okuno, Y., Yang, J., Taneishi, K., Yabuuchi, H., Tsujimoto, G. “GLIDA: GPCR-Ligand database for
chemical genomic drug discovery” Nucleic Acids Res. 34, D673-7, 2006
Yokoyama, U., Minamisawa, S., Quan, H., Ghatak, S., Akaike, T., Segi-Nishida, E., Iwasaki, S.,
Iwamoto, M., Misra, S., Tamura, K., Hori, H., Yokota, S., Toole, B.P., Sugimoto, Y., and Ishikawa, Y.
2006. Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal
formation in the ductus arteriosus. J Clin Invest 116:3026-3034.
Yang, L., Huang, Y., Porta, R., Yanagisawa, K., Gonzalez, A., Segi, E., Johnson, D.H., Narumiya, S.,
and Carbone, D.P. 2006. Host and direct antitumor effects and profound reduction in tumor metastasis
with selective EP4 receptor antagonism. Cancer Res 66:9665-9672.
Honda, T., Segi-Nishida, E., Miyachi, Y., and Narumiya, S. 2006. Prostacyclin-IP signaling and
prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced
arthritis. J Exp Med 203:325-335.
㸦⥲ㄝ㸧
1.
2.
3.
4.
5.
6.
7.
๰⸆ࣂ࣮ࣜࣗࢳ࢙࢖ࣥࡢ࢖ࣥࢩࣜࢥᢏ⾡ࢆά⏝ࡋࡓ㜼ᐖ๣㛤Ⓨࡢヨࡳ
஭ୖ ㇦, Ᏻ㐩 ᏹ᫛, ᳃ ຬ௓, 㧗㔝 ࿴ᩥ, ᯇᮧ ᾈ⏤, ᮧୖ ⪽, ⚟す ᛌᩥ, ୰ᮧ ᫓ᮌ, ᮌୗ
㄃ᐩ, ௰す ຌ, ዟ㔝 ᜤྐ, ༡᪉ ⪷ྖ, బஂ㛫 ಇᗈ, 㧗⏣ ಇ࿴, ໭ᓥ ṇே, ⚟ᒸ Ⰻᛅ, ᆏ⏣
ᜏ᫛, ᪥ᮏ⤖ᬗᏛ఍ㄅ52, 89-94, 2010
Tsuchiya, S., Terasawa, K., Kunimoto, R., Okuno, Y., Sato, F., Shimizu, K., Tsujimoto, G. "Biogenesis
and Function Mechanisms of Micro-RNAs and Their Role as Oncogenes and Tumor Suppressors"
Systems Biology, Springer, 183-9, 2009
ࢣ࣑࢝ࣝࢤࣀ࣑ࢡࢫ࡟ᇶ࡙ࡃ࢖ࣥࢩࣜࢥ๰⸆
᪂ᓥ ⪽, ዟ㔝 ᜤྐ, ᪥ᮏ⸆⌮Ꮫ㞧ㄅ, 133:3, 173-4, 2009
Tsuchiya, S., Okuno, Y., Tsujimoto, G. "MicroRNAs and Discovery of New Targets" Genomics and
Pharmacogenomics in Anticancer Drug Development and Clinical Response, Humana Press, 47-56,
2009
Okuno, Y. “In silico drug discovery based on the integration of bioinformatics and chemoinformatics”
YAKUGAKU ZASSHI 128 (11), 1645-51, 2008
ࢣ࣑࢝ࣝࢤࣀ࣑ࢡࢫ᝟ሗࢆ⏝࠸ࡓ᪂つࣜ࢞ࣥࢻ᥈⣴ᡭἲ
⸭ෆ ᘯ᫛, ዟ㔝 ᜤྐ, SAR News, 14, 2-6, 2008
Inoue, T., Adachi, H., Murakami, S., Takano, K., Matsumura, H., Mori, Y., Fukunishi, Y., Nakamura, H.,
− 352 −
8.
Kinoshita, T., Nakanishi, I., Okuno, Y., Minakata, S., Shimojo, S., Sakata, T. “New progress in
crystallization technology of membrane protein and introduction of pharamaceutical innovation value
chain” YAKUGAKU ZASSHI 128 (4), 497-505, 2008
ࢣ࣑࣭࢝ࣝࣂ࢖࢜᝟ሗ࡟ᇶ࡙ࡃ๰⸆࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ◊✲
ዟ㔝 ᜤྐ, Pharma VISION NEWS, 9, 13-16, 2007
㸦ⴭ᭩㸧
1.
2.
3.
4.
5.
6.
ዟ㔝ᜤྐ௚ࠕ་⸆ࢪ࣮ࣕࢼࣝ ቑหྕ ᪂⸆ᒎᮃ2010ࠖ ओ་⸆ࢪ࣮ࣕࢼࣝ♫ 2010ᖺ
ዟ㔝ᜤྐ௚ࠕḟୡ௦๰⸆ࢸࢡࣀࣟࢪ࣮ ᐇ㊶㸸࢖ࣥࢩࣜࢥ๰⸆ࡢ᭱๓⥺ࠖ㸪ओ࣓ࢹ࢕࣭࢝ࣝࢻ
ࢗ㸪2009ᖺ9᭶
ዟ㔝ᜤྐ௚ ࠕࢥࣥࣆ࣮ࣗࢱ࣮࡛⸆ࢆ๰ࢁ࠺ࠖ, ओ໬Ꮫྠே,2009ᖺ6᭶
ዟ㔝ᜤྐ௚ ࠕ࢖ࣥࢩࣜࢥ๰⸆⛉Ꮫ̿ࢤࣀ࣒᝟ሗ࠿ࡽ๰⸆࡬̿ࠖ㸪ி㒔ᘅᕝ᭩ᗑ㸪2008ᖺ7᭶
ዟ㔝ᜤྐ௚ ࠕ⏕≀≀⌮Ꮫࣁࣥࢻࣈࢵࢡࠖ㸪ᮅ಴᭩ᗑ㸪2007ᖺ4᭶
ዟ㔝ᜤྐ௚ ࠕࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ஦඾ࠖ㸪ඹ❧ฟ∧㸪2006ᖺ7᭶
− 353 −
๰⸆⚄⤒⛉Ꮫㅮᗙ
ᩍ ᤵ㸦⸆Ꮫ༤ኈ㸧ᮡᮏ ඵ㑻㸦ࡍࡂࡶ࡜ ࡣࡕࢁ࠺㸧
㸦2003.4 ╔௵㸧
᫛࿴㸯㸵ᖺ㸯㸰᭶㸰㸵᪥⏕
᫛࿴㸲㸲ᖺ୰ኸ኱Ꮫ༞ࠊᖹᡂ㸶ᖺᗈᓥ኱Ꮫ༤ኈ㸦⸆Ꮫ㸧ྲྀᚓ
෸ᩍᤵ㸦⸆Ꮫ༤ኈ㸧᪂␃ ᚭᗈ㸦࡟࠸࡝ࡵ ࡚ࡘࡦࢁ㸧
㸦2003.4 ╔௵㸧
᫛࿴㸱㸳ᖺ㸯㸮᭶㸯㸵᪥⏕
᫛࿴㸳㸶ᖺ஑ᕞ኱Ꮫ༞ࠊ᫛࿴㸴㸯ᖺ஑ᕞ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ಟኈㄢ⛬ಟ஢ࠊ
ᖹᡂ㸵ᖺ஑ᕞ኱Ꮫ༤ኈ㸦⸆Ꮫ㸧ྲྀᚓ
ㅮ ᖌ㸦་Ꮫ༤ኈ㸧ᮌཎ Ṋኈ㸦ࡁࡣࡽ ࡓࡅࡋ㸧㸦2005.2 ╔௵㸧
᫛࿴㸲㸮ᖺ㸲᭶㸰㸮᪥⏕
ᖹᡂ㸲ᖺி㒔኱Ꮫ༞ࠊᖹᡂ㸯㸯ᖺி㒔኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉༤ኈㄢ⛬㏥Ꮫࠊ
ᖹᡂ㸯㸱ᖺி㒔኱Ꮫ༤ኈ㸦་Ꮫ㸧ྲྀᚓࠊᖹᡂ㸯㸳ᖺ๰⸆⚄⤒⛉Ꮫㅮᗙຓᡭ
◊✲ࡢᴫせ
ᙜㅮᗙࡣ 2003 ᖺ 4 ᭶ 1 ᪥࠿ࡽ࢚࣮ࢨ࢖ᰴᘧ఍♫ࡢᐤ㝃ㅮᗙ࡜ࡋ࡚ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ෆ࡟タ❧ࡉ
ࢀࡓࠋྠ◊✲⛉࡜ࡋ࡚ࡣึࡵ࡚ࡢᐤ㝃ㅮᗙ࡛࠶ࡗࡓࠋྠㅮᗙࡣ 2010 ᖺ 3 ᭶ 31 ᪥ࢆࡶࡗ࡚⤊஢ࡋࡓࠋࡇࡢ
㛫 7 ᖺ㛫࡟Ώࡿ◊✲ᡂᯝ࡟ࡘࡋ࡚እほࡋ࡚௨ୗ࡟グࡍࠋ
ᙜ๰⸆⚄⤒⛉Ꮫㅮᗙࡣ࢔ࣝࢶࣁ࢖࣐࣮⑓ࢆ௦⾲࡜ࡍࡿ㐍⾜ᛶࡢ⚄⤒ኚᛶ⑌ᝈࡢ๰⸆◊✲ࢆ୺せㄢ㢟࡜ࡍ
ࡿࠋపศᏊ໬ྜ≀ࡢᵓ㐀άᛶ┦㛵࠿ࡽ⣽⬊࡛ࡢホ౯࣭ື≀࡛ࡢホ౯࡟⮳ࡿᖜᗈ࠸ศ㔝࡛ࡢ๰⸆◊✲ࢆᑐ㇟
࡜ࡋࠊ1) ࢔ࣝࢶࣁ࢖࣐࣮⑓࡟௦⾲ࡉࢀࡿ⚄⤒ኚᛶ⑌ᝈࡢ⑓ᅉゎ᫂࡟ᇶ࡙ࡃ๰⸆◊✲ࠊ2) ⏕యෆ≀㉁ࡸኳ↛
≀ࡢ୰࠿ࡽ๰⸆ࡢࢩ࣮ࢻ࡟࡞ࡾᚓࡿ⏕⌮άᛶ≀㉁ࡢⓎぢࠊ3) ࢤࣀ࣒ࡸ⚄⤒෌⏕་⒪ᢏ⾡ࢆ㥑౑ࡋࡓ๰⸆࢔
ࣉ࣮ࣟࢳ࡟㛵ࡍࡿ◊✲ࠊ4) ࢔ࢭࢳࣝࢥ࢚ࣜࣥࢫࢸ࣮ࣛࢮ㜼ᐖ⸆ࡢ⚄⤒⣽⬊ಖㆤస⏝ࡢ࣓࢝ࢽࢬ࣒ゎ᫂࡟ᇶ
࡙ࡃ๰⸆◊✲ࢆᐇ᪋ࡋࡓࠋ
◊✲άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ᙜㅮᗙࡀタ❧ࡉࢀࡓᙜึࡢ 1 ᖺ㛫ࡣ⸆ရస⏝ゎᯒᏛศ㔝ࡢᐇ㦂ᐊࢆ೉⏝ࡋ࡚࠸ࡓࡀࠊࡑࡢᚋ⮬๓ࡢᐇ㦂
ᐊࢆᣢࡘࡇ࡜ࡀ࡛ࡁࠊపศᏊ໬ྜ≀࣭㑇ఏᏊ࣭⣽⬊࣭ື≀ࢆᑐ㇟࡜ࡍࡿᐇ㦂⣔ࢆ୍㏻ࡾࢭࢵࢺ࢔ࢵࣉࡍࡿ
ࡇ࡜ࡀ࡛ࡁࡓࠋ࢔ࣝࢶࣁ࢖࣐࣮⑓ࢆ௦⾲࡜ࡍࡿ㐍⾜ᛶࡢ⚄⤒ኚᛶ⑌ᝈࡢ๰⸆◊✲࡟㛵ࡍࡿ᭱ึࡢ◊✲ᡂᯝ
࡜ࡋ࡚≉チࢆฟ㢪ࡍࡿࡇ࡜ࡀ࡛ࡁࡓ㸦≉㢪 2004-141371㸧
ࠋᙜㅮᗙࡀ 2010 ᖺ 3 ᭶࡟⤊஢ࡋࡓࡀࠊࡑࡢᡂᯝ࡜
ࡋ࡚≉チฟ㢪 4 ௳ࠊᏛ఍Ⓨ⾲ 60 ௳ࠊḢᩥㄅ࡟Ⓨ⾲ࡉࢀࡓㄽᩥᩘ 59 ௳ࠊ㑥ᩥㄅ 19 ࡜࠸࠺ෆᐜ࡛࠶ࡗࡓࠋ▷
࠸ᮇ㛫࡛࠶ࡗࡓ࡟ࡶ㛵ࢃࡽࡎண᝿ࢆୖᅇࡿᐇ⦼ࢆ♧ࡍࡇ࡜ࡀ࡛ࡁࡓࠋ
ᩍ⫱ࡢᴫせ
Ꮫ㒊ᩍ⫱㸸ᙜㅮᗙࡣ 1 ᅇ⏕๓ᮇࡢ⸆Ꮫᴫㄽࠊ2 ᅇ⏕ᚋᮇࡢᇶ♏ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࠊ4 ᅇ⏕๓ᮇࡢ
⸆≀἞⒪Ꮫࡢ୍㒊ࢆᢸᙜࡋࡓࠋྛㅮᖌࡢࡇࢀࡲ࡛ࡢ⤒㦂㸦〇⸆࣓࣮࣮࢝ࡢ◊✲⫋໅ົࠊ⚄⤒ෆ⛉་㸧ࢆά
࠿ࡋࠊ〇⸆࣓࣮࣮࢝ࡢ◊✲ᡤࡸ⮫ᗋࡢ⌧ሙࡀឤࡌࡽࢀࡿࡼ࠺࡞ㅮ⩏ࢆ⾜ࡗࡓࠋ
༞ᴗᐇ⩦࠾ࡼࡧ኱Ꮫ㝔ᩍ⫱㸸ᙜㅮᗙࡢ≉ᚩࡣ๰⸆◊✲࡟ᚲ㡲࡛࠶ࡿ໬Ꮫྜᡂࠊ⸆⌮ࠊ⮫ᗋࡢྛᑓ㛛ᐙࡀ
ྠࡌㅮᗙ࡛◊✲ࡋ࡚࠸ࡓࡇ࡜ࡣ኱ࡁ࡞≉㛗࡛ࡶ࠶ࡗࡓࠋ๰⸆ࢆ◊✲ࡢ୰ᚰ࡟ᤣ࠼ࠊᏛ⏕ࡀపศᏊ໬ྜ≀࠿
ࡽ⣽⬊࣭ື≀࡛ࡢホ౯࡟⮳ࡿࡲ࡛ᖜᗈ࠸ศ㔝࡛๰⸆࡟ࡘ࠸࡚ࡢᢏ⾡࣭▱㆑ࢆ῝ࡵࡿࡇ࡜࡛㇏ᐩ࡞ぢ㆑ࢆᣢ
ࡘ◊✲⪅ࢆ⫱ᡂࡋࠊ⚄⤒⛉Ꮫ㡿ᇦ࡟࠾ࡅࡿ㈉⊩࡛ࡁࡓ࡜⮬㈇ࡋ࡚࠸ࡿࠋࡲࡓࠊ୍ே୍ࢸ࣮࣐ࢆᇶᮏ࡜ࡋྛ
⮬ࡢ⮬ぬࢆಁࡍ࡜࡜ࡶ࡟ࣅࢹ࢜➼ࢆ฼⏝ࡋ࡚⚄⤒ኚᛶ⑌ᝈࡢᝈ⪅ࡢ⌧ᐇࢆ▱ࡽࡏࡿ࡜ྠ᫬࡟๰⸆࡟ࡘ࠸࡚
Ꮫ⏕ࡢࣔࢳ࣮࣋ࢩࣙࣥࡀ኱࠸࡟ୖࡀࡗࡓࡇ࡜ࡣ႐ࡤࡋ࠸㝈ࡾ࡛࠶ࡗࡓࠋ
ᩍ⫱άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
ࢹ࣮ࢱሗ࿌఍ࠊࢹ࣮ࢱ᳨ウ఍࡛ࡢࢹ࢕ࢫ࢝ࢵࢩࣙࣥࢆ㏻ࡌ࡚ 4 ᅇ⏕ࡸ኱Ꮫ㝔Ꮫ⏕ࡢ๰⸆◊✲࡟ࡘ࠸࡚ࡢ
ᢏ⾡࣭▱㆑ࢆ῝ࡵ࡚ࡁࡓࠋࡲࡓࠊ୍㒊ࡢᏛ⏕࡟ࡘ࠸࡚ࡣ〇⸆࣓࣮࣮࢝ࡢ⌧ᙺࡢ◊✲⪅࡜஺ὶࡍࡿᶵ఍ࢆタ
ࡅࡓࡇ࡜࡟ࡼࡾࠊ〇⸆࣓࣮࣮࢝ࡢ◊✲⫋࡟ᑐࡋ࡚࢖࣓࣮ࢪࡋࡸࡍࡃ࡞ࡗࡓ࡜ᛮࢃࢀࡿࠋ7 ᖺ㛫ࡢ⥲ᣓ࡜ࡋ࡚
Ꮫ⏕ࡀᮍࡔ⤒㦂ࡋ࡚࠸࡞࠸๰⸆◊✲࡟ࡘ࠸࡚⌧ሙࡢᐇ㝿ࢆ‽య㦂ࡉࡏࡿࡇ࡜ࡀ࡛ࡁࡓࡇ࡜ࡣࠊ௒ᚋᙼࡽ࠿
− 354 −
ᙼዪࡽࡣ〇⸆௻ᴗࡢ◊✲⫋࡟ᦠࢃࡗࡓ࡜ࡁ࡟኱ࡁ࡞ᚰࡢᨭ࠼࡟࡞ࡿࡇ࡜ࢆಙࡌ࡚࠸ࡿࠋ
㸦ཎⴭ㸧
1. Abeta-induced BACE-1 cleaves N-terminal sequence of mPGES-2. Kihara T., Shimmyo Y., Akaike A., Niidome
T., Sugimoto H., Biochem. Biophys. Res. Commun. 2010, in press
2. PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes. Wu X., Kihara T., Akaike A.,
Niidome T., Sugimoto H., Biochem. Biophys. Res. Commun. 2010, in press
3. Design, synthesis, evaluation and QSAR analysis of N1-substituted norcymserine derivatives as selective
butyrylcholinesterase inhibitors. Takahashi J., Hijikuro I., Kihara T., Murugesh M.G., Fuse S., Kunimoto R.,
Tsumura Y., Akaike A., Niidome T., Okuno Y., Takahashi T., Sugimoto H., Bioorg. Med. Chem. Lett. 2010, in
press
4. Design, synthesis and evaluation of carbamate-modified (-)-N1-phenethylnorphysostigmine derivatives as
selective butyrylcholinesterase inhibitors. Takahashi J., Hijikuro I., Kihara T., Murugesh M.G., Fuse S.,
Kunimoto R., Tsumura Y., Akaike A., Niidome T., Okuno Y., Takahashi T., Sugimoto H., Bioorg. Med. Chem.
Lett. 2010, in press
5. A comparison of the amyloid ȕ fibril-destabilizing activities of leaves among varieties of the mulberry.
Khaengkhan P., Takahashi K., Niidome T., Ichida M., Sugimoto H., Harada S., Kamei K., Journal of Insect
Biotechnology and Sericology. 2010, in press
6. Mechanism of chronic nicotine treatment-induced enhancement of the sensitivity of cortical neurons to the
neuroprotective effect of donepezil in cortical neurons. Takada-Takatori Y., Kume T., Izumi Y., Niidome T., Fujii
T., Sugimoto H., Akaike A., J. Pharmacol. Sci. 2010, in press
7. PI3K inhibition causes the accumulation of ubiquitinated presenilin 1 without affecting the proteasome activity.
Aoyagi N., Uemura K., Kuzuya A., Kihara T., Kawamata J., Shimohama S., Kinoshita A., Takahashi R.,
Biochem. Biophys. Res. Commun. 391, 1240-1245, 2010
8. Basic fibroblast growth factor promotes the generation of microtubule-associated protein 2-positive cells from
microglia. Niidome T., Nonaka H., Akaike A., Kihara T., Sugimoto H., Biochem. Biophys. Res. Commun. 390,
1018-1022, 2009
9. Identification of an antiamyloidogenic substance from mulberry leaves. Khaengkhan P., Nishikaze Y., Niidome
T., Kanaori K., Tajima K., Ichida M., Harada S., Sugimoto H., Kamei K., NeuroReport 20, 1214-1218, 2009
10. Non-fibrillar amyloid-beta peptide reduces NMDA-induced neurotoxicity, but not AMPA-induced neurotoxicity.
Niidome T., Goto Y., Kato M., Wang P-L., Goh S., Tanaka N., Akaike A., Kihara T., Sugimoto H., Biochem.
Biophys. Res. Commun. 386, 734-738, 2009
11. APP promotes ER stress-induced cell death via CHOP mediated pathway. Takahashi K., Niidome T., Akaike A.,
Kihara T., Sugimoto H., J. Neurochem. 109, 1324-1337, 2009
12. Rac1 inhibition negatively regulates the transcriptional activity of the amyloid precursor protein gene. Wang P.,
Niidome T., Akaike A., Kihara T., Sugimoto H., J. Neurosci. Res. 87, 2105-2114, 2009
13. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor
up-regulation. Takada-Takatori Y., Kume T., Izumi Y., Ohgi Y., Niidome T., Fujii T., Sugimoto H., Akaike A.,
Biol. Pharm. Bull. 32, 318-324, 2009
14. A role for SOX2 in the generation of microtubule-associated protein 2-positive cells from microglia. Nonaka H.,
Niidome T., Shinozuka Y., Akaike A., Kihara T., Sugimoto H., Biochem. Biophys. Res. Commun. 380, 60-64,
2009
15. Serofendic acid promotes stellation induced by cAMP and cGMP analogs in cultured cortical astrocytes. Kume
T., Ito R., Taguchi R., Izumi Y., Katsuki H., Niidome T., Takada-Takatori Y., Sugimoto H., Akaike A., J.
Pharmacol. Sci. 109, 110-118, 2009
16. AMPA reduces surface expression of NR1 through regulation of GSK3. Nishimoto T., Kihara T., Akaike A.,
Niidome T., Sugimoto H., NeuroReport 20, 161-165, 2009
17. Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Kitaguchi H.,
Tomimoto H., Ihara M., Shibata M., Uemura K., Kalaria R.N., Kihara T., Asada-Utsugi M., Kinoshita A.,
Takahashi R., Brain Res. 1294, 202-210, 2009
18. Impairment of the cortical GABAergic inhibitory system in catatonic stupor: a case report with neuroimaging.
Iseki K., Ikeda A., Kihara T., Kawamoto Y., Mezaki T., Hanakawa T., Hashikawa K., Fukuyama H., Shibasaki H.,
Epileptic Disord. 11, 126-131, 2009
19. Phosphorylation of amyloid precursor protein (APP) at Tyr687 regulates APP processing by alpha- and
gamma-secretase. Takahashi K., Niidome T., Akaike A., Kihara T., Sugimoto H., Biochem. Biophys. Res.
− 355 −
Commun. 377, 544-549, 2008
20. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces
neurite outgrowth in PC12 cells. Oda T., Kume T., Izumi Y., Takada-Takatori Y., Niidome T., Akaike A., Eur. J.
Pharmacol. 598, 27-31, 2008
21. Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic
phenotype. Kume T., Kawato Y., Osakada F., Izumi Y., Katsuki H., Nakagawa T., Kaneko S., Niidome T.,
Takada-Takatori Y., Akaike A., Neurosci. Lett. 443, 199-203, 2008
22. Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with
donepezil. Takada-Takatori Y., Kume T., Ohgi Y., Izumi Y., Niidome T., Fujii T., Sugimoto H., Akaike A., J.
Neurosci. Res. 86, 3575-3583, 2008
23. Mechanisms of alpha7-nicotinic receptor up-regulation and sensitization to donepezil-induced by chronic
donepezil treatment. Takada-Takatori Y., Kume T., Ohgi Y., Fujii T., Niidome T., Sugimoto H., Akaike A., Eur. J.
Pharmacol. 590, 150-156, 2008
24. Differential regulation of neurogenesis in two neurogenic regions of APPswe/PS1dE9 transgenic mice. Niidome
T., Taniuchi N., Akaike A., Kihara T., Sugimoto H., NeuroReport 19, 1361-1364, 2008
25. Ca2+ mobilization mediated by transient receptor potential canonical 3 is associated with thrombin-induced
morphological changes in 1321N1 human astrocytoma cells. Nakao K., Shirakawa H., Sugishita A., Matsutani I.,
Niidome T., Nakagawa T., Kaneko S., J. Neurosci. Res. 86, 2722-2732, 2008
26. Epigallocatechin-3-gallate and curcumin suppress A-induced BACE-1 up-regulation. ShimmyoY., Kihara T.,
Akaike A. Niidome T., Sugimoto H., NeuroReport 19, 1329-1333, 2008
27. Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in rats.
Nakamura T., Kume T., Katsuki H., Niidome T., Sugimoto H., Akaike A., Eur. J. Pharmacol. 586, 151-155, 2008
28. A molecular pathway involved in the generation of microtubule-associated protein 2-positive cells from
microglia. Niidome T., Matsuda S., Nonaka H., Akaike A., Kihara T., Sugimoto H., Biochem. Biophys. Res.
Commun. 370, 184-188, 2008
29. Microtubule-associated protein 2-positive cells derived from microglia possess properties of functional neuron.
Matsuda S., Niidome T., Nonaka H., Goto Y., Fujimura K., Kato M., Nakanishi M., Akaike A., Kihara T.,
Sugimoto H., Biochem. Biophys. Res. Commun. 368, 971-976, 2008
30. Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of
Alzheimer’s disease. Goto Y., Niidome T., Hongo H., Akaike A., Kihara T., Sugimoto H., Eur. J. Pharmacol. 583,
84-91, 2008
31. Flavonols and flavone as BACE-1 inhibitors: Structure-activity relationship in cell-free, cell-based and in silico
studies reveal novel pharmacophore features. Shimmyo Y., Kihara T., Akaike A., Niidome T., Sugimoto H.,
Biochimica Biophysica Acta. 1780, 819-825, 2008
32. Three distinct neuroprotective functions of myricetin against glutamate-induced neuronal cell death:
involvement of direct inhibition of caspase-3. Shimmyo Y., Kihara T., Akaike A., Niidome T., Sugimoto H., J.
Neurosci. Res. 86, 1836-1845, 2008AMPA attenuates glutamate-induced caspase-3 cleavage via regulation of
GSK3. Nishimoto T., Kihara T., Akaike A., Niidome T., Sugimoto H., J. Neurosci. Res. 86, 1096-1105, 2008
33. Multifunction of myricetin on A: Neuroprotection via a conformational change of A and reduction of A via
the interference of secretases. Shimmyo Y., Kihara T., Akaike A., Niidome T., Sugimoto H., J. Neurosci. Res. 86,
368-377, 2008
34. Decreased proliferation of hippocampal progenitor cells in APPswe/PS1dE9 transgenic mice. Taniuchi N.,
Niidome T., Goto Y., Akaike A., Kihara T., Sugimoto H., NeuroReport 18, 1801-1805, 2007
35. Synthesis and pharmacological profile of serofendic acids A and B. Terauchi T., Asai N., Doko T., Taguchi R.,
Takenaka O., Sakurai H., Yonaga M., Kimura T., Kajiwara A., Niidome T., Kume T., Akaike A., Sugimoto H.,
Bioorg. Med. Chem. 15, 7098-7107, 2007
36. Donepezil potentiates nerve growth factor-induced neurite outgrowth in PC12 cells. Oda T., Kume T., Katsuki H.,
Niidome T., Sugimoto H., Akaike A., J. Pharmacol. Sci. 104, 349-354, 2007
37. Mulberry leaf extract prevents amyloid beta-peptide fibril formation and neurotoxicity. Niidome T., Takahashi K.,
Goto Y., Goh S., Tanaka N., Kamei K., Ichida M., Hara S., Akaike A., Kihara T., Sugimoto H., NeuroReport 18,
813-816, 2007
38. Microglia-derived interleukin-6 and leukemia inhibitory factor promote astrocytic differentiation of neural
stem/progenitor cells. Nakanishi M., Niidome T., Matsuda S., Akaike A., Kihara T., Sugimoto H., Eur. J.
Neurosci. 25, 649-658, 2007
39. Presenilin 1 is involved in the maturation of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1).
Kuzuya A., Uemura K., Kitagawa N., Aoyagi N., Kihara T., Ninomiya H., Ishiura S., Takahashi R. and
− 356 −
Shimohama S., J. Neurosci. Res. 85, 153-165, 2007
40. Amyloid -peptide preconditioning protects hippocampal neurons against glutamate-induced neurotoxicity by
promoting endocytosis of NMDA receptor. Goto Y., Niidome T., Akaike A., Kihara T., Sugimoto H., Biochem.
Biophys. Res. Commun. 351, 259-265, 2006
41. Distinct mechanism underlie distinct polyphenol-induced neuroprotection against excitotoxicity. Yazawa K.,
Kihara T., Shen H., Niidome T., Sugimoto H., FEBS Lett. 580, 6623-6628, 2006
42. Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. Takada-Takatori Y., Kume
T., Sugimoto M., Katsuki H., Niidome T., Sugimoto H., Fujii T., Okabe S., Akaike A., Eur. J. Pharmacol. 549,
19-26, 2006
43. Mechanisms of cell death of neural progenitor cells caused by trophic support deprivation. Niidome T.,
Morimoto N., Iijima S., Akaike A., Kihara T., Sugimoto H., Eur. J. Pharmacol. 548, 1-8, 2006
44. Synthesis and neuroprotective effects of serofendic acid analogues. Terauchi T., Doko T., Yonaga M., Kajiwara
A., Niidome T., Taguchi, R., Kume T., Akaike A., Sugimoto H., Bioorg. Med. Chem. Lett. 16, 5080-5083, 2006
45. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via
nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Takada-Takatori Y., Kume T.,
Sugimoto M., Katsuki H., Sugimoto H. and Akaike A., Neuropharmacology 51, 474-486, 2006
46. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Uemura K., Kihara T., Kuzuya A.,
Okawa K., Nishimoto T., Ninomiya H., Sugimoto H., Kinoshita A. and Shimohama S., Neurosci. Lett. 402,
278-283, 2006
47. Activity-dependent regulation of beta-catenin via epsilon-cleavage of N-cadherin. Uemura K., Kihara T.,
Kuzuya A., Okawa K., Nishimoto T., Bito H., Ninomiya H., Sugimoto H., Kinoshita A. and Shimohama S.,
Biochem. Biophys. Res. Commun. 345, 951-958, 2006
48. Serofendic acid, a neuroprotective substance derived from fetal calf serum, inhibits mitochondrial membrane
depolarization and caspase-3 activation. Kume T., Taguchi R., Katsuki H., Akao M., Sugimoto H., Kaneko S.
and Akaike A., Eur. J. Pharmacol. 542, 69-76, 2006
49. Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical
neurons. Kume T., Sugimoto M., Takada Y., Yamaguchi T., Yonezawa A., Katsuki H., Sugimoto H. and Akaike
A., Eur. J. Pharmacol. 527, 77-85, 2005
㸦ⴭ᭩㸧
1. ๰⸆࡬ࡢ㏵ 㸫᪂㔘๰⸆ᴫㄽ. ᮡᮏඵ㑻, ๰⸆࡬⥆ࡃ㸯㸮ࡢ≀ㄒ㸫, ி㒔ᘅᕝ᭩ᗑ (2010).
2. ㄆ▱⑕ࢣ࢔࡛౑ࢃࢀࡿ⸆ࡢ᭱᪂▱ぢ ㄆ▱⑕௓ㆤ. ᮌཎ Ṋኈ vol.10. ᫓ྕ 74-79ࠊኟྕ 96-102ࠊ⛅ྕ
94-100ࠊ෤ྕࠊ68-74 (2009).
3. ᪥ᮏⓎ ୡ⏺ࡀ㦫࠸ࡓ࢔ࣝࢶࣁ࢖࣐࣮⑓἞⒪⸆ࡢ㛤Ⓨ, ᪂ࡋ࠸⸆ࢆ࡝࠺๰ࡿ࠿㸫๰⸆◊✲ࡢ᭱๓⥺㸫,
ᮡᮏ ඵ㑻㸦ඹⴭ㸧, ࣈ࣮ࣝࣂࢵࢡࢫ, ➨ 7 ❶ 197-211 (2007).
4. ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫ஦඾㸦᪥ᮏࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫᏛ఍⦅㞟㸧. ᪂␃ ᚭᗈ㸦ඹⴭ㸧(2006).
5. ࢔ࣝࢶࣁ࢖࣐࣮⑓἞⒪⸆࡟ᠱࡅࡿᙉ࠸᝟⇕᭶หᐇ㦂་Ꮫ. ᮡᮏ ඵ㑻, 24, 1799-1803 (2006).
6. Nicotinic receptor-mediated protection against neurotoxicity and apoptosis Alzheimer’s Disease and Nicotinic
Acetylcholine Receptors: Neurocognitive Enhancement and Neuroprotection Kihara T. and Shimohama S.
CHAPTER 7 (2006).
7. ሷ㓟ࢻࢿ࣌ࢪࣝࡢ◊✲㛤Ⓨᡓ␎㸫ࡑࡢග࡜ᙳ➨ 19 ᅇࠕ኱Ꮫ࡜⛉Ꮫࠖබ㛤ࢩ࣏ࣥࢪ࣒࢘ㅮ₇཰㘓㞟. ᮡ
ᮏ ඵ㑻, 146-159 (2005).
8. ࢔ࣝࢶࣁ࢖࣐࣮⑓἞⒪⸆㛤Ⓨࡢክࢆ㏣ࡗ࡚. ᮡᮏ ඵ㑻, ࣂ࢖࢜ࢧ࢖࢚ࣥࢫ࡜࢖ࣥࢲࢫࢺ࣮ࣜ 63,
11-15 (2005).
9. ぢᯝ࡚ࡠ๰⸆ࡢክ. ᮡᮏ ඵ㑻, ᪥⸆⌮ㄅ࢔ࢦࣛ 126, 167-168 (2005).
10. ࢔ࣝࢶࣁ࢖࣐࣮⑓࡜ࢽࢥࢳࣥᛶ࢔ࢭࢳࣝࢥࣜࣥཷᐜయ. ᮌཎ Ṋኈࠊୗ℈ ಇ, D&N Trends Nicotine
Lecture (2005).
11. ࣇ࢓࣐ࣝࢩ࢔㺀ᱩ⊃㛫ⓗ㺁๰⸆ࡢࡍࡍࡵ. ᮡᮏඵ㑻, 40, 889 (2004).
12. ࢻࢿ࣌ࢪࣝ㸸㛤Ⓨ࡜἞⒪ࡢⓎᒎ. ᮡᮏඵ㑻, ᪥⸆⌮ㄅ 124, 163-170 (2004).
− 357 −
ක⮎ຠℂ⺰⸳⸘ቇ⻠ᐳ
ᜂᒰᢎ᝼㧔ℂቇඳ჻㧕ർᶆ๺ᄦ㧔߈ߚ߁ࠄ ߆ߕ߅㧕
㧔2003.8-2006.3 ቴຬᢎ᝼‫ ޔ‬
2006.4-2008.7 ᜂᒰᢎ᝼㧕
ᤘ๺ 46 ᐕᄢ㒋Ꮢ┙ᄢቇත‫ޔ‬ᤘ๺ 51 ᐕหᄢቇᄢቇ㒮ℂቇ⎇ⓥ⑼
ඳ჻⺖⒟ୃੌ
ነ㒝⻠ᐳಎᢎ᝼㧔ඳ჻㧔⮎ቇ㧕㧕ખ⷏ ഞ㧔ߥ߆ߦߒ ޿ߐ߅㧕㧔2003.8-2007.3
ነ㒝⻠ᐳഥᢎ᝼‫ޔ‬2007.4-2008.3 ነ㒝⻠ᐳಎᢎ᝼‫ޔ‬2008.3 ㅌ⡯㧕
ᤘ๺ 58 ᐕᄢ㒋ᄢቇත‫ޔ‬ᤘ๺ 60 ᐕᄢ㒋ᄢቇᄢቇ㒮⮎ቇ⎇ⓥ⑼ୃ჻⺖⒟ୃ
ੌ
ነ㒝⻠ᐳഥᢎ㧔ඳ჻㧔ℂቇ㧕㧕᧛↰స⟤㧔߻ࠄߚ ߆ߟߺ㧕
㧔2003.10-2008.7㧕
ᐔᚑ 11 ᐕජ⪲ᄢቇත‫ޔ‬ᐔᚑ 15 ᐕ✚ว⎇ⓥᄢቇ㒮ᄢቇᢙ‛⑼ቇ⎇ⓥ⑼
ඳ჻⺖⒟ਛㅌ
㧔ർᶆᢎ᝼㧕
⎇ⓥߩ᭎ⷐ
ᧄ⻠ᐳߪ‫⮮ޔ‬ᴛ⮎ຠᎿᬺ㧔ᩣ㧕㧔⃻ࠕࠬ࠹࡜ࠬ⵾⮎㧔ᩣ㧕
㧕ߦࠃࠆነ㒝⻠ᐳߢ‫ޔ‬ᐔᚑ 15 ᐕ 8 ᦬߆ࠄᐔ
ᚑ 20 ᐕ 7 ᦬߹ߢߩ 5 ᐕ㑆⸳⟎ߐࠇߚ‫⻠ᧄޕ‬ᐳߢߪ‫ᦨޔ‬వ┵ߩ⸘▚ൻቇ࡮ℂ⺰ൻቇ⊛⸘▚ᚻᴺࠍᵴ↪ߒ
ߡ‫ޔ‬Structure-Based Drug Design(SBDD)ߦ᦭↪ߥᣇᴺ⺰ࠍ㐿⊒ߔࠆߎߣࠍ⋡ᮡߣߒߡ⎇ⓥࠍⴕߞߚ‫ޕ‬SBDD
ߪ‫ޔ‬1990 ᐕઍೋ㗡ߦᚑഞ଀߇ႎ๔ߐࠇ‫ߪߢ੹ޔ‬ഃ⮎⎇ⓥߢᏱ↪ߐࠇࠆࠕࡊࡠ࡯࠴ߦߥߞߡ߅ࠅ‫੹ޔ‬ᓟ⋉‫ޘ‬
㊀ⷐߥഃ⮎ᛛⴚߦߥࠆߎߣ߇ᦼᓙߐࠇߡ޿ࠆ‫⃻ޕ‬࿷ SBDD ߩࡏ࠻࡞ࡀ࠶ࠢߪ‫ߚߒࡦࠗࠩ࠺ޔ‬ൻว‛ߩ࠲
࡯ࠥ࠶࠻࠲ࡦࡄࠢ⾰ߦኻߔࠆᵴᕈ㧔ࠕࡈࠖ࠾࠹ࠖ㧕ߩቯ㊂⊛ߥ⹏ଔߦ޽ࠅ‫੍ࠖ࠹࠾ࠖࡈࠕޔ‬᷹ߩ㜞♖ᐲ
ൻ߇᳞߼ࠄࠇߡ޿ࠆ‫⻠ᧄޕ‬ᐳߢߪ‫ᦨߦ․ޔ‬ᣂߩ㊂ሶൻቇ⸘▚ᴺࠍᵴ↪ߒߡࠕࡈࠖ࠾࠹ࠖߩ㜞♖ᐲ੍᷹ᴺ
ߩ㐿⊒ߦขࠅ⚵ࠎߛ‫ޔߚ߹ޕ‬ᢎ⢒ߢߪ‫ޔ‬ක⮎ຠ⸳⸘ߦ߅ߌࠆ⸘▚ൻቇߩᓎഀࠍᾫ⍮ߒߚഃ⮎ࡑࠗࡦ࠼ߣ
㜞޿ࠬࠠ࡞ࠍ᦭ߔࠆ⎇ⓥ⠪ߩ⢒ᚑߦ㊀ὐࠍ⟎޿ߚ‫⻠ᧄޕ‬ᐳߩ⚳ੌᓟߪ‫⻠ᧄޔ‬ᐳߩ⎇ⓥ࡮ᢎ⢒ߩᚑᨐߪࠪ
ࠬ࠹ࡓࠤࡕ࠮࡜ࡇ࡯㧔ഃ⮎⸘▚ൻቇ㧕ಽ㊁ߦฃߌ⛮߇ࠇߚ‫ޕ‬
㔚ሶ⁁ᘒℂ⺰ߦࠃࠆ࠲ࡦࡄࠢ⾰ߣක⮎ຠ୥⵬ൻว‛ߩಽሶ㑆⋧੕૞↪ߩ♖ኒ⸃ᨆ
࠲ࡦࡄࠢ⾰ߣ࡝ࠟࡦ࠼ߩࠕࡈࠖ࠾࠹ࠖࠍ♖ᐲࠃߊ⸘▚੍᷹ߔࠆߚ߼ߦߪ‫ޔ‬ਔಽሶ㑆ߦ௛ߊ⋧੕૞↪
ࠍ♖ኒߦ⸃ᨆߔࠆߎߣ߇ၮᧄߣߥࠆ‫ޕ‬ᓥ᧪‫ߪࠇߎޔ‬ฎౖ⊛࡮⚻㛎⊛ߥಽሶജ႐ߦࠃࠆ⸘▚ࠍⴕ߁ߎ
ߣ߇৻⥸⊛ߢ޽ߞߚ‫ߩߎޔߒ߆ߒޕ‬ᣇᴺߪ CH/Ǹߥߤ࡝ࠟࡦ࠼⚿วߦ㊀ⷐߥᒙ޿⋧੕૞↪ߩ⴫⃻ߪ
♖ᐲ߇ਇචಽߢ޽ࠆ‫৻ޕ‬ᣇ‫ޔ‬㊂ሶൻቇ⸘▚ߪᒙ޿⋧੕૞↪ߦߟ޿ߡ߽ḩ⿷ߢ߈ࠆ♖ᐲߢ⸘▚ߢ߈ࠆ
ߎߣ߇⍮ࠄࠇߡ޿ࠆ߇‫ߥ߁ࠃߩ⾰ࠢࡄࡦ࠲ޔ‬Ꮒᄢಽሶߢߪ⸘▚ᤨ㑆߇߆߆ࠅߔ߉ࠆߚ߼‫ޔ‬ታ㓙ߦ⸘
▚ࠍⴕ߁ߩߪ࿎㔍ߢ޽ߞߚ‫߇ߜߚ⑳ޕ‬㐿⊒ߒߚࡈ࡜ࠣࡔࡦ࠻ಽሶ゠㆏(FMO)ᴺߪ‫⾰ࠢࡄࡦ࠲ޔ‬㧙࡝
ࠟࡦ࠼ⶄว૕ࠍਣߏߣ⸘▚ߔࠆߎߣࠍน⢻ߦߒߚᣇᴺߢ޽ࠅ‫ߩߎޔ‬ᣇᴺߦࠃࠅ FK506 ⚿ว࠲ࡦࡄࠢ
⾰ࠍ㗴᧚ߦߒߡ‫ޔ‬ಽሶ㑆⋧੕૞↪ࠍ⹦⚦ߦ⸃ᨆߒ‫⼂⹺࠼ࡦࠟ࡝ߩ⾰ࠢࡄࡦ࠲ߩߎޔ‬᭽ᑼࠍ᣿ࠄ߆ߦ
ߒߚ‫ޕ‬
⛔⸘࡮ᖱႎಣℂߦࠃࠆක⮎ຠ୥⵬ൻว‛ߩࠕࡈࠖ࠾࠹੍᷹ࠖᴺߩ㐿⊒
㊂ሶൻቇ⸘▚ߪಽሶ㑆⋧੕૞↪ߩ㜞♖ᐲ⸃ᨆߦㆡߒߡ޿ࠆ߇‫ޔ‬ᄙᢙߩ࡝ࠟࡦ࠼ಽሶߦߟ޿ߡߩ⸘▚
ࠍⴕ߁ߦߪ⸘▚ᤨ㑆߇߆߆ࠅߔ߉ࠆ‫ޕ‬ഃ⮎⎇ⓥߩㆊ⒟ߢߪ‫ޔ‬ᄙዋ♖ᐲ߇ૐߊߡ߽⸘▚ᤨ㑆߇ዋߥߊ
ߡߔ߻⸘▚ᴺ߇ᔅⷐߢ޽ࠆ‫ޕ‬ᢙ 10 ਁൻว‛ߩࡃ࡯࠴ࡖ࡞ࠬࠢ࡝࡯࠾ࡦࠣࠍⴕ߁ߎߣࠍᔨ㗡ߦ‫࠲ޔ‬
ࡦࡄࠢ⾰ߣ࡝ࠟࡦ࠼ߩ⋧੕૞↪ࠛࡀ࡞ࠡ࡯ࠍ⸥ㅀሶߣߔࠆቯ㊂⊛᭴ㅧᵴᕈ⋧㑐ࡕ࠺࡞ߩ᭴▽ࠍⴕ
޿‫ ߿࠯࡯࠳ࡒࠕ࠺ࡦࠪࡁ࠺ࠕޔ‬HIV-1 ࡊࡠ࠹ࠕ࡯࠯ࠍ࠲࡯ࠥ࠶࠻࠲ࡦࡄࠢ⾰ߣߒߡ᦭ലᕈࠍᬌ⸽ߒ
ߚ‫ޕ‬
⎇ⓥᵴേߦኻߔࠆ⥄Ꮖὐᬌ࡮⹏ଔ
⎇ⓥ⺰ᢥ‫ࠍߤߥᦠ⪺ޔ⺑✚ޔ‬ᄙᢙ⊒⴫ߒߡ߅ࠅ‫⎇ޔ‬ⓥᵴേߪᵴ⊒ߢ޽ࠆߣ⸒߃ࠆ‫ޔߚ߹ޕ‬ർᶆᢎ᝼߇
࿖ౝᄖߩቇળ࡮ࠪࡦࡐࠫ࠙ࡓ╬ߢࠥࠬ࠻ࠬࡇ࡯ࠞ࡯ߣߒߡᄙᢙߩ⻠Ṷࠍⴕߞߡ޿ࠆߎߣߪ‫ޔ‬ౝᄖ߆ࠄ㜞
޿⹏ଔࠍฃߌߡ޿ࠆߎߣߩ⸽ߢ޽ࠆߣ⠨߃ߡ޿ࠆ‫ޕ‬
ᢎ⢒ߩ᭎ⷐ
ቇㇱᢎ⢒㧦ᒰಽ㊁ߪ‫ޔ‬2 ࿁↢೨ᦼߩ‛ℂൻቇΣ㧔㊂ሶൻቇ㧕‫ޔ‬ഃ⮎‛ℂൻቇṶ⠌ 1‫ޔ‬3 ࿁↢೨ᦼߩ⮎ቇ
ኾ㐷ታ⠌Σ㧔ಽሶ゠㆏ᴺ⸘▚ታ⠌㧕ࠍᜂᒰߒߡ޿ࠆ‫ޕ‬ಽሶߩ᭴ㅧ࡮෻ᔕ࡮ᕈ⾰ߐࠄߦߪ࠼࡜࠶ࠣ࠺ࠩࠗ
ࡦߢ㊀ⷐߥᒙ޿ಽሶ㑆⋧੕૞↪ࠍℂ⸃ߔࠆߚ߼ߩၮ␆ߣߒߡߩ㊂ሶൻቇࠍಽ߆ࠅ߿ߔߊ⻠⟵ߒߡ޿ࠆ‫ޕ‬
᝼ᬺߪ‫ޔ‬㓐ᤨዊ࠹ࠬ࠻ࠍⴕ޿Ṷ⠌ߣ޽ࠊߖߡ‫ޔ‬ℂ⸃ᐲࠍᛠីߒߥ߇ࠄㅴ߼ߡ޿ࠆ‫ޔߚ߹ޕ‬ಽሶ゠㆏ᴺ⸘
− 358 −
▚ታ⠌ࠍឭଏߒ‫ޔ⟵⻠ޔ‬Ṷ⠌‫ޔ‬ታ⠌ࠍ⚵ߺวࠊߖߡℂ⸃߇ᷓ߹ࠆࠃ߁ߦᎿᄦߒߡ޿ࠆ‫ޕ‬
තᬺታ⠌෸߮ᄢቇ㒮ᢎ⢒㧦ቇㇱቇ↢ߦߪ‫ᦨޔ‬ೋߦ 3 ࡩ᦬⒟ᐲߩ㑆ߦ㓸ਛ⊛ߦಽሶേജቇᴺߣಽሶ゠㆏
ᴺߩℂ⺰ߩቇ⠌ߣ⸘▚Ṷ⠌ࠍ⺖ߒ‫ޔ‬ၮᧄ⊛ߥ⍮⼂ߣᛛⴚࠍ⠌ᓧߢ߈ࠆࠃ߁ߦߒߡ޿ࠆ‫ߩߘޕ‬ᓟߦ⎇ⓥ⺖
㗴ࠍਈ߃‫⺖ޔ‬㗴ߦኒធߦ㑐ㅪߔࠆ⺰ᢥࠍෳ⠨ߦߒߡ‫⺖ߦࠄߐޔ‬㗴⎇ⓥㆀⴕߢᔅⷐߣߥࠆ୘೎ౕ૕⊛ߥ⍮
⼂ߣ⸘▚ᚻᴺࠍ⠌ᓧߢ߈ࠆࠃ߁ߦߒߡ޿ࠆ‫ߩߘޕ‬ᓟߪฦ⥄ߩ⊒ᗐߦၮߠ޿ߡ‫⎇ߦ↱⥄ޔ‬ⓥࠍⴕ߁ࠃ߁ߦ
ᜰዉߒߡ޿ࠆ‫ޕ‬Ფㅳࠣ࡞࡯ࡊ࠮ࡒ࠽࡯ߦ߅޿ߡฦ⥄߇⎇ⓥߩㅴ᝞⁁ᴫࠍႎ๔ߒ‫ో࡯ࡃࡦࡔޔ‬ຬߦࠃࠆ⼏
⺰ࠍㅢߓߡ⎇ⓥߩㅴ߼ᣇࠍᜰዉߒߡ޿ࠆ‫৻ޕ‬ᣇ‫ޔ‬ㅳ 1 ࿁㔀⹹ળߢฦ⥄ߩ⺖㗴ߦ㑐ㅪߒߚ⺰ᢥ⚫੺ࠍ⺖ߒ‫ޔ‬
ᦨᣂߩ⎇ⓥേะࠍᛠីߔࠆߣߣ߽ߦ‫⺰ߩ࡯ࡃࡦࡔߩઁޔ‬ᢥ⚫੺ࠍ⡞޿ߡ᏷ᐢߊᦨᣂߩ⎇ⓥᚑᨐࠍቇ߱ߎ
ߣ߇ߢ߈ࠆࠃ߁ߦߒߡ޿ࠆ‫ࡦ࡚ࠪ࡯࠹ࡦ࠯࡟ࡊޔߦࠄߐޕ‬⢻ജࠍะ਄ߐߖࠆߚ߼ߦ‫࡯࠽ࡒ࠮ࡊ࡯࡞ࠣޔ‬
ߢߪࡄࡢ࡯ࡐࠗࡦ࠻ේⓂࠍ૞ᚑߒߡ⊒⴫ߔࠆߎߣߦߒߡ޿ࠆ‫ޕ‬
ᢎ⢒ᵴേߦኻߔࠆ⥄Ꮖὐᬌ࡮⹏ଔ
ቇㇱቇ↢ߩ⻠⟵ߦߟ޿ߡߪ‫ޔ‬ቇ↢ߩ᝼ᬺ⹏ଔߩ⚿ᨐࠍෳ⠨ߦߒߡᡷༀࠍ࿑ߞߡ޿ࠆ‫⎇ޕ‬ⓥቶߢߩᢎ⢒
ߪ‫ޔ‬ᣧߌࠇ߫ୃ჻ 1 ᐕ‫ޔ‬ᮡḰ⊛ߦߪୃ჻ 2 ᐕߢቇળ⊒⴫ࠍⴕ߁ߎߣࠍ⋡ᮡߦᜰዉߒ‫ోޔ‬ຬߎࠇࠍ㆐ᚑߒ
ߡ޿ࠆ‫ߢ⴫⊒ߩࠄࠇߎޔߦࠄߐޕ‬ቇ↢ߩ߶ߣࠎߤోຬ߇ࡐࠬ࠲࡯⾨ߥߤࠍฃ⾨ߒ‫ ߜ߁ޔ‬2 ฬ߇ୃ჻⺖⒟
࿷ቇਛߦ⺰ᢥߣߒߡ߹ߣ߼ߡ࿖㓙⹹ߦឝタߐࠇߚ‫ޔߚ߹ޕ‬࿖㓙ળ⼏ߢߩ⊒⴫ࠍផᅑߒߡ߅ࠅ‫ߢ߹ࠇߎޔ‬
ߦ࿷☋ߒߚ㒮↢ߩ߁ߜ 3 ฬ߇࿖ᄖߢ㐿߆ࠇߚ࿖㓙ળ⼏ߢ⊒⴫ࠍⴕߞߚ‫ୃޕ‬჻⺖⒟ୃੌ⠪ߪ‫ޔ‬ᄢቇഥᚻ㧔㧝
ฬ㧕‫⎇ઁޔ‬ⓥ⑼ඳ჻⺖⒟ቇ↢㧔1 ฬ㧕
‫⮎⵾ޔ‬ડᬺ⎇ⓥ⡯㧔1 ฬ㧕‫⮎ޔ‬೷Ꮷ㧔1 ฬ㧕ߣߒߡᵴべߒߡ޿ࠆ‫ߎޕ‬
ࠇࠄߩߎߣߪ‫ᧄޔ‬ಽ㊁ߩᢎ⢒ߣ⎇ⓥ߇᏷ᐢߊ߆ߟ㜞޿࡟ࡌ࡞ߦ޽ࠆߎߣ߇⹏ଔߐࠇߚ⸽ߢ޽ࠆ‫ޕ‬
㧔ේ⪺㧕
1. Conformational change of adenosine deaminase during ligand-exchange in a crystal, Takayoshi Kinoshita,
Toshiji Tada, Isao Nakanishi, Biochem. Biophys. Res. Commun. 373, 53-57 (2008).
2. Accuracy of the three-body fragment molecular orbital method (FMO) applied to Møller-Plesset perturbation
theory, Dmitri G. Fedorov, Kazuya Ishimura, Toyokazu Ishida, Kazuo Kitaura, Peter Pulay, Shigeru Nagase
J. Comp.Chem., 28, 1476-1484 (2007).
3. Molecular recognition mechanism of FK506 binding protein (FKBP): All electron fragment molecular
orbital (FMO) study, Isao Nakanishi, Dmitri G. Fedorov, Kazuo Kitaura, Proteins: Struct., Funct., Bioinf., 68,
145-158 (2007).
4. Change in a protein’s electronic structure induced by an explicit solvent: an ab initio Fragment Molecular
Orbital (FMO) study of ubiquitin, Yuto Komeiji, Toyokazu Ishida, Dmitri G. Fedorov, Kazuo Kitaura,
J.Comp. Chem., 28, 1750-1762 (2007).
5. The fragment molecular orbital method for geometry optimizations of polypeptides and proteins, Dmitri G.
Fedorov,Toyokazu Ishida, Masami Uebayasi, Kazuo Kitaura, J. Phys. Chem. A, 111, 2722-2732 (2007).
6. Time-dependent density functional theory with multilayer fragment molecular orbital method, Mahito Chiba,
Dmitri G. Fedorov, Kazuo Kitaura, Chem. Phys. Lett., 444, 346-350 (2007).
7. Ab Initio NMR Chemical-shift Calculations on Proteins Using Fragment Molecular Orbitals with
Electrostatic Environment, Qi Gao, Satoshi Yokojima, Toshiyuki Kohno, Toyokazu Ishida, Dmitri G.
Fedorov, Kazuo Kitaura, Masamichi Fujihira, and Shinichiro Nakamura, Chem. Phys. Lett.,
445,331-339(2007).
8. Time-dependent density functional theory based on fragment molecular orbital method, Mahito Chiba,
Dmitri G. Fedorov, Kazuo Kitaura, J. Chem. Phys.,127,104108-104119 (2007).
9. Pair interaction energy decomposition analysis, Dmitri G. Fedorov, Kazuo Kitaura, J. Comp. Chem., 28,
222-237 (2007).
10. All electron quantum chemical calculation of the entire enzyme system confirms a collective catalytic device
in the chorismate mutase reaction, Toyokazu Ishida, Dmitri G. Fedorov and Kazuo Kitaura, J. Phys. Chem. B,
110, 1457-1463 (2006).
11. The polarizable continuum model (PCM) interfaced with the fragment molecular orbital method (FMO),
Dmitri G. Fedorov, Kazuo Kitaura, Hui Li, Jan H. Jensen, Mark S. Gordon, J. Comp. Chem., 27, 976-985
(2006).
12. Stereoselective synthesis of 3,6-disubstituted-3,6-dihydropyridin-2-ones as potential diketopiperazine
mimetics using organocopper-mediated anti-S(N)2 ' reactions and their use in the preparation of low-
molecule CXCR4 antagonists, Niida A, Tanigaki H, Inokuchi E, Sasaki Y, Oishi S, Ohno H, Tamamura H,
Wang ZX, Peiper SC, Kitaura K, Otaka A, Fujii N, J. Org.Chem., 71, 3942-3951 (2006).
13. Synthesis of (Z)-alkene and (E)-fluoroalkene-containing diketopiperazine mimetics utilizing organocopper-mediated reduction-alkylation and diastereoselectivity examination using DFT calculations, Niida A,
Mizumoto M, Narumi T, Inokuchi E, Oishi S, Ohno H, Otaka A, Kitaura K, Fujii N, J. Org.Chem., 71,
− 359 −
4118-4129 (2006).
14. Molecular interactions between estrogen receptor and its ligand studied by ab initio fragment molecular
orbital method, Kaori Fukuzawa, Yuji Mochizuki, Sigenori Tanaka, Kazuo Kitaura, Tatsuya Nakano, J. Phys.
Chem. B, 110, 16102-16110 (2006).
15. Binding affinity prediction of non-peptide inhibitors of HIV-1 protease using the COMBINE model
introduced from peptide inhibitors, Sinya Nakamura, Isao Nakanishi, Kazuo Kitaura, Bioorganic &
Medicinal Chemistry Letters, 16, 6334-6337 (2006).
16. Three-body fragment molecular orbital method for accurate calculations of large systems, Dmitri G. Fedorov,
Kazuo Kitaura, Chem. Phys. Lett., 433, 182-187 (2006).
㧔✚⺑㧕
1. Extending the power of quantum chemistry to large systems with the fragment molecular orbital method,
Dmitri G. Fedorov, Kazuo Kitaura, J. Phys. Chem. A, 111, 6904-6914 (2007).
㧔⪺ᦠ㧕
1. ⮎ࠍ࠺ࠩࠗࡦߔࠆ㨪ൊߣ⚻㛎߆ࠄࠦࡦࡇࡘ࡯࠲࠽ࡆࠥ࡯࡚ࠪࡦ߳㨪, ખ⷏ഞ, ഃ⮎⎇ⓥߩᦨ೨✢‫ޔ‬
⻠⺣␠, pp. 109-142 (2007).
2. Theoretical development of the fragment molecular orbital (FMO) method, Dmitri G. Fedorov and Kazuo
Kitaura, In Modern methods for theoretical physical chemistry and biopolymers, E. Starikow, S. Tanaka and J.
Lewis (Eds.), Elsevier (Amsterdam), pp. 3-38 (2006).
− 360 −
ᐇ㊶⮫ᗋ⸆Ꮫศ㔝
㸦⤫ྜ⸆Ꮫᩍ⫱㛤Ⓨࢭࣥࢱ࣮㸧
≉ᐃᩍᤵ㸦⸆Ꮫ༤ኈ㸧ᰤ⏣ᩄஅ㸦ࡉ࠿࠼ࡔ ࡜ࡋࡺࡁ㸧㸦2010. 8 ╔௵㸧
᫛࿴ 58 ᖺி㒔኱Ꮫ༞ࠊ᫛࿴ 63 ᖺྠ኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉
༤ኈㄢ⛬ಟ஢
㸦ᰤ⏣ᩍᤵ㸧
ࢭࣥࢱ࣮ࡢᴫせ
་⸆ရ㛤Ⓨࡣࠊ๰⸆ࢱ࣮ࢤࢵࢺ᥈⣴ࠊ࣮ࣜࢻ໬ྜ≀ࡢ๰ᡂ㺃᭱㐺໬ࠊ᭷ຠᛶ࣭Ᏻ඲ᛶホ౯ࠊ⮫ᗋ◊✲
➼ࠊከᒱ࡟Ώࡿ୍㐃ࡢࣉࣟࢭࢫ࠿ࡽ࡞ࡿࠋ㏆ᖺࠊᚑ᮶ࡢὶࢀ࡟ἢࡗ࡚ྛࣉࣟࢭࢫࢆಶู࡟ 㐍ࡵࡿࡔࡅ
࡛ࡣ㛤Ⓨࡀᅔ㞴࡞ᑐ㇟໬ྜ≀ࡀከࡃࠊ᪂ࡓ࡟ࣉࣟࢭࢫ඲యࢆಠ▔ࡋࡓ㛤Ⓨࡀồࡵࡽࢀ࡚࠸ࡿࠋᚑࡗ࡚ࡇ
ࢀ࠿ࡽࡢ๰⸆⛉Ꮫ⪅࡟ࡣࠊಶูࡢᑓ㛛㡿ᇦࡢࢫ࣌ࢩࣕࣜࢫࢺࡢ㈨㉁ࡢࡳ࡞ࡽࡎࠊ ་⸆ရ㛤Ⓨࣉࣟࢭࢫ
඲యࢆど㔝࡟ศ㔝ᶓ᩿ⓗ࡞▱㆑ࠊᢏ⬟ࠊែᗘࢆවࡡഛ࠼࡚࠸ࡿࡇ࡜ࡀ୙ྍḞ࡜࡞ࡿࠋ
ி㒔኱Ꮫ⸆Ꮫ㒊࣭⸆Ꮫ◊✲⛉࡛ࡣࠊ⸆Ꮫ࡟࠾ࡅࡿ͆๰͇࡜͆⒪͇ࡢᣐⅬᙧᡂࢆᩍ⫱࣭◊✲ࡢᇶᮏⓗ⌮
ᛕ࡜ࡋ࡚ᥖࡆࠊ኱Ꮫタ⨨ᇶ‽࡟ᇶ࡙ࡁࠊᏛ㒊ᩍ⫱࡟࠾࠸࡚ࡣࠊᖹᡂ 18 ᖺᗘ࡟ᑟධࡉࢀࡓ㧗ᗘ࡞⸆๣ᖌ
ᩍ⫱ࢆ┠ᣦࡍ 6 ᖺไᩍ⫱ไᗘ࡜ࠊ๰⸆◊✲⪅ࢆึࡵ࡜ࡍࡿከᵝ࡞ேᮦࡢ㣴ᡂࢆ┠ⓗ࡜ࡍࡿ 4 ᖺไᩍ⫱ไ
ᗘࢆ୪⨨ࡋࠊྛ㡿ᇦ࡛ࡢࢫ࣌ࢩࣕࣜࢫࢺ㣴ᡂࢆ┠ᣦࡋ࡚ᩍ⫱ࢆ㐍ࡵ࡚࠸ࡿࠋྛไᗘࡢᏛ⏕ࡀ௚᪉ࡢไᗘ
ࡢ࣒࢝ࣜ࢟ࣗࣛࢆᒚಟࡋ࡚┦஫࡟⛉┠ࢆྲྀࡾྜ࠺ࡇ࡜ࡀ࡛ࡁࡿࡼ࠺㓄៖ࡋࠊ࠾஫࠸࡟᩿∦ⓗ࡟ࡣྛ㡿ᇦ
࡟㛵ࡍࡿᏛ⩦ࡀྍ⬟࡞≧ἣ࡛࠶ࡿࠋ
ࡇࡢࡼ࠺࡞⫼ᬒࡢࡶ࡜ࠊ௒ᅇࡢྲྀ⤌ࡳࡣࠊࡇࢀ࠿ࡽࡢ๰⸆࡟ồࡵࡽࢀࡿ⬟ຊࢆ⫱ᡂࡍࡿࡓࡵࠊ⌧ᅾࡢ
ಶูࡢᑓ㛛㡿ᇦࡢࢫ࣌ࢩࣕࣜࢫࢺࡢ㈨㉁⫱ᡂᩍ⫱࡟ຍ࠼ࠊ་⸆ရ㛤Ⓨࢆಠ▔ⓗ࡟ᤊ࠼ᝈ⪅࡟Ⰻ㉁ࡢ⸆≀
἞⒪ࢆᥦ౪ࡍࡿ࡜࠸࠺⸆Ꮫࡢᮏ㉁࡟㛵ࢃࡾࠊ⤫୍ⓗ࡟ᚲせ࡜ࡉࢀࡿ⸆Ꮫ⥲ྜᇶ♏ᩍ⫱ࢆ᪂つ࡟ᒎ㛤ࡍࡿ
ࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚ࠊ᪂⸆Ꮫᩍ⫱ไᗘୗ࡛ࡢྛᏛ⛉ࡢᯟࢆ㉸࠼࡚ࠊ་⸆ရ◊✲⌧ሙ࡬ࡢཧຍ࣭య㦂ᆺᏛ⩦
ཬࡧࣔࢹࣝ་⸆ရ㛤Ⓨ࣭་⒪ᛂ⏝஦ᴗ࡬ࡢཧຍࢆ᝿ᐃࡋࡓၥ㢟ゎỴᆺࡢ₇⩦࣭ᐇ⩦ࢆ୰ᚰ࡜ࡋࡓ᪂ࡓ࡞
ᩍ⫱࣒࢝ࣜ࢟ࣗࣛࠕ๰⸆࣭⫱⸆ຊ⫱ᡂࣉࣟࢢ࣒ࣛࠖࢆᵓ⠏ࡍࡿࠋࡉࡽ࡟ࠊࡑࡢᡂᯝࢆ㧗Ꮫᖺࠊ኱Ꮫ㝔ᩍ
⫱࡛㐍ᒎࡉࡏࡿࡇ࡜࡟ࡼࡗ࡚ศ㔝ᶓ᩿ⓗ࡞๰⸆࣭⫱⸆ຊࢆᣢࡗࡓඛᑟⓗ๰⸆◊✲࣮ࣜࢲ࣮ࢆ⫱ᡂࡍࡿࡓ
ࡵࡢᶓ᩿ⓗ⤫ྜᆺᩍ⫱ࡢࣉࣛࢵࢺࣇ࢛࣮࣒ࢆ⠏ࡁࠊᏛኈຊࢆ⥲ྜⓗ࡟㧗ࡵࡿᩍ⫱ࢩࢫࢸ࣒ࢆᵓ⠏ࡍࡿࠋ
ࢭࣥࢱ࣮άື࡟ᑐࡍࡿ⮬ᕫⅬ᳨࣭ホ౯
᪂ࡓ࡟ࠕ་⸆ရ㛤Ⓨࣉࣟࢪ࢙ࢡࢺ₇⩦Ϩࠖ
㸦3 ᖺḟࠊ₇⩦⛉┠ࠊ㞟୰㸧
ࠊ
ࠕ་⸆ရ㛤Ⓨࣉࣟࢪ࢙ࢡࢺ₇⩦
ϩࠖ
㸦4 ᖺḟࠊ₇⩦⛉┠ࠊ㞟୰㸧ࠊࠕ⤫ྜᆺ⸆Ꮫ₇⩦ࠖ㸦1ࠊ3 ᖺḟࠊ₇⩦⛉┠ࠊ㞟୰㸧ࠊࠕ་⒪೔⌮ᐇ⩦ࠖ
㸦1ࠊ
4 ᖺḟࠊㅮ⩏₇⩦⛉┠ࠊ㞟୰㸧ࢆ㛤ㅮࡋࡓࠋᏛ⏕ࡢホุࡣ㠀ᖖ࡟ࡼࡃࠊศ㔝ᶓ᩿ⓗ࡞๰⸆࣭⫱⸆ຊࢆᣢ
ࡗࡓඛᑟⓗ๰⸆◊✲࣮ࣜࢲ࣮ࢆ⫱ᡂࡍࡿࡓࡵࡢᶓ᩿ⓗ⤫ྜᆺᩍ⫱ࡢᇶ┙ࡀᙧᡂ࡛ࡁࡓ࡜⪃࠼࡚࠸ࡿࠋ
㸦ཎⴭ㸧
1. K.Seki, K.Senzaki, Y.Tsuduki, T.Ioroi, M.Fujii, H.Yamauchi, Y.Shiraishi, I.Nakata, K.Nishiguchi,
T.Matsubayashi, Y.Takakubo, N.Okamura, M.Yamamori, T.Tamura and T.Sakaeda, Risk factors for
oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer,
Int.J.Med.Sci., in press.
2. M.Yagi, T.Nakamura, Y.Okizuka, Y.Oyazato, Y.Kawasaki, S.Tsuneishi, T.Sakaeda, M.Matsuo, K.Okumura
and N.Okamura, Effect of CPS1 4217C>A genotype on valproic acid-induced hyperammonemia, Pediatr.Int.,
52(5), 744-748 (2010).
3. T.Yagami, Y.Yamamoto, K.Takase, K.Ueda, N.Takasu, N.Okamura, T.Sakaeda and M.Fujimoto, Fibroblast
growth factor 2 induces apoptosis in the early primary culture of rat cortical neurons, Exp.Cell Res., 316(14),
2278-2290 (2010).
4. M.Horinouchi, M.Yagi, H.Imanishi, T.Mori, T.Yanai, A.Hayakawa, Y.Takeshima, M.Hijioka, N.Okamura,
T.Sakaeda, M.Matsuo, K.Okumura and T.Nakamura, Association of genetic polymorphisms with
hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma,
Pediatr.Hematol.Oncol., 27(5), 344-354 (2010).
5. A.Kuwahara, M.Yamamori, M.Fujita, T.Okuno, T.Tamura, K.Kadoyama, N.Okamura, T.Nakamura and
T.Sakaeda, TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive
− 361 −
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell
carcinoma, J.Exp.Clin.Cancer Res., 29:100 (2010).
Y.Takaoka, M.Ohta, A.Takeuchi, K.Miura, M.Matsuo, T.Sakaeda, A.Sugano and H.Nishio, Ligand
orientation governs conjugation capacity of UDP-glucuronosyltransferase 1A1, J.Biochem., 148(1), 25-28
(2010).
A.Kuwahara, M.Yamamori, K.Nishiguchi, T.Okuno, N.Chayahara, I.Miki, T.Tamura, K.Kadoyama,
T.Inokuma, Y.Takemoto, T.Nakamura, K.Kataoka and T.Sakaeda, Effect of dose-escalation of 5-fluorouracil
on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous
cell carcinoma, Int.J.Med.Sci., 7(1), 48-54 (2010).
A.Kuwahara, M.Yamamori, K.Nishiguchi, T.Okuno, N.Chayahara, I.Miki, T.Tamura, T.Inokuma,
Y.Takemoto, T.Nakamura, K.Kataoka and T.Sakaeda, Replacement of cisplatin with nedaplatin in a
definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophagealsquamous
cell carcinoma, Int.J.Med.Sci., 6(6), 305-311 (2009).
K.Takara, T.Sakaeda, M.Kakumoto, Y.Tanigawara, H.Kobayashi, K.Okumura, N.Ohnishi and T.Yokoyama,
Effects of Į-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular
transport, Oncol.Rep., 17(11-12), 527-533 (2009).
T.Inokuma, K.Takasu, T.Sakaeda and Y.Takemoto, Hydroxyl group-directed organocatalytic asymmetric
Michael addition of alpha, beta-unsaturated ketones with alkenylboronic acids, Org.Lett., 11(11), 2425-2428
(2009).
K.Takara, N.Kitada, E.Yoshikawa, K.Yamamoto, S.Horibe, T.Sakaeda, K.Nishiguchi, N.Ohnishi and
T.Yokoyama, Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of
irinotecan hydrochloride, Cancer Lett., 278(1), 88-96 (2009).
D.Yamasaki, T.Nakamura, N.Okamura, M.Kokudai, N.Inui, K.Takeuchi, H.Watanabe, M.Hirai, K.Okumura
and T.Sakaeda, Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors on the induction of MDR1 expression and function in LS180 cells, Eur.J.Pharm.Sci., 37(2),
126-132 (2009).
M.Kokudai, N.Inui, K.Takeuchi, T.Sakaeda, Y.Kagawa and H.Watanabe, Effects of statins on the
pharmacokinetics of midazolam in healthy volunteers, J.Clin.Pharmacol., 49(5), 568-573 (2009).
T.Nakamura, N.Okamura, M.Yagi, H.Omatsu, M.Yamamori, A.Kuwahara, K.Nishiguchi, M.Horinouchi,
K.Okumura and T.Sakaeda, Effects of ABCB1 3435C>T genotype on serum levels of cortisol and aldosterone
in women with normal menstrual cycles, Genet.Mol.Res., 8(2), 397-403 (2009).
Y.Shirasaka, R.Konishi, N.Funami, Y.Kadowaki, Y.Nagai, T.Sakaeda and S.Yamashita, Expression levels of
human P-glycoprotein in in vitro cell lines: correlation between mRNA and protein levels for P-glycoprotein
expressed in cells, Biopharm.Drug Dispos., 30(3), 149-152 (2009).
N.Chayahara, T.Tamura, M.Yamamori, Y.Kadowaki, T.Okuno, I.Miki, M.Tsuda, H.Nishisaki, T.Maeda,
Y.Inoue, K.Okumura, T.Azuma, M.Kasuga, T.Sakaeda and M.Hirai, Phase I and pharmacokinetic study of
tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced
colorectal cancer, Am.J.Clin.Oncol., 32(1), 56-60 (2009).
N.Kitada, K.Takara, T.Minegaki, C.Itoh, M.Tsujimoto, T.Sakaeda and T.Yokoyama, Factors affecting
sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines, Cancer
Chemother.Pharmacol., 62(4), 577-587 (2008).
N.Okamura, T.Masuda, A.Gotoh, T.Shirakawa, S.Terao, N.Kaneko, K.Suganuma, M.Watanabe, T.Matsubara,
R.Seto, J.Matsumoto, M.Kawakami, M.Yamamori, T.Nakamura, T.Yagami, T.Sakaeda, M.Fujisawa,
O.Nishimura and K.Okumura, Quantitative proteomic analysis to discover potential diagnostic markers and
therapeutic targets in human renal cell carcinoma, Proteomics, 8(15), 3194-3203 (2008).
T.Sakaeda, M.Yamamori, A.Kuwahara, S.Hiroe, T.Nakamura, K.Okumura, T.Okuno, I.Miki, N.Chayahara,
N.Okamura and T.Tamura, VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy
for esophageal squamous cell carcinoma in Japanese, Ther.Drug Monit., 30(4), 497-503 (2008).
A.Okamura, M.Yamamori, M.Shimoyama, Y.Kawano, H.Kawano, Y.Kawamori, S.Nishikawa, K.Minagawa,
K.Yakushijin, Y.Katayama, T.Sakaeda, M.Hirai and T.Matsui, Pharmacokinetics-based optimal
dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation,
Int.J.Hematol., 88(1), 104-110 (2008).
N.Kitada, K.Takara, C.Itoh, T.Minegaki, M.Tsujimoto, T.Sakaeda and T.Yokoyama, Comparative analysis of
cell injury after exposure to antitumor platinum derivatives in kidney tubular epithelial cells, Chemotherapy,
54(3), 217-223 (2008).
M.Yamamori, M.Taniguchi, S.Maeda, T.Nakamura, N.Okamura, A.Kuwahara, K.Iwaki, T.Tamura,
N.Aoyama, S.Markova, M.Kasuga, K.Okumura, T.Sakaeda, VEGF T-1498C polymorphism, a predictive
marker of differentiation of colorectal adenocarcinomas in Japanese, Int.J.Med.Sci., 5(2), 80-86 (2008).
C.Komoto, T.Nakamura, M.Yamamori, N.Ohmoto, H.Kobayashi, A.Kuwahara, K.Nishiguchi, K.Takara,
Y.Tanigawara, N.Okamura, K.Okumura and T.Sakaeda, Reversal effects of Ca2+ antagonists on multidrug
− 362 −
resistance via down-regulation of MDR1 mRNA, Kobe J.Med.Sci., 53(6), 355-363 (2007).
24. C.Komoto, T.Nakamura, N.Ohmoto, H.Kobayashi, T.Yagami, K.Nishiguchi, K.Iwaki, A.Kuwahara,
M.Yamamori, N.Okamura, K.Okumura and T.Sakaeda, Three-dimensional, but not two-dimensional, culture
results in tumor growth enhancement after exposure to anticancer drugs, Kobe J.Med.Sci., 53(6), 335-343
(2007).
25. T.Nakamura, K.Nozu, K.Iijima, N.Yoshikawa, Y.Moriya, M.Yamamori, A.Kako, M.Matsuo, A.Sakurai,
N.Okamura, T.Ishikawa, K.Okumura and T.Sakaeda, Association of cumulative cyclosporine dose with its
irreversible nephrotoxicity in Japanese patients with pediatric-onset auto-immune diseases, Biol.Pharm.Bull.,
30(12), 2371-2375 (2007).
26. K.Nishida, M.Okazaki, R.Sakamoto, N.Inaoka, H.Miyake, S.Fumoto, J.Nakamura, M.Nakashima, H.Sasaki,
M.Kakumoto and T.Sakaeda, Change in pharmacokinetics of model compounds with different elimination
processes in rats during hypothermia, Biol.Pharm.Bull., 30(9): 1763-1767 (2007).
27. S.Markova, T.Nakamura, H.Makimoto, T.Ichijima, M.Yamamori, A.Kuwahara, K.Iwaki, K.Nishiguchi,
N.Okamura, K.Okumura and T.Sakaeda, IL-1beta genotype-related effect of prednisolone on IL-1beta
production in human peripheral blood mononuclear cells under acute inflammation, Biol.Pharm.Bull., 30(8):
1481-1487 (2007).
28. A.Sakurai, Y.Onishi, H.Hirano, M.Seigneuret, K.Obanayama, G.Kim, E.L.Liew, T.Sakaeda, K.Yoshiura,
N.Niikawa, M.Sakurai and T.Ishikawa, Quantitative structure--activity relationship analysis and molecular
dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter
ABCB1 (P-glycoprotein/MDR1), Biochemistry, 46(26): 7678-7693 (2007).
29. K.Takara, M.Tsujimoto, M.Kokufu, N.Kitada, T.Sakaeda, N.Ohnishi and T.Yokoyama, Down-regulation of
MDR1 by cintinuous exposure to cisplatin in LLC-PK1 cells, Cancer Ther., 5A, 89-96 (2007).
30. M.Kawakami, T.Nakamura, N.Okamura, C.Komoto, S.Markova, H.Kobayashi, N.Hashimoto, K.Okumura
and T.Sakaeda, Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells, Biol.Pharm.Bull.,
30(6), 1065-1073 (2007).
31. T.Okuno, T.Tamura, M.Yamamori, N.Chayahara, T.Yamada, I.Miki, N.Okamura, Y.Kadowaki, N.Aoyama,
T.Nakamura, K.Okumura, T.Azuma, M.Kasuga and T.Sakaeda, Favorable genetic polymorphisms predictive
of clinical outcome of chemoradiotherapy for Stage II/III esophageal squamous cell carcinoma in Japanese,
Am.J.Clin.Oncol., 30(3), 252-257 (2007).
32. N.Kitada, K.Takara, M.Tsujimoto, T.Sakaeda, N.Ohnishi and T.Yokoyama, Effects of platinum derivatives on
the function and expression of P-glycoprotein/MDR1 in LLC-PK1 cells: in the cases of carboplatin and
nedaplatin, J.Cancer Molecules, 3(1), 23-28 (2007).
33. H.Imanishi, N.Okamura, M.Yagi, Y.Noro, Y.Moriya, T.Nakamura, A.Hayakawa, Y.Takeshima, T.Sakaeda,
M.Matsuo and K.Okumura, Genetic polymorphisms associated with adverse events and elimination of
methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma, J.Hum.Genet., 52(2),
166-171 (2007).
34. K.Iwaki, T.Sakaeda, M.Kakumoto, T.Nakamura, C.Komoto, N.Okamura, K.Nishiguchi, T.Shiraki,
M.Horinouchi and K.Okumura, Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein,
J.Pharm.Pharmacol., 58(12), 1617-1622 (2006).
35. K.Takara, Y.Obata, E.Yoshikawa, N.Kitada, T.Sakaeda, N.Ohnishi and T.Yokoyama, Molecular changes to
HeLa cells on continuous exposure to cisplatin or paclitaxel, Cancer Chemother.Pharmacol., 58(6), 785-793
(2006).
36. T.Sakaeda, K.Iijima, K.Nozu, T.Nakamura, Y.Moriya, M.Nishikawa, A.Wada, N.Okamura, M.Matsuo and
K.Okumura, Prediction of systemic exposure to cyclosporine in Japanese pediatric patients, J.Hum.Genet.,
51(11), 969-976 (2006).
37. N.Kitada, K.Takara, H.Kishi, T.Sakaeda, N.Ohnishi and T.Yokoyama, Oxaliplatin up-regulated the function
and expression of P-glycoprotein/MDR1 in porcine kidney epithelial LLC-PK1 cells, EXCLI J., 5, 179-190
(2006).
38. Y.Shirasaka, M.Kawasaki, T.Sakane, H.Omatsu, Y.Moriya, T.Nakamura, T.Sakaeda, K.Okumura, P.Langguth
and S.Yamashita, Induction of human P-glycoprotein in Caco-2 cells: Development of a highly sensitive
assay system for P-glycoprotein-mediated drug transport, Drug Metab.Pharmacokinet., 21(5), 414-423
(2006).
39. J.-S.Jin, T.Sakaeda, M.Kakumoto, K.Nishiguchi, T.Nakamura, N.Okamura and K.Okumura, Effect of
therapeutic moderate hypothermia on multi-drug resistance protein 1-mediated transepithelial transport of
drugs, Neurol.Med.Chir.(Tokyo), 46(7), 321-327 (2006).
40. T.Koyama, T.Nakamura, C.Komoto, T.Sakaeda, M.Taniguchi, N.Okamura, T.Tamura, N.Aoyama,
T.Kamigaki, Y.Kuroda, M.Kasuga, K.Kadoyama and K.Okumura, MDR1 T-129C polymorphism can be
predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese,
Biol.Pharm.Bull., 29(7), 1449-1453 (2006).
41. S.Markova, T.Nakamura, T.Sakaeda, H.Makimoto, H.Uchiyama, N.Okamura and K.Okumura,
− 363 −
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood
mononuclear cells under acute inflammation, Drug Metab.Pharmacokinet., 21(3), 194-200 (2006).
T.Nakamura, T.Ioroi, T.Sakaeda, M.Horinouchi, N.Hayashi, K.Saito, M.Kosaka, N.Okamura, K.Kadoyama,
S.Kumagai and K.Okumura, Serum cystatin C levels to predict serum concentration of digoxin in Japanese
patients, Int.J.Med.Sci., 3(3), 92-96 (2006).
Y.Takeshima, M.Yagi, H.Wada, K.Ishibashi, A.Nishiyama, M.Kakumoto, T.Sakaeda, K.Okumura and
M.Matsuo, Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle
dystrophin mRNA of Duchenne muscular dystrophy, Pediatr.Res., 59(5), 690-694 (2006).
C.Komoto, T.Nakamura, T.Sakaeda, Deanna L. Kroetz, T.Yamada, H.Omatsu, T.Koyama, N.Okamura, I.Miki,
T.Tamura, N.Aoyama, M.Kasuga and K.Okumura, MDR1 haplotype frequencies in Japanese and Caucasian,
and in Japanese patients with colorectal cancer and esophageal cancer, Drug Metab.Pharmacokinet., 21(2),
126-132 (2006).
Y.Moriya, T.Nakamura, N.Okamura, T.Sakaeda, M.Horinouchi, T.Tamura, N.Aoyama, M.Kasuga and
K.Okumura, Comparison of synthetic DNA templates with authentic cDNA templates in terms of
quantification by real-time quantitative reverse transferase polymerase chain reaction, Biol.Pharm.Bull.,
29(3), 535-538 (2006).
T.Sakaeda, H.Fujino, C.Komoto, M.Kakumoto, J.-S.Jin, K.Iwaki, K.Nishiguchi, T.Nakamura, N.Okamura
and K.Okumura, Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated
metabolism and MDR1-mediated transport, Pharm.Res., 23(3), 506-512 (2006).
T.Osuga, T.Sakaeda, T.Nakamura, T.Yamada, T.Koyama, T.Tamura, N.Aoyama, N.Okamura, M.Kasuga and
K.Okumura, MDR1 C3435T polymorphism is predictive of later onset of ulcerative colitis in Japanese,
Biol.Pharm.Bull., 29(2), 324-329 (2006).
ᑠᯘᫀᏹࠊ➉ᮎⰾ⏕ࠊ㇂ᕝཎ♸௓ࠊ୕㬞ᘅ⦾ࠊᮌᮧ฼⨾ࠊᖹ⏣⣧⏕ࠊⓑ▼ṇࠊᰤ⏣ᩄஅࠊ㧗಴ಇ஧ࠊ
ᢠ MRSA ⸆ࡢ TDM ࡟㛵ࡍࡿ඲ᅜ࢔ࣥࢣ࣮ࢺㄪᰝࠊ᪥ᮏ໬Ꮫ⒪ἲᏛ఍㞧ㄅࠊ➨ 58 ᕳࠊ➨ 2 ྕࠊ119-124
㡫ࠊ2010 ᖺ
᱔ཎᬗᏊࠊᒣ᳃ඖ༤ࠊ㛛⬥♸ᏊࠊඵᮌᩗᏊࠊ୰ᮧ௵ࠊዟ㔝㐩ဢࠊⲔᒇཎ⳯✑Ꮚࠊ୕ᮌ⏕ஓࠊ⏣ᮧᏕ
㞝ࠊᖹ஭ࡳ࡝ࡾࠊᰤ⏣ᩄஅࠊ㣗㐨ࡀࢇ໬Ꮫᨺᑕ⥺⒪ἲ࡟࠾ࡅࡿ 5-ࣇࣝ࢜ࣟ࢘ࣛࢩࣝ⾑₢୰⃰ᗘ࡜๪
స⏝࡜ࡢ┦㛵ࠊTDM ◊✲ࠊ➨ 26 ᕳࠊ1 ྕࠊ7-13 㡫ࠊ2009 ᖺ
ᒣୗ࿴ᙪࠊ୰ᮧ௵ࠊ⏣୰೺ኴࠊᮤ᐀Ꮚࠊᮌୗᢎⓡࠊᶓᒣ┤ᶞࠊᰤ⏣ᩄஅࠊᖹ஭ࡳ࡝ࡾࠊⲨᕝ๰୍ࠊ
⎔ቃឤᰁࠊ➨ 23 ᕳࠊ5 ྕࠊ366-370 㡫ࠊ2008 ᖺ
᱔ཎᬗᏊࠊᒣ᳃ඖ༤ࠊ㛛⬥♸ᏊࠊඵᮌᩗᏊࠊ୰ᮧ௵ࠊዟ㔝㐩ဢࠊⲔᒇཎ⳯✑Ꮚࠊ୕ᮌ⏕ஓࠊ⏣ᮧᏕ
㞝ࠊᖹ஭ࡳ࡝ࡾࠊᰤ⏣ᩄஅࠊ㣗㐨ࡀࢇ໬Ꮫᨺᑕ⥺⒪ἲ࡟࠾ࡅࡿ 5-ࣇࣝ࢜ࣟ࢘ࣛࢩࣝ⾑₢୰⃰ᗘ࡜἞
⒪ຠᯝ࡜ࡢ┦㛵ࠊTDM ◊✲ࠊ➨ 25 ᕳࠊ4 ྕࠊ145-151 㡫ࠊ2008 ᖺ
㛵ᜤᏊࠊඛᓮ೺㐀ࠊ⧰ᮌᗣኵࠊ஬ⓒⶶṊኈࠊ⸨஭㐨ᏊࠊᒣෆᐶᏊࠊⓑ▼ᖾᡂࠊ୰ከἨࠊすཱྀᕤྖࠊ
ᯇᯘ↷ஂࠊ㧗ஂಖె⚽ࠊᒸᮧ᪼ࠊᰤ⏣ᩄஅࠊFOLFOX ⒪ἲ᪋⾜࡟క࠺࢔ࣞࣝࢠ࣮཯ᛂ࡟㛵ࡍࡿከ᪋
タඹྠ◊✲ࠊ་⒪⸆Ꮫࠊ➨ 34 ᕳࠊ10 ྕࠊ919-926 㡫ࠊ2008 ᖺ
᱔ཎᬗᏊࠊᒣ᳃ඖ༤ࠊᵐᮏ༤㞝ࠊすཱྀᕤྖࠊඵᮌᩗᏊࠊዟ㔝㐩ဢࠊⲔᒇཎ⳯✑Ꮚࠊ୕ᮌ⏕ஓࠊ⏣ᮧ
Ꮥ㞝ࠊᖹ஭ࡳ࡝ࡾࠊᰤ⏣ᩄஅࠊ㣗㐨ࡀࢇ໬Ꮫᨺᑕ⥺⒪ἲ࡟࠾ࡅࡿ⑓ᮇࠊዌຠ࡜ணᚋ࡜ࡢ┦㛵ࠊ་⒪
⸆Ꮫࠊ➨ 34 ᕳࠊ1 ྕࠊ13-19 㡫ࠊ2008 ᖺ
▼ᕝ⿱Ꮚࠊᒾᇛ᫭୍ࠊⓑᮌᏕࠊ㛗㇂ᕝὈᏊࠊ㭯⏣᪩ⱑࠊ኱▼⨾᝴ࠊすཱྀᕤྖࠊዟᮧ຾ᙪࠊᰤ⏣ᩄஅࠊ
⑓Ჷྥࡅ⥭ᛴ⏝་⸆ရࡢᶆ‽໬࡜ࢺ࣮ࣞ஺᥮᪉ᘧ࡟ࡼࡿ౪⤥⟶⌮ࠊ་⒪⸆Ꮫࠊ➨ 33 ᕳࠊ5 ྕࠊ431-437
㡫ࠊ2007 ᖺ
୰ᮧ௵ࠊ஬ⓒⶶṊኈࠊ኱ᯇ⚽᫂ࠊᒣୗ࿴ᙪࠊⓑᮌᏕࠊᇼஅෆṇ๎ࠊすཱྀᕤྖࠊ⚟ᮏᕦࠊලⱥᡂࠊᒸ
ᮧ᪼ࠊゅᒣᆂ୍ࠊዟᮧ຾ᙪࠊᰤ⏣ᩄஅࠊCyclosporine ࠿ࡽ sirolimus ࡬ࡢษࡾ᭰࠼࡟㝿ࡋࠊsirolimus
⾑୰⃰ᗘࡢ୍㐣ᛶୖ᪼ࢆㄆࡵࡓ⑕౛ࠊTDM ◊✲ࠊ➨ 24 ᕳࠊ2 ྕࠊ98-103 㡫ࠊ2007 ᖺ
㧗ᶫᝆᏊࠊ୰ᮧ௵ࠊᏲᒇ཭ຍࠊⓑᮌᏕࠊᯘఙⱥࠊ⇃㇂ಇ୍ࠊᒸᮧ᪼ࠊඵᮌ㯞⌮Ꮚࠊ➉ᓥὈᘯࠊᯇᑿ
㞞ᩥࠊᰤ⏣ᩄஅࠊዟᮧ຾ᙪࠊ➽ࢪࢫࢺࣟࣇ࢕࣮ᝈ⪅࡟ᑐࡍࡿࢤࣥࢱ࣐࢖ࢩࣥ⒪ἲ᫬࡟࠾ࡅࡿ⭈ᶵ⬟
ホ౯ࠊ་⒪⸆Ꮫࠊ➨ 32 ᕳࠊ11 ྕࠊ1111-1116 㡫ࠊ2006 ᖺ
኱ᯇ⚽᫂ࠊᡴಖ⿱Ꮚࠊ஬ⓒⶶṊኈࠊᏲᒇ཭ຍࠊ⬌ᮏ༓✑ࠊⓑᮌᏕࠊ୰ᮧ௵ࠊすཱྀᕤྖࠊᒸᮧ᪼ࠊᰤ
⏣ᩄஅࠊዟᮧ຾ᙪࠊప⃰ᗘᇦࡢࢱࢡ࣒ࣟࣜࢫ⾑୰⃰ᗘ ᐃ࡟ࡘ࠸࡚ࡢၥ㢟Ⅼ࡜ࡑࡢᑐᛂ⟇ࠊTDM
◊✲ࠊ➨ 23 ᕳࠊ4 ྕࠊ276-280 㡫ࠊ2006 ᖺ
୰ᮧ௵ࠊᏲᒇ཭ຍࠊ⬌ᮏ༓✑ࠊᡴಖ⿱Ꮚࠊ㊊❧ᜨ⨾ࠊᒸᮧ᪼ࠊᰤ⏣ᩄஅࠊඵᮌ㯞⌮Ꮚࠊ➉ᓥὈᘯࠊ
ᯇᑿ㞞ᩥࠊዟᮧ຾ᙪࠊ➽ࢪࢫࢺࣟࣇ࢕࣮ᝈ⪅࡟ᑐࡍࡿࢤࣥࢱ࣐࢖ࢩࣥ⒪ἲ᫬࡟࠾ࡅࡿࢤࣥࢱ࣐࢖ࢩ
ࣥ TDMࠊTDM ◊✲ࠊ➨ 23 ᕳࠊ4 ྕࠊ242-247 㡫ࠊ2006 ᖺ
− 364 −
㸦⥲ㄝ㸧
1. T.Sakaeda, M.Yamamori, A.Kuwahara and K.Nishiguchi, Pharmacokinetics and pharmacogenomics in
esophageal cancer chemoradiotherapy, Adv.Drug Deliv.Rev., 61(5), 388-401 (2009).
2. T.Nakamura, M.Yamamori and T.Sakaeda, Pharmacogenetics of intestinal absorption, Curr.Drug Deliv., 5(3),
153-169 (2008).
3. K.Takara, T.Sakaeda and K.Okumura, An update on overcoming MDR1-mediated multidrug resistance in
cancer chemotherapy, Curr.Pharm.Des., 12(3), 273-286 (2006).
4. ᰤ⏣ᩄஅࠊゅᒣ㤶⧊ࠊᒣ᳃ඖ༤ࠊPK-PD ⌮ㄽࡢ☜❧࠿ࡽ 20 ᖺ㹼᭱㏆ࡢ▱ぢ࡜௒ᚋࡢᒎ㛤㹼ࠊ
Jpn.J.Antiobiot.ࠊ➨ 62 ᕳࠊ➨ 6 ྕࠊ483-491 㡫ࠊ2009 ᖺ
5. ୰ᮧ௵ࠊᰤ⏣ᩄஅࠊዟᮧ຾ᙪࠊᑠඣᝈ⪅࡟࠾ࡅࡿࢩࢡࣟࢫ࣏ࣜࣥࡢ TDM㸫ࢿ࣮࢜ࣛࣝ C2 ࣔࢽࢱࣜ
ࣥࢢࡢ⌧≧࡜ㄢ㢟㸫ࠊTDM ◊✲ࠊ➨ 24 ᕳࠊ➨ 2 ྕࠊ77-85 㡫ࠊ2007 ᖺ
㸦ゎㄝ㸧
1. ➉ᮎⰾ⏕ࠊ㇂ᕝཎ♸௓ࠊᑠᯘᫀᏹࠊ୕㬞ᘅ⦾ࠊᮌᮧ฼⨾ࠊᖹ⏣⣧⏕ࠊⓑ▼ṇࠊᰤ⏣ᩄஅࠊ㧗಴ಇ஧ࠊ
Vancomycin ࡢ Therapeutic drug monitoring㸦TDM㸧ᐇ᪋࡟㛵ࡍࡿᢠ⳦໬Ꮫ⒪ἲㄆᐃ⸆๣ᖌไᗘㄆᐃጤ
ဨ఍࡞ࡽࡧ࡟ᢠ⳦⸆ TDM ᶆ‽໬࣮࣡࢟ࣥࢢࢢ࣮ࣝࣉࡢぢゎࠊ᪥ᮏ໬Ꮫ⒪ἲᏛ఍㞧ㄅࠊ58(1)ࠊ18-19ࠊ
2010.
2. ᰤ⏣ᩄஅࠊࡀࢇ໬Ꮫ⒪ἲ࡜㑇ఏᏊ㛵㐃᝟ሗࡢ฼⏝ࠊ་⸆ࢪ࣮ࣕࢼࣝࠊ44(12)ࠊ61(2765)-66(2770)ࠊ2008.
3. ᰤ⏣ᩄஅࠊᒣ᳃ඖ༤ࠊ᱔ཎᬗᏊࠊすཱྀᕤྖࠊ㣗㐨ࡀࢇ໬Ꮫᨺᑕ⥺⒪ἲࡢಶู໬ࠊ་⸆ࢪ࣮ࣕࢼࣝࠊ
44(12)ࠊ93(2797)-99(2803)ࠊ2008.
4. ᰤ⏣ᩄஅࠊWorld congress of pharmacy and pharmaceutical sciences 2007, 67th international congress of FIP
㸦➨ 67 ᅇᅜ㝿⸆Ꮫ఍㆟㸧ཧຍሗ࿌ࠊ໬Ꮫ࡜⸆ᏛࡢᩍᐊࠊNo.157ࠊ28-32ࠊ2007.
5. ኱ᯇ⚽᫂ࠊᰤ⏣ᩄஅࠊἪᒀჾ⛉㡿ᇦឤᰁ⑕࡟࠾ࡅࡿ PK/PD ࡟ᇶ࡙ࡃᢞ୚タィࠊ⸆ᒁࠊ58(6)ࠊ
71(2079)-74(2081)ࠊ2007.
6. ᰤ⏣ᩄஅࠊᢠ MRSA ⸆࡜ TDMࠊឤᰁ࡜ᢠ⳦⸆ࠊ10(3)ࠊ223-232ࠊ2007.
7. ዟ㔝㐩ဢࠊ⏣ᮧᏕ㞝ࠊᰤ⏣ᩄஅࠊᮾ೺ࠊStage II/III 㣗㐨ᡥᖹୖ⓶⒴ᝈ⪅࡟ᑐࡍࡿ໬Ꮫᨺᑕ⥺⒪ἲࡢ἞
⒪ຠᯝࡢணᚋᅉᏊ࡛࠶ࡿ࡜⪃࠼ࡽࢀࡿ㑇ఏᏊ࡟ࡘ࠸࡚ࠊᾘ໬ჾ⛉ࠊ44(4)ࠊ352-358ࠊ2007.
8. ᰤ⏣ᩄஅࠊ᪂་⒪⸆Ꮫࢭ࣑ࢼ࣮ ࡃࡍࡾࡢ┦஫స⏝࡟ࡘ࠸࡚㸦➨ 1㹼12 ᅇ㸧ࠊර⸆⏺ࠊNo.602ࠊ2006.
9. ᒣୗ࿴ᙪࠊᰤ⏣ᩄஅࠊዟᮧ຾ᙪࠊࢺࣛࢫࢶࢬ࣐ࣈࠊ⸆ᒁࠊ57(3)ࠊ63(407)-68(412)ࠊ2006.
10. ᰤ⏣ᩄஅࠊච␿ᢚไ⸆ Q. ᑠඣ⛣᳜ච␿࡟࠾ࡅࡿ TDM ࡢὀពⅬࡣఱ࡛ࡋࡻ࠺࠿㸽ࠊ⸆ᒁࠊ57(2)ࠊ
71(231)-73(233)ࠊ2006.
11. ᰤ⏣ᩄஅࠊ≉㞟࣭MRSA ࡢ᪂ࡓ࡞ᒎ㛤㸭4. ᢠ⳦⸆ࡢ㐺ṇ౑⏝࡜ TDM㹼ᢠ MRSA ⸆ࢆ୰ᚰ࡜ࡋ࡚㹼ࠊ
໬Ꮫ⒪ἲࡢ㡿ᇦࠊ22(2)ࠊpp..44(192)-51(199)ࠊ2006.
12. ᰤ⏣ᩄஅࠊ㑇ఏᏊデ᩿࡜ TDMࠊGlobalpharmacistࠊ2(1)ࠊpp.9-10ࠊ2006.
㸦ⴭ᭩ࠊ⦅㞟㸧
1. ࠕ་⸆ရ᝟ሗᏛ㸦ᰤ⏣ᩄஅࠊᶫワຮ ⦅㞟ࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ┘ಟ㸧
ࠖ
ࠊᘅᕝ᭩ᗑࠊ༳ๅ୰
2. ࠕ໬Ꮫᵓ㐀࡜⸆⌮స⏝㸦すฟ႐௦἞ࠊబࠎᮌⱱ㈗ࠊᰤ⏣ᩄஅ ⦅㞟ࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ┘
ಟ㸧ࠖࠊᘅᕝ᭩ᗑࠊ2010.10.
3. ࠕᐇົᐇ⩦஦๓Ꮫ⩦ࡢࡓࡵࡢㄪ๣Ꮫィ⟬ࢻࣜࣝ㸦ᰤ⏣ᩄஅ ⦅㞟ࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ┘
ಟ㸧ࠖࠊᘅᕝ᭩ᗑࠊ2010.3.
4. ࠕ་⸆ရ㛤Ⓨㄽ㸦ᰤ⏣ᩄஅࠊཎⱥᙲࠊᒸᮧ᪼ ⦅㞟ࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ┘ಟ㸧ࠖࠊᘅᕝ᭩
ᗑࠊ2010.2.
5. ࠕ⸆≀ືែᏛ㸦ᰤ⏣ᩄஅࠊᒣᓮᾈྐࠊℿ஭㞞⾜ ⦅㞟ࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ┘ಟ㸧ࠖ
ࠊᘅᕝ
᭩ᗑࠊ2010.2.
6. ࠕศᯒ໬ᏛϨ㸫ᇶ♏໬Ꮫ࠿ࡽ་⒪⸆Ꮫ࡬㸦Ᏻ஭⿱அࠊᰤ⏣ᩄஅࠊᒸᑦ⏨ ⦅㞟ࠊᰘᓮṇ຾ࠊ㉥ụ᫛
⣖ࠊబ἞ⱥ㑻 ┘ಟ㸧ࠖࠊᘅᕝ᭩ᗑࠊ2010.2.
7. ࠕศᯒ໬Ꮫϩ㸫ᶵჾศᯒࡢ་⒪⸆Ꮫ࡬ࡢᛂ⏝㸦ᒸᑦ⏨ࠊᰤ⏣ᩄஅࠊᏳ஭⿱அ ⦅㞟ࠊᰘᓮṇ຾ࠊ㉥
ụ᫛⣖ࠊబ἞ⱥ㑻 ┘ಟ㸧ࠖࠊᘅᕝ᭩ᗑࠊ2010.2.
8. ࠕ〇๣Ꮫ࣭≀⌮⸆๣Ꮫ㸦ᰤ⏣ᩄஅࠊ၈⃝೺ࠊᒸᮏᾈ୍ ⦅㞟ࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊᶫ⏣඘ ┘ಟ㸧ࠖࠊ
ᘅᕝ᭩ᗑࠊ2009.8.
9. ࠕᐇົᐇ⩦஦๓Ꮫ⩦ࡢࡓࡵࡢㄪ๣Ꮫ㸦ཌ⏣ᖾ୍㑻ࠊ␇ᓮᴿࠊᰤ⏣ᩄஅ ⦅㞟ࠊᰘᓮṇ຾ࠊ㉥ụ᫛⣖ࠊ
ᶫ⏣඘ ┘ಟ㸧ࠖࠊᘅᕝ᭩ᗑࠊ2009.4.
10. ࠕࢃ࠿ࡾࡸࡍ࠸㍺ᾮ〇๣㸦㒆ಟᚨࠊᰤ⏣ᩄஅ ⦅㞟㸧ࠖࠊᘅᕝ᭩ᗑࠊ2009.3.
− 365 −
㸦ⴭ᭩ࠊศᢸᇳ➹㸧
1. ᶫ⏣඘ࠊᰤ⏣ᩄஅࠊᒣୗᐩ⩏㸸ࢭࢡࢩࣙࣥ㸯㸬DDS࡜ࡣఱ࠿ࠊIn㸸ᅗゎ࡛ᏛࡪDDS㸦ᶫ⏣඘ ┘ಟࠊ
㧗಴႐ಙ ⦅㞟㸧ࠊࡌ࡯࠺ࠊp.1-22ࠊ2010.
2. ᰤ⏣ᩄஅ㸸ࢭࢡࢩࣙࣥ㸯㸮㸬་⒪࡟࠾ࡅࡿDDSࡢᙺ๭㸸⌧≧࡜ᮍ᮶ࠊIn㸸ᅗゎ࡛ᏛࡪDDS㸦ᶫ⏣඘ ┘
ಟࠊ㧗಴႐ಙ ⦅㞟㸧ࠊࡌ࡯࠺ࠊp.151-156ࠊ2010.
3. ゅᒣ㤶⧊ࠊᰤ⏣ᩄஅ㸸ᚠ⎔ჾ⑌ᝈࡢ⸆≀୍ぴࠊIn㸸ᚠ⎔ჾ⑌ᝈ᭱᪂ࡢ἞⒪2010-2011㸦ᇼṇ஧ࠊỌ஭
Ⰻ୕ ⦅㞟㸧ࠊ༡Ụᇽࠊp.516-558ࠊ2010.
4. ᰤ⏣ᩄஅ㸸㸯㸯㸧DDS࡟ࡼࡿ་⒪ࡢ㧗ᗘ໬࡜๪స⏝ᅇ㑊㸭➨㸳❶DDS㛤Ⓨࡢ⌧≧࡜་⒪ࡢ⌧ሙ࡟࠾
ࡅࡿホ౯ࠊIn㸸ࣇ࢓࣮࣒ࢸࢵࢡࢪࣕࣃࣥ2009ᖺ⮫᫬ቑหྕ㸦➨25ᕳࠊ➨13ྕ㸧ࠊDDS἞⒪ࢩࢫࢸ࣒ࡢ
タィ࡜ホ౯㸦ᶫ⏣඘ ⦅㞟㸧ࠊࡌ࡯࠺ࠊp.152(2740)-156(2744)ࠊ2009.
5. ᰤ⏣ᩄஅ㸸㸰㸧PK/PDࣉࣟࣇ࢓࢖ࣝ࡟ᇶ࡙ࡃங⒴἞⒪㸭㸵㸬⸆≀἞⒪඲⯡㸭ϭ❶἞⒪ࠊIn㸸ࡳࢇ࡞
࡟ᙺ❧ࡘங⒴ࡢᇶ♏࡜⮫ᗋ㸦ᡞ஭㞞࿴ ⦅㞟㸧ࠊ་⸆ࢪ࣮ࣕࢼࣝ♫ࠊp.801-811ࠊ2009.
6. ᰤ⏣ᩄஅ㸸➨2㒊 ࢤࣀ࣒་⒪ࡢᐇ㊶࡟ྥࡅ࡚㸭➨4❶ ಶู໬་⒪㸦ࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪㸧ࡢ⌧≧࡜
ᒎᮃ㸭㸯㸬ࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪ࡢᚲせᛶࠊIn㸸ᐇ㊶ࢤࣀ࣒ࡢ᭱๓⥺㸦஭ᮧ⿱ኵ ┘ಟࠊ⚄ᡞ኱Ꮫ኱Ꮫ
㝔་Ꮫ◊✲⛉ࢡࣜࢽ࢝ࣝࢤࣀ࣒࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࣘࢽࢵࢺ ⦅㞟㸧ࠊභ↛♫ࠊp.236-241ࠊ2009.
7. ᰤ⏣ᩄஅ㸸➨2㒊 ࢤࣀ࣒་⒪ࡢᐇ㊶࡟ྥࡅ࡚㸭➨4❶ ಶู໬་⒪㸦ࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪㸧ࡢ⌧≧࡜
ᒎᮃ㸭㸰㸬ࡀࢇ໬Ꮫ⒪ἲ࡟࠾ࡅࡿࢸ࣮࣮࣓ࣛ࢖ࢻ་⒪ࠊIn㸸ᐇ㊶ࢤࣀ࣒ࡢ᭱๓⥺㸦஭ᮧ⿱ኵ ┘ಟࠊ
⚄ᡞ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ࢡࣜࢽ࢝ࣝࢤࣀ࣒࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫࣘࢽࢵࢺ ⦅㞟㸧ࠊභ↛♫ࠊ
p.242-249ࠊ2009.
8. ᰤ⏣ᩄஅࠊゅᮏᖿኵ㸸➨ϰ❶ ་⒪⏝㯞⸆࣭ྥ⢭⚄⸆➼ࡢ⟶⌮ᴗົࠊIn㸸 2008ᖺᗘ∧⸆Ꮫ⏕ࡢࡓࡵ
ࡢ⑓㝔࣭⸆ᒁᐇ⩦ࢸ࢟ࢫࢺ㸦⸆Ꮫᩍ⫱༠㆟఍ ⑓㝔࣭⸆ᒁᐇົᐇ⩦㏆␥ᆅ༊ㄪᩚᶵᵓ ┘ಟࠊ᪥ᮏ⑓
㝔⸆๣ᖌ఍㏆␥ࣈࣟࢵࢡ㸭᪥ᮏ⸆๣ᖌ఍኱㜰࣭㏆␥ࣈࣟࢵࢡ ⦅㞟㸧ࠊࡌ࡯࠺ࠊp.114-126ࠊ2008.
9. 㡑⚽ድࠊᰤ⏣ᩄஅ㸸➨Ϯ❶ ་⸆ရ᝟ሗ㸦DI㸧ࠊIn㸸 2008ᖺᗘ∧⸆Ꮫ⏕ࡢࡓࡵࡢ⑓㝔࣭⸆ᒁᐇ⩦ࢸ࢟
ࢫࢺ㸦⸆Ꮫᩍ⫱༠㆟఍ ⑓㝔࣭⸆ᒁᐇົᐇ⩦㏆␥ᆅ༊ㄪᩚᶵᵓ ┘ಟࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㏆␥ࣈࣟࢵ
ࢡ㸭᪥ᮏ⸆๣ᖌ఍኱㜰࣭㏆␥ࣈࣟࢵࢡ ⦅㞟㸧ࠊࡌ࡯࠺ࠊp.71-90ࠊ2008.
10. ゅᒣ㤶⧊ࠊᰤ⏣ᩄஅ㸸ᚠ⎔ჾ⑌ᝈࡢ⸆≀୍ぴࠊIn㸸ᚠ⎔ჾ⑌ᝈ᭱᪂ࡢ἞⒪2008-2009㸦ᇼṇ஧ࠊỌ஭
Ⰻ୕ ⦅㞟㸧ࠊ༡Ụᇽࠊp.509-553ࠊ2008.
11. ᰤ⏣ᩄஅ㸸➨ϰ❶ ་⒪⏝㯞⸆࣭ྥ⢭⚄⸆➼ࡢ⟶⌮ᴗົࠊIn㸸 2007ᖺᗘ∧⸆Ꮫ⏕ࡢࡓࡵࡢ⑓㝔࣭⸆
ᒁᐇ⩦ࢸ࢟ࢫࢺ㸦⸆Ꮫᩍ⫱༠㆟఍ ⑓㝔࣭⸆ᒁᐇົᐇ⩦㏆␥ᆅ༊ㄪᩚᶵᵓ ┘ಟࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍
㏆␥ࣈࣟࢵࢡ㸭᪥ᮏ⸆๣ᖌ఍኱㜰࣭㏆␥ࣈࣟࢵࢡ ⦅㞟㸧ࠊࡌ࡯࠺ࠊp.110-122ࠊ2007.
12. 㡑⚽ድࠊᰤ⏣ᩄஅ㸸➨Ϯ❶ ་⸆ရ᝟ሗ㸦DI㸧ࠊIn㸸 2007ᖺᗘ∧⸆Ꮫ⏕ࡢࡓࡵࡢ⑓㝔࣭⸆ᒁᐇ⩦ࢸ࢟
ࢫࢺ㸦⸆Ꮫᩍ⫱༠㆟఍ ⑓㝔࣭⸆ᒁᐇົᐇ⩦㏆␥ᆅ༊ㄪᩚᶵᵓ ┘ಟࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㏆␥ࣈࣟࢵ
ࢡ㸭᪥ᮏ⸆๣ᖌ఍኱㜰࣭㏆␥ࣈࣟࢵࢡ ⦅㞟㸧ࠊࡌ࡯࠺ࠊp.71-90ࠊ2007.
13. ᰤ⏣ᩄஅ㸸➨3❶MRSAࡢឤᰁᑐ⟇ࠊMRSAࡢデ᩿࣭἞⒪ࠊ⸆≀⾑୰⃰ᗘ ᐃ㸦TDM㸧ࠊIn㸸INFECTION
CONTROL 2007ᖺ᫓ᏘቑหྕࠊICTࡀ࠾ࡉ࠼࡚࠾ࡁࡓ࠸MRSAᑐ⟇ࡢࡍ࡭࡚㸦⸨⏣┤ஂ ⦅㞟㸧ࠊ࣓ࢹ
࢕࢝ฟ∧ࠊpp.184-195ࠊ2007.
14. ㇂⸨ளᕼᏊࠊゅᒣ㤶⧊ࠊᰤ⏣ᩄஅ㸸⭈⑌ᝈ἞⒪⸆ࠊIn㸸⸆ᒁ2007ᖺ3᭶ቑหྕ㸦➨58ᕳࠊ➨4ྕ㸧ࠊ⑓
Ẽ࡜⸆ࡢㄝ᫂࢞࢖ࢻ 2007㸦ෆᒣ඘ ⦅㞟㸧ࠊ༡ᒣᇽࠊp.349(869)-362(882)ࠊ2007.
15. ᰤ⏣ᩄஅ㸸Ϫ㸫㸯㸬⸆≀ືែ᝟ሗࡢά⏝㸸PK/PD㸭➨ 2 ❶ ་⸆ရࡢ㐺ṇ౑⏝࡜⸆≀ືែ᝟ሗࡢά
⏝ࠊIn㸸་⒪⸆Ꮫࣇࣟࣥࢸ࢕࢔ࠊ⸆≀ືែ᝟ሗ࡜⸆≀἞⒪⦅㸦་⒪⸆Ꮫ఍⦅㸧ࠊ⸆஦᪥ሗ♫ࠊp.35-53ࠊ
2006.
16. ᒸᮧ᪼ࠊᰤ⏣ᩄஅ㸸➨2❶ ᝟ሗ᳨⣴ࢆᐇົ࡟⏕࠿ࡍ࡟ࡣ㸭12. ⸆๣⟶⌮ᣦᑟ㸫㑇ఏⓗ⣲ᅉࢆ⪃៖ࡋ
ࡓ௓ධ㸫ࠊIn㸸࣑ࢡࢫ⸆Ꮫᐇ㊶ࢩ࣮ࣜࢬࠊ⸆๣ᖌࡢ⮫ᗋᴗົ࡟ᙺ❧ࡘ᝟ሗά⏝ἲ㹙ᨵゞ∧㹛㸦ᢡ஭Ꮥ
⏨ ┘ಟ㸧ࠊ࢚ࣝࢮࣅ࢔࣭ࢪࣕࣃࣥࠊp.98-103ࠊ2006.
17. ᰤ⏣ᩄஅ㸸➨ϰ❶ ་⒪⏝㯞⸆࣭ྥ⢭⚄⸆➼ࡢ⟶⌮ᴗົࠊIn㸸 2006ᖺᗘ∧⸆Ꮫ⏕ࡢࡓࡵࡢ⑓㝔࣭⸆
ᒁᐇ⩦ࢸ࢟ࢫࢺ㸦⸆Ꮫᩍ⫱༠㆟఍ ⑓㝔࣭⸆ᒁᐇົᐇ⩦㏆␥ᆅ༊ㄪᩚᶵᵓ㸦㏆␥ᆅ༊⸆Ꮫ㒊Ꮫ⏕ᐇ
ົᐇ⩦࡟㛵ࡍࡿ༠㆟఍㸧┘ಟࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㏆␥ࣈࣟࢵࢡ㸭᪥ᮏ⸆๣ᖌ఍኱㜰࣭㏆␥ࣈࣟࢵࢡ
⦅㞟㸧ࠊࡌ࡯࠺ࠊp.108-120ࠊ2006.
18. 㡑⚽ድࠊᰤ⏣ᩄஅ㸸➨Ϯ❶ ་⸆ရ᝟ሗ㸦DI㸧ࠊIn㸸 2006ᖺᗘ∧⸆Ꮫ⏕ࡢࡓࡵࡢ⑓㝔࣭⸆ᒁᐇ⩦ࢸ࢟
ࢫࢺ㸦⸆Ꮫᩍ⫱༠㆟఍ ⑓㝔࣭⸆ᒁᐇົᐇ⩦㏆␥ᆅ༊ㄪᩚᶵᵓ㸦㏆␥ᆅ༊⸆Ꮫ㒊Ꮫ⏕ᐇົᐇ⩦࡟㛵
ࡍࡿ༠㆟఍㸧┘ಟࠊ᪥ᮏ⑓㝔⸆๣ᖌ఍㏆␥ࣈࣟࢵࢡ㸭᪥ᮏ⸆๣ᖌ఍኱㜰࣭㏆␥ࣈࣟࢵࢡ ⦅㞟㸧ࠊࡌ
࡯࠺ࠊp.71-90ࠊ2006.
− 366 −
ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊⮬ᕫⅬ᳨࣭ホ౯ጤဨ఍
ጤဨ㛗 బ ἞ ⱥ 㑻
ጤ ဨ ㎷ ᮏ ㇦ ୕ ୰ ᒣ ࿴ ஂ
➉ ᮏ ె ྖ 㧗 ಴ ႐ ಙ
ᯇ ᓮ ຾ ᕭ ຍ ⸨ ༤ ❶
ᑠ ಴ ୍ ኵ
ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉࠾ࡼࡧ⸆Ꮫ㒊ࡢ⌧≧࡜ㄢ㢟
⮬ᕫⅬ᳨࣭ホ౯ሗ࿌᭩
ᖹᡂ㸰㸱ᖺ㸰᭶
⦅㞟 ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊⮬ᕫⅬ᳨࣭ホ౯ጤဨ఍
Ⓨ⾜ ி㒔኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉࣭⸆Ꮫ㒊
࠰606-8501 ி㒔ᕷᕥி༊ྜྷ⏣ୗ㜿㐩⏫
‫܄‬075-753-4510㸦ࢲ࢖ࣖࣝ࢖ࣥ㸧

工学部の学部改組

東棟 - 北海道大学 理学部

学 生 募 集 要 項